PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Saglam, A; Balaban, S; Yildirim, T; Erdem, Y; Uner, A; Buyukasik, Y				Saglam, Arzu; Balaban, Seda; Yildirim, Tolga; Erdem, Yunus; Uner, Aysegul; Buyukasik, Yahya			Monoclonal gammopathy of renal significance presenting as monotypic plasma cell interstitial nephritis in two patients with Sjogren's syndrome	VIRCHOWS ARCHIV			English	Article							KIDNEY; INVOLVEMENT; OUTCOMES		[Saglam, Arzu; Uner, Aysegul] Hacettepe Univ, Dept Pathol, Sch Med, Sihhiye, TR-06100 Ankara, Turkey; [Balaban, Seda; Buyukasik, Yahya] Hacettepe Univ, Sch Med, Dept Internal Med, Div Hematol, Ankara, Turkey; [Yildirim, Tolga; Erdem, Yunus] Hacettepe Univ, Sch Med, Dept Internal Med, Div Nephrol, Ankara, Turkey	Saglam, A (reprint author), Hacettepe Univ, Dept Pathol, Sch Med, Sihhiye, TR-06100 Ankara, Turkey.	eminearzusaglam@yahoo.com	Uner, Aysegul/A-9028-2011	Uner, Aysegul/0000-0002-2522-1606			Attias P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004391; Bossini N, 2001, NEPHROL DIAL TRANSPL, V16, P2328, DOI 10.1093/ndt/16.12.2328; Brito-Zeron P, 2012, J AUTOIMMUN, V39, P43, DOI 10.1016/j.jaut.2012.01.010; Cho SY, 2014, INT J RHEUM DIS, V17, P635, DOI 10.1111/1756-185X.12267; Colvin RB, 2016, DIAGNOSTIC PATHOLOGY; Francois H, 2016, NAT REV NEPHROL, V12, P82, DOI 10.1038/nrneph.2015.174; Jasiek M, 2017, RHEUMATOLOGY, V56, P362, DOI 10.1093/rheumatology/kew376; Kidder D, 2015, NEPHROL DIAL TRANSPL, V30, P1363, DOI 10.1093/ndt/gfv042; Leung N, 2012, BLOOD, V120, P4292, DOI 10.1182/blood-2012-07-445304; Markowitz GS, 2004, ADV ANAT PATHOL, V11, P49, DOI 10.1097/00125480-200401000-00005; Mei YH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006092; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rosner MH, 2016, CLIN J AM SOC NEPHRO, V11, P2280, DOI 10.2215/CJN.02920316; Tuzun S, 2012, OSTEOPOROSIS INT, V23, P949, DOI 10.1007/s00198-011-1655-5; Vos JM, 2016, BRIT J HAEMATOL, V175, P623, DOI 10.1111/bjh.14279	15	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					865	869		10.1007/s00428-017-2270-4			5	Pathology	Pathology	GG9NI	WOS:000433027400017	29147924				2019-10-28	
J	Laco, J; Kovarikova, H; Chmelarova, M; Vosmikova, H; Sieglova, K; Baranova, I; Dundr, P; Nemejcova, K; Michalek, J; Satankova, J; Vosmik, M; Ryska, A				Laco, Jan; Kovarikova, Helena; Chmelarova, Marcela; Vosmikova, Hana; Sieglova, Katerina; Baranova, Ivana; Dundr, Pavel; Nemejcova, Kristyna; Michalek, Jaroslav; Satankova, Jana; Vosmik, Milan; Ryska, Ales			MicroRNA expression in SMARCB1/INI1-deficient sinonasal carcinoma: a clinicopathological and molecular genetic study	VIRCHOWS ARCHIV			English	Article							SQUAMOUS-CELL CARCINOMA; SMARCB1; METHYLATION; PROFILES; TUMOR; HPV		[Laco, Jan; Vosmikova, Hana; Sieglova, Katerina; Ryska, Ales] Charles Univ Prague, Fingerland Dept Pathol, Fac Med, Sokolska 581, Hradec Kralove 50005, Czech Republic; [Laco, Jan; Vosmikova, Hana; Sieglova, Katerina; Ryska, Ales] Charles Univ Prague, Fingerland Dept Pathol, Univ Hosp, Sokolska 581, Hradec Kralove 50005, Czech Republic; [Kovarikova, Helena; Chmelarova, Marcela; Baranova, Ivana] Charles Univ Prague, Inst Clin Biochem & Diagnost, Fac Med, Hradec Kralove, Czech Republic; [Kovarikova, Helena; Chmelarova, Marcela; Baranova, Ivana] Charles Univ Prague, Inst Clin Biochem & Diagnost, Univ Hosp, Hradec Kralove, Czech Republic; [Dundr, Pavel; Nemejcova, Kristyna] Charles Univ Prague, Dept Pathol, Fac Med 1, Prague, Czech Republic; [Dundr, Pavel; Nemejcova, Kristyna] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic; [Michalek, Jaroslav] Palacky Univ, Dept Clin & Mol Pathol, Fac Med & Dent, Olomouc, Czech Republic; [Michalek, Jaroslav] Palacky Univ, Univ Hosp, Olomouc, Czech Republic; [Satankova, Jana] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med, Hradec Kralove, Czech Republic; [Satankova, Jana; Vosmik, Milan] Charles Univ Prague, Univ Hosp, Hradec Kralove, Czech Republic; [Vosmik, Milan] Charles Univ Prague, Dept Radiotherapy & Oncol, Fac Med, Hradec Kralove, Czech Republic	Laco, J (reprint author), Charles Univ Prague, Fingerland Dept Pathol, Fac Med, Sokolska 581, Hradec Kralove 50005, Czech Republic.; Laco, J (reprint author), Charles Univ Prague, Fingerland Dept Pathol, Univ Hosp, Sokolska 581, Hradec Kralove 50005, Czech Republic.	lacoj@lfhk.cuni.cz	Baranova, Ivana/S-5881-2016; Kovarikova, Helena/S-4857-2016; Nemejcova, Kristyna/C-7373-2017; Laco, Jan/L-9715-2017	Baranova, Ivana/0000-0001-8273-2595; Kovarikova, Helena/0000-0001-5040-4140; Nemejcova, Kristyna/0000-0001-9340-9320; /0000-0002-7891-9979; Michalek, Jaroslav/0000-0002-3454-5880; Laco, Jan/0000-0002-9602-7501	Charles University Research Development Program [PROGRES Q40/11]; Ministry of Education, Youth and Sports; Czech RepublicMinistry of Education, Youth & Sports - Czech RepublicCzech Republic Government [BBMRI-CZ LM2015089]; European Regional Development Fund-Project BBMRI-CZ.: Biobank network-a versatile platform for the research of the etiopathogenesis of diseases [EF16 013/0001674]; conceptual development of research organization MH CZ-DRO (FNHK) [00179906]	The study was supported by the Charles University Research Development Program PROGRES Q40/11, by the project BBMRI-CZ LM2015089 (Ministry of Education, Youth and Sports; Czech Republic), by the European Regional Development Fund-Project BBMRI-CZ.: Biobank network-a versatile platform for the research of the etiopathogenesis of diseases, no. EF16 013/0001674 (Ministry of Education, Youth and Sports; Czech Republic), and by the conceptual development of research organization MH CZ-DRO (FNHK) 00179906 (Ministry of Health, Czech Republic). The funding sources had no influence on the study design, on collection, analysis, and interpretation of data, on writing of the report, and on decision to submit the article for publication.	Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Allison DB, 2016, DIAGN CYTOPATHOL, V44, P700, DOI 10.1002/dc.23503; Bell D, 2015, VIRCHOWS ARCH, V467, P649, DOI 10.1007/s00428-015-1853-1; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Chmelarova M, 2016, FOLIA BIOL-PRAGUE, V62, P110; Grupenmacher AT, 2013, CHILD NERV SYST, V29, P1977, DOI 10.1007/s00381-013-2268-4; Jamali Z, 2015, ORAL ONCOL, V51, P321, DOI 10.1016/j.oraloncology.2015.01.008; Kohashi K, 2014, MODERN PATHOL, V27, P832, DOI 10.1038/modpathol.2013.213; Kovarikova H, 2017, HEAD NECK-J SCI SPEC, V39, P2528, DOI 10.1002/hed.24930; Laco J, 2018, NEOPLASMA, V65, P113, DOI 10.4149/neo_2018_161122N581; Laco J, 2012, NEOPLASMA, V59, P398, DOI 10.4149/neo_2012_052; Laco J, 2017, PATHOL RES PRACT, V213, P133, DOI 10.1016/j.prp.2016.10.012; Laco J, 2015, VIRCHOWS ARCH, V467, P405, DOI 10.1007/s00428-015-1812-x; Laco J, 2011, VIRCHOWS ARCH, V458, P179, DOI 10.1007/s00428-010-1037-y; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI [10.1038/nrd.2016246, 10.1038/nrd.2016.246]; Sapi Z, 2016, GENE CHROMOSOME CANC, V55, P786, DOI 10.1002/gcc.22379; Sredni ST, 2010, CHILD NERV SYST, V26, P279, DOI 10.1007/s00381-009-1028-y; Wasserman JK, 2017, HEAD NECK PATHOL, V11, P256, DOI 10.1007/s12105-016-0752-3	19	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					871	875		10.1007/s00428-018-2293-5			5	Pathology	Pathology	GG9NI	WOS:000433027400018	29327137				2019-10-28	
J	Maia, T; Amendoeira, I				Maia, Tiago; Amendoeira, Isabel			Breast sebaceous carcinoma-a rare entity. Clinico-pathological description of two cases and brief review	VIRCHOWS ARCHIV			English	Review							METAPLASIA; DIFFERENTIATION; GLAND		[Maia, Tiago; Amendoeira, Isabel] Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal; [Maia, Tiago; Amendoeira, Isabel] Univ Porto FMUP, Fac Med, Porto, Portugal; [Amendoeira, Isabel] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Porto, Portugal	Maia, T (reprint author), Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal.; Maia, T (reprint author), Univ Porto FMUP, Fac Med, Porto, Portugal.	tiagomaia_21@hotmail.com					Cai RZY, 2005, PATHOLOGY, V37, P557, DOI 10.1080/00313020500368394; Carlucci M, 2012, INT J SURG PATHOL, V20, P284, DOI 10.1177/1066896911417711; Eusebi V, 2012, WHO CLASSIFICATION T, P71; Hisaoka M, 2006, VIRCHOWS ARCH, V449, P484, DOI 10.1007/s00428-006-0264-8; Jiao YF, 2001, VIRCHOWS ARCH, V438, P505, DOI 10.1007/s004280000366; Mazzella FM, 1995, PATHOLOGY, V27, P280, DOI 10.1080/00313029500169123; Murakami A, 2009, PATHOL INT, V59, P188, DOI 10.1111/j.1440-1827.2009.02349.x; Ramljak V, 2010, COLLEGIUM ANTROPOL, V34, P201; Svajdler M, 2015, POL J PATHOL, V66, P142, DOI 10.5114/PJP.2015.53010; TAKATA T, 1989, VIRCHOWS ARCH A, V414, P459, DOI 10.1007/BF00718631; TAVASSOLI FA, 1986, ARCH PATHOL LAB MED, V110, P1045; Tavassoli FA, 1992, PATHOLOGY BREAST, P555; VANBOGAERT LJ, 1977, VIRCHOWS ARCH A, V375, P345; Varga Z, 2000, PATHOL INT, V50, P63, DOI 10.1046/j.1440-1827.2000.01003.x	14	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAY	2018	472	5					877	880		10.1007/s00428-018-2327-z			4	Pathology	Pathology	GG9NI	WOS:000433027400019	29556777				2019-10-28	
J	Kim, YJ; Park, JS; Ko, K; Jeong, CR				Kim, Yong-Jin; Park, Jeong Sik; Ko, Karam; Jeong, Chang Rok			Let Archived Paraffin Blocks Be Utilized for Research with Waiver of Informed Consent	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Review						Paraffin block; Bioethics and Safety Act; Pathology research; Human biospecimen; Written consent		Advances in biomedical and genetic research have contributed to more effective public health improvement via bench-to-bed research and the emergence of personalized medicine. This has certainly showcased the importance of archived human tissues, especially paraffin-embedded blocks in pathology. Currently in Korea, undue legislative regulations of the Bioethics and Safety Act suspend and at times discourage studies from taking place. In this paper, the authors underline the value of paraffin blocks in the era of personalized and translational medicine. We discuss detailed clauses regarding the applicability of paraffin blocks from a legal perspective and compare Korea's regulations with those of other countries. The necessity for allowing waived consent and Institutional Review Board (IRB) approval will be argued throughout. The authors suggest that researchers declare the following to obtain IRB approval and waiver of informed consents: research could not be practically carried out without a waiver of consent; the proposed research presents no more than minimal risk of harm to subjects, and the waiver of consent will not adversely affect the rights and welfare of subjects; and research will not utilize a tissue block if only 1 is available for each subject, to allow future clinical use such as re-evaluation or further studies.	[Kim, Yong-Jin] Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea; [Park, Jeong Sik] Kyungpook Natl Univ, Coll Humanities, Dept Philosophy, Daegu, South Korea; [Ko, Karam] Korea Study Grp Biomed Eth, Seoul, South Korea; [Jeong, Chang Rok] Kyungpook Natl Univ, Teachers Coll, Dept Eth Educ, 80 Daehak Ro, Daegu 41566, South Korea	Jeong, CR (reprint author), Kyungpook Natl Univ, Teachers Coll, Dept Eth Educ, 80 Daehak Ro, Daegu 41566, South Korea.	canthos@hanmail.net					Dry S, 2009, LABMEDICINE, V40, P69, DOI 10.1309/LM3XP8HBKDSGICJH; Information Portal of Institutional Review Boards designated by the Ministry of Health and Welfare, 2015, 100 QUEST 100 ANSW; Lee HJ, 2015, KANGWON LAW REV, V45, P479; McDonald SA, 2010, BIOPRESERV BIOBANK, V8, P197, DOI 10.1089/bio.2010.0018; National Bioethics Advisory Committee, 2002, HUM TISS BIOM RES TU; Office for Human Research Protections, 2011, ATT D FAQS TERMS REC; Ryu YJ, 2012, J KOREAN MED ASSOC, V55, P292, DOI 10.5124/jkma.2012.55.3.292; The Royal College of Pathologists of Australasia, 2014, ETH LEG ISS REL US H; Tsutsumi H, 2014, QUESTION DOCTOR QUOT	9	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					141	147		10.4132/jptm.2018.02.07			7	Pathology	Pathology	GF6GU	WOS:000432065900001	29621880	DOAJ Gold, Green Published			2019-10-28	
J	Ku, BM; Heo, MH; Kim, JH; Cho, BC; Cho, EK; Min, YJ; Lee, KH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Kim, TJ; Lee, HY; Kim, H; Lee, KJ; Ahn, MJ				Ku, Bo Mi; Heo, Mi Hwa; Kim, Joo-Hang; Cho, Byoung Chul; Cho, Eun Kyung; Min, Young Joo; Lee, Ki Hyeong; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Kim, Tae Jung; Lee, Ho Yun; Kim, Hojoong; Lee, Kyung-Jong; Ahn, Myung-Ju			Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; non-small cell lung; Targeted next-generation sequencing; Small biopsy; Receptor; epidermal growth factor	NEEDLE-ASPIRATION SPECIMENS; TYROSINE KINASE INHIBITORS; MUTATIONS; EGFR; ADENOCARCINOMA; GENE; KRAS; FEASIBILITY; PREDICTION; RESISTANCE	Background: Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC. Methods: DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2. Results: The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study. Conclusions: These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.	[Ku, Bo Mi] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Seoul, South Korea; [Heo, Mi Hwa; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea; [Kim, Joo-Hang] CHA Univ, CHA Bundang Med Ctr, Seongnam, South Korea; [Cho, Byoung Chul] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea; [Cho, Eun Kyung] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Med Oncol, Incheon, South Korea; [Min, Young Joo] Ulsan Univ Hosp, Dept Hematol & Oncol, Div Oncol, Ulsan, South Korea; [Lee, Ki Hyeong] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Div Med Oncol, Cheongju, South Korea; [Kim, Tae Jung; Lee, Ho Yun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul, South Korea; [Kim, Tae Jung; Lee, Ho Yun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Imaging Sci, Seoul, South Korea; [Kim, Hojoong; Lee, Kyung-Jong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm & Crit Care Med, 81 Irwon Ro, Seoul 06351, South Korea	Ahn, MJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea.; Lee, KJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm & Crit Care Med, 81 Irwon Ro, Seoul 06351, South Korea.	kj2011.lee@samsung.com; silk.ahn@samsung.com			Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16 C1984]	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16 C1984).	Ballester LY, 2016, EXPERT REV MOL DIAGN, V16, P357, DOI 10.1586/14737159.2016.1133298; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205; Gleeson FC, 2015, J THORAC ONCOL, V10, P531, DOI 10.1097/JTO.0000000000000391; Glubb DM, 2011, CLIN CANCER RES, V17, P5257, DOI 10.1158/1078-0432.CCR-11-0379; Han JY, 2014, LUNG CANCER, V85, P161, DOI 10.1016/j.lungcan.2014.04.009; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jung KW, 2016, CANCER RES TREAT, V48, P451, DOI 10.4143/crt.2016.092; Karachaliou N, 2013, CLIN LUNG CANCER, V14, P205, DOI 10.1016/j.cllc.2012.09.007; Kim HJ, 2012, LUNG CANCER, V75, P321, DOI 10.1016/j.lungcan.2011.08.005; Kim HR, 2014, LUNG CANCER, V83, P374, DOI 10.1016/j.lungcan.2013.12.011; Kim ST, 2015, ONCOTARGET, V6, P33358, DOI 10.18632/oncotarget.5188; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Ku BM, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0299-6; Kuan FC, 2015, BRIT J CANCER, V113, P1519, DOI 10.1038/bjc.2015.356; Lee GD, 2017, J THORAC ONCOL, V12, P1233, DOI 10.1016/j.jtho.2017.04.031; Lim EH, 2009, J THORAC ONCOL, V4, P12, DOI 10.1097/JTO.0b013e3181913e28; Lim SM, 2016, ONCOTARGET, V7, P36311, DOI 10.18632/oncotarget.8904; Maki-Nevala S, 2016, LUNG CANCER, V99, P102, DOI 10.1016/j.lungcan.2016.06.024; Murakami I, 2000, CLIN CANCER RES, V6, P526; Padmanabhan V, 2017, ARCH PATHOL LAB MED, V141, P402, DOI 10.5858/arpa.2016-0096-OA; Pecuchet N, 2017, ONCOTARGET, V8, P23831, DOI 10.18632/oncotarget.6379; Rathi V, 2017, PATHOLOGY, V49, P75, DOI 10.1016/j.pathol.2016.08.016; Richer AL, 2015, PHARMACOGEN PERS MED, V8, P63, DOI 10.2147/PGPM.S52845; Roberts PJ, 2013, J CLIN ONCOL, V31, P1112, DOI 10.1200/JCO.2012.43.0454; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Silva IP, 2016, CLIN CANCER RES, V22, P2377, DOI 10.1158/1078-0432.CCR-15-1811; Zheng G, 2016, AM J CLIN PATHOL, V145, P696, DOI [10.1093/AJCP/AQW043, 10.1093/ajcp/aqw043]	30	5	5	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					148	156		10.4132/jptm.2018.03.12			9	Pathology	Pathology	GF6GU	WOS:000432065900002	29575851	DOAJ Gold, Green Published			2019-10-28	
J	Kwon, JH; Jeong, BK; Yoon, YS; Yu, CS; Kim, J				Kwon, Jeong-Hwa; Jeong, Byung-Kwan; Yoon, Yong Sik; Yu, Chang Sik; Kim, Jihun			Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Colorectal neoplasms; BRAF mutation; Immunohistochemistry; DNA sequencing	MICROSATELLITE INSTABILITY; ANTIBODY; CARCINOMA; SPECIMENS; COLON; KRAS	Background: BRAF mutation has been recognized as an important biomarker of colorectal cancer (CRC) for targeted therapy and prognosis prediction. However, sequencing for every CRC case is not cost-effective. An antibody specific for BRAF V600E mutant protein has been introduced, and we thus examined the utility of BRAF VE1 immunohistochemistry for evaluating BRAF mutations in CRC. Methods: Fifty-one BRAF-mutated CRCs and 100 age and sex-matched BRAF wild-type CRCs between 2005 and 2015 were selected from the archives of Asan Medical Center. Tissue microarrays were constructed and stained with BRAF VE1 antibody. Results: Forty-nine of the 51 BRAF-mutant CRCs (96.1%) showed more than moderate cytoplasmic staining, except for two weakly stained cases. Six of 100 BRAF wild-type cases also stained positive with BRAF VE1 antibody; four stained weakly and two stained moderately. Normal colonic crypts showed nonspecific weak staining, and a few CRC cases exhibited moderate nuclear reactivity (3 BRAF-mutant and 10 BRAF wild-type cases). BRAF-mutated CRC patients had higher pathologic stages and worse survival than BRAF wild-type patients. Conclusions: BRAF VE1 immunohistochemistry showed high sensitivity and specificity, but occasional nonspecific staining in tumor cell nuclei and normal colonic crypts may limit their routine clinical use. Thus, BRAF VE1 immunohistochemistry may be a useful screening tool for BRAF V600E mutation in CRCs, provided that additional sequencing studies can be done to confirm the mutation in BRAF VE1 antibody-positive cases.	[Kwon, Jeong-Hwa; Jeong, Byung-Kwan; Kim, Jihun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Yoon, Yong Sik; Yu, Chang Sik] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea	Kim, J (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	jihunkim@amc.seoul.kr					Adackapara CA, 2013, HISTOPATHOLOGY, V63, P187, DOI 10.1111/his.12154; Ardekani GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047054; Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248; Bledsoe JR, 2014, AM J SURG PATHOL, V38, P1418, DOI 10.1097/PAS.0000000000000263; Boulagnon C, 2016, APPL IMMUNOHISTO M M, V24, P88, DOI 10.1097/PAI.0000000000000157; de Castro DG, 2012, BRIT J CANCER, V107, P345, DOI 10.1038/bjc.2012.259; Lang AH, 2011, J MOL DIAGN, V13, P23, DOI 10.1016/j.jmoldx.2010.11.007; Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173; Loes IM, 2015, TUMOR BIOL, V36, P1003, DOI 10.1007/s13277-014-2711-5; Mesteri I, 2014, MODERN PATHOL, V27, P135, DOI 10.1038/modpathol.2013.126; Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Qiu T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09211; Ritterhouse LL, 2015, SEMIN DIAGN PATHOL, V32, P400, DOI 10.1053/j.semdp.2015.02.010; Schafroth C, 2015, ONCOTARGET, V6, P41453, DOI 10.18632/oncotarget.6162; Shin SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176340; Zlobec I, 2010, INT J CANCER, V127, P367, DOI 10.1002/ijc.25042	17	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					157	163		10.4132/jptm.2018.03.28			7	Pathology	Pathology	GF6GU	WOS:000432065900003	29590746	DOAJ Gold, Green Published			2019-10-28	
J	Usman, HA; Hernowo, BS; Tobing, MDL; Hindritiani, R				Usman, Hermin Aminah; Hernowo, Bethy S.; Tobing, Maringan Diapari Lumban; Hindritiani, Reti			The Major Role of NF-kappa B in the Depth of Invasion on Acral Melanoma by Decreasing CD8(+) T Cells	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Acral; CD8(+) T cells; Invasion; Melanoma; NF-kappa B; PD-L1	TUMOR-INFILTRATING LYMPHOCYTES; PD-L1 EXPRESSION; CANCER; PATHWAY; IMMUNOTHERAPY; INFLAMMATION; SURVIVAL	Background: The tumor microenvironment including immune surveillance affects malignant melanoma (MM) behavior. Nuclear factor kappa B (NF-kappa B) stimulates the transcription of various genes in the nucleus and plays a role in the inflammatory process and in tumorigenesis. CD8(+) T cells have cytotoxic properties important in the elimination of tumors. However, inhibitory receptors on the cell surface will bind to programmed death-ligand 1 (PD-L1), causing CD8(+) T cells to lose their ability to initiate an immune response. This study analyzed the association of NF-kappa B and PD-L1 expression levels and CD8(+) T-cell counts with depth of invasion of acral MM, which may be a predictor of aggressiveness related to an increased risk of metastasis. Methods: A retrospective cross-sectional study was conducted in the Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital using 96 cases of acral melanoma. Immunohistochemical staining was performed on paraffin blocks using anti-NF-kappa B, -PD-L1, and -CD8 antibodies and invasion depth was measured using dotSlide-imaging software. Results: The study showed significant associations between the individual expression of NF-kappa B and PD-L1 and CD8(+) T-cell number, with MM invasion depth. NF-kappa B was found to be a confounding variable of CD8(+) T-cell number (p < .05), but not for PD-L1 expression (p = .154). Through multivariate analysis it was found that NF-kappa B had the greatest association with the depth of invasion (p < .001), whereas PD-L1 was unrelated to the depth of invasion because it depends on the number of CD8(+) T cells (p = .870). Conclusions: NF-kappa B plays a major role in acral MM invasion, by decreasing the number of CD8(+) T cells in acral MM.	[Usman, Hermin Aminah; Hernowo, Bethy S.] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Fac Med, Dept Anat Pathol, Bandung, Indonesia; [Tobing, Maringan Diapari Lumban] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Fac Med, Dept Obstet & Gynecol, Bandung, Indonesia; [Hindritiani, Reti] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Fac Med, Dept Dermatovenerol, Bandung, Indonesia	Usman, HA (reprint author), Univ Padjadjaran, Fac Med, Dept Anat Pathol, Jl Eyckman 38, Bandung, Indonesia.	hermin@unpad.ac.id					Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bommarito A, 2011, ENDOCR-RELAT CANCER, V18, P669, DOI 10.1530/ERC-11-0076; Castaneda CA, 2017, CLIN TRANSL ONCOL, V19, P1478, DOI 10.1007/s12094-017-1685-3; Chou JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099432; Dai JQ, 2013, CANCER INVEST, V31, P111, DOI 10.3109/07357907.2012.762781; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dolan DE, 2014, CANCER CONTROL, V21, P231, DOI 10.1177/107327481402100308; Frydenlund N, 2017, MODERN PATHOL, V30, P357, DOI 10.1038/modpathol.2016.210; Guarneri C, 2017, ONCOL REP, V37, P737, DOI 10.3892/or.2017.5362; Hersey P, 2013, CLIN CANCER RES, V19, P514, DOI 10.1158/1078-0432.CCR-12-3312; Jang TJ, 2013, KOREAN J PATHOL, V47, P443, DOI 10.4132/KoreanJPathol.2013.47.5.443; Kakavand H, 2015, CLIN CANCER RES, V21, P3140, DOI 10.1158/1078-0432.CCR-14-2023; Kluger HM, 2015, CLIN CANCER RES, V21, P3052, DOI 10.1158/1078-0432.CCR-14-3073; Lin Kimberly, 2010, Genes Cancer, V1, P409; Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103; Momtaz P, 2014, PHARMACOGEN PERS MED, V7, P357, DOI 10.2147/PGPM.S53163; Nguyen LK, 2015, CELL MOL LIFE SCI, V72, P2431, DOI 10.1007/s00018-015-1850-1; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Oliveira-Costa JP, 2015, ONCOTARGET, V6, P20902, DOI 10.18632/oncotarget.3939; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Qing Y, 2015, DRUG DES DEV THER, V9, P901, DOI 10.2147/DDDT.S75152; Sideras K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273309; Soliman H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088557; Song FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108507; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Thomas NE, 2013, J CLIN ONCOL, V31, P4252, DOI 10.1200/JCO.2013.51.3002; Tjin EPM, 2014, CANCER IMMUNOL RES, V2, P538, DOI 10.1158/2326-6066.CIR-13-0097; Wang YW, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0655-2; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Xue S, 2017, ONCOTARGET, V8, P49702, DOI 10.18632/oncotarget.17922; Yang G, 2011, CLIN CANCER RES, V17, P2181, DOI 10.1158/1078-0432.CCR-10-3265	32	0	1	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					164	170		10.4132/jptm.2018.04.04			7	Pathology	Pathology	GF6GU	WOS:000432065900004	29673240	DOAJ Gold, Green Published			2019-10-28	
J	Sung, YE; Lee, YS; Lee, J; Lee, KY				Sung, Yeoun Eun; Lee, Yoon Seo; Lee, Jieun; Lee, Kyo Young			Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Erdheim-Chester disease; Lymph nodes; Vertebrae; Pleura; Liver	IMATINIB MESYLATE; HISTIOCYTOSES	Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis and multisystem disease. First described in 1930, there are no more than 750 cases reported. The etiology remains unknown, but a majority of cases of ECD and Langerhans cell histiocytosis were found to have clonal mutations involving genes of the mitogen-activated protein kinase pathway. We recently encountered a 53-year-old male patient with extensive ECD involving the systemic lymph nodes, pleura, liver, and long bones clinically mimicking malignant lymphoma. Biopsies were performed at multiple sites, including a pleural mass, an external iliac lymph node, bone marrow, and the liver. Based on histopathological and immunohistochemical findings of positivity for CD68 and negativity for CD1a and S-100, the patient was diagnosed with ECD. Interferon-a was administered as the first-line treatment, but the patient rapidly progressed to hepatic failure after 2 months of treatment. We report this rare case of ECD clinically mimicking malignant lymphoma and diagnosed by careful pathological review.	[Sung, Yeoun Eun; Lee, Kyo Young] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Pathol, Seoul, South Korea; [Lee, Yoon Seo; Lee, Jieun] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Med Oncol,Dept Internal Med, Seoul, South Korea; [Lee, Jieun] Catholic Univ Korea, Canc Res Inst, Seoul, South Korea	Lee, KY (reprint author), Catholic Univ Korea, Dept Hosp Pathol, Seoul St Marys Hosp, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.	leekyoyo@catholic.ac.kr		Sung, Yeoun Eun/0000-0002-9408-0085			Arnaud L, 2011, BLOOD, V117, P2778, DOI 10.1182/blood-2010-06-294108; Bindra J, 2014, SKELETAL RADIOL, V43, P835, DOI 10.1007/s00256-013-1793-2; Disease EC, 2015, EUR J INTERN MED, V26, P223, DOI 10.1016/j.ejim.2015.03.004; Cha YJ, 2012, KOREAN J PATHOL, V46, P489, DOI 10.4132/KoreanJPathol.2012.46.5.489; Cohen-Aubart F, 2016, BLOOD, V127, P1509, DOI 10.1182/blood-2015-09-672667; Diamond EL, 2014, BLOOD, V124, P483, DOI 10.1182/blood-2014-03-561381; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Emile JF, 2014, BLOOD, V124, P3016, DOI 10.1182/blood-2014-04-570937; Haroche J, 2008, BLOOD, V111, P5413, DOI 10.1182/blood-2008-03-148304; Haroche J, 2007, PRESSE MED, V36, P1663, DOI 10.1016/j.lpm.2007.04.032; Haroche J, 2017, LANCET ONCOL, V18, pE113, DOI 10.1016/S1470-2045(17)30031-1; Hervier B, 2014, BLOOD, V124, P1119, DOI 10.1182/blood-2013-12-543793; Ivan D, 2003, ARCH PATHOL LAB MED, V127, P337; Janku F, 2010, J CLIN ONCOL, V28, pE633, DOI 10.1200/JCO.2010.29.9073; Lim J, 2016, CANCER RES TREAT, V48, P415, DOI 10.4143/crt.2014.160; Munoz J, 2014, MAYO CLIN PROC, V89, P985, DOI 10.1016/j.mayocp.2014.01.023; Nordmann TM, 2017, BLOOD, V129, P879, DOI 10.1182/blood-2016-09-740217; Pavlidakey PG, 2011, CASE REP HEMATOL, DOI 10.1155/2011/941637; Sheu SY, 2004, J CLIN PATHOL, V57, P1225, DOI 10.1136/jcp.2004.018481; Tzoulis Charalampos, 2015, BMC Res Notes, V8, P171, DOI 10.1186/s13104-015-1135-7	20	2	2	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					183	190		10.4132/jptm.2017.10.16			8	Pathology	Pathology	GF6GU	WOS:000432065900007	29281781	DOAJ Gold, Green Published			2019-10-28	
J	Kim, NR; Cho, HY; Chung, DH; Kim, KK; Cho, JH; Choi, SJ				Kim, Na Rae; Cho, Hyun Yee; Chung, Dong Hae; Kim, Keon Kuk; Cho, Jae Hee; Choi, Seung Joon			Post-transplant Amputation Traumatic Neuroma of the Hilum and Extrahepatic Duct in a Liver Donor	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							TRANSPLANTATION; OBSTRUCTION	Traumatic neuromas develop after injury to nerve fibers encased in Schwann cells. They occur mainly in the amputated stump of the extremities.(1) Biliary traumatic neuroma was first described in 1928 by Husseinoff.(2) Since then, less than 100 cases of biliary traumatic neuroma have been reported.(3,4) Most occur at the cystic duct stump after cholecystectomy. It may also occur in the main biliary tract following any injury, even liver transplantation.(5,6) Herein, we report a case of post-transplant biliary traumatic neuroma in a donor after an 8-year interval. This rare biliary traumatic neuroma may be a risk factor for liver transplantation-related biliary stricture.	[Kim, Na Rae; Cho, Hyun Yee; Chung, Dong Hae] Gachon Univ, Gil Med Ctr, Dept Pathol, 21 Namdong Daero 774beon Gil, Incheon 21565, South Korea; [Kim, Keon Kuk] Gachon Univ, Gil Med Ctr, Dept Gen Surg, Incheon, South Korea; [Cho, Jae Hee] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Gastroenterol, Incheon, South Korea; [Choi, Seung Joon] Gachon Univ, Gil Med Ctr, Dept Radiol, Incheon, South Korea	Chung, DH (reprint author), Gachon Univ, Gil Med Ctr, Dept Pathol, 21 Namdong Daero 774beon Gil, Incheon 21565, South Korea.	dhchung@gilhospital.com					COLINA F, 1994, HISTOPATHOLOGY, V25, P151, DOI 10.1111/j.1365-2559.1994.tb01571.x; Ghobrial RM, 2008, GASTROENTEROLOGY, V135, P468, DOI 10.1053/j.gastro.2008.04.018; Husseinoff D., 1928, ZBL ALLG PATH, V43, P344; Iannelli A, 2003, ACTA GASTRO-ENT BELG, V66, P28; Jeon H, 2010, CURR OPIN ORGAN TRAN, V15, P283, DOI 10.1097/MOT.0b013e32833983ee; Lee SG, 2010, BRIT MED BULL, V94, P33, DOI 10.1093/bmb/ldq003; Navez J, 2016, CLIN TRANSPLANT, V30, P1366, DOI 10.1111/ctr.12802; Necmioglu S, 2004, PROSTHET ORTHOT INT, V28, P37; Pickens A, 1999, AM SURGEON, V65, P47; Sosa I, 2005, EXP NEUROL, V195, P7, DOI 10.1016/j.expneurol.2005.04.016	10	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					191	194		10.4132/jptm.2017.01.20			4	Pathology	Pathology	GF6GU	WOS:000432065900008	28774160	DOAJ Gold, Green Published			2019-10-28	
J	Cho, WC; Balarezo, F				Cho, Woo Cheal; Balarezo, Fabiola			Expression of CD34 and beta-Catenin in Malignant Rhabdoid Tumor of the Liver Mimicking Proximal-Type Epithelioid Sarcoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article								Malignant rhabdoid tumor (MRT) is a rare, aggressive malignant neoplasm often arising in the kidney in infants or young children. MRT was first described in 1978 as a rhabdomyosarcomatoid variant of Wilms tumor with unfavorable prognosis due to its morphologic resemblance to rhabdomyoblasts.(1) Since the first description outside the kidney, MRTs have been described in almost every conceivable location in the body, including the central nervous system where it is commonly referred to as atypical teratoid/rhabdoid tumor.(2) Involvement of the liver, however, is still exceedingly rare, with only fewer than 60 cases of primary MRT arising in the liver reported in the literature. Herein, we describe a rare case of MRT of the liver in a 1-year-old male infant with CD34 and beta-catenin expression mimicking proximal-type epithelioid sarcoma (ES).	[Cho, Woo Cheal; Balarezo, Fabiola] Hartford Hosp, Dept Pathol & Lab Med, 80 Seymour St, Hartford, CT 06102 USA	Cho, WC (reprint author), Hartford Hosp, Dept Pathol & Lab Med, 80 Seymour St, Hartford, CT 06102 USA.	woocheal.cho@hhchealth.org	Cho, Woo Cheal/R-2872-2019	Cho, Woo Cheal/0000-0001-5867-1403			Armah HB, 2009, ARCH PATHOL LAB MED, V133, P814, DOI 10.1043/1543-2165-133.5.814; BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Oda Y, 2006, PATHOL INT, V56, P287, DOI 10.1111/j.1440-1827.2006.01962.x; Oita S, 2015, PEDIATRIC REP, V7, DOI 10.4081/pr.2015.5578; Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056; Vokuhl C, 2016, GENE CHROMOSOME CANC, V55, P925, DOI 10.1002/gcc.22390	7	1	1	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					195	197		10.4132/jptm.2017.05.15			3	Pathology	Pathology	GF6GU	WOS:000432065900009	28683521	DOAJ Gold, Green Published			2019-10-28	
J	Lim, S; Shim, MK; Cho, EY; Cho, SY				Lim, Sharon; Shim, Min Keun; Cho, Eun Yoon; Cho, Soo Youn			Secretory Carcinoma Arising in a Fibroadenoma: A Brief Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							BREAST-CARCINOMA; CANCER; FUSION	Secretory carcinoma is a rare subtype of breast cancer, accounting for less than 0.1% of invasive breast cancers.(1) It is characterized by distinctive intracellular and extracellular secretory material in solid, microcystic, and tubular growth patterns. Recently, we experienced this rare tumor arising in a fibroad-enoma (FA). Ductal epithelium within FA can undergo carcinomatous change. There have been several case reports of carcinoma arising in FA, usually in forms of lobular or ductal carcinoma in situ.(2-4) However, there has been no reported case of secretory carcinoma arising in a FA.	[Lim, Sharon] Hanyang Univ, Dept Pathol, Guri Hosp, Coll Med, Guri, South Korea; [Shim, Min Keun] Foryou Pathol Lab, Gwangju, South Korea; [Cho, Eun Yoon; Cho, Soo Youn] Sungkyunkwan Univ, Coll Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea	Cho, SY (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 06351, South Korea.	sooyoun.cho@samsung.com					Chintamani, 2009, Cases J, V2, P9348, DOI 10.1186/1757-1626-2-9348; DIAZ NM, 1991, AM J CLIN PATHOL, V95, P614, DOI 10.1093/ajcp/95.5.614; Horowitz DP, 2012, BREAST, V21, P350, DOI 10.1016/j.breast.2012.02.013; Jacob JD, 2016, J SURG ONCOL, V113, P721, DOI 10.1002/jso.24241; Lae M, 2009, MODERN PATHOL, V22, P291, DOI 10.1038/modpathol.2008.184; MCDIVITT RW, 1966, J AMER MED ASSOC, V195, P388, DOI 10.1001/jama.195.5.388; TAVASSOLI FA, 1980, CANCER, V45, P2404, DOI 10.1002/1097-0142(19800501)45:9<2404::AID-CNCR2820450928>3.0.CO;2-8; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Vasudev P, 2011, ARCH PATHOL LAB MED, V135, P1606, DOI 10.5858/arpa.2010-0351-RS; Wu YT, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-335	10	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					198	201		10.4132/jptm.2017.08.01			4	Pathology	Pathology	GF6GU	WOS:000432065900010	28994273	DOAJ Gold, Green Published			2019-10-28	
J	Go, JH				Go, Jai-Hyang			Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							MULTIPLE-MYELOMA; PLASMABLASTIC LYMPHOMA; DIAGNOSTIC PITFALL; FEATURES	Aberrant expression of CD3 is extremely rare in plasma cell neoplasm (PCN), and only a few cases have been reported. 1-6 Moreover, no studies have compared the expression pattern of CD3 between initial tumor and recurrent tumor in PCN. Herein, we describe an unusual case of PCN, which initially presented as CD3-negative plasmacytoma but exhibited aberrant CD3 expression at relapse. The tumor cells in both the initial tumor and relapsed tumor were positive for Epstein-Barr virus (EBV)-encoded RNA (EBER) in situ hybridization (ISH).	[Go, Jai-Hyang] Dankook Univ, Coll Med, Dept Pathol, 119 Dandae Ro, Cheonan 31116, South Korea	Go, JH (reprint author), Dankook Univ, Coll Med, Dept Pathol, 119 Dandae Ro, Cheonan 31116, South Korea.	cyjy555@hanmail.net					Gorczyca W, 2014, ATLAS DIFFERENTIAL D, P359; Luo XD, 2016, PATHOLOGY, V48, P378, DOI 10.1016/j.pathol.2016.02.019; Mishra P, 2017, ACTA CLIN BELG, V72, P250, DOI 10.1080/17843286.2016.1201629; Oliveira JL, 2012, AM J SURG PATHOL, V36, P1364, DOI 10.1097/PAS.0b013e31825e63a9; SPIER CM, 1990, MODERN PATHOL, V3, P302; Sun JL, 2011, PATHOLOGY, V43, P54, DOI 10.1097/PAT.0b013e328340bbba; Taddesse-Heath L, 2010, MODERN PATHOL, V23, P991, DOI 10.1038/modpathol.2010.72; Tang YL, 2012, PATHOLOGY, V44, P668, DOI 10.1097/PAT.0b013e328359fba6; Vega F, 2005, MODERN PATHOL, V18, P806, DOI 10.1038/modpathol.3800355; Yagci M, 2002, ACTA HAEMATOL-BASEL, V107, P38, DOI 10.1159/000046628	10	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAY	2018	52	3					202	205		10.4132/jptm.2017.09.05			4	Pathology	Pathology	GF6GU	WOS:000432065900011	29268594	DOAJ Gold, Green Published			2019-10-28	
J	Haroske, G; Zwonitzer, R; Hufnagl, P				Haroeske, G.; Zwoenitzer, R.; Hufnagl, P.		Komm Digitale Pathologie	"Digital Pathology in Diagnostics" guideline. Reporting on digital images	PATHOLOGE			German	Article						Computer-assisted image interpretation; Microscopy; Pathology; Reproducibility of results; Workflow		Background. The digitization of medicine is gaining momentum in pathology. Long-known technologies have reached such a degree of maturity that their use in primary diagnostics in routine pathology will be possible. In spite of the complexity of technological solutions and the far-reaching consequences in terms of diagnostic reliability, as well as due to the high investments, the decision for a specific product may become highly sophisticated for a pathologist. Aim. An implementation guide for Digital Diagnostics in Pathology is presented to describe technical and legal conditions for making this new technology feasible for the single pathologist. Results and discussion. For more than two years, the Digital Pathology Commission of the Federal Association of German Pathologists developed and discussed this implementation guide for digital diagnostics, especially for the use of virtual microscopy in the daily pathology routine in Germany. The key is the principal comparability of diagnostic reliability between conventional stained microscopic slides and their digital images, which have to be shown by the potential user. In eight chapters, the validation procedure as well as technical minimum requirements in slide scanners, the visualization pipeline, archiving, and integration in the pathology workflow are described.	[Haroeske, G.] Bundesverband Deutsch Pathologen eV, Kommiss Digitale Pathol, Robert Koch Pl 9, D-10115 Berlin, Germany; [Zwoenitzer, R.] Imassense GmbH, Berlin, Germany; [Hufnagl, P.] Charite, Inst Pathol, Berlin, Germany	Haroske, G (reprint author), Bundesverband Deutsch Pathologen eV, Kommiss Digitale Pathol, Robert Koch Pl 9, D-10115 Berlin, Germany.	haroske@icloud.com					Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Hufnagl P, 2018, LEITFADEN DIGITALE P; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Kayser G, 2012, PATHOLOGE S1, V33, P177; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP	5	2	2	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					216	221		10.1007/s00292-018-0433-y			6	Pathology	Pathology	GF0UY	WOS:000431647800002	29623403				2019-10-28	
J	Hufnagl, P; Lohmann, S; Schluns, K; Zerbe, N				Hufnagl, P.; Lohmann, S.; Schluens, K.; Zerbe, N.			Implementation of the "Digital Pathology in Diagnostics" guideline. Support systems and their functionality	PATHOLOGE			German	Article						Benchmarking; Computer-assisted diagnostics; Microscopy; Calibration; Validation studies		Background. The "Digital Pathology in Diagnostics - Assessment of Digital Images" guideline describes the technical and legal framework under which the use of this digital technology is justifiable for the individual pathologist. The focus is on conducting a validation study, defining minimum requirements for the generation and management of whole slide images, and ensuring the functionality and quality of the virtual microscopy solution used. By establishing a special web-based service, supportive services can be provided to assist the pathologist in the introduction of virtual microscopy and quality assurance. Aim. Presentation of the Digitale-Pathologie. de server and description of its services in the context of the guideline. Results and discussion. In the context of several scanner contests at the Charite in Berlin, as well as with the introduction of virtual microscopy in practice, many experiences were collected, which will be presented systematically. Essentially, this will provide support for the application of the guideline in practice. The following fields are discussed: implementation of the guideline recommendations, planning and evaluation of the validation study, and ensuring the correct color calibration of the slide scanner being used. Via the Digitale-Pathologie. de server, the possibility for self-monitoring and anonymously benchmarking will be offered. For example, errors in setup can be detected quickly and optimal settings can be identified.	[Hufnagl, P.; Lohmann, S.; Schluens, K.; Zerbe, N.] Charite, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany	Hufnagl, P (reprint author), Charite, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany.	peter.hufnagl@charite.de					Haroske G, 2018, PATHOLOGE, V39, P216, DOI 10.1007/s00292-018-0433-y; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Sharma G, 2005, COLOR RES APPL, V30, P21, DOI 10.1002/col.20070; Shrestha P, 2014, J MED IMAGING, V1, DOI 10.1117/1.JMI.1.2.027501	5	1	1	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					222	227		10.1007/s00292-018-0436-8			6	Pathology	Pathology	GF0UY	WOS:000431647800003	29704046				2019-10-28	
J	Grobholz, R				Grobholz, R.			Digital pathology. The time has come!	PATHOLOGE			German	Article						Automatic data processing; Computer-assisted image interpretation; Informatics; Pathology; Workflow		Background. Digital pathology (DP) and whole-slide imaging (WSI) technology have matured substantially over the last few years. Meanwhile, commercial systems are available that can be used in routine practice. Aims. Illustration of DP experiences in a routine diagnostic setting. Results and Conclusions. A DP system offers several advantages: 1) glass slides are no longer unique; 2) access to cases is possible from any location; 3) digital image analysis can be applied; and 4) archived WSI can be easily accessed. From this point, several secondary advantages arise: a) the slide compilation of the case and the case assignment is fast and safe; b) carrying cases to the pathologist is obsolete and paperless work is possible; c) WSI can be used for a second opinion and be accessible in remote locations; d) WSI of referred cases are still accessible after returning the slides; e) histological images can easily be provided in tumor boards; f) the office desk is clean; and g) a "home office" is possible. To introduce a DP system, a comprehensive workflow analysis is needed that clarifies the needs and wishes of the respective institute. In order to optimally meet the requirements, open DP platforms are of particular advantage, because they enable the integration of scanners from various manufacturers. Further developments in image analysis, such as virtual tissue reconstruction, could enrich the diagnostic process in the future and improve treatment quality.	[Grobholz, R.] Kantonsspital Aarau, Inst Pathol, Tellstr 25, CH-5001 Aarau, Switzerland; [Grobholz, R.] Univ Zurich, Med Fak, Zurich, Switzerland	Grobholz, R (reprint author), Kantonsspital Aarau, Inst Pathol, Tellstr 25, CH-5001 Aarau, Switzerland.	Rainer.Grobholz@ksa.ch					Cheng CL, 2017, J CLIN PATHOL, V70, P454, DOI 10.1136/jclinpath-2016-204272; Cheng CL, 2016, J CLIN PATHOL, V69, P784, DOI 10.1136/jclinpath-2015-203600; Fisher BA, 2017, ANN RHEUM DIS, V76, P1161, DOI 10.1136/annrheumdis-2016-210448; Fraggetta Filippo, 2017, J Pathol Inform, V8, P51, DOI 10.4103/jpi.jpi_58_17; Grobholz R, 2017, MANAG KRANKENH, V36, P25; Grobholz R, 2017, TRILLIUM DIAGN, V15, P100; Hufnagl P, 2018, LEITFADEN DIGITALE P; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP	8	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					228	235		10.1007/s00292-018-0431-0			8	Pathology	Pathology	GF0UY	WOS:000431647800004	29691675				2019-10-28	
J	Warth, A; Fink, L				Warth, A.; Fink, L.			Aerogenic tumor seeding. A new invasive criterion for lung carcinomas	PATHOLOGE			German	Article						Airborne tumor dissemination; Lung cancer; Pulmonary adenocarcinoma; STAS; Spread through air spaces	AIR SPACES STAS; SQUAMOUS-CELL CARCINOMA; CANCER RESECTION SPECIMENS; PULMONARY ADENOCARCINOMA; PROGNOSTIC IMPACT; SEMIQUANTITATIVE ASSESSMENT; LIMITED RESECTION; SPREAD; RECURRENCE; PATTERNS	The new concept of spread through air spaces (STAS) was introduced for pulmonary adenocarcinomas in the 2015 WHO classification for lung cancer. Yet, available data demonstrate that STAS is of high prognostic impact and associated with specific clinic-pathological characteristics. This article provides a comprehensive overview of recent developments in this field.	[Warth, A.; Fink, L.] UGP MVZ, Inst Pathol Zytol & Mol Pathol Giessen Wetzlar Li, Forsthausstr 1, D-35578 Wetzlar, Germany	Warth, A (reprint author), UGP MVZ, Inst Pathol Zytol & Mol Pathol Giessen Wetzlar Li, Forsthausstr 1, D-35578 Wetzlar, Germany.	warth@patho-uegp.de					Bains S, 2017, J THORAC ONCOL, V12, pS766; Bittar HET, 2015, MODERN PATHOL, V28, P1058, DOI 10.1038/modpathol.2015.71; Blaauwgeers H, 2017, J THORAC ONCOL, V12, pS1123; Blaauwgeers H, 2017, AM J SURG PATHOL, V41, P1226, DOI 10.1097/PAS.0000000000000889; CLAYTON F, 1986, CANCER, V57, P1555, DOI 10.1002/1097-0142(19860415)57:8<1555::AID-CNCR2820570820>3.0.CO;2-N; Dai CY, 2017, J THORAC ONCOL, V12, P1052, DOI 10.1016/j.jtho.2017.03.020; Eguchi T, 2017, J THORAC ONCOL, V12, pS270; Flechsig P, 2015, CLIN IMAG, V39, P56, DOI 10.1016/j.clinimag.2014.10.005; Isaka T, 2017, PATHOL INT, V67, P487, DOI 10.1111/pin.12570; Kadota K, 2017, AM J SURG PATHOL, V41, P1077, DOI 10.1097/PAS.0000000000000872; Kadota K, 2015, J THORAC ONCOL, V10, P806, DOI 10.1097/JTO.0000000000000486; Kadota K, 2014, J THORAC ONCOL, V9, P1126, DOI 10.1097/JTO.0000000000000253; Kameda K, 2017, J THORAC ONCOL, V12, pS411; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; Lu SH, 2017, J THORAC ONCOL, V12, pS1137; Lu SH, 2017, J THORAC ONCOL, V12, P223, DOI 10.1016/j.jtho.2016.09.129; Masai K, 2017, J THORAC ONCOL, V12, P1788, DOI 10.1016/j.jtho.2017.08.015; Masuda R, 2012, MOL MED REP, V6, P937, DOI 10.3892/mmr.2012.1048; Morales-Oyarvide V, 2016, PATHOL INT, V66, P1, DOI 10.1111/pin.12368; Morimoto J, 2016, J THORAC CARDIOV SUR, V152, P64, DOI 10.1016/j.jtcvs.2016.03.088; Nakajima T, 2014, ANN THORAC SURG, V97, P1771, DOI 10.1016/j.athoracsur.2014.01.048; Onozato ML, 2013, AM J SURG PATHOL, V37, P287, DOI 10.1097/PAS.0b013e31826885fb; Onozato ML, 2012, ANAL CELL PATHOL, V35, P79, DOI 10.3233/ACP-2011-0030; Shiono S, 2005, ANN THORAC SURG, V80, P1040, DOI 10.1016/j.athoracsur.2004.12.033; Shiono S, 2005, ANN THORAC SURG, V79, P278, DOI 10.1016/j.athoracsur.2004.06.096; Shiono S, 2016, INTERACT CARDIOV TH, V23, P567, DOI 10.1093/icvts/ivw211; Thunnissen E, 2016, ARCH PATHOL LAB MED, V140, P212, DOI 10.5858/arpa.2015-0292-OA; Uruga H, 2017, J THORAC ONCOL, V12, P1046, DOI 10.1016/j.jtho.2017.03.019; Walts AE, 2018, ARCH PATHOL LAB MED, V142, P59, DOI 10.5858/arpa.2016-0635-OA; Warth A, 2017, CANCER RES, V6, P501; Warth A, 2017, J THORAC DIS, V9, P1792, DOI 10.21037/jtd.2017.06.53; Warth A, 2017, J THORAC ONCOL, V12, P176, DOI 10.1016/j.jtho.2016.10.020; Warth A, 2016, AM J SURG PATHOL, V40, P818, DOI 10.1097/PAS.0000000000000622; Warth A, 2015, AM J SURG PATHOL, V39, P793, DOI 10.1097/PAS.0000000000000409; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; Yanagawa N, 2017, J THORAC ONCOL, V12, pS1119; Yeh YC, 2015, HISTOPATHOLOGY, V66, P922, DOI 10.1111/his.12468; Zhao Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001634	38	0	0	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					236	241		10.1007/s00292-018-0429-7			6	Pathology	Pathology	GF0UY	WOS:000431647800005	29523927				2019-10-28	
J	Abraham, L; Kreipe, H; Raab, P; Hussein, K				Abraham, L.; Kreipe, H.; Raab, P.; Hussein, K.			Clinical and pathological characteristics of intravascular lymphomas	PATHOLOGE			German	Article						Intravascular lymphoma; Histology; Immunohistochemistry; Neuroradiology	B-CELL LYMPHOMA; T-CELL; CYTOTOXIC PHENOTYPE; CXCR4 EXPRESSION; NATURAL-HISTORY; ASIAN VARIANT; VIRUS; MANIFESTATIONS; PRESENTATIONS; CHEMOTHERAPY	Intravascular B-cell lymphomas (IVL) are rare neoplasms that can manifest at any age (mean age similar to 62-63 years). About half of the cases are associated with Epstein-Barr virus. The most common sites of manifestation are the brain, skin, and bone marrow. The diagnosis is difficult due to unspecific clinical presentation and laboratory changes. FACS (fluorescence-activated cell sorting) and clonality analysis from peripheral blood and radiological findings are often not diagnostic. The most sensitive and most specific diagnostic method is the histopathological and immunohistochemical evaluation of a tissue biopsy. Because of the rarity of this disease, little is known about therapy and prognosis, whereby therapy is mainly similar to non-IVL lymphomas. The prognosis is poor; median survival after diagnosis is approximately one year.	[Abraham, L.; Kreipe, H.; Hussein, K.] Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Raab, P.] Hannover Med Sch, Inst Diagnost & Intervent Neuroradiol, Hannover, Germany	Hussein, K (reprint author), Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Hussein.Kais@mh-hannover.de					Au WY, 1997, HISTOPATHOLOGY, V31, P563, DOI 10.1046/j.1365-2559.1997.3050903.x; Bauer WM, 2018, BRIT J DERMATOL, V178, P215, DOI 10.1111/bjd.15841; Bi YL, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0336-7; Brunet V, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005985; Cerroni L, 2008, AM J SURG PATHOL, V32A, P891, DOI 10.1097/PAS.0b013e31815d29c9; Colavolpe C, 2015, HEMATOL ONCOL, V33, P99, DOI 10.1002/hon.2140; Crane GM, 2014, AM J SURG PATHOL, V38, P426, DOI 10.1097/PAS.0000000000000128; Ferreri AJM, 2004, ANN ONCOL, V15, P1215, DOI 10.1093/annonc/mdh274; Ferreri AJM, 2004, BRIT J HAEMATOL, V127, P173, DOI 10.1111/j.1365-2141.2004.05177.x; Ferry JA, 2009, MOL PATHOL, V34, P1608; Fonkem E, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0509-8; Fonkem E, 2014, CANCER MED-US, V3, P1010, DOI 10.1002/cam4.269; GLASS J, 1993, CANCER-AM CANCER SOC, V71, P3156, DOI 10.1002/1097-0142(19930515)71:10<3156::AID-CNCR2820711043>3.0.CO;2-O; Ha JM, 2014, CANCER RES TREAT, V46, P307, DOI 10.4143/crt.2014.46.3.307; Heinrich A, 2005, EUR NEUROL, V54, P55, DOI 10.1159/000087719; Hsiao CH, 1999, AM J SURG PATHOL, V23, P482, DOI 10.1097/00000478-199904000-00015; Moreno MJ, 2015, J PATHOL, V235, P445, DOI 10.1002/path.4446; Kambara Rumi, 2015, Nihon Jibiinkoka Gakkai Kaiho, V118, P770; Kato M, 2009, J AM ACAD DERMATOL, V61, P888, DOI 10.1016/j.jaad.2009.02.007; Keszei M, 2014, J IMMUNOL RES, DOI 10.1155/2014/303782; Khalidi HS, 1998, MODERN PATHOL, V11, P983; Kim MJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006925; Momota H, 2012, NAGOYA J MED SCI, V74, P353; Murase T, 2000, BRIT J HAEMATOL, V111, P826; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Nakajima S, 2010, ARCH DERMATOL, V146, P686, DOI 10.1001/archdermatol.2010.113; Nakamura S, 2017, WHO CLASSIFICATION T, pS317; Ozsan N, 2014, TURK J HEMATOL, V31, P403, DOI 10.4274/tjh.2013.0090; Patel SS, 2014, LABMEDICINE, V45, P248, DOI 10.1309/LMSVEOKLN18M5XTV; PFLEGER L, 1959, Hautarzt, V10, P359; Ponzoni M, 2000, HUM PATHOL, V31, P220, DOI 10.1016/S0046-8177(00)80223-3; Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313; Ponzoni M, 2006, HEMATOL ONCOL, V24, P105, DOI 10.1002/hon.776; Sawahara Hiroaki, 2017, Nihon Shokakibyo Gakkai Zasshi, V114, P1446, DOI 10.11405/nisshoshi.114.1446; Sharma TL, 2017, NEUROPATHOLOGY, V37, P365, DOI 10.1111/neup.12376; SHEIBANI K, 1986, NEW ENGL J MED, V314, P943, DOI 10.1056/NEJM198604103141502; Shimada K, 2008, J CLIN ONCOL, V26, P3189, DOI 10.1200/JCO.2007.15.4278; SHIMOKAWA I, 1991, HUM PATHOL, V22, P200, DOI 10.1016/0046-8177(91)90044-P; Shinkawa Y, 2016, MOD RHEUMATOL, V11, P1; Souza CA, 2009, J THORAC IMAG, V24, P231, DOI 10.1097/RTI.0b013e31819724d9; STROUP RM, 1990, CANCER, V66, P1781, DOI 10.1002/1097-0142(19901015)66:8<1781::AID-CNCR2820660824>3.0.CO;2-5; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Wang JC, 2017, INT J SURG PATHOL, V25, P118, DOI 10.1177/1066896916665203; Williams RL, 1998, AM J NEURORADIOL, V19, P427; Wong SWJ, 2004, LEUKEMIA LYMPHOMA, V45, P2491, DOI 10.1080/10428190410001723449; Yamamoto A, 2012, AM J NEURORADIOL, V33, P292, DOI 10.3174/ajnr.A2770; Yoshikawa S, 2002, INTERNAL MED, V41, P1215, DOI 10.2169/internalmedicine.41.1215	47	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					242	248		10.1007/s00292-018-0427-9			7	Pathology	Pathology	GF0UY	WOS:000431647800006	29541829				2019-10-28	
J	Synoracki, S; Kathemann, S; Schmid, KW; Jastrow, H; Baba, HA				Synoracki, S.; Kathemann, S.; Schmid, K. W.; Jastrow, H.; Baba, H. A.			Lysosomal acid lipase deficiency (LAL-D). Diagnostic and therapeutic options in an underdiagnosed disease	PATHOLOGE			German	Article						Liver cirrhosis; Lysosomal acid lipase deficiency; Non-alcoholic fatty liver disease; Sebelipase alfa; Wolman disease	ESTER STORAGE DISEASE; SEBELIPASE ALPHA	Background and clinical setting. Lysosomal acid lipase deficiency is an autosomal recessive storage disease caused by mutations in the LIPA gene. The accumulation of cholesteryl esters and triglycerides in hepatocytes lead to hepatomegaly with progressive fibrosis and liver cirrhosis. Characteristically, patients have a hepatomegaly combined with high serum levels of cholesterol, LDL-cholesterol and in some cases triglyceride, whereas HDL-cholesterol is decreased. Histologically, hepatocytes show a microvesicular steatosis with typically ballooned Kupffer cells. Even though histological morphology is typical, it is not characteristic. Therefore LAL-D is supposed to be an underdiagnosed disease with a high number of unreported cases misdiagnosed as uncharacteristic fatty liver disease (NASH, NAFLD, cryptogenic liver cirrhosis). Further, there is overlap with other storage diseases, complicating a correct diagnosis. Therapy. Until recently, different therapeutic options could not prevent development of liver cirrhosis. Patients with Wolman's disease have an especially rapid progression and die within the first six months of life. With the recent development of a new enzyme replacement therapy with sebelipase alfa (Kanuma (R)), new therapeutic options with significant improvement of dyslipidemia and reduction of transaminases have become reality. Positive clinical results seem to have the potential to significantly raise life expectancy. Conclusion. These new therapeutic options warrant an increase in awareness of LAL-D by clinicians and pathologists. Correct diagnosis of LAL-D is important for effective therapy and long-term survival.	[Synoracki, S.; Schmid, K. W.; Baba, H. A.] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany; [Kathemann, S.] Univ Duisburg Essen, Univ Klinikum Essen, Klin Kinderheilkunde 2, Essen, Germany; [Jastrow, H.] Univ Duisburg Essen, Univ Klinikum Essen, Imaging Ctr Essen, Essen, Germany	Synoracki, S (reprint author), Univ Duisburg Essen, Univ Klinikum Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.	sarah.synoracki@uk-essen.de					Bernstein DL, 2013, J HEPATOL, V58, P1230, DOI 10.1016/j.jhep.2013.02.014; Boldrini R, 2004, PATHOL RES PRACT, V200, P231, DOI 10.1016/j.prp.2003.11.001; Burton BK, 2015, NEW ENGL J MED, V373, P1010, DOI 10.1056/NEJMoa1501365; Chora JR, 2017, J CLIN LIPIDOL, V11, P477, DOI 10.1016/j.jacl.2016.11.002; Drebber U, 2005, WORLD J GASTROENTERO, V11, P2364, DOI 10.3748/wjg.v11.i15.2364; Erwin AL, 2017, THER ADV GASTROENTER, V10, P553, DOI 10.1177/1756283X17705775; Frampton JE, 2016, AM J CARDIOVASC DRUG, V16, P461, DOI 10.1007/s40256-016-0203-2; Hamilton J, 2012, CLIN CHIM ACTA, V413, P1207, DOI 10.1016/j.cca.2012.03.019; Himes RW, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0214; Hoffman E.P., 1993, GENEREVIEWS R; McGovern MM, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0572-x; Nagral A, 2014, J CLIN EXP HEPATOL, V4, P37, DOI 10.1016/j.jceh.2014.02.005; Pronicki M, 2017, HAND CLINIC, V142, P71, DOI 10.1016/B978-0-444-63625-6.00007-0; Reiner Z, 2014, ATHEROSCLEROSIS, V235, P21, DOI 10.1016/j.atherosclerosis.2014.04.003; Su K, 2016, APPL CLIN GENET, V9, P157, DOI 10.2147/TACG.S86760; Valayannopoulos V, 2017, MOL GENET METAB, V120, P62, DOI 10.1016/j.ymgme.2016.11.002; Weiskirchen R, 2017, CURR MED RES OPIN, P1; Zhou H, 2008, PATHOLOGE, V29, P73, DOI 10.1007/s00292-007-0954-2	18	0	0	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					249	254		10.1007/s00292-017-0400-z			6	Pathology	Pathology	GF0UY	WOS:000431647800007	29234937				2019-10-28	
J	Sipos, B				Sipos, B.			Neuroendocrine neoplasms of the auditory, olfactory, and visual sensory organs	PATHOLOGE			German	Article						Nasal cavity; Neuroendocrine carcinoma; Olfactory esthesioneuroblastoma; Pituitary neoplasms; Sense organs	MIDDLE-EAR; SINONASAL TRACT; CARCINOID-TUMOR; CELL LYMPHOMA; ESTHESIONEUROBLASTOMA; HEAD; NECK; DIFFERENTIATION; NEUROBLASTOMA; PROGNOSIS	Neuroendocrine neoplasms (NENs) are infrequent in sensory organs. There are well-differentiated neuroendocrine neoplasms that should be classified as neuroendocrine tumors, in analogy to their gastrointestinal counterparts, however the nomenclature is inconsistent. The best defined entities are neuroendocrine tumors in the middle ear and ectopic pituitary adenoma in the sphenoid region. Poorly differentiated NENs most often arise in the olfactory organ and nasal cavity that are represented by olfactory neuroblastomas and poorly differentiated neuroendocrine carcinomas. They have several mimickers such as the sinonasal undifferentiated carcinoma, poorly differentiated squamous cell carcinoma, mucosal malignant melanoma, rhabdomyosarcoma, Ewing sarcoma/primitive neuroectodermal tumor and non-Hodgkin lymphoma.	[Sipos, B.] Univ Klinikum Tubingen, Inst Allgemeine Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany	Sipos, B (reprint author), Univ Klinikum Tubingen, Inst Allgemeine Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.	Bence.Sipos@med.uni-tuebingen.de					Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2015, HISTOPATHOLOGY, V66, P182, DOI 10.1111/his.12447; Agaimy A, 2014, HISTOPATHOLOGY, V65, P60, DOI 10.1111/his.12366; ALEXAKIS PG, 1989, J BONE JOINT SURG AM, V71A, P1412, DOI 10.2106/00004623-198971090-00023; Alos L, 2016, VIRCHOWS ARCH, V469, P277, DOI 10.1007/s00428-016-1982-1; Bell D, 2017, VIRCHOWS ARCH, V471, P667, DOI 10.1007/s00428-017-2155-6; Bell D, 2016, HEAD NECK-J SCI SPEC, V38, pE2259, DOI 10.1002/hed.24152; Bell D, 2015, HEAD NECK PATHOL, V9, P51, DOI 10.1007/s12105-014-0547-3; de la Vega LL, 2017, MOL CANCER RES, V15, P1551, DOI 10.1158/1541-7786.MCR-17-0135; Devaiah AK, 2009, LARYNGOSCOPE, V119, P1412, DOI 10.1002/lary.20280; Fukushima S, 2012, BRAIN TUMOR PATHOL, V29, P207, DOI 10.1007/s10014-012-0083-3; Fundakowski CE, 2013, LARYNGOSCOPE, V123, P779, DOI 10.1002/lary.23434; Furuta A, 2010, AURIS NASUS LARYNX, V37, P381, DOI 10.1016/j.anl.2009.09.007; Gallagher KK, 2014, ANN OTO RHINOL LARYN, V123, P353, DOI 10.1177/0003489414526368; Gay LM, 2017, ONCOLOGIST, V22, P834, DOI 10.1634/theoncologist.2016-0287; Hyams VJ, 1982, SPECIAL TUMORS HEAD, pS24; Kanumuri VV, 2014, AM J OTOLARYNG, V35, P154, DOI 10.1016/j.amjoto.2013.09.003; Li SY, 2013, AM J SURG PATHOL, V37, P14, DOI 10.1097/PAS.0b013e31826731b5; Li YK, 2012, CASE REP OTOLARYNGOL, DOI 10.1155/2012/941065; Likhacheva A, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-32; Lombard M, 2015, EUR ANN OTORHINOLARY, V132, P271, DOI 10.1016/j.anorl.2015.08.015; Lopez F, 2016, HEAD NECK-J SCI SPEC, V38, P147, DOI 10.1002/hed.23872; Macintosh PW, 2015, SURV OPHTHALMOL, V60, P486, DOI 10.1016/j.survophthal.2015.03.002; Mooney EE, 1999, HEAD NECK-J SCI SPEC, V21, P72, DOI 10.1002/(SICI)1097-0347(199901)21:1<72::AID-HED10>3.0.CO;2-G; MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002; Nikanne E, 2004, ACTA OTO-LARYNGOL, V124, P754, DOI 10.1080/00016480410016612; Pelosi S, 2015, OTOLARYNG CLIN N AM, V48, P305, DOI 10.1016/j.otc.2014.12.005; Platek ME, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-41; Pointer KB, 2017, ORAL ONCOL, V69, P92, DOI 10.1016/j.oraloncology.2017.04.009; Rushing EJ, 2009, HEAD NECK PATHOL, V3, P116, DOI 10.1007/s12105-009-0118-1; Salzman R, 2012, OTOL NEUROTOL, V33, P1418, DOI 10.1097/MAO.0b013e3182693888; Shah K, 2016, HEAD NECK PATHOL, V10, P85, DOI 10.1007/s12105-016-0696-7; Soldatova L, 2016, J NEUROL SURG PART B, V77, P456, DOI 10.1055/s-0036-1582432; Szablewski V, 2015, LARYNGOSCOPE, V125, P615, DOI 10.1002/lary.24910; Thompson ED, 2016, AM J SURG PATHOL, V40, P471, DOI 10.1097/PAS.0000000000000580; Thompson LDR, 2018, HEAD NECK PATHOL, V12, P181, DOI 10.1007/s12105-017-0851-9; Thompson LDR, 2012, HEAD NECK PATHOL, V6, P75, DOI 10.1007/s12105-012-0336-9; Thyparampil PJ, 2018, OPHTHAL PLAST RECONS, V34, pE17, DOI 10.1097/IOP.0000000000000968; Torske KR, 2002, MODERN PATHOL, V15, P543, DOI 10.1038/modpathol.3880561; Woo CG, 2018, APPL IMMUNOHISTO M M, V26, P632, DOI 10.1097/PAI.0000000000000501; Wooff JC, 2011, AM J SURG PATHOL, V35, P1786, DOI 10.1097/PAS.0b013e3182363b78	41	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					255	263		10.1007/s00292-017-0411-9			9	Pathology	Pathology	GF0UY	WOS:000431647800008	29392404				2019-10-28	
J	von Laffert, M; Elezkurtaj, S; Sehouli, J; Barinoff, J; Grutzmacher, EB; Arsenic, R; Blaker, H				von Laffert, M.; Elezkurtaj, S.; Sehouli, J.; Barinoff, J.; Gruetzmacher, E. Boschetti; Arsenic, R.; Blaeker, H.			Ichthyosis uteri (psoriasis uteri). A very rare disorder	PATHOLOGE			German	Article						Ichthyosis uteri; Psoriasis uteri; Squamous metaplasia; Malignant neoplasm		In ichthyosis uteri, the entire endometrium is replaced by squamous, sometimes even keratotic epithelium. The etiology is discussed controversially and not fully understood. However, in most cases a chronic inflammatory stimulus is identified. An association with malignancy is possible. Therefore, adequate consecutive diagnostic procedures, as well as exact macro-and micromorphologic evaluation is mandatory. In this case report we describe this currently rare disorder and review the main literature on this topic.	[von Laffert, M.; Elezkurtaj, S.; Arsenic, R.; Blaeker, H.] Charite, Campus Charite Mitte, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany; [von Laffert, M.] BIH, Berlin, Germany; [Sehouli, J.; Barinoff, J.; Gruetzmacher, E. Boschetti] Charite, Campus Benjamin Franklin, Klin Gynakol, Berlin, Germany; [Sehouli, J.; Barinoff, J.; Gruetzmacher, E. Boschetti] Charite, Campus Benjamin Franklin, Brustzentrum, Berlin, Germany	von Laffert, M (reprint author), Charite, Campus Charite Mitte, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany.	maximilian.von-laffert@charite.de					BERSCH W, 1984, PATHOLOGE, V5, P148; Bewtra C, 2005, ARCH PATHOL LAB MED, V129, P124; BROWN D, 1982, SOUTHERN MED J, V75, P593, DOI 10.1097/00007611-198205000-00022; Fadare O, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-8; HECKEROTH V, 1986, GEBURTSH FRAUENHEILK, V46, P248, DOI 10.1055/s-2008-1035908; Kabukcuoglu S, 2011, EUR J GYNAECOL ONCOL, V32, P699; Kanno K, 2016, J OBSTET GYNAECOL RE, V42, P1599, DOI 10.1111/jog.13108; McCluggage WG, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P305, DOI 10.1007/978-1-4419-0489-8_7; Murhekar K, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-4; Nisal MK, 2011, J OBSTET GYNAECOL, V31, P94, DOI 10.3109/01443615.2010.517329; Pailoor K, 2014, ONLINE J HLTH ALLIED, V13, P10; PATTON WT, 1962, AM J OBSTET GYNECOL, V84, P858, DOI 10.1016/0002-9378(62)90060-1; Rosai J, 2011, ROSAI ACKERMANS SURG, V2, pS1483; Zeller A, 1885, Z GEBURTSH GYNAKOL, V11, P56; ZSCHOCH H, 1987, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V133, P355	15	0	0	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					264	268		10.1007/s00292-017-0403-9			5	Pathology	Pathology	GF0UY	WOS:000431647800009	29313082				2019-10-28	
J	Schmidt, D				Schmidt, D.			The new S3 guideline "Prevention of cervical carcinoma". What is important for pathology?	PATHOLOGE			German	Article						Cytology; Biomarkers; HPV DNA test; Ki-67 antigen; HPV-16		Of the numerous aspects involved in the diagnosis, treatment, and follow-up of cervical uterine precursor lesions, epidemiology, virology, cytology, human papillomavirus (HPV) testing, and diagnostic algorithms for equivocal and HPV-positive findings are important for pathologists. Cytology will continue to be used as a preventive medical check-up in young women, while HPV-based screening is suggested for older women. HPV screening has yielded a significant reduction in cancer precursors and invasive cervical carcinoma in numerous studies. In contrast to the sensitivity, the specificity of the HPV test is inferior to that of cytology and the morphological biomarker p16/Ki-67, so that they are suitable as methods in the triage of HPV-positive findings. Cytological abnormalities and mildly dysplastic changes could be further clarified by an HPV test or the p16/Ki-67 test. The HPV test should also be used in the follow-up of patients after conization.	[Schmidt, D.] Inst Pathol & Zytol, Gereonstr 14a, D-41747 Viersen, Germany	Schmidt, D (reprint author), Inst Pathol & Zytol, Gereonstr 14a, D-41747 Viersen, Germany.	dischmi57@gmail.com					Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097/01.AOG.0000296488.85807.b3; Arbyn M, 2006, VACCINE, V24, P78, DOI 10.1016/j.vaccine.2006.05.117; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; GRIESSER H, 2013, FRAUENARZT, V11, P2; Herfs M, 2013, AM J SURG PATHOL, V37, P1311, DOI 10.1097/PAS.0b013e3182989ee2; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1; Ikenberg H, 2013, JNCI-J NATL CANCER I, V105, P1550, DOI 10.1093/jnci/djt235; Krebsgesellschaft Deutsche, 2017, 015027OL AWMF; Marquardt K, 2016, PATHOLOGE, V37, P78, DOI 10.1007/s00292-015-0120-1; Pirog EC, 2014, MODERN PATHOL, V27, P1559, DOI 10.1038/modpathol.2014.55; Robert Koch-Institut, 2013, KREBS DEUTSCHL 2009; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	MAY	2018	39	3					269	279		10.1007/s00292-018-0441-y			11	Pathology	Pathology	GF0UY	WOS:000431647800010	29700570				2019-10-28	
J	Singh, JA; Ohe, C; Smith, SC				Singh, Jaime A.; Ohe, Chisato; Smith, Steven Christopher			High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis	PATHOLOGY INTERNATIONAL			English	Review						collecting duct carcinoma; fumarate hydratase-deficient renal cell carcinoma; renal cell carcinoma; renal medullary carcinoma; unclassified; with medullary phenotype	COLLECTING DUCT CARCINOMA; TRACT UROTHELIAL CARCINOMAS; LARGE T-ANTIGEN; MEDULLARY CARCINOMA; HEREDITARY LEIOMYOMATOSIS; TUBULOCYSTIC CARCINOMA; UTERINE LEIOMYOMAS; RHABDOID FEATURES; BK-POLYOMAVIRUS; KIDNEY TUMORS	Collecting duct carcinoma was described over 30 years ago as a renal tumor, based in the medullary collecting system, with tubulopapillary morphology, prominent infiltrative growth, and stromal desmoplasia. While diagnostic workup has always emphasized exclusion of upper tract urothelial carcinoma and metastatic adenocarcinoma to the kidney, the molecular era of renal cell carcinoma classification has enabled recognition of and provided tools for diagnosis of new entities in this morphologic differential. In this review, we consider these developments, with emphasis on renal medullary carcinoma, closely related renal cell carcinoma, unclassified with medullary phenotype, and fumarate hydratase-deficient renal cell carcinoma. Integration of ancillary studies with suggestive patterns of morphology is emphasized for practical implementation in contemporary diagnosis, and several emerging tumor types in the morphologic differential are presented.	[Singh, Jaime A.; Smith, Steven Christopher] VCU Sch Med, Dept Pathol, Richmond, VA USA; [Ohe, Chisato] Kansai Med Univ, Dept Pathol & Lab Med, Osaka, Japan; [Smith, Steven Christopher] VCU Sch Med, Dept Surg, Div Urol, Richmond, VA USA	Smith, SC (reprint author), Virginia Commonwealth Univ, Sch Med, Surg Pathol, 1200 E Marshall St,Gateway 6-205,POB 980622, Richmond, VA 23298 USA.	steven.c.smith@vcuhealth.org					Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Albadine R, 2010, AM J SURG PATHOL, V34, P965, DOI 10.1097/PAS.0b013e3181dc5e8a; Alexiev BA, 2013, HUM PATHOL, V44, P908, DOI 10.1016/j.humpath.2012.09.019; Amin MB, 2014, AM J SURG PATHOL, V38, P871, DOI 10.1097/PAS.0000000000000222; Amin MB, 2009, AM J SURG PATHOL, V33, P384, DOI 10.1097/PAS.0b013e3181872d3f; Amin MB, 1997, ADV ANAT PATHOL, V4, P85; Andrici J, 2018, SEMIN DIAGN PATHOL, V35, P161, DOI 10.1053/j.semdp.2017.05.004; Argani P, 2016, AM J SURG PATHOL, V40, P1484, DOI 10.1097/PAS.0000000000000720; Becker F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078137; Bennett JA, 2017, MODERN PATHOL, V30, P1476, DOI 10.1038/modpathol.2017.56; Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Calderaro J, 2016, EUR UROL, V69, P1055, DOI 10.1016/j.eururo.2015.09.027; Calderaro J, 2012, HISTOPATHOLOGY, V61, P428, DOI 10.1111/j.1365-2559.2012.04228.x; Carlo MI, 2017, CLIN GENITOURIN CANC, V15, pE987, DOI 10.1016/j.clgc.2017.04.012; Carvalho JC, 2012, HISTOPATHOLOGY, V60, P597, DOI 10.1111/j.1365-2559.2011.04093.x; Chao D, 2002, J UROLOGY, V167, P71, DOI 10.1016/S0022-5347(05)65385-2; Chen YB, 2015, MOD PATHOL S2, V28, p211A; Chen YB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13131; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Cheng LA, 2010, EXPERT REV ANTICANC, V10, P843, DOI [10.1586/era.10.72, 10.1586/ERA.10.72]; Colombo P, 2015, UROL CASE REP, V3, P215, DOI 10.1016/j.eucr.2015.07.011; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; Divatia M, 2015, MODERN PATHOL, V95, P216; Don M, 2017, MODERN PATHOL, V30, p221A; Emerson LL, 2008, PEDIATR TRANSPLANT, V12, P600, DOI 10.1111/j.1399-3046.2007.00855.x; FLEMING S, 1986, HISTOPATHOLOGY, V10, P1131, DOI 10.1111/j.1365-2559.1986.tb02553.x; FOOT NC, 1949, JAMA-J AM MED ASSOC, V139, P356, DOI 10.1001/jama.1949.02900230010003; Gatalica Z, 2011, HUM PATHOL, V42, P1979, DOI 10.1016/j.humpath.2011.02.026; Gill AJ, 2014, AM J SURG PATHOL, V38, P1588, DOI 10.1097/PAS.0000000000000292; Gill AJ, 2011, NEW ENGL J MED, V364, P885, DOI 10.1056/NEJMc1012357; Gokden N, 2000, AM J SURG PATHOL, V24, P1329; Gonzalez-Roibon N, 2013, HUM PATHOL, V44, P2651, DOI 10.1016/j.humpath.2013.07.006; Gupta R, 2008, ADV ANAT PATHOL, V15, P127, DOI 10.1097/PAP.0b013e31817145a9; Gupta R, 2012, AM J SURG PATHOL, V36, P1265, DOI 10.1097/PAS.0b013e3182635954; Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24; Hakimi AA, 2007, UROLOGY, V70, P878, DOI 10.1016/j.urology.2007.06.1124; Harper HL, 2017, MODERN PATHOL, V30, P146, DOI 10.1038/modpathol.2016.171; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Kalyanpur A, 1997, AM J ROENTGENOL, V169, P1037, DOI 10.2214/ajr.169.4.9308460; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Kim HJ, 2009, AM J SURG PATHOL, V33, P1276, DOI 10.1097/PAS.0b013e3181a2aa36; Kopp RP, 2017, CANCER-AM CANCER SOC, V123, P2452, DOI 10.1002/cncr.30605; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Kuroda N, 2015, POL J PATHOL, V66, P3, DOI 10.5114/PJP.2015.51147; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; Li YJ, 2018, HISTOPATHOLOGY, V72, P588, DOI 10.1111/his.13395; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Liu QY, 2013, AM J SURG PATHOL, V37, P368, DOI 10.1097/PAS.0b013e3182770406; Malouf GG, 2016, SCI REP-UK, V6, DOI 10.1038/srep30988; Martin EE, 2017, AJSP-REV REP, V22, P305, DOI 10.1097/PCR.0000000000000214; Mazzucchelli R, 2014, INT J IMMUNOPATH PH, V27, P509, DOI 10.1177/039463201402700406; Menko FH, 2014, FAM CANCER, V13, P637, DOI 10.1007/s10689-014-9735-2; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; Miettinen M, 2016, AM J SURG PATHOL, V40, P1661, DOI 10.1097/PAS.0000000000000703; Mirsadraei L, 2017, AJSP-REV REP, V22, P301, DOI 10.1097/PCR.0000000000000215; Moch H, 2016, WHO CLASSIFICATIONS; Mochel MC, 2017, AJSP-REV REP, V22, P313, DOI 10.1097/PCR.0000000000000220; Monzon FA, 2008, MODERN PATHOL, V21, P599, DOI 10.1038/modpathol.2008.20; Muller DC, 2018, J PATHOL, V244, P265, DOI 10.1002/path.5012; O'Donnell PH, 2010, NAT REV UROL, V7, P110, DOI 10.1038/nrurol.2009.255; Ohe C, 2018, AM J SURG PATHOL, V42, P279, DOI 10.1097/PAS.0000000000001000; Osunkoya AO, 2009, AM J SURG PATHOL, V33, P1103, DOI 10.1097/PAS.0b013e3181a13e7b; Pal SK, 2016, EUR UROL, V70, P516, DOI 10.1016/j.eururo.2015.06.019; Peyromaure M, 2003, J UROLOGY, V170, P1138, DOI 10.1097/01.ju.0000086616.40603.ad; Rao P, 2012, AM J SURG PATHOL, V36, P583, DOI 10.1097/PAS.0b013e3182417d78; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Sanz-Ortega J, 2013, AM J SURG PATHOL, V37, P74, DOI 10.1097/PAS.0b013e31825ec16f; Scarpelli M, 2014, PATHOLOGY, V46, P653, DOI 10.1097/PAT.0000000000000175; Schmidt LS, 2014, INT J NEPHROL RENOV, V7, P253, DOI 10.2147/IJNRD.S42097; Schultz KAP, 2017, CLIN CANCER RES, V23, pE76, DOI 10.1158/1078-0432.CCR-17-0629; Siegler L, 2018, VIRCHOWS ARCH, V472, P789, DOI 10.1007/s00428-018-2292-6; Sigauke E, 2006, MODERN PATHOL, V19, P717, DOI 10.1038/modpathol.3800581; Sirohi D, 2017, HUM PATHOL, V67, P134, DOI 10.1016/j.humpath.2017.07.006; Skala SL, 2018, MODERN PATHOL, V31, P179, DOI 10.1038/modpathol.2017.99; Smith S, 2015, MODERN PATHOL, V28, p260A; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Smith SC, 2014, HISTOPATHOLOGY, V65, P132, DOI 10.1111/his.12360; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Srigley JR, 1998, SEMIN DIAGN PATHOL, V15, P54; Stelow EB, 2018, SEMIN DIAGN PATHOL, V35, P143, DOI 10.1053/j.semdp.2017.11.012; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Stratton KL, 2016, UROL ONCOL, V34, P238; Swartz MA, 2002, UROLOGY, V60, P1083, DOI 10.1016/S0090-4295(02)02154-4; Tan PH, 2013, AM J SURG PATHOL, V37, P1518, DOI 10.1097/PAS.0b013e318299f12e; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Tong GX, 2009, MODERN PATHOL, V22, P1218, DOI 10.1038/modpathol.2009.88; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Udager AM, 2014, AM J SURG PATHOL, V38, P567, DOI 10.1097/PAS.0000000000000127; Wang JM, 2016, ONCOTARGET, V7, P29901, DOI 10.18632/oncotarget.9093; Watanabe IC, 2007, MODERN PATHOL, V20, P914, DOI 10.1038/modpathol.3800934; Waterfall JJ, 2014, BIOCHEM BIOPH RES CO, V455, P16, DOI 10.1016/j.bbrc.2014.08.003; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506; Williamson SR, 2017, AM J SURG PATHOL, V41, P287, DOI 10.1097/PAS.0000000000000776; Williamson SR, 2015, MODERN PATHOL, V28, P80, DOI 10.1038/modpathol.2014.86; Yan L, 2016, HUM PATHOL, V48, P122, DOI 10.1016/j.humpath.2015.09.021; Zhang Q, 2018, INT J GYNECOL PATHOL, V37, P421, DOI 10.1097/PGP.0000000000000447	103	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					265	277		10.1111/pin.12667			13	Pathology	Pathology	GF1CK	WOS:000431669600001	29665139				2019-10-28	
J	Sasahira, T; Bosserhoff, AK; Kirita, T				Sasahira, Tomonori; Bosserhoff, Anja Katrin; Kirita, Tadaaki			The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer	PATHOLOGY INTERNATIONAL			English	Review						MIA; MIA2; oral cancer; TANGO	GLYCATION END-PRODUCTS; COLLAGEN SECRETION; NODAL METASTASIS; ACTIVITY MIA; EXPRESSION; PROTEIN; RECEPTOR; MATRIX; TANGO; LYMPHANGIOGENESIS	Oral squamous cell carcinoma has a high potential for locoregional invasion and nodal metastasis. Consequently, early detection of such malignancies is of immense importance. The melanoma inhibitory activity (MIA) gene family comprises MIA, MIA2, transport and Golgi organization protein 1 (TANGO), and otoraplin (OTOR). These members of the MIA gene family have a highly conserved Src homology 3 (SH3)-like structure. Although the molecules of this family share 34-45% amino acid homology and 47-59% cDNA sequence homology, those members, excluding OTOR, play different tumor-associated functions. MIA has a pivotal role in the progression and metastasis of melanoma; MIA2 and TANGO have been suggested to possess tumor-suppressive functions; and OTOR is uniquely expressed in cochlea of the inner ear. Therefore, the definite functions of the MIA gene family in cancer cells remain unclear. Since the members of the MIA gene family are secreted proteins, these molecules might be useful tumor markers that can be detected in the body fluids, including serum and saliva. In this review, we described the molecular biological functions of the MIA gene family in oral cancer.	[Sasahira, Tomonori] Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan; [Bosserhoff, Anja Katrin] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany; [Kirita, Tadaaki] Nara Med Univ, Dept Oral & Maxillofacial Surg, Kashihara, Nara, Japan	Sasahira, T (reprint author), Nara Med Univ, Dept Mol Pathol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	sasa@naramed-u.ac.jp			Japan Society for the Promotion of Science, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	We want to acknowledge the support of several colleagues. Especially, we would like to give special thanks to Dr. Miyako Kurihara-Shimomura and Yukiko Nishiguchi for their helpful support. This work was supported in part by Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Japan. Tomonori Sasahira has been announced as the winner of the Japanese Society of Pathology Research Award, 2017.	Arndt S, 2007, J LEUKOCYTE BIOL, V82, P1466, DOI 10.1189/jlb.0407219; Arndt S, 2007, ONCOL REP, V18, P885; Arndt S, 2006, INT J CANCER, V119, P2812, DOI 10.1002/ijc.22242; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bauer R, 2006, J BIOL CHEM, V281, P11669, DOI 10.1074/jbc.M511367200; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 2005, PIGM CELL RES, V18, P411, DOI 10.1111/j.1600-0749.2005.00274.x; Bosserhoff AK, 2004, GENE EXPR PATTERNS, V4, P473, DOI 10.1016/j.modgep.2003.12.002; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 2003, J BIOL CHEM, V278, P15225, DOI 10.1074/jbc.M212639200; Bremmer JF, 2011, ORAL ONCOL, V47, P956, DOI 10.1016/j.oraloncology.2011.07.025; Califano J, 1996, CANCER RES, V56, P2488; Cohen-Salmon M, 2000, J BIOL CHEM, V275, P40036, DOI 10.1074/jbc.M002876200; Fenstad MH, 2010, MOL HUM REPROD, V16, P960, DOI 10.1093/molehr/gaq064; Graf SA, 2014, J INVEST DERMATOL, V134, P2212, DOI 10.1038/jid.2014.128; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hellerbrand C, 2008, GUT, V57, P243, DOI 10.1136/gut.2007.129544; Hellerbrand C, 2005, LIVER INT, V25, P357, DOI 10.1111/j.1478-3231.2005.01099.x; Hofmann MA, 2011, J DERMATOL, V38, P880, DOI 10.1111/j.1346-8138.2011.01219.x; Jachimczak P, 2005, INT J CANCER, V113, P88, DOI 10.1002/ijc.20549; Koch W, 2011, THROMB HAEMOSTASIS, V105, P670, DOI 10.1160/TH10-10-0641; Kong B, 2015, SCI REP-UK, V5, DOI 10.1038/srep08109; Kurihara M, 2013, BRIT J CANCER, V108, P1460, DOI 10.1038/bjc.2013.27; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Li XC, 2013, ATHEROSCLEROSIS, V231, P136, DOI 10.1016/j.atherosclerosis.2013.08.031; Perez-Sayans M, 2009, ONCOL REP, V22, P1277, DOI 10.3892/or_00000565; Pitiyage G, 2009, J ORAL PATHOL MED, V38, P737, DOI 10.1111/j.1600-0714.2009.00804.x; Pitman JL, 2011, J LIPID RES, V52, P1775, DOI 10.1194/jlr.M017277; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003; Poser I, 2002, CANCER RES, V62, P5962; Robertson NG, 2000, GENOMICS, V66, P242, DOI 10.1006/geno.2000.6224; Saito K, 2011, MOL BIOL CELL, V22, P2301, DOI 10.1091/mbc.E11-02-0143; Sasahira T, 2007, HISTOPATHOLOGY, V51, P166, DOI 10.1111/j.1365-2559.2007.02739.x; Sasahira T, 2005, VIRCHOWS ARCH, V446, P411, DOI 10.1007/s00428-005-1210-x; Sasahira T, 2008, CANCER SCI, V99, P1806, DOI 10.1111/j.1349-7006.2008.00894.x; Sasahira T, 2007, VIRCHOWS ARCH, V450, P287, DOI 10.1007/s00428-006-0359-2; Sasahira T, 2016, ONCOTARGET, V7, P31137, DOI 10.18632/oncotarget.9082; Sasahira T, 2016, ONCOTARGET, V7, P26751, DOI 10.18632/oncotarget.8495; Sasahira T, 2014, EUR J CANCER, V50, P2142, DOI 10.1016/j.ejca.2014.05.006; Sasahira T, 2010, EUR J CANCER, V46, P2285, DOI 10.1016/j.ejca.2010.04.027; Savino W, 2002, TRENDS IMMUNOL, V23, P305, DOI 10.1016/S1471-4906(02)02224-X; Schmidt J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037941; Schmidt J, 2009, INT J CANCER, V125, P1587, DOI 10.1002/ijc.24508; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tscheudschilsuren G, 2006, EXP CELL RES, V312, P63, DOI 10.1016/j.yexcr.2005.09.017; Wilson DG, 2011, J CELL BIOL, V193, P935, DOI 10.1083/jcb.201007162; Wu JY, 2010, ORAL ONCOL, V46, P226, DOI 10.1016/j.oraloncology.2010.01.007; Xu YL, 2011, BIOCHEM BIOPH RES CO, V416, P379, DOI 10.1016/j.bbrc.2011.11.046	51	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					278	286		10.1111/pin.12672			9	Pathology	Pathology	GF1CK	WOS:000431669600002	29655307				2019-10-28	
J	Han, SS; Masaki, A; Sakamoto, Y; Takino, H; Murase, T; Iida, S; Inagaki, H				Han, Shusen; Masaki, Ayako; Sakamoto, Yuma; Takino, Hisashi; Murase, Takayuki; Iida, Shinsuke; Inagaki, Hiroshi			Improved clonality detection in Hodgkin lymphoma using a semi-nested modification of the BIOMED-2 PCR assay for IGH and IGK rearrangements: A paraffin-embedded tissue study	PATHOLOGY INTERNATIONAL			English	Article						BIOMED-2 PCR assay; formalin-fixed; Hodgkin lymphoma; IGH gene; IGK gene; immunoglobulin gene rearrangements; paraffin-embedded tissues; semi-nested modification	GENE REARRANGEMENTS; PRIMERS; LYMPHOPROLIFERATIONS; IMMUNOGLOBULIN; PROTOCOLS; HEAVY	The BIOMED-2 PCR protocols targeting IGH and IGK genes may be useful for detecting clonality in Hodgkin lymphoma (HL). The clonality detection rates, however, have not been very high with these methods using paraffin-embedded tumor sections. We previously described the usefulness of the semi-nested BIOMED-2 IGH assay in B-cell malignancies. In this study, we devised a novel semi-nested BIOMED-2 IGK assay. Employing 58 cases of classical HL, we carried out the standard BIOMED-2, BIOMED-2 followed by BIOMED-2 re-amplification, and BIOMED-2 followed by semi-nested BIOMED-2, all targeting IGH and IGK, using paraffin-embedded tissues. In both IGH and IGK assays, semi-nested assays yielded significantly higher clonality detection rates than the standard assays and re-amplification assays. Clonality was detected in 13/58 (22.4%) classical HL cases using the standard IGH/IGK assays while it was detected in 38/58 (65.5%) cases using semi-nested IGH/IGK assays. The detection rates were not associated with the HL subtypes, CD30-positive cell density, CD20-positive cell density, or Epstein-Barr virus (EBV) positivity. In conclusion, tumor clonality was detected in nearly two-thirds of classical HL cases using semi-nested BIOMED-2 IGH/IGK assays using paraffin tumor sections. These semi-nested assays may be useful when the standard IGH/IGK assays fail to detect clonality in histopathologically suspected HLs.	[Han, Shusen; Masaki, Ayako; Sakamoto, Yuma; Takino, Hisashi; Murase, Takayuki; Inagaki, Hiroshi] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan; [Iida, Shinsuke] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan	Inagaki, H (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan.	hinagaki@med.nagoya-cu.ac.jp					Beaufils N, 2012, LEUKEMIA RES, V36, P1119, DOI 10.1016/j.leukres.2012.06.003; Burack WR, 2010, AM J CLIN PATHOL, V134, P104, DOI 10.1309/AJCPK6SBE0XOODHB; Chute DJ, 2008, DIAGN MOL PATHOL, V17, P65, DOI 10.1097/PDM.0b013e318150d695; EDWARDS MC, 1994, PCR METH APPL, V3, pS65; Ghorbian S, 2016, HEMATOLOGY, V21, P133, DOI 10.1179/1607845415Y.0000000035; Green MR, 2012, MOL CLONING, P455; Hartmann S, 2013, PATHOL RES PRACT, V209, P495, DOI 10.1016/j.prp.2013.05.004; Hebeda K M, 2009, J Hematop, V2, P34, DOI 10.1007/s12308-009-0024-1; Kainz P, 2000, BBA-GENE STRUCT EXPR, V1494, P23, DOI 10.1016/S0167-4781(00)00200-1; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Sakamoto Y, 2017, PATHOL INT, V67, P453, DOI 10.1111/pin.12566; Swerdlow SH, 2017, WHO CLASSIFICATION T, V2; Tapia G, 2012, HISTOPATHOLOGY, V60, P768, DOI 10.1111/j.1365-2559.2011.04135.x; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202	15	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					287	293		10.1111/pin.12660			7	Pathology	Pathology	GF1CK	WOS:000431669600003	29575591				2019-10-28	
J	Jun, SY; Hong, SM; Bae, YK; Kim, HK; Jang, KY; Eom, DW				Jun, Sun-Young; Hong, Seung-Mo; Bae, Young Kyung; Kim, Hee Kyung; Jang, Kyu Yun; Eom, Dae Woon			Clinicopathological and prognostic significance of heme oxygenase-1 expression in small intestinal adenocarcinomas	PATHOLOGY INTERNATIONAL			English	Article						heme oxygenase-1; immunohistochemistry; small intestine; survival	INVASIVE BLADDER-CANCER; PEGYLATED ZINC PROTOPORPHYRIN; CELL LUNG-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER; TUMOR; INHIBITION; ANGIOGENESIS; INVOLVEMENT; CARCINOMA	Heme oxygenase-1 (HO-1), a stress-response protein, is highly induced in various carcinomas. It is implicated in carcinogenesis and tumor progression. High HO-1 expression is associated with better prognosis of patients with colorectal and gastric cancers. Induction or inhibition of HO-1 can mediate chemo-sensitivity, therefore it might be a therapeutic target to develop anticancer agents. To define the clinicopathological and prognostic significance of HO-1 expression in small-intestinal adenocarcinomas (SIACs), immunohistochemical microarray analysis of HO-1 expression was performed for 191 surgically resected SIAC cases and results were compared with various clinicopathologic variables, including survival. HO-1 was highly expressed in 127 (66.5%) cases. Patients with high HO-1 expression were associated with younger age (P=0.048), lower pT category (P=0.017), and less pancreatic invasion (P=0.047). Patients with high HO-1 expression tended to have longer overall survival (median, 38.5 months) than those with low HO-1 expression (24.5 months), although the difference in overall survival was not statistically significant (P=0.677). In summary, high HO-1 expression is frequently observed in SIACs. It is related to favorable clinicopathologic parameters, including younger age, lower T category, and less pancreatic invasion. Therefore, HO-1 may serve as a prognostic marker and a new target to modulate chemotherapeutic effects in patients with SIACs.	[Jun, Sun-Young] Catholic Univ Korea, Incheon St Marys Hosp, Dept Pathol, Incheon, South Korea; [Hong, Seung-Mo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; [Bae, Young Kyung] Yeungnam Univ, Coll Med, Dept Pathol, Daegu, South Korea; [Kim, Hee Kyung] Soonchunhyang Univ, Bucheon Hosp, Dept Pathol, Bucheon, South Korea; [Jang, Kyu Yun] Chonbuk Natl Univ, Med Sch, Dept Pathol, Jeonju, South Korea; [Eom, Dae Woon] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pathol, 38 Bangdong Gil, Kangnung 25440, South Korea	Eom, DW (reprint author), Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Pathol, 38 Bangdong Gil, Kangnung 25440, South Korea.	edwjyh@gnah.co.kr		Hong, Seung-Mo/0000-0002-8888-6007	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2017R1D1A1B03031817]; Gangneung Asan Hospital Biomedical Research Center Promotion Fund [2016-0004]	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03031817) and a grant (2016-0004) from the Gangneung Asan Hospital Biomedical Research Center Promotion Fund. We would like to thank members of the Korean Small Intestinal Cancer Study Group for providing samples and data for this study: Dr. Hee-Kyung Chang, Kosin University College of Medicine, Pusan; Dr. Kee-Taek Jang, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Dr. Ghil Suk Yoon, Kyungpook National University School of Medicine, Dague; Dr. Joon Mee Kim, Inha University College of Medicine, Incheon; Dr. Hyun-Jung Kim, Inje University Sanggye Paik Hospital, Seoul; Dr. Gwang Il Kim, CHA Bundang Medical Center, CHA University, Seongnam; Dr. Su-Jin Shin, Hanyang University College of Medicine, Seoul; Dr. Jinwon Seo, Hallym University Sacred Heart Hospital, Anyang; Dr. Eun Kyoung Kwak, Fatima Hospital, Daegu; Dr. Eun Sun Jung, The Catholic University of Korea College of Medicine, Seoul; Dr. Young-Ha Oh, Hanyang University College of Medicine, Guri; Dr. Jae Bok Park, Catholic University of Daegu, Daegu; Dr. Soo Jin Jung, Inje University College of Medicine, Busan; Dr. Gyeong Hoon Kang, Seoul National University College of Medicine, Seoul; Dr. Heae Sung Park, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; and Dr. Ji Shin Lee, Chonnam National University Medical School, Gwangju, Korea.	Alaoui-Jamali MA, 2009, CANCER RES, V69, P8017, DOI 10.1158/0008-5472.CAN-09-0419; Becker JC, 2007, SCAND J GASTROENTERO, V42, P852, DOI 10.1080/00365520701192383; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Busserolles J, 2006, INT J BIOCHEM CELL B, V38, P1510, DOI 10.1016/j.biocel.2006.03.013; Andres NC, 2014, EXP MOL PATHOL, V97, P321, DOI 10.1016/j.yexmp.2014.09.012; Degese MS, 2012, LUNG CANCER, V77, P168, DOI 10.1016/j.lungcan.2012.02.016; Fang J, 2003, CANCER RES, V63, P3567; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Gueron G, 2009, MOL CANCER RES, V7, P1745, DOI 10.1158/1541-7786.MCR-08-0325; Hirai K, 2007, INT J CANCER, V120, P500, DOI 10.1002/ijc.22287; Jun SY, 2017, ONCOTARGET, V8, P21483, DOI 10.18632/oncotarget.15277; Jun SY, 2016, MODERN PATHOL, V29, P402, DOI 10.1038/modpathol.2016.40; Jun SY, 2014, MODERN PATHOL, V27, P1364, DOI 10.1038/modpathol.2014.36; Kang KA, 2012, TUMOR BIOL, V33, P1031, DOI 10.1007/s13277-012-0336-0; Kim JN, 2014, HUM PATHOL, V45, P1830, DOI 10.1016/j.humpath.2014.04.020; Kim JH, 2007, CLIN CANCER RES, V13, P3875, DOI 10.1158/1078-0432.CCR-06-2893; Lin CW, 2008, MOL CANCER THER, V7, P1195, DOI 10.1158/1535-7163.MCT-07-2199; Matsuo T, 2017, ONCOL LETT, V13, P275, DOI 10.3892/ol.2016.5416; Miyake M, 2011, ONCOL REP, V25, P653, DOI 10.3892/or.2010.1125; Miyake M, 2010, UROL INT, V85, P355, DOI 10.1159/000317785; Naito Y, 2004, ALIMENT PHARM THERAP, V20, P177, DOI 10.1111/j.1365-2036.2004.01992.x; Noh SJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-516; Nuhn P, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-37; Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081; Tsai JR, 2012, CELL ONCOL, V35, P461, DOI 10.1007/s13402-012-0105-5; Tsuji MH, 1999, CANCER LETT, V138, P53, DOI 10.1016/S0304-3835(98)00372-3; Wang TY, 2015, HISTOPATHOLOGY, V66, P447, DOI 10.1111/his.12562; Yin HZ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-436; Yin YJ, 2012, EXP BIOL MED, V237, P362, DOI 10.1258/ebm.2011.011193; Zaanan A, 2011, CANCER-AM CANCER SOC, V117, P1422, DOI 10.1002/cncr.25614	31	1	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					294	300		10.1111/pin.12657			7	Pathology	Pathology	GF1CK	WOS:000431669600004	29537718				2019-10-28	
J	Yoshizawa, H; Motooka, D; Matsumoto, Y; Katada, R; Nakamura, S; Morii, E; Iida, T; Matsumoto, H				Yoshizawa, Hidenori; Motooka, Daisuke; Matsumoto, Yuki; Katada, Ryuichi; Nakamura, Shota; Morii, Eiichi; Iida, Tetsuya; Matsumoto, Hiroshi			A case of severe soft tissue infection due to Streptococcus tigurinus diagnosed by necropsy in which genomic analysis was useful for clarifying its pathogenicity	PATHOLOGY INTERNATIONAL			English	Article						post-mortem microbiology; soft tissue infection; Streptococcus tigurinus; whole-genome sequencing		Post-mortem detection of pathogenetic microorganisms in severe infectious death is significantly important for diagnosing the cause of death as well as for public health. However, it is difficult to recognize whether a microorganism detected from post-mortem materials is truly pathogenic or not. We report a case of severe soft tissue infection due to Streptococcus oralis subsp. tigurinus (S. tigurinus), a recently reported species, in which whole-genome analysis was performed to clarify its pathogenicity. A 46-year-old woman had died with symptoms of a severe infectious disease. A post-mortem examination was performed by a medical examiner. The external findings suggested a soft tissue infection; subsequently, pathological specimens sampled by necropsy revealed findings compatible with necrotizing fasciitis. In the post-mortem bacterial test, S. tigurinus was detected from the localized autopsy sample. Whole-genome sequencing was performed to analyze its pathogenicity and detected a strain of S. tigurinus with genetic determinants that were specific and unique to its highly virulent strains as a result of gene annotation. Utilizing various technologies, such as whole-genome sequencing, may be a powerful tool for diagnosing the cause of infectious death accurately and safely.	[Yoshizawa, Hidenori; Katada, Ryuichi; Matsumoto, Hiroshi] Osaka Univ, Sch Med, Dept Legal Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Yoshizawa, Hidenori; Matsumoto, Hiroshi] Osaka Univ, Grad Sch Med, Project Death Control & Prevent, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Yoshizawa, Hidenori; Katada, Ryuichi; Matsumoto, Hiroshi] Osaka Prefectural Med Examiners Off, Chuo Ku, 1-6 Banbacho, Osaka, Osaka 5400007, Japan; [Yoshizawa, Hidenori; Morii, Eiichi] Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan; [Motooka, Daisuke; Matsumoto, Yuki; Nakamura, Shota; Iida, Tetsuya] Osaka Univ, Res Inst Microbial Dis, Dept Infect Metagen, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan	Matsumoto, H (reprint author), Osaka Univ, Sch Med, Dept Legal Med, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	hmatsumo@legal.med.osaka-u.ac.jp	Nakamura, Shota/E-3033-2010	Nakamura, Shota/0000-0003-2058-5942	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26893135]	H.Y. is supported in part by JSPS KAKENHI grant no. 26893135. We thank the staff members of the Osaka Prefectural Medical Examiner's office Laboratory for assistance with pathological examination.	Bourassa L, 2015, J CLIN MICROBIOL, V53, P3574, DOI 10.1128/JCM.01551-15; Chin CS, 2013, NAT METHODS, V10, P563, DOI [10.1038/NMETH.2474, 10.1038/nmeth.2474]; Diene SM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160554; Hidenori Y, 2017, GENOME ANNOUNC, V5; Land M, 2015, FUNCT INTEGR GENOMIC, V15, P141, DOI 10.1007/s10142-015-0433-4; Morris JA, 2007, CURR DIAGN PATHOL, V13, P65, DOI DOI 10.1016/J.CDIP.2006.07.005; Palmiere C, 2016, J FORENSIC SCI, V61, P367, DOI 10.1111/1556-4029.12991; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Veloso TR, 2013, INT J MED MICROBIOL, V303, P498, DOI 10.1016/j.ijmm.2013.06.006; Zbinden A, 2015, VIRULENCE, V6, P177, DOI 10.4161/21505594.2014.970472; Zbinden A, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0231-5; Zbinden A, 2014, J CLIN MICROBIOL, V52, P467, DOI 10.1128/JCM.02801-13; Zbinden A, 2012, INT J SYST EVOL MICR, V62, P2941, DOI 10.1099/ijs.0.038299-0; Zbinden A, 2012, J CLIN MICROBIOL, V50, P2969, DOI 10.1128/JCM.00849-12	15	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					301	306		10.1111/pin.12656			6	Pathology	Pathology	GF1CK	WOS:000431669600005	29570912				2019-10-28	
J	Ohata, Y; Kayamori, K; Yukimori, A; Sumikura, K; Ohsako, T; Harada, H; Sakamoto, K; Ikeda, T				Ohata, Yae; Kayamori, Kou; Yukimori, Akane; Sumikura, Kanako; Ohsako, Toshimitsu; Harada, Hiroyuki; Sakamoto, Kei; Ikeda, Tohru			A lesion categorized between ghost cell odontogenic carcinoma and dentinogenic ghost cell tumor with CTNNB1 mutation	PATHOLOGY INTERNATIONAL			English	Article						CTNNB1 mutation; ghost cells; ghost cell odontogenic carcinoma; ghost cell tumor	COLORECTAL-CANCER; EXPRESSION; CATENIN	Ghost cell odontogenic carcinoma (GCOC) is a rare malignant neoplasm characterized by the presence of ghost cells. It is considered to arise either de novo or from a preexisting benign precursor, calcifying odontogenic cyst (COC), or dentinogenic ghost cell tumor (DGCT). We report a case of a 44-year-old Japanese male with a left maxillary tumor. The patient received treatment to resect the left maxillary cyst 25 years prior; however, the details were uncertain. The tumor was resected with clear margins. Taken together with the results of histological and immunohistochemical examinations, the tumor was categorized between GCOC and DGCT, and we diagnosed the tumor as GCOC suggesting similarity to DGCT. Further, we focused on CTNNB1, which encodes -catenin and is frequently mutated in COCs. In this tumor, we identified CTNNB1 Ser33Cys, one of the mutations typically found in COCs. This finding suggests that CTNNB1 is a common target for the pathogenesis of tumors accompanied by ghost cells.	[Ohata, Yae; Kayamori, Kou; Sakamoto, Kei; Ikeda, Tohru] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Tokyo, Japan; [Yukimori, Akane] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Diagnost Oral Pathol, Tokyo, Japan; [Sumikura, Kanako; Ohsako, Toshimitsu; Harada, Hiroyuki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral & Maxillofacial Surg, Tokyo, Japan	Kayamori, K (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kayamori.mpa@tmd.ac.jp			Iwadare Scholarship Foundation	The author Yae Ohata was the recipient of The Iwadare Scholarship Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arashiyama T, 2012, ORAL SURG ORAL MED O, V114, P35; Bose P, 2015, ORAL ONCOL, V51, pE71, DOI 10.1016/j.oraloncology.2015.06.013; Cheng Y, 2004, DENTOMAXILLOFAC RAD, V33, P152, DOI 10.1259/dmfr/67909783; Del Corso G, 2015, ORAL MAXILLOFAC SURG, V19, P85, DOI 10.1007/s10006-014-0465-2; El-Naggar A, 2017, WHO CLASSIFICATION H; GRODJESK JE, 1987, ORAL SURG ORAL MED O, V63, P576, DOI 10.1016/0030-4220(87)90231-3; Kim J, 2000, ORAL SURG ORAL MED O, V90, P630, DOI 10.1067/moe.2000.109016; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kusama K, 2005, AM J CLIN PATHOL, V123, P376, DOI 10.1309/WVTRR1DXYMC8PBMK; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Motosugi U, 2009, ANN DIAGN PATHOL, V13, P394, DOI 10.1016/j.anndiagpath.2009.02.008; Polakis P, 2000, GENE DEV, V14, P1837; Rappaport MJ, 2015, RARE TUMORS, V7, P96, DOI 10.4081/rt.2015.5813; Sekine S, 2003, AM J PATHOL, V163, P1707, DOI 10.1016/S0002-9440(10)63528-6; Sparks AB, 1998, CANCER RES, V58, P1130; Stojanov IJ, 2016, OR SURG OR MED OR PA, V122, P117, DOI 10.1016/j.oooo.2015.10.019; Yukimori A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180224; Zhu ZY, 2012, KOREAN J PATHOL, V46, P478, DOI [10.4132/KoreanJPathol.2012.465.478, 10.4132/KoreanJPathol.2012.46.5.478]	18	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					307	312		10.1111/pin.12659			6	Pathology	Pathology	GF1CK	WOS:000431669600006	29575443				2019-10-28	
J	Kitagawa, H; Kaneko, M; Kano, M; Ibuki, Y; Amatya, VJ; Takeshima, Y; Hirabayashi, N; Hirota, S				Kitagawa, Hiroki; Kaneko, Mayumi; Kano, Mikihiro; Ibuki, Yuta; Amatya, Vishwa Jeet; Takeshima, Yukio; Hirabayashi, Naoki; Hirota, Seiichi			Coexistence of gastrointestinal stromal tumor and leiomyosarcoma of the stomach presenting as a collision tumor: A case report and review of literature	PATHOLOGY INTERNATIONAL			English	Review						collision tumor; gastrointestinal stromal tumor; leiomyosarcoma; stomach	OF-THE-LITERATURE; MUTATIONS	Collision tumor of the stomach is rare. We report a rare case of a gastric collision tumor consisting of gastrointestinal stromal tumors (GISTs) and leiomyosarcoma (LMS). Computed tomography scan revealed a 15cm sized mass in the posterior wall of the body of the stomach. Gross examination of the wedge resection specimen showed the tumor located in the muscularis propria with extramural protrusion into the peritoneal cavity and the gastric cavity with geographic necrosis, hemorrhage, and mucosal ulceration. Histologically, the majority of the tumor consisted of the GIST component and the minor area in the submucosal region consisted of the LMS component. The tumor showed an abrupt transition between GIST and LMS by histologically and immunohistochemically, suggesting a collision tumor. Furthermore, the GIST components exhibited a c-kit exon 11 mutation. On the other hand, LMS component exhibited neither c-kit nor platelet-derived growth factor receptor-alpha (PDGFRA) mutation. Here we describe a case of the collision tumor consisting of GIST and LMS and its literature review.	[Kitagawa, Hiroki; Kano, Mikihiro; Ibuki, Yuta; Hirabayashi, Naoki] Hiroshima City Asa Citizens Hosp, Dept Surg, Hiroshima, Japan; [Kaneko, Mayumi] Hiroshima City Asa Citizens Hosp, Dept Pathol, Hiroshima, Japan; [Amatya, Vishwa Jeet; Takeshima, Yukio] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathol, Hiroshima, Japan; [Hirota, Seiichi] Hyogo Med Coll Med, Dept Surg Oncol, Nishinomiya, Hyogo, Japan	Kitagawa, H (reprint author), Hiroshima City Asa Citizens Hosp, Dept Surg, Asakita Ku, 2-1-1 Kabe Minami, Hiroshima 7310293, Japan.	hiroki054839@gmail.com	Amatya, Vishwa Jeet/B-5164-2009	Amatya, Vishwa Jeet/0000-0002-4986-2109; Kitagawa, Hiroki/0000-0003-1651-0091			Antonescu CR, 2013, AM J SURG PATHOL, V37, P385, DOI 10.1097/PAS.0b013e31826c1761; Antonescu CR, 2011, J PATHOL, V223, P251, DOI 10.1002/path.2798; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Insabato L, 2012, INT J SURG PATHOL, V20, P74, DOI 10.1177/1066896911414018; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Jung JH, 2013, PATHOL INT, V63, P479, DOI 10.1111/pin.12095; Lazar A, 2013, WHO CLASSIFICATION T, P111; Liegl B, 2009, AM J SURG PATHOL, V33, P218, DOI 10.1097/PAS.0b013e31817ec2e6; Nicolas MM, 2010, HUM PATHOL, V41, P663, DOI 10.1016/j.humpath.2009.10.005; Oda Y, 2001, AM J SURG PATHOL, V25, P1030, DOI 10.1097/00000478-200108000-00007; Pauwels P, 2005, HISTOPATHOLOGY, V47, P41, DOI 10.1111/j.1365-2559.2005.02179.x; Perez-Montiel MD, 2006, AM J DERMATOPATH, V28, P105, DOI 10.1097/01.dad.0000200009.02939.cc; Seo M, 2015, CLIN ENDOSC, V48, P322, DOI 10.5946/ce.2015.48.4.322; Yamamoto H, 2013, HISTOPATHOLOGY, V63, P194, DOI 10.1111/his.12159	15	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					313	317		10.1111/pin.12662			5	Pathology	Pathology	GF1CK	WOS:000431669600007	29575341				2019-10-28	
J	Oide, T; Kan, M; Masunaga, A; Nishino, T; Hiroshima, K				Oide, Takashi; Kan, Motoyasu; Masunaga, Atsuko; Nishino, Takayoshi; Hiroshima, Kenzo			Histopathology of immature (ongoing) squamous metaplasia of the stomach	PATHOLOGY INTERNATIONAL			English	Letter									[Oide, Takashi; Masunaga, Atsuko; Hiroshima, Kenzo] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, 477-96 Owada Shinden, Chiba 2768524, Japan; [Kan, Motoyasu; Nishino, Takayoshi] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Gastroenterol, 477-96 Owada Shinden, Chiba 2768524, Japan	Oide, T (reprint author), Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, 477-96 Owada Shinden, Chiba 2768524, Japan.						Atkins KA, 2012, HISTOLOGY PATHOLOGIS, P1071; Fitzgerald RC, 2005, GUT, V54, pI21, DOI 10.1136/gut.2004.041558; Giroux V, 2017, NAT REV CANCER, V17, P594, DOI 10.1038/nrc.2017.68; Noffsinger A, 2007, ATLAS NONTUMOR PATHO, P147; Takita J, 2005, HEPATO-GASTROENTEROL, V52, P969	5	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					318	320		10.1111/pin.12636			3	Pathology	Pathology	GF1CK	WOS:000431669600008	29393560				2019-10-28	
J	Nomoto, K				Nomoto, Kazuhiro			A rare case of uterine tumor resembling ovarian sex-cord tumor with necrosis and increased mitotic activity	PATHOLOGY INTERNATIONAL			English	Letter									[Nomoto, Kazuhiro] Takaoka Kouseiren Hosp, Pathol Lab, Takaoka, Toyama, Japan	Nomoto, K (reprint author), Takaoka Kouseiren Hosp, Pathol Lab, Takaoka, Toyama, Japan.						Clement PB, 2014, ATLAS GYNECOLOGIC SU, P218; Endo D, 2016, TAIWAN J OBSTET GYNE, V55, P751, DOI 10.1016/j.tjog.2015.04.008; O'Meara AC, 2009, GYNECOL ONCOL, V114, P140, DOI 10.1016/j.ygyno.2009.03.021; Oliva E, 2014, WHO CLASSIFICATION T, P135; Pradhan D, 2013, ARCH PATHOL LAB MED, V137, P1832, DOI 10.5858/arpa.2012-0634-RS	5	0	0	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					321	323		10.1111/pin.12642			3	Pathology	Pathology	GF1CK	WOS:000431669600009	29446516				2019-10-28	
J	Ito, Y; Sugita, S; Segawa, K; Sugawara, T; Tsujiwaki, M; Fujita, H; Ono, Y; Morita, T; Emori, M; Hasegawa, T				Ito, Yumika; Sugita, Shintaro; Segawa, Keiko; Sugawara, Taro; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Morita, Tomonori; Emori, Makoto; Hasegawa, Tadashi			Giant cell-rich osteosarcoma of the vertebra with murine double minute chromosome 2-and cyclin-dependent kinase 4-positive and histone H3F3A mutant p.Gly34Trp-negative immunophenotypes	PATHOLOGY INTERNATIONAL			English	Letter							CDK4; MDM2		[Ito, Yumika; Sugita, Shintaro; Segawa, Keiko; Sugawara, Taro; Tsujiwaki, Mitsuhiro; Fujita, Hiromi; Ono, Yusuke; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan; [Morita, Tomonori; Emori, Makoto] Sapporo Med Univ, Sch Med, Dept Orthoped Surg, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan	Ito, Y (reprint author), Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.						Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; BATHURST N, 1986, BRIT J RADIOL, V59, P667, DOI 10.1259/0007-1285-59-703-667; Chow LTC, 2016, VIRCHOWS ARCH, V468, P741, DOI 10.1007/s00428-016-1926-9; Hirose K, 2017, HISTOPATHOLOGY, V70, P1171, DOI 10.1111/his.13141; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124	5	1	1	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAY	2018	68	5					324	326		10.1111/pin.12650			3	Pathology	Pathology	GF1CK	WOS:000431669600010	29446514				2019-10-28	
J	Soderquist, CR; Ewalt, MD; Czuchlewski, DR; Geyer, JT; Rogers, HJ; Hsi, ED; Wang, SA; Bueso-Ramos, CE; Orazi, A; Arber, DA; Hexner, EO; Babushok, DV; Bagg, A				Soderquist, Craig R.; Ewalt, Mark D.; Czuchlewski, David R.; Geyer, Julia T.; Rogers, Heesun J.; Hsi, Eric D.; Wang, Sa A.; Bueso-Ramos, Carlos E.; Orazi, Attilio; Arber, Daniel A.; Hexner, Elizabeth O.; Babushok, Daria V.; Bagg, Adam			Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group	MODERN PATHOLOGY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL TRANSLOCATION; POLYCYTHEMIA-VERA; JAK2(V617F) MUTATION; JAK2V617F MUTATION; JAK2-V617F MUTATION; ESSENTIAL THROMBOCYTHEMIA; PATIENT; IMATINIB	Myeloproliferative neoplasms arise from hematopoietic stem cells with somatically altered tyrosine kinase signaling. Classification of myeloproliferative neoplasms is based on hematologic, histopathologic and molecular characteristics including the presence of the BCR-ABL1 and JAK2 V617F. Although thought to be mutually exclusive, a number of cases with co-occurring BCR-ABL1 and JAK2 V617F have been identified. To characterize the clinicopathologic features of myeloproliferative neoplasms with concomitant BCR-ABL1 and JAK2 V617F, and define the frequency of co-occurrence, we conducted a retrospective multi-institutional study. Cases were identified using a search of electronic databases over a decade at six major institutions. Of 1570 patients who were tested for both BCR-ABL1 and JAK2 V617F, six were positive for both. An additional five patients were identified via clinical records providing a total of 11 cases for detailed evaluation. For each case, clinical variables, hematologic and genetic data, and bone marrow histomorphologic features were analyzed. The sequence of identification of the genetic abnormalities varied: five patients were initially diagnosed with a JAK2 V617F+ myeloproliferative neoplasm, one patient initially had BCR-ABL1+ chronic myeloid leukemia, while both alterations were identified simultaneously in five patients. Classification of the BCR-ABL1-negative myeloproliferative neoplasms varied, and in some cases, features only became apparent following tyrosine kinase inhibitor therapy. Seven of the 11 patients showed myelofibrosis, in some cases before identification of the second genetic alteration. Our data, reflecting the largest reported study comprehensively detailing clinicopathologic features and response to therapy, show that the co-occurrence of BCR-ABL1 and JAK2 V617F is rare, with an estimated frequency of 0.4%, and most often reflects two distinct ('composite') myeloproliferative neoplasms. Although uncommon, it is important to be aware of this potentially confounding genetic combination, lest these features be misinterpreted to reflect resistance to therapy or disease progression, considerations that could lead to inappropriate management.	[Soderquist, Craig R.; Bagg, Adam] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Ewalt, Mark D.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA; [Czuchlewski, David R.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Geyer, Julia T.; Orazi, Attilio] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Rogers, Heesun J.; Hsi, Eric D.] Cleveland Clin, Dept Lab Med, Cleveland, OH 44106 USA; [Wang, Sa A.; Bueso-Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Arber, Daniel A.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Hexner, Elizabeth O.; Babushok, Daria V.] Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; [Soderquist, Craig R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA	Soderquist, CR (reprint author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, Div Hematopathol, 630 West 168th St,VC 14-240, New York, NY 10032 USA.	csoderquist2@gmail.com	Ewalt, Mark D/Y-4878-2019; Bagg, Adam/R-8450-2019	Ewalt, Mark D/0000-0003-4245-752X; 	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K08 HL132101]		Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bee PC, 2010, INT J HEMATOL, V91, P136, DOI 10.1007/s12185-009-0471-6; Bocchia M, 2007, LANCET ONCOL, V8, P864, DOI 10.1016/S1470-2045(07)70295-4; Cambier N, 2008, LEUKEMIA, V22, P1454, DOI 10.1038/sj.leu.2405088; Campiotti Leonardo, 2009, Leuk Res, V33, pe212, DOI 10.1016/j.leukres.2009.06.011; Caocci G, 2010, LEUKEMIA RES, V34, pE27, DOI 10.1016/j.leukres.2009.08.009; Cappetta M, 2013, INT J LAB HEMATOL, V35, pE4, DOI 10.1111/ijlh.12010; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Conchon MRD, 2008, INT J HEMATOL, V88, P243, DOI 10.1007/s12185-008-0131-2; Gattenlohner S, 2009, AM J HEMATOL, V84, P306, DOI 10.1002/ajh.21296; Grisouard J, 2013, BLOOD, V122, P3694, DOI 10.1182/blood-2013-07-516385; Hummel JM, 2012, DIAGN MOL PATHOL, V21, P176, DOI 10.1097/PDM.0b013e318246975e; Hussein K, 2008, LEUKEMIA, V22, P1059, DOI 10.1038/sj.leu.2404993; Hussein K, 2007, BLOOD, V109, P4106, DOI 10.1182/blood-2006-12-061135; Inami M, 2007, LEUKEMIA, V21, P1103, DOI 10.1038/sj.leu.2404591; Inokuchi K, 2012, J CLIN EXP HEMATOP, V52, P145, DOI 10.3960/jslrt.52.145; Jallades L, 2008, LEUKEMIA RES, V32, P1608, DOI 10.1016/j.leukres.2008.03.004; Kim YK, 2008, LEUKEMIA RES, V32, P993, DOI 10.1016/j.leukres.2007.10.018; Kramer A, 2007, LANCET ONCOL, V8, P658, DOI 10.1016/S1470-2045(07)70206-1; Laibe S, 2009, LEUKEMIA RES, V33, P1133, DOI 10.1016/j.leukres.2009.01.034; Lee YJ, 2013, INT J HEMATOL, V97, P804, DOI 10.1007/s12185-013-1326-8; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Martin-Cabrera P, 2017, BRIT J HAEMATOL, V176, P135, DOI 10.1111/bjh.13932; MELO JV, 1994, LEUKEMIA, V8, P208; Mirza I, 2007, ARCH PATHOL LAB MED, V131, P1719; Ohsaka A, 2002, INTERNAL MED, V41, P1183, DOI 10.2169/internalmedicine.41.1183; Pardini S, 2008, EUR J HAEMATOL, V81, P75, DOI 10.1111/j.1600-0609.2008.01063.x; Park SH, 2013, ANN LAB MED, V33, P229, DOI 10.3343/alm.2013.33.3.229; Pastore F, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-24; Pieri L, 2011, BLOOD, V118, P3445, DOI 10.1182/blood-2011-07-365007; Pingali SRK, 2009, CLIN LYMPHOMA MYELOM, V9, pE25, DOI 10.3816/CLM.2009.n.080; Qin YW, 2014, INDIAN J HEMATOL BLO, V30, pS331, DOI 10.1007/s12288-014-0385-1; Soderquist C, 2014, BLOOD, V124, P2463, DOI 10.1182/blood-2014-06-585141; Swerdlow SH, 2008, WHO CLASSIFICATION T, P29; Tefferi A, 2010, EUR J HAEMATOL, V85, P86, DOI 10.1111/j.1600-0609.2010.01458.x; Toogeh G, 2011, MED ONCOL, V28, P1555, DOI 10.1007/s12032-010-9570-8; Traverse-Glehen A, 2007, LEUKEMIA, V21, P1824, DOI 10.1038/sj.leu.2404730; Veronese L, 2010, LEUKEMIA RES, V34, pE94, DOI 10.1016/j.leukres.2009.09.025; Wang XL, 2013, BLOOD, V121, P1238, DOI 10.1182/blood-2012-11-467787; Xiao X, 2012, ACTA HAEMATOL-BASEL, V127, P47, DOI 10.1159/000331564; Xu WY, 2014, INT J HEMATOL, V99, P87, DOI 10.1007/s12185-013-1480-z; Zhou A, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.77	42	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					690	704		10.1038/modpathol.2017.182			15	Pathology	Pathology	GE9VN	WOS:000431579000001	29327708	Green Accepted, Bronze			2019-10-28	
J	Reinig, EF; Greipp, PT; Chiu, A; Howard, MT; Reichard, KK				Reinig, Erica F.; Greipp, Patricia T.; Chiu, April; Howard, Matthew T.; Reichard, Kaaren K.			De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity	MODERN PATHOLOGY			English	Article							HEALTH-ORGANIZATION CLASSIFICATION; HEMOGLOBIN-STABILIZING PROTEIN; MARROW BIOPSY SPECIMENS; ACUTE MYELOID-LEUKEMIA; PRECURSORS; ERYTHROLEUKEMIA; NEOPLASMS; MARKER; PROLIFERATIONS	Per the revised fourth edition World Health Organization classification of acute myeloid leukemia, pure erythroid leukemia is now the sole type of acute erythroid leukemia. The diagnosis of this rare entity is often challenging and the cytologic overlap with non-neoplastic (eg, megaloblastic anemia) and neoplastic entities (eg, other types of acute leukemia and non-hematopoietic malignancies) warrants a significant degree of clinical, laboratory, immunophenotypic, and genetic investigation. Given the limited number of reports of this rare and diagnostically challenging entity, we report detailed clinicopathologic characteristics from 15 patients, the largest series thus far, of primary de novo pure erythroid leukemia to provide further diagnostic insights into this entity and reveal strategies for making the diagnosis. We found that de novo pure erythroid leukemia is a disease of adults (median age 68 years), exhibits a striking male predominance, is universally associated with an abnormal karyotype and has an exceedingly poor overall median survival of 1.4 months. Given the general inability of immunophenotypic markers to discriminate neoplastic from non-neoplastic erythroid proliferations, key features identified in this study to help establish the diagnosis of pure erythroid leukemia and exclude mimickers include circulating pronormoblasts, clear-cut dysplasia in erythroid, granulocytic, and/or megakaryocytic lineage, utilization of a broad immunophenotypic panel, TP53 immunohistochemical positivity, and identification of a complex, often highly complex, karyotype. Given the gravity of a diagnosis of de novo pure erythroid leukemia, it should be rendered with utmost confidence.	[Reinig, Erica F.; Chiu, April; Howard, Matthew T.; Reichard, Kaaren K.] Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, 200 1st St Hilton Bldg 8-00C, Rochester, MN 55902 USA; [Greipp, Patricia T.] Mayo Clin, Dept Lab Med & Pathol, Div Lab Genet & Genom, Rochester, MN USA	Reichard, KK (reprint author), Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, 200 1st St Hilton Bldg 8-00C, Rochester, MN 55902 USA.	reichard.kaaren@mayo.edu					Arber DA, 2017, WHO CLASSIFICATION T, P161; Arber DA, 2017, CURR OPIN HEMATOL, V24, P146, DOI 10.1097/MOH.0000000000000314; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bacher U, 2011, HAEMATOL-HEMATOL J, V96, P1284, DOI 10.3324/haematol.2011.043687; Cervera N, 2016, LEUKEMIA, V30, P966, DOI 10.1038/leu.2015.198; Domingo-Claros A, 2002, HAEMATOLOGICA, V87, P148; Dong HY, 2011, AM J SURG PATHOL, V35, P723, DOI 10.1097/PAS.0b013e31821247a8; Fernandez-Pol S, 2017, MODERN PATHOL, V30, P382, DOI 10.1038/modpathol.2016.206; Grossmann V, 2013, LEUKEMIA, V27, P1940, DOI 10.1038/leu.2013.144; Hasserjian Robert P, 2013, Surg Pathol Clin, V6, P641, DOI 10.1016/j.path.2013.08.006; Hasserjian RP, 2010, BLOOD, V115, P1985, DOI 10.1182/blood-2009-09-243964; Lessard M, 2005, CANCER GENET CYTOGEN, V163, P113, DOI 10.1016/j.cancergencyto.2005.05.006; Li HM, 2016, AM J CLIN PATHOL, V145, P538, DOI 10.1093/ajcp/aqw033; Linu JA, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.712; Liu CJ, 2012, LEUKEMIA LYMPHOMA, V53, P289, DOI 10.3109/10428194.2011.607526; Liu W, 2011, MODERN PATHOL, V24, P375, DOI 10.1038/modpathol.2010.194; MacKinnon Ruth N., 2013, Evolution Medicine and Public Health, P225, DOI 10.1093/emph/eot020; McGowan-Jordan J, 2016, ISCN 2016 INT SYSTEM; Montalban-Bravo G, 2017, BLOOD, V129, P2584, DOI 10.1182/blood-2016-11-749903; Morice WG, 2008, MAYO CLIN PROC, V83, P776, DOI 10.4065/83.7.776; Park DC, 2017, HISTOPATHOLOGY, V71, P316, DOI 10.1111/his.13207; Park S, 2002, LEUKEMIA RES, V26, P423, DOI 10.1016/S0145-2126(01)00146-1; Raess PW, 2012, AM J SURG PATHOL, V36, P1538, DOI 10.1097/PAS.0b013e31825fa501; Rollins-Raval MA, 2012, AM J CLIN PATHOL, V137, P30, DOI 10.1309/AJCP0QFQ0FTSZCPW; Wang SA, 2016, MODERN PATHOL, V29, P1221, DOI 10.1038/modpathol.2016.118; Wang SA, 2015, AM J CLIN PATHOL, V144, P44, DOI 10.1309/AJCPRKYAT6EZQHC7; Wang SA, 2012, HUM PATHOL, V43, P153, DOI 10.1016/j.humpath.2011.08.008; Wang W, 2017, AM J HEMATOL, V92, P292, DOI 10.1002/ajh.24626; Wang W, 2013, HISTOPATHOLOGY, V62, P931, DOI 10.1111/his.12101; Wong E, 2015, J CLIN PATHOL, V68, P301, DOI 10.1136/jclinpath-2014-202740; Yu HB, 2016, APPL IMMUNOHISTO M M, V24, P51, DOI 10.1097/PAI.0000000000000139; Zuo Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041485	32	1	1	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					705	717		10.1038/modpathol.2017.175			13	Pathology	Pathology	GE9VN	WOS:000431579000002	29327715	Bronze			2019-10-28	
J	Pan, ZG; Chen, MY; Zhang, QY; Wang, ED; Yin, LQ; Xu, YY; Huang, Q; Yuan, YZ; Zhang, XH; Zheng, G; Yuan, J				Pan, Zenggang; Chen, Mingyi; Zhang, Qianyun; Wang, Endi; Yin, Liqun; Xu, Youyuan; Huang, Qin; Yuan, Youzhong; Zhang, Xiaohui; Zheng, Gang; Yuan, Ji			CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall	MODERN PATHOLOGY			English	Article							OF-THE-LITERATURE; ABERRANT EXPRESSION; GENE REARRANGEMENTS; HISTIOCYTIC SARCOMA; FOLLICULAR LYMPHOMA; CD3 EXPRESSION; TRANSFORMATION; TRANSDIFFERENTIATION; DIFFERENTIATION; ANTIGENS	Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3+ plasmablastic B-cell neoplasms, including 12 plasmablastic lymphomas and 5 plasmablastic plasma cell myelomas. All 17 cases occurred in the extranodal sites with a male predominance (13/17). Four cases were initially misinterpreted by outside institutions, among which three were diagnosed as 'peripheral T-cell lymphoma, not otherwise specified' and one was classified as 'poorly differentiated neuroendocrine carcinoma'. The plasmablastic cells were present in all 17 cases diffusely or in a subset of tumor cells. CD3 expression was mostly diffuse (12/17) and moderate to strong (11/16) with a cytoplasmic staining pattern (14/16). Other T-cell markers were nearly absent, including CD2 (0/10), CD4 (1/13), CD5 (0/14), CD7 (0/11), and CD8 (0/13). CD138 was positive in all 17 cases and CD79a was variably positive in 8 of 14 cases. Only one case had immunoreactivity to CD20 (1/17) and PAX5 (1/12). CD56 expression and EBV infection were detected in 8/15 and 6/17, respectively. No HHV8 infection was noted in all 11 cases tested. Most cases (11/13) revealed either kappa or lambda light chain restriction. Of the nine cases studied, six had clonal IGH rearrangements but no clonal TRG rearrangements. Our study further emphasizes that the accurate classification of CD3+ plasmablastic neoplasms requires thorough morphologic examination, incorporation of more B-cell and T-cell markers in addition to CD3 and CD20, frequent addition of CD138 staining, and utilization of necessary molecular and genetic studies.	[Pan, Zenggang] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Chen, Mingyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Zhang, Qianyun] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Yin, Liqun] Incyte Diagnost, Spokane Valley, WA USA; [Xu, Youyuan] Woodhull Med & Mental Hlth Ctr, Dept Pathol, Brooklyn, NY USA; [Huang, Qin] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA; [Yuan, Youzhong] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Zhang, Xiaohui] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematopathol & Lab Med, Tampa, FL USA; [Zheng, Gang] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Yuan, Ji] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Pan, ZG (reprint author), Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA.	zenggang.pan@ucdenver.edu		Zheng, Gang/0000-0003-0276-9430			GREINER TC, 1995, AM J PATHOL, V146, P46; Kaleem Z, 2001, AM J CLIN PATHOL, V115, P396; Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007; Lee M, 2013, BLOOD RES, V48, P156, DOI 10.5045/br.2013.48.2.156; Luo XD, 2016, PATHOLOGY, V48, P378, DOI 10.1016/j.pathol.2016.02.019; Matnani RG, 2013, CASE REP HEMATOL, DOI 10.1155/2013/183134; Mehrotra S, 2015, DIAGN CYTOPATHOL, V43, P659, DOI 10.1002/dc.23285; Mishra P, 2017, ACTA CLIN BELG, V72, P250, DOI 10.1080/17843286.2016.1201629; Oliveira JL, 2012, AM J SURG PATHOL, V36, P1364, DOI 10.1097/PAS.0b013e31825e63a9; Pan ZG, 2012, AM J SURG PATHOL, V36, P1129, DOI 10.1097/PAS.0b013e31825b38ec; Pan ZG, 2017, AM J SURG PATHOL, V41, P25, DOI 10.1097/PAS.0000000000000753; Pan ZG, 2013, HUM PATHOL, V44, P2139, DOI 10.1016/j.humpath.2013.04.008; Petitjean B, 2002, AM J SURG PATHOL, V26, P724, DOI 10.1097/01.PAS.0000015151.82934.6F; SEGAL GH, 1994, HUM PATHOL, V25, P1269, DOI 10.1016/0046-8177(94)90084-1; Shao HP, 2011, MODERN PATHOL, V24, P1421, DOI 10.1038/modpathol.2011.102; Sun JL, 2011, PATHOLOGY, V43, P54, DOI 10.1097/PAT.0b013e328340bbba; Suzuki Y, 2013, ACTA HAEMATOL-BASEL, V130, P230, DOI 10.1159/000348550; Suzuki Y, 2010, INTERNAL MED, V49, P1801, DOI 10.2169/internalmedicine.49.3164; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tachibana T, 2011, INTERNAL MED, V50, P495, DOI 10.2169/internalmedicine.50.4386; Tang YL, 2012, PATHOLOGY, V44, P668, DOI 10.1097/PAT.0b013e328359fba6; Thakral B, 2017, EUR J HAEMATOL, V98, P415, DOI 10.1111/ejh.12847; Tzankov A, 2005, MODERN PATHOL, V18, P1542, DOI 10.1038/modpathol.3800473; Wallentine JC, 2009, J PEDIAT HEMATOL ONC, V31, P124, DOI 10.1097/MPH.0b013e31818b354a; Wang ED, 2011, AM J SURG PATHOL, V35, P457, DOI 10.1097/PAS.0b013e3182098799; Wang E, 2010, INT J HEMATOL, V91, P509, DOI 10.1007/s12185-010-0501-4; Wang J, 2009, AM J SURG PATHOL, V33, P505, DOI 10.1097/PAS.0b013e318185d231; West DS, 2013, AM J SURG PATHOL, V37, P978, DOI 10.1097/PAS.0b013e318283099f; Wu B, 2016, ANN HEMATOL, V95, P1671, DOI 10.1007/s00277-016-2749-0; Yin LQ, 2016, HISTOPATHOLOGY, V69, P775, DOI 10.1111/his.13017	30	2	2	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					718	731		10.1038/modpathol.2017.177			14	Pathology	Pathology	GE9VN	WOS:000431579000003	29327711				2019-10-28	
J	Rymkiewicz, G; Grygalewicz, B; Chechlinska, M; Blachnio, K; Bystydzienski, Z; Romejko-Jarosinska, J; Woroniecka, R; Zajdel, M; Domanska-Czyz, K; Martin-Garcia, D; Nadeu, F; Swoboda, P; Rygier, J; Pienkowska-Grela, B; Siwicki, JK; Prochorec-Sobieszek, M; Salaverria, I; Siebert, R; Walewski, J				Rymkiewicz, Grzegorz; Grygalewicz, Beata; Chechlinska, Magdalena; Blachnio, Katarzyna; Bystydzienski, Zbigniew; Romejko-Jarosinska, Joanna; Woroniecka, Renata; Zajdel, Michalina; Domanska-Czyz, Katarzyna; Martin-Garcia, David; Nadeu, Ferran; Swoboda, Pawel; Rygier, Jolanta; Pienkowska-Grela, Barbara; Siwicki, Jan Konrad; Prochorec-Sobieszek, Monika; Salaverria, Itziar; Siebert, Reiner; Walewski, Jan			A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration	MODERN PATHOLOGY			English	Article							B-CELL LYMPHOMAS; MYC TRANSLOCATION; EXPRESSION; REARRANGEMENT; DIAGNOSIS; PATTERN; TRIAL; CD38	We previously described a subset of MYC translocation-negative aggressive B-cell lymphomas resembling Burkitt lymphoma, characterized by proximal gains and distal losses in chromosome 11. In the 2016 WHO classification, these MYC-negative lymphomas were recognized as a new provisional entity, 'Burkitt-like lymphoma with 11q aberration'. Here we present an immunophenotype analysis of Burkitt-like lymphomas with 11q aberration. Cells were acquired by fine needle aspiration biopsy from 10 young adult patients, 80% of whom presented recurrence-free 5-year survival. Twenty-three MYC-positive Burkitt lymphomas, including three carrying both MYC rearrangement and 11q aberration, served as controls. By immunohistochemistry, all Burkitt-like lymphomas with 11q aberration were CD20+/CD10+/BCL6+/BCL2-/MUM1-/MYC+/EBV-, usually LMO2+/CD44-/CD43- and sometimes CD56+, and showed high proliferation rate. By flow cytometry, Burkitt-like lymphoma with 11q aberration immunophenotypically resembled MYC-positive Burkitt lymphoma, except for significantly (adjusted P<0.001) more frequent CD38(higher) expression in Burkitt lymphoma (91% MYC-positive Burkitt lymphoma vs 10% Burkitt-like lymphoma with 11q aberration), more frequently diminished CD45 expression in Burkitt lymphoma (74% vs 10%), an exclusive CD16/CD56 and highly restricted CD8 expression in Burkitt-like lymphoma with 11q aberration (60% vs 0% and 40% vs 4%, respectively). We showed high diagnostic accuracy and effectiveness of flow cytometry in Burkitt lymphoma. CD16/CD56 expression without CD38higher and the lack of CD16/CD56 with CD38higher expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively. In addition, we confirmed a pattern of an inverted duplication with telomeric loss of 11q, as a recurrent 11q abnormality, but one case presented alternative changes, possibly resulting in an equivalent molecular effect. Our findings reveal similarities along with subtle but essential differences in the immunophenotype of Burkitt-like lymphoma with 11q aberration and MYC-positive Burkitt lymphoma, important for the differential diagnosis, but also for understanding the pathogenesis of Burkitt-like lymphoma with 11q aberration.	[Rymkiewicz, Grzegorz; Blachnio, Katarzyna; Bystydzienski, Zbigniew] Maria Sklodowska Curie Inst Oncol Ctr, Dept Pathol & Lab Diagnost, Flow Cytometry Lab, 5 Roentgen St, PL-02781 Warsaw, Poland; [Rymkiewicz, Grzegorz; Prochorec-Sobieszek, Monika] Maria Sklodowska Curie Inst Oncol Ctr, Dept Pathol & Lab Diagnost, Pathol Lab, Warsaw, Poland; [Grygalewicz, Beata; Woroniecka, Renata; Rygier, Jolanta; Pienkowska-Grela, Barbara] Maria Sklodowska Curie Inst Oncol Ctr, Dept Pathol & Lab Diagnost, Cytogenet Lab, Warsaw, Poland; [Chechlinska, Magdalena; Zajdel, Michalina; Swoboda, Pawel; Siwicki, Jan Konrad] Maria Sklodowska Curie Inst Oncol Ctr, Dept Immunol, Warsaw, Poland; [Romejko-Jarosinska, Joanna; Domanska-Czyz, Katarzyna; Walewski, Jan] Maria Sklodowska Curie Inst Oncol Ctr, Dept Lymphoid Malignancies, Warsaw, Poland; [Martin-Garcia, David; Nadeu, Ferran; Salaverria, Itziar] Univ Barcelona, CIBERONC, IDIBAPS, Hematopathol Unit,Hosp Clin, Barcelona, Spain; [Siebert, Reiner] Univ Ulm, Inst Human Genet, Ulm, Germany; [Siebert, Reiner] Ulm Univ, Med Ctr, Ulm, Germany	Rymkiewicz, G (reprint author), Maria Sklodowska Curie Inst Oncol Ctr, Dept Pathol & Lab Diagnost, Flow Cytometry Lab, 5 Roentgen St, PL-02781 Warsaw, Poland.	grzegorzrymkiewicz@coi.waw.pl	Siebert, Reiner/A-8049-2010; Rymkiewicz, Grzegorz/AAB-7301-2019; Nadeu, Ferran/O-7732-2017	Nadeu, Ferran/0000-0003-2910-9440; Martin Garcia, David/0000-0002-0289-5915; Zajdel, Michalina/0000-0003-1868-6402; Chechlinska, Magdalena/0000-0001-6139-1234; Walewski, Jan/0000-0003-4247-2674	Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (ISCIII) [CP13-/00159, PI15/00580]; European Regional Development Fund 'Una manera de fer Europa'; CERCA Programme/Generalitat de Catalunya; Kinder Krebs Initiative Buchholz/Holm-Seppensen	We thank Elzbieta Kulczycka, MSc, for performing the immunohistochemical staining, Dr Agnieszka Giza for clinical data of patient 8, Dr Witold Gerke and Dr Tomasz Wocial for participating in the ultrasound-guided fine needle aspiration biopsy, especially in abdominal tumors and Dr Marcin Ligaj for the critical reading of the manuscript. We also thank Guillem Clot (IDIBAPS) for his help in the statistical analysis. IS was supported by the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (ISCIII) (Miguel Servet contract CP13-/00159 and PI15/00580), the European Regional Development Fund 'Una manera de fer Europa' and 'CERCA Programme/Generalitat de Catalunya'. This work was partially developed at the Centro Esther Koplowitz (CEK), Barcelona, Spain. RS is being supported for research on pediatric lymphomas by the Kinder Krebs Initiative Buchholz/Holm-Seppensen.	Chisholm KM, 2015, AM J SURG PATHOL, V39, P294, DOI 10.1097/PAS.0000000000000365; Colomo L, 2017, AM J SURG PATHOL, V41, P877, DOI 10.1097/PAS.0000000000000839; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Drillenburg P, 2000, BLOOD, V95, P1900, DOI 10.1182/blood.V95.6.1900; Ferreiro JF, 2015, HAEMATOLOGICA, V100, pE275, DOI 10.3324/haematol.2015.124305; Grygalewicz B, 2016, MOL CYTOGENET, V9, DOI 10.1186/s13039-015-0212-x; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; ISCN, 2016, INT SYST HUM CYT NOM, P2016; Maleki A, 2009, LEUKEMIA LYMPHOMA, V50, P1054, DOI 10.1080/10428190902930470; Mead GM, 2008, BLOOD, V112, P2248, DOI 10.1182/blood-2008-03-145128; Pienkowska-Grela B, 2011, MED ONCOL, V28, P1589, DOI 10.1007/s12032-010-9614-0; Rodig SJ, 2008, AM J SURG PATHOL, V32, P113, DOI 10.1097/PAS.0b013e3180959e09; Rymkiewicz G, 2014, BLOOD, V124, P1640; Rymkiewicz G, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1754.1754; Rymkiewicz G, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.2679.2679; Salaverria I, 2014, BLOOD, V123, P1187, DOI 10.1182/blood-2013-06-507996; Scholtysik R, 2010, HAEMATOL-HEMATOL J, V95, P2047, DOI 10.3324/haematol.2010.026831; Seegmiller AC, 2010, MODERN PATHOL, V23, P909, DOI 10.1038/modpathol.2010.76; Sevilla DW, 2007, AM J CLIN PATHOL, V128, P981, DOI 10.1309/C1PP15P7CDB8UY39; Swerdlow SH, 2008, WHO CLASSIFICATION T, P262; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Walewski J, 2011, RECOMMENDATIONS EURO, P29; Weisberger J, 2006, APPL IMMUNOHISTO M M, V14, P369, DOI 10.1097/01.pai.0000208279.66189.43; Woroniecka R, 2015, AM J CLIN PATHOL, V143, P25, DOI 10.1309/AJCPATRQWANW2O3N; Wu JM, 2006, AM J CLIN PATHOL, V126, P39, DOI 10.1309/X8LBRRBBC43PL9HC; Zajdel M, 2015, TUMOR BIOL, V36, P5377, DOI 10.1007/s13277-015-3203-y	28	6	7	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					732	743		10.1038/modpathol.2017.186			12	Pathology	Pathology	GE9VN	WOS:000431579000004	29327714	Bronze			2019-10-28	
J	Yoshida, A; Makise, N; Wakai, S; Kawai, A; Hiraoka, N				Yoshida, Akihiko; Makise, Naohiro; Wakai, Susumu; Kawai, Akira; Hiraoka, Nobuyoshi			INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma	MODERN PATHOLOGY			English	Article							INSULINOMA-ASSOCIATED PROTEIN-1; NEUROENDOCRINE DIFFERENTIATION; FUSION PROTEIN; NUCLEAR RECEPTOR; TRANSLOCATION; MARKER; TUMORS; IA-1; PHENOTYPE; PARTNER	Extraskeletal myxoid chondrosarcoma is a rare subtype of sarcoma that affects the soft tissue and bones in middle-aged and elderly adults. Its diagnosis can be challenging, with the differential diagnoses including a wide variety of mesenchymal tumors. The line of differentiation of extraskeletal myxoid chondrosarcoma has been controversial, but recent evidence suggests a neuroendocrine phenotype. INSM1 is a zinc-finger transcription factor that plays a pivotal role in neuroendocrine differentiation, and has been proposed as a promising immunohistochemical marker of neuroendocrine carcinoma. The aim of this study was to determine the prevalence of INSM1 expression in extraskeletal myxoid chondrosarcoma and to understand its significance in sarcoma diagnosis. We immunostained the representative sections of 31 NR4A3-rearranged extraskeletal myxoid chondrosarcomas and 187 histological mimics. Nuclear staining of moderate or higher intensity in at least 5% of tumor cells was considered positive. Twenty-eight of the 31 extraskeletal myxoid chondrosarcomas (90%) were positive for INSM1, providing strong evidence for neuroendocrine differentiation. The staining was diffuse (>50%) in 17 cases, with most immunopositive tumors showing at least focal strong expression. The INSM1 staining extent was not correlated with cytomorphology, synaptophysin expression, or fusion types (EWSR1 vs non-EWSR1). In contrast, INSM1 expression was negative in 94% of the 187 other mesenchymal tumors. INSM1-positive mimics comprised a small subset of chordoma (1 of 10), soft tissue myoepithelioma (1 of 20), ossifying fibromyxoid tumor (3 of 10), and Ewing sarcoma (3 of 10), among other tumor types. The majority of these cases showed labeling in <25% of the tumor cells. Although not entirely sensitive or specific, INSM1 could be a potential marker for the diagnosis of extraskeletal myxoid chondrosarcoma when molecular genetic access is limited.	[Yoshida, Akihiko; Makise, Naohiro; Wakai, Susumu; Hiraoka, Nobuyoshi] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan; [Yoshida, Akihiko; Kawai, Akira] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan; [Makise, Naohiro] Univ Tokyo, Dept Pathol, Tokyo, Japan; [Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo, Japan	Yoshida, A (reprint author), Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	akyoshid@ncc.go.jp		Makise, Naohiro/0000-0002-6991-747X	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K19065]	We thank Sachiko Miura, Toshiko Sakaguchi, and Chizu Kina for technical assistance. The study was supported in part by JSPS Grant-in-Aid for Young Scientists (15K19065).	Agaram NP, 2014, HUM PATHOL, V45, P1084, DOI 10.1016/j.humpath.2014.01.007; Aigner T, 2004, MODERN PATHOL, V17, P214, DOI 10.1038/modpathol.3800036; Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Benini S, 2014, J MOL DIAGN, V16, P314, DOI 10.1016/j.jmoldx.2013.12.002; Broehm CJ, 2014, CANCER GENET-NY, V207, P276, DOI 10.1016/j.cancergen.2014.06.024; Cummings TJ, 2000, J CUTAN PATHOL, V27, P141, DOI 10.1034/j.1600-0560.2000.027003141.x; Demicco EG, 2013, AM J SURG PATHOL, V37, P752, DOI 10.1097/PAS.0b013e3182796e46; ENZINGER FM, 1972, HUM PATHOL, V3, P421, DOI 10.1016/S0046-8177(72)80042-X; Farkas LM, 2008, NEURON, V60, P40, DOI 10.1016/j.neuron.2008.09.020; Filion C, 2009, J PATHOL, V217, P83, DOI 10.1002/path.2445; Filion C, 2012, TUMOR BIOL, V33, P1599, DOI 10.1007/s13277-012-0415-2; Flucke U, 2012, VIRCHOWS ARCH, V460, P621, DOI 10.1007/s00428-012-1240-0; Fujino K, 2017, INT J CLIN EXP PATHO, V10, P5393; Fujino K, 2015, AM J PATHOL, V185, P3164, DOI 10.1016/j.ajpath.2015.08.018; Gierl MS, 2006, GENE DEV, V20, P2465, DOI 10.1101/gad.381806; Goh YW, 2001, HISTOPATHOLOGY, V39, P514, DOI 10.1046/j.1365-2559.2001.01277.x; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Graham RPD, 2011, AM J SURG PATHOL, V35, P1615, DOI 10.1097/PAS.0b013e3182284a3f; Harris M, 2000, AM J SURG PATHOL, V24, P1020, DOI 10.1097/00000478-200007000-00015; Hisaoka M, 2004, GENE CHROMOSOME CANC, V40, P325, DOI 10.1002/gcc.20044; Hisaoka M, 2003, MODERN PATHOL, V16, P453, DOI 10.1097/01.MP.0000067422.61241.64; Hornick JL, 2003, AM J SURG PATHOL, V27, P1183, DOI 10.1097/00000478-200309000-00001; Kuji S, 2017, GYNECOL ONCOL, V144, P384, DOI 10.1016/j.ygyno.2016.11.020; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Lucas DR, 1999, HISTOPATHOLOGY, V35, P201; Lucas DR, 2013, WHO CLASSIFICATION T, P223; Meis-Kindblom JM, 1999, AM J SURG PATHOL, V23, P636, DOI 10.1097/00000478-199906000-00002; Noguchi H, 2010, HUM PATHOL, V41, P336, DOI 10.1016/j.humpath.2009.04.028; Okamoto S, 2001, HUM PATHOL, V32, P1116, DOI 10.1053/hupa.2001.28226; Oliveira AM, 2000, MODERN PATHOL, V13, P900, DOI 10.1038/modpathol.3880161; Poulin H, 2006, BIOCHEM BIOPH RES CO, V346, P306, DOI 10.1016/j.bbrc.2006.05.134; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Rosenbaum JN, 2015, AM J CLIN PATHOL, V144, P579, DOI 10.1309/AJCPGZWXXBSNL4VD; Rosenbaum JN, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-6; Shao R, 2016, ANN DIAGN PATHOL, V23, P14, DOI 10.1016/j.anndiagpath.2016.04.004; Sjogren H, 2003, AM J PATHOL, V162, P781, DOI 10.1016/S0002-9440(10)63875-8; STOUT AP, 1953, CANCER, V6, P581, DOI 10.1002/1097-0142(195305)6:3<581::AID-CNCR2820060315>3.0.CO;2-T; Subramanian S, 2005, J PATHOL, V206, P433, DOI 10.1002/path.1792; Urbini M, 2017, GENE CHROMOSOME CANC, V56, P582, DOI 10.1002/gcc.22462; Wildner H, 2008, DEVELOPMENT, V135, P473, DOI 10.1242/dev.011783; Xie JP, 2002, GENOMICS, V80, P54, DOI 10.1006/geno.2002.6800	42	11	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					744	752		10.1038/modpathol.2017.189			9	Pathology	Pathology	GE9VN	WOS:000431579000005	29327709	Bronze			2019-10-28	
J	Smit, KN; van Poppelen, NM; Vaarwater, J; Verdijk, R; van Marion, R; Kalirai, H; Coupland, SE; Thornton, S; Farquhar, N; Dubbink, HJ; Paridaens, D; de Klein, A; Kilic, E				Smit, Kyra N.; van Poppelen, Natasha M.; Vaarwater, Jolanda; Verdijk, Robert; van Marion, Ronald; Kalirai, Helen; Coupland, Sarah E.; Thornton, Sophie; Farquhar, Neil; Dubbink, Hendrikus-Jan; Paridaens, Dion; de Klein, Annelies; Kilic, Emine			Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma	MODERN PATHOLOGY			English	Article							DEPENDENT PROBE AMPLIFICATION; CHOROIDAL MELANOMA; SOMATIC MUTATIONS; SF3B1 MUTATIONS; SURVIVAL; IMMUNOHISTOCHEMISTRY; ABNORMALITIES; HETEROGENEITY; EXPRESSION; PREDICTS	Uveal melanoma is a highly aggressive cancer of the eye, in which nearly 50% of the patients die from metastasis. It is the most common type of primary eye cancer in adults. Chromosome and mutation status have been shown to correlate with the disease-free survival. Loss of chromosome 3 and inactivating mutations in BAP1, which is located on chromosome 3, are strongly associated with 'high-risk' tumors that metastasize early. Other genes often involved in uveal melanoma are SF3B1 and EIF1AX, which are found to be mutated in intermediate-and low-risk tumors, respectively. To obtain genetic information of all genes in one test, we developed a targeted sequencing method that can detect mutations in uveal melanoma genes and chromosomal anomalies in chromosome 1, 3, and 8. With as little as 10 ng DNA, we obtained enough coverage on all genes to detect mutations, such as substitutions, deletions, and insertions. These results were validated with Sanger sequencing in 28 samples. In 490% of the cases, the BAP1 mutation status corresponded to the BAP1 immunohistochemistry. The results obtained in the Ion Torrent single-nucleotide polymorphism assay were confirmed with several other techniques, such as fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, and Illumina SNP array. By validating our assay in 27 formalin-fixed paraffin-embedded and 43 fresh uveal melanomas, we show that mutations and chromosome status can reliably be obtained using targeted next-generation sequencing. Implementing this technique as a diagnostic pathology application for uveal melanoma will allow prediction of the patients' metastatic risk and potentially assess eligibility for new therapies.	[Smit, Kyra N.; van Poppelen, Natasha M.; Vaarwater, Jolanda; Kilic, Emine] Erasmus Univ, Med Ctr, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Smit, Kyra N.; van Poppelen, Natasha M.; de Klein, Annelies] Erasmus Univ, Med Ctr, Dept Clin Genet, Rotterdam, Netherlands; [Verdijk, Robert; van Marion, Ronald; Dubbink, Hendrikus-Jan] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands; [Kalirai, Helen; Coupland, Sarah E.; Thornton, Sophie; Farquhar, Neil] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England; [Paridaens, Dion] Rotterdam Eye Hosp, Rotterdam, Netherlands	Kilic, E (reprint author), Erasmus Univ, Med Ctr, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.kilic@erasmusmc.nl	Kilic, Emine/G-8026-2017	Kilic, Emine/0000-0002-6867-3792; Thornton, Sophie/0000-0001-7693-7279	Combined Ophthalmic Research Rotterdam	We thank Quincy van den Bosch for his assistance with imaging and Tom Brands and Tom de Vries-Lentsch for helping with the figures. This study was supported by a grant of the Combined Ophthalmic Research Rotterdam.	Coupland SE, 1996, ARCH OPHTHALMOL-CHIC, V114, P751, DOI 10.1001/archopht.1996.01100130743022; Damato B, 2011, PROG RETIN EYE RES, V30, P285, DOI 10.1016/j.preteyeres.2011.05.003; Damato B, 2010, CLIN CANCER RES, V16, P6083, DOI 10.1158/1078-0432.CCR-10-2076; de Lange MJ, 2015, ONCOTARGET, V6, P37824, DOI 10.18632/oncotarget.5637; Dogrusoz M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20212; Dubbink HJ, 2016, J MOL DIAGN, V18, P775, DOI 10.1016/j.jmoldx.2016.06.002; Ewens KG, 2013, INVEST OPHTH VIS SCI, V54, P5721, DOI 10.1167/iovs.13-12195; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Harbour J, 2006, SCIENCE, V330, P1410; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Johansson P, 2016, ONCOTARGET, V7, P4624, DOI 10.18632/oncotarget.6614; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Kilic E, 2005, INVEST OPHTH VIS SCI, V46, P2253, DOI 10.1167/iovs.04-1460; Koopmans AE, 2013, BRIT J CANCER, V109, P493, DOI 10.1038/bjc.2013.299; Koopmans AE, 2014, MODERN PATHOL, V27, P1321, DOI 10.1038/modpathol.2014.43; Lake SL, 2012, INVEST OPHTH VIS SCI, V53, P2647, DOI 10.1167/iovs.12-9584; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Mensink HW, 2009, INVEST OPHTH VIS SCI, V50, P500, DOI 10.1167/iovs.08-2279; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Onken MD, 2004, CANCER RES, V64, P7205, DOI 10.1158/0008-5472.CAN-04-1750; PRESCHER G, 1990, J NATL CANCER I, V82, P1765, DOI 10.1093/jnci/82.22.1765; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Royer-Bertrand B, 2016, AM J HUM GENET, V99, P1190, DOI 10.1016/j.ajhg.2016.09.008; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Vaarwater J, 2012, MELANOMA RES, V22, P30, DOI 10.1097/CMR.0b013e32834e6a67; van de Nes JAP, 2016, AM J SURG PATHOL, V40, P796, DOI 10.1097/PAS.0000000000000645; van den Bosch T, 2012, INVEST OPHTH VIS SCI, V53, P2668, DOI 10.1167/iovs.11-8697; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; White VA, 1998, CANCER, V83, P354, DOI 10.1002/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.3.CO;2-C; Woodman SE, 2012, CANCER J, V18, P148, DOI 10.1097/PPO.0b013e31824bd256; Yavuzyigitoglu S, 2016, INVEST OPHTH VIS SCI, V27, P2232; Yavuzyigitoglu S, 2016, OPHTHALMOLOGY, V123, P1118, DOI 10.1016/j.ophtha.2016.01.023	33	9	9	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					763	771		10.1038/modpathol.2017.187			9	Pathology	Pathology	GE9VN	WOS:000431579000007	29327717	Bronze			2019-10-28	
J	Sinha, N; Rigby, MH; McNeil, ML; Taylor, SM; Trites, JRB; Hart, RD; Bullock, MJ				Sinha, Namita; Rigby, Matthew H.; McNeil, Michael L.; Taylor, S. Mark; Trites, Jonathan R. B.; Hart, Robert D.; Bullock, Martin J.			The histologic risk model is a useful and inexpensive tool to assess risk of recurrence and death in stage I or II squamous cell carcinoma of tongue and floor of mouth	MODERN PATHOLOGY			English	Article							ORAL-CANCER; SURGICAL MARGINS; SURVIVAL; HEAD	Surgery is the mainstay of treatment for low-stage (stage I/II, ie, T1N0/T2N0) squamous cell carcinoma of oral cavity. However, a significant percentage of low-stage squamous cell carcinoma of oral cavity will develop local recurrence and disease-related mortality. In this study, we stratified 64 patients with low-stage of oral tongue and floor of mouth patients into high-, intermediate-and low-risk categories based on existing histologic risk model. The classification of these risk categories was based on presence or absence of perineural invasion and evaluation of tumor-host junction for worst pattern of invasion and lymphocytic host response. We correlated risk category and other variables with recurrence and death. In a univariate model, high-risk category tumors had a significantly higher rate of recurrence and death due to recurrence compared with low/intermediate-risk categories (P=0.000 and P=0.047, respectively). Controlling for margin status and T-stage, high-risk category had a 12.4 odds ratio of later recurrence when compared with low/intermediate-risk categories, with a P-value of 0.001. In conclusion, we found low-stage oral cavity squamous cell carcinoma patients with high-risk category have a significantly higher risk for recurrence when compared with patients in the low-or intermediate-risk category, even when controlling for margin status and T-stage. These patients may be suitable candidates for adjuvant treatment to decrease morbidity and mortality associated with a recurrence. Our results indicate that the histologic risk model is a useful and simple tool to assess risk of recurrence in stage I or II squamous cell carcinoma of oral cavity.	[Sinha, Namita; Bullock, Martin J.] Dalhousie Univ, Dept Pathol, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; [Rigby, Matthew H.; McNeil, Michael L.; Taylor, S. Mark; Trites, Jonathan R. B.; Hart, Robert D.] Dalhousie Univ, Div Otolaryngol Head & Neck Surg, Dept Surg, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada	Sinha, N (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 425 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	drnamitasinha1@gmail.com					Braakhuis BJM, 2010, ORAL ONCOL, V46, P485, DOI 10.1016/j.oraloncology.2010.01.019; Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167; Brandwein-Gensler M, 2010, AM J SURG PATHOL, V34, P676, DOI 10.1097/PAS.0b013e3181d95c37; BRYNE M, 1989, J ORAL PATHOL MED, V18, P432, DOI 10.1111/j.1600-0714.1989.tb01339.x; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Curry JM, 2014, SEMIN ONCOL, V41, P217, DOI 10.1053/j.seminoncol.2014.03.003; Iseli TA, 2012, J LARYNGOL OTOL, V126, P289, DOI 10.1017/S002221511100332X; Li YF, 2013, HEAD NECK PATHOL, V7, P211, DOI 10.1007/s12105-012-0412-1; LOREE TR, 1990, AM J SURG, V160, P410, DOI 10.1016/S0002-9610(05)80555-0; Omura K, 2014, INT J CLIN ONCOL, V19, P423, DOI 10.1007/s10147-014-0689-z; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pulte D, 2010, ONCOLOGIST, V15, P994, DOI 10.1634/theoncologist.2009-0289; Rennemo E, 2010, J ORAL PATHOL MED, V39, P657, DOI 10.1111/j.1600-0714.2010.00905.x; Shah JP, 2009, ORAL ONCOL, V45, P394, DOI 10.1016/j.oraloncology.2008.05.017; Sinha P, 2015, HEAD NECK-J SCI SPEC, V37, P52, DOI 10.1002/hed.23553; Sutton DN, 2003, INT J ORAL MAX SURG, V32, P30, DOI 10.1054/ijom.2002.0313; Weijers M, 2004, INT J ORAL MAX SURG, V33, P146, DOI 10.1054/ijom.2002.0469; ZELEFSKY MJ, 1990, HEAD NECK-J SCI SPEC, V12, P470, DOI 10.1002/hed.2880120604	18	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					772	779		10.1038/modpathol.2017.183			8	Pathology	Pathology	GE9VN	WOS:000431579000008	29393297	Bronze			2019-10-28	
J	von der Thusen, JH; Vandermeulen, E; Vos, R; Weynand, B; Verbeken, EK; Verleden, SE				von der Thusen, Jan H.; Vandermeulen, Elly; Vos, Robin; Weynand, Birgit; Verbeken, Erik K.; Verleden, Stijn E.			The histomorphological spectrum of restrictive chronic lung allograft dysfunction and implications for prognosis	MODERN PATHOLOGY			English	Article							BRONCHIOLITIS OBLITERANS SYNDROME; STEM-CELL TRANSPLANTATION; DIFFUSE ALVEOLAR DAMAGE; PLEUROPARENCHYMAL FIBROELASTOSIS; PHENOTYPES; PNEUMONIA; DIAGNOSIS; SURVIVAL	Chronic lung allograft dysfunction continues to be the main contributor to poor long-term allograft survival after lung transplantation. The restrictive phenotype of chronic lung allograft dysfunction carries a particularly poor prognosis. Little is known about the pathogenetic mechanisms involved in restrictive chronic lung allograft dysfunction. In this study, we performed histomorphological and immunohistochemical analysis of restrictive chronic lung allograft dysfunction lungs. Explant lung tissue from 21 restrictive chronic lung allograft dysfunction patients was collected and histopathologic patterns of rejection, fibrosis and vascular changes were scored after routine histochemical stains and additional immunohistochemistry for endothelial markers and C4d. In all, 75% of cases showed evidence of acute cellular rejection; lymphocytic bronchiolitis was absent in most lungs, whereas in 55% there was obliterative bronchiolitis. Almost half of the cases showed a pattern consistent with pleuroparenchymal fibro-elastosis (n=10), and a subset showed nonspecific interstitial pneumonia (n=5) or irregular emphysema (n=5). Fibrinous alveolar exudates were frequently seen in association with fibrosis (n=6), but no diffuse alveolar damage was found. Evidence of microvascular damage was present in most cases. An emphysematous pattern of fibrosis was associated with a better survival (P=0.0030), whereas fibrinous exudates were associated with a worse survival (P=0.0007). In addition to the previously described nonspecific interstitial pneumonia and pleuroparenchymal fibro-elastosis patterns in restrictive chronic lung allograft dysfunction, we are the first to describe a pattern of fibrosis-induced subpleural/paraseptal emphysema. This pattern confers a better survival, whereas fibrinous exudates are associated with a worse survival. We believe that our findings offer a pathogenetic theory for pleuroparenchymal fibro-elastosis in restrictive chronic lung allograft dysfunction, and show that restrictive chronic lung allograft dysfunction is an increasingly heterogeneous disease with presumably different mechanisms of subpattern formation.	[von der Thusen, Jan H.] Erasmus MC, Dept Pathol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands; [Vandermeulen, Elly; Vos, Robin; Verleden, Stijn E.] Katholieke Univ Leuven, Lung Transplant Unit, Dept Clin & Expt Med, Leuven, Belgium; [Weynand, Birgit; Verbeken, Erik K.] Katholieke Univ Leuven, Dept Pathol, Leuven, Belgium	von der Thusen, JH (reprint author), Erasmus MC, Dept Pathol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	j.vonderthusen@erasmusmc.nl	Weynand, Birgit/H-9587-2019				Jonigk D, 2017, J PATHOL CLIN RES, V3, P17, DOI 10.1002/cjp2.60; Martinu T, 2006, CHEST, V129, P1016, DOI 10.1378/chest.129.4.1016; Meyer KC, 2014, EUR RESPIR J, V44, P1479, DOI 10.1183/09031936.00107514; Ofek E, 2013, MODERN PATHOL, V26, P350, DOI 10.1038/modpathol.2012.171; Paraskeva M, 2013, AM J RESP CRIT CARE, V187, P1360, DOI 10.1164/rccm.201210-1831OC; Reddy TL, 2012, EUR RESPIR J, V40, P377, DOI 10.1183/09031936.00165111; Sato M, 2013, J HEART LUNG TRANSPL, V32, P23, DOI 10.1016/j.healun.2012.09.026; Sato M, 2012, J HEART LUNG TRANSPL, V31, P354, DOI 10.1016/j.healun.2011.12.015; Sato M, 2011, J HEART LUNG TRANSPL, V30, P735, DOI 10.1016/j.healun.2011.01.712; Shino MY, 2013, AM J RESP CRIT CARE, V188, P1117, DOI 10.1164/rccm.201305-0861OC; Stewart S, 2007, J HEART LUNG TRANSPL, V26, P1229, DOI 10.1016/j.healun.2007.10.017; Takeuchi Y, 2015, HISTOPATHOLOGY, V66, P536, DOI 10.1111/his.12553; Todd JL, 2014, AM J RESP CRIT CARE, V189, P159, DOI 10.1164/rccm.201306-1155OC; Verleden SE, 2016, J HEART LUNG TRANSPL, V35, P1078, DOI 10.1016/j.healun.2016.03.022; Verleden SE, 2015, EUR RESPIR J, V46, P1430, DOI 10.1183/09031936.00010615; Verleden SE, 2015, J HEART LUNG TRANSPL, V34, P625, DOI 10.1016/j.healun.2014.11.007; Verleden SE, 2014, AM J RESP CRIT CARE, V189, P292, DOI 10.1164/rccm.201310-1894OC; Von der Thusen JH, 2013, CURR RESPIR MED REV, V9, P238, DOI 10.2174/1573398X113096660025; von der Thusen JH, 2011, MODERN PATHOL, V24, P1633, DOI 10.1038/modpathol.2011.114; Yusen RD, 2015, J HEART LUNG TRANSPL, V34, P1264, DOI 10.1016/j.healun.2015.08.014	20	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					780	790		10.1038/modpathol.2017.180			11	Pathology	Pathology	GE9VN	WOS:000431579000009	29327719	Bronze			2019-10-28	
J	Rosenbaum, JN; Bloom, R; Forys, JT; Hiken, J; Armstrong, JR; Branson, J; McNulty, S; Velu, PD; Pepin, K; Abel, H; Cottrell, CE; Pfeifer, JD; Kulkarni, S; Govindan, R; Konnick, EQ; Lockwood, CM; Duncavage, EJ				Rosenbaum, Jason N.; Bloom, Ryan; Forys, Jason T.; Hiken, Jeff; Armstrong, Jon R.; Branson, Julie; McNulty, Samantha; Velu, Priya D.; Pepin, Kymberlie; Abel, Haley; Cottrell, Catherine E.; Pfeifer, John D.; Kulkarni, Shashikant; Govindan, Ramaswamy; Konnick, Eric Q.; Lockwood, Christina M.; Duncavage, Eric J.			Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer	MODERN PATHOLOGY			English	Article							ANAPLASTIC LYMPHOMA KINASE; IN-SITU HYBRIDIZATION; EML4-ALK FUSION; CRIZOTINIB RESISTANCE; GENE REARRANGEMENT; TYROSINE KINASE; COPY NUMBER; RT-PCR; IDENTIFICATION; ADENOCARCINOMA	In lung adenocarcinoma, canonical EML4-ALK inversion results in a fusion protein with a constitutively active ALK kinase domain. Evidence of ALK rearrangement occurs in a minority (2-7%) of lung adenocarcinoma, and only similar to 60% of these patients will respond to targeted ALK inhibition by drugs such as crizotinib and ceritinib. Clinically, targeted anti-ALK therapy is often initiated based on evidence of an ALK genomic rearrangement detected by fluorescence in situ hybridization (FISH) of interphase cells in formalin-fixed, paraffin-embedded tissue sections. At the genomic level, however, ALK rearrangements are heterogeneous, with multiple potential breakpoints in EML4, and alternate fusion partners. Using next-generation sequencing of DNA and RNA together with ALK immunohistochemistry, we comprehensively characterized genomic breakpoints in 33 FISH-positive lung adenocarcinomas. Of these 33 cases, 29 (88%) had detectable DNA level ALK rearrangements involving EML4, KIF5B, or non-canonical partners including ASXL2, ATP6V1B1, PRKAR1A, and SPDYA. A subset of 12 cases had material available for RNA-Seq. Of these, eight of eight (100%) cases with DNA rearrangements showed ALK fusion transcripts from RNA-Seq; three of four cases (75%) without detectable DNA rearrangements were similarly negative by RNA-Seq, and one case was positive by RNA-Seq but negative by DNA next-generation sequencing. By immunohistochemistry, 17 of 19 (89%) tested cases were clearly positive for ALK protein expression; the remaining cases had no detectable DNA level rearrangement or had a non-canonical rearrangement not predicted to form a fusion protein. Survival analysis of patients treated with targeted ALK inhibitors demonstrates a significant difference in mean survival between patients with next-generation sequencing confirmed EML4-ALK rearrangements, and those without (20.6 months vs 5.4 months, P<0.01). Together, these data demonstrate abundant genomic heterogeneity among ALK-rearranged lung adenocarcinoma, which may account for differences in treatment response with targeted ALK inhibitors.	[Rosenbaum, Jason N.; Velu, Priya D.] Univ Penn, Dept Pathol & Lab Med, Ctr Personalized Diagnost, 3020 Market St Ste 220, Philadelphia, PA 19104 USA; [Bloom, Ryan] Unum Therapeut, Cambridge, MA USA; [Forys, Jason T.; Hiken, Jeff; Armstrong, Jon R.] Cofactor Genom, St Louis, MO USA; [Branson, Julie; McNulty, Samantha; Pfeifer, John D.; Duncavage, Eric J.] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Anat & Mol Pathol, St Louis, MO USA; [Pepin, Kymberlie; Govindan, Ramaswamy] Washington Univ, Sch Med, Dept Internal Med, Div Med Oncol, St Louis, MO 63110 USA; [Abel, Haley] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63110 USA; [Cottrell, Catherine E.] Nationwide Childrens Hosp, Inst Genom Med, Columbus, OH USA; [Kulkarni, Shashikant] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Konnick, Eric Q.; Lockwood, Christina M.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA	Rosenbaum, JN (reprint author), Univ Penn, Dept Pathol & Lab Med, Ctr Personalized Diagnost, 3020 Market St Ste 220, Philadelphia, PA 19104 USA.	Jason.Rosenbaum@uphs.upenn.edu		Rosenbaum, Jason/0000-0002-7969-7423; Konnick, Eric/0000-0001-5904-1788; Lockwood, Christina/0000-0001-9036-7604			Abel HJ, 2014, J MOL DIAGN, V16, P405, DOI 10.1016/j.jmoldx.2014.03.006; Ali SM, 2016, ONCOLOGIST, V21, P762, DOI 10.1634/theoncologist.2015-0497; [Anonymous], 2017, FUSIONPLEX ALK RET R; Antoniu SA, 2011, EXPERT OPIN THER TAR, V15, P351, DOI 10.1517/14728222.2011.550880; Armstrong F, 2004, ONCOGENE, V23, P6071, DOI 10.1038/sj.onc.1207813; Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429; Boland JM, 2009, HUM PATHOL, V40, P1152, DOI 10.1016/j.humpath.2009.01.012; Chaft JE, 2012, MOL CANCER THER, V11, P485, DOI 10.1158/1535-7163.MCT-11-0692; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Conde E, 2016, EXPERT REV MOL DIAGN, V16, P707, DOI 10.1586/14737159.2016.1172963; Cottrell CE, 2014, J MOL DIAGN, V16, P89, DOI 10.1016/j.jmoldx.2013.10.002; Demidova I, 2017, LUNG CANCER, V103, P17, DOI 10.1016/j.lungcan.2016.11.001; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Fang DD, 2014, J THORAC ONCOL, V9, P285, DOI 10.1097/JTO.0000000000000087; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Hallberg B, 2010, NEW ENGL J MED, V363, P1760, DOI 10.1056/NEJMe1010404; Hong M, 2014, J THORAC ONCOL, V9, P419, DOI 10.1097/JTO.0000000000000061; Inamura K, 2008, J THORAC ONCOL, V3, P13, DOI 10.1097/JTO.0b013e31815e8b60; Inamura K, 2009, MODERN PATHOL, V22, P508, DOI 10.1038/modpathol.2009.2; Jividen K, 2014, GENE CHROMOSOME CANC, V53, P963, DOI 10.1002/gcc.22207; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Jung Y, 2012, GENE CHROMOSOME CANC, V51, P590, DOI 10.1002/gcc.21945; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kelly LM, 2014, P NATL ACAD SCI USA, V111, P4233, DOI 10.1073/pnas.1321937111; Kim S, 2013, J THORAC ONCOL, V8, P415, DOI 10.1097/JTO.0b013e318283dcc0; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lin JJ, 2016, J CLIN ONCOL, V34, P3363, DOI 10.1200/JCO.2016.68.5891; Lin YT, 2016, CLIN LUNG CANCER, V17, pE77, DOI 10.1016/j.cllc.2016.03.005; Ma H, 2016, ONCOTARGET, V7, P70128, DOI 10.18632/oncotarget.11806; Majewski IJ, 2013, J PATHOL, V230, P270, DOI 10.1002/path.4209; Mano H, 2008, CANCER SCI, V99, P2349, DOI 10.1111/j.1349-7006.2008.00972.x; Martelli MP, 2009, AM J PATHOL, V174, P661, DOI 10.2353/ajpath.2009.080755; McLeer-Florin A, 2012, J THORAC DIS, V4, P240, DOI 10.3978/j.issn.2072-1439.2012.06.05; McLeer-Florin A, 2012, J THORAC ONCOL, V7, P348, DOI 10.1097/JTO.0b013e3182381535; Miyata K, 2017, DIAGN CYTOPATHOL, V45, P963, DOI 10.1002/dc.23800; Ou SHI, 2014, J THORAC ONCOL, V9, P1821, DOI 10.1097/JTO.0000000000000368; Paik JH, 2011, J THORAC ONCOL, V6, P466, DOI 10.1097/JTO.0b013e31820b82e8; Pekar-Zlotin M, 2015, ONCOLOGIST, V20, P316, DOI 10.1634/theoncologist.2014-0389; Perner S, 2008, NEOPLASIA, V10, P298, DOI 10.1593/NEO.07878; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Pritchard CC, 2012, J MOL DIAGN, V14, P357, DOI 10.1016/j.jmoldx.2012.03.002; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Roth A, 2014, J CLIN PATHOL, V67, P839, DOI 10.1136/jclinpath-2014-202394; Saber A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153065; Salido M, 2011, J THORAC ONCOL, V6, P21, DOI 10.1097/JTO.0b013e3181fb7cd6; Sasaki T, 2011, CANCER RES, V71, P6051, DOI 10.1158/0008-5472.CAN-11-1340; Savic S, 2015, LUNG CANCER, V89, P104, DOI 10.1016/j.lungcan.2015.05.012; Sehn JK, 2014, AM J SURG PATHOL, V38, P534, DOI 10.1097/PAS.0000000000000161; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2011, CLIN CANCER RES, V17, P2081, DOI 10.1158/1078-0432.CCR-10-1591; Society A. C, 2017, CANC FACTS FIG 2015; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Taheri D, 2016, VIRCHOWS ARCH, V469, P345, DOI 10.1007/s00428-016-1969-y; Takeuchi K, 2008, CLIN CANCER RES, V14, P6618, DOI 10.1158/1078-0432.CCR-08-1018; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Teixido C, 2014, TRANSL LUNG CANCER R, V3, P70, DOI 10.3978/j.issn.2218-6751.2014.02.02; Togashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031323; U.S. Food and Drug Administration, 2017, LIST APPR COMP DIAGN; van der Wekken AJ, 2016, CRIT REV ONCOL HEMAT, V100, P107, DOI 10.1016/j.critrevonc.2016.01.024; von Laffert M, 2014, J THORAC ONCOL, V9, P1685, DOI 10.1097/JTO.0000000000000332; Vysis ALK, 2017, BREAK APART FISH PRO; Wang YW, 2011, NEOPLASIA, V13, P704, DOI 10.1593/neo.11222; Weickhardt AJ, 2013, CANCER-AM CANCER SOC, V119, P1467, DOI 10.1002/cncr.27913; WHO, 2017, CANC FACT SHEET; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Wynes MW, 2014, J THORAC ONCOL, V9, P631, DOI 10.1097/JTO.0000000000000115; Yang JCH, 2017, J CLIN ONCOL, V35, P1288, DOI 10.1200/JCO.2016.70.3223; Yi ES, 2011, J THORAC ONCOL, V6, P459, DOI 10.1097/JTO.0b013e318209edb9; Yoshida T, 2016, J CLIN ONCOL S, V34, P3383; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626	76	8	8	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					791	808		10.1038/modpathol.2017.181			18	Pathology	Pathology	GE9VN	WOS:000431579000010	29327716	Bronze			2019-10-28	
J	Amatya, VJ; Kushitani, K; Kai, Y; Suzuki, R; Miyata, Y; Okada, M; Takeshima, Y				Amatya, Vishwa Jeet; Kushitani, Kei; Kai, Yuichiro; Suzuki, Rui; Miyata, Yoshihiro; Okada, Morihito; Takeshima, Yukio			Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma	MODERN PATHOLOGY			English	Article							WORLD-HEALTH-ORGANIZATION; PANCREATIC-CANCER; MALIGNANT MESOTHELIOMA; CELLS; CLASSIFICATION; CARCINOMA; PLEURA; TUMORS	Histological morphology alone is not sufficient for the pathological diagnosis of malignant mesothelioma. Positive and negative immunohistochemical markers are necessary to differentiate it from lung adenocarcinoma. As calretinin and D2-40, the recognized positive markers of mesothelioma, are expressed in lung adenocarcinoma to some extent, novel markers with high specificity are desirable. In this study, we investigated the applicability of glypican-1 immunohistochemistry to differentiate epithelioid mesothelioma from lung adenocarcinoma. We investigated 82 cases of epithelioid mesothelioma and 97 cases of lung adenocarcinoma for glypican-1 expression by immunohistochemistry using a commercially available antibody. All 82 cases of epithelioid mesothelioma showed glypican-1 expression, most with diffuse and strong reactivity. In contrast, only three cases of lung adenocarcinoma showed focal glypican-1 expression. Glypican-1 expression showed 100 sensitivity, 97% specificity, and a 98% accuracy rate to differentiate epithelioid mesothelioma from lung adenocarcinoma. The sensitivity of glypican -1 immunohistochemistry is as high as that of calretinin and D2-40, and its specificity is far better than that of calretinin and D2-40. Therefore, we recommend including glypican -1 immunohistochemistry as a positive marker of epithelioid mesothelioma.	[Amatya, Vishwa Jeet; Kushitani, Kei; Kai, Yuichiro; Suzuki, Rui; Takeshima, Yukio] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathol, Hiroshima, Japan; [Kai, Yuichiro; Miyata, Yoshihiro; Okada, Morihito] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan	Takeshima, Y (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ykotake@hiroshima-u.ac.jp	Okada, Morihito/H-1495-2019; Amatya, Vishwa Jeet/B-5164-2009	Amatya, Vishwa Jeet/0000-0002-4986-2109	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K08742]	We thank Yukari Go and Tasuya Nakagawa of the Technical Center in Hiroshima University for excellent technical assistance, and Naomi Fukuhara for administrative support. This work was supported by JSPS KAKENHI Grant Number 17K08742.	Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Attanoos RL, 2003, HISTOPATHOLOGY, V43, P444, DOI 10.1046/j.1365-2559.2003.01674.x; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Duan L, 2013, ASIAN J SURG, V36, P7, DOI 10.1016/j.asjsur.2012.08.001; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; Hara H, 2016, BRIT J CANCER, V115, P66, DOI 10.1038/bjc.2016.183; Harada E, 2017, ONCOTARGET, V8, P24741, DOI 10.18632/oncotarget.15799; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kuraoka M, 2017, AM J SURG PATHOL, V41, P1045, DOI 10.1097/PAS.0000000000000852; Lamoureux F, 2007, BIOESSAYS, V29, P758, DOI 10.1002/bies.20612; Matsuda K, 2001, CANCER RES, V61, P5562; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Su G, 2006, AM J PATHOL, V168, P2014, DOI 10.2353/ajpath.2006.050800; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507	18	3	3	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					809	815		10.1038/modpathol.2017.190			7	Pathology	Pathology	GE9VN	WOS:000431579000011	29327712				2019-10-28	
J	Jesinghaus, M; Konukiewitz, B; Foersch, S; Stenzinger, A; Steiger, K; Muckenhuber, A; Gross, C; Mollenhauer, M; Roth, W; Detlefsen, S; Weichert, W; Kloppel, G; Pfarr, N; Schlitter, AM				Jesinghaus, Moritz; Konukiewitz, Bjoern; Foersch, Sebastian; Stenzinger, Albrecht; Steiger, Katja; Muckenhuber, Alexander; Gross, Claudia; Mollenhauer, Martin; Roth, Wilfried; Detlefsen, Sonke; Weichert, Wilko; Kloepel, Gunter; Pfarr, Nicole; Schlitter, Anna Melissa			Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix	MODERN PATHOLOGY			English	Article							MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; BETA-CATENIN; LUNG-CANCER; TUMORS; ASSOCIATION; STABILITY; BEHAVIOR; FEATURES; EGFR	The appendix gives rise to goblet cell carcinoids, which represent special carcinomas with distinct biological and histological features. Their genetic background and molecular relationship to colorectal adenocarcinoma is largely unknown. We therefore performed a next-generation sequencing analysis of 25 appendiceal carcinomas including 11 goblet cell carcinoids, 7 adenocarcinomas ex-goblet cell carcinoid, and 7 primary colorectal-type adenocarcinomas, using a modified Colorectal Cancer specific Panel comprising 32 genes linked to colorectal and neuroendocrine tumorigenesis. The mutational profiles of these neoplasms were compared with those of conventional adenocarcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine carcinomas of the colorectum. In addition, a large-scale pan-cancer sequencing panel covering 409 genes was applied to selected cases of goblet cell carcinoid/adenocarcinoma ex-goblet cell carcinoid (n=2, respectively). Mutations in colorectal cancer-related genes (eg, TP53, KRAS, APC) were rare to absent in both, goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid, but frequent in primary colorectal-type adenocarcinomas of the appendix. Additional large-scale sequencing of selected goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid revealed mutations in Wnt-signaling-associated genes (USP9X, NOTCH1, CTNNA1, CTNNB1, TRRAP). These data suggest that appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid constitute a morphomolecular entity, histologically and genetically distinct from appendiceal colorectal-type adenocarcinomas and its colorectal counterparts. Altered Wnt-signaling associated genes, apart from APC, may act as potential drivers of these neoplasms. The absence of KRAS/NRAS mutations might render some of these tumors eligible for anti-EGFR directed therapy regimens.	[Jesinghaus, Moritz; Konukiewitz, Bjoern; Steiger, Katja; Muckenhuber, Alexander; Gross, Claudia; Mollenhauer, Martin; Weichert, Wilko; Kloepel, Gunter; Pfarr, Nicole; Schlitter, Anna Melissa] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany; [Jesinghaus, Moritz; Muckenhuber, Alexander; Weichert, Wilko; Schlitter, Anna Melissa] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany; [Foersch, Sebastian; Roth, Wilfried] Univ Hosp Mainz, Inst Pathol, Mainz, Germany; [Stenzinger, Albrecht] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Stenzinger, Albrecht] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Detlefsen, Sonke] Univ Hosp Odense, Dept Clin Pathol, Odense, Denmark	Jesinghaus, M (reprint author), Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany.	moritz.jesinghaus@tum.de		Steiger, Katja/0000-0002-7269-5433			Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Brierley JD, 2017, TNM ONLINE, P93, DOI DOI 10.1002/9780471420194.TNMC19.PUB3; CARR NJ, 1995, CANCER-AM CANCER SOC, V75, P757, DOI 10.1002/1097-0142(19950201)75:3<757::AID-CNCR2820750303>3.0.CO;2-F; Carr NJ, 2010, WHO CLASSIFICATION T, P122; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Dimmler A, 2014, PATHOL RES PRACT, V210, P274, DOI 10.1016/j.prp.2014.01.002; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Finkbeiner MG, 2008, CELL CYCLE, V7, P3908, DOI 10.4161/cc.7.24.7354; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hristov AC, 2007, AM J SURG PATHOL, V31, P1502, DOI 10.1097/PAS.0b013e31804f7aa1; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; Jesinghaus M, 2016, GENE CHROMOSOME CANC, V55, P505, DOI 10.1002/gcc.22352; Jesinghaus M, 2016, GENE CHROMOSOME CANC, V55, P268, DOI 10.1002/gcc.22330; Jesinghaus M, 2015, AM J SURG PATHOL, V39, P1140, DOI 10.1097/PAS.0000000000000423; Katzin WE, 2012, MILLS SE PATHOLOGIST, P698; Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Liu X, 2014, CLIN CHEM, V60, P1004, DOI 10.1373/clinchem.2014.225565; Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pfarr N, 2017, GENE CHROMOSOME CANC, V56, P758, DOI 10.1002/gcc.22480; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378; Premarathne S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05451-5; Ramnani DM, 1999, CANCER, V86, P14, DOI 10.1002/(SICI)1097-0142(19990701)86:1<14::AID-CNCR4>3.0.CO;2-X; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Rossi RE, 2015, SURG ONCOL, V24, P47, DOI 10.1016/j.suronc.2015.01.001; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Stenzinger A, 2015, ONCOLOGIST, V20, pE10, DOI 10.1634/theoncologist.2014-0280; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Taggart MW, 2015, ARCH PATHOL LAB MED, V139, P782, DOI 10.5858/arpa.2013-0047-OA; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Tang LH, 2010, ARCH PATHOL LAB MED, V134, P1612, DOI 10.1043/2010-0073-CCR.1; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150; Yang B, 2016, ONCOTARGET, V7, P79501, DOI 10.18632/oncotarget.12819; Yuan ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058685	41	6	6	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAY	2018	31	5					829	839		10.1038/modpathol.2017.184			11	Pathology	Pathology	GE9VN	WOS:000431579000013	29327707	Bronze			2019-10-28	
J	Pratt, VM; Del Tredici, AL; Hachad, H; Ji, Y; Kalman, LV; Scott, SA; Weck, KE				Pratt, Victoria M.; Del Tredici, Andria L.; Hachad, Houda; Ji, Yuan; Kalman, Lisa V.; Scott, Stuart A.; Weck, Karen E.			Recommendations for Clinical CYP2C19 Genotyping Allele Selection A Report of the Association for Molecular Pathology	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; DNA REFERENCE MATERIALS; COLLABORATIVE-PROJECT; POLYMORPHISM; METABOLISM; CYP2D6; GUIDELINES; INHIBITORS; UPDATE; GENES	This document was developed by the Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee, whose aim is to recommend variants for inclusion in clinical pharmacogenomic testing panels. The goals of the Association for Molecular Pathology PGx Working Group are to define the key attributes of PGx alleles recommended for clinical testing and to define a minimum set of variants that should be included in clinical PGx genotyping assays. These recommendations include a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing PGx assays. The Working Group considered variant allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. These CYP2C19 genotyping recommendations are the first of a series of recommendations for PGx testing. These recommendations are not to be interpreted as restrictive, but they are meant to provide a helpful guide.	[Pratt, Victoria M.; Del Tredici, Andria L.; Hachad, Houda; Ji, Yuan; Kalman, Lisa V.; Scott, Stuart A.; Weck, Karen E.] Assoc Mol Pathol, Clin Practice Comm, Pharmacogen Working Grp, Bethesda, MD USA; [Pratt, Victoria M.] Indiana Univ Sch Med, Dept Med & Mol Genet, 550 N Univ Dr,AOC 6029, Indianapolis, IN 46202 USA; [Del Tredici, Andria L.] Millennium Hlth LLC, San Diego, CA USA; [Hachad, Houda] Translat Software, Bellevue, WA USA; [Ji, Yuan] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; [Ji, Yuan] Univ Utah, Sch Med, ARUP Labs, Salt Lake City, UT USA; [Kalman, Lisa V.] Ctr Dis Control & Prevent, Div Lab Syst, Atlanta, GA USA; [Scott, Stuart A.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Scott, Stuart A.] Sema4, Stamford, CT USA; [Weck, Karen E.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Weck, Karen E.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA	Pratt, VM (reprint author), Indiana Univ Sch Med, Dept Med & Mol Genet, 550 N Univ Dr,AOC 6029, Indianapolis, IN 46202 USA.	vpratt@iu.edu		Scott, Stuart/0000-0001-5720-1864; Hachad, Houda/0000-0001-9953-6398; Weck, Karen/0000-0002-8516-333X	Association for Molecular Pathology	Supported by the Association for Molecular Pathology.	Chaudhry AS, 2015, DRUG METAB DISPOS, V43, P1226, DOI 10.1124/dmd.115.064428; DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594; DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419; Flockhart D A, 1995, Clin Pharmacokinet, V29 Suppl 1, P45; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Gray KA, 2015, NUCLEIC ACIDS RES, V43, pD1079, DOI 10.1093/nar/gku1071; Grody WW, 2001, GENET MED, V3, P87, DOI 10.1097/00125817-200103000-00001; Hicks JK, 2017, CLIN PHARMACOL THER, V102, P37, DOI 10.1002/cpt.597; Hicks JK, 2015, CLIN PHARMACOL THER, V98, P127, DOI 10.1002/cpt.147; Ingelman-Sundberg M, 2000, PHARMACOGENETICS, V10, P91, DOI 10.1097/00008571-200002000-00012; Kitts A., 2013, NCBI HDB; Mattocks CJ, 2010, EUR J HUM GENET, V18, P1276, DOI 10.1038/ejhg.2010.101; Moriyama B, 2017, CLIN PHARMACOL THER, V102, P45, DOI 10.1002/cpt.583; Moyer AM, 2017, AM J MED, V130, P1342, DOI 10.1016/j.amjmed.2017.07.012; Pratt VM, 2016, J MOL DIAGN, V18, P109, DOI 10.1016/j.jmoldx.2015.08.005; Pratt VM, 2010, J MOL DIAGN, V12, P835, DOI 10.2353/jmoldx.2010.100090; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Scott SA, 2013, CLIN PHARMACOL THER, V94, P317, DOI 10.1038/clpt.2013.105; Scott SA, 2012, PHARMACOGENOMICS J, V12, P297, DOI 10.1038/tpj.2011.5; Scott SA, 2013, J MOL DIAGN, V15, P783, DOI 10.1016/j.jmoldx.2013.06.004; Scott SA, 2012, PHARMACOGENET GENOM, V22, P159, DOI 10.1097/FPC.0b013e32834d4962; Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002; Skierka JM, 2014, PHARMACOGENOMICS, V15, P1197, DOI [10.2217/PGS.14.72, 10.2217/pgs.14.72]; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Watson Michael S, 2004, Genet Med, V6, P387, DOI 10.1097/01.GIM.0000139506.11694.7C; Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96; Yang Y, 2017, PHARMACOGENOMICS, V18, P673, DOI 10.2217/pgs-2017-0033	27	9	9	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					269	276		10.1016/j.jmoldx.2018.01.011			8	Pathology	Pathology	GE3EF	WOS:000431095900001	29474986	Green Published, Bronze			2019-10-28	
J	Shen, F; Sergi, C; Sun, HL				Shen, Fan; Sergi, Consolato; Sun, Hui-lung			Hepatitis B Virus Covalently Closed Circular DNA-Selective Droplet Digital PCR A Sensitive and Noninvasive Method for Hepatocellular Carcinoma Diagnosis?	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Editorial Material							INFECTION		[Shen, Fan; Sergi, Consolato] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada; [Sergi, Consolato] Stollery Childrens Hosp, Dept Pediat, Edmonton, AB, Canada; [Sun, Hui-lung] Univ Chicago, Howard Hughes Med Inst, Dept Chem, 929 E 57 St, Chicago, IL 60637 USA; [Sun, Hui-lung] Univ Chicago, Howard Hughes Med Inst, Inst Biophys Dynam, 929 E 57 St, Chicago, IL 60637 USA	Sun, HL (reprint author), Univ Chicago, Howard Hughes Med Inst, Dept Chem, 929 E 57 St, Chicago, IL 60637 USA.; Sun, HL (reprint author), Univ Chicago, Howard Hughes Med Inst, Inst Biophys Dynam, 929 E 57 St, Chicago, IL 60637 USA.	huilung@uchicago.edu	Sergi, Consolato/A-1126-2009				Hong XP, 2017, HEPATOLOGY, V66, P2066, DOI 10.1002/hep.29479; Huang JT, 2018, J MOL DIAGN, V20, P334, DOI 10.1016/j.jmoldx.2018.01.010; Levrero M, 2009, J HEPATOL, V51, P581, DOI 10.1016/j.jhep.2009.05.022; Li XL, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060139; Mu D, 2015, BIOTECHNOL LETT, V37, P2063, DOI 10.1007/s10529-015-1890-5; Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031; Sola I., 2015, GUIDELINES PREVENTIO; Sunbul M, 2014, WORLD J GASTROENTERO, V20, P5427, DOI 10.3748/wjg.v20.i18.5427; Yang HC, 2018, VIRUS RES, V244, P304, DOI 10.1016/j.virusres.2017.06.010	9	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					277	278		10.1016/j.jmoldx.2018.03.001			2	Pathology	Pathology	GE3EF	WOS:000431095900002	29572198				2019-10-28	
J	Gunn, SR; Govender, S; Sims, CL; Khurana, A; Koo, S; Scoggin, J; Moore, MW; Cotter, PD				Gunn, Shelly R.; Govender, Shailin; Sims, Cynthe L.; Khurana, Aditi; Koo, Samuel; Scoggin, Jayne; Moore, Mathew W.; Cotter, Philip D.			Reference Size Matching, Whole-Genome Amplification, and Fluorescent Labeling as a Method for Chromosomal Microarray Analysis of Clinically Actionable Copy Number Alterations in Formalin-Fixed, Paraffin-Embedded Tumor Tissue	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CANCER; CARCINOMA; DNA	Cancer genome copy number alterations (CNAs) assist clinicians in selecting targeted therapeutics. Solid tumor CNAs are most commonly evaluated in formalin-fixed, paraffin-embedded (FFPE) tissue by fluorescence in situ hybridization. Although fluorescence in situ hybridization is a sensitive and specific assay for interrogating preselected genomic regions, it provides no information about coexisting clinically significant copy number changes. Chromosomal microarray analysis is an alternative DNA-based method for interrogating genome-wide CNAs in solid tumors. However, DNA extracted from FFPE tumor tissue produces an essential, yet problematic, sample type. The College of American Pathologists/American Society of Clinical Oncology guidelines for optimal tumor tissue handling, published in 2007 for breast cancer and in 2016 for gastroesophageal adenocarcinomas, are lacking for other solid tumors. Thus, cold ischemia times are seldom monitored in non breast cancer and non gastroesophageal adenocarcinomas, and all tumor biospecimens are affected by chemical fixation. Although intended to preserve specimens for long-term storage, formalin fixation causes Loss of genetic information through DNA damage. Herein, we describe a reference size matching, whole-genome amplification, and fluorescent labeling method for FFPE-derived DNA designed to improve chromosomal microarray results from suboptimal nucleic acids and salvage highly degraded samples. With this technological advance, whole-genome copy number analysis of tumor DNA can be reliably performed in the clinical laboratory for a wide variety of tissue conditions and tumor types.	[Gunn, Shelly R.; Govender, Shailin; Sims, Cynthe L.; Khurana, Aditi; Koo, Samuel; Scoggin, Jayne; Moore, Mathew W.; Cotter, Philip D.] ResearchDx PacificDx, Clin Lab, Irvine, CA USA; [Gunn, Shelly R.] Targeted Genom, San Antonio, TX USA	Gunn, SR (reprint author), ResearchDx PacificDx, 5 Mason, Irvine, CA 92618 USA.	sgunn@researchdx.com					Barley AN, 2017, J CLIN ONCOL, V35, P449; Chiba M, 2016, INT J ONCOL, V49, P2236, DOI 10.3892/ijo.2016.3736; Chou A, 2013, GENOME MED, V5, DOI 10.1186/gm482; Garrido-Castro AC, 2013, TRANSL LUNG CANCER R, V2, P122, DOI 10.3978/j.issn.2218-6751.2013.02.02; Cox WG, 2004, BIOTECHNIQUES, V36, P114, DOI 10.2144/04361RR02; Craig JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038881; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Gowryshankar A, 2014, J GASTROINTEST ONCOL, V5, P25, DOI 10.3978/j.issn.2078-6891.2013.039; Gunn S, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-2; Gunn S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-396; Iolascon A, 1998, HEPATOLOGY, V27, P989, DOI 10.1002/hep.510270414; Jacobs S, 2007, CANCER RES, V67, P2544, DOI 10.1158/0008-5472.CAN-06-3597; Levsky JM, 2003, J CELL SCI, V116, P2833, DOI 10.1242/jcs.00633; Limaye SA, 2013, ONCOLOGIST, V18, P294, DOI 10.1634/theoncologist.2012-0369; Perez EA, 2014, CANCER TREAT REV, V40, P276, DOI 10.1016/j.ctrv.2013.09.001; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Schneider SA, 2014, MODERN PATHOL, V27, P758, DOI 10.1038/modpathol.2013.201; Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wong H, 2013, THER ADV GASTROENTER, V6, P15, DOI 10.1177/1756283X12453636; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zook JM, 2014, NAT BIOTECHNOL, V32, P246, DOI 10.1038/nbt.2835	25	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					279	288		10.1016/j.jmoldx.2018.01.004			10	Pathology	Pathology	GE3EF	WOS:000431095900003	29471114				2019-10-28	
J	Denis, J; Forouzanfar, F; Herbrecht, R; Toussaint, E; Kessler, R; Sabou, M; Candolfi, E; Letsher-Bru, V				Denis, Julie; Forouzanfar, Faezeh; Herbrecht, Raoul; Toussaint, Elise; Kessler, Romain; Sabou, Marcela; Candolfi, Ermanno; Letsher-Bru, Valerie			Evaluation of Two Commercial Real-Time PCR Kits for Aspergillus DNA Detection in Bronchoalveolar Lavage Fluid in Patients with Invasive Pulmonary Aspergillosis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							POLYMERASE-CHAIN-REACTION; GALACTOMANNAN ENZYME-IMMUNOASSAY; LATERAL-FLOW DEVICE; AZOLE RESISTANCE; HEMATOLOGICAL MALIGNANCIES; IMMUNOCOMPROMISED PATIENTS; FUNGAL-INFECTIONS; CLINICAL-SAMPLES; SERUM SAMPLES; DIAGNOSIS	Invasive pulmonary aspergillosis (IPA) is a common complication of immunosuppression. Rapid diagnosis using molecular techniques is essential to improve patient survival. PCR techniques are promising in enhancing Aspergillus detection in blood and respiratory samples. We evaluate for the first time the performances of two commercial real-time PCR kits, the A. fumigatus Bio-Evolution and the MycoGENIE A. fumigatus for the detection of A. fumigatus DNA in bronchoalveolar lavage (BAL) from patients with and without IPA. Seventy-three BAL samples were included. Thirty-one of them corresponded to patients with probable IPA, 11 to patients with possible IPA, and 31 to patients without aspergillosis, according to the 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. In the probable IPA group, A. fumigatus Bio-Evolution and the MycoGENIE A. fumigatus real-time PCR kits showed a specificity of 100% and a sensitivity of 81% and 71 %, respectively. The A. fumigatus Bio-Evolution detected Aspergillus DNA in the 14 BAL samples with a positive Aspergillus culture result, whereas the MycoGENIE A. fumigatus PCR result was positive only for 12. In the possible IPA group, there were no positive real-time PCR or positive Aspergillus culture results. For the patients without aspergillosis, no positive result was observed for real-time PCR kit, despite the presence of various other non-Aspergillus pathogens in this group. Our study demonstrates an excellent specificity and a good sensitivity of A. fumigatus DNA detection in BAL samples with both kits.	[Denis, Julie; Forouzanfar, Faezeh; Sabou, Marcela; Candolfi, Ermanno; Letsher-Bru, Valerie] Hop Univ Strasbourg, Lab Parasitol & Mycol Med, 1 Pl Hop, F-67000 Strasbourg, France; [Forouzanfar, Faezeh] Univ Strasbourg, Inst Parasitol & Pathol Trop, Federat Med Translat, Strasbourg, France; [Herbrecht, Raoul; Toussaint, Elise] Hop Univ Strasbourg, Serv Oncol & Hematol, Hop Hautepierre, Strasbourg, France; [Herbrecht, Raoul; Toussaint, Elise] Univ Strasbourg, Strasbourg, France; [Kessler, Romain] CHU Strasbourg, Pole Pathol Thorac, Strasbourg, France	Denis, J (reprint author), Hop Univ Strasbourg, Lab Parasitol & Mycol Med, 1 Pl Hop, F-67000 Strasbourg, France.	denisj@unistra.fr		Herbrecht, Raoul/0000-0002-9381-4876			Arvanitis M, 2014, J CLIN MICROBIOL, V52, P3731, DOI 10.1128/JCM.01365-14; Bergeron A, 2012, BLOOD, V119, P1831, DOI 10.1182/blood-2011-04-351601; Blot SI, 2012, AM J RESP CRIT CARE, V186, P56, DOI 10.1164/rccm.201111-1978OC; Boch T, 2015, MYCOSES, V58, P735, DOI 10.1111/myc.12424; Chen JJ, 2013, INT J MED SCI, V10, P1625, DOI 10.7150/ijms.6824; Chong GM, 2016, J ANTIMICROB CHEMOTH, V71, P3528, DOI 10.1093/jac/dkw323; Chong GLM, 2015, J CLIN MICROBIOL, V53, P868, DOI 10.1128/JCM.03216-14; Choukri F, 2015, MED MYCOL, V53, P593, DOI 10.1093/mmy/myv029; Dannaoui E, 2017, J CLIN MICROBIOL, V55, P3210, DOI 10.1128/JCM.01032-17; Danylo A, 2014, MED MYCOL, V52, P577, DOI 10.1093/mmy/myu025; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Eigl S, 2017, MED MYCOL, V55, P528, DOI 10.1093/mmy/myw102; Eigl S, 2015, INT J ANTIMICROB AG, V46, P401, DOI 10.1016/j.ijantimicag.2015.05.017; Francesconi A, 2008, J CLIN MICROBIOL, V46, P1978, DOI 10.1128/JCM.02246-07; Gu ZM, 2014, ARCH PATHOL LAB MED, V138, P1474, DOI 10.5858/arpa.2013-0592-OA; Heng SC, 2014, DIAGN MICR INFEC DIS, V79, P322, DOI 10.1016/j.diagmicrobio.2014.03.020; Herbrecht R, 2012, ANN NY ACAD SCI, V1272, P23, DOI 10.1111/j.1749-6632.2012.06829.x; Herbrecht R, 2012, J ANTIMICROB CHEMOTH, V67, P2731, DOI 10.1093/jac/dks266; Hoenigl M, 2014, J CLIN MICROBIOL, V52, P2039, DOI 10.1128/JCM.00467-14; Imbert S, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.01.027; Johnson GL, 2015, J CLIN MICROBIOL, V53, P2103, DOI 10.1128/JCM.00110-15; Khot PD, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-73; Kurosawa M, 2012, INT J HEMATOL, V96, P748, DOI 10.1007/s12185-012-1210-y; Ledoux MP, 2017, J ANTIMICROB CHEMOTH, V72, pI48, DOI 10.1093/jac/dkx033; Lortholary O, 2011, CLIN MICROBIOL INFEC, V17, P1882, DOI 10.1111/j.1469-0691.2011.03548.x; Maertens J, 2009, CLIN INFECT DIS, V49, P1688, DOI 10.1086/647935; Mengoli C, 2009, LANCET INFECT DIS, V9, P89, DOI 10.1016/S1473-3099(09)70019-2; Montesinos I, 2017, J CLIN MICROBIOL, V55, P2391, DOI 10.1128/JCM.00520-17; Musher B, 2004, J CLIN MICROBIOL, V42, P5517, DOI 10.1128/JCM.42.12.5517-5522.2004; Orsi CF, 2015, NEW MICROBIOL, V38, P75; Orsi CF, 2012, DIAGN MICR INFEC DIS, V73, P138, DOI 10.1016/j.diagmicrobio.2012.03.001; Patterson TF, 2016, CLIN INFECT DIS, V63, P433, DOI 10.1093/cid/ciw444; Paulussen C, 2017, MICROB BIOTECHNOL, V10, P296, DOI 10.1111/1751-7915.12367; Perkhofer S, 2010, INT J ANTIMICROB AG, V36, P531, DOI 10.1016/j.ijantimicag.2010.08.010; Perry MD, 2014, J MED MICROBIOL, V63, P1160, DOI 10.1099/jmm.0.076315-0; Pini P, 2015, EUR J CLIN MICROBIOL, V34, P131, DOI 10.1007/s10096-014-2211-y; Rotjanapan P, 2018, MED MYCOL, V56, P186, DOI 10.1093/mmy/myx029; TACCONE FS, 2015, CRIT CARE, V19; Torelli R, 2011, J CLIN MICROBIOL, V49, P4273, DOI 10.1128/JCM.05026-11; Tuon Felipe Francisco, 2007, Revista Iberoamericana de Micologia, V24, P89; van der Linden JWM, 2015, EMERG INFECT DIS, V21, P1041, DOI 10.3201/eid2106.140717; Wheat LJ, 2008, EUR J CLIN MICROBIOL, V27, P245, DOI 10.1007/s10096-007-0437-7; White PL, 2015, CLIN INFECT DIS, V61, P1293, DOI 10.1093/cid/civ507; White PL, 2011, J CLIN MICROBIOL, V49, P3842, DOI 10.1128/JCM.05316-11; Zou MX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043347	45	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					298	306		10.1016/j.jmoldx.2017.12.005			9	Pathology	Pathology	GE3EF	WOS:000431095900005	29471112	Bronze			2019-10-28	
J	Erlichster, M; Tye-Din, JA; Varney, MD; Skafidas, E; Kwan, P				Erlichster, Michael; Tye-Din, Jason A.; Varney, Michael D.; Skafidas, Efstratios; Kwan, Patrick			Rapid, Loop-Mediated Isothermal Amplification Detection of Celiac Disease Risk Alleles	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							DIAGNOSTIC-ACCURACY; DNA AMPLIFICATION; VISUAL DETECTION; CARE; POINT; PREVALENCE; LAMP; GASTROENTEROLOGY; PATHOGENESIS; GUIDELINES	Human leukocyte antigen (HLA) genotyping has become a useful investigation in the diagnostic work up of celiac disease (CD), with utility in risk stratification and screening. However, broad application of this technology has been hindered by the cost and time burden of conventional laboratory-based assays. We have developed and validated CD loop-mediated isothermal amplification (CD-LAMP), a LAMP assay, which enables rapid identification of the signature CD risk genotypes, HLA-DQ2.5, HLA-DQ8, HLA-DQ2.2, and HLA-DQA1*05. Sample-to-answer is achieved in approximately 65 minutes without DNA purification, thermal cycling, or specialized analytical equipment. CD-LAMP genotyping of samples was 100% concordant with accredited pathology genotyping on a panel of 40 blood and 20 saliva samples. In a panel of 100 purified DNA samples, genotyping of the high-risk DQ2.5 genotype was 100% concordant with accredited pathology genotyping, with slightly reduced sensitivity for the DQ8 genotype (97.1%) and reduced specificity for the DQ8 (93.9%) and DQ2.2 (95.1%) genotypes. CD-LAMP results are easily visualized and instrument free through the addition of a DNA intercalating dye after amplification. Combined with point-of-care antibody testing, CD-LAMP may enable immediate, confident CD diagnosis at a low cost in the clinical setting.	[Erlichster, Michael; Skafidas, Efstratios] Univ Melbourne, Ctr Neural Engn, Melbourne, Vic, Australia; [Erlichster, Michael; Kwan, Patrick] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Tye-Din, Jason A.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Skafidas, Efstratios; Kwan, Patrick] Univ Melbourne, Dept Elect & Elect Engn, Melbourne, Vic, Australia; [Tye-Din, Jason A.] Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic, Australia; [Tye-Din, Jason A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tye-Din, Jason A.] Royal Melbourne Hosp, Dept Gastroenterol, Melbourne, Vic, Australia; [Kwan, Patrick] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia; [Varney, Michael D.] Australian Red Cross Blood Serv, Victorian Transplantat & Immunogenet Serv, Melbourne, Vic, Australia; [Skafidas, Efstratios] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia	Kwan, P (reprint author), Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia.	kwan@unimelb.edu.au	Tye-Din, Jason A./A-6109-2019	Tye-Din, Jason A./0000-0001-7687-9654; Skafidas, Efstratios/0000-0003-4263-9972	Australian Postgraduate Award scholarship; Melbourne Neuroscience Institute postgraduate award; Mathison Centenary Fellowship from the University of Melbourne; Coeliac Australia	Supported by an Australian Postgraduate Award scholarship (M.E.), a Melbourne Neuroscience Institute postgraduate award (M.E.), the Mathison Centenary Fellowship from the University of Melbourne (J.A.T.-D.), and Coeliac Australia (J.A.T.-D.).	Abadie V, 2011, ANNU REV IMMUNOL, V29, P493, DOI 10.1146/annurev-immunol-040210-092915; Anderson RP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-188; Benkebil F, 2013, WORLD J GASTROENTERO, V19, P5111, DOI 10.3748/wjg.v19.i31.5111; Chang M, 2009, J CLIN GASTROENTEROL, V43, P43, DOI 10.1097/MCG.0b013e318187311d; Cheng SH, 2009, CLIN CHEM, V55, P1568, DOI 10.1373/clinchem.2009.127894; Cheung YK, 2014, BRIT J DERMATOL, V171, P90, DOI 10.1111/bjd.12897; Cook J, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0573-y; Craw P, 2012, LAB CHIP, V12, P2469, DOI [10.1039/c2lc40100b, 10.1039/c21c40100b]; Curtis KA, 2008, J VIROL METHODS, V151, P264, DOI 10.1016/j.jviromet.2008.04.011; Ferre-Lopez S, 2004, CLIN GASTROENTEROL H, V2, P480, DOI 10.1016/S1542-3565(04)00166-1; Fu SJ, 2011, APPL BIOCHEM BIOTECH, V163, P845, DOI 10.1007/s12010-010-9088-8; Gujral N, 2012, WORLD J GASTROENTERO, V18, P6036, DOI 10.3748/wjg.v18.i42.6036; Hayashida K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003578; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Iwamoto T, 2003, J CLIN MICROBIOL, V41, P2616, DOI 10.1128/JCM.41.6.2616-2622.2003; Jones HJ, 2010, ARCH DIS CHILD, V95, DOI 10.1136/adc.2009.173849; Karell K, 2003, HUM IMMUNOL, V64, P469, DOI 10.1016/S0198-8859(03)00027-2; Klitz W, 2003, TISSUE ANTIGENS, V62, P296, DOI 10.1034/j.1399-0039.2003.00103.x; Korponay-Szabo IR, 2007, BMJ-BRIT MED J, V335, P1244, DOI 10.1136/bmj.39405.472975.80; Koskinen L, 2009, IMMUNOGENETICS, V61, P247, DOI 10.1007/s00251-009-0361-3; Ludvigsson JF, 2008, GUT, V57, P1074, DOI 10.1136/gut.2007.133868; Ludvigsson JF, 2014, GUT, V63, P1210, DOI 10.1136/gutjnl-2013-306578; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; Mack SJ, 2013, TISSUE ANTIGENS, V81, P194, DOI 10.1111/tan.12093; Martinelli P, 2000, GUT, V46, P332, DOI 10.1136/gut.46.3.332; Mustalahti K, 2010, ANN MED, V42, P587, DOI 10.3109/07853890.2010.505931; Newnham Evan D, 2015, Med J Aust, V202, P418; Njiru ZK, 2011, DIAGN MICR INFEC DIS, V69, P205, DOI 10.1016/j.diagmicrobio.2010.08.026; Norstrom F, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-118; Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63; Profaizer T, 2011, TISSUE ANTIGENS, V78, P31, DOI 10.1111/j.1399-0039.2011.01676.x; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Stedtfeld RD, 2012, LAB CHIP, V12, P1454, DOI 10.1039/c2lc21226a; Tanner N. A., 2014, CURR PROTOC MOL BIOL, V105; Tanner NA, 2015, BIOTECHNIQUES, V58, P59, DOI 10.2144/000114253; Tomita N, 2008, NAT PROTOC, V3, P877, DOI 10.1038/nprot.2008.57; Toumazou C, 2013, NAT METHODS, V10, P641, DOI 10.1038/nmeth.2520; Tye-Din JA, 2015, INTERN MED J, V45, P441, DOI 10.1111/imj.12716; Varney Michael D, 2012, Methods Mol Biol, V882, P27, DOI 10.1007/978-1-61779-842-9_3; Ventura A, 2002, GUT, V51, P897, DOI 10.1136/gut.51.6.897; Vijzelaar R, 2016, GENET TEST MOL BIOMA, V20, P158, DOI 10.1089/gtmb.2015.0233; Wahab PJ, 2002, AM J CLIN PATHOL, V118, P459; West J, 2004, BRIT MED J, V329, P716, DOI 10.1136/bmj.38169.486701.7C; Zhang C, 2016, DEV MKT SCI, P6	46	0	0	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					307	315		10.1016/j.jmoldx.2018.01.005			9	Pathology	Pathology	GE3EF	WOS:000431095900006	29458095	Bronze			2019-10-28	
J	Sieuwerts, AM; Mostert, B; van der Vlugt-Daane, M; Kraan, J; Beaufort, CM; Van, M; Prager, WJC; De Laere, B; Beije, N; Hamberg, P; Westgeest, HM; Tascilar, M; Dirix, LY; Onstenk, W; de Wit, R; Lolkema, MP; Mathijssen, RHJ; Martens, JWM; Sleijfer, S				Sieuwerts, Anieta M.; Mostert, Bianca; van der Vlugt-Daane, Michelle; Kraan, Jaco; Beaufort, Corine M.; Van, Mai; Prager, Wendy J. C.; De Laere, Bram; Beije, Nick; Hamberg, Paul; Westgeest, Hans M.; Tascilar, Metin; Dirix, Luc Y.; Onstenk, Wendy; de Wit, Ronald; Lolkema, Martijn P.; Mathijssen, Ron H. J.; Martens, John W. M.; Sleijfer, Stefan			An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							RESISTANT PROSTATE-CANCER; ENZALUTAMIDE; ABIRATERONE; MEN	Recent reports have emphasized the clinical relevance of detecting AR-V7 in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to measure AR-V7 by quantitative RT-PCR (RT-qPCR) in RNA isolated from CellSearch-enriched CTCs to provide an AR-V7 positive or AR-V7 negative score in a clinically acceptable time range. CellSearch-enirched CTCs from patients with metastatic castration resistant prostate cancer were characterized by RT-qPCR. After optimization, it was prospectively tested whether it was possible to report the AR-V7 status within 11 days (PRELUDE study). In the range of the RNA equivalent of 0.2 to 12 VCaP cells, the CV for AR-V7 was 9% (n = 37). The limit of detection was 0.3, and the limit of quantitation was 3 cells in the final RT-qPCR. No differences were observed between AR-V7 data generated by five technicians or in two different laboratories. For the 45 patients in PRELUDE, 13 patients were ineligible, 22 patients were AR-V7 negative, and 10 were AR-V7 positive. The median time to inform the physician of the test result was 7 days (range, 2 to 11 days). This assay can establish the AR-V7 status in CTCs from patients with metastatic castration resistant prostate cancer. Furthermore, it was possible to provide an AR-V7 outcome within 11 days, indicating that it may be used to choose between an anti androgen receptor or taxane-based cabazitaxel treatment.	[Sieuwerts, Anieta M.; Mostert, Bianca; van der Vlugt-Daane, Michelle; Kraan, Jaco; Beaufort, Corine M.; Van, Mai; Prager, Wendy J. C.; Beije, Nick; Onstenk, Wendy; de Wit, Ronald; Lolkema, Martijn P.; Mathijssen, Ron H. J.; Martens, John W. M.; Sleijfer, Stefan] Erasmus MC, Dept Med Oncol, Inst Canc, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Sieuwerts, Anieta M.; Mostert, Bianca; van der Vlugt-Daane, Michelle; Kraan, Jaco; Beaufort, Corine M.; Van, Mai; Prager, Wendy J. C.; Beije, Nick; Onstenk, Wendy; de Wit, Ronald; Lolkema, Martijn P.; Mathijssen, Ron H. J.; Martens, John W. M.; Sleijfer, Stefan] Canc Genom Netherlands, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [De Laere, Bram; Dirix, Luc Y.] GZA Hosp Sint Augustinus, Dept Oncol Res, Antwerp, Belgium; [De Laere, Bram; Dirix, Luc Y.] Univ Antwerp, Oncol Res Ctr, Antwerp, Belgium; [Hamberg, Paul] Franciscus Gasthuis & Vlietland, Dept Internal Med, Rotterdam, Netherlands; [Westgeest, Hans M.] Amphia Ziekenhuis, Dept Internal Med, Breda, Netherlands; [Tascilar, Metin] Isala Ziekenhuis, Dept Internal Med, Zwolle, Netherlands	Sieuwerts, AM (reprint author), Erasmus MC, Dept Med Oncol, Inst Canc, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.; Sieuwerts, AM (reprint author), Canc Genom Netherlands, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	a.sieuwerts@erasmusmc.nl		De Laere, Bram/0000-0002-1174-0384; Westgeest, Hans/0000-0002-5735-3638	Cancer Genomics Netherlands	We thank all of the patients and their physicians for their willingness to provide samples for this study and Cancer Genomics Netherlands for their support.	Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961; Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; De Laere B, 2017, EUR UROL, V72, P192, DOI 10.1016/j.eururo.2017.01.011; Fletcher C, 2017, CURR OPIN UROL, V27, P500, DOI 10.1097/MOU.0000000000000416; Gorges TM, 2016, CLIN CHEM, V62, P1504, DOI 10.1373/clinchem.2016.260299; Hawkins R, 2012, ANN LAB MED, V32, P5, DOI 10.3343/alm.2012.32.1.5; Korenchuk S, 2001, IN VIVO, V15, P163; Lokhandwala PM, 2017, J MOL DIAGN, V19, P115, DOI 10.1016/j.jmoldx.2016.08.003; Luk AWS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051047; Markowski MC, 2016, PROSTATE, V76, P1484, DOI 10.1002/pros.23232; Nakazawa M, 2015, ANN ONCOL, V26, P1859, DOI 10.1093/annonc/mdv282; Nieuweboer AJM, 2017, CLIN CANCER RES, V23, P1679, DOI 10.1158/1078-0432.CCR-16-2110; Onstenk W, 2015, EUR UROL, V68, P939, DOI 10.1016/j.eururo.2015.07.007; Qu FF, 2017, CLIN CANCER RES, V23, P726, DOI 10.1158/1078-0432.CCR-16-1070; Scher HI, 2017, EUR UROL, V71, P874, DOI 10.1016/j.eururo.2016.11.024; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Sieuwerts AM, 2011, CLIN CANCER RES, V17, P3600, DOI 10.1158/1078-0432.CCR-11-0255; Sieuwerts AM, 2009, BREAST CANCER RES TR, V118, P455, DOI 10.1007/s10549-008-0290-0; Todenhofer T, 2017, J UROLOGY, V197, P135, DOI 10.1016/j.juro.2016.06.094	20	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					316	325		10.1016/j.jmoldx.2018.01.008			10	Pathology	Pathology	GE3EF	WOS:000431095900007	29474983	Bronze			2019-10-28	
J	Aggarwal, A; Jamwal, M; Viswanathan, GK; Sharma, P; Sachdeva, MS; Bansal, D; Malhotra, P; Das, R				Aggarwal, Anu; Jamwal, Manu; Viswanathan, Ganesh K.; Sharma, Prashant; Sachdeva, ManUpdesh S.; Bansal, Deepak; Malhotra, Pankaj; Das, Reena			Optimal Reference Gene Selection for Expression Studies in Human Reticulocytes	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							TRANSCRIPTION-PCR DATA; REAL-TIME PCR; HEREDITARY SPHEROCYTOSIS; HOUSEKEEPING GENES; QRT-PCR; NORMALIZATION; RNA; INAPPROPRIATE; GUIDELINES; DIAGNOSIS	Reference genes are indispensable for normalizing mRNA levels across samples in real-time quantitative PCR. Their expression levels vary under different experimental conditions and because of several inherent characteristics. Appropriate reference gene selection is thus critical for gene-expression studies. This study aimed at selecting optimal reference genes for gene-expression analysis of reticulocytes and at validating them in hereditary spherocytosis (HS) and beta-thalassemia intermedia (beta TI) patients. Seven reference genes (PGK1, MPP1, HPRT1, ACTB, GAPDH, RN18S1, and SDHA) were selected because of published reports. Real-time quantitative PCR was performed on reticulocytes in 20 healthy volunteers, 15 HS patients, and 10 beta TI patients. Threshold cycle values were compared with fold-change method and Ref-Finder software. The stable reference genes recommended by RefFinder were validated with SLC4A1 and flow cytometric eosin-5'-maleimide binding assay values in HS patients and HBG2 and high performance liquid chromatography derived percentage of hemoglobin F in beta TI. Comprehensive ranking predicted MPP1 and GAPDH as optimal reference genes for reticulocytes that were not affected in HS and beta TI. This was further confirmed on validation with eosin-5'-maleimide results and percentage of hemoglobin F in HS and beta TI patients, respectively. Hence, MPP1 and GAPDH are good reference genes for reticulocyte expression studies compared with ACTB and RN18S1, the two most commonly used reference genes.	[Aggarwal, Anu; Jamwal, Manu; Viswanathan, Ganesh K.; Sharma, Prashant; Sachdeva, ManUpdesh S.; Das, Reena] Post Grad Inst Med Educ & Res, Dept Hematol, Chandigarh 160012, India; [Malhotra, Pankaj] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh 160012, India; [Bansal, Deepak] Post Grad Inst Med Educ & Res, Hematol Oncol Unit, Dept Pediat, Adv Pediat Ctr, Chandigarh 160012, India	Das, R (reprint author), Post Grad Inst Med Educ & Res, Dept Hematol, Chandigarh 160012, India.	reenadaspgi@hotmail.com		Bansal, Deepak/0000-0002-1009-7649	Department of Biotechnology, New Delhi, IndiaDepartment of Biotechnology (DBT) India [DBT/PR14802/MED/12/494/2010]; Indian Council of Medical ResearchIndian Council of Medical Research	Supported by the Department of Biotechnology, New Delhi, India, grant DBT/PR14802/MED/12/494/2010 (R.D., M.S.S., D.B., and P.M.). A.A. and M.J. received a Junior Research fellowship from the Indian Council of Medical Research.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Bolton-Maggs PHB, 2012, BRIT J HAEMATOL, V156, P37, DOI 10.1111/j.1365-2141.2011.08921.x; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chervoneva I, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-253; de Vasconcellos JF, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1273-x; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Falkenberg Virginia R, 2011, BMC Res Notes, V4, P324, DOI 10.1186/1756-0500-4-324; Guenin S, 2009, J EXP BOT, V60, P487, DOI 10.1093/jxb/ern305; Haj Khelil A, 2011, BLOOD CELL MOL DIS, V46, P133, DOI 10.1016/j.bcmd.2010.11.002; Italia Khushnooma, 2013, Indian J Hum Genet, V19, P251; Italia KY, 2009, CLIN CHIM ACTA, V407, P10, DOI 10.1016/j.cca.2009.06.019; Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201; Joshi P, 2016, INT J LAB HEMATOL, V38, P520, DOI 10.1111/ijlh.12533; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Lee TY, 2016, TURK J HEMATOL, V33, P15, DOI 10.4274/tjh.2014.0197; Maciag M, 2009, BRIT J HAEMATOL, V146, P326, DOI 10.1111/j.1365-2141.2009.07759.x; Mane Viraj P, 2008, J Biomol Tech, V19, P342; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Ranjbaran R, 2013, J CLIN LAB ANAL, V27, P267, DOI 10.1002/jcla.21594; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Silver N, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-33; Singleton BK, 2000, BLOOD, V95, P12; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Xie FL, 2012, PLANT MOL BIOL, V80, P75, DOI 10.1007/s11103-012-9885-2; Yao WJ, 2010, J BIOL CHEM, V285, P31408, DOI 10.1074/jbc.M110.130278	29	4	5	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					326	333		10.1016/j.jmoldx.2018.01.009			8	Pathology	Pathology	GE3EF	WOS:000431095900008	29474985	Bronze			2019-10-28	
J	Huang, JT; Yang, Y; Hu, YM; Liu, XH; Liao, MY; Morgan, R; Yuan, EF; Li, X; Liu, SM				Huang, Jing-Tao; Yang, Ying; Hu, Yi-Min; Liu, Xing-Hui; Liao, Mei-Yan; Morgan, Roy; Yuan, Er-Feng; Li, Xia; Liu, Song-Mei			A Highly Sensitive and Robust Method for Hepatitis B Virus Covalently Closed Circular DNA Detection in Single Cells and Serum	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							DROPLET DIGITAL PCR; HEPATOCELLULAR-CARCINOMA; CYSTATIN-C; CANCER PATIENTS; HEPATOCYTES; THERAPY; CCCDNA; INFECTION; QUANTIFICATION; QUANTITATION	Despite implications of persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the development of hepatocellular carcinoma (HCC), little is known about serum cccDNA in HBV-infected diseases. We developed a cccDNA-selective droplet digital PCR (ddPCR) to assess cccDNA content and dynamics across different stages of HCC development. One hundred forty-seven serum samples and 35 formalin-fixed, paraffin-embedded tumor tissues were derived from patients with HCC or HBV hepatitis/cirrhosis. After specific amplification and selective digestion, probe-based ddPCR was used to quantify cccDNA copy numbers in single cells and clinical samples. The cccDNA in single HepG2.2.15 cells ranged from 0 to 10.8 copies/cell. Compared with non-HCC patients, HCC patients showed a higher cccDNA-positive rate (89.9% versus 53.2%; P = 4.22 x 10(-6)) and increased serum cccDNA contents (P = 0.002 and P = 0.041 for hepatitis and cirrhosis patients, respectively). Serum cccDNA ranged from 84 to 1.07 x 10(5) copies/mL. Quantification of serum cccDNA and HBV-DNA was an effective way to discriminate HCC patients from non-HCC patients, with areas under the curve of receiver operating characteristic of 0.847 (95 % CI, 0.759-0.935; sensitivity, 74.5 %; specificity, 93.7%). cccDNA-selective ddPCR is sensitive to detect cccDNA in single cells and different clinical samples. Combined analysis of serum cccDNA and HBV-DNA may be a promising strategy for HBV-induced HCC surveillance and antiviral therapy evaluation.	[Huang, Jing-Tao; Yang, Ying; Yuan, Er-Feng; Liu, Song-Mei] Wuhan Univ, Ctr Gene Diag, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Liao, Mei-Yan] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China; [Hu, Yi-Min] Hunan Prov Peoples Hosp, Dept Clin Lab, Changsha, Hunan, Peoples R China; [Liu, Xing-Hui] Second Mil Med Univ, Dept Clin Lab, Gongli Hosp, Shanghai, Peoples R China; [Morgan, Roy] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA; [Li, Xia] Wuhan Med Treatment Ctr, Div Liver Dis, Wuhan, Hubei, Peoples R China	Liu, SM (reprint author), Wuhan Univ, Ctr Gene Diag, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	smliu@whu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81772276, 81472023]; National Basic Research Program of China 973 ProgramNational Basic Research Program of China [2012CB720600, 2012CB720605]; disciplines group construction project of Pudong Health 265, Bureau of Shanghai [PWZxq2017-15]	Supported by National Natural Science Foundation of China grants 81772276 and 81472023 (S.M.-L.), National Basic Research Program of China 973 Program grants 2012CB720600 and 2012CB720605 (S.M.-L.), and the disciplines group construction project of Pudong Health 265, Bureau of Shanghai PWZxq2017-15 (X.-H.L.).	Allenson K, 2017, ANN ONCOL, V28, P741, DOI 10.1093/annonc/mdx004; Amaddeo G, 2015, GUT, V64, P820, DOI 10.1136/gutjnl-2013-306228; Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Dahmcke CM, 2016, EUR UROL, V70, P916, DOI 10.1016/j.eururo.2016.06.035; Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012; Dong CS, 2015, ANTIVIR RES, V118, P110, DOI 10.1016/j.antiviral.2015.03.015; Durantel D, 2016, J HEPATOL, V64, pS117, DOI 10.1016/j.jhep.2016.02.016; Gao Y, 2017, HEPATOLOGY, V66, P1413, DOI 10.1002/hep.29316; Gish RG, 2015, ANTIVIR RES, V121, P97, DOI 10.1016/j.antiviral.2015.06.019; Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633; Hosaka T, 2010, LIVER INT, V30, P1461, DOI 10.1111/j.1478-3231.2010.02344.x; Huang JT, 2015, CLIN CHEM, V61, P290, DOI 10.1373/clinchem.2014.230227; Klover PJ, 2004, INT J BIOCHEM CELL B, V36, P753, DOI 10.1016/j.biocel.2003.10.002; KOCK J, 1993, J VIROL, V67, P4867; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kopitz C, 2005, CANCER RES, V65, P8608, DOI 10.1158/0008-5472; Lucifora J, 2016, J HEPATOL, V64, pS41, DOI 10.1016/j.jhep.2016.02.009; Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462; MacLachlan JH, 2015, LANCET, V386, P1515, DOI 10.1016/S0140-6736(15)61116-3; Margeridon S, 2008, ANTIMICROB AGENTS CH, V52, P3068, DOI 10.1128/AAC.01318-07; Mori J, 2016, CANCER SCI, V107, P298, DOI 10.1111/cas.12881; NAGAFUCHI Y, 1986, HEPATOLOGY, V6, P20, DOI 10.1002/hep.1840060105; Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809; Pei Yan-zhen, 2011, Zhonghua Gan Zang Bing Za Zhi, V19, P743, DOI 10.3760/cma.j.issn.1007-3418.2011.10.006; Ruelle J, 2014, J INT AIDS SOC, V17, P121, DOI 10.7448/IAS.17.4.19675; Rybicka M, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.41; Sahini N, 2014, PROG LIPID RES, V54, P86, DOI 10.1016/j.plipres.2014.02.002; Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031; Tian H, 2016, ANAL CHEM, V88, P11384, DOI 10.1021/acs.analchem.6b01225; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Volz T, 2007, GASTROENTEROLOGY, V133, P843, DOI 10.1053/j.gastro.2007.06.057; Volz T, 2013, J HEPATOL, V58, P861, DOI 10.1016/j.jhep.2012.12.008; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Wong DKH, 2006, J HEPATOL, V45, P553, DOI 10.1016/j.jhep.2006.05.014; Wong DKH, 2004, HEPATOLOGY, V40, P727, DOI 10.1002/hep.20353; Wu T, 2017, SCI REP-UK, V7, DOI 10.1038/srep42710; Xia YC, 2016, GASTROENTEROLOGY, V150, P194, DOI 10.1053/j.gastro.2015.09.026; Yegane S, 2004, TOHOKU J EXP MED, V203, P53, DOI 10.1620/tjem.203.53; Yuen MF, 2005, AM J GASTROENTEROL, V100, P1099, DOI 10.1111/j.1572-0241.2005.41530.x; Zoulim F, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021501	41	4	4	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					334	343		10.1016/j.jmoldx.2018.01.010			10	Pathology	Pathology	GE3EF	WOS:000431095900009	29656833				2019-10-28	
J	Schneider, T; Smith, GH; Rossi, MR; Hill, CE; Zhang, LS				Schneider, Thomas; Smith, Geoffrey H.; Rossi, Michael R.; Hill, Charles E.; Zhang, Linsheng			Validation of a Customized Bioinformatics Pipeline for a Clinical Next-Generation Sequencing Test Targeting Solid Tumor-Associated Variants	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							GENETIC-VARIATION; STANDARDS	Bioinformatic analysis is an integral and critical part of clinical next-generation sequencing. It is especially challenging for some pipelines to consistently identify insertions and deletions. We present the validation of an open source tumor amplicon pipeline (OTA-pipeline) for clinical next-generation sequencing targeting solid tumor associated variants. Raw data generated from 557 TruSight Tumor 26 samples and in silico data were analyzed by the OTA-pipeline and legacy pipeline and compared. Discrepant results were confirmed by orthogonal methods. The OTA-pipeline reported 22 variants that were not detected by the previously validated pipeline, including seven synonymous or intronic single-nucleotide variants, five single-nucleotide variants at frequency <5%, one insertion, and nine deletions. Variant allele frequencies reported by the two pipelines were highly concordant, although a few significant discrepancies were present. Analysis of in silico FASTQ files demonstrated a higher sensitivity of detecting complex insertions and deletions with the OTA-pipeline. The higher sensitivity came at a cost, because false-positive calls were increased in difficult-to-sequence regions. However, these calls were all flagged by our strand bias filter, distinguishing them from true variants. Our validation process provides a model for laboratories that want to establish an in-house bioinformatics pipeline for clinical next-generation sequencing.	[Schneider, Thomas; Smith, Geoffrey H.; Rossi, Michael R.; Hill, Charles E.; Zhang, Linsheng] Emory Univ, Sch Med, Dept Pathol & Lab Med, 531 Asbury Circle,Ste N252A, Atlanta, GA 30222 USA; [Rossi, Michael R.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA	Zhang, LS (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 531 Asbury Circle,Ste N252A, Atlanta, GA 30222 USA.	linsheng.zhang@emory.edu			Department of Pathology at Emory University; Emory Medical Laboratories	Supported by the Department of Pathology at Emory University and Emory Medical Laboratories.	Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163; Davies KD, 2016, J MOL DIAGN, V18, P572, DOI 10.1016/j.jmoldx.2016.03.002; Duncavage EJ, 2017, J MOL DIAGN, V19, P35, DOI 10.1016/j.jmoldx.2016.09.005; Fisher KE, 2016, J MOL DIAGN, V18, P299, DOI 10.1016/j.jmoldx.2015.11.006; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Huang WC, 2012, BIOINFORMATICS, V28, P593, DOI 10.1093/bioinformatics/btr708; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Little S, 2001, Curr Protoc Hum Genet, VChapter 9, DOI 10.1002/0471142905.hg0908s07; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	17	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					355	365		10.1016/j.jmoldx.2018.01.007			11	Pathology	Pathology	GE3EF	WOS:000431095900011	29471113				2019-10-28	
J	Wang, Y; Vnencak-Jones, CL; Cates, JM; Shi, CJ				Wang, Yang; Vnencak-Jones, Cindy L.; Cates, Justin M.; Shi, Chanjuan			Deciphering Elevated Microsatellite Alterations at Selected Tetra/Pentanucleotide Repeats, Microsatellite Instability, and Loss of Heterozygosity in Colorectal Cancers	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							TETRANUCLEOTIDE REPEATS; PROSTATE-CANCER; EMAST; METASTASIS; SEQUENCES	Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) are common in colorectal cancers (CRCs). The association between EMAST and classic mono/dinucleotide microsatellite instability (MSI) is unknown. We assessed the stability of 13 tetranucleotide and three pentanucleotide repeat markers in tumor and normal tissue from 22 MSI-high and 107 microsatellite-stable CRC samples. When present, instability was observed at tetra/pentanucleotide repeats and was defined as elevated microsatellite alterations at selected tetra/pentanucleotide repeats high (EMASTP-H; >30% instability), low (EMASTP-L; <30% instability), or stable (EMASTP-S). EMASTP instability, including high and low, was observed in 50 of 123 CRCs (41%), including all MSI-high tumors and 28 of 101 microsatellite-stable tumors (28%). MSI-high CRCs were more likely to be EMASTP-H compared with microsatellite-stable tumors with EMASTP instability. Tetranucleotide markers VWA and D13S317 were the two most frequently altered loci. Loss of heterozygosity was more common in EMASTP-L/S than in EMASTP-H CRCs. Frequencies of loss of heterozygosity at three loci were different between EMASTP-L and EMASTP-S tumors. In addition, right-sided tumor site, Large tumor size, high tumor grade, and the presence of Crohn-like reaction were significantly associated with EMASTP-H CRCs. However, there were no differences in clinicopathologic features between EMASTP-L and EMASTP-S tumors. In summary, more CRCs exhibited genomic instability as EMASTP than as MSI. EMASTP instability may prove to be an important prognostic/therapeutic indicator in CRCs.	[Wang, Yang; Vnencak-Jones, Cindy L.; Cates, Justin M.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN 2310D,Med Ctr N, Nashville, TN 37232 USA	Shi, CJ (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN 2310D,Med Ctr N, Nashville, TN 37232 USA.	chanjuan.shi@vanderbilt.edu	Cates, Justin/D-5927-2014	Cates, Justin/0000-0002-7336-5196	Vanderbilt University Medical Center	We thank Dr. William Dupont for assistance in statistical analysis and Vanderbilt University Medical Center for all funding sources.	Boland CR, 1998, CANCER RES, V58, P5248; Burger M, 2006, J MOL MED-JMM, V84, P833, DOI 10.1007/s00109-006-0074-0; Carethers JM, 2015, GENES-BASEL, V6, P185, DOI 10.3390/genes6020185; Choi YD, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-88; Cushman-Vokoun AM, 2013, CLIN COLORECTAL CANC, V12, P168, DOI 10.1016/j.clcc.2013.04.005; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Devaraj B, 2010, J GASTROINTEST SURG, V14, P1521, DOI 10.1007/s11605-010-1340-6; Garcia M, 2012, GASTROENTEROLOGY, V143, P48, DOI 10.1053/j.gastro.2012.03.034; Haugen AC, 2008, CANCER RES, V68, P8465, DOI 10.1158/0008-5472.CAN-08-0002; Hile SE, 2013, MUTAT RES-FUND MOL M, V743, P67, DOI 10.1016/j.mrfmmm.2012.11.003; Koi M, 2016, GASTROENTEROLOGY, V150, P944, DOI 10.1053/j.gastro.2015.12.032; Lee SY, 2010, GASTROENTEROLOGY, V139, P1519, DOI 10.1053/j.gastro.2010.08.001; Perinchery G, 2000, INT J ONCOL, V16, P1203; Singer G, 2004, INT J CANCER, V112, P643, DOI 10.1002/ijc.20455; Venderbosch S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124538; Watson MM, 2016, CANCER MED-US, V5, P1580, DOI 10.1002/cam4.709; Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0; Yamada K, 2010, ONCOL REP, V23, P551, DOI 10.3892/or_00000669	19	1	1	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					366	372		10.1016/j.jmoldx.2018.02.001			7	Pathology	Pathology	GE3EF	WOS:000431095900012	29474982	Green Published			2019-10-28	
J	Lin, GG; Zhang, K; Peng, RX; Han, YX; Xie, JH; Li, JM				Lin, Guigao; Zhang, Kuo; Peng, Rongxue; Han, Yanxi; Xie, Jiehong; Li, Jinming			Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CANDIDATE REFERENCE MATERIALS; TARGETED INTEGRATION; GENOME; CRISPR-CAS9; CRISPR/CAS9; RECOMBINATION; NUCLEASES; CANCER; CAS9	Genome-edited human cell tines are important resources for producing quality control materials for clinical molecular genetic testing. Generating cell lines with defined mutations through homology-directed repair based methods are inefficient and can Lead to unwanted insertions and deletions in the target loci. Nonhomologous end joining in the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated endonuclease Cas9 (Cas9) system was harnessed to generate genome-engineered cell lines harboring target mutations. Donor plasmids containing target sites for the single guide RNA (sgRNA) and homologous DNA fragments harboring important cancer gene mutations were cotransfected with the Cas9/sg RNA vector into wild-type human cells. The introduced mutations were validated in-house and in 44 laboratories using various techniques, including next-generation sequencing. Exogenous sequences containing the target mutations were efficiently integrated into the ALK receptor tyrosine kinase (ALK) locus in HEK293T and A549 cells. Successful introduction of artificial mutations was confirmed via both Sanger sequencing and the amplification refractory mutation system. Results of external pilot testing revealed that the DNA samples derived from genome-edited cell lines were widely applicable across multiple platforms and laboratories. This study demonstrates that CRISPR/Cas9-induced nonhomologous end joining is a valuable and novel method for generating artificial mutants for use in quality control applications in clinical molecular genetics.	[Lin, Guigao; Zhang, Kuo; Peng, Rongxue; Han, Yanxi; Xie, Jiehong; Li, Jinming] Beijing Hosp, Natl Ctr Gerontol, Natl Ctr Clin Labs, Beijing, Peoples R China; [Lin, Guigao; Zhang, Kuo; Peng, Rongxue; Han, Yanxi; Xie, Jiehong; Li, Jinming] Beijing Hosp, Beijing Engn Res Ctr Lab Med, Beijing, Peoples R China; [Peng, Rongxue; Li, Jinming] Chinese Acad Med Sci, Grad Sch, Peking Union Med Coll, Beijing, Peoples R China	Li, JM (reprint author), Beijing Hosp, Natl Ctr Clin Labs, 1 Dahua Rd, Beijing 100730, Peoples R China.	jmli@nccl.org.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81601841]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7164295]; Special Fund for Health-Scientific Research in the Public Interest from National Population and Family Planning Commission of the P R China [201402018]	Supported by National Natural Science Foundation of China grant 81601841 (G.L.), Beijing Natural Science Foundation grant 7164295 (G.L.), and the Special Fund for Health-Scientific Research in the Public Interest from National Population and Family Planning Commission of the P R China grant 201402018 (J.L.).	Clinical and Laboratory Standards Institute, 2012, MM01A3 CLSI; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Deveson IW, 2016, NAT METHODS, V13, P784, DOI [10.1038/NMETH.3957, 10.1038/nmeth.3957]; He XJ, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw064; Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955; Jarvis M, 2005, J MOL DIAGN, V7, P247, DOI 10.1016/S1525-1578(10)60551-X; Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Maresca M, 2013, GENOME RES, V23, P539, DOI 10.1101/gr.145441.112; Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190; Paquet D, 2016, NATURE, V533, P125, DOI 10.1038/nature17664; Peng RX, 2017, J MOL DIAGN, V19, P766, DOI 10.1016/j.jmoldx.2017.06.003; Pratt VM, 2016, J MOL DIAGN, V18, P109, DOI 10.1016/j.jmoldx.2015.08.005; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227; Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565; Tack V, 2015, ONCOLOGIST, V20, P257, DOI 10.1634/theoncologist.2014-0382; Whittaker MH, 1999, AM J CLIN PATHOL, V111, P449; Xiao Y, 2009, CLIN CHEM, V55, P1307, DOI 10.1373/clinchem.2008.120576; Yao X, 2017, CELL RES, V27, P801, DOI 10.1038/cr.2017.76	21	0	0	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					373	380		10.1016/j.jmoldx.2018.02.002			8	Pathology	Pathology	GE3EF	WOS:000431095900013	29680088	Bronze			2019-10-28	
J	Kricke, S; Mhaldien, L; Fernandes, R; Villanueva, C; Shaw, A; Veys, P; Adams, S				Kricke, Susanne; Mhaldien, Lana; Fernandes, Rozendo; Villanueva, Charizel; Shaw, Alistair; Veys, Paul; Adams, Stuart			Chimerism Analysis in the Pediatric Setting Direct PCR from Bone Marrow, Whole Blood, and Cell Fractions	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							HEMATOLOGIC MALIGNANCIES; PERIPHERAL-BLOOD; MIXED CHIMERISM; TRANSPLANTATION; HSCT; AMPLIFICATION; CHILDREN; RECOVERY; THERAPY; REGIMEN	Certain blood components and anticoagulants interfere with the PCR process and subsequent analysis. Here we demonstrate that reliable test results can be obtained for chimerism analysis despite omitting a DNA-extraction step and performing PCR and fragment analysis directly on bone marrow, whole blood, and individual cell fractions. For chimerism analysis, direct-tissue PCR is possible with the use of a robust, commercially available PCR mix containing a DNA polymerase capable of DNA amplification directly from the sample without the need for pretreatment. A total of 178 chimerism samples were processed directly, and results were compared to those obtained from the corresponding DNA sample. No differences were observed between the two sets of results. For the cell fraction purity assessment, commercially available PCR kits were used directly on T and B cells without the use of any additional lysing agent. A total of 53 purity samples and their corresponding DNA samples were analyzed and showed a correlation similar to that obtained for the chimerism samples. The results show that chimerism testing and associated cell fraction purity assessment can be performed reliably without the need for prior DNA extraction and that this method can easily be integrated into existing routine laboratory procedures.	[Kricke, Susanne; Mhaldien, Lana; Fernandes, Rozendo; Villanueva, Charizel; Shaw, Alistair; Adams, Stuart] Great Ormond St Hosp Sick Children, Specialist Integrated Haematol & Malignancy Diagn, Dept Haematol, Camelia Botnar Labs, London, England; [Veys, Paul] Great Ormond St Hosp Sick Children, Dept Blood & Marrow Transplantat, London, England	Kricke, S (reprint author), Great Ormond St Hosp Sick Children, SIHMDS Mol Haematol, Camelia Botnar Labs, Level 2, London WC1N 3JH, England.	susanne.kricke@gosh.nhs.uk			Olivia Hodson Cancer Fund	Supported by the Olivia Hodson Cancer Fund.	Abu Al-Soud W, 2000, J CLIN MICROBIOL, V38, P4463; Armenian SH, 2011, BLOOD, V118, P1413, DOI 10.1182/blood-2011-01-331835; Bensinger WI, 1996, BLOOD, V88, P2794, DOI 10.1182/blood.V88.7.2794.bloodjournal8872794; BURCKHARDT J, 1994, PCR METH APPL, V3, P239; Champlin RE, 2000, BLOOD, V95, P3702; Clark JR, 2015, BRIT J HAEMATOL, V168, P26, DOI 10.1111/bjh.13073; Martinez-Montiel MD, 2014, WORLD J GASTROENTERO, V20, P1211, DOI 10.3748/wjg.v20.i5.1211; Dvorak CC, 2017, BONE MARROW TRANSPL, V52, P1036, DOI 10.1038/bmt.2017.74; Gyurkocza B, 2014, BLOOD, V124, P344, DOI 10.1182/blood-2014-02-514778; Jillella AP, 2007, AM J HEMATOL, V82, P419, DOI 10.1002/ajh.20862; Kawauchi S, 2014, SYSMEX J INT, V24, P1; Kim HT, 2014, AM J HEMATOL, V89, P591, DOI 10.1002/ajh.23695; Lebedeva T, 2014, HUM IMMUNOL, V75, P103, DOI 10.1016/j.humimm.2014.08.138; Liou A, 2017, BONE MARROW TRANSPL, V52, P1057, DOI 10.1038/bmt.2017.45; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Preuner S, 2014, METHODS MOL BIOL, V1109, P271, DOI 10.1007/978-1-4614-9437-9_14; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Vnencak-Jones CL, 2009, CURR PROTOC HUM GENE, V62; Willasch A, 2010, BONE MARROW TRANSPL, V45, P181, DOI 10.1038/bmt.2009.89; Wynn R, 2011, HEMATOL-AM SOC HEMAT, P285, DOI 10.1182/asheducation-2011.1.285	20	1	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAY	2018	20	3					381	388		10.1016/j.jmoldx.2018.02.003			8	Pathology	Pathology	GE3EF	WOS:000431095900014	29474984	Bronze			2019-10-28	
J	Loke, BN; Nasir, NDM; Thike, AA; Lee, JYH; Lee, CS; Teh, BT; Tan, PH				Loke, Benjamin Nathanael; Nasir, Nur Diyana Md; Thike, Aye Aye; Lee, Jonathan Yu Han; Lee, Cheok Soon; Teh, Bin Tean; Tan, Puay Hoon			Genetics and genomics of breast fibroadenomas	JOURNAL OF CLINICAL PATHOLOGY			English	Review						cancer; genetics; breast pathology; molecular pathology	RENAL-TRANSPLANT RECIPIENTS; PROLACTIN RECEPTOR VARIANTS; GROUP PROTEIN GENE; PHYLLODES TUMOR; CHROMOSOME-ABNORMALITIES; FIBROEPITHELIAL TUMORS; UTERINE LEIOMYOMAS; MED12 MUTATIONS; CELLULAR FIBROADENOMAS; MOLECULAR ALTERATIONS	Fibroadenomas of the breast are benign fibroepithelial tumours most frequently encountered in women of reproductive age, although they may be diagnosed at any age. The fibroadenoma comprises a proliferation of both stromal and epithelial components. The mechanisms underlying fibroadenoma pathogenesis remain incompletely understood. In the clinical setting, distinguishing cellular fibroadenomas from benign phyllodes tumours is a common diagnostic challenge due to subjective histopathological criteria and interobserver differences. Recent sequencing studies have demonstrated the presence of highly recurrent mutations in fibroadenomas, and also delineated the genomic landscapes of fibroadenomas and the closely related phyllodes tumours, revealing differences at the gene level, which may be of potential adjunctive diagnostic use. The present article provides an overview of key studies uncovering genetic and genomic abnormalities in fibroadenomas, from initial karyotype reports revealing myriad cytogenetic aberrations to next-generation sequencing-based approaches that led to the discovery of highly recurrent MED12 mutations. A thorough understanding of these abnormalities is important to further elucidate the mechanisms by which fibroadenomas arise and to refine diagnostic assessment of this very common tumour.	[Loke, Benjamin Nathanael] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Loke, Benjamin Nathanael; Nasir, Nur Diyana Md; Thike, Aye Aye; Tan, Puay Hoon] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore; [Thike, Aye Aye; Teh, Bin Tean; Tan, Puay Hoon] Duke NUS Med Sch, Singapore, Singapore; [Lee, Jonathan Yu Han] Western Sydney Univ, Sch Sci & Hlth, Sydney, NSW, Australia; [Lee, Cheok Soon] Western Sydney Univ, Discipline Pathol, Sch Med, Sydney, NSW, Australia; [Lee, Cheok Soon] Liverpool Hosp, Dept Anat Pathol, Liverpool, NSW, Australia; [Lee, Cheok Soon] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Lee, Cheok Soon] Royal Prince Alfred Hosp, Dept Tissue Pathol, Sydney, NSW, Australia; [Lee, Cheok Soon] Univ Sydney, Canc Pathol Lab, Bosch Inst, Sydney, NSW, Australia; [Teh, Bin Tean] Natl Canc Ctr Singapore, Lab Canc Epigenome, Singapore, Singapore; [Teh, Bin Tean] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Teh, Bin Tean] Inst Mol & Cell Biol, Singapore, Singapore; [Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, Singapore, Singapore	Tan, PH (reprint author), Singapore Gen Hosp, Div Pathol, Singapore, Singapore.	tan.puay.hoon@singhealth.com.sg					Alkhunaizi AM, 2004, TRANSPL P, V36, P1839, DOI 10.1016/j.transproceed.2004.07.013; Bernardes J R M Jr, 2003, Breast J, V9, P302, DOI 10.1046/j.1524-4741.2003.09410.x; Bogorad RL, 2008, P NATL ACAD SCI USA, V105, P14533, DOI 10.1073/pnas.0800685105; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; CALABRESE G, 1991, GENE CHROMOSOME CANC, V3, P202, DOI 10.1002/gcc.2870030305; CARNEY JA, 1991, AM J SURG PATHOL, V15, P713, DOI 10.1097/00000478-199108000-00001; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; Cavalli LR, 1992, CANCER GENET CYTOGEN, V63, P156, DOI [10. 1016/0165-4608(92)90491-P, DOI 10.1016/0165-4608(92)90491-P]; Chakhtoura Z, 2016, J CLIN ENDOCR METAB, V101, P4449, DOI 10.1210/jc.2016-2372; Courtillot C, 2010, J CLIN ENDOCR METAB, V95, P271, DOI 10.1210/jc.2009-1494; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; DUPONT WD, 1994, NEW ENGL J MED, V331, P10, DOI 10.1056/NEJM199407073310103; Eom M, 2008, PATHOL INT, V58, P226, DOI 10.1111/j.1440-1827.2008.02215.x; Euhus DM, 1999, J SURG RES, V83, P13, DOI 10.1006/jsre.1998.5549; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERTIPASSANTONOPOULOU AD, 1987, CANCER GENET CYTOGEN, V27, P289, DOI 10.1016/0165-4608(87)90011-2; Fine RE, 2003, AM J SURG, V186, P362, DOI 10.1016/S0002-9610(03)00263-0; FLETCHER JA, 1991, AM J PATHOL, V138, P1199; Franco N, 2003, ARCH SURG-CHICAGO, V138, P291, DOI 10.1001/archsurg.138.3.291; Franco N, 2001, CANCER RES, V61, P7955; GELEICK D, 1990, CANCER GENET CYTOGEN, V46, P217, DOI 10.1016/0165-4608(90)90107-L; Geschickter C F, 1934, Am J Cancer, V21, P828; Gill S, 2001, J CLIN PATHOL, V54, P956, DOI 10.1136/jcp.54.12.956; Greenberg R, 1998, J GEN INTERN MED, V13, P640, DOI 10.1046/j.1525-1497.1998.cr188.x; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; Iaria G, 2010, TRANSPL P, V42, P1169, DOI 10.1016/j.transproceed.2010.03.035; Kampjarvi K, 2012, BRIT J CANCER, V107, P1761, DOI 10.1038/bjc.2012.428; Kampjarvi K, 2014, HUM MUTAT, V35, P1136, DOI 10.1002/humu.22612; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kasami M, 1998, BREAST CANCER RES TR, V50, P185, DOI 10.1023/A:1006050208157; Kaya Resmiye, 2001, Pathology and Oncology Research, V7, P213; Kobayashi S, 1999, BREAST CANC, V6, P201, DOI DOI 10.1007/BF02967168; Konstantinova AM, 2017, ANN DIAGN PATHOL, V28, P12, DOI 10.1016/j.anndiagpath.2017.02.004; Korcheva VB, 2011, APPL IMMUNOHISTO M M, V19, P119, DOI 10.1097/PAI.0b013e3181f5349a; KOUTSELINI H, 1991, ANTICANCER RES, V11, P1415; KRIEGER N, 1992, AM J EPIDEMIOL, V135, P619, DOI 10.1093/oxfordjournals.aje.a116341; Krings G, 2017, SEMIN DIAGN PATHOL, V34, P438, DOI 10.1053/j.semdp.2017.05.006; Krishnamurthy S, 2000, CANCER CYTOPATHOL, V90, P342, DOI 10.1002/1097-0142(20001225)90:6<342::AID-CNCR4>3.3.CO;2-9; Kuijper A, 2002, J PATHOL, V197, P575, DOI 10.1002/path.1161; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR S, 1987, BRIT J CANCER, V55, P307, DOI 10.1038/bjc.1987.60; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lawton TJ, 2014, INT J SURG PATHOL, V22, P695, DOI 10.1177/1066896914548763; LEUSCHNER E, 1994, CANCER GENET CYTOGEN, V76, P145, DOI 10.1016/0165-4608(94)90466-9; LEVI F, 1994, INT J CANCER, V57, P681, DOI 10.1002/ijc.2910570512; Lien HC, 2016, HISTOPATHOLOGY, V68, P433, DOI 10.1111/his.12764; Lim WK, 2014, NAT GENET, V46, P877, DOI 10.1038/ng.3037; LIZARDNACOL S, 1995, CANCER RES, V55, P4416; Loda M, 2017, PATHOLOGY EPIDEMIOLO; Lozada JR, 2017, HISTOPATHOLOGY, V71, P626, DOI 10.1111/his.13258; LU YJ, 1993, CANCER GENET CYTOGEN, V69, P91, DOI 10.1016/0165-4608(93)90081-V; Makinen N, 2014, BRIT J CANCER, V110, P2246, DOI 10.1038/bjc.2014.138; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANNI A, 1986, CANCER RES, V46, P1669; McCulloch RK, 1998, BREAST CANCER RES TR, V49, P165, DOI 10.1023/A:1005930429002; MCDIVITT RW, 1992, CANCER, V69, P1408, DOI 10.1002/1097-0142(19920315)69:6<1408::AID-CNCR2820690617>3.0.CO;2-C; Mertani HC, 1998, INT J CANCER, V79, P202; MILLIKAN R, 1995, J CLIN ONCOL, V13, P2293, DOI 10.1200/JCO.1995.13.9.2293; Mishima C, 2015, BREAST CANCER RES TR, V152, P305, DOI 10.1007/s10549-015-3469-1; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; NOGUCHI S, 1993, CANCER RES, V53, P4071; NOGUCHI S, 1995, CANCER, V76, P1779, DOI 10.1002/1097-0142(19951115)76:10<1779::AID-CNCR2820761015>3.0.CO;2-0; OZISIK YY, 1994, CANCER GENET CYTOGEN, V77, P125, DOI 10.1016/0165-4608(94)90227-5; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P51, DOI 10.1002/gcc.2870060110; Pfarr N, 2015, GENE CHROMOSOME CANC, V54, P444, DOI 10.1002/gcc.22256; Piscuoglio S, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.35; Piscuoglio S, 2015, HISTOPATHOLOGY, V67, P719, DOI 10.1111/his.12712; ROHEN C, 1993, CANCER GENET CYTOGEN, V69, P68, DOI 10.1016/0165-4608(93)90117-5; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; Schneider L, 2009, ENDOCRINE, V35, P118, DOI 10.1007/s12020-008-9124-4; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Seo YL, 2005, TRANSPLANT P, V37, P4315, DOI 10.1016/j.transproceed.2005.10.111; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; SREEKANTAIAH C, 1991, CANCER RES, V51, P422; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; STEPHENSON CF, 1992, CANCER GENET CYTOGEN, V63, P32, DOI 10.1016/0165-4608(92)90060-L; Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409; Tan PH, 2017, ATLAS DIFFERENTIAL D; Tan WJ, 2016, J CLIN PATHOL, V69, P858, DOI 10.1136/jclinpath-2015-203590; Vilela MHT, 2014, INT J SURG PATHOL, V22, P485, DOI 10.1177/1066896914521290; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Troxell ML, 2010, MODERN PATHOL, V23, P27, DOI 10.1038/modpathol.2009.142; Turunen M, 2014, CELL REP, V7, P654, DOI 10.1016/j.celrep.2014.03.047; Umekita Y, 1999, PATHOL INT, V49, P807, DOI 10.1046/j.1440-1827.1999.00950.x; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Volckmar AL, 2017, GENE CHROMOSOME CANC, V56, P11, DOI 10.1002/gcc.22396; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang ZGC, 2006, BREAST CANCER RES TR, V97, P301, DOI 10.1007/s10549-005-9124-5; WELSCH CW, 1979, BRIT J CANCER, V40, P866, DOI 10.1038/bjc.1979.278; WILLIAMSON MER, 1993, ANN ROY COLL SURG, V75, P161; Yu Ji Hoon, 2013, Obstet Gynecol Sci, V56, P143, DOI 10.5468/ogs.2013.56.3.143; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; Zhu HH, 2014, NEW ENGL J MED, V370, P1864, DOI 10.1056/NEJMc1316382	109	2	2	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					381	387		10.1136/jclinpath-2017-204838			7	Pathology	Pathology	GD9LV	WOS:000430835100001	29248888	Green Published, Bronze			2019-10-28	
J	Wong, NACS; Amary, F; Butler, R; Byers, R; Gonzalez, D; Haynes, HR; Ilyas, M; Salto-Tellez, M; Taniere, P				Wong, Newton A. C. S.; Amary, Fernanda; Butler, Rachel; Byers, Richard; Gonzalez, David; Haynes, Harry R.; Ilyas, Mohammad; Salto-Tellez, Manuel; Taniere, Philippe			HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee	JOURNAL OF CLINICAL PATHOLOGY			English	Article						adenocarcinoma stomach; oesophagus; HER2; immunohistochemistry; in-situ hybridisation; guidance	IN-SITU HYBRIDIZATION; GASTRIC-CANCER; BREAST-CANCER; AMERICAN-PATHOLOGISTS; GUIDELINE; RECOMMENDATIONS; VALIDATION; ESOPHAGEAL; SOCIETY; IMPACT	The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.	[Wong, Newton A. C. S.] Southmead Hosp, Dept Cellular Pathol, Bristol BS10 5NB, Avon, England; [Amary, Fernanda] Royal Natl Orthopaed Hosp, Dept Cellular & Mol Pathol, Stanmore, Middx, England; [Butler, Rachel] Univ Hosp Wales, All Wales Genet Lab, Cardiff, S Glam, Wales; [Byers, Richard] Cent Manchester Univ Hosp NHS Trust, Dept Histopathol, Manchester, Lancs, England; [Gonzalez, David] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [Haynes, Harry R.] Univ Bristol, Dept Cellular Pathol, Bristol, Avon, England; [Haynes, Harry R.] Southmead Hosp, Bristol, Avon, England; [Ilyas, Mohammad] Queens Med Ctr, Div Canc & Stem Cells, Nottingham, England; [Ilyas, Mohammad] Queens Med Ctr, Nottingham Mol Pathol Node, Nottingham, England; [Salto-Tellez, Manuel] Queens Univ, Northern Ireland Mol Pathol Lab, Belfast, Antrim, North Ireland; [Taniere, Philippe] Queen Elizabeth Hosp, Dept Cellular Pathol, Birmingham, W Midlands, England	Wong, NACS (reprint author), Southmead Hosp, Dept Cellular Pathol, Bristol BS10 5NB, Avon, England.	Nacs.Wong@bristol.ac.uk		Byers, Richard/0000-0003-0796-0365	RocheRoche Holding	MI has received sponsorship from Roche to support a Molecular Diagnostics Training School.	Ajani JA, 2015, J NATL COMPR CANC NE, V13, P194, DOI 10.6004/jnccn.2015.0028; Babic A, 2010, METHODS, V52, P287, DOI 10.1016/j.ymeth.2010.08.012; Bang YJ, 2010, LANCET, V376, P1302; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; EMA, 2017, EMEAHC000278IB129; Fassan M, 2012, HISTOPATHOLOGY, V61, P769, DOI 10.1111/j.1365-2559.2012.04272.x; Groenen PJTA, 2011, HISTOPATHOLOGY, V59, P1, DOI 10.1111/j.1365-2559.2010.03711.x; Kim WH, 2018, APPL IMMUNOHISTO M M, V26, P239, DOI 10.1097/PAI.0000000000000423; Kurokawa Y, 2015, GASTRIC CANCER, V18, P691, DOI 10.1007/s10120-014-0430-7; Lee S, 2011, HISTOPATHOLOGY, V59, P832, DOI 10.1111/j.1365-2559.2011.04017.x; Matsusaka S, 2016, GASTRIC CANCER, V19, P839, DOI 10.1007/s10120-015-0518-8; Maxwell P, 2016, CANCER CYTOPATHOL, V124, P540, DOI 10.1002/cncy.21692; Naini BV, 2016, AM J SURG PATHOL, V40, pE45, DOI 10.1097/PAS.0000000000000598; NICE, 2010, TRAST TREAT HER2 POS; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198; Ruschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2; Salto-Tellez M, 2011, ARCH PATHOL LAB MED, V135, P693, DOI 10.1043/2011-0084-ED.1; Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197; Tan SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142466; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wong NACS, 2014, J CLIN PATHOL, V67, P751, DOI 10.1136/jclinpath-2014-202467; Yamashita-Kashima Y, 2014, GASTRIC CANCER, V17, P638, DOI 10.1007/s10120-013-0329-8; Yoshida H, 2014, VIRCHOWS ARCH, V465, P145, DOI 10.1007/s00428-014-1597-3	26	2	2	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					388	394		10.1136/jclinpath-2017-204943			7	Pathology	Pathology	GD9LV	WOS:000430835100002	29439009				2019-10-28	
J	Hewer, E; Hammer, C; Fricke-Vetsch, D; Baumann, C; Perren, A; Schmitt, AM				Hewer, Ekkehard; Hammer, Caroline; Fricke-Vetsch, Daniela; Baumann, Cinzia; Perren, Aurel; Schmitt, Anja M.			Implementation of a "lean' cytopathology service: towards routine same-day reporting	JOURNAL OF CLINICAL PATHOLOGY			English	Article						laboratory management; cytology; reports	PROCESS MISIDENTIFICATION DEFECTS; WORK PROCESS STANDARDIZATION; FORD,HENRY PRODUCTION SYSTEM; SURGICAL PATHOLOGY; QUALITY IMPROVEMENT; ANATOMIC PATHOLOGY; PATIENT SAFETY; PROCESS REDESIGN; POSITIVE IMPACT; PRINCIPLES	Objectives To systematically assess the effects of a Lean management intervention in an academic cytopathology service. Methods We monitored outcomes including specimen turnaround times during stepwise implementation of a lean cytopathology workflow for gynaecological and non-gynaecological cytology. Results The intervention resulted in a major reduction of turnaround times for both gynaecological (3rd quartile 4.1 vs 2.3 working days) and non-gynaecological cytology (3rd quartile 1.9 vs. 1.2 working days). Introduction of fully electronic reporting had additional effect over continuous staining of slides alone. The rate of non-gynaecological specimens reported the same day increased from 4.5% to 56.5% of specimens received before noon. Conclusions Lean management principles provide a useful framework for organization of a cytopathology workflow. Stepwise implementation beginning with a simplified gynaecological cytology workflow allowed involved staff to monitor the effects of individual changes and allowed for a smooth transition.	[Hewer, Ekkehard; Hammer, Caroline; Fricke-Vetsch, Daniela; Baumann, Cinzia; Perren, Aurel; Schmitt, Anja M.] Univ Bern, Inst Pathol, Murtenstr 31, CH-3010 Bern, Switzerland	Hewer, E (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3010 Bern, Switzerland.	ekkehard.hewer@pathology.unibe.ch	Perren, Aurel/N-5979-2019; Hewer, Ekkehard/W-8670-2019; Perren, Aurel/A-9383-2018	Perren, Aurel/0000-0002-6819-6092; Hewer, Ekkehard/0000-0002-9128-0364; Perren, Aurel/0000-0002-6819-6092			Buesa RJ, 2009, ANN DIAGN PATHOL, V13, P322, DOI 10.1016/j.anndiagpath.2009.06.005; Callahan Rick, 2012, MLO Med Lab Obs, V44, P34; Cankovic M, 2009, J MOL DIAGN, V11, P390, DOI 10.2353/jmoldx.2009.090002; Clark D, 2016, VIRCHOWS ARCH, V468, P5, DOI 10.1007/s00428-015-1838-0; Clark DM, 2013, J CLIN PATHOL, V66, P638, DOI 10.1136/jclinpath-2013-201553; Condel JL, 2004, CLIN LAB MED, V24, P865, DOI 10.1016/j.cll.2004.07.001; D'Angelo R, 2007, AM J CLIN PATHOL, V128, P423, DOI 10.1309/X6N1Y3V2CB9HUL8G; Dimenstein IB, 2009, AM J CLIN PATHOL, V132, P975, DOI 10.1309/AJCPLGKP7QFBB1SZ; Hassell LA, 2010, BMC CLIN PATHOL, V10, DOI 10.1186/1472-6890-10-2; Hayes KJ, 2014, J HEALTH ORGAN MANAG, V28, P229, DOI 10.1108/JHOM-03-2013-0064; Knowles S, 2013, J CLIN PATHOL, V66, P635, DOI 10.1136/jclinpath-2013-201624; Meier FA, 2011, ADV ANAT PATHOL, V18, P406, DOI 10.1097/PAP.0b013e318229bf20; Michael CW, 2013, AM J CLIN PATHOL, V139, P574, DOI 10.1309/AJCPIWKS7DJXEEQQ; Nicolay CR, 2012, BRIT J SURG, V99, P324, DOI 10.1002/bjs.7803; Ogrinc Greg, 2016, BMJ Qual Saf, V25, P986, DOI 10.1136/bmjqs-2015-004411; Pantanowitz L, 2008, CYTOJOURNAL, V5, DOI 10.4103/1742-6413.44773; Raab SS, 2008, J CLIN PATHOL, V61, P1193, DOI 10.1136/jcp.2007.051326; Raab SS, 2006, AM J CLIN PATHOL, V126, P585, DOI 10.1309/NJQ1L7KA10UKV93Q; Raab SS, 2013, CLIN BIOCHEM, V46, P1180, DOI 10.1016/j.clinbiochem.2013.04.024; Raab SS, 2008, J LOW GENIT TRACT DI, V12, P103, DOI 10.1097/LGT.0b013e31815ae9a1; Roberson J, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.107983; Serrano L, 2010, ADV ANAT PATHOL, V17, P215, DOI 10.1097/PAP.0b013e3181d98c81; Smith ML, 2012, AM J CLIN PATHOL, V138, P367, DOI 10.1309/AJCP3YXID2UHZPHT; Smith ML, 2012, ADV ANAT PATHOL, V19, P331, DOI 10.1097/PAP.0b013e31826661b7; Sugianto JZ, 2015, LABMEDICINE, V46, P259, DOI 10.1309/LMJCUFUN0LT8C6DB; Wong R, 2012, ARCH PATHOL LAB MED, V136, P183, DOI 10.5858/arpa.2011-0139-OA; Zarbo RJ, 2007, AM J CLIN PATHOL, V128, P1015, DOI 10.1309/RGF6JD1NAP2DU88Q; Zarbo RJ, 2009, AM J CLIN PATHOL, V131, P468, DOI 10.1309/AJCPPTJ3XJY6ZXDB	28	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					395	401		10.1136/jclinpath-2017-204504			7	Pathology	Pathology	GD9LV	WOS:000430835100003	28974539				2019-10-28	
J	Kao, KR; Popadiuk, P; Thoms, J; Aoki, S; Anwar, S; Fitzgerald, E; Andrews, P; Voisey, K; Gai, L; Challa, S; He, ZJ; Gonzales-Aguirre, P; Simmonds, A; Popadiuk, C				Kao, Kenneth R.; Popadiuk, Paul; Thoms, John; Aoki, Satoko; Anwar, Shahgul; Fitzgerald, Emily; Andrews, Phillip; Voisey, Kim; Gai, Luis; Challa, Satya; He, Zhijian; Gonzales-Aguirre, Paola; Simmonds, Andrea; Popadiuk, Catherine			PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy	JOURNAL OF CLINICAL PATHOLOGY			English	Article						prostatectomy; recurrence; immunohistochemistry; biomarker	BREAST-CANCER; ACTIVE SURVEILLANCE; ESTROGEN-RECEPTOR; CELL-GROWTH; ACTIVATION; TRANSCRIPTION; METASTASIS; EXPERIENCE; PROTEIN; MEN	Aims Prostate cancer (PrCa) is the most frequently diagnosed non-cutaneous cancer in men. Without clear pathological indicators of disease trajectory at diagnosis, management of PrCa is challenging, given its wide-ranging manifestation from indolent to highly aggressive disease. This study examines the role in PrCa of the Pygopus (PYGO)2 chromatin effector protein as a risk stratification marker in PrCa. Methods RNA expression was performed in PrCa cell lines using Northern and RT-PCR analyses. Protein levels were assessed using immunoblot and immunofluorescence. Immunohistochemistry was performed on tissue microarrays constructed from radical prostatectomies with 5-year patient follow-up data including Gleason score tumour staging, margin and lymph node involvement and prostate serum antigen (PSA) levels. Biochemical recurrence (BR) was defined as a postoperative PSA level of >0.2nL. Univariate and multivariate analyses were performed using SAS and Kaplan-Meier curves using graphPad (Prism). Results In vitro depletion of PYGO2 by RNAi in both androgen receptor positive and negative PrCa cell lines attenuated growth and reduced Ki67 and 47S rRNA expression, while PYGO2 protein was localised to the nuclei of tumours as determined by immunohistochemistry. High expression levels of PYGO2 in tumours (n=156) were correlated with BR identified as PSA progression, after 7-year follow-up independent of other traditional risk factors. Most importantly, high PYGO2 levels in intermediate grade tumours suggested increased risk of recurrence over those with negative or weak expression. Conclusion Our data suggest that elevated PYGO2 expression in primary prostate adenocarcinoma is a potential risk factor for BR.	[Kao, Kenneth R.; Anwar, Shahgul; Voisey, Kim; Gai, Luis; Simmonds, Andrea] Eastern Hlth, Div Anat Pathol, Lab Med Program, St John, NF A1B 3V6, Canada; [Kao, Kenneth R.; Fitzgerald, Emily; Andrews, Phillip; He, Zhijian; Gonzales-Aguirre, Paola] Mem Univ, Biomed Sci, St John, NF, Canada; [Popadiuk, Paul] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Thoms, John; Aoki, Satoko; Challa, Satya] Mem Univ Newfoundland, Fac Med, Discipline Oncol, St John, NF, Canada; [Popadiuk, Catherine] Mem Univ Newfoundland, Fac Med, Div Gynecol Oncol, St John, NF, Canada	Kao, KR (reprint author), Eastern Hlth, Div Anat Pathol, Lab Med Program, St John, NF A1B 3V6, Canada.	kkao@mun.ca			Avalon Motorcycle Ride for Dad; CIHRCanadian Institutes of Health Research (CIHR); RDC, NL	This work was funded by the Avalon Motorcycle Ride for Dad, the CIHR and RDC, NL. We thank Marjan Afrousian, Ines Gai, Cynthia Curtis, Khisal Quereshi, Kweku Dankwa and Dan Fontaine for assistance.	Andrews PGP, 2008, MOL CANCER RES, V6, P259, DOI 10.1158/1541-7786.MCR-07-0068; Andrews PGP, 2007, INT J ONCOL, V30, P357; Andrews PGP, 2016, BIOCHEM J, V473, P4193, DOI 10.1042/BCJ20160590; Andrews PGP, 2013, BIOCHEM J, V453, P61, DOI 10.1042/BJ20121667; Andrews PGP, 2009, BIOCHEM J, V422, P493, DOI 10.1042/BJ20090134; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Cantu C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4598; Carver BS, 2006, J UROLOGY, V176, P564, DOI 10.1016/j.juro.2006.03.093; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Chen YY, 2011, MED ONCOL, V28, P631, DOI 10.1007/s12032-010-9488-1; Garisto JD, 2017, ONCOLOGY-NY, V31, P333; Gerber GS, 1997, EUR UROL, V32, P385, DOI 10.1159/000480794; Hatakeyama S, 2017, INT J CLIN ONCOL, V22, P214, DOI 10.1007/s10147-016-1049-y; Hsu CY, 2007, EUR UROL, V51, P121, DOI 10.1016/j.eururo.2006.05.024; Jessen S, 2008, BIOESSAYS, V30, P448, DOI 10.1002/bies.20757; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Leapman MS, 2017, UROL ONCOL-SEMIN ORI, V35, P42, DOI 10.1016/j.urolonc.2016.09.003; LERNER SE, 1995, J UROLOGY, V154, P1447, DOI 10.1016/S0022-5347(01)66888-5; Liu Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-346; Masic S, 2017, CURR OPIN UROL, V27, P231, DOI 10.1097/MOU.0000000000000387; Popadiuk CM, 2006, CLIN CANCER RES, V12, P2216, DOI 10.1158/1078-0432.CCR-05-2433; Ritch CR, 2014, UROLOGY, V83, P1309, DOI 10.1016/j.urology.2014.02.023; Schneider JA, 2018, MOL CELL ENDOCRINOL, V462, P3, DOI 10.1016/j.mce.2017.02.008; Thangavel C, 2017, CANCER RES, V77, P982, DOI 10.1158/0008-5472.CAN-16-1589; Tzenov YR, 2016, J CLIN PATHOL, V69, P518, DOI 10.1136/jclinpath-2015-203395; Tzenov YR, 2013, MOL CANCER RES, V11, P19, DOI 10.1158/1541-7786.MCR-12-0510; Wang ZX, 2010, J NEURO-ONCOL, V100, P31, DOI 10.1007/s11060-010-0144-6; Ward JF, 2005, BJU INT, V95, P751, DOI 10.1111/j.1464-410X.2005.05394.x; Woolcott CG, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-130; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Yang XHR, 2013, BREAST CANCER RES TR, V137, P837, DOI 10.1007/s10549-012-2380-2; Ying J, 2015, AM J CLIN ONCOL-CANC, P1, DOI [10. 1097/COC. 0000000000000207, DOI 10.1097/C0C.0000000000000207]; Zhang S, 2015, HISTOPATHOLOGY, V67, P176, DOI 10.1111/his.12637; Zhang S, 2015, ONCOTARGET, V6, P11074, DOI 10.18632/oncotarget.3570; Zhou SY, 2014, ONCOL LETT, V7, P233	36	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					402	411		10.1136/jclinpath-2017-204718			10	Pathology	Pathology	GD9LV	WOS:000430835100004	28924059				2019-10-28	
J	McKeating, C; White, PL; Posso, R; Palmer, M; Johnson, E; McMullan, R				McKeating, Cara; White, P. Lewis; Posso, Raquel; Palmer, Michael; Johnson, Elizabeth; McMullan, Ronan			Diagnostic accuracy of fungal PCR and beta-D-glucan for detection of candidaemia: a preliminary evaluation	JOURNAL OF CLINICAL PATHOLOGY			English	Article						yeast; mycology; infections; fungi; diagnostics	POLYMERASE-CHAIN-REACTION; BLOOD-STREAM INFECTIONS; INVASIVE CANDIDIASIS; RAPID DIAGNOSIS; THERAPY; CANDIDEMIA; ASSAY; ASPERGILLOSIS; CULTURES; SEPSIS	Aims Although treatment for candidaemia is time critical, culture-based tests prolong turnaround times and may promote underdiagnosis. Non-culture-based tests have the potential to overcome these difficulties but are in limited clinical use. The aim of this work was to undertake an initial evaluation of two non-culture-based tests for diagnosis of candidaemia. Methods Patients with candidaemia were identified prospectively over a 4-month period. Sera drawn from case (candidaemic) and control (non-candidaemic) patients on the same day as the positive blood culture were tested with both the Renishaw RenDx Fungiplex test and a commercial -d-glucan (BDG) assay (Fungitell, Associates of Cape Cod). Sensitivity and specificity were calculated independently and in combination, using paired blood culture as the reference standard. Results There were 10 eligible case patients and 39 negative controls. PCR sensitivity and specificity were found to be 44.4% (95% CI 18.9% to 73.3%) and 87.2% (72.8% to 94.8%), respectively. BDG sensitivity and specificity were 80% (47.9% to 95.4%) and 89.7% (75.9% to 96.5%), respectively. When combining PCR and BDG, sensitivity was 90% (95% CI 57.4% to 100%) and specificity was 79.5% (64.2% to 89.5%). When two sequential specimens were tested, PCR sensitivity increased to 60% (95% CI 31.2% to 83.3%) and BDG sensitivity to 90% (54.7% to 100%). Conclusion A combination of tests, or a single test at multiple time points, may be preferable to relying on one test at a single time point. This should be accounted for in design of future diagnostic accuracy studies of tests for invasive candidosis.	[McKeating, Cara; McMullan, Ronan] Royal Hosp, Belfast Hlth & Social Care Trust, Dept Microbiol, Belfast BT12 6BA, Antrim, North Ireland; [White, P. Lewis; Posso, Raquel] Univ Hosp Wales, Mycol Reg Reference Unit, Cardiff, S Glam, Wales; [Palmer, Michael; Johnson, Elizabeth] Publ Hlth England South West, Mycol Reference Lab, Bristol, Avon, England; [McMullan, Ronan] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland	McKeating, C (reprint author), Royal Hosp, Belfast Hlth & Social Care Trust, Dept Microbiol, Belfast BT12 6BA, Antrim, North Ireland.	caramckeating@gmail.com	White, P. Lewis/I-6428-2019		Northern Ireland Public Health Agency Research and Development Division	This work was supported by the Northern Ireland Public Health Agency Research and Development Division. Renishaw Diagnostics provided reagents for PCR testing at no cost.	Alanio A, 2016, J ANTIMICROB CHEMOTH, V71, P2075, DOI 10.1093/jac/dkw036; Arendrup MC, 2010, CLIN MICROBIOL INFEC, V16, P855, DOI 10.1111/j.1469-0691.2009.02931.x; Avni T, 2011, J CLIN MICROBIOL, V49, P665, DOI 10.1128/JCM.01602-10; BERENGUER J, 1993, DIAGN MICR INFEC DIS, V17, P103, DOI 10.1016/0732-8893(93)90020-8; Bloos F, 2013, J CRIT CARE, V28, P2, DOI 10.1016/j.jcrc.2012.07.011; Bravo D, 2011, INT J INFECT DIS, V15, pE326, DOI 10.1016/j.ijid.2011.01.003; Garey KW, 2006, CLIN INFECT DIS, V43, P25, DOI 10.1086/504810; He S, 2015, J MICROBIOL IMMUNOL, V48, P351, DOI 10.1016/j.jmii.2014.06.009; Kollef M, 2012, CLIN INFECT DIS, V54, P1739, DOI 10.1093/cid/cis305; Lucignano B, 2011, J CLIN MICROBIOL, V49, P2252, DOI 10.1128/JCM.02460-10; Aguado JM, 2015, CLIN INFECT DIS, V60, P405, DOI 10.1093/cid/ciu833; Mohr JF, 2011, J CLIN MICROBIOL, V49, P58, DOI 10.1128/JCM.01240-10; Mylonakis E, 2015, CLIN INFECT DIS, V60, P892, DOI 10.1093/cid/ciu959; Nguyen MH, 2012, CLIN INFECT DIS, V54, P1240, DOI 10.1093/cid/cis200; Vincent JL, 2015, CRIT CARE MED, V43, P2283, DOI 10.1097/CCM.0000000000001249; White PL, 2014, J CLIN MICROBIOL, V52, P3536, DOI 10.1128/JCM.01135-14	16	0	0	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					420	424		10.1136/jclinpath-2017-204692			5	Pathology	Pathology	GD9LV	WOS:000430835100006	28970296				2019-10-28	
J	Gupta, K; Rawat, A; Agrawal, P; Jindal, A; Nada, R; Saikia, B; Chan, KW; Lau, YL; Minz, RW; Singh, S				Gupta, Kirti; Rawat, Amit; Agrawal, Parimal; Jindal, Ankur; Nada, Ritambhra; Saikia, Biman; Chan, Koon Wing; Lau, Yu Lung; Minz, Ranjana Walker; Singh, Surjit			Infectious and non-infectious complications in primary immunodeficiency disorders: an autopsy study from North India	JOURNAL OF CLINICAL PATHOLOGY			English	Article						autopsy pathology; histopathology; immunodeficiency; immunopathology; paediatric pathology	CHRONIC GRANULOMATOUS-DISEASE; X-LINKED AGAMMAGLOBULINEMIA; NUCLEOSIDE PHOSPHORYLASE-DEFICIENCY; RAG MUTATIONS; UNITED-STATES; PNEUMONIA; CLASSIFICATION; AMYLOIDOSIS; REGISTRY; PATIENT	Background Primary immunodeficiency disorders (PID) include a wide spectrum of inherited disorders characterised by functional abnormalities of one or more components of the immune system. Recent updates from the genomic data have contributed significantly to its better understanding with identification of new entities. Diagnosis is always challenging due to their variable clinical presentation. With the evolution of molecular diagnosis, many of these children are being diagnosed early and offered appropriate therapy. However, in developing countries, early diagnosis is still not being made: as a result these patients succumb to their disease. Autopsy data on PID is notably lacking in the literature with histopathological evaluation of PID being limited to rare case reports. Objective To analyse the clinical, immunologic (including mutational) and morphologic features at autopsy in 10 proven and suspected cases of primary immunodeficiency disorders diagnosed at our Institute over the past decade. Methods Study includes a detailed clinico-pathological analysis of 10 proven and suspected cases of primary immunodeficiency disorders. Results A varied spectrum of infectious and non-infectious complications were identified in these cases of which fungal infections were found to be more frequent compared with viral or bacterial infections. Rare and novel morphological findings, like granulomatous involvement of the heart in a patient with chronic granulomatous disease, systemic amyloidosis in a teenage girl with X-linked agammaglobulinemia, are highlighted which is distinctly lacking in the literature. Conclusions The present study is perhaps the first autopsy series on PID. Even in the molecular era, such analysis is still important, as correlation of pathological features with clinical symptoms provides clues for a timely diagnosis and appropriate therapeutic intervention.	[Gupta, Kirti; Agrawal, Parimal; Nada, Ritambhra] Postgrad Inst Med Educ & Res PGIMER, Dept Histopathol, Chandigarh, India; [Rawat, Amit; Jindal, Ankur; Singh, Surjit] Postgrad Inst Med Educ & Res PGIMER, Dept Paediat, Allergy & Immunol Unit, Chandigarh, India; [Saikia, Biman; Minz, Ranjana Walker] Postgrad Inst Med Educ & Res PGIMER, Dept Immunopathol, Chandigarh, India; [Chan, Koon Wing; Lau, Yu Lung] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	Gupta, K (reprint author), Postgrad Inst Med Educ & Res PGIMER, Dept Histopathol, Chandigarh, India.	kirtigupta10@yahoo.co.in	Rawat, Amit/A-3909-2014	Rawat, Amit/0000-0002-5875-2892; Nada, Ritambhra/0000-0002-8955-1428	Indian Council of Medical Research (ICMR), New Delhi, IndiaIndian Council of Medical Research; Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, New Delhi, India [48/2014-DHR]; Foundation for Primary Immunodeficiencies (FPID), USA	Authors thankfully acknowledge Indian Council of Medical Research (ICMR), New Delhi, India and Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, New Delhi, India for funding vide Grant No./48/2014-DHR and Foundation for Primary Immunodeficiencies (FPID), USA.	Apisarnthanarak A, 2005, CLIN CHEST MED, V26, P47, DOI 10.1016/j.ccm.2004.10.016; Arslan S, 2015, J CLIN IMMUNOL, V35, P344, DOI 10.1007/s10875-015-0151-7; BAEHNER R L, 1990, Pediatric Pathology, V10, P143; Berrington JE, 2000, ARCH DIS CHILD, V82, P144, DOI 10.1136/adc.82.2.144; Blumental S, 2011, CLIN INFECT DIS, V53, pE159, DOI 10.1093/cid/cir731; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Buckley Rebecca H, 2004, Paediatr Respir Rev, V5 Suppl A, pS225, DOI 10.1016/S1526-0542(04)90043-7; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Conley ME, 2000, CLIN REV ALLERG IMMU, V19, P183, DOI 10.1385/CRIAI:19:2:183; DUNCAN RA, 1993, NEW ENGL J MED, V328, P393, DOI 10.1056/NEJM199302113280604; Ferrans V J, 1985, Heart Vessels Suppl, V1, P262, DOI 10.1007/BF02072406; Gonzalo-Garijo MA, 2014, J CLIN IMMUNOL, V34, P119, DOI 10.1007/s10875-013-9972-4; Gupta K, 2015, INDIAN PEDIATR, V52, P601, DOI 10.1007/s13312-015-0683-1; Gupta K, 2014, INDIAN PEDIATR, V51, P819, DOI 10.1007/s13312-014-0509-6; Kadiroglu Ali Kemal, 2012, Case Rep Nephrol, V2012, P860208, DOI 10.1155/2012/860208; KAGE M, 1993, ARCH PATHOL LAB MED, V117, P942; Lundgren IS, 2012, PEDIATR INFECT DIS J, V31, P95, DOI 10.1097/INF.0b013e31822db772; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; NEZELOF C, 1992, HISTOPATHOLOGY, V21, P499, DOI 10.1111/j.1365-2559.1992.tb00437.x; Nonas S, 2015, IMMUNOL ALLERGY CLIN, V35, P753, DOI 10.1016/j.iac.2015.07.004; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Ochs HD, 2007, PRIMARY IMMUNODEFICI; Ozkinay F, 2007, J CHILD NEUROL, V22, P741, DOI 10.1177/0883073807302617; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Rawat A, 2014, J CLIN IMMUNOL, V34, P58, DOI 10.1007/s10875-013-9963-5; Roifman CM, 2005, IMMUNOL REV, V203, P143, DOI 10.1111/j.0105-2896.2005.00236.x; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; Segal BH, 1998, MEDICINE, V77, P345, DOI 10.1097/00005792-199809000-00004; Shapiro RS, 2011, AM J HEMATOL, V86, P48, DOI 10.1002/ajh.21903; Somech R, 2013, IMMUNOL RES, V56, P150, DOI 10.1007/s12026-012-8380-9; Szczawinska-Poplonyk A, 2014, CENT EUR J IMMUNOL, V39, P392, DOI 10.5114/ceji.2014.45953; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walong Edwin, 2014, BMC Res Notes, V7, P425, DOI 10.1186/1756-0500-7-425; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Wu XH, 2000, NATURE, V405, P477	40	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					425	435		10.1136/jclinpath-2017-204708			11	Pathology	Pathology	GD9LV	WOS:000430835100007	28970295				2019-10-28	
J	Miguelez-Rodriguez, A; Santos-Juanes, J; Vicente-Etxenausia, I; de Heredia-Goni, KP; Garcia, B; Quiros, LM; Lorente-Gea, L; Guerra-Merino, I; Aguirre, JJ; Fernandez-Vega, I				Miguelez-Rodriguez, Aitzol; Santos-Juanes, Jorge; Vicente-Etxenausia, Ikerne; Perez de Heredia-Goni, Katty; Garcia, Beatriz; Quiros, Luis M.; Lorente-Gea, Laura; Guerra-Merino, Isabel; Aguirre, Jose J.; Fernandez-Vega, Ivan			Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease	JOURNAL OF CLINICAL PATHOLOGY			English	Article						neurodegeneration; brain; immunohistochemistry; neuropathology; proteins	PRION PROTEIN; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; PATHOLOGIES; DEMENTIA; PROPAGATION; EXPERIENCE; PHENOTYPE; SCRAPIE; EUROPE	Aims To investigate the expression of major proteins related to primary neurodegenerative diseases and their prognostic significance in brains with Creutzfeldt-Jakob disease (CJD). Materials and methods Thirty consecutive cases of confirmed CJD during the period 2010-2015 at Basque Brain bank were retrospectively reviewed. Moreover, major neurodegenerative-associated proteins (phosphorylated Tau, 4R tau, 3R tau, alpha-synuclein, TDP43, amyloid beta) were tested. Clinical data were reviewed. Cases were divided according to the presence or absence of copathology. Survival curves were also determined. Results Copathology was significantly associated with survival in brains with CJD (4.21.2 vs 9.2 +/- 1.9; P=0.019) and in brains with MM1/MV1CJD (2.1 +/- 1.0 vs 6.7 +/- 2.8; P=0.012). Besides, the presence of more than one major neurodegenerative-associated protein was significantly associated with survival (4.2 +/- 1.2 vs 10.7 +/- 2.6; P=0.017). Thus, univariate analyses further pointed out variables significantly associated with better survival: copathology in CJD (HR=0.430; P=0.033); more than one neurodegenerative-associated protein in CJD (HR=0.369; P=0.036) and copathology in MM1/MV1CJD (HR=0.525; P=0.032). Conclusion The existence of copathology significantly prolongs survival in patients with rapidly progressive dementia due to CJD. The study of major neurodegenerative-associated proteins in brains with CJD could allow us to further understand the molecular mechanisms behind prion diseases.	[Miguelez-Rodriguez, Aitzol; Guerra-Merino, Isabel] Univ Basque Country, Fac Med, Vitoria, Spain; [Santos-Juanes, Jorge; Fernandez-Vega, Ivan] Hosp Univ Cent Asturias, Dept Pathol, Oviedo, Spain; [Vicente-Etxenausia, Ikerne; Perez de Heredia-Goni, Katty; Guerra-Merino, Isabel; Fernandez-Vega, Ivan] Hosp Univ Araba, Brain Bank, Biobanco Vasco Invest O EHun, Vitoria, Spain; [Garcia, Beatriz; Quiros, Luis M.] Inst Univ Fernandez Vega, Sci Dept, Oviedo, Spain; [Quiros, Luis M.] Univ Oviedo, Dept Funct Biol, Oviedo, Spain; [Lorente-Gea, Laura; Guerra-Merino, Isabel; Aguirre, Jose J.; Fernandez-Vega, Ivan] Hosp Univ Araba Txagorritxu, Dept Pathol, Vitoria, Spain	Fernandez-Vega, I (reprint author), Hosp Univ Araba Txagorritxu, Serv Anat Pathol, C Jose Atxotegui S-N, E-01009 Vitoria, Spain.	ivan_fernandez_vega@hotmail.com	Garcia, Beatriz/K-4231-2019; Quiros, Luis/T-3822-2017; Fernandez-Vega, Ivan/A-6776-2016	Garcia, Beatriz/0000-0002-5235-5167; Quiros, Luis/0000-0003-3505-3762; Fernandez-Vega, Ivan/0000-0002-3141-6493; Aguirre Anda, Jose Javier/0000-0001-9946-7521	Pathology Department of Hospital Universitario de Araba	This work was fully supported by Pathology Department of Hospital Universitario de Araba.	Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; Capellari S, 2011, ACTA NEUROPATHOL, V121, P21, DOI 10.1007/s00401-010-0760-4; Cummings JL, 2003, ANN NEUROL, V54, P147, DOI 10.1002/ana.10616; Echavarri C, 2011, ANAT REC, V294, P1191, DOI 10.1002/ar.21413; Fein JA, 2008, AM J PATHOL, V172, P1683, DOI 10.2353/ajpath.2008.070829; Fernandez-Vega I, 2015, NEUROPATHOLOGY, V35, P56, DOI 10.1111/neup.12150; Gambetti P, 1996, CURR TOP MICROBIOL, V207, P19; Gambetti P, 2008, ANN NEUROL, V63, P697, DOI 10.1002/ana.21420; Garden GA, 2012, NEURON, V73, P886, DOI 10.1016/j.neuron.2012.02.017; Grau-Rivera O, 2015, NEURODEGENER DIS, V15, P350, DOI 10.1159/000439251; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Head MW, 2012, NEUROPATH APPL NEURO, V38, P296, DOI 10.1111/j.1365-2990.2012.01265.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Josephs KA, 2009, ARCH NEUROL-CHICAGO, V66, P201, DOI 10.1001/archneurol.2008.534; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Lee SJ, 2011, NEUROSCI RES, V70, P339, DOI 10.1016/j.neures.2011.05.008; Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8; Parchi P, 2009, ACTA NEUROPATHOL, V118, P659, DOI 10.1007/s00401-009-0585-1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Puoti G, 2012, LANCET NEUROL, V11, P618, DOI 10.1016/S1474-4422(12)70063-7; Reiniger L, 2011, ACTA NEUROPATHOL, V121, P5, DOI 10.1007/s00401-010-0691-0; Requena JR, 2017, PROG MOL BIOL TRANSL, V150, P341, DOI 10.1016/bs.pmbts.2017.06.009; Ritchie DL, 2017, ACTA NEUROPATHOL, V133, P579, DOI 10.1007/s00401-016-1638-x; Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24; Sweeney P, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0077-5; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Uchihara T, 2016, ACTA NEUROPATHOL, V131, P1, DOI 10.1007/s00401-015-1517-x; Will RG, 1998, ANN NEUROL, V43, P763, DOI 10.1002/ana.410430611; Yates D, 2012, NAT REV NEUROSCI, V13, P290, DOI [10.1038/nrn3248, 10.1038/nrn3235]; Zerr I, 2009, BRAIN, V132, P2659, DOI 10.1093/brain/awp191	31	1	1	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					446	450		10.1136/jclinpath-2017-204794			5	Pathology	Pathology	GD9LV	WOS:000430835100010	29097599				2019-10-28	
J	Hedner, C; Borg, D; Nodin, B; Karnevi, E; Jirstrom, K; Eberhard, J				Hedner, Charlotta; Borg, David; Nodin, Bjorn; Karnevi, Emelie; Jirstrom, Karin; Eberhard, Jakob			Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment	JOURNAL OF CLINICAL PATHOLOGY			English	Article						oesophagus; stomach; histopathology; immunohistochemistry; in situ hybridisation	CLINICAL-PRACTICE GUIDELINES; HER2-POSITIVE BREAST-CANCER; GENE AMPLIFICATION; PROTEIN EXPRESSION; TISSUE MICROARRAY; LUNG-CANCER; FOLLOW-UP; HER2; SURVIVAL; HETEROGENEITY	Aims Neoadjuvant treatment has now become the standard of care for oesophageal and gastric cancer. The aim of this study was to investigate the influence of neoadjuvant therapy on the expression of human epidermal growth factor receptor 1 (HER1/EGFR), HER2 and HER3, in oesophageal and gastric adenocarcinoma. Methods Immunohistochemical expression of EGFR, HER2 and HER3 was examined and compared in pretreatment biopsies, post-treatment surgical resection specimens and metastases in a retrospective cohort of 166 patients with adenocarcinoma of the oesophagus or stomach. The relationship between expression of the investigative markers and histopathological response to neoadjuvant treatment, overall survival (OS) and recurrence free survival (RFS) was analysed. Results Conversion of protein expression between pretreatment biopsy and post-treatment surgical resection was seen in 4.6% of the cases for EGFR, 5.9% for HER2% and 19.4% for HER3. Histopathological response to neoadjuvant treatment was significantly and stepwise associated with OS and RFS . High HER3 protein expression in post-treatment surgical resection specimens was significantly associated with a prolonged OS in univariable analysis (HR=0.39; 95% CI 0.17 to 0.93), but did not remain significant in multivariable analysis. Expression of EGFR and HER2 in post-treatment surgical resection specimens was not prognostic. No correlation between pretreatment HER-protein expression and histopathological response was seen. Conclusions The results from this study underscore the need for further studies on the influence of neoadjuvant treatment on biomarker expression, as this may influence treatment strategy as well as prognosis. Histopathological response is validated as a useful prognostic factor.	[Hedner, Charlotta; Borg, David; Nodin, Bjorn; Karnevi, Emelie; Jirstrom, Karin; Eberhard, Jakob] Lund Univ, Skane Univ Hosp, Div Oncol & Pathol, Dept Clin Sci Lund, Lund, Sweden	Hedner, C (reprint author), Lund Univ, Dept Clin Sci, Div Oncol & Pathol, SE-22185 Lund, Sweden.	charlotta.hedner@med.lu.se		Borg, David/0000-0001-9461-7391	Swedish Cancer SocietySwedish Cancer Society; Crafoord Foundation; Olle Engkvist Foundation; Anna Lisa and Sven Eric Lundgren Foundation; Lund University Faculty of Medicine and University Hospital Research Grants; Swedish Government Grant for Clinical Research	This study was supported by grants from the Swedish Cancer Society, the Crafoord Foundation, the Olle Engkvist Foundation, the Anna Lisa and Sven Eric Lundgren Foundation, Lund University Faculty of Medicine and University Hospital Research Grants and the Swedish Government Grant for Clinical Research.	Allison KH, 2014, ONCOLOGY-NY, V28, P772; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Anagnostou VK, 2010, CANCER EPIDEM BIOMAR, V19, P982, DOI 10.1158/1055-9965.EPI-10-0097; Baiocchi G, 2009, INT J COLORECTAL DIS, V24, P1059, DOI 10.1007/s00384-009-0702-6; Bang YJ, 2010, LANCET, V376, P1302; Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Bhargava R, 2006, CANCER-AM CANCER SOC, V106, P1857, DOI 10.1002/cncr.21782; Bosetti C, 2008, INT J CANCER, V122, P1118, DOI 10.1002/ijc.23232; Buas MF, 2013, SEMIN RADIAT ONCOL, V23, P3, DOI 10.1016/j.semradonc.2012.09.008; Chen C, 2013, ARCH MED RES, V44, P380, DOI 10.1016/j.arcmed.2013.07.001; Chirieac LR, 2005, CANCER-AM CANCER SOC, V103, P1347, DOI 10.1002/cncr.20916; Cho EY, 2013, MODERN PATHOL, V26, P677, DOI 10.1038/modpathol.2012.205; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Desai MD, 2013, EXPERT OPIN INV DRUG, V22, P341, DOI 10.1517/13543784.2013.761972; Elebro J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153533; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gamboa-Dominguez A, 2004, MODERN PATHOL, V17, P579, DOI 10.1038/modpathol.3800085; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Goldhirsch A, 2013, LANCET, V382, P1021, DOI 10.1016/S0140-6736(13)61094-6; Gowryshankar A, 2014, J GASTROINTEST ONCOL, V5, P25, DOI 10.3978/j.issn.2078-6891.2013.039; Hechtman JF, 2012, ARCH PATHOL LAB MED, V136, P691, DOI 10.5858/arpa.2011-0168-RS; Hedner C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148101; Hedner C, 2016, HISTOPATHOLOGY, V68, P230, DOI 10.1111/his.12744; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Jarde T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138336; Linderoth J, 2007, EUR J HAEMATOL, V79, P146, DOI 10.1111/j.1600-0609.2007.00892.x; Ocana A, 2013, JNCI-J NATL CANCER I, V105, P266, DOI 10.1093/jnci/djs501; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198; Ruschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2; Russo A, 2015, ONCOTARGET, V6, P26814, DOI 10.18632/oncotarget.4254; Seo AN, 2015, VIRCHOWS ARCH, V466, P645, DOI 10.1007/s00428-015-1747-2; Seol H, 2012, MODERN PATHOL, V25, P938, DOI 10.1038/modpathol.2012.36; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sobin LH, 2010, CANCER-AM CANCER SOC, V116, P5336, DOI 10.1002/cncr.25537; Stahl M, 2013, ANN ONCOL, V24, P51, DOI 10.1093/annonc/mdt342; Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318; Thiel A, 2015, APMIS, V123, P365, DOI 10.1111/apm.12359; Tominaga N, 2016, GASTRIC CANCER, V19, P553, DOI 10.1007/s10120-015-0502-3; Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Waddell T, 2014, EJSO-EUR J SURG ONC, V40, P584, DOI 10.1016/j.ejso.2013.09.020; Warneke VS, 2013, ANN ONCOL, V24, P725, DOI 10.1093/annonc/mds528; Watson S, 2013, ANN ONCOL, V24, P3035, DOI 10.1093/annonc/mdt393; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					451	462		10.1136/jclinpath-2017-204774			12	Pathology	Pathology	GD9LV	WOS:000430835100011	29138285				2019-10-28	
J	Williams, BJ; Lee, J; Oien, KA; Treanor, D				Williams, Bethany Jill; Lee, Jessica; Oien, Karin A.; Treanor, Darren			Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute's CM-Path initiative	JOURNAL OF CLINICAL PATHOLOGY			English	Article						digital pathology; histopathology; information technology		Aim To canvass the UK pathology community to ascertain current levels of digital pathology usage in clinical and academic histopathology departments, and prevalent attitudes to digital pathology. Methods A 15-item survey was circulated to National Health Service and academic pathology departments across the UK using the SurveyMonkey online survey tool. Responses were sought at a departmental or institutional level. Where possible, departmental heads were approached and asked to complete the survey, or forward it to the most relevant individual in their department. Data were collected over a 6-month period from February to July 2017. Results 41 institutes from across the UK responded to the survey. 60% (23/39) of institutions had access to a digital pathology scanner, and 60% (24/40) had access to a digital pathology workstation. The most popular applications of digital pathology in current use were undergraduate and postgraduate teaching, research and quality assurance. Investigating the deployment of digital pathology in their department was identified as a high or highest priority by 58.5% of institutions, with improvements in efficiency, turnaround times, reporting times and collaboration in their institution anticipated by the respondents. Access to funding for initial hardware, software and staff outlay, pathologist training and guidance from the Royal College of Pathologists were identified as factors that could enable respondent institutions to increase their digital pathology usage. Conclusion Interest in digital pathology adoption in the UK is high, with usage likely to increase in the coming years. In light of this, pathologists are seeking more guidance on safe usage.	[Williams, Bethany Jill] St James Univ Hosp, Histopathol Dept, Leeds LS9 7T, W Yorkshire, England; [Lee, Jessica] Natl Inst Canc Res, London, England; [Oien, Karin A.] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Treanor, Darren] Univ Leeds, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England	Williams, BJ (reprint author), St James Univ Hosp, Histopathol Dept, Leeds LS9 7T, W Yorkshire, England.	Bethany.williams2@nhs.net					Bell J., LIFE SCI IND STRATEG; Cancer Research Uk, TEST TIM COM EV PATH; Cross SS, 2002, HISTOPATHOLOGY, V41, P91, DOI 10.1046/j.1365-2559.2002.01423.x; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Royal College of Pathologists, 2017, DIG PATH GUID; Williams BJ, 2017, ARCH PATHOL LAB MED, V141, P1712, DOI 10.5858/arpa.2016-0494-OA; Williams BJ, 2017, J CLIN PATHOL, V70, P1010, DOI 10.1136/jclinpath-2017-204644	7	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					463	466		10.1136/jclinpath-2017-204808			4	Pathology	Pathology	GD9LV	WOS:000430835100012	29317516	Green Published, Green Accepted, Other Gold			2019-10-28	
J	Raspollini, MR; Montagnani, I; Montironi, R; Castiglione, F; Martignoni, G; Cheng, L; Lopez-Beltran, A				Raspollini, Maria Rosaria; Montagnani, Ilaria; Montironi, Rodolfo; Castiglione, Francesca; Martignoni, Guido; Cheng, Liang; Lopez-Beltran, Antonio			Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						uropathology; carcinoma; molecular pathology	INTERNATIONAL-SOCIETY; EVOLUTION	Clear cell renal cell carcinoma (ccRCC) is an heterogeneous tumour at architectural, cellular and molecular level, a reason why the 2014 International Society of Urological Pathology consensus recommended wide sampling of RCC masses to include at least 1 block/cm of tumour together with perpendicular sections of the tumour/perinephric fat interface and the tumour/renal sinus interface. Intratumoural molecular heterogeneity may be a limitation at the moment of defining precision medicine strategies based on gene mutation status. This study analyses the presence of any mutation of KRAS, NRAS, BRAF, PIK3CA, ALK, ERBB2, DDR2, MAP2K1, RET and EGFR genes in 20 tissue blocks from a case of ccRCC and its metastasis. We observed the presence of the mutation at pH1047R of PIK3CA gene in five samples of the tumour, while the remaining 15 samples did not show any mutation at PIK3CA or any other investigated gene. There is a great need to develop novel RCC sampling strategies to overcome tumour heterogeneity prior to define precision oncology strategies.	[Raspollini, Maria Rosaria; Montagnani, Ilaria; Castiglione, Francesca] Univ Hosp Careggi, Histopathol & Mol Diagnost, I-30134 Florence, Italy; [Montironi, Rodolfo] Polytech Univ Marche Reg, Dept Biomed Sci & Publ Hlth, Sect Pathol Anat, Sch Med,United Hosp, Ancona, Italy; [Martignoni, Guido] Univ Verona, Dept Pathol, Anat Pathol, Verona, Italy; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Lopez-Beltran, Antonio] Cordoba Univ, Sch Med, Dept Surg, Anat Pathol Unit, Cordoba, Spain	Raspollini, MR (reprint author), Univ Hosp Careggi, Histopathol & Mol Diagnost, I-30134 Florence, Italy.	mariarosaria.raspollini@unifi.it					Amin M, 2017, AM JOINT COMMITTEE C; Barber LJ, 2015, CURR OPIN GENET DEV, V30, P1, DOI 10.1016/j.gde.2014.12.001; Brannon A Rose, 2010, Genes Cancer, V1, P152; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; de Peralta-Venturina M, 2001, AM J SURG PATHOL, V25, P275, DOI 10.1097/00000478-200103000-00001; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Jiang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164554; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lopez JI, 2013, APMIS, V121, P1187, DOI 10.1111/apm.12073; Martinez P, 2013, J PATHOL, V230, P356, DOI 10.1002/path.4214; Moch H, 2016, WHO CLASSIFICATION T; Ruiz-Cerda JL, 1999, CANCER, V86, P664, DOI 10.1002/(SICI)1097-0142(19990815)86:4<664::AID-CNCR16>3.0.CO;2-E; Sankin A, 2014, CANCER MED-US, V3, P1485, DOI 10.1002/cam4.293; Shuch B, 2015, EUR UROL, V67, P85, DOI 10.1016/j.eururo.2014.04.029; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; von Roemeling CA, 2014, ONCOTARGET, V5, P5320, DOI 10.18632/oncotarget.2097; Walter D, 2017, ONCOTARGET, V8, P14957, DOI 10.18632/oncotarget.14844; Yates LR, 2017, BREAST, V34, pS36, DOI 10.1016/j.breast.2017.06.025	20	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					467	471		10.1136/jclinpath-2017-204931			5	Pathology	Pathology	GD9LV	WOS:000430835100013	29317515				2019-10-28	
J	Wiggins, J; Hayes, E; Heymann, M; Hawari, R; Carr, RA				Wiggins, James; Hayes, Emily; Heymann, Marc; Hawari, Rand; Carr, Richard A.			Rare necrotic lesion in a pregnant woman	JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material						virus; infections; histopathology; dermatopathology; pox viruses	INFECTION		[Wiggins, James; Hayes, Emily; Carr, Richard A.] South Warwickshire NHS Fdn Trust, Dept Histopathol, Warwick, England; [Heymann, Marc] Queens Hosp, Resp Med, Romford, Essex, England; [Hawari, Rand] Derby Teaching Hosp NHS Fdn Trust, Dept Histopathol, Derby, England	Carr, RA (reprint author), Warwick Hosp, Dept Histopathol, Warwick CV34 5BW, England.	Richard.Carr@swft.nhs.uk					BLACKFORD S, 1993, BRIT J DERMATOL, V129, P628, DOI 10.1111/j.1365-2133.1993.tb00500.x; Calonje E, 2012, DIS CAUSED ORTHOPOX, P781; Gazzani P, 2017, PEDIATR NEPHROL, V32, P533, DOI 10.1007/s00467-016-3534-y; Vogel S, 2012, ACTA DERM-VENEREOL, V92, P126, DOI 10.2340/00015555-1227; Zaba R, 2017, NEW MICROBIOL, V40, P148	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					472	472		10.1136/jclinpath-2017-204459			1	Pathology	Pathology	GD9LV	WOS:000430835100014	29549216				2019-10-28	
J	Haslam, K; Dell, S; Atkinson, E; Enright, H; Thornton, P; Langabeer, SE				Haslam, Karl; Dell, Sarah; Atkinson, Emer; Enright, Helen; Thornton, Patrick; Langabeer, Stephen E.			False-negative CALR mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						myeloproliferative disease; diagnostics; haemato-oncology	CALRETICULIN		[Haslam, Karl; Atkinson, Emer; Langabeer, Stephen E.] St James Hosp, Canc Mol Diagnost, D08 E9P6, Dublin, Ireland; [Dell, Sarah] Sheffield Childrens NHS Fdn Trust, Sheffield Diagnost Genet Serv, Sheffield, S Yorkshire, England; [Enright, Helen] Tallaght Hosp, Dept Haematol, Dublin, Ireland; [Thornton, Patrick] Beaumont Hosp, Dept Haematol, Dublin, Ireland	Langabeer, SE (reprint author), St James Hosp, Canc Mol Diagnost, D08 E9P6, Dublin, Ireland.	slangabeer@stjames.ie					Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Clinton A, 2016, J CLIN PATHOL, V69, P841, DOI 10.1136/jclinpath-2016-203899; Gardner JA, 2016, AM J CLIN PATHOL, V146, P448, DOI [10.1093/AJCP/AQW129, 10.1093/ajcp/aqw129]; Haslam K, 2014, BRIT J HAEMATOL, V166, P800, DOI 10.1111/bjh.12904; Jonesa AV, 2015, LEUKEMIA RES, V39, P82, DOI 10.1016/j.leukres.2014.11.019; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Lippert E, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.107656; Park JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141010	8	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAY	2018	71	5					473	474		10.1136/jclinpath-2018-205029			2	Pathology	Pathology	GD9LV	WOS:000430835100015	29463578				2019-10-28	
J	Mishima, C; Kagara, N; Ikeda, J; Morii, E; Miyake, T; Tanei, T; Naoi, Y; Shimoda, M; Shimazu, K; Kim, SJ; Noguchi, S				Mishima, Chieko; Kagara, Naofumi; Ikeda, Jun-ichiro; Morii, Eiichi; Miyake, Tomohiro; Tanei, Tomonori; Naoi, Yasuto; Shimoda, Masafumi; Shimazu, Kenzo; Kim, Seung Jin; Noguchi, Shinzaburo			Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components	AMERICAN JOURNAL OF PATHOLOGY			English	Article							POLYMERASE-CHAIN-REACTION; DUCTAL HYPERPLASIA; CLONAL ANALYSIS; MAMMARY-GLAND; CANCER; SUBSEQUENT; PATHWAY; BENIGN; RISK	The pathologic feature of intraductal papillomas is defined as a papillary structure composed of a fibrovascular stromal core lined by luminal epithelial cells and myoepithelial cells. We used droplet digital PCR for the mutational analysis of AKT1 (E17K) and PIK3CA (H1047R, E542K, and E545K) in 60 papillomas. AKT1 and PIK3CA mutations were detected in 12 (20%) and 17 (28%) of the papillomas, respectively. In five tumors harboring mutations, mutational analysis of AKT1 or PIK3CA was performed separately using luminal epithelial cells and myoepithelial cells sorted using anti cytokeratin 19 antibody and anti a smooth muscle actin antibody. The two types of cells from a given papilloma had the identical mutation. Three patients with the PIK3CA mutation positive papilloma developed breast cancers at the resection site of the papilloma, but none of these subsequent breast cancers had the PIK3CA mutation. These results indicate that a papilloma stems from a bipotent progenitor cell that contains the AKT1 or PIK3CA mutation and proliferates and differentiates to form the papilloma. Papilloma can be a risk factor for developing breast cancer but is unlikely to be its obligate precursor.	[Mishima, Chieko; Kagara, Naofumi; Miyake, Tomohiro; Tanei, Tomonori; Naoi, Yasuto; Shimoda, Masafumi; Shimazu, Kenzo; Kim, Seung Jin; Noguchi, Shinzaburo] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka, Japan; [Ikeda, Jun-ichiro; Morii, Eiichi] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka, Japan	Kagara, N (reprint author), Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, 2-2-E10 Yamadaoka, Suita, Osaka, Japan.	kagaran@onsurg.med.osaka-u.ac.jp		MIYAKE, TOMOHIRO/0000-0002-9362-9822			Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; CIATTO S, 1991, TUMORI, V77, P41; Jahn SW, 2016, AM J PATHOL, V186, P15, DOI 10.1016/j.ajpath.2015.09.004; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017; MacGrogan G, 2003, VIRCHOWS ARCH, V443, P609, DOI 10.1007/s00428-003-0888-x; Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267; Mulligan AM, 2007, ADV ANAT PATHOL, V14, P108, DOI 10.1097/PAP.0b013e318032508d; NOGUCHI S, 1995, CANCER LETT, V90, P57, DOI 10.1016/0304-3835(94)03678-C; NOGUCHI S, 1994, AM J PATHOL, V144, P1320; OHUCHI N, 1984, BREAST CANCER RES TR, V4, P117, DOI 10.1007/BF01806394; Oshiro C, 2015, BREAST CANCER RES TR, V150, P299, DOI 10.1007/s10549-015-3322-6; Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO;2-V; Petersen OW, 2003, CELL PROLIFERAT, V36, P33, DOI 10.1046/j.1365-2184.36.s.1.4.x; Raju U, 1996, HUM PATHOL, V27, P1231, DOI 10.1016/S0046-8177(96)90320-2; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Rudolph M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2626-1; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Troxell ML, 2010, MODERN PATHOL, V23, P27, DOI 10.1038/modpathol.2009.142; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	23	0	0	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1106	1112		10.1016/j.ajpath.2018.01.005			7	Pathology	Pathology	GD6TK	WOS:000430641100001	29454754	Bronze			2019-10-28	
J	Lofdahl, A; Wenglen, C; Rydell-Tormanen, K; Westergren-Thorsson, G; Larsson-Callerfelt, AK				Lofdahl, Anna; Wenglen, Christina; Rydell-Tormanen, Kristina; Westergren-Thorsson, Gunilla; Larsson-Callerfelt, Anna-Karin			Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SMOOTH-MUSCLE-CELLS; CUT LUNG SLICES; EXTRACELLULAR-MATRIX; MAST-CELLS; AIRWAY; SEROTONIN; ASTHMA; FIBROSIS; EXPRESSION; MODULATION	Serotonin [5-hydroxyttyptamine (5-HT)] is associated with several chronic pulmonary diseases, recognizing 5-HT2 receptor antagonists as potential inhibitors of tissue remodeling. However, the effects of 5-HT2 receptors, especially 5-HT2B receptors on airway function and remodeling, are unclear. We investigated the role of 5-HT2B receptors on airway smooth muscle contractility and remodeling processes. Murine precision-cut lung slices were pretreated with 5-HT2B receptor antagonists (EXT5, EXT9, RS 127445, and PRX 08066), as well as ketanserin (5-HT2A/2C receptor antagonist) (1, 10 mu mol/L), before addition of cumulative concentrations of 5-HT to induce bronchoconstriction. Remodeling effects after treatment with 10 mu mol/L 5-HT and 5-HT2 receptor antagonists were further studied in distal lung tissue by examining release of profibrotic transforming growth factor (TGF)-beta 1 and proliferation of human bronchial smooth muscle cells (HBSMCs). 5-HT induced bronchoconstriction was significantly reduced by EXT5, EXT9, and ketanserin, but not by RS 127445 or PRX 08066. The 5-HT2B receptor antagonists significantly reduced TGF-beta 1 release. 5-HT, in combination with TGF-beta 1, increased proliferation of HBSMCs, a process reduced by EXT5 and EXT9. Our results indicate that EXT5 and EXT9 may relieve bronchoconstriction in murine airways and serve as an add-on effect in attenuating pulmonary remodeling by improving airway function. The antiproliferative effect on HBSMCs and the inhibition of TGF-beta 1 release further support a role of 5-HT2B receptors in pathologic remodeling processes.	[Lofdahl, Anna; Rydell-Tormanen, Kristina; Westergren-Thorsson, Gunilla; Larsson-Callerfelt, Anna-Karin] Lund Univ, Dept Expt Med Sci, Lung Biol Grp, BMC C12, SE-22184 Lund, Sweden; [Wenglen, Christina] AnaMar AB, Lund, Sweden	Lofdahl, A (reprint author), Lund Univ, Dept Expt Med Sci, Lung Biol Grp, BMC C12, SE-22184 Lund, Sweden.	anna.lofdahl@med.lu.se			Swedish Research Council in Medicine and Health [11550, 2013-03316]; Evy and Gunnar Sandberg Foundation; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation [20130507]; Crafoord Foundation; Greta and John Kock Foundation; Alfred Osterlund Foundation; Royal Physiographical Society in LundRoyal Society of London; Medical Faculty of Lund University, ALF; Swedish Foundation of Strategic ResearchSwedish Foundation for Strategic Research [SBE13-0130]; AnaMar AB	Supported by The Swedish Research Council in Medicine and Health grants 11550 and 2013-03316, the Evy and Gunnar Sandberg Foundation, the Swedish Heart-Lung Foundation grant 20130507, The Crafoord Foundation, Greta and John Kock Foundation, the Alfred Osterlund Foundation, the Royal Physiographical Society in Lund, the Medical Faculty of Lund University, ALF, the Swedish Foundation of Strategic Research grant SBE13-0130, and AnaMar AB.	Altman DG, 1991, PRACTICAL STAT MED R; Andersson CK, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-139; Beamish JA, 2010, TISSUE ENG PART B-RE, V16, P467, DOI [10.1089/ten.teb.2009.0630, 10.1089/ten.TEB.2009.0630]; Berair R, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-145; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; CAZZOLA M, 1990, ALLERGY, V45, P151, DOI 10.1111/j.1398-9995.1990.tb00473.x; Chan V, 2006, AM J RESP CRIT CARE, V174, P379, DOI 10.1164/rccm.200509-1420OC; de las Casas-Engel M, 2013, J IMMUNOL, V190, P2301, DOI 10.4049/jimmunol.1201133; Dees C, 2011, J EXP MED, V208, P961, DOI 10.1084/jem.20101629; Eurlings IMJ, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-90; Fabre A, 2008, EUR RESPIR J, V32, P426, DOI 10.1183/09031936.00126907; FULMER JD, 1977, J CLIN INVEST, V60, P595, DOI 10.1172/JCI108811; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; Henjakovic M, 2008, TOXICOL SCI, V106, P444, DOI 10.1093/toxsci/kfn178; Henjakovic M, 2008, TOXICOL APPL PHARM, V231, P68, DOI 10.1016/j.taap.2008.04.003; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Hutcheson JD, 2012, J MOL CELL CARDIOL, V53, P707, DOI 10.1016/j.yjmcc.2012.08.012; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Kim SK, 2011, J CHEM INF MODEL, V51, P420, DOI 10.1021/ci100375b; Knight AR, 2004, N-S ARCH PHARMACOL, V370, P114, DOI 10.1007/s00210-004-0951-4; Konigshoff M, 2010, THORAX, V65, P949, DOI 10.1136/thx.2009.134353; Kummer W, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-65; Larsson-Callerfelt AK, 2013, EUR J PHARMACOL, V699, P141, DOI 10.1016/j.ejphar.2012.11.039; Launay JM, 2002, NAT MED, V8, P1129, DOI 10.1038/nm764; Lechin F, 1998, J CLIN PHARMACOL, V38, P918, DOI 10.1002/j.1552-4604.1998.tb04387.x; Lechin F, 1996, ANN ALLERG ASTHMA IM, V77, P245, DOI 10.1016/S1081-1206(10)63263-2; Li N, 1997, BLOOD COAGUL FIBRIN, V8, P517, DOI 10.1097/00001721-199711000-00006; Lofdahl A, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12873; McKay S, 2000, AM J RESP CELL MOL, V23, P103, DOI 10.1165/ajrcmb.23.1.3765; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Nau F, 2015, AM J PHYSIOL-LUNG C, V308, pL191, DOI 10.1152/ajplung.00138.2013; Oenema TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065580; Polosukhin VV, 2012, EXP LUNG RES, V38, P135, DOI 10.3109/01902148.2012.658595; Ressmeyer AR, 2006, EUR RESPIR J, V28, P603, DOI 10.1183/09031936.06.00004206; Taller A. L., 2011, J IMMUNOL, V187, P6094; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wygrecka M, 2013, AM J PATHOL, V182, P2094, DOI 10.1016/j.ajpath.2013.02.013; Zhang YP, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-29	41	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1113	1119		10.1016/j.ajpath.2018.01.006			7	Pathology	Pathology	GD6TK	WOS:000430641100002	29454752	Bronze			2019-10-28	
J	Cybulska, P; Stewart, JM; Sayad, A; Virtanen, C; Shaw, PA; Clarke, B; Stickle, N; Bernardini, MQ; Neel, BG				Cybulska, Paulina; Stewart, Jocelyn M.; Sayad, Azin; Virtanen, Carl; Shaw, Patricia A.; Clarke, Blaise; Stickle, Natalie; Bernardini, Marcus Q.; Neel, Benjamin G.			A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PATIENT-DERIVED XENOGRAFTS; CELL LUNG-CANCER; IN-VIVO; STAGE-III; MODELS; CISPLATIN; MICE; ESTABLISHMENT; CARBOPLATIN; INTRAPERITONEAL	High-grade serous ovarian cancer (HGSC) is the leading cause of morbidity and mortality from gynecologic malignant tumors. Overall survival remains low because of the nearly ubiquitous emergence of platinum resistance and the paucity of effective next-line treatments. Current cell culture-based models show limited similarity to HGSC and are therefore unreliable predictive models for preclinical evaluation of investigational drugs. This deficiency could help explain the low overall rate of successful drug development and the decades of Largely unchanged approaches to HGSC treatment. We used gene expression, copy number variation, and exome sequencing analyses to credential HGSC patient-derived xenografts (PDXs) as effective preclinical models that recapitulate the features of human HGSC. Mice bearing PDXs were also treated with standard-of-care carboplatin therapy. PDXs showed similar sensitivity to carboplatin as the patient's tumor at the time of sampling. PDXs also recapitulated the diversity of genomic alterations (copy number variation and mutation profiles) previously described in large data sets that profiled HGSC. Furthermore, mRNA profiling showed that the PDXs represent all HGSC subtypes with the exception of the immunoreactive group. Credentialing of PDX models of HGSC should aid progress in HGSC research by providing improved preclinical models of HGSC that can be used to test novel targets and more accurately evaluate their likelihood of success.	[Cybulska, Paulina; Bernardini, Marcus Q.] Univ Toronto, Dept Obstet & Gynecol, Toronto, ON, Canada; [Stewart, Jocelyn M.; Neel, Benjamin G.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Cybulska, Paulina] Mem Sloan Kettering Canc Ctr, Dept Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA; [Cybulska, Paulina; Stewart, Jocelyn M.; Sayad, Azin; Virtanen, Carl; Stickle, Natalie; Bernardini, Marcus Q.; Neel, Benjamin G.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Shaw, Patricia A.; Clarke, Blaise] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Bernardini, Marcus Q.] Univ Hlth Network, Dept Gynecol Oncol, Toronto, ON, Canada; [Neel, Benjamin G.] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA	Neel, BG (reprint author), 522 First Ave,Smilow Bldg,Twelfth Floor,Ste 1201, New York, NY 10016 USA.	benjamin.neel@nyumc.org		Clarke, Blaise/0000-0002-2585-8391	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR-MOP-191992]; Canadian Cancer Society Research Institute Terry Fox Program [020003]; Samuel Waxman Cancer Research Foundation; Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Princess Margaret Cancer FoundationUniversity of Toronto; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR-CGS-200710MDR]; J.W. Knox Ritchie Research Award; Kristi Piia Callum Memorial Fund in Ovarian Cancer Research; Teresina Florio Graduate Scholarship in Cancer Research; Thomas G. Ryley Clinical Investigators Award	Supported by Canadian Institutes of Health Research grant CIHR-MOP-191992, Canadian Cancer Society Research Institute Terry Fox Program Project grant 020003, and the Samuel Waxman Cancer Research Foundation (B.G.N.). B.G.N. was a Canada Research Chair, Tier 1, and work in his Toronto laboratory was partially supported by a grant from the Ontario Ministry of Health and Long Term Care and the Princess Margaret Cancer Foundation. J.M.S. was supported by scholarship fund CIHR-CGS-200710MDR from the Canadian Institutes for Health Research. P.C. was funded by a J.W. Knox Ritchie Research Award, the Kristi Piia Callum Memorial Fund in Ovarian Cancer Research, the Teresina Florio Graduate Scholarship in Cancer Research, and a Thomas G. Ryley Clinical Investigators Award.	AlHilli MM, 2016, GYNECOL ONCOL, V143, P379, DOI 10.1016/j.ygyno.2016.08.328; Bankert RB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024420; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Das B, 2008, NEOPLASIA, V10, P1105, DOI 10.1593/neo.08466; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong RF, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0318-6; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; Fichtner I, 2008, CLIN CANCER RES, V14, P6456, DOI 10.1158/1078-0432.CCR-08-0138; Garrido-Laguna I, 2011, CLIN CANCER RES, V17, P5793, DOI 10.1158/1078-0432.CCR-11-0341; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; George E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89760; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jandial DD, 2009, GYNECOL ONCOL, V115, P362, DOI 10.1016/j.ygyno.2009.08.028; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Lee CH, 2005, GYNECOL ONCOL, V96, P48, DOI 10.1016/j.ygyno.2004.09.025; Lee WS, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000298; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Liu JF, 2017, CLIN CANCER RES, V23, P1263, DOI 10.1158/1078-0432.CCR-16-1237; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Markman M, 2009, INT J GYNECOL CANCER, V19, pS40, DOI 10.1111/IGC.0b013e3181bf8143; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Merk J, 2009, EUR J CARDIO-THORAC, V36, P454, DOI 10.1016/j.ejcts.2009.03.054; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Press JZ, 2008, GYNECOL ONCOL, V110, P256, DOI 10.1016/j.ygyno.2008.03.011; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2; Reyal F, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3095; Ricci F, 2014, CANCER RES, V74, P6980, DOI 10.1158/0008-5472.CAN-14-0274; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Scott CL, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00295; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sivanand S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003643; Stebbing J, 2014, CANCER-AM CANCER SOC, V120, P2006, DOI 10.1002/cncr.28696; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Topp MD, 2014, MOL ONCOL, V8, P656, DOI 10.1016/j.molonc.2014.01.008; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weroha SJ, 2014, CLIN CANCER RES, V20, P1288, DOI 10.1158/1078-0432.CCR-13-2611; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081	54	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1120	1131		10.1016/j.ajpath.2018.01.019			12	Pathology	Pathology	GD6TK	WOS:000430641100003	29458007	Bronze			2019-10-28	
J	Taylor, MS; Chivukula, RR; Myers, LC; Jeck, WR; Waghray, A; Tata, PR; Selig, MK; O'Donnell, WJ; Farver, CF; Thompson, BT; Rajagopal, J; Kradin, RL				Taylor, Martin S.; Chivukula, Raghu R.; Myers, Laura C.; Jeck, William R.; Waghray, Avinash; Tata, Purushothama R.; Selig, Martin K.; O'Donnell, Walter J.; Farver, Carol F.; Thompson, B. Taylor; Rajagopal, Jayaraj; Kradin, Richard L.			A Conserved Distal Lung Regenerative Pathway in Acute Lung Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; DIFFUSE ALVEOLAR DAMAGE; AIRWAY STEM-CELLS; BIOPSY; MECHANISMS; PARENCHYMA; PROGENITOR; PLASTICITY; INFECTION; PATHOLOGY	Improved tools have led to a burgeoning understanding of lung regeneration in mice, but it is not yet known how these insights may be relevant to acute lung injury in humans. We report in detail two cases of fulminant idiopathic acute lung injury requiring extracorporeal membrane oxygenation in previously healthy young adults with acute respiratory distress syndrome, one of whom required lung transplantation. Biopsy specimens showed diffuse alveolar injury with a striking paucity of alveolar epithelial regeneration, rare hyaline membranes, and diffuse contiguous airspace lining by macrophages. This novel constellation was termed diffuse alveolar injury with delayed epithelization. In addition, mirroring data from murine models of lung injury/regeneration, peribronchiolar basaloid pods (previously described as squamous metaplasia) and ciliated bronchiolarization were identified in these patients and in 39% of 57 historical cases with diffuse alveolar damage. These findings demonstrate a common and clinically relevant human disease correlate for murine models of severe acute lung injury. Evidence suggests that peribronchiolar basaloid pods and bronchiolarization are related spatially and temporally and likely represent overlapping sequential stages of the response to severe distal airway injury.	[Taylor, Martin S.; Jeck, William R.; Selig, Martin K.; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Dept Internal Med, Boston, MA 02114 USA; [Chivukula, Raghu R.; Myers, Laura C.; Waghray, Avinash; Tata, Purushothama R.; O'Donnell, Walter J.; Thompson, B. Taylor; Rajagopal, Jayaraj; Kradin, Richard L.] Massachusetts Gen Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Boston, MA 02114 USA; [Farver, Carol F.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA	Kradin, RL (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren 225, Boston, MA 02114 USA.	rkradin@mgh.harvard.edu		Taylor, Martin/0000-0001-5824-142X; Waghray, Avinash/0000-0003-3242-2227	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL116756, R01HL118185, K99HL127181]	Supported in part by NIH grants R01HL116756 (J.R.), R01HL118185 (J.R.), and K99HL127181 (P.R.T). J.R. is a Howard Hughes Medical Institute Faculty Scholar, a New York Stem Cell Foundation Robertson Investigator, a Maroni Research Scholar at Massachusetts General Hospital, and a member of the Ludwig Cancer Institute at Harvard Medical School.	Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Beasley MB, 2008, DAIL HAMMARS PULMONA, P64; Cardinal-Fernandez P, 2016, CHEST, V149, P1155, DOI 10.1016/j.chest.2016.02.635; CHOU P, 1993, HUM PATHOL, V24, P405, DOI 10.1016/0046-8177(93)90089-Y; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Kanegai CM, 2016, AM J RESP CELL MOL, V55, P613, DOI 10.1165/rcmb.2015-0387LE; Katzenstein A-LA, 2006, MAJOR PROBLEMS PATHO; Kotton DN, 2014, NAT MED, V20, P822, DOI 10.1038/nm.3642; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Ogino S, 2002, HUM PATHOL, V33, P1052, DOI 10.1053/hupa.2002.128246; Papazian L, 2007, CRIT CARE MED, V35, P755, DOI 10.1097/01.CCM.0000257325.88144.30; Patel SR, 2004, CHEST, V125, P197, DOI 10.1378/chest.125.1.197; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Ray S, 2016, STEM CELL REP, V7, P817, DOI 10.1016/j.stemcr.2016.09.010; Shenoy ES, 2015, NEW ENGL J MED, V373, P2456, DOI 10.1056/NEJMcpc1507212; Tata PR, 2017, DEVELOPMENT, V144, P755, DOI 10.1242/dev.143784; Taylor MS, 2018, AM J RESP CRIT CARE, V197, P522, DOI 10.1164/rccm.201706-1094LE; Thompson BT, 2016, INTENS CARE MED, V42, P653, DOI 10.1007/s00134-016-4296-5; Vaughan AE, 2015, NATURE, V517, P621, DOI 10.1038/nature14112; YELDANDI AV, 1994, HUM PATHOL, V25, P47, DOI 10.1016/0046-8177(94)90170-8; Zheng DH, 2014, AM J RESP CELL MOL, V50, P595, DOI 10.1165/rcmb.2013-0327OC; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	24	6	6	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1149	1160		10.1016/j.ajpath.2018.01.021			12	Pathology	Pathology	GD6TK	WOS:000430641100005	29476724	Green Published, Bronze			2019-10-28	
J	Hung, LY; Oniskey, TK; Sen, D; Krummel, MF; Vaughan, AE; Cohen, NA; Herbert, DR				Hung, Li-Yin; Oniskey, Taylor K.; Sen, Debasish; Krummel, Matthew F.; Vaughan, Andrew E.; Cohen, Noam A.; Herbert, De'Broski R.			Trefoil Factor 2 Promotes Type 2 Immunity and Lung Repair through Intrinsic Roles in Hematopoietic and Nonhematopoietic Cells	AMERICAN JOURNAL OF PATHOLOGY			English	Article							REGULATORY T-CELLS; MACROPHAGE ACTIVATION; T(H)2-TYPE RESPONSES; HELMINTH INFECTION; TISSUE PROTECTION; AMPHIREGULIN; INFLAMMATION; INDUCTION; MONOCYTES; CANCER	Trefoil factors (IFFs) are small secreted proteins that regulate tissue integrity and repair at mucosal surfaces, particularly in the gastrointestinal tract. However, their relative contribution(s) to controlling baseline lung function or the extent of infection-induced lung injury are unknown issues. With the use of irradiation bone marrow chimeras, we found that TFF2 produced from both hematopoietic- and nonhematopoietic-derived cells is essential for host protection, proliferation of alveolar type 2 cells, and restoration of pulmonary gas exchange after infection with the hookworm parasite Nippostrongylus brosiliensis. In the absence of TFF2, lung epithelia were unable to proliferate and expressed reduced lung mRNA transcript levels for type 2 response-inducing IL-25 and IL-33 after infectious injury. Strikingly, even in the absence of infection or irradiation, TFF2 deficiency compromised lung structure and function, as characterized by distended alveoli and reduced blood oxygen levels relative to wild type control mice. Taken together, we show a previously unappreciated role for TFF2, produced by either hematopoietic or nonhematopoietic sources, as a pro-proliferative factor for lung epithelial cells under steady-state and infectious injury conditions.	[Hung, Li-Yin; Oniskey, Taylor K.; Herbert, De'Broski R.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA; [Sen, Debasish; Krummel, Matthew F.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Vaughan, Andrew E.] Univ Penn, Sch Vet Med, Dept Biol Sci, Philadelphia, PA 19104 USA; [Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	Herbert, DR (reprint author), Univ Penn, Sch Vet Med, Dept Pathobiol, 3800 Spruce St,Old Vet Quad Rm 369E, Philadelphia, PA 19104 USA.	debroski@vet.upenn.edu	Hung, Li-Yin/L-6758-2019	Vaughan, Andrew/0000-0001-5740-643X; Hung, Li-Yin/0000-0001-7623-1946	NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R00HL131817, R01DC013588, R01GM083204, R01AI095289, U01AI125940]; McCabe Pilot Fund Award [015802]; Veterans Administration Merit Review grantUS Department of Veteran Affairs [CX001617]	Supported by NIH grants R00HL131817 (A.E.V.), R01DC013588 (N.A.C.), R01GM083204 (D.R.H.), R01AI095289 (D.R.H.), and U01AI125940 (D.R.H.), McCabe Pilot Fund Award 015802 (A.E.V.), and Veterans Administration Merit Review grant CX001617 (N.A.C.).	Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; Dhar DK, 2003, LAB INVEST, V83, P1343, DOI 10.1097/01.LAB.0000085190.99749.15; Dubeykovskaya Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10517; Dubeykovskaya Z, 2009, J BIOL CHEM, V284, P3650, DOI 10.1074/jbc.M804935200; Giraud AS, 2004, PEPTIDES, V25, P803, DOI 10.1016/j.peptides.2004.01.019; Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065; Judd LM, 2015, AM J PHYSIOL-GASTR L, V308, pG12, DOI 10.1152/ajpgi.00172.2014; Kurt-Jones EA, 2007, INFECT IMMUN, V75, P471, DOI 10.1128/IAI.02039-05; Lechner AJ, 2017, CELL STEM CELL, V21, P120, DOI 10.1016/j.stem.2017.03.024; Marsland BJ, 2008, EUR J IMMUNOL, V38, P479, DOI 10.1002/eji.200737827; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; McBerry C, 2012, J IMMUNOL, V189, P3078, DOI 10.4049/jimmunol.1103374; Meng C, 2015, BIOCHEM BIOPH RES CO, V466, P393, DOI 10.1016/j.bbrc.2015.09.037; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Reece JJ, 2008, INFECT IMMUN, V76, P3511, DOI 10.1128/IAI.00192-08; Siracusa MC, 2008, J LEUKOCYTE BIOL, V84, P1422, DOI 10.1189/jlb.0308199; Tjota MY, 2014, J ALLERGY CLIN IMMUN, V134, P706, DOI 10.1016/j.jaci.2014.06.013; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; Wills-Karp M, 2012, J EXP MED, V209, P607, DOI 10.1084/jem.20110079; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023	26	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1161	1170		10.1016/j.ajpath.2018.01.020			10	Pathology	Pathology	GD6TK	WOS:000430641100006	29458008	Bronze, Green Published			2019-10-28	
J	Liu, W; Jing, ZT; Wu, SX; He, Y; Lin, YT; Chen, WN; Lin, XJ; Lin, X				Liu, Wei; Jing, Zhen-Tang; Wu, Shu-Xiang; He, Yun; Lin, Yan-Ting; Chen, Wan-Nan; Lin, Xin-Jian; Lin, Xu			A Novel AKT Activator, SC79, Prevents Acute Hepatic Failure Induced by Fas-Mediated Apoptosis of Hepatocytes	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE LIVER-FAILURE; KAPPA-B ACTIVATION; CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; MOUSE HEPATOCYTES; SIGNALING COMPLEX; LIPID RAFTS; CD95; RECEPTOR	Acute liver failure is a serious clinical problem of which the underlying pathogenesis remains unclear and for which effective therapies are lacking. The Fas receptor/ligand system, which is negatively regulated by AKT, is known to play a prominent role in hepatocytic cell death. We hypothesized that AKT activation may represent a strategy to alleviate Fas-induced fulminant liver failure. We report here that a novel AKT activator, SC79, protects hepatocytes from apoptosis induced by agonistic anti-Fas antibody CH11 (for humans) or Jo2 (for mice) and significantly prolongs the survival of mice given a lethal dose of Jo2. Under Fas-signaling stimulation, SC79 inhibited Fas aggregation, prevented the recruitment of the adaptor molecule Fas-associated death domain (FADD) and procaspase-8 [or FADD-like IL-I beta-converting enzyme (FLICE)] into the death-inducing signaling complex (DISC), but SC79 enhanced the recruitment of the long and short isoforms of cellular FLICE-inhibitory protein at the DISC. All of the SC79-induced hepatoprotective and DISC-interruptive effects were confirmed to have been reversed by the Akt inhibitor LY294002. These results strongly indicate that SC79 protects hepatocytes from Fas-induced fatal hepatic apoptosis. The potent alleviation of Fas-mediated hepatotoxicity by the relatively safe drug SC79 highlights the potential of our findings for immediate hepatoprotective translation.	[Liu, Wei; Jing, Zhen-Tang; Wu, Shu-Xiang; He, Yun; Lin, Yan-Ting; Chen, Wan-Nan; Lin, Xin-Jian; Lin, Xu] Fujian Med Univ, Sch Basic Med Sci, Minist Educ Gastrointestinal Canc, Key Lab, 1 Xue Fu North Rd, Fuzhou 350122, Fujian, Peoples R China; [Jing, Zhen-Tang; Chen, Wan-Nan; Lin, Xu] Fujian Med Univ, Dept Med Microbiol, Fujian Key Lab Tumor Microbiol, Fuzhou, Fujian, Peoples R China	Lin, X (reprint author), Fujian Med Univ, Sch Basic Med Sci, Minist Educ Gastrointestinal Canc, Key Lab, 1 Xue Fu North Rd, Fuzhou 350122, Fujian, Peoples R China.	linxu@mail.fjmu.edu.cn		Liu, Wei/0000-0001-7118-815X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81601776]; State Key Project Specialized for Infectious Diseases grant [2017ZX10202203-005-002]; Joint Funds for the Innovation of Science and Technology, Fujian Province [2016Y91030022]	Supported by National Natural Science Foundation of China grant 81601776 (Y.-T.L.), State Key Project Specialized for Infectious Diseases grant 2017ZX10202203-005-002 (X.L.), and Joint Funds for the Innovation of Science and Technology, Fujian Province, grant 2016Y91030022 (X.L.).	Bernal W, 2013, NEW ENGL J MED, V369, P2525, DOI 10.1056/NEJMra1208937; Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; CASCINO I, 1995, J IMMUNOL, V154, P2706; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Faggioni R, 2001, J IMMUNOL, V167, P5913, DOI 10.4049/jimmunol.167.10.5913; Faubion WA, 1999, HEPATOLOGY, V29, P1, DOI 10.1002/hep.510290101; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Gajate C, 2015, J LEUKOCYTE BIOL, V98, P739, DOI 10.1189/jlb.2MR0215-055R; Gajate C, 2015, APOPTOSIS, V20, P584, DOI 10.1007/s10495-015-1104-6; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357; Hayashi N, 1999, J VIRAL HEPATITIS, V6, P357, DOI 10.1046/j.1365-2893.1999.00175.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jo H, 2012, P NATL ACAD SCI USA, V109, P10581, DOI 10.1073/pnas.1202810109; Komarov AP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.45; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lavrik IN, 2012, CELL DEATH DIFFER, V19, P36, DOI 10.1038/cdd.2011.155; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; Li ST, 2016, BIOCHEM BIOPH RES CO, V479, P54, DOI 10.1016/j.bbrc.2016.09.027; Li WC, 2010, METHODS MOL BIOL, V633, P185, DOI 10.1007/978-1-59745-019-5_13; Liu W, 2015, FASEB J, V29, P1113, DOI 10.1096/fj.14-263822; Luedde T, 2014, GASTROENTEROLOGY, V147, P765, DOI 10.1053/j.gastro.2014.07.018; Malhi H, 2008, GASTROENTEROLOGY, V134, P1641, DOI 10.1053/j.gastro.2008.03.002; Mendizabal M, 2016, WORLD J GASTROENTERO, V22, P1523, DOI 10.3748/wjg.v22.i4.1523; Moumen A, 2007, HEPATOLOGY, V45, P1210, DOI 10.1002/hep.21604; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Nagaki M, 1999, J HEPATOL, V31, P997, DOI 10.1016/S0168-8278(99)80311-0; Nagaki M, 2008, HEPATOL RES, V38, pS19, DOI 10.1111/j.1872-034X.2008.00422.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Ozes ON, 1999, NATURE, V401, P82; Peter ME, 2015, CELL DEATH DIFFER, V22, P549, DOI 10.1038/cdd.2015.3; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pianko S, 2001, J VIRAL HEPATITIS, V8, P406, DOI 10.1046/j.1365-2893.2001.00316.x; Rossin A, 2015, CELL DEATH DIFFER, V22, P643, DOI 10.1038/cdd.2014.153; Ryo K, 2000, AM J GASTROENTEROL, V95, P2047; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Singhal S, 2009, APPL IMMUNOHISTO M M, V17, P282, DOI 10.1097/PAI.0b013e3181906f6d; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549; Valva P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053519; Wang QF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044398; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zhang DD, 2016, ACS CHEM NEUROSCI, V7, P710, DOI 10.1021/acschemneuro.5b00306	52	7	9	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1171	1182		10.1016/j.ajpath.2018.01.013			12	Pathology	Pathology	GD6TK	WOS:000430641100007	29673487				2019-10-28	
J	Pant, A; Kopec, AK; Baker, KS; Cline-Fedewa, H; Lawrence, DA; Luyendyk, JP				Pant, Asmita; Kopec, Anna K.; Baker, Kevin S.; Cline-Fedewa, Holly; Lawrence, Daniel A.; Luyendyk, James P.			Plasminogen Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ACUTE LIVER-FAILURE; BILE-DUCT LIGATION; REBALANCED HEMOSTASIS; IN-VIVO; INJURY; MICE; FIBROSIS; PAI-1; CONSEQUENCES; REGENERATION	Acetaminophen (APAP) induced liver injury in mice is associated with activation of the coagulation cascade and deposition of fibrin in liver. Plasminogen activator inhibitor-1 (PAI-1) is an important physiological inhibitor of tissue-type plasminogen activator (tPA) and plays a critical role in fibrinolysis. PAI-1 expression is increased in both experimental APAP-induced liver injury and patients with acute liver failure. Prior studies have shown that PAI-1 prevents intrahepatic hemorrhage and mortality after APAP challenge, but the downstream mechanisms are not clear. We tested the hypothesis that PAI-1 limits liver-related morbidity after APAP challenge by reducing tPA-dependent fibrinolysis. Compared with APAP-challenged (300 mg/kg) wild-type mice, hepatic deposition of cross-linked fibrin was reduced, with intrahepatic congestion and hemorrhage increased in PAI-1-deficient mice 24 hours after APAP overdose. Administration of recombinant wild-type human PAI-1 reduced intrahepatic hemorrhage 24 hours after APAP challenge in PAI-1(-/-) mice, whereas a mutant PAI-1 lacking anti protease function had no effect. Of interest, tPA deficiency alone did not affect APAP-induced liver damage. In contrast, fibrinolysis, intrahepatic congestion and hemorrhage, and mortality driven by PAI-1 deficiency were reduced in APAP-treated tPA(-/-)/PAI-1(-/-) double-knockout mice. The results identify PAI-1 as a critical regulator of intrahepatic fibrinolysis in experimental liver injury. Moreover, the results suggest that the balance between PAI-1 and tPA activity is an important determinant of liver pathology after APAP overdose.	[Pant, Asmita; Kopec, Anna K.; Cline-Fedewa, Holly; Luyendyk, James P.] Michigan State Univ, Dept Pathobiol & Diagnost Invest, 253 Food Safety & Toxicol Bldg,1129 Farm Ln, E Lansing, MI 48824 USA; [Baker, Kevin S.; Luyendyk, James P.] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA; [Pant, Asmita; Kopec, Anna K.; Baker, Kevin S.; Luyendyk, James P.] Michigan State Univ, Inst Integrat Toxicol, E Lansing, MI 48824 USA; [Lawrence, Daniel A.] Univ Michigan, Dept Internal Med, Med Sch, Div Cardiovasc Med, Ann Arbor, MI 48109 USA	Luyendyk, JP (reprint author), Michigan State Univ, Dept Pathobiol & Diagnost Invest, 253 Food Safety & Toxicol Bldg,1129 Farm Ln, E Lansing, MI 48824 USA.	luyendyk@cvm.msu.edu		Pant, Asmita/0000-0003-4468-8639; Lawrence, Daniel/0000-0003-3126-1935	NIH, National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK087886, R01 DK105099]	Supported by the NIH, National Institute of Diabetes and Digestive and Kidney Diseases grants R01 DK087886 and R01 DK105099 (J.P.L.).	Agarwal B, 2012, J HEPATOL, V57, P780, DOI 10.1016/j.jhep.2012.06.020; Aleman MM, 2014, J CLIN INVEST, V124, P3590, DOI 10.1172/JCI75386; Bajt ML, 2008, TOXICOL SCI, V104, P419, DOI 10.1093/toxsci/kfn091; Beier JI, 2016, ANN HEPATOL, V15, P762, DOI 10.5604/16652681.1212590; Bergheim I, 2006, J PHARMACOL EXP THER, V316, P592, DOI 10.1124/jpet.105.095042; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cate JM, 2007, CURR DRUG TARGETS, V8, P971; Davydov L, 2001, CLIN THER, V23, P982, DOI 10.1016/S0149-2918(01)80086-2; De Gasperi A, 2009, TRANSPL P, V41, P1256, DOI 10.1016/j.transproceed.2009.03.007; Draxler DF, 2015, TRANSFUS MED REV, V29, P102, DOI 10.1016/j.tmrv.2014.09.006; Flick MJ, 2004, EXP BIOL MED, V229, P1105; Ganey PE, 2007, HEPATOLOGY, V46, P1177, DOI 10.1002/hep.21779; Holt MP, 2008, J LEUKOCYTE BIOL, V84, P1410, DOI 10.1189/jlb.0308173; IZUMI S, 1994, GUT, V35, P982, DOI 10.1136/gut.35.7.982; Joshi N, 2014, J PHARMACOL EXP THER, V349, P383, DOI 10.1124/jpet.113.210880; Kang LI, 2015, LAB INVEST, V95, P1117, DOI 10.1038/labinvest.2015.94; Kopec AK, 2017, J HEPATOL, V66, P787, DOI [10.1016/j.jhep.2016.12, 10.1016/j.jhep.2016.12.004]; LAKI K, 1948, SCIENCE, V108, P280, DOI 10.1126/science.108.2802.280; Lee WM, 2008, HEPATOL RES, V38, pS3, DOI 10.1111/j.1872-034X.2008.00419.x; Lisman T, 2012, J THROMB HAEMOST, V10, P1312, DOI 10.1111/j.1538-7836.2012.04770.x; Lisman T, 2015, SEMIN THROMB HEMOST, V41, P468, DOI 10.1055/s-0035-1550430; Lisman T, 2010, BLOOD, V116, P878, DOI 10.1182/blood-2010-02-261891; LORAND L, 1948, Hung Acta Physiol, V1, P192; Luyendyk JP, 2009, AM J PHYSIOL-GASTR L, V296, pG840, DOI 10.1152/ajpgi.90639.2008; Olson JD, 2015, ADV CLIN CHEM, V69, P1, DOI 10.1016/bs.acc.2014.12.001; PERNAMBUCO JRB, 1993, HEPATOLOGY, V18, P1350, DOI 10.1002/hep.1840180611; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Sullivan BP, 2013, BLOOD, V121, P1868, DOI 10.1182/blood-2012-09-455436; Sullivan BP, 2012, AM J PATHOL, V180, P2321, DOI 10.1016/j.ajpath.2012.02.011; Tschanz SA, 2011, J MICROSC-OXFORD, V243, P47, DOI 10.1111/j.1365-2818.2010.03481.x; von Montfort C, 2010, AM J PHYSIOL-GASTR L, V298, pG657, DOI 10.1152/ajpgi.00107.2009; Wang H, 2007, FEBS LETT, V581, P3098, DOI 10.1016/j.febslet.2007.05.049; Wang HT, 2005, HEPATOLOGY, V42, P1099, DOI 10.1002/hep.20903; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212	36	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1204	1212		10.1016/j.ajpath.2018.01.010			9	Pathology	Pathology	GD6TK	WOS:000430641100010	29454747	Green Published, Bronze			2019-10-28	
J	Chiyonobu, N; Shimada, S; Akiyama, Y; Mogushi, K; Itoh, M; Akahoshi, K; Matsumura, S; Ogawa, K; Ono, H; Mitsunori, Y; Ban, D; Kudo, A; Arii, S; Suganami, T; Yamaoka, S; Ogawa, Y; Tanabe, M; Tanaka, S				Chiyonobu, Norimichi; Shimada, Shu; Akiyama, Yoshimitsu; Mogushi, Kaoru; Itoh, Michiko; Akahoshi, Keiichi; Matsumura, Satoshi; Ogawa, Kosuke; Ono, Hiroaki; Mitsunori, Yusuke; Ban, Daisuke; Kudo, Atsushi; Arii, Shigeki; Suganami, Takayoshi; Yamaoka, Shoji; Ogawa, Yoshihiro; Tanabe, Minoru; Tanaka, Shinji			Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; MOUSE MODELS; CANCER; ASSOCIATION; EXPRESSION; OBESITY; MICE; ATHEROSCLEROSIS; INFLAMMATION	Metabolic syndrome is a newly identified risk factor for hepatocellular carcinoma (HCC); however, tumor specific biomarkers still remain unclear. We performed cross-species analysis to compare gene signatures of HCC from human patients and melanocortin 4 receptor-knockout mice, which develop HCC with obesity, insulin resistance, and dyslipidemia. Unsupervised hierarchical clustering and principle component analysis of 746 differentially expressed orthologous genes classified HCC of 152 human patients and melanocortin 4 receptor-knockout mice into two distinct subgroups, one of which included mouse HCC and was causatively associated with metabolic risk factors. Nine genes commonly overexpressed in human and mouse metabolic disease-associated HCC were identified; fatty acid binding protein 4 (FABP4) was remarkably enriched in intratumoral activated hepatic stellate cells (HSCs). Subclones constitutively expressing FABP4 were established from a human HSC cell line in which expression levels of inflammatory chemokines, including IL-1A and IL-6, were up-regulated through NF-kappa B nuclear translocation, resulting in recruitment of macrophages. An immunohistochemical validation study of 106 additional human HCC samples indicated that FABP4-positive HSCs were distributed in tumors of 38 cases, and the FABP4-high group consisted of patients with nonviral and nonalcoholic HCC (P = 0.027) and with multiple metabolic risk factors (P < 0.001) compared with the FABP4-low group. Thus, FABP4 overexpression in HSCs may contribute to hepatocarcinogenesis in patients with metabolic risk factors by modulation of inflammatory pathways.s	[Chiyonobu, Norimichi; Shimada, Shu; Akiyama, Yoshimitsu; Mogushi, Kaoru; Tanaka, Shinji] Tokyo Med & Dent Univ, Dept Mol Oncol, Grad Sch Med, Tokyo, Japan; [Chiyonobu, Norimichi; Akahoshi, Keiichi; Matsumura, Satoshi; Ogawa, Kosuke; Ono, Hiroaki; Mitsunori, Yusuke; Ban, Daisuke; Kudo, Atsushi; Arii, Shigeki; Tanabe, Minoru; Tanaka, Shinji] Tokyo Med & Dent Univ, Dept Hepatobiliary Pancreat Surg, Grad Sch Med, Tokyo, Japan; [Itoh, Michiko] Tokyo Med & Dent Univ, Dept Organ Network & Metab, Grad Sch Med, Tokyo, Japan; [Yamaoka, Shoji] Tokyo Med & Dent Univ, Dept Mol Virol, Grad Sch Med, Tokyo, Japan; [Ogawa, Yoshihiro] Tokyo Med & Dent Univ, Dept Mol & Cellular Metab, Grad Sch Med, Tokyo, Japan; [Suganami, Takayoshi] Nagoya Univ, Dept Mol Med & Metab, Res Inst Environm Med, Nagoya, Aichi, Japan; [Ogawa, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Japan; [Ogawa, Yoshihiro] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol AMED CREST, Tokyo, Japan	Tanaka, S (reprint author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	tanalta.monc@tmd.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Princess Takamatsu Cancer Research Fund; Japan Agency for Medical Research and DevelopmentJapan Agency for Medical Research and Development (AMED) [JP17cm0106518, JP17fk0210304]	Supported by a Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a research grant from the Princess Takamatsu Cancer Research Fund (S.T.); and P-CREATE grant JP17cm0106518 and Program for Basic and Clinical Research on Hepatitis grant JP17fk0210304 from the Japan Agency for Medical Research and Development (S.T.).	Akahoshi K, 2016, J GASTROENTEROL, V51, P910, DOI 10.1007/s00535-015-1159-8; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cataltepe O, 2012, NEUROPATH APPL NEURO, V38, P400, DOI 10.1111/j.1365-2990.2011.01237.x; CnmIchom S, 2016, NAT REV DRUG DISCOV, V15, P86; Coulouarn C, 2014, J HEPATOL, V60, P1306, DOI 10.1016/j.jhep.2014.02.003; Daniels SR, 2011, CIRCULATION, V124, P1673, DOI 10.1161/CIRCULATIONAHA.110.016170; El-Serag HB, 2014, HEPATOLOGY, V60, P1767, DOI 10.1002/hep.27222; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fujii M, 2013, MED MOL MORPHOL, V46, P141, DOI 10.1007/s00795-013-0016-1; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014; Graeber TG, 2005, NAT GENET, V37, P7, DOI 10.1038/ng0105-7; Graupera I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01709-0; Hara M, 2015, FIBROGENESIS TISSUE, V8, DOI 10.1186/s13069-015-0034-9; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Hill-Baskin AE, 2009, HUM MOL GENET, V18, P2975, DOI 10.1093/hmg/ddp236; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hotamisligil GS, 2015, NAT REV ENDOCRINOL, V11, P592, DOI 10.1038/nrendo.2015.122; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Hu BF, 2015, J HEPATOL, V63, P855, DOI 10.1016/j.jhep.2015.05.030; Itoh M, 2011, AM J PATHOL, V179, P2454, DOI 10.1016/j.ajpath.2011.07.014; Kirsch R, 2003, J GASTROEN HEPATOL, V18, P1272, DOI 10.1046/j.1440-1746.2003.03198.x; Kordes C, 2013, CELL PHYSIOL BIOCHEM, V31, P290, DOI 10.1159/000343368; Kostyuk S, 2015, OXID MED CELL LONGEV, DOI 10.1155/2015/782123; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Maher JJ, 2016, HEPATOLOGY, V64, P1398, DOI 10.1002/hep.28823; Naschberger E, 2016, J CLIN INVEST, V126, P4187, DOI 10.1172/JCI78260; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Oba A, 2017, J HEPATOL, V66, P942, DOI 10.1016/j.jhep.2016.12.026; Pei YH, 2009, VIRCHOWS ARCH, V454, P639, DOI 10.1007/s00428-009-0772-4; Roca-Rivada A, 2015, SCI REP-UK, V5, DOI 10.1038/srep12214; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rosenthal N, 2007, NAT CELL BIOL, V9, P993, DOI 10.1038/ncb437; Solymoss BC, 2004, AM J CARDIOL, V93, P159, DOI 10.1016/j.amjcard.2003.09.032; Stahl S, 2005, HEPATOLOGY, V42, P353, DOI 10.1002/hep.20768; Starley BQ, 2010, HEPATOLOGY, V51, P1820, DOI 10.1002/hep.23594; Su XM, 2015, SCI REP-UK, V5, DOI 10.1038/srep18588; Teufel A, 2016, GASTROENTEROLOGY, V151, P513, DOI 10.1053/j.gastro.2016.05.051; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Xie LF, 2016, J HEPATOL, V65, P113, DOI 10.1016/j.jhep.2016.03.008; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347	46	4	5	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1213	1224		10.1016/j.ajpath.2018.01.012			12	Pathology	Pathology	GD6TK	WOS:000430641100011	29454748	Bronze			2019-10-28	
J	Liang, CC; Li, CS; Weng, IC; Chen, HY; Lu, HH; Huang, CC; Liu, FT				Liang, Chih-Chia; Li, Chi-Shan; Weng, I-Chun; Chen, Huan-Yuan; Lu, Hsueh-Han; Huang, Chiu-Ching; Liu, Fu-Tong			Galectin-9 Is Critical for Mucosal Adaptive Immunity through the T Helper 17-IgA Axis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INTESTINAL IGA; DOWN-REGULATION; PLASMA-CELLS; TH17 CELLS; IMMUNOGLOBULIN; HOMEOSTASIS; GENERATION; EXPRESSION; INDUCTION; PROMOTES	Impairment of the intestinal mucosal immunity significantly increases the risk of acute and chronic diseases. IgA plays a major role in humoral mucosal immunity to provide protection against pathogens and toxins in the gut. Here, we investigated the role of endogenous galectin-9, a tandem repeat-type beta-galactoside -binding protein, in intestinal mucosal immunity. By mucosal immunization of Lgals9(-/-) and littermate control mice, it was found that lack of galectin-9 impaired mucosal antigen-specific IgA response in the gut. Moreover, Lgals9(-/-) mice were more susceptible to developing watery diarrhea and more prone to death in response to high-dose cholera toxin. The results indicate the importance of galectin-9 in modulating intestinal adaptive immunity. Furthermore, bone marrow chimera mice were established, and galectin-9 in hematopoietic cells was found to be critical for adaptive IgA response. In addition, immunized Lgals9(-/-) mice exhibited lower expression of Il17 and fewer T helper 17 (Th17) cells in the lamina propria, implying that the Th17-IgA axis is involved in this mechanism. Taken together, these findings suggest that galectin-9 plays a role in mucosal adaptive immunity through the Th17-IgA axis. By manipulating the expression or activity of galectin-9, intestinal mucosal immune response can be altered and may benefit the development of mucosal vaccination.	[Liang, Chih-Chia; Huang, Chiu-Ching; Liu, Fu-Tong] China Med Univ, PhD Program Translat Med, Taichung, Taiwan; [Liang, Chih-Chia; Huang, Chiu-Ching; Liu, Fu-Tong] Acad Sinica, Taichung, Taiwan; [Liang, Chih-Chia; Huang, Chiu-Ching] China Med Univ, Coll Med, Dept Med, Taichung, Taiwan; [Liang, Chih-Chia; Huang, Chiu-Ching] China Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Liang, Chih-Chia; Li, Chi-Shan; Weng, I-Chun; Chen, Huan-Yuan; Lu, Hsueh-Han; Liu, Fu-Tong] Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 11529, Taiwan; [Liu, Fu-Tong] Univ Calif Davis, Dept Dermatol, Sch Med, Sacramento, CA 95817 USA	Liu, FT (reprint author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 11529, Taiwan.	fliu@ucdavis.edu	Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	China Medical University Hospital funding [DMR-106-028]	Supported by China Medical University Hospital funding DMR-106-028 (C.-C.L.).	Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bergqvist P, 2006, J IMMUNOL, V177, P7772, DOI 10.4049/jimmunol.177.11.7772; Blaschitz C, 2010, J CLIN IMMUNOL, V30, P196, DOI 10.1007/s10875-010-9368-7; Borsutzky S, 2004, J IMMUNOL, V173, P3305, DOI 10.4049/jimmunol.173.5.3305; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Cao AT, 2015, MUCOSAL IMMUNOL, V8, P1072, DOI 10.1038/mi.2014.134; Cao AT, 2012, J IMMUNOL, V189, P4666, DOI 10.4049/jimmunol.1200955; Chu VT, 2014, IMMUNITY, V40, P582, DOI 10.1016/j.immuni.2014.02.014; Dann SM, 2015, EXP PARASITOL, V156, P68, DOI 10.1016/j.exppara.2015.06.003; Datta SK, 2010, P NATL ACAD SCI USA, V107, P10638, DOI 10.1073/pnas.1002348107; de Kivit S, 2012, ALLERGY, V67, P343, DOI 10.1111/j.1398-9995.2011.02771.x; de la Fuente H, 2012, J PATHOL, V228, P193, DOI 10.1002/path.3996; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Ikeda M, 2017, ALLERGOL INT, V66, P432, DOI 10.1016/j.alit.2016.10.007; Kadowaki T, 2013, CRIT CARE, V17, DOI 10.1186/cc13147; Katoh S, 2007, AM J RESP CRIT CARE, V176, P27, DOI 10.1164/rccm.200608-1243OC; Kunisawa J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2718; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Lipkowitz MS, 2001, J CLIN INVEST, V107, P1103, DOI 10.1172/JCI12471; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Macpherson AJ, 2012, TRENDS IMMUNOL, V33, P160, DOI 10.1016/j.it.2012.02.002; Mantis NJ, 2011, MUCOSAL IMMUNOL, V4, P603, DOI 10.1038/mi.2011.41; Masedunskas Andrius, 2012, Cells, V1, P1121, DOI 10.3390/cells1041121; Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012; Milpied PJ, 2013, NAT IMMUNOL, V14, P313, DOI 10.1038/ni.2567; Mishra R, 2010, P NATL ACAD SCI USA, V107, P17633, DOI 10.1073/pnas.1012424107; Moritoki M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060807; Nochi T, 2007, P NATL ACAD SCI USA, V104, P10986, DOI 10.1073/pnas.0703766104; Pabst O, 2012, NAT REV IMMUNOL, V12, P821, DOI 10.1038/nri3322; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Saigusa R, 2017, J INVEST DERMATOL, V137, P1850, DOI 10.1016/j.jid.2017.04.035; Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]; Seki M, 2008, CLIN IMMUNOL, V127, P78, DOI 10.1016/j.clim.2008.01.006; Seo GY, 2009, J LEUKOCYTE BIOL, V85, P744, DOI 10.1189/jlb.0708450; Sharma S, 2011, P NATL ACAD SCI USA, V108, P19001, DOI 10.1073/pnas.1107087108; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Tanoue T, 2016, NAT REV IMMUNOL, V16, P295, DOI 10.1038/nri.2016.36; Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Tsai HC, 2013, J IMMUNOL, V191, P4095, DOI 10.4049/jimmunol.1301079; WAKATSUKI Y, 1993, J EXP MED, V178, P129, DOI 10.1084/jem.178.1.129; Wei M, 2011, NAT IMMUNOL, V12, P264, DOI 10.1038/ni.1991; WEINSTEIN PD, 1991, J IMMUNOL, V147, P4126; Wu C, 2014, IMMUNITY, V41, P270, DOI 10.1016/j.immuni.2014.06.011; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	49	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1225	1235		10.1016/j.ajpath.2018.01.017			11	Pathology	Pathology	GD6TK	WOS:000430641100012	29458010	Bronze			2019-10-28	
J	Schmidt, CA; Amorese, AJ; Ryan, TE; Goldberg, EJ; Tarpey, MD; Green, TD; Karnekar, RR; Yamaguchi, DJ; Spangenburg, EE; McClung, JM				Schmidt, Cameron A.; Amorese, Adam J.; Ryan, Terence E.; Goldberg, Emma J.; Tarpey, Michael D.; Green, Thomas D.; Karnekar, Reema R.; Yamaguchi, Dean J.; Spangenburg, Espen E.; McClung, Joseph M.			Strain-Dependent Variation in Acute Ischemic Muscle Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ARTERIAL; ANGIOGENESIS; DYSTROPHIN; MYOPATHY; MITOCHONDRIAL; EXPRESSION; PERFUSION; DISEASE; CELLS; MODEL	Limited efficacy of clinical interventions for peripheral arterial disease necessitates a better understanding of the environmental and genetic determinants of tissue pathology. Existing research has largely ignored the early skeletal muscle injury response during hind limb ischemia (HLI). We compared the hind limb muscle response, after 6 hours of ischemia, in two mouse strains that differ dramatically in their postischemic extended recovery: C57BL/6J and BALB/cJ. Perfusion, measured by laser Doppler and normalized to the control limb, differed only slightly between strains after HLI (<12% across all measures). Similar (<10%) effect sizes in lectin-perfused vessel area and no differences in tissue oxygen saturation measured by reflectance spectroscopy were also found. Muscles from both strains were functionally impaired after HLI, but greater muscle necrosis and loss of dystrophin-positive immunostaining were observed in BALB/cJ muscle compared with C57BL/63. MuscLe cell-specific dystrophin loss and reduced viability were also detected in additional models of ischemia that were independent of residual perfusion differences. Our results indicate that factors other than the completeness of ischemia alone (ie, background genetics) influence the magnitude of acute ischemic muscle injury. These findings may have implications for future development of therapeutic interventions for limb ischemia and for understanding the phasic etiology of chronic and acute ischemic muscle pathophysiology.	[Schmidt, Cameron A.; Amorese, Adam J.; Ryan, Terence E.; Goldberg, Emma J.; Tarpey, Michael D.; Green, Thomas D.; Karnekar, Reema R.; Spangenburg, Espen E.; McClung, Joseph M.] East Carolina Univ, Dept Physiol, Greenville, NC USA; [Schmidt, Cameron A.; Amorese, Adam J.; Ryan, Terence E.; Goldberg, Emma J.; Tarpey, Michael D.; Green, Thomas D.; Karnekar, Reema R.; Spangenburg, Espen E.; McClung, Joseph M.] East Carolina Univ, Brody Sch Med, East Carolina Diabet & Obes Inst, Greenville, NC USA; [Yamaguchi, Dean J.; McClung, Joseph M.] East Carolina Univ, Dept Cardiovasc Sci, Greenville, NC USA; [Yamaguchi, Dean J.] East Carolina Univ, Div Vasc Surg, Greenville, NC USA	McClung, JM (reprint author), East Carolina Univ, Diabet & Obes Inst, East Carolina Heart Inst, Brody Sch Med, Off 4109,Mail Stop 743,115 Heart Dr, Greenville, NC 27834 USA.	mcclungj@ecu.edu	Ryan, Terence/W-5576-2019	Schmidt, Cameron/0000-0001-6628-6329	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL125695, R01AR066660, F32HL129632]	Supported by NIH grants R01HL125695 (J.M.M.), R01AR066660 (E.E.S), and F32HL129632 (T.E.R.).	Armstrong SC, 2001, J MOL CELL CARDIOL, V33, P1165, DOI 10.1006/jmcc.2001.1380; Brass EP, 2000, VASC MED, V5, P55, DOI 10.1177/1358836X0000500109; Callum K, 2000, BRIT MED J, V320, P764, DOI 10.1136/bmj.320.7237.764; Carter WO, 1998, J APPL PHYSIOL, V85, P1676; Chalothorn D, 2007, PHYSIOL GENOMICS, V30, P179, DOI 10.1152/physiolgenomics.00047.2007; Chalothorn D, 2010, PHYSIOL GENOMICS, V42, P469, DOI 10.1152/physiolgenomics.00070.2010; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chu LH, 2015, PHYSIOL GENOMICS, V47, P331, DOI 10.1152/physiolgenomics.00125.2014; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cramer NP, 2015, PHYSIOL BEHAV, V143, P158, DOI 10.1016/j.physbeh.2015.01.036; Cunha FF, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt245; Dokun AO, 2015, AM J PHYSIOL-HEART C, V309, pH790, DOI 10.1152/ajpheart.00803.2014; Goodney PP, 2009, J VASC SURG, V50, P54, DOI 10.1016/j.jvs.2009.01.035; Hamburg NM, 2017, CIRC J, V81, P281, DOI 10.1253/circj.CJ-16-1286; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; HARMAN JW, 1947, AM J PATHOL, V23, P551; Helisch A, 2006, ARTERIOSCL THROM VAS, V26, P520, DOI 10.1161/01.ATV.0000202677.55012.a0; Hiatt WR, 2015, CIRC RES, V116, P1527, DOI 10.1161/CIRCRESAHA.116.303566; Howlett RA, 2001, J APPL PHYSIOL, V91, P632; Imoukhuede PI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044791; Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7; Kawada T, 2005, BBA-PROTEINS PROTEOM, V1751, P73, DOI 10.1016/j.bbapap.2005.01.001; Keum S, 2010, CIRC-CARDIOVASC GENE, V2, P591; Keum S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003807; Kido M, 2004, AM J PHYSIOL-HEART C, V287, pH81, DOI 10.1152/ajpheart.01140.2003; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kochi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084047; Kullo IJ, 2015, CIRC RES, V116, P1551, DOI 10.1161/CIRCRESAHA.116.303518; Leary S, 2013, AVMA GUIDELINES EUTH; Lerman I, 2002, J APPL PHYSIOL, V92, P2245, DOI 10.1152/japplphysiol.01045.2001; Mac Gabhann F, 2010, MICROCIRCULATION, V17, P333, DOI 10.1111/j.1549-8719.2010.00034.x; McClung JM, 2017, CIRCULATION, V136, P281, DOI 10.1161/CIRCULATIONAHA.116.024873; McClung JM, 2016, J VASC SURG, V64, P1101, DOI 10.1016/j.jvs.2015.06.139; McClung JM, 2012, AM J PATHOL, V180, P2156, DOI 10.1016/j.ajpath.2012.01.032; Md AOD, 2008, CIRCULATION, V117, P1207, DOI 10.1161/CIRCULATIONAHA.107.736447; Meisner JK, 2012, MICROCIRCULATION, V19, P619, DOI 10.1111/j.1549-8719.2012.00197.x; Mofarrahi M, 2015, AM J PHYSIOL-REG I, V308, pR576, DOI 10.1152/ajpregu.00267.2014; Montagutelli X, 2000, J AM SOC NEPHROL, V11, pS101; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Norgren L, 2007, EUR J VASC ENDOVASC, V33, pS5, DOI 10.1016/j.ejvs.2006.09.024; Paoni NF, 2002, PHYSIOL GENOMICS, V11, P263, DOI 10.1152/physiolgenomics.00110.2002; Paradis S, 2016, AM J PHYSIOL-CELL PH, V310, pC968, DOI 10.1152/ajpcell.00356.2015; Petkov PM, 2004, GENOME RES, V14, P1806, DOI 10.1101/gr.2825804; Renault MA, 2013, CIRC RES, V112, P762, DOI 10.1161/CIRCRESAHA.113.300871; Rodriguez M, 2005, J MOL CELL CARDIOL, V38, P723, DOI 10.1016/j.yjmcc.2005.02.019; Ryan TE, 2016, J MOL CELL CARDIOL, V97, P191, DOI 10.1016/j.yjmcc.2016.05.015; Ryan TE, 2016, DIABETES, V65, P2553, DOI 10.2337/db16-0387; Sampson UKA, 2014, GLOB HEART, V9, P145, DOI 10.1016/j.gheart.2013.12.008; Schmidt CA, 2017, J VASC SURG, V65, P1504, DOI 10.1016/j.jvs.2016.04.041; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scholz D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/jmcc.2002.2013; Sealock R, 2014, CIRC RES, V114, P660, DOI 10.1161/CIRCRESAHA.114.302931; Sellers RS, 2012, VET PATHOL, V49, P32, DOI 10.1177/0300985811429314; Shah AP, 2010, CARDIOVASC RES, V87, P683, DOI 10.1093/cvr/cvq111; Spangenburg EE, 2008, J PHYSIOL-LONDON, V586, P283, DOI 10.1113/jphysiol.2007.141507; Tang GL, 2005, J VASC SURG, V41, P312, DOI 10.1016/j.jvs.2004.11.012; van Weel V, 2007, ARTERIOSCL THROM VAS, V27, P2310, DOI 10.1161/ATVBAHA.107.151407; Wang SL, 2010, CIRC RES, V107, P558, DOI 10.1161/CIRCRESAHA.110.224634; Zbinden S, 2007, AM J PHYSIOL-HEART C, V292, pH1891, DOI 10.1152/ajpheart.00537.2006	59	4	4	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1246	1262		10.1016/j.ajpath.2018.01.008			17	Pathology	Pathology	GD6TK	WOS:000430641100014	29454751	Green Published			2019-10-28	
J	DiMario, JX				DiMario, Joseph X.			KLF10 Gene Expression Modulates Fibrosis in Dystrophic Skeletal Muscle	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TRANSFORMING-GROWTH-FACTOR; INDUCIBLE EARLY GENE; FACTOR-BETA; MECHANICAL-PROPERTIES; MUSCULAR-DYSTROPHY; SATELLITE CELLS; MICE DISPLAY; DIFFERENTIATION; PROLIFERATION; REGENERATION	Dystrophic skeletal muscle is characterized by fibrotic accumulation of extracellular matrix components that compromise muscle structure, function, and capacity for regeneration. Tissue fibrosis is often initiated and sustained through transforming growth factor-beta (TGF-beta) signaling, and Kriippel-like factor 10 (KLF10) is an immediate early gene that is transcriptionally activated in response to TGF-beta signaling. It encodes a transcriptional regulator that mediates the effects of TGF-beta signaling in a variety of cell types. This report presents results of investigation of the effects of loss of KLF10 gene expression in wild-type and dystrophic (mdx) skeletal muscle. On the basis of RT-PCR, Western blot, and histological analyses of mouse tibialis anterior and diaphragm muscles, collagen type I (Col1a1) and fibronectin gene expression and protein deposition were increased in KLF10(-/-) mice, contributing to increased fibrosis. KLF10(-/-) mice displayed increased expression of genes encoding SMAD2, SMAD3, and SMAD7, particularly in diaphragm muscle. SMAD4 gene expression was unchanged. Expression of the extracellular matrix remodeling genes, MMP2 and TIMP1, was also increased in KLF10-deficient mouse muscle. Histological analyses and assays of hydroxyproline content indicated that the loss of KLF10 increased fibrosis. Dystrophic KLF10-null mice also had reduced grip strength. The effects of loss of KLF10 gene expression were most pronounced in dystrophic diaphragm muscle, suggesting that KLF10 moderates the fibrotic effects of TGF-beta signaling in chronically damaged regenerating muscle.	[DiMario, Joseph X.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Cell Biol & Anat, 3333 Green Bay Rd, N Chicago, IL 60064 USA	DiMario, JX (reprint author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Cell Biol & Anat, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	joseph.dimario@rosalindfranklin.edu			Rosalind Franklin University of Medicine and Science	Supported by Rosalind Franklin University of Medicine and Science.	Accornero F, 2014, HUM MOL GENET, V23, P6903, DOI 10.1093/hmg/ddu413; Andreetta F, 2006, J NEUROIMMUNOL, V175, P77, DOI 10.1016/j.jneuroim.2006.03.005; Bensamoun SF, 2006, BONE, V39, P1244, DOI 10.1016/j.bone.2006.05.021; Bensamoun SF, 2006, J APPL PHYSIOL, V101, P1419, DOI 10.1152/japplphysiol.00800.2005; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; Carlson CG, 2009, TREAT NMD NEUROMUSCU; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; Cen MQ, 2017, INT J MOL MED, V39, P569, DOI 10.3892/ijmm.2017.2889; Chang NC, 2016, TRENDS MOL MED, V22, P479, DOI 10.1016/j.molmed.2016.04.002; Cohen TV, 2015, J PHYSIOL-LONDON, V593, P2479, DOI 10.1113/JP270201; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Dadgar S, 2014, J CELL BIOL, V207, P139, DOI 10.1083/jcb.201402079; Dijkmans TF, 2009, BRAIN RES, V1249, P19, DOI 10.1016/j.brainres.2008.10.050; DIMARIO J, 1988, DIFFERENTIATION, V39, P42, DOI 10.1111/j.1432-0436.1988.tb00079.x; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Gillies AR, 2011, MUSCLE NERVE, V44, P318, DOI 10.1002/mus.22094; Goldstein JA, 2014, HUM MOL GENET, V23, P6722, DOI 10.1093/hmg/ddu390; Gumez L, 2010, J APPL PHYSIOL, V108, P1706, DOI 10.1152/japplphysiol.00356.2010; Hanel JV, 2001, MUSCLE NERVE, V24, P428; Hawse JR, 2008, BONE, V42, P1025, DOI 10.1016/j.bone.2008.02.004; Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681; Johnsen SA, 2002, J CELL BIOCHEM, V87, P233, DOI 10.1002/jcb.10299; Kammoun M, 2017, MUSCLE NERVE, V55, P410, DOI 10.1002/mus.25252; Kammoun M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164566; Kharraz Y, 2014, BIOMED RES INT, DOI 10.1155/2014/965631; Lacmann A, 2007, NEUROSCIENCE, V150, P647, DOI 10.1016/j.neuroscience.2007.09.046; Lieber RL, 2013, AM J PHYSIOL-CELL PH, V305, pC241, DOI 10.1152/ajpcell.00173.2013; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Mitsumoto M, 2003, FREE RADICAL BIO MED, V34, P1607, DOI 10.1016/S0891-5849(03)00211-9; Miyake M, 2011, J CELL PHYSIOL, V226, P1128, DOI 10.1002/jcp.22434; Narola J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079356; Parakati R, 2013, J BIOL CHEM, V288, P13876, DOI 10.1074/jbc.M113.457648; Quattrocelli M, 2017, BBA-MOL CELL RES, V1864, P572, DOI 10.1016/j.bbamcr.2016.12.020; Rajamannan NM, 2017, J CELL PHYSL, V100, P315; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Smith LR, 2014, AM J PHYSIOL-CELL PH, V306, pC889, DOI 10.1152/ajpcell.00383.2013; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Subramaniam M, 2005, MOL CELL BIOL, V25, P1191, DOI 10.1128/MCB.25.3.1191-1199.2005; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; Thou L, 2006, NEUROMUSCULAR DISORD, V16, P32; Venuprasad K, 2008, NAT IMMUNOL, V9, P245, DOI 10.1038/ni1564; Wahab NA, 2005, J AM SOC NEPHROL, V16, P340, DOI 10.1681/ASN.2003100905; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Zanotti S, 2007, MATRIX BIOL, V26, P615, DOI 10.1016/j.matbio.2007.06.004	46	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1263	1275		10.1016/j.ajpath.2018.01.014			13	Pathology	Pathology	GD6TK	WOS:000430641100015	29458012	Bronze			2019-10-28	
J	Kunita, A; Baeriswyl, V; Meda, C; Cabuy, E; Takeshita, K; Giraudo, E; Wicki, A; Fukayama, M; Christofori, G				Kunita, Akiko; Baeriswyl, Vanessa; Meda, Claudia; Cabuy, Erik; Takeshita, Kimiko; Giraudo, Enrico; Wicki, Andreas; Fukayama, Masashi; Christofori, Gerhard			Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; PREDICTS POOR-PROGNOSIS; TYPE-16 TRANSGENIC MICE; PLATELET-AGGREGATION; GLYCOSYLATED PODOPLANIN; LUNG ADENOCARCINOMA; ENRICHMENT ANALYSIS; RECEPTOR CLEC-2; PA2.26 ANTIGEN	Tumor invasion is a critical first step in the organismic dissemination of cancer cells and the formation of metastasis in distant organs, the most important prognostic factor and the actual cause of death in most of the cancer patients. We report herein that the cell surface protein podoplanin (PDPN), a potent inducer of cancer cell invasion, is conspicuously expressed by the invasive front of squamous cell carcinomas (SCCs) of the cervix in patients and in the transgenic human papillomavirus/estrogen mouse model of cervical cancer. Laser capture microscopy combined with gene expression profiling reveals that the expression of interferon-responsive genes is up-regulated in PDPN-expressing cells at the tumor invasive front, which are exposed to CD45-positive inflammatory cells. Indeed, PDPN expression can be induced in cultured SCC cell lines by single or combined treatments with interferon-gamma, transforming growth factor-beta, and/or tumor necrosis factor-alpha. Notably, shRNA-mediated ablation of either PDPN or STATE in A431 SCC cells repressed cancer cell invasion on s.c. transplantation into immunodeficient mice. The results highlight the induction of tumor cell invasion by the inflammatory cytoldne-stimulated expression of PDPN in the outermost cell Layers of cervical SCC.	[Kunita, Akiko; Baeriswyl, Vanessa; Wicki, Andreas; Christofori, Gerhard] Univ Basel, Dept Biomed, Mattenstr 28, CH-4058 Basel, Switzerland; [Kunita, Akiko; Takeshita, Kimiko; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan; [Meda, Claudia; Giraudo, Enrico] IRCCS, Candiol Canc Inst, Fdn Piemonte Oncol, Lab Transgen Mouse Models, Turin, Italy; [Meda, Claudia; Giraudo, Enrico] Univ Torino, Dept Sci & Drug Technol, Candiolo, Italy; [Cabuy, Erik] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Cabuy, Erik] CAEX NV, CAEX Project, Lier, Belgium	Christofori, G (reprint author), Univ Basel, Dept Biomed, Mattenstr 28, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch	Giraudo, Enrico/K-3192-2016; Giraudo, Enrico/K-6441-2019	Giraudo, Enrico/0000-0003-4128-4786; Giraudo, Enrico/0000-0003-4128-4786; Wicki, Andreas/0000-0002-2924-8080	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [23890036]; Italian Association for Cancer Research L' Associazione Italians per la Ricerca sul Cancro-Investigator Grant [15645]; Swiss National Science FoundationSwiss National Science Foundation (SNSF) [31003A-144206]; Swiss Cancer League grant [OCS-02102-08-2007]; Krebsliga Beider Basel grant [04-2010]	Supported by Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research grant 23890036 (A.K.), Italian Association for Cancer Research L' Associazione Italians per la Ricerca sul Cancro-Investigator Grant 15645 (E.G.), the Swiss National Science Foundation grant 31003A-144206 (G.C. and A.W.), the Swiss Cancer League grant OCS-02102-08-2007 (G.C. and A.W.), and the Krebsliga Beider Basel grant 04-2010 (G.C. and A.W.).	Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; ARBEIT JM, 1994, J VIROL, V68, P4358; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Atsumi N, 2008, BIOCHEM BIOPH RES CO, V373, P36, DOI 10.1016/j.bbrc.2008.05.163; Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3; Cueni LN, 2009, EXP CELL RES, V315, P1715, DOI 10.1016/j.yexcr.2009.02.021; Dumoff KL, 2006, MODERN PATHOL, V19, P708, DOI 10.1038/modpathol.3800580; Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008-5472.CAN-08-0299; Erpenbeck L, 2010, BLOOD, V115, P3427, DOI 10.1182/blood-2009-10-247296; Evangelou E, 2005, MODERN PATHOL, V18, P1490, DOI 10.1038/modpathol.3800457; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gandarillas A, 1997, MOL CARCINOGEN, V20, P10, DOI 10.1002/(SICI)1098-2744(199709)20:1<10::AID-MC3>3.0.CO;2-M; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Haeger A, 2015, TRENDS CELL BIOL, V25, P556, DOI 10.1016/j.tcb.2015.06.003; Honma M, 2012, J DERMATOL SCI, V65, P134, DOI 10.1016/j.jdermsci.2011.11.011; Hoshino A, 2011, CANCER RES, V71, P4769, DOI 10.1158/0008-5472.CAN-10-3228; Ito T, 2009, LUNG CANCER, V63, P418, DOI 10.1016/j.lungcan.2008.06.008; Kaneko MK, 2006, GENE, V378, P52, DOI 10.1016/j.gene.2006.04.023; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; Kato Y, 2008, CANCER SCI, V99, P54, DOI 10.1111/j.1349-7006.2007.00634.x; Kato Y, 2006, BIOCHEM BIOPH RES CO, V349, P1301, DOI 10.1016/j.bbrc.2006.08.171; Kato Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05924; Kawase A, 2008, INT J CANCER, V123, P1053, DOI 10.1002/ijc.23611; Krishnan H, 2013, J BIOL CHEM, V288, P12215, DOI 10.1074/jbc.C112.446823; Kunita A, 2007, AM J PATHOL, V170, P1337, DOI 10.2353/ajpath.2007.060790; Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027; Martin-Villar E, 2005, INT J CANCER, V113, P899, DOI 10.1002/ijc.20656; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Martin-Villar E, 2010, MOL BIOL CELL, V21, P4387, DOI 10.1091/mbc.E10-06-0489; Nagae M, 2014, STRUCTURE, V22, P1711, DOI 10.1016/j.str.2014.09.009; Nogales-Cadenas R, 2009, NUCLEIC ACIDS RES, V37, pW317, DOI 10.1093/nar/gkp416; Ordonez NG, 2005, ARCH PATHOL LAB MED, V129, P1407; Peterziel H, 2012, NEURO-ONCOLOGY, V14, P426, DOI 10.1093/neuonc/nos055; Renart J, 2015, INT REV CEL MOL BIO, V317, P185, DOI 10.1016/bs.ircmb.2015.01.009; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Scholl FG, 1999, J CELL SCI, V112, P4601; Shibahara J, 2006, VIRCHOWS ARCH, V448, P493, DOI 10.1007/s00428-005-0133-x; SmithMcCune K, 1997, CANCER RES, V57, P1294; Suzuki-Inoue K, 2017, J THROMB HAEMOST, V15, P219, DOI 10.1111/jth.13590; Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402; Ugorski M, 2016, AM J CANCER RES, V6, P370; Uhrin P, 2010, BLOOD, V115, P3997, DOI 10.1182/blood-2009-04-216069; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Wicki A, 2007, BRIT J CANCER, V96, P1, DOI 10.1038/sj.bjc.6603518; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	48	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1276	1288		10.1016/j.ajpath.2018.01.016			13	Pathology	Pathology	GD6TK	WOS:000430641100016	29458011	Other Gold			2019-10-28	
J	Yamakawa, D; Jia, WZ; Kidoya, H; Hosojima, S; Torigata, M; Zhang, L; Takakura, N				Yamakawa, Daishi; Jia, Weizhen; Kidoya, Hiroyasu; Hosojima, Shoko; Torigata, Miku; Zhang, Li; Takakura, Nobuyuki			Visualization of Proliferative Vascular Endothelial Cells in Tumors in Vivo by Imaging Their Partner of Sld5-1 Promoter Activity	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEMATOPOIETIC STEM-CELLS; PATHOLOGICAL ANGIOGENESIS; GROWTH; DLL4; LYMPHANGIOGENESIS; ANGIOPOIETIN-1; NORMALIZATION; MAINTENANCE; VEGF; PSF1	Vascular endothelial cells (ECs) isolated from tumors characteristically express certain genes. It has recently been suggested that tumor vessel normalization facilitates effective drug delivery into tumors; however, how tumor vessel normalization can be recognized on the basis of the molecules expressed by tumor ECs is not clearly defined. The degree of cell proliferation is an important indicator to characterize the condition of the ECs. Herein, we generated transgenic mice expressing enhanced green fluorescent protein (EGFP) under the transcriptional control of the DNA replication factor partner of Sld5-1 (PSF1; official name GINS1) promoter to assess whether active ECs can be distinguished from dormant ECs. Predictably, ECs in the adult skin exhibited no EGFP signals. However, after s.c. injection of tumor cells, some ECs shifted to EGFP positivity, enabling distinction of EGFP-positive from EGFP-negative cells. We found that only a fraction of the EGFP-negative ECs strongly expressed the glycosylphosphatidylinositol-anchor protein CD109 associated with the phosphatidylinositol 3-kinase pathway. Taken together, these data indicate that areas of vascular normalization in tumors can be detected by CD109 expression, and this provides a window of opportunity for timing chemotherapy.	[Yamakawa, Daishi; Jia, Weizhen; Kidoya, Hiroyasu; Hosojima, Shoko; Torigata, Miku; Zhang, Li; Takakura, Nobuyuki] Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan; [Yamakawa, Daishi] Mie Univ, Grad Sch Med, Dept Physiol, Tsu, Mie, Japan	Takakura, N (reprint author), Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp			Japan Agency for Medical Research and Development Projects for Technological Development, Research Center Network for Realization of Regenerative MedicineJapan Agency for Medical Research and Development (AMED); Japan Agency for Medical Research and Development Projects for Development of Innovative Research on Cancer TherapeuticsJapan Agency for Medical Research and Development (AMED); Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15H02545, JP20631097]; Takeda Science FoundationTakeda Science Foundation (TSF)	Supported by the Japan Agency for Medical Research and Development Projects for Technological Development, Research Center Network for Realization of Regenerative Medicine and for Development of Innovative Research on Cancer Therapeutics (N.T.), Japan Society for the Promotion of Science grant-in-aid for Scientific Research (A) 15H02545 (N.T.) and grant-in-aid for Young Scientists (B) JP20631097 (D.Y.), and the Takeda Science Foundation (D.Y.).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Corada M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3609; Dhondt J, 2011, FASEB J, V25, P1461, DOI 10.1096/fj.10-170944; Finnson KW, 2006, FASEB J, V20, P1525, DOI 10.1096/fj.05-5229fje; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Franco CA, 2008, DEV CELL, V15, P448, DOI 10.1016/j.devcel.2008.07.019; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742; Kidoya H, 2015, DEV CELL, V33, P247, DOI 10.1016/j.devcel.2015.02.024; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Lee JY, 2010, CELL STEM CELL, V7, P593, DOI 10.1016/j.stem.2010.09.015; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Nagahama Y, 2010, CANCER RES, V70, P1215, DOI 10.1158/0008-5472.CAN-09-3662; Naito H, 2012, EMBO J, V31, P842, DOI 10.1038/emboj.2011.465; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Sakai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054788; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Satoh N, 2008, CANCER SCI, V99, P2373, DOI 10.1111/j.1349-7006.2008.00961.x; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Sivaraj KK, 2013, DEV CELL, V25, P427, DOI 10.1016/j.devcel.2013.04.008; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; Ueno M, 2009, BLOOD, V113, P555, DOI 10.1182/blood-2008-01-136879; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; Westenskow PD, 2013, J CLIN INVEST, V123, P4900, DOI 10.1172/JCI70230; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Woo KV, 2011, J CLIN INVEST, V121, P1624, DOI 10.1172/JCI42040; Yanh H, 2013, J CLIN INVEST, V123, P418, DOI 10.1172/JCI64547; Zhang L, 2003, CANCER RES, V63, P3403; Zhang L, 2016, CANCER SCI, V107, P36, DOI 10.1111/cas.12836; Zhang P, 2016, CIRC RES, V118, P388, DOI 10.1161/CIRCRESAHA.115.308040; Zhang Q, 2005, ARTHRITIS RHEUM-US, V52, P2708, DOI 10.1002/art.21236	44	2	2	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAY	2018	188	5					1300	1314		10.1016/j.ajpath.2018.01.015			15	Pathology	Pathology	GD6TK	WOS:000430641100018	29650228				2019-10-28	
J	Vega, JEV; Brat, DJ				Vega, Jose E. Velazquez; Brat, Daniel J.			Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						infiltrating glioma; neuroepithelial tumor; glioblastoma; ependymoma; medulloblastoma; atypical teratoid/rhabdoid tumor; embryonal tumor with multilayered rosettes; embryonal neoplasm; molecular-genetic; biomarker; IDH; 1p/19q codeletion; RELA-fusion; C19MC; INI1; K27M; BRAF	CENTRAL-NERVOUS-SYSTEM; TERT PROMOTER MUTATIONS; TERATOID RHABDOID TUMORS; ATYPICAL TERATOID/RHABDOID TUMORS; POSTERIOR-FOSSA EPENDYMOMA; HIGH-GRADE ASTROCYTOMAS; INTEGRATED GENOMIC ANALYSIS; ADULT MALIGNANT GLIOMAS; CHOROID-PLEXUS TUMORS; COPY NUMBER ANALYSIS	Recent advances in molecular pathology have reshaped the practice of brain tumor diagnostics. The classification of gliomas has been restructured with the discovery of isocitrate dehydrogenase (IDH) 1/2 mutations in the vast majority of lower grade infiltrating gliomas and secondary glioblastomas (GBM), with IDH-mutant astrocytomas further characterized by TP53 and ATRX mutations. Whole-arm 1p/19q codeletion in conjunction with IDH mutations now define oligodendrogliomas, which are also enriched for CIC, FUBP1, PI3K, NOTCH1, and TERT-p mutations. IDH-wild-type (wt) infiltrating astrocytomas are mostly primary GBMs and are characterized by EGFR, PTEN, TP53, NF1, RB1, PDGFRA, and CDKN2A/B alterations, TERT-p mutations, and characteristic copy number alterations including gains of chromosome 7 and losses of 10. Other clinically and genetically distinct infiltrating astrocytomas include the aggressive H3K27M-mutant midline gliomas, and smaller subsets that occur in the setting of NF1 or have BRAF V600E mutations. Low-grade pediatric gliomas are both genetically and biologically distinct from their adult counterparts and often harbor a single driver event often involving BRAF, FGFR1, or MYB/MYBL1 genes. Large scale genomic and epigenomic analyses have identified distinct subgroups of ependymomas tightly linked to tumor location and clinical behavior. The diagnosis of embryonal neoplasms also integrates molecular testing: (I) 4 molecularly defined, biologically distinct subtypes of medulloblastomas are now recognized; (II) 3 histologic entities have now been reclassified under a diagnosis of embryonal tumor with multilayered rosettes (ETMR), C19MC-altered; and (III) atypical teratoid/rhabdoid tumors (AT/RT) now require SMARCB1 (INI1) or SMARCA4 (BRG1) alterations for their diagnosis. We discuss the practical use of contemporary biomarkers for an integrative diagnosis of central nervous system neoplasia.	[Vega, Jose E. Velazquez] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Vega, Jose E. Velazquez] Childrens Healthcare Atlanta, Atlanta, GA USA; [Brat, Daniel J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Ward 3-140,303 East Chicago Ave, Chicago, IL 60611 USA; [Brat, Daniel J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Brat, DJ (reprint author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, Ward 3-140,303 East Chicago Ave, Chicago, IL 60611 USA.; Brat, DJ (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.	daniel.brat@northwestern.edu					Abedalthagafi M, 2013, MODERN PATHOL, V26, P1425, DOI 10.1038/modpathol.2013.90; Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Aibaidula A, 2017, NEURO-ONCOLOGY, V19, P1327, DOI 10.1093/neuonc/nox078; Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1; Alexandrescu S, 2016, BRAIN PATHOL, V26, P215, DOI 10.1111/bpa.12295; Aoki K, 2018, NEURO-ONCOLOGY, V20, P66, DOI 10.1093/neuonc/nox132; Appay R, 2017, AM J SURG PATHOL, V41, P1254, DOI 10.1097/PAS.0000000000000866; Appin CL, 2015, MOL ASPECTS MED, V45, P87, DOI 10.1016/j.mam.2015.05.002; Appin CL, 2015, ADV ANAT PATHOL, V22, P50, DOI 10.1097/PAP.0000000000000048; Appin CL, 2014, CANCER J, V20, P66, DOI 10.1097/PPO.0000000000000020; Araki A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0349-9; Archer TC, 2014, NAT GENET, V46, P2, DOI 10.1038/ng.2857; Arita H, 2013, ACTA NEUROPATHOL, V126, P267, DOI 10.1007/s00401-013-1141-6; Bai H, 2016, NAT GENET, V48, P59, DOI 10.1038/ng.3457; Bailey P, 1926, CLASSIFICATION TUMOR, P175; Ballester LY, 2017, HUM PATHOL, V69, P15, DOI 10.1016/j.humpath.2017.05.005; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Bandopadhayay P, 2016, NAT GENET, V48, P273, DOI 10.1038/ng.3500; Bayliss J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aah6904; Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Bergthold G, 2015, NEURO-ONCOLOGY, V17, P1486, DOI 10.1093/neuonc/nov045; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; BIEGEL JA, 1990, J NEUROSURG, V73, P710, DOI 10.3171/jns.1990.73.5.0710; BIEGEL JA, 1989, NEW ENGL J MED, V321, P906; Biegel Jaclyn A, 2006, Neurosurg Focus, V20, pE11; Bienkowski M, 2015, CLIN NEUROPATHOL, V34, P250, DOI 10.5414/NP300904; Brandner S, 2015, NEUROPATH APPL NEURO, V41, P694, DOI 10.1111/nan.12246; Brat DJ, 2015, ARCH PATHOL LAB MED, V139, P1087, DOI 10.5858/arpa.2014-0588-CP; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brat DJ, 2004, NEURO-ONCOLOGY, V6, P96, DOI 10.1215/S1152851703000231; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Buckner J, 2017, NAT REV NEUROL, V13, P340, DOI 10.1038/nrneurol.2017.54; Buczkowicz P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00147; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Camelo-Piragua S, 2010, ACTA NEUROPATHOL, V119, P509, DOI 10.1007/s00401-009-0632-y; Capper D, 2009, ACTA NEUROPATHOL, V118, P599, DOI 10.1007/s00401-009-0595-z; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chan AKY, 2015, MODERN PATHOL, V28, P177, DOI 10.1038/modpathol.2014.94; Chi AS, 2013, J CLIN ONCOL, V31, pE233, DOI 10.1200/JCO.2012.46.0220; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cimino PJ, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0443-7; Clark KH, 2013, NEUROPATH APPL NEURO, V39, P706, DOI 10.1111/nan.12031; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Cohen A, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0213-3; Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7; Cryan JB, 2014, ONCOTARGET, V5, P8083, DOI 10.18632/oncotarget.2342; Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DeWitt JC, 2017, NEURO-ONCOLOGY, V19, P1640, DOI 10.1093/neuonc/nox120; Di Stefano AL, 2015, CLIN CANCER RES, V21, P3307, DOI 10.1158/1078-0432.CCR-14-2199; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Dubbink HJ, 2016, J MOL DIAGN, V18, P775, DOI 10.1016/j.jmoldx.2016.06.002; Dubbink HJ, 2016, NEURO-ONCOLOGY, V18, P388, DOI 10.1093/neuonc/nov182; Ebrahimi A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0331-6; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; El-Ayadi M, 2017, ONCOTARGET, V8, P64564, DOI 10.18632/oncotarget.18478; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Elsasser SJ, 2012, NATURE, V491, P560, DOI 10.1038/nature11608; Figarella-Branger D, 2016, NEURO-ONCOLOGY, V18, P919, DOI 10.1093/neuonc/now025; Figarella-Branger D, 2016, NEURO-ONCOLOGY, V18, P888, DOI 10.1093/neuonc/now085; Filbin MG, 2016, ANNU REV PATHOL-MECH, V11, P497, DOI 10.1146/annurev-pathol-012615-044208; Fischer-Valuck BW, 2017, CANCER-AM CANCER SOC, V123, P682, DOI 10.1002/cncr.30405; Fontebasso AM, 2014, NAT GENET, V46, P462, DOI 10.1038/ng.2950; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Fossey M, 2017, J NEURO-ONCOL, V132, P155, DOI 10.1007/s11060-016-2353-0; Fruhwald MC, 2016, NEURO-ONCOLOGY, V18, P764, DOI 10.1093/neuonc/nov264; Fuller CE, 2016, SEMIN DIAGN PATHOL, V33, P427, DOI 10.1053/j.semdp.2016.08.003; Geisenberger C, 2015, ACTA NEUROPATHOL, V130, P419, DOI 10.1007/s00401-015-1427-y; Gessi M, 2016, ACTA NEUROPATHOL, V132, P635, DOI 10.1007/s00401-016-1608-3; Giannini C, 2001, J NEUROPATH EXP NEUR, V60, P248, DOI 10.1093/jnen/60.3.248; Gierke M, 2016, J CANCER RES CLIN, V142, P89, DOI 10.1007/s00432-015-2006-2; Godfraind C, 2012, ACTA NEUROPATHOL, V124, P247, DOI 10.1007/s00401-012-0981-9; Gojo J, 2017, NEURO-ONCOLOGY, V19, P1183, DOI 10.1093/neuonc/nox027; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Granberg KJ, 2017, NEURO-ONCOLOGY, V19, P1206, DOI 10.1093/neuonc/nox028; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Guan XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091216; Hartmann C, 2013, CLIN CANCER RES, V19, P5146, DOI 10.1158/1078-0432.CCR-13-0017; Hartmann C, 2010, ACTA NEUROPATHOL, V120, P707, DOI 10.1007/s00401-010-0781-z; Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9; Hasselblatt M, 2006, AM J SURG PATHOL, V30, P66, DOI 10.1097/01.pas.0000176430.88702.e0; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hinrichs BH, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-015-0270-7; Hirose Y, 2013, BRAIN TUMOR PATHOL, V30, P203, DOI 10.1007/s10014-013-0148-y; Huang DS, 2015, EUR J CANCER, V51, P969, DOI 10.1016/j.ejca.2015.03.010; Huse JT, 2015, J CHILD NEUROL, V30, P1838, DOI 10.1177/0883073815579709; Huse JT, 2015, ACTA NEUROPATHOL, V129, P151, DOI 10.1007/s00401-014-1359-y; Ichimura K, 2015, ACTA NEUROPATHOL, V129, P789, DOI 10.1007/s00401-015-1439-7; Ida CM, 2015, BRAIN PATHOL, V25, P575, DOI 10.1111/bpa.12217; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Jiao YC, 2012, ONCOTARGET, V3, P709, DOI 10.18632/oncotarget.588; Johann PD, 2017, BRAIN PATHOL, V27, P411, DOI 10.1111/bpa.12413; Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001; Jones C, 2017, NEURO-ONCOLOGY, V19, P153, DOI 10.1093/neuonc/now101; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Judkins AR, 2005, J NEUROPATH EXP NEUR, V64, P391, DOI 10.1093/jnen/64.5.391; Judkins AR, 2004, AM J SURG PATHOL, V28, P644, DOI 10.1097/00000478-200405000-00013; Kamoun A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11263; Kannan K, 2012, ONCOTARGET, V3, P1194; Karremann M, 2018, NEURO-ONCOLOGY, V20, P123, DOI 10.1093/neuonc/nox149; Kaur K, 2016, BRAIN PATHOL, V26, P334, DOI 10.1111/bpa.12293; Kilday JP, 2012, CLIN CANCER RES, V18, P2001, DOI 10.1158/1078-0432.CCR-11-2489; Killela PJ, 2014, ONCOTARGET, V5, P1515, DOI 10.18632/oncotarget.1765; Killela PJ, 2014, ONCOTARGET, V5, P1452, DOI 10.18632/oncotarget.1505; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kleinman CL, 2014, NAT GENET, V46, P39, DOI 10.1038/ng.2849; Kleinschmidt-DeMasters BK, 2015, AM J SURG PATHOL, V39, P528, DOI 10.1097/PAS.0000000000000363; Kleinschmidt-DeMasters BK, 2013, AM J SURG PATHOL, V37, P685, DOI 10.1097/PAS.0b013e31827f9c5e; Kline CN, 2017, NEURO-ONCOLOGY, V19, P699, DOI 10.1093/neuonc/now254; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kool M, 2012, MEMO-MAG EUR MED ONC, V5, P228, DOI 10.1007/s12254-012-0037-9; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Korshunov A, 2017, ACTA NEUROPATHOL, V134, P507, DOI 10.1007/s00401-017-1710-1; Korshunov A, 2015, ACTA NEUROPATHOL, V129, P669, DOI 10.1007/s00401-015-1405-4; Korshunov A, 2014, ACTA NEUROPATHOL, V128, P279, DOI 10.1007/s00401-013-1228-0; Korshunov A, 2012, ACTA NEUROPATHOL, V124, P875, DOI 10.1007/s00401-012-1068-3; Korshunov A, 2010, J CLIN ONCOL, V28, P3182, DOI 10.1200/JCO.2009.27.3359; Korshunov A, 2010, ACTA NEUROPATHOL, V120, P253, DOI 10.1007/s00401-010-0688-8; Korshunov A, 2010, J CLIN ONCOL, V28, P3054, DOI 10.1200/JCO.2009.25.7121; Labussiere M, 2014, BRIT J CANCER, V111, P2024, DOI 10.1038/bjc.2014.538; Lafay-Cousin L, 2012, EUR J CANCER, V48, P353, DOI 10.1016/j.ejca.2011.09.005; Lasorella A, 2017, NEURO-ONCOLOGY, V19, P475, DOI 10.1093/neuonc/now240; Lee J, 2017, J NEURO-ONCOL, V132, P1, DOI 10.1007/s11060-016-2349-9; Leeper HE, 2015, ONCOTARGET, V6, P30295, DOI 10.18632/oncotarget.4497; Liu XY, 2012, ACTA NEUROPATHOL, V124, P615, DOI 10.1007/s00401-012-1031-3; Lopez GY, 2017, ACTA NEUROPATHOL, V134, P961, DOI 10.1007/s00401-017-1780-0; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Louis DN, 2014, BRAIN PATHOL, V24, P429, DOI 10.1111/bpa.12171; Louis DN, 2016, WHO CLASSIFICATION T, P408; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Malta TM, 2017, NEUROONCOL; Mazor T, 2017, P NATL ACAD SCI USA, V114, P10743, DOI 10.1073/pnas.1708914114; Metellus P, 2010, ACTA NEUROPATHOL, V120, P719, DOI 10.1007/s00401-010-0777-8; Nakae S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142750; Nauen D, 2016, BRAIN PATHOL, V26, P206, DOI 10.1111/bpa.12291; Neill SG, 2017, ARCH PATHOL LAB MED, V141, P355, DOI 10.5858/arpa.2016-0276-SAI; Nguyen DN, 2013, BRAIN PATHOL, V23, P237, DOI 10.1111/j.1750-3639.2012.00630.x; Nobusawa S, 2009, CLIN CANCER RES, V15, P6002, DOI 10.1158/1078-0432.CCR-09-0715; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Odia Y, 2013, J NEURO-ONCOL, V115, P249, DOI 10.1007/s11060-013-1221-4; Oh JE, 2016, BRAIN PATHOL, V26, P517, DOI 10.1111/bpa.12328; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Olar A, 2015, ACTA NEUROPATHOL, V129, P585, DOI 10.1007/s00401-015-1398-z; Pajtler KW, 2017, ACTA NEUROPATHOL, V133, P5, DOI 10.1007/s00401-016-1643-0; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Panwalkar P, 2017, ACTA NEUROPATHOL, V134, P705, DOI 10.1007/s00401-017-1752-4; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pekmezci M, 2017, ACTA NEUROPATHOL, V133, P1001, DOI 10.1007/s00401-017-1690-1; Perry A, 2010, PRACTICAL SURG NEURO, Vxxxiii; Pfister S, 2009, ACTA NEUROPATHOL, V117, P457, DOI 10.1007/s00401-008-0467-y; Phillips JJ, 2013, BRAIN PATHOL, V23, P565, DOI 10.1111/bpa.12043; Pietsch T, 2016, CLIN NEUROPATHOL, V35, P344; Preusser M, 2008, CLIN NEUROPATHOL, V27, P388; Qaddoumi I, 2016, ACTA NEUROPATHOL, V131, P833, DOI 10.1007/s00401-016-1539-z; Raghunathan A, 2013, BRAIN PATHOL, V23, P584, DOI 10.1111/bpa.12050; Ramaswamy V, 2016, ACTA NEUROPATHOL, V131, P821, DOI 10.1007/s00401-016-1569-6; Ramaswamy V, 2016, NEURO-ONCOLOGY, V18, P291, DOI 10.1093/neuonc/nou357; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Remke M, 2013, ACTA NEUROPATHOL, V126, P917, DOI 10.1007/s00401-013-1198-2; Remke M, 2011, J CLIN ONCOL, V29, P2717, DOI 10.1200/JCO.2011.34.9373; Reuss DE, 2015, ACTA NEUROPATHOL, V130, P407, DOI 10.1007/s00401-015-1454-8; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Richardson TE, 2017, J NEURO-ONCOL, V133, P183, DOI 10.1007/s11060-017-2431-y; Robinson C, 2017, J NEUROPATH EXP NEUR, V76, P151, DOI 10.1093/jnen/nlw112; Rodriguez FJ, 2015, ACTA NEUROPATHOL, V129, P609, DOI 10.1007/s00401-015-1400-9; Rodriguez FJ, 2014, AM J SURG PATHOL, V38, P1058, DOI 10.1097/PAS.0000000000000221; Rodriguez FJ, 2013, ANNU REV PATHOL-MECH, V8, P361, DOI 10.1146/annurev-pathol-020712-164009; Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056; Roth JJ, 2014, CANCER GENET-NY, V207, P111, DOI 10.1016/j.cancergen.2014.03.002; Ryall S, 2017, BRAIN TUMOR PATHOL, V34, P51, DOI 10.1007/s10014-017-0282-z; Sahm F, 2017, NEUROPATHOL APPL NEU; Sahm F, 2016, ACTA NEUROPATHOL, V131, P903, DOI 10.1007/s00401-015-1519-8; Sahm F, 2012, ACTA NEUROPATHOL, V123, P853, DOI 10.1007/s00401-012-0993-5; Schittenhelm J, 2017, EXPERT REV MOL DIAGN, V17, P83, DOI 10.1080/14737159.2017.1266259; Schittenhelm J, 2012, AM J CLIN PATHOL, V138, P85, DOI 10.1309/AJCPPRKNNL09JTLP; Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833; Shankar GM, 2016, ACTA NEUROPATHOL, V131, P147, DOI 10.1007/s00401-015-1492-2; Shih DJH, 2014, J CLIN ONCOL, V32, P886, DOI 10.1200/JCO.2013.50.9539; Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336; Spence T, 2014, ACTA NEUROPATHOL, V128, P291, DOI 10.1007/s00401-014-1291-1; Sturm D, 2017, J CLIN ONCOL; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Suzuki Y, 2016, BRAIN TUMOR PATHOL, V33, P40, DOI 10.1007/s10014-015-0234-4; Tanboon J, 2016, J NEUROPATH EXP NEUR, V75, P4, DOI 10.1093/jnen/nlv009; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Theeler BJ, 2015, J NEUROL SCI, V353, P92, DOI 10.1016/j.jns.2015.04.014; Torchia J, 2016, CANCER CELL, V30, P891, DOI 10.1016/j.ccell.2016.11.003; Torchia J, 2015, LANCET ONCOL, V16, P569, DOI 10.1016/S1470-2045(15)70114-2; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van den Bent MJ, 2017, NEURO-ONCOLOGY, V19, P614, DOI 10.1093/neuonc/now277; van den Bent MJ, 2010, ACTA NEUROPATHOL, V120, P297, DOI 10.1007/s00401-010-0725-7; Velazquez Vega J, 2017, MOD PATHOL S2, V30, p438A; Venneti S, 2015, ADV ANAT PATHOL, V22, P94, DOI 10.1097/PAP.0000000000000049; Venneti S, 2014, ACTA NEUROPATHOL, V128, P743, DOI 10.1007/s00401-014-1338-3; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang X, 2015, ACTA NEUROPATHOL, V129, P449, DOI 10.1007/s00401-015-1389-0; Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958; Weingart MF, 2015, ONCOTARGET, V6, P3165, DOI 10.18632/oncotarget.3078; Weller M, 2015, ACTA NEUROPATHOL, V129, P679, DOI 10.1007/s00401-015-1409-0; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Wesseling P, 2015, ACTA NEUROPATHOL, V129, P809, DOI 10.1007/s00401-015-1424-1; Wiestler B, 2014, ACTA NEUROPATHOL, V128, P561, DOI 10.1007/s00401-014-1315-x; Wiestler B, 2013, ACTA NEUROPATHOL, V126, P443, DOI 10.1007/s00401-013-1156-z; Wijnenga MMJ, 2017, ACTA NEUROPATHOL, V134, P957, DOI 10.1007/s00401-017-1781-z; Witt H, 2011, CANCER CELL, V20, P143, DOI 10.1016/j.ccr.2011.07.007; Wong LH, 2010, GENOME RES, V20, P351, DOI 10.1101/gr.101477.109; Wood MD, 2017, BRAIN PATHOL; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang P, 2016, NEURO-ONCOLOGY, V18, P1099, DOI 10.1093/neuonc/now021; Yip S, 2012, J PATHOL, V226, P7, DOI 10.1002/path.2995; Zacher A, 2017, BRAIN PATHOL, V27, P146, DOI 10.1111/bpa.12367; Zapotocky M, 2017, J NEUROSURG PEDIAT; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Zhao F, 2016, NEURO-ONCOLOGY, V18, P982, DOI 10.1093/neuonc/now050; Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052	228	2	2	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAY	2018	25	3					143	171		10.1097/PAP.0000000000000186			29	Pathology	Pathology	GD2II	WOS:000430322900001	29521646				2019-10-28	
J	Nath, MC; Erickson, LA				Nath, Meryl C.; Erickson, Lori A.			Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						papillary thyroid carcinoma; tall cell; columnar; hobnail; solid; variant of papillary thyroid carcinoma	PROGNOSTIC-SIGNIFICANCE; MOLECULAR-FEATURES; DIAGNOSTIC-CRITERIA; BIOLOGIC BEHAVIOR; CASE SERIES; PREVALENCE; SURVIVAL; PATTERN; MICROPAPILLARY; CANCER	Papillary thyroid carcinomas are the most common endocrine cancer and are usually associated with good survival. However, some variants of papillary thyroid carcinomas may behave more aggressively than classic papillary thyroid carcinomas. The tall cell variant of papillary thyroid carcinoma is the most common aggressive variant of papillary thyroid carcinoma. The aggressive behavior has been ascribed to the histologic subtype and/or to the clinicopathologic features, an issue that remains controversial. The columnar variant of papillary thyroid carcinoma can be aggressive, particularly in older patients, with larger tumors showing a diffusely infiltrative growth pattern and extrathyroidal extension. A papillary thyroid carcinoma is designated as solid/trabecular variant when all or nearly all of a tumor not belonging to any of the other variants has a solid, trabecular, or nested (insular) appearance. This tumor must be distinguished from poorly differentiated thyroid carcinoma which has the same growth pattern but lacks nuclear features of papillary thyroid carcinoma and may show tumor necrosis and high mitotic activity. New to the fourth edition of the WHO Classification of Tumours of Endocrine Organs, the hobnail variant of papillary thyroid carcinoma is a moderately differentiated papillary thyroid carcinoma variant with aggressive clinical behavior and significant mortality. All of these variants are histologically unique and important to recognize due to their aggressive behavior.	[Nath, Meryl C.; Erickson, Lori A.] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA	Erickson, LA (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	erickson.lori@mayo.edu					Akslen LA, 2000, CANCER, V88, P1902, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1902::AID-CNCR20>3.0.CO;2-Y; Amacher AM, 2015, AM J SURG PATHOL, V39, P260, DOI 10.1097/PAS.0000000000000329; Ambrosi F, 2017, ENDOCR PATHOL, V28, P293, DOI 10.1007/s12022-017-9502-7; Asioli S, 2014, DIAGN CYTOPATHOL, V42, P78, DOI 10.1002/dc.23028; Asioli S, 2013, HUM PATHOL, V44, P320, DOI 10.1016/j.humpath.2012.06.003; Asioli S, 2010, AM J SURG PATHOL, V34, P44, DOI 10.1097/PAS.0b013e3181c46677; Bellevicine C, 2012, ACTA CYTOL, V56, P560, DOI 10.1159/000338395; Cameselle-Teijeiro JM, 2017, AM J SURG PATHOL, V41, P854, DOI 10.1097/PAS.0000000000000793; Chen JH, 2011, MODERN PATHOL, V24, P739, DOI 10.1038/modpathol.2011.2; Dettmer M, 2011, AM J SURG PATHOL, V35, P1866, DOI 10.1097/PAS.0b013e31822cf962; Dettmer MS, 2015, ENDOCR-RELAT CANCER, V22, P419, DOI 10.1530/ERC-15-0057; Ganly I, 2014, THYROID, V24, P662, DOI 10.1089/thy.2013.0503; Ghossein R, 2008, THYROID, V18, P1179, DOI 10.1089/thy.2008.0164; Ghossein RA, 2007, THYROID, V17, P655, DOI 10.1089/thy.2007.0061; HAWK WA, 1976, CLEVELAND CLIN Q, V43, P207, DOI 10.3949/ccjm.43.4.207; Ieni A, 2016, REV ENDOCR METAB DIS, V17, P521, DOI 10.1007/s11154-016-9398-4; Ito Y, 2008, WORLD J SURG, V32, P1535, DOI 10.1007/s00268-007-9406-7; Ito Y, 2017, WORLD J SURG, V41, P742, DOI 10.1007/s00268-016-3784-7; Kazaure HS, 2012, ANN SURG ONCOL, V19, P1874, DOI 10.1245/s10434-011-2129-x; Lee YS, 2015, INT J CLIN EXP PATHO, V8, P7988; Lilo MT, 2017, DIAGN CYTOPATHOL, V45, P754, DOI 10.1002/dc.23723; LiVolsi VA, 2010, ENDOCR PATHOL, V21, P12, DOI 10.1007/s12022-010-9106-y; Lloyd RV, 2017, WHO CLASSIFICATION T; Lubitz CC, 2014, THYROID, V24, P958, DOI 10.1089/thy.2013.0573; Michels JJ, 2007, HUM PATHOL, V38, P212, DOI 10.1016/j.humpath.2006.08.001; Morandi L, 2017, ENDOCR-RELAT CANCER, V24, P107, DOI 10.1530/ERC-16-0546; Morris LGT, 2010, THYROID, V20, P153, DOI 10.1089/thy.2009.0352; Motosugi U, 2009, THYROID, V19, P535, DOI 10.1089/thy.2008.0271; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Prendiville S, 2000, OTOLARYNG HEAD NECK, V122, P352, DOI 10.1016/S0194-5998(00)70047-7; Rivera M, 2008, CANCER-AM CANCER SOC, V113, P48, DOI 10.1002/cncr.23515; Rosai J, 2014, TUMORS THYROID PARAT; Lino-Silva LS, 2012, HUM PATHOL, V43, P1596, DOI 10.1016/j.humpath.2011.10.027; Schwock J, 2015, DIAGN CYTOPATHOL, V43, P990, DOI 10.1002/dc.23338; Shi XG, 2016, J CLIN ENDOCR METAB, V101, P263, DOI 10.1210/jc.2015-2917; Sujoy V, 2013, THYROID, V23, P714, DOI 10.1089/thy.2012.0455; Teng LH, 2017, ONCOTARGET, V8, P22023, DOI 10.18632/oncotarget.15786; TERRY JH, 1994, AM J SURG, V168, P459, DOI 10.1016/S0002-9610(05)80099-6; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a; Wang XF, 2016, ONCOTARGET, V7, P40792, DOI 10.18632/oncotarget.8215; Wenig BN, 1998, CANCER, V82, P740, DOI 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.3.CO;2-T; Yang GCH, 2013, DIAGN CYTOPATHOL, V41, P757, DOI 10.1002/dc.22935	43	9	11	2	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAY	2018	25	3					172	179		10.1097/PAP.0000000000000184			8	Pathology	Pathology	GD2II	WOS:000430322900002	29351089				2019-10-28	
J	Akhtar, M; Al-Bozom, IA; Al Hussain, T				Akhtar, Mohammed; Al-Bozom, Issam A.; Al Hussain, Turki			Molecular and Metabolic Basis of Clear Cell Carcinoma of the Kidney	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						renal carcinoma; clear cell; VHL; metabolism; HIF; mutation; chromosome 3; deletion	SARCOMATOID TRANSFORMATION; RHABDOID FEATURES; LINDAU DISEASE; VHL; CLASSIFICATION; CANCER; MUTATIONS; HYPOXIA; BAP1; OVEREXPRESSION	Renal cell carcinoma (RCC) is a heterogenous group of tumors, >70% of which belong to the category of clear cell carcinoma. In recent years, crucial advances have been made in our understanding of the molecular and metabolic basis of clear cell carcinoma. This tumor manifests significant alterations in the cellular metabolism, so that the tumor cells preferentially induce the hypoxia response pathway using aerobic glycolysis, rather than the normal oxidative phosphorylation for energy. Most of the clear cell carcinomas (sporadic as well as familial) have mutations and deletions in the VHL gene located at 3p (p3.25). Normally, pVHL plays a crucial role in the proteasomal degradation of hypoxia-inducible factors (HIF)1 and HIF2. Lack of a functioning pVHL owing to genetic alterations results in stabilization and accumulation of these factors, which promotes cell growth, cell proliferation, and angiogenesis, contributing to a neoplastic phenotype. Several other genes normally located adjacent to VHL (BAP1, SETD2, PBRM1) may also be lost. These are tumor suppressor genes whose loss not only plays a role in carcinogenesis but may also influence the clinical course of these neoplasms. In addition, interaction among a variety of other genes located at several different chromosomes may also play a role in the genesis and progression of clear cell carcinoma.	[Akhtar, Mohammed; Al-Bozom, Issam A.] Hamad Med Corp, Dept Lab Med & Pathol, POB 3050, Doha, Qatar; [Al Hussain, Turki] King Faisal Specialist Hosp & Res Ctr, Dept Pathol & Lab Med, Riyadh, Saudi Arabia	Akhtar, M (reprint author), Hamad Med Corp, Dept Lab Med & Pathol, POB 3050, Doha, Qatar.	makhtar@hamad.qa		Al Bozom, Issam/0000-0001-9514-7731			American Cancer Society, TARG THER KIDN CANC; American cancer Society, 2018, WHAT AR KEY STAT KID; Audenet F, 2012, BJU INT, V109, P1864, DOI 10.1111/j.1464-410X.2011.10661.x; Bailey R, LEARN CELLULAR RESP; Bender DA, 2011, HARPERS ILLUSTRATED; Bi M, 2016, P NATL ACAD SCI USA, V113, P2170, DOI 10.1073/pnas.1525735113; Brugarolas J, 2014, J CLIN ONCOL, V32, P1968, DOI 10.1200/JCO.2012.45.2003; Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; Cheville JC, 2004, AM J SURG PATHOL, V28, P435, DOI 10.1097/00000478-200404000-00002; Chittiboina Prashant, 2015, Handb Clin Neurol, V132, P139, DOI 10.1016/B978-0-444-62702-5.00010-X; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Clark PE, 2009, KIDNEY INT, V76, P939, DOI 10.1038/ki.2009.296; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen RJ, SARCOMATOID RHABDOID; Cohen RJ, PATHOLOGY CLEAR CELL; Collins TE, 1894, T OPHTHAL SOC UK, V14, P141; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; de Peralta-Venturina M, 2001, AM J SURG PATHOL, V25, P275, DOI 10.1097/00000478-200103000-00001; Delahunt B, 2015, SEMIN DIAGN PATHOL, V32, P90, DOI 10.1053/j.semdp.2015.02.002; Delahunt B, 2014, UROLOGY, V83, P969, DOI 10.1016/j.urology.2014.02.004; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Gossage L, 2014, GENE CHROMOSOME CANC, V53, P38, DOI 10.1002/gcc.22116; Gunawan B, 2001, CANCER RES, V61, P7731; Haas NB, 2014, ADV CHRONIC KIDNEY D, V21, P81, DOI 10.1053/j.ackd.2013.10.001; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hoglund M, 2004, CANCER GENET CYTOGEN, V153, P1, DOI 10.1016/j.cancergencyto.2003.12.019; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.9, 10.1038/nrdp.2017.10]; Kaelin WG, 2010, ANN NY ACAD SCI, V1210, P1, DOI 10.1111/j.1749-6632.2010.05781.x; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; Kumar H, 2015, MEDIAT INFLAMM, V584758, P11; Kuroiwa K, 2002, HISTOPATHOLOGY, V41, P538, DOI 10.1046/j.1365-2559.2002.01427.x; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Leroy X, 2007, ARCH PATHOL LAB MED, V131, P102; Li MQ, 2011, J CELL MOL MED, V15, P187, DOI 10.1111/j.1582-4934.2010.01238.x; LINDAU ARVID, 1927, ACTA OPHTHALMOL, V4, P193; Linehan WM, 2013, SEMIN CANCER BIOL, V23, P46, DOI 10.1016/j.semcancer.2012.06.002; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Lipworth Loren, 2009, Clin Epidemiol, V1, P33; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Meneses AM, 2016, HYPOXIA, V4, P53, DOI 10.2147/HP.S53576; Minardi D, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.03.006; Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107; Nanus DM, 2016, EUR UROL, V69, P658, DOI 10.1016/j.eururo.2015.09.020; National Cancer Institute, 2014, SEER STAT FACT SHEET; ODA H, 1995, CANCER RES, V55, P658; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Pinthus JH, 2011, CUAJ-CAN UROL ASSOC, V5, P274, DOI 10.5489/cuaj.10196; Piva F, 2015, EXPERT REV MOL DIAGN, V15, P1201, DOI 10.1586/14737159.2015.1068122; Popova T, 2013, AM J HUM GENET, V92, P974, DOI 10.1016/j.ajhg.2013.04.012; Protzel C, 2012, EUR UROL SUPPL, V11, P52, DOI 10.1016/j.eursup.2012.05.002; Schodel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007; Schonenberger MJ, 2015, FRONT CELL DEV BIOL, V3, P1; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Shuch B, 2014, J CLIN ONCOL, V32, P431, DOI 10.1200/JCO.2013.50.8192; Shuch B, 2012, ONCOLOGIST, V17, P46, DOI 10.1634/theoncologist.2011-0227; Sormendi S, 2016, TRANSL CANCER RES, V5, pS1503, DOI 10.21037/tcr.2016.12.30; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; von Hippel E, 1904, ARCH OPHTHALMOL-CHIC, V59, P83, DOI DOI 10.1007/BF01994821; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59; Woodward ER, 2000, GENOMICS, V65, P253, DOI 10.1006/geno.2000.6144; Yang XQ, 2016, INT J CLIN EXP PATHO, V9, P129; YOSHIDA MA, 1986, CANCER RES, V46, P2139; Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699	75	4	4	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAY	2018	25	3					189	196		10.1097/PAP.0000000000000185			8	Pathology	Pathology	GD2II	WOS:000430322900004	29465421				2019-10-28	
J	Bisceglia, M; Muscarella, LA; Galliani, CA; Zidar, N; Ben-Dor, D; Pasquinelli, G; la Torre, A; Sparaneo, A; Fanburg-Smith, JC; Lamovec, J; Michal, M; Bacchi, CE				Bisceglia, Michele; Muscarella, Lucia A.; Galliani, Carlos A.; Zidar, Nina; Ben-Dor, David; Pasquinelli, Gianandrea; la Torre, Annamaria; Sparaneo, Angelo; Fanburg-Smith, Julie C.; Lamovec, Janez; Michal, Michal; Bacchi, Carlos E.			Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						hemangioblastoma; extraneuraxial hemangioblastoma; von Hippel-Lindau syndrome; VHL gene; molecular analysis	HIPPEL-LINDAU-DISEASE; RENAL-CELL CARCINOMA; CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR GENE; SUPRATENTORIAL LEPTOMENINGEAL HEMANGIOBLASTOMA; SPORADIC CEREBELLAR HEMANGIOBLASTOMAS; PRIMARY CAPILLARY HEMANGIOBLASTOMA; INTRA-EXTRADURAL HEMANGIOBLASTOMA; DUMBBELL-SHAPED HEMANGIOBLASTOMA; CAUDA-EQUINA HEMANGIOBLASTOMA	Extraneuraxial hemangioblastoma occurs in nervous paraneuraxial structures, somatic tissues, and visceral organs, as part of von Hippel-Lindau disease (VHLD) or in sporadic cases. The VHL gene plausibly plays a key role in the initiation and tumorigenesis of both central nervous system and extraneuraxial hemangioblastoma, therefore, the underlying molecular and genetic mechanisms of the tumor growth are initially reviewed. The clinical criteria for the diagnosis of VHLD are summarized, with emphasis on the distinction of sporadic hemangioblastoma from the form fruste of VHLD (eg, hemangioblastoma-only VHLD). The world literature on the topic of extraneuraxial hemangioblastomas has been comprehensively reviewed with approximate to 200 cases reported to date: up to 140 paraneuraxial, mostly of proximal spinal nerve roots, and 65 peripheral, 15 of soft tissue, 6 peripheral nerve, 5 bone, and 39 of internal viscera, including 26 renal and 13 nonrenal. A handful of possible yet uncertain cases from older literature are not included in this review. The clinicopathologic features of extraneuraxial hemangioblastoma are selectively presented by anatomic site of origin, and the differential diagnosis is emphasized in these subsets. Reference is made also to 10 of the authors' personal cases of extraneuraxial hemangioblastomas, which include 4 paraneuraxial and 6 peripheral (2 soft tissue hemangioblastoma and 4 renal).	[Bisceglia, Michele] Etromapmacs Pole, Dept Anat Pathol, Sch Biomed Sci, Lesina, FG, Italy; [Muscarella, Lucia A.; la Torre, Annamaria; Sparaneo, Angelo] IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy; [Pasquinelli, Gianandrea] Univ Bologna, Dept Hemathol Oncol & Clin Pathol, S Orsola Polyclin, Bologna, Italy; [Ben-Dor, David] Barzilai Govt Hosp, Dept Pathol, Ashqelon, Israel; [Fanburg-Smith, Julie C.] Natl Acad Pathol, Mclean, VA USA; [Fanburg-Smith, Julie C.] NIH, Bldg 10, Bethesda, MD 20892 USA; [Galliani, Carlos A.] Childrens Hosp & Clin Minnesota, Dept Pathol, Minneapolis, MN USA; [Zidar, Nina] Univ Ljubljana, Inst Pathol, Fac Med, Ljubljana, Slovenia; [Lamovec, Janez] Inst Oncol, Dept Pathol, Ljubljana, Slovenia; [Michal, Michal] Charles Univ Prague, Med Fac Hosp, Dept Pathol, Plzen, Czech Republic; [Bacchi, Carlos E.] Lab Bacchi, Botucatu, SP, Brazil	Bisceglia, M (reprint author), Via Santa Chiara 9, I-71043 Manfredonia, FG, Italy.	bismich@alice.it		Sparaneo, Angelo/0000-0002-3211-3072			Acikalin MF, 2003, ARCH PATHOL LAB MED, V127, P382; Agostinelli C, 2004, J NEUROSURG, V101, P122, DOI 10.3171/ped.2004.101.2.0122; Ajler P, 2012, Acta Neurol Taiwan, V21, P176; Akhaddar A, 2008, NEUROCHIRURGIE, V54, P101, DOI 10.1016/j.neuchi.2008.01.007; Aldape KD, 2007, WHO CLASSIFICATION T, P184; Aytar MH, 2016, J CRANIOVERTEBRAL JU, V7, P197, DOI 10.4103/0974-8237.193255; Bader HL, 2012, FEBS LETT, V586, P1562, DOI 10.1016/j.febslet.2012.04.032; Bansal Divya, 2015, J Clin Diagn Res, V9, pED07, DOI 10.7860/JCDR/2015/15950.6602; Barrett R, 2008, OPHTHALMOLOGY, V115, P2094, DOI 10.1016/j.ophtha.2008.06.003; Barrey C, 2005, NEUROSURGERY, V56, P625, DOI 10.1227/01.NEU.0000154134.83900.05; Bertalanffy H, 2003, SPINE, V28, pE191, DOI 10.1097/00007632-200305150-00027; Bilgen IG, 2001, J NEURORADIOLOGY, V28, P205; BIRD AV, 1959, BRIT J SURG, V47, P173, DOI 10.1002/bjs.18004720212; Bisceglia M, 2006, ADV ANAT PATHOL, V13, P131, DOI 10.1097/00125480-200605000-00005; BOCKHOVEN S, 1947, ARCH OPHTHALMOL-CHIC, V38, P461, DOI 10.1001/archopht.1947.00900010474004; Bohling T, 1996, J NEUROPATH EXP NEUR, V55, P522; Boyd AS, 2001, AM J DERMATOPATH, V23, P482, DOI 10.1097/00000372-200110000-00016; BRODKEY JA, 1995, NEUROSURGERY, V36, P198, DOI 10.1227/00006123-199501000-00028; BROWNE TR, 1976, ARCH NEUROL-CHICAGO, V33, P435, DOI 10.1001/archneur.1976.00500060041009; Browning L, 2008, PATHOLOGY, V40, P429, DOI 10.1080/00313020802040675; BURNS C, 1987, AM J MED SCI, V293, P119, DOI 10.1097/00000441-198702000-00009; Butman JA, 2008, JAMA-J AM MED ASSOC, V300, P1334, DOI 10.1001/jama.300.11.1334; CAHILL GF, 1942, T AM A GENITOURIN SU, V35, P271; Capone F, 2013, SPINE J, V13, pE27, DOI 10.1016/j.spinee.2013.07.428; Salman-Monte TC, 2018, REUMATOL CLIN, V14, P115, DOI 10.1016/j.reuma.2016.10.006; Carney EM, 2011, AM J SURG PATHOL, V35, P262, DOI 10.1097/PAS.0b013e3182064d11; Catapano D, 2005, NEUROSURGERY, V56, P1215, DOI 10.1227/01.NEU.0000159646.15026.D6; Chan CC, 2007, RETINA-J RET VIT DIS, V27, P1, DOI 10.1097/01.iae.0000244659.62202.ee; Chazono M, 1999, J NEUROSURG, V90, P160, DOI 10.3171/spi.1999.90.1.0160; Chen CY, 2008, COMPUT MED IMAG GRAP, V32, P78, DOI 10.1016/j.compmedimag.2007.08.008; Cheng HX, 2015, BRAIN TUMOR PATHOL, V32, P112, DOI 10.1007/s10014-014-0208-y; Chew Emily Ying, 2005, Trans Am Ophthalmol Soc, V103, P495; Cho H, 2011, J KOREAN NEUROSURG S, V49, P381, DOI 10.3340/jkns.2011.49.6.381; Choudhury T, 2012, Mymensingh Med J, V21, P184; CHRISTOFERSON L, 1961, JAMA-J AM MED ASSOC, V178, P280, DOI 10.1001/jama.1961.03040420020005; Chu BC, 2001, AM J NEURORADIOL, V22, P206; Ciappetta P, 2007, J EXP CLIN CANC RES, V26, P281; Clark PE, 2008, CANCER-AM CANCER SOC, V113, P1768, DOI 10.1002/cncr.23645; Conway JE, 2001, NEUROSURGERY, V48, P55, DOI 10.1097/00006123-200101000-00009; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Courcoutsakis NA, 2009, AM J NEURORADIOL, V30, P758, DOI 10.3174/ajnr.A1360; Curras-Freixes M, 2015, J MED GENET, V52, P647, DOI 10.1136/jmedgenet-2015-103218; da Costa LB, 2003, ARQ NEURO-PSIQUIAT, V61, P456, DOI 10.1590/S0004-282X2003000300024; Deb P, 2012, ENDOCR PATHOL, V23, P187, DOI 10.1007/s12022-012-9207-x; Delanghe SE, 2015, CLIN CHIM ACTA, V438, P304, DOI 10.1016/j.cca.2014.09.013; Deng XF, 2014, J NEUROSURG-SPINE, V21, P260, DOI 10.3171/2014.1.SPINE13866; Dessauvagie BF, 2015, J CLIN NEUROSCI, V22, P215, DOI 10.1016/j.jocn.2014.04.024; DJINDJIAN M, 1978, SURG NEUROL, V9, P223; Doyle LA, 2014, AM J SURG PATHOL, V38, P119, DOI 10.1097/PAS.0b013e3182a266c1; Dwarakanath S, 2008, J CLIN NEUROSCI, V15, P1366, DOI 10.1016/j.jocn.2007.04.014; EMERY E, 1994, NEUROCHIRURGIE, V40, P165; Erdogan H, 2014, TURK NEUROSURG, V24, P151, DOI 10.5137/1019-5149.JTN.8317-13.1; Escott EJ, 2004, SURG NEUROL, V61, P262, DOI 10.1016/S0090-3019(03)00399-9; Fanburg-Smith J C, 2000, Ann Diagn Pathol, V4, P81, DOI 10.1016/S1092-9134(00)90016-9; Farneti M, 2001, J Neurosurg Sci, V45, P58; Fiumara E, 1996, J Neurosurg Sci, V40, P153; Franco Arie, 2017, CNS Oncol, V6, P101, DOI 10.2217/cns-2016-0027; Frantzen C, 1993, VON HIPPEL LINDAU SY; Fukaya T, 1976, No Shinkei Geka, V4, P585; Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387; Gardini AC, 2013, INT J SURG PATHOL, V21, P192, DOI 10.1177/1066896912475082; Giannini C, 1998, MODERN PATHOL, V11, P999; Glasker S, 2006, CANCER RES, V66, P4167, DOI 10.1158/0008-5472.CAN-05-3505; Glasker S, 2005, NEUROSURGERY, V56, P503, DOI 10.1227/01.NEU.0000153909.70381.C8; Glasker S, 2001, J NEUROL NEUROSUR PS, V70, P644, DOI 10.1136/jnnp.70.5.644; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Grahovac G, 2015, NEUROL SCI, V36, P1537, DOI 10.1007/s10072-015-2216-z; Gurses I, 2012, APPL IMMUNOHISTO M M, V20, P277, DOI 10.1097/PAI.0b013e31823e5ba8; Haddad NMN, 2013, SEMIN OPHTHALMOL, V28, P377, DOI 10.3109/08820538.2013.825281; HARDWIG P, 1984, OPHTHALMOLOGY, V91, P263; Hermier M, 2002, NEURORADIOLOGY, V44, P494, DOI 10.1007/s00234-001-0749-8; Hes FJ, 2000, J MED GENET, V37, P939, DOI 10.1136/jmg.37.12.939; Higashida T, 2007, NEUROL MED-CHIR, V47, P215, DOI 10.2176/nmc.47.215; Higgins JNP, 1996, NEURORADIOLOGY, V38, pS107; Hoang MP, 2003, AM J SURG PATHOL, V27, P1152, DOI 10.1097/00000478-200308000-00014; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; Huang Y, 2014, INT J CLIN EXP PATHO, V7, P1777; HURTH M, 1975, NEUROCHIRURGIE, V21, P1; Hussein MR, 2007, INT J EXP PATHOL, V88, P311, DOI 10.1111/j.1365-2613.2007.00535.x; Ichikawa T, 2011, BRAIN TUMOR PATHOL, V28, P279, DOI 10.1007/s10014-011-0031-7; Ingold B, 2008, HISTOPATHOLOGY, V52, P674, DOI 10.1111/j.1365-2559.2008.03003.x; Ip YT, 2010, AM J SURG PATHOL, V34, P1695, DOI 10.1097/PAS.0b013e3181f2d9b8; Isaka T, 1999, NEUROSURG REV, V22, P140; Ishikawa E, 2002, J CLIN NEUROSCI, V9, P713, DOI 10.1054/jocn.2001.1035; ISMAIL SM, 1984, J NEUROSURG, V60, P1279, DOI 10.3171/jns.1984.60.6.1279; Itoh S, 1988, Rinsho Hoshasen, V33, P1047; Jaggi RS, 2009, NEUROL INDIA, V57, P677, DOI 10.4103/0028-3886.57797; Jalikis FG, 2017, CASE REP PATHOL, DOI 10.1155/2017/4206489; Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057; Jiang JG, 2013, INT J CLIN EXP PATHO, V6, P1953; Johnson J, 2005, AM J ROENTGENOL, V184, pS10, DOI 10.2214/ajr.184.3_supplement.01840s10; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; KANNO H, 1994, CANCER RES, V54, P4845; Kern M, 2006, J CLIN NEUROSCI, V13, P929, DOI 10.1016/j.jocn.2005.12.034; Kim DH, 2005, J NEUROSURG, V102, P256, DOI 10.3171/jns.2005.102.2.0256; Kim H, 2013, J KOREAN NEUROSURG S, V54, P415, DOI 10.3340/jkns.2013.54.5.415; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kitanaka Chifumi, 1993, Neurologia Medico-Chirurgica, V33, P377, DOI 10.2176/nmc.33.377; Kline DG, 1995, NERVE INJURIES OPERA, P559; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Konovalov N A, 2016, Zh Vopr Neirokhir Im N N Burdenko, V80, P88, DOI 10.17116/neiro201680688-92; Koo HW, 2016, ACTA NEUROCHIR, V158, P1169, DOI 10.1007/s00701-016-2798-0; Krucke W, 1974, HDB NEUROCHIRURGIE 3, V7; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P251, DOI 10.5858/arpa.2011-0615-OA; Kryvenko ON, 2011, AM J CLIN PATHOL, V136, P450, DOI 10.1309/AJCPJPW34QCQYTMT; Kunihiro N, 2011, NEUROL MED-CHIR, V51, P732, DOI 10.2176/nmc.51.732; Kuroda N, 2015, INT J CLIN EXP PATHO, V8, P2131; Lamovec J, SEMINAR 37 CASE 11; Lapierre F, 1999, NEUROCHIRURGIE, V45, P29; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Laviv Y, 2015, BRIT J NEUROSURG, V29, P281, DOI 10.3109/02688697.2014.958056; Law EK, 2014, CASE REP RADIOL, V2014; Lee DK, 2003, J NEURO-ONCOL, V61, P27, DOI 10.1023/A:1021297622944; Lee GI, 2015, J KOREAN NEUROSURG S, V57, P465, DOI 10.3340/jkns.2015.57.6.465; Lee JY, 1998, CANCER RES, V58, P504; LEE KR, 1978, NEUROLOGY, V28, P727, DOI 10.1212/WNL.28.7.727; Li M, 2014, FOLIA NEUROPATHOL, V52, P234, DOI 10.5114/fn.2014.45564; Li Z, 2015, INT J CLIN EXP PATHO, V8, P7553; Lindau A, 1926, ACTA PATH MICROBIO S, V1, P1; LINDSTEDT G, 1994, CLIN CHEM, V40, P2093; Liu A, 2016, NEUROL RES, V38, P205, DOI 10.1179/1743132815Y.0000000097; Liu XS, 2015, INT J CLIN EXP MED, V8, P5576; Liu Y, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-49; Lonser RR, 2003, J NEUROSURG, V99, P64, DOI 10.3171/spi.2003.99.1.0064; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lonser RR, 2014, J NEUROSURG, V120, P1055, DOI 10.3171/2014.1.JNS131431; Basave HNL, 2015, RARE TUMORS, V7, P14, DOI 10.4081/rt.2015.5679; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ma DX, 2016, TUMOR BIOL, V37, P3765, DOI 10.1007/s13277-015-4200-x; Ma DX, 2011, CANCER BIOL THER, V12, P727, DOI 10.4161/cbt.12.8.16598; Ma DX, 2011, CARCINOGENESIS, V32, P102, DOI 10.1093/carcin/bgq214; Maher E. R., 2003, PATHOLOGY GENETICS T, P230; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAIRE P, 1978, SCHWEIZ ARCH NEUROL, V123, P37; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McEvoy AW, 2000, EUR SPINE J, V9, P434, DOI 10.1007/s005860000193; MCGRATH FP, 1992, CLIN RADIOL, V45, P37, DOI 10.1016/S0009-9260(05)81467-9; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Michal M, 2004, AM J SURG PATHOL, V28, P962, DOI 10.1097/00000478-200407000-00018; Miller CR, 2004, ADV ANAT PATHOL, V11, P325; Mills SA, 2012, NEURO-ONCOLOGY, V14, P1097, DOI 10.1093/neuonc/nos133; MILNES JN, 1953, J NEUROL NEUROSUR PS, V16, P158, DOI 10.1136/jnnp.16.3.158; Miquel C, 2011, AM J SURG PATHOL, V35, P623, DOI 10.1097/PAS.0b013e31820f6d11; Mitchell A, 2013, CLIN NEUROPATHOL, V32, P91, DOI 10.5414/NP300504; Moller P M, 1952, Acta Ophthalmol (Copenh), V30, P154; Montironi R, 2014, EUR UROL, V66, P806, DOI 10.1016/j.eururo.2014.04.022; MORII K, 1993, BIOCHEM BIOPH RES CO, V194, P749, DOI 10.1006/bbrc.1993.1885; MUROTA T, 1989, NEUROSURGERY, V25, P699, DOI 10.1227/00006123-198911000-00003; Muscarella LA, 2014, J NEUROPATH EXP NEUR, V73, P50, DOI [10.1097/NEN.0000000000000024, 10.1097/NEN.0000000000000026]; Muscarella LA, 2013, INT J BIOL MARKER, V28, P208, DOI [10.5301/JBM.5000011, 10.5301/jbm.5000011]; Nadkarni TD, 2006, J CLIN NEUROSCI, V13, P285, DOI 10.1016/j.jocn.2005.02.025; NEUMANN HPH, 1989, J NEUROSURG, V70, P24, DOI 10.3171/jns.1989.70.1.0024; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Nishimura Y, 2012, NEUROL MED-CHIR, V52, P659, DOI 10.2176/nmc.52.659; Nonaka D, 2007, AM J SURG PATHOL, V31, P1545, DOI 10.1097/PAS.0b013e3180457bfc; North PE, 2000, CLIN NEUROPATHOL, V19, P131; Oberstrass J, 1996, J PATHOL, V179, P151, DOI 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0; Olschwang S, 1998, HUM MUTAT, V12, P424, DOI 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H; OMIM, VON HIPP LIND SYNDR; Ortega-Martinez M, 2007, J NEUROSURG-SPINE, V7, P254, DOI 10.3171/SPI-07/08/254; Oviedo A, 2005, PEDIATR DEVEL PATHOL, V8, P386, DOI 10.1007/s10024-005-0119-3; Panelos J, 2010, INT J SURG PATHOL, V18, P580, DOI 10.1177/1066896908320549; Park DM, 2007, PLOS MED, V4, P333, DOI 10.1371/journal.pmed.0040060; Parsa AT, 2004, J NEURO-ONCOL, V69, P291, DOI 10.1023/B:NEON.0000041889.71136.62; Patton KT, 2005, HUM PATHOL, V36, P1135, DOI 10.1016/j.humpath.2005.07.003; Peker S, 2005, J CLIN NEUROSCI, V12, P85, DOI 10.1016/j.jocn.2004.02.025; Pierscianek D, 2017, NEUROPATHOLOGY, V37, P3, DOI 10.1111/neup.12316; Plate KH, 2007, WHO CLASSIFICATION T, P215; Pluta Ryszard M, 2003, Neurosurg Focus, V15, pE11; Polydorides AD, 2007, ARCH PATHOL LAB MED, V131, P641; Ponnaluri VKC, 2013, BIOCHEM BIOPH RES CO, V438, P71, DOI 10.1016/j.bbrc.2013.07.028; Prabhu K, 2009, BRIT J NEUROSURG, V23, P561, DOI 10.1080/02688690902965964; Prieto R, 2005, NEUROCIRUGIA, V16, P58; Provenzale JM, 1996, AM J NEURORADIOL, V17, P713; Prowse AH, 1997, AM J HUM GENET, V60, P765; Purandare HR, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.12.010; Raghavan R, 2000, NEUROSURGERY, V47, P1443, DOI 10.1097/00006123-200012000-00038; Rasulic L, 2015, NEUROSURG REV, V38, P205, DOI 10.1007/s10143-014-0587-x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Richard S, 1994, Adv Nephrol Necker Hosp, V23, P1; Riesenburger RI, 2009, SOUTH MED J, V102, P408, DOI 10.1097/SMJ.0b013e31819496c2; Roessler K, 1999, NEUROSURG REV, V22, P130; ROHDE V, 1995, ZBL NEUROCHIR, V56, P78; ROJIANI AM, 1991, AM J SURG PATHOL, V15, P81, DOI 10.1097/00000478-199101000-00010; Roman-de Aragon M, 2014, NEUROCIRUGIA, V25, P286, DOI 10.1016/j.neucir.2014.06.005; Roncaroli F, 1999, J NEUROSURG, V91, P175, DOI 10.3171/spi.1999.91.2.0175; Roncaroli F, 2000, J NEUROSURG, V92, P229, DOI 10.3171/spi.2000.92.2.0229; Rosai J, 2003, SEMIN DIAGN PATHOL, V20, P247, DOI 10.1053/S0740-2570(03)00063-7; RUSSELL DS, 1989, PATHOL TUMOURS NER, P639; Sacko O, 2010, NEUROCHIRURGIE, V56, P382, DOI 10.1016/j.neuchi.2009.11.006; Sancheti S, 2015, INDIAN J PATHOL MICR, V58, P354, DOI 10.4103/0377-4929.162898; Sangoi AR, 2010, ADV ANAT PATHOL, V17, P377, DOI 10.1097/PAP.0b013e3181f89400; Sasaki A, 1978, No Shinkei Geka, V6, P695; Sawyer B, 2007, AUSTRALAS RADIOL, V51, pB28, DOI 10.1111/j.1440-1673.2007.01835.x; Seki T, 2001, NEUROL SURG TOKYO, V29, P331; Sergides IG, 2009, ACTA NEUROL BELG, V109, P55; Shankar GM, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0167-x; SHARMA RR, 1995, BRIT J NEUROSURG, V9, P81, DOI 10.1080/02688699550041809; Sherman JH, 2007, ACTA NEUROCHIR, V149, P969, DOI 10.1007/s00701-007-1180-7; Shi HJ, 2014, INT J CLIN EXP PATHO, V7, P7054; Shirakabe H, 1966, Rinsho Hoshasen, V11, P405; Sid-Ahmed S, 2006, NEUROCHIRURGIE, V52, P533, DOI 10.1016/S0028-3770(06)71362-5; Singh RR, 2015, MODERN PATHOL, V28, P1225, DOI 10.1038/modpathol.2015.68; Skalova A, 2008, PATHOL RES PRACT, V204, P599, DOI 10.1016/j.prp.2008.01.016; SMITH ROGER A., 1963, BULL LOS ANGELES NEUROL SOC, V28, P79; Son RC, 2009, J KOREAN SOC RADIOL, V61, P211; SPIRIG J, 2011, SCHWEIZ RUNDSCH MED, V100, P849; Staub Blake N, 2014, Surg Neurol Int, V5, P33, DOI 10.4103/2152-7806.128430; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Steinmetz MP, 2005, NEUROSURGERY, V57, P405, DOI 10.1093/neurosurgery/57.2.405a; STEVENS J, 1983, BRIT J RADIOL, V56, P571, DOI 10.1259/0007-1285-56-668-571; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.3.CO;2-B; Sun HI, 2014, WORLD NEUROSURG, V82, P836, DOI 10.1016/j.wneu.2014.05.024; Sun YH, 2012, BRIT J NEUROSURG, V26, P576, DOI 10.3109/02688697.2011.635821; Takami T, 2015, NEUROL MED-CHIR, V55, P317, DOI 10.2176/nmc.ra.2014-0344; Takei H, 2010, ADV ANAT PATHOL, V17, P150, DOI 10.1097/PAP.0b013e3181cfb7ae; Takeuchi H, 2008, NEUROPATHOLOGY, V28, P98, DOI 10.1111/j.1440-1789.2007.00834.x; Tang ZW, 2014, J CLIN NEUROSCI, V21, P333, DOI 10.1016/j.jocn.2013.01.017; Taniguchi S, 2009, SPINE, V34, pE969, DOI 10.1097/BRS.0b013e3181b8e4f4; Taraszewska A, 2001, FOLIA NEUROPATHOL, V39, P119; TARLOV IM, 1947, RADIOLOGY, V49, P717, DOI 10.1148/49.6.717; Tender GC, 2004, J NEUROSURG-SPINE, V1, P142, DOI 10.3171/spi.2004.1.1.0142; Tibbs RE, 1999, NEUROSURGERY, V44, P221, DOI 10.1097/00006123-199901000-00137; Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a; Toktas ZO, 2016, SPINE J, V16, pE27, DOI 10.1016/j.spinee.2015.08.049; Toy BC, 2012, OPHTHALMOLOGY, V119, P2622, DOI 10.1016/j.ophtha.2012.06.026; Toyoda H, 2004, J SPINAL DISORD TECH, V17, P343, DOI 10.1097/01.bsd.0000083630.91606.af; Tronnier V, 1999, ZBL NEUROCHIR, V60, P86; Tse JYM, 1997, AM J CLIN PATHOL, V107, P459; Tsugu H, 1999, NEUROL MED-CHIR, V39, P45, DOI 10.2176/nmc.39.45; Vortmeyer AO, 2006, J PATHOL, V210, P374, DOI 10.1002/path.2062; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; Vortmeyer AO, 2004, ANN NEUROL, V55, P721, DOI 10.1002/ana.20090; Vortmeyer AO, 2003, CANCER RES, V63, P7051; Wang CC, 2012, INT J SURG PATHOL, V20, P519, DOI 10.1177/1066896911434548; Wang YD, 2013, ONCOL LETT, V5, P360, DOI 10.3892/ol.2012.942; Wei Jianguo, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P749; Weil RJ, 2003, J NEUROSURG, V98, P95, DOI 10.3171/jns.2003.98.1.0095; Weinbreck N, 2008, AM J SURG PATHOL, V32, P1051, DOI 10.1097/PAS.0b013e3181609d7d; WISOFF HS, 1978, J NEUROSURG, V48, P461, DOI 10.3171/jns.1978.48.3.0461; WOLBERS JG, 1985, CLIN NEUROL NEUROSUR, V87, P55, DOI 10.1016/0303-8467(85)90070-8; Wong GKC, 2007, SURG NEUROL, V68, P211, DOI 10.1016/j.surneu.2006.10.044; Woodward ER, 2007, BRAIN, V130, P836, DOI 10.1093/brain/awl362; Wu L, 2013, NEUROL INDIA, V61, P338, DOI 10.4103/0028-3886.115103; Wu Y, 2015, J CLIN PATHOL, V68, P1020, DOI 10.1136/jclinpath-2015-202900; Wyburn-Mason R, 1944, VASCULAR ABNORMALITI; Xie T, 2013, NEUROL MED-CHIR, V53, P735, DOI 10.2176/nmc.cr2011-0016; Yin LX, 2014, J CLIN NEUROSCI, V21, P250, DOI 10.1016/j.jocn.2013.03.037; Yin WH, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-39; Yoshida A, 2010, APPL IMMUNOHISTO M M, V18, P479, DOI 10.1097/PAI.0b013e3181daad26; Zakaria R, 2014, CLIN NEUROPATHOL, V33, P157, DOI 10.5414/NP300692; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3; Zeitlin H., 1942, J NEUROPATHOL EXP NE, V1, P14; Zhang Xueping, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P377; Zhao M, 2013, HUM PATHOL, V44, P2247, DOI 10.1016/j.humpath.2013.05.007; ZORLUDEMIR S, 1995, AM J SURG PATHOL, V19, P493, DOI 10.1097/00000478-199505000-00001	258	1	1	4	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAY	2018	25	3					197	215		10.1097/PAP.0000000000000176			19	Pathology	Pathology	GD2II	WOS:000430322900005	29189208				2019-10-28	
J	Griffin, BB; Chou, PM; George, D; Jennings, LJ; Arva, NC				Griffin, Brannan B.; Chou, Pauline M.; George, David; Jennings, Lawrence J.; Arva, Nicoleta C.			Malignant Ectomesenchymoma: Series Analysis of a Histologically and Genetically Heterogeneous Tumor	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						ectomesenchymoma; neural crest; rhabdomyosarcoma; primitive neuroectodermal tumor	ROUND-CELL TUMORS; EMBRYONAL RHABDOMYOSARCOMA; DIAGNOSTIC PITFALL; DIFFERENTIATION; EXPRESSION; CHILDHOOD; MYOGENIN; SARCOMA; ABNORMALITIES; ADOLESCENTS	Aims. Malignant ectomesenchymoma is a rare pediatric neoplasm with dual mesenchymal and neuroectodermal elements. Mesenchymal component is usually rhabdomyosarcoma, particularly embryonal subtype, whereas neuroectodermal derivatives are frequently a neuroblastic tumor. Ectomesenchymoma manifests in various sites given the wide migration of neural crest cells during development, though the pelvis/perineum is most often involved. Moreover, no unique unifying molecular abnormality has been determined. Methods. We conducted a retrospective study to analyze the spectrum of ectomesenchymal tumors encountered in our pediatric population. Six patients were identified and data pertaining to patients' demographic, tumor size and site, histologic components with immunophenotypic profile, molecular alterations, treatment, and outcome were collected. Results. Mesenchymal elements, represented by rhabdomyosarcoma in all instances, were the dominant component in the majority of cases (5/6). Embryonal and alveolar morphology had similar distribution (3/6) and all patients with alveolar subtype harbored the characteristic translocations of this entity. The neuroectodermal component was most often a neuroblastic-like neoplasm (4/6); however, 2/6 cases demonstrated primitive neuroectodermal tumor-like morphology. No unifying alterations were found on molecular studies. Conclusions. Our analysis extends the histologic and molecular spectrum of these tumors and highlights their heterogeneity. The percentage of cases with alveolar rhabdomyosarcoma or primitive neuroectodermal-like tumor components suggests that these types of elements might be underreported. This study is also the first to demonstrate FOXO1 gene rearrangements in malignant ectomesenchymoma with alveolar rhabdomyosarcoma subtype.	[Griffin, Brannan B.] Northwestern Univ, Chicago, IL 60611 USA; [Chou, Pauline M.; George, David; Jennings, Lawrence J.; Arva, Nicoleta C.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA	Arva, NC (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, 225 East Chicago Ave, Chicago, IL 60611 USA.	narva@luriechildrens.org					Bahrami A, 2008, MODERN PATHOL, V21, P795, DOI 10.1038/modpathol.2008.86; Boue DR, 2000, PEDIATR DEVEL PATHOL, V3, P290, DOI 10.1007/s100249910039; Dantonello TM, 2013, PEDIATR BLOOD CANCER, V60, P224, DOI 10.1002/pbc.24174; Floris G, 2007, DIAGN MOL PATHOL, V16, P243, DOI 10.1097/PDM.0b013e3180645105; Goldsby RE, 1998, J PEDIAT HEMATOL ONC, V20, P160, DOI 10.1097/00043426-199803000-00015; Howley S, 2012, HUM PATHOL, V43, P299, DOI 10.1016/j.humpath.2011.03.010; Huang SC, 2016, AM J SURG PATHOL, V40, P876, DOI 10.1097/PAS.0000000000000612; KARCIOGLU Z, 1977, CANCER, V39, P2486, DOI 10.1002/1097-0142(197706)39:6<2486::AID-CNCR2820390627>3.0.CO;2-E; Kleinschmidt-DeMasters BK, 2007, ACTA NEUROPATHOL, V113, P695, DOI 10.1007/s00401-007-0210-0; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Magro G, 2015, ACTA HISTOCHEM, V117, P397, DOI 10.1016/j.acthis.2015.03.011; MCCUNE BK, 1993, AM J PATHOL, V142, P49; Mouton SCE, 1996, PEDIATR PATHOL LAB M, V16, P607, DOI 10.1080/107710496175543; Nael A, 2014, CASE REP PEDIAT, DOI 10.1155/2014/792925; Nael A, 2017, SOC PED PATH SPRING; NAKA A, 1975, CANCER, V36, P1050, DOI 10.1002/1097-0142(197509)36:3<1050::AID-CNCR2820360331>3.0.CO;2-C; Rudzinski ER, 2014, AM J SURG PATHOL, V38, P654, DOI 10.1097/PAS.0000000000000195; SORENSEN PHB, 1995, CANCER RES, V55, P1385; WANG NP, 1995, AM J PATHOL, V147, P1799; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Yohe ME, 2013, J PEDIAT SURG CASE R, V1, P20, DOI 10.1016/j.epsc.2013.01.003	21	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					200	212		10.1177/1066896917734915			13	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500001	28994342				2019-10-28	
J	Kim, B; Yoo, Y; Lee, J; Park, S; Cho, MS; Sung, SH; Kwon, GY				Kim, Bomi; Yoo, Youngeun; Lee, Junghye; Park, Sanghui; Cho, Min-Sun; Sung, Sun Hee; Kwon, Ghee Young			Pitfalls of Frozen Section Diagnosis for Paraganglioma: A Clinicopathologic Analysis and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						paraganglioma; frozen section; permanent section	PHEOCHROMOCYTOMA	Few paraganglioma (PG) cases include frozen section diagnoses, and therefore, the accuracy of frozen section diagnosis for PG remains unknown. To better understand the histologic characteristics and pitfalls of frozen section findings for PG, 15 PG cases with frozen section diagnoses were selected from 12 articles through PubMed (1984-2015). In addition, we included 3 cases of PG for which intraoperative consultations were requested during a 5-year period (2012-2016) in 2 hospitals. Seven PGs were from the thyroid; 2 from the pancreas; 4 from the mediastinum, retroperitoneum, or mesentery; 1 from the middle ear; and 4 from the urinary bladder (UB). Out of 18 PGs, correct diagnoses were rendered in only 2 cases, and no thyroid or UB PGs were correctly diagnosed on intraoperative consultation. Thyroid PGs were frequently misdiagnosed as medullary thyroid carcinomas (4/7, 57%) and UB PGs were frequently misdiagnosed as malignancies.	[Kim, Bomi] Linewalks, Seoul, South Korea; [Kim, Bomi; Yoo, Youngeun; Lee, Junghye; Park, Sanghui; Cho, Min-Sun; Sung, Sun Hee] Ewha Womans Univ, Dept Pathol, Seoul, South Korea; [Kwon, Ghee Young] Sungkyunkwan Univ, Dept Pathololgy, Seoul, South Korea	Park, S (reprint author), Ewha Womans Univ, Dept Pathol, Coll Med, 911-1 Mok Dong, Seoul 158710, South Korea.	spark0430@ewha.ac.kr					Armstrong MJ, 2012, THYROID, V22, P88, DOI 10.1089/thy.2011.0110; Dilbaz B, 2006, SURG LAPARO ENDO PER, V16, P58, DOI 10.1097/01.sle.0000202194.51699.2a; ELIZALDE JM, 1993, J LARYNGOL OTOL, V107, P755, DOI 10.1017/S0022215100124351; Guo N, 2009, J CLIN NEUROSCI, V16, P1650, DOI 10.1016/j.jocn.2009.03.015; Lack EE, 1998, AM J SURG PATHOL, V22, P265, DOI 10.1097/00000478-199802000-00018; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Mehta CK, 2015, ANN THORAC SURG, V100, P702, DOI 10.1016/j.athoracsur.2014.09.068; Nakamura E, 2006, ENDOCR PATHOL, V17, P97, DOI 10.1385/EP:17:2:97; Sangster G, 2010, HPB SURG, V2010; Thompson LDR, 2006, ENDOCR PATHOL, P330; Vijan Sandeep S, 2008, Endocr Pract, V14, P603; Yu BH, 2013, HEAD NECK PATHOL, V7, P373, DOI 10.1007/s12105-013-0467-7; Yu X, 2015, ONCOL LETT, V10, P1000, DOI 10.3892/ol.2015.3292; ZAMIR O, 1984, AM J GASTROENTEROL, V79, P761	14	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					213	220		10.1177/1066896917742199			8	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500002	29169281				2019-10-28	
J	Wales, C; Fadare, O				Wales, Cameron; Fadare, Oluwole			Chemotherapy-Associated Endometrial Atypia: A Potential Diagnostic Pitfall	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						chemotherapy; epithelial atypia; pseudoneoplastic	PATHOLOGY	Cytotoxic chemotherapy, typically as a component of a multimodal approach, is a standard of patient care for numerous malignancies. Chemotherapy-associated cytologic alterations in otherwise normal tissues have been reported at several anatomic sites. We describe in this article distinctive cytologic alterations of the endometrium, including severe severe cytologic atypia, that was attributed to chemotherapy.	[Wales, Cameron; Fadare, Oluwole] Univ Calif San Diego, La Jolla, CA 92093 USA	Fadare, O (reprint author), UC San Diego Hlth, 9300 Campus Point Dr,MC 7723,Suite 1-200, La Jolla, CA 92037 USA.	oluwolefadare@yahoo.com					Clement PB, 2002, ADV ANAT PATHOL, V9, P145, DOI 10.1097/00125480-200205000-00001; Feeley C, 2007, HISTOPATHOLOGY, V50, P958, DOI 10.1111/j.1365-2559.2007.02704.x; Kim EK, 2016, AM J TRANSL RES, V8, P2459; KOSS LG, 1965, AM J CLIN PATHOL, V44, P385; WESTON JT, 1955, CANCER, V8, P179, DOI 10.1002/1097-0142(1955)8:1<179::AID-CNCR2820080125>3.0.CO;2-Q	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					229	231		10.1177/1066896917741552			3	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500004	29482404				2019-10-28	
J	Bharani, V; Sharma, P; Bal, A; Prakash, G				Bharani, Vani; Sharma, Prashant; Bal, Amanjit; Prakash, Gaurav			A Plasma Cell Myeloma With Post-Therapy Anaplastic Morphology, Osteomyelosclerosis, and Strong Pan-Cytokeratin (AE1/AE3) Expression: A Potential Diagnostic Pitfall	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						plasma cell myeloma; pan-cytokeratin; osteomyelosclerosis; metastatic tumor; bone marrow infiltration; histomorphology	NEOPLASMS; PROFILE	Reactive and neoplastic plasma cells can display considerable morphological anaplasia as well as variable immunoreactivity for epithelial markers including epithelial membrane antigen, pan-cytokeratin (panCK) and high-molecular-weight cytokeratin, potentially creating diagnostic dilemmas. We describe the case of a 51-year-old male, previously treated for IgG plasma cell myeloma, whose bone marrow biopsy showed focal replacement by sheets of pleomorphic malignant cells and grade 3 myelofibrosis, raising the morphological possibility of a carcinomatous infiltration. First-line immunohistochemistry revealed strong panCK as well as CD138 positivity. However, subsequent MUM-1 and CD38 stains were also positive, clinching the diagnosis of relapsed plasma cell myeloma with anaplastic morphology and aberrant strong cytokeratin expression. The case warns of the perils of using limited immunohistochemical panels in poorly differentiated metastatic neoplasms and the importance of providing a complete clinical background to the reporting pathologist.	[Bharani, Vani; Sharma, Prashant; Bal, Amanjit; Prakash, Gaurav] Postgrad Inst Med Educ & Res, Chandigarh, India	Sharma, P (reprint author), Postgrad Inst Med Educ & Res, Dept Hematol, Sect 12, Chandigarh 160012, India.	sharma.prashant@pgimer.edu.in					Adams H, 2008, PATHOL RES PRACT, V204, P569, DOI 10.1016/j.prp.2008.02.008; Bain B, 2010, BONE MARROW PATHOLOG, V2010, P421; Baldus SE, 2007, HISTOL HISTOPATHOL, V22, P889, DOI 10.14670/HH-22.889; Gulati R, 2015, AM J CLIN PATHOL, V144, pA148, DOI 10.1093/ajcp/144.suppl2.148; Liu AY, 2004, AM J PATHOL, V165, P1543, DOI 10.1016/S0002-9440(10)63412-8; Natkunam Y, 2001, MODERN PATHOL, V14, P686, DOI 10.1038/modpathol.3880373; O'Connell FP, 2004, AM J CLIN PATHOL, V121, P254, DOI 10.1309/617DWB5GNFWXHW4L; van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389; Xu XW, 2000, ARCH PATHOL LAB MED, V124, P1310	9	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					232	235		10.1177/1066896917750472			4	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500005	29278963				2019-10-28	
J	Handra-Luca, A				Handra-Luca, Adriana			Thyroid Follicular Microcarcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Handra-Luca, Adriana] GHU Avicenne, AP HP, Bobigny, France; [Handra-Luca, Adriana] Univ Paris Nord, Bobigny, France	Handra-Luca, A (reprint author), Univ Paris Nord Sorbonne Cite, GHU Avicenne, AP HP, Serv Anat Pathol, 125 Rue Stalingrad, F-93009 Bobigny, France.	adriana.handra-luca@aphp.fr					Asa SL, 2017, PATHOLOGY, V49, P229, DOI 10.1016/j.pathol.2017.01.001; Clerici T, 2010, BRIT J SURG, V97, P839, DOI 10.1002/bjs.6969; Kuo EJ, 2013, SURGERY, V154, P1246, DOI 10.1016/j.surg.2013.04.033; Lloyd R, 2004, WHO CLASSIFICATION T, V10; Rosai J, 1992, TUMORS THYROID GLAND; Thompson LDR, 2001, CANCER-AM CANCER SOC, V91, P505, DOI 10.1002/1097-0142(20010201)91:3<505::AID-CNCR1029>3.0.CO;2-6; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304	7	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					236	237		10.1177/1066896917733102			2	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500006	28954568				2019-10-28	
J	Arriola, AGP; Martin, ND; Tondon, R				Arriola, Aileen Grace P.; Martin, Niels D.; Tondon, Rashmi			Crystals in Perforated Bowel: Culprits or Innocent Bystanders	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							GASTROINTESTINAL-TRACT; SEVELAMER CRYSTALS; MUCOSAL-INJURY		[Arriola, Aileen Grace P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Martin, Niels D.; Tondon, Rashmi] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA	Tondon, R (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	rashmi.tondon@uphs.upenn.edu					Chintamaneni P, 2014, ACG CASE REP J, V1, P145, DOI 10.14309/crj.2014.32; Desai Meeta, 2016, Case Rep Gastroenterol, V10, P332, DOI 10.1159/000446575; Kim J, 2016, PEDIATR NEPHROL, V31, P339, DOI 10.1007/s00467-015-3269-1; Swanson BJ, 2013, AM J SURG PATHOL, V37, P1686, DOI 10.1097/PAS.0b013e3182999d8d	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					238	239		10.1177/1066896917735172			2	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500007	28982290				2019-10-28	
J	Tiremu, SN; Revankar, SA; Pai, SA				Tiremu, Shamil Nuri; Revankar, Santosh A.; Pai, Sanjay A.			An Unusual Cause of Granulomatous Ileitis - With a Brief History of the Pathology of Typhoid	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							FEVER		[Tiremu, Shamil Nuri; Revankar, Santosh A.; Pai, Sanjay A.] Columbia Asia Referral Hosp, Bangalore, Karnataka, India	Pai, SA (reprint author), Columbia Asia Referral Hosp, Dept Pathol, Bengaluru 560055, Karnataka, India.	sanjayapai@gmail.com					Bharadwaj S, 2009, MED PRIN PRACT, V18, P239, DOI 10.1159/000204357; Brown I, 2018, VIRCHOWS ARCH, V472, P3, DOI 10.1007/s00428-017-2210-3; Bryan CS, 1996, CLIN INFECT DIS, V23, P1139, DOI 10.1093/clinids/23.5.1139; Cheung C, 2012, CAN MED ASSOC J, V184, P1808, DOI 10.1503/cmaj.120714; Harvey AM, 1967, SELECTED SECTIONS CO; Kraus MD, 1999, MODERN PATHOL, V12, P949; Mallory F B, 1898, J Exp Med, V3, P611, DOI 10.1084/jem.3.6.611; REYES E, 1986, DIS COLON RECTUM, V29, P511, DOI 10.1007/BF02562606; SILVER GA, 1987, AM J PUBLIC HEALTH, V77, P82, DOI 10.2105/AJPH.77.1.82	9	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					240	241		10.1177/1066896917735894			2	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500008	29034754				2019-10-28	
J	Viswanathan, K; Cheng, E; Linver, MN; Feddersen, R; Hoda, S				Viswanathan, Kartik; Cheng, Esther; Linver, Michael N.; Feddersen, Richard; Hoda, Syed			Bilateral Multiple Mammary Myofibroblastomas in an Adult Male	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Viswanathan, Kartik; Cheng, Esther; Hoda, Syed] Weill Cornell, 525 East 68th St,Starr 1031c, New York, NY 10065 USA; [Linver, Michael N.] Univ New Mexico, Albuquerque, NM 87131 USA; [Feddersen, Richard] Presbyterian Hosp, Albuquerque, NM USA	Hoda, S (reprint author), Weill Cornell, 525 East 68th St,Starr 1031c, New York, NY 10065 USA.	sahoda@med.cornell.edu					Eyden B, 2009, J CLIN PATHOL, V62, P236, DOI 10.1136/jcp.2008.061630; HameleBena D, 1996, MODERN PATHOL, V9, P786; Howitt BE, 2016, AM J SURG PATHOL, V40, P361, DOI 10.1097/PAS.0000000000000540; Lerwill MF, 2014, ROSENS BREAST PATHOL, P1019; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015	5	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					242	244		10.1177/1066896917735895			3	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500009	29017376				2019-10-28	
J	Zamecnik, M; Rychnovsky, J; Syrovatka, J				Zamecnik, Michal; Rychnovsky, Jiri; Syrovatka, Jakub			Sinonasal SMARCB1 (INI1) Deficient Carcinoma With Yolk Sac Tumor Differentiation: Report of a Case and Comparison With INI1 Expression in Gonadal Germ Cell Tumors	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						SMARCB1 (INI1) deficient carcinoma; sinonasal carcinoma; yolk sac tumor; gonadal mixed germ cell tumor	ENDODERMAL SINUS TUMOR; PARA-NASAL SINUSES; MALIGNANT TERATOMA; HYPERCALCEMIC TYPE; NEOPLASIA; FEATURES	SMARCB1 (INI1) deficient sinonasal carcinoma is a recently recognized entity with wide histomorphologic spectrum. We present a case of this carcinoma that contained, in addition to a common morphology, scattered foci of yolk sac tumor differentiation. The tumor occurred in paranasal sinuses in a 44-year-old woman. Immunohistochemically, it was diffusely negative for INI1, whereas an expression of yolk sac tumor markers (-fetoprotein, glypican-3, CDX2) was limited to the yolk sac tumor component. For comparison with the present case, we performed INI1 immunostaining on a series of 11 gonadal germ cell tumors with yolk sac tumor differentiation. All of these cases showed strong and diffuse expression of INI1, in contrast with the present sinonasal tumor. Our findings expand the morphologic spectrum of SMARCB1 (INI1) deficient sinonasal carcinoma. In addition, we show preliminarily that gonadal germ cell tumors with yolk sac tumor differentiation are not SMARCB1/INI1-deficient.	[Zamecnik, Michal; Rychnovsky, Jiri] Agel Labs As, Dept Pathol, Novy Jicin, Czech Republic; [Zamecnik, Michal] Medirex Grp Acad, Bratislava, Slovakia; [Syrovatka, Jakub] Agel Hosp, Dept Otorhinolaryngol Head & Neck Surg, Novy Jicin, Czech Republic	Zamecnik, M (reprint author), Medicyt Sro, Lab Trencin, Legionarska 28, Trencin 91171, Slovakia.	zamecnikm@seznam.cz			AGEL a.s., Internal Grant [INT2015007]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the AGEL a.s., Internal Grant No. INT2015007.	Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Agaimy A, 2014, AM J SURG PATHOL, V38, P1274, DOI 10.1097/PAS.0000000000000236; Allison DB, 2016, DIAGN CYTOPATHOL, V44, P700, DOI 10.1002/dc.23503; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; Bell D, 2015, VIRCHOWS ARCH, V467, P649, DOI 10.1007/s00428-015-1853-1; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Cheng L, 2017, HUM PATHOL, V59, P10, DOI 10.1016/j.humpath.2016.08.002; DEHNER LP, 1983, HUM PATHOL, V14, P493, DOI 10.1016/S0046-8177(83)80004-5; GARCIA RL, 1985, HUM PATHOL, V16, P955, DOI 10.1016/S0046-8177(85)80137-4; HEFFNER DK, 1984, CANCER, V53, P2140, DOI 10.1002/1097-0142(19840515)53:10<2140::AID-CNCR2820531025>3.0.CO;2-Y; Kupryjanczyk J, 2013, POL J PATHOL, V64, P238, DOI 10.5114/PJP.2013.39331; Lee MJ, 2012, TUMOR BIOL, V33, P2185, DOI 10.1007/s13277-012-0479-z; MANIVEL C, 1986, ARCH PATHOL LAB MED, V110, P198; McCluggage WG, 2017, HISTOPATHOLOGY, V70, P1147, DOI 10.1111/his.13177; Mei XL, 2015, APMIS, V123, P810, DOI 10.1111/apm.12409; Nogales FF, 2014, HISTOPATHOLOGY, V65, P51, DOI 10.1111/his.12373; Wasserman JK, 2017, HEAD NECK PATHOL, V11, P256, DOI 10.1007/s12105-016-0752-3; Zamecnik M, 2003, VIRCHOWS ARCH, V442, P186, DOI 10.1007/s00428-002-0736-4; Zamecnik M., 1999, J UROL PATHOL, V11, P161	19	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					245	249		10.1177/1066896917741549			5	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500010	29166820				2019-10-28	
J	Yabuki, K; Matsuyama, A; Shiba, E; Nagatani, G; Hisaoka, M				Yabuki, Kei; Matsuyama, Atsuji; Shiba, Eisuke; Nagatani, Gunji; Hisaoka, Masanori			Sclerosing Mucoepidermoid Carcinoma in the Parotid Gland With CRTC1-MAML2 Fusion: A Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						CRTC1-MAML2; gene fusion; eosinophilia; IgG4; salivary gland; sclerosing mucoepidermoid carcinoma	EOSINOPHILIA; TRANSCRIPT; SALIVARY; SIALADENITIS; VARIANT; CELLS	In this article, we report a case of sclerosing mucoepidermoid carcinoma (MEC) arising in the parotid gland, with CRTC1-MAML2 gene fusion. A 73-year-old woman with a mass in the right parotid region was referred to our hospital. Radiological imaging tests revealed a well-defined mass, measuring 25 mm in diameter, with foci of calcification in the deep lobe of the parotid gland, extending to the parapharyngeal space. Microscopically, the tumor was composed of a proliferation of atypical glandular epithelial cells having intracytoplasmic mucin, squamoid cells, and intermediate cells arranged in nests embedded in a fibrosclerotic stroma, associated with a dense chronic inflammatory infiltrate containing immunoglobulin G4-immunoreactive plasma cells. Reverse transcription-polymerase chain reaction analysis using a formalin-fixed, paraffin-embedded tumor tissue specimen revealed the CRTC1-MAML2 fusion gene transcript. This is the first report of sclerosing MEC with the detection of the MEC-associated fusion gene, reinforcing a common genetic association between MEC and sclerosing MEC.	[Yabuki, Kei; Matsuyama, Atsuji; Shiba, Eisuke; Nagatani, Gunji; Hisaoka, Masanori] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan	Yabuki, K (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Pathol & Oncol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	kyabuki@med.uoeh-u.ac.jp					Carlson DL, 2009, ARCH PATHOL LAB MED, V133, P692, DOI 10.1043/1543-2165-133.5.692; Ellis GL, 2008, AFIP ATLAS TUMOR PAT, P173; Fujimaki M, 2011, HUM PATHOL, V42, P2052, DOI 10.1016/j.humpath.2011.02.021; Geyer JT, 2010, AM J SURG PATHOL, V34, P202, DOI 10.1097/PAS.0b013e3181c811ad; Heptinstall L, 2017, HEAD NECK PATHOL, V11, P506, DOI 10.1007/s12105-017-0821-2; Ishibashi K, 2015, AM J SURG PATHOL, V39, P1479, DOI 10.1097/PAS.0000000000000507; Jee KJ, 2013, MODERN PATHOL, V26, P213, DOI 10.1038/modpathol.2012.154; Kobayashi Yoshikazu, 2015, J Med Case Rep, V9, P41, DOI 10.1186/s13256-015-0525-8; Lewis JE, 2001, HUM PATHOL, V32, P596, DOI 10.1053/hupa.2001.25000; Matsuyama A, 2011, VIRCHOWS ARCH, V458, P583, DOI 10.1007/s00428-011-1063-4; Nakayama T, 2009, MODERN PATHOL, V22, P1575, DOI 10.1038/modpathol.2009.126; O'Neill ID, 2009, ORAL ONCOL, V45, P2, DOI 10.1016/j.oraloncology.2008.03.012; Okumura Y, 2011, HISTOPATHOLOGY, V59, P90, DOI 10.1111/j.1365-2559.2011.03890.x; Roden AC, 2014, MODERN PATHOL, V27, P1479, DOI 10.1038/modpathol.2014.72; Shah AA, 2017, MODERN PATHOL, V30, P329, DOI 10.1038/modpathol.2016.180; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Tajima S, 2017, MED MOL MORPHOL, V50, P117, DOI 10.1007/s00795-015-0120-5; Tasaki T, 2013, PATHOL INT, V63, P125, DOI 10.1111/pin.12035; Tian W, 2012, AM J SURG PATHOL, V36, P973, DOI 10.1097/PAS.0b013e318258f018; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Urano M, 2002, PATHOL RES PRACT, V198, P305, DOI 10.1078/0344-0338-00259	21	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					250	255		10.1177/1066896917742721			6	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500011	29169286				2019-10-28	
J	Jawad, H; McCarthy, P; O'Leary, G; Heffron, CC				Jawad, Hadeel; McCarthy, Peter; O'Leary, Gerard; Heffron, Cynthia C.			Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						parotid gland; Warthin tumor; chronic lymphocytic leukemia; small lymphocytic lymphoma	OF-THE-LITERATURE; NON-HODGKINS-LYMPHOMA; MALIGNANT-LYMPHOMA; GENE REARRANGEMENT; PAROTID-GLAND; CELL LYMPHOMA; ADENOLYMPHOMA; DIAGNOSIS; STROMA	Warthin tumor is the second most common salivary gland neoplasm. It occurs more commonly in males than in females. Malignant transformation in Warthin tumor is a rare but well-recognized phenomenon; however, the development or presentation of lymphoma in a Warthin tumor is rare. An 80-year-old man presented with painless mass of the right parotid gland of 2 years duration with recent ulceration of the overlying skin and right cervical lymphadenopathy underwent a surgical resection of parotid mass and biopsy of the periglandular lymph nodes. The histological diagnosis was malignant lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, present within the stroma of a Warthin tumor, and also present within the adjacent lymph node. This case is the third reported case describing a collision of Warthin tumor and chronic lymphocytic leukemia/small lymphocytic lymphoma. It also emphasizes the importance of careful examination of the lymphoid stroma of these tumors.	[Jawad, Hadeel; McCarthy, Peter; Heffron, Cynthia C.] Cork Univ Hosp, Cork, Ireland; [O'Leary, Gerard] South Infirm Victoria Univ Hosp, Cork, Ireland	Jawad, H (reprint author), Cork Univ Hosp, Dept Pathol, Cork, Ireland.	hadeelebossi@yahoo.com					Arcega RS, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0444-4; AUCLAIR PL, 1994, ORAL SURG ORAL MED O, V77, P19, DOI 10.1016/S0030-4220(06)80102-7; BANIK S, 1985, J PATHOL, V146, P167, DOI 10.1002/path.1711460303; BUNKER ML, 1989, AM J CLIN PATHOL, V91, P341, DOI 10.1093/ajcp/91.3.341; CHAPNIK JS, 1983, LARYNGOSCOPE, V93, P695; Cheuk W, 2007, DIAGNOSTIC HISTOPATH, P266; Colby T V, 1979, Pathol Annu, V14 Pt 2, P307; Ellis Gary L, 2007, Med Oral Patol Oral Cir Bucal, V12, pE479; Ellis GL, 2000, J PATHOL, V192, P564; GIARDINI R, 1990, TUMORI, V76, P212; Gorai S, 2007, TOHOKU J EXP MED, V212, P199, DOI 10.1620/tjem.212.199; GRIESSER GH, 1986, VIRCHOWS ARCH A, V408, P491, DOI 10.1007/BF00705302; HALL G, 1985, HUM PATHOL, V16, P424, DOI 10.1016/S0046-8177(85)80238-0; Marioni G, 2004, ACTA OTO-LARYNGOL, V124, P318, DOI 10.1080/00016480310015263; MEDEIROS LJ, 1990, HUM PATHOL, V21, P974; MILLER R, 1982, CANCER, V50, P2948, DOI 10.1002/1097-0142(19821215)50:12<2948::AID-CNCR2820501240>3.0.CO;2-B; Ozkok G, 2013, KOREAN J PATHOL, V47, P579, DOI 10.4132/KoreanJPathol.2013.47.6.579; Park CK, 2000, AM J CLIN PATHOL, V113, P113; Romero M, 2016, COLOMB MEDICA, V47, P59; Rosai J., 2011, ROSAI ACKERMANS SURG, P826; Saxena A, 2005, J CLIN PATHOL, V58, P331, DOI 10.1136/jcp.2004.019760; Shikhani A H, 1993, Ear Nose Throat J, V72, P264; Shinohara M, 1996, ACTA HISTOCHEM CYTOC, V29, P17, DOI 10.1267/ahc.29.17; Simpson RH, 2005, WHO CLASSIFICATION T, P265; Song KC, 2009, AM J TRANSL RES, V1, P352	25	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					256	260		10.1177/1066896917734371			5	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500012	28978260				2019-10-28	
J	Arnoux, G; Pusztaszeri, M				Arnoux, Gregoire; Pusztaszeri, Marc			"Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features" With Focal Spindle Cell Metaplasia	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						thyroid; follicular adenoma; spindle cell; NIFTP; papillary carcinoma; metaplasia	FINE-NEEDLE-ASPIRATION; DIFFERENTIAL-DIAGNOSIS; NODULAR GOITER; CARCINOMA; CANCER; ADENOMA; GLAND; EXPRESSION; COMPONENT; VARIANT	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a recent reclassification of the encapsulated follicular variant of papillary thyroid carcinoma, which is supposed to reflect its indolent clinical behavior and to prevent overtreatment of patients with this neoplasm. The diagnosis of NIFTP can only be made histologically on the surgical specimen according to specific inclusion and exclusion criteria, which requires the examination of the whole nodule and its capsule. Spindle cell proliferations, especially of follicular cell origin, arising within thyroid follicular neoplasms are very rare and may cause diagnostic difficulties. Few reports described spindle cell proliferations arising in follicular thyroid adenoma and papillary thyroid carcinoma. To the best of our knowledge, only one case has been reported in NIFTP so far. In this article, we report a unique case of NIFTP associated with a spindle cell proliferation that was characterized immunohistochemically. Specific issues related to this case are discussed.	[Arnoux, Gregoire; Pusztaszeri, Marc] Geneva Univ Hosp, Geneva, Switzerland; [Pusztaszeri, Marc] Jewish Gen Hosp, Dept Pathol, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada; [Pusztaszeri, Marc] McGill Univ, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada	Pusztaszeri, M (reprint author), Geneva Ctr Med Univ, Div Clin Pathol, Rue Michel Servet 1, CH-1211 Geneva 14, Switzerland.	marc.pusztaszeri@mcgill.ca					Agaimy A, 2012, INT J CLIN EXP PATHO, V5, P143; Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841; Aker FV, 2004, ENDOCR J, V51, P457, DOI 10.1507/endocrj.51.457; Al Rasheed MRH, 2017, PATHOL RES PRACT, V213, P416, DOI 10.1016/j.prp.2016.12.026; Baloch ZW, 1999, AM J CLIN PATHOL, V111, P70; Burgess JR, 2006, THYROID, V16, P47, DOI 10.1089/thy.2006.16.47; Corrado S, 2014, ENDOCR PATHOL, V25, P307, DOI 10.1007/s12022-013-9290-7; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; GREENBURG G, 1988, DEVELOPMENT, V102, P605; HAZARD JB, 1954, AMA ARCH PATHOL, V58, P554; HERRMANN ME, 1993, GENE CHROMOSOME CANC, V6, P239, DOI 10.1002/gcc.2870060409; Hirokawa M, 2010, PATHOL INT, V60, P586, DOI 10.1111/j.1440-1827.2010.02562.x; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; LIVOLSI VA, 1994, PATHOL ANNU, V29, P99; Lubitz CC, 2016, CANCER-AM CANCER SOC, V122, P3754, DOI 10.1002/cncr.30201; Magro G, 2005, VIRCHOWS ARCH, V446, P91, DOI 10.1007/s00428-004-1128-8; Miettinen M, 2000, HUM PATHOL, V31, P1139, DOI 10.1053/hupa.2000.16667; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Patel KN, 2016, JAMA ONCOL, V2, P1005, DOI 10.1001/jamaoncol.2016.0714; Pusztaszeri M, 2015, CANCER CYTOPATHOL, V123, P19, DOI 10.1002/cncy.21494; Rodriguez I, 2001, AM J SURG PATHOL, V25, P1424, DOI 10.1097/00000478-200111000-00011; ROSAI J, 1992, ATLAS TUMOR PATHOLOG; Shikama Y, 2006, J ENDOCRINOL INVEST, V29, P168, DOI 10.1007/BF03344092; Vergilio J, 2002, AM J CLIN PATHOL, V117, P199; Wenig BN, 1998, CANCER, V82, P740, DOI 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.3.CO;2-T; Yang YJ, 2015, YONSEI MED J, V56, P1503, DOI 10.3349/ymj.2015.56.6.1503	26	2	2	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					261	265		10.1177/1066896917741548			5	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500013	29212393				2019-10-28	
J	AbdullGaffar, B; Seliem, RM				AbdullGaffar, Badr; Seliem, Rania M.			De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						CD20; CD20 negative; diffuse large B-cell lymphoma; large B-cell lymphoma; HIV; unclassifiable		CD20-negative diffuse large B-cell lymphomas (DLBCLs) constitute a rare and heterogeneous group of aggressive lymphomas. Known well-documented variants include plasmablastic lymphomas, primary effusion lymphomas, anaplastic kinase-positive large B-cell lymphomas, and large B-cell lymphomas arising in human herpesvirus 8 (HHV8)-associated multicentric Castleman disease. They impose diagnostic challenges for pathologists and therapeutic confrontations for clinicians. CD20 loss in B-cell lymphomas is a well-known phenomenon after rituximab therapy. De novo loss of CD20 has been reported in human immunodeficiency virus (HIV)-positive patients. Rare cases of primary CD20-negative DLBCLs that did not meet the criteria of the well-established subtypes of CD20-negative DLBCLs have been reported. This might expand the spectrum of unclassifiable CD20-negative DLBCLs with aberrant genetic and immunophenotypes. This imposes further diagnostic and therapeutic challenges. We report a case of a primary CD20-negative DLBCL in an HIV-infected female patient with an Epstein Barr virus (EBV) coinfection, who presented with generalized lymphadenopathy and fever. The nodal neoplastic immunoblasts were positive for LCA, PAX5, CD30, OCT2, BOB1, MUM1, CD79a, and CD19. Ki67 proliferation index was 100%. They were negative for CD20, CD3, ALK, EMA, CD138, CD38, EBV, and HHV8. Our case did not meet the criteria of the known variants of CD20-negative DLBCLs. The aim of this study is to highlight the diagnostic challenges associated with CD20-negative DLBCLs. De novo unclassifiable CD20-negative DLBCLs might raise an insight into the complex genetic mechanisms of CD20 concealment with variable immunoprofiles and resistance to conventional chemotherapies.	[AbdullGaffar, Badr; Seliem, Rania M.] Rashid Hosp, Dubai, U Arab Emirates	AbdullGaffar, B (reprint author), Rashid Hosp, Pathol Sect, POB 7272, Dubai, U Arab Emirates.	badraah009@yahoo.com					Castillo JJ, 2015, EXPERT REV HEMATOL, V8, P343, DOI 10.1586/17474086.2015.1007862; Colomo L, 2004, AM J SURG PATHOL, V28, P736, DOI 10.1097/01.pas.0000126781.87158.e3; Garg M, 2015, AM J HEMATOL, V90, pE49, DOI 10.1002/ajh.23904; Gaur S, 2013, LYMPHOMA, V2013, P5; Li J, 2016, TUMOR BIOL, V37, P3619, DOI 10.1007/s13277-015-4205-5; Li YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-84; Montes-Moreno S, 2010, HAEMATOL-HEMATOL J, V95, P1342, DOI 10.3324/haematol.2009.016113; Nakatsuka S, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0606-7; Shukla S, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.140792; Tomita A, 2016, J CLIN EXP HEMATOP, V56, P89	10	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					266	270		10.1177/1066896917735170			5	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500014	28982264				2019-10-28	
J	Tariq, H; Sharkey, FE				Tariq, Hamza; Sharkey, Francis E.			Leukocyte Cell-Derived Chemotaxin-2 Amyloidosis (ALECT2) in a Patient With Lung Adenocarcinoma: An Autopsy Report and Literature Review	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						amyloid; ALECT2; mass spectrometry	CHEMOTACTIC FACTOR-2 AMYLOIDOSIS; 2-ASSOCIATED AMYLOIDOSIS; RENAL AMYLOIDOSIS; LECT2 AMYLOIDOSIS; CARCINOMA; BRONCHUS	Amyloidosis caused by deposition of leukocyte cell-derived chemotaxin-2 amyloidosis (ALECT2) is the most recently described form of systemic amyloidosis and has quickly emerged as a common and possibly underdiagnosed cause of slowly declining renal function, particularly in patients of Hispanic ancestry. We describe the autopsy findings in a 70-year-old Hispanic woman who died of metastatic lung adenocarcinoma and was incidentally found to have extensive amyloid deposition in the kidneys, liver, spleen, adrenal glands, small intestine, gallbladder, lungs, bilateral ovaries, and uterus. The type of amyloid was confirmed to be ALECT2 by mass spectrometry. The pattern of amyloid deposition in the kidneys and the liver was typical for what has been described for ALECT2. In addition, a unique pattern of amyloid deposition was observed in spleen, adrenal glands, small intestine, gallbladder, lungs, ovaries, and uterus. The pattern of amyloid deposition in ALECT2 is distinct from amyloid A and amyloid light-chain and needs to be recognized to avoid misdiagnosis as amyloid light-chain or amyloid A amyloidosis. After recognition, an accurate diagnosis by mass spectrometry and/or immunohistochemical staining is essential to guide treatment and avoid toxic therapies.	[Tariq, Hamza; Sharkey, Francis E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	Tariq, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol & Lab Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	TariqH@uthscsa.edu					Asl LH, 1997, BLOOD, V90, P4799; Castano E, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0046-0; Dogan A, 2010, AMYLOID, V17, P69; Dogan A, 2017, ANNU REV PATHOL-MECH, V12, P277, DOI 10.1146/annurev-pathol-052016-100200; Garthwaite EA, 2003, NEPHROL DIAL TRANSPL, V18, P1031, DOI 10.1093/ndt/gfg063; Hutton HL, 2014, AM J KIDNEY DIS, V64, P790, DOI 10.1053/j.ajkd.2014.06.017; Larsen CP, 2016, AMYLOID, V23, P119, DOI 10.3109/13506129.2016.1145110; Larsen CP, 2016, MODERN PATHOL, V29, P416, DOI 10.1038/modpathol.2016.29; Larsen CP, 2014, KIDNEY INT, V86, P378, DOI 10.1038/ki.2014.11; Mereuta OM, 2014, BLOOD, V123, P1479, DOI 10.1182/blood-2013-07-517938; Murphy CL, 2010, AM J KIDNEY DIS, V56, P1100, DOI 10.1053/j.ajkd.2010.08.013; Nasr SH, 2015, CLIN J AM SOC NEPHRO, V10, P2084, DOI 10.2215/CJN.12551214; Nasr SH, 2013, KIDNEY INT, V83, P463, DOI 10.1038/ki.2012.414; Palapattu Ganesh S, 2002, Rev Urol, V4, P163; RICHMOND I, 1990, THORAX, V45, P156, DOI 10.1136/thx.45.2.156; Said SM, 2014, KIDNEY INT, V86, P370, DOI 10.1038/ki.2013.558; Sipe JD, 2012, AMYLOID, V19, P167, DOI 10.3109/13506129.2012.734345	17	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					271	275		10.1177/1066896917735893			5	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500015	29017384				2019-10-28	
J	Windon, AL; Shroff, SG				Windon, Annika L.; Shroff, Stuti G.			Iatrogenic Kaposi's Sarcoma in an HIV-Negative Young Male With Crohn's Disease and IgA Nephropathy: A Case Report and Brief Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						Kaposi's sarcoma; Crohn's disease; HIV; inflammatory bowel disease; ulcerative colitis; Kaposi sarcoma-associated herpesvirus	PROTEIN-COUPLED RECEPTOR; ULCERATIVE-COLITIS; DNA-SEQUENCES; ASSOCIATION; HERPESVIRUS; PATIENT; THERAPY; COLON	Background. Kaposi's sarcoma (KS) is a vascular tumor arising in association with human herpesvirus-8 (HHV-8) infection, and different variants show different clinical presentations. Isolated intestinal KS in the background of Crohn's disease (CD) is exceedingly rare with only 3 cases reported in the English literature (from 1966 to 2016). Case Presentation. Herein, we report a case of intestinal KS in a 21-year-old HIV-negative Ethiopian male with a long-standing history of steroid therapy for his underlying IgA nephropathy. Recent gastrointestinal biopsies confirmed an additional diagnosis of CD. Despite the addition of Infliximab to his therapy, his CD remained refractory, and a laparoscopic-assisted ileocolectomy was performed to alleviate a partial small bowel obstruction. Examination of his terminal ileum demonstrated a polypoid mass with adjacent incidental ileal submucosal nodules. These nodules were composed of plump spindle cells with scattered mitoses and vascular channels with extravasated red blood cells. Intratumoral hyaline globules were also noted. Immunohistochemistry revealed HHV-8 positivity, confirming the histologic impression of KS. Conclusions. Here we report the fourth case of KS in CD in an HIV-negative patient and only the third case of isolated intestinal KS in the setting of CD. A review of the literature suggests that attenuation of immunosuppressive therapy may be adequate management of iatrogenic KS in the absence of a systemic HHV-8 infection.	[Windon, Annika L.; Shroff, Stuti G.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA	Shroff, SG (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St,6-076 Founders, Philadelphia, PA 19104 USA.	stuti.shroff@uphs.upenn.edu					ADLERSBERG R, 1970, AM J CLIN PATHOL, V54, P143; Bais C, 1998, NATURE, V391, P86; Bhagwat G P, 1980, Med J Zambia, V14, P61; Bursics A, 2005, GUT, V54, P1049, DOI 10.1136/gut.2005.069500; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cohen RL, 2001, AM J GASTROENTEROL, V96, P3028; DAMICO G, 1987, Q J MED, V64, P709; Filiopoulos V, 2010, RENAL FAILURE, V32, P523, DOI 10.3109/08860221003710554; Forshaw MJ, 2005, INT J COLORECTAL DIS, V20, P463, DOI 10.1007/s00384-004-0696-z; Girelli CM, 2009, DIGEST LIVER DIS, V41, P170, DOI 10.1016/j.dld.2007.10.007; GORDON HW, 1966, GASTROENTEROLOGY, V50, P248; Hamzaoui L, 2013, PAN AFR MED J, V15, DOI 10.11604/pamj.2013.15.154.2988; Herculano R, 2014, INT J COLORECTAL DIS, V29, P1441, DOI 10.1007/s00384-014-1912-0; HIRSCH DJ, 1992, AM J KIDNEY DIS, V20, P189, DOI 10.1016/S0272-6386(12)80550-6; Kaposi M, 1872, DERMOTOL SYPHILIS, V2, P265; KOOP HO, 1987, AM J MED, V83, P787, DOI 10.1016/0002-9343(87)90916-8; McCallum D, 1997, PEDIATR NEPHROL, V11, P637, DOI 10.1007/s004670050355; MELTZER SJ, 1987, AM J GASTROENTEROL, V82, P378; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; NAGY J, 1988, CLIN NEPHROL, V29, P275; Nagy S, 2000, TRANSPLANTATION, V69, P2230, DOI 10.1097/00007890-200005270-00053; OETTLE AG, 1962, ACTA UNION INT CONTR, V18, P330; Pioche M, 2013, INFLAMM BOWEL DIS, V19, pE12, DOI 10.1002/ibd.21921; PUYMONTBRUN T, 1991, DIGEST DIS SCI, V36, P528, DOI 10.1007/BF01298888; Rodriguez-Pelaez M, 2010, J CROHNS COLITIS, V4, P586, DOI 10.1016/j.crohns.2010.03.006; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SIEGEL JH, 1969, J AMER MED ASSOC, V207, P1493, DOI 10.1001/jama.207.8.1493; SLAVIN G, 1970, J PATHOL, V100, P187, DOI 10.1002/path.1711000307; STRIBLING J, 1978, CANCER, V42, P442, DOI 10.1002/1097-0142(197808)42:2<442::AID-CNCR2820420210>3.0.CO;2-2; Svrcek M, 2009, DIS COLON RECTUM, V52, P154, DOI 10.1007/DCR.0b013e318197217f; Takemura T, 2002, PEDIATR NEPHROL, V17, P863, DOI 10.1007/s00467-002-0943-x; Tedesco M, 1999, ANTICANCER RES, V19, P3045; THOMPSON GB, 1989, DIS COLON RECTUM, V32, P73, DOI 10.1007/BF02554731	35	2	2	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					276	282		10.1177/1066896917736610			7	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500016	29169276				2019-10-28	
J	Hernandez, A; Chiaffarano, J; Mittal, K; Marcus, A				Hernandez, Andrea; Chiaffarano, Jeanine; Mittal, Khushbakhat; Marcus, Alan			Arias-Stella Reaction With Signet Ring-Like Cell Histomorphology	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						Arias-Stella; signet ring-like; endometrium; benign	ENDOMETRIAL; ADENOCARCINOMA	Cells with their nucleus pushed to the periphery in a crescent-like fashion by intracytoplasmic vacuole(s) are referred to as signet ring cells when the vacuole(s) contain mucin and signet ring-like cells when they are empty or contain a material other than mucin. Signet ring cells are commonly associated with adenocarcinomas. These cells are uncommon in the endometrium and have been found to be associated with both malignant and benign processes. We report the first case of signet ring-like cells within endometrial glands with Arias-Stella reaction.	[Hernandez, Andrea; Chiaffarano, Jeanine; Mittal, Khushbakhat; Marcus, Alan] NYU, New York, NY USA	Chiaffarano, J (reprint author), NYU, Dept Pathol, Sch Med, 550 First Ave,TH 412, New York, NY 10016 USA.	Jchiaf01@gmail.com		Chiaffarano, Jeanine/0000-0002-4283-4519			Boyd C, 2010, INT J GYNECOL PATHOL, V29, P579, DOI 10.1097/PGP.0b013e3181e20c66; CLEMENT PB, 1988, INT J GYNECOL PATHOL, V7, P152, DOI 10.1097/00004347-198805000-00006; Iezzoni JC, 2001, AM J CLIN PATHOL, V115, P249; Jacques SM, 1996, PATHOL RES PRACT, V192, P33, DOI 10.1016/S0344-0338(96)80127-0; Kuhn E, 2006, INT J SURG PATHOL, V14, P227, DOI 10.1177/1066896906290361; Lim S, 2012, J CLIN GYNECOL OBSTE, V1, P82; NOGALES FF, 1993, J CUTAN PATHOL, V20, P87, DOI 10.1111/j.1600-0560.1993.tb01257.x	7	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					283	286		10.1177/1066896917741368			4	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500017	29172819				2019-10-28	
J	Arafah, MA; Raddaoui, LE				Arafah, Maria A.; Raddaoui, Leen E.			Malignant Mixed Germ Cell Tumor Overgrowing a Gonadoblastoma in a Female With a 46, XX Karyotype: A Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						germ cell tumor; gonadoblastoma; malignant mixed germ cell; ovary	YOLK-SAC TUMOR; OVARIAN GONADOBLASTOMA; WOMAN; DYSGERMINOMA; DERIVATIVES; PATHOLOGY	Gonadoblastoma is an uncommon ovarian tumor arising primarily in females with gonadal dysgenesis and a 46, XY karyotype. Germ cell tumors arising within and/or overgrowing a gonadoblastoma have been reported. We report a rare case of a malignant mixed germ cell tumor (yolk sac tumor and choriocarcinoma) arising in a gonadoblastoma of the left ovary in a 19-year-old female with a 46, XX karyotype. The patient's initial -fetoprotein level was 20 000 KIU/L. The patient underwent a laparoscopic unilateral salpingo-oophorectomy with omentectomy and peritoneal washing followed by adjuvant chemotherapy.	[Arafah, Maria A.] King Saud Univ, Riyadh, Saudi Arabia; [Arafah, Maria A.] King Khaled Univ Hosp, POB 2925, Riyadh 11461, Saudi Arabia; [Raddaoui, Leen E.] Alfaisal Univ, Riyadh, Saudi Arabia	Arafah, MA (reprint author), King Khaled Univ Hosp, POB 2925, Riyadh 11461, Saudi Arabia.; Arafah, MA (reprint author), King Saud Univ, Coll Med, Dept Pathol 32, POB 2925, Riyadh 11461, Saudi Arabia.	marafah83@gmail.com		Arafah, Maria/0000-0002-6847-5884			DEBACALAO E, 1969, AM J OBSTET GYNECOL, V105, P1279, DOI 10.1016/0002-9378(69)90303-2; ERHAN Y, 1992, J CLIN PATHOL, V45, P828, DOI 10.1136/jcp.45.9.828; Gelincik I, 2010, INDIAN J PATHOL MICR, V53, P345, DOI 10.4103/0377-4929.64344; Gru AA, 2017, AM J SURG PATHOL, V41, P1290, DOI 10.1097/PAS.0000000000000888; Madiwale C V, 2003, J Postgrad Med, V49, P175; NAKASHIMA N, 1989, HUM PATHOL, V20, P814, DOI 10.1016/0046-8177(89)90080-4; Ng SB, 2008, HISTOPATHOLOGY, V52, P644, DOI 10.1111/j.1365-2559.2008.02988.x; OBATA NH, 1995, GYNECOL ONCOL, V58, P124, DOI 10.1006/gyno.1995.1195; SCHELLHAHF, 1974, OBSTET GYN PART 1, V44, P298; SCULLY RE, 1970, CANCER, V25, P1107, DOI 10.1002/1097-0142(197005)25:5<1107::AID-CNCR2820250516>3.0.CO;2-7; SCULLY RE, 1970, CANCER, V25, P1340, DOI 10.1002/1097-0142(197006)25:6<1340::AID-CNCR2820250612>3.0.CO;2-N; TALERMAN A, 1971, OBSTET GYNECOL, V38, P416; TALERMAN A, 1972, CANCER, V30, P1219, DOI 10.1002/1097-0142(197211)30:5<1219::AID-CNCR2820300512>3.0.CO;2-U; TALERMAN A, 1974, OBSTET GYNECOL, V43, P138; TALERMAN A, 1990, CANCER, V66, P2668, DOI 10.1002/1097-0142(19901215)66:12<2668::AID-CNCR2820661234>3.0.CO;2-5; TALERMAN A, 1980, PATHOL RES PRACT, V170, P24, DOI 10.1016/S0344-0338(80)80153-1; Talerman A, 2007, INT J GYNECOL PATHOL, V26, P313, DOI 10.1097/01.pgp.0000250148.52215.ce; Talerman A, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P847, DOI 10.1007/978-1-4419-0489-8_16; Zhao SM, 2000, PATHOL INT, V50, P332, DOI 10.1046/j.1440-1827.2000.01041.x; Zhu HL, 2016, CHINESE MED J-PEKING, V129, P1752, DOI 10.4103/0366-6999.185864	20	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	MAY	2018	26	3					287	292		10.1177/1066896917744342			6	Pathology; Surgery	Pathology; Surgery	GD1AD	WOS:000430231500018	29183227				2019-10-28	
J	Bosse, T; Nout, RA; McAlpine, JN; McConechy, MK; Britton, H; Hussein, YR; Gonzalez, C; Ganesan, R; Steele, JC; Harrison, BT; Oliva, E; Vidal, A; Matias-Guiu, X; Abu-Rustum, NR; Levine, DA; Gilks, CB; Soslow, RA				Bosse, Tjalling; Nout, Remi A.; McAlpine, Jessica N.; McConechy, Melissa K.; Britton, Heidi; Hussein, Yaser R.; Gonzalez, Carlene; Ganesan, Raji; Steele, Jane C.; Harrison, Beth T.; Oliva, Esther; Vidal, August; Matias-Guiu, Xavier; Abu-Rustum, Nadeem R.; Levine, Douglas A.; Gilks, C. Blake; Soslow, Robert A.			Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						POLE exonuclease domain mutations; endometrial cancer; molecular classification	MISMATCH-REPAIR DEFICIENCY; CARCINOMA; MUTATIONS; RISK; IMMUNOHISTOCHEMISTRY; REPRODUCIBILITY; DIAGNOSIS; FEATURES; PROMISE; PD-1	Our aim was to investigate whether molecular classification can be used to refine prognosis in grade 3 endometrial endometrioid carcinomas (EECs). Grade 3 EECs were classified into 4 subgroups: p53 abnormal, based on mutant-like immunostaining (p53abn); MMR deficient, based on loss of mismatch repair protein expression (MMRd); presence of POLE exonuclease domain hotspot mutation (POLE); no specific molecular profile (NSMP), in which none of these aberrations were present. Overall survival (OS) and recurrence-free survival (RFS) rates were compared using the Kaplan-Meier method (Log-rank test) and univariable and multivariable Cox proportional hazard models. In total, 381 patients were included. The median age was 66 years (range, 33 to 96y). Federation Internationale de Gynecologie et d'Obstetrique stages (2009) were as follows: IA, 171 (44.9%); IB, 120 (31.5%); II, 24 (6.3%); III, 50 (13.1%); IV, 11 (2.9%). There were 49 (12.9%) POLE, 79 (20.7%) p53abn, 115 (30.2%) NSMP, and 138 (36.2%) MMRd tumors. Median follow-up of patients was 6.1 years (range, 0.2 to 17.0y). Compared to patients with NSMP, patients with POLE mutant grade 3 EEC (OS: hazard ratio [HR], 0.36 [95% confidence interval, 0.18-0.70]; P = 0.003; RFS: HR, 0.17 [0.05-0.54]; P = 0.003) had a significantly better prognosis; patients with p53abn tumors had a significantly worse RFS (HR, 1.73 [1.09-2.74]; P = 0.021); patients with MMRd tumors showed a trend toward better RFS. Estimated 5-year OS rates were as follows: POLE 89%, MMRd 75%, NSMP 69%, p53abn 55% (Log rank P = 0.001). Five-year RFS rates were as follows: POLE 96%, MMRd 77%, NSMP 64%, p53abn 47% (P = 0.000001), respectively. In a multivariable Cox model that included age and Federation Internationale de Gynecologie et d'Obstetrique stage, POLE and MMRd status remained independent prognostic factors for better RFS; p53 status was an independent prognostic factor for worse RFS. Molecular classification of grade 3 EECs reveals that these tumors are a mixture of molecular subtypes of endometrial carcinoma, rather than a homogeneous group. The addition of molecular markers identifies prognostic subgroups, with potential therapeutic implications.	[Bosse, Tjalling; Nout, Remi A.] Leiden Univ, Med Ctr, Dept Pathol & Radiat Oncol, Leiden, Netherlands; [McAlpine, Jessica N.] Univ British Columbia, Div Gynecol Oncol, Dept Gynecol & Obstet, Vancouver, BC, Canada; [McConechy, Melissa K.; Britton, Heidi; Gilks, C. Blake] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [McConechy, Melissa K.; Britton, Heidi; Gilks, C. Blake] BC Canc Agcy, Vancouver, BC, Canada; [Hussein, Yaser R.; Gonzalez, Carlene; Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Abu-Rustum, Nadeem R.; Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Harrison, Beth T.; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Ganesan, Raji; Steele, Jane C.] Birmingham Womens HS Fdn Trust, Birmingham, W Midlands, England; [Vidal, August; Matias-Guiu, Xavier] Univ Lleida, Univ Hosp Arnau de Vilanova, Dept Pathol, Lleida, Spain; [Vidal, August; Matias-Guiu, Xavier] Univ Lleida, Bellvitge Univ Hosp, Lleida, Spain; [Vidal, August; Matias-Guiu, Xavier] Univ Barcelona, Idibell, Irblleida, Ciberonc, Barcelona, Spain; [Levine, Douglas A.] NYU, Langone Med Ctr, New York, NY USA	Soslow, RA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	soslowr@mskcc.org	Vidal, August/N-4662-2016; matias-guiu, xavier/C-3039-2009	Vidal, August/0000-0001-5727-2099; matias-guiu, xavier/0000-0002-7201-6605; Britton, Heidi/0000-0003-2983-1476	Dutch Cancer SocietyKWF Kankerbestrijding [KWF-UL2012-5719]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]	Supported in part by the Dutch Cancer Society (KWF-UL2012-5719) (Dr Bosse, Dr Nout) and in part through the NIH/NCI Support Grant P30 CA008748 (Dr Abu-Rustum, Dr Levine, Dr Soslow). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Bakhsh S, 2016, HISTOPATHOLOGY, V68, P916, DOI 10.1111/his.12878; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Depreeuw J, 2017, CLIN CANCER RES, V23, P7232, DOI 10.1158/1078-0432.CCR-17-0566; Garg K, 2009, AM J SURG PATHOL, V33, P925, DOI 10.1097/PAS.0b013e318197a046; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Hoang LN, 2017, AM J SURG PATHOL, V41, P245, DOI 10.1097/PAS.0000000000000764; Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hussein YR, 2016, INT J GYNECOL PATHOL, V35, P16, DOI 10.1097/PGP.0000000000000212; Hussein YR, 2015, MODERN PATHOL, V28, P505, DOI 10.1038/modpathol.2014.143; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Liu Y, 2014, JNCI-J NATL CANCER I, V106, P9; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; McMeekin DS, 2016, J CLIN ONCOL, V34, P3062, DOI 10.1200/JCO.2016.67.8722; Micheel CM, 2012, EVOLUTION TRANSLATIO; NIH National Cancer Institute, 2017, SURV EP END RES PROG; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Piulats JM, 2017, GYNECOL ONCOL, V145, P200, DOI 10.1016/j.ygyno.2016.12.015; Proctor L, 2017, GYNECOL ONCOL, V146, P596, DOI 10.1016/j.ygyno.2017.06.020; Shia J, 2008, HUM PATHOL, V39, P116, DOI 10.1016/j.humpath.2007.05.022; Stelloo E, 2017, ANN ONCOL, V28, P96, DOI 10.1093/annonc/mdw542; Stelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878; Stelloo E, 2015, MODERN PATHOL, V28, P836, DOI 10.1038/modpathol.2015.43; Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Talhouk A, 2016, GYNECOL ONCOL, V143, P46, DOI 10.1016/j.ygyno.2016.07.090; Van Gool IC, 2018, HISTOPATHOLOGY, V72, P248, DOI 10.1111/his.13338; van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057	30	18	20	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					561	568		10.1097/PAS.0000000000001020			8	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500001	29505428	Green Accepted			2019-10-28	
J	Kurt, H; Bueso-Ramos, CE; Khoury, JD; Routbort, MJ; Kanagal-Shamanna, R; Patel, UV; Jorgensen, JL; Wang, SA; Ravandi, F; DiNardo, C; Luthra, R; Medeiros, LJ; Patel, KP				Kurt, Habibe; Bueso-Ramos, Carlos E.; Khoury, Joseph D.; Routbort, Mark J.; Kanagal-Shamanna, Rashmi; Patel, Umang V.; Jorgensen, Jeffrey L.; Wang, Sa A.; Ravandi, Farhad; DiNardo, Courtney; Luthra, Rajyalakshmi; Medeiros, L. Jeffrey; Patel, Keyur P.			Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						IDH1 mutation; mutation-specific antibody; anti-IDH1 p.R132H antibody; myeloid neoplasm	MYELODYSPLASTIC SYNDROMES; PROGNOSTIC-SIGNIFICANCE; LEUKEMIA; DIFFERENTIATION; MSMAB-1; GENES; R132H	Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations occur in a variety of myeloid neoplasms. Immunohistochemistry (IHC)-based direct visualization of mutant clones of hematopoietic cells can be useful for rapid diagnostic screening and for monitoring treatment response. In this study, we first evaluated the sensitivity and specificity of the IDH1 p.R132H mutation-specific antibody by IHC. All IDH1 wild type cases (n = 11) and IDH1 mutant cases with a non-p.R132H mutation (n = 30) were negative by IHC, demonstrating 100% antibody specificity. All the initial diagnostic specimens with IDH1 p.R132H mutation including acute myeloid leukemia (n = 30), myelodysplastic syndromes (MDS) (n = 10), MDS/myeloproliferative neoplasms (MPN) (n = 4), and MPN (n = 5) were positive by IHC, demonstrating 100% antibody sensitivity. Both immature and mature myeloid cells showed immunoreactivity. Erythroid precursors, lymphoid cells, endothelial cells, and osteoblasts were consistently negative by IHC. We then evaluated the follow-up specimens with a known IDH1 mutation status including acute myeloid leukemia (n = 23), MDS (n = 2), MDS/MPN (n = 2), and MPN (n = 2). Thirty-three IDH1 p.R132H mutant cases were positive by IHC and 12 IDH1 mutation negative cases were negative by IHC. However, IHC reactivity in up to 25% of bone marrow cells was noted in 8 of 20 polymerase chain reaction-negative cases, all from patients with a known history of IDH1 p.R132H mutation indicating sampling error or a sensitivity issue with molecular tests. These data indicate that IHC is a highly specific and sensitive tool to detect IDH1 p.R132H mutation in bone marrow involved by myeloid neoplasms. In addition, IDH1 p.R132H IHC also allows localization and assessment of the maturation stage of the clones carrying the mutation.	[Kurt, Habibe; Bueso-Ramos, Carlos E.; Khoury, Joseph D.; Routbort, Mark J.; Kanagal-Shamanna, Rashmi; Patel, Umang V.; Jorgensen, Jeffrey L.; Wang, Sa A.; Luthra, Rajyalakshmi; Medeiros, L. Jeffrey; Patel, Keyur P.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Div Pathol & Lab Med, Houston, TX 77030 USA; [Ravandi, Farhad; DiNardo, Courtney] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Patel, KP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 6565 MD Anderson Blvd Unit 1062, Houston, TX 77030 USA.	kppatel@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019		NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA016672]		Abbas S, 2010, BLOOD, V116, P2122, DOI 10.1182/blood-2009-11-250878; Andrulis M, 2010, LEUKEMIA RES, V34, P1091, DOI 10.1016/j.leukres.2010.02.014; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Birendra KC, 2016, CL LYMPH MYELOM LEUK, V16, P460, DOI 10.1016/j.clml.2016.04.006; Capper D, 2010, BRAIN PATHOL, V20, P245, DOI 10.1111/j.1750-3639.2009.00352.x; Chen C, 2013, GENE DEV, V27, P1974, DOI 10.1101/gad.226613.113; Chou WC, 2011, LEUKEMIA, V25, P246, DOI 10.1038/leu.2010.267; DiNardo CD, 2015, AM J HEMATOL, V90, P732, DOI 10.1002/ajh.24072; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Fujii T, 2016, DISCOV MED, V21, P373; Green A, 2010, NEW ENGL J MED, V362, P369, DOI 10.1056/NEJMc0910063; Green CL, 2011, BLOOD, V118, P409, DOI 10.1182/blood-2010-12-322479; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Kaneko MK, 2013, TOHOKU J EXP MED, V230, P103, DOI 10.1620/tjem.230.103; Kato Y, 2015, BRAIN TUMOR PATHOL, V32, P3, DOI 10.1007/s10014-014-0202-4; Kats LM, 2014, CELL STEM CELL, V14, P329, DOI 10.1016/j.stem.2013.12.016; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Luthra R, 2014, HAEMATOLOGICA, V99, P465, DOI 10.3324/haematol.2013.093765; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Molenaar RJ, 2015, LEUKEMIA, V29, P2134, DOI 10.1038/leu.2015.91; Nomdedeu J, 2012, LEUKEMIA RES, V36, P990, DOI 10.1016/j.leukres.2012.03.019; PALITTI F, 1993, BIOCHIM BIOPHYS ACTA, V1216, P50, DOI 10.1016/0167-4781(93)90036-D; Pardanani A, 2010, LEUKEMIA, V24, P1146, DOI 10.1038/leu.2010.77; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Patel KP, 2011, J MOL DIAGN, V13, P678, DOI 10.1016/j.jmoldx.2011.06.004; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Preusser M, 2011, CLIN NEUROPATHOL, V30, P217, DOI 10.5414/NP300422; Ravandi F, 2012, CANCER-AM CANCER SOC, V118, P2665, DOI 10.1002/cncr.26580; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schnittger S, 2010, BLOOD, V116, P5486, DOI 10.1182/blood-2010-02-267955; Stein B, 2015, BLOOD, V126; Takano S, 2015, BRAIN TUMOR PATHOL, V32, P169, DOI 10.1007/s10014-015-0214-8; Tefferi A, 2012, LEUKEMIA, V26, P475, DOI 10.1038/leu.2011.253; Tefferi A, 2010, LEUKEMIA, V24, P1302, DOI 10.1038/leu.2010.113; Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494; Wagner K, 2010, J CLIN ONCOL, V28, P2356, DOI 10.1200/JCO.2009.27.6899; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yaqub F, 2015, LANCET ONCOL, V16, pE9, DOI 10.1016/S1470-2045(14)71140-4	42	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					569	577		10.1097/PAS.0000000000000970			9	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500002	29635257				2019-10-28	
J	Hui, L; Rashid, A; Foo, WC; Katz, MH; Chatterjee, D; Wang, H; Fleming, JB; Tamm, EP; Wang, HM				Hui, Ling; Rashid, Asif; Foo, Wai Chin; Katz, Matthew H.; Chatterjee, Deyali; Wang, Hua; Fleming, Jason B.; Tamm, Eric P.; Wang, Huamin			Significance of T1a and T1b Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pancreas mucinous cystic neoplasm; T1a; T1b carcinoma; prognosis	OSTEOCLASTIC GIANT-CELLS; UNDIFFERENTIATED CARCINOMA; CLINICOPATHOLOGICAL FEATURES; PROGNOSIS; MANAGEMENT; STROMA; CYSTADENOCARCINOMA; CYSTADENOMAS; TUMORS	Mucinous cystic neoplasm (MCN) of pancreas is one of the precursor lesions of pancreatic ductal adenocarcinoma. The 5-year disease-specific survival for noninvasive MCNs was 100% and 20% to 60% for those with pancreatic ductal adenocarcinoma arising in a MCN. However, the significance of T1a (<= 0.5 cm) and T1b (<= 0.5 and <1.0 cm) carcinoma arising in MCN as defined by the upcoming American Joint Committee on Cancer, eighth edition is unclear. In this study, we examined 3 cases of MCN with T1a or T1b carcinoma and compared their clinicopathologic characteristics and survival to 46 cases of MCN with low-grade dysplasia (MCN-LGD), 7 cases of MCN with high-grade dysplasia (MCN-HGD), and 7 cases of MCN with advanced invasive carcinoma (T2 or higher T stage). The tumors from all 3 cases were submitted in their entirety in 123, 296, and 200 blocks, respectively. All 3 patients were alive with no recurrence during the follow-up of 20.0, 113.8, and 137.2 months, respectively. Similarly, none of the patients who had MCN with either LGD or HGD had recurrence or died of disease. In contrast, 5 of 7 patients who had MCN with advanced invasive carcinoma had recurrence and later died of disease with a median survival of 22.9 months (P <0.001). Our study showed that MCN with T1a and T1b carcinoma had an excellent prognosis similar to MCNs with LGD or HGD after complete tumor sampling for histologic examination. Our results along with the previous studies suggest that close follow-up, rather than aggressive systemic therapy, may be a better approach for these patients.	[Hui, Ling; Rashid, Asif; Foo, Wai Chin; Chatterjee, Deyali; Wang, Huamin] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 085,1515 Holcombe Blvd, Houston, TX 77030 USA; [Katz, Matthew H.; Fleming, Jason B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Wang, Hua] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Tamm, Eric P.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA	Wang, HM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 085,1515 Holcombe Blvd, Houston, TX 77030 USA.	hmwang@mdanderson.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 CA196941-01A1]; Khalifa Bin Zayed Al Nahyan Foundation Institute for Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center	Supported by the National Institutes of Health grant (1R01 CA196941-01A1) and Khalifa Bin Zayed Al Nahyan Foundation Institute for Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Bosman FT, 2010, WHO CLASSIFICATION T; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P289; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P573; Crippa S, 2008, ANN SURG, V247, P571, DOI 10.1097/SLA.0b013e31811f4449; Edge SB, 2010, AJCC CANC STAGING MA; Fallahzadeh Mohammad Kazem, 2014, J La State Med Soc, V166, P67; Jang KT, 2015, AM J SURG PATHOL, V39, P179, DOI 10.1097/PAS.0000000000000357; Kosmahl M, 2004, VIRCHOWS ARCH, V445, P168, DOI 10.1007/s00428-004-1043-z; Le Borgne J, 1999, ANN SURG, V230, P152, DOI 10.1097/00000658-199908000-00004; Lewis GH, 2013, AM J SURG PATHOL, V37, P601, DOI 10.1097/PAS.0b013e318273f3b0; Molberg KH, 1998, CANCER-AM CANCER SOC, V82, P1279, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1279::AID-CNCR10>3.0.CO;2-3; Muraki T, 2016, AM J SURG PATHOL, V40, P1203, DOI 10.1097/PAS.0000000000000689; Nilsson LN, 2016, PANCREATOLOGY, V16, P1028, DOI 10.1016/j.pan.2016.09.011; Noe Michael, 2016, Surg Pathol Clin, V9, P561, DOI 10.1016/j.path.2016.05.004; Reddy RP, 2004, CLIN GASTROENTEROL H, V2, P1026, DOI 10.1016/S1542-3565(04)00450-1; Reid MD, 2017, CANCER CYTOPATHOL, V125, P563, DOI 10.1002/cncy.21859; Suzuki M, 2005, J GASTROENTEROL, V40, P1070, DOI 10.1007/s00535-005-1697-6; Suzuki Y, 2004, PANCREAS, V28, P241, DOI 10.1097/00006676-200404000-00005; Tanaka M, 2006, PANCREATOLOGY, V6, P17, DOI 10.1159/000090023; Testini M, 2010, WORLD J GASTROENTERO, V16, P5682, DOI 10.3748/wjg.v16.i45.5682; Thompson LDR, 1999, AM J SURG PATHOL, V23, P1, DOI 10.1097/00000478-199901000-00001; Tokuyama Y, 2011, RARE TUMORS, V3, DOI 10.4081/rt.2011.e14; Westra WH, 1998, AM J SURG PATHOL, V22, P1247, DOI 10.1097/00000478-199810000-00010; Wilentz RE, 1999, AM J SURG PATHOL, V23, P1320, DOI 10.1097/00000478-199911000-00002; Wouters K, 1998, VIRCHOWS ARCH, V432, P187, DOI 10.1007/s004280050154; Xourafas D, 2015, SURGERY, V157, P473, DOI 10.1016/j.surg.2014.09.028; Yamao K, 2011, PANCREAS, V40, P67, DOI 10.1097/MPA.0b013e3181f749d3; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005	28	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					578	586		10.1097/PAS.0000000000001040			9	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500003	29462092	Green Accepted			2019-10-28	
J	Carney, JA; Lyssikatos, C; Seethala, RR; Lakatos, P; Perez-Atayde, A; Lahner, H; Stratakis, CA				Carney, J. Aidan; Lyssikatos, Charalampos; Seethala, Raja R.; Lakatos, Peter; Perez-Atayde, Antonio; Lahner, Harald; Stratakis, Constantine A.			The Spectrum of Thyroid Gland Pathology in Carney Complex The Importance of Follicular Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Carney complex; pathology; thyroid; thyroid neoplasms	PSAMMOMATOUS MELANOTIC SCHWANNOMA; INCLUDING CARDIAC MYXOMA; ENDOCRINE OVERACTIVITY; SPOTTY PIGMENTATION; CUSHING SYNDROME; ATRIAL-MYXOMA; TUMOR; LENTIGINES; PRKAR1A; HYPERTHYROIDISM	The initial description of Carney complex (CNC) in 1985 included myxomas, spotty skin pigmentation, and endocrine overactivity (of the adrenal, the pituitary, and the testis). In 1997, thyroid neoplasms were found in 3 patients with CNC and involvement of the gland in the syndrome was apparent. Herein, we describe the clinical, pathologic, and follow-up findings in 26 patients with CNC and a disorder of the thyroid gland. The patients were predominantly middle-aged women with an asymptomatic thyroid mass. Four patients had hyperthyroidism, which was caused by follicular hyperplasia in 2 patients and by toxic adenoma in 2 others. Pathologic findings included benign lesions (follicular hyperplasia, nodular hyperplasia, and follicular adenoma) in 16 patients and carcinomas (follicular or papillary) in 10 patients. The follicular carcinomas had unusual features, multifocality, bilaterality, and lymph node metastasis. The tumor was fatal in >= 3 of 4 patients with a tumor >= 3 cm in diameter. One patient had an unusual multifocal microscopic follicular hyperplasia. Detection and treatment of the thyroid neoplasms in patients with CNC requires long-term follow-up of patients with the syndrome.	[Carney, J. Aidan] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA; [Lyssikatos, Charalampos; Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, NIH, Bethesda, MD USA; [Seethala, Raja R.] Univ Pittsburgh, Presbyterian Hosp, Dept Pathol, Pittsburgh, PA 15213 USA; [Perez-Atayde, Antonio] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Lakatos, Peter] Semmelweis Univ, Dept Med, Budapest, Hungary; [Lahner, Harald] Univ Essen Gesamthsch, Dept Endocrinol & Metab, Essen, Germany	Carney, JA (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	carney.aidan@mayo.edu			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA HD008920-05]		ATHERTON DJ, 1980, BRIT J DERMATOL, V103, P421, DOI 10.1111/j.1365-2133.1980.tb07266.x; Bertherat J, 2009, J CLIN ENDOCR METAB, V94, P2085, DOI 10.1210/jc.2008-2333; BIER B, 1989, THORAC CARDIOV SURG, V37, P317, DOI 10.1055/s-2007-1020342; Campo MR, 2015, HORM-INT J ENDOCRINO, V14, P300, DOI 10.14310/horm.2002.1514; Carney JA, 1996, AM J SURG PATHOL, V20, P259, DOI 10.1097/00000478-199603000-00001; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; Carney JA, 2003, ENDOCRINOLOGIST, V13, P23, DOI 10.1097/00019616-200301000-00007; Carney JA, 2001, AM J SURG PATHOL, V25, P164, DOI 10.1097/00000478-200102000-00004; CARNEY JA, 1985, MEDICINE, V64, P270, DOI 10.1097/00005792-198507000-00007; CARNEY JA, 1990, AM J SURG PATHOL, V14, P206, DOI 10.1097/00000478-199003000-00002; Courcoutsakis N, 2009, THYROID, V19, P293, DOI 10.1089/thy.2008.0404; DANOFF A, 1987, ARCH INTERN MED, V147, P443, DOI 10.1001/archinte.147.3.443; GREBE SKG, 1995, ENDOCRIN METAB CLIN, V24, P761, DOI 10.1016/S0889-8529(18)30021-5; Halaszlaki C, 2012, PATHOL ONCOL RES, V18, P149, DOI 10.1007/s12253-012-9502-3; Havrankova E, 2014, ANN THORAC CARDIOVAS, V20, P890, DOI 10.5761/atcs.cr.13-00121; HONEY M, 1962, BRIT HEART J, V24, P667; Iacobellis G, 2001, ENDOCRINOLOGIST, V11, P327, DOI 10.1097/00019616-200107000-00012; Lahner H, 2014, EXP CLIN ENDOCR DIAB, V122, DOI 10.1055/s-0034-1372001; Lee B, 2008, INT J CARDIOL, V130, pE63, DOI 10.1016/j.ijcard.2007.11.061; LOIRE R, 1991, ANN CARDIOL ANGEIOL, V40, P1; Lowe KM, 2017, AM J SURG PATHOL, V41, P171, DOI 10.1097/PAS.0000000000000748; MARTIN LW, 1987, ANN THORAC SURG, V44, P77, DOI 10.1016/S0003-4975(10)62362-4; Nwokoro NA, 1997, AM J MED GENET, V73, P369, DOI 10.1002/(SICI)1096-8628(19971231)73:4<369::AID-AJMG1>3.0.CO;2-J; Piper SN, 1997, THORAC CARDIOV SURG, V45, P245, DOI 10.1055/s-2007-1013736; Pringle DR, 2012, ENDOCR-RELAT CANCER, V19, P435, DOI 10.1530/ERC-11-0306; Rhee SY, 2012, EXP CLIN ENDOCR DIAB, V120, P7, DOI 10.1055/s-0031-1287790; RHODES AR, 1984, J AM ACAD DERMATOL, V10, P72, DOI 10.1016/S0190-9622(84)80047-X; Sardar Muhammad Rizwan, 2014, J Med Case Rep, V8, P134, DOI 10.1186/1752-1947-8-134; SCHUIKI E, 1987, SCHWEIZ MED WSCHR, V117, P595; Seidl M, 2013, PATHOLOGE, V34, P343, DOI 10.1007/s00292-012-1736-z; Stratakis CA, 1997, J CLIN ENDOCR METAB, V82, P2037, DOI 10.1210/jc.82.7.2037; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407; Zhang YL, 2015, ARCH IRAN MED, V18, P324, DOI 0151805/AIM.0013	33	2	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					587	594		10.1097/PAS.0000000000000975			8	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500004	29635258	Green Accepted			2019-10-28	
J	Perron, E; Pissaloux, D; Barra, CC; Karanian, M; Lamant, L; Parfait, S; Alberti, L; de la Fouchardiere, A				Perron, Emilie; Pissaloux, Daniel; Barra, Celine Charon; Karanian, Marie; Lamant, Laurence; Parfait, Sophie; Alberti, Laurent; de la Fouchardiere, Arnaud			Melanocytic Myxoid Spindle Cell Tumor With ALK Rearrangement (MMySTAR) Report of 4 Cases of a Nevus Variant With Potential Diagnostic Challenge	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ALK rearrangement; melanocytic tumor; nevus variant; myxoid deposits; Spitz tumor	PLEXIFORM SPITZ NEVUS; GENE FUSIONS; FEATURES; MELANOMAS; BRAF; IDENTIFICATION; HISTIOCYTOMA; NTRK1; LUNG	Melanocytic tumors rarely display extensive dermal myxoid deposits except in the myxoid variant of melanoma. We describe in 4 patients the unusual association of morphologic and genetic features. All cases occurred in males and were located on the limbs or proximal girdle area. Age at diagnosis ranged from 8 to 47 years. Size ranged from 6 to 11 mm. Microscopic analysis showed compound, but mainly dermal melanocytic nevi, all presenting a deep dermal expansion with fascicules of amelanotic spindled cells floating in a myxoid background. Cytologic atypia and mitotic activity were low. The superficial portion was either of spitzoid or nevoid cytology with a limited junctional component. In the initial case, the dermal myxoid component was predominant with rare, barely visible, superficial melanocytic nests. This peculiar morphology was responsible for a delayed diagnostic, which required an extensive panel of antibodies ruling out most, potentially myxoid, soft tissue tumors. We later observed the presence of similar, but more limited, dermal morphologic features in 3 other cases. Immunohistochemistry in the deep myxoid areas was melanA(-), ALK(+), SOX10(+), and MiTF(+). Molecular studies confirmed the ALK rearrangement by an ALK break-apart fluorescence in situ hybridization technique and by RNA sequencing. The latter identified 4 different 5'-fusion partners. Two gene fusions were undescribed: FBXO28(e2)-ALK(e19) and NPAS2(e2)-ALK(e19), and 2 previously described: TPM3(e7)-ALK(e20) and PPFIBP1(e9)-ALK(e19). No relapse or metastatic evolution was seen during follow-up (3 to 24 mo). We denominated this potentially challenging new variant of compound nevus linked to a kinase fusion: Melanocytic Myxoid Spindle Cell Tumor with ALK Rearrangement.	[Perron, Emilie; Pissaloux, Daniel; Karanian, Marie; Alberti, Laurent; de la Fouchardiere, Arnaud] Ctr Leon Berard, Dept Biopathol, 28 Rue Laennec, F-69008 Lyon, France; [Barra, Celine Charon] Ctr George Francois Leclerc, Dijon, France; [Lamant, Laurence] Univ Hosp Toulouse, Dept Histopathol, Toulouse, France; [Parfait, Sophie] Pathol Lab Auxerre, Auxerre, France; [Perron, Emilie] Univ Laval, CHU Quebec, Dept Pathol, Quebec City, PQ, Canada; [Perron, Emilie] Univ Laval, Fac Med, Dept Mol Biol & Med Biochem, Quebec City, PQ, Canada	de la Fouchardiere, A (reprint author), Ctr Leon Berard, Dept Biopathol, 28 Rue Laennec, F-69008 Lyon, France.	arnaud.delafouchardiere@lyon.unicancer.fr	de la Fouchardiere, Arnaud/I-2807-2019	de la Fouchardiere, Arnaud/0000-0003-2251-8241; PISSALOUX, Daniel/0000-0003-1118-950X	Bourse McLaughlin du Doyen de la Faculte de medecine de l'Universite Laval; TEVA Innovation Canada	E.P. gratefully acknowledges the "Bourse McLaughlin du Doyen de la Faculte de medecine de l'Universite Laval" and the TEVA Innovation Canada fellowship grants. For the remaining authors none were declared.	Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Clarke B, 2002, INT J SURG PATHOL, V10, P69, DOI 10.1177/106689690201000112; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Doyle LA, 2015, MODERN PATHOL, V28, P904, DOI 10.1038/modpathol.2015.49; Hitchcock MG, 1999, AM J SURG PATHOL, V23, P1506, DOI 10.1097/00000478-199912000-00008; Hoang MP, 2003, J CUTAN PATHOL, V30, P566, DOI 10.1034/j.1600-0560.2003.00100.x; Jedrych J, 2015, BRIT J DERMATOL, V172, P1427, DOI 10.1111/bjd.13548; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Kiuru M, 2016, INT J SURG PATHOL, V24, P200, DOI 10.1177/1066896916630375; Mehregan DR, 1996, AM J DERMATOPATH, V18, P400, DOI 10.1097/00000372-199608000-00012; Niu HT, 2013, PIGM CELL MELANOMA R, V26, P646, DOI 10.1111/pcmr.12129; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Spatz A, 1999, AM J DERMATOPATH, V21, P542, DOI 10.1097/00000372-199912000-00007; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Takeuchi K, 2011, CLIN CANCER RES, V17, P3341, DOI 10.1158/1078-0432.CCR-11-0063; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Turner J, 2017, PIGM CELL MELANOMA R, V30, P53, DOI 10.1111/pcmr.12560; Uguen A, 2016, AM J SURG PATHOL, V40, P1437, DOI 10.1097/PAS.0000000000000686; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Yeh I, 2016, J PATHOL, V240, P282, DOI 10.1002/path.4775; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406; Zou YR, 2016, J CUTAN PATHOL, V43, P903, DOI 10.1111/cup.12749	26	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					595	603		10.1097/PAS.0000000000000973			9	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500005	29635259				2019-10-28	
J	Cheng, CL; Su, YC; Chao, TY; Lin, CW; Chou, SC; Yao, M; Kuo, SH; Yu, SC				Cheng, Chieh-Lung; Su, Yung-Cheng; Chao, Tsu-Yi; Lin, Chung-Wu; Chou, Sheng-Chieh; Yao, Ming; Kuo, Sung-Hsin; Yu, Shan-Chi			Intralymphatic Spread is a Rare Finding Associated With Poor Prognosis in Diffuse Large B-Cell Lymphoma With Extranodal Involvements	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						intralymphatic spread; extranodal; diffuse large B-cell lymphoma; prognosis	NON-HODGKINS-LYMPHOMA; VEGF-C; CD30+T-CELL PROLIFERATION; INTRAVASCULAR LYMPHOMA; LYMPHATIC METASTASIS; LYMPHANGIOGENESIS; CLASSIFICATION; EXPRESSION; TRAFFICKING; MECHANISMS	Intralymphatic spread is common in solid cancers, but has been rarely studied in lymphomas. Review of 635 extranodal specimens from 475 diffuse large B-cell lymphoma (DLBCL) patients revealed intralymphatic spread in 10 surgical resection specimens from 10 patients including 9 de novo DLBCLs and 1 Richter transformation. The prevalence in de novo DLBCL with extranodal involvements was 1.65%. The most common involved site of intralymphatic spread was the gastrointestinal tract, followed by the female genital tract and breasts. Lymphatic vessels, lined by D2-40-positive endothelial cells, were expanded by lymphoma cells, reminiscent of intravascular lymphoma or tumor emboli. None of the involved lymphatic vessels were located in the mucosa. Patients with intralymphatic spread had a trend of lower overall response rate and a trend of higher progressive disease than those without intralymphatic spread. Compared with patients without intralymphatic spread, those patients with intralymphatic spread had a shorter median overall survival (14.3 vs. 96.2 mo; P = 0.004) and a shorter median progression-free survival (11.2 vs. 64.2 mo; P = 0.01), respectively. Multivariate analyses showed that intralymphatic spread was an independent poor prognostic factor for overall survival (hazard ratio, 3.029; 95% confidence interval, 1.315-6.978; P = 0.009), irrespective of the National Comprehensive Cancer Network-International Prognostic Index, B symptoms, and serum albumin levels. Among patients who underwent surgical resection, intralymphatic spread was still an independent prognostic factor. In conclusion, our study demonstrated extranodal intralymphatic spread in DLBCL. Inspiringly, this rare morphologic finding may serve as a new negative prognostic indicator in DLBCL with extranodal involvements.	[Cheng, Chieh-Lung; Chou, Sheng-Chieh; Yao, Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan; [Lin, Chung-Wu; Yu, Shan-Chi] Natl Taiwan Univ Hosp, Dept Pathol, Room 03-104,7 Chung Shan South Rd, Taipei 100, Taiwan; [Cheng, Chieh-Lung] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Yu, Shan-Chi] Taipei Med Univ, Coll Med, Grad Inst Microbiol, Taipei, Taiwan; [Su, Yung-Cheng] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Cheng, Chieh-Lung] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan; [Chao, Tsu-Yi] Taipei Med Univ, Inst Clin Res, Taipei, Taiwan; [Kuo, Sung-Hsin] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Kuo, Sung-Hsin] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Su, Yung-Cheng; Chao, Tsu-Yi] Taipei Med Univ, Shuang Ho Hosp, Dept Med, Div Hematol Oncol, New Taipei, Taiwan	Yu, SC (reprint author), Natl Taiwan Univ Hosp, Dept Pathol, Room 03-104,7 Chung Shan South Rd, Taipei 100, Taiwan.	b88401002@ntu.edu.tw		Cheng, Chieh-Lung/0000-0001-5442-1079	Department of Medical Research, National Taiwan University Hospital [105N-3211, UN106-016]	Supported by Department of Medical Research, National Taiwan University Hospital (105N-3211 and UN106-016). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Calamaro P, 2016, AM J DERMATOPATH, V38, P536, DOI 10.1097/DAD.0000000000000466; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Fan PY, 2017, J CUTAN PATHOL, V44, P616, DOI 10.1111/cup.12933; Ferrara G, 2015, AM J SURG PATHOL, V39, P1511, DOI 10.1097/PAS.0000000000000474; Fukunaga M, 2005, HISTOPATHOLOGY, V46, P396, DOI 10.1111/j.1365-2559.2005.02098.x; Gratzinger D, 2015, AM J DERMATOPATH, V37, P767, DOI 10.1097/DAD.0000000000000377; Gratzinger D, 2009, LEUKEMIA LYMPHOMA, V50, P311, DOI 10.1080/10428190902763525; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Jaffe ES, 2008, BLOOD, V112, P4384, DOI 10.1182/blood-2008-07-077982; Kadowaki I, 2005, BRIT J HAEMATOL, V130, P869, DOI 10.1111/j.1365-2141.2005.05695.x; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Kempf W, 2014, AM J CLIN PATHOL, V142, P694, DOI [10.1309/AJCPX0E61CJDOAJI, 10.1309/AJCPXOE61CJDOAJI]; Ma SP, 2012, ONCOL LETT, V4, P695, DOI 10.3892/ol.2012.817; Metcalf RA, 2013, AM J SURG PATHOL, V37, P617, DOI 10.1097/PAS.0b013e318280aa9c; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Park C, 2012, BLOOD, V119, P978, DOI 10.1182/blood-2011-06-364273; Paydas S, 2009, LEUKEMIA LYMPHOMA, V50, P366, DOI 10.1080/10428190802706665; Pazgal I, 2007, LEUKEMIA LYMPHOMA, V48, P2213, DOI 10.1080/10428190701632822; Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood-2004-07-2909; Samols MA, 2014, AM J SURG PATHOL, V38, P1203, DOI 10.1097/PAS.0000000000000217; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Swerdlow SH, 2017, WHO CLASSIFICATION T; Till KJ, 2014, INT J ONCOL, V45, P5, DOI 10.3892/ijo.2014.2395; Weingertner N, 2016, J CUTAN PATHOL, V43, P1036, DOI 10.1111/cup.12772; Xie Y, 2015, SEMIN HEMATOL, V52, P57, DOI 10.1053/j.seminhematol.2015.01.006; Zhou Z, 2014, BLOOD, V123, P837, DOI 10.1182/blood-2013-09-524108	31	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					616	624		10.1097/PAS.0000000000001045			9	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500007	29505426				2019-10-28	
J	Kudose, S; Hoshi, M; Jain, S; Gaut, JP				Kudose, Satoru; Hoshi, Masato; Jain, Sanjay; Gaut, Joseph P.			Renal Histopathologic Findings Associated With Severity of Clinical Acute Kidney Injury	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						kidney; acute kidney injury; acute tubular injury	ACUTE TUBULAR-NECROSIS; CRITICALLY-ILL PATIENTS; MOLECULE-1 KIM-1; ANIMAL-MODELS; FAILURE; NEPHROPATHY; MORPHOLOGY; DISEASE; ULTRASTRUCTURE; BIOPSIES	Acute kidney injury (AKI) is a significant cause of morbidity and mortality. Acute tubular injury is considered to be the early pathologic manifestation of AKI, however, the underlying pathology is complex, lacks standards for interpretation, and its relationship with AKI often is unclear or inconsistent. To clarify clinicopathologic correlations in AKI, we evaluated 32 histologic findings in 100 kidney biopsies from patients with AKI as a training set to correlate pathologic findings with clinical AKI grades. Kidney Injury Molecule-1 quantitative immunohistochemistry was performed to confirm tubular injury. A separate cohort of 50 biopsies were evaluated blinded to clinical information to validate the findings. Pathologic tubular injury correlated best with Kidney Disease Improving Global Outcomes criteria. Tubular epithelial simplification, tubular epithelial mitosis, and cell sloughing correlated well with clinically severe AKI and were used to construct a tubular injury classification scheme with sensitivity of 0.93 (0.85, 1), specificity of 0.95 (0.83, 1), and area under the receiver-operating characteristic curve of 0.98 (0.98, 1) for grades 2 to 3 AKI. Predictive ability of the model did not improve when Kidney Injury Molecule-1 immunostaining results were added. The results show a strong correlation between pathologic tubular injury and modern clinical definitions of AKI. The proposed classification scheme may aid in development of more precise and clinically meaningful interpretations of pathologic tubular injury in native kidney biopsies and provides simple pathologic criteria without special studies that can easily be adopted globally.	[Kudose, Satoru; Jain, Sanjay; Gaut, Joseph P.] Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA; [Hoshi, Masato; Jain, Sanjay; Gaut, Joseph P.] Washington Univ, Sch Med, Dept Internal Med, Nephrol, St Louis, MO 63110 USA	Gaut, JP (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	jpgaut@wustl.edu		Hoshi, Masato/0000-0003-2874-1807			Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Barisoni L, 2016, MODERN PATHOL, V29, P671, DOI 10.1038/modpathol.2016.58; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; BOHLE A, 1976, KIDNEY INT, V10, pS9; BRUN C, 1957, LANCET, V1, P603; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; Cerda J, 2015, CLIN J AM SOC NEPHRO, V10, P1859, DOI 10.2215/CJN.01170215; Chang A, 2012, CLIN J AM SOC NEPHRO, V7, P1365, DOI 10.1016/j.humpath.2012.04.009; FINCKH ES, 1962, Q J MED, V31, P429; Fliser D, 2012, NEPHROL DIAL TRANSPL, V27, P4263, DOI 10.1093/ndt/gfs375; Gadegbeku CA, 2013, KIDNEY INT, V83, P749, DOI 10.1038/ki.2012.428; Gelman A, 2008, ANN APPL STAT, V2, P1360, DOI 10.1214/08-AOAS191; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; HARMAN JW, 1949, ARCH PATHOL, V47, P29; Heung M, 2014, NEPHRON CLIN PRACT, V127, P30, DOI 10.1159/000363675; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Improving Global Outcomes (KDIGO) Acute Kid-ney Injury Work Group, 2012, KIDNEY INT S, V2, P1, DOI DOI 10.1038/kisup.2012.1; Kellum JA, 2015, CRIT CARE CLIN, V31, P621, DOI 10.1016/j.ccc.2015.06.001; Kuhn M, 2008, J STAT SOFTW, V28, P1; Larsen CP, 2015, MODERN PATHOL, V28, P95, DOI 10.1038/modpathol.2014.92; Liangos O, 2006, CLIN J AM SOC NEPHRO, V1, P43, DOI 10.2215/CJN.00220605; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Marcussen N, 1996, TRANSPLANT P, V28, P470; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; NADASDY T, 1995, HUM PATHOL, V26, P230, DOI 10.1016/0046-8177(95)90042-X; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; Nast CC, 2015, SEMIN NEPHROL, V35, P266, DOI 10.1016/j.semnephrol.2015.04.006; OLIVER J, 1951, J CLIN INVEST, V30, P1307, DOI 10.1172/JCI102550; OLSEN S, 1989, MEDICINE, V68, P173, DOI 10.1097/00005792-198905000-00005; OLSEN TS, 1985, VIRCHOWS ARCH A, V406, P75; OLSEN TS, 1967, ACTA PATHOL MIC SC, V71, P203; OLSEN TS, 1985, VIRCHOWS ARCH A, V406, P91; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Palevsky PM, 2009, NEW ENGL J MED, V361, P1699, DOI 10.1056/NEJMe0907831; Racusen L C, 1997, Adv Ren Replace Ther, V4, P3; RACUSEN LC, 1991, LAB INVEST, V64, P546; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rosen S, 2001, KIDNEY INT, V60, P1220, DOI 10.1046/j.1523-1755.2001.00930.x; SOLEZ K, 1993, KIDNEY INT, V43, P1058, DOI 10.1038/ki.1993.148; Solez K, 2001, CONTRIB NEPHROL, V132, P68; SOLEZ K, 1974, KIDNEY INT, V6, P24, DOI 10.1038/ki.1974.74; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; Takasu O, 2013, AM J RESP CRIT CARE, V187, P509, DOI 10.1164/rccm.201211-1983OC; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Uchino S, 2007, INTENS CARE MED, V33, P1563, DOI 10.1007/s00134-007-0754-4; van Timmeren MM, 2007, J PATHOL, V212, P209, DOI 10.1002/path.2175; van Timmeren MM, 2007, TRANSPLANTATION, V84, P1625, DOI 10.1097/01.tp.0000295982.78039.ef; van Timmeren MM, 2006, AM J PHYSIOL-RENAL, V291, pF456, DOI 10.1152/ajprenal.00403.2005; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zhang PL, 2008, KIDNEY INT, V73, P608, DOI 10.1038/sj.ki.5002697	52	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					625	635		10.1097/PAS.0000000000001028			11	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500008	29537990				2019-10-28	
J	Makise, N; Sekimizu, M; Kubo, T; Wakai, S; Hiraoka, N; Komiyama, M; Fukayama, M; Kawai, A; Ichikawa, H; Yoshida, A				Makise, Naohiro; Sekimizu, Masaya; Kubo, Takashi; Wakai, Susumu; Hiraoka, Nobuyoshi; Komiyama, Motokiyo; Fukayama, Masashi; Kawai, Akira; Ichikawa, Hitoshi; Yoshida, Akihiko			Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						malignant peripheral nerve sheath tumor; dedifferentiated liposarcoma; MDM2; H3K27me3; heterologous differentiation	METAPLASTIC BONE-FORMATION; MENINGOTHELIAL-LIKE WHORLS; IN-SITU HYBRIDIZATION; FIBROUS HISTIOCYTOMAS; MDM2 AMPLIFICATION; CDK4; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; P16; EXPRESSION	Malignant peripheral nerve sheath tumor (MPNST) and dedifferentiated liposarcoma (DDLPS) are 2 major types of pleomorphic spindle cell sarcoma. The differentiation of MPNST and DDLPS by histomorphology alone can be problematic. Although MDM2 amplification and PRC2 alteration leading to H3K27me3 deficiency are genetic hallmarks of DDLPS and MPNST, respectively, a small number of MDM2-amplified MPNSTs and H3K27me3-deficient DDLPSs have been reported in the literature. We systematically compared MDM2 and H3K27me3 status in 68 MPNSTs and 47 DDLPSs. Of the 62 MPNSTs, 22 were immunopositive for MDM2, mostly in a weak and/or focal manner. Of the 21 MDM2-positive MPNSTs successfully tested by fluorescence in situ hybridization, high-level MDM2 amplification was observed in 1 case. In contrast, MDM2 staining and high-level MDM2 amplification were positive in all the DDLPS tested (28/28 and 20/20). Of the 68 MPNSTs, 42 cases (62%) exhibited complete loss of H3K27me3. All the 13 MPNSTs that showed heterologous differentiation were deficient in H3K27me3. Of the 47 DDLPSs, 3 cases (6%) had complete loss of H3K27me3, all of which exhibited heterologous differentiation. One case of H3K27me3-deficient DDLPS exhibited homozygous loss of EED according to targeted next-generation sequencing, whereas there were no alterations in NF1 and CDKN2A. In conclusion, high-level MDM2 amplification strongly suggests DDLPS over MPNST. Although a good marker for MPNST, H3K27me3 deficiency also uncommonly occurs in DDLPS in association with PRC2 mutational inactivation. Because both markers are imperfectly specific, rare sarcomas with dual features could be encountered, and their classification should integrate other parameters.	[Makise, Naohiro; Wakai, Susumu; Hiraoka, Nobuyoshi; Yoshida, Akihiko] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan; [Komiyama, Motokiyo] Natl Canc Ctr, Dept Urol, Tokyo, Japan; [Kawai, Akira] Natl Canc Ctr, Dept Musculoskeleltal Oncol, Tokyo, Japan; [Komiyama, Motokiyo; Kawai, Akira; Yoshida, Akihiko] Natl Canc Ctr, Rare Canc Ctr, Tokyo, Japan; [Makise, Naohiro; Fukayama, Masashi] Univ Tokyo, Dept Pathol, Tokyo, Japan; [Sekimizu, Masaya; Ichikawa, Hitoshi] Natl Canc Ctr, Res Inst, Dept Clin Genom, Tokyo, Japan; [Kubo, Takashi; Ichikawa, Hitoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Genom, Tokyo, Japan	Yoshida, A (reprint author), Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	akyoshid@ncc.go.jp			AMEDJapan Agency for Medical Research and Development (AMED) [17ck0106168h0003]; National Cancer Center Research and Development FundNational Cancer Center - Japan [26-A-9]; JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K19065]	Supported in part by AMED (17ck0106168h0003, A.Y.), the National Cancer Center Research and Development Fund (26-A-9, A.Y.), and JSPS Grant-in-Aid for Young Scientists (15K19065, A.Y.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Aleixo PB, 2009, J CLIN PATHOL, V62, P1127, DOI 10.1136/jcp.2009.070201; [Anonymous], 2012, CBIOPORTAL CANC GEN; Asano N, 2017, ONCOTARGET, V8, P12941, DOI 10.18632/oncotarget.14652; Asano N, 2017, HISTOPATHOLOGY, V70, P385, DOI 10.1111/his.13072; Binh MBN, 2007, AM J SURG PATHOL, V31, P1557, DOI 10.1097/PAS.0b013e31804b4109; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Chung L, 2009, AM J SURG PATHOL, V33, P1594, DOI 10.1097/PAS.0b013e3181accb01; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Coindre JM, 2004, J PATHOL, V203, P822, DOI 10.1002/path.1579; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Evans HL, 2007, AM J SURG PATHOL, V31, P1, DOI 10.1097/01.pas.0000213406.95440.7a; Fanburg-Smith JC, 1998, HISTOPATHOLOGY, V33, P414, DOI 10.1046/j.1365-2559.1998.00536.x; Fletcher C, 2013, WHO CLASSIFICATION T; Hasegawa T, 2000, HUM PATHOL, V31, P717, DOI 10.1053/hupa.2000.8222; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Italiano A, 2009, CLIN CANCER RES, V15, P5696, DOI 10.1158/1078-0432.CCR-08-3185; Kammerer-Jacquet SF, 2017, HUM PATHOL, V59, P34, DOI 10.1016/j.humpath.2016.08.009; Kang Y, 2017, APPL IMMUNOHISTO M M, V25, P58, DOI 10.1097/PAI.0000000000000270; Le Guellec S, 2016, AM J SURG PATHOL, V40, P896, DOI 10.1097/PAS.0000000000000655; Le Guellec S, 2014, AM J SURG PATHOL, V38, P293, DOI 10.1097/PAS.0000000000000131; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Makise N, 2017, AM J SURG PATHOL, V41, P1523, DOI 10.1097/PAS.0000000000000910; Mastrangelo G, 2012, CANCER-AM CANCER SOC, V118, P5339, DOI 10.1002/cncr.27555; Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398; Nascimento AG, 1998, AM J SURG PATHOL, V22, P945, DOI 10.1097/00000478-199808000-00004; Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Thway K, 2012, AM J SURG PATHOL, V36, P462, DOI 10.1097/PAS.0b013e3182417330; Thway K, 2011, AM J SURG PATHOL, V35, P356, DOI 10.1097/PAS.0b013e31820832c1; Wallander ML, 2012, ARCH PATHOL LAB MED, V136, P95, DOI 10.5858/arpa.2010-0729-OA; Weaver J, 2008, MODERN PATHOL, V21, P943, DOI 10.1038/modpathol.2008.84; Yu JS, 2011, CLIN CANCER RES, V17, P1924, DOI 10.1158/1078-0432.CCR-10-1551; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116	37	9	11	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					656	664		10.1097/PAS.0000000000001014			9	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500011	29309298				2019-10-28	
J	Rooper, LM; Bishop, JA; Westra, WH				Rooper, Lisa M.; Bishop, Justin A.; Westra, William H.			INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						head and neck tumors; neuroendocrine tumors; INSM1; immunohistochemistry; surgical pathology	INSULINOMA-ASSOCIATED PROTEIN-1; SINONASAL TRACT; LUNG-CANCER; ABERRANT EXPRESSION; CELL-CARCINOMA; NEOPLASMS; DIAGNOSIS; IA-1; LARYNX; CHROMOGRANIN	The head and neck is the site of a wide and sometimes bewildering array of neuroendocrine (NE) tumors. Although recognition of NE differentiation may be necessary for appropriate tumor classification and treatment, traditional NE markers such as synaptophysin, chromogranin, and CD56 are not always sufficiently sensitive or specific to make this distinction. Insulinoma-associated protein 1 (INSM1) is a novel transcription factor that has recently demonstrated excellent sensitivity and specificity for NE differentiation in various anatomic sites, but has not yet been extensively evaluated in tumors of the head and neck. We performed INSM1 immunohistochemistry on NE tumors (n = 97) and non-NE tumors (n = 626) across all histologic grades and anatomic subsites of the head and neck. INSM1 was positive in all types of head and neck NE tumors evaluated here (99.0% sensitivity), including middle ear adenoma, pituitary adenoma, paraganglioma, medullary thyroid carcinoma, olfactory neuroblastoma, small cell carcinoma, large cell NE carcinoma, and sinonasal teratocarcinosarcoma. Notably, it was positive in the vast majority of high-grade NE malignancies (95.8% sensitivity). INSM1 also was negative in almost all non-NE tumors (97.6% specificity) with the highest rates of reactivity in alveolar rhabdomyosarcoma and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1 (SMARCB1)-deficient sinonasal carcinoma. These findings confirm that INSM1 may be used as a standalone first-line marker of NE differentiation for tumors of the head and neck.	[Rooper, Lisa M.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Westra, William H.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA	Rooper, LM (reprint author), Johns Hopkins Med Inst, Dept Pathol, 401 N Broadway,Weinberg 2242, Baltimore, MD 21231 USA.	rooper@jhmi.edu		Rooper, Lisa/0000-0001-5636-9753	Joseph C. Eggleston Award in Surgical Pathology at The Johns Hopkins Hospital	Supported by the Joseph C. Eggleston Award in Surgical Pathology at The Johns Hopkins Hospital. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Bahrami A, 2008, MODERN PATHOL, V21, P795, DOI 10.1038/modpathol.2008.86; Bell D, 2016, HEAD NECK-J SCI SPEC, V38, pE2259, DOI 10.1002/hed.24152; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Breslin MB, 2002, NUCLEIC ACIDS RES, V30, P1038, DOI 10.1093/nar/30.4.1038; FERLITO A, 1991, ORL J OTO-RHINO-LARY, V53, P235, DOI 10.1159/000276222; Ferlito A, 2011, EUR ARCH OTO-RHINO-L, V268, P1247, DOI 10.1007/s00405-011-1666-z; Fujino K, 2015, AM J PATHOL, V185, P3164, DOI 10.1016/j.ajpath.2015.08.018; Ghosh R, 2015, OTOLARYNG HEAD NECK, V153, P966, DOI 10.1177/0194599815594386; Gierl MS, 2006, GENE DEV, V20, P2465, DOI 10.1101/gad.381806; GOTO Y, 1992, J BIOL CHEM, V267, P15252; ITO K, 1990, ACTA PATHOL JAPON, V40, P279; Khan A, 2003, ENDOCR PATHOL, V14, P249, DOI 10.1007/s12022-003-0017-z; Kuji S, 2017, GYNECOL ONCOL, V144, P384, DOI 10.1016/j.ygyno.2016.11.020; Kulke MH, 2015, J NATL COMPR CANC NE, V13, P78, DOI 10.6004/jnccn.2015.0011; Lan MS, 2009, FASEB J, V23, P2024, DOI 10.1096/fj.08-125971; LAN MS, 1993, CANCER RES, V53, P4169; Lee H, 2011, APPL IMMUNOHISTO M M, V19, P48, DOI 10.1097/PAI.0b013e3181ee8dcb; Lewis JS, 2011, LARYNGOSCOPE, V121, P1187, DOI 10.1002/lary.21790; Lewis JS, 2017, HEAD NECK PATHOL; NELSON RS, 1995, HUM PATHOL, V26, P639, DOI 10.1016/0046-8177(95)90169-8; Rinaldo A, 2004, ACTA OTO-LARYNGOL, V124, P638, DOI 10.1080/00016480410016540; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Rooper Lisa M, 2017, Surg Pathol Clin, V10, P103, DOI 10.1016/j.path.2016.10.005; Rosenbaum JN, 2015, AM J CLIN PATHOL, V144, P579, DOI 10.1309/AJCPGZWXXBSNL4VD; Rosenbaum JN, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-6; Roy S, 2009, HEAD NECK PATHOL, V3, P163, DOI 10.1007/s12105-009-0114-5; Satoh F, 2001, ENDOCR PATHOL, V12, P291, DOI 10.1385/EP:12:3:291; Schartinger VH, 2012, J LARYNGOL OTOL, V126, P1261, DOI 10.1017/S0022215112002265; Schwartz LE, 2013, HEAD NECK PATHOL, V7, P311, DOI 10.1007/s12105-013-0442-3; Serrano MF, 2008, HUM PATHOL, V39, P591, DOI 10.1016/j.humpath.2007.08.019; Shah K, 2016, HEAD NECK PATHOL, V10, P85, DOI 10.1007/s12105-016-0696-7; SOUSSI AC, 1990, J LARYNGOL OTOL, V104, P504, DOI 10.1017/S0022215100113015; Tanigawa M, 2017, MED MOL MORPHOL; Taniwaki M, 2006, INT J ONCOL, V29, P567; Thompson LDR, 2017, HEAD NECK PATHOL; Tomita T, 1999, ENDOCR PATHOL, V10, P145, DOI 10.1007/BF02739826; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335	40	19	20	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					665	671		10.1097/PAS.0000000000001037			7	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500012	29438167				2019-10-28	
J	Makela, K; Hodgson, U; Piilonen, A; Kelloniemi, K; Bloigu, R; Sutinen, E; Salmenkivi, K; Ronty, M; Lappi-Blanco, E; Myllarniemi, M; Kaarteenaho, R				Makela, Kati; Hodgson, Ulla; Piilonen, Anneli; Kelloniemi, Katariina; Bloigu, Risto; Sutinen, Eva; Salmenkivi, Kaisa; Roenty, Mikko; Lappi-Blanco, Elisa; Myllaerniemi, Marjukka; Kaarteenaho, Riitta			Analysis of the Histologic Features Associated With Interobserver Variation in Idiopathic Pulmonary Fibrosis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						idiopathic pulmonary fibrosis; usual interstitial pneumonia; histology; survival; interobserver agreement	USUAL INTERSTITIAL PNEUMONIA; CHRONIC HYPERSENSITIVITY PNEUMONITIS; PROGNOSTIC-SIGNIFICANCE; COMPUTED-TOMOGRAPHY; DIAGNOSIS; AGREEMENT; PATTERN; ACCURACY; DISEASE; BIOPSY	The histologic manifestation of idiopathic pulmonary fibrosis (IPF) is usual interstitial pneumonia (UIP), which is a good prognostic determinant of survival compared with other histologic interstitial lung disease patterns. According to the current international guidelines, the histologic features of suspected IPF/UIP are divided into 4 categories: UIP, probable UIP, possible UIP, and not UIP pattern. Four pulmonary pathologists who were blinded to clinicoradiologic information reevaluated 50 surgical lung biopsies (83.3%), 6 lung explant (10.0%), and 4 autopsy samples (6.7%) from the FinnishIPF registry (N = 60) using the current diagnostic guidelines. Additional histologic features atypical for UIP were also evaluated and compared with clinicora-diologic information. The interobserver agreement of pathologists was examined by Cohen kappa (kappa) coefficient; the survival of the patients was estimated with Kaplan-Meier curves. The histologic reevaluation indicated that 38 of 60 patients (63.3%) had definite UIP. Inflammation was the most common additional histologic finding (15/60, 25.0%). The interobserver agreement on histologic diagnosis ranged from slight (kappa = 0.044) to substantial (kappa = 0.779). The interobserver agreement varied extensively with regard to the presence of giant cells. The observed histologic features displayed no association with radiologic patterns or survival. Definite UIP and honeycombing findings in high-resolution computed tomography correlated with poor prognosis. A high level of interobserver variability was observed between pathologists, even in this well-defined cohort of IPF patients, which highlights the importance of multidisciplinary decision making in IPF diagnostics and stresses the need for a reassessment of the histologic criteria.	[Makela, Kati; Hodgson, Ulla; Sutinen, Eva; Myllaerniemi, Marjukka] Univ Helsinki, Heart & Lung Ctr, Helsinki, Finland; [Piilonen, Anneli; Kelloniemi, Katariina] Univ Helsinki, HUS Med Imaging Ctr, Radiol, Helsinki, Finland; [Piilonen, Anneli; Kelloniemi, Katariina] Helsinki Univ Hosp, Helsinki, Finland; [Salmenkivi, Kaisa] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Roenty, Mikko] Univ Helsinki, Helsinki, Finland; [Salmenkivi, Kaisa] Helsinki Univ Hosp, HUSLAB, Helsinki, Finland; [Bloigu, Risto] Univ Oulu, Med Informat & Stat Res Grp, Oulu, Finland; [Lappi-Blanco, Elisa] Univ Oulu, Inst Diagnost, Dept Pathol, Oulu, Finland; [Kaarteenaho, Riitta] Univ Oulu, Res Unit Internal Med, Resp Dis, Oulu, Finland; [Lappi-Blanco, Elisa] Oulu Univ Hosp, Dept Pathol, Oulu, Finland; [Kaarteenaho, Riitta] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland; [Roenty, Mikko] Fimlab Labs, Tampere, Finland	Makela, K (reprint author), Haartman Inst, Transplantat Lab, Pulm Dis, B410b,Haartmaninkatu 3, FI-00290 Helsinki, Finland.	kati.makela@helsinki.fi		Makela, Kati/0000-0002-6065-3527; Myllarniemi, L Marjukka/0000-0001-9343-0867	Foundation of the Finnish Anti-Tuberculosis Association; Research Foundation of the Pulmonary Diseases; Vaino and Laina Kivi Foundation; University of Helsinki; Bio-medicum Helsinki Foundation; Boehringer IngelheimBoehringer Ingelheim; Chiesi; RocheRoche Holding; Oy Eli Lilly Finland; PfizerPfizer; Astra ZenecaAstraZeneca; BMSBristol-Myers Squibb; MSD; Sigrid Juselius FoundationSigrid Juselius Foundation; Academy of FinlandAcademy of Finland; Orion; GSKGlaxoSmithKline; Health Care Foundation of North Finland; Kuopio University Hospital; Oulu University Hospital	K.M. has received grants from the Foundation of the Finnish Anti-Tuberculosis Association, the Research Foundation of the Pulmonary Diseases, the Vaino and Laina Kivi Foundation, the University of Helsinki, and the Bio-medicum Helsinki Foundation. U.H. has received congress and meeting travel costs from Boehringer Ingelheim, Chiesi, and Roche, and lecture fees from Boehringer Ingelheim and Roche. E.L.-B. has received grants from the Foundation of the Finnish Anti-Tuberculosis Association, lecture fees from Oy Eli Lilly Finland, Pfizer, and Roche, congress and meeting travel costs from Astra Zeneca, Roche, BMS, and MSD, and advisory board fees from Pfizer and Roche. M.M. has received grants for the FinnishIPF study from Sigrid Juselius Foundation and the Academy of Finland, Roche, and Boehringer Ingelheim. R.K. has received congress and meeting travel costs from Roche, Boehringer Ingelheim, and Orion, a lecture fee from Roche, an advisory board fee from GSK, and grants for the research group from the Foundation of the Finnish Anti-Tuberculosis Association, the Research Foundation of the Pulmonary Diseases, the Health Care Foundation of North Finland, and state subsidies of the Kuopio and Oulu University Hospitals. For the remaining authors none were declared.	Aalokken TM, 2012, ACTA RADIOL, V53, P296, DOI 10.1258/ar.2011.110482; Akashi T, 2009, AM J CLIN PATHOL, V131, P405, DOI 10.1309/AJCPNWX4SLZRP9SW; American Thoracic Society, 2002, Am J Respir Crit Care Med, V165, P277; Balestro E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154516; Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; Casoni GL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086716; Castonguay MC, 2015, HUM PATHOL, V46, P607, DOI 10.1016/j.humpath.2014.12.017; Chiba S, 2016, CHEST, V149, P1473, DOI 10.1016/j.chest.2015.12.030; Chung JH, 2015, CHEST, V147, P450, DOI 10.1378/chest.14-0976; Churg A, 2006, AM J SURG PATHOL, V30, P201, DOI 10.1097/01.pas.0000184806.38037.3c; Collard HR, 2007, HISTOPATHOLOGY, V50, P258, DOI 10.1111/j.1365-2559.2006.02554.x; Flaherty KR, 2003, THORAX, V58, P143, DOI 10.1136/thorax.58.2.143; Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P1722, DOI 10.1164/ajrccm.164.9.2103074; Hashisako M, 2016, ARCH PATHOL LAB MED, V140, P1375, DOI 10.5858/arpa.2016-0012-OA; Hunninghake GW, 2001, AM J RESP CRIT CARE, V164, P193, DOI 10.1164/ajrccm.164.2.2101090; Katzenstein ALA, 2002, AM J SURG PATHOL, V26, P1567, DOI 10.1097/00000478-200212000-00004; Kaunisto J, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0074-3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Loveman E, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-63; Lynch D. A., 2017, LANCET RESP MED; Monaghan H, 2004, CHEST, V125, P522, DOI 10.1378/chest.125.2.522; Moua T, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0154-6; Nicholson AC, 2000, AM J RESP CRIT CARE, V162, P2213, DOI 10.1164/ajrccm.162.6.2003049; Nicholson AG, 2004, THORAX, V59, P500, DOI 10.1136/thx.2003.011734; Rabeyrin M, 2015, ANN DIAGN PATHOL, V19, P269, DOI 10.1016/j.anndiagpath.2015.05.003; Raghu G, 1999, CHEST, V116, P1168, DOI 10.1378/chest.116.5.1168; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Romei C, 2015, RADIOL MED, V120, P930, DOI 10.1007/s11547-015-0526-0; Schettino IAL, 2002, PATHOL RES PRACT, V198, P347, DOI 10.1078/0344-0338-00265; Sumikawa H, 2008, AM J RESP CRIT CARE, V177, P433, DOI 10.1164/rccm.200611-1696OC; Sumikawa H, 2014, RADIOLOGY, V272, P549, DOI 10.1148/radiol.14130853; Takemura T, 2012, HISTOPATHOLOGY, V61, P1026, DOI 10.1111/j.1365-2559.2012.04322.x; Taniguchi H, 2010, EUR RESPIR J, V35, P821, DOI 10.1183/09031936.00005209; Thomeer M, 2008, EUR RESPIR J, V31, P585, DOI 10.1183/09031936.00063706; Tomassetti S, 2016, AM J RESP CRIT CARE, V193, P745, DOI 10.1164/rccm.201504-0711OC; Tomassetti S, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-96; Walsh SLF, 2016, THORAX, V71, P45, DOI 10.1136/thoraxjnl-2015-207252; Yagihashi K, 2016, EUR RESPIR J, V47, P1189, DOI 10.1183/13993003.01680-2015; Yamauchi H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166168	40	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					672	678		10.1097/PAS.0000000000001031			7	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500013	29438171				2019-10-28	
J	Guilbert, MC; Overmoyer, B; Lester, SC				Guilbert, Marie-Christine; Overmoyer, Beth; Lester, Susan C.			Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy A Rare Pattern of Residual Breast Carcinoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						lymph-vascular invasion; intralymphatic carcinoma; neoadjuvant treatment of breast cancer; residual carcinoma after neoadjuvant treatment	LYMPH-NODE STATUS; PATHOLOGICAL COMPLETE RESPONSE; CANCER PATIENTS; CLINICAL-TRIALS; TUMOR SIZE; CHEMOTHERAPY; SURVIVAL; RECOMMENDATIONS; DISEASE; RADIOTHERAPY	Rarely is intralymphatic/lymph-vascular invasion (LVI) the only residual disease in the breast after neoadjuvant chemotherapy. Only 12 patients have been reported in 2 prior studies. Prognosis was poor, with only 2 patients remaining alive and disease-free. The purpose of this study was to gather more data on this pattern of residual disease. Cases in which LVI was the only residual disease in the breast were retrospectively identified. Eighteen cases were identified including 10 of 669 (1.5%) consecutive surgical cases between 2003 and 2015. The mean tumor size was 3.4 cm. Seven cancers were negative for estrogen receptor and HER2, 8 were HER2 positive, and 3 were estrogen receptor positive and HER2 negative. In 15 cases, lymph nodes were either suspicious by imaging or proven positive by biopsy. After neoadjuvant chemotherapy, 9 patients were node negative, 7 were node positive, and 2 had isolated tumor cells. Mean follow-up was 63.8 months (7 to 138 mo). Two deaths occurred in patients with positive nodes. One death occurred and 2 patients are alive with metastatic disease in the node-negative group. The remaining 13 patients are alive without disease. The outcome associated with residual LVI might not be as dismal as previously reported. Although the better outcome may be due to stage at presentation or the type of chemotherapy, it is difficult to compare the cohorts of the 3 studies. However, the death of 3 of 13 node-negative patients over the 3 studies supports not classifying residual LVI as a pathologic complete response.	[Guilbert, Marie-Christine; Lester, Susan C.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Overmoyer, Beth] Dana Farber Canc Inst, Susan F Smith Ctr Womens Canc, Boston, MA 02115 USA; [Guilbert, Marie-Christine] Maisonneuve Rosemont Hosp, Dept Pathol, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada	Guilbert, MC (reprint author), Maisonneuve Rosemont Hosp, Dept Pathol, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	mc.guilbert@umontreal.ca					Abe O, 2005, LANCET, V366, P2087; [Anonymous], 2017, AJCC CANC STAGING MA; Beenken SW, 2003, ANN SURG, V237, P732, DOI 10.1097/00000658-200305000-00016; Bossuyt V, 2015, ANN ONCOL, V26, P1280, DOI 10.1093/annonc/mdv161; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Cheng E, 2017, AM J SURG PATHOL, V41, P1275, DOI 10.1097/PAS.0000000000000896; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Hance KW, 2005, JNCI-J NATL CANCER I, V97, P966, DOI 10.1093/dji172; Hennessy BT, 2005, J CLIN ONCOL, V23, P9304, DOI 10.1200/JCO.2005.02.5023; Jeruss JS, 2008, J CLIN ONCOL, V26, P246, DOI 10.1200/JCO.2007.11.5352; Klauber-DeMore N, 2006, ANN SURG ONCOL, V13, P685, DOI 10.1245/ASO.2006.03.010; Liu YL, 2016, BREAST CANCER RES TR, V157, P555, DOI 10.1007/s10549-016-3837-5; Loya A, 2009, CANCER-AM CANCER SOC, V115, P1605, DOI 10.1002/cncr.24173; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Rabban JT, 2009, AM J SURG PATHOL, V33, P256, DOI 10.1097/PAS.0b013e31817fbdb4; Rakha EA, 2012, CANCER-AM CANCER SOC, V118, P3670, DOI 10.1002/cncr.26711; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Recht A, 2016, PRACT RADIAT ONCOL, V6, pE219, DOI 10.1016/j.prro.2016.08.009; ROSEN PP, 1983, PATHOL ANNU, V18, P215; Sahoo S, 2009, ARCH PATHOL LAB MED, V133, P633, DOI 10.1043/1543-2165-133.4.633; Sakakibara M, 2009, ANN SURG ONCOL, V16, P2470, DOI 10.1245/s10434-009-0612-4; Saxena N, 2011, EUR J CANCER, V47, P1186, DOI 10.1016/j.ejca.2010.12.009; Symmans WF, 2017, J CLIN ONCOL, V35, P1049, DOI 10.1200/JCO.2015.63.1010; van Nijnatten TJA, 2017, BREAST CANCER RES TR, V163, P159, DOI 10.1007/s10549-017-4157-0; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; Wolmark N, 2001, J Natl Cancer Inst Monogr, P96; Zhang GC, 2013, CURR ONCOL, V20, pE180, DOI 10.3747/co.20.1294	29	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					679	686		10.1097/PAS.0000000000001029			8	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500014	29394169				2019-10-28	
J	Gagne, A; Enlow, W; Pigeon, MA; Orain, M; Turcotte, S; Bosse, Y; Joubert, P				Gagne, Andreanne; Enlow, William; Pigeon, Marc-Antoine; Orain, Michele; Turcotte, Stephane; Bosse, Yohan; Joubert, Philippe			Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays Impact of the Architecture Pattern and the Number of Cores	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						lung adenocarcinoma; PD-L1; staining heterogeneity	CELL LUNG-CANCER; DEATH-LIGAND 1; SQUAMOUS-CELL; CLINICOPATHOLOGICAL ANALYSIS; SMALL BIOPSY; EXPRESSION; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; CARCINOMA; NIVOLUMAB	Checkpoint inhibitors directed against programmed death receptor 1 (PD-1) and its ligand (PD-L1) changed the treatment of advanced lung non-small cell carcinomas. The decision to treat patients is influenced by PD-L1 expression by tumor cells, but evidence indicates that this staining is heterogenous within a tumor. As PD-L1 staining is tested mostly on biopsies, false negative results can occur due to sampling issues. The clinical impact of this heterogeneity has not been established. We selected 241 patients who underwent pulmonary resection for adenocarcinoma. Tissue microarrays were constructed with five 1 mm cores representative of the histologic patterns observed in each tumor and stained for PD-L1. For each core, the histologic pattern and the percentage of PD-L1 positive tumor cells were noted. Staining heterogeneity was defined as cases with both positive and negative cores at positivity thresholds of 1%, 10%, and 50% of tumor cells. At the 50% cut-off, 37.8% of patients were PD-L1 positive, whereas 22.4% showed staining heterogeneity. Among patients with 1 negative core, 26.5% also had a positive core and could have been misclassified based on 1 biopsy. Mean staining of PD-L1 was higher in solid (47.9%) and micropapillary (24.2%) patterns and was lower in acinar (14.1%), papillary (3.4%), and lepidic (6.4%) architectures. A significant proportion of patients presented a heterogenous staining for PD-L1. A total of 26.5% of patients negative on 1 core turned out to be positive on another core, which raises the consideration of rebiopsy, in particular when lepidic, acinar, or papillary patterns are observed on a biopsy.	[Gagne, Andreanne; Enlow, William; Pigeon, Marc-Antoine; Orain, Michele; Bosse, Yohan; Joubert, Philippe] Quebec City Heart & Lung Inst Res Ctr, Quebec City, PQ, Canada; [Turcotte, Stephane] Ctr Hosp Univ Quebec Res Ctr, Evaluat & Clin Res Platform, Quebec City, PQ, Canada; [Bosse, Yohan] Laval Univ, Dept Mol Med, Quebec City, PQ, Canada; [Joubert, Philippe] Laval Univ, Dept Mol Biol, Med Biochem & Pathol, Quebec City, PQ, Canada	Joubert, P (reprint author), Inst Univ Cardiol & Pneumol Quebec, Quebec Heart & Lung Inst, Dept Pathol, Pavillon Cent,Porte C2259,2725 Chemin St Foy, Quebec City, PQ G1V 4G5, Canada.	philippe.joubert.1@ulaval.ca		Gagne, Andreanne/0000-0002-3833-4159			[Anonymous], 2017, FOOD DRUG ADM PEMBRO; [Anonymous], 2015, FOOD DRUG ADM FDA EX; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Cell Signaling Technology, 2017, PD L1 E1L3N XP RABB; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Gniadek TJ, 2017, MODERN PATHOL, V30, P530, DOI 10.1038/modpathol.2016.213; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Howlader N, 2016, SEER CANC STAT REV 1; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; Kasper D, 2015, HARRISONS PRINCIPLES; Kerr KM, 2016, ARCH PATHOL LAB MED, V140, P249, DOI 10.5858/arpa.2015-0303-SA; Kerr KM, 2015, J THORAC ONCOL, V10, P985, DOI 10.1097/JTO.0000000000000526; Kim MY, 2015, LUNG CANCER, V88, P24, DOI 10.1016/j.lungcan.2015.01.016; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Koh J, 2015, MODERN PATHOL, V28, P1154, DOI 10.1038/modpathol.2015.63; Mansfield AS, 2016, ANN ONCOL, V27, P1953, DOI 10.1093/annonc/mdw289; Mansfield AS, 2016, CLIN CANCER RES, V22, P2177, DOI 10.1158/1078-0432.CCR-15-2246; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pinato DJ, 2016, ONCOIMMUNOLOGY, V5, P2162; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Tsao MS, 2017, IASLC ATLAS PD L1 IM	28	8	8	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					687	694		10.1097/PAS.0000000000001013			8	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500015	29309297				2019-10-28	
J	Agaimy, A; Moskalev, EA; Weisser, W; Bach, T; Haller, F; Hartmann, A				Agaimy, Abbas; Moskalev, Evgeny A.; Weisser, Wera; Bach, Thorsten; Haller, Florian; Hartmann, Arndt			Low-grade Endometrioid Stromal Sarcoma of the Paratestis A Novel Report With Molecular Confirmation of JAZF1/SUZ12 Translocation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Mullerian cystadenoma; ovarian-like stroma; paratestis; epididymis; rete testis; endometrioid stromal sarcoma; JAZF1/SUZ12 translocation	CELL TUMORS; OVARIAN; TESTIS; FUSION; CYSTADENOMA; GENERATION; NEOPLASMS; TISSUE; SERIES; GENES	Tumors with Mullerian-like serous or mucinous phenotypes originating in the testis and its adnexa are rare neoplasms that have been increasingly recognized in recent years. Cystadenomas with or without ovarian-type stroma, borderline tumors, and adenocarcinomas are the main documented types. Although a handful cases of putative endometrioid adenocarcinomas have been reported, to our knowledge no case of endometrial stromal-type neoplasm has ever been reported in the literature. A 59-year-old man presented with a 2 cm left intrascrotal mass that was found on sonographic examination to arise from the epididymal tail with prominent vascularization. He was otherwise healthy without significant clinical history, endocrinopathy, or external hormone therapy. His testicular tumor markers (beta-HCG, AFP) were normal. Histologic examination of the resection showed a multinodular tumor closely associated with the epididymis and composed of monotonous rounded to ovoid cells with scanty cytoplasm and prominent spiral-like arterioles and capillaries. Mitotic activity was high. No other tumor component was seen. Immunohistochemistry revealed strong and diffuse expression of vimentin, CD10, estrogen receptor, and progesterone receptor. Molecular examination (performed on paraffin-embedded tumor tissue using a 517 gene fusion next-generation sequencing assay) showed a JAZF1/SUZ12 translocation, which was then confirmed by fluorescence in situ hybridization (FISH). These findings are consistent with a low-grade endometrioid stromal sarcoma originating in the paratestis. This report represents a novel addition to the growing spectrum of Mullerian-analog testicular adnexal neoplasms.	[Agaimy, Abbas; Moskalev, Evgeny A.; Haller, Florian; Hartmann, Arndt] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany; [Weisser, Wera] Asklepios Clin Harburg, Inst Hematopathol, Hamburg, Germany; [Bach, Thorsten] Asklepios Clin Harburg, Dept Urol, Hamburg, Germany	Agaimy, A (reprint author), Univ Hosp Erlangen, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Carano KS, 1997, MODERN PATHOL, V10, P414; CHANG KL, 1993, INT J GYNECOL PATHOL, V12, P282, DOI 10.1097/00004347-199310000-00002; Conklin CMJ, 2014, ADV ANAT PATHOL, V21, P383, DOI 10.1097/PAP.0000000000000046; Cornejo KM, 2014, AM J SURG PATHOL, V38, P1242, DOI 10.1097/PAS.0000000000000216; Cummings OW, 1997, AM J SURG PATHOL, V21, P219, DOI 10.1097/00000478-199702000-00013; Huang HY, 2004, AM J SURG PATHOL, V28, P224, DOI 10.1097/00000478-200402000-00010; Jakate K, 2013, MODERN PATHOL, V26, P95, DOI 10.1038/modpathol.2012.136; JONES MA, 1995, AM J SURG PATHOL, V19, P1359, DOI 10.1097/00000478-199512000-00003; KARIMINEJAD MH, 1973, CANCER-AM CANCER SOC, V31, P671, DOI 10.1002/1097-0142(197303)31:3<671::AID-CNCR2820310328>3.0.CO;2-K; KERNOHAN NM, 1990, HISTOPATHOLOGY, V17, P147, DOI 10.1111/j.1365-2559.1990.tb00686.x; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Li XD, 2016, HISTOPATHOLOGY, V69, P551, DOI 10.1111/his.12966; Masand RP, 2013, AM J SURG PATHOL, V37, P1635, DOI 10.1097/PAS.0000000000000083; McCluggage WG, 1996, HISTOPATHOLOGY, V28, P77, DOI 10.1046/j.1365-2559.1996.272317.x; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Michal M, 2013, ANN DIAGN PATHOL, V17, P151, DOI 10.1016/j.anndiagpath.2012.09.002; Nascimento AF, 2005, AM J SURG PATHOL, V29, P1106; Paluru S, 2018, AM J SURG PATHOL, V42, P141, DOI 10.1097/PAS.0000000000000997; Priemer DS, 2017, INT J SURG PATHOL, V25, P480, DOI 10.1177/1066896917707040; Sherwani AY, 2014, INT J SURG CASE REP, V5, P1285, DOI 10.1016/j.ijscr.2014.10.020; Ulbright TM, 2003, AM J SURG PATHOL, V27, P1221, DOI 10.1097/00000478-200309000-00005; ULBRIGHT TM, 1981, AM J CLIN PATHOL, V76, P371; Yantiss RK, 2000, AM J SURG PATHOL, V24, P513, DOI 10.1097/00000478-200004000-00005; YOUNG RH, 1986, AM J CLIN PATHOL, V86, P146, DOI 10.1093/ajcp/86.2.146	24	2	2	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					695	700		10.1097/PAS.0000000000001030			6	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500016	29394168				2019-10-28	
J	Macagno, N; Etchevers, HC; Malissen, N; Rome, A; Hesse, S; Mallet, S; Degardin, N; Gaudy, C				Macagno, Nicolas; Etchevers, Heather C.; Malissen, Nausicaa; Rome, Angelique; Hesse, Sylvie; Mallet, Stephanie; Degardin, Nathalie; Gaudy, Caroline			Reduced H3K27me3 Expression is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules Reply	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter									[Macagno, Nicolas] Timone Univ Hosp, AP HM, Dept Pathol, Marseille, France; [Malissen, Nausicaa; Hesse, Sylvie; Mallet, Stephanie; Gaudy, Caroline] Timone Univ Hosp, AP HM, Dept Oncodermatol, Marseille, France; [Rome, Angelique] Timone Univ Hosp, AP HM, Dept Pediat Oncol, Marseille, France; [Degardin, Nathalie] Timone Univ Hosp, AP HM, Dept Pediat Plast Surg, Marseille, France; [Etchevers, Heather C.] Aix Marseille Univ, INSERM, MMG, Marseille, France	Macagno, N (reprint author), Timone Univ Hosp, AP HM, Dept Pathol, Marseille, France.		Etchevers, Heather/B-5813-2012	Etchevers, Heather/0000-0003-0201-3799; Macagno, Nicolas/0000-0002-9882-2162			Asano N, 2017, HISTOPATHOLOGY, V70, P385, DOI 10.1111/his.13072; Bahrami A, 2017, PEDIAT BLOOD CANC, V76; Busam KJ, 2017, AM J SURG PATHOL, V41, P396, DOI 10.1097/PAS.0000000000000769; Cleven AH, 2016, MODERN PATHOL, V29, P1; Dessars B, 2009, J INVEST DERMATOL, V129, P139, DOI 10.1038/jid.2008.203; Etchevers HC, 2014, J INVEST DERMATOL, V134, P879, DOI 10.1038/jid.2013.531; Kampilafkos P, 2015, AM J DERMATOPATH, V37, P138, DOI 10.1097/DAD.0b013e31828a2d54; Krengel S, 2013, J AM ACAD DERMATOL, V68, P441, DOI 10.1016/j.jaad.2012.05.043; Le Guellec S, 2017, MODERN PATHOL, V514, P247; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Moran B, 2018, SEMIN CANCER BIOL, V51, P80, DOI 10.1016/j.semcancer.2017.10.006; Prieto-Granada CN, 2016, AM J SURG PATHOL, V40, P479, DOI 10.1097/PAS.0000000000000564; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092	13	0	0	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAY	2018	42	5					701	704		10.1097/PAS.0000000000001026			4	Pathology; Surgery	Pathology; Surgery	GD3LD	WOS:000430404500017	29369061				2019-10-28	
J	Webster, JD				Webster, Joshua D.			Multifaceted Roles of Autophagy in Health and Disease	VETERINARY PATHOLOGY			English	Editorial Material						autophagy; homeostasis; immunity; immunologic; inflammation	DOGS		[Webster, Joshua D.] Genentech Inc, Res Pathol, 1 DNA Way, San Francisco, CA 94080 USA	Webster, JD (reprint author), Genentech Inc, Res Pathol, 1 DNA Way, San Francisco, CA 94080 USA.	websterj@gene.com					Kinsella R, 2018, VET PATHOL; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Ogawa M, 2015, VET PATHOL, V52, P1099, DOI 10.1177/0300985815570070; Singh SS, ONCOGENE; Syrja P, 2017, VET PATHOL, V54, P953, DOI 10.1177/0300985817712793	8	0	0	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					361	362		10.1177/0300985818759773			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000001	29635994				2019-10-28	
J	Brown, CC; Alves, DA; Corner, SM; Zabka, TS				Brown, Corrie C.; Alves, Derron A.; Corner, Sarah M.; Zabka, Tanja S.			Promoting Global Health Through Pathology: Initiation of the Global Health Pathology Network	VETERINARY PATHOLOGY			English	Editorial Material						American College of Veterinary Pathologists; globalization; sustainable development; OIE; World Organisation for Animal Health; veterinary medicine; veterinary pathology; World Trade Organization	ANIMAL SOURCE FOODS		[Brown, Corrie C.] Univ Georgia, Dept Pathol, Athens, GA 30602 USA; [Alves, Derron A.] Def Hlth Agcy, Joint Pathol Ctr, Vet Pathol Serv, Silver Spring, MD USA; [Corner, Sarah M.] Michigan State Univ, Dept Pathobiol & Diagnost Invest, E Lansing, MI 48824 USA; [Zabka, Tanja S.] Genentech Inc, Dept Safety Assessment, San Francisco, CA USA	Brown, CC (reprint author), Univ Georgia, Dept Vet Pathol, 501 DW Brooks Dr, Athens, GA 30602 USA.	corbrown@uga.edu					Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Dunbar M, 2007, P 12 WILDL DAM MAN C; Gonzales F, 2012, POLICY PRIORITIES IN, P175; James AE, 2015, INT J CHILD HEALTH N, V4, P94, DOI 10.6000/1929-4247.2015.04.02.5; Mishar S, 2011, 5606 POL RES; Neumann C, 2002, NUTR RES, V22, P193, DOI 10.1016/S0271-5317(01)00374-8; *OIE, TERR AN HLTH COD; World Bank, 2016, POV SHAR PROSP 2016; World Tourism Organization, 2015, MEAS EC VAL WILDL WA; World Trade Organization, WTO AGR APPL SAN PHY; World Trade Organization, 2015, TRAD SERV MOST DYN S	11	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					363	365		10.1177/0300985817717771			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000002	29635993	Bronze			2019-10-28	
J	Kinsella, RL; Nehls, EM; Stallings, CL				Kinsella, Rachel L.; Nehls, Eric M.; Stallings, Christina L.			Roles for Autophagy Proteins in Immunity and Host Defense	VETERINARY PATHOLOGY			English	Review						review; autophagy; xenophagy; host-directed therapies; immunity; infection	GENOME-WIDE ASSOCIATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRO-INFLAMMATORY RESPONSE; T-CELL HOMEOSTASIS; CLASS-I PATHWAY; DENDRITIC CELLS; ANTIGEN PRESENTATION; CROSS-PRESENTATION; B-CELLS; IL-1-BETA PRODUCTION	There is a clear link between defects in autophagy and the development of autoimmune and chronic inflammatory diseases, raising interest in better understanding the roles of autophagy within the immune system. In addition, autophagy has been implicated in the immune response to infection by pathogenic microbes. As such, there are efforts currently underway to develop modulators of autophagy as a therapeutic strategy for the treatment of the autoimmune, inflammatory, and infectious diseases. In this review, we discuss the numerous roles for autophagy in immunity and how these activities are linked to disease. We highlight how autophagy affects pathogen clearance, phagocytosis, pattern recognition receptor signaling, inflammation, antigen presentation, cell death, and immune cell development and maintenance. With these diverse and extensive immune-related functions for autophagy in mind, we finish by considering the possible implications of targeting autophagy as a therapeutic strategy.	[Kinsella, Rachel L.; Nehls, Eric M.; Stallings, Christina L.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Stallings, CL (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	stallings@wustl.edu		Nehls, Eric/0000-0003-2038-1288	NIH NIGMS training grant [T32 07200]; Burroughs Wellcome FundBurroughs Wellcome Fund	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: C.L.S. is supported by an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. E.M.N. is supported by an NIH NIGMS training grant T32 07200.	Acharya M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10917; Arnold J, 2016, CELL DEATH DIFFER, V23, P853, DOI 10.1038/cdd.2015.149; Arsov I, 2011, J IMMUNOL, V186, P2201, DOI 10.4049/jimmunol.1002223; Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069; Blomgran R, 2012, CELL HOST MICROBE, V11, P81, DOI 10.1016/j.chom.2011.11.012; Blomgran R, 2011, J IMMUNOL, V186, P7110, DOI 10.4049/jimmunol.1100001; Bonilla DL, 2013, IMMUNITY, V39, P537, DOI 10.1016/j.immuni.2013.08.026; Boxx GM, 2016, CELL HOST MICROBE, V19, P760, DOI 10.1016/j.chom.2016.05.016; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Chiu HC, 2009, ANTIMICROB AGENTS CH, V53, P5236, DOI 10.1128/AAC.00555-09; Conway KL, 2013, AUTOPHAGY, V9, P528, DOI 10.4161/auto.23484; Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069; Dasari V, 2016, IMMUNOL CELL BIOL, V94, P964, DOI 10.1038/icb.2016.59; Deretic V, 2015, J CLIN INVEST, V125, P75, DOI 10.1172/JCI73945; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Fattah EA, 2015, J IMMUNOL, V194, P5407, DOI 10.4049/jimmunol.1402277; Gomez-Puerto MC, 2016, STEM CELLS, V34, P1651, DOI 10.1002/stem.2347; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911; Heckmann BL, 2017, J MOL BIOL, V429, P3561, DOI 10.1016/j.jmb.2017.08.012; Into T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01246-w; Ireland JM, 2011, J EXP MED, V208, P2625, DOI 10.1084/jem.20110640; Jagannath C, 2009, NAT MED, V15, P267, DOI 10.1038/nm.1928; Jia W, 2011, J IMMUNOL, V186, P1564, DOI 10.4049/jimmunol.1001822; Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104; Kanayama M, 2015, J IMMUNOL, V194, P5465, DOI 10.4049/jimmunol.1403249; Keller CW, 2017, AUTOPHAGY, V13, P1025, DOI 10.1080/15548627.2017.1297907; Kimmey JM, 2016, TRENDS MOL MED, V22, P1060, DOI 10.1016/j.molmed.2016.10.008; Kinchen JM, 2010, NATURE, V464, P778, DOI 10.1038/nature08853; Kolb JP, 2017, TRENDS IMMUNOL, V38, P705, DOI 10.1016/j.it.2017.06.009; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li YH, 2008, CANCER RES, V68, P6889, DOI 10.1158/0008-5472.CAN-08-0161; Liu F, 2010, BLOOD, V116, P4806, DOI 10.1182/blood-2010-06-288589; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Lo JH, 2014, ANTIMICROB AGENTS CH, V58, P7375, DOI 10.1128/AAC.03778-14; Ma J, 2012, J BIOL CHEM, V287, P34149, DOI 10.1074/jbc.M112.382812; Martin CJ, 2012, CELL HOST MICROBE, V12, P289, DOI 10.1016/j.chom.2012.06.010; Martinez J, 2016, NATURE, V533, P115, DOI 10.1038/nature17950; Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108; Mintern JD, 2015, AUTOPHAGY, V11, P906, DOI 10.1080/15548627.2015.1045178; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mortensen M, 2010, P NATL ACAD SCI USA, V107, P832, DOI 10.1073/pnas.0913170107; Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208; Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Parekh VV, 2013, J IMMUNOL, V190, P5086, DOI 10.4049/jimmunol.1202071; Parihar SP, 2014, J INFECT DIS, V209, P754, DOI 10.1093/infdis/jit550; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Petrovski G, 2007, AUTOPHAGY, V3, P509; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706; Ravindran R, 2014, SCIENCE, V343, P313, DOI 10.1126/science.1246829; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Russmann H, 2010, INFECT IMMUN, V78, P5138, DOI 10.1128/IAI.00155-10; Sahoo M, 2011, THESCIENTIFICWORLDJO, V11, P2037, DOI 10.1100/2011/212680; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Schlie K, 2015, J IMMUNOL, V194, P4277, DOI 10.4049/jimmunol.1402571; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Shi M, 2016, J BIOL CHEM, V291, P1243, DOI 10.1074/jbc.M115.687376; Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273; Shoji-Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866; Stanley SA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003946; Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133; Strisciuglio C, 2013, INFLAMM BOWEL DIS, V19, P2339, DOI 10.1097/MIB.0b013e3182a6a11c; Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106; Tey SK, 2012, BLOOD, V120, P994, DOI 10.1182/blood-2012-01-402404; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; Uhl M, 2009, CELL DEATH DIFFER, V16, P991, DOI 10.1038/cdd.2009.8; Walczak M, 2013, AUTOPHAGY, V9, P424, DOI 10.4161/auto.22931; Weil J, 2016, NAT IMMUNOL, V17, P277, DOI 10.1038/ni.3365; Wildenberg ME, 2017, MUCOSAL IMMUNOL, V10, P352, DOI 10.1038/mi.2016.65; Willinger T, 2012, P NATL ACAD SCI USA, V109, P8670, DOI 10.1073/pnas.1205305109; Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025; Yang Z, 2015, J MOL MED, V93, P707, DOI 10.1007/s00109-015-1297-8; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhang JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108156; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	94	4	4	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					366	373		10.1177/0300985818754967			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000003	29433400	Bronze			2019-10-28	
J	Ramos-Vara, JA; Miller, MA; Dusold, DM				Ramos-Vara, Jose A.; Miller, Margaret A.; Dusold, Dee M.			Immunohistochemical Expression of CD31 (PECAM-1) in Nonendothelial Tumors of Dogs	VETERINARY PATHOLOGY			English	Article						canine diseases; immunohistochemistry; carcinomas; sarcomas; CD31	CELL-ADHESION MOLECULE-1; QUANTITATIVE IMMUNOCYTOCHEMICAL ASSAYS; SINUSOIDAL ENDOTHELIAL-CELLS; HEPATOCELLULAR-CARCINOMA; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; BREAST CARCINOMAS; KAPOSIS-SARCOMA; IN-VIVO; ANTIGEN	CD31 immunoreactivity has been reported in human nonendothelial tumors of both epithelial and mesenchymal origin. This study examined CD31 immunoreactivity of 347 formalin-fixed, paraffin-embedded normal, nonneoplastic, and neoplastic canine tissues. CD31 expression was considered positive if at least 10% of the cell population had membranous reactivity. Labeling with the CD31 antibody (clone JC/70A) was observed in 16 samples of normal organs (liver, kidney, lymph node), 6 of 6 specimens of hepatic nodular hyperplasia, 3 of 3 hepatic regenerative nodules, 1 of 4 anal sac carcinomas, 6 of 6 hemangiosarcomas, 18 of 20 hepatocellular carcinomas, 1 of 6 mammary carcinomas, 3 of 5 plasmacytomas, 18 of 53 renal cell carcinomas, and 1 of 5 cutaneous histiocytomas. CD31 expression did not correlate with case outcome in hepatocellular or renal cell carcinomas. Although distinguishing hemangiosarcoma from other neoplasms is typically straightforward, pathologists should be aware of potential cross-reactivity when relying on CD31 immunohistochemistry for diagnosis, particularly in small biopsy samples or when faced with an epithelioid or poorly differentiated vascular neoplasm.	[Ramos-Vara, Jose A.; Miller, Margaret A.; Dusold, Dee M.] Purdue Univ, Dept Comparat Pathobiol, 406 S Univ St, W Lafayette, IN 47907 USA	Ramos-Vara, JA (reprint author), Purdue Univ, Dept Comparat Pathobiol, 406 S Univ St, W Lafayette, IN 47907 USA.	ramosja@purdue.edu					ARIHIRO K, 1998, BREAST CANC, V5, P131; Castro-Lopez J, 2014, VET REC CASE REP, V1; CHARPIN C, 1995, AM J CLIN PATHOL, V103, P443; Charpin C, 1997, AM J CLIN PATHOL, V107, P534; Cheung K, 2015, P NATL ACAD SCI USA, V112, pE5815, DOI 10.1073/pnas.1509627112; COUVELARD A, 1993, AM J PATHOL, V143, P738; De Young BR, 1998, AM J CLIN PATHOL, V110, P374, DOI 10.1093/ajcp/110.3.374; de Young BR, 1993, APPL IMMUNOHISTO M M, V1, P97; DeLeve LD, 2013, J CLIN INVEST, V123, P1861, DOI 10.1172/JCI66025; DeLeve LD, 2004, AM J PHYSIOL-GASTR L, V287, pG757, DOI 10.1152/ajpgi.00017.2004; DEYOUNG BR, 1995, J CUTAN PATHOL, V22, P215; Doyle LA, 2014, DIAGNOSTIC IMMUNOHIS, P73; Fernandez JE, 1998, J BIOL REGUL HOMEOST, V12, P8191; FERRER L, 1995, J COMP PATHOL, V112, P319, DOI 10.1016/S0021-9975(05)80013-1; Fosmire SP, 2004, LAB INVEST, V84, P562, DOI 10.1038/labinvest.3700080; Frachon S, 2001, J HEPATOL, V34, P850, DOI 10.1016/S0168-8278(01)00049-6; Fujii T, 2008, MODERN PATHOL, V21, P125, DOI 10.1038/modpathol.3800986; Govender R, 1997, J CLIN PATHOL, V50, P490, DOI 10.1136/jcp.50.6.490; HARATAKE J, 1990, CANCER, V65, P1985, DOI 10.1002/1097-0142(19900501)65:9<1985::AID-CNCR2820650918>3.0.CO;2-C; Hornick JL, 2004, AM J SURG PATHOL, V28, P1133, DOI 10.1097/01.pas.0000131541.95394.23; Jennings RN, 2012, VET PATHOL, V49, P532, DOI 10.1177/0300985811429312; Kahn HJ, 2002, MODERN PATHOL, V15, P434, DOI 10.1038/modpathol.3880543; Lalor PF, 2006, WORLD J GASTROENTERO, V12, P5429, DOI 10.3748/wjg.v12.i34.5429; Lertkiatmongkol P, 2016, CURR OPIN HEMATOL, V23, P253, DOI 10.1097/MOH.0000000000000239; Liu L, 2012, CARDIOVASC RES, V94, P3, DOI 10.1093/cvr/cvs108; McKenney JK, 2001, AM J SURG PATHOL, V25, P1167, DOI 10.1097/00000478-200109000-00007; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; Nicholson SA, 2000, APPL IMMUNOHISTO M M, V8, P19, DOI 10.1097/00022744-200003000-00003; OHSAWA M, 1995, CANCER, V75, P2867, DOI 10.1002/1097-0142(19950615)75:12<2867::AID-CNCR2820751212>3.0.CO;2-8; Ortiz-Hidalgo C, 2000, APPL IMMUNOHISTO M M, V8, P334, DOI 10.1097/00022744-200012000-00012; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; Peat TJ, 2017, VET PATHOL, V54, P588, DOI 10.1177/0300985817698211; Privratsky JR, 2014, CELL TISSUE RES, V355, P607, DOI 10.1007/s00441-013-1779-3; Ramos-Vara J. A., 2017, Tumors in domestic animals, P44; Righi L, 2003, AM J PATHOL, V162, P1163, DOI 10.1016/S0002-9440(10)63912-0; Rizzo M, 2000, J HEART LUNG TRANSPL, V19, P858, DOI 10.1016/S1053-2498(00)00165-0; Salva KA, 2014, JAMA DERMATOL, V150, P73, DOI 10.1001/jamadermatol.2013.7141; Sapino A, 2001, J PATHOL, V194, P254, DOI 10.1002/1096-9896(200106)194:2<254::AID-PATH880>3.0.CO;2-2; SCHAFFNER F, 1963, GASTROENTEROLOGY, V44, P239; SCOAZEC JY, 1994, J HEPATOL, V20, P296, DOI 10.1016/S0168-8278(05)80072-8; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; Thaunat O, 2015, P NATL ACAD SCI USA, V112, P13133, DOI 10.1073/pnas.1517580112; Warren AL, 2007, VET PATHOL, V44, P15, DOI 10.1354/vp.44-1-15; Weninger W, 1999, LAB INVEST, V79, P243; Woodfin A, 2007, ARTERIOSCL THROM VAS, V27, P2514, DOI 10.1161/ATVBAHA.107.151456; Yao SZ, 2013, J HISTOCHEM CYTOCHEM, V61, P639, DOI 10.1369/0022155413492771	46	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					402	408		10.1177/0300985817751217			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000006	29343200				2019-10-28	
J	Hoggard, N; Munday, JS; Luff, J				Hoggard, Nathan; Munday, John S.; Luff, Jennifer			Localization of Felis catus Papillomavirus Type 2 E6 and E7 RNA in Feline Cutaneous Squamous Cell Carcinoma	VETERINARY PATHOLOGY			English	Article						feline; skin; papillomavirus; squamous cell carcinoma; in situ hybridization	IN-SITU CARCINOMAS; VIRAL PLAQUES; P16(CDKN2A) PROTEIN; FREQUENT DETECTION; DNA-SEQUENCES; IMMUNOSUPPRESSION; SKIN	Findings from polymerase chain reaction-based methods have suggested a role of Felis catus papillomavirus 2 (FcaPV-2) in the development of feline cutaneous squamous cell carcinoma (SCC). However, because polymerase chain reaction cannot localize deoxyribonucleic acid or ribonucleic acid within the lesion, it is difficult to differentiate a coincidental FcaPV-2 infection and a causative association. Given that a key event in the pathogenesis of human papillomavirus-induced cancer is the expression of viral E6 and E7 oncogenes, localization of FcaPV-2 E6 and E7 transcription within neoplastic cells in feline SCCs would support a causative role for this papillomavirus. Therefore, RNAscope in situ hybridization was used to localize FcaPV-2 E6 and E7 transcripts in 18 formalin-fixed paraffin-embedded samples of cutaneous SCC. Positive signals were present within 5 of 9 samples (56%) from ultraviolet-protected sites and 0 of 9 samples from ultraviolet-exposed sites. In the 4 in situ hybridization-positive samples that contained adjacent hyperplastic skin, hybridization patterns in these regions were characterized by intense nuclear signals within the superficial epidermis and punctate signals within the basal epithelial layers. However, within the 5 SCCs, punctate signals were present within all layers of the epidermis, with progressive loss of intense nuclear signals within the superficial epidermis. This hybridization pattern is consistent with unregulated E6 and E7 transcription and decreased viral replication and is similar to the pattern observed in human papillomavirus-induced cancers as they progress from hyperplastic lesions containing productive infections to nonproductive neoplasms. These findings support a causative role for FcaPV-2 in the pathogenesis of feline SCC.	[Hoggard, Nathan; Luff, Jennifer] North Carolina State Univ, Coll Vet Med, Raleigh, NC USA; [Munday, John S.] Massey Univ, Inst Vet Anim & Biomed Sci, Palmerston North, New Zealand	Luff, J (reprint author), North Carolina State Univ, Dept Populat Hlth & Pathobiol, Coll Vet Med, Res Bldg 310,1060 William Moore Dr, Raleigh, NC 27607 USA.	jaluff@ncsu.edu			North Carolina State University, College of Veterinary Medicine	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by research funds provided by North Carolina State University, College of Veterinary Medicine.	Altamura G, 2016, VIROLOGY, V496, P1, DOI 10.1016/j.virol.2016.05.017; Boscolo-Rizzo P, 2016, CANCER TREAT REV, V42, P24, DOI 10.1016/j.ctrv.2015.10.009; Connolly K, 2014, CANCER TREAT REV, V40, P205, DOI 10.1016/j.ctrv.2013.08.005; Doorbar J, 2005, J CLIN VIROL, V32, pS7, DOI 10.1016/j.jcv.2004.12.006; Evans MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091142; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P1, DOI 10.1002/9780470752487; Luff JA, 2012, J VET DIAGN INVEST, V24, P576, DOI 10.1177/1040638712443360; Munday JS, 2013, VET PATHOL, V50, P269, DOI 10.1177/0300985812452582; Munday JS, 2012, VET PATHOL, V49, P538, DOI 10.1177/0300985811419534; Munday JS, 2011, VET PATHOL, V48, P460, DOI 10.1177/0300985810374844; Munday JS, 2009, NEW ZEAL VET J, V57, P248, DOI 10.1080/00480169.2009.36911; Munday JS, 2008, VET DERMATOL, V19, P259, DOI 10.1111/j.1365-3164.2008.00685.x; Munday JS, 2007, VET DERMATOL, V18, P241, DOI 10.1111/j.1365-3164.2007.00600.x; Munday JS, 2014, VET J, V199, P340, DOI 10.1016/j.tvjl.2013.11.025; Munday JS, 2011, VET DERMATOL, V22, P360, DOI 10.1111/j.1365-3164.2011.00958.x; Munday JS, 2010, J VET DIAGN INVEST, V22, P946, DOI 10.1177/104063871002200615; Munday JS, 2010, VET DERMATOL, V21, P307, DOI 10.1111/j.1365-3164.2009.00811.x; Murphy S, 2013, J FELINE MED SURG, V15, P401, DOI 10.1177/1098612X13483238; Rector A, 2013, VIROLOGY, V445, P213, DOI 10.1016/j.virol.2013.05.007; Thomson NA, 2016, J GEN VIROL, V97, P1189, DOI 10.1099/jgv.0.000416; Wieland U, 2014, CURR PROBL DERMATOL, V45, P154, DOI 10.1159/000357907; World Health Organization, 2013, WHO GUID SCREEN TREA	22	3	3	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					409	416		10.1177/0300985817750456			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000007	29343198	Bronze, Green Accepted			2019-10-28	
J	Seung, BJ; Lim, HY; Shin, JI; Kim, HW; Cho, SH; Kim, SH; Sur, JH				Seung, Byung-Joon; Lim, Ha-Young; Shin, Jong-Il; Kim, Hyun-Woo; Cho, Seung-Hee; Kim, Soo-Hyeon; Sur, Jung-Hyang			CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors	VETERINARY PATHOLOGY			English	Article						canine; mammary gland tumor; tumor-associated macrophage; M2-polarized macrophage; CD204	SCAVENGER RECEPTOR; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; INFILTRATION; GROWTH; ANGIOGENESIS; PHENOTYPE; SURVIVAL; OBESITY	Tumor-associated macrophages (TAMs) are an important component of leukocyte infiltration in tumors. TAMs can be classified into M1 and M2 phenotypes. In the present study, the expression of CD204, an M2-polarized macrophage receptor, was investigated by immunohistochemistry in the area surrounding TAMs in 101 cases of canine mammary gland tumor (CMT). We examined the relationship between M2-polarized TAMs and malignancy, histological subtype, histological grade, molecular subtype, hormone receptor (HR) status, and clinical obesity indices. The mean number of CD204-positive macrophages was significantly higher in malignant CMTs than in benign CMTs (P = .000). The number of CD204-positive macrophages differed significantly between histological grades (P = .000) and were significantly higher in grade III than in grades I and II. Moreover, the mean number of CD204-positive macrophages was significantly higher in HR-negative malignant CMTs than in HR-positive malignant CMTs (P = .035) and in malignant CMTs with lymphatic invasion compared to malignant CMTs without lymphatic invasion (P = .000). These findings suggest that CD204-positive macrophages might affect the development and behavior of CMTs and highlight the potential of CD204 as a prognostic factor.	[Seung, Byung-Joon; Lim, Ha-Young; Shin, Jong-Il; Kim, Hyun-Woo; Cho, Seung-Hee; Kim, Soo-Hyeon; Sur, Jung-Hyang] Konkuk Univ, Dept Vet Pathol, Coll Vet Med, Small Anim Tumor Diagnost Ctr, 120 Neuengdong Ro, Seoul 05029, South Korea	Sur, JH (reprint author), Konkuk Univ, Dept Vet Pathol, Coll Vet Med, Small Anim Tumor Diagnost Ctr, 120 Neuengdong Ro, Seoul 05029, South Korea.	jsur@konkuk.ac.kr		Sur, Jung-Hyang/0000-0003-4496-7582	Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [2016M3A9B6903437]	The author(s) disclose the receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (2016M3A9B6903437).	Al Murri AM, 2008, BRIT J CANCER, V99, P1013, DOI 10.1038/sj.bjc.6604667; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; BRANDTZAEG P, 1988, J CLIN PATHOL, V41, P963, DOI 10.1136/jcp.41.9.963; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Carvalho MI, 2017, VET COMP ONCOL, V15, P619, DOI 10.1111/vco.12206; Carvalho MI, 2016, BIOMED RES INT, DOI 10.1155/2016/4917387; Chang CC, 2009, JAVMA-J AM VET MED A, V235, P391, DOI 10.2460/javma.235.4.391; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Clemente M, 2010, VET PATHOL, V47, P265, DOI 10.1177/0300985809353167; de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200; Farinha P, 2005, BLOOD, V106, P2169, DOI 10.1182/blood-2005-04-1565; Gama A, 2008, VIRCHOWS ARCH, V453, P123, DOI 10.1007/s00428-008-0644-3; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Ichimura T, 2014, ANN SURG ONCOL, V21, P2105, DOI 10.1245/s10434-014-3503-2; Im KS, 2013, VET J, V195, P366, DOI 10.1016/j.tvjl.2012.07.014; Kato Y, 2013, J COMP PATHOL, V148, P188, DOI 10.1016/j.jcpa.2012.06.009; Kelley JL, 2014, CRIT REV IMMUNOL, V34, P241, DOI 10.1615/CritRevImmunol.2014010267; Kim NH, 2013, J COMP PATHOL, V148, P298, DOI 10.1016/j.jcpa.2012.08.009; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Komohara Y, 2016, ADV DRUG DELIVER REV, V99, P180, DOI 10.1016/j.addr.2015.11.009; Komohara Y, 2015, PATHOL INT, V65, P170, DOI 10.1111/pin.12259; Komohara Y, 2014, CANCER SCI, V105, P1, DOI 10.1111/cas.12314; Krol M, 2011, POL J VET SCI, V14, P3, DOI 10.2478/v10181-011-0001-3; Leek RD, 1996, CANCER RES, V56, P4625; Lim HY, 2015, VET J, V203, P326, DOI 10.1016/j.tvjl.2015.01.005; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Mahmoud SMA, 2012, J CLIN PATHOL, V65, P159, DOI 10.1136/jclinpath-2011-200355; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Neyen C, 2013, J IMMUNOL, V190, P3798, DOI 10.4049/jimmunol.1203194; Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239; Nishie A, 1999, CLIN CANCER RES, V5, P1107; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ohtaki Y, 2010, J THORAC ONCOL, V5, P1507, DOI 10.1097/JTO.0b013e3181eba692; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Perdiguero EG, 2013, GLIA, V61, P112, DOI 10.1002/glia.22393; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Raposo T, 2014, VET COMP ONCOL, V12, P10, DOI 10.1111/j.1476-5829.2012.00326.x; Raposo TP, 2015, VET COMP ONCOL, V13, P464, DOI 10.1111/vco.12067; Raposo TP, 2015, VET J, V205, P161, DOI 10.1016/j.tvjl.2015.04.015; Rasotto R, 2017, VET PATHOL, V54, P571, DOI 10.1177/0300985817698208; Sassi F, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-5; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Simpson JW, 1993, CLIN NUTR DOG CAT; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; Tang XQ, 2013, CANCER LETT, V332, P3, DOI 10.1016/j.canlet.2013.01.024; Tsutsui S, 2005, ONCOL REP, V14, P425; Volodko N, 1998, BREAST, V7, P99, DOI 10.1016/S0960-9776(98)90065-0; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775	60	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					417	424		10.1177/0300985817750457			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000008	29343199	Bronze			2019-10-28	
J	Fernandez, M; Braun, U; Frei, S; Schweizer, M; Hilbe, M				Fernandez, Miguel; Braun, Ueli; Frei, Sandra; Schweizer, Matthias; Hilbe, Monika			Border Disease Virus Infection of Bovine Placentas	VETERINARY PATHOLOGY			English	Article						border disease virus; placentitis; pathology; pestivirus; cattle; bovine viral diarrhea virus; inflammation; placenta	VIRAL-DIARRHEA-VIRUS; FETAL MEMBRANES; EARLY-PREGNANCY; FEEDLOT CATTLE; PESTIVIRUS; ABORTION; APOPTOSIS; ANTIGEN; FETUS; GOATS	Subsequent to a previous study of border disease virus (BDV) horizontal transmission from a persistently BDV-infected calf to 6 seronegative pregnant heifers, the heifers were slaughtered 60 days after exposure to the infected calf, and their fetuses and placentas were examined. Immunohistochemical examination of fetal organs and placenta showed positive labeling of moderate intensity for pestivirus antigen in 3 of 6 heifers. BDV infection in these 3 animals was confirmed by the detection of BDV RNA in different organs using reverse transcription quantitative polymerase chain reaction. In the placenta, the positive cells were visualized mostly on the fetal side. In those 3 heifers that harbored an infected fetus, the placental tissue in the placentome region showed a moderate to severe mononuclear and fibrosing placentitis and, in severe cases, necrotic areas. The inflammatory population was composed predominantly of T and B cells, a substantial number of macrophages, and, to a lesser extent, plasma cells. This is a novel report of placentitis in persistently BDV-infected fetuses from pregnant heifers that became acutely infected by cohousing with a calf persistently infected with BDV, which extends previous reports on bovine viral diarrhea virus-infected and BDV-infected cattle and sheep, respectively.	[Fernandez, Miguel; Hilbe, Monika] Univ Zurich, Inst Vet Pathol, Vetsuisse Fac, Winterthurerstr 268, CH-8057 Zurich, Switzerland; [Braun, Ueli; Frei, Sandra] Univ Zurich, Vetsuisse Fac, Dept Farm Anim, Zurich, Switzerland; [Schweizer, Matthias] Univ Bern, Fed Food Safety & Vet Off FSVO, Bern, Switzerland; [Schweizer, Matthias] Univ Bern, Vetsuisse Fac, Inst Immunol & Virol, Bern, Switzerland	Hilbe, M (reprint author), Univ Zurich, Inst Vet Pathol, Vetsuisse Fac, Winterthurerstr 268, CH-8057 Zurich, Switzerland.	hilbe@vetpath.uzh.ch		Schweizer, Matthias/0000-0002-8616-0640	University of Zurich	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The University of Zurich financed the experimental part of this study.	Bachofen C, 2008, VET MICROBIOL, V131, P93, DOI 10.1016/j.vetmic.2008.02.023; Bachofen C, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-32; Becher P, 2003, VIROLOGY, V311, P96, DOI 10.1016/S0042-6822(03)00192-2; Bildfell RJ, 2000, J VET DIAGN INVEST, V12, P419, DOI 10.1177/104063870001200505; Boos A, 2003, REPRODUCTION, V126, P469, DOI 10.1530/rep.0.1260469; Borel N, 2006, VET PATHOL, V43, P702, DOI 10.1354/vp.43-5-702; Braun U, 2014, VET MICROBIOL, V168, P98, DOI 10.1016/j.vetmic.2013.11.004; Braun U, 2015, BMC VET RES, V11, DOI 10.1186/s12917-014-0275-7; Broaddus CC, 2009, VET PATHOL, V46, P45, DOI 10.1354/vp.46-1-45; Brodersen BW, 2014, VET PATHOL, V51, P453, DOI 10.1177/0300985813520250; Canal CW, 1998, VET MICROBIOL, V63, P85; Canton GJ, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-11; CARLSSON U, 1994, ACTA VET SCAND, V35, P79; Castano P, 2016, VET RES, V47, DOI 10.1186/s13567-016-0327-z; Danuser R, 2009, SCHWEIZ ARCH TIERH, V151, P109, DOI [10.1024/0036-7281.151.3.109, 10.1021/0036.7281.151.3.109]; Fredriksen B, 1999, VET PATHOL, V36, P267, DOI 10.1354/vp.36-4-267; Hansen TR, 2015, ANIM HEALTH RES REV, V16, P15, DOI 10.1017/S1466252315000122; Hay KE, 2016, PREV VET MED, V126, P159, DOI 10.1016/j.prevetmed.2016.01.025; Henningson JN, 2013, VET PATHOL, V50, P308, DOI 10.1177/0300985812447827; Hilbe M, 2013, VET PATHOL, V50, P46, DOI 10.1177/0300985812447826; Hilbe M, 2007, J VET DIAGN INVEST, V19, P28, DOI 10.1177/104063870701900105; Lamm CG, 2009, VET PATHOL, V46, P54, DOI 10.1354/vp.46-1-54; Larson RL, 2015, VET CLIN N AM-FOOD A, V31, P367, DOI 10.1016/j.cvfa.2015.05.007; Liebler-Tenorio EM, 2005, BOVINE VIRAL DIARRHEA VIRUS: DIAGNOSIS, MANAGEMENT, AND CONTROL, P121, DOI 10.1002/9780470344453.ch7; McFadden AMJ, 2012, NEW ZEAL VET J, V60, P290, DOI 10.1080/00480169.2012.675568; McNaughton AP, 2009, VET REC, V165, P615, DOI 10.1136/vr.165.21.615; MOENNIG V, 1990, VET MICROBIOL, V23, P35, DOI 10.1016/0378-1135(90)90135-I; Nettleton PF, 1998, VET RES, V29, P327; OSBURN BI, 1991, ARCH VIROL, P71; Passler Thomas, 2010, Animal Health Research Reviews, V11, P191, DOI 10.1017/S1466252309990065; Peter AT, 2013, THERIOGENOLOGY, V80, P693, DOI 10.1016/j.theriogenology.2013.06.004; Peterhans E, 2010, VET RES, V41, DOI 10.1051/vetres/2010016; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Scherer CFC, 2001, VET MICROBIOL, V79, P285, DOI 10.1016/S0378-1135(00)00357-6; Schlafer DH, 2000, ANIM REPROD SCI, V60, P145, DOI 10.1016/S0378-4320(00)00132-9; Schweizer M, 2014, ANNU REV ANIM BIOSCI, V2, P141, DOI 10.1146/annurev-animal-022513-114209; Strong R, 2010, VET MICROBIOL, V141, P208, DOI 10.1016/j.vetmic.2009.09.010; Swasdipan S, 2002, MICROB PATHOGENESIS, V32, P49, DOI 10.1006/mpat.2001.0480; Swasdipan S, 2001, VET PATHOL, V38, P275, DOI 10.1354/vp.38-3-275; Thur B, 1997, AM J VET RES, V58, P1371; Waldner CL, 2010, CAN VET J, V51, P1227; WOODING FBP, 1980, J REPROD FERTIL, V59, P425; Xavier MN, 2009, J COMP PATHOL, V140, P149, DOI 10.1016/j.jcpa.2008.10.004	44	2	2	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					425	433		10.1177/0300985817754123			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000009	29402208	Bronze			2019-10-28	
J	Piewbang, C; Jo, WK; Puff, C; Ludlow, M; van der Vries, E; Banlunara, W; Rungsipipat, A; Kruppa, J; Jung, K; Techangamsuwan, S; Baumgartner, W; Osterhaus, ADME				Piewbang, Chutchai; Jo, Wendy K.; Puff, Christina; Ludlow, Martin; van der Vries, Erhard; Banlunara, Wijit; Rungsipipat, Anudep; Kruppa, Jochen; Jung, Klaus; Techangamsuwan, Somporn; Baumgaertner, Wolfgang; Osterhaus, Albert D. M. E.			Canine Bocavirus Type 2 Infection Associated With Intestinal Lesions	VETERINARY PATHOLOGY			English	Article						bocavirus; canine minute virus; dogs; genetic analysis; pathology; recombination	HOST GENETIC DIVERSITY; MINUTE VIRUS; REVERSE TRANSCRIPTION; FAMILY PARVOVIRIDAE; BOVINE PARVOVIRUS; IDENTIFICATION; RECOMBINATION; DOGS; MVC; CATS	Bocaviruses are small nonenveloped DNA viruses belonging to the Bocaparvovirus genus of the Parvoviridae family and have been linked to both respiratory and enteric disease in humans and animals. To date, 3 bocaviruses, canine bocaviruses 1 to 3 (CBoV-1-3), have been shown to affect dogs with different disease manifestations reported for infected animals. We used next-generation sequencing to identify a novel strain of canine CBoV-2 (CBoV TH-2016) in a litter of puppies that died in Thailand from acute dyspnea and hemoptysis, for which no causal pathogen could be identified in routine assays. Analysis of the complete coding sequences of CBoV TH-2016 showed that this virus was most closely related to a strain previously identified in South Korea (isolate 14D193), with evidence of genetic recombination in the VP2 gene with related strains from South Korea and Hong Kong. Use of quantitative polymerase chain reaction showed the presence of CBoV TH-2016 in several tissues, suggesting hematogenous virus spread, while only intestinal tissue was found to be positive by in situ hybridization and electron microscopy. Histologic small intestinal lesions associated with CBoV TH-2016 infection were eosinophilic intranuclear inclusion bodies within villous enterocytes without villous atrophy or fusion, similar to those previously considered pathognomonic for CBoV-1 infection. Therefore, this study provides novel insights in the pathogenicity of canine bocavirus infections and suggests that a novel recombinant CBoV-2 may result in atypical findings of CBoV infection. Although the specific cause of death of these puppies remained undetermined, a contributory role of enteric CBoV TH-2016 infection is possible.	[Piewbang, Chutchai; Banlunara, Wijit; Rungsipipat, Anudep; Techangamsuwan, Somporn] Chulalongkorn Univ, Dept Pathol, Fac Vet Sci, Bangkok 10330, Thailand; [Piewbang, Chutchai; Jo, Wendy K.; Ludlow, Martin; van der Vries, Erhard; Osterhaus, Albert D. M. E.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses, Hannover, Germany; [Puff, Christina; Baumgaertner, Wolfgang] Univ Vet Med, Dept Pathol, Hannover, Germany; [Kruppa, Jochen; Jung, Klaus] Univ Vet Med, Inst Anim Breeding & Genet, Hannover, Germany; [Techangamsuwan, Somporn] Chulalongkorn Univ, Fac Vet Sci, STAR Diag & Monitoring Anim Pathogen, Bangkok, Thailand	Techangamsuwan, S (reprint author), Chulalongkorn Univ, Dept Pathol, Fac Vet Sci, Bangkok 10330, Thailand.	somporn62@hotmail.com		Ludlow, Martin/0000-0002-0061-1106; Jung, Klaus/0000-0001-9955-748X	Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany; COMPARE project from the European Union's Horizon research and innovation program COMPARE [643476]; 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship; Oversea Research Experience Scholarship for Graduate Students; Thailand Research FundThailand Research Fund (TRF) [TRG5780250]; grant for Joint Funding of External Research Project, Ratchadaphiseksomphot Endowment Fund, Veterinary Science Research Fund, Chulalongkorn University [RES_57_397_31_037]; National Research Council of ThailandNational Research Council of Thailand (NRCT) [GRB_APS_38_59_31_02]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was in part supported by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany, and also by the COMPARE project, which received funding from the European Union's Horizon 2020 research and innovation program COMPARE (grant agreement no. 643476). C.P. was supported by the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship and Oversea Research Experience Scholarship for Graduate Students. This work was partially funded by the Thailand Research Fund (S.T., grant number TRG5780250); grant for Joint Funding of External Research Project, Ratchadaphiseksomphot Endowment Fund, Veterinary Science Research Fund, Chulalongkorn University (S.T., grant number RES_57_397_31_037); and the National Research Council of Thailand (S.T., grant number GRB_APS_38_59_31_02).	Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698; BINN L N, 1970, Infection and Immunity, V1, P503; Bodewes R, 2014, VET MICROBIOL, V174, P1, DOI 10.1016/j.vetmic.2014.08.025; CARMICHAEL LE, 1994, J VET DIAGN INVEST, V6, P165, DOI 10.1177/104063879400600206; Choi JW, 2016, ARCH VIROL, V161, P2299, DOI 10.1007/s00705-016-2895-7; Choi JW, 2015, VET MICROBIOL, V179, P177, DOI 10.1016/j.vetmic.2015.07.023; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Decaro N, 2002, MICROBIOLOGICA, V25, P291; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Endoh D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni064; Garigliany M, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0657-0; Guido M, 2016, WORLD J GASTROENTERO, V22, P8684, DOI 10.3748/wjg.v22.i39.8684; HARRISON LR, 1992, J VET DIAGN INVEST, V4, P19, DOI 10.1177/104063879200400105; Hoelzer K, 2008, J VIROL, V82, P11096, DOI 10.1128/JVI.01003-08; HOGAN A, 1986, MOL CELL BIOL, V6, P3005, DOI 10.1128/MCB.6.8.3005; Huson DH, 2014, BIOINFORMATICS, V30, P38, DOI 10.1093/bioinformatics/btt254; Jarplid B, 1996, J VET DIAGN INVEST, V8, P484; Kapoor A, 2009, J INFECT DIS, V199, P196, DOI 10.1086/595831; Kapoor A, 2012, J GEN VIROL, V93, P341, DOI 10.1099/vir.0.036624-0; Kapoor A, 2010, J INFECT DIS, V201, P1633, DOI 10.1086/652416; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lau SKP, 2012, J GEN VIROL, V93, P1573, DOI 10.1099/vir.0.042531-0; Lau SKP, 2011, J GEN VIROL, V92, P2047, DOI 10.1099/vir.0.033688-0; Lehmbecker A, 2014, TOXICOL PATHOL, V42, P1041, DOI 10.1177/0192623313509906; Li LL, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-54; Lole KS, 1999, J VIROL, V73, P152; MACARTNEY L, 1988, CORNELL VET, V78, P131; Manteufel J, 2008, INTERVIROLOGY, V51, P328, DOI 10.1159/000173734; Mochizuki M, 2002, J CLIN MICROBIOL, V40, P3993, DOI 10.1128/JCM.40.11.3993-3998.2002; Nguyen QT, 2002, VIROLOGY, V301, P374, DOI 10.1006/viro.2002.1585; Ohshima T, 2010, VET MICROBIOL, V145, P334, DOI 10.1016/j.vetmic.2010.03.033; Pfankuche V, VET PATHOL; Piewbang C, 2016, J VET MED SCI, V78, P1847, DOI 10.1292/jvms.16-0342; Schaudien D, 2010, J CLIN MICROBIOL, V48, P3169, DOI 10.1128/JCM.01582-09; Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07; Schwartz D, 2002, VIROLOGY, V302, P219, DOI 10.1006/viro.2002.1674; Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002; Sun YN, 2009, J VIROL, V83, P3956, DOI 10.1128/JVI.02569-08; Tong S, 2008, J CLIN MICROBIOL, V46, P2652, DOI 10.1128/JCM.00192-08; VanDevanter DR, 1996, J CLIN MICROBIOL, V34, P1666	42	5	5	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					434	441		10.1177/0300985818755253			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000010	29421972	Bronze			2019-10-28	
J	Bergmann, W; Bergknut, N; Veraa, S; Grone, A; Vernooij, H; Wijnberg, ID; Back, W; Grinwis, GCM				Bergmann, Wilhelmina; Bergknut, Niklas; Veraa, Stefanie; Grone, Andrea; Vernooij, Hans; Wijnberg, Inge D.; Back, Willem; Grinwis, Guy C. M.			Intervertebral Disc Degeneration in Warmblood Horses: Morphology, Grading, and Distribution of Lesions	VETERINARY PATHOLOGY			English	Article						horses; intervertebral disc degeneration; grading; gross; histology; nucleus pulposus; annulus fibrosus	EQUINE THORACOLUMBAR SPINE; VERTEBRAL COLUMN; CERVICAL-SPINE; PART 1; DOGS; DISEASE; MYELOPATHY; MODEL; JOINT; CLASSIFICATION	Equine intervertebral disc degeneration is thought to be rare and of limited clinical relevance, although research is lacking. To objectively assess pathological changes of the equine intervertebral disc and their clinical relevance, description of the normal morphology and a practical, biologically credible grading scheme are needed. The objectives of this study are to describe the gross and histological appearance of the equine intervertebral discs and to propose a grading scheme for macroscopic degeneration. Spinal units from 33 warmblood horses were grossly analyzed and scored. Of the 286 intervertebral discs analyzed, 107 (37%) were assigned grade 1 and grade 2 (considered normal) and were analyzed histologically. A nucleus pulposus and an annulus fibrosus could be identified macroscopically and histologically. Histologically, the nucleus pulposus was composed of a cartilaginous matrix and the annulus fibrosus of parallel collagenous bands. A transition zone was also histologically visible. Intra- and inter-observer reliability scores were high for all observers. Higher grades were associated with greater age. Gross changes associated with equine intervertebral disc degeneration (grades 3-5)that is, yellow discoloration, cleft formation (tearing), and changes in consistency of the nucleus pulposuswere largely similar to those in humans and dogs and were most prevalent in the caudal cervical spine. Equine intervertebral disc degeneration was not associated with osteophyte formation. Changes of the vertebral bone were most common in the thoracolumbar spine but were not correlated with higher grades of intervertebral disc degeneration. Thus, changes of the vertebral bone should be excluded from grading for equine intervertebral disc degeneration.	[Bergmann, Wilhelmina; Grone, Andrea; Grinwis, Guy C. M.] Univ Utrecht, Dept Pathobiol, Fac Vet Med, Yalelaan 1, NL-3584 CL Utrecht, Netherlands; [Bergknut, Niklas] Univ Utrecht, Dept Clin Sci Compan Anim, Fac Vet Med, Utrecht, Netherlands; [Veraa, Stefanie] Univ Utrecht, Div Diagnost Imaging, Dept Clin Sci Compan Anim, Fac Vet Med, Utrecht, Netherlands; [Vernooij, Hans] Univ Utrecht, Dept Farm Anim Hlth, Fac Vet Med, Utrecht, Netherlands; [Wijnberg, Inge D.; Back, Willem] Univ Utrecht, Dept Equine Sci, Fac Vet Med, Utrecht, Netherlands; [Back, Willem] Univ Ghent, Dept Surg & Anaesthesia Domest Anim, Fac Vet Med, Merelbeke, Belgium; [Bergknut, Niklas] North Downs Specialist Referrals, Bletchingley, England	Bergmann, W (reprint author), Univ Utrecht, Dept Pathobiol, Fac Vet Med, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.; Bergknut, N (reprint author), North Downs Specialist Referrals, Bletchingley, England.	W.Bergmann@uu.nl	Vernooij, Johannes/J-3991-2019	Vernooij, Johannes/0000-0002-2646-9216			Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c; Bergknut N, 2013, VET J, V195, P156, DOI 10.1016/j.tvjl.2012.05.027; Bergknut N, 2013, VET J, V195, P282, DOI 10.1016/j.tvjl.2012.10.024; Bergknut N, 2012, JAVMA-J AM VET MED A, V240, P1300, DOI 10.2460/javma.240.11.1300; Bergknut N, 2012, SPINE, V37, P351, DOI 10.1097/BRS.0b013e31821e5665; Bergknut N, 2011, AM J VET RES, V72, P899, DOI 10.2460/ajvr.72.7.899; Bollwein A, 1989, Tierarztl Prax, V17, P73; Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632-200212010-00002; Cherrone KL, 2004, J AM ANIM HOSP ASSOC, V40, P316, DOI 10.5326/0400316; Clayton HM, 2010, EQUINE VET J, V42, P688, DOI 10.1111/j.2042-3306.2010.00196.x; Down SS, 2009, EQUINE VET J, V41, P518, DOI 10.2746/042516409X391015; Dyson SJ, 2011, VET CLIN N AM-EQUINE, V27, P417, DOI 10.1016/j.cveq.2011.08.005; Faber M, 2001, Equine Vet J Suppl, P145; Faber M, 2001, AM J VET RES, V62, P757, DOI 10.2460/ajvr.2001.62.757; FOSS RR, 1983, CAN VET J, V24, P188; Fuentealba I C, 1991, J Vet Diagn Invest, V3, P176; FURR MO, 1991, J AM VET MED ASSOC, V198, P2095; Gruber HE, 2002, BIOTECH HISTOCHEM, V77, P81, DOI 10.1080/714028181; Hadjipavlou AG, 2008, J BONE JOINT SURG BR, V90B, P1261, DOI 10.1302/0301-620X.90B10.20910; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; Haussler K K, 2001, Equine Vet J Suppl, P160; Ho-Pham LT, 2015, CALCIFIED TISSUE INT, V96, P510, DOI 10.1007/s00223-015-9986-4; Ikegawa S, 2013, ANNU REV GENOM HUM G, V14, P245, DOI 10.1146/annurev-genom-091212-153427; Jansson N, 2001, J AM VET MED ASSOC, V219, P1681, DOI 10.2460/javma.2001.219.1681; JEFFCOTT LB, 1980, EQUINE VET J, V12, P197, DOI 10.1111/j.2042-3306.1980.tb03427.x; JEFFCOTT LB, 1980, EQUINE VET J, V12, P101, DOI 10.1111/j.2042-3306.1980.tb03393.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine JM, 2007, J VET INTERN MED, V21, P812, DOI 10.1892/0891-6640(2007)21[812:CAPCVC]2.0.CO;2; McInerney J, 2000, Neurosurg Focus, V9, pe1, DOI 10.3171/foc.2000.9.4.2; MCKELVEY WAC, 1979, J AM VET MED ASSOC, V175, P295; Meij BP, 2010, VET CLIN N AM-SMALL, V40, P983, DOI 10.1016/j.cvsm.2010.05.006; NAPPERT G, 1989, CAN VET J, V30, P802; NIXON AJ, 1984, VET SURG, V13, P154, DOI 10.1111/j.1532-950X.1984.tb00781.x; Pagger H, 2010, VET J, V186, P338, DOI 10.1016/j.tvjl.2009.09.015; POWERS BE, 1986, VET PATHOL, V23, P392, DOI 10.1177/030098588602300408; Rooney JR, 1982, VET CLIN EQUINE PRAC, V4, P17; Rutges JPHJ, 2013, OSTEOARTHR CARTILAGE, V21, P2039, DOI 10.1016/j.joca.2013.10.001; Sebastian MM, 2004, J VET MED A, V51, P341, DOI 10.1111/j.1439-0442.2004.00648.x; Seiler GS, 2002, AM J VET RES, V63, P86, DOI 10.2460/AJVR.2002.63.86; SHARP NJH, 1992, J SMALL ANIM PRACT, V33, P491, DOI 10.1111/j.1748-5827.1992.tb01032.x; Sleutjens J, 2010, EQUINE VET J, V42, P425, DOI 10.1111/j.2042-3306.2010.00226.x; Smit TH, 2002, EUR SPINE J, V11, P137, DOI 10.1007/s005860100346; Smolders LA, 2013, VET J, V195, P292, DOI 10.1016/j.tvjl.2012.10.011; Speltz MC, 2006, J EQUINE VET SCI, V26, P413, DOI 10.1016/j.jevs.2006.07.007; STADLER P, 1988, J S AFR VET ASSOC, V59, P31; Taher F, 2012, ADV ORTHOP, DOI 10.1155/2012/970752; Takeuchi T, 1999, SPINE, V24, P1414, DOI 10.1097/00007632-199907150-00005; TAYLOR HW, 1977, VET PATHOL, V14, P479, DOI 10.1177/030098587701400507; Teraguchi M, 2014, OSTEOARTHR CARTILAGE, V22, P104, DOI 10.1016/j.joca.2013.10.019; THOMPSON JP, 1990, SPINE, V15, P411, DOI 10.1097/00007632-199005000-00012; THOMPSON JP, 1988, T ORTHOP RES SOC, V13, P276; TOWNSEND HGG, 1986, EQUINE VET J, V18, P107, DOI 10.1111/j.2042-3306.1986.tb03559.x; TOWNSEND HGG, 1984, EQUINE VET J, V16, P461, DOI 10.1111/j.2042-3306.1984.tb01981.x; Urban JPG, 2003, ARTHRITIS RES THER, V5, P120, DOI 10.1186/ar629; Walling BE, 2011, JAVMA-J AM VET MED A, V239, P199, DOI 10.2460/javma.239.2.199; WHITWELL K E, 1980, In Practice, V2, P23; Wijnberg D, 2015, PRAKT TIERARZT, V96, P150; YOVICH JV, 1985, AM J VET RES, V46, P2372	58	4	4	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					442	452		10.1177/0300985817747950			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000011	29301464	Bronze			2019-10-28	
J	Jungwirth, N; Junginger, J; Andrijczuk, C; Baumgartner, W; Wohlsein, P				Jungwirth, Nicole; Junginger, Johannes; Andrijczuk, Christoph; Baumgaertner, Wolfgang; Wohlsein, Peter			Plexiform Vasculopathy in Feline Cervical Lymph Nodes	VETERINARY PATHOLOGY			English	Article						cat; plexiform vasculopathy; lymphendothelium; immunohistochemistry; Prox-1	VASCULAR TRANSFORMATION; KAPOSIS-SARCOMA; SINUSES; LYMPHANGIOSARCOMA; LYMPHADENOPATHY; VESSELS; TUMORS; BLOOD; CATS	Plexiform vasculopathy refers to an endothelial proliferative disorder affecting cervical or inguinal lymph nodes of cats. The cause of this disorder and the origin of the proliferating endothelial cells are still unknown. In 4 cats with a history of a slowly growing, well-demarcated, nonpainful mass adjacent to the thyroid gland, an enlarged dark brown to red lymph node was removed. Histologically, the lymph nodes showed severe loss of lymphoid tissue with accumulations of erythrocytes. In addition, networks of capillary structures with well-differentiated endothelial cells on a collagen-rich stroma were observed, consistent with benign plexiform vasculopathy. Immunohistochemistry revealed the expression of the vascular endothelial markers CD31 and factor VIII-related antigen. In addition, immunolabeling with a Prox-1 antibody indicated a lymphendothelial origin. With respect to our findings, a lymphendothelial origin has to be considered in cases of intranodal vascular neoplasms.	[Jungwirth, Nicole; Junginger, Johannes; Baumgaertner, Wolfgang; Wohlsein, Peter] Univ Vet Med Hannover, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany; [Jungwirth, Nicole; Baumgaertner, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Andrijczuk, Christoph] Evidensia Small Anim Clin Norderstedt GmbH, Norderstedt, Germany	Wohlsein, P (reprint author), Univ Vet Med Hannover, Dept Pathol, Bunteweg 17, D-30559 Hannover, Germany.	peter.wohlsein@tiho-hannover.de		Junginger, Johannes/0000-0002-4965-4553			CHAN JKC, 1991, AM J SURG PATHOL, V15, P732, DOI 10.1097/00000478-199108000-00003; CHAN JKC, 1992, AM J SURG PATHOL, V16, P335, DOI 10.1097/00000478-199204000-00003; Galeotti F, 2004, VET DERMATOL, V15, P13, DOI 10.1111/j.1365-3164.2004.00354.x; Gelberg HB, 2011, VET PATHOL, V48, P530, DOI 10.1177/0300985810375241; HIDDEN G, 1985, ANAT CLIN, V7, P83, DOI 10.1007/BF01655509; Hinrichs U, 1999, VET PATHOL, V36, P164, DOI 10.1354/vp.36-2-164; Ioachim HL, 2009, IOACHIMS LYMPH NODE, P48; Jennings RN, 2012, VET PATHOL, V49, P532, DOI 10.1177/0300985811429312; Lempp C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175469; LUCKE VM, 1987, J COMP PATHOL, V97, P109, DOI 10.1016/0021-9975(87)90030-2; Pirola S, 2012, INT J SURG PATHOL, V20, P175, DOI 10.1177/1066896911434550; Ramos-Vara J. A., 2017, Tumors in domestic animals, P44; Roof-Wages E, 2015, VET PATHOL, V52, P331, DOI 10.1177/0300985814537528; Samet A, 2001, J LARYNGOL OTOL, V115, P760; Sleeckx N, 2013, J COMP PATHOL, V148, P307, DOI 10.1016/j.jcpa.2012.09.007; STEINMANN G, 1982, LAB INVEST, V47, P43; Sugiyama A, 2007, J COMP PATHOL, V137, P174, DOI 10.1016/j.jcpa.2007.06.004; Welsh EM, 1999, J SMALL ANIM PRACT, V40, P291, DOI 10.1111/j.1748-5827.1999.tb03082.x; Yin T, 2003, WORLD J GASTROENTERO, V9, P40, DOI 10.3748/wjg.v9.i1.40; Zidan M, 2010, CELL TISSUE RES, V340, P491, DOI 10.1007/s00441-010-0962-z	20	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					453	456		10.1177/0300985817747949			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000012	29343196	Bronze			2019-10-28	
J	Molin, J; Asin, J; Vitoria, A; Sanz, A; Gimeno, M; Romero, A; Sanchez, J; Pinczowski, P; Vazquez, FJ; Rodellar, C; Lujan, L				Molin, Jessica; Asin, Javier; Vitoria, Arantzazu; Sanz, Arianne; Gimeno, Marina; Romero, Antonio; Sanchez, Javier; Pinczowski, Pedro; Vazquez, Francisco J.; Rodellar, Clementina; Lujan, Lluis			Congenital Hepatic Fibrosis in a Purebred Spanish Horse Foal: Pathology and Genetic Studies on PKHD1 Gene Mutations	VETERINARY PATHOLOGY			English	Article						congenital hepatic fibrosis; ductal plate malformation; embryonic development; horse; liver; PKHD1 gene mutations	DUCTAL PLATE MALFORMATION; BILIARY ATRESIA; LIVER-DISEASE; CALVES; CATS; DOGS; CALF	A 1-month-old Purebred Spanish Horse (PSH) foal presented with progressive hepatic failure culminating in death. Hepatic lesions were consistent with congenital hepatic fibrosis (CHF). Genetic studies in the PKHD1 gene in the affected foal revealed that it was heterozygous for the 2 previously described single-nucleotide polymorphisms (SNPs) linked to CHF in Swiss Franches-Montagnes (SFM) horses. In addition, 2 novel mutations were detected, the foal being homozygous for one of them and heterozygous for the other. Genetic studies in a healthy PSH population (n = 35) showed a 3-fold higher genotypic frequency for PKHD1 SNP g.49,630,834G>A and a 5-fold higher genotypic frequency for PKHD1 SNP g.49,597,760A>T compared with those reported for SFM horses. SNPs in the PKHD1 gene in CHF-affected SFM horses might not fully explain the CHF observed in the PSH. Other mutations in the PKHD1 gene could play a more important role in the PSH.	[Molin, Jessica; Asin, Javier; Vitoria, Arantzazu; Gimeno, Marina; Romero, Antonio; Pinczowski, Pedro; Vazquez, Francisco J.; Lujan, Lluis] Univ Zaragoza, Fac Vet, Dept Anim Pathol, 177 Miguel Servet St, E-50013 Zaragoza, Spain; [Sanz, Arianne; Sanchez, Javier; Rodellar, Clementina] Univ Zaragoza, Dept Anat Embryol & Genet, Zaragoza, Spain	Molin, J (reprint author), Univ Zaragoza, Fac Vet, Dept Anim Pathol, 177 Miguel Servet St, E-50013 Zaragoza, Spain.	jmolin@unizar.es	Vazquez, FJ/H-7941-2015	Vazquez, FJ/0000-0002-8712-2275			BASTIANELLO SS, 1987, J S AFR VET ASSOC, V58, P89; Bosje JT, 1998, VET QUART, V20, P136, DOI 10.1080/01652176.1998.9694858; Bourque AC, 2001, CAN VET J, V42, P145; Brown DL, 2010, VET PATHOL, V47, P102, DOI 10.1177/0300985809353313; Cullen JM, 2016, JUBB KENNEDY PALMERS, P259; DESMET VJ, 1992, HISTOPATHOLOGY, V20, P465; Drogemuller M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110125; Haechler S, 2000, VET PATHOL, V37, P669, DOI 10.1354/vp.37-6-669; Movassaghi AR, 2011, IRAN J VET RES, V12, P262; Nakanuma Y, 2010, HISTOL HISTOPATHOL, V25, P223, DOI 10.14670/HH-25.223; Pillai S, 2016, VET PATHOL, V53, P602, DOI 10.1177/0300985815610567; SMALL AC, 1993, J VET MED A, V40, P213, DOI 10.1111/j.1439-0442.1993.tb00619.x; Stocker H, 1996, Tierarztl Prax, V24, P44; Testoni S, 2009, VET REC, V164, P693, DOI 10.1136/vr.164.22.693; VANDERLUER RJT, 1982, EQUINE VET J, V14, P91; Wallace S, 2009, VET PATHOL, V46, P84, DOI 10.1354/vp.46-1-84; Yoshikawa H, 2002, VET PATHOL, V39, P143, DOI 10.1354/vp.39-1-143; Zandvliet MMJM, 2005, J VET INTERN MED, V19, P765, DOI 10.1892/0891-6640(2005)19[765:APSICS]2.0.CO;2; Zeitoun D, 2004, RADIOLOGY, V231, P109, DOI 10.1148/radiol.2311030108	19	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					457	461		10.1177/0300985817754122			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000013	29402207	Bronze			2019-10-28	
J	Clancy, CS; Jensen, KA; Van Wettere, AJ				Clancy, Chad S.; Jensen, Khrista A.; Van Wettere, Arnaud J.			Congenital Short-Bowel Syndrome in an Adult Dog	VETERINARY PATHOLOGY			English	Article						dogs; congenital; gastrointestinal disease; intestinal hypoplasia; malabsorption; short bowel syndrome; intestinal length	SMALL-INTESTINE; RESECTION	A 3.5-year-old, neutered male pit bull dog was euthanized following an approximately 1-year history of intractable diarrhea and weight loss of undetermined cause. At necropsy, the dog was emaciated. The ratio of total intestinal length (duodenum to rectum) to crown-to-rump length was 2.5, in contrast to an average of 5.3 (range, 3.7-6.1) in 10 control dogs examined at necropsy. There was diffuse dilation of the intestinal lumen, consistent with congenital intestinal hypoplasia resulting in short-bowel syndrome. Histologically, the intestinal mucosal was hyperplastic, further supporting the diagnosis of short-bowel syndrome. To the authors' knowledge, this is the first case of this condition in the veterinary literature.	[Clancy, Chad S.; Van Wettere, Arnaud J.] Utah State Univ, Sch Vet Med, Utah Vet Diagnost Lab, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA; [Jensen, Khrista A.] Mt View Vet Clin, North Logan, UT USA	Van Wettere, AJ (reprint author), Utah State Univ, Dept Anim Dairy & Vet Sci, Utah State Vet Diagnost Lab, 950 East 1400 North, Logan, UT 84341 USA.	arnaud.vanwettere@usu.edu		Clancy, Chad/0000-0002-5354-9270			Colin G, 1871, TRAITE PHYSL COMP AN; Dyce KM, 2002, TXB VET ANATOMY; Ettinger S, 2010, TXB VET INTERNAL MED; Hasosah M, 2008, CAN J GASTROENTEROL, V22, P71, DOI 10.1155/2008/590143; Mair TS, 2010, EQUINE VET EDUC, V18, P299; O'Keefe SJD, 2006, CLIN GASTROENTEROL H, V4, P6, DOI 10.1053/S1542-3565(05)00994-8; OIKAWA M, 1990, JPN J VET SCI, V52, P855; Paulsen DB, 2003, AM J VET RES, V64, P618, DOI 10.2460/ajvr.2003.64.618; QUIGLEY EMM, 1994, DIGEST DIS SCI, V39, P1222, DOI 10.1007/BF02093787; VANDERHOOF JA, 1992, J PEDIATR GASTR NUTR, V14, P359, DOI 10.1097/00005176-199205000-00001; Wales PW, 2005, J PEDIATR SURG, V40, P755, DOI 10.1016/j.jpedsurg.2005.01.037; William E, 1989, J AM VET MED ASSOC, V195, P87; WILLIAMS DA, 1981, J SMALL ANIM PRACT, V22, P263, DOI 10.1111/j.1748-5827.1981.tb00607.x; YANOFF SR, 1992, VET SURG, V21, P217, DOI 10.1111/j.1532-950X.1992.tb00049.x	14	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					462	465		10.1177/0300985817750455			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000014	29310549	Bronze			2019-10-28	
J	Haskins, DL; Howerth, EW; Tuberville, TD				Haskins, David L.; Howerth, Elizabeth W.; Tuberville, Tracey D.			Experimentally Induced Selenosis in Yellow-Bellied Slider Turtles (Trachemys scripta scripta)	VETERINARY PATHOLOGY			English	Article						reptiles; selenomethionine; selenosis; turtles; toxicosis; yellow-bellied slider turtles (Trachemys scripta scripta)	SELENIUM; TOXICITY; ACCUMULATION; EXPOSURE; LESIONS; HEALTH	Selenosis, or selenium toxicosis, occurs in wildlife and livestock, usually because of excessive intake of selenium via selenium-containing plants. Although it is known that wild slider turtles can accumulate large amounts of selenium, little is known about how selenium exposure may affect these reptiles. In this study, the authors report histopathologic changes in yellow-bellied sliders (Trachemys scripta scripta) caused by experimental exposure to selenomethionine. Microscopic changes in kidney and claw tissue were most significant and resembled those reported in birds. Turtles in the selenium treatment groups had acute tubular degeneration and regeneration in the kidney, with hyaline droplets in the high-dose animals, and changes in the claws ranging from epidermal hyperplasia with disorganization and intercellular edema to ulceration, and accumulation of seroheterophilic exudate between the epidermis and cornified layer. Although selenium burdens in this study are comparable with values found in wild slider turtles, more data are needed to determine if similar histopathologic abnormalities arise in wild animals exposed to high levels of selenium.	[Haskins, David L.; Tuberville, Tracey D.] Univ Georgia, Savannah River Ecol Lab, Aiken, SC 29802 USA; [Haskins, David L.] Univ Georgia, DB Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA; [Howerth, Elizabeth W.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA	Haskins, DL (reprint author), Univ Georgia, Savannah River Ecol Lab, Aiken, SC 29802 USA.	david.haskins@uga.edu			US Department of EnergyUnited States Department of Energy (DOE) [DE-FC09-07SR22506]; Savannah River Nuclear Solutions - Area Completions Project	We would like to thank Caitlin Kupar, Matt Hamilton, Katrina Woods, Naya Eady, Jarad Cochran, Amanda Jones, and Sam Dean for their help with animal husbandry, selenium administration, turtle dissections, and tissue preparation. This research was funded by the US Department of Energy under award number DE-FC09-07SR22506 to the University of Georgia Research Foundation and by Savannah River Nuclear Solutions - Area Completions Project.	[Anonymous], 1990, LIFE HIST ECOLOGY SL; [Anonymous], 2011, ENV CONTAMINANTS BIO; Canadian Council of Animal Care, CCAC SPEC SPEC REC A; CONGDON JD, 1986, AM MIDL NAT, V115, P165, DOI 10.2307/2425846; Finger JW, 2017, ARCH ENVIRON CON TOX, V72, P439, DOI 10.1007/s00244-017-0370-4; FISHER EDWIN R., 1964, EXP MOL PATHOL, V3, P304, DOI 10.1016/0014-4800(64)90003-6; Ganser LR, 2003, J HERPETOL, V37, P219, DOI 10.1670/0022-1511(2003)037[0219:LHOTSW]2.0.CO;2; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Green DE, 1997, J WILDLIFE DIS, V33, P385, DOI 10.7589/0090-3558-33.3.385; Haskins DL, 2017, ECOTOXICOLOGY, V26, P1134, DOI 10.1007/s10646-017-1839-7; Haskins DL, 2017, ENVIRON POLLUT, V224, P810, DOI 10.1016/j.envpol.2017.01.048; HILTON JW, 1983, J NUTR, V113, P1241; KOLLER LD, 1986, CAN J VET RES, V50, P297; Morris JS, 2013, NUTRIENTS, V5, P1024, DOI 10.3390/nu5041024; OToole D, 1997, VET PATHOL, V34, P330, DOI 10.1177/030098589703400409; OTOOLE D, 1995, J VET DIAGN INVEST, V7, P364, DOI 10.1177/104063879500700312; Unrine JM, 2007, ENVIRON POLLUT, V149, P182, DOI 10.1016/j.envpol.2007.01.039; Young T.F., 2010, ECOLOGICAL ASSESSMEN, P7	18	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					473	477		10.1177/0300985817750454			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000016	29291674				2019-10-28	
J	Pasolini, MP; Pagano, TB; Costagliola, A				Pasolini, M. P.; Pagano, T. B.; Costagliola, A.			Inflammatory Myopathy in Horses With Chronic Piroplasmosis (vol 55, pg 133, 2017)	VETERINARY PATHOLOGY			English	Correction								Pasolini MP, Pagano TB, Costagliola A, et al. Inflammatory Myopathy in Horses With Chronic Piroplasmosis. Vet Path. 2017; 55(1):133-143. (Original DOI: 10.1177/0300985817716262) In volume 55, issue 1, page 133, the tenth author Vincenzo Veneziano was incorrectly listed as Veneziano Veneziano. This has been corrected online.								Pasolini MP, 2018, VET PATHOL, V55, P133, DOI 10.1177/0300985817716262	1	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	MAY	2018	55	3					478	478		10.1177/0300985818771320			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GC7MI	WOS:000429977000017		Bronze			2019-10-28	
J	Sirintrapun, SJ				Sirintrapun, S. Joseph			Preparing for a Computational Pathology Future Through Informaticians and a Computational Technologist Workforce	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							HEALTH-CARE; CHALLENGES		[Sirintrapun, S. Joseph] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Sirintrapun, SJ (reprint author), 1275 York Ave A515, New York, NY 10065 USA.	sirintrs@mskcc.org		Sirintrapun, S. Joseph/0000-0003-2921-8831			Caban JJ, 2015, J AM MED INFORM ASSN, V22, P260, DOI 10.1093/jamia/ocv006; Fuchs TJ, 2011, COMPUT MED IMAG GRAP, V35, P515, DOI 10.1016/j.compmedimag.2011.02.006; Fuchs TJ, 2008, LECT NOTES COMPUT SC, V5242, P1, DOI 10.1007/978-3-540-85990-1_1; Granville V., DIFFERENCE MACHINE L; Louis DN, 2016, ARCH PATHOL LAB MED, V140, P41, DOI 10.5858/arpa.2015-0093-SA; McKenna B., DATA SCI NEW QUANT; Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393	7	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					369	372		10.1093/ajcp/aqy009			4	Pathology	Pathology	GC0FX	WOS:000429453400001	29538613	Bronze			2019-10-28	
J	Lin, GP; Li, H; Kuang, JY; Tang, KJ; Guo, YB; Han, AJ; Xie, CM				Lin, Gengpeng; Li, Hui; Kuang, Jianyi; Tang, Kejing; Guo, Yubiao; Han, Anjia; Xie, Canmao			Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Invasive mucinous adenocarcinoma; Lung adenocarcinoma; Prognosis; Pathologic subtype	INTERNATIONAL-ASSOCIATION; CLASSIFICATION; FUSIONS	Invasive mucinous adenocarcinoma (IMA) is a variant of lung adenocarcinoma with several growth patterns, such as lepidic acinar and papillary. However, to our knowledge, no study regarding prognostic and clinicopathologic aspects of IMAs with different growth patterns has been reported. Of 2,236 patients with primary lung adenocarcinoma, 16 were identified as having lepidic-predominant IMA and 10 as having acinar-predominant IMA. Data regarding the clinicopathologic characteristics, computed tomography (CT) features, and prognosis were collected. No statistically significant difference was notedsignificantly higher in acinar-predominant IMA (P = .046). Both gro in sex, age, smoker proportion, and T classification between both groups. The proportion of lymph node metastasis was ups shared many signs in CT findings. Air bronchogram was a relatively specific sign for lepidic-predominant IMA. Survival analysis showed that acinar-predominant IMA had a poorer prognosis (P = .0294). Lepidic-predominant and acinar-predominant IMA are two different subtypes of IMA. Acinar-predominant IMA is associated with lymph node metastasis and a poorer prognosis.	[Lin, Gengpeng; Tang, Kejing; Guo, Yubiao; Xie, Canmao] Sun Yat Sen Univ, Inst Resp Dis, Resp Dept, 58 Zhongshan 2nd Rd, Guangzhou, Guangdong, Peoples R China; [Li, Hui; Han, Anjia] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Kuang, Jianyi] Sun Yat Sen Univ, Dept Radiol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Han, AJ (reprint author), Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.; Xie, CM (reprint author), Sun Yat Sen Univ, Resp Dept, Affiliated Hosp 1, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	han_anjia@outlook.com; xiecanmao@outlook.com		xie, canmao/0000-0002-3134-7416	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502492, 81402000]; PhD Start-up Fund of Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2014A030310167]	This work was supported by National Natural Science Foundation of China (81502492 and 81402000) and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province (2014A030310167).	Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandez-Cuesta L, 2014, CANCER DISCOV, V4, P415, DOI 10.1158/2159-8290.CD-13-0633; Ichinokawa H, 2013, HUM PATHOL, V44, P2636, DOI 10.1016/j.humpath.2013.05.026; Kadota K, 2014, AM J SURG PATHOL, V38, P1118, DOI 10.1097/PAS.0000000000000246; Lee HY, 2016, J THORAC ONCOL, V11, P1064, DOI 10.1016/j.jtho.2016.03.011; Lee HY, 2009, LUNG CANCER, V65, P170, DOI 10.1016/j.lungcan.2008.11.009; Lee KS, 1997, RADIOGRAPHICS, V17, P1345, DOI 10.1148/radiographics.17.6.9397450; Makinen JM, 2015, LUNG CANCER, V90, P568, DOI 10.1016/j.lungcan.2015.10.014; Nakaoku T, 2014, CLIN CANCER RES, V20, P3087, DOI 10.1158/1078-0432.CCR-14-0107; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Shim HS, 2015, J THORAC ONCOL, V10, P1156, DOI 10.1097/JTO.0000000000000579; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Watanabe H, 2015, ANN THORAC SURG, V99, P975, DOI 10.1016/j.athoracsur.2014.10.065; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232	17	1	1	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					373	378		10.1093/ajcp/aqx170			6	Pathology	Pathology	GC0FX	WOS:000429453400002	29538611				2019-10-28	
J	Gullo, I; Batista, R; Rodrigues-Pereira, P; Soares, P; Barroca, H; do Bom-Sucesso, M; Sobrinho-Simoes, M				Gullo, Irene; Batista, Rui; Rodrigues-Pereira, Pedro; Soares, Paula; Barroca, Helena; do Bom-Sucesso, Maria; Sobrinho-Simoes, Manuel			Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						DICER1 syndrome; Multinodular goiter; Well-differentiated thyroid carcinoma; Botryoid-type embryonal rhabdomyosarcoma	DIFFERENTIATED THYROID-CARCINOMA; LEYDIG CELL TUMOR; PLEUROPULMONARY BLASTOMA; MUTATIONS; CANCER; ASSOCIATION; CHILD	Multinodular goiter (MNG) and well-differentiated thyroid carcinoma (WDTC) are emerging phenotypes of DICER1 syndrome. Histologic and molecular findings of botryoid-type embryonal rhabdomyosarcoma (bERMS) and thyroid nodules from a 12-year-old DICER1 mutation carrier (p.Arg1060Ilefs*7) were investigated, providing interesting clues for understanding thyroid carcinogenesis. The patient had bERMS at age 7 years. The thyroid was enlarged and multinodular (61 g). Histologically, some nodules were classified as adenomatous and others as tumors with "intermediate" nuclei. One displayed vascular invasion and was classified as WDTC not otherwise specified (NOS). Somatic DICER1 mutations were identified in bERMS, two tumors with "intermediate" nuclei and WDTC. No somatic DICER1 mutations were found in adenomatous nodules. No molecular alterations were detected in BRAF600, NRAS61, HRAS12/61, KRAS12/61, TERT promoter, RET/PTC1, RET/PTC3, and PAX8/PPAR gamma. The findings obtained from this single case support the assumption that DICER1 syndrome-related WDTC NOS may develop on a background of MNG, via a stepwise process, involving DICER1 somatic mutations and additional molecular events, distinct from the classic pathways of papillary/follicular carcinoma.	[Gullo, Irene; Rodrigues-Pereira, Pedro; Barroca, Helena; Sobrinho-Simoes, Manuel] Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal; [do Bom-Sucesso, Maria] Ctr Hosp Sao Joao, Pediat Hematol Oncol Unit, Dept Pediat, Porto, Portugal; [Gullo, Irene; Soares, Paula; Sobrinho-Simoes, Manuel] Univ Porto, Fac Med, Dept Pathol, Porto, Portugal; [Gullo, Irene; Batista, Rui; Soares, Paula; Sobrinho-Simoes, Manuel] Univ Porto, Inst Mol Pathol & Immunol, Porto, Portugal; [Gullo, Irene; Batista, Rui; Soares, Paula; Sobrinho-Simoes, Manuel] Univ Porto, Inst Res Innovat Hlth, Porto, Portugal	Gullo, I (reprint author), Univ Porto, Dept Pathol, Fac Med, Ctr Hosp Sao Joao, Al Prof Hernani Monteiro, P-4200319 Porto, Portugal.	igullo@ipatimup.pt	Sobrinho-Simoes, Manuel/J-8290-2013; Soares, Paula/B-6054-2008; Gullo, Irene/A-4427-2016	Soares, Paula/0000-0001-9607-6998; Gullo, Irene/0000-0003-3377-0530	Portuguese Foundation for Science and Technology [SFRH/BD/111321/2015]; FCTFundacao para a Ciencia e a Tecnologia (FCT); FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal; Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologial Ministerio da Ciencia, Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]; project "Advancing Cancer Research: From Basic Knowledgment to Application" - Norte Programa Operacional Regional do Norte [NORTE-01-0145-FEDER-000029]; "Projetos Estruturados de I&D&I" - Norte Programa Operacional Regional do Norte	This study was supported by the Portuguese Foundation for Science and Technology through a PhD grant to R. B. (ref.: SFRH/BD/111321/2015). IPATIMUP integrates the i3S Research Unit, which is partially supported by FCT. This work was financed by FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologial Ministerio da Ciencia, Tecnologia e Inovacao in the framework of the project "Institute for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274). Further funding was obtained from the project "Advancing Cancer Research: From Basic Knowledgment to Application" (NORTE-01-0145-FEDER-000029) and "Projetos Estruturados de I&D&I," funded by Norte 2020-Programa Operacional Regional do Norte.	de Kock L, 2016, J CLIN ENDOCR METAB, V101, P3637, DOI 10.1210/jc.2016-1328; de Kock L, 2014, J CLIN ENDOCR METAB, V99, pE1072, DOI 10.1210/jc.2013-4206; Doros L, 1993, GENEREVIEWS; Durieux E, 2016, VIRCHOWS ARCH, V468, P631, DOI 10.1007/s00428-016-1922-0; Foulkes WD, 2014, NAT REV CANCER, V14, P662, DOI 10.1038/nrc3802; Khan NE, 2017, J CLIN ENDOCR METAB, V102, P1614, DOI 10.1210/jc.2016-2954; Oue T, 2008, PEDIATR BLOOD CANCER, V50, P901, DOI 10.1002/pbc.21265; Poiana C, 2010, GYNECOL ENDOCRINOL, V26, P617, DOI 10.3109/09513591003686361; Puckett Y, 2015, J PEDIAT SURG CASE R, V3, P312, DOI 10.1016/j.epsc.2015.06.004; Rome A, 2008, PEDIATR BLOOD CANCER, V50, P1081, DOI 10.1002/pbc.21431; Rutter MM, 2016, J CLIN ENDOCR METAB, V101, P1, DOI 10.1210/jc.2015-2169; Schultz KA, 2014, AJSP-REV REP, V19, P90, DOI 10.1097/PCR.0000000000000027; Shin SH, 2012, THYROID, V22, P547, DOI 10.1089/thy.2011.0161; Slade I, 2011, J MED GENET, V48, P273, DOI 10.1136/jmg.2010.083790; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239	15	2	2	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					379	386		10.1093/ajcp/aqy004			8	Pathology	Pathology	GC0FX	WOS:000429453400003	29538609	Bronze			2019-10-28	
J	Garcia, E; Kundu, I; Ali, A; Soles, R				Garcia, Edna; Kundu, Iman; Ali, Asma; Soles, Ryan			The American Society for Clinical Pathology's 2016-2017 Vacancy Survey of Medical Laboratories in the United States	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Anatomic pathology; Clinical pathology; ASCP Vacancy Survey; Laboratory; Certification; Laboratory departments; Laboratory staff; Laboratory workforce		To determine the extent and distribution of workforce shortages within the nation's medical laboratories. The 2016-2017 Vacancy Survey was conducted through collaboration between the American Society for Clinical Pathology's Institute of Science, Technology, & Policy in Washington, DC, and the Evaluation, Measurement, and Assessment division and Board of Certification in Chicago, Illinois. Data were collected via an internet survey that was distributed to individuals who were able to report on staffing and certifications for their laboratories. Results of the 2016-2017 Vacancy Survey shows decreased vacancy rates for laboratory positions across all departments surveyed compared with 2014. While overall, the data show that vacancy rates are decreasing, overall retirement rates and certification requirements are higher. Focus on the qualifications and certification status of laboratory professionals would be crucial factors in addressing the needs of the laboratory workforce. The field needs to intensify its efforts on recruiting the next generation of laboratory personnel.	[Garcia, Edna; Kundu, Iman] ASCP, Inst Sci Technol & Policy, Washington, DC USA; [Ali, Asma; Soles, Ryan] ASCP, Evaluat Measurement & Assessment Dept, Chicago, IL USA	Garcia, E (reprint author), 1225 New York Ave NW,Ste 350, Washington, DC 20005 USA.	Edna.Garcia@ascp.org					Garcia E, 2015, AM J CLIN PATHOL, V144, P432, DOI 10.1309/AJCPN7G0MXMSTXCD; Gibbon G. A., 1996, Laboratory Automation and Information Management, V32, P1, DOI 10.1016/1381-141X(95)00024-K; Skobelev DO, 2011, MEAS TECH+, V53, P1182, DOI 10.1007/s11018-011-9638-7	3	4	4	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					387	400		10.1093/ajcp/aqy005			14	Pathology	Pathology	GC0FX	WOS:000429453400004	29522068	Bronze			2019-10-28	
J	Castanon, A; Pierre, G; Willis, R; Harris, EN; Papalardo, E; Romay-Penabad, Z; Schleh, A; Jajoria, P; Smikle, M; DeCeulaer, K; Tebo, A; Jaskowski, T; Guerra, MM; Branch, DW; Salmon, JE; Petri, M; Gonzalez, EB				Castanon, Amaris; Pierre, Grant; Willis, Rohan; Harris, E. Nigel; Papalardo, Elizabeth; Romay-Penabad, Zurina; Schleh, Alvaro; Jajoria, Praveen; Smikle, Monica; DeCeulaer, Karel; Tebo, Anne; Jaskowski, Troy; Guerra, Marta M.; Branch, D. Ware; Salmon, Jane E.; Petri, Michelle; Gonzalez, Emilio B.			Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Antiphospholipid; Anticardiolipin; APhL; Antiphosphatidylserine; Antiphosphatidylinositol; Assay; Noncriteria	SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECURRENT PREGNANCY LOSS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; INTERNATIONAL-CONGRESS; PHOSPHATIDYLSERINE; THROMBOSIS; CRITERIA; RISK; CLASSIFICATION	We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-beta 2 glycoprotein I (anti-beta 2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-beta 2GPI, anti-PS, anti-PI, and APhL ELISA assays. All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.	[Castanon, Amaris; Pierre, Grant; Willis, Rohan; Papalardo, Elizabeth; Romay-Penabad, Zurina; Schleh, Alvaro; Gonzalez, Emilio B.] Univ Texas Med Branch, Rheumatol Internal Med, Galveston, TX 77555 USA; [Harris, E. Nigel; Smikle, Monica; DeCeulaer, Karel] Univ West Indies, Mona Campus, Kingston, Jamaica; [Jajoria, Praveen] Pinnacle Hlth Rheumatol, Lemoyne, PA USA; [Tebo, Anne; Jaskowski, Troy] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA; [Tebo, Anne] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Guerra, Marta M.; Salmon, Jane E.] Hosp Special Surg, Rheumatol, 535 E 70th St, New York, NY 10021 USA; [Branch, D. Ware] Univ Utah, Maternal Fetal Med, Salt Lake City, UT USA; [Branch, D. Ware] Intermt Healthcare, Salt Lake City, UT USA; [Petri, Michelle] Johns Hopkins Univ, Rheumatol, Baltimore, MD USA	Gonzalez, EB (reprint author), Univ Texas Med Branch, Dept Internal Med, Div Rheumatol, Antiphospholipid Standardizat Lab, 122 6th St,2-108 Brackenridge Hall, Galveston, TX 77555 USA.	ebgon-zal@utmb.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR43727, AR69572, AR056745-01A1]; Mallinckrodt-Questcor Fellowship Grant	This work was supported by the National Institutes of Health (AR43727 and AR69572 to M.P. and AR056745-01A1 to E. B. G. and R. W.) and a Mallinckrodt-Questcor Fellowship Grant (R. W.).	Amoroso A, 2003, HUM IMMUNOL, V64, P265, DOI 10.1016/S0198-8859(02)00789-9; Bertolaccini ML, 2014, AUTOIMMUN REV, V13, P917, DOI 10.1016/j.autrev.2014.05.001; Devreese KMJ, 2014, J THROMB HAEMOST, V12, P792, DOI 10.1111/jth.12537; ESCALANTE A, 1995, AM J MED, V98, P559, DOI 10.1016/S0002-9343(99)80014-X; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; HARRIS EN, 1995, BLOOD, V85, P2276, DOI 10.1182/blood.V85.8.2276.bloodjournal8582276; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Katsuragawa H, 1997, BIOL REPROD, V56, P50, DOI 10.1095/biolreprod56.1.50; Laroche P, 1996, AM J CLIN PATHOL, V106, P549; Levine SR, 1997, STROKE, V28, P1660, DOI 10.1161/01.STR.28.9.1660; Merkel PA, 1999, J RHEUMATOL, V26, P591; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Musial J, 2003, J RHEUMATOL, V30, P723; Neville C, 2003, THROMB HAEMOSTASIS, V90, P108; Oku K, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0674-4; Peterson LK, 2016, ADV CLIN CHEM, V73, P1, DOI 10.1016/bs.acc.2015.10.003; Pierangeli SS, 2011, LUPUS, V20, P182, DOI 10.1177/0961203310395055; Pierangeli SS, 2008, NAT PROTOC, V3, P840, DOI 10.1038/nprot.2008.48; ROTE NS, 1990, AM J OBSTET GYNECOL, V163, P575, DOI 10.1016/0002-9378(90)91201-M; Sater MS, 2012, EUR J OBSTET GYN R B, V163, P170, DOI 10.1016/j.ejogrb.2012.04.001; Suh-Lailam BB, 2012, INT J CLIN EXP PATHO, V5, P210; Tebo AE, 2008, CLIN EXP IMMUNOL, V154, P332, DOI 10.1111/j.1365-2249.2008.03774.x; Tebo AE, 2014, LUPUS, V23, P1313, DOI 10.1177/0961203314544534; Tebo AE, 2008, AM J CLIN PATHOL, V129, P870, DOI 10.1309/6MPULFBL24FM9B50; Ulcova-Gallova Z, 2005, AM J REPROD IMMUNOL, V54, P112, DOI 10.1111/j.1600-0897.2005.00294.x; Van Hoecke F, 2012, INT J LAB HEMATOL, V34, P630, DOI 10.1111/j.1751-553X.2012.01448.x; Willis R, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-014-0485-9; Willis R, 2014, SEMIN THROMB HEMOST, V40, P172, DOI 10.1055/s-0033-1364207; Yetman DL, 1996, FERTIL STERIL, V66, P540, DOI 10.1016/S0015-0282(16)58565-3; Zuo Y, 2017, LUPUS, V26, P606, DOI 10.1177/0961203316671812	32	3	4	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					401	411		10.1093/ajcp/aqy003			11	Pathology	Pathology	GC0FX	WOS:000429453400005	29547897	Bronze, Green Published			2019-10-28	
J	Chen, YY; Ho, HL; Lin, SC; Ho, TDH; Hsu, CY				Chen, Yen-Ying; Ho, Hsiang-Ling; Lin, Shih-Chieh; Ho, Tiffany Dai-Hwa; Hsu, Chih-Yi			Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Glioblastoma; microRNA; MGMT; Methylation; Prognosis	TEMOZOLOMIDE RESISTANCE; ADJUVANT TEMOZOLOMIDE; STEM-CELLS; EXPRESSION; GLIOMA; PROLIFERATION; APOPTOSIS; RADIOTHERAPY; METHYLATION; SUPPRESSION	To evaluate the prognostic values of microRNAs (miRNAs) in glioblastoma, and to see if there is an association between miRNAs and MGMT promoter methylation status. We collected paraffin blocks from resection specimens from 114 glioblastoma patients who had received temozolomide treatment and radiotherapy. Real-time quantitative PCR was performed to determine the expression levels of five miRNAs. Upregulation of miR 125b-5p, miR 181d-3p, miR 221-3p, miR-222-3p, and miR 224-5p was observed in 13.2%, 5.3%, 12.3%, 32.5%, and 78.9% of the cases, respectively. The expression level of miRNAs was not significantly different in tumors with MGMT promoter methylation vs tumors without such methylation. Upregulation of miR 125b-5p, miR 181d-3p, or miR 221-3p was significantly associated with shorter survival in MGMT-unmethylated glioblastoma patients. miR 125b-5p, miR 181d-3p, and miR 221-3p are useful in predicting poor prognosis in patients with MGMT-unmethylated glioblastomas.	[Chen, Yen-Ying; Ho, Hsiang-Ling; Lin, Shih-Chieh; Hsu, Chih-Yi] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan; [Chen, Yen-Ying; Ho, Hsiang-Ling; Lin, Shih-Chieh; Hsu, Chih-Yi] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Ho, Tiffany Dai-Hwa] Duke Univ, Dept Comp Sci, Durham, NC 27706 USA; [Ho, Tiffany Dai-Hwa] Duke Univ, Dept Stat, Durham, NC USA; [Hsu, Chih-Yi] Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei, Taiwan	Hsu, CY (reprint author), Taipei Vet Gen Hosp, Dept Pathol & Lab Med, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan.	cyhsu@vghtpe.gov.tw	ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 104-2320-B-075-003, MOST 104-2320-B-075-004]; Taipei Veterans General HospitalTaipei Veterans General Hospital [V105C-185, V105C-187, V106C-037]	This work was supported by Ministry of Science and Technology, Taiwan (grant numbers MOST 104-2320-B-075-003, MOST 104-2320-B-075-004); and Taipei Veterans General Hospital (grant numbers V105C-185, V105C-187, V106C-037).	Blough MD, 2007, CANCER RES, V67, P580, DOI 10.1158/0008-5472.CAN-06-2782; Cheng W, 2015, ONCOTARGET, V6, P29285, DOI 10.18632/oncotarget.4978; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Crone TM, 1996, MUTAT RES-DNA REPAIR, V363, P15, DOI 10.1016/0921-8777(95)00058-5; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gao XC, 2014, CANCER LETT, V353, P25, DOI 10.1016/j.canlet.2014.07.011; Haemmig S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.245; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hsu CY, 2015, J NEURO-ONCOL, V122, P179, DOI 10.1007/s11060-014-1701-1; IMAI Y, 1995, CARCINOGENESIS, V16, P2441; Khalil S, 2016, ONCOTARGET, V7, P28195, DOI 10.18632/oncotarget.8618; Kim SW, 2012, P NATL ACAD SCI USA, V109, P7865, DOI 10.1073/pnas.1200081109; Kitange GJ, 2012, CLIN CANCER RES, V18, P4070, DOI 10.1158/1078-0432.CCR-12-0560; Kreth S, 2013, ACTA NEUROPATHOL, V125, P671, DOI 10.1007/s00401-013-1081-1; Kushwaha D, 2014, ONCOTARGET, V5, P4026, DOI 10.18632/oncotarget.1974; Le MTN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002242; Li XX, 2016, MOL NEUROBIOL, V53, P577, DOI 10.1007/s12035-014-9017-x; Quintavalle C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074466; Ramalho-Carvalho J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058206; Song MK, 2013, TOXICOL APPL PHARM, V273, P130, DOI 10.1016/j.taap.2013.08.016; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Upraity S, 2014, BIOCHEM BIOPH RES CO, V448, P225, DOI 10.1016/j.bbrc.2014.04.095; Wan Y, 2014, NEUROREPORT, V25, P289, DOI 10.1097/WNR.0000000000000085; Wang XF, 2012, J CANCER RES CLIN, V138, P573, DOI 10.1007/s00432-011-1114-x; Wu N, 2013, BRIT J CANCER, V109, P2853, DOI 10.1038/bjc.2013.672; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Yang JK, 2017, J NEURO-ONCOL, V131, P255, DOI 10.1007/s11060-016-2308-5; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang CZ, 2009, INT J ONCOL, V34, P1653, DOI 10.3892/ijo_00000296; Zhang JX, 2010, INT J ONCOL, V36, P913, DOI 10.3892/ijo_00000570; Zhang W, 2012, NEURO-ONCOLOGY, V14, P712, DOI 10.1093/neuonc/nos089; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	35	5	5	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					412	417		10.1093/ajcp/aqy008			6	Pathology	Pathology	GC0FX	WOS:000429453400006	29538610				2019-10-28	
J	Pendse, AA; Bauer, AE; Dodd, L; Scanga, L				Pendse, Avani A.; Bauer, Anna E.; Dodd, Leslie; Scanga, Lori			Increased Rate of ASCUS Diagnosis With Concomitant Request for High-Risk Human Papillomavirus Reflex Testing May Be Due to Cognitive Bias	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Pap test; ASCUS; Reflex HPV testing; Bias	CLINICAL DECISION-MAKING; AMERICAN-CANCER-SOCIETY; CERVICAL-CANCER; CONSENSUS GUIDELINES; PAP TESTS; MANAGEMENT; STRATEGIES	To determine if concomitant high-risk human papillomavirus (HPV-HR) reflex testing may bias the cytologic interpretation of Papanicolaou (Pap) tests. Percentage of atypical squamous cells of undetermined significance (ASCUS) and HPV-HR positivity was compared between Pap tests with HPV-HR cotesting and HPV-HR reflex testing for ASCUS, with subset analysis of cytopathologists' experience. ASCUS in the reflex group (41.5%) was significantly higher than the cotesting group (33.0%) (P = .02). There was no difference in HPV-HR positivity or ASCUS/squamous intraepithelial lesion (SIL) ratios between the two groups. The cytopathologists' experience inversely correlated with the proportion of ASCUS but did not explain the higher reflex group ASCUS. HPV-HR reflex testing may introduce bias in cytologic diagnosis, making it more likely that an ASCUS diagnosis is rendered. HPV-HR and ASCUS/SIL ratios were similar between the groups, so cytopathologist performance was not significantly affected. There was no effect of cytopathologists' experience.	[Pendse, Avani A.] Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA; [Pendse, Avani A.; Dodd, Leslie; Scanga, Lori] Univ N Carolina, Sch Med, Dept Pathol & Lab, Chapel Hill, NC USA; [Bauer, Anna E.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA	Pendse, AA (reprint author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	avani.pendse@duke.edu					Croskerry P, 2002, ACAD EMERG MED, V9, P1184, DOI 10.1111/j.1553-2712.2002.tb01574.x; Croskerry P, 2013, NEW ENGL J MED, V368, P2445, DOI 10.1056/NEJMp1303712; Doxtader EE, 2017, CANCER CYTOPATHOL, V125, P60, DOI 10.1002/cncy.21783; Gunia S, 2011, PATHOL RES PRACT, V207, P116, DOI 10.1016/j.prp.2010.11.007; Huh WK, 2015, J LOW GENIT TRACT DI, V19, P91, DOI 10.1097/LGT.0000000000000103; Juskevicius R, 2001, AM J CLIN PATHOL, V116, P331, DOI 10.1309/0BL4-6H9V-DQVV-UGXR; Larson AR, 2015, AM J CLIN PATHOL, V143, P143, DOI 10.1309/AJCP0HFEY0WFBNAP; Makretsov N., 2014, ANN CLIN PATHOL, V2, P1039; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Moriarty AT, 2014, ARCH PATHOL LAB MED, V138, P1182, DOI 10.5858/arpa.2012-0115-CP; Peng Y, 2006, DIAGN CYTOPATHOL, V34, P585, DOI 10.1002/dc.20526; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Saslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; Schmidt RL, 2013, ARCH PATHOL LAB MED, V137, P558, DOI 10.5858/arpa.2012-0198-RA; Shin Dmitriy, 2017, J Pathol Inform, V8, P29, DOI 10.4103/jpi.jpi_29_17; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SKOV BG, 1994, LUNG CANCER-J IASLC, V11, P365, DOI 10.1016/0169-5002(94)92165-2; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; The American College of Obstetricians and Gynecologist, 2016, OBSTET GYNECOL, V128, P111; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120	21	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					425	433		10.1093/ajcp/aqy011			9	Pathology	Pathology	GC0FX	WOS:000429453400008	29562239	Bronze			2019-10-28	
J	Campbell, MR; Milam, KK; Fisher, KR				Campbell, Michelle R.; Milam, Karrie K.; Fisher, Kelly R.			Body Fluid Processing Workspace Quality Improvement Initiative in a High-Volume Reference Laboratory	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Aim statement; Spaghetti diagram; Fishbone and root cause analysis; Counterbalance measure; Plan-Do-Study-Act (PDSA) cycle; Quality improvement project (QIP)		In a clinical laboratory, the design of the workspace directs the workflow and significantly affects the productivity of clinical laboratory scientists (CLS). With the chronic shortage of CLS, a well-designed workspace is essential to take full advantage of available staff, especially in high-volume laboratories. Through the use of quality improvement tools, a manual body fluid testing workspace was redesigned to address weaknesses in the layout that led to excessive physical steps taken by staff. System engineering tools such as a fishbone diagram, spaghetti diagrams, Plan-Do-Study-Act cycles, and a counterbalance measure were all used in a CLS-led quality improvement initiative to redesign a workspace in the manual body fluid processing area of a clinical laboratory at Mayo Clinic. After the redesign, physical steps taken and time to process body fluids were reduced by an average of 40% and 32%, respectively, demonstrating the utility of quality improvement tools in clinical laboratory settings.	[Campbell, Michelle R.; Milam, Karrie K.; Fisher, Kelly R.] Mayo Clin, Rochester, MN USA	Campbell, MR (reprint author), 7221 Farmhome Lane, Cherry Valley, IL 61016 USA.	m.campbell118266@yahoo.com					Bialek R., 2009, PUBLIC HLTH QUALITY; Iftadi I, 2017, AIP CONF PROC, V1902, DOI 10.1063/1.5010658; Leviton LC, 2016, BMJ QUAL SAF, V25, P803, DOI 10.1136/bmjqs-2015-004814; Minnesota Department of Health, FISHB DIAGR; Mourshed M, 2012, J ENVIRON PSYCHOL, V32, P362, DOI 10.1016/j.jenvp.2012.06.004; Taylor MJ, 2014, BMJ QUAL SAF, V23, P290, DOI 10.1136/bmjqs-2013-001862; World Health Organization, TRANSF HLTH PRIOR PR	7	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					434	441		10.1093/ajcp/aqy006			8	Pathology	Pathology	GC0FX	WOS:000429453400009	29618001				2019-10-28	
J	Moussa, RA; Eesa, AN; Abdallah, ZF; Abdelmeged, A; Mahran, A; Bahaa, H				Moussa, Rabab A.; Eesa, Ahmed N.; Abdallah, Zeinab F.; Abdelmeged, Ayman; Mahran, Ahmed; Bahaa, Haitham			Diagnostic Utility of Twist1, Ki-67, and E-Cadherin in Diagnosing Molar Gestations and Hydropic Abortions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Complete hydatidiform mole; Partial hydatidiform mole; Hydropic abortion; p57; Flow cytometry; Twist1; Ki-67; E-cadherin	TRIPLOID HYDATIDIFORM MOLE; TROPHOBLASTIC DISEASES; DIFFERENTIAL-DIAGNOSIS; P57(KIP2) IMMUNOHISTOCHEMISTRY; P57 IMMUNOHISTOCHEMISTRY; ANCILLARY TECHNIQUES; PLOIDY ANALYSIS; FLOW-CYTOMETRY; EXPRESSION; PREGNANCIES	This study aims to assess whether the expression of Twist1, Ki-67, and E-cadherin can guide the differential diagnosis of complete hydatidiform mole (CHM), partial hydatidiform mole (PHM), and hydropic abortion (HA). Differential expression of Twist1, Ki-67, and E-cadherin was analyzed in gestational products from 55 cases of CHM, PHM, and HA using immunohistochemistry. Prior to analysis, the studied cases were confirmed for their diagnosis by flow cytometric assessment of DNA ploidy and p57 immunostaining. Twist1 expression can distinguish CHM from PHM and HA with 100% sensitivity, 100%, specificity, 100% positive predictive value (PPV), and 100% negative predictive value (NPV). Furthermore, combined Ki-67 and E-cadherin expression could differentiate PHM and HA with 100% sensitivity, 93.3% specificity, 92.3% PPV, and 100% NPV. Twist1 expression is a highly reliable marker for the diagnosis of CHM, where combined Ki-67 and E-cadherin immunoreactivity can distinguish PHM from nonmolar pregnancies.	[Moussa, Rabab A.] Menia Univ, Dept Pathol, Fac Med, Mailbox 61111, Al Minya 61111, Egypt; [Abdelmeged, Ayman; Mahran, Ahmed; Bahaa, Haitham] Menia Univ, Dept Obstet & Gynecol, Fac Med, Al Minya, Egypt; [Eesa, Ahmed N.] Cairo Univ, Fac Med, Dept Pathol, Cairo, Egypt; [Abdallah, Zeinab F.] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Virol & Immunol Unit, Cairo, Egypt	Moussa, RA (reprint author), Menia Univ, Dept Pathol, Fac Med, Mailbox 61111, Al Minya 61111, Egypt.	rababmossa00@gmail.com	Moussa, Rabab/W-3456-2019	Moussa, Rabab/0000-0003-3212-4131			BARCLAY IDR, 1993, AM J CLIN PATHOL, V100, P451, DOI 10.1093/ajcp/100.4.451; Batistatou A, 2007, PLACENTA, V28, P590, DOI 10.1016/j.placenta.2006.09.004; Berkowitz RS, 2009, GYNECOL ONCOL, V112, P654, DOI 10.1016/j.ygyno.2008.09.005; Brown LM, 2005, HISTOCHEM CELL BIOL, V124, P499, DOI 10.1007/s00418-005-0051-7; Cheville JC, 1996, PEDIATR PATHOL LAB M, V16, P41, DOI 10.1080/107710496175868; Chew SH, 2000, HUM PATHOL, V31, P914, DOI 10.1053/hupa.2000.9085; Crisp H, 2003, HISTOPATHOLOGY, V43, P363, DOI 10.1046/j.1365-2559.2003.01716.x; DeScipio C, 2011, AM J SURG PATHOL, V35, P1586, DOI 10.1097/PAS.0b013e31822d5cff; Erfanian M, 2009, J RES MED SCI, V14, P375; Erol O, 2016, PATHOL ONCOL RES, V22, P515, DOI 10.1007/s12253-015-0031-8; Floridon C, 2000, MOL HUM REPROD, V6, P943, DOI 10.1093/molehr/6.10.943; Fukunaga M, 2005, AM J SURG PATHOL, V29, P942, DOI 10.1097/01.pas.0000157996.23059.c1; Genest DR, 2001, INT J GYNECOL PATHOL, V20, P315, DOI 10.1097/00004347-200110000-00001; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HEDLEY DW, 1989, CYTOMETRY, V10, P229, DOI 10.1002/cyto.990100302; Jun SY, 2003, HISTOPATHOLOGY, V43, P17, DOI 10.1046/j.1365-2559.2003.01667.x; Kale A, 2001, AM J OBSTET GYNECOL, V184, P567, DOI 10.1067/mob.2001.111243; Khooei A, 2013, IRAN RED CRESCENT ME, V15, P590, DOI 10.5812/ircmj.5348; Kim J, 2014, EMBO REP, V15, P1062, DOI 10.15252/embr.201438587; Kokkinos MI, 2010, PLACENTA, V31, P747, DOI 10.1016/j.placenta.2010.06.017; Landolsi H, 2009, PATHOL RES PRACT, V205, P789, DOI 10.1016/j.prp.2009.05.013; Luchini C, 2015, PLACENTA, V36, P1318, DOI 10.1016/j.placenta.2015.09.012; McConnell TG, 2009, AM J SURG PATHOL, V33, P805, DOI 10.1097/PAS.0b013e318191f309; Merchant SH, 2005, HUM PATHOL, V36, P180, DOI 10.1016/j.humpath.2004.12.007; Murphy KM, 2010, AJSP-REV REP, V15, P126, DOI 10.1097/PCR.0b013e3181e70fe0; Niemann I, 2007, BJOG-INT J OBSTET GY, V114, P1273, DOI 10.1111/j.1471-0528.2007.01449.x; Oun A., 2014, AL AZHAR ASSIUT MED, V12, P335; Paradinas FJ, 1994, CURR DIAGN PATHOL, V1, P24; Petignat P, 2003, HUM REPROD, V18, P243, DOI 10.1093/humrep/deg091; Pirinen E, 2014, APMIS, V122, P530, DOI 10.1111/apm.12187; Romaguera RL, 2004, FETAL PEDIATR PATHOL, V23, P181, DOI 10.1080/15227950490890351; Ronnett BM, 2011, INT J GYNECOL PATHOL, V30, P101, DOI 10.1097/PGP.0b013e3181f4de77; Schammel DP, 1996, INT J GYNECOL PATHOL, V15, P158, DOI 10.1097/00004347-199604000-00011; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shu HM, 2013, INT J GYNECOL CANCER, V23, P749, DOI 10.1097/IGC.0b013e31827da23f; Soper JT, 2006, OBSTET GYNECOL, V108, P176, DOI 10.1097/01.AOG.0000224697.31138.a1; Soper JT, 2004, GYNECOL ONCOL, V93, P575, DOI 10.1016/j.ygyno.2004.05.013; Steigrad SJ, 2003, BEST PRACT RES CL OB, V17, P837, DOI 10.1016/S1521-6934(03)00049-X; TOPALOVSKI M, 1995, AM J CLIN PATHOL, V103, P409; Vang R, 2012, AM J SURG PATHOL, V36, P443, DOI 10.1097/PAS.0b013e31823b13fe; Xue WC, 2003, INT J GYNECOL CANCER, V13, P879, DOI 10.1136/ijgc-00009577-200311000-00022	41	2	2	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					442	455		10.1093/ajcp/aqy012			14	Pathology	Pathology	GC0FX	WOS:000429453400010	29562309	Bronze			2019-10-28	
J	Birindelli, S; Pasqualetti, S; Panteghini, M				Birindelli, Sarah; Pasqualetti, Sara; Panteghini, Mauro			Offering Aspartate Aminotransferase as a Reflex Test: An Easy but Effective Way to Improve Appropriateness of Laboratory Requests	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Letter							ALANINE AMINOTRANSFERASE; ALT; AST		[Birindelli, Sarah; Pasqualetti, Sara; Panteghini, Mauro] ASST Fatebenefratelli Sacco, Clin Pathol Unit, Milan, Italy	Birindelli, S (reprint author), ASST Fatebenefratelli Sacco, Clin Pathol Unit, Milan, Italy.						Ceriotti F, 2010, CLIN CHEM LAB MED, V48, P1593, DOI 10.1515/CCLM.2010.315; Ferraro S, 2017, CLIN BIOCHEM, V50, P555, DOI 10.1016/j.clinbiochem.2017.03.002; Lilford RJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003099; Panteghini M, 2001, CLIN CHEM, V47, pA25; Panteghini M, 2018, TIETZ TXB CLIN CHEM, P404; Panteghini M, 2017, CLIN CHEM, V63, P1196, DOI 10.1373/clinchem.2017.274977; Sak ME, 2012, EUR REV MED PHARMACO, V16, P1399; Salinas M, 2013, ANN CLIN BIOCHEM, V50, P353, DOI 10.1177/0004563212474568; Xu Q, 2015, AM J CLIN PATHOL, V144, P423, DOI 10.1309/AJCPO47VAWYRIDHG	9	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAY	2018	149	5					456	457		10.1093/ajcp/aqy015			2	Pathology	Pathology	GC0FX	WOS:000429453400011	29547948	Bronze			2019-10-28	
J	Hatano, Y; Fukuda, S; Makino, H; Tomita, H; Morishige, K; Hara, A				Hatano, Yuichiro; Fukuda, Shinya; Makino, Hiroshi; Tomita, Hiroyuki; Morishige, Ken-ichirou; Hara, Akira			High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis	DIAGNOSTIC PATHOLOGY			English	Article						Fallopian tube; Ovary; High-grade serous carcinoma; p53 signature; gamma-H2AX	ENDOMETRIAL INTRAEPITHELIAL CARCINOMA; OVARIAN-CARCINOMA; TP53 MUTATIONS; FALLOPIAN-TUBE; CANCER; GAMMA-H2AX; LESIONS; MARKER	Background: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. Case presentation: A 56-year-old woman was referred to the gynecologist on account of abdominal distention. Since radiological and serological workup suggested that her illness was due to advanced ovarian cancer (FIGO Stage IVB), she received neoadjuvant chemotherapy, and the clinical evaluation of the chemotherapeutic response was a partial response. She underwent total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and intra-pelvic and para-aortic lymphadenectomy. Histologically, the cancer cells showed high-grade nuclear atypia and spread into the bilateral ovaries, omentum, uterine serosa, and left fallopian tube. The cancer cells showed complete absence of p53 but overexpressed p16, whereas some of benign-appearing tubal epithelial cells overexpressed p53 but lacked p16 expression. The results of direct sequence analysis revealed that the ovarian cancer contains a 1 bp deletion in exon 8 of TP53. Finally, the histological diagnosis of HGSC with discordant p53 signature was made. Interestingly, nuclear expression of gamma-H2AX, a well-known marker of DNA damage, was not only observed in both p53 aberrantly-expressing lesions but also the benign-appearing tubal epithelium without p53 overexpression. After the histological confirmation, she received adjuvant chemotherapy and has been in disease-free condition without any detectable tumor for 5 months. Conclusion: Recent evidence suggests that p53 signature is the putative precursor of p53 overexpression-type HGSC. Because the putative precursors of the other p53 immunophenotypical HGSC are not proposed, we presume gamma-H2AX-expressing cells without p53 overexpression may be a potent candidate of null-type TP53-mutated tubal cells, which are named "gamma-H2AX responsive foci."	[Hatano, Yuichiro; Fukuda, Shinya; Tomita, Hiroyuki; Hara, Akira] Gifu Univ, Grad Sch Med, Dept Tumor Pathol, 1-1 Yanagido, Gifu 5011194, Japan; [Makino, Hiroshi; Morishige, Ken-ichirou] Gifu Univ, Grad Sch Med, Dept Obstet & Gynecol, Gifu 5011194, Japan	Hatano, Y (reprint author), Gifu Univ, Grad Sch Med, Dept Tumor Pathol, 1-1 Yanagido, Gifu 5011194, Japan.	yuha@gifu-u.ac.jp	Tomita, Hiroyuki/L-5571-2019; Hatano, Yuichiro/K-7454-2013	Tomita, Hiroyuki/0000-0002-3291-0274; Hatano, Yuichiro/0000-0002-5121-6325	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18K15207]	This work was supported by JSPS KAKENHI (18K15207)	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Anglesio MS, 2017, HISTOPATHOLOGY, V71, P1014, DOI 10.1111/his.13327; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bohm S, 2015, J CLIN ONCOL, V33, P2457, DOI 10.1200/JCO.2014.60.5212; Chen EY, 2011, NAT CELL BIOL, V13, P1161; Cole AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26191; Furuya M, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0585-0; Jia L, 2015, MODERN PATHOL, V28, P118, DOI 10.1038/modpathol.2014.76; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Meserve EEK, 2017, MODERN PATHOL, V30, P710, DOI 10.1038/modpathol.2016.238; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Siddiqui MS, 2015, MUTAT RES-REV MUTAT, V766, P1, DOI 10.1016/j.mrrev.2015.07.001; Singh N, 2017, HISTOPATHOLOGY, V71, P339, DOI 10.1111/his.13248; Staff S, 2014, INT J GYNECOL PATHOL, V33, P309, DOI 10.1097/PGP.0b013e31829c673b; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85; Zhang MY, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0605-8	22	3	3	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	APR 27	2018	13								24	10.1186/s13000-018-0702-3			6	Pathology	Pathology	GE9IS	WOS:000431544000001	29703236	DOAJ Gold, Green Published			2019-10-28	
J	Sanfilippo, F; Powell, D; Folberg, R; Tykocinski, M				Sanfilippo, Fred; Powell, Deborah; Folberg, Robert; Tykocinski, Mark			Dealing With Deans and Academic Medical Center Leadership: Advice From Leaders	ACADEMIC PATHOLOGY			English	Article						advice; AHC leaders; conflicts; department chair; senior fellows	CHAIR	The 2017 Association of Pathology Chairs Annual Meeting included a session for department chairs and other department leaders on "how to deal with deans and academic medical center leadership." The session was focused on discussing ways to foster positive relationships with university, medical school, and health system leaders, and productively address issues and opportunities with them. Presentations and a panel discussion were provided by 4 former pathology chairs who subsequently have served as medical deans and in other leadership positions including university provost, medical center CEO, and health system board chair. There was a strong consensus among the participants on how best to deal with superiors about problems, conflicts, and requests for additional resources and authority. The importance of teamwork and accountability in developing a constructive and collaborative relationship with leaders and peers was discussed in detail. Effectiveness in communication, negotiation, and departmental advocacy were highlighted as important skills. As limited resources and increased regulations have become growing problems for universities and health systems, internal stress and competition have increased. In this rapidly changing environment, advice on how chairs can interact most productively with institutional leaders is becoming increasingly important.	[Sanfilippo, Fred] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Powell, Deborah] Univ Minnesota, Dept Pathol & Lab Med, Minneapolis, MN USA; [Folberg, Robert] Oakland Univ, William Beaumont Sch Med, Rochester, MI 48063 USA; [Tykocinski, Mark] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA	Sanfilippo, F (reprint author), Emory Univ, 730GCR,1518 Clifton Rd, Atlanta, GA 30322 USA.	fred.sanfilippo@emory.edu					Bailey DN, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516673651; Bailey DN, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517733734; GABARRO JJ, 1980, HARVARD BUS REV, V58, P92; Gorstein F, ASS PATHOLOGY CHAIRS; Grigsby RK, 2009, FACULTY HLTH ACAD ME, P115; Grigsby RK, 2010, ACAD PHYS SCI    JAN, P4; Kastor JA, 2013, ACAD MED, V88, P912, DOI 10.1097/ACM.0b013e318294ff56; LaFasto F., 2001, TEAMS WORK BEST 6000; Lees DN, 2014, ACAD LEADER, V30, P1; Lencioni P., 2002, 5 DYSFUNCTIONS TEAM; Lieff S, 2013, ACAD MED, V88, P960, DOI 10.1097/ACM.0b013e318294ff36; Mallon WT, 2016, AAMC SUCCESSFUL MED; Souba W, 2011, ACAD MED, V86, P974, DOI 10.1097/ACM.0b013e31822223b2; Wiseman L, 2014, ACAD MED, V89, P376, DOI 10.1097/ACM.0000000000000146	14	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	APR 8	2018	5								UNSP 2374289518765462	10.1177/2374289518765462			7	Pathology	Pathology	GC4HA	WOS:000429744400001	29662949	DOAJ Gold, Green Published			2019-10-28	
J	Choi, E; Kim, W; Joo, SK; Park, S; Park, JH; Kang, YK; Jin, SY; Chang, MS				Choi, Euno; Kim, Won; Joo, Sae Kyung; Park, Sunyoung; Park, Jeong Hwan; Kang, Yun Kyung; Jin, So-Young; Chang, Mee Soo			Expression patterns of STAT3, ERK and estrogen-receptor alpha are associated with development and histologic severity of hepatic steatosis: a retrospective study	DIAGNOSTIC PATHOLOGY			English	Article						Hepatic steatosis; Non-alcoholic; Alcoholic; mTOR; pSTAT3; pERK; Estrogen-receptor alpha	FATTY LIVER-DISEASE; STELLATE CELLS; NONALCOHOLIC STEATOHEPATITIS; INDUCED ACTIVATION; SCORING SYSTEM; FIBROSIS; LEPTIN; MTOR; INJURY; MICE	Background: Hepatic steatosis renders hepatocytes vulnerable to injury, resulting in the progression of preexisting liver disease. Previous animal and cell culture studies implicated mammalian target of rapamycin (mTOR), signal transducer and activator of transcription-3 (STAT3), extracellular signal-regulated kinase (ERK) and estrogen-receptor a in the pathogenesis of hepatic steatosis and disease progression. However, to date there have been few studies performed using human liver tissue to study hepatic steatosis. We examined the expression patterns of mTOR, STAT3, ERK and estrogen-receptor a in liver tissues from patients diagnosed with hepatic steatosis. Methods: We reviewed the clinical and histomorphological features of 29 patients diagnosed with hepatic steatosis: 18 with non-alcoholic fatty liver disease (NAFLD), 11 with alcoholic fatty acid disease (AFLD), and a control group (16 biliary cysts and 22 hepatolithiasis). Immunohistochemistry was performed on liver tissue using an automated immunostainer. The histologic severity of hepatic steatosis was evaluated by assessing four key histomorphologic parameters common to NAFLD and AFLD: steatosis, lobular inflammation, ballooning degeneration and fibrosis. Results: mTOR, phosphorylated STAT3, phosphorylated pERK, estrogen-receptor a were found to be more frequently expressed in the hepatic steatosis group than in the control group. Specifically, mTOR was expressed in 78% of hepatocytes, and ERK in 100% of hepatic stellate cells, respectively, in patients with NAFLD. Interestingly, estrogen-receptor a was diffusely expressed in hepatocytes in all NALFD cases. Phosphorylated (active) STAT3 was expressed in 73% of hepatocytes and 45% of hepatic stellate cells in patients with AFLD, and phosphorylated (active) ERK was expressed in hepatic stellate cells in all AFLD cases. Estrogen-receptor a was expressed in all AFLD cases (focally in 64% of AFLD cases, and diffusely in 36%). Phosphorylated STAT3 expression in hepatocytes and hepatic stellate cells correlated with severe lobular inflammation, severe ballooning degeneration and advanced fibrosis, whereas diffusely expressed estrogen-receptor a correlated with a mild stage of fibrosis. Conclusions: Our data indicate ERK activation and estrogen-receptor a may be relevant in the development of hepatic steatosis. However, diffuse expression of estrogen-receptor a would appear to impede disease progression, including hepatic fibrosis. Finally, phosphorylated STAT3 may also contribute to disease progression.	[Choi, Euno; Park, Sunyoung; Park, Jeong Hwan; Chang, Mee Soo] Seoul Natl Univ, Boramae Hosp, Dept Pathol, Coll Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea; [Kim, Won; Joo, Sae Kyung] Seoul Natl Univ, Coll Med, Boramae Hosp, Dept Internal Med, 20 Boramae Ro 5 Gil, Seoul, South Korea; [Kang, Yun Kyung] Inje Univ, Coll Med, Dept Pathol, Seoul Paik Hosp, Mareunnae Ro 9, Seoul, South Korea; [Jin, So-Young] Soon Chun Hyang Univ Hosp, Dept Pathol, 59 Daesagwan Ro, Seoul, South Korea	Chang, MS (reprint author), Seoul Natl Univ, Boramae Hosp, Dept Pathol, Coll Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.	meesooch@snu.ac.kr	Kim, Won/H-6940-2019		National Research Foundation of Korea - Ministry of Education [2016R1D1A1B01010316]	This work was supported by the Basic Science Research Program of the National Research Foundation of Korea, which is funded by the Ministry of Education (2016R1D1A1B01010316).	[Anonymous], 2000, AS PAC PERSP RED OB, P8; Arteel GE, 2003, GASTROENTEROLOGY, V124, P778, DOI 10.1053/gast.2003.50087; Bai XP, 2017, TOXICOL APPL PHARM, V324, P12, DOI 10.1016/j.taap.2017.03.022; Bedossa P, 2014, HEPATOLOGY, V60, P565, DOI 10.1002/hep.27173; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Cao Q, 2004, J BIOL CHEM, V279, P4292, DOI 10.1074/jbc.M308351200; Chang MS, 2012, PATHOBIOLOGY, V79, P45, DOI 10.1159/000332739; Choi E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130839; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056, DOI 10.1016/0016-5085(88)90183-7; Eagon PK, 2010, WORLD J GASTROENTERO, V16, P1377, DOI 10.3748/wjg.v16.i11.1377; Elinav E, 2009, HEPATOLOGY, V49, P278, DOI 10.1002/hep.22584; Erkan G, 2013, PATHOL RES PRACT, V209, P429, DOI 10.1016/j.prp.2013.04.010; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gavaler JS, 1998, ALCOHOL HEALTH RES W, V22, P220; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hellerbrand C, 2010, DIGEST DIS, V28, P783, DOI 10.1159/000324286; Holcomb VB, 2012, MENOPAUSE, V19, P680, DOI 10.1097/gme.0b013e31823cf6ee; Itagaki T, 2005, GUT, V54, P1782, DOI 10.1136/gut.2005.053278; Kagan P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176173; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kojima H, 2005, ALCOHOL CLIN EXP RES, V29, p259S, DOI 10.1097/01/alc.0000191776.37626.30; Kong XN, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00069; Kubrusly MS, 2010, HISTOL HISTOPATHOL, V25, P1123, DOI 10.14670/HH-25.1123; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Li JJ, 2003, LIFE SCI, V73, P1083, DOI 10.1016/S0024-3205(03)00383-7; Mahli A, 2017, GUT; Maya-Monteiro CM, 2008, CELL CYCLE, V7, P1713, DOI 10.4161/cc.7.12.6157; Miller AM, 2011, HEPATOLOGY, V54, P846, DOI 10.1002/hep.24517; Mintziori G, 2017, MINERVA ENDOCRINOL, V42, P145, DOI 10.23736/S0391-1977.16.02570-0; Moreira RK, 2007, ARCH PATHOL LAB MED, V131, P1728; Naran NH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191388; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Powell EE, 2005, HEPATOLOGY, V42, P5, DOI 10.1002/hep.20750; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Saxena NK, 2003, J CELL BIOCHEM, V89, P311, DOI 10.1002/jcb.10494; Saxena NK, 2002, HEPATOLOGY, V35, P762, DOI 10.1053/jhep.2002.32029; Shigekawa M, 2011, BIOCHEM BIOPH RES CO, V406, P614, DOI 10.1016/j.bbrc.2011.02.105; Shimizu I, 2003, LIVER INT, V23, P63, DOI 10.1034/j.1600-0676.2003.00811.x; Sozio MS, 2010, SEMIN LIVER DIS, V30, P378, DOI 10.1055/s-0030-1267538; Spahr L, 2005, Rev Med Suisse, V1, P2032; Svegliati-Baroni G, 2003, J HEPATOL, V39, P528, DOI 10.1016/S0168-8278(03)00291-5; Tang LY, 2017, J BIOL CHEM, V292, P4302, DOI 10.1074/jbc.M116.773085; Tsang CK, 2010, CELL CYCLE, V9, P953, DOI 10.4161/cc.9.5.10876; Uebi T, 2015, GENES CELLS, V20, P217, DOI 10.1111/gtc.12214; Wang H, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-14; Wang X, 2017, APPL PHYSIOL NUTR ME, V42, P1082, DOI 10.1139/apnm-2016-0635; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yasuda M, 1999, HEPATOLOGY, V29, P719, DOI 10.1002/hep.510290307; Yip WW, 2006, SEMIN DIAGN PATHOL, V23, P149, DOI 10.1053/j.semdp.2006.11.002; Zhang F, 2014, MOL CELL ENDOCRINOL, V382, P197, DOI 10.1016/j.mce.2013.09.020; Zhang M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071405; Zhang W, 2013, INT J BIOCHEM CELL B, V45, P736, DOI 10.1016/j.biocel.2012.12.019	55	2	2	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	APR 3	2018	13								23	10.1186/s13000-018-0698-8			9	Pathology	Pathology	GB4WG	WOS:000429062300001	29615085	DOAJ Gold, Green Published			2019-10-28	
J	Kim, HJ				Kim, Hyun-Jung			Fine needle aspiration cytology finding of a parotid mass with chondromyxoid matrix and variable epithelial cytological atypia	CYTOJOURNAL			English	Editorial Material							EX PLEOMORPHIC ADENOMA; LESIONS		[Kim, Hyun-Jung] Inje Univ, Sanggye Paik Hosp, Dept Pathol, Seoul, South Korea	Kim, HJ (reprint author), Inje Univ, Sanggye Paik Hosp, Dept Pathol, Seoul, South Korea.	hjkim@paik.ac.kr					Di Palma S, 2013, HEAD NECK PATHOL, V7, pS68, DOI 10.1007/s12105-013-0454-z; El-Nagger AK, 2017, WHO CLASSIFICATION H, P176; Handa U, 2009, DIAGN CYTOPATHOL, V37, P11, DOI 10.1002/dc.20951; Hashimoto K, 2012, HISTOPATHOLOGY, V60, pE131, DOI 10.1111/j.1365-2559.2012.04201.x; Klijanienko J, 1996, DIAGN CYTOPATHOL, V14, P195, DOI 10.1002/(SICI)1097-0339(199604)14:3<195::AID-DC1>3.0.CO;2-H; Logasundaram R, 2008, EUR ARCH OTO-RHINO-L, V265, P1563, DOI 10.1007/s00405-008-0615-y; Mok Y, 2016, HEAD NECK-J SCI SPEC, V38, pE2483, DOI 10.1002/hed.24462; Nigam S, 2004, ACTA CYTOL, V48, P309, DOI 10.1159/000326378	8	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	APR 2	2018	15								10	10.4103/cytojournal.cytojournal_25_17			3	Pathology	Pathology	GH4PZ	WOS:000433387700001	29719559	DOAJ Gold, Green Published			2019-10-28	
J	Sharma, S; Gupta, N; Singh, N; Chaturvedi, R; Behera, D; Rajwanshi, A				Sharma, Saniya; Gupta, Nalini; Singh, Navneet; Chaturvedi, Rini; Behera, Digambar; Rajwanshi, Arvind			Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma	CYTOJOURNAL			English	Article						Cytomorphological features; epidermal growth factor receptor mutation; fine needle aspiration cytology; lung adenocarcinoma	EGFR GENE MUTATION; INTERNATIONAL-ASSOCIATION; CANCER; SUBTYPES; CLASSIFICATION; CARCINOMA; SPECIMENS; SURVIVAL; THERAPY	Background: Epidermal growth factor receptor mutation-positive (EGFR-p) lung adenocarcinomas are sensitive to tyrosine kinase inhibitors. Although histopathological subtype is an independent predictor of mutation status, there is a paucity of data on the cytomorphological features correlating with the EGFR mutation status. Therefore, the aim of this study was to determine whether certain cytomorphological features correlate with EGFR mutation in lung adenocarcinoma. Materials and Methods: A retrospective analysis of 48 lung adenocarcinoma cases diagnosed on fine needle aspiration cytology with known EGFR mutation status was conducted. All cytology smears with cellblock sections were reviewed. The cytomorphological features including tumor pattern, stromal features, nuclear and cytoplasmic features, and tumor grade were evaluated. Clinicoradiological features such as age, sex, smoking, tumor size, clinical stage, metastases, and presence of mass, nodule, lymphadenopathy, pleural effusion, and clinical outcome were also assessed. Results: Of 48 cases, 19 were EGFR-p and 29 were negative. EGFR-p cases showed a positive and significant correlation with flat monolayered sheets and acini, mild nuclear atypia, fine chromatin and smooth nuclear margins and these tumors were well differentiated. EGFR-negative tumors were moderate to poorly differentiated with predominance of solid clusters, moderate to marked nuclear atypia, with irregular nuclear margins and coarse chromatin. Clinically, female sex, nonsmoking status, smaller tumor size, and good clinical outcome correlated with EGFR-p status. Conclusion: Certain cytomorphological features correlate with and may suggest EGFR mutation status in advanced lung adenocarcinoma in an appropriate clinical context.	[Sharma, Saniya; Gupta, Nalini; Chaturvedi, Rini; Rajwanshi, Arvind] Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh, India; [Singh, Navneet; Behera, Digambar] Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh, India	Gupta, N (reprint author), Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh, India.	drsaniya.sharma@gmail.com; nalini203@gmail.com; navneetchd@hotmail.com; rini.chaturvedi@gmail.com; dirlrsi@gmail.com; rajwanshiarvind@hotmail.com					Blons H, 2006, AM J SURG PATHOL, V30, P1309, DOI 10.1097/01.pas.0000213285.65907.31; Boldrini L, 2007, J THORAC ONCOL, V2, P1086, DOI 10.1097/JTO.0b013e31815ba1fa; Brachtel EF, 2007, DIAGN CYTOPATHOL, V35, P257, DOI 10.1002/dc.20617; Cheng L, 2012, MODERN PATHOL, V25, P347, DOI 10.1038/modpathol.2011.215; Choughule A, 2013, INDIAN J CANCER, V50, P107, DOI 10.4103/0019-509X.117023; Clark DP, 2009, CANCER CYTOPATHOL, V117, P289, DOI 10.1002/cncy.20045; Dacic S, 2010, MODERN PATHOL, V23, P159, DOI 10.1038/modpathol.2009.154; Haneda H, 2006, JPN J CLIN ONCOL, V36, P69, DOI 10.1093/jjco/hyi228; Hu HC, 2014, ONCOTARGETS THER, V7, P1423, DOI 10.2147/OTT.S58900; Li ZB, 2014, AM J CLIN PATHOL, V141, P420, DOI 10.1309/AJCPHF51LSPCAXTA; Ma ESK, 2012, ACTA CYTOL, V56, P661, DOI 10.1159/000343606; Marotti JD, 2013, DIAGN CYTOPATHOL, V41, P15, DOI 10.1002/dc.21749; Maturu VN, 2016, LUNG INDIA, V33, P257, DOI 10.4103/0970-2113.180801; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pikor LA, 2013, LUNG CANCER, V82, P179, DOI 10.1016/j.lungcan.2013.07.025; Rekhtman N, 2011, J THORAC ONCOL, V6, P451, DOI 10.1097/JTO.0b013e31820517a3; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Varsegi GM, 2009, J VIS EXP; Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123	21	3	3	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	APR 2	2018	15								11	10.4103/cytojournal.cytojournal_45_17			9	Pathology	Pathology	GH4PZ	WOS:000433387700002	29719560	DOAJ Gold, Green Published			2019-10-28	
J	Mrak, RE; Parslow, TG; Tomaszewski, JE				Mrak, Robert E.; Parslow, Tristram G.; Tomaszewski, John E.			Outsourcing of Academic Clinical Laboratories: Experiences and Lessons From the Association of Pathology Chairs Laboratory Outsourcing Survey	ACADEMIC PATHOLOGY			English	Article						academic medical centers; clinical laboratories; clinical pathology; joint ventures; outsourcing; resident education in pathology		American hospitals are increasingly turning to service outsourcing to reduce costs, including laboratory services. Studies of this practice have largely focused on nonacademic medical centers. In contrast, academic medical centers have unique practice environments and unique mission considerations. We sought to elucidate and analyze clinical laboratory outsourcing experiences in US academic medical centers. Seventeen chairs of pathology with relevant experience were willing to participate in in-depth interviews about their experiences. Anticipated financial benefits from joint venture arrangements often eroded after the initial years of the agreement, due to increased test pricing, management fees, duplication of services in support of inpatients, and lack of incentive for utilization control on the part of the for-profit partner. Outsourcing can preclude development of lucrative outreach programs; such programs were successfully launched in several cases after joint ventures were either avoided or terminated. Common complaints included poor test turnaround time and problems with test quality (especially in molecular pathology, microbiology, and flow cytometry), leading to clinician dissatisfaction. Joint ventures adversely affected retention of academically oriented clinical pathology faculty, with adverse effects on research and education, which further exacerbated clinician dissatisfaction due to lack of available consultative expertise. Resident education in pathology and in other disciplines (especially infectious disease) suffered both from lack of on-site laboratory capabilities and from lack of teaching faculty. Most joint ventures were initiated with little or no input from pathology leadership, and input from pathology leadership was seen to have been critical in those cases where such arrangements were declined or terminated.	[Mrak, Robert E.] Univ Toledo, Coll Med & Life Sci, Dept Pathol, 3000 Arlington Ave, Toledo, OH 43614 USA; [Parslow, Tristram G.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Tomaszewski, John E.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Pathol & Anat Sci, Buffalo, NY USA	Mrak, RE (reprint author), Univ Toledo, Coll Med & Life Sci, Dept Pathol, 3000 Arlington Ave, Toledo, OH 43614 USA.	robert.mrak@utoledo.edu					[Anonymous], 2006, J ONCOL PRACT, V2, P162; Borchardt JK, 2009, LAB MANAGER; Chasin BS, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.07.024; De Jesus J., 2013, INFINIT HEALTHCARE; Forsman R W, 2001, Clin Leadersh Manag Rev, V15, P217; Friedman B., 2016, LAB SOFT NEWS; LaBeau Kathleen M, 2002, MLO Med Lab Obs, V34, P24; Lee Jaimy, 2014, Mod Healthc, V44, P14; Osborne J., 2016, MED LAB OBSERVER; Scott K., 2017, CLIN LAB NEWS AACC	10	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	APR 2	2018	5								UNSP 2374289518765435	10.1177/2374289518765435			5	Pathology	Pathology	GC4GZ	WOS:000429744300001	29637086	DOAJ Gold, Green Published			2019-10-28	
J	Zhao, CL; Amin, A; Hui, Y; Yang, DF; Cao, WB				Zhao, Chaohui Lisa; Amin, Ali; Hui, Yiang; Yang, Dongfang; Cao, Weibiao			TGR5 expression in normal kidney and renal neoplasms	DIAGNOSTIC PATHOLOGY			English	Article						G protein-coupled bile acid receptor; TGR5; Renal cell carcinoma; Urothelial cell carcinoma; Oncocytoma	ACID RECEPTOR TGR5; GLOMERULAR MESANGIAL CELLS; BILE-ACIDS; ACTIVATION; CARCINOMA; CANCER; ADENOCARCINOMA; NEPHRONS	Background: The G protein-coupled bile acid receptor (TGR5) is a cell surface receptor which induces the production of intracellular cAMP and promotes epithelial-mesenchymal transition in gastric cancer cell lines. TGR5 is found in a wide variety of tissues including the kidney. However, the patterns of TGR5 expression have not been well characterized in physiologic kidney or renal neoplasms. We explore the expression of TGR5 in benign renal tissue and renal neoplasms and assess its utility as a diagnostic marker. Methods: Sixty-one renal cortical neoplasms from 2000 to 2014 were retrieved. TGR5 protein expression was examined by immunohistochemistry. TGR5 mRNA was also measured by real-time PCR. Results: In normal renal tissue, TGR5 was strongly positive in collecting ducts, distal convoluted tubules and thin loop of Henle. Proximal convoluted tubules showed absent or focal weak staining. In clear cell renal cell carcinomas (RCCs), 25 of 27 cases (92%) were negative for TGR5 (p < 0.001). TGR5 mRNA was also significantly decreased in clear cell RCCs, suggesting that decreased TGR5 protein expression may be attributable to the downregulation of TGR5 mRNA in these tumors. All 11 papillary RCCs expressed TGR5 with 45% (5/11) exhibiting moderate to strong staining. All chromophobe RCCs and oncocytomas were positive for TGR5 with weak to moderate staining. TGR5 mRNA expression in these tumors was similar to normal kidney. All urothelial carcinomas of the renal pelvis strongly expressed TGR5 including a poorly differentiated urothelial carcinoma with sarcomatoid features. Conclusion: TGR5 is strongly expressed in collecting ducts, distal convoluted tubules and thin loop of Henle. TGR5 protein and mRNA expression were notably decreased in clear cell RCCs and may be helpful in differentiating these tumors from other RCCs.	[Zhao, Chaohui Lisa; Amin, Ali; Hui, Yiang; Yang, Dongfang; Cao, Weibiao] Rhode Isl Hosp, Dept Pathol, 593 Eddy St,APC 12, Providence, RI 02903 USA; [Zhao, Chaohui Lisa; Amin, Ali; Hui, Yiang; Yang, Dongfang; Cao, Weibiao] Brown Univ, Warren Alpert Med Sch, 593 Eddy St,APC 12, Providence, RI 02903 USA; [Cao, Weibiao] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA	Cao, WB (reprint author), Rhode Isl Hosp, Dept Pathol, 593 Eddy St,APC 12, Providence, RI 02903 USA.; Cao, WB (reprint author), Brown Univ, Warren Alpert Med Sch, 593 Eddy St,APC 12, Providence, RI 02903 USA.; Cao, WB (reprint author), Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA.	Weibiao_Cao@brown.edu					Alshenawy HA, 2015, PATHOL ONCOL RES, V21, P893, DOI 10.1007/s12253-015-9898-7; Axelson H, 2013, SEMIN CANCER BIOL, V23, P56, DOI 10.1016/j.semcancer.2012.06.005; Ayerbes MV, 2008, CLIN TRANSL ONCOL, V10, P697, DOI 10.1007/s12094-008-0276-8; Cao WB, 2013, AM J PHYSIOL-GASTR L, V304, pG322, DOI 10.1152/ajpgi.00263.2012; Carino A, 2016, ONCOTARGET, V7, P61021, DOI 10.18632/oncotarget.10477; Fleming S, 2015, SEMIN DIAGN PATHOL, V32, P114, DOI 10.1053/j.semdp.2015.02.004; GARG LC, 1988, J CLIN INVEST, V81, P1204, DOI 10.1172/JCI113436; Herman-Edelstein M, 2018, CURR OPIN NEPHROL HY, V27, P56, DOI 10.1097/MNH.0000000000000374; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Katsuma S, 2005, BIOCHEM BIOPH RES CO, V329, P386, DOI 10.1016/j.bbrc.2005.01.139; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Kuroda N, 2014, MED MOL MORPHOL, V47, P68, DOI 10.1007/s00795-013-0033-0; Li D, 2016, SCI REP-UK, V6, DOI 10.1038/srep31538; Masyuk AI, 2013, AM J PHYSIOL-GASTR L, V304, pG1013, DOI 10.1152/ajpgi.00383.2012; McCormick JA, 2015, COMPR PHYSIOL, V5, P45, DOI 10.1002/cphy.c140002; Nagashima Y, 2000, PATHOL INT, V50, P872, DOI 10.1046/j.1440-1827.2000.01131.x; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SNARSKI J, 1985, CELL BIOCHEM FUNCT, V3, P127, DOI 10.1002/cbf.290030208; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; VALTIN H, 1977, AM J PHYSIOL, V233, pF491; Wang XXX, 2016, J AM SOC NEPHROL, V27, P1362, DOI 10.1681/ASN.2014121271; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Xiong FX, 2016, ENDOCRINE, V54, P657, DOI 10.1007/s12020-016-1032-4; Yang ZY, 2016, PHARMACOL RES, V111, P226, DOI 10.1016/j.phrs.2016.05.035	25	0	0	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	APR 2	2018	13								22	10.1186/s13000-018-0700-5			6	Pathology	Pathology	GB2RM	WOS:000428902500001	29606134	DOAJ Gold, Green Published			2019-10-28	
J	Sucre, JMS; Deutsch, GH; Jetter, CS; Ambalavanan, N; Benjamin, JT; Gleaves, LA; Millis, BA; Young, LR; Blackwell, TS; Kropski, JA; Guttentag, SH				Sucre, Jennifer M. S.; Deutsch, Gail H.; Jetter, Christopher S.; Ambalavanan, Namasivayam; Benjamin, John T.; Gleaves, Linda A.; Millis, Bryan A.; Young, Lisa R.; Blackwell, Timothy S.; Kropski, Jonathan A.; Guttentag, Susan H.			A Shared Pattern of beta-Catenin Activation in Bronchoputmonary Dysptasia and Idiopathic Pulmonary Fibrosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DISEASE; IDENTIFICATION; DIAGNOSIS; ADHESION; REPAIR	Wnt/beta-catenin signaling is necessary for normal lung development, and abnormal Wnt signaling contributes to the pathogenesis of both bronchopulmonary dysplasia (BPD) and idiopathic pulmonary fibrosis (IPF), fibrotic lung diseases that occur during infancy and aging, respectively. Using a library of human normal and diseased human lung samples, we identified a distinct signature of nuclear accumulation of beta-catenin phosphorylated at tyrosine 489 and epithelial cell cytosolic localization of beta-catenin phosphorylated at tyrosine 654 in early normal lung development and fibrotic lung diseases BPD and IPF. Furthermore, this signature was recapitulated in murine models of BPD and IPF. Image analysis of immunoftuorescence colocalization demonstrated a consistent pattern of elevated nuclear phosphorylated beta-catenin in the lung epithelium and surrounding mesenchyme in BPD and IPF, closely resembling the pattern observed in 18-week fetal Lung. Nuclear beta-catenin phosphorylated at tyrosine 489 associated with an increased expression of Wnt target gene AXIN2, suggesting that the observed beta-catenin signature is of functional significance during normal development and injury repair. The association of specific modifications of beta-catenin during normal lung development and again in response to lung injury supports the widely held concept that repair of lung injury involves the recapitulation of developmental programs. Furthermore, these observations suggest that beta-catenin phosphorylation has potential as a therapeutic target for the treatment and prevention of both BPD and IPF.	[Sucre, Jennifer M. S.; Jetter, Christopher S.; Benjamin, John T.; Guttentag, Susan H.] Vanderbilt Univ, Dept Pediat, Mildred Stahlman Div Neonatol, Nashville, TN USA; [Millis, Bryan A.; Young, Lisa R.] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Millis, Bryan A.] Vanderbilt Univ, Cell Imaging Shared Resource, 221 Kirkland Hall, Nashville, TN 37235 USA; [Millis, Bryan A.] Vanderbilt Univ, Vanderbilt Biophoton Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [Deutsch, Gail H.] Seattle Childrens Hosp, Dept Pathol, Seattle, WA USA; [Deutsch, Gail H.] Univ Washington, Seattle, WA 98195 USA; [Ambalavanan, Namasivayam] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Young, Lisa R.; Blackwell, Timothy S.; Kropski, Jonathan A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Gleaves, Linda A.; Young, Lisa R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pulm Med, Nashville, TN 37232 USA; [Blackwell, Timothy S.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; [Blackwell, Timothy S.] Nashville Vet Affairs Med Ctr, Nashville, TN USA	Sucre, JMS (reprint author), Vanderbilt Univ, 2215B Garland Ave,1125 Light Hall, Nashville, TN 37232 USA.	jennifer.sucre@vanderbilt.edu	Guttentag, Susan H/D-8705-2013	Guttentag, Susan H/0000-0003-4420-5879; Deutsch, Gail/0000-0002-0571-0285; Ambalavanan, Namasivayam/0000-0003-0731-9092; Sucre, Jennifer/0000-0002-6613-1439	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD087023, CA68485, DK20593, DK58404, DK5963]; National Institute of General Medical Sciences grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM108807]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K08HL133484, R01HL119503, K08HL130595, P01HL92870, R01HL085317]; Department of Veterans Affairs grantUS Department of Veteran Affairs [BX002378]; Francis Family Foundation; Pulmonary Fibrosis Foundation; Julia Carrell Stadler Chair in Pediatrics	Supported by NIH grant K12 HD087023 (J.M.S.S.); National Institute of General Medical Sciences grant GM108807 (S.H.G.); National Heart, Lung, and Blood Institute grants K08HL133484 (J.T.B.), R01HL119503 (L.R.Y.), K08HL130595 (J.A.K.), P01HL92870 (T.S.B.), and R01HL085317 (T.S.B.); Department of Veterans Affairs grant BX002378 (T.S.B.); the Francis Family Foundation (J.A.K.); the Pulmonary Fibrosis Foundation (J.A.K.); and the Julia Carrell Stadler Chair in Pediatrics (S.H.G.). Experiments were performed, in part, through the use of the Vanderbilt University Cell Imaging Shared Resource, supported by NIH grants CA68485, DK20593, DK58404, and DK5963.	Ambalavanan N, 2008, AM J PHYSIOL-LUNG C, V295, pL86, DOI 10.1152/ajplung.00534.2007; Baarsma HA, 2017, J EXP MED, V214, P143, DOI 10.1084/jem.20160675; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Beers MF, 2011, J CLIN INVEST, V121, P2065, DOI 10.1172/JCI45961; Degryse AL, 2012, EXP LUNG RES, V38, P124, DOI 10.3109/01902148.2012.658148; Degryse AL, 2010, AM J PHYSIOL-LUNG C, V299, pL442, DOI 10.1152/ajplung.00026.2010; Frank DB, 2016, CELL REP, V17, P2312, DOI 10.1016/j.celrep.2016.11.001; Hadchouel A, 2014, BIRTH DEFECTS RES A, V100, P158, DOI 10.1002/bdra.23237; Jobe AH, 2011, CURR OPIN PEDIATR, V23, P167, DOI 10.1097/MOP.0b013e3283423e6b; Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142; Kropski JA, 2015, EUR RESPIR J, V45, P1717, DOI 10.1183/09031936.00163814; Lawson WE, 2011, P NATL ACAD SCI USA, V108, P10562, DOI 10.1073/pnas.1107559108; Li JJ, 2015, AM J RESP CRIT CARE, V192, P589, DOI 10.1164/rccm.201501-0168OC; Li N, 2016, DEV DYNAM, V245, P822, DOI [10.1002/dvdy.24423, 10.1002/DVDY.24423]; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Ota Chiharu, 2016, Mol Cell Pediatr, V3, P34; Paul MK, 2014, CELL STEM CELL, V15, P199, DOI 10.1016/j.stem.2014.05.009; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Ramani M, 2015, AM J RESP CELL MOL, V52, P594, DOI 10.1165/rcmb.2013-0491OC; Rhee J, 2007, NAT CELL BIOL, V9, P883, DOI 10.1038/ncb1614; Richeldi L, 2017, LANCET, V389, P1941, DOI 10.1016/S0140-6736(17)30866-8; Sucre JMS, 2017, AM J PHYSIOL-LUNG C, V312, pL186, DOI 10.1152/ajplung.00477.2016; Sucre JMS, 2016, AM J PHYSIOL-LUNG C, V310, pL889, DOI 10.1152/ajplung.00446.2015; Tanjore H, 2013, AM J RESP CRIT CARE, V187, P630, DOI 10.1164/rccm.201205-0972OC; van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460; Verheyen EM, 2010, DEV DYNAM, V239, P34, DOI 10.1002/dvdy.22019; Voynow JA, 2017, PAEDIATR RESPIR REV, V24, P17, DOI 10.1016/j.prrv.2017.06.006; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wilkinson DC, 2017, STEM CELL TRANSL MED, V6, P622, DOI 10.5966/sctm.2016-0192; Xi Y, 2013, ONCOGENE, V32, P5048, DOI 10.1038/onc.2012.530; Yilmaz O, 2015, GROWTH FACTORS, V33, P366, DOI 10.3109/08977194.2015.1109511; Zhang MF, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-21	33	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					853	862		10.1016/j.ajpath.2017.12.004			10	Pathology	Pathology	GB6NH	WOS:000429185400004	29355514	Bronze, Green Published			2019-10-28	
J	Rotti, PG; Xie, WL; Poudel, A; Yi, YL; Sun, XS; Tyler, SR; Uc, A; Norris, AW; Hara, M; Engelhardt, JF; Gibson-Corley, KN				Rotti, Pavana G.; Xie, Weiliang; Poudel, Ananta; Yi, Yaling; Sun, Xingshen; Tyler, Scott R.; Uc, Aliye; Norris, Andrew W.; Hara, Manami; Engelhardt, John F.; Gibson-Corley, Katherine N.			Pancreatic and Islet Remodeling in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Knockout Ferrets	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ENDOCRINE PANCREAS; EXOCRINE PANCREAS; LUNG-FUNCTION; CELLS; INSULIN; REGENERATION; MICE; ACTIVATION; SECRETION; PHENOTYPE	In cystic fibrosis (CF), there is early destruction of the exocrine pancreas, and this results in a unique form of diabetes that affects approximately half of adult CF individuals. An animal model of cystic fibrosis-related diabetes has been developed in the ferret, which progresses through phases of glycemic abnormalities because of islet remodeling during and after exocrine destruction. Herein, we quantified the pancreatic histopathological changes that occur during these phases. There was an increase in percentage ductal, fat, and islet area in CF ferrets over time compared with age-matched wild-type controls. We also quantified islet size, shape, islet cell composition, cell proliferation (Ki-67), and expression of remodeling markers (matrix metalloprotease-7, desmin, and a-smooth muscle actin). Pancreatic ducts were dilated with scattered proliferating cells and were surrounded by activated stellate cells, indicative of tissue remodeling. The timing of islet and duct proliferation, stellate cell activation, and matrix remodeling coincided with the previously published stages of glycemic crisis and inflammation. This mapping of remodeling events in the CF ferret pancreas provides insights into early changes that control glycemic intolerance and subsequent recovery during the evolution of CF pancreatic disease.	[Rotti, Pavana G.; Xie, Weiliang; Yi, Yaling; Sun, Xingshen; Tyler, Scott R.; Engelhardt, John F.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA USA; [Rotti, Pavana G.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biomed Engn, Iowa City, IA USA; [Gibson-Corley, Katherine N.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA USA; [Poudel, Ananta; Hara, Manami] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Uc, Aliye; Norris, Andrew W.] Univ Chicago, Roy J & Lucille A Carver Coll Med, Stead Family Dept Pediat, Chicago, IL USA	Gibson-Corley, KN (reprint author), Univ Iowa, Med Labs 1167, Iowa City, IA 52242 USA.	katherine-gibson-corley@uiowa.edu	Norris, Andrew/O-5499-2018	Norris, Andrew/0000-0001-8396-9543; Uc, Aliye/0000-0003-2004-5743; Engelhardt, John/0000-0003-2389-9277; Gibson-Corley, Katherine/0000-0002-1846-1580	NIH R24 grants [DK096518, HL123482, R01 DK097820]; Fraternal Order of Eagles Diabetes Research Center scholar award; University of Iowa Center for Gene Therapy grant [DK54759]; Carver Chair in Molecular Medicine award; UK Cystic Fibrosis Trust [SRC007]	Supported by NIH R24 grants DK096518 (J.F.E.), HL123482 (J.F.E.), and R01 DK097820 (A.U. and A.W.N.); a Fraternal Order of Eagles Diabetes Research Center scholar award (A.W.N.); the University of Iowa Center for Gene Therapy grant DK54759 (J.F.E.); the Carver Chair in Molecular Medicine award (J.F.E.); and the UK Cystic Fibrosis Trust grant SRC007 (J.F.E).	Abu-El-Haija M, 2012, AM J PATHOL, V181, P499, DOI 10.1016/j.ajpath.2012.04.024; Aguayo-Mazzucato C, 2017, CELL METAB, V25, P898, DOI 10.1016/j.cmet.2017.03.015; Aye T, 2010, J HISTOCHEM CYTOCHEM, V58, P369, DOI 10.1369/jhc.2009.954909; Bonner-Weir Susan, 2012, Rev Diabet Stud, V9, P407, DOI 10.1900/RDS.2012.9.407; Megias MC, 2015, ENDOCRINOL NUTR, V62, P91, DOI 10.1016/j.endonu.2014.08.002; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; DUMM CLAG, 1995, PANCREAS, V11, P396, DOI 10.1097/00006676-199511000-00012; Gibson-Corley KN, 2016, J PATHOL, V238, P311, DOI 10.1002/path.4634; Inada A, 2008, P NATL ACAD SCI USA, V105, P19915, DOI 10.1073/pnas.0805803105; Ishiguro H, 2009, J GEN PHYSIOL, V133, P315, DOI 10.1085/jgp.200810122; Keiser NW, 2011, CURR OPIN PULM MED, V17, P478, DOI 10.1097/MCP.0b013e32834b14c9; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li WC, 2010, J CELL SCI, V123, P2792, DOI 10.1242/jcs.065268; Lindkvist B, 2013, WORLD J GASTROENTERO, V19, P7258, DOI 10.3748/wjg.v19.i42.7258; Marselli L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011499; MORAN A, 1994, DIABETES, V43, P1020, DOI 10.2337/diabetes.43.8.1020; Moran A, 2009, DIABETES CARE, V32, P1626, DOI 10.2337/dc09-0586; Murtaugh LC, 2008, PANCREATIC STEM CELL; Olivier AK, 2012, J CLIN INVEST, V122, P3755, DOI 10.1172/JCI60610; Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Plikus MV, 2017, SCIENCE, V355, P748, DOI 10.1126/science.aai8792; Poudel A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34049; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Scotti ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030509; Steiner DJ, 2010, ISLETS, V2, P135, DOI 10.4161/isl.2.3.11815; Strowski MZ, 2000, ENDOCRINOLOGY, V141, P111, DOI 10.1210/en.141.1.111; Sun X, 2008, J CLIN INVEST, V118, P1578, DOI 10.1172/JCI34599; Sun XS, 2014, AM J PATHOL, V184, P1309, DOI 10.1016/j.ajpath.2014.01.035; Sun XS, 2014, AM J RESP CELL MOL, V50, P502, DOI 10.1165/rcmb.2013-0261OC; Sun XS, 2010, J CLIN INVEST, V120, P3149, DOI 10.1172/JCI43052; Terliesner N, 2017, J PEDIATR ENDOCR MET, V30, P815, DOI 10.1515/jpem-2017-0005; Uc A, 2015, CLIN SCI, V128, P131, DOI 10.1042/CS20140059; Welsh L, 2014, PEDIATR PULM, V49, P873, DOI 10.1002/ppul.22946; Wilschanski M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a009746; Yagihashi S, 2016, J DIABETES INVEST, V7, P155, DOI 10.1111/jdi.12424; Yi YL, 2016, AM J RESP CRIT CARE, V194, P974, DOI 10.1164/rccm.201512-2518OC; Yi YL, 2016, ENDOCRINOLOGY, V157, P1852, DOI 10.1210/en.2015-1935	39	6	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					876	890		10.1016/j.ajpath.2017.12.015			15	Pathology	Pathology	GB6NH	WOS:000429185400006	29366680	Bronze, Green Published			2019-10-28	
J	de la Rosa, X; Norris, PC; Chiang, N; Rodriguez, AR; Spur, BW; Serhan, CN				de la Rosa, Xavier; Norris, Paul C.; Chiang, Nan; Rodriguez, Ana R.; Spur, Bernd W.; Serhan, Charles N.			Identification and Complete Stereochemical Assignments of the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that Stimulate Proresolving Phagocyte Functions and Tissue Regeneration	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LIPID MEDIATORS; MACROPHAGE EFFEROCYTOSIS; DOCOSAHEXAENOIC ACID; BONE-MARROW; RESOLUTION; INFLAMMATION; OMEGA-3-FATTY-ACIDS; INTERLEUKIN-11; MECHANISMS; CHEMOTAXIS	Resolvin conjugates in tissue regeneration (RCTRs) are new chemical signals that accelerate resolution of inflammation, infection, and tissue regeneration. Herein, using liquid chromatography-tandem mass spectrometry-based metabololipidomics, we identified RCTRs in human spleen, lymph node, bone marrow, and brain. In human spleen incubated with Staphylococcus aureus, endogenous RCTRs were increased along with conversion of deuterium-labeled docosahexaenoic acid, conferring pathway activation. Physical and biological properties of endogenous RCTRs were matched with those prepared by total organic synthesis. The complete stereochemicaL assignment of bioactive RCTR1 is 8R-glutathionyl-7S,17S-dihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, RCTR2 is 8R-cysteinylglycinyl-7S,17S-dihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, and RCTR3 is 8R-cysteinyt-7S,17S-dihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid. These stereochemically defined RCTRs stimulated human macrophage phagocytosis, efferocytosis, and planaria tissue generation. Proteome profiling demonstrated that RCTRs regulated both proinftammatory and anti-inflammatory cytokines with human macrophages. In microfluidic chambers, the three RCTRs limited human polymorphonuclear cell migration. In hind-Limb ischemia-reperfusion-initiated organ injury, both RCTR2 and RCTR3 reduced polymorphonuclear cell infiltration into lungs. In infectious peritonitis, RCTR1 shortened the resolution intervals. Each RCTR (1 nmol/L) accelerated planaria tissue regeneration by approximately 0.5 days, with direct comparison to both maresin and protectin CTRs. Together, these results identify a new bioactive RCTR (ie, RCTR3) in human tissues and establish the complete stereochemistry and rank-order potencies of three RCTRs in vivo. Moreover, RCTR1, RCTR2, and RCTR3 each exert potent anti-inflammatory and proresolving actions with human leukocytes.	[de la Rosa, Xavier; Norris, Paul C.; Chiang, Nan; Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Bldg Transformat Med, Boston, MA 02115 USA; [de la Rosa, Xavier; Norris, Paul C.; Chiang, Nan; Serhan, Charles N.] Harvard Med Sch, Boston, MA USA; [Rodriguez, Ana R.; Spur, Bernd W.] Rowan Univ, Sch Med, Dept Cell Biol, Stratford, NJ USA	Serhan, CN (reprint author), Ctr Expt Therapeut & Reperfus Injury, 60 Fenwood Rd,BTM 3-016N, Boston, MA 02115 USA.	cserhan@bwh.harvard.edu		Serhan, Charles N./0000-0003-4627-8545; Norris, Paul/0000-0003-2512-0829	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01GM095467]; American Society for Investigative Pathology (ASIP)	Supported in part by NIH grant P01GM095467 (C.N.S.).; The Rous-Whipple Award is given by the American Society for Investigative Pathology (ASIP) to a senior pathologist with a distinguished career in experimental pathology research and continued productivity at the time of the award. This article stems from the ASIP Rous-Whipple Award Lecture: "Decoding Novel Resolution Mediators and Mechanisms in Infectious Inflammation and Tissue Regeneration," presented by C.N.S. at the annual meeting of the American Society for Investigative Pathology in San Diego, CA, April 21 to 25, 2018.	Allers K, 2014, J INFECT DIS, V209, P739, DOI 10.1093/infdis/jit547; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Calder PC, 2015, BBA-MOL CELL BIOL L, V1851, P469, DOI 10.1016/j.bbalip.2014.08.010; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Chiang N, 2017, MOL ASPECTS MED, V58, P114, DOI 10.1016/j.mam.2017.03.005; Chiang N, 2017, J IMMUNOL, V198, P842, DOI 10.4049/jimmunol.1601650; Chiurchiu V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7483; CHOMARAT P, 1995, J IMMUNOL, V154, P1432; Claria J, 2017, MOL ASPECTS MED, V58, P83, DOI 10.1016/j.mam.2017.03.004; Colas RA, 2014, AM J PHYSIOL-CELL PH, V307, pC39, DOI 10.1152/ajpcell.00024.2014; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, P1425; Dalli J, 2016, P NATL ACAD SCI USA, V113, P12232, DOI 10.1073/pnas.1607003113; Dalli J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149319; Dalli J, 2015, FASEB J, V29, P2120, DOI 10.1096/fj.14-268441; Dalli J, 2014, P NATL ACAD SCI USA, V111, pE4753, DOI 10.1073/pnas.1415006111; Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525; Delano MJ, 2016, J CLIN INVEST, V126, P23, DOI 10.1172/JCI82224; Elliott SA, 2013, WIRES DEV BIOL, V2, P301, DOI 10.1002/wdev.82; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Eming SA, 2017, SCIENCE, V356, P1026, DOI 10.1126/science.aam7928; English JT, 2017, PROSTAG LEUKOTR ESS, V117, P17, DOI 10.1016/j.plefa.2017.01.004; Fiala M, 2015, J ALZHEIMERS DIS, V48, P293, DOI 10.3233/JAD-150367; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gurfein BT, 2009, J IMMUNOL, V183, P4229, DOI 10.4049/jimmunol.0900622; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kasuga K, 2008, J IMMUNOL, V181, P8677, DOI 10.4049/jimmunol.181.12.8677; Kim N, 2016, EUR J IMMUNOL, V46, P81, DOI 10.1002/eji.201545673; Li Y, 2006, J INVEST DERMATOL, V126, P2096, DOI 10.1038/sj.jid.5700350; Libby P, 2014, CIRC RES, V114, P1867, DOI 10.1161/CIRCRESAHA.114.302699; Majno G, 2004, CELLS TISSUES DIS PR; Malawista SE, 2008, P NATL ACAD SCI USA, V105, P17949, DOI 10.1073/pnas.0802572105; Malet-Engra G, 2013, CANCER RES, V73, P3412, DOI 10.1158/0008-5472.CAN-12-3564; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; McCauley LK, 2014, J IMMUNOL, V193, P26, DOI 10.4049/jimmunol.1301945; Miki Y, 2013, J EXP MED, V210, P1217, DOI 10.1084/jem.20121887; Norling LV, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85922; Oh SF, 2012, J IMMUNOL, V188, P4527, DOI 10.4049/jimmunol.1103652; Perretti M, 2017, NAT REV RHEUMATOL, V13, P87, DOI 10.1038/nrrheum.2016.193; Poulsen RC, 2008, AM J HEMATOL, V83, P437, DOI 10.1002/ajh.21170; Ramon S, 2016, AM J PATHOL, V186, P962, DOI 10.1016/j.ajpath.2015.12.012; Reategui E, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0094; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rodriguez AR, 2017, TETRAHEDRON LETT, V58, P1662, DOI 10.1016/j.tetlet.2017.03.041; Salem N, 2015, PROSTAG LEUKOTR ESS, V92, P15, DOI 10.1016/j.plefa.2014.10.003; Samuelsson B, 2012, J BIOL CHEM, V287, P10070, DOI 10.1074/jbc.X112.351437; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan C.N., 2010, FUNDAMENTALS INFLAMM; Serhan CN, 2017, MOL ASPECTS MED, V58, P1, DOI 10.1016/j.mam.2017.03.001; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11-201442; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Titos E, 2016, J IMMUNOL, V197, P3360, DOI 10.4049/jimmunol.1502522; Walmsley M, 1998, IMMUNOLOGY, V95, P31; Werner S, 2007, J INVEST DERMATOL, V127, P998, DOI 10.1038/sj.jid.5700786; Yang R, 2011, CURR PROTOC IMMUNOL, V95; Yu JJ, 2016, CLIN RES HEPATOL GAS, V40, P562, DOI 10.1016/j.clinre.2015.11.009	60	9	9	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					950	966		10.1016/j.ajpath.2018.01.004			17	Pathology	Pathology	GB6NH	WOS:000429185400012	29571326	Green Published, Bronze			2019-10-28	
J	Liu, ZZ; Wang, ZL; Choi, TI; Huang, WT; Wang, HT; Han, YY; Zhu, LY; Kim, HT; Choi, JH; Lee, JS; Kim, HG; Zhao, J; Chen, Y; Lu, Z; Tian, XL; Pan, BX; Li, BM; Kim, CH; Xu, HA				Liu, Zhi-Zhi; Wang, Zi-Long; Choi, Tae-Ik; Huang, Wen-Ting; Wang, Han-Tsing; Han, Ying-Ying; Zhu, Lou-Yin; Kim, Hyun-Taek; Choi, Jung-Hwa; Lee, Jin-Soo; Kim, Hyung-Goo; Zhao, Jian; Chen, Yue; Lu, Zhuo; Tian, Xiao-Li; Pan, Bing-Xing; Li, Bao-Ming; Kim, Cheol-Hee; Xu, Hong A.			Chd7 Is Critical for Early T-Cell Development and Thymus Organogenesis in Zebrafish	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CHARGE SYNDROME; PHENOTYPIC SPECTRUM; IMMUNODEFICIENCY; PROGENITOR; EXPRESSION; MUTATIONS; FOXN1; BMP4; TRANSPLANTATION; MOUSE	Coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness (CHARGE) syndrome is a congenital disorder affecting multiple organs and mainly caused by mutations in CHD7, a gene encoding a chromatin-remodeling protein. Immunodeficiency and reduced T cells have been noted in CHARGE syndrome. However, the mechanisms underlying T lymphopenia are largely unexplored. Herein, we observed dramatic decrease of T cells in both chd7knockdown and knockout zebrafish embryos. Unexpectedly, hematopoietic stem and progenitor cells and, particularly, lymphoid progenitor cells were increased peripherally in nonthymic areas in chd7-deficient embryos, unlikely to contribute to the T-cell decrease. Further analysis demonstrated that both the organogenesis and homing function of the thymus were seriously impaired. Chd7 might regulate thymus organogenesis through modulating the development of both neural crest cell-derived mesenchyme and pharyngeal endoderm-derived thymic epithelial cells. The expression of faxn1, a central regulator of thymic epithelium, was remarkably down-regulated in the pharyngeal region in chd7-deficient embryos. Moreover, the T-cell reduction in chd7-deficient embryos was partially rescued by overexpressingfoxnl, suggesting that restoring thymic epithelium may be a potential therapeutic strategy for treating immunodeficiency in CHARGE syndrome. Collectively, the results indicated that chd7 was critical for thymic development and T-lymphopenia in CHARGE syndrome may be mainly attributed to the defects of thymic organogenesis. The current finding may benefit the diagnosis and therapy of T lymphopenia and immunodeficiency in CHARGE syndrome.	[Liu, Zhi-Zhi; Wang, Zi-Long; Wang, Han-Tsing; Han, Ying-Ying; Zhu, Lou-Yin; Lu, Zhuo; Pan, Bing-Xing; Li, Bao-Ming; Xu, Hong A.] Nanchang Univ, Inst Life Sci, Nanchang 330031, Jiangxi, Peoples R China; [Liu, Zhi-Zhi; Huang, Wen-Ting; Wang, Han-Tsing; Han, Ying-Ying; Zhu, Lou-Yin; Lu, Zhuo; Tian, Xiao-Li] Nanchang Univ, Sch Life Sci, Nanchang, Jiangxi, Peoples R China; [Wang, Zi-Long] Nanchang Univ, Queen Mary Sch, Nanchang, Jiangxi, Peoples R China; [Zhao, Jian] Nanchang Univ, Hosp Nanchang Univ, Nanchang, Jiangxi, Peoples R China; [Kim, Hyung-Goo; Chen, Yue] Childrens Hosp Jiang Xi, Nanchang, Jiangxi, Peoples R China; [Liu, Zhi-Zhi; Pan, Bing-Xing; Li, Bao-Ming; Xu, Hong A.] Jiangxi Prov Collaborat Innovat Ctr Cardiovasc Di, Nanchang, Jiangxi, Peoples R China; [Choi, Tae-Ik; Kim, Hyun-Taek; Choi, Jung-Hwa; Kim, Cheol-Hee] Chungnam Natl Univ, Dept Biol, Daejeon 34134, South Korea; [Lee, Jin-Soo] Natl Canc Ctr, Goyang, South Korea; [Kim, Hyung-Goo] Augusta Univ, Dept Obstet & Gynecol, Augusta, GA USA; [Kim, Hyung-Goo] Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA USA	Xu, HA (reprint author), Nanchang Univ, Inst Life Sci, Nanchang 330031, Jiangxi, Peoples R China.; Kim, CH (reprint author), Chungnam Natl Univ, Dept Biol, Daejeon 34134, South Korea.	zebrakim@cnu.ac.kr; xuhong@ncu.edu.cn		Xu, Hong A./0000-0003-4938-0203; Kim, Cheol-Hee/0000-0002-3019-0699	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [31400988, 81160144, 31171044]; Young Scientist of Jiangxi Province [20122BCB23007]; Natural Science Foundation of Jiangxi ProvinceNatural Science Foundation of Jiangxi Province [20151BAB215015]; National Cancer Center [NCC1210360]	Supported by the National Natural Science Foundation of China grants 31400988 (Z.-Z.L.), 81160144 (H.X.), and 31171044 (H.X.), Young Scientist of Jiangxi Province grant 20122BCB23007 (H.X.), the Natural Science Foundation of Jiangxi Province grant 20151BAB215015 (Z.Z.L.), and the National Cancer Center grant NCC1210360 (C.H.K.).	Assing K, 2013, HUM IMMUNOL, V74, P1047, DOI 10.1016/j.humimm.2013.06.002; Bajoghli B, 2009, CELL, V138, P186, DOI 10.1016/j.cell.2009.04.017; Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733; Barsanti M, 2017, EUR J IMMUNOL, V47, P291, DOI 10.1002/eji.201646553; Bergman JEH, 2012, HUM MUTAT, V33, P1251, DOI 10.1002/humu.22106; Blake KD, 1998, CLIN PEDIATR, V37, P159, DOI 10.1177/000992289803700302; Blake KD, 2008, AM J MED GENET A, V146A, P585, DOI 10.1002/ajmg.a.32179; Bleul CC, 2005, J IMMUNOL, V175, P5213, DOI 10.4049/jimmunol.175.8.5213; Boudny P, 2000, PATHOL RES PRACT, V196, P577, DOI 10.1016/S0344-0338(00)80031-X; Bredenkamp N, 2014, NAT CELL BIOL, V16, P902, DOI 10.1038/ncb3023; Bredenkamp N, 2014, DEVELOPMENT, V141, P1627, DOI 10.1242/dev.103614; Chalasani SH, 2007, J NEUROSCI, V27, P973, DOI 10.1523/JNEUROSCI.4132-06.2007; Chalouhi C, 2005, PEDIATRICS, V116, pE81, DOI 10.1542/peds.2004-1970; Chen LZ, 2010, P NATL ACAD SCI USA, V107, P10555, DOI 10.1073/pnas.1005129107; Chinn IK, 2015, IMMUNOL ALLERGY CLIN, V35, P671, DOI 10.1016/j.iac.2015.07.002; Chopra C, 2009, ACTA PAEDIATR, V98, P408, DOI 10.1111/j.1651-2227.2008.01077.x; Crump JG, 2004, PLOS BIOL, V2, P1432, DOI 10.1371/journal.pbio.0020244; Gennery AR, 2008, CLIN EXP IMMUNOL, V153, P75, DOI 10.1111/j.1365-2249.2008.03681.x; Gordon J, 2004, NAT IMMUNOL, V5, P546, DOI 10.1038/ni1064; Gordon J, 2011, DEVELOPMENT, V138, P3865, DOI 10.1242/dev.059998; Gordon J, 2010, DEV BIOL, V339, P141, DOI 10.1016/j.ydbio.2009.12.026; Griffith AV, 2009, DEV BIOL, V327, P216, DOI 10.1016/j.ydbio.2008.12.019; Hager-Theodorides AL, 2014, CELL CYCLE, V13, P324, DOI 10.4161/cc.27118; Huang HT, 2013, NAT CELL BIOL, V15, P1516, DOI 10.1038/ncb2870; Janda A, 2007, PEDIATR TRANSPLANT, V11, P441, DOI 10.1111/j.1399-3046.2007.00702.x; Jenkinson WE, 2008, J IMMUNOL, V181, P6101, DOI 10.4049/jimmunol.181.9.6101; Jiang X, 2012, AM J PATHOL, V181, P626, DOI 10.1016/j.ajpath.2012.05.006; Jongmans MCJ, 2006, J MED GENET, V43, P306, DOI 10.1136/jmg.2005.036061; Jyonouchi S, 2009, PEDIATRICS, V123, pE871, DOI 10.1542/peds.2008-3400; Langenau DM, 2005, NAT REV IMMUNOL, V5, P307, DOI 10.1038/nri1590; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; Li L, 2012, J BIOL CHEM, V287, P25353, DOI 10.1074/jbc.M112.349126; Ma DY, 2013, DEV COMP IMMUNOL, V39, P91, DOI 10.1016/j.dci.2011.12.013; Markert ML, 2009, IMMUNOL RES, V44, P61, DOI 10.1007/s12026-008-8082-5; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; McGhee SA, 2009, IMMUNOL RES, V45, P37, DOI 10.1007/s12026-009-8108-7; Neves H, 2012, DEV BIOL, V361, P208, DOI 10.1016/j.ydbio.2011.10.022; Nowell CS, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002348; Parent AV, 2013, CELL STEM CELL, V13, P219, DOI 10.1016/j.stem.2013.04.004; Patel SR, 2006, GENE EXPR PATTERNS, V6, P794, DOI 10.1016/j.modgep.2006.01.011; Piotrowski T, 2000, DEV BIOL, V225, P339, DOI 10.1006/dbio.2000.9842; Randall V, 2009, J CLIN INVEST, V119, P3301, DOI 10.1172/JCI37561; Rice HE, 2004, J PEDIATR SURG, V39, P1607, DOI 10.1016/j.jpedsurg.2004.07.020; Romano R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00187; Sanlaville D, 2006, J MED GENET, V43, P211, DOI 10.1136/jmg.2005.036160; Sanlaville D, 2007, EUR J HUM GENET, V15, P389, DOI 10.1038/sj.ejhg.5201778; SIEBERT JR, 1985, TERATOLOGY, V31, P331, DOI 10.1002/tera.1420310303; Soza-Ried C, 2008, J IMMUNOL, V181, P5272, DOI 10.4049/jimmunol.181.8.5272; Swann JB, 2014, CELL REP, V8, P1184, DOI 10.1016/j.celrep.2014.07.017; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Vaccaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042117; Vaidya HJ, 2016, EUR J IMMUNOL, V46, P1826, DOI 10.1002/eji.201545814; Vissers LELM, 2004, NAT GENET, V36, P955, DOI 10.1038/ng1407; Wang RY, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e32; Wang SF, 2015, DEV CELL, V34, P621, DOI 10.1016/j.devcel.2015.07.011; Williams MS, 2005, AM J MED GENET A, V133A, P318, DOI 10.1002/ajmg.a.30561; Wong MTY, 2015, EUR J HUM GENET, V23, P1451, DOI 10.1038/ejhg.2015.7; Yu H, 2016, J ALLERGY CLIN IMMUN, V138, P1142, DOI 10.1016/j.jaci.2016.05.035; Zentner GE, 2010, AM J MED GENET A, V152A, P674, DOI 10.1002/ajmg.a.33323; Zhen T, 2017, BLOOD, V130, P2431, DOI 10.1182/blood-2017-04-780106; Zook EC, 2011, BLOOD, V118, P5723, DOI 10.1182/blood-2011-03-342097	61	0	0	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1043	1058		10.1016/j.ajpath.2017.12.005			16	Pathology	Pathology	GB6NH	WOS:000429185400019	29353058				2019-10-28	
J	Wu, B; Shah, SN; Lu, PJ; Bollinger, LE; Blaeser, A; Sparks, S; Harper, AD; Lu, QL				Wu, Bo; Shah, Sapana N.; Lu, Peijuan; Bollinger, Lauren E.; Blaeser, Anthony; Sparks, Susan; Harper, Amy D.; Lu, Qi L.			Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BODY-COMPOSITION CHANGES; FUKUTIN-RELATED PROTEIN; MUSCULAR-DYSTROPHY; ALPHA-DYSTROGLYCAN; RIBITOL-PHOSPHATE; BREAST-CANCER; MOUSE MODEL; FIBROSIS; MUTATIONS; TISSUE	The third most common form of limb-girdle muscular dystrophies is caused by mutations of the Fukutinrelated protein (FKRP) gene, with no effective therapy available. Selective estrogen receptor modulators, tamoxifen and raloxifene, have been widely used for human conditions for their anti-inflammatory, antifibrosis, prevention of bone loss, and muscle building effects (essential features for muscular dystrophy therapies). We evaluated therapeutic values of tamoxifen and raloxifene in FKRPP448L mutant mouse with severe dystrophic phenotype. The mice were treated with the drugs for 1 year through daily gavage. We demonstrate that tamoxifen and raloxifene significantly ameliorated the disease progression. The improvement includes increase in grip force production, extended running time and distance in treadmill test, and enhancement in cardiac and respiratory functions. Significant reduction in muscle pathology includes diminished fibrosis and fiber degeneration. Tamoxifen and raloxifene also significantly mitigated bone Loss. Tamoxifen, but not raloxifene, caused severe adverse effects on male reproductive organs. The results demonstrate that tamoxifen and raloxifene hold significant potential for treating FKRP-related muscular dystrophy and probably other muscular dystrophies. Sex-related differential effects of the drugs call for a careful consideration for the drug and dosage selection in male and female patient populations.	[Wu, Bo; Shah, Sapana N.; Lu, Peijuan; Bollinger, Lauren E.; Blaeser, Anthony; Lu, Qi L.] Levine Childrens Hosp, Carolinas Med Ctr, McColl Lockwood Lab Muscular Dystrophy Res, Charlotte, NC USA; [Sparks, Susan; Harper, Amy D.] Levine Childrens Hosp, Carolinas Med Ctr, Clin Genet, Dept Pediat, Charlotte, NC USA	Wu, B; Lu, QL (reprint author), Carolinas Med Ctr, Dept Neurol, Lab Muscular Dystrophy Res, Neuromuscular ALS Ctr, 1000 Blythe Blvd, Charlotte, NC 28231 USA.	bo.wu@carolinashealthcare.org; qi.lu@carolinashealthcare.org			Carolinas Muscular Dystrophy Research Endowment at the Carolinas HealthCare Foundation	Supported by the Carolinas Muscular Dystrophy Research Endowment at the Carolinas HealthCare Foundation.	Agnusdei D., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P127; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; Blaeser A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164187; Brown SC, 1999, J CELL SCI, V112, P209; Carthy JM, 2015, J CELL PHYSIOL, V230, P3084, DOI 10.1002/jcp.25049; Chan YM, 2010, HUM MOL GENET, V19, P3995, DOI 10.1093/hmg/ddq314; Cho E, 2015, J ORTHOP RES, V33, P1846, DOI 10.1002/jor.22964; Colon JM, 2016, NEURAL REGEN RES, V11, P1208, DOI 10.4103/1673-5374.189164; Delle H, 2012, J AM SOC NEPHROL, V23, P37, DOI 10.1681/ASN.2011010046; Dorchies OM, 2013, AM J PATHOL, V182, P485, DOI 10.1016/j.ajpath.2012.10.018; Gerin I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11534; Hesselbarth N, 2015, BIOCHEM BIOPH RES CO, V464, P724, DOI 10.1016/j.bbrc.2015.07.015; Hoffman JR, 2006, J SPORT SCI MED, V5, P182; Huang JW, 2011, BLOOD PURIFICAT, V31, P252, DOI 10.1159/000322255; Jamdade VS, 2016, PATHOL ONCOL RES, V22, P145, DOI 10.1007/s12253-015-9988-6; Kanagawa M, 2016, CELL REP, V14, P2209, DOI 10.1016/j.celrep.2016.02.017; Loureiro J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061165; Luo FQ, 2015, DIGEST DIS SCI, V60, P2730, DOI 10.1007/s10620-015-3660-6; Madaro L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031515; Mercuri E, 2003, ANN NEUROL, V53, P537, DOI 10.1002/ana.10559; Muchmore D B, 2000, Oncologist, V5, P388, DOI 10.1634/theoncologist.5-5-388; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Patel BM, 2014, PHARMACOL REP, V66, P264, DOI 10.1016/j.pharep.2014.02.004; Praissman JL, 2016, ELIFE, V5, DOI 10.7554/eLife.14473; Ramaswamy B, 2003, SEMIN ONCOL, V30, P763, DOI 10.1053/S0093-7754(03)00478-0; Sheean PM, 2012, BREAST CANCER RES TR, V135, P663, DOI 10.1007/s10549-012-2200-8; Vaglio A, 2011, LANCET, V378, P338, DOI 10.1016/S0140-6736(11)60934-3; Wibowo E, 2016, ANDROLOGY-US, V4, P776, DOI 10.1111/andr.12197; Wu B, 2016, AM J PATHOL, V186, P1635, DOI 10.1016/j.ajpath.2016.02.015; Zheng K, 2014, BIOCHEM BIOPH RES CO, V446, P990, DOI 10.1016/j.bbrc.2014.03.050	30	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1069	1080		10.1016/j.ajpath.2017.12.011			12	Pathology	Pathology	GB6NH	WOS:000429185400021	29571322	Bronze			2019-10-28	
J	Parimon, T; Brauer, R; Schlesinger, SY; Xie, T; Jiang, DH; Ge, LY; Huang, Y; Birkland, TP; Parks, WC; Habiel, DM; Hogaboam, CM; Gharib, SA; Deng, N; Liu, ZQ; Chen, P				Parimon, Tanyalak; Brauer, Rena; Schlesinger, Saundra Y.; Xie, Ting; Jiang, Dianhua; Ge, Lingyin; Huang, Ying; Birkland, Timothy P.; Parks, William C.; Habiel, David M.; Hogaboam, Cory M.; Gharib, Sina A.; Deng, Nan; Liu, Zhenqui; Chen, Peter			Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RNA COMPOSITION; GROWTH-FACTOR; CANCER; EXPRESSION; MICRORNAS; BIOGENESIS; INTEGRINS; MIGRATION; RECEPTOR; ADHESION	Syndecan-1 is a transmembrane proteoglycan expressed prominently by lung epithelium and has pleiotropic functions such as regulating cell migration, proliferation, and survival. Loss of syndecan-1 expression by lung cancer cells is associated with higher-grade cancers and worse clinical prognosis. We evaluated the effects of syndecan-1 in various cell-based and animal models of lung cancer and found that lung tumorigenesis was moderated by syndecan-1. We also demonstrate that syndecan-1 (or lack thereof) alters the miRNA cargo carried within exosomes exported from lung cancer cells. Analysis of the changes in miRNA expression identified a distinct shift toward augmented procancer signaling consistent with the changes found in lung adenocarcinoma. Collectively, our work identifies syndecan-1 as an important factor in lung cancer cells that shapes the tumor microenvironment through alterations in miRNA packaging within exosomes.	[Parimon, Tanyalak; Brauer, Rena; Xie, Ting; Jiang, Dianhua; Ge, Lingyin; Huang, Ying; Parks, William C.; Habiel, David M.; Hogaboam, Cory M.; Liu, Zhenqui; Chen, Peter] Cedars Sinai Med Ctr, Div Pulm & Crit Care, Los Angeles, CA 90048 USA; [Parks, William C.; Hogaboam, Cory M.; Chen, Peter] Cedars Sinai Med Ctr, Dept Med, Womens Guild Lung Inst, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Deng, Nan; Liu, Zhenqui; Chen, Peter] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Schlesinger, Saundra Y.; Birkland, Timothy P.; Gharib, Sina A.] Univ Washington, Dept Med, Div Pulm Crit Care & Sleep Med, Seattle, WA USA	Chen, P (reprint author), 127 S San Vicente Blvd,A9401, Los Angeles, CA 90048 USA.	peter.chen@cshs.org	Xie, Ting/I-9538-2019; Jiang, Dianhua/B-1421-2009	Hogaboam, Cory/0000-0003-3366-4850; GHARIB, SINA A./0000-0002-2480-4367; Chen, Peter/0000-0002-5330-1718; Jiang, Dianhua/0000-0002-4508-3829; Brauer, Rena/0000-0002-5900-4853	NHLBI/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL084396, HL103868]; Samuel Oschin Comprehensive Cancer Institute Lung Cancer Research Award	Supported by NHLBI/NIH grants HL084396 (P.C.) and HL103868 (P.C.), and the Samuel Oschin Comprehensive Cancer Institute Lung Cancer Research Award (P.C.).	Altemeier WA, 2012, J CELL SCI, V125, P5188, DOI 10.1242/jcs.109884; Altemeier WA, 2012, J BIOL CHEM, V287, P34927, DOI 10.1074/jbc.M112.376814; Anttonen A, 2001, LUNG CANCER-J IASLC, V32, P297, DOI 10.1016/S0169-5002(00)00230-0; Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502; Beauvais DM, 2009, J EXP MED, V206, P691, DOI 10.1084/jem.20081278; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Brauer R, 2016, AM J RESP CRIT CARE, V194, P333, DOI 10.1164/rccm.201509-1878OC; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cha DJ, 2015, ELIFE, V4, DOI 10.7554/eLife.07197; Chen P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006565; Chopin V, 2016, CELL MOL LIFE SCI, V73, P1859, DOI 10.1007/s00018-016-2156-7; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Feng L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105639; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Gallimidi AB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174343; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gazdar AF, 2010, JNCI-J NATL CANCER I, V102, P1310, DOI 10.1093/jnci/djq279; Gouw AM, 2017, P NATL ACAD SCI USA, V114, P4300, DOI 10.1073/pnas.1617709114; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Iavello A, 2016, INT J MOL MED, V37, P958, DOI 10.3892/ijmm.2016.2488; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Joensuu H, 2002, CANCER RES, V62, P5210; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; KATO M, 1995, MOL BIOL CELL, V6, P559; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Le MTN, 2014, J CLIN INVEST, V124, P5109, DOI 10.1172/JCI75695; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.27; McKenzie AJ, 2016, CELL REP, V15, P978, DOI 10.1016/j.celrep.2016.03.085; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Nackaerts K, 1997, INT J CANCER, V74, P335, DOI 10.1002/(SICI)1097-0215(19970620)74:3<335::AID-IJC18>3.0.CO;2-A; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Plaisier CL, 2011, NUCLEIC ACIDS RES, V39, pW125, DOI 10.1093/nar/gkr374; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Riffo-Campos AL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121987; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Santangelo L, 2016, CELL REP, V17, P799, DOI 10.1016/j.celrep.2016.09.031; Sethupathy P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606; Shah L, 2004, CANCER-AM CANCER SOC, V101, P1632, DOI 10.1002/cncr.20542; Shurtleff MJ, 2017, P NATL ACAD SCI USA, V114, pE8987, DOI 10.1073/pnas.1712108114; Shurtleff MJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19276; Sinkevicius KW, 2014, P NATL ACAD SCI USA, V111, P10299, DOI 10.1073/pnas.1404399111; Stepp MA, 2010, MOL CARCINOGEN, V49, P363, DOI 10.1002/mc.20609; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Wang X, 2014, BRIT J CANCER, V111, P1965, DOI 10.1038/bjc.2014.493; Wei JX, 2015, HEPATOLOGY, V61, P1284, DOI 10.1002/hep.27660; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	61	8	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1094	1103		10.1016/j.ajpath.2017.12.009			10	Pathology	Pathology	GB6NH	WOS:000429185400023	29355516	Bronze, Green Published			2019-10-28	
J	Johann, PD; Bens, S; Oyen, F; Wagener, R; Giannini, C; Perry, A; Raisanen, JM; Reis, GF; Nobusawa, S; Arita, K; Felsberg, J; Reifenberger, G; Agaimy, A; Buslei, R; Capper, D; Pfister, SM; Schneppenheim, R; Siebert, R; Fruhwald, MC; Paulus, W; Kool, M; Hasselblatt, M				Johann, Pascal D.; Bens, Susanne; Oyen, Florian; Wagener, Rabea; Giannini, Caterina; Perry, Arie; Raisanen, Jack M.; Reis, Gerald F.; Nobusawa, Sumihito; Arita, Kazunori; Felsberg, Joerg; Reifenberger, Guido; Agaimy, Abbas; Buslei, Rolf; Capper, David; Pfister, Stefan M.; Schneppenheim, Reinhard; Siebert, Reiner; Fruehwald, Michael C.; Paulus, Werner; Kool, Marcel; Hasselblatt, Martin			Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						atypical teratoid; rhabdoid tumor; pituitary; SMARCB1; INI1; DNA methylation profiling; outcome	TERATOID RHABDOID TUMOR; SMALL-CELL CARCINOMA; HYPERCALCEMIC TYPE; ABERRATIONS; PROGNOSIS; TURCICA; AT/RT; OVARY	Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly encountered in infants. Mutations of the SMARCB1 gene are the characteristic genetic lesion. A small group of ATRT stands out clinically, because these tumors are located in the sellar region of adults. To investigate if sellar region ATRT in adults represents a molecular distinct entity, we characterized molecular alterations in 7 sellar region ATRTs in adults as compared with 150 pediatric ATRTs and 47 pituitary adenomas using SMARCB1 sequencing, multiplex ligation-dependent probe amplification and fluorescence in situ hybridization as well as DNA methylation profiling. The median age of the 6 female and 1 male patients was 56 years. On histopathologic examination, all tumors were malignant rhabdoid tumors showing loss of SMARCB1/INI1 protein expression. Two cases displayed compound heterozygous SMARCB1 point mutations, 3 cases showed heterozygous SMARCB1 deletions with point mutations of the other allele and 1 case a homozygous SMARCB1 deletion; in 1 case, underlying SMARCB1 alterations could not be identified. On unsupervised hierarchical cluster analysis of DNA methylation profiles, sellar region ATRTs did not form a distinct group, but clustered with ATRT-MYC, 1 of 3 recently described molecular subgroups of ATRT. On analysis of DNA methylation array intensity data, only 1 sellar region ATRT showed characteristic features of pediatric ATRT-MYC, that is, major copy number losses affecting the SMARCB1 region. In conclusion, these results suggest that sellar region ATRTs in adults form a clinically distinct entity with a different mutational spectrum, but epigenetic similarities with pediatric ATRTs of the ATRT-MYC subgroup.	[Johann, Pascal D.; Pfister, Stefan M.; Kool, Marcel] NCT Heidelberg, Hopp Childrens Canc Ctr, Heidelberg, Germany; [Johann, Pascal D.; Pfister, Stefan M.; Kool, Marcel] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany; [Johann, Pascal D.; Pfister, Stefan M.; Kool, Marcel] German Canc Consortium DKTK, Heidelberg, Germany; [Johann, Pascal D.; Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Pediat Oncol & Hematol, Heidelberg, Germany; [Bens, Susanne; Wagener, Rabea; Siebert, Reiner] Univ Ulm, Inst Human Genet, Ulm, Germany; [Bens, Susanne; Wagener, Rabea; Siebert, Reiner] Univ Hosp Ulm, Ulm, Germany; [Oyen, Florian; Schneppenheim, Reinhard] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Felsberg, Joerg; Reifenberger, Guido] Heinrich Heine Univ, Fac Med, Inst Neuropathol, Dusseldorf, Germany; [Felsberg, Joerg; Reifenberger, Guido] Partner Site Essen Dusseldorf, German Canc Consortium DKTK, Dusseldorf, Germany; [Agaimy, Abbas] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany; [Buslei, Rolf] Sozialstiftung Bamberg, Dept Neuropathol, Bamberg, Germany; [Capper, David] Charite Univ Med Berlin, Dept Neuropathol, Berlin, Germany; [Fruehwald, Michael C.] Childrens Hosp Augsburg, Swabian Childrens Canc Ctr, Augsburg, Germany; [Fruehwald, Michael C.] EU RHAB Registry, Augsburg, Germany; [Paulus, Werner; Hasselblatt, Martin] Univ Hosp Munster, Inst Neuropathol, Munster, Germany; [Giannini, Caterina] Mayo Clin, Dept Pathol, Rochester, MN USA; [Perry, Arie] UCSF Med Ctr, Div Neuropathol, San Francisco, CA USA; [Raisanen, Jack M.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Reis, Gerald F.] Mem Reg Hosp, Dept Pathol, Hollywood, FL USA; [Nobusawa, Sumihito] Gunma Univ, Dept Human Pathol, Grad Sch Med, Gunma, Japan; [Arita, Kazunori] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan	Hasselblatt, M (reprint author), Inst Neuropathol, Pottkamp 2, D-48149 Munster, Germany.	hasselblatt@uni-muenster.de	Siebert, Reiner/A-8049-2010; Capper, David/I-8500-2014; Pfister, Stefan M/F-6860-2013	Capper, David/0000-0003-1945-497X; Pfister, Stefan M/0000-0002-5447-5322	IZKF Munster [Ha3/019/15]; DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO)	Supported by IZKF Munster (Ha3/019/15) and the DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Arita K, 2008, ACTA NEUROCHIR, V150, P491, DOI 10.1007/s00701-008-1500-y; Biswas S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00236; Bozzai B, 2017, PEDIATR BLOOD CANCER, V64, P96, DOI 10.1002/pbc.26173; Chacko G, 2007, J NEURO-ONCOL, V84, P217, DOI 10.1007/s11060-007-9361-z; Clarke BA, 2016, HISTOPATHOLOGY, V69, P727, DOI 10.1111/his.12988; Fruhwald MC, 2006, PEDIATR BLOOD CANCER, V47, P273, DOI 10.1002/pbc.20526; Fruhwald MC, 2016, NEURO-ONCOLOGY, V18, P764, DOI 10.1093/neuonc/nov264; Gorayski P, 2013, J CLIN NEUROSCI, V20, P1466, DOI 10.1016/j.jocn.2013.03.041; Han ZY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10421; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x; Hasselblatt M, 2013, GENE CHROMOSOME CANC, V52, P185, DOI 10.1002/gcc.22018; Johann PD, 2017, BRAIN PATHOL, V27, P411, DOI 10.1111/bpa.12413; Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001; Judkins AR, 2004, AM J SURG PATHOL, V28, P644, DOI 10.1097/00000478-200405000-00013; Kleinschmidt-DeMasters BK, 2011, AM J SURG PATHOL, V35, P1894, DOI 10.1097/PAS.0b013e3182382a3f; Makuria AT, 2008, J NEURO-ONCOL, V88, P321, DOI 10.1007/s11060-008-9571-z; Nakata S, 2017, AM J SURG PATHOL, V41, P932, DOI 10.1097/PAS.0000000000000845; Nobusawa S, 2016, VIRCHOWS ARCH, V469, P711, DOI 10.1007/s00428-016-2017-7; Oliveira E, 2016, CHILD NERV SYST, V32, P1573, DOI 10.1007/s00381-016-3187-y; Park Hae Gi, 2014, Brain Tumor Res Treat, V2, P108, DOI 10.14791/btrt.2014.2.2.108; Prabowo AS, 2015, NEUROPATH APPL NEURO, V41, P743, DOI 10.1111/nan.12235; Raisanen J, 2005, BRAIN PATHOL, V15, P23; Schneiderhan TM, 2011, NEUROPATH APPL NEURO, V37, P326, DOI 10.1111/j.1365-2990.2010.01111.x; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Takahashi K, 2011, BRAIN TUMOR PATHOL, V28, P71, DOI 10.1007/s10014-010-0008-y; Torchia J, 2016, CANCER CELL, V30, P891, DOI 10.1016/j.ccell.2016.11.003; Trautmann K, 2001, INT J CANCER, V91, P809, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1127>3.0.CO;2-E; Wang X, 2015, ACTA NEUROPATHOL, V129, P449, DOI 10.1007/s00401-015-1389-0; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Zarovnaya EL, 2007, J NEURO-ONCOL, V84, P49, DOI 10.1007/s11060-007-9339-x	31	5	6	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					506	511		10.1097/PAS.0000000000001023			6	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200010	29324471				2019-10-28	
J	Louie, CY; Gomez, AJ; Sibley, RK; Bass, D; Longacre, TA				Louie, Christine Y.; Gomez, Adam J.; Sibley, Richard K.; Bass, Dorsey; Longacre, Teri A.			Histologic Features of Gastrointestinal Tract Biopsies in IgA Vasculitis (Henoch-Schonlein Purpura)	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						Henoch-Schonlein purpura; HSP; IgA vasculitis; leukocytoclastic vasculitis; GI biopsy; duodenitis	CHILDREN; DISEASE	Immunoglobulin A (IgA) vasculitis or Henoch-Schonlein purpura (HSP) typically occurs in the pediatric population, although rare cases also occur in adults. Gastrointestinal (GI) involvement is common. The "classic" histologic finding in IgA vasculitis (HSP) is leukocytoclastic vasculitis (LCV); other histologic features in biopsies of IgA vasculitis (HSP) have only been rarely described. The pathology archival files at our institution were searched for GI biopsies from patients with IgA vasculitis (HSP). Slides were retrieved and histologic and clinical features were reviewed. We identified 16 patients with IgA vasculitis (HSP) with a GI biopsy series, including both adult and pediatric patients. The most common histologic abnormality was lamina propria hemorrhage (all cases) with many cases also showing lamina propria fibrin deposition with red cell sludging and nuclear debris (7 cases). Twelve of the 16 duodenal biopsies had acute duodenitis; 3 of which were severe and erosive. Several also had an eosinophilic infiltrate. Seven of the 9 jejunal and/or ileal biopsies had acute jejunitis or ileitis. An acute colitis or proctitis was observed in 9/12 colorectal biopsies. Four biopsies contained LCV; in each of these cases, the involved vessels were small capillaries within the lamina propria. Only 1 biopsy contained deeper submucosal vessels, but they were uninvolved. Sites involved by LCV included the colorectum (2 cases), colorectum and terminal ileum, terminal ileum only, duodenum, and jejunum (1 case each). All patients presented with abdominal pain; 13/16 developed a rash, 1 following the index biopsy. Other presenting symptoms included diarrhea and/or hematochezia (8 cases), nausea/vomiting (5 cases), and intussusception (1 case). Four patients had concurrent skin biopsies showing LCV; only 1 of these patients had LCV on GI biopsy. Indications for biopsy included nonspecific presenting symptoms, absence of rash at presentation, and/or failure to respond adequately to steroid therapy. Biopsies are commonly performed in patients with or without suspected IgA vasculitis (HSP) to rule out infection, inflammatory bowel disease, and less commonly, vasculitis. In general, vasculitis is not commonly observed in GI biopsies of patients with IgA vasculitis (HSP), and the spectrum of findings includes neutrophilic infiltrate within the small bowel and colon, with the duodenum most commonly affected. While the clinical and histologic findings may mimic early inflammatory bowel disease, the presence of predominant small bowel involvement, especially erosive duodenitis, should raise suspicion for IgA vasculitis (HSP). Biopsies should be obtained before steroid therapy is initiated, if possible.	[Louie, Christine Y.] Vet Affairs Palo Alto Hlth Care Syst, Dept Pathol, Palo Alto, CA USA; [Gomez, Adam J.; Sibley, Richard K.; Longacre, Teri A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Bass, Dorsey] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA	Louie, CY (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Dept Pathol 113, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	christine.louie@va.gov					ALLEN DM, 1960, AMA J DIS CHILD, V99, P833, DOI 10.1001/archpedi.1960.02070030835021; Calvo-Rio V, 2014, MEDICINE, V93, P106, DOI 10.1097/MD.0000000000000019; Cappell MS, 2011, DIGEST DIS SCI, V56, P1919, DOI 10.1007/s10620-010-1502-0; Chang WL, 2004, ACTA PAEDIATR, V93, P1427, DOI 10.1080/08035250410020181; Chetty R, 2017, J CLIN PATHOL, V70, P470, DOI 10.1136/jclinpath-2016-204308; Esaki M, 2002, GASTROINTEST ENDOSC, V56, P920, DOI 10.1067/mge.2002.129592; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Magro CM, 1999, AM J DERMATOPATH, V21, P234, DOI 10.1097/00000372-199906000-00005; Nam EJ, 2014, ENDOSCOPY, V46, P981, DOI 10.1055/s-0034-1377757; NOVAK J, 1995, GASTROINTEST ENDOSC, V41, P519, DOI 10.1016/S0016-5107(05)80017-3; Ozen S, 2010, ANN RHEUM DIS, V69, P798, DOI 10.1136/ard.2009.116657; Pore G, 2002, GASTROINTEST ENDOSC, V55, P283, DOI 10.1067/mge.2002.120785; Rathore M, 2014, INDIAN J PEDIATR, V81, P189, DOI 10.1007/s12098-013-1010-2; Saulsbury FT, 1999, MEDICINE, V78, P395, DOI 10.1097/00005792-199911000-00005; Sohagia AB, 2010, GASTROENT RES PRACT, DOI 10.1155/2010/597648; WHITE RHR, 1994, NEPHRON, V68, P1, DOI 10.1159/000188216	16	4	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					529	533		10.1097/PAS.0000000000001036			5	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200013	29438165				2019-10-28	
J	Antonescu, CR; Agaram, NP; Sung, YS; Zhang, L; Swanson, D; Dickson, BC				Antonescu, Cristina R.; Agaram, Narasimhan P.; Sung, Yun-Shao; Zhang, Lei; Swanson, David; Dickson, Brendan C.			A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						GLI1; ACTB; MALAT1; PTCH1; SHH; pericytoma; gastroblastoma; S100 protein	PLEXIFORM FIBROMYXOMA; ACTB-GLI1 FUSION; PERICYTOMA; T(7/12); DEFINE; BENIGN; SUBSET; TUMORS; ACTB; BONE	ACTB-GLI1 fusions have been reported as the pathognomonic genetic abnormality defining an unusual subset of actin-positive, perivascular myoid tumors, known as "pericytoma with the t(7;12) translocation." In addition, GLI1 oncogenic activation through a related MALAT1-GLI1 gene fusion has been recently reported in 2 unrelated gastric tumors, namely plexiform fibromyxoma and gastroblastoma. Triggered by unexpected targeted RNA-sequencing results detecting GLI1-related fusions in a group of malignant neoplasms with round to epithelioid morphology, and frequently strong S100 protein immunoreactivity, we investigated their clinicopathologic features in relation to other known pathologic entities sharing similar genetics. On the basis of a combined approach of targeted RNA sequencing and fluorescence in situ hybridization screening, we identified 6 cases with GLI1 gene fusions, including 4 fused to ACTB, 1 with MALAT1 and 1 with PTCH1 gene. Patients had a mean age of 36 years at diagnosis (range, 16 to 79 y) and slight female predilection all except 1 tumor originated in the soft tissue. Microscopically, the tumors had a monomorphic epithelioid phenotype arranged in a distinctive nested or cord-like architecture, separated by thin septae and delicate capillary network. All except 2 cases were strongly positive for S100 protein, whereas being negative for SOX10, SMA, and EMA. Only 1 tumor showed focal cytokeratin positivity in rare cells. Although the tumors showed some resemblance to pericytic/glomus tumors or myoepithelial tumors, the immunoprofile was not supportive of either lineage. Moreover, in contrast to the benign course of so-called pericytoma with t(7;12), 3 patients in this series developed metastatic disease to either lymph nodes or lung. In fact the only patient with lung metastases showed a novel PTCH1-GLI1 gene fusion. It remains to be determined whether these tumors represent a clinically and immunohistologically distinct subset of pericytoma, or an altogether novel soft tissue sarcoma. Our findings open new opportunities for targeted therapy, as tumors with GLI1 oncogenic activation, and subsequent PTCH1 over-expression, might be sensitive to sonic hedgehog pathway inhibitors.	[Antonescu, Cristina R.; Agaram, Narasimhan P.; Sung, Yun-Shao; Zhang, Lei] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Swanson, David; Dickson, Brendan C.] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada	Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	antonesc@mskcc.org			Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30-CA008748]	Supported in part by P50 CA140146-01 (CRA); P30-CA008748 (CRA); Kristen Ann Carr Foundation (CRA); Cycle for Survival (CRA).	Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Bridge JA, 2012, HUM PATHOL, V43, P1524, DOI 10.1016/j.humpath.2012.01.019; Castro E, 2016, HUM PATHOL, V53, P137, DOI 10.1016/j.humpath.2016.02.015; Dahlen A, 2004, BIOCHEM BIOPH RES CO, V325, P1318, DOI 10.1016/j.bbrc.2004.10.172; Dahlen A, 2004, AM J PATHOL, V164, P1645, DOI 10.1016/S0002-9440(10)63723-6; Flucke U, 2017, GENE CHROMOSOME CANC, V56, P663, DOI 10.1002/gcc.22470; Graham RP, 2017, MODERN PATHOL, V30, P1443, DOI 10.1038/modpathol.2017.68; Hung YP, 2017, AM J SURG PATHOL, V41, P1034, DOI 10.1097/PAS.0000000000000862; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Miettinen M, 2009, AM J SURG PATHOL, V33, P1624, DOI 10.1097/PAS.0b013e3181ae666a; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P1075, DOI 10.1002/gcc.22102; Rimkus TK, 2016, CANCERS, V22, P1; Spans L, 2016, J PATHOL, V239, P335, DOI 10.1002/path.4730; Stein U, 1999, CANCER RES, V59, P1890; Takahashi Y, 2007, AM J SURG PATHOL, V31, P724, DOI 10.1097/01.pas.0000213448.54643.2f; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989	16	10	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					553	560		10.1097/PAS.0000000000001010			8	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200016	29309307	Green Accepted			2019-10-28	
J	Mutton, S; Pesesse, L; Weatherspoon, A; Florquin, S; Van de Poel, JF; Martin, P; Vincke, G; Hoyoux, R; Maree, R; Verpoorten, D; Bonnet, P; Quatresooz, P; Defaweux, V				Multon, Sylvie; Pesesse, Laurence; Weatherspoon, Alodie; Florquin, Sandra; Van de Poel, Jean-Francois; Martin, Pierre; Vincke, Gregoire; Hoyoux, Renaud; Maree, Raphael; Verpoorten, Dominique; Bonnet, Pierre; Quatresooz, Pascale; Defaweux, Valerie			A Massive Open Oneline Course (MOOC) on pratical histology: A goal, a tool, a large public ! Return on a first experience	ANNALES DE PATHOLOGIE			French	Article						Massive open online cours (MOOC); Histology; Virtual microscopy; Education; Motivation	ONLINE COURSE MOOC; MOTIVATION	A goal ! The MOOC entitled "Introduction to Histology, A Human Tissue Exploration" correspond to our vision of the practice of General Histology, which is based on the ability to diagnose 5 families of biological tissues. Ultimately, participants must be able to recognize the different types of cells and all the surrounding elements in order to understand how they organize themselves to form tissues with specific functions. A tool ! This know-how is based on reasoning from observations of microscopic structures. Learners are therefore invited to manipulate a virtual microscope to explore biological samples on histological slides digitized. Annotations, comments, drawings or photos are associated with landmarks that enrich the study of these histological sections. A target audience ! Two educational paths allow deepening the subject in a different way and thus matching the goals or motivations of each one. After a first year of experience, usage statistics and surveys of our learners show that the MOOC Histo has allowed each of them to find an interest and federate a community of motivated learners. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Multon, Sylvie; Pesesse, Laurence; Weatherspoon, Alodie; Florquin, Sandra; Quatresooz, Pascale; Defaweux, Valerie] Univ Liege, Histol Humaine, Dept Sci Preclin & Morphol, Fac Med, Batiment B36,Ave Hippocrate 15, B-4000 Liege 1, Belgium; [Van de Poel, Jean-Francois; Martin, Pierre; Vincke, Gregoire; Verpoorten, Dominique] Univ Liege, IFRES, Batiment B63B,Quartier Urbanistes 1, B-4000 Liege 1, Belgium; [Hoyoux, Renaud; Maree, Raphael] Univ Liege, Fac Sci Appl, Dept Elect Elect & Informat, Syst & Modelisat, Batiment B28,Quartier Polytech 1, B-4000 Liege 1, Belgium; [Bonnet, Pierre; Defaweux, Valerie] Univ Liege, Fac Med, Dept Sci Preclin & Morphol, Anat Humaine, Batiment B35,Ave Hop 13, B-4000 Liege 1, Belgium	Defaweux, V (reprint author), Univ Liege, Histol Humaine, Dept Sci Preclin & Morphol, Fac Med, Batiment B36,Ave Hippocrate 15, B-4000 Liege 1, Belgium.; Defaweux, V (reprint author), Univ Liege, Fac Med, Dept Sci Preclin & Morphol, Anat Humaine, Batiment B35,Ave Hop 13, B-4000 Liege 1, Belgium.	valerie.defaweux@uliege.be		Maree, Raphael/0000-0002-9587-1954			Adam M, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0305-2; Barak M, 2016, COMPUT EDUC, V94, P49, DOI 10.1016/j.compedu.2015.11.010; Bonnet P, 2006, PROGR MICROGRADUEE E, P3; Downes S., 2011, HUFFPOST ED; Eick CJ, 2012, J COLL SCI TEACH, P42; Gardair C, 2016, ANN PATHOL, V36, P305, DOI 10.1016/j.annpat.2016.08.013; Goldberg LR, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0344-z; Grobusch MP, 2015, TRAVEL MED INFECT DI, V13, P263, DOI 10.1016/j.tmaid.2015.03.015; Holland C, 2016, ADV HEALTH SCI EDUC, V21, P695, DOI 10.1007/s10459-015-9643-8; Jordan K, 2014, INT REV RES OPEN DIS, V15; Kusurkar RA, 2011, MED TEACH, V33, pE242, DOI 10.3109/0142159X.2011.558539; Linsen L, 2012, VISUALIZATION MED LI; Liyanagunawardena TR, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3439; Maree R, 2016, BIOINFORMATICS, V32, P1395, DOI 10.1093/bioinformatics/btw013; Max Woolf, 2014, WHO PERFORMS BEST ON; Multon S, 2015, MED EDUC, V49, P1166, DOI 10.1111/medu.12866; Pappano L., 2012, THE YEAR OF THE MOOC; Pelaccia T, 2017, MED TEACH, V39, P136, DOI 10.1080/0142159X.2016.1248924; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Siemens G., 2005, ELEARNSPACE; Swinnerton BJ, 2016, ANAT SCI EDUC, V80, P121	21	0	0	0	5	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					76	84		10.1016/j.annpat.2018.02.002			9	Pathology	Pathology	GK1OU	WOS:000435888900005	29571562	Green Published			2019-10-28	
J	Oddo, D; Mendez, GP; Retamal, Y; Oddo, A				Oddo, David; Mendez, Gonzalo P.; Retamal, Yasmina; Oddo, Aaron			Intestinal isosporiasis in patients with acquired immunodeficiency syndrome (AIDS). Pathologic diagnosis in small intestinal mucosal biopsies	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Editorial Material							BELLI INFECTION; CHRONIC DIARRHEA; LIFE-CYCLE; AIDS; CRYPTOSPORIDIUM; OOCYSTS; CYSTS		[Oddo, David; Mendez, Gonzalo P.; Retamal, Yasmina] Pontificia Univ Catolica Chile, Fac Med, Dept Anat Pathol, Santiago, Chile; [Oddo, Aaron] Univ Mayor, Fac Med, Santiago, Chile	Oddo, D (reprint author), Pontificia Univ Catolica Chile, Fac Med, Dept Anat Pathol, Santiago, Chile.	doddo@med.puc.cl		Mendez, Gonzalo/0000-0003-4657-7107; Oddo, David/0000-0002-3974-7393			Agholi M, 2013, AIDS RES HUM RETROV, V29, P35, DOI [10.1089/AID.2012.0119, 10.1089/aid.2012.0119]; Agnamey P, 2010, J TRAVEL MED, V17, P141, DOI [10.1111/j.1708-8305.2010.00393.x, 10.1111/j.1708-8305.2009.00393.x]; BENATOR DA, 1994, ANN INTERN MED, V121, P663, DOI 10.7326/0003-4819-121-9-199411010-00006; Bernard E, 1997, EUR J CLIN MICROBIOL, V16, P699, DOI 10.1007/BF01708565; Cali A, 2001, TOPICS PATHOLOGY PRO, P1; Cox FEG, 2015, MANUAL CLIN MICROBIO, V2, P1898; Da Silva CV, 2005, SCAND J INFECT DIS, V37, P211, DOI 10.1080/00365540410020875; FIGUEROA F, 1985, REV MED CHILE, V113, P772; Frenkel Jacob K., 2003, Rev. Soc. Bras. Med. Trop., V36, P409, DOI 10.1590/S0037-86822003000300014; Frenkel JK, 2003, J EUKARYOT MICROBIOL, V50, P682, DOI 10.1111/j.1550-7408.2003.tb00686.x; Ghimire TR, 2008, J NEPAL HLTH RES COU, V4, P25; Guiguet M, 2007, HIV MED, V8, P124, DOI 10.1111/j.1468-1293.2007.00441.x; Gutierrez Y., 2000, DIAGNOSTIC PATHOLOGY, P179; JARPA A, 1981, Boletin Chileno de Parasitologia, V36, P49; Jongwutiwes S, 2007, AM J TROP MED HYG, V77, P107, DOI 10.4269/ajtmh.2007.77.107; Kashyap Bineeta, 2010, J Parasit Dis, V34, P63, DOI 10.1007/s12639-011-0020-0; Kim MJ, 2013, KOREAN J PARASITOL, V51, P207, DOI 10.3347/kjp.2013.51.2.207; Klassen-Ficher MK, 2001, TOPICS PATHOLOGY PRO, P1; Koru Oezguer, 2007, Turkiye Parazitoloji Dergisi, V31, P98; Lindsay DS, 1997, CLIN MICROBIOL REV, V10, P19, DOI 10.1128/CMR.10.1.19; Malik Ajay, 2013, Indian J Sex Transm Dis AIDS, V34, P119, DOI 10.4103/0253-7184.120548; Marek A, 2012, AM J GASTROENTEROL, V107, P1109, DOI 10.1038/ajg.2012.74; MICHIELS JF, 1994, PATHOL RES PRACT, V190, P1089, DOI 10.1016/S0344-0338(11)80908-8; Mochizuki Y, 1994, I TO CHO, V29, P969; Navaneethan U, 2012, J CROHNS COLITIS, V6, P236, DOI 10.1016/j.crohns.2011.08.010; Neira P, 2010, REV CHIL INFECTOL, V27, P219, DOI [/S0716-10182010000300007, 10.4067/S0716-10182010000300007]; Odder D., 2013, PARASITOLOGIA HUMANA, P98; ODDO D, 1993, PATHOL RES PRACT, V189, P209, DOI 10.1016/S0344-0338(11)80094-4; Orenstein JM, 1997, PATHOLOGY INFECT DIS, V2, P1185; Orenstein JM, 1997, PATHOLOGY INFECT DIS, V2, P1223; Ortega YR, 2010, CLIN MICROBIOL REV, V23, P218, DOI 10.1128/CMR.00026-09; Ortega YR, 1997, J INFECT DIS, V176, P1584, DOI 10.1086/514158; Pacheco FTF, 2013, J PARASITOL, V99, P1002, DOI 10.1645/12-33.1; Perez-Ayala A, 2011, J TRAVEL MED, V18, P212, DOI 10.1111/j.1708-8305.2010.00494.x; Rao A. C. K., 2012, Asian Pacific Journal of Tropical Disease, V2, P251, DOI 10.1016/S2222-1808(12)60055-3; RESTREPO C, 1987, AM J CLIN PATHOL, V87, P536, DOI 10.1093/ajcp/87.4.536; Sagua H, 1979, Rev Chil Pediatr, V50, P15; Sasaki M, 2004, J GASTROENTEROL, V39, P88, DOI 10.1007/s00535-003-1254-0; Sun T, 1996, AM J CLIN PATHOL, V105, P216; ten Hove RJ, 2008, DIAGN MICR INFEC DIS, V61, P280, DOI 10.1016/j.diagmicrobio.2008.03.003; Tsang Owen Tak-yin, 2013, BMC Res Notes, V6, P521, DOI 10.1186/1756-0500-6-521; VanNhieu JT, 1996, HUM PATHOL, V27, P1107, DOI 10.1016/S0046-8177(96)90294-4; Velasquez JN, 2001, HUM PATHOL, V32, P500, DOI 10.1053/hupa.2001.24326; Walther Z, 2009, HUM PATHOL, V40, P1342, DOI 10.1016/j.humpath.2009.01.020	44	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						17	22		10.1016/j.anndiagpath.2017.11.002			6	Pathology	Pathology	GB7ZR	WOS:000429294200004	29566942				2019-10-28	
J	Fus, LP; Pihowicz, P; Koperski, L; Marczewska, JM; Gornicka, B				Fus, Lukasz Piotr; Pihowicz, Pawel; Koperski, Lukasz; Marczewska, Janina Maja; Gornicka, Barbara			High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Bladder cancer; HuR; Stage; Grade; Microvessel density	INCREASED CYCLOOXYGENASE-2 EXPRESSION; MESSENGER-RNA STABILIZATION; HUMAN-ANTIGEN R; PROTEIN HUR; OVARIAN-CARCINOMA; CANCER; ANGIOGENESIS; TUMORS; CELLS; COX-2	Purpose: HuR (human antigen R) protein is a RNA binding protein that stabilizes the mRNA and controls the translation of genes involved in cell proliferation, differentiation, and carcinogenesis. Overexpression of HuR was reported in a variety of cancers, however its clinical significance in urothelial bladder cancer (UBC) is still unknown. Our aim is to investigate the association between HuR expression and selected histopathological factors, such as tumor grade, pT stage, regional lymph nodes status and microvessel density (MVD). Methods: We studied expression of HuR protein in 119 patients with UBC in stages pTis and pTa-pT4 using immunohistochemistry (IHC). Tumor MVD was evaluated immunohistochemically using anti-CD31 antibody. Results: We observed no association between nuclear HuR immunoreactivity and tumor grade, stage or MVD. We found a significant association between cytoplasmic HuR positivity and high tumor grade, pT stage and MVD (p < 0,001). We also observed significantly higher MVD values in cases with positive cytoplasmic HuR expression (p < 0,001). No association between HuR immunoreactivity and lymph nodes status was found. Conclusions: Our results may suggest that HuR is involved in the process of acquiring malignant histopathological features and ability to invade the muscularis propria by UBC cells. Considering frequent difficulties in diagnosing UBC in specimens obtained from transurethral tumor resection and the risk of understaging, cytoplasmic HuR expression would suggest an advanced disease and necessitate serial sectioning of the specimen in search of muscle invasion. Association between HuR expression and MVD could suggest HuR involvement in the process of angiogenesis in UBC.	[Fus, Lukasz Piotr; Pihowicz, Pawel; Koperski, Lukasz; Marczewska, Janina Maja; Gornicka, Barbara] Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland	Fus, LP (reprint author), Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland.	lukasz.fus@wum.edu.pl	Koperski, Lukasz/U-4594-2018	Koperski, Lukasz/0000-0001-8163-1813			Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; Dotter A, 2007, MOL BIOL CELL, V18, P2137; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Guo JW, 2016, ONCOTARGET, V7, P45249, DOI 10.18632/oncotarget.9932; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj/bjc/6600315; Heinonen M, 2011, J PATHOL, V224, P529, DOI 10.1002/path.2889; Herr HW, 1999, J UROLOGY, V162, P74, DOI 10.1097/00005392-199907000-00018; Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200; Kirkali Z, 2005, UROLOGY, V66, P4, DOI 10.1016/j.urology.2005.07.062; Knies-Bamforth UE, 2004, CANCER RES, V64, P6563, DOI 10.1158/0008-5472.CAN-03-3176; Kurosu T, 2011, BRIT J CANCER, V104, P819, DOI 10.1038/bjc.2011.20; Liang PI, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-611; Lim SJ, 2009, CANCER RES TREAT, V41, P87, DOI 10.4143/crt.2009.41.2.87; Lopez de Silanes Isabel, 2005, RNA Biol, V2, P11; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; MIYATA Y, 2013, PLOS ONE, V8; Palanisamy V, 2008, J DENT RES, V87, P772, DOI 10.1177/154405910808700803; Qi C, 1999, BIOCHEM BIOPH RES CO, V263, P265, DOI 10.1006/bbrc.1999.1328; Ronkainen H, 2011, TUMOR BIOL, V32, P481, DOI 10.1007/s13277-010-0141-6; Serini S, 2012, CARCINOGENESIS, V33, P164, DOI 10.1093/carcin/bgr240; Wang J, 2011, MED ONCOL, V28, pS577, DOI 10.1007/s12032-010-9734-6; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weidner N, 2008, METHOD ENZYMOL, V444, P305, DOI 10.1016/S0076-6879(08)02814-0; Xu J, 2013, CHINESE MED J-PEKING, V126, P4322, DOI 10.3760/cma.j.issn.0366-6999.20130049; Yuan Z, 2011, ANTICANCER RES, V31, P303	29	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						40	44		10.1016/j.anndiagpath.2017.12.002			5	Pathology	Pathology	GB7ZR	WOS:000429294200008	29566946				2019-10-28	
J	Senarathne, W; Vranic, S; Xiu, J; Rose, I; Gates, P; Gatalica, Z				Senarathne, Wijendra; Vranic, Semir; Xiu, Joanne; Rose, Inga; Gates, Peggy; Gatalica, Zoran			Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						PD-L1; PD-1; Immunohistochemistry; Sequencing; Mutational load; Primary lung; Metastasis	PREDICTIVE BIOMARKERS; PD-1 BLOCKADE; OPEN-LABEL; MICROSATELLITE INSTABILITY; CHECKPOINT INHIBITOR; MUTATIONAL LANDSCAPE; COLORECTAL-CANCER; ATEZOLIZUMAB; MULTICENTER; EXPRESSION	Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-Ll is an important predictor of the of response to immune check-point inhibition in NSCLC, while the composition of the immune cells (IC) in the tumor microenvironment including PD-L1 + cells is believed to predict responses in tumors of some other primary sites. Total mutational load (TML) and microsatellite instability (MSI) also play a role in response to the immune checkpoint blockade. We investigated immune microenvironment characteristics (PD-1, PD-L1, CD8) of 257 lung biopsies including 81 primary (NSCLC) and 176 metastatic tumors to the lungs. TML and MSI were calculated from massively parallel sequencing (592-gene panel). TC expression of PD-L1 was more common in NSCLC than in metastatic carcinomas (28% vs. 10%, p = 0.009), while PD-L1-positive IC were present at relevant percentages (1-5%) exclusively in metastatic carcinomas (31% IC positive vs. 0%, p < 0.001). Metastatic carcinomas carried significantly lower TML in comparison with the NSCLCs (6.6 mutations on average vs. 10, p = 0.01). All primary NSCLC were microsatellite stable, and only 2 metastatic carcinomas exhibited MSI-H status. The number of PD-1 + and CD8 + tumor infiltrating lymphocytes did not differ significantly between the primary and metastatic carcinomas. Our study revealed significant differences in tumor immune microenvironment (PD-L1 in IC and TC), and its relationship to TML between NSCLC and metastatic cancers. These differences could determine the choice of a predictive biomarker test and subsequently effect(s) of the immune therapy treatments in various advanced cancers.	[Senarathne, Wijendra; Xiu, Joanne; Rose, Inga; Gates, Peggy; Gatalica, Zoran] Caris Life Sci, 4610 South,44th Pl, Phoenix, AZ 85040 USA; [Vranic, Semir] Qatar Univ, Coll Med, Doha, Qatar	Gatalica, Z (reprint author), Caris Life Sci, 4610 South,44th Pl, Phoenix, AZ 85040 USA.	zgatalica@carisls.com	Vranic, Semir/I-6823-2019	Vranic, Semir/0000-0001-9743-7265			Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brown SD, 2014, GENOME RES, V24, P743, DOI 10.1101/gr.165985.113; Carbognin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130142; Chabanon RM, 2016, CLIN CANCER RES, V22, P4309, DOI 10.1158/1078-0432.CCR-16-0903; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fuchs CS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4003; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gatalica Z, 2016, J THORAC ONCOL, V11, pS57, DOI 10.1016/S1556-0864(16)30116-2; Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Grigg C, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0153-x; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; Joneja U, 2017, J CLIN PATHOL, V70, P255, DOI 10.1136/jclinpath-2016-203874; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Liu XM, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0136-7; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rimm DL, 2017, JAMA ONCOL; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Scheel AH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1131379; Shien K, 2016, LUNG CANCER, V99, P79, DOI 10.1016/j.lungcan.2016.06.016; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Vranic S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166266	39	1	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						62	68		10.1016/j.anndiagpath.2017.12.004			7	Pathology	Pathology	GB7ZR	WOS:000429294200012	29566951	Green Published, Other Gold			2019-10-28	
J	Liu, L; Yang, ZT; Ni, WD; Xuan, YH				Liu, Lan; Yang, Zhaoting; Ni, Weidong; Xuan, Yanhua			ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Esophageal squamous cell carcinoma; ADAMTS-6; Twist-1; Prognosis	CANCER; METALLOPROTEINASES; EPIDEMIOLOGY; METASTASIS; ROLES	Background: A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progression are rare. It is unclear whether ADAMTS-6 could be an independent ESCC biomarker. Methods: ADAMTS-6 expression was detected by immunohistochemistry (IHC) in 171 paraffin-embedded ESCC specimens; relationships with patients' clinicopathological features and Twist-1 expression were analyzed by the Pearson Chi-square method, respectively. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan-Meier method and compared using the long-rank test. Results: ADAMTS-6 was expressed mainly in the cytoplasm and nucleus; the expression was significantly higher in tumor tissues. Increased expression of ADAMTS-6 correlated with clinical stage (P = 0.009), pT stage (P = 0.042), lymph node metastasis (P = 0.014) and recurrence (P = 0.033). There were no significant correlations between ADAMTS-6 expression and other clinicopathological parameters including age, sex, tumor size, distant metastasis, differentiation, ... chemotherapy, radiotherapy, CD68 expression and epithelial mesenchymal transition (EMT) status. Kaplan-Meier survival curves revealed that upregulated expression of ADAMTS-6 indicated short OS (P = 0.001) and DFS (P = 0.002). Multivariate analysis confirmed that high ADAMTS-6 expression was an independent factor for ESCC prognosis. ADAMTS-6 expression was significantly correlated with Twist-1 expression in ESCC cancer cells (P = 0.007) and stromal cells (P < 0.001). Patients with ESCC revealing expression of both ADAMTS-6 and Twist-1 exhibited significantly reduced OS and DFS rates than other patients. Conclusions: High ADAMTS-6 expression is a useful marker of poor prognosis in patients with ESCC.	[Liu, Lan; Yang, Zhaoting; Ni, Weidong; Xuan, Yanhua] Yanbian Univ, Coll Med, Minist Educ, Key Lab Nat Resources Changbai Mt & Funct Mol, Yanji 13302, Peoples R China; [Liu, Lan] Yanbian Univ, Affiliated Hosp, Dept Pathol, Yanji 133002, Peoples R China; [Yang, Zhaoting; Ni, Weidong; Xuan, Yanhua] Yanbian Univ, Coll Med, Dept Pathol, Yanji 13302, Peoples R China	Xuan, YH (reprint author), Yanbian Univ, Minist Educ, Key Lab Nat Resources Changbai Mt & Funct Mol, 977 Gongyuan Rd, Yanji 133002, Peoples R China.	xuanyh1@ybu.edu.cn			National Natural Science Funds of ChinaNational Natural Science Foundation of China [81460390, 81760531, 81560400]	This study was supported by grants from National Natural Science Funds of China (81460390, 81760531, 81560400).	Binder MJ, 2017, CANCER LETT, V385, P55, DOI 10.1016/j.canlet.2016.11.001; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Cal S, 2015, MATRIX BIOL, V44-46, P77, DOI 10.1016/j.matbio.2015.01.013; Ekman S, 2008, EXPERT REV ANTICANC, V8, P1433, DOI 10.1586/14737140.8.9.1433; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kelwick R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0676-3; Kumar Saran, 2012, Cancers (Basel), V4, P1252, DOI 10.3390/cancers4041252; Lee KW, 2012, ANN SURG ONCOL, V19, P326, DOI 10.1245/s10434-011-1867-0; Osugi H, 2017, J THORAC DIS, V9, pS741, DOI 10.21037/jtd.2017.05.25; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Ryan AM, 2011, CANCER EPIDEMIOL, V35, P309, DOI 10.1016/j.canep.2011.03.001; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Tang WR, 2015, INT J HYG ENVIR HEAL, V218, P12, DOI 10.1016/j.ijheh.2014.10.004; Tyan SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035128; van Goor H, 2009, J PATHOL, V219, P277, DOI 10.1002/path.2594; Wagstaff L, 2011, FRONT BIOSCI-LANDMRK, V16, P1861, DOI 10.2741/3827; Wheeler JB, 2012, SURG CLIN N AM, V92, P1077, DOI 10.1016/j.suc.2012.07.008; Yang ZT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145807; Yeo SY, 2017, ONCOTARGET, V8, P65265, DOI 10.18632/oncotarget.17941	20	1	1	4	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					134	139		10.1016/j.yexmp.2018.02.004			6	Pathology	Pathology	GC8IO	WOS:000430037300005	29475036				2019-10-28	
J	Tang, H; Pei, H; Xia, QF; Tang, YM; Huang, J; Huang, J; Pei, F				Tang, Hui; Pei, Hua; Xia, Qianfeng; Tang, Yimei; Huang, Ji; Huang, Jie; Pei, Fang			Role of gene polymorphisms/haplotypes and serum levels of interleukin-17A in susceptibility to viral myocarditis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Viral myocarditis; Interleukin (IL)-17A; Polymorphism	SINGLE-NUCLEOTIDE POLYMORPHISMS; COXSACKIEVIRUS B3-INDUCED MYOCARDITIS; REGULATORY T-CELLS; TH17 CELLS; HUMAN GENOME; ASSOCIATION; POPULATION; PATHWAY; DISEASE; UPDATE	Interleukin-17A (IL-17A) has been implicated in the pathogenesis of viral myocarditis (VMC). However, the role of IL-17A polymorphisms in susceptibility to VMC has not been reported to date. The aim of this study was to explore the association between IL-17A variants as well as serum IL-17 levels with VMC. Three single-nucleotide polymorphisms (SNPs) (rs2275913, rs3819025, and rs3748067) were analyzed by the polymerase chain reaction-restriction fragment length polymorphism method in 236 VMC patients and 259 controls from China. Serum IL-17A levels were measured by enzyme-linked immunosorbent assay kits. Multivariable logistic regression analysis that the rs2275913 AA genotype and the haplotype -197A/+45G/+1249G (AGG) were associated with an increased risk of VMC (all P < 0.05). Consistent with these findings, the rs2275913 AA genotype was linked to higher serum IL-17A compared to GG/AG genotype (all P < 0.001). We observed no associations between the other two SNPs and risk of VMC. Serum IL-17A levels were significantly higher in the VMC group than controls (P < 0.001) and gradually increased with the increase of New York Heart Association grade in VMC patients (P < 0.05). Spearman correlation test revealed that the serum IL-17A level was correlated with the cardiac damage and left ventricular systolic functions among VMC patients (all P < 0.05). Our study reveals that IL-17A expression may contribute to the development and severity of VMC. The SNP rs2275913 in the IL-17A gene might exert influence on susceptibility to VMC via linking with the serum IL-17A level.	[Tang, Hui; Tang, Yimei] Peoples Hosp Shuangqiao Econ & Technol Dev Zone, Dept Cardiol, Chongqing, Peoples R China; [Pei, Hua; Xia, Qianfeng] Hainan Med Univ, Lab Trop Biomed & Biotechnol, Haikou, Hainan, Peoples R China; [Pei, Fang] Guilin Med Univ, Affiliated Hosp 2, Dept Cardiol, 212 RenMin Rd, Guilin 541199, Guangxi, Peoples R China; [Huang, Ji; Huang, Jie; Pei, Fang] Chinese Peoples Armed Police Force, Dept Cardiol, Chongqing Municipal Corps Hosp, Chongqing, Peoples R China	Pei, F (reprint author), Guilin Med Univ, Affiliated Hosp 2, Dept Cardiol, 212 RenMin Rd, Guilin 541199, Guangxi, Peoples R China.	gypeifang@163.com			Chongqing Base and Cutting-edge Research Projects [cstc2015jcyjA10047]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81641166]	This work was supported by grants from the Chongqing Base and Cutting-edge Research Projects (cstc2015jcyjA10047), and the National Natural Science Foundation of China (No. 81641166).	Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Du J, 2016, MED SCI MONITOR, V22, P780, DOI 10.12659/MSM.895494; Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229; Fairweather D, 2012, CURR OPIN RHEUMATOL, V24, P401, DOI 10.1097/BOR.0b013e328353372d; Fan YH, 2011, VIROL J, V8, DOI [10.1186/1743-422X-8-17, 10.1186/1743-422X-8-492]; Fung G, 2016, CIRC RES, V118, P496, DOI 10.1161/CIRCRESAHA.115.306573; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gorbea C, 2010, J BIOL CHEM, V285, P23206, DOI 10.1074/jbc.M109.047464; Han L, 2014, GENE, V533, P119, DOI 10.1016/j.gene.2013.09.113; Hayashi R, 2013, CLIN EXP MED, V13, P239, DOI 10.1007/s10238-012-0206-5; Hu YD, 2014, ARCH VIROL, V159, P2411, DOI 10.1007/s00705-014-2098-z; Huber SA, 2016, CURR PHARM DESIGN, V22, P408, DOI 10.2174/1381612822666151222160500; Jin Y, 2015, J ASTHMA, V52, P981, DOI 10.3109/02770903.2015.1044251; Kathiresan S, 2005, CIRCULATION, V112, P1728, DOI 10.1161/CIRCULATIONAHA.105.547836; Kindermann I, 2012, J AM COLL CARDIOL, V59, P779, DOI 10.1016/j.jacc.2011.09.074; Liao Y, 2015, EUR REV MED PHARMACO, V19, P3500; Liu XKK, 2004, J BIOL CHEM, V279, P52762, DOI 10.1074/jbc.M405764200; Liu YF, 2012, INT IMMUNOL, V24, P605, DOI 10.1093/intimm/dxs056; Long Q, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00171; Martinez NE, 2012, FUTURE VIROL, V7, P593, DOI 10.2217/FVL.12.44; Marwa OS, 2017, IMMUNOL LETT, V183, P24, DOI 10.1016/j.imlet.2017.01.013; Reddy J, 2013, CURR OPIN RHEUMATOL, V25, P502, DOI 10.1097/BOR.0b013e3283620036; Rose NR, 2016, CURR OPIN RHEUMATOL, V28, P383, DOI 10.1097/BOR.0000000000000303; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Shuang L, 2015, INT J CLIN EXP PATHO, V8, P11653; Task Force on Myocarditis and Cardiomyopathy of Chinese Journal of Cardiology Editor Committee, 1999, CHIN J CARDIOL, V27, P405; Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26; Wiltshire SA, 2011, J IMMUNOL, V186, P6398, DOI 10.4049/jimmunol.1100159; Wynne J, 2001, HEART DIS TXB CARDIO, P1751; Xie YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072158; Xie YQ, 2012, FEMS IMMUNOL MED MIC, V64, P343, DOI 10.1111/j.1574-695X.2011.00918.x; Xie YQ, 2011, VIROLOGY, V421, P78, DOI 10.1016/j.virol.2011.09.006; Yu M, 2013, CELL PHYSIOL BIOCHEM, V32, P1437, DOI 10.1159/000356581; Yuan J, 2010, J IMMUNOL, V185, P4004, DOI 10.4049/jimmunol.1001718; Yuan J, 2010, INT IMMUNOPHARMACOL, V10, P272, DOI 10.1016/j.intimp.2009.11.010; Yuan J, 2010, J CLIN IMMUNOL, V30, P226, DOI 10.1007/s10875-009-9355-z; Zhu HS, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0418-x	38	2	2	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					140	145		10.1016/j.yexmp.2018.03.002			6	Pathology	Pathology	GC8IO	WOS:000430037300006	29530464				2019-10-28	
J	Volpi, CC; Ciniselli, CM; Gualeni, AV; Plebani, M; Alfieri, S; Verderio, P; Locati, L; Perrone, F; Quattrone, P; Carbone, A; Pilotti, S; Gloghini, A				Volpi, Chiara C.; Ciniselli, Chiara M.; Gualeni, Ambra V.; Plebani, Maddalena; Alfieri, Salvatore; Verderio, Paolo; Locati, Laura; Perrone, Federica; Quattrone, Pasquale; Carbone, Antonino; Pilotti, Silvana; Gloghini, Annunziata			In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating	HUMAN PATHOLOGY			English	Article						HPV E6/E7 mRNA ISH; HPV 16; Oropharyngeal squamous cell carcinoma; p16; HR-HPV DNA ISH	RISK HUMAN-PAPILLOMAVIRUS; SQUAMOUS-CELL CARCINOMA; CANCER; HEAD; AGREEMENT; DIAGNOSIS; ASSAY	The aim of this study is to compare 2 in situ hybridization (ISH) detection methods for human papilloma virus (HPV) 16 E6/E7 mRNA, that is, the RNAscope 2.0 High Definition (HD) and the upgraded RNAscope 2.5 HD version. The RNAscope 2.5 HD has recently replaced the RNAscope 2.0 HD detection kit. Therefore, this investigation starts from the need to analytically validate the new mRNA ISH assay and, possibly, to refine the current algorithm for HPV detection in oropharyngeal squamous cell carcinoma with the final goal of applying it to daily laboratory practice. The study was based on HPV status and on generated data, interpreted by a scoring algorithm. The results highlighted that the compared RNAscope HPV tests had a good level of interchangeability and enabled to identify oropharyngeal squamous cell carcinoma that are truly driven by high-risk HPV infection. This was also supported by the comparison of the RNA-scope HPV test with HPV E6/E7 mRNA real-time reverse-transcription polymerase chain reaction in a fraction of cases where material for HPV E6/E7 mRNA real-time reverse-transcription polymerase chain reaction was available. Furthermore, the algorithm that associates p16 immunohistochemistry with the identification of HPV mRNA by RNAscope was more effective than the one that associated p16 immunohistochemistry with the identification of HPV DNA by ISH. (C) 2017 Elsevier Inc. All rights reserved.	[Volpi, Chiara C.; Gualeni, Ambra V.; Perrone, Federica; Quattrone, Pasquale; Gloghini, Annunziata] Fdn IRCCS, Ist Nazl Tumori, Dept Pathol & Lab Med, I-20133 Milan, Italy; [Ciniselli, Chiara M.; Plebani, Maddalena; Verderio, Paolo] Fdn IRCCS Ist Nazl Tumori, Unit Med Stat Biometry & Bioinformat, I-20133 Milan, Italy; [Alfieri, Salvatore; Locati, Laura] Fdn IRCCS, Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy; [Carbone, Antonino] IRCCS, Natl Canc Inst, Ctr Riferimento Oncol, Dept Pathol, I-33081 Aviano, Italy; [Pilotti, Silvana] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Lab Expt Mol Pathol, I-20133 Milan, Italy	Gloghini, A (reprint author), Fdn IRCCS Ist Nazl Tumori, Dept Diagnost Pathol & Lab Med, Via Venezian 1, I-20133 Milan, Italy.	annunziata.gloghini@istitutotumori.mi.it	Alfieri, Salvatore/B-7827-2017; Carbone, Antonino/AAA-2217-2019; Gloghini, Annunziata/AAB-4809-2019; Verderio, Paolo/B-5034-2017; Ciniselli, Chiara M/C-4518-2017; Perrone, Federica/S-6171-2016	Alfieri, Salvatore/0000-0001-8485-2275; Carbone, Antonino/0000-0003-2211-639X; Gloghini, Annunziata/0000-0002-7226-1942; Verderio, Paolo/0000-0002-9231-1281; Ciniselli, Chiara M/0000-0003-4488-885X; Perrone, Federica/0000-0003-4406-8245	Fondazione IRCCS, Istituto Nazionale dei Tumori Milano	C. C. V. is recipient of a fellowship supported by an institutional grant from Fondazione IRCCS, Istituto Nazionale dei Tumori Milano, for a project on "Identification of head and neck cancer and HPV-related infections by profiling volatile organic compounds in exhaled breath."	Banks L, 2012, IARC MONOGRAPHS EVAL; Bishop JA, 2012, AM J SURG PATHOL, V36, P1874, DOI 10.1097/PAS.0b013e318265fb2b; Bussolati Gianni, 2015, Recent Results Cancer Res, V199, P1, DOI 10.1007/978-3-319-13957-9_1; Bussolati G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021043; Ciniselli CM, 2016, HUM PATHOL, V47, P157, DOI 10.1016/j.humpath.2015.06.026; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Gloghini A, 2015, WORLD CANCER RES J, V2; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lewis JS, 2012, HISTOPATHOLOGY, V60, P982, DOI 10.1111/j.1365-2559.2011.04169.x; Mendez-Pena JE, 2017, HUM PATHOL, V63, P184, DOI 10.1016/j.humpath.2017.02.021; Mills AM, 2017, AM J SURG PATHOL, V41, P607, DOI 10.1097/PAS.0000000000000800; Mirghani H, 2016, ORAL ONCOL, V62, P101, DOI 10.1016/j.oraloncology.2016.10.009; Mirghani H, 2015, MODERN PATHOL, V28, P1518, DOI 10.1038/modpathol.2015.113; Mirghani H, 2014, ORAL ONCOL, V50, P1, DOI 10.1016/j.oraloncology.2013.10.008; Perrone F, 2011, AM J SURG PATHOL, V35, P774, DOI 10.1097/PAS.0b013e3182116a45; Rooper LM, 2016, ORAL ONCOL, V55, P11, DOI 10.1016/j.oraloncology.2016.02.008; Shi W, 2009, J CLIN ONCOL, V27, P6213, DOI 10.1200/JCO.2009.23.1670; Terrenato I, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-58; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d	19	4	4	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						32	42		10.1016/j.humpath.2017.09.011			11	Pathology	Pathology	GF4KZ	WOS:000431933100005	28993274				2019-10-28	
J	Zhou, N; Liu, C; Wang, XD; Mao, QS; Jin, Q; Li, P				Zhou, Nan; Liu, Can; Wang, Xudong; Mao, Qinsheng; Jin, Qin; Li, Peng			Downregulated SASH1 expression indicates poor clinical prognosis in gastric cancer	HUMAN PATHOLOGY			English	Article						Gastric cancer; Immunohistochemistry; Prognosis; SASH1; Tissue microarray	TUMOR-SUPPRESSOR GENE; SAM DOMAIN; CELL-PROLIFERATION; INVASION; PATHWAY; APOPTOSIS; RISK; ROR2; EMT	SASH1 (SAM- and SH3-domain containing 1), a novel candidate tumor suppressor, has attracted attention due to its role in intracellular signal transduction and its tumor prognostic value in diverse cancers. Reports have demonstrated that reduced SASH1 expression correlates with tumor proliferation, invasion, and metastasis. However, the expression and prognostic significance of SASH1 in gastric cancer (GC) remain unclear. In this study, 8 paired fresh-frozen GC tissues and corresponding gastric mucosal tissues were examined by Western blot to analyze the protein expression of SASH1. Seven hundred twenty-six formalin-fixed, paraffin-embedded (FFPE) gastric tissue samples were evaluated by immunohistochemical (IHC) to determine the correlations of SASH1 expression with clinicopathological factors and prognosis. Compared with adjacent noncancerous tissues, SASH1 was significantly downregulated in GC specimens. Analysis using the chi(2) test revealed that low SASH1 expression was significantly associated with advanced TNM stage (P < .001) in GC. Cox regression multivariable analyses demonstrated that SASH1 expression (P < .001), TNM stage (P < .001), preoperative CEA level (P = .003) and preoperative CA19-9 level (P = .002) were independent prognostic factors. Our clinical findings suggest that downregulated SASH1 expression could be used as an independent biomarker for poor prognosis in GC. (C) 2018 Published by Elsevier Inc.	[Zhou, Nan; Liu, Can] Nantong Univ Affiliated Hosp, Dept Oncol, Nantong 226001, Jiangsu, Peoples R China; [Zhou, Nan; Liu, Can] Nantong Univ Affiliated Hosp, Dept Clin Biobank, Nantong 226001, Jiangsu, Peoples R China; [Wang, Xudong] Nantong Univ Affiliated Hosp, Ctr Clin Lab Med, Nantong 226001, Jiangsu, Peoples R China; [Mao, Qinsheng; Li, Peng] Nantong Univ Affiliated Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China; [Jin, Qin] Nantong Univ Affiliated Hosp, Dept Pathol, Nantong 226001, Jiangsu, Peoples R China; [Li, Peng] Nantong Univ, Neural Regenerat Coinnovat Ctr Jiangsu Prov, Nantong 226007, Jiangsu, Peoples R China	Li, P (reprint author), Nantong Univ Affiliated Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China.	pengli@ntu.edu.cn		Jin, Qin/0000-0002-7246-4651	National Natural Science Funds of ChinaNational Natural Science Foundation of China [81101615]; Six Talent Peaks Project of Jiangsu, China [WSW-029]	This study was supported by the National Natural Science Funds of China (81101615) and the Six Talent Peaks Project (WSW-029) of Jiangsu, China.	Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004; Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chen EG, 2012, TUMOR BIOL, V33, P1393, DOI 10.1007/s13277-012-0387-2; Chen H, 2016, MOL MED REP, V13, P3613, DOI 10.3892/mmr.2016.4946; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Dauphinee SM, 2013, J IMMUNOL, V191, P892, DOI 10.4049/jimmunol.1200583; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; He MA, 2014, GUT, V63, P143, DOI 10.1136/gutjnl-2012-303434; He P, 2016, ONCOL RES, V24, P25, DOI 10.3727/096504016X14575597858609; Huang JF, 2017, J CONTROL RELEASE, V245, P1, DOI 10.1016/j.jconrel.2016.11.024; Huang JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12991; Huang JF, 2011, J CLIN PATHOL, V64, P343, DOI 10.1136/jcp.2010.085142; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Lin SY, 2012, MOL MED REP, V6, P1243, DOI 10.3892/mmr.2012.1099; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Martini M, 2011, INT J BIOCHEM CELL B, V43, P1630, DOI 10.1016/j.biocel.2011.07.012; Meng QB, 2013, MOL CELL BIOCHEM, V373, P201, DOI 10.1007/s11010-012-1491-8; Mocellin S, 2015, GUT, V64, P1209, DOI 10.1136/gutjnl-2015-309168; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rahman R, 2014, WORLD J GASTROENTERO, V20, P4483, DOI 10.3748/wjg.v20.i16.4483; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ren XY, 2016, ONCOL LETT, V11, P3123, DOI 10.3892/ol.2016.4345; Rimkus C, 2006, BRIT J CANCER, V95, P1419, DOI 10.1038/sj.bjc.6603452; Sun DW, 2015, INT J CLIN EXP PATHO, V8, P12276; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Yang L, 2012, TUMOR BIOL, V33, P2255, DOI 10.1007/s13277-012-0487-z; Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474; Zhou DA, 2013, CELL SIGNAL, V25, P1526, DOI 10.1016/j.cellsig.2012.12.025	32	5	6	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						83	91		10.1016/j.humpath.2018.01.008			9	Pathology	Pathology	GF4KZ	WOS:000431933100010	29320755				2019-10-28	
J	Jelloul, FZ; Chen, QH; Yang, TY; Haghi, N; Brody, J; Zhang, XM; Sheikh-Fayyaz, S				Jelloul, Fatima Zahra; Chen, Qiang Hua; Yang, Tianyu; Haghi, Nina; Brody, Judith; Zhang, Xinmin; Sheikh-Fayyaz, Silvat			Composite Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Clinicopathological Study of Six Cases	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						composite lymphoma; follicular lymphoma; small lymphocytic lymphoma; chronic lymphocytic leukemia	NON-HODGKINS-LYMPHOMA; T-CELL LYMPHOMA; B-CELL; BICLONAL LYMPHOMAS; IN-SITU; EXPRESSION; SURVIVAL; RECEPTOR; DISEASE; PATIENT	Background: Composite small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and follicular lymphoma (FL) is extremely rare, and only 13 cases have been reported previously. Methods: We identified 6 cases of composite SLL/CLL and FL in our database and studied their clinical, histologic, immunophenotypic, and cytogenetic features. A literature review of the existing cases was also conducted. Results: The patients included 4 males and 2 females, with a median age of 72 years. Four patients presented with lymphadenopathy and 2 with extranodal diseases. Lymphocytosis was seen in 2 cases. Serum lactate dehydrogenase levels were within normal range in all but one case. There were 2 histologic patterns: SLL/CLL predominant pattern (type I) and FL predominant or mixed pattern (type II). The type I pattern was exclusively associated with in situ follicular neoplasia (ISFN). The SLL/CLL showed typical morphology and immunophenotype in all the cases. The FL component included low grade (n = 3), ISFN (n = 2), and primary cutaneous FL (n = 1). Four cases had staging bone marrow biopsies including 3 cases with involvement by SLL/CLL and 1 case with involvement by SLL/CLL and FL. Four patients received treatments, one was under clinical surveillance, and one had no available information. All patients were alive after a median follow-up of 22 months. Conclusions: This is the largest case serial of composite SLL/CLL and FL. The CL affects elderly individuals, presents with advanced clinical stage, and appears to have a relatively indolent clinical course.	[Jelloul, Fatima Zahra; Chen, Qiang Hua; Yang, Tianyu; Haghi, Nina; Brody, Judith; Zhang, Xinmin; Sheikh-Fayyaz, Silvat] Hofstra Northwell Sch Med, Lake Success, NY USA	Zhang, XM (reprint author), Hofstra Northwell Sch Med, Dept Pathol & Lab Med, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA.	Xzhang2@northwell.edu					BENNETT MH, 1991, ANN ONCOL, V2, P83, DOI 10.1093/annonc/2.suppl_2.83; Boiocchi L, 2012, AM J CLIN PATHOL, V137, P647, DOI 10.1309/AJCPHXO5UGW2OELA; Briones J, 2002, EXP HEMATOL, V30, P135, DOI 10.1016/S0301-472X(01)00774-3; Copur MS, 2004, LEUKEMIA LYMPHOMA, V45, P1071, DOI 10.1080/1042819032000159870; Demurtas A, 2011, AM J CLIN PATHOL, V135, P541, DOI 10.1309/AJCPQKE25ADCFZWN; diSibio G, 2010, EXP MOL PATHOL, V89, P260, DOI 10.1016/j.yexmp.2010.07.001; Endo T, 2007, BLOOD, V109, P703, DOI 10.1182/blood-2006-06-027755; Fend F, 1999, AM J PATHOL, V154, P1857, DOI 10.1016/S0002-9440(10)65443-0; Hirose Y, 2004, INT J HEMATOL, V79, P260, DOI 10.1532/IJH97.03156; JAFFE ES, 1994, ANN ONCOL, V5, pS7, DOI 10.1093/annonc/5.suppl_1.S7; Jegalian AG, 2011, BLOOD, V118, P2976, DOI 10.1182/blood-2011-05-355255; Kang SJ, 2007, OPHTHAL PLAST RECONS, V23, P143, DOI 10.1097/IOP.0b013e31802f20a0; Khan WN, 2009, J IMMUNOL, V183, P3561, DOI 10.4049/jimmunol.0800933; KIM H, 1993, AM J CLIN PATHOL, V99, P445, DOI 10.1093/ajcp/99.4.445; KIM H, 1977, CANCER, V40, P959, DOI 10.1002/1097-0142(197709)40:3<959::AID-CNCR2820400302>3.0.CO;2-3; Kuppers R, 2014, LANCET ONCOL, V15, pE435, DOI 10.1016/S1470-2045(14)70153-6; MEDEIROS LJ, 1992, AM J CLIN PATHOL, V98, P387, DOI 10.1093/ajcp/98.4.387; Mokhtar Nadia M, 2007, J Egypt Natl Canc Inst, V19, P171; Novak AJ, 2002, BLOOD, V100, P2973, DOI 10.1182/blood-2002-02-0558; Pillai RK, 2013, HAEMATOLOGICA, V98, P1571, DOI 10.3324/haematol.2013.085506; Rabiller F, 2008, ANN PATHOL, V28, P41, DOI 10.1016/j.annpat.2007.09.001; Tennese A, 2017, INT J SURG PATHOL, V25, P276, DOI 10.1177/1066896916671195; Tucci A, 2005, HAEMATOLOGICA, V90, P348; Wu WN, 2014, J HEMATOP, V7, P95, DOI 10.1007/s12308-014-0212-5	24	1	1	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					135	144		10.1177/1066896917737161			10	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800004	29069998				2019-10-28	
J	Xu, LY; Rassaei, N; Caruso, C				Xu, Liyan; Rassaei, Negar; Caruso, Carla			Pleuroparenchymal Fibroelastosis With Long History of Asbestos and Silicon Exposure	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						pleuroparenchymal fibroelastosis; asbestos; silicon; injury	LUNG INJURY; ENTITY; TRANSPLANTATION; CHEMOTHERAPY; FIBROSIS; DISEASE	Pleuroparenchymal fibroelastosis (PPFE) is an uncommon interstitial lung disease. PPFE is characterized by fibroelastosis involving the pleura and subjacent parenchyma with a predominantly upper lobe distribution. While different possible environmental and familial etiologies have been postulated in the literature, the etiology of this disease remains essentially unclear and most cases are considered as idiopathic. In this report, we describe a rare case of PPFE with multiple lung lobe involvements and prolonged asbestos and silica exposure. Our goal is to investigate the exposure of asbestos and silica and try to identify their possible association with PPFE.	[Xu, Liyan; Rassaei, Negar; Caruso, Carla] Penn State Hlth Milton S Hershey Med Ctr, 500 Univ Dr,POB 850, Hershey, PA 17033 USA	Xu, LY (reprint author), Penn State Hlth Milton S Hershey Med Ctr, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.	xuliyan1@yahoo.com					Amitani R, 1992, KOKYU, V11, P693; Attanoos RL, 2013, DIAGN HISTOPATHOL, V19, P282; Azoulay E, 1999, EUR RESPIR J, V14, P971, DOI 10.1034/j.1399-3003.1999.14d41.x; Cagle PT, 2008, DAIL HAMMARS PULMONA, V1, p[984, 912]; Camus P, 2014, EUR RESPIR J, V44, P289, DOI 10.1183/09031936.00088414; Chen FS, 2014, ANN THORAC SURG, V98, pE115, DOI 10.1016/j.athoracsur.2014.07.045; Cheng SKH, 2016, ARCH PATHOL LAB MED, V140, P849, DOI 10.5858/arpa.2015-0166-RS; Frankel SK, 2004, CHEST, V126, P2007, DOI 10.1378/chest.126.6.2007; Hirota T, 2015, HISTOPATHOLOGY, V66, P545, DOI 10.1111/his.12554; Hirota T, 2013, EUR RESPIR J, V41, P243, DOI 10.1183/09031936.00103912; Nakatani T, 2015, EUR RESPIR J, V45, P1183, DOI 10.1183/09031936.00214714; Parish JM, 2003, MAYO CLIN PROC, V78, P630, DOI 10.4065/78.5.630; Piciucchi S, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-111; Portillo K, 2015, ARCH BRONCONEUMOL, V51, P509, DOI 10.1016/j.arbres.2015.05.002; Reddy TL, 2012, EUR RESPIR J, V40, P377, DOI 10.1183/09031936.00165111; Rosenbaum JN, 2015, HUM PATHOL, V46, P137, DOI 10.1016/j.humpath.2014.10.007; SCHWARTZ DA, 1991, CHEST, V99, P191, DOI 10.1378/chest.99.1.191; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213	19	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					190	193		10.1177/1066896917739399			4	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800016	29113529				2019-10-28	
J	Pekkarinen, H; Airas, N; Savolainen, LE; Rantala, M; Kilpinen, S; Miuku, O; Speeti, M; Karkamo, V; Malkamaki, S; Vaara, M; Sukura, A; Syrja, P				Pekkarinen, H.; Airas, N.; Savolainen, L. E.; Rantala, M.; Kilpinen, S.; Miuku, O.; Speeti, M.; Karkamo, V; Malkamaki, S.; Vaara, M.; Sukura, A.; Syrja, P.			Non-tuberculous Mycobacteria can Cause Disseminated Mycobacteriosis in Cats	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cat; mycobacteriosis; non-tuberculous mycobacteria	AVIUM INFECTION; DISEASE; IDENTIFICATION; EPIDEMIOLOGY; TUBERCULOSIS; SHIMOIDEI; XENOPI; ASSAY	Mycobacteriosis caused by non-tuberculous mycobacteria (NTM) is a rising concern in human medicine both in immunocompromised and immunocompetent patients. In cats, mycobacteriosis caused by NTM is considered mostly to be a focal or dermal infection, with disseminated disease mostly caused by Mycobacterium avium. We describe three cases of disseminated mycobacteriosis in cats, caused by Mycobacterium malmoense, Mycobacterium branderi/shimoidei and M. avium, with no identified underlying immunosuppression. In all cases, extracellular mycobacteria were seen in the pulmonary epithelium, intestinal lumen and glomerular tufts, which could affect the shedding of the organism. The present study highlights the importance of mycobacteriosis as a differential even in immunocompetent animals. Considering the close relationship of owners and pets and the potential presence of free mycobacteria in secretions, cats should be considered as a possible environmental reservoir for mycobacteria. (C) 2018 Elsevier Ltd. All rights reserved.	[Pekkarinen, H.; Airas, N.; Malkamaki, S.; Sukura, A.; Syrja, P.] Univ Helsinki, Fac Vet Med, Dept Vet Biosci, POB 66, Helsinki, Finland; [Savolainen, L. E.; Vaara, M.] Univ Helsinki, Dept Clin Microbiol, Helsinki, Finland; [Savolainen, L. E.; Vaara, M.] Helsinki Univ Hosp, HUSLAB, Helsinki, Finland; [Rantala, M.; Kilpinen, S.; Miuku, O.] Univ Helsinki, Fac Vet Med, Dept Equine & Small Anim Med, POB 57, Helsinki, Finland; [Speeti, M.] Herttoniemi Vet Clin, Hiihtomaentie 35, Helsinki, Finland; [Karkamo, V] Finnish Food Safety Author Evira, Pathol Res Unit, Mustialankatu 3, Helsinki, Finland	Pekkarinen, H (reprint author), Univ Helsinki, Fac Vet Med, Dept Vet Biosci, POB 66, Helsinki, Finland.	henna.pekkarinen@helsinki.fi	Rantala, Merja/AAC-5544-2019	Syrja, Pernilla Elisabet Sofia/0000-0001-9740-2636; Malkamaki, Sanna/0000-0001-6707-1581			Avanzi C, 2016, SCIENCE, V354, P744, DOI 10.1126/science.aah3783; Balamayooran G, 2015, CLIN DERMATOL, V33, P108, DOI [10.1016/j.clindermatol.2014.07.001, 10.1016/j.clindermato1.2014.07.001]; Baral RM, 2006, J FELINE MED SURG, V8, P23, DOI 10.1016/j.jfms.2005.06.004; Barry M, 2002, CAN VET J, V43, P369; Bittner MJ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TNMI7-0012-2016; Broughan JM, 2013, VET J, V198, P339, DOI 10.1016/j.tvjl.2013.09.006; Cowell RL, 2014, COWELL TYLERS DIAGNO, P49; Cummings L, 2002, FEMS MICROBIOL LETT, V216, P133, DOI 10.1111/j.1574-6968.2002.tb11426.x; Daley CL, 2017, MICROBIOLOGY SPECTRU, V5, DOI [10.1128/micro-biolspec.TNMI7-0045-2017, DOI 10.1128/MICRO-BIOLSPEC.TNMI7-0045-2017]; de Groot PHS, 2010, VET MICROBIOL, V144, P527, DOI 10.1016/j.vetmic.2010.05.028; Dietrich U, 2003, J SMALL ANIM PRACT, V44, P121, DOI 10.1111/j.1748-5827.2003.tb00132.x; Elze J, 2013, J FELINE MED SURG, V15, P1141, DOI 10.1177/1098612X13490711; Esteban J, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TNMI7-0021-2016; Fitzgerald DW, 2010, PRINCIPLES PRACTICE, P3129; Galizzi N, 2013, J CLIN MICROBIOL, V51, P3467, DOI 10.1128/JCM.01028-13; Griffin A, 2003, J AM VET MED ASSOC, V222, P1097, DOI 10.2460/javma.2003.222.1097; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Gunn-Moore DA, 2013, TRANSBOUND EMERG DIS, V60, P338, DOI 10.1111/j.1865-1682.2012.01352.x; Gunn-Moore DA, 2014, VET J, V201, P230, DOI 10.1016/j.tvjl.2014.02.014; Gunn-Moore DA, 2011, J FELINE MED SURG, V13, P934, DOI 10.1016/j.jfms.2011.07.012; Gunn-Moore DA, 2011, J FELINE MED SURG, V13, P945, DOI 10.1016/j.jfms.2011.09.009; Hetzel U, 2012, VET REC, V171, DOI 10.1136/vr.100926; Ioannidis P, 2011, J CLIN MICROBIOL, V49, P3068, DOI 10.1128/JCM.00718-11; Jeon MK, 2015, TUBERC RESPIR DIS, V78, P293, DOI 10.4046/trd.2015.78.3.293; Kanaji N, 2013, AM J CASE REP, V14, P543, DOI 10.12659/AJCR.889684; Kipar A, 1998, VET IMMUNOL IMMUNOP, V65, P243, DOI 10.1016/S0165-2427(98)00158-5; Knippel A, 2004, J VET MED B, V51, P464, DOI 10.1111/j.1439-0450.2004.00803.x; Koh WJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0024-2016; Lee SH, 2017, J COMP PATHOL, V157, P215, DOI 10.1016/j.jcpa.2017.07.009; Lloret A, 2013, J FELINE MED SURG, V15, P591, DOI 10.1177/1098612X13489221; MacWilliams PS, 1998, VET CLIN PATH, V27, P50, DOI 10.1111/j.1939-165X.1998.tb01015.x; Mauldin EA, 2016, JUBB KENNEDY PALMERS, V1, P639; Meeks C, 2008, J VET INTERN MED, V22, P1043, DOI 10.1111/j.1939-1676.2008.0108.x; Morfitt D C, 1989, J Vet Diagn Invest, V1, P354; Pesciaroli M, 2014, RES VET SCI, V97, pS78, DOI 10.1016/j.rvsc.2014.05.015; Poncelet L, 2008, VET PATHOL, V45, P140, DOI 10.1354/vp.45-2-140; Quinn PJ, 2011, VET MICROBIOLOGY MIC, P250; Raskin RE, 2010, CANINE FELINE CYTOLO, P34; Renault CA, 2010, MANDELL DOUGLAS BENN, P3165; Riviere D, 2011, J FELINE MED SURG, V13, P125, DOI 10.1016/j.jfms.2010.09.002; Russo C, 2006, J CLIN MICROBIOL, V44, P334, DOI 10.1128/JCM.44.2.334-339.2006; Schrenzel Mark D, 2012, Vet Clin North Am Exot Anim Pract, V15, P1, DOI 10.1016/j.cvex.2011.11.001; Shah NM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1521-3; Thirunavukkarasu S, 2017, ZOONOSES PUBLIC HLTH, V64, P401, DOI 10.1111/zph.12334; Turvey SL, 2017, INT J INFECT DIS, V58, P65, DOI 10.1016/j.ijid.2017.03.002; Tuuminen T, 2006, J CLIN MICROBIOL, V44, P3048, DOI 10.1128/JCM.00521-06	46	2	2	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						1	9		10.1016/j.jcpa.2018.02.002			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800001	29729715	Green Accepted			2019-10-28	
J	Jesinghaus, M; Strehl, J; Boxberg, M; Bruhl, F; Wenzel, A; Konukiewitz, B; Schlitter, AM; Steiger, K; Warth, A; Schnelzer, A; Kiechle, M; Beckmann, MW; Noske, A; Hartmann, A; Mehlhorn, G; Koch, MC; Weichert, W				Jesinghaus, Moritz; Strehl, Johanna; Boxberg, Melanie; Bruehl, Frido; Wenzel, Adrian; Konukiewitz, Bjoern; Schlitter, Anna M.; Steiger, Katja; Warth, Arne; Schnelzer, Andreas; Kiechle, Marion; Beckmann, Matthias W.; Noske, Aurelia; Hartmann, Arndt; Mehlhorn, Grit; Koch, Martin C.; Weichert, Wilko			Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						cervical carcinoma; cell nest size; budding; grading; prognosis; survival	HUMAN-PAPILLOMAVIRUS; PREDICTS PROGNOSIS; CANCER; INVASION; PROPOSAL	A novel histopathological grading system based on tumour budding and cell nest size has recently been shown to outperform conventional (WHO-based) grading algorithms in several tumour entities such as lung, oral, and oesophageal squamous cell carcinoma (SCC) in terms of prognostic patient stratification. Here, we tested the prognostic value of this innovative grading approach in two completely independent cohorts of SCC of the uterine cervix. To improve morphology-based grading, we investigated tumour budding activity and cell nest size as well as several other histomorphological factors (e.g., keratinization, nuclear size, mitotic activity) in a test cohort (n=125) and an independent validation cohort (n=122) of cervical SCC. All parameters were correlated with clinicopathological factors and patient outcome. Small cell nest size and high tumour budding activity were strongly associated with a dismal patient prognosis (p<0.001 for overall survival [OS], disease-specific survival, and disease-free survival; test cohort) in both cohorts of cervical SCC. A novel grading algorithm combining these two parameters proved to be a highly effective, stage-independent prognosticator in both cohorts (OS: p<0.001, test cohort; p=0.001, validation cohort). In the test cohort, multivariate statistical analysis of the novel grade revealed that the hazard ratio (HR) for OS was 2.3 for G2 and 5.1 for G3 tumours compared to G1 neoplasms (p=0.010). In the validation cohort, HR for OS was 3.0 for G2 and 7.2 for G3 tumours (p=0.012). In conclusion, our novel grading algorithm incorporating cell nest size and tumour budding allows strongly prognostic histopathological grading of cervical SCC superior to WHO-based grading. Therefore, our data can be regarded as a cross-organ validation of previous results demonstrated for oesophageal, lung, and oral SCC. We suggest this grading algorithm as an additional morphology-based parameter for the routine diagnostic assessment of this tumour entity.	[Jesinghaus, Moritz; Boxberg, Melanie; Bruehl, Frido; Wenzel, Adrian; Konukiewitz, Bjoern; Schlitter, Anna M.; Steiger, Katja; Noske, Aurelia; Weichert, Wilko] Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany; [Jesinghaus, Moritz; Schlitter, Anna M.; Weichert, Wilko] German Canc Consortium DKTK, Heidelberg, Germany; [Strehl, Johanna; Hartmann, Arndt] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany; [Warth, Arne] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Schnelzer, Andreas; Kiechle, Marion] Tech Univ Munich, Dept Gynecol & Obstet, Munich, Germany; [Beckmann, Matthias W.; Mehlhorn, Grit; Koch, Martin C.] Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr Erlangen EMN, Erlangen Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany	Weichert, W (reprint author), Tech Univ Munich, Inst Pathol, Trogerstr 18, D-81675 Munich, Germany.	Wilko.Weichert@tum.de		Bruehl, Frido/0000-0001-6409-0824			Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boxberg M, 2017, HISTOPATHOLOGY, V70, P1125, DOI 10.1111/his.13173; Brierley JD, 2017, TNM CLASSIFICATION M, P10; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; CRISSMAN JD, 1985, CANCER-AM CANCER SOC, V55, P1590, DOI 10.1002/1097-0142(19850401)55:7<1590::AID-CNCR2820550730>3.0.CO;2-O; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Horn LC, 2007, GYNECOL ONCOL, V107, P310, DOI 10.1016/j.ygyno.2007.06.026; Huang BX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166311; Jesinghaus M, 2017, AM J SURG PATHOL, V41, P1112, DOI 10.1097/PAS.0000000000000865; Kadota K, 2014, J THORAC ONCOL, V9, P1126, DOI 10.1097/JTO.0000000000000253; Koike M, 2008, ANN SURG ONCOL, V15, P1977, DOI 10.1245/s10434-008-9901-6; Kurman RJ, 2014, WHO CLASSIFICATION T; Mitobe J, 2013, SCAND J GASTROENTERO, V48, P1173, DOI 10.3109/00365521.2013.832365; Miyata H, 2009, CANCER, V115, P3324, DOI 10.1002/cncr.24390; Nakagawa Y, 2013, ANTICANCER RES, V33, P5023; Nakanishi Y, 2011, WORLD J SURG, V35, P349, DOI 10.1007/s00268-010-0880-y; Niwa Y, 2014, J SURG ONCOL, V110, P764, DOI 10.1002/jso.23694; Roh MS, 2004, DIS ESOPHAGUS, V17, P333, DOI 10.1111/j.1442-2050.2004.00436.x; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; STENDAHL U, 1979, ACTA RADIOL ONCOL, V18, P481, DOI 10.3109/02841867909129078; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; ZAINO RJ, 1992, CANCER, V69, P1750, DOI 10.1002/1097-0142(19920401)69:7<1750::AID-CNCR2820690717>3.0.CO;2-S	26	6	6	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					93	102		10.1002/cjp2.95			10	Pathology	Pathology	GD2CH	WOS:000430307200003	29665323	DOAJ Gold, Green Published			2019-10-28	
J	Tretiakova, M; Fulton, R; Kocherginsky, M; Long, T; Ussakli, C; Antic, T; Gown, A				Tretiakova, Maria; Fulton, Regan; Kocherginsky, Masha; Long, Thomas; Ussakli, Cigdem; Antic, Tatjana; Gown, Allen			Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression	MODERN PATHOLOGY			English	Article							CELL LUNG-CANCER; PROGRAMMED DEATH LIGAND-1; UROTHELIAL CARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; HETEROGENEITY; ATEZOLIZUMAB; CHEMOTHERAPY; ASSOCIATION; BIOMARKER	Therapy with anti-PD-L1 immune check-point inhibitors is approved for several cancers, including advanced urothelial carcinomas. PD-L1 prevalence estimates vary widely in bladder cancer, and lack of correlation between expression and clinical outcomes and immunotherapy response may be attributed to methodological differences of the immunohistochemical reagents and procedures. We characterized PD-L1 expression in 235 urothelial carcinomas including 79 matched pairs of primary and metastatic cancers using a panel of four PD-L1 immunoassays in comparison with RNAscope assay using PD-L1-specific probe (CD274). The antibody panel included three FDA-approved clones (22C3 for pembrolizumab, 28.8 for nivolumab, SP142 for atezolizumab), and a commonly used clone E1L3N. Manual scoring of tissue microarrays was performed in each of 235 tumors (624 tissue cores) and compared to an automated image analysis. Expression of PD-L1 in tumor cells by >= 1 marker was detected in 41/142 (28.9%) primary tumors, 13/77 (16.9%) lymph nodes, and 2/16 (12.5%) distant metastases. In positive cases, high PD-L1 expression (>50% cells) was detected in 34.1% primary and 46.7% metastases. Concordant PD-L1 expression status was present in 71/79 (89.9%) cases of matched primary and metastatic urothelial carcinomas. PD-L1 sensitivity ranked from highest to lowest as follows: RNAscope, clone 28.8, 22C3, E1L3N, and SP142. Pairwise concordance correlation coefficients between the four antibodies in 624 tissue cores ranged from 0.76 to 0.9 for tumor cells and from 0.30 to 0.85 for immune cells. RNA and protein expression levels showed moderate to high agreement (0.72-0.87). Intra-tumor expression heterogeneity was low for both protein and RNA assays (interclass correlation coefficients: 0.86-0.94). Manual scores were highly concordant with automated Aperio scores (0.94-0.97). A significant subset of 56/235 (23.8%) urothelial carcinomas stained positive for PD-L1 with high concordance between all four antibodies and RNA ISH assay. Despite some heterogeneity in staining, the overall results are highly concordant suggesting diagnostic equivalence of tested assays.	[Tretiakova, Maria; Long, Thomas; Ussakli, Cigdem] Univ Washington, Med Ctr, Dept Pathol, 325 9th Ave, Seattle, WA 98104 USA; [Fulton, Regan; Gown, Allen] PhenoPath Labs, Seattle, WA USA; [Kocherginsky, Masha] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Antic, Tatjana] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA	Tretiakova, M (reprint author), Univ Washington, Med Ctr, Dept Pathol, 325 9th Ave, Seattle, WA 98104 USA.	mariast@uw.edu					Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Baras AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134412; Bellmunt J, 2015, ANN ONCOL, V26, P812, DOI 10.1093/annonc/mdv009; Bellmunt J, 2017, CANCER TREAT REV, V54, P58, DOI 10.1016/j.ctrv.2017.01.007; Cogswell J, 2017, MOL DIAGN THER, V21, P85, DOI 10.1007/s40291-016-0237-9; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1243, DOI 10.5858/arpa.2015-0542-OA; Ettinger DS, 2016, J NATL COMPR CANC NE, V14, P255, DOI 10.6004/jnccn.2016.0031; Faraj SF, 2015, UROLOGY, V85, DOI 10.1016/j.urology.2014.10.020; Gandini S, 2016, CRIT REV ONCOL HEMAT, V100, P88, DOI 10.1016/j.critrevonc.2016.02.001; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Inaguma S, 2017, ONCOTARGET, V8, P26744, DOI 10.18632/oncotarget.15814; Inman BA, 2007, CANCER, V109, P1499, DOI 10.1002/cncr.22588; Kerr KM, 2016, ARCH PATHOL LAB MED, V140, P326, DOI 10.5858/arpa.2015-0522-SA; Le Goux C, 2017, UROL ONCOL-SEMIN ORI, V35, P257, DOI 10.1016/j.urolonc.2017.01.014; Lin L, 2002, J AM STAT ASSOC, V97, P257, DOI 10.1198/016214502753479392; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Ning YM, 2017, ONCOLOGIST, V22, P743, DOI 10.1634/theoncologist.2017-0087; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Plimack ER, 2015, EUR UROL, V68, P959, DOI 10.1016/j.eururo.2015.07.009; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; R Core Team, 2016, R LANG ENV STAT COMP; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sheffield BS, 2016, J HISTOCHEM CYTOCHEM, V64, P587, DOI 10.1369/0022155416665338; Stevenson M, 2016, EPIR TOOLS ANAL EPID; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wolak ME, 2012, METHODS ECOL EVOL, V3, P129, DOI 10.1111/j.2041-210X.2011.00125.x	31	23	23	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					623	632		10.1038/modpathol.2017.188			10	Pathology	Pathology	GD3LE	WOS:000430404600009	29271413	Bronze			2019-10-28	
J	Goode, B; Joseph, NM; Stevers, M; Van Ziffle, J; Onodera, C; Talevich, E; Grenert, JP; Yeh, I; Bastian, BC; Phillips, JJ; Garg, K; Rabban, JT; Zaloudek, C; Solomon, DA				Goode, Benjamin; Joseph, Nancy M.; Stevers, Meredith; Van Ziffle, Jessica; Onodera, Courtney; Talevich, Eric; Grenert, James P.; Yeh, Iwei; Bastian, Boris C.; Phillips, Joanna J.; Garg, Karuna; Rabban, Joseph T.; Zaloudek, Charles; Solomon, David A.			Adenomatoid tumors of the male and female genital tract are defined by &ITTRAF7&IT mutations that drive aberrant NF-kB pathway activation	MODERN PATHOLOGY			English	Article							GENOMIC ANALYSIS; TRAF7 MUTATIONS; PAIRED-END; UTERUS; GENES; MENINGIOMAS; FUSIONS; PATIENT; SETD2; MED12	Adenomatoid tumors are the most common neoplasm of the epididymis, and histologically similar adenomatoid tumors also commonly arise in the uterus and fallopian tube. To investigate the molecular pathogenesis of these tumors, we performed genomic profiling on a cohort of 31 adenomatoid tumors of the male and female genital tracts. We identified that all tumors harbored somatic missense mutations in the TRAF7 gene, which encodes an E3 ubiquitin ligase belonging to the family of tumor necrosis factor receptor-associated factors (TRAFs). These mutations all clustered into one of five recurrent hotspots within the WD40 repeat domains at the C-terminus of the protein. Functional studies in vitro revealed that expression of mutant but not wild-type TRAF7 led to increased phosphorylation of nuclear factor-kappa B (NF-kB) and increased expression of L1 cell adhesion molecule (L1CAM), a marker of NF-kB pathway activation. Immunohistochemistry demonstrated robust L1CAM expression in adenomatoid tumors that was absent in normal mesothelial cells, malignant peritoneal mesotheliomas and multilocular peritoneal inclusion cysts. Together, these studies demonstrate that adenomatoid tumors of the male and female genital tract are genetically defined by TRAF7 mutation that drives aberrant NF-kB pathway activation.	[Goode, Benjamin; Joseph, Nancy M.; Stevers, Meredith; Van Ziffle, Jessica; Grenert, James P.; Yeh, Iwei; Bastian, Boris C.; Phillips, Joanna J.; Garg, Karuna; Rabban, Joseph T.; Zaloudek, Charles; Solomon, David A.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,Box 0102,Hlth Sci West 451, San Francisco, CA 94143 USA; [Joseph, Nancy M.; Van Ziffle, Jessica; Onodera, Courtney; Talevich, Eric; Grenert, James P.; Yeh, Iwei; Bastian, Boris C.; Solomon, David A.] Univ Calif San Francisco, Clin Canc Genom Lab, San Francisco, CA 94143 USA; [Phillips, Joanna J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	Solomon, DA (reprint author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,Box 0102,Hlth Sci West 451, San Francisco, CA 94143 USA.	david.solomon@ucsf.edu		Yeh, Iwei/0000-0002-3941-3561	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP5 OD021403]; UCSF Physician-Scientist Scholar Program; NIH SPORE grant [P50CA097257]	This study was supported by NIH Director's Early Independence Award (DP5 OD021403) and the UCSF Physician-Scientist Scholar Program to DAS. We thank the UCSF Brain Tumor Research Center (supported by NIH SPORE grant P50CA097257) for assistance with L1CAM immunohistochemistry.	Acikalin MF, 2009, INT J GYNECOL CANCER, V19, P242, DOI 10.1111/IGC.0b013e31819bc8f9; Broad Institute, PIC; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Cheng CL, 2003, INT J GYNECOL PATHOL, V22, P198, DOI 10.1097/01.PGP.0000054825.24394.9F; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Ferenczy A, 1976, CANCER, V37, P1478; Figarella-Branger D, 2016, NEURO-ONCOLOGY, V18, P919, DOI 10.1093/neuonc/now025; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Garrison E, 12073907V2QBIOGN ARX; Joseph NM, 2017, MODERN PATHOL, V30, P246, DOI 10.1038/modpathol.2016.188; Klein CJ, 2017, ANN NEUROL, V81, P316, DOI 10.1002/ana.24854; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lim WK, 2014, NAT GENET, V46, P877, DOI 10.1038/ng.3037; LIVINGSTON EG, 1992, INT J GYNECOL PATHOL, V11, P288, DOI 10.1097/00004347-199210000-00007; MACKAY B, 1971, CANCER-AM CANCER SOC, V27, P109, DOI 10.1002/1097-0142(197101)27:1<109::AID-CNCR2820270116>3.0.CO;2-7; Makinen N, 2011, SCIENCE, V334, P252, DOI 10.1126/science.1208930; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Mizutani T, 2016, GYNECOL ONCOL REP, V17, P96, DOI 10.1016/j.gore.2016.05.003; Nogales FF, 2002, INT J GYNECOL PATHOL, V21, P34, DOI 10.1097/00004347-200201000-00007; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; SAID JW, 1982, HUM PATHOL, V13, P1106, DOI 10.1016/S0046-8177(82)80247-5; Sangoi AR, 2009, MODERN PATHOL, V22, P1228, DOI 10.1038/modpathol.2009.90; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; TAXY JB, 1974, CANCER-AM CANCER SOC, V34, P306, DOI 10.1002/1097-0142(197408)34:2<306::AID-CNCR2820340214>3.0.CO;2-G; Tiras MB, 2000, EUR J OBSTET GYN R B, V92, P205; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750-2187-8-7; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zotti T, 2017, J CELL PHYSIOL, V232, P1233, DOI 10.1002/jcp.25676	34	7	7	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					660	673		10.1038/modpathol.2017.153			14	Pathology	Pathology	GD3LE	WOS:000430404600013	29148537	Green Accepted, Bronze			2019-10-28	
J	Ngernyuang, N; Shao, R; Suwannarurk, K; Limpaiboon, T				Ngernyuang, Nipaporn; Shao, Rong; Suwannarurk, Komsun; Limpaiboon, Temduang			Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer	PATHOLOGY			English	Article						YKL-40; vasculogenic mimicry; angiogenesis; dual staining	SERUM YKL-40; OVARIAN-CANCER; ANGIOGENESIS INHIBITORS; MELANOMA-CELLS; BREAST-CANCER; IN-VIVO; MARKER; INVOLVEMENT; METASTASIS; PLASTICITY	Vasculogenic mimicry (VM) is an alternative microvascular system which tumour cells orchestrate, independent of endothelial cell-mediated angiogenesis. VM develops tumour vascular networks that correlate with tumour growth, metastasis, and short survival time of patients with a number of cancers. However, little is known regarding VM in the vascularisation of cervical cancer. Chitinase 3 like 1 (CHI3L1) has been previously reported to display the ability to induce angiogenesis in cervical cancer. Here, we explored a pathological role of CHI3L1 in tumour cell-mediated vascularisation. Sixty-six samples of cervical cancer were collected to examine CHI3L1 expression and VM formation using immunohistochemistry and CD34-periodic acid-Schiff (PAS) dual staining. CHI3L1 expression was significantly correlated with formation of tumour cell-associated vascular channels in the absence of endothelial cells (p = 0.031). Interestingly, tumour samples lacking VM were positively correlated with non-metastasis (p = 0.035). Patients with VM positive tumours tended to have decreased overall survival (OS) compared to those with VM negative samples (43.9 versus 64.6 months, p = 0.079). In addition, recombinant CHI3L1 enhanced cervical cancer cell lines to form tube-like structures, supporting the notion that CHI3L1 mediates VM in cervical cancer. Our present data reveal the crucial role of CHI3L1 in the formation of VM, which may contribute to tumour aggressiveness. Therefore, targeting CHI3L1 may be a valuable strategy for the reduction of cervical cancer vascularisation and metastasis.	[Ngernyuang, Nipaporn] Thammasat Univ, Chulabhorn Int Coll Med, Rangsit Campus, Pathum Thani, Thailand; [Shao, Rong] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol, Shanghai, Peoples R China; [Suwannarurk, Komsun] Thammasat Univ, Fac Med, Dept Obstet & Gynaecol, Rangsit Campus, Pathum Thani, Thailand; [Limpaiboon, Temduang] Khon Kaen Univ, Fac Associated Med Sci, Med Diagnost Labs, Ctr Res & Dev, Khon Kaen 40002, Thailand	Limpaiboon, T (reprint author), Khon Kaen Univ, Fac Associated Med Sci, Med Diagnost Labs, Ctr Res & Dev, Khon Kaen 40002, Thailand.	temduang@kku.ac.th	Suwannarurk, Komsun/H-8080-2019	Limpaiboon, Temduang/0000-0003-0827-4375	Thailand Research Fund (TRF) under TRF Grant for New Researcher [TRG5880156]; Thammasat University Research Fund under the TU Research Scholar [2/47/2558]	This project was financially supported by Thailand Research Fund (TRF) under TRF Grant for New Researcher, Contract No. TRG5880156, and Thammasat University Research Fund under the TU Research Scholar, Contract No. 2/47/2558. All authors declare they have no conflicts of interest to disclose.	Ana O, 2016, EUR ONCOL HAEMATOL, V12, P32; Bernardi D, 2003, CLIN CHEM, V49, P1685, DOI 10.1373/49.10.1685; Colombo N, 2012, ANN ONCOL, V23, P27, DOI 10.1093/annonc/mds268; Dehn H, 2003, ACTA OBSTET GYN SCAN, V82, P287, DOI 10.1034/j.1600-0412.2003.00010.x; Dunleavey James M, 2012, Curr Angiogenes, V1, P133; Dupont J, 2004, J CLIN ONCOL, V22, P3330, DOI 10.1200/JCO.2004.09.112; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540; Guzman G, 2007, ARCH PATHOL LAB MED, V131, P1776; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Jiang J, 2011, ONCOGENE, V30, P4498, DOI 10.1038/onc.2011.154; Johansen JS, 2006, CANCER EPIDEM BIOMAR, V15, P194, DOI 10.1158/1055-EPI-05-0011; Johansen JS, 2005, RESP MED, V99, P396, DOI 10.1016/j.rmed.2004.09.016; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Lebensztejn DM, 2007, ADV MED SCI-POLAND, V52, P120; Liu XM, 2011, J NEURO-ONCOL, V105, P173, DOI 10.1007/s11060-011-0578-5; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mitsuhashi A, 2009, ANN ONCOL, V20, P71, DOI 10.1093/annonc/mdn552; Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909; Ngernyuang N, 2014, INT J BIOCHEM CELL B, V51, P45, DOI [10.1016/j.biocel.2014.03.021, 10.1016/j.bioce1.2014.03.021]; Nordenbaek C, 2005, SCAND J RHEUMATOL, V34, P293, DOI 10.1080/03009740510018598; Qi LS, 2015, INT J MOL SCI, V16, P18564, DOI 10.3390/ijms160818564; Quinn M, 2006, INT J GYNECOL OBSTET, V95, pS43, DOI 10.1016/S0020-7292(06)60030-1; Shao R, 2015, ONCOTARGET, V6, P40507, DOI 10.18632/oncotarget.5943; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Shirakawa K, 2003, BREAST CANCER RES, V5, P136, DOI 10.1186/bcr585; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Steeg PS, 2003, NAT MED, V9, P822, DOI 10.1038/nm0703-822; Su M, 2008, INT J GYNECOL CANCER, V18, P476, DOI 10.1111/j.1525-1438.2007.01034.x; Sun BC, 2008, HUM PATHOL, V39, P444, DOI 10.1016/j.humpath.2007.07.018; Sun BC, 2006, ONCOL REP, V16, P693; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; Wang W, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-60; Yu S, 2015, AM J HEMATOL-ONCOL, V11, P26; Yue WY, 2005, J HISTOCHEM CYTOCHEM, V53, P997, DOI 10.1369/jhc.4A6521.2005	39	4	5	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					293	297		10.1016/j.pathol.2017.09.015			5	Pathology	Pathology	GA7OF	WOS:000428525100006	29452694				2019-10-28	
J	Lim, JCT; Yeong, JPS; Lim, CJ; Ong, CCH; Wong, SC; Chew, VSP; Ahmed, SS; Tan, PH; Iqbal, J				Lim, Jeffrey Chun Tatt; Yeong, Joe Poh Sheng; Lim, Chun Jye; Ong, Clara Chong Hui; Wong, Siew Cheng; Chew, Valerie Suk Peng; Ahmed, Syed Salahuddin; Tan, Puay Hoon; Iqbal, Jabed			An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use	PATHOLOGY			English	Article						Automation; formalin-fixed paraffin-embedded tissues; multi-plexing; multispectral; immunofluorescence; fluorescence-immunohistochemistry; imaging; immune cells	TUMOR-INFILTRATING LYMPHOCYTES; CD8 T-CELLS; BREAST-CANCER; FOXP3 EXPRESSION; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; IMMUNOHISTOCHEMISTRY; RECOMMENDATIONS; LOCALIZATION; HALLMARKS	Multiplex immunofluorescence (mIF) allows simultaneous antibody-based detection and quantification of the expression of up to six markers, plus a nuclear counterstain, on a single tissue section. Recent studies have shown the potential for mIF to advance our understanding of complex disease processes, including cancer. It is important that the technique be standardised and validated to facilitate its transition into clinical use. Traditional approaches to mIF rely on manual processing of sections, which is time-consuming and a source of significant variation between samples/individuals. Here we determined if an automated diagnostic tissue stainer could be used for mIF incorporating tyramide signal amplification (TSA), and how the final image quality compared with sections stained semi-automatically or manually. Using tissue microarrays of fixed human breast tumour sections, we observed comparable antibody labelling between the diagnostic autostainer and manual technique. The diagnostic autostainer produced higher signal intensity with similar spectral unmixing efficiency. We also found that microwave treatment for antibody stripping during TSA labelling could be replaced by the heating option incorporated within the diagnostic-use autostainer. These data show that diagnostic autostainers used for traditional immunohistochemistry protocols can be readily adapted to achieve rapid preparation of high-quality sections using a TSA method for clinical mIF.	[Lim, Jeffrey Chun Tatt; Yeong, Joe Poh Sheng; Ong, Clara Chong Hui; Ahmed, Syed Salahuddin; Iqbal, Jabed] Singapore Gen Hosp, Dept Anat Pathol, 20 Coll Rd,Diagnost Tower, Singapore 169856, Singapore; [Yeong, Joe Poh Sheng; Wong, Siew Cheng] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore; [Lim, Chun Jye; Chew, Valerie Suk Peng] SingHlth Translat Immunol & Inflammat Ctr, Singapore, Singapore; [Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, Singapore, Singapore; [Tan, Puay Hoon] Duke NUS Med Sch, Singapore, Singapore	Iqbal, J (reprint author), Singapore Gen Hosp, Dept Anat Pathol, 20 Coll Rd,Diagnost Tower, Singapore 169856, Singapore.	jabed.iqbal@singhealth.com.sg		Yeong, Joe/0000-0002-6674-7153	SingHealth Duke-NUS Pathology Academic Clinical Program Pitch for Funds (Scientific) grant [ACP PATH PFF 15 004]; SingHealth Duke-NUS Pathology Academic Clinical Program Budding Clinician-Scientist grant [ACP PATH BCS 14 001]; Singapore National Medical Research Council Transition Award [NMRC/TA/0041/2015]	This study was supported by the SingHealth Duke-NUS Pathology Academic Clinical Program Pitch for Funds (Scientific) grant (ACP PATH PFF 15 004) and Budding Clinician-Scientist grant (ACP PATH BCS 14 001), and the Singapore National Medical Research Council Transition Award (NMRC/TA/0041/2015). The authors state that there are no conflicts of interest to disclose.	Abcam PLC, IMM APPL GUID; Abel EJ, 2014, HUM PATHOL, V45, P1092, DOI 10.1016/j.humpath.2014.01.008; Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Badoual C, 2013, CANCER RES, V73, P128, DOI 10.1158/0008-5472.CAN-12-2606; Beckers RK, 2016, HISTOPATHOLOGY, V69, P25, DOI 10.1111/his.12904; Botti G, 2017, INT J MOL SCI, P10; Chung TDY, 2010, MOLECULES, V15, P3010, DOI 10.3390/molecules15053010; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Douglass S, 2014, J PATHOL, V234, P74, DOI 10.1002/path.4381; Feng ZP, 2016, J IMMUNOL, V196, P3943, DOI 10.4049/jimmunol.1502635; Gehring AJ, 2009, GASTROENTEROLOGY, V137, P682, DOI 10.1053/j.gastro.2009.04.045; Hainaut P, 2013, CURR OPIN ONCOL, V25, P50, DOI 10.1097/CCO.0b013e32835b651e; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Idikio HA, 2010, INT J CLIN EXP PATHO, V3, P169; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lu HL, 2009, J CLIN ONCOL, V27, P1735, DOI 10.1200/JCO.2008.20.0675; Ma GF, 2014, BRIT J CANCER, V110, P1552, DOI 10.1038/bjc.2014.47; Muenst S, 2010, DIS MARKERS, V29, P47, DOI 10.3233/DMA-2010-0725; NAKANE PK, 1966, J HISTOCHEM CYTOCHEM, V14, P929, DOI 10.1177/14.12.929; PerkinElmer Inc, 2017, OP 4 COL 7 COL AUT I; PerkinElmer Inc, 2010, TSA SIGN AMPL IMM IH; ROBINSON G, 1975, J CLIN PATHOL, V28, P631, DOI 10.1136/jcp.28.8.631; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; Takenaka M, 2013, MOL CLIN ONCOL, V1, P625, DOI 10.3892/mco.2013.107; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yeong J, 2017, BREAST CANCER RES TR, V163, P21, DOI 10.1007/s10549-017-4161-4	29	5	5	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					333	341		10.1016/j.pathol.2017.11.087			9	Pathology	Pathology	GA7OF	WOS:000428525100013	29429740				2019-10-28	
J	Narayanappa, H; Low, TH; Calderon, ACV; Selinger, C; Gupta, R				Narayanappa, Harini; Low, Tsu-Hui (Hubert); Calderon, Ana Cristina Vargas; Selinger, Christina; Gupta, Ruta			Inflammatory myofibroblastic tumours of the head and neck	PATHOLOGY			English	Letter							ALK EXPRESSION; PROLIFERATIONS; 2P23		[Narayanappa, Harini; Calderon, Ana Cristina Vargas; Selinger, Christina; Gupta, Ruta] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Low, Tsu-Hui (Hubert)] Chris OBrien Lifehouse, Head & Neck Surg, Sydney, NSW, Australia; [Low, Tsu-Hui (Hubert); Gupta, Ruta] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia	Gupta, R (reprint author), Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia.; Gupta, R (reprint author), Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia.	Ruta.Gupta@sswahs.nsw.gov.au		Gupta, Ruta/0000-0003-2940-313X; Low, Tsu-Hui (Hubert)/0000-0001-8958-736X			Brtum H, 1939, J THORAC SURG, V9, P119; Coffin CM, 2007, AM J SURG PATHOL, V31, P509, DOI 10.1097/01.pas.0000213393.57322.c7; Coffin CM, 2001, MODERN PATHOL, V14, P569, DOI 10.1038/modpathol.3880352; COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001; Fletcher C, 2013, WHO CLASSIFICATION T; Gleason BC, 2008, J CLIN PATHOL, V61, P428, DOI 10.1136/jcp.2007.049387; Griffin CA, 1999, CANCER RES, V59, P2776; Harik LR, 2006, AM J SURG PATHOL, V30, P787, DOI 10.1097/01.pas.0000208903.46354.6f; Hirsch MS, 2006, HISTOPATHOLOGY, V48, P569, DOI 10.1111/j.1365-2559.2006.02376.x; Karnak I, 2001, J PEDIATR SURG, V36, P908, DOI 10.1053/jpsu.2001.23970; UMIKER WO, 1954, J THORAC SURG, V28, P55; Viswanathan S, 2010, HEAD NECK PATHOL, V4, P265, DOI 10.1007/s12105-010-0204-4	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					356	358		10.1016/j.pathol.2017.09.019			3	Pathology	Pathology	GA7OF	WOS:000428525100019	29478692				2019-10-28	
J	Hou, WH; Wei, P; Xie, JL; Zheng, YY; Zhang, YL; Zhou, XG				Hou, Weihua; Wei, Ping; Xie, Jianlan; Zheng, Yuanyuan; Zhang, Yanlin; Zhou, Xiaoge			The degree of overlap between the follicular dendritic cell meshwork and tumor cells in mantle cell lymphoma is associated with prognosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lymphoma; Non-Hodgkin; Mantle cell lymphoma; Follicular dendritic cell; Ki-67; Prognosis	KI-67 PROLIFERATION INDEX; NON-HODGKIN-LYMPHOMA; MOLECULAR PATHOGENESIS; RANDOMIZED-TRIALS; GROWTH-PATTERN; ADVANCED-STAGE; IMAGE-ANALYSIS; OPEN-LABEL; RITUXIMAB; DISEASE	This study concerning mantle cell lymphoma (MCL) investigated retrospectively an association between patient prognosis and the percentage of the total number of lymphoma cells found in the follicular dendritic cell (FDC) meshwork, that is, the degree of overlap of lymphoma cells. Two hundred and nine MCL patients were apportioned to grades I-III in which the CD21-positive FDC meshwork covered <= 50%, 51%-89%, and >= 90% of the tumor area, respectively. Significant differences among the grades (all, P < 0.01) were found in the following: duration of disease (from onset of clinical manifestation to diagnosis); clinical staging; extranodal involvement (non-lymphoid organs); histological subtype; and Ki-67 proliferation index (PI). After removing the aggressive variants, the overall survival rates of grade I (n = 92) and II (n = 57) patients were similar. The overall survival rates of grade III (n = 46) patients differed from that of grade I + II patients (P < 0.01). The grades negatively correlated with the Ki-67 PI value (r = -0.234, P = 0.001). At each grade the OSR of patients with Ki-67 PI <= 30% was similar to that of patients with Ki-67 > 30%. In the Ki-67 PI <= 30% group, the OSRs of the patients differed significantly among the grades. In the Ki-67 > 30% group the OSRs of the grades were similar. The results of multivariate Cox regression analysis showed that the degree of overlap, age and Ki-67 PI was the independent prognostic factors of the OSRs of MCL patients. Our data suggests that MCL patients in whom there was a high degree of overlap between the FDC meshwork and tumor area have a better clinical prognosis. The degree of overlap correlates well with the Ki-67 PI, which can be used to predict the prognosis of patients.	[Hou, Weihua; Wei, Ping; Xie, Jianlan; Zheng, Yuanyuan; Zhang, Yanlin; Zhou, Xiaoge] Capital Med Univ, Beijing Friendship Hosp, Dept Pathol, 95 Yonganlu, Beijing 100050, Peoples R China; [Hou, Weihua] Peoples Liberat Amy 152 Hosp, Dept Pathol, 44 Jianshe Rd, Pingdingshan 467000, Henan, Peoples R China	Zhou, XG (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Pathol, 95 Yonganlu, Beijing 100050, Peoples R China.	zhouxiaoge59@hotmail.com			Internal Start-up Science Foundation of Beijing Friendship [Yyqdkt2013-15]; Beijing Hospital Management Bureau clinical technology innovation project [XMLX201502]	This work was supported by the Internal Start-up Science Foundation of Beijing Friendship (Yyqdkt2013-15) and Beijing Hospital Management Bureau clinical technology innovation project (XMLX201502).	ALAVAIKKO MJ, 1994, AM J CLIN PATHOL, V101, P761, DOI 10.1093/ajcp/101.6.761; Albano D, 2016, EUR J RADIOL, V85, P313, DOI 10.1016/j.ejrad.2015.12.006; Allen CDC, 2008, SEMIN IMMUNOL, V20, P14, DOI 10.1016/j.smim.2007.12.001; Ardeshna KM, 2014, LANCET ONCOL, V15, P424, DOI 10.1016/S1470-2045(14)70027-0; Baur AS, 1998, HISTOPATHOLOGY, V32, P512, DOI 10.1046/j.1365-2559.1998.t01-1-00418.x; Blaker YN, 2015, HISTOPATHOLOGY, V67, P62, DOI 10.1111/his.12624; Carbone A, 2014, ADV ANAT PATHOL, V21, P260, DOI 10.1097/PAP.0000000000000030; Chakhachiro ZI, 2013, CANCER-AM CANCER SOC, V119, P3318, DOI 10.1002/cncr.28219; Chapman-Fredricks J, 2014, ANN DIAGN PATHOL, V18, P214, DOI 10.1016/j.anndiagpath.2014.03.006; Cohen JB, 2016, CANCER-AM CANCER SOC, V122, P2356, DOI 10.1002/cncr.30068; Cui W, 2011, PATHOL INT, V61, P737, DOI 10.1111/j.1440-1827.2011.02736.x; Dreyling M, 2015, LEUKEMIA LYMPHOMA, V56, P866, DOI 10.3109/10428194.2014.940584; Felten F., 2003, CESK PATOL, V39, P96; Fernandez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Hoster E, 2016, J CLIN ONCOL, V34, P1386, DOI 10.1200/JCO.2015.63.8387; Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466; Hu ZH, 2017, AM J SURG PATHOL, V41, P216, DOI 10.1097/PAS.0000000000000758; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Jeong TD, 2016, BLOOD RES, V51, P127, DOI 10.5045/br.2016.51.2.127; Jin MK, 2011, HISTOPATHOLOGY, V58, P586, DOI 10.1111/j.1365-2559.2011.03779.x; Klapper Wolfram, 2009, J Hematop, V2, P103, DOI 10.1007/s12308-009-0036-x; Lamonica D, 2017, J NUCL MED, V58, P62, DOI 10.2967/jnumed.116.173542; Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210; Lwin T, 2010, BLOOD, V116, P5228, DOI 10.1182/blood-2010-03-275925; Martin P, 2009, J CLIN ONCOL, V27, P1209, DOI 10.1200/JCO.2008.19.6121; PETRASCH S, 1994, LEUKEMIA LYMPHOMA, V15, P33, DOI 10.3109/10428199409051675; Rezk SA, 2013, HUM PATHOL, V44, P937, DOI 10.1016/j.humpath.2012.10.005; Royo C, 2011, SEMIN CANCER BIOL, V21, P322, DOI 10.1016/j.semcancer.2011.09.007; Ruan J, 2016, CURR HEMATOL MALIG R, V11, P234, DOI 10.1007/s11899-016-0324-3; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; Salek D, 2014, LEUKEMIA LYMPHOMA, V55, P802, DOI 10.3109/10428194.2013.815349; Sander B, 2016, VIRCHOWS ARCH, V468, P245, DOI 10.1007/s00428-015-1840-6; Sandoval-Sus Jose D, 2017, Hematol Oncol Stem Cell Ther, V10, P99, DOI 10.1016/j.hemonc.2017.02.003; Schaffel R, 2010, ANN ONCOL, V21, P133, DOI 10.1093/annonc/mdp495; Schrader C, 2006, VIRCHOWS ARCH, V448, P151, DOI 10.1007/s00428-005-0049-5; Shi Yun-fei, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P222, DOI 10.3760/cma.j.issn.0529-5807.2013.04.003; Swerdlow S, 2017, WHO CLASSIFICATION T, P285; Swerdlow SH, 2008, WHO CLASSIFICATION T, P229; Takata K, 2009, MODERN PATHOL, V22, P940, DOI 10.1038/modpathol.2009.51; Vogt N, 2017, LEUKEMIA LYMPHOMA, V58, P1530, DOI 10.1080/10428194.2016.1248965; Vose JM, 2017, AM J HEMATOL, V92, P806, DOI 10.1002/ajh.24797	42	0	3	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					513	520		10.1016/j.prp.2018.02.015			8	Pathology	Pathology	GD8BJ	WOS:000430736900007	29525403				2019-10-28	
J	Souza, NP; Hard, GC; Arnold, LL; Foster, KW; Pennington, KL; Cohen, SM				Souza, Nathalia P.; Hard, Gordon C.; Arnold, Lora L.; Foster, Kirk W.; Pennington, Karen L.; Cohen, Samuel M.			Epithelium Lining Rat Renal Papilla: Nomenclature and Association with Chronic Progressive Nephropathy (CPN)	TOXICOLOGIC PATHOLOGY			English	Article						renal papilla epithelium; urothelium; hyperplasia; proliferation; chronic progressive nephropathy	SCANNING-ELECTRON-MICROSCOPY; HUMAN RISK-ASSESSMENT; URINARY-BLADDER; ULTRASTRUCTURE; DISEASE; LESIONS; KIDNEY; CANCER	Chronic progressive nephropathy (CPN) occurs commonly in rats, more frequently and severely in males than females. High-grade CPN is characterized by increased layers of the renal papilla lining, designated as urothelial hyperplasia in the International Harmonization of Nomenclature and Diagnostic Criteria classification. However, urothelium lining the pelvis is not equivalent to the epithelium lining the papilla. To evaluate whether the epithelium lining the renal papilla is actually urothelial in nature and whether CPN-associated multicellularity represents proliferation, kidney tissues from aged rats with CPN, from rats with multicellularity of the renal papilla epithelium of either low-grade or marked severity, and from young rats with normal kidneys were analyzed and compared. Immunohistochemical staining for uroplakins (urothelial specific proteins) was negative in the papilla epithelium in all rats with multicellularity or not, indicating these cells are not urothelial. Mitotic figures were rarely observed in this epithelium, even with multicellularity. Immunohistochemical staining for Ki-67 was negative. Papilla lining cells and true urothelium differed by scanning electron microscopy. Based on these findings, we recommend that the epithelium lining the papilla not be classified as urothelial, and the CPN-associated lesion be designated as vesicular alteration of renal papilla instead of hyperplasia and distinguished in diagnostic systems from kidney pelvis urothelial hyperplasia.	[Souza, Nathalia P.; Arnold, Lora L.; Foster, Kirk W.; Pennington, Karen L.; Cohen, Samuel M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 983500 Nebraska Med Ctr, Omaha, NE 68198 USA; [Souza, Nathalia P.] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Pathol, Ctr Evaluat Environm Impact Human Hlth TOXICAM, Sao Paulo, Brazil	Cohen, SM (reprint author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 983500 Nebraska Med Ctr, Omaha, NE 68198 USA.	scohen@unmc.edu		Pereira de Souza, Nathalia/0000-0001-6052-0356	Fred and Pamela Buffett Cancer Center support grant [P30CA036727]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Fred and Pamela Buffett Cancer Center support grant (P30CA036727).	ANDREWS PM, 1974, AM J ANAT, V140, P81, DOI 10.1002/aja.1001400107; BULGER RE, 1974, AM J ANAT, V139, P483, DOI 10.1002/aja.1001390403; CARROLL N, 1974, J ANAT, V117, P447; Cohen SM, 2007, TOXICOL PATHOL, V35, P337, DOI 10.1080/01926230701197115; Cohen SM, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P1775, DOI 10.1016/B978-0-12-415759-0.00048-0; COHEN SM, 1995, CARCINOGENESIS, V16, P2743, DOI 10.1093/carcin/16.11.2743; Cohen SM, 1998, TOXICOL PATHOL, V26, P121, DOI 10.1177/019262339802600114; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P537, DOI 10.1016/B978-0-444-53856-7.00010-5; Hard GC, 2005, TOXICOL PATHOL, V33, P641, DOI 10.1080/01926230500299716; Hard GC, 2004, TOXICOL PATHOL, V32, P171, DOI 10.1080/01926230490422574; Hard GC, 2013, TOXICOL SCI, V132, P268, DOI 10.1093/toxsci/kfs305; Hard GC, 2011, REGUL TOXICOL PHARM, V59, P430, DOI 10.1016/j.yrtph.2011.01.007; Hard GC, 2009, CRIT REV TOXICOL, V39, P332, DOI 10.1080/10408440802368642; HICKS RM, 1974, PHILOS T ROY SOC B, V268, P23, DOI 10.1098/rstb.1974.0013; JACOBS JB, 1976, CANCER RES, V36, P2512; Jennette J. C., 2015, HEPTINSTALLS PATHOLO, V1; Jennette JC, 2015, HEPTINSTALLS PATHOLO, VII; KHORSHID MR, 1974, J ANAT, V118, P561; Lee Gilho, 2011, Int Neurourol J, V15, P4, DOI 10.5213/inj.2011.15.1.4; Miyazaki J, 2017, INT J UROL, V24, P730, DOI 10.1111/iju.13376; National Toxicology Program. U.S. Department of Health and Human Services. National Institutes of Health, 2007, NIH PUBLICATION; PAULI BU, 1983, PATHOLOGY BLADDER CA, V2, P41; SILVERBLATT FJ, 1974, KIDNEY INT, V5, P214, DOI 10.1038/ki.1974.26; Song RF, 2011, PEDIATR NEPHROL, V26, P353, DOI 10.1007/s00467-010-1629-4; Taal M. W., 2012, BRENNER RECTORS KIDN, V1; Taal M. W., 2012, BRENNER RECTORS KIDN, V2; Wolf DC, 1998, TOXICOL PATHOL, V26, P724, DOI 10.1177/019262339802600602; Wolf DC, 2005, TOXICOL APPL PHARM, V202, P302, DOI 10.1016/j.taap.2004.06.022; Wood CE, 2015, TOXICOL PATHOL, V43, P760, DOI 10.1177/0192623315576005; Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73	31	4	4	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					266	272		10.1177/0192623318762694			7	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800003	29504493	Bronze			2019-10-28	
J	Ureshino, RP; Costa, AJ; Erustes, AG; Pereira, GJD; Sinigaglia-Coimbra, R; Smaili, SS				Ureshino, Rodrigo Portes; Costa, Angelica Jardim; Erustes, Adolfo Garcia; da Silva Pereira, Gustavo Jose; Sinigaglia-Coimbra, Rita; Smaili, Soraya Soubhi			Effects of Aging in the Striatum and Substantia Nigra of a Parkinson's Disease Animal Model	TOXICOLOGIC PATHOLOGY			English	Article						aging; Parkinson's disease model; rotenone; nigrostriatal pathway; mitochondria; lipofuscin	DOPAMINERGIC-NEURONS; AXIS THEORY; CELL-DEATH; MITOCHONDRIA; INHIBITION; MECHANISM; TOXICITY; CALCIUM; MPTP	Aging is a multifactorial process associated with functional deficits, and the brain is more prone to developing chronic degenerative diseases such as Parkinson's disease. Several groups have tried to correlate the age-related ultrastructural alterations to the neurodegeneration process using in vivo pharmacological models, but due to the limitations of the animal models, particularly in aged animals, the results are difficult to interpret. In this work, we investigated neurodegeneration induced by rotenone, as a pharmacological model of Parkinson's disease, in both young and aged Wistar rats. We assessed animal mobility, tyrosine hydroxylase staining in the substantia nigra pars compacta (SNpc), and TdT-mediated dUTP-biotin nick end labeling-positive nuclei and reactive oxygen species production in the striatum. Interestingly, the mobility impairment, dopaminergic neuron loss, and elevated number of apoptotic nuclei in the striatum of aged control rats were similar to young rotenone-treated animals. Moreover, we observed many ultrastructural alterations, such as swollen mitochondria in the striatum, and massive lipofuscin deposits in the SNpc of the aged rotenone-treated animals. We conclude that the rotenone model can be employed to explore age-related alterations in the ontogeny that can increase vulnerability in the striatum and SNpc, which may contribute to Parkinson's disease pathogenesis.	[Ureshino, Rodrigo Portes] Univ Fed Sao Paulo, Dept Biol Sci, 275 Arthur Ridel St, BR-09972270 Diadema, SP, Brazil; [Costa, Angelica Jardim; Erustes, Adolfo Garcia; da Silva Pereira, Gustavo Jose; Smaili, Soraya Soubhi] Univ Fed Sao Paulo, Dept Pharmacol, Sao Paulo, Brazil; [Sinigaglia-Coimbra, Rita] Univ Fed Sao Paulo, Ctr Electron Microscopy, Sao Paulo, Brazil	Ureshino, RP (reprint author), Univ Fed Sao Paulo, Dept Biol Sci, 275 Arthur Ridel St, BR-09972270 Diadema, SP, Brazil.	rodrigo_ureshino@yahoo.com.br	Sinigaglia-Coimbra, Rita/C-9155-2012; Ureshino, Rodrigo/C-4095-2014; Pereira, Gustavo/H-4636-2012	Sinigaglia-Coimbra, Rita/0000-0001-8747-6316; Ureshino, Rodrigo/0000-0003-3371-3376; Pereira, Gustavo/0000-0002-6765-1276	Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP-2012/08273-3, 2013/20073-2]; Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for Scientific and Technological Development (CNPq) [CNPq-PVE 401236/2014-5]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-2012/08273-3; 2013/20073-2), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-PVE 401236/2014-5), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES).	Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Cannon JR, 2009, NEUROBIOL DIS, V34, P279, DOI 10.1016/j.nbd.2009.01.016; Cepeda C, 1996, NEUROSCIENCE, V73, P733, DOI 10.1016/0306-4522(96)00056-5; Dawson TM, 2010, NEURON, V66, P646, DOI 10.1016/j.neuron.2010.04.034; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; Emborg ME, 2004, J NEUROSCI METH, V139, P121, DOI 10.1016/j.jneumeth.2004.08.004; Emborg ME, 1998, J COMP NEUROL, V401, P253; Ferrante RJ, 1997, BRAIN RES, V753, P157, DOI 10.1016/S0006-8993(97)00008-5; Foltynie T, 2002, J NEUROL NEUROSUR PS, V73, P363, DOI 10.1136/jnnp.73.4.363; GERLACH M, 1991, EUR J PHARM-MOLEC PH, V208, P273, DOI 10.1016/0922-4106(91)90073-Q; Gershanik OS, 2003, FRONT BIOSCI-LANDMRK, V8, pS568, DOI 10.2741/1100; Langston J. W., 1983, NEW ENGL J MED, P309, DOI DOI 10.1056/NEJM198308043090511; LEHMANN J, 1983, NEUROSCIENCE, V10, P1105, DOI 10.1016/0306-4522(83)90102-1; LINDEFORS N, 1990, NEUROSCI LETT, V115, P248, DOI 10.1016/0304-3940(90)90463-J; Phinney AL, 2006, PARKINSONISM RELAT D, V12, P228, DOI 10.1016/j.parkreldis.2005.12.002; SANER A, 1971, MOL PHARMACOL, V7, P147; Sherer TB, 2003, J NEUROSCI, V23, P10756; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013; Tieu K, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a009316; Ureshino RP, 2010, J NEUROSCI RES, V88, P438, DOI 10.1002/jnr.22214; Ureshino RP, 2014, EXP GERONTOL, V58, P120, DOI 10.1016/j.exger.2014.07.014; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Wang XW, 2015, MICRO NANO LETT, V10, P9, DOI 10.1049/mnl.2014.0166	26	4	4	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					348	358		10.1177/0192623318767065			11	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800011	29683090				2019-10-28	
J	Pelosi, G; Bianchi, F; Dama, E; Simbolo, M; Mafficini, A; Sonzogni, A; Pilotto, S; Harari, S; Papotti, M; Volante, M; Fontanini, G; Mastracci, L; Albini, A; Bria, E; Calabrese, F; Scarpa, A				Pelosi, Giuseppe; Bianchi, Fabrizio; Dama, Elisa; Simbolo, Michele; Mafficini, Andrea; Sonzogni, Angelica; Pilotto, Sara; Harari, Sergio; Papotti, Mauro; Volante, Marco; Fontanini, Gabriella; Mastracci, Luca; Albini, Adriana; Bria, Emilio; Calabrese, Fiorella; Scarpa, Aldo			Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm	VIRCHOWS ARCHIV			English	Article						Lung; Neuroendocrine; Tumours; Cluster analysis; Transition	SMALL-CELL CARCINOMA; CHROMATIN-REMODELING GENES; PULMONARY CARCINOIDS; NEOPLASMS; CANCER; CLASSIFICATION; EXPRESSION; MUTATIONS; MARKERS; GENOME	Among lung neuroendocrine tumours (Lung-NETs), typical carcinoid (TC) and atypical carcinoid (AC) are considered separate entities as opposed to large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). By means of two-way clustering analysis of previously reported next-generation sequencing data on 148 surgically resected Lung-NETs, six histology-independent clusters (C1 -> C6) accounting for 68% of tumours were identified. Low-grade Lung-NETs were likely to evolve into high-grade tumours following two smoke-related paths. Tumour composition of the first path (C5 -> C1 -> C6) was coherent with the hypothesis of an evolution of TC to LCNEC, even with a conversion of SCLC-featuring tumours to LCNEC. The second path (C4 -> C2-C3) had a tumour composition supporting the evolution of AC to SCLC-featuring tumours. The relevant Ki-67 labelling index varied accordingly, with median values being 5%, 9% and 50% in the cluster sequence C5 -> C1 -> C6, 12% in cluster C4 and 50-60% in cluster C2-C3. This proof-of-concept study suggests an innovative view on the progression of pre-existing TC or AC to high-grade NE carcinomas in most Lung-NET instances.	[Pelosi, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Pelosi, Giuseppe] IRCCS MultiMed, Inter Hosp Pathol Div, Sci & Technol Pk, Milan, Italy; [Pelosi, Giuseppe] IRCCS MultiMed, Serv Int Anat Patol, Polo Sci & Tecnol, Via Gaudenzio Fantoli 16-15, I-20138 Milan, Italy; [Bianchi, Fabrizio; Dama, Elisa] IRCCS Casa Sollievo Sofferenza, Inst Stem Cell Biol, ISBREMIT, Regenerat Med & Innovat Therapies, San Giovanni Rotondo, FG, Italy; [Simbolo, Michele; Mafficini, Andrea; Scarpa, Aldo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, ARC NET Res Ctr, Verona, Italy; [Simbolo, Michele; Mafficini, Andrea; Scarpa, Aldo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Sect Pathol, Verona, Italy; [Sonzogni, Angelica] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Milan, Italy; [Pilotto, Sara; Bria, Emilio] Univ & Hosp Trust Verona, Sect Med Oncol, Dept Med, Verona, Italy; [Harari, Sergio] IRCCS MultiMed, San Giuseppe Hosp, Dept Med Sci, Milan, Italy; [Harari, Sergio] IRCCS MultiMed, San Giuseppe Hosp, Div Pneumol, Milan, Italy; [Papotti, Mauro] Univ Turin, Dept Oncol, City Hlth & Sci, Turin, Italy; [Papotti, Mauro] Molinette Mauriziano Hosp, Pathol Unit, Turin, Italy; [Volante, Marco] Univ Turin, Dept Oncol, Turin, Italy; [Volante, Marco] San Luigi Hosp, Pathol Unit, Turin, Italy; [Fontanini, Gabriella] Univ Pisa, Dept Surg, Med Mol Pathol & Crit Area, Pisa, Italy; [Mastracci, Luca] Univ Genoa, Dept Surg & Diagnost Sci DISC, Genoa, Italy; [Mastracci, Luca] IRCCS San Martino IST Univ Hosp, Genoa, Italy; [Albini, Adriana] IRCCS MultiMed, Lab Vasc Biol & Angiogenesis, Sci & Technol Pk, Milan, Italy; [Calabrese, Fiorella] Univ Padua, Sch Med, Pathol Anat Sect, Dept Cardiothorac & Vasc Sci, Padua, Italy	Pelosi, G (reprint author), Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.; Pelosi, G (reprint author), IRCCS MultiMed, Inter Hosp Pathol Div, Sci & Technol Pk, Milan, Italy.; Pelosi, G (reprint author), IRCCS MultiMed, Serv Int Anat Patol, Polo Sci & Tecnol, Via Gaudenzio Fantoli 16-15, I-20138 Milan, Italy.	giuseppe.pelosi@unimi.it	Albini, Adriana/J-3701-2018; Pilotto, Sara/G-3725-2018; Simbolo, Michele/AAB-1851-2019; Bria, Emilio/A-8574-2019; Pelosi, Giuseppe/F-5073-2012	Pilotto, Sara/0000-0003-2229-4874; Simbolo, Michele/0000-0002-0866-4499; Bria, Emilio/0000-0002-2333-704X; Pelosi, Giuseppe/0000-0003-4725-4692; Albini, Adriana/0000-0002-9624-5103	Italian Association for Cancer Research (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG17568, 5x1000 18182, MFAG14282, IG19238]; International Association for Lung Cancer (IASLC)	Fabrizio Bianchi (FB), Aldo Scarpa (AS), Sara Pilotto (SP), Emilio Bria (EB) and Marco Volante (MV) were supported by grants from the Italian Association for Cancer Research (AIRC) as follows: FB, MFAG17568; AS, 5x1000 18182; SP and EB, MFAG14282; and MV, MFAG17568, 5x1000 18182 and IG19238. SP was also supported by a fellowship award of the International Association for Lung Cancer (IASLC).	Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1; Asamura H, 2006, J CLIN ONCOL, V24, P70, DOI 10.1200/JCO.2005.04.1202; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; den Bakker MA, 2013, J CLIN PATHOL, V66, P862, DOI 10.1136/jclinpath-2012-201310; den Bakker MA, 2010, HISTOPATHOLOGY, V56, P356, DOI 10.1111/j.1365-2559.2010.03486.x; Desmeules P, 2017, MODERN PATHOL, V30, p475A; Fabbri A, 2017, VIRCHOWS ARCH, V471, P31, DOI 10.1007/s00428-017-2130-2; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Fusco N, 2016, MODERN PATHOL, V29, P1292, DOI 10.1038/modpathol.2016.134; Hijioka S, 2017, CLIN CANCER RES, V23, P4625, DOI 10.1158/1078-0432.CCR-16-3135; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Klimstra DS, 2016, HEMATOL ONCOL CLIN N, V30, P1, DOI 10.1016/j.hoc.2015.08.005; Klimstra David S, 2015, Am Soc Clin Oncol Educ Book, P92, DOI 10.14694/EdBook_AM.2015.35.92; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; Lloyd RV, 2017, WHO CLASSIFICATION T; Meder L, 2016, INT J CANCER, V138, P927, DOI 10.1002/ijc.29835; Miyoshi T, 2017, CLIN CANCER RES, V23, P757, DOI 10.1158/1078-0432.CCR-16-0355; Moran CA, 2000, AM J CLIN PATHOL, V113, P345; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/01.PAS.0000022995.91977.CD; Ohgaki H, 2014, CLIN CANCER RES, V20, P2013, DOI 10.1158/1078-0432.CCR-14-0238; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Pelosi G, 1996, HUM PATHOL, V27, P1124, DOI 10.1016/S0046-8177(96)90303-2; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Rietman EA, 2016, J BIOL PHYS, V42, P339, DOI 10.1007/s10867-016-9410-y; Righi L, 2010, ANN ONCOL, V21, P548, DOI 10.1093/annonc/mdp334; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Simbolo M, 2017, J PATHOL, V241, P488, DOI 10.1002/path.4853; Strobel P, 2014, GENE CHROMOSOME CANC, V53, P738, DOI 10.1002/gcc.22183; Swarts DRA, 2014, J CLIN ENDOCR METAB, V99, pE374, DOI 10.1210/jc.2013-2782; Swarts DRA, 2013, CARCINOGENESIS, V34, P2726, DOI 10.1093/carcin/bgt271; Swarts DRA, 2013, CLIN CANCER RES, V19, P2197, DOI 10.1158/1078-0432.CCR-12-3078; Swarts DRA, 2012, BBA-REV CANCER, V1826, P255, DOI 10.1016/j.bbcan.2012.05.001; Swarts DRA, 2011, AM J PATHOL, V179, P1129, DOI 10.1016/j.ajpath.2011.05.028; Tang LH, 2016, AM J SURG PATHOL, V40, P1192, DOI 10.1097/PAS.0000000000000662; Tang LH, 2016, CLIN CANCER RES, V22, P1011, DOI 10.1158/1078-0432.CCR-15-0548; Travis WD, 1998, AM J SURG PATHOL, V22, P934, DOI 10.1097/00000478-199808000-00003; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Vijayvergia N, 2016, BRIT J CANCER, V115, P564, DOI 10.1038/bjc.2016.229; Vollbrecht C, 2015, BRIT J CANCER, V113, P1704, DOI 10.1038/bjc.2015.397; Voortman J, 2010, P NATL ACAD SCI USA, V107, P13040, DOI 10.1073/pnas.1008132107; WICK MR, 1982, CANCER, V48, P1652, DOI 10.1002/1097-0142(19820415)49:8<1652::AID-CNCR2820490820>3.0.CO;2-0; Yang ZH, 2013, SEMIN DIAGN PATHOL, V30, P186, DOI 10.1053/j.semdp.2013.06.005	46	8	8	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					567	577		10.1007/s00428-018-2307-3			11	Pathology	Pathology	GE4HL	WOS:000431176200005	29388013				2019-10-28	
J	Schwegler, C; Kaufmann, D; Pfeiffer, D; Aebi, S; Diebold, J; Gautschi, O				Schwegler, Christine; Kaufmann, Dinu; Pfeiffer, David; Aebi, Stefan; Diebold, Joachim; Gautschi, Oliver			Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study	VIRCHOWS ARCHIV			English	Article						Molecular diagnosis; Chemotherapy; Targeted therapy; Population study	CELL LUNG-CANCER; ONCOGENIC DRIVERS; TRIAL; CHEMOTHERAPY; METAANALYSIS; CRIZOTINIB; DOCETAXEL	Large cancer centres in the USA demonstrated that molecular diagnosis and targeted therapy improved overall survival of patients with advanced pulmonary adenocarcinoma. We validated this finding in a rural area of Switzerland, served by private practices, community hospitals and a tertiary referral centre. We conducted a prospective cohort study with the Cancer Registry of Central Switzerland, covering 4 cantons and 517,000 inhabitants. All residents newly diagnosed with stage IV pulmonary adenocarcinoma from 2010 to 2014 were enrolled. We obtained information on patients, tumour, molecular testing, therapy and survival. Three hundred forty-eight patients were included in the study. Molecular testing was performed in 279 (80%); 132 (38%) had oncogenic driver mutations: Kirsten rat sarcoma (KRAS, 16%), epidermal growth factor receptor (EGFR, 11%), anaplastic lymphoma kinase (ALK, 5%), human epidermal growth factor receptor 2 (HER2, 2%), B rapidly accelerated fibrosarcoma (BRAF, 1%), rearranged during transfection (RET, 0.5%), MET proto-oncogene (0.5%) and multiple mutations (2%). Fifty-six patients with an oncogenic driver mutation, mostly epidermal growth factor receptor (34) and anaplastic lymphoma kinase (12), received genotype-matched targeted therapy, at least 25 (45%) of whom in a clinical trial or named patient programme. Median overall survival was 18 months for patients with driver mutations and targeted therapy, 8 months for patients with driver mutations and conventional therapy and 10 months for patients with no driver mutation and conventional therapy. For patients with driver mutations and targeted therapy, overall survival was significantly better than that for patients with driver mutations and conventional therapy (HR 0.64, p = 0.04). Rigorous testing combined with optimal access to targeted therapy in clinical trials improved the prognosis of patients with advanced pulmonary adenocarcinoma in Central Switzerland. This effect was mainly driven by therapies targeting epidermal growth factor receptor and anaplastic lymphoma kinase.	[Schwegler, Christine; Pfeiffer, David; Diebold, Joachim] Cantonal Hosp Lucerne, Canc Registry Cent Switzerland, Luzern, Switzerland; [Kaufmann, Dinu] Univ Basel, Inst Comp Sci, Basel, Switzerland; [Pfeiffer, David; Diebold, Joachim] Cantonal Hosp Lucerne, Inst Pathol, Luzern, Switzerland; [Aebi, Stefan; Gautschi, Oliver] Cantonal Hosp Lucerne, Dept Med Oncol, Luzern, Switzerland	Schwegler, C (reprint author), Cantonal Hosp Lucerne, Canc Registry Cent Switzerland, Luzern, Switzerland.	christineschwegler@gmx.ch	Aebi, Stefan/F-2004-2010	Aebi, Stefan/0000-0002-3383-9449	Cancer League of Central Switzerland, Lucerne, Switzerland	This study was funded by the Cancer League of Central Switzerland, Lucerne, Switzerland.	Arndt V, 2016, SWISS CANC REPORT 20; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Cox D. R., 1992, REGRESSION MODELS LI; Enewold L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156728; Ess SM, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12721; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Gautschi O, 2015, MEMO-MAG EUR MED ONC, V8, P81, DOI 10.1007/s12254-014-0192-2; Gautschi O, 2015, CLIN LUNG CANCER, V16, P358, DOI 10.1016/j.cllc.2015.02.007; Janne PA, 2017, JAMA-J AM MED ASSOC, V317, P1844, DOI 10.1001/jama.2017.3438; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Lorez M, 2017, SCHWEIZER KREBSBULLE, V37, P179; Machin D, 2006, SURVIVAL ANAL PRACTI, DOI [10.1002/0470034572, DOI 10.1002/0470034572]; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Shaw AT, 2017, LANCET ONCOL, V18, P874, DOI 10.1016/S1470-2045(17)30339-X; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; SOUQUET PJ, 1993, LANCET, V342, P19; Steffen JA, 2014, J PERS MED, V4, P102, DOI 10.3390/jpm4010102; Swiss Personalized Health Network, 2017, FACTSH SPHN GLANC; Travis WD, 2015, WHO CLASSIFICATION T; Wittekind C, 2010, TNM CLASSIFICATION M	22	2	2	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					581	588		10.1007/s00428-017-2268-y			8	Pathology	Pathology	GE4HL	WOS:000431176200007	29198034				2019-10-28	
J	Filipe, EC; Chitty, JL; Cox, TR				Filipe, Elysse C.; Chitty, Jessica L.; Cox, Thomas R.			Charting the unexplored extracellular matrix in cancer	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Review						cancer; extracellular matrix; imaging; metastasis; proteomics; remodelling	IMAGING MASS-SPECTROMETRY; CELL LUNG-CANCER; GLYCATION END-PRODUCTS; INDUCED LYSYL OXIDASE; BREAST-CANCER; TENASCIN-C; MAMMOGRAPHIC DENSITY; 3-DIMENSIONAL VISUALIZATION; PANCREATIC ADENOCARCINOMA; ENDOTHELIAL-CELLS	The extracellular matrix (ECM) is present in all solid tissues and considered a master regulator of cell behaviour and phenotype. The importance of maintaining the correct biochemical and biophysical properties of the ECM, and the subsequent regulation of cell and tissue homeostasis, is illustrated by the simple fact that the ECM is highly dysregulated in many different types of disease, especially cancer. The loss of tissue ECM homeostasis and integrity is seen as one of the hallmarks of cancer and typically defines transitional events in progression and metastasis. The vast majority of cancer studies place an emphasis on exploring the behaviour and intrinsic signalling pathways of tumour cells. Their goal was to identify ways to target intracellular pathways regulating cancer. Cancer progression and metastasis are powerfully influenced by the ECM and thus present a vast, unexplored repository of anticancer targets that we are only just beginning to tap into. Deconstructing the complexity of the tumour ECM landscape and identifying the interactions between the many cell types, soluble factors and extracellular-matrix proteins have proved challenging. Here, we discuss some of the emerging tools and platforms being used to catalogue and chart the ECM in cancer.	[Filipe, Elysse C.; Chitty, Jessica L.; Cox, Thomas R.] Garvan Inst Med Res, Canc Div, Sydney, NSW 2010, Australia; [Filipe, Elysse C.; Chitty, Jessica L.; Cox, Thomas R.] Kinghorn Canc Ctr, Sydney, NSW 2010, Australia; [Cox, Thomas R.] UNSW Sydney, St Vincents Clin Sch, Fac Med, Sydney, NSW, Australia	Cox, TR (reprint author), Garvan Inst Med Res, Canc Div, Sydney, NSW 2010, Australia.; Cox, TR (reprint author), Kinghorn Canc Ctr, Sydney, NSW 2010, Australia.	t.cox@garvan.org.au	; Chitty, Jessica/C-8005-2017	Cox, Thomas/0000-0001-9294-1745; Chitty, Jessica/0000-0003-1776-1618; Filipe, Elysse/0000-0003-1956-0852	Susan G. Komen Career Catalyst awardSusan G. Komen Breast Cancer Foundation; Cancer Institute of New South Wales (CINSW); National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia; British Society for Matrix Biology (BSMB) John Scott Young Investigator Award	We apologize to authors whose work could not be discussed here because of space limitations. TRC is supported by a Susan G. Komen Career Catalyst award and the Cancer Institute of New South Wales (CINSW). JLC and ECF are supported by the National Health and Medical Research Council (NHMRC) of Australia. TRC was the recipient of the 2016 British Society for Matrix Biology (BSMB) John Scott Young Investigator Award.	Acuna A, 2018, DEV BIOL, V435, P122, DOI 10.1016/j.ydbio.2017.12.022; Alexander J, 2016, CURR OPIN CELL BIOL, V42, P80, DOI 10.1016/j.ceb.2016.05.002; Arroyo AG, 2010, CARDIOVASC RES, V86, P226, DOI 10.1093/cvr/cvq049; Aszodi A, 2006, ANNU REV CELL DEV BI, V22, P591, DOI 10.1146/annurev.cellbio.22.010305.104258; Bailey AJ, 2001, MECH AGEING DEV, V122, P735, DOI 10.1016/S0047-6374(01)00225-1; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447; Baker AM, 2011, JNCI-J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bateman JF, 2009, NAT REV GENET, V10, P173, DOI 10.1038/nrg2520; Becker K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033916; Benson AB, 2017, ONCOLOGIST, V22, P241, DOI 10.1634/theoncologist.2017-0024; Bissell M J, 1987, Prog Clin Biol Res, V249, P251; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Boyle Sarah T, 2016, Small GTPases, V7, P139, DOI 10.1080/21541248.2016.1173771; Brassart-Pasco S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029587; Brellier F, 2009, SCAND J MED SCI SPOR, V19, P511, DOI 10.1111/j.1600-0838.2009.00916.x; BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569; Byron A, 2013, INT J EXP PATHOL, V94, P75, DOI 10.1111/iep.12011; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Cathcart J, 2015, GENES DIS, V2, P26, DOI 10.1016/j.gendis.2014.12.002; Chang J, 2017, ONCOTARGET, V8, P26066, DOI 10.18632/oncotarget.15257; Chin VT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8504; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Chlenski A, 2010, SEMIN CELL DEV BIOL, V21, P55, DOI 10.1016/j.semcdb.2009.11.018; Chong HC, 2012, J ONCOL, DOI 10.1155/2012/351089; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chu IM, 2012, ONCOGENE, V31, P2017, DOI 10.1038/onc.2011.382; Chung K, 2013, NAT METHODS, V10, P508, DOI [10.1038/NMETH.2481, 10.1038/nmeth.2481]; Colorado PC, 2000, CANCER RES, V60, P2520; Contie S, 2011, INT J CANCER, V128, P352, DOI 10.1002/ijc.25591; Cornett DS, 2008, ANAL CHEM, V80, P5648, DOI 10.1021/ac800617s; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Cui XZ, 2009, LIFE SCI, V85, P573, DOI 10.1016/j.lfs.2009.08.010; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; DeKeyser SS, 2007, J PROTEOME RES, V6, P1782, DOI 10.1021/pr060603v; Dekker LJM, 2009, RAPID COMMUN MASS SP, V23, P1183, DOI 10.1002/rcm.3981; Didem T, 2014, TUMOR BIOL, V35, P6777, DOI 10.1007/s13277-014-1923-z; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Erturk A, 2013, EXP NEUROL, V242, P57, DOI 10.1016/j.expneurol.2012.10.018; Faye C, 2009, J BIOL CHEM, V284, P22029, DOI 10.1074/jbc.M109.002840; Fischer I, 2017, BIOMED MATER, V12, DOI 10.1088/1748-605X/aa6c6d; FRANK RN, 1991, OPHTHALMOLOGY, V98, P586; Fukushima N, 2008, MODERN PATHOL, V21, P1044, DOI 10.1038/modpathol.2008.77; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; GERSTENFELD LC, 1993, J BONE MINER RES, V8, P1031; Gessel M, 2015, J MASS SPECTROM, V50, P1288, DOI 10.1002/jms.3696; Ghazi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048351; Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016; Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236; Guerra FS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14216-z; Haeger A, 2014, BBA-GEN SUBJECTS, V1840, P2386, DOI 10.1016/j.bbagen.2014.03.020; Hama H, 2011, NAT NEUROSCI, V14, P1481, DOI 10.1038/nn.2928; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hecht JR, 2017, ONCOLOGIST, V22, P243, DOI 10.1634/theoncologist.2016-0479; Hingorani SR, 2018, J CLIN ONCOL, V36, P359, DOI 10.1200/JCO.2017.74.9564; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; Huo CW, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0592-1; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilmonen S, 2004, HISTOPATHOLOGY, V45, P405, DOI 10.1111/j.1365-2559.2004.01976.x; Ishiba T, 2014, SCI REP-UK, V4, DOI 10.1038/srep07069; Ishihara J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0401; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jacob K, 1999, CANCER RES, V59, P4453; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Jansen KA, 2017, SEMIN CELL DEV BIOL, V71, P75, DOI 10.1016/j.semcdb.2017.07.027; Jean C, 2014, J CELL BIOL, V204, P247, DOI 10.1083/jcb.201307067; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Keire PA, 2014, J BIOL CHEM, V289, P34089, DOI 10.1074/jbc.M114.607168; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kubota SI, 2017, CELL REP, V20, P236, DOI 10.1016/j.celrep.2017.06.010; Kular J, 2015, DEV CELL, V35, P759, DOI 10.1016/j.devcel.2015.11.026; Kuljanin M, 2017, BIOMATERIALS, V144, P130, DOI 10.1016/j.biomaterials.2017.08.012; Kuwajima T, 2013, DEVELOPMENT, V140, P1364, DOI 10.1242/dev.091844; Laczko R, 2007, NEUROPATH APPL NEURO, V33, P631, DOI 10.1111/j.1365-2990.2007.00858.x; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; Lampi MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0475; LANE TF, 1994, FASEB J, V8, P163; Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001; Leeming DJ, 2011, BIOMARKERS, V16, P193, DOI 10.3109/1354750X.2011.557440; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Ley K, 2016, NAT REV DRUG DISCOV, V15, P173, DOI 10.1038/nrd.2015.10; Li X, 2017, ONCOGENE, V36, P5432, DOI 10.1038/onc.2017.125; Liang H, 2016, SCI REP-UK, V6, DOI 10.1038/srep18205; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Magnon C, 2005, CANCER RES, V65, P4353, DOI 10.1158/0008-5472.CAN-04-3536; Maki JM, 2009, HISTOL HISTOPATHOL, V24, P651, DOI 10.14670/HH-24.651; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663; Mayorca-Guiliani AE, 2017, NAT MED, V23, P890, DOI 10.1038/nm.4352; McConnell JC, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0664-2; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; Miller BW, 2015, EMBO MOL MED, V7, P1063, DOI 10.15252/emmm.201404827; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mori M, 1996, ANTICANCER RES, V16, P3075; Morrissey MA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005905; Moy AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053753; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Naba A, 2017, J PROTEOME RES, V16, P3083, DOI 10.1021/acs.jproteome.7b00191; Naba A, 2017, SCI REP-UK, V7, DOI 10.1038/srep40495; Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003; Naba A, 2015, JOVE-J VIS EXP, DOI 10.3791/53057; Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647; Nasrollahi S, 2017, BIOMATERIALS, V146, P146, DOI 10.1016/j.biomaterials.2017.09.012; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nicolas A, 2004, P NATL ACAD SCI USA, V101, P12520, DOI 10.1073/pnas.0403539101; Olivares O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16031; Oskarsson T, 2012, EMBO J, V31, P254, DOI 10.1038/emboj.2011.469; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pauli C, 2002, ANTICANCER RES, V22, P3093; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Pearce OMT, 2018, CANCER DISCOV, V8, P304, DOI 10.1158/2159-8290.CD-17-0284; Pedretti M, 2009, LUNG CANCER, V64, P28, DOI 10.1016/j.lungcan.2008.07.013; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Pirinen R, 2005, HUM PATHOL, V36, P44, DOI 10.1016/j.humpath.2004.10.010; Podhajcer OL, 2008, CANCER METAST REV, V27, P523, DOI 10.1007/s10555-008-9135-x; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Puglisi F, 2008, J CLIN PATHOL, V61, P494, DOI 10.1136/jcp.2007.052506; Rachman-Tzemah C, 2017, CELL REP, V19, P774, DOI 10.1016/j.celrep.2017.04.005; Raspanti M, 2018, INT J BIOL MACROMOL, V107, P1668, DOI 10.1016/j.ijbiomac.2017.10.037; Rath N, 2017, EMBO MOL MED, V9, P198, DOI 10.15252/emmm.201606743; Reffay M, 2014, NAT CELL BIOL, V16, P217, DOI 10.1038/ncb2917; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reynaud C, 2017, CANCER RES, V77, P268, DOI 10.1158/0008-5472.CAN-15-2621; Reyzer ML, 2003, J MASS SPECTROM, V38, P1081, DOI 10.1002/jms.525; Ricard-Blum S, 2014, EXP DERMATOL, V23, P457, DOI 10.1111/exd.12435; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Ricciardelli C, 2007, J BIOL CHEM, V282, P10814, DOI 10.1074/jbc.M606991200; Ricciardelli C, 2009, CANCER METAST REV, V28, P233, DOI 10.1007/s10555-009-9182-y; Riching KM, 2014, BIOPHYS J, V107, P2546, DOI 10.1016/j.bpj.2014.10.035; Rodriguez-Teja M, 2015, J PATHOL, V235, P581, DOI 10.1002/path.4485; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1984, J BIOL CHEM, V259, P3993; Sakai M, 2009, ANN SURG ONCOL, V16, P2494, DOI 10.1245/s10434-009-0559-5; Sasaki H, 2001, CANCER, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Saupe F, 2013, CELL REP, V5, P482, DOI 10.1016/j.celrep.2013.09.014; Schaefer L, 2010, CELL TISSUE RES, V339, P237, DOI 10.1007/s00441-009-0821-y; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; Scott JE, 1998, EXP CELL RES, V243, P59, DOI 10.1006/excr.1998.4089; Shaheed SU, 2013, J PROTEOME RES, V12, P5696, DOI 10.1021/pr400662k; Sharaf H, 2015, BBA-MOL BASIS DIS, V1852, P429, DOI 10.1016/j.bbadis.2014.12.009; Shawky MS, 2015, J MAMMARY GLAND BIOL, V20, P121, DOI 10.1007/s10911-015-9346-z; Sherratt MJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0701-9; Sherratt MJ, 2009, AGE, V31, P305, DOI 10.1007/s11357-009-9103-6; Sironen RK, 2011, EXP CELL RES, V317, P383, DOI 10.1016/j.yexcr.2010.11.017; Sivan SS, 2008, J BIOL CHEM, V283, P8796, DOI 10.1074/jbc.M709885200; Sudhakar A, 2005, J CLIN INVEST, V115, P2801, DOI 10.1172/JCI24813; Susaki EA, 2014, CELL, V157, P726, DOI 10.1016/j.cell.2014.03.042; Sutton CW, 2010, J PROTEOME RES, V9, P3891, DOI 10.1021/pr100113a; Syrokou A, 1999, BIOCHIMIE, V81, P733, DOI 10.1016/S0300-9084(99)80131-X; Tainaka K, 2014, CELL, V159, P911, DOI 10.1016/j.cell.2014.10.034; Takanami I, 2008, INT J BIOL MARKER, V23, P182; Taylor MA, 2011, NEOPLASIA, V13, P406, DOI 10.1593/neo.101086; TERMINE JD, 1981, J BIOL CHEM, V256, P403; Thompson CB, 2010, MOL CANCER THER, V9, P3052, DOI 10.1158/1535-7163.MCT-10-0470; Tilman G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-80; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Tran KT, 2005, J DERMATOL SCI, V40, P11, DOI 10.1016/j.jdermsci.2005.05.001; Trivedi MA, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-1; Tseng SJ, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3158998; van Helvert S, 2018, NAT CELL BIOL, V20, P8, DOI 10.1038/s41556-017-0012-0; Vennin Claire, 2017, Small GTPases, P1, DOI 10.1080/21541248.2017.1345712; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Ween MP, 2011, CLIN EXP METASTAS, V28, P113, DOI 10.1007/s10585-010-9363-7; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Whatcott CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183871; Williams J., 2018, J CELL SCI, V131; Woods AS, 2006, AAPS J, V8, pE391, DOI 10.1007/BF02854910; Yang N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14287; Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023; Yoshida T, 1997, J PATHOL, V182, P421; Yuzhalin AE, 2018, BRIT J CANCER, V118, P435, DOI 10.1038/bjc.2017.458; Zanivan S, 2008, J PROTEOME RES, V7, P5314, DOI 10.1021/pr800599n; Zhang K, 2016, J CELL SCI, V129, P1989, DOI 10.1242/jcs.180539	206	4	4	6	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	APR	2018	99	2					58	76		10.1111/iep.12269			19	Pathology	Pathology	GL9TY	WOS:000437684000001	29671911	Green Published			2019-10-28	
J	Zhang, GX; Zou, XF; Liu, QL; Xie, TP; Huang, RH; Kang, H; Lai, CF; Zhu, JX				Zhang, Guoxi; Zou, Xiaofeng; Liu, Quanliang; Xie, Tianpeng; Huang, Ruohui; Kang, Huan; Lai, Changfu; Zhu, Jiaxing			MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						aldosterone secretion; CYP11B2 aldosterone-producing adrenocortical adenoma; miR-193a-3p; target gene	HUMAN ADRENAL-CORTEX; HORMONE RECEPTOR; LUNG-CANCER; EXPRESSION; DIAGNOSIS; PROLIFERATION; GENES; CELLS; APOPTOSIS	The mechanism of aldosterone-producing adrenocortical adenoma (APA) pathogenesis and the role of microRNAs (miRNAs) in APA pathogenesis have not been completely clarified. We examined the expression and function of miR-140-3p, miR-193a-3p and miR-22-3p, which have binding sites in CYP11B2. Expression of miRNAs and CYP11B2 mRNA was measured by quantitative reverse transcription PCR (qRT-PCR). Cell proliferation was monitored by colorimetric analysis, and cell apoptosis and cell cycle progression were analysed by flow cytometry. ELISA was carried out to detect aldosterone levels in cell culture supernatants. Luciferase reporter assays, qRT-PCR and Western blotting were performed to identify CYP11B2 as a target of miR-193a-3p. Of the three miRNAs examined, miR-193a-3p exhibited a significant decrease and CYP11B2 mRNA exhibited a significant increase in expression in APA compared with adjacent normal adrenal gland tissue. Transfection of miR-193a-3p mimic into the human adrenocortical cell line H295R showed that elevated miR-193a-3p expression inhibits proliferation and aldosterone secretion, induces G1-phase arrest and promotes apoptosis in H295R cells. Furthermore, in luciferase reporter assays, overexpression of miR-193a-3p in H295R cells significantly reduced the luciferase activity of the wild-type CYP11B2 3'-UTR construct, which could be reversed by mutation of the miR-193a-3p-binding site. Moreover, miR-193a-3p overexpression downregulated CYP11B2 mRNA and protein expression. Finally, overexpression of CYP11B2 diminished the effects of miR-193a-3p on H295R cells. Taken together, our results suggest that CYP11B2 levels may be modulated by miR-193a-3p in APA, which could explain, at least partially, why downregulation of miR-193a-3p during APA formation may promote cell growth and suppress apoptosis.	[Zhang, Guoxi; Zou, Xiaofeng; Liu, Quanliang; Xie, Tianpeng; Huang, Ruohui; Kang, Huan; Lai, Changfu; Zhu, Jiaxing] Gannan Med Univ, Affiliated Hosp 1, Dept Urol, Ganzhou, Jiangxi, Peoples R China	Zou, XF (reprint author), Gannan Med Univ, Affiliated Hosp 1, Ganzhou Econ Developing Area, Dept Urol, 128 Jingling Rd, Ganzhou 341000, Jiangxi, Peoples R China.	gyfyurology@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81260128, 81100561, 81170732]; Science and Technology Research Project of Jiangxi Provincial Education Department [GJJ12549]	This work was supported by National Natural Science Foundation of China (NO. 81260128, 81100561, 81170732) and Science and Technology Research Project of Jiangxi Provincial Education Department (NO. GJJ12549).	Bassett MH, 2004, MOL CELL ENDOCRINOL, V217, P67, DOI 10.1016/j.mce.2003.10.011; Choudhuri S, 2010, J BIOCHEM MOL TOXIC, V24, P195, DOI 10.1002/jbt.20325; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; Funder JW, 2016, J CLIN ENDOCR METAB, V101, P1889, DOI 10.1210/jc.2015-4061; He J, 2015, CLIN ENDOCRINOL, V83, P581, DOI 10.1111/cen.12814; HOLLAND OB, 1984, HYPERTENSION, V6, P717, DOI 10.1161/01.HYP.6.5.717; Khoo CP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44137; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liang HW, 2015, J BIOL CHEM, V290, P926, DOI 10.1074/jbc.M114.621409; Lichtenauer UD, 2013, HORM METAB RES, V45, P124, DOI 10.1055/s-0032-1323810; Moneva M.H., 2001, CURR OPIN ENDOCRINOL, V8, P124; Mulatero P, 1998, J CLIN ENDOCR METAB, V83, P2573, DOI 10.1210/jc.83.7.2573; Nakamura Y, 2016, TOHOKU J EXP MED, V240, P183, DOI 10.1620/tjem.240.183; Nakamura Y, 2014, MOL CELL ENDOCRINOL, V384, P102, DOI 10.1016/j.mce.2014.01.016; Nakano H, 2013, INT J ONCOL, V42, P1875, DOI 10.3892/ijo.2013.1896; Nanba K, 2016, J CLIN ENDOCR METAB, V101, P999, DOI 10.1210/jc.2015-3239; Nusrin S, 2014, MAR POLLUT BULL, V85, P344, DOI 10.1016/j.marpolbul.2014.04.002; Robertson S, 2013, HYPERTENSION, V62, P572, DOI 10.1161/HYPERTENSIONAHA.113.01102; Rossi GP, 2008, J HYPERTENS, V26, P613, DOI 10.1097/HJH.0b013e3282f4b3e6; Rossi GPD, 2011, REV ENDOCR METAB DIS, V12, P27, DOI 10.1007/s11154-011-9162-8; Sakuma I, 2013, ENDOCR J, V60, P329; Saner-Amigh K, 2006, J CLIN ENDOCR METAB, V91, P1136, DOI 10.1210/jc.2005-1298; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Wang JL, 2013, CELL PHYSIOL BIOCHEM, V32, P1707, DOI 10.1159/000356605; Williams TA, 2014, HYPERTENSION, V63, P188, DOI 10.1161/HYPERTENSIONAHA.113.01733; Yoshii Y, 2016, HYPERTENSION, V68, P1432, DOI 10.1161/HYPERTENSIONAHA.116.08313	26	2	2	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	APR	2018	99	2					77	86		10.1111/iep.12267			10	Pathology	Pathology	GL9TY	WOS:000437684000002	29665181	Green Published			2019-10-28	
J	Selemetjev, S; Bartolome, A; Dencic, TI; Doric, I; Paunovic, I; Tatic, S; Cvejic, D				Selemetjev, Sonja; Bartolome, Aleksandar; Dencic, Tijana Isic; Doric, Ilona; Paunovic, Ivan; Tatic, Svetislav; Cvejic, Dubravka			Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						epidermal growth factor receptor; focal adhesion kinase; papillary thyroid carcinoma; predictive markers; tumour progression	PROGNOSTIC-FACTORS; SIGNALING PATHWAYS; CELL-MIGRATION; FAK EXPRESSION; CANCER; INVASION; MARKER; FAMILY; EGFR	Epidermal growth factor receptor (EGFR) and its downstream effector, focal adhesion kinase (FAK), have been shown to be overexpressed frequently in human malignancies and implicated in tumour aggressiveness. We aimed to investigate the relationship between EGFR and FAK expression and their possible correlation with the clinical phenotype of patients with papillary thyroid carcinoma (PTC). Expression profiles of EGFR and FAK were analysed in PTC tissue samples (n=104) by immunohistochemistry and Western blotting. Additionally, EGFR and FAK were immunohistochemically analysed in 20 primary tumours paired with their metastatic tissue in lymph nodes. High expression of EGFR and FAK was found in 55.77% and 57.69% cases, respectively, with a strong positive association between them (P<0.0001, Spearman's correlation coefficient=0.844). Expression of each molecule and their coexpression correlated significantly with the presence of lymph node metastasis (LNM), degree of tumour infiltration, extrathyroid invasion and pT status of the patients. Western blot analysis confirmed that coexpression of high levels of EGFR and FAK correlated with adverse clinicopathological features. When compared to the corresponding primary tumour, increased or maintained high levels of EGFR and FAK were found in LNM, indicating their concordant expression during lymphatic spread. In conclusion, high levels of EGFR and its downstream effector, FAK, in association with lymphatic spread and tumour infiltration indicate their involvement in PTC progression and suggest that both molecules may predict its aggressive behaviour. Furthermore, FAK could be a potential target for anticancer therapy in patients with advanced thyroid cancer.	[Selemetjev, Sonja; Bartolome, Aleksandar; Dencic, Tijana Isic; Doric, Ilona; Cvejic, Dubravka] Univ Belgrade, Inst Applicat Nucl Energy INEP, Belgrade, Serbia; [Paunovic, Ivan] Clin Ctr Serbia, Inst Endocrinol Diabet & Dis Metab, Ctr Endocrine Surg, Belgrade, Serbia; [Tatic, Svetislav] Univ Belgrade, Inst Pathol, Med Fac, Belgrade, Serbia	Cvejic, D (reprint author), Univ Belgrade, Inst Applicat Nucl Energy INEP, Banatska 31b, Zemun Belgrade 11080, Serbia.	dubravka@inep.co.rs		Selemetjev, Sonja/0000-0002-2898-6671	Ministry of Education, Science and Technological Development of the Republic of Serbia [173050]	This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, project 173050: 'Molecular characterization of thyroid gland tumours: biological and clinical aspects'.	American Joint Committee on Cancer, 2010, AJCC CANC STAGING MA, P87; Basolo F, 2010, J CLIN ENDOCR METAB, V95, P4197, DOI 10.1210/jc.2010-0337; Chatzizacharias NA, 2008, HISTOL HISTOPATHOL, V23, P629, DOI 10.14670/HH-23.629; Choi H, 2015, AM J SURG, V210, P298, DOI 10.1016/j.amjsurg.2014.12.047; DeLellis RA, 2004, WHO CLASSIFICATION T, P54; Fisher KE, 2013, J SURG RES, V185, P217, DOI 10.1016/j.jss.2013.05.003; Golubovskaya VM, 2009, HISTOL HISTOPATHOL, V24, P503, DOI 10.14670/HH-24.503; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hauck CR, 2001, CANCER RES, V61, P7079; HOELTING T, 1994, J CLIN ENDOCR METAB, V79, P401, DOI 10.1210/jc.79.2.401; Ito Y, 2013, NAT REV ENDOCRINOL, V9, P178, DOI 10.1038/nrendo.2012.257; Ito Y, 2009, ENDOCR J, V56, P177, DOI 10.1507/endocrj.K08E-166; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kim SJ, 2004, J KOREAN MED SCI, V19, P710, DOI 10.3346/jkms.2004.19.5.710; Landriscina M, 2011, THYROID, V21, P1227, DOI 10.1089/thy.2011.0172; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Michailidi C, 2010, PATHOL ONCOL RES, V16, P497, DOI 10.1007/s12253-010-9269-3; Nedergaard MK, 2012, BIODRUGS, V26, P83, DOI 10.2165/11599760-000000000-00000; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Park JH, 2016, INT J ONCOL, V49, P1230, DOI 10.3892/ijo.2016.3585; PARSONS JT, 1994, J CELL SCI, P109; Rothhut B, 2007, BIOCHIMIE, V89, P613, DOI 10.1016/j.biochi.2007.01.015; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Siironen P, 2005, TUMOR BIOL, V26, P57, DOI 10.1159/000085586; Sipos JA, 2010, CLIN ONCOL-UK, V22, P395, DOI 10.1016/j.clon.2010.05.004; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tai YL, 2015, BIOMED RES INT, DOI 10.1155/2015/690690; Tang C, 2014, INT J CLIN EXP PATHO, V7, P3213; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yeh MW, 2006, ENDOCR-RELAT CANCER, V13, P1173, DOI 10.1677/erc.1.01226; Yoon H, 2015, J HISTOCHEM CYTOCHEM, V63, P114, DOI 10.1369/0022155414561498; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001; Zhao Y, 2012, TUMORI, V98, P233, DOI 10.1700/1088.11935	34	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	APR	2018	99	2					87	94		10.1111/iep.12268			8	Pathology	Pathology	GL9TY	WOS:000437684000003	29665129	Green Published			2019-10-28	
J	Punhagui, APF; Teixeira, GR; de Freitas, MC; Seraphim, PM; Fernandes, GSA				Franco Punhagui, Ana Paula; Teixeira, Giovana Rampazzo; de Freitas, Marcelo Conrado; Seraphim, Patricia Monteiro; Alves Fernandes, Glaura Scantamburlo			Intermittent resistance exercise and obesity, considered separately or combined, impair spermatic parameters in adult male Wistar rats	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						androgen receptor; intermittent resistance exercise; obesity; testis	DIET-INDUCED OBESITY; HORMONAL RESPONSES; ESTROGEN-RECEPTORS; OXIDATIVE STRESS; ANDROGEN; ETHANOL; LOCALIZATION; ADAPTATIONS; DAMAGE; MODEL	Obesity and absence of physical exercise are global problems that affect concentration and sperm quality in the male reproductive system. The purpose of this study was to examine the effect of obesity and resistance training, considered separately or in association, on testicular function and reproductive capacity. Twenty pubertal male Wistar rats were distributed into four groups: control (C) and exercise (E) groups that received standard rat chow; and obese (O) and obese with exercise (OE) groups that received a high-fat diet. All the groups received filtered water during the experimental conditions. Groups E and OE were submitted to 8 weeks of high-intensity intermittent training. Afterwards, testes were collected for sperm count, spermatogenic kinetics, histopathology, morphometry and immunodetection of androgen receptors (AR). The vas deferens was collected for sperm morphology. The results showed that obesity increased body weight, naso-anal length, liver and epididymal fat weight, abnormal spermatozoa and immunodetectable AR. Intermittent exercise decreased daily sperm production (DSP), sperm count and normal spermatozoa, whereas the number of tubules with immunodetectable AR increased. The combination of obesity and intermittent training led to reduced sperm count and DSP, although abnormal spermatozoa and the number of tubules with immunodetectable AR increased. Thus, in conclusion, both obesity and resistance training impaired testicular function during puberty in rats; and this type of exercise has also been shown to be detrimental to testicular physiology.	[Franco Punhagui, Ana Paula; Alves Fernandes, Glaura Scantamburlo] Univ Estadual Londrina, Biol Sci Ctr, Gen Biol Dept, Londrina, Brazil; [Franco Punhagui, Ana Paula] Univ Estadual Londrina, Biol Sci Ctr, Gen Pathol Dept, Londrina, Brazil; [Teixeira, Giovana Rampazzo; de Freitas, Marcelo Conrado] Julio de Mesquita Filho State Univ Sao Paulo, Phys Educ Dept, Presidente Prudente, Brazil; [Seraphim, Patricia Monteiro] Julio de Mesquita Filho State Univ Sao Paulo, Physiotherapy Dept, Presidente Prudente, Brazil	Fernandes, GSA (reprint author), State Univ Londrina UEL, Dept Gen Biol, Londrina, Brazil.	glaura@uel.br	Teixeira, Giovana R/C-1342-2012	Teixeira, Giovana R/0000-0002-0044-2939; Fernandes, Glaura/0000-0002-6043-1131	Foundation of the State of Sao Paulo FAPESP (Foundation for Research Support) [11324-0/2016]	This study was supported by a grant from the Foundation of the State of Sao Paulo FAPESP (Foundation for Research Support, Procs No. 11324-0/2016).	Abd EL-Meseeh NA, 2016, ANN ANAT, V205, P37, DOI 10.1016/j.aanat.2016.01.003; Alhashem F, 2014, EXCLI J, V13, P551; Barauna VG, 2005, CLIN EXP PHARMACOL P, V32, P249, DOI 10.1111/j.1440-1681.2005.04180.x; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; Campion SN, 2013, REPROD TOXICOL, V38, P16, DOI 10.1016/j.reprotox.2013.02.003; Chen XL, 2013, ANIMAL, V7, P287, DOI 10.1017/S1751731112001528; Erdemir F, 2012, ACTAS UROL ESP, V36, P153, DOI 10.1016/j.acuro.2011.06.019; Favaro WJ, 2008, INT J ANDROL, V31, P609, DOI 10.1111/j.1365-2605.2007.00817.x; Fernandes GSA, 2007, REPROD TOXICOL, V23, P106, DOI 10.1016/j.reprotox.2006.09.002; Fernandes GSA, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-105; Fernandez CDB, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-32; Speretta GFF, 2012, CLINICS, V67, P1469, DOI 10.6061/clinics/2012(12)19; Punhagui APF, 2016, MICROSC RES TECHNIQ, V79, P541, DOI 10.1002/jemt.22664; Goncalves GD, 2017, MICROSC RES TECHNIQ, V80, P378, DOI 10.1002/jemt.22806; Hofny ERM, 2010, FERTIL STERIL, V94, P581, DOI 10.1016/j.fertnstert.2009.03.085; Jensen TK, 2004, FERTIL STERIL, V82, P863, DOI 10.1016/j.fertnstert.2004.03.056; Johnson LH., 2015, REFERENCE MODULE BIO, P5; Kraemer WJ, 2005, SPORTS MED, V35, P339, DOI 10.2165/00007256-200535040-00004; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; Liu Y, 2014, MOL REPROD DEV, V81, P55, DOI 10.1002/mrd.22281; Mortazavi Motahareh, 2014, J Reprod Infertil, V15, P22; O'Hara L, 2015, BEST PRACT RES CL EN, V29, P595, DOI 10.1016/j.beem.2015.04.006; Panveloski-Costa AC, 2012, REV BRAS MED ESPORTE, V18, P122, DOI 10.1590/S1517-86922012000200012; Panveloski-Costa AC, 2011, ARQ BRAS ENDOCRINOL, V55, P155, DOI 10.1590/S0004-27302011000200008; Raastad T, 2000, EUR J APPL PHYSIOL, V82, P121, DOI 10.1007/s004210050661; ROBB GW, 1978, J REPROD FERTIL, V54, P103; Siervo GEML, 2015, TOXICOLOGY, V330, P1, DOI 10.1016/j.tox.2015.01.016; Stanislaus D., 2017, BIRTH DEFECTS RES, P1; TAMAKI T, 1992, MED SCI SPORT EXER, V24, P881; Vendramini V, 2014, REPROD SCI, V21, P221, DOI 10.1177/1933719113493511; Walker William H, 2011, Spermatogenesis, V1, P116; WHO  World Health Organization, 2014, WHO LIB CAT, V302; WHO  World Health Organization, 2010, WHO LIB CAT, V60; Zhou Q, 2002, J ANDROL, V23, P870	34	1	1	4	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	APR	2018	99	2					95	102		10.1111/iep.12270			8	Pathology	Pathology	GL9TY	WOS:000437684000004	29781539	Green Published			2019-10-28	
J	Lloyd, RV; Asa, SL; LiVolsi, VA; Sadow, PM; Tischler, AS; Ghossein, RA; Tuttle, RM; Nikiforov, YE				Lloyd, Ricardo V.; Asa, Sylvia L.; LiVolsi, Virginia A.; Sadow, Peter M.; Tischler, Arthur S.; Ghossein, Ronald A.; Tuttle, R. Michael; Nikiforov, Yuri E.			The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)	HUMAN PATHOLOGY			English	Editorial Material							OBSERVER VARIATION; CARCINOMA; VARIANT; OVERTREATMENT; CRITERIA; LESIONS		[Lloyd, Ricardo V.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA; [Asa, Sylvia L.] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4, Canada; [LiVolsi, Virginia A.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Sadow, Peter M.] Harvard Med Sch, Boston, MA 02114 USA; [Tischler, Arthur S.] Tufts Univ, Sch Med, Tuft Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA; [Ghossein, Ronald A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Tuttle, R. Michael] Mem Sloan Kettering Canc Ctr, Dept Endocrinol, New York, NY 10065 USA; [Nikiforov, Yuri E.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Lloyd, RV (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA.	rvfloyd@wisc.edu	Sadow, Peter/E-7691-2015	Sadow, Peter/0000-0003-1036-6367; Asa, Sylvia/0000-0001-8418-5054			Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Brandler TC, 2017, CANCER CYTOPATHOL, V125, P378, DOI 10.1002/cncy.21848; Bychkov A, 2017, THYROID, V27, P983, DOI 10.1089/thy.2017.0079; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Casey MB, 2003, ENDOCR PATHOL, V14, P55, DOI 10.1385/EP:14:1:55; CHEN KTK, 1977, AM J SURG PATHOL, V1, P123, DOI 10.1097/00000478-197706000-00003; Cheung CC, 2001, MODERN PATHOL, V14, P338, DOI 10.1038/modpathol.3880312; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Crescenzi A, 2017, ENDOCR PATHOL, V28, P71, DOI 10.1007/s12022-016-9466-z; Elsheikh TM, 2008, AM J CLIN PATHOL, V130, P736, DOI 10.1309/AJCPKP2QUVN4RCCP; Esserman LJ, 2014, LANCET ONCOL, V15, pE234, DOI 10.1016/S1470-2045(13)70598-9; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Howitt BE, 2013, THYROID, V23, P1256, DOI 10.1089/thy.2013.0018; Kim TH, 2018, HISTOPATHOLOGY, V72, P648, DOI 10.1111/his.13401; Lindsay S., 1960, CARCINOMA THYROID GL; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2017, WHO CLASSIFICATION T, P78; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohori NP, 2017, CANCER CYTOPATHOL, V125, P692, DOI 10.1002/cncy.21892; Parente DN, 2018, WORLD J SURG, V42, P321, DOI 10.1007/s00268-017-4182-5; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rosario PW, 2016, ENDOCR-RELAT CANCER, V23, P893, DOI 10.1530/ERC-16-0379; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Xu B, 2017, THYROID, V27, P512, DOI 10.1089/thy.2016.0649	27	21	21	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						1	4		10.1016/j.humpath.2017.12.027			4	Pathology	Pathology	GF4KZ	WOS:000431933100001	29339178				2019-10-28	
J	Yabe, M; Miranda, RN; Medeiros, LJ				Yabe, Mariko; Miranda, Roberto N.; Medeiros, L. Jeffrey			Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors	HUMAN PATHOLOGY			English	Review						Hepatosplenic T-cell lymphoma; Pathogenesis; Cytogenetic and molecular findings; Differential diagnosis; Prognostic factors	GRANULAR LYMPHOCYTIC-LEUKEMIA; INFLAMMATORY-BOWEL-DISEASE; RECEPTOR-GAMMA-DELTA; MOLECULAR-FEATURES; PERIPHERAL-BLOOD; STAT5B MUTATIONS; JAK-STAT; ENTITY; TRANSPLANTATION; THERAPY	Hepatosplenic T-cell lymphoma (HSTCL) is a rare and clinically aggressive type of T-cell lymphoma that arises most often in adolescents and young adults. Patients with HSTCL commonly present with B-symptoms and cytopenias, which may suggest a diagnosis of acute leukemia initially. Patients present with extranodal disease involving the spleen, liver and bone marrow; lymphadenopathy is usually absent. The lymphoma cells can show a spectrum of cell sizes and are of T-cell lineage, often negative for CD4 and CD8 and positive for T-cell receptor gamma delta or, less often, alpha beta. Recent studies have identified gene mutations in oncogenic pathways that are likely involved in pathogenesis and may be targets for therapy. Mutations in STAT3 or STAT5B lead to activation of the JAK/STAT pathway, and mutations involving SETD2, 1N080 and ARID1 are involved in chromatin modification. Currently, there is no consensus standard of care for HSTCL patients, although several studies support a role for allogeneic hematopoietic stem cell transplant. Although patients with HSTCL are best treated in the context of clinical trials, the rarity of these neoplasms likely necessitates a multi-institutional approach. In this review, we focus on the clinicopathologic and genetic characteristics of HSTCL. We also discuss the differential diagnosis and therapeutic approaches. (C) 2018 Elsevier Inc. All rights reserved.	[Yabe, Mariko] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, 1275 York Ave,Suite C-563H, New York, NY 10065 USA; [Miranda, Roberto N.; Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Yabe, M (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, 1275 York Ave,Suite C-563H, New York, NY 10065 USA.	yabem@mskcc.org	Medeiros, L. Jeffrey/AAB-1018-2019				Alekshun TJ, 2007, AM J HEMATOL, V82, P481, DOI 10.1002/ajh.20853; Alonsozana ELC, 1997, LEUKEMIA, V11, P1367, DOI 10.1038/sj.leu.2400742; Arnoux I, 2016, BLOOD, V127, P269, DOI 10.1182/blood-2015-10-676544; Belhadj K, 2003, BLOOD, V102, P4261, DOI 10.1182/blood-2003-05-1675; Boehrer S, 2001, BRIT J HAEMATOL, V112, P201, DOI 10.1046/j.1365-2141.2001.02559.x; Chen YH, 2011, AM J CLIN PATHOL, V136, P289, DOI 10.1309/AJCPTFFQ18JMYKDF; Chien YH, 2007, IMMUNOL REV, V215, P46, DOI 10.1111/j.1600-065X.2006.00470.x; Crescenzo R, 2015, CANCER CELL, V27, P516, DOI 10.1016/j.ccell.2015.03.006; Daibata M, 2004, INT J CANCER, V108, P845, DOI 10.1002/ijc.11647; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dearden C, 2011, BRIT J HAEMATOL, V152, P273, DOI 10.1111/j.1365-2141.2010.08494.x; Deepak P, 2013, AM J GASTROENTEROL, V108, P99, DOI 10.1038/ajg.2012.334; DENNING SM, 1988, CLIN LAB MED, V8, P1; Durani U, 2017, AM J HEMATOL, V92, pE99, DOI 10.1002/ajh.24711; Falchook GS, 2009, ANN ONCOL, V20, P1080, DOI 10.1093/annonc/mdn751; FALINI B, 1989, J IMMUNOL, V143, P2480; FARCET JP, 1990, BLOOD, V75, P2213; Ferreiro JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102977; Gaulard P, 2017, WHO CLASSIFICATION T, P381; GENTILE TC, 1994, BLOOD, V84, P2315; GIACOMELLI R, 1994, CLIN EXP IMMUNOL, V98, P83; HAVRAN WL, 1994, CURR OPIN IMMUNOL, V6, P442, DOI 10.1016/0952-7915(94)90125-2; Herrinton LJ, 2011, AM J GASTROENTEROL, V106, P2146, DOI 10.1038/ajg.2011.283; Hocker TL, 2011, J CUTAN PATHOL, V38, P899, DOI 10.1111/j.1600-0560.2011.01741.x; INGHIRAMI G, 1990, AM J PATHOL, V136, P357; Jaeger G, 2008, ANN ONCOL, V19, P1025, DOI 10.1093/annonc/mdn119; KADIN ME, 1981, NEW ENGL J MED, V304, P648, DOI 10.1056/NEJM198103123041106; Kandiel A, 2005, GUT, V54, P1121, DOI 10.1136/gut.2004.049460; Karpate A, 2016, VIRCHOWS ARCH, V469, P591, DOI 10.1007/s00428-016-2006-x; Kelsen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017890; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Kucuk C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7025; Lee S, 2015, ONCOTARGET, V6, P17764, DOI 10.18632/oncotarget.3776; Lopez C, 2016, BRIT J HAEMATOL, V173, P265, DOI 10.1111/bjh.13952; Lu CL, 2011, HUM PATHOL, V42, P1965, DOI 10.1016/j.humpath.2011.01.034; Macon WR, 1996, BLOOD, V87, P1474, DOI 10.1182/blood.V87.4.1474.bloodjournal8741474; Macon WR, 2001, AM J SURG PATHOL, V25, P285, DOI 10.1097/00000478-200103000-00002; McKinney M, 2017, CANCER DISCOV, V7, P369, DOI 10.1158/2159-8290.CD-16-0330; Moffitt AB, 2017, J EXP MED, V214, P1371, DOI 10.1084/jem.20160894; Moser B, 2007, IMMUNOL REV, V215, P89, DOI 10.1111/j.1600-065X.2006.00472.x; Nairismagi ML, 2016, LEUKEMIA, V30, P1311, DOI 10.1038/leu.2016.13; Nicolae A, 2014, LEUKEMIA, V28, P2244, DOI 10.1038/leu.2014.200; Ok Chi Young, 2014, Clin Lymphoma Myeloma Leuk, V14, pe95, DOI 10.1016/j.clml.2013.12.017; Pizzi M, 2016, CL LYMPH MYELOM LEUK, V16, pE47, DOI 10.1016/j.clml.2015.11.019; Przybylski GK, 2000, J MOL DIAGN, V2, P11, DOI 10.1016/S1525-1578(10)60610-1; Rajala HLM, 2013, BLOOD, V121, P4541, DOI 10.1182/blood-2012-12-474577; Rashidi A, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.43; Sandberg Y, 2006, LEUKEMIA, V20, P505, DOI 10.1038/sj.leu.2404112; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Soderstrom K, 1996, J IMMUNOL, V156, P2331; Sokol H, 2009, GUT, V58, P1427, DOI 10.1136/gut.2009.181982; Tanase A, 2015, LEUKEMIA, V29, P686, DOI 10.1038/leu.2014.280; Thai A, 2010, J CROHNS COLITIS, V4, P511, DOI 10.1016/j.crohns.2010.05.006; Tordjman R, 1996, LEUKEMIA, V10, P1514; Travert M, 2012, BLOOD, V119, P5795, DOI 10.1182/blood-2011-12-396150; Tripodo C, 2009, NAT REV CLIN ONCOL, V6, P707, DOI 10.1038/nrclinonc.2009.169; Vega F, 2001, AM J CLIN PATHOL, V116, P410, DOI 10.1309/BM40-YM6J-9T3X-MH8H; Vega F, 2007, AM J CLIN PATHOL, V127, P869, DOI 10.1309/LRKX8CE7GVPCR1FT; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Voss MH, 2013, CL LYMPH MYELOM LEUK, V13, P8, DOI 10.1016/j.clml.2012.09.002; WANG CC, 1995, GENE CHROMOSOME CANC, V12, P161, DOI 10.1002/gcc.2870120302; Weidmann E, 2000, LEUKEMIA, V14, P991, DOI 10.1038/sj.leu.2401784; Yabe M, 2017, ANN DIAGN PATHOL, V26, P16, DOI 10.1016/j.anndiagpath.2016.10.005; Yabe M, 2017, AM J SURG PATHOL, V41, P82, DOI 10.1097/PAS.0000000000000743; Yabe M, 2016, AM J SURG PATHOL, V40, P676, DOI 10.1097/PAS.0000000000000614; Yabe M, 2016, HUM PATHOL, V50, P109, DOI 10.1016/j.humpath.2015.11.010; Yabe M, 2015, AM J CLIN PATHOL, V144, P607, DOI 10.1309/AJCPJSA1E1YWSZEY; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	70	6	7	2	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						5	16		10.1016/j.humpath.2018.01.005			12	Pathology	Pathology	GF4KZ	WOS:000431933100002	29337025				2019-10-28	
J	Liu, XC; Qiu, HB; Zhang, P; Feng, XY; Chen, T; Li, Y; Tao, KX; Li, GX; Sun, XW; Zhou, ZW				Liu, Xuechao; Qiu, Haibo; Zhang, Peng; Feng, Xingyu; Chen, Tao; Li, Yong; Tao, Kaixiong; Li, Guoxin; Sun, Xiaowei; Zhou, Zhiwei		China Gastrointestinal Stromal Tum	Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients	HUMAN PATHOLOGY			English	Article						Ki-67; Gastrointestinal stromal tumor; Prognosis; Targeted therapy; GIST	ADJUVANT IMATINIB MESYLATE; PROGNOSTIC-SIGNIFICANCE; KI67; METAANALYSIS; MANAGEMENT; PATHOLOGY; SURGERY; ANTIGEN; ORIGIN; MARKER	We sought to determine whether Ki-67 labeling index (LI) was an independent prognostic factor for gastrointestinal stromal tumor (GIST). A multicenter cohort of 1022 patients undergoing surgical resection of primary GIST between August 2004 and October 2015 was retrospectively analyzed. Immunohistochemical analysis was performed to evaluate expression of Ki-67 in their paraffin-embedded tissue samples. The optimal cutoff value of Ki-67 LI was determined as 6% by receiver operating characteristics curve analysis. Multivariate analysis showed that Ki-67 LI was a significant predictor of overall survival (OS) (hazard ratio: 1.793; 95% confidence interval, 1.240-2.593; P = .002). When stratified by modified National Institutes of Health classification, it was still independently associated with OS in high-risk and non-high-risk patients (P = .001 and P = .055, respectively). Of note, the prognostic significance of Ki-67 LI was also maintained when stratified by tumor size, mitotic index, tumor site, and histological subtype (all Ps < .05). In addition, high-risk patients with Ki-67 LI >6% exhibited a significantly poorer OS rate than those with Ki-67 LI <= 6% (53.6% versus 88.7%, respectively; P = .001). The area under the receiver operating characteristics curve for Ki-67 LI was higher than that of modified National Institutes of Health classification component in high-risk patients (P = .029). Therefore, Ki-67 LI is a promising predictor of outcome in GIST, especially in high-risk patients, and it may have important clinical utility in identifying "very high-risk" patients for rational targeted therapy. (C) 2017 Elsevier Inc. All rights reserved.	[Liu, Xuechao; Qiu, Haibo; Sun, Xiaowei; Zhou, Zhiwei] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Xuechao; Qiu, Haibo; Sun, Xiaowei; Zhou, Zhiwei] Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 E Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, Peng; Tao, Kaixiong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan 430000, Hubei, Peoples R China; [Feng, Xingyu; Li, Yong] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou 510080, Guangdong, Peoples R China; [Chen, Tao; Li, Guoxin] Southern Med Univ Nanfang Hosp, Dept Gen Surg, Guangzhou 510515, Guangdong, Peoples R China	Sun, XW; Zhou, ZW (reprint author), Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 E Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China.	sunxw@sysucc.org.cn; zhouzhw@sysucc.org.cn			National Science Foundation of China: Beijing, ChinaNational Natural Science Foundation of China [81372474, 81602061]; Science and Technology Program of Guangzhou: Guangzhou, China [2014J4100179]	This study was funded by the National Science Foundation of China: Beijing, China (grants 81372474 and 81602061) and the Science and Technology Program of Guangzhou: Guangzhou, China (grant 2014J4100179).	Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Cerski MR, 2011, PATHOL RES PRACT, V207, P701, DOI 10.1016/j.prp.2011.09.008; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; DeMatteo RP, 2013, ANN SURG, V258, P422, DOI 10.1097/SLA.0b013e3182a15eb7; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1; Di Vizio D, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-134; GERDES J, 1991, AM J PATHOL, V138, P867; He X, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-153; Hohenberger P, 2009, LANCET, V373, P1058, DOI 10.1016/S0140-6736(09)60562-6; Jeong Seong Yeon, 2014, Korean J Gastroenterol, V64, P87; Joensuu H, 2002, LANCET ONCOL, V3, P655, DOI 10.1016/S1470-2045(02)00899-9; Joensuu H, 2008, HUM PATHOL, V39, P1411, DOI 10.1016/j.humpath.2008.06.025; Joensuu H, 2012, LANCET ONCOL, V13, P265, DOI 10.1016/S1470-2045(11)70299-6; Kucukmetin NT, 2015, EUR J GASTROEN HEPAT, V27, P1276, DOI 10.1097/MEG.0000000000000454; Luo YH, 2015, INT J CLIN EXP MED, V8, P10235; Martinez-Marin V, 2016, GASTROENTEROL CLIN N, V45, P477, DOI 10.1016/j.gtc.2016.04.006; Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001; Milhem M, 2015, CURR CLIN PHARMACOL, V10, P311, DOI 10.2174/1574884710666151020100518; Petrelli F, 2015, BREAST CANCER RES TR, V153, P477, DOI 10.1007/s10549-015-3559-0; Piri Reza, 2015, Asian Pac J Cancer Prev, V16, P6997; Pyo JS, 2016, INT J BIOL MARKER, V31, pE204, DOI 10.5301/jbm.5000183; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Sozutek D, 2014, INT J CLIN EXP MED, V7, P1914; Tian YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158891; Wang H, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-89; Wang W, 2016, ONCOTARGET, V7, P31079, DOI 10.18632/oncotarget.9075; Wen S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1524-2; Wozniak A, 2014, CLIN CANCER RES, V20, P6105, DOI 10.1158/1078-0432.CCR-14-1677; Xie S, 2016, J CANCER, V7, P758, DOI 10.7150/jca.14214; Yamamoto H, 2015, PATHOL INT, V65, P9, DOI 10.1111/pin.12230; Zhao WY, 2014, INT J CLIN EXP PATHO, V7, P2298	32	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						17	24		10.1016/j.humpath.2017.09.003			8	Pathology	Pathology	GF4KZ	WOS:000431933100003	28962945				2019-10-28	
J	Clemmensen, T; Matoso, A; Graham, T; Lai, WS; Rais-Bahrami, S; Gordetsky, J				Clemmensen, Tyler; Matoso, Andres; Graham, Tiffany; Lai, Win Shun; Rais-Bahrami, Soroush; Gordetsky, Jennifer			Pathologic and clinical characteristics of early onset renal cell carcinoma	HUMAN PATHOLOGY			English	Article						Renal cell carcinoma; Cancer staging; Cancer grading; Radical nephrectomy; Renal tumor; Early onset	FEATURES; CANCER; SUBTYPES; TUMORS	The majority of renal cell carcinomas (RCCs) occur within the 7th decade of life, uncommonly arising in adults <= 46 years. We reviewed the clinicopathologic features of early onset RCC and evaluated the role of immunohistochemistry (NC) in potentially identifying diagnoses of newly recognized RCC sub-types that may have been previously misclassified. A retrospective review was performed from 2011-2016 for cases of RCC. Early onset RCC was defined as <= 46 years of age. Clinicopathologic findings and hematoxylin and eosin (H&E) slides were reviewed on early onset RCC patients. IHC was performed on all cases previously diagnosed as unclassified or papillary. Clinicopathologic findings were compared to a control group of RCC patients >46 years over the same time period. We identified 98/598 (16.4%) early onset RCCs. The median age in the early onset RCC and control group was 38.4 and 62.8 years, respectively. The early onset RCC group contained 33/96 (34.3%) females and 63/96 (65.6%) males, including 52/96 (54.2%) whites, 39/96 (40.6%) African Americans, 4/96 (4.2%) Hispanics, and 1/96 (1%) Asian. Nonwhites were significantly more likely to develop early onset RCC (P = .004). Early onset RCCs included 52% clear cell, 28.6% papillary, 8.2% unclassified, 5.1% chromophobe, 3.1% clear cell papillary(CCP), and 3 other rare tumors. Six unclassified and 26 papillary RCCs had tissue available for NC. Two of 6 (33.3%) unclassified RCCs were reclassified (1 CCP, 1 Xp11 translocation). One of 26 (3.8%) papillary RCCs was reclassified as CCP. Early onset RCCs were more likely to occur in nonwhites (P =.004), be lower stage (P = .03), and undergo partial nephrectomy (P = .002). Few unclassified and papillary tumors were reclassified with NC. (C) 2017 Elsevier Inc. All rights reserved.	[Clemmensen, Tyler; Graham, Tiffany] Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA; [Matoso, Andres; Gordetsky, Jennifer] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21205 USA; [Lai, Win Shun; Rais-Bahrami, Soroush; Gordetsky, Jennifer] Univ Alabama Birmingham, Dept Urol, Birmingham, AL 35249 USA; [Rais-Bahrami, Soroush] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35249 USA	Gordetsky, J (reprint author), Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA.	jgordetsky@uabmc.edu					Adeniran AJ, 2015, AM J SURG PATHOL, V39, pe1, DOI 10.1097/PAS.0000000000000562; Agnihotri S, 2014, INDIAN J MED RES, V140, P624; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Kauffman EC, 2014, NAT REV UROL, V11, P465, DOI 10.1038/nrurol.2014.162; Lipworth L, 2016, BJU INT, V117, P260, DOI 10.1111/bju.12950; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; Moch H, 2016, WHO CLASSIFICATION T; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Patard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055; Sankin A, 2011, INT BRAZ J UROL, V37, P29, DOI [10.1590/S1677-55382011000100004, 10.1590/S1677-55382011000700004]; Schmidt LS, 2016, SEMIN ONCOL, V43, P566, DOI 10.1053/j.seminoncol.2016.09.001; Shuch B, 2014, J CLIN ONCOL, V32, P431, DOI 10.1200/JCO.2013.50.8192; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siemer S, 2006, J UROLOGY, V175, P1240, DOI 10.1016/S0022-5347(05)00696-8; Varma J R, 1990, J Am Board Fam Pract, V3, P54; Wang K, 2017, UROLOGY, V103, P136, DOI 10.1016/j.urology.2016.12.002; Zhou HJ, 2014, HUM PATHOL, V45, P59, DOI 10.1016/j.humpath.2013.08.004; Zisman A, 2002, J UROLOGY, V168, P950, DOI 10.1097/01.ju.0000026869.95198.bb	18	1	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						25	31		10.1016/j.humpath.2017.11.005			7	Pathology	Pathology	GF4KZ	WOS:000431933100004	29133143				2019-10-28	
J	Enomoto, A; Sato, E; Yasuda, T; Isomura, T; Nagao, T; Chikazu, D				Enomoto, Ai; Sato, Eiichi; Yasuda, Takashi; Isomura, Tatsuya; Nagao, Toshitaka; Chikazu, Daichi			Intraepithelial CD8+lymphocytes as a predictive diagnostic biomarker for the remission of oral lichen planus	HUMAN PATHOLOGY			English	Article						Oral lichen planus; Cytotoxic immunity; Immunohistochemistry; Histological diagnosis; Regulatory T cells	CURRENT CONTROVERSIES; T-CELLS; PATHOGENESIS; INFLAMMATION; EXPRESSION; LESIONS; TH17; TH2	Oral lichen planus (OLP) is an autoimmune inflammatory disease of the oral mucosa whose etiology remains unknown. Moreover, the possibility of OLP being a premalignant change is under debate. Various types of immune cells infiltrate the OLP lesion and affect its clinicopathological features. However, the diversity of infiltrating immune cells has not been fully clarified in relation to OLP diagnosis. In this study, we quantitatively examined CD8+ lymphocyte infiltration by immunohistochemistry, which is the principal effector of cytotoxic immune reaction in 123 cases of OLP specimens. Our examination revealed that high-grade intraepithelial CD8+ lymphocyte infiltration was associated with a high remission rate. Evaluation of the infiltration of T-bet+ and FoxP3+ lymphocytes, which corresponded to the Th1 and Treg CD4+ subsets, respectively, showed that intraepithelial CD8+ lymphocytes were associated with the remission rate in the subgroup with a higher T-bet/FoxP3 subset balance that is inducible for cytotoxic immunity. We also investigated the cutoff value of CD8+ lymphocyte infiltration for histopathological diagnosis. By microscopic counting, 16 cells/high-power field, which was also confirmed in the validation cohort, was established as the cutoff value for intraepithelial CD8+ lymphocyte infiltration for predicting the remission of OLP. Remitting OLP might be different from refractory OLP in terms of etiology and clinical behavior. Thus, intraepithelial CD8+ lymphocytes may serve not only as a predictive biomarker for remission but also as an area for further biomedical research regarding the etiology and premalignant potential of OLP. (C) 2017 Elsevier Inc. All rights reserved.	[Enomoto, Ai; Yasuda, Takashi; Chikazu, Daichi] Tokyo Med Univ, Dept Oral & Maxillofacial Surg, Tokyo 1600023, Japan; [Enomoto, Ai; Nagao, Toshitaka] Tokyo Med Univ, Dept Diagnost Pathol, Fac Med, Tokyo 1600023, Japan; [Sato, Eiichi] Tokyo Med Univ, Inst Med Sci, Med Res Ctr, Dept Pathol, Tokyo 1600023, Japan; [Isomura, Tatsuya] Tokyo Med Univ, Inst Med Sci, Div Clin Res Consultat, Tokyo 1608402, Japan; [Isomura, Tatsuya] Clin Study Support Inc, Nagoya, Aichi 4600003, Japan	Sato, E (reprint author), Tokyo Med Univ, Inst Med Sci, Med Res Ctr, Dept Pathol,Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	sato-e@tokyo-med.ac.jp			Ishidsu Shun Memorial Scholarship (Tokyo, Japan); JSPS KAKENHI (Japanese Society for the Promotion of Science, Tokyo Japan) [JP26462857]	Grant support was obtained from Ishidsu Shun Memorial Scholarship (Tokyo, Japan, Ai Enomoto) and JSPS KAKENHI Grant (JP26462857) (Japanese Society for the Promotion of Science, Tokyo Japan, Daichi Chikazu).	Araujo-Pires AC, 2014, J APPL ORAL SCI, V22, P336, DOI 10.1590/1678-775720140140; Casparis S, 2015, ORAL MAXILLOFAC SURG, V19, P149, DOI 10.1007/s10006-014-0469-y; Eisenberg E, 2000, J ORAL MAXIL SURG, V58, P1278, DOI 10.1053/joms.2000.16629; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Guido L, 2013, J ORAL PATHOL MED, V42, P642, DOI 10.1111/jop.12058; Ismail Sumairi B, 2007, J Oral Sci, V49, P89; KRAMER I R H, 1978, Oral Surgery Oral Medicine Oral Pathology, V46, P518; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lodi G, 2005, ORAL SURG ORAL MED O, V100, P164, DOI 10.1016/j.tripleo.2004.06.076; Lodi G, 2005, ORAL SURG ORAL MED O, V100, P40, DOI 10.1016/j.tripleo.2004.06.077; Muller S, 2011, HEAD NECK PATHOL, V5, P36, DOI 10.1007/s12105-010-0237-8; Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098; Piccinni MP, 2014, ORAL DIS, V20, P212, DOI 10.1111/odi.12094; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Silverman S, 2000, J ORAL MAXIL SURG, V58, P1286, DOI 10.1053/joms.2000.16630; Sugerman PB, 2002, CRIT REV ORAL BIOL M, V13, P350, DOI 10.1177/154411130201300405; Sun Y, 2016, MEDIATORS INFLAMM; Teng MWL, 2015, J CLIN INVEST, V125, P3338, DOI 10.1172/JCI80004; van der Meij EH, 2007, ORAL ONCOL, V43, P742, DOI 10.1016/j.oraloncology.2006.09.006; van der Meij EH, 2003, J ORAL PATHOL MED, V32, P507, DOI 10.1034/j.1600-0714.2003.00125.x; van der Waal I, 2010, ORAL ONCOL, V46, P423, DOI 10.1016/j.oraloncology.2010.02.016; Vered M, 2013, CLIN ORAL INVEST, V17, P1365, DOI 10.1007/s00784-012-0814-1; Wang H, 2016, J ORAL PATHOL MED, V45, P385, DOI 10.1111/jop.12405; Zhou XJJ, 2002, J ORAL PATHOL MED, V31, P23, DOI 10.1046/j.0904-2512.2001.10063.x	24	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						43	53		10.1016/j.humpath.2017.12.008			11	Pathology	Pathology	GF4KZ	WOS:000431933100006	29288692				2019-10-28	
J	Huhns, M; Krohn, S; Escobar, HM; Prall, F				Huehns, Maja; Krohn, Saskia; Escobar, Hugo Murua; Prall, Friedrich			Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain?	HUMAN PATHOLOGY			English	Article						Intratumoral heterogeneity; Genomic aberrations; Colorectal carcinoma; Next-generation targeted sequencing; Multiregional sampling	ISLAND METHYLATOR PHENOTYPE; CANCER; TUMOR; PROGRESSION; MUTATION; BREAST; CELLS	Progression of solid cancers, colorectal carcinomas among them, from their primaries to metastatic lesions traditionally is thought to proceed by a stepwise acquisition of and selection for genomic aberrations. To test if patterns of genomic aberrations would be consistent with this model, we studied 10 colorectal carcinoma primary-metastasis pairs, 9 with 1 liver metastasis each and 1 with 2 metastases. Next-generation targeted sequencing (50-gene panel) with samples obtained from different regions of the primaries and their metastases demonstrated 1-11 gene mutations per lesion. But only in 2 tumors were there seen mutations in all samples from the metastasis and not any of the primaries (BRAF(D594N) and SMARCB1(R377C) mutation, respectively). However, allelotyping the multiregional samples with polymorphous microsatellite markers (17p13.1, D9S942, D9S1748, D5S346, D5S1385) and DNA methylation studies with a marker panel (MLH1, CDNK2A, NEUROG1, CRABP1, CACNA1G, IGF2, RUNX3, SOCS1) showed remarkably "insular" genomic aberrations in all cases for at least some of the analyses. The marked preponderance of mutations shared by the primaries and their metastases throughout the lesions over mutations private to metastases suggests that, at least in many cases, colorectal carcinomas might be endowed with a mutational load sufficient for fully fledged metastases even at a very early stage ("born bad"). But the very focal allelic imbalances and methylations observed here, hypothetically, could play a role in clinically metastasizing disease, a process of years rather than months and very much a matter of tumor-host interactions when tumor cells adapt to the host microenvironment. (C) 2018 Elsevier Inc. All rights reserved.	[Huehns, Maja; Prall, Friedrich] Univ Med Rostock, Inst Pathol, D-18055 Rostock, Germany; [Krohn, Saskia; Escobar, Hugo Murua] Univ Rostock, Univ Med Ctr Rostock, Clin Hematol Oncol & Palliat Care, D-18057 Rostock, Germany	Prall, F (reprint author), Inst Pathol, Strempelstr 14, D-18055 Rostock, Germany.	maja.huehns@med.uni-rostock.de; saskia.krohn@med.uni-rostock.de; hugo.murua.escobar@med.uni-rostock.de; friedrich.prall@med.uni-rostock.de			University Medicine Rostock (Rostock, Germany) [889012]	This work was supported by the University Medicine Rostock (Rostock, Germany) faculty grant number 889012.	Agaimy A, 2014, AM J SURG PATHOL, V38, P910, DOI 10.1097/PAS.0000000000000173; Akagi Y, 2013, MOL CLIN ONCOL, V1, P582, DOI 10.3892/mco.2013.116; [Anonymous], 2000, SEMIN CANCER BIOL; Boland CR, 1998, CANCER RES, V58, P5248; Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7; Jesinghaus M, 2015, AM J SURG PATHOL, V39, P1140, DOI 10.1097/PAS.0000000000000423; Kim TM, 2015, CLIN CANCER RES, V21, P4461, DOI 10.1158/1078-0432.CCR-14-2413; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Lee YX, 2014, PLOS ONE, V9; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lu YW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152673; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ostwald C, 2009, INT J ONCOL, V35, P321, DOI 10.3892/ijo_00000343; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Uchi R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005778; Vignot S, 2015, EUR J CANCER, V51, P791, DOI 10.1016/j.ejca.2015.02.012; Wang J, 2016, HUM PATHOL, V55, P83, DOI 10.1016/j.humpath.2016.04.018; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xie T, 2014, GENOMICS, V104, P234, DOI 10.1016/j.ygeno.2014.07.012	26	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						54	63		10.1016/j.humpath.2017.12.015			10	Pathology	Pathology	GF4KZ	WOS:000431933100007	29307628				2019-10-28	
J	Lee, HE; Smyrk, TC; Zhang, LZ				Lee, Hee Eun; Smyrk, Thomas C.; Zhang, Lizhi			Histologic and immunohistochemical differences between hereditary and sporadic diffuse gastric carcinoma	HUMAN PATHOLOGY			English	Article						Gastric carcinoma; Hereditary diffuse gastric carcinoma; CDH1 mutation; p16; CDX2	RING CELL-CARCINOMA; E-CADHERIN MUTATIONS; P16(INK4A) OVEREXPRESSION; CLINICAL MANAGEMENT; GERMLINE MUTATIONS; CYCLE INHIBITOR; CANCER PATIENTS; EXPRESSION; GENE; PROGNOSIS	We aimed to identify histopathologic features unique in hereditary diffuse gastric cancer (HDGC) by comparing with its sporadic counterpart (SDGC). 11 patients with confirmed CDH1 mutation who were found to have HDGC in a prophylactic total gastrectomy were collected. Median age of HDGC patients was 39 years (range 24-57). All HDGC cases had intramucosal signet ring cell carcinoma. Twenty-three invasive tumor foci from 7 patients with HDGC were available for ancillary studies, and we evaluated each focus separately. Almost all foci (20/23) showed two distinct tumor cell populations, namely, large signet ring cells and small signet ring cells. The large cells were located just beneath the surface epithelium and were positive for mucicarmine and pCEA, while the small cells were found in the deeper lamina propria and were mostly negative for mucicarmine and pCEA. A subset of small cells (6 foci from two resected stomachs) showed poorly differentiated morphology with p16 positivity. All other tumor cells with well-differentiated signet ring cell morphology were negative for p16. In contrast, 18 of 20 SDGCs were positive for p16. In addition, all HDGCs were negative for CDX2, while 19 of 20 SDGCs were positive. We propose that there are three distinct tumor cell populations in HDGC: well-differentiated large cells, well-differentiated small cells, and poorly differentiated small cells, and that the latter group with aberrant p16 expression may represents a more aggressive phenotype. The absence of CDX2 in HDGC suggests that it may develop along a carcinogenetic pathway different from that of SDGC. (C) 2018 Elsevier Inc. All rights reserved.	[Lee, Hee Eun; Smyrk, Thomas C.; Zhang, Lizhi] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA	Zhang, LZ (reprint author), Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA.	Zhang.Lizhi@mayo.edu					Barber ME, 2008, J PATHOL, V216, P286, DOI 10.1002/path.2415; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275; Caldas C, 1999, J MED GENET, V36, P873; Carneiro F, 2010, WHO CLASSIFICATION T, P59; Chu PG, 2004, AM J CLIN PATHOL, V121, P884, DOI 10.1309/A09ERYMFR64NERDW; Edge SB, 2010, CANC STAGING MANUAL; Fan ZQ, 2005, CLIN CANCER RES, V11, P6162, DOI 10.1158/1078-0432.CCR-05-0278; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/S0046-8177(03)29723-3; Ferlay J, 2013, GLOBOCAN 2012 V1 0; Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hansford S, 2015, JAMA ONCOL, V1, P23, DOI 10.1001/jamaoncol.2014.168; He XS, 2005, WORLD J GASTROENTERO, V11, P2218, DOI 10.3748/wjg.v11.i15.2218; Henshall SM, 2001, CLIN CANCER RES, V7, P544; Humar B, 2007, CANCER RES, V67, P2480, DOI 10.1158/0008-5472.CAN-06-3021; Huntsman DG, 2001, NEW ENGL J MED, V344, P1904, DOI 10.1056/NEJM200106213442504; Larque AB, 2015, VIRCHOWS ARCH, V466, P375, DOI 10.1007/s00428-015-1725-8; Lee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288; Lynch BC, 2008, ANN DIAGN PATHOL, V12, P161, DOI 10.1016/j.anndiagpath.2007.06.003; Lynch HT, 2008, SURG CLIN N AM, V88, P759, DOI 10.1016/j.suc.2008.04.006; Majewski IJ, 2013, J PATHOL, V229, P621, DOI 10.1002/path.4152; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Pinheiro H, 2014, BEST PRACT RES CL GA, V28, P1055, DOI 10.1016/j.bpg.2014.09.007; Rogers WM, 2008, AM J SURG PATHOL, V32A, P799, DOI 10.1097/PAS.0b013e31815e7f1a; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Sentani K, 2008, AM J SURG PATHOL, V32, P1182, DOI 10.1097/PAS.0b013e318163a8f8; Terada T, 2013, INT J CLIN EXP PATHO, V6, P630; Tian MM, 2007, WORLD J GASTROENTERO, V13, P3189, DOI 10.3748/wjg.v13.i23.3189; Tsujie M, 2000, ONCOLOGY-BASEL, V58, P126, DOI 10.1159/000012089; van der Post RS, 2016, ADV EXP MED BIOL, V908, P371, DOI 10.1007/978-3-319-41388-4_18; van der Post RS, 2015, J MED GENET, V52, P361, DOI 10.1136/jmedgenet-2015-103094; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Worthley DL, 2012, GUT, V61, P774, DOI 10.1136/gutjnl-2011-300348	35	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						64	72		10.1016/j.humpath.2017.12.023			9	Pathology	Pathology	GF4KZ	WOS:000431933100008	29307626				2019-10-28	
J	Kalhor, N; Moran, CA				Kalhor, Neda; Moran, Cesar A.			Primary thymic adenocarcinomas: a clinicopathological and immunohistochemical study of 16 cases with emphasis on the morphological spectrum of differentiation	HUMAN PATHOLOGY			English	Article						Thymus; Adenocarcinoma; Immunohistochemistry; Thymoma; Thymic carcinoma	OF-THE-LITERATURE; MUCINOUS ADENOCARCINOMA; ENTERIC TYPE; CARCINOMA; FEATURES; PAPILLARY; THYMOMA; SUBTYPE; VARIANT; TUMOR	Sixteen cases of primary thymic adenocarcinoma are presented. The patients are 9 men and 7 women between the ages of 22 and 68 years (average, 45 years) who presented with non-specific symptoms including cough, chest pain, and dyspnea. Diagnostic imaging revealed the presence of an anterior mediastinal mass, which was surgically removed in all of the patients. Histologically, none of the tumors was encapsulated and showed different growth patterns including mucinous, non-mucinous, and papillary features. The majority of cases showed mixed growth pattern, and the tumor was limited to the mediastinum with only a few cases extending to lymph nodes or pericardium. In two cases, the adenocarcinoma was associated with a thymoma. Immunohistochemical stains were performed, and their positive staining varied depending on the histology of the tumors, showing positive staining in some cases for keratin 7, keratin 20, CEA, CD5, CD117, and CDX-2. PAX8 and TTF-1 were negative in all the tumors. Follow-up information was obtained in 10 patients over a period of 1 to 12 years, indicating that three patients had died within a period of 14 months, one with brain metastasis, while seven patients have remained alive without recurrence. The cases herein described span the spectrum of thymic epithelial tumors and highlight the importance of recognizing this particular type of carcinoma, as it may follow a different outcome and require different treatment options. (C) 2018 Elsevier Inc. All rights reserved.	[Kalhor, Neda; Moran, Cesar A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Moran, CA (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	cesarmoran@mdanderson.org					Abdul-Ghafar J, 2012, KOREAN J PATHOL, V46, P377, DOI 10.4132/KoreanJPathol.2012.46.4.377; Akiba J, 2016, PATHOL INT, V66, P29, DOI 10.1111/pin.12361; Chalabreysse L, 2004, HISTOPATHOLOGY, V44, P367, DOI 10.1111/j.1365-2559.2004.01796.x; Choi WWL, 2003, AM J SURG PATHOL, V27, P124, DOI 10.1097/00000478-200301000-00014; Di Tommaso L, 2007, AM J SURG PATHOL, V31, P1161, DOI 10.1097/PAS.0b013e3180555ba8; Franke A, 2004, AM J SURG PATHOL, V28, P250, DOI 10.1097/00000478-200402000-00014; Hosaka Y, 2010, GEN THORAC CARDIOVAS, V58, P488, DOI 10.1007/s11748-009-0580-4; Kalhor N, 2011, AM J SURG PATHOL, V35, P372, DOI 10.1097/PAS.0b013e318208354b; Kapur P, 2006, ARCH PATHOL LAB MED, V130, P201; Kinoshita F, 2018, GEN THORAC CARDIOVAS, V66, P111, DOI 10.1007/s11748-017-0781-1; Kwon AY, 2017, PATHOL RES PRACT, V213, P106, DOI 10.1016/j.prp.2016.11.012; Lee Y, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3282-9; Maeda D, 2009, LUNG CANCER, V64, P22, DOI 10.1016/j.lungcan.2008.06.019; Maghbool M, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-17; Morikawa H, 2010, GEN THORAC CARDIOVAS, V58, P295, DOI 10.1007/s11748-009-0518-x; Moser B, 2015, AM J SURG PATHOL, V39, P541, DOI 10.1097/PAS.0000000000000359; Ogawa K, 2002, CANCER-AM CANCER SOC, V94, P3115, DOI 10.1002/cncr.10588; Ra SH, 2007, AM J SURG PATHOL, V31, P1330, DOI 10.1097/PAS.0b013e31802f72ef; Sawai T, 2006, INT J SURG PATHOL, V14, P243, DOI 10.1177/1066896906290364; SUSTER S, 1995, AM J SURG PATHOL, V19, P1277, DOI 10.1097/00000478-199511000-00008; SUSTER S, 1991, CANCER-AM CANCER SOC, V67, P1025, DOI 10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F; Suster S, 1996, AM J SURG PATHOL, V20, P1469, DOI 10.1097/00000478-199612000-00006; Takahashi F, 2005, HUM PATHOL, V36, P219, DOI 10.1016/j.humpath.2004.11.008; Toprani Tushar H, 2003, Ann Diagn Pathol, V7, P106; Wang LM, 2015, INT J CLIN EXP PATHO, V8, P5890; Weissferdt A, 2012, AM J CLIN PATHOL, V138, P103, DOI 10.1309/AJCP88FZTWANLRCB; Weissferdt A, 2012, AM J CLIN PATHOL, V138, P115, DOI 10.1309/AJCPLF3XAT0OHADV; Weissferdt A, 2012, HUM PATHOL, V43, P874, DOI 10.1016/j.humpath.2011.07.015; Yano M, 2008, J THORAC ONCOL, V3, P265, DOI 10.1097/JTO.0b013e3181653c71	29	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						73	82		10.1016/j.humpath.2018.01.011			10	Pathology	Pathology	GF4KZ	WOS:000431933100009	29339175				2019-10-28	
J	Kato, A; Naiki-Ito, A; Naitoh, I; Hayashi, K; Nakazawa, T; Shimizu, S; Nishi, Y; Okumura, F; Inoue, T; Takada, H; Kondo, H; Yoshida, M; Takahashi, S; Joh, T				Kato, Akihisa; Naiki-Ito, Aya; Naitoh, Itaru; Hayashi, Kazuki; Nakazawa, Takahiro; Shimizu, Shuya; Nishi, Yuji; Okumura, Fumihiro; Inoue, Tadahisa; Takada, Hiroki; Kondo, Hiromu; Yoshida, Michihiro; Takahashi, Satoru; Joh, Takashi			The absence of class III beta-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma	HUMAN PATHOLOGY			English	Article						Class III beta-tubulin; TUBB3; Unresectable pancreatic ductal adenocarcinoma; Nab-paclitaxel and gemcitabine; EUS-FNA	CELL LUNG-CANCER; CLINICAL-PRACTICE GUIDELINE; ALBUMIN-BOUND PACLITAXEL; HUMAN PROSTATE CARCINOMA; GROWTH-FACTOR RECEPTOR; AMERICAN SOCIETY; SPARC EXPRESSION; PLUS GEMCITABINE; BREAST-CANCER; TRIAL	The combined administration of nab-paclitaxel and gemcitabine (nab-P + Gem) is a standard chemotherapy for unresectable pancreatic ductal adenocarcinoma (UR-PDAC); thus, a predictive biomarker to identify patients best suited for nab-P + Gem therapy would be useful. Class III beta-tubulin (TUBB3) has been reported to be a predictive marker for taxane resistance in various tumors. However, the correlation between TUBB3 expression and the response to nab-P + Gem in patients with UR-PDAC has not been evaluated. We retrospectively reviewed 75 patients with UR-PDAC who received nab-P + Gem. TUBB3 expression was examined immunohistochemically in specimens obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). From 67 analyzable specimens that were available for TUBB3 staining, 14 (21%) were negative for TUBB3 immunostaining and 53 (79%) were positive. Patients with negative TUBB3 expression showed a significantly higher disease control rate (100% vs. 64.2%; P = .008) and longer progression-free survival (PFS); (7.1 months vs. 3.7 months; log-rank test, P = .036) than those of patients with positive. Furthermore, negative TUBB3 expression was an independent predictive marker of a prolonged PFS on multivariate analysis (hazard ratio, 2.41; 95% confidence interval, 1.11-5.24; P = .026). Our data indicate that an absence of TUBB3 expression in specimens obtained by EUS-FNA may be a favorable predictive marker of the response to nab-P + Gem in patients with UR-PDAC, highlighting its use as a potential new biomarker for treatment optimization. (C) 2018 Elsevier Inc. All rights reserved.	[Kato, Akihisa; Naitoh, Itaru; Hayashi, Kazuki; Kondo, Hiromu; Yoshida, Michihiro; Joh, Takashi] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi 4678601, Japan; [Naiki-Ito, Aya; Takahashi, Satoru] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan; [Nakazawa, Takahiro; Shimizu, Shuya] Nagoya Daini Red Cross Hosp, Dept Gastroenterol, Nagoya, Aichi 4668650, Japan; [Nishi, Yuji] Toyokawa City Hosp, Dept Gastroenterol, Toyokawa 4428561, Japan; [Okumura, Fumihiro] Gifu Prefectural Tajimi Hosp, Dept Gastroenterol, Tajimi 5078522, Japan; [Inoue, Tadahisa] Aichi Med Univ, Sch Med, Dept Gastroenterol, Nagakute, Aichi 4801195, Japan; [Takada, Hiroki] Kasugai Municipal Hosp, Dept Gastroenterol, Kasugai, Aichi 4868510, Japan	Naitoh, I (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	inaito@med.nagoya-cu.ac.jp		Naitoh, Itaru/0000-0001-8342-886X	Ministry of Culture and Science of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17K09479]	This study was supported by a Grants-in-Aid for Scientific Research from the Ministry of Culture and Science of Japan (17K09479).	Balaban EP, 2016, J CLIN ONCOL, V34, P2654, DOI 10.1200/JCO.2016.67.5561; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Conroy T, 2016, EUR J CANCER, V57, P10, DOI 10.1016/j.ejca.2015.12.026; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634; Felip E, 2008, CLIN CANCER RES, V14, P3867, DOI 10.1158/1078-0432.CCR-07-5186; Ferrandina G, 2006, CLIN CANCER RES, V12, P2774, DOI 10.1158/1078-0432.CCR-05-2715; Gan PP, 2007, CANCER RES, V67, P9356, DOI 10.1158/0008-5472.CAN-07-0509; Ganansia-Leymarie Valerie, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P291, DOI 10.2174/1568011033482422; Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937; Hackert T, 2016, ANN SURG, V264, P457, DOI 10.1097/SLA.0000000000001850; Hasegawa S, 2003, CLIN CANCER RES, V9, P2992; Hidalgo M, 2015, CLIN CANCER RES, V21, P4811, DOI 10.1158/1078-0432.CCR-14-3222; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; MATSUMURA Y, 1986, CANCER RES, V46, P6387; McCarroll JA, 2015, ONCOTARGET, V6, P2235, DOI 10.18632/oncotarget.2946; Nyman DW, 2005, J CLIN ONCOL, V23, P7785, DOI 10.1200/JCO.2004.00.6148; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Paradiso A, 2005, ANN ONCOL, V16, P14, DOI 10.1093/annonc/mdi902; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Ranganathan S, 1997, PROSTATE, V30, P263, DOI 10.1002/(SICI)1097-0045(19970301)30:4<263::AID-PROS6>3.0.CO;2-M; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Seve P, 2005, MOL CANCER THER, V4, P2001, DOI 10.1158/1535-7163.MCT-05-0244; Seve P, 2007, CLIN CANCER RES, V13, P994, DOI 10.1158/1078-0432.CCR-06-1503; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Socinski MA, 2012, J CLIN ONCOL, V30, P2055, DOI 10.1200/JCO.2011.39.5848; Sohal DPS, 2016, J CLIN ONCOL, V34, P2784, DOI 10.1200/JCO.2016.67.1412; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742	32	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						92	98		10.1016/j.humpath.2018.01.009			7	Pathology	Pathology	GF4KZ	WOS:000431933100011	29339176				2019-10-28	
J	Gansler, T; Fedewa, S; Amin, MB; Lin, CC; Jemal, A				Gansler, Ted; Fedewa, Stacey; Amin, Mahul B.; Lin, Chun Chieh; Jemal, Ahmedin			Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type	HUMAN PATHOLOGY			English	Article						Renal cell carcinoma; Pathology; Classification; Registries; Healthcare quality	INTERNATIONAL-SOCIETY; PRACTICES RECOMMENDATIONS; CLASSIFICATION; IMMUNOHISTOCHEMISTRY; SURVIVAL; DATABASE; SYSTEM; IMPACT; TUMORS	Histological classification of renal cell carcinoma (RCC) has become increasingly important for clinical management. We identified 295 483 RCC diagnosed from 1998-2014 in the National Cancer Database (NCDB) to examine temporal trends in proportions of RCC with unspecified histology and several specific histologies from the 1998 and 2004 World Health Organization classifications of RCC. Further, multivariable log binomial analysis of 101 062 RCC diagnosed from 2010 to 2014 was used to determine whether the association of diagnosing/treating facility type and the proportion of unspecified RCC is independent of patient demographic and clinical factors. Between 1998 and 2014, the proportion of histologically unspecified RCC decreased substantially in all facility types, with the decrease smallest in community programs (from 86.0% to 28.1%) and largest in National Cancer Institute designated centers (from 85.1% to 9.8%). These decreases were offset by increases in percentages of papillary, clear cell, and chromophobe RCC cases. During 2010 to 2014, relative to community programs, RCCs were 21% less likely to be reported as unspecified histology (adjusted prevalence ratio [aPR] = 0.79; 95% CI, 0.68-0.92) in comprehensive community programs, 32% less likely in integrated network programs (aPR = 0.68; 95% CI, 0.57-0.92) and academic programs (aPR = 0.68; 95% CI, 0.54-0.87), and 63% less likely (aPR = 0.37; 95% CI, 0.26-0.52) in National Cancer Institute designated programs. These results have implications for the optimal selection of targeted systemic therapies for patients with advanced disease, and for the potential value of cancer registry data in pathology quality improvement programs to promote more rapid and consistent adoption of new classifications of RCC and other neoplasms. (C) 2018 Elsevier Inc. All rights reserved.	[Gansler, Ted; Fedewa, Stacey; Lin, Chun Chieh; Jemal, Ahmedin] Amer Canc Soc, Intramural Res, Atlanta, GA 30303 USA; [Amin, Mahul B.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA	Gansler, T (reprint author), Amer Canc Soc, Intramural Res, Atlanta, GA 30303 USA.	ted.gansler@cancer.org; stacey.fedewa@cancer.org; mamin5@uthsc.edu; peach891@gmail.com; Ahmedin.Jemal@cancer.org			American College of Surgeons; American Cancer SocietyAmerican Cancer Society	This study used the National Cancer Data Base (NCDB), which is supported by the American College of Surgeons and the American Cancer Society. The authors acknowledge the efforts of the American College of Surgeons and the Commission on Cancer in the creation of the National Cancer Data Base. The data used in the study are derived from the limited data set of the NCDB. The American College of Surgeons and the Commission on Cancer have not verified and are riot responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the authors.	American College of Surgeons, 2016, CANC PROGR CAT; Amin MB, 2014, AM J SURG PATHOL, V38, P1017, DOI 10.1097/PAS.0000000000000254; Amin MB, 2002, AM J SURG PATHOL, V26, P281, DOI 10.1097/00000478-200203000-00001; Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Boffa DJ, 2017, JAMA ONCOL, V3, P1722, DOI 10.1001/jamaoncol.2016.6905; Cheng L, 2016, PATHOLOGY GENETICS T, P41; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Eble JN, 2004, PATHOLOGY GENETICS T, P10; Gansler T, 2017, ARCH PATHOL LAB MED, V141, P1686, DOI 10.5858/arpa.2016-0611-OA; Gansler Ted, 2012, J Registry Manag, V39, P43; Griswold ME, 2013, STAT, V2, P129, DOI 10.1002/sta4.22; Keegan KA, 2012, J UROLOGY, V188, P391, DOI 10.1016/j.juro.2012.04.006; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Lerro CC, 2013, ANN SURG ONCOL, V20, P1759, DOI 10.1245/s10434-013-2901-1; Leung C, 2016, CURR OPIN UROL, V26, P396, DOI 10.1097/MOU.0000000000000322; Lipworth L, 2016, BJU INT, V117, P260, DOI 10.1111/bju.12950; Moch H, 2000, CANCER, V89, P604, DOI 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.3.CO;2-H; Moch H, 2016, PATHOLOGY GENETICS T, P14; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Motzer RJ, 2017, NCCN CLIN PRACTICE G; Motzer TJ, 2007, NCCN CLIN PRACTICE G; Nese N, 2009, ANN DIAGN PATHOL, V13, P1, DOI 10.1016/j.anndiagpath.2008.10.002; Olshan AF, 2013, CANCER MED-US, V2, P744, DOI 10.1002/cam4.110; Patard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055; Percy C, 2001, CONVERSION NEOPLASMS; Purdue MP, 2013, INT J CANCER, V132, P2640, DOI 10.1002/ijc.27934; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Shuch B, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2012.08.011; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Tilki D, 2014, EUR UROL, V66, P577, DOI 10.1016/j.eururo.2013.06.048; Udager AM, 2016, ARCH PATHOL LAB MED, V140, P1026, DOI 10.5858/arpa.2016-0218-RA	32	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						99	108		10.1016/j.humpath.2018.01.010			10	Pathology	Pathology	GF4KZ	WOS:000431933100012	29339177				2019-10-28	
J	Huang, T; McHugh, JB; Berry, GJ; Myers, JL				Huang, Tao; McHugh, Jonathan B.; Berry, Gerald J.; Myers, Jeffrey L.			Primary mammary analogue secretory carcinoma of the lung: a case report	HUMAN PATHOLOGY			English	Article						Lung; Mammary analogue secretory carcinoma (MASC); Salivary gland tumor; ETV6-NTRK3 fusion	ETV6 GENE REARRANGEMENT; SALIVARY-GLANDS; SKIN; DIAGNOSIS; UPDATE; ORIGIN; ENTITY	Mammary analogue secretory carcinoma (MASC) is a recently discovered salivary gland tumor described mostly in the major salivary glands and occasionally in the skin. We report a primary endobronchial tumor with histology, immunophenotype, and ETV6 rearrangement characteristic of MASC in a 62-year-old woman. The diagnosis was initially made on a transbronchial biopsy with fluorescence in situ hybridization confirmation of ETV6 rearrangement. The patient underwent lobectomy demonstrating a large endobronchial mass. To our knowledge, this is the first report of MASC arising as a primary pulmonary tumor. This tumor was unusual in that it is the largest (8.5 cm) MASC ever reported, showed an increased mitotic count (6/10 high-power fields) without high-grade cytology, and presented with advanced -stage disease that included visceral pleural invasion and lymph node metastasis. (C) 2017 Elsevier Inc. All rights reserved.	[Huang, Tao; McHugh, Jonathan B.; Myers, Jeffrey L.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Berry, Gerald J.] Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	Myers, JL (reprint author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.						Albus J, 2015, AM J DERMATOPATH, V37, pE41; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Bishop JA, 2013, HEAD NECK PATHOL, V7, P35, DOI 10.1007/s12105-013-0429-0; Brandt SM, 2009, AM J SURG PATHOL, V33, P950, DOI 10.1097/PAS.0b013e31819c2628; Chang CY, 2017, CLIN GASTROENTEROL H; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Falk N, 2016, ADV ANAT PATHOL, V23, P13, DOI 10.1097/PAP.0000000000000099; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Jung MJ, 2013, KOREAN J PATHOL, V47, P36, DOI 10.4132/KoreanJPathol.2013.47.1.36; Kazakov DV, 2010, AM J SURG PATHOL, V34, P1226, DOI 10.1097/PAS.0b013e3181e4f49d; Khurram SA, 2016, OR SURG OR MED OR PA, V122, P731, DOI 10.1016/j.oooo.2016.07.008; Luk PP, 2015, PATHOLOGY, V47, P659, DOI 10.1097/PAT.0000000000000322; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Molina JR, 2007, CANCER-AM CANCER SOC, V110, P2253, DOI 10.1002/cncr.23048; Patel KR, 2013, HUM PATHOL, V44, P2501, DOI 10.1016/j.humpath.2013.06.010; Petersson F, 2012, HEAD NECK PATHOL, V6, P135, DOI 10.1007/s12105-011-0283-x; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Said-Al-Naief N, 2017, INT J SURG PATHOL, V25, P127, DOI 10.1177/1066896916670005; Sethi R, 2014, LARYNGOSCOPE, V124, P188, DOI 10.1002/lary.24254; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2016, ARCH PATHOL LAB MED, V140, P997, DOI 10.5858/arpa.2015-0075-RS	27	8	8	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						109	113		10.1016/j.humpath.2017.10.027			5	Pathology	Pathology	GF4KZ	WOS:000431933100013	29104113				2019-10-28	
J	Chang, KP; Liu, JH; Yu, SC; Lin, CW				Chang, Koping; Liu, Jia-Hau; Yu, Shan-Chi; Lin, Chung-Wu			FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report	HUMAN PATHOLOGY			English	Article						Myeloproliferative neoplasm; Systemic mastocytosis; Lymphoblastic lymphoma; ZMYM2-FGFRI translocation; Intron and exon sequencing	ABNORMALITY	FGFRI translocation may cause myeloid or lymphoid neoplasm but rarely systemic mastocytosis (SM). Conversely, SM is associated with myeloproliferative neoplasm (MPN) but rarely lymphoblastic lymphoma (LBL) or FGFRI translocation. We report the first case of FGFRI translocation in a patient with concurrent LBL, MPN, and SM. A 21-year-old male patient presented with diffuse lymphadenopathies and leukocytosis. TdT(+)/cytoCD3(+)/CD79a(weakly+) LBL was identified in the lymph node. Bone marrow had MPN, SM, and TdT(+)/CD79a(+)/cytoCD3(weakly+) LBL. The cytogenetic study, reverse-transcription polymerase chain reaction, and sequencing revealed t(8;13)(p11;q12) involving FGFRI and ZMYM2. Under the hyper cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen, complete remission of LBL was achieved despite persistent MPN and SM in the bone marrow. This rare case implies FGFR1 trans location in a precursor cell capable of differentiation into mast cells and lymphoblasts, strengthening the relationship between the 2 tumors in the World Health Organization classification: myeloid and lymphoid neoplasms with FGFRI abnormalities, and SM with an associated hematologic neoplasm. (C) 2017 Elsevier Inc. All rights reserved.	[Chang, Koping; Yu, Shan-Chi; Lin, Chung-Wu] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Pathol, Taipei 100, Taiwan; [Liu, Jia-Hau] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Div Hematol,Dept Med, Taipei 100, Taiwan; [Lin, Chung-Wu] Natl Taiwan Univ, Coll Med, Grad Inst Pathol, 1 Jen Ai Rd,Sect 1, Taipei 100, Taiwan	Lin, CW (reprint author), Natl Taiwan Univ, Coll Med, Grad Inst Pathol, 1 Jen Ai Rd,Sect 1, Taipei 100, Taiwan.	chungwulin@ntu.edu.tw					ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; BAIN BJ, 2008, WHO CLASSIFICATION T, P68; Duckworth CB, 2014, INT J CLIN EXP PATHO, V7, P801; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Horny HP, 2008, WHO CLASSIFICATION T, V2, P54; Iliakis T, 2014, CASE REP MED, DOI 10.1155/2014/526129; Jackson CC, 2010, HUM PATHOL, V41, P461, DOI 10.1016/j.humpath.2009.11.003; Kumar KR, 2015, AM J CLIN PATHOL, V143, P738, DOI 10.1309/AJCPUD6W1JLQQMNA; Mayeur-Rousse C, 2012, LEUKEMIA RES, V36, P377, DOI 10.1016/j.leukres.2011.10.009; Pardanani A, 2016, AM J HEMATOL, V91, P1147, DOI 10.1002/ajh.24553; Pardanani A, 2016, AM J HEMATOL, V91, P888, DOI 10.1002/ajh.24426; Tzankov A, 2008, J CLIN PATHOL, V61, P958, DOI 10.1136/jcp.2008.058073	12	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						114	121		10.1016/j.humpath.2017.10.019			8	Pathology	Pathology	GF4KZ	WOS:000431933100014	29107667				2019-10-28	
J	Pinto, A; Kahn, RM; Rosenberg, AE; Slomovitz, B; Quick, CM; Whisman, MK; Huang, M				Pinto, Andre; Kahn, Ryan M.; Rosenberg, Andrew E.; Slomovitz, Brian; Quick, Charles Matthew; Whisman, Michella K.; Huang, Marilyn			Uterine rhabdomyosarcoma in adults	HUMAN PATHOLOGY			English	Article						Rhabdomyosarcoma; Uterus; Sarcoma; Gynecologic; Malignancy	OF-THE-LITERATURE; ALVEOLAR RHABDOMYOSARCOMA; CLINICOPATHOLOGICAL FEATURES; EMBRYONAL RHABDOMYOSARCOMA; CERVIX; CORPUS; UTERUS; SARCOMAS; WOMEN	Rhabdomyosarcoma (RMS) is an aggressive mesenchymal tumor most commonly diagnosed in the pediatric population, and when occurring in adults, tends to develop in the deep soft tissue of the limbs. Primary uterine RMS comprises an even more restricted subset, with little known or reported when compared to most other gynecologic sarcomas. Our goal with this study was to retrospectively evaluate cases from two academic institutions and describe the main histopathologic findings of this rare gynecologic malignancy. A total of 8 cases were identified, consisting of 4 pleomorphic rhabdomyosarcomas (PRMS), 2 alveolar rhabdomyosarcomas (ARMS), and 2 embryonal rhabdomyosarcomas (ERMS). They occurred in patients ranging from 22 to 70 years old, and the most common presenting symptom was vaginal bleeding. Most patients presented with advanced stage at diagnosis, including metastatic disease to lymph nodes and to distant sites. The masses were mostly (6/8) centered in the myometrium, while two cases arose in the cervix (2/8). Histologic characteristics of the tumors were dependent on the RMS subtype, although all cases demonstrated a similar immunohistochemical profile regardless of their subclassification. RMS of the uterus has a very poor prognosis, and data regarding treatment of this rare malignancy is limited, and usually extrapolated from non-uterine sites. (C) 2018 Elsevier Inc. All rights reserved.	[Pinto, Andre; Rosenberg, Andrew E.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Kahn, Ryan M.] New York Presbyterian Hosp Weill Cornell, Dept Obstet & Gynecol, New York, NY 10021 USA; [Slomovitz, Brian; Huang, Marilyn] Univ Miami, Miller Sch Med, Dept Gynecol Oncol, Miami, FL 33136 USA; [Quick, Charles Matthew; Whisman, Michella K.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	Pinto, A (reprint author), Univ Miami, Miller Sch Med, 1611 NW 12th Ave,Holtz 2145, Miami, FL 33136 USA.	Apinto1@med.miami.edu					Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Case AS, 2005, GYNECOL ONCOL, V96, P850, DOI 10.1016/j.ygyno.2004.11.009; D'Angelo E, 2010, GYNECOL ONCOL, V116, P131, DOI 10.1016/j.ygyno.2009.09.023; Fadare O, 2010, INT J GYNECOL PATHOL, V29, P122, DOI 10.1097/PGP.0b013e3181bc98c0; Ferguson SE, 2007, AM J SURG PATHOL, V31, P382, DOI 10.1097/01.pas.0000213352.87885.75; Ferrari A, 2003, CANCER-AM CANCER SOC, V98, P571, DOI 10.1002/cncr.11550; Fletcher CD, 2013, DIAGNOSTIC HISTOPATH; Fukunaga M, 2011, PATHOL INT, V61, P377, DOI 10.1111/j.1440-1827.2011.02672.x; Gerber NK, 2013, INT J RADIAT ONCOL, V86, P58, DOI 10.1016/j.ijrobp.2012.12.016; Hawkins WG, 2001, CANCER, V91, P794, DOI 10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.3.CO;2-H; Kriseman ML, 2012, GYNECOL ONCOL, V126, P351, DOI 10.1016/j.ygyno.2012.05.008; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Li RF, 2013, AM J SURG PATHOL, V37, P344, DOI 10.1097/PAS.0b013e31826e0271; McCluggage WG, 2002, INT J GYNECOL CANCER, V12, P128, DOI 10.1046/j.1525-1438.2002.01069.x; MONTAG TW, 1986, GYNECOL ONCOL, V25, P171, DOI 10.1016/0090-8258(86)90098-3; Ng TY, 2003, GYNECOL ONCOL, V91, P623, DOI 10.1016/S0090-8258(03)00252-X; Odoi A T, 2009, Afr J Reprod Health, V13, P167; Ogilvie CM, 2010, AM J CLIN ONCOL-CANC, V33, P128, DOI 10.1097/COC.0b013e3181979222; Ordi J, 1997, INT J GYNECOL PATHOL, V16, P369, DOI 10.1097/00004347-199710000-00013; Rivasi F, 2008, INT J GYNECOL PATHOL, V27, P442, DOI [10.1097/PGP.001301816085ce, 10.1097/PGP.0b013e31816085ce]; Szewczyk B, 2017, CURR DRUG TARGETS, V18, P98, DOI 10.2174/1389450117666151209124123; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239	22	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						122	128		10.1016/j.humpath.2018.01.007			7	Pathology	Pathology	GF4KZ	WOS:000431933100015	29320751				2019-10-28	
J	Luo, P; Wang, X; Zhou, JP; Li, L; Jing, ZT				Luo, Peng; Wang, Xin; Zhou, Jinpeng; Li, Long; Jing, Zhitao			C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis	HUMAN PATHOLOGY			English	Article						C-Cbl and Cbl-b; Skull base chordomas; Tumor progression; Prognosis; Biomarker	CANCER CELLS; SACROCOCCYGEAL CHORDOMA; OPERATIVE MANAGEMENT; PROSTATE-CANCER; UBIQUITINATION; PATHWAYS; KINASE; GROWTH; EGFR	Chordomas are rare, locally aggressive malignancies that are often difficult to eradicate. Surgery and radiotherapy are the first-line treatments, but the probability of local recurrence is high. According to our previous research, c-Cbl and Cbl-b have been linked to tumor progression and poor prognosis of glioma. However, their role in skull base chordomas is unclear. To clarify this issue, in the present study, we analyzed the expression of c-Cbl and Cbl-b in relation to the clinicopathological features and clinical outcome of skull base chordoma patients (n = 70). C-Cbl and Cbl-b expression was evaluated by immunohistochemistry, and a survival analysis was performed based on clinical data. We found that c-Cbl and Cbl-b were upregulated in 30 of 70 (42.9%) and 32 of 70 (45.7%) patients with skull base chordomas, respectively. A Kaplan-Meier analysis and log-rank test indicated that high c-Cbl and Cbl-b levels were significantly associated with overall survival (P = .003 and P = .008, respectively) and progression-free survival (P < .001 and P = .022, respectively). These data indicated that c-Cbl and Cbl-b expression in skull base chordomas can predict tumor invasion and poor prognosis and is therefore a potential therapeutic target for chordoma treatment. (C) 2018 Elsevier Inc. All rights reserved.	[Luo, Peng; Wang, Xin; Zhou, Jinpeng; Li, Long; Jing, Zhitao] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang 110001, Liaoning, Peoples R China	Jing, ZT (reprint author), China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang 110001, Liaoning, Peoples R China.	jingzhitao@hotmail.com					ARIEL I M, 1975, Journal of Surgical Oncology, V7, P27, DOI 10.1002/jso.2930070106; Baratti D, 2003, ANN SURG ONCOL, V10, P291, DOI 10.1245/ASO.2003.06.002; Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1; Cristobal I, 2014, INT J COLORECTAL DIS, V29, P641, DOI 10.1007/s00384-014-1839-5; Dong Q, 2016, ONCOTARGET, V7, P82338, DOI 10.18632/oncotarget.11001; Fan YB, 2016, ONCOL LETT, V12, P1113, DOI 10.3892/ol.2016.4730; Feng D, 2013, INT J MOL SCI, V14, P24399, DOI 10.3390/ijms141224399; Fuchs B, 2005, J BONE JOINT SURG AM, V87A, P2211, DOI 10.2106/JBJS.D.02693; Ito R, 2004, VIRCHOWS ARCH, V444, P324, DOI 10.1007/s00428-004-0982-8; Jing ZT, 2016, ONCOL LETT, V11, P2787, DOI 10.3892/ol.2016.4318; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kayani B, 2015, WORLD NEUROSURG, V84, P1354, DOI 10.1016/j.wneu.2015.06.030; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Kwak SY, 2015, FEBS J, V282, P1512, DOI 10.1111/febs.13238; Lee H, 2010, J CELL BIOCHEM, V111, P1169; Lee Y, 2008, BLOOD, V111, P885, DOI 10.1182/blood-2007-03-082941; Liyasova MS, 2015, CLIN CANCER RES, V21, P1789, DOI 10.1158/1078-0432.CCR-13-2490; Makishima H, 2009, J CLIN ONCOL, V27, P6109, DOI 10.1200/JCO.2009.23.7503; Mohapatra B, 2013, BBA-MOL CELL RES, V1833, P122, DOI 10.1016/j.bbamcr.2012.10.010; Osaka S, 2006, J CANCER RES CLIN, V132, P213, DOI 10.1007/s00432-005-0067-3; RICH TA, 1985, CANCER, V56, P182, DOI 10.1002/1097-0142(19850701)56:1<182::AID-CNCR2820560131>3.0.CO;2-J; Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0; Yonemoto T, 1999, CANCER, V85, P878, DOI 10.1002/(SICI)1097-0142(19990215)85:4<878::AID-CNCR15>3.3.CO;2-Z; Zhou SK, 2014, J CHIN MED ASSOC, V77, P630, DOI 10.1016/j.jcma.2014.03.008	26	2	2	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						129	134		10.1016/j.humpath.2017.12.019			6	Pathology	Pathology	GF4KZ	WOS:000431933100016	29317233				2019-10-28	
J	Ojalvo, LS; Thompson, ED; Wang, TL; Meeker, AK; Shih, IM; Fader, AN; Cimino-Mathews, A; Emens, LA				Ojalvo, Laureen S.; Thompson, Elizabeth D.; Wang, Tian-Li; Meeker, Alan K.; Shih, Ie-Ming; Fader, Amanda N.; Cimino-Mathews, Ashley; Emens, Leisha A.			Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer	HUMAN PATHOLOGY			English	Article						Ovarian cancer; CD8+T cells; Regulatory T cells; Tumor-associated macrophages; PD-1/PD-L1	T-CELLS; INFILTRATING LYMPHOCYTES; PROGNOSTIC-SIGNIFICANCE; CYTOREDUCTIVE SURGERY; FAVORABLE PROGNOSIS; PD-L1 EXPRESSION; IMPACT; SURVIVAL; CARCINOMA	Tumor-infiltrating lymphocytes (TILs) are associated with better prognosis in newly diagnosed epithelial ovarian cancer (EOC), but clinical trials of immunotherapies in patients with heavily treated disease reveal limited activity. Understanding the tumor microenvironment (TME) of primary and recurrent EOC should guide future trials. Here, we evaluated the TME of paired primary and recurrent tumors (n = 17), and non-paired primary (n = 20) and recurrent (n = 15) tumors, for CD8+ T cells, FOXP3+ regulatory T cells (Tregs), CD68+ tumor-associated macrophages (TAMs), programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1). CD8+ T cells were similar in primary and recurrent tumors, but Tregs were higher in recurrent tumors (P = .0210). Higher TAM density (>= 5%) associated with higher Tregs (P = .001) and CD8+ T cells (P < .001) in recurrent tumors, but only with higher Tregs in primary tumors (P = .02). TAM-dense recurrent tumors expressed PD-L1 on tumor and immune cells, whereas TAM-dense primary tumors expressed PD-L1 predominantly on immune cells. In survival analyses, higher Tregs in primary tumors correlated with decreased time to first recurrence (17.0 versus 28.5 months, P = .022). Conversely, higher Tregs in recurrent tumors correlated with longer overall survival (OS) from recurrence (median not met versus 20.0 months, P = .022). TAM density did not affect patient survival. However, patients with increased TAMs at recurrence (n = 5) had longer OS from recurrence compared to patients without increased TAMs (n = 12) (56.0 versus 20.0 months); with the small sample size, this did not reach statistical significance (P = .074). Further characterization of the evolution of the TME is warranted. (C) 2017 Elsevier Inc. All rights reserved.	[Ojalvo, Laureen S.; Wang, Tian-Li; Shih, Ie-Ming; Fader, Amanda N.] Johns Hopkins Univ Hosp, Dept Gynecol & Obstet, Kelly Gynecol Oncol Serv, Baltimore, MD 21287 USA; [Thompson, Elizabeth D.; Wang, Tian-Li; Meeker, Alan K.; Shih, Ie-Ming; Cimino-Mathews, Ashley] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Thompson, Elizabeth D.; Cimino-Mathews, Ashley; Emens, Leisha A.] Bloomberg Kimmel Inst Johns Hopkins, Baltimore, MD 21287 USA; [Emens, Leisha A.] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA	Emens, LA (reprint author), Johns Hopkins Univ, Sch Med, 1650 Orleans St,Room 409,Canc Res Bldg 1, Baltimore, MD 21231 USA.	emensle@jhmi.edu			HERA Ovarian Cancer Foundation Outside-the-Box Grant	HERA Ovarian Cancer Foundation Outside-the-Box Grant awarded to L.S.O.	Aust S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42929; Bristow RE, 2009, GYNECOL ONCOL, V112, P265, DOI 10.1016/j.ygyno.2008.08.033; Chatterjee J, 2017, CLIN CANCER RES, V23, P3453, DOI 10.1158/1078-0432.CCR-16-2366; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429; Deleeuw RJ, 2015, CANCER IMMUNOL RES, V3, P245, DOI 10.1158/2326-6066.CIR-14-0146; Emens LA, 2016, CURR OPIN OBSTET GYN, V28, P142, DOI 10.1097/GCO.0000000000000257; Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654; Gottlieb CE, 2017, GYNECOL ONCOL, V144, P607, DOI 10.1016/j.ygyno.2016.12.021; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hanker LC, 2012, ANN ONCOL, V23, P2605, DOI 10.1093/annonc/mds203; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Kyi C, 2016, IMMUNOTHERAPY-UK, V8, P821, DOI 10.2217/imt-2016-0002; Lee CK, 2015, GYNECOL ONCOL, V136, P18, DOI 10.1016/j.ygyno.2014.09.017; Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nelson BH, 2008, IMMUNOL REV, V222, P101, DOI 10.1111/j.1600-065X.2008.00614.x; Ojalvo LS, 2015, DISCOV MED, V20, P97; Ozols RF, 2005, INT J GYNECOL CANCER, V15, P3, DOI 10.1111/j.1525-1438.2005.15351.x; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Yuan X, 2017, GYNECOL ONCOL, V147, P181, DOI 10.1016/j.ygyno.2017.07.007; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946	32	5	6	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						135	147		10.1016/j.humpath.2017.12.010			13	Pathology	Pathology	GF4KZ	WOS:000431933100017	29288043				2019-10-28	
J	Kobayashi, M; Nagashio, R; Saito, K; Aguilar-Bonavides, C; Ryuge, S; Katono, K; Igawa, S; Tsuchiya, B; Jiang, SX; Ichinoe, M; Murakumo, Y; Saegusa, M; Satoh, Y; Sato, Y				Kobayashi, Makoto; Nagashio, Ryo; Saito, Keita; Aguilar-Bonavides, Clemente; Ryuge, Shinichiro; Katono, Ken; Igawa, Satoshi; Tsuchiya, Benio; Jiang, Shi-Xu; Ichinoe, Masaaki; Murakumo, Yoshiki; Saegusa, Makoto; Satoh, Yukitoshi; Sato, Yuichi			Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma	HUMAN PATHOLOGY			English	Article						Lung adenocarcinoma; S100A16; Localization; hnmunohistochemistry; Prognosis	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; EXPRESSION; TTF-1; TUMORS; CLASSIFICATION; PHENOTYPE; PROTEIN	To discover novel tumor markers for lung adenocarcinoma (AC), we performed proteomics analysis and reported a correlation between S100A16 membranous expression in AC tissues and a poor prognosis. However, some patients with a good prognosis also showed S100A16 membranous staining. We re-evaluated immunohistochemically stained tissues, and found membrane-positive and nucleus-negative expressions to be significantly higher in the presence of the following: male, smoker, positive nodal metastasis, higher p-TNM stage, larger tumor, poorer differentiation, positive for lymphatic invasion, positive for vascular invasion, and positive for pleural invasion (all factors P < .05). This pattern of staining was also an independent prognostic factor. Furthermore, we analyzed S100A16 mRNA expression using TCGA and Kaplan-Meier plotter databases, and found that higher S100A16 mRNA expression in AC was significantly correlated with poorer survival. To our knowledge, there has been no comprehensive study focused on both S100A16 protein and mRNA expression levels in AC patients. Our results suggest that the subcellular localization of S100A16 and S100A16 mRNA expression levels is a promising prognostic marker for AC. (C) 2018 Elsevier Inc. All rights reserved.	[Kobayashi, Makoto; Nagashio, Ryo; Saito, Keita; Tsuchiya, Benio; Sato, Yuichi] Kitasato Univ, Grad Sch Med Sci, Dept Appl Tumor Pathol, Sagamihara, Kanagawa 2520373, Japan; [Aguilar-Bonavides, Clemente] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Ryuge, Shinichiro; Katono, Ken; Igawa, Satoshi] Kitasato Univ, Sch Med, Dept Resp Med, Sagamihara, Kanagawa 2520374, Japan; [Jiang, Shi-Xu; Ichinoe, Masaaki; Murakumo, Yoshiki; Saegusa, Makoto] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa 2520374, Japan; [Satoh, Yukitoshi] Kitasato Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Sagamihara, Kanagawa 2520374, Japan	Sato, Y (reprint author), Kitasato Univ, Grad Sch Med Sci, Dept Appl Tumor Pathol, Minami Ku, Kitasato 1-15-1, Sagamihara, Kanagawa 2520373, Japan.	yuichi@med.kitasato-u.ac.jp		Kobayashi, Makoto/0000-0001-7176-7207	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23590414, 26460441]; Graduate School of Medical Sciences, Kitasato University	This study was supported in part by JSPS KAKENHI Grant numbers 23590414 and 26460441, the 2013-2014 Project Study from the Graduate School of Medical Sciences, Kitasato University.	Aoi T, 2016, GEN THORAC CARDIOVAS, V64, P517, DOI 10.1007/s11748-016-0682-8; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Chen HY, 2014, AM J CANCER RES, V4, P89; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Katono K, 2017, ONCOTARGETS THER, V10, P5273, DOI 10.2147/OTT.S145072; Ma YF, 2015, TUMOR BIOL, V36, P8085, DOI 10.1007/s13277-015-3478-z; Maeshima AM, 2008, PATHOL INT, V58, P31, DOI 10.1111/j.1440-1827.2007.02185.x; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V313, P237, DOI 10.1016/j.bbrc.2003.11.115; Nagashio R, 2015, SCI REP-UK, V5, DOI 10.1038/srep08649; Qian HH, 2015, CLIN CHIM ACTA, V451, P208, DOI 10.1016/j.cca.2015.01.023; Saito Keita, 2015, Asian Pac J Cancer Prev, V16, P7039; Sakurai H, 2014, EUR J CARDIO-THORAC, V45, P100, DOI 10.1093/ejcts/ezt284; Sapkota D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1622-1; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Tanaka M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1059-6; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Tripathi SC, 2016, P NATL ACAD SCI USA, V113, pE1555, DOI 10.1073/pnas.1521812113; Valladares-Ayerbes M, 2008, CANCER DETECT PREV, V32, P236, DOI 10.1016/j.cdp.2008.08.002; Zhou WB, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0097-8	20	2	3	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						148	155		10.1016/j.humpath.2018.01.001			8	Pathology	Pathology	GF4KZ	WOS:000431933100018	29320753				2019-10-28	
J	Li, YH; Liu, HT; Xu, J; Xing, AY; Zhang, J; Wang, YW; Yin, G; Gao, P				Li, Yu-hong; Liu, Hai-ting; Xu, Jing; Xing, Ai-yan; Zhang, Jie; Wang, Ya-wen; Yin, Gang; Gao, Peng			The value of detection of S100A8 and ASAH1 in predicting the chemotherapy response for breast cancer patients	HUMAN PATHOLOGY			English	Article						S100A8; ASAHl; Neoadjuvant chemotherapy; Breast cancer; Drug resistance	CALCIUM-BINDING PROTEINS; ACID CERAMIDASE; NEOADJUVANT CHEMOTHERAPY; PROSTATE-CANCER; EXPRESSION SIGNATURE; PROGNOSIS; CARCINOMA; MARKERS; SPHINGOSINE; PROMOTES	Chemotherapy plays an important role in the treatment of breast cancer. However, chemoresistance remains the main obstacle for effective treatment, leading to poor prognosis. This study aims to investigate the value of detection of S100A8 and ASAH1 in predicting the chemotherapy response. Miller and Payne grades were used to assess the chemotherapy response in breast cancers. The expression of S100A8 and ASAH1, as well as ER, PR, HER2 and Ki-67 were assessed by immunohistochemical staining in 120 cases of non special type invasive ductal carcinoma (IDC-NOS). S100A8 expression was higher in chemosensitive breast cancers than chemoresistant ones. Moreover, S100A8 expression was significantly correlated with the molecular subtypes and histological grade, but not with patients' age, tumor size and lymph nodes status. However, there was no significant difference in ASAH1 expression between chemoresistant and chemosensitive group. We also found that higher ASAH1 expression was correlated with positive lymph nodes status, but not with age, tumor size, molecular subtypes and histological grade. S100A8 was valuable in predicting chemotherapy response in breast cancers. The expression of ASAH1 was associated significantly with lymph nodes metastasis, indicating that ASAH1 may serve as a biomarker to predict patients' lymph nodes status in breast cancers. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Yu-hong; Liu, Hai-ting; Xu, Jing; Xing, Ai-yan; Wang, Ya-wen; Gao, Peng] Shandong Univ, QiLu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China; [Li, Yu-hong; Zhang, Jie] Peoples Hosp Liaocheng, Dept Pathol, Liaocheng, Peoples R China; [Yin, Gang] Shandong Univ, Qilu Hosp, Dept Surg, Jinan, Shandong, Peoples R China; [Xu, Jing] Qingdao Cent Hosp, Dept Pathol, Qingdao, Peoples R China	Gao, P (reprint author), Shandong Univ, QiLu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China.; Yin, G (reprint author), Shandong Univ, Qilu Hosp, Dept Surg, Jinan, Shandong, Peoples R China.	yg_2000@sina.com; gaopeng@sdu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372856, 81172351]; Taishan Scholars Program of Shandong Province [ts201511096]	This work was supported by the National Natural Science Foundation of China (No.81372856 and 81172351) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Arai K, 2008, CURR CANCER DRUG TAR, V8, P243, DOI 10.2174/156800908784533445; Beckham TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076593; Beckham TH, 2012, INT J CANCER, V131, P2034, DOI 10.1002/ijc.27480; Camacho L, 2013, J LIPID RES, V54, P1207, DOI 10.1194/jlr.M032375; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; El-Rifai W, 2002, CANCER RES, V62, P6823; Hermani A, 2005, CLIN CANCER RES, V11, P5146, DOI 10.1158/1078-0432.CCR-05-0352; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460; Lee HW, 2013, VIRCHOWS ARCH, V463, P489, DOI 10.1007/s00428-013-1461-x; Lim SY, 2008, J IMMUNOL, V181, P5627, DOI 10.4049/jimmunol.181.8.5627; Lu CW, 2017, CANCER LETT, V388, P130, DOI 10.1016/j.canlet.2016.11.033; Lucki NC, 2012, MOL CELL BIOL, V32, P4419, DOI 10.1128/MCB.00378-12; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; McKiernan E, 2011, TUMOR BIOL, V32, P441, DOI 10.1007/s13277-010-0137-2; Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140; Musumarra G, 2003, BIOL CHEM, V384, P321, DOI 10.1515/BC.2003.037; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Parris TZ, 2014, INT J CANCER, V134, P1617, DOI 10.1002/ijc.28497; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Realini N, 2016, J BIOL CHEM, V291, P2422, DOI 10.1074/jbc.M115.666909; Ruckhaberle E, 2009, CLIMACTERIC, V12, P502, DOI 10.3109/13697130902939913; Sanger N, 2015, MOL ONCOL, V9, P58, DOI 10.1016/j.molonc.2014.07.016; Tan SF, 2016, ONCOTARGET, V7, P83208, DOI 10.18632/oncotarget.13079; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Yang WS, 2012, J PROTEOME RES, V11, P1078, DOI 10.1021/pr2008187; Yin CG, 2013, BREAST CANCER RES TR, V142, P297, DOI 10.1007/s10549-013-2737-1; Zheng Y, 2015, J CANCER, V6, P671, DOI 10.7150/jca.11616	29	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						156	163		10.1016/j.humpath.2018.01.004			8	Pathology	Pathology	GF4KZ	WOS:000431933100019	29320752				2019-10-28	
J	Osmond, A; Ashok, D; Francoeur, CA; Miller, M; Walsh, JC				Osmond, Allison; Ashok, Dhandapani; Francoeur, Courtney A.; Miller, Michael; Walsh, Joanna C.			Is focal active colitis of greater clinical significance in pediatric patients? A retrospective review of 68 cases with clinical correlation	HUMAN PATHOLOGY			English	Review						Focal active colitis; Pediatric; Inflammatory bowel disease; Crohn's disease	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PHOSPHATE BOWEL PREPARATION	Focal active colitis (FAC) is a histopathologic finding of uncertain clinical significance in individual patients. In adults, infection accounts for approximately 50%, Crohn's disease (CD) for 0-13%, and 20%-30% are idiopathic. One previous study of 29 cases of pediatric FAC showed a 28% rate of CD. This study reviewed a larger cohort of pediatric patients to determine what proportion had IBD, and whether an amount or pattern of inflammation could predict IBD. Sixty-eight patients aged years with FAC were identified and reviewed. Patients with a prior diagnosis of IBD or chronic colitis in the index biopsies were excluded. Slides were assessed for a number of inflammatory criteria. Clinical data and final diagnoses were recorded. Data were analyzed using Pearson correlations and Fisher's exact chi(2) analyses. Sixteen patients (24%) had a final diagnosis of IBD. When cases with terminal ileal (TI) inflammation were excluded, 6 of 54 patients had a final diagnosis of IBD (11%). A final diagnosis of IBD was significantly associated with crypt abscesses and elevated serum inflammatory markers. MD was significantly associated with TI inflammation. An amount or pattern of inflammation that could be used to predict IBD was not determined. This study demonstrated a 24% rate of IBD in pediatric patients With FAC; however, when patients with associated TI inflammation were excluded, the rate was 11%, similar to reported rates in adults. FAC in pediatric patients without terminal ileal inflammation does not appear to warrant more aggressive follow-up. (C) 2018 Elsevier Inc. All rights reserved.	[Osmond, Allison; Walsh, Joanna C.] Western Univ, London, ON, Canada; [Osmond, Allison; Walsh, Joanna C.] London Hlth Sci Ctr, London, ON, Canada; [Ashok, Dhandapani; Francoeur, Courtney A.; Miller, Michael] Childrens Hosp Western Ontario, London, ON, Canada	Walsh, JC (reprint author), Univ Hosp, London Hlth Sci Ctr, Dept Pathol & Lab Med, 339 Windermere Rd, London, ON N6A 5A5, Canada.	Joanna.walsh@lhsc.on.ca					Dial S, 2005, JAMA-J AM MED ASSOC, V294, P2989, DOI 10.1001/jama.294.23.2989; Driman DK, 1998, HUM PATHOL, V29, P972, DOI 10.1016/S0046-8177(98)90203-9; Goldstein NS, 1998, AM J CLIN PATHOL, V110, P622, DOI 10.1093/ajcp/110.5.622; Greenson JK, 1997, HUM PATHOL, V28, P729, DOI 10.1016/S0046-8177(97)90183-0; Henderson P, 2014, AM J GASTROENTEROL, V109, P637, DOI 10.1038/ajg.2013.131; Kurahara K, 2001, AM J GASTROENTEROL, V96, P473; Lee FD, 1994, DRUG RELATED PATHOLO, P303; Mpofu S, 2004, ANN RHEUM DIS, V63, P588, DOI 10.1136/ard.2003.010355; Ozdil K, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-96; Pall H, 2014, J PEDIATR GASTR NUTR, V59, P409, DOI 10.1097/MPG.0000000000000447; Parfitt JR, 2007, HUM PATHOL, V38, P527, DOI 10.1016/j.humpath.2007.01.014; Shetty S, 2011, HISTOPATHOLOGY, V59, P850, DOI 10.1111/j.1365-2559.2011.04019.x; Volk EE, 1998, MODERN PATHOL, V11, P789; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; Wong NACS, 2000, HISTOPATHOLOGY, V36, P476; Xin W, 2003, AM J SURG PATHOL, V27, P1134, DOI 10.1097/00000478-200308000-00011; Zwas FR, 1996, GASTROINTEST ENDOSC, V43, P463; 2007, J PEDIATR GASTR NUTR, V44, P653	18	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						164	169		10.1016/j.humpath.2018.01.012			6	Pathology	Pathology	GF4KZ	WOS:000431933100020	29360496				2019-10-28	
J	Lam, AKY; Fridman, M				Lam, Alfred King-yin; Fridman, Mikhail			Characteristics of cribriform morular variant of papillary thyroid carcinoma in post-Chernobyl affected region	HUMAN PATHOLOGY			English	Article						Thyroid; Papillary thyroid carcinoma; Cribriform morular; Variant; Radiation; Pathology; Chernobyl	FAMILIAL ADENOMATOUS POLYPOSIS; RADIATION; BYELARUS; CHILDREN; CANCER; ADOLESCENTS; EXPOSURE; COHORT	The aim is to study the characteristics of cribriform morular variant of papillary thyroid carcinoma (CMV-PTC) in patients living in the radiation-affected area of Belarus. The clinical and pathological features of 35 patients with CMV-PTC from Belarus were studied and compared with those of conventional papillary thyroid carcinoma diagnosed in the same period. The patients with CMV-PTC were all females and were younger at presentation (mean age = 24) than those with conventional papillary thyroid carcinoma. Familial adenomatous polyposis (FAP) was identified in 20% of the patients with CMV-PTC. The majority of the CMV-PTCs (29/35; 83%) were staged as pT1 and were less advanced than conventional papillary thyroid carcinoma. There was no evidence of lymph node metastases or distant metastases. CMV-PTCs were positive for beta-catenin, APC (adenomatous polyposis coli) and p53 proteins. No psammoma bodies were identified on microscopic examination. Over a median follow-up of 9 years, all the patients were alive, and there was no cancer recurrence or mortality related to the thyroid cancer. To conclude, CMV-PTC in patients in the radiation-affected region behaves in an indolent fashion. They had distinctive features that are different from patients with conventional papillary thyroid carcinoma living in the same region. (C) 2018 Elsevier Inc. All rights reserved.	[Lam, Alfred King-yin] Griffith Univ, Sch Med, Discipline Pathol, Gold Coast 4222, Australia; [Lam, Alfred King-yin] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast 4222, Australia; [Fridman, Mikhail] Republican Ctr Thyroid Tumors, Nezavisimosty Av 64, Minsk 220013, BELARUS	Lam, AKY (reprint author), Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld 4222, Australia.	a.lam@griffith.edu.au	Lam, Alfred/C-1652-2008	Lam, Alfred/0000-0003-2771-564X			Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; CHAN JKC, 1990, ARCH PATHOL LAB MED, V114, P622; DeLellis RA, 2004, PATHOLOGY GENETICS T, P57; Drozdovitch V, 2013, RADIAT RES, V179, P597, DOI 10.1667/RR3153.1; Fenton PA, 2001, THYROID, V11, P193, DOI 10.1089/105072501300042965; Fridman M, 2016, CLIN ENDOCRINOL, V85, P971, DOI 10.1111/cen.13137; Fridman M, 2015, EXP MOL PATHOL, V98, P527, DOI 10.1016/j.yexmp.2015.03.039; Garcia EBG, 2009, LANCET ONCOL, V10, P727, DOI 10.1016/S1470-2045(09)70167-6; Hirokawa M, 2010, DIAGN CYTOPATHOL, V38, P890, DOI 10.1002/dc.21309; Ito Y, 2011, ENDOCR J, V58, P685, DOI 10.1507/endocrj.EJ11-0022; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; Lam AKY, 2005, ENDOCR PATHOL, V16, P323, DOI 10.1385/EP:16:4:323; Lam AKY, 2006, ANN SURG ONCOL, V13, P176, DOI 10.1245/ASO.2006.03.062; Lam AKY, 2017, AJSP-REV REP, V22, P209, DOI 10.1097/PCR.0000000000000183; Lam AKY, 2017, ENDOCR-RELAT CANCER, V24, pR109, DOI 10.1530/ERC-17-0014; Lam AKY, 2014, WORLD J GASTROENTERO, V20, P6815, DOI 10.3748/wjg.v20.i22.6815; Lam AKY, 2011, AM J SURG, V202, P39, DOI 10.1016/j.amjsurg.2010.05.012; Leoz ML, 2015, APPL CLIN GENET, V8, P95, DOI 10.2147/TACG.S51484; Levy RA, 2014, FAM CANCER, V13, P547, DOI 10.1007/s10689-014-9732-5; Liu S, 2017, ONCOGENE, V36, P1374, DOI 10.1038/onc.2016.301; Lloyd RV, 2017, WHO CLASSIFICATION T; Michael Tuttle R, 2017, AJCC CANC STAGING MA, P873, DOI DOI 10.1007/978-3-319-40618-3_; Mitsutake N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16976; Pillai S, 2015, CRIT REV ONCOL HEMAT, V94, P64, DOI 10.1016/j.critrevonc.2014.12.001; Reguart Noemi, 2005, Future Oncol, V1, P787, DOI 10.2217/14796694.1.6.787; Skomorowski M, 2012, CLIN GASTROENTEROL H, V10, pXXIV, DOI 10.1016/j.cgh.2012.06.013; Soravia C, 1999, AM J PATHOL, V154, P127, DOI 10.1016/S0002-9440(10)65259-5; Zablotska LB, 2015, CANCER-AM CANCER SOC, V121, P457, DOI 10.1002/cncr.29073	28	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						170	177		10.1016/j.humpath.2018.01.006			8	Pathology	Pathology	GF4KZ	WOS:000431933100021	29320754				2019-10-28	
J	Tessitore, A; Bruera, G; Mastroiaco, V; Cannita, K; Cortellini, A; Cocciolone, V; Dal Mas, A; Calvisi, G; Zazzeroni, F; Ficorella, C; Ricevuto, E; Alesse, E				Tessitore, Alessandra; Bruera, Gemma; Mastroiaco, Valentina; Cannita, Katia; Cortellini, Alessio; Cocciolone, Valentina; Dal Mas, Antonella; Calvisi, Giuseppe; Zazzeroni, Francesca; Ficorella, Corrado; Ricevuto, Enrico; Alesse, Edoardo			KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease	HUMAN PATHOLOGY			English	Article						mCRC; KRAS mutation; PI3KCA mutation; FIr-B/FOx; Anti-VEGF; Anti-EGFR	ANTI-EGFR; BIOMARKER; THERAPY; BENEFIT; PTEN	We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease. KRAS, NRAS, BRAF, and PI3KCA were analyzed in primary tumor and liver metastasis. KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C). The c.1645G>C was never reported in colorectal cancer. Akt/p-Akt(Ser473), phosphatase and tensin homolog, mismatch repair, and epidermal growth factor receptor expression was evaluated. Normal mismatch repair and epidermal growth factor receptor expression was detected. Akt was shown by primary tumor and liver metastasis, whereas p-Akt(Ser473) was identified only in the latter, despite positive phosphatase and tensin homolog expression. Patient showed 7 months of progression-free survival and 15 months of overall survival, lower than median values reported in KRAS exon 2-mutant patients treated with the same therapy. Results lead to the hypothesis of a putative role of these mutations in worsening of the disease and are open to further confirmatory studies. (C) 2018 Elsevier Inc. All rights reserved.	[Tessitore, Alessandra; Bruera, Gemma; Mastroiaco, Valentina; Cortellini, Alessio; Cocciolone, Valentina; Zazzeroni, Francesca; Ficorella, Corrado; Ricevuto, Enrico; Alesse, Edoardo] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy; [Bruera, Gemma; Ricevuto, Enrico] Univ Aquila, S Salvatore Hosp, Oncol Network ASL1 Abruzzo, Oncol Terr Care, I-67100 Laquila, Italy; [Cannita, Katia; Cortellini, Alessio; Ficorella, Corrado] S Salvatore Hosp, Med Oncol Unit, I-67100 Laquila, Italy; [Dal Mas, Antonella; Calvisi, Giuseppe] S Salvatore Hosp, Pathol Unit, I-67100 Laquila, Italy	Tessitore, A (reprint author), Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.	alessandra.tessitore@univaq.it; gemma.gbb@gmail.com; valentina.mastroiaco@graduate.univaq.it; kcannita@gmail.com; alessiocortellini@gmail.com; antonella.dalmas@gmail.com; GCalvisi@asl1abruzzo.it; francesca.zazzeroni@univaq.it; corrado.ficorella@univaq.it; enrico.ricevuto@univaq.it; edoardo.alesse@univaq.it	Cortellini, Alessio/AAB-8609-2019; ravegnini, gloria/K-1330-2016	Cortellini, Alessio/0000-0002-1209-5735; ravegnini, gloria/0000-0002-7774-402X			Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19; Bruera G, 2015, CRIT REV ONCOL HEMAT, V93, P190, DOI 10.1016/j.critrevonc.2014.10.004; Bruera G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-135; Bruera G, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-567; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Feng QY, 2014, WORLD J GASTROENTERO, V20, P4263, DOI 10.3748/wjg.v20.i15.4263; Herzig DO, 2015, J SURG ONCOL, V111, P96, DOI 10.1002/jso.23806; Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769; Li X, 2012, PATHOL ONCOL RES, V18, P57, DOI 10.1007/s12253-011-9416-5; Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054; Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173; Sakr RA, 2010, APPL IMMUNOHISTO M M, V18, P371, DOI 10.1097/PAI.0b013e3181d50bd5; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568	17	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						178	182		10.1016/j.humpath.2018.01.021			5	Pathology	Pathology	GF4KZ	WOS:000431933100022	29409955				2019-10-28	
J	Nasir, A; Amateau, SK; Khan, S; Simpson, RW; Snover, DC; Amin, K				Nasir, Aqsa; Amateau, Stuart K.; Khan, Sabina; Simpson, Ross W.; Snover, Dale C.; Amin, Khalid			The many faces of intestinal tract gastric heterotopia; a series of four cases highlighting clinical and pathological heterogeneity	HUMAN PATHOLOGY			English	Article						Gastric heterotopia; Intestinal tract; Polyps; Endoscopic biopsies; Iron deficiency anemia	MUCOSA; DUODENUM; METAPLASIA	Gastric heterotopia of the intestinal tract can have a diverse clinicopathologic presentation, resulting in a diagnostic dilemma. We present a series of four cases, two male and two female patients with age range of 31-82 years, found in the duodenum, jejunum, and transverse colon. The most common and rather unusual clinical presentation was iron deficiency anemia, seen in three cases, while one patient presented with abdominal pain. Endoscopically, two cases were visualized as pedunculated polyps and two as sessile/plaque-like lesions. Polypectomy was performed in three patients, and one patient underwent biopsy followed by resection. Two cases showed oxyntic-type epithelium, and two cases exhibited pyloric-type gastric epithelium. Three patients were relieved of their presenting symptoms after therapeutic procedures with no evidence of recurrence noted on follow-up. Follow-up was not available on one patient. This case series highlights a diverse clinicopathologic spectrum of gastric heterotopia. Accurate diagnosis is essential for proper management. (C) 2018 Elsevier Inc. All rights reserved.	[Nasir, Aqsa; Snover, Dale C.; Amin, Khalid] Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE MMC609 D142 Mayo Bldg, Minneapolis, MN 55455 USA; [Amateau, Stuart K.] Univ Minnesota, Dept Med, Div Gastroenterol, Box 736 UMHC, Minneapolis, MN 55455 USA; [Khan, Sabina] Gastroenterol Specialty Clin, Ridgeview Med Ctr Profess Bldg, Waconia, MN 55387 USA; [Simpson, Ross W.] Lab Methodist Hosp, Pk Nicollet, Louis Pk, MN 55426 USA	Nasir, A (reprint author), Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE MMC609 D142 Mayo Bldg, Minneapolis, MN 55455 USA.	nasir013@umn.edu; amateau@umn.edu; sabina.khan@ridgeviewmedical.org; Ross.W.Simpson@HealthPartners.com; snoverd@umn.edu; kamin@umn.edu					Akanuma N, 2013, SURG TODAY, V43, P446, DOI 10.1007/s00595-012-0206-9; Assimakopoulos SF, 2013, J GASTROEN HEPATOL, V28, P1432, DOI 10.1111/jgh.12326; Fang Y, 2014, WORLD J GASTROENTERO, V20, P17588, DOI 10.3748/wjg.v20.i46.17588; Genta RM, 2010, HUM PATHOL, V41, P1593, DOI 10.1016/j.humpath.2010.04.010; HOEDEMAEKER PJ, 1970, DIGESTION, V3, P165, DOI 10.1159/000197027; Jiang Kun, 2015, Case Rep Gastroenterol, V9, P233, DOI 10.1159/000437047; Jimenez JC, 2005, J PEDIATR SURG, V40, P1654, DOI 10.1016/j.jpedsurg.2005.06.010; JOHANSEN A, 1973, ACTA PATH MICRO IM A, VA 81, P676; Martins F, 2013, OR SURG OR MED OR PA, V115, pE51, DOI 10.1016/j.oooo.2012.12.010; Matsubara A, 2015, BRIT J CANCER, V112, P1398, DOI 10.1038/bjc.2015.104; Moschler O, 2014, ENDOSCOPY, V46, pE24, DOI 10.1055/s-0033-1358807; Nakagawa M, 2014, VIRCHOWS ARCH, V465, P253, DOI 10.1007/s00428-014-1612-8; Omotosho PA, 2007, J LAPAROENDOSC ADV S, V17, P249, DOI 10.1089/lap.2006.0071; Ozgun G, 2017, TURK J PATHOL, V33, P58, DOI 10.5146/tjpath.2014.01227; Tanpowpong P, 2011, DIS ESOPHAGUS, V24, pE32, DOI 10.1111/j.1442-2050.2011.01192.x	15	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						183	187		10.1016/j.humpath.2018.01.003			5	Pathology	Pathology	GF4KZ	WOS:000431933100023	29320750				2019-10-28	
J	Creytens, D; Mentzel, T; Ferdinande, L; van Gorp, J; Van Dorpe, J; Flucke, U				Creytens, David; Mentzel, Thomas; Ferdinande, Liesbeth; van Gorp, Joost; Van Dorpe, Jo; Flucke, Uta			Atypical multivacuolated tipoblasts and atypical mitoses are not compatible with the diagnosis of spindle cell/pleomorphic lipoma	HUMAN PATHOLOGY			English	Letter							PLEOMORPHIC LIPOMAS; CELL; TUMOR		[Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Dept Pathol, B-9000 Ghent, Belgium; [Creytens, David] Univ Ghent, Ghent Univ Hosp, CRIG, Canc Res Inst Ghent, B-9000 Ghent, Belgium; [Mentzel, Thomas] Dermatopathol Bodensee, D-88048 Friedrichshafen, Germany; [Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Canc Res Inst Ghent, Ghent CRIG, Ghent Univ Hosp, B-9000 Ghent, Belgium; [van Gorp, Joost] Diakonessenhuis Utrecht, Dept Pathol, NL-3582 KE Utrecht, Netherlands; [Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Creytens, D (reprint author), Univ Ghent, Dept Pathol, B-9000 Ghent, Belgium.; Creytens, D (reprint author), Univ Ghent, Ghent Univ Hosp, CRIG, Canc Res Inst Ghent, B-9000 Ghent, Belgium.	creytensdavid@hotmail.com					Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Fletcher C, 2013, PATHOLOGY GENETICS T; Marino-Enriquez A, 2017, AM J SURG PATHOL, V41, P234, DOI 10.1097/PAS.0000000000000770; Michal M, 2017, HUM PATHOL, V70, P143, DOI 10.1016/j.humpath.2017.06.024; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006	5	6	6	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						188	189		10.1016/j.humpath.2017.11.023			2	Pathology	Pathology	GF4KZ	WOS:000431933100024	29317234				2019-10-28	
J	Michal, M; Kazakov, DV; Michalova, K; Michal, M				Michal, Michael; Kazakov, Dmitry V.; Michalova, Kvetoslava; Michal, Michal			Atypical multivacuolated lipoblasts and atypical mitoses are not compatible with the diagnosis of spindle cell/pleomorphic lipoma-reply	HUMAN PATHOLOGY			English	Letter							PLEOMORPHIC LIPOMAS; CELL		[Michal, Michael; Kazakov, Dmitry V.; Michalova, Kvetoslava; Michal, Michal] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen 30460, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 30460, Czech Republic	Michal, M (reprint author), Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Plzen 30460, Czech Republic.; Michal, M (reprint author), Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 30460, Czech Republic.	michael.michal@medima.cz	Michal, Michael/I-3497-2017	Michal, Michael/0000-0003-4403-7027; Michalova, Kvetoslava/0000-0003-3231-6870			Cheah A, 2015, HISTOPATHOLOGY, V66, P430, DOI 10.1111/his.12548; Creytens D, 2017, AM J SURG PATHOL, V41, P1443, DOI 10.1097/PAS.0000000000000936; Michal M, 2017, HUM PATHOL, V70, P143, DOI 10.1016/j.humpath.2017.06.024; Michal M, 2017, HUM PATHOL, V65, P140, DOI 10.1016/j.humpath.2017.05.006	4	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	APR	2018	74						189	189		10.1016/j.humpath.2017.11.024			1	Pathology	Pathology	GF4KZ	WOS:000431933100025	29320749				2019-10-28	
J	Badoual, C				Badoual, Cecile			Rich and sad topics	ANNALES DE PATHOLOGIE			French	Editorial Material									[Badoual, Cecile] Hop Europeen Georges Pompidou, Serv Anatomopathol, Fac Med Paris Descartes, 20-40 Rue Leblanc, F-75908 Paris 15, France	Badoual, C (reprint author), Hop Europeen Georges Pompidou, Serv Anatomopathol, Fac Med Paris Descartes, 20-40 Rue Leblanc, F-75908 Paris 15, France.	cecile.badoual@aphp.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					69	69		10.1016/j.annpat.2018.03.003			1	Pathology	Pathology	GK1OU	WOS:000435888900001	29703419				2019-10-28	
J	L'Hermine-Coulomb, A; Capron, F				L'Hermine-Coulomb, Aurore; Capron, Frederique			In Memoriam: Liliane Boccon-Gibod, 1941-2017, has works published, Pathologist	ANNALES DE PATHOLOGIE			French	Biographical-Item									[L'Hermine-Coulomb, Aurore] Sorbonne Univ, Hop Armand Trousseau, Serv Anat & Cytol Pathol, 26 Ave Dr Arnold Netter, F-75571 Paris 12, France; [Capron, Frederique] Sorbonne Univ, Hop Pitie Salpetriere, Serv Anat & Cytol Pathol, 47 Blvd Hop, F-75651 Paris 13, France	L'Hermine-Coulomb, A (reprint author), Sorbonne Univ, Hop Armand Trousseau, Serv Anat & Cytol Pathol, 26 Ave Dr Arnold Netter, F-75571 Paris 12, France.	aurore.coulomb@aphp.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					70	72		10.1016/j.annpat.2018.03.004			3	Pathology	Pathology	GK1OU	WOS:000435888900002					2019-10-28	
J	Capron, F				Capron, Frederique			Tribute Issam Abd Alsamad: Witness, has works published, Doctor	ANNALES DE PATHOLOGIE			French	Biographical-Item									[Capron, Frederique] Sorbonne Univ, Hop Pitie Salpetriere, Serv Anat & Cytol Pathol, 47 Blvd Hop, F-75651 Paris 13, France	Capron, F (reprint author), Sorbonne Univ, Hop Pitie Salpetriere, Serv Anat & Cytol Pathol, 47 Blvd Hop, F-75651 Paris 13, France.	frederique.capron@aphp.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					73	73		10.1016/j.annpat.2018.03.007			1	Pathology	Pathology	GK1OU	WOS:000435888900003					2019-10-28	
J	Galateau-Salle, F				Galateau-Salle, Francoise			Tribute Issam Abd Alsamad: Witness, has works published, Doctor	ANNALES DE PATHOLOGIE			French	Biographical-Item									[Galateau-Salle, Francoise] Ctr Lutte Canc Leon Berard, 28 Rue Laennec, F-69373 Lyon, France	Galateau-Salle, F (reprint author), Ctr Lutte Canc Leon Berard, 28 Rue Laennec, F-69373 Lyon, France.	francoise.galateau@lyon.unicancer.fr						0	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					74	75		10.1016/j.annpat.2018.03.008			2	Pathology	Pathology	GK1OU	WOS:000435888900004					2019-10-28	
J	Doghri, R; Yahyaoui, Y; Gabsi, A; Driss, M; Boujelbene, N; Charfi, L; Amel, M; Mrad, K				Doghri, Raoudha; Yahyaoui, Yosra; Gabsi, Azza; Driss, Maha; Boujelbene, Nadia; Charfi, Lamia; Amel, Mezlini; Mrad, Karima			Endometrial carcinoma: An histopathological and histoprognotic study about 62 patients in a center in the Tunisian north	ANNALES DE PATHOLOGIE			French	Article						Histopathology; Carcinoma; Endometrium; Prognosis	PROGNOSTIC-FACTORS; ADENOCARCINOMA; CANCER	Endometrial cancer is the most prevalent genital tract cancer in occident and the third most common cancer among women in Tunisia. It is dominated by carcinoma. The identification of prognostic factors allows a better understanding of its outcome and guides its therapeutic approach. We propose to describe the clinicopathological features and identify the histoprognostic factors of this cancer. It is a retrospective analysis of a series of 62 total hysterectomy specimens with bilateral salpingo-oophorectomy from women with primary carcinoma of the endometrium, colligated in Anatomy Laboratory and Pathology Salah Azaiz Institute of Tunis over a period of 5 years, from January 2003 to December 2007. The median age was 60 years. At the time of diagnosis, 25% of patients were nulliparous and 86% were menopaused. The endometrioid adenocarcinoma was the most common, accounting for 84% of cases (5% of them were grade 3). A myometrial invasion superior or equal to 50% was observed in 40% of cases. 42% of cases were classified as stage IA, 14% in stage IB, 16% in stage II, 18% stage III and 10% in stage IV. 22% of patients had nodal involvement. Overall survival at 5 years was 81%. In multivariate analysis, stage IV, nodal involvement and brachytherapy have influenced this rate. Event-free survival at 5 years was 71%. It was directly related to stage and nodal involvement. Stage, histological type, tumor grade, invasion of more than half of the myometrium and lymph node involvement were the most important adverse prognostic factors, dictating an appropriate management of these tumors. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Doghri, Raoudha; Driss, Maha; Boujelbene, Nadia; Charfi, Lamia; Mrad, Karima] Inst Salah Azaiz, Dept Pathol, Tunis 1006, Tunisia; [Yahyaoui, Yosra; Gabsi, Azza; Amel, Mezlini] Inst Salah Azaiz, Dept Med Oncol, Tunis 1006, Tunisia	Gabsi, A (reprint author), Route X3,Immeuble Oliviers Appart B34, Tunis 5022, Tunisia.	azza_g86@yahoo.fr					Ben Abdallah M., 2012, REGISTRE CANC NORD T; Bremond A, 2002, B CANCER, V89, P697; Collinet P, 2008, J GYNECOL OBST BIO R, pF57; Creutzberg CL, 2011, CURR ONCOL REP, V13, P472, DOI 10.1007/s11912-011-0191-y; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Hertel JD, 2014, INT J GYNECOL PATHOL, V33, P127, DOI 10.1097/PGP.0b013e318285657b; Huijgens ANJ, 2013, FACTS VIEWS VIS OBGY, V5, P179; Lee NK, 2007, OBSTET GYNECOL, V109, P655, DOI 10.1097/01.AOG.0000255980.88205.15; Longacre TA, 1999, AM J SURG PATHOL, V23, P69, DOI 10.1097/00000478-199901000-00007; MCCLUGGAGE WG, 2009, DIAGN HISTOPATHOL, V15, P571; McGunigal M, 2017, INT J GYNECOL CANCER, V27, P85, DOI 10.1097/IGC.0000000000000844; MITTAL KR, 1988, AM J SURG PATHOL, V12, P754, DOI 10.1097/00000478-198810000-00003; Salvesen HB, 2002, APMIS, V110, P673, DOI 10.1034/j.1600-0463.2002.1101001.x; Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051; Talhouk A, 2016, Gynecol Oncol Res Pract, V3, P14, DOI 10.1186/s40661-016-0035-4; Topuz S, 2016, EUR J GYNAECOL ONCOL, V37, P320, DOI 10.12892/ejgo2662.2016	16	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					85	91		10.1016/j.annpat.2017.12.001			7	Pathology	Pathology	GK1OU	WOS:000435888900006	29398146				2019-10-28	
J	Macagno, N; Caselles, K; Aubert, S; Audard, V; Gomez-Brouchet, A; Galant, C; Guinebretiere, JM; Karanian, M; Larousserie, F; Marie, B; de Pinieux, G; Bouvier, C				Macagno, Nicolas; Caselles, Kevin; Aubert, Sebastien; Audard, Virginie; Gomez-Brouchet, Anne; Galant, Christine; Guinebretiere, Jean -Marc; Karanian, Marie; Larousserie, Frederique; Marie, Beatrice; de Pinieux, Gonzague; Bouvier, Corinne			Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques	ANNALES DE PATHOLOGIE			French	Article						Chondroblastoma; Giant cell tumor of bone; Aneurysmal bone cyst; Brown tumor; Cortical defect; Giant cells	CHONDROBLASTOMA; USP6; MUTATION; H3F3A; TUMOR; CYST; ONCOGENES; ANTIBODY; VARIANT	The infiltration by numerous osteoclastic giant cells is a frequent finding in bone tumors and pseudo-tumors. Pathologists must integrate clinical and radiological data to achieve a correct diagnosis in bone pathology. Benign giant-cell rich lesions of bone encompass giant cell tumor of bone, aneurysmal bone cyst, chondroblastoma, brown tumor and fibrous cortical defect/non-ossifying fibroma. Amongst malignant neoplasms, variants of conventional osteosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma and bone metastasis must be discussed. Recently, new diagnostic markers, antibodies for immuno-histochemistry and genetic markers, have been developed and are helpful to diagnose such lesions. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Macagno, Nicolas; Caselles, Kevin; Bouvier, Corinne] CHU Timone, AP HP, Serv Anat Pathol & Neuropathol, Dept Pathol, BMT Timone 2,2 Etage,264 Rue St Pierre, F-13000 Marseille, France; [Aubert, Sebastien] CHR Lille, Ctr Biol Pathol, F-59007 Lille, France; [Audard, Virginie; Larousserie, Frederique] Hop Cochin, AP HP, Serv Anat Pathol, F-75014 Paris, France; [Gomez-Brouchet, Anne] IUCT Oncopole, Serv Anat & Cytol Pathol, F-31059 Toulouse, France; [Galant, Christine] Hop Univ Leuven, Serv Pathol, B-3000 Brussels, Belgium; [Guinebretiere, Jean -Marc] Inst Curie, Serv Biopathol, F-75005 Paris, France; [Karanian, Marie] Ctr Leon Berard, Serv Pathol, F-69008 Lyon, France; [Marie, Beatrice] CHU Nancy, Serv Pathol, F-54035 Nancy, France; [de Pinieux, Gonzague] CHU Tours, Serv Pathol, F-37004 Tours, France	Macagno, N (reprint author), CHU Timone, AP HP, Serv Anat Pathol & Neuropathol, Dept Pathol, BMT Timone 2,2 Etage,264 Rue St Pierre, F-13000 Marseille, France.	nicolas.macagno@gmail.com		Macagno, Nicolas/0000-0002-9882-2162			Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Bousdras K, 2007, HISTOPATHOLOGY, V51, P414, DOI 10.1111/j.1365-2559.2007.02777.x; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; De Paula AM, 2014, VIRCHOWS ARCH, V465, P487, DOI 10.1007/s00428-014-1637-z; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Konishi E, 2010, HUM PATHOL, V41, P208, DOI 10.1016/j.humpath.2009.07.014; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Nohr E, 2017, HUM PATHOL, V68, P119, DOI 10.1016/j.humpath.2017.08.030; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#	15	1	1	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					92	102		10.1016/j.annpat.2018.01.008			11	Pathology	Pathology	GK1OU	WOS:000435888900007	29580573				2019-10-28	
J	Delteil, C; Meyronet, D; de Paula, AM; Jouvet, A; Piercecchi-Marti, MD				Delteil, Clemence; Meyronet, David; de Paula, Andre Maues; Jouvet, Anne; Piercecchi-Marti, Marie-Dominique			Neuropathology of sudden infant death syndrome: Review of the literature and proposal of a protocol for neuropathological examination	ANNALES DE PATHOLOGIE			French	Review						Neuropathology; Sudden infant death; Protocolisation; Amyloid beta precursor antibodies	PROTEIN BETA-APP; UNEXPECTED DEATH; SYNDROME SIDS; BRAIN-STEM	According to the French High Authority for Health, sudden unexpected death in infants (SUDI) is defined as "a sudden death that occurs in an infant, whereas nothing in its known history could have predicted it". This is an exclusion diagnosis. There are great interregional disparities despite the professional recommendations established in February 2007. For the examination of the brain, instructions are not adapted to current and research practice. The role of the pathologist, like anyone involved in SUDI, is to eliminate an abuse head trauma and to determine the cause of death. Major neuropathological lesions by definition do not exist. Lesions of hypoxia/ischemia are the most frequent but not specific. The accessibility of anti APP immunoblotting has highlighted the role of anoxia in the development of axonal diffuse damages. Many studies are looking for a neurological substratum of the SUDI (neuropathological and/or neurobiochinic). This article aims to define a detailed sampling protocol based on foreign consensus and current data of science in order to assist pathologists and to promote a homogeneous data bank in France. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Delteil, Clemence; Piercecchi-Marti, Marie-Dominique] Hop Timone Adultes, Inst Medicolegal Marseille, 264 Rue St Pierre, F-13385 Marseille 5, France; [Delteil, Clemence; Piercecchi-Marti, Marie-Dominique] Aix Marseille Univ, ADES UMR 7268, EFS, CNRS, F-13916 Marseille, France; [Meyronet, David; Jouvet, Anne] Hop Mere Enfant, Serv Biopathol, 32 Ave Doyen Jean Lepine, F-69500 Bron, France; [de Paula, Andre Maues] Hop La Timone, Lab Anat Pathol Neuropathol, 264 Rue St Pierre, F-13385 Marseille 5, France	Delteil, C (reprint author), Hop Timone Adultes, Inst Medicolegal Marseille, 264 Rue St Pierre, F-13385 Marseille 5, France.; Delteil, C (reprint author), Aix Marseille Univ, ADES UMR 7268, EFS, CNRS, F-13916 Marseille, France.	clemence.delteil@ap-hm.fr		Delteil, Clemence/0000-0001-5171-8520			Bajanowski T, 2007, FORENSIC SCI INT, V165, P129, DOI 10.1016/j.forsciint.2006.05.028; Broadbelt KG, 2011, J NEUROPATH EXP NEUR, V70, P799, DOI 10.1097/NEN.0b013e31822c09bc; Byard RW, 2006, AM J FOREN MED PATH, V27, P340, DOI 10.1097/01.paf.0000248774.62686.8c; CruzSanchez FF, 1997, J NEUROPATH EXP NEUR, V56, P340, DOI 10.1097/00005072-199704000-00002; Duckett S, 1995, PEDIAT NEUROPATHOLOG; Duncan JR, 2010, JAMA-J AM MED ASSOC, V303, P430, DOI 10.1001/jama.2010.45; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; HAS, 2007, PRIS CHARG CAS MORT, P46; Jensen LL, 2014, NEUROPATH APPL NEURO, V40, P385, DOI 10.1111/nan.12109; Kinney H, 2009, ACTA NEUROPATHOL, V117, P247, DOI 10.1007/s00401-009-0490-7; Lavezzi AM, 2005, DEV BRAIN RES, V154, P71, DOI 10.1016/j.devbrainres.2004.10.007; Leestma JE, 2014, FORENSIC NEUROPATHOL; Levieux K, 2015, ARCH PEDIATRIE, V22, P360, DOI 10.1016/j.arcped.2015.01.003; Machaalani R, 2003, J NEUROPATH EXP NEUR, V62, P1076, DOI 10.1093/jnen/62.10.1076; Mitchell EA, 2015, J PAEDIATR CHILD H, V51, P108, DOI 10.1111/jpc.12818; Paine SML, 2014, NEUROPATH APPL NEURO, V40, P364, DOI 10.1111/nan.12095; Rognum TO, 2003, NORD RETTSMEDISIN; Viemari JC, 2013, M S-MED SCI, V29, P875, DOI 10.1051/medsci/20132910015; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002	20	1	1	1	4	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					103	109		10.1016/j.annpat.2018.01.001			7	Pathology	Pathology	GK1OU	WOS:000435888900008	29429858				2019-10-28	
J	Lantuejoul, S; Adam, J; Girard, N; Duruisseaux, M; Mansuet-Lupo, A; Cazes, A; Rouquette, I; Gibault, L; Garcia, S; Antoine, M; Vignaud, JM; Galateau-Salle, F; Sagan, C; Badoual, C; Penault-Llorca, F; Damotte, D				Lantuejoul, Sylvie; Adam, Julien; Girard, Nicolas; Duruisseaux, Mickael; Mansuet-Lupo, Audrey; Cazes, Aurelie; Rouquette, Isabelle; Gibault, Laure; Garcia, Stephane; Antoine, Martine; Vignaud, Jean Michael; Galateau-Salle, Francoise; Sagan, Christine; Badoual, Cecile; Penault-Llorca, Frederique; Damotte, Diane		Grp Pathologistes Thoraciques Val	PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists	ANNALES DE PATHOLOGIE			French	Review						PD-L1; Immunohistochemistry; Lung cancer; Guidelines	DEATH-LIGAND 1; SQUAMOUS-CELL; SMALL BIOPSY; CLINICAL IMMUNOHISTOCHEMISTRY; QUALITY-ASSURANCE; 2014 UPDATE; EXPRESSION; CHEMOTHERAPY; DOCETAXEL; NIVOLUMAB	Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO (R), Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA (R), Merck Et Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ (R), Genentech), durvalumab (IMFINZI (R), Astra-Zeneca), and avelumab (BAVENCIO (R), EMD Serono). The prescription of pembrolizumab for advanced stage non-small cell lung carcinoma (NSCLC) patients requires the demonstration of PD-L1 expression by tumor cells by immunohistochemistry (IHC) (minimum of 50% of positive tumor cells is required for first-line setting, and of 1% for second-line and beyond) and PD-L1 assay is now considered as a companion diagnostic tool for this drug. Numerous standardized PD-L1 assays performed on dedicated platforms have been validated in clinical trials, each antibody being associated to one specific PD1 or PD-L1 inhibitor. However, not all pathologists have access to the dedicated platforms and the high cost of these assays is still a limitation to their implementation; in addition, the small size of the NSCLC tumor samples does not allow to perform at the same time multiple assays for multiple drugs. The use of laboratory-developed tests seems feasible but their validation must guarantee the same sensitivities and specificities as standardized tests. In this context, the French group of thoracic pathologists PATTERN has teamed up with thoracic oncologists to provide recommendations on the indication, the critical technical steps and the interpretation of the PD-L1 IHC test to help pathologists to implement quickly and in the best conditions this new theranostic test. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Lantuejoul, Sylvie] Ctr Leon Berard UNICANCER, Dept Biopathol, 28 Rue Laennec, F-69008 Lyon, France; [Lantuejoul, Sylvie] Ctr Leon Berard UNICANCER, Dept Rech Translationnelle & Innovat, 28 Rue Laennec, F-69008 Lyon, France; [Lantuejoul, Sylvie] Grenoble Alpes Univ, Inst Adv Biosci, CNRS 5309, Inserm U1209, F-38700 La Tronche, France; [Adam, Julien] Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France; [Adam, Julien] Gustave Roussy, Inserm U981, F-94805 Villejuif, France; [Girard, Nicolas] Inst Curie, Inst Thorax Curie Montsouris, F-75005 Paris, France; [Girard, Nicolas] Univ Claude Bernard Lyon 1, Univ Lyon, F-69622 Villeurbanne, France; [Duruisseaux, Mickael] Hop Louis Pradel, Serv Pneumol, IC HCL, Ctr Rech Cancerol Lyon,Inserm 1052,CNRS 5286, F-69008 Lyon, France; [Mansuet-Lupo, Audrey; Damotte, Diane] Univ Paris 05, Hop Cochin, AP HP, Dept Pathol, F-74014 Paris, France; [Cazes, Aurelie] Univ Paris Diderot, Hop Bichat, Dept Pathol, Inserm UMR1152, F-75018 Paris, France; [Rouquette, Isabelle] CHU Toulouse, IUCT Oncopole, Dept Pathol, F-31059 Toulouse, France; [Gibault, Laure; Badoual, Cecile] Hop Europeen Georges Pompidou, AP HP, Dept Pathol, F-75015 Paris, France; [Gibault, Laure; Badoual, Cecile] Georges Pompidou European Hosp, Paris Ctr Rech Cardiovasc, Inserm UMR S970, F-75015 Paris, France; [Garcia, Stephane] Aix Marseille Univ, CRCM, Hop Nord, AP HM,Dept Pathol, F-13015 Marseille, France; [Antoine, Martine] Hop Tenon, AP HP, Serv Anat Pathol, F-75020 Paris, France; [Antoine, Martine] UPMC Univ Paris 06, GRC 04, F-75252 Paris, France; [Vignaud, Jean Michael] CHRU Nancy, Dept Pathol, F-54035 Nancy, France; [Vignaud, Jean Michael] Univ Lorraine, Inserm 1256, F-54505 Vandoeuvre Les Nancy, France; [Galateau-Salle, Francoise] Ctr Natl Referent MESOPATH, Base Clinicobiol Natl MESOBANK, Registre Multictr MESONAT, Ctr Leon Berard,Dept Biopathol, F-69008 Lyon, France; [Sagan, Christine] CHU Nantes, Hop Hotel Dieu, Serv Anat & Cytol Pathol, Inst Thorax,Inserm U1087, F-44093 Nantes, France; [Penault-Llorca, Frederique] Univ Clermont Auvergne, Dept Pathol, Ctr Jean Perrin, UMR Inserm IMoST 1240, F-63011 Clermont Ferrand, France	Lantuejoul, S (reprint author), Ctr Leon Berard UNICANCER, Dept Biopathol, 28 Rue Laennec, F-69008 Lyon, France.; Lantuejoul, S (reprint author), Ctr Leon Berard UNICANCER, Dept Rech Translationnelle & Innovat, 28 Rue Laennec, F-69008 Lyon, France.; Lantuejoul, S (reprint author), Grenoble Alpes Univ, Inst Adv Biosci, CNRS 5309, Inserm U1209, F-38700 La Tronche, France.	sylvie.lantuejoul@lyon.unicancer.fr	Duruisseaux, Michael/D-8371-2017	Duruisseaux, Michael/0000-0003-1495-0966			Adam J, 2018, ANN ONCOL, DOI [10.1093/annonchndy014, DOI 10.1093/ANNONCHNDY014]; Aisner DL, 2016, ARCH PATHOL LAB MED, V140, P1206, DOI 10.5858/arpa.2016-0156-RA; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Bass BP, 2014, ARCH PATHOL LAB MED, V138, P1520, DOI 10.5858/arpa.2013-0691-RA; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Bussolati Gianni, 2015, Recent Results Cancer Res, V199, P1, DOI 10.1007/978-3-319-13957-9_1; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cheung CC, 2017, APPL IMMUNOHISTO M M, V25, P227, DOI 10.1097/PAI.0000000000000469; Cho JH, 2017, CLIN LUNG CANCER, V18, pE473, DOI 10.1016/j.cllc.2017.04.008; Cooper WA, 2017, CLIN CANCER RES, V23, P4569, DOI 10.1158/1078-0432.CCR-17-0151; Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Duruisseaux M, 2017, ANN PATHOL, V37, P61, DOI 10.1016/j.annpat.2016.12.009; Engel KB, 2011, ARCH PATHOL LAB MED, V135, P537, DOI 10.1043/2010-0702-RAIR.1; Funaki S, 2017, ONCOL REP, V38, P2277, DOI 10.3892/or.2017.5894; Gadjeel S, 2017, CLIN EFFICACY ATEZOL; Granier C, 2017, ANN PATHOL, V37, P18, DOI 10.1016/j.annpat.2016.12.007; Han JJ, 2016, CLIN LUNG CANCER, V17, P263, DOI 10.1016/j.cllc.2015.11.006; Haratake N, 2017, ANTICANCER RES, V37, P5713, DOI 10.21873/anticanres.12009; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Heymann JJ, 2017, CANCER CYTOPATHOL, V125, P896, DOI 10.1002/cncy.21937; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Jiang XM, 2017, ACTA PHARMACOL SIN, V38, P1512, DOI 10.1038/aps.2017.123; Khoury T, 2012, APPL IMMUNOHISTO M M, V20, P531, DOI 10.1097/PAI.0b013e318248bf6d; Kim S, 2017, EUR J CANCER, V75, P141, DOI 10.1016/j.ejca.2017.01.004; Kitazono S, 2015, CLIN LUNG CANCER, V16, P385, DOI 10.1016/j.cllc.2015.03.008; Lin KL, 2015, BIOCHEM BIOPH RES CO, V463, P95, DOI 10.1016/j.bbrc.2015.05.030; MacGrogan G, 2014, ANN PATHOL, V34, P366, DOI 10.1016/j.annpat.2014.08.017; Mansfield AS, 2016, ANN ONCOL, V27, P1953, DOI 10.1093/annonc/mdw289; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Penault-Llorca F, 2014, ANN PATHOL, V34, P352, DOI 10.1016/j.annpat.2014.08.018; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Roussel H, 2017, ANN PATHOL, V37, P7, DOI 10.1016/j.annpat.2016.12.014; Sakakibara R, 2017, CLIN LUNG CANCER, V18, P527, DOI 10.1016/j.cllc.2016.12.002; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Sheng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20090; Song ZB, 2016, LUNG CANCER, V99, P166, DOI 10.1016/j.lungcan.2016.07.013; Stoy SP, 2018, CANCER CYTOPATHOL, V126, P122, DOI 10.1002/cncy.21941; Torlakovic EE, 2017, APPL IMMUNOHISTO M M, V25, P151, DOI 10.1097/PAI.0000000000000470; Torlakovic EE, 2017, APPL IMMUNOHISTO M M, V25, P79, DOI 10.1097/PAI.0000000000000444; Wu SP, 2018, J THORAC ONCOL, V13, P521, DOI 10.1016/j.jtho.2017.11.132; Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018; Zhang PP, 2016, CANCER SCI, V107, P1563, DOI 10.1111/cas.13072	49	5	5	0	8	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					110	125		10.1016/j.annpat.2018.01.007			16	Pathology	Pathology	GK1OU	WOS:000435888900009	29571563				2019-10-28	
J	Delteil, C; Malissen, N; Appay, R; Magis, Q; Aubert, S; Bouvier, C; Richard, MA; Macagno, N				Delteil, Clemence; Malissen, Nausicaa; Appay, Romain; Magis, Quentin; Aubert, Sebastien; Bouvier, Corinne; Richard, Marie-Aleth; Macagno, Nicolas			Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma	ANNALES DE PATHOLOGIE			French	Article						Chordoma; Chordoma cutis; Differential diagnosis; Brachyury; Soft tissus	CUTANEOUS METASTASIS; SACRAL CHORDOMA; CELL-TUMORS; EXPRESSION	Chordoma cutis represents an unusual clinical presentation of a rare neoplasm. The involvement of skin or sub-cutaneous soft tissues can be the consequence of local infiltration or metastasis; the latter may occur several years following the initial diagnosis of chordoma and therefore, may pose a diagnosis challenge when the clinical history of the patient is unknown. The clinical forms, morphology, immuno-histochemical profile and the main differential diagnoses of chordoma cutis are presented here through an anatomoclinical case. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Delteil, Clemence; Appay, Romain; Bouvier, Corinne; Macagno, Nicolas] CHU Timone, Serv Anat Pathol & Neuropathol, 264 Rue St Pierre, F-13005 Marseille 5, France; [Malissen, Nausicaa; Magis, Quentin; Richard, Marie-Aleth] CHU Timone, AP HM, Serv Cancerol Cutanee, F-13005 Marseille, France; [Aubert, Sebastien] CHR Lille, Ctr Biol Pathol, F-59000 Lille, France	Delteil, C (reprint author), CHU Timone, Serv Anat Pathol & Neuropathol, 264 Rue St Pierre, F-13005 Marseille 5, France.	clemence.delteil@ap-hm.fr		Sempe, Christine/0000-0001-6903-1575; Macagno, Nicolas/0000-0002-9882-2162			Boriani S, 1996, SPINE, V21, P1569, DOI 10.1097/00007632-199607010-00017; Collins GR, 2012, J CUTAN PATHOL, V39, P637, DOI 10.1111/j.1600-0560.2012.01895.x; Deshpande V, 2007, AM J SURG PATHOL, V31, P1573, DOI 10.1097/PAS.0b013e31805c9967; Fletcher CDM, 2013, IARC, P17; Gleghorn K, 2017, AM J DERMATOPATH, V39, pE54, DOI 10.1097/DAD.0000000000000757; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; Persichetti G, 2007, DERMATOL SURG, V33, P1520, DOI 10.1111/j.1524-4725.2007.33329.x; Rubin AI, 2005, J AM ACAD DERMATOL, V52, pS105, DOI 10.1016/j.jaad.2004.07.055; Ruiz HA, 2000, DERMATOL SURG, V26, P259, DOI 10.1046/j.1524-4725.2000.09216.x; SU WPD, 1993, J AM ACAD DERMATOL, V29, P63	10	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					126	130		10.1016/j.annpat.2018.01.004			5	Pathology	Pathology	GK1OU	WOS:000435888900010	29449046				2019-10-28	
J	Brandone, N; Borrione, C; Rome, A; de Paula, AM				Brandone, Nicolas; Borrione, Claude; Rome, Angelique; de Paula, Andre Maues			Ovarian Sertoli-Leydig tumor: A tricky tumor	ANNALES DE PATHOLOGIE			French	Article						Sertoli-leydig tumor; Heterologous elements; Ovary; Pediatrics	CELL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; HETEROLOGOUS ELEMENT; MRI FINDINGS; CT	We report the case of a 15 years old teenage girl presenting with a primary amenorrhea and hypervirilisation symptoms. The clinical assessement found a 16 cm wide heterogenous ovarian mass testosteronemia and alpha-foeto protein levels were increased. On gross exam the tumor was solid and cystic, multilocular containing serous and mucinous liquids. Microscopically, there was a sertoli cells rich solid area in which the cells had a trabecular and nested organization with Leydig cells between them and there was also a cystic area made of glandular structures lined with an intestinal muco-secreting epithelium. Next to these area, there were Sertoli cells and an oedematous stroma. The immunostaining showed that the Sertoli cells expressed, among others, the inhibine and the glands expressed the cytokeratins 7 and 20. A Sertoli and Leydig cells tumor of intermediate differentiation with heterologous elements diagnostic was made. This is a rare tumor, representing less than 0.5% of ovary tumors. Well differentiated tumors are not frequent. In one third of the cases, there are hypervirilisation symptoms, the imaging exams will serve to narrow the diagnosis and to do a full work-up to establish an extension. There are several histologic sub types caracterised by the existence of retiforms structures or heterologous elements. There are no specific immunostainings, this will only help to narrow the diagnosis and rule out some hypothesis. There are no guidelines for the management of the patients, indeed each center has its own practices. Those tumors have quite a good prognosis thanks to their early diagnosis at a stade where they are still confined to the ovary. (C) 2018 Published by Elsevier Masson SAS.	[Brandone, Nicolas; de Paula, Andre Maues] CHU Timone, Serv Anat & Cytol Pathol, 264 Rue St Pierre, F-13005 Marseille, France; [Borrione, Claude] CHU Timone, Serv Chirurg Pediat, 264 Rue St Pierre, F-13005 Marseille, France; [Rome, Angelique] CHU Timone, Serv Oncol Pediat, 264 Rue St Pierre, F-13005 Marseille, France	Brandone, N (reprint author), AP HM, Pathol, 254 Rue St Pierre, F-13005 Marseille, France.	nicolas.brandone@gmail.com					Abu-Zaid Ahmed, 2013, Case Rep Obstet Gynecol, V2013, P858501, DOI 10.1155/2013/858501; Bhat RA, 2013, J OBSTET GYNAECOL RE, V39, P305, DOI 10.1111/j.1447-0756.2012.01928.x; Cai SQ, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-73; Chen LW, 2014, INT J CLIN EXP PATHO, V7, P1176; Colombo N, 2012, ANN ONCOL, V23, P20, DOI 10.1093/annonc/mds223; Jung SE, 2005, AM J ROENTGENOL, V185, P207, DOI 10.2214/ajr.185.1.01850207; Jung SE, 2002, RADIOGRAPHICS, V22, P1305, DOI 10.1148/rg.226025033; Kommoss F, 1998, MODERN PATHOL, V11, P656; MELDRUM DR, 1979, OBSTET GYNECOL, V53, P36; Mooney EE, 2002, HISTOPATHOLOGY, V41, P110, DOI 10.1046/j.1365-2559.2002.01426.x; Movahedi-Lankarani S, 2002, AM J SURG PATHOL, V26, P1477, DOI 10.1097/00000478-200211000-00010; NOURIANI M, 2002, CME, V7, P114; PRUNTY FTG, 1967, J ENDOCRINOL, V38, P203, DOI 10.1677/joe.0.0380203; ROTH LM, 1981, CANCER, V48, P187, DOI 10.1002/1097-0142(19810701)48:1<187::AID-CNCR2820480130>3.0.CO;2-1; Sharma S, 2015, J CLIN DIAGN RES, V9, DOI 10.7860/JCDR/2015/12311.6145; Sigismondi C, 2012, GYNECOL ONCOL, V125, P673, DOI 10.1016/j.ygyno.2012.03.024; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Virk R, 2010, PATHOL RES PRACT, V206, P489, DOI 10.1016/j.prp.2009.07.012; YOUNG RH, 1982, CANCER, V50, P2448, DOI 10.1002/1097-0142(19821201)50:11<2448::AID-CNCR2820501133>3.0.CO;2-T; YOUNG RH, 1985, AM J SURG PATHOL, V9, P543, DOI 10.1097/00000478-198508000-00001	20	1	1	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					131	136		10.1016/j.annpat.2018.01.002			6	Pathology	Pathology	GK1OU	WOS:000435888900011	29398147				2019-10-28	
J	Hamon, M; Balladur, P; Flejou, JF				Hamon, Maxime; Balladur, Pierre; Flejou, Jean-Francois			Simple mucinous cyst of the pancreas: Case-report and literature review	ANNALES DE PATHOLOGIE			French	Review						Simple mucinous cyst; Pancreatic cyst; Mucinous cystic neoplasm	FINE-NEEDLE-ASPIRATION; NONNEOPLASTIC CYST; LESIONS; NEOPLASMS	Simple mucinous cyst of the pancreas is an unusual pancreatic cyst, first described by Kosmahl et al. in 2002 with 5 cases. We describe a case of simple mucinous cyst of the pancreas, followed by a literature review. The physiopathology of this cyst is still unclear. It is an epithelial cyst, presenting as unilocular cystic lesion of the pancreatic body or tail, with a clear content, and no communication with the pancreatic duct. Microscopically, the cyst is lined by mucin-producing cells with mild atypia, and contains a fibrous wall without ovarian like stroma. The prognosis is excellent, as no recurrent disease and progression to malignancy have been described. The non neoplastic origin of this lesion is debated, as cases with KRAS mutation and intra-epithelial neoplastic lesions have been recently reported. It is important to distinguish this lesion from macrocystic serous cystadenoma, mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, by clinical, radiological and pathological features, as the treatment varies from simple surveillance to surgical resection. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Hamon, Maxime; Flejou, Jean-Francois] Hop St Antoine, Serv Anat & Cytol Pathol, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France; [Balladur, Pierre] Hop St Antoine, Serv Chirurg Gen & Digest, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France	Hamon, M (reprint author), Hop St Antoine, Serv Anat & Cytol Pathol, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	maxime.hamon@aphp.fr; pierre.balladur@aphp.fr; jean-francois.flejou@aphp.fr					Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Cao WQ, 2010, HUM PATHOL, V41, P513, DOI 10.1016/j.humpath.2009.05.017; Goh BKP, 2005, WORLD J GASTROENTERO, V11, P2045; Kalb B, 2009, RADIOGRAPHICS, V29, P1749, DOI 10.1148/rg.296095506; Kim YS, 2015, CLIN ENDOSC, V48, P31, DOI 10.5946/ce.2015.48.1.31; Kosmahl M, 2002, MODERN PATHOL, V15, P154, DOI 10.1038/modpathol.3880507; Kosmahl M, 2004, VIRCHOWS ARCH, V445, P168, DOI 10.1007/s00428-004-1043-z; Krasinskas AM, 2017, AM J SURG PATHOL, V41, P121, DOI 10.1097/PAS.0000000000000750; Nadig SN, 2012, PANCREAS, V41, P441, DOI 10.1097/MPA.0b013e318229b9b8; Zhan XB, 2013, J DIGEST DIS, V14, P191, DOI 10.1111/1751-2980.12027; Zhu B, 2016, HUM PATHOL, V55, P159, DOI 10.1016/j.humpath.2016.05.009; Zhu B, 2013, PANCREAS, V42, P27, DOI 10.1097/MPA.0b013e318258ce2f	12	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					137	142		10.1016/j.annpat.2017.12.004			6	Pathology	Pathology	GK1OU	WOS:000435888900012	29415811				2019-10-28	
J	Kesrouani, C; Zemoura, L; Lae, M				Kesrouani, Carole; Zemoura, Leila; Lae, Marick			A peculiar intra-uterine lesion: Inflammatory myofibroblastic tumor (IMT)	ANNALES DE PATHOLOGIE			French	Article						Inflammatory myofibroblastic tumor (IMT); ALK	FUSIONS; UTERUS; ALK	A 25-year-old woman presented with a spontaneous vaginal expulsion of a 4 cm well-circumscribed nodule a few weeks after delivery. An inflammatory myofibroblastic tumor diagnosis was made by morphologic, immunohistochemistry and FISH analysis of the nodule. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Kesrouani, Carole] Hotel Dieu France, Serv Pathol, Blvd Alfred Naccache, Beirut, Lebanon; [Zemoura, Leila] Hop Foch, Serv Pathol, 40 Rue Worth, F-92150 Suresnes, France; [Kesrouani, Carole; Lae, Marick] Inst Curie Paris, Serv Pathol, 26 Rue Ulm, F-75248 Paris, France	Kesrouani, C (reprint author), Hotel Dieu France, Serv Pathol, Blvd Alfred Naccache, Beirut, Lebanon.; Kesrouani, C (reprint author), Inst Curie Paris, Serv Pathol, 26 Rue Ulm, F-75248 Paris, France.	carole.kesrouani@gmail.com					Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056; Coffin CM, 2013, WHO CLASSIFICATION T, P83; Haimes JD, 2017, AM J SURG PATHOL, V41, P773, DOI 10.1097/PAS.0000000000000801; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; Parra-Herran C, 2015, AM J SURG PATHOL, V39, P157, DOI 10.1097/PAS.0000000000000330; Schaefer IM, 2017, HISTOPATHOLOGY, V70, P1138, DOI 10.1111/his.13176; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2	10	0	0	1	2	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					143	146		10.1016/j.annpat.2017.12.003			4	Pathology	Pathology	GK1OU	WOS:000435888900013	29397221				2019-10-28	
J	Tauziede-Espariat, A; Sun, SR; Raffoul, J; Monnin, C; Lassabe, C				Tauziede-Espariat, Arnault; Sun, Shan Rong; Raffoul, Johnny; Monnin, Christine; Lassabe, Catherine			A "four-leaf clover" case of colonic adenocarcinoma	ANNALES DE PATHOLOGIE			French	Editorial Material							PANETH; CELLS		[Tauziede-Espariat, Arnault; Sun, Shan Rong; Raffoul, Johnny; Monnin, Christine; Lassabe, Catherine] Ctr Hosp Montbeliard Belfort, Lab Anat & Cytol Pathol, 12 Rue Docteur Flamand, F-25200 Montbeliard, France; [Tauziede-Espariat, Arnault] Ctr Hosp St Anne, Lab Neuropathol, 1 Rue Cabanis, F-75014 Paris, France	Tauziede-Espariat, A (reprint author), Ctr Hosp Montbeliard Belfort, Lab Anat & Cytol Pathol, 12 Rue Docteur Flamand, F-25200 Montbeliard, France.; Tauziede-Espariat, A (reprint author), Ctr Hosp St Anne, Lab Neuropathol, 1 Rue Cabanis, F-75014 Paris, France.	arnault.tauziedeespariat@gmail.com					Bosman FT, 2010, WHO CLASSIFICATION T, P138; GIBBS NM, 1967, J CLIN PATHOL, V20, P826, DOI 10.1136/jcp.20.6.826; Joo M, 2009, HUM PATHOL, V40, P872, DOI 10.1016/j.humpath.2008.12.003; Mora Jorge I., 2004, Archives of Pathology & Laboratory Medicine, V128, P908; OHTANI H, 1988, ACTA PATHOL JAPON, V38, P861; SHOUSHA S, 1979, HISTOPATHOLOGY, V3, P489, DOI 10.1111/j.1365-2559.1979.tb03030.x	6	0	0	0	0	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0242-6498			ANN PATHOL	Ann. Pathol.	APR	2018	38	2					147	149		10.1016/j.annpat.2018.01.003			3	Pathology	Pathology	GK1OU	WOS:000435888900014	29398148				2019-10-28	
J	Hsueh, CS; Li, WT; Jeng, CR; Pang, VF; Chang, HW				Hsueh, C-S; Li, W-T; Jeng, C-R; Pang, V. F.; Chang, H-W			Diffuse-type Gastric Mucinous and Signet Ring Cell Adenocarcinoma in a Captive California King Snake (Lampropeltis getula californiae)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						signet ring cell adenocarcinoma; snake; stomach	CLASSIFICATION; CARCINOMA; NEOPLASIA	An adult female California king snake (Lampropeltis getula califoniae) housed in Taipei Zoo was presented with a 2-week history of anorexia, fatigue and abdominal swelling. Exploratory laparotomy revealed a gastric mass with two circular perforations and multiple mottled white to beige protuberances along the mucosal surface. Histologically, the gastric mass showed an invasive, transmural growth of epithelial cells arranged in nests, lobules, acini and sheets in the mucosa and submucosa that progressively transformed into signet ring cells in the muscularis externa and subserosa. All of the neoplastic cells expressed pan-cytokeratin immunohistochemically. Based on the World Health Organization histological criteria, a diagnosis of diffuse-type gastric mucinous and signet ring cell adenocarcinoma was made. (C) 2018 Elsevier Ltd. All rights reserved.	[Hsueh, C-S; Li, W-T; Jeng, C-R; Pang, V. F.; Chang, H-W] Natl Taiwan Univ, Sch Vet Med, Grad Inst Mol & Comparat Pathobiol, Taipei, Taiwan; [Jeng, C-R; Pang, V. F.; Chang, H-W] Natl Taiwan Univ, Sch Vet Med, Taipei, Taiwan	Chang, HW (reprint author), Natl Taiwan Univ, Sch Vet Med, Grad Inst Mol & Comparat Pathobiol, Taipei, Taiwan.; Chang, HW (reprint author), Natl Taiwan Univ, Sch Vet Med, Taipei, Taiwan.	huiwenchang@ntu.edu.tw	Li, Wen-Ta/H-3718-2017	Li, Wen-Ta/0000-0002-4181-249X			Baron HR, 2014, AUST VET J, V92, P405, DOI 10.1111/avj.12233; Berlth F, 2014, WORLD J GASTROENTERO, V20, P5679, DOI 10.3748/wjg.v20.i19.5679; Catao-Dias JL, 1999, J COMP PATHOL, V120, P89, DOI 10.1053/jcpa.1998.0253; Chandra AMS, 2001, VET PATHOL, V38, P561, DOI 10.1354/vp.38-5-561; Dehlawi G.Y., 1989, JKAU SCI, V1, P95; Garner Michael M, 2004, Vet Clin North Am Exot Anim Pract, V7, P653, DOI 10.1016/j.cvex.2004.04.002; Hu B, 2012, J GASTROINTEST ONCOL, V3, P251, DOI 10.3978/j.issn.2078-6891.2012.021; Isobe T, 2015, MOL CLIN ONCOL, V3, P44, DOI 10.3892/mco.2014.447; Kao CF, 2016, J VET DIAGN INVEST, V28, P599, DOI 10.1177/1040638716661380; Kawamura H, 2001, Gastric Cancer, V4, P83, DOI 10.1007/PL00011728; Khamas W, 2011, ANAT HISTOL EMBRYOL, V40, P307, DOI 10.1111/j.1439-0264.2011.01072.x; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lauwers GY, 2010, WHO CLASSIFICATION T, P46; MARTIN JC, 1994, J ZOO WILDLIFE MED, V25, P133; Munday JS, 2017, TUMORS DOMESTIC ANIM, P555; Ramsay EC, 1996, J ZOO WILDLIFE MED, V27, P28; SULLIVAN M, 1987, VET REC, V120, P79, DOI 10.1136/vr.120.4.79; Wong HH, 2012, J GASTROINTEST ONCOL, V3, P262, DOI 10.3978/j.issn.2078-6891.2012.019	18	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						10	14		10.1016/j.jcpa.2018.02.004			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800002	29729716				2019-10-28	
J	Rissi, DR; Porter, BF; Boudreau, CE; Krimer, PM; Miller, AD				Rissi, D. R.; Porter, B. F.; Boudreau, C. E.; Krimer, P. M.; Miller, A. D.			Immunohistochemical Characterization of Immune Cell Infiltration in Feline Glioma	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						brain; cat; glioma; tumour microenvironment	OF-THE-LITERATURE; INTRACRANIAL NEOPLASIA; TUMOR MICROENVIRONMENT; CANINE; GLIOBLASTOMA; IMMUNOTHERAPY; INFLAMMATION; ASTROCYTOMA; FEATURES; THERAPY	The relationship between inflammatory cells and tumour biology has been defined in many human intracranial neoplasms, but it is relatively poorly characterized in veterinary medicine. The aim of this study was to define the immune cell infiltration in cases of feline glioma and its possible association with tumour morphology and type. A retrospective search identified 18 gliomas that met inclusion criteria. Tumours were subjected to immunohistochemistry (IHC) for CD3, CD20, Ibal, MAC387 and factor VIII-related antigen. For each antibody, the number of labelled cells was counted in 10 high-power (x400) fields and a cumulative score for each antibody was generated, Intratumoural and peritumoural CD3(+) T lymphocytes were observed in all cases and occurred primarily within perivascular spaces and rarely around areas of necrosis or leptomeningeal spread. Perivascular CD20(+) B lymphocytes were detected in 12/18 (67%) cases and occurred within and around tumours and near areas of leptomeningeal spread. MAC387 immunoreactivity highlighted intravascular monocytes in 9/18 (50%) cases, but failed to highlight tumour-associated macrophages. Intratumoural and peritumoural Ibal immunoreactivity was observed in all cases, with increased overall intensity around areas of necrosis and leptomeningeal spread. Intratumoural and peritumoural factor VIII-related antigen immunoreactivity was also detected in all cases and was concentrated in areas of microvascular proliferation and necrosis. No significant associations were found between IHC scores for immune cells (i.e. lymphocytes and macrophages) and tumour morphology and type. Average factor VIII reactivity was higher in astrocytomas than oligodendrogliomas (P = 0.003). (C) 2018 Elsevier Ltd. All rights reserved.	[Rissi, D. R.; Krimer, P. M.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA; [Rissi, D. R.; Krimer, P. M.] Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA; [Porter, B. F.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX USA; [Boudreau, C. E.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Small Anim Clin Sci, College Stn, TX 77843 USA; [Miller, A. D.] Cornell Univ, Coll Vet Med, Dept Biomed Sci, Sect Anat Pathol, Ithaca, NY 14853 USA	Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA.; Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA.	rissi@uga.edu					Andersen BM, 2013, CANCER RES, V73, P2987, DOI 10.1158/0008-5472.CAN-12-3366; Bentley RT, 2013, VET J, V198, P463, DOI 10.1016/j.tvjl.2013.08.015; Boozer LB, 2012, VET PATHOL, V49, P784, DOI 10.1177/0300985811417249; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Curran CS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-11; Dillman RO, 2011, CANCER BIOTHER RADIO, V26, P1, DOI 10.1089/cbr.2010.0902; Domingues P, 2016, BRAIN BEHAV IMMUN, V53, P1, DOI 10.1016/j.bbi.2015.07.019; Dunn Gavin P, 2007, Cancer Immun, V7, P12; Fossati G, 1999, ACTA NEUROPATHOL, V98, P349, DOI 10.1007/s004010051093; Frieboes HB, 2007, NEUROIMAGE, V37, pS59, DOI 10.1016/j.neuroimage.2007.03.008; Hammond JJ, 2014, J VET DIAGN INVEST, V26, P513, DOI 10.1177/1040638714533118; Ingram M., 1990, Veterinary Medicine Report, V2, P398; Johnson GC, 2014, VET PATHOL, V51, P146, DOI 10.1177/0300985813509387; Klopp LS, 2009, J VET INTERN MED, V23, P108, DOI 10.1111/j.1939-1676.2008.0234.x; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Lorger Mihaela, 2012, Cancers (Basel), V4, P218, DOI 10.3390/cancers4010218; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; McBride R, 2017, J COMP PATHOL, V156, P162, DOI 10.1016/j.jcpa.2016.10.011; MORRIS CS, 1991, J NEUROL SCI, V101, P47, DOI 10.1016/0022-510X(91)90017-2; Pluhar GE, 2010, VACCINE, V28, P3371, DOI 10.1016/j.vaccine.2010.02.082; Rissi DR, 2017, J FELINE MED SURG, V19, P1307, DOI [10.1177/1098612X16689506, 10.1177/1098612x16689506]; Rissi DR, 2017, J VET DIAGN INVEST, V29, P126, DOI 10.1177/1040638716673127; Roggendorf W, 1996, ACTA NEUROPATHOL, V92, P288, DOI 10.1007/s004010050520; ROSSI ML, 1987, ACTA NEUROPATHOL, V74, P269, DOI 10.1007/BF00688191; Sen E, 2011, DRUG DISCOV TODAY, V16, P1044, DOI 10.1016/j.drudis.2011.09.003; Sloma EA, 2015, J COMP PATHOL, V153, P92, DOI 10.1016/j.jcpa.2015.05.003; Sowers JL, 2014, ADV EXP MED BIOL, V816, P75, DOI 10.1007/978-3-0348-0837-8_4; Thomas AA, 2012, CANCER J, V18, P59, DOI 10.1097/PPO.0b013e3182431a73; Troxel MT, 2004, J VET INTERN MED, V18, P176, DOI 10.1892/0891-6640(2004)18<176:MRIFOF>2.0.CO;2; Troxel MT, 2003, J VET INTERN MED, V17, P850, DOI 10.1892/0891-6640(2003)017<0850:FINRRO>2.3.CO;2; Vega EA, 2008, FUTURE ONCOL, V4, P433, DOI 10.2217/14796694.4.3.433; Yang I, 2011, J NEUROSURG, V115, P505, DOI 10.3171/2011.4.JNS101172	32	1	1	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						15	22		10.1016/j.jcpa.2018.02.003			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800003	29729717				2019-10-28	
J	Liu, MM; Flanagan, TC; Jockenhovel, S; Black, A; Lu, CC; French, AT; Argyle, DJ; Corcoran, BM				Liu, M-M; Flanagan, T. C.; Jockenhovel, S.; Black, A.; Lu, C-C; French, A. T.; Argyle, D. J.; Corcoran, B. M.			Development and Evaluation of a Tissue-Engineered Fibrin-based Canine Mitral Valve Three-dimensional Cell Culture System	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						myxomatous mitral valve disease; tissue engineering; valve endothelial cell; valve interstitial cell	VALVULAR INTERSTITIAL-CELLS; MYXOMATOUS DEGENERATION; ENDOTHELIAL-CELLS; HEART-VALVES; DISEASE ENDOCARDIOSIS; EXTRACELLULAR-MATRIX; 3D CULTURE; IN-VITRO; DOGS; PHENOTYPE	Myxomatous mitral valve disease is the most common cardiac disease of the dog, but examination of the associated cellular and molecular events has relied on the use of cadaveric valve tissue, in which functional studies cannot be undertaken. The aim of this study was to develop a three-dimensional (3D) cell co-culture model as an experimental platform to examine disease pathogenesis. Mitral valve interstitial (VIC) and endothelial (VEC) cells were cultured from normal and diseased canine (VIC only) valves. VICs were embedded in a fibrin-based hydrogel matrix and one surface was lined with VECs. The 3D static cultures (constructs) were examined qualitatively and semiquantitatively by light microscopy, immunofluorescence microscopy and protein immunoblotting. Some constructs were manipulated and the endothelium damaged, and the response examined. The construct gross morphology and histology demonstrated native tissue-like features and comparable expression patterns of cellular (alpha-smooth muscle actin [SMA] and embryonic smooth muscle myosin heavy chain [SMemb]) and extracellular matrix associated markers (matrix metalloproteinase [MMP]-1 and MMP-3), reminiscent of diseased valves. There were no differences between constructs containing normal valve VICs and VECs (type 1) and those containing diseased valve VICs and normal valve VECs (type 2). Mechanical manipulation and endothelial damage (type 3) tended to decrease alpha-SMA and SMemb expression, suggesting reversal of VIC activation, but with retention of SMemb(+) cells adjacent to the wounded endothelium consistent with response to injury. Fibrin-based 3D mitral valve constructs can be produced using primary cell cultures derived from canine mitral valves, and show a phenotype reminiscent of diseased valves. The constructs demonstrate a response to endothelial damage indicating their utility as experimental platforms. (C) 2018 Elsevier Ltd. All rights reserved.	[Liu, M-M; Lu, C-C; French, A. T.; Argyle, D. J.; Corcoran, B. M.] Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Roslin, Midlothian, Scotland; [Flanagan, T. C.] Univ Coll Dublin, Hlth Sci Ctr, Sch Med, Dublin, Ireland; [Jockenhovel, S.] Rhein Westfal TH Aachen, Dept Tissue Engn & Text Implants, AME Helmholtz Inst Biomed Engn, Aachen, Germany; [Black, A.] Natl Univ Ireland Galway, Dept Anat, Galway, Ireland	Corcoran, BM (reprint author), Univ Edinburgh, Roslin Inst, Royal Dick Sch Vet Studies, Roslin, Midlothian, Scotland.	Brendan.Corcoran@ed.ac.uk			China State PhD Scholarship	We thank R. Muirhead of the Roslin Institute for help and training in cell culture systems. The current address for A.T. French is University of Glasgow, School of Veterinary Medicine, Bearsden Road, Glasgow, Scotland, UK. The findings of this study were presented at the 7th Society of Heart Valve Disease Biennial Meeting, Venice, Italy, September 2013. M.-M. Liu was funded by a China State PhD Scholarship.	Aupperle H, 2009, J COMP PATHOL, V141, P41, DOI 10.1016/j.jcpa.2009.02.002; Aupperle H, 2009, RES VET SCI, V87, P277, DOI 10.1016/j.rvsc.2009.01.009; Barth PJ, 2005, PATHOL RES PRACT, V201, P301, DOI 10.1016/j.prp.2005.02.001; BEARDOW AW, 1993, J AM VET MED ASSOC, V203, P1023; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Black A, 2005, AM J VET RES, V66, P1408, DOI 10.2460/ajvr.2005.66.1408; Buchanan J W, 1977, Adv Vet Sci Comp Med, V21, P75; Butcher JT, 2006, TISSUE ENG, V12, P905, DOI 10.1089/ten.2006.12.905; Butcher JT, 2004, ARTERIOSCL THROM VAS, V24, P1429, DOI 10.1161/01.ATV.0000130462.50769.5a; Carrier RL, 1999, BIOTECHNOL BIOENG, V64, P580, DOI 10.1002/(SICI)1097-0290(19990905)64:5<580::AID-BIT8>3.0.CO;2-X; Cholewinski E, 2009, TISSUE ENG PT A, V15, P3645, DOI [10.1089/ten.tea.2009.0235, 10.1089/ten.TEA.2009.0235]; COLE WG, 1984, BIOCHEM J, V219, P451, DOI 10.1042/bj2190451; Connell PS, 2012, J VET CARDIOL, V14, P31, DOI 10.1016/j.jvc.2011.11.003; Corcoran BM, 2004, AM J VET RES, V65, P198, DOI 10.2460/ajvr.2004.65.198; Disatian S, 2008, J HEART VALVE DIS, V17, P402; Flanagan TC, 2006, BIOMATERIALS, V27, P2233, DOI 10.1016/j.biomaterials.2005.10.031; Flanagan TC, 2007, BIOMATERIALS, V28, P3388, DOI 10.1016/j.biomaterials.2007.04.012; Gotlieb AI, 2002, J THORAC CARDIOV SUR, V124, P591, DOI 10.1067/mtc.2002.123812; Gupta V, 2008, ANN BIOMED ENG, V36, P1092, DOI 10.1007/s10439-008-9501-4; Gupta V, 2008, ACTA BIOMATER, V4, P88, DOI 10.1016/j.actbio.2007.08.009; Gupta V, 2009, CARDIOVASC PATHOL, V18, P191, DOI 10.1016/j.carpath.2008.05.001; Hadian Mojtaba, 2010, Cardiovasc Pathol, V19, pe141, DOI 10.1016/j.carpath.2009.05.001; Han RI, 2013, VET J, V197, P388, DOI 10.1016/j.tvjl.2013.01.027; Han RI, 2008, AM J VET RES, V69, P763, DOI 10.2460/ajvr.69.6.763; Han RI, 2010, J HEART VALVE DIS, V19, P60; Hayek E, 2005, LANCET, V365, P507; Jockenhoevel S, 2001, EUR J CARDIO-THORAC, V19, P424, DOI 10.1016/S1010-7940(01)00624-8; Kural MH, 2016, ACTA BIOMATER, V32, P223, DOI 10.1016/j.actbio.2015.12.031; Latif N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127844; LESTER WM, 1993, IN VITRO CELL DEV-AN, V29A, P41, DOI 10.1007/BF02634370; LESTER WM, 1992, J MOL CELL CARDIOL, V24, P43, DOI 10.1016/0022-2828(92)91158-2; Liu MM, 2015, VET J, V204, P32, DOI 10.1016/j.tvjl.2015.01.011; Lu CC, 2016, J VET CARDIOL, V18, P100, DOI 10.1016/j.jvc.2015.12.003; Lu CC, 2015, VET J, V204, P23, DOI 10.1016/j.tvjl.2015.02.021; Mow T, 1999, J VET MED A, V46, P465, DOI 10.1046/j.1439-0442.1999.00239.x; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109; Pedersen HD, 2000, CARDIOVASC RES, V47, P234, DOI 10.1016/S0008-6363(00)00113-9; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rabkin-Aikawa E, 2004, J HEART VALVE DIS, V13, P841; Rabkin-Aikawa E, 2005, ADV BIOCHEM ENG BIOT, V94, P141, DOI 10.1007/b100003; STEIN PD, 1989, AM J CARDIOL, V64, P392, DOI 10.1016/0002-9149(89)90543-2; Stephens EH, 2010, J HEART VALVE DIS, V19, P759; Stephens EH, 2011, ACTA BIOMATER, V7, P75, DOI 10.1016/j.actbio.2010.07.001; TAMURA K, 1995, AM HEART J, V129, P1149, DOI 10.1016/0002-8703(95)90397-6; Tamura K, 2000, J HEART VALVE DIS, V9, P53; Waxman AS, 2012, J VET CARDIOL, V14, P211, DOI 10.1016/j.jvc.2012.02.006; WHITNEY JC, 1974, J SMALL ANIM PRACT, V15, P511, DOI 10.1111/j.1748-5827.1974.tb06529.x; Ye Q, 2000, ASAIO J, V46, P730, DOI 10.1097/00002480-200011000-00014	48	1	1	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						23	33		10.1016/j.jcpa.2018.02.001			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800004	29729718				2019-10-28	
J	Romanucci, M; Massimini, M; Aste, G; Defourny, SVP; Crisi, PE; Boari, A; Della Salda, L				Romanucci, M.; Massimini, M.; Aste, G.; Defourny, S. V. P.; Crisi, P. E.; Boari, A.; Della Salda, L.			Diffuse Pulmonary Adenocarcinoma with Micropapillary Growth Pattern in a Cat	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						adenocarcinoma; cat; lung; micropapillary growth	LUNG ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; CLASSIFICATION; DIAGNOSIS; CARCINOMA; PNEUMONIA; TUMORS; DOG	A 12-year-old female European shorthair cat was presented with severe dyspnoea. Echocardiography revealed hypertrophic cardiomyopathy and pleural effusion. The cat died from acute decompensated left heart failure. At necropsy examination, the lungs were diffusely congested and firm, with multifocal grey areas and sparse haemorrhages. No solid masses were detected. Histopathology revealed a diffuse neoplastic proliferation characterized by irregular growth along alveolar walls with a micropapillary pattern. Tumour cells were large, highly pleomorphic and intensely positive for pan-cytokeratin and CAM 5.2. Tumour growth was obscured by simultaneous lesions related to chronic pulmonary congestion and interstitial lung disease. Histological features were consistent with a diffuse invasive pulmonary adenocarcinoma with a micropapillary pattern of tumour growth. Differential diagnosis included large cell carcinoma, which is usually characterized by rosettes or solid clusters of cells occupying alveolar lumen. Extensive cytokeratin immunolabelling was helpful in the differentiation from histiocytic proliferative disease. (C) 2018 Elsevier Ltd. All rights reserved.	[Romanucci, M.; Massimini, M.; Aste, G.; Defourny, S. V. P.; Crisi, P. E.; Boari, A.; Della Salda, L.] Univ Teramo, Fac Vet Med, Loc Piano DAccio SP 18, Teramo, Italy	Romanucci, M (reprint author), Univ Teramo, Fac Vet Med, Loc Piano DAccio SP 18, Teramo, Italy.	mromanucci@unite.it	Della Salda, Leonardo/P-9290-2018	Della Salda, Leonardo/0000-0002-6796-8206; ASTE, Giovanni/0000-0001-8744-7611			Ballegeer EA, 2002, VET RADIOL ULTRASOUN, V43, P267, DOI 10.1111/j.1740-8261.2002.tb01001.x; Bertazzolo W, 2002, J SMALL ANIM PRACT, V43, P265, DOI 10.1111/j.1748-5827.2002.tb00071.x; Busch MDM, 2008, VET PATHOL, V45, P816, DOI 10.1354/vp.45-6-816; Caswell J. L., 2016, JUBB KENNEDY PALMERS, V2, P465, DOI DOI 10.1016/B978-0-7020-5318-4.00011-5; Cote E, 2017, VET CLIN N AM-SMALL, V47, P1055, DOI 10.1016/j.cvsm.2017.04.008; Dungworth DL, 1999, HISTOLOGICAL CLASSIF, V5, P25; Hahn KA, 1998, VET SURG, V27, P307, DOI 10.1111/j.1532-950X.1998.tb00132.x; McNiel EA, 1997, J AM VET MED ASSOC, V211, P1422; MOULTON JE, 1981, VET PATHOL, V18, P513, DOI 10.1177/030098588101800409; Raparia K, 2014, AM J SURG PATHOL, V38, P921, DOI 10.1097/PAS.0000000000000227; SESTINI P, 1985, EUR J RESPIR DIS, V66, P55; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P685, DOI 10.5858/arpa.2012-0264-RA; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wilson D. W., 2017, Tumors in domestic animals, P467; Yagil-Kelmer E, 2005, JAVMA-J AM VET MED A, V226, P1983, DOI 10.2460/javma.2005.226.1983; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232	16	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						34	38		10.1016/j.jcpa.2018.02.006			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800005	29729719				2019-10-28	
J	Malatos, JM; Kurpios, NA; Duhamel, GE				Malatos, J. M.; Kurpios, N. A.; Duhamel, G. E.			Small Intestinal Lymphatic Hypoplasia in Three Dogs with Clinical Signs of Protein-losing Enteropathy	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; intestinal lymphatic hypoplasia; lacteal; lymphatics		Intestinal lymphatic hypoplasia (ILH) is a rare but well-documented cause of protein-losing enteropathy (PLE) in human infants. To our knowledge, this condition has not been reported previously in veterinary medicine. Here we report the clinical and histopathological findings in three dogs that presented with clinical signs of PLE. The onset of PLE was early in an 18-month-old Great Pyrenees, while the other two dogs, a pug and a Tibetan terrier, had a later onset at 4 and 12 years of age, respectively. The presence of intestinal lymphatic and blood vessels was assessed by immunohistochemistry for human prospero homeobox 1 (pros-1), a lymphatic endothelial nuclear transcription factor and human von Willebrand factor (vWf), a marker of vascular endothelial cells, respectively. Small intestinal specimens taken from each dog showed severe mucosal oedema with a lack of prox-1 labelling of villous lacteals, dilated and tortuous vWf immunoreactive villous arterial and capillary blood vessels, and variable lamina propria mixed inflammatory cell infiltrates. Other histological features of ILH included club-shaped villi that were lined by low cuboidal epithelium or epithelial cells with cytoplasmic pallor and microvacuolar change, extrusion zone epithelial inversion and thin and inconspicuous villous longitudinal smooth muscles. While ILH is an uncommon diagnosis, it should be considered as a differential in dogs with clinical signs of PLE. The cause of canine ILH is unknown; however, a congenital abnormality with early or late onset of clinical signs is suspected. Diagnosis of ILH can be challenging; however, immunohistochemical labelling of lymphatic endothelial cells with pros-1 is essential for making this diagnosis. (C) 2018 Elsevier Ltd. All rights reserved.	[Malatos, J. M.; Duhamel, G. E.] Cornell Univ, Coll Vet Med, New York Anim Hlth Diagnost Ctr, Dept Biomed Sci, New York, NY 10021 USA; [Kurpios, N. A.] Cornell Univ, Coll Vet Med, Dept Mol Med, New York, NY 10021 USA	Duhamel, GE (reprint author), Cornell Univ, Coll Vet Med, New York Anim Hlth Diagnost Ctr, Dept Biomed Sci, New York, NY 10021 USA.	ged36@cornell.edu			College of Veterinary Medicine at Cornell University	The authors thank the referring veterinarians and the owners of the dogs including Drs. K. Arrington and A. Terry (dog 1), Dr. E. Jones (dog 2) and Dr. M. Kornet (dog 3) for contributing clinical history and laboratory data, the residents and faculty colleagues in the Anatomic Pathology Section for contributing original reports, L. Dong in the Immunohistochemistry Research and Development Laboratory for validation of the prox-1 antibody, and the staff of the AHDC Histology Laboratory for excellent technical assistance. This work was supported in part by funds from the College of Veterinary Medicine at Cornell University.	Bernier-Latmani J, 2015, J CLIN INVEST, V125, P4572, DOI 10.1172/JCI82045; Chen L, 2010, J CELL BIOL, V189, P417, DOI 10.1083/jcb.200912037; D'Alessio S, 2014, J CLIN INVEST, V124, P3863, DOI 10.1172/JCI72189; Davis NM, 2008, DEV CELL, V15, P134, DOI 10.1016/j.devcel.2008.05.001; Day MJ, 2008, J COMP PATHOL, V138, pS1, DOI 10.1016/j.jcpa.2008.01.001; Dossin O, 2011, VET CLIN N AM-SMALL, V41, P399, DOI 10.1016/j.cvsm.2011.02.002; Hardikar W, 1997, J PEDIATR GASTR NUTR, V25, P217, DOI 10.1097/00005176-199708000-00016; Hasegawa Kosei, 2009, Clin Pediatr Endocrinol, V18, P87, DOI 10.1297/cpe.18.87; Kim KE, 2007, DEV DYNAM, V236, P2020, DOI 10.1002/dvdy.21200; Lecoindre A, 2016, J SMALL ANIM PRACT, V57, P465, DOI 10.1111/jsap.12522; Mahadevan A, 2014, DEV CELL, V31, P690, DOI 10.1016/j.devcel.2014.11.002; Miller MJ, 2010, ANN NY ACAD SCI, V1207, pE21, DOI 10.1111/j.1749-6632.2010.05708.x; Norrmen C, 2010, BLOOD, V115, P906, DOI 10.1182/blood-2009-03-212274; Nurmi H, 2015, EMBO MOL MED, V7, P1418, DOI 10.15252/emmm.201505731; Pecoraro HL, 2017, J VET DIAGN INVEST, V29, P860, DOI 10.1177/1040638717712757; Peterson PB, 2003, VET CLIN N AM-SMALL, V33, P1061, DOI 10.1016/S0195-5616(03)00055-X; Pierezan F, 2014, J COMP PATHOL, V151, P347, DOI 10.1016/j.jcpa.2014.07.003; Simmerson SM, 2014, J VET INTERN MED, V28, P331, DOI 10.1111/jvim.12291; SIMPSON AJ, 1979, AM J GASTROENTEROL, V72, P95; Sleeckx N, 2013, J COMP PATHOL, V148, P307, DOI 10.1016/j.jcpa.2012.09.007; Stormon MO, 2002, J PEDIATR GASTR NUTR, V35, P691, DOI 10.1097/00005176-200211000-00020; Ulvmar MH, 2016, CARDIOVASC RES, V111, P310, DOI 10.1093/cvr/cvw175; VANKRUININGEN HJ, 1984, VET PATHOL, V21, P377, DOI 10.1177/030098588402100403; WALDMANN TA, 1966, GASTROENTEROLOGY, V50, P422; Willard MD, 2000, J VET INTERN MED, V14, P298, DOI 10.1892/0891-6640(2000)014<0298:ICLAWP>2.3.CO;2; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Zeng YP, 2005, PEDIATR DEVEL PATHOL, V8, P541, DOI 10.1007/s10024-005-0023-x	27	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						39	49		10.1016/j.jcpa.2018.02.005			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800006	29729720				2019-10-28	
J	Murakami, T; Sassa, Y				Murakami, T.; Sassa, Y.			Pleomorphic Malignant Mesothelioma in a Broiler Breeder Infected with Avian Leucosis Virus Subgroup J	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						avian leucosis virus subtype J; chicken; immunohistochemistry; malignant mesothelioma	INTESTINAL ADENOCARCINOMA; MYELOID LEUKOSIS; HPRS-103 STRAIN; CHICKEN; TUMORS; IDENTIFICATION; DIAGNOSIS; SAMPLES; LINES; PCR	Avian leucosis virus (ALV) is an oncogenic retrovirus that induces tumours including lymphoid leucosis and myeloid lcucosis. Pleomorphic malignant mesothelioma and myelocytoma, which were thought to be induced by ALV subgroup J (ALV-J)infection, were identified in a 432-day-old broiler breeder. The bird showed no clinical signs; however, at necropsy examination there were multiple nodules in the alimentary tract. Microscopical analysis showed that these consisted of pleomorphic cells and myelocyte-like cells. Immunohistochemistry revealed that the pleomorphic cells were atypical and expressed cytokeratin, vimentin, c-kit, calretinin and ALV. The myelocyte-like cells were also positive for ALV. Retroviral type C particles were observed by electron microscopy. ALV-E and ALV-J nucleotide sequences were detected in DNA extracted from formalin-fixed and paraffin wax-embedded small intestinal tissue. Based on these results, the tumours were diagnosed as pleomorphic malignant mesothelioma and myelocytoma and were thought to have been induced by ALV-J infection. This is the first report of malignant mesothelioma associated with naturally acquired ALV-J infection. (C) 2018 Elsevier Ltd. All rights reserved.	[Murakami, T.] Tokyo Univ Agr & Technol, Lab Vet Toxicol, 3-5-8 Saiwai Cho, Fuchu, Tokyo, Japan; [Sassa, Y.] Tokyo Univ Agr & Technol, Lab Vet Infect Dis, 3-5-8 Saiwai Cho, Fuchu, Tokyo, Japan	Murakami, T (reprint author), Tokyo Univ Agr & Technol, Lab Vet Toxicol, 3-5-8 Saiwai Cho, Fuchu, Tokyo, Japan.	sassa_y@cc.tuat.ac.jp	Murakami, Tomoaki/D-4654-2015	Murakami, Tomoaki/0000-0002-5706-7842	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K17702, 17K15369]	The authors thank Dr. K. Tsukamoto for provision of antibodies and Dr. S. Nakaba for technical assistance in preparing ultrathin sections. This research was partially supported by JSPS KAKENHI, Grant Number 17K17702 and 17K15369.	ANDREASEN JR, 1992, AVIAN DIS, V36, P799, DOI 10.2307/1591788; Baigent SJ, 2016, J VIROL METHODS, V233, P23, DOI 10.1016/j.jviromet.2016.03.002; Cai LM, 2013, J GEN VIROL, V94, P2278, DOI 10.1099/vir.0.054239-0; Cheng ZQ, 2010, J VET MED SCI, V72, P1027, DOI 10.1292/jvms.09-0564; Fadly AM, 2008, DIS POULTRY, P514; Galateau-Salle F, 2016, J THORAC ONCOL, V11, P142, DOI 10.1016/j.jtho.2015.11.005; HELMBOLDT C F, 1972, Journal of Wildlife Diseases, V8, P3; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Kadota K, 2011, J THORAC ONCOL, V6, P896, DOI 10.1097/JTO.0b013e318211127a; Li YH, 2013, VET MICROBIOL, V166, P356, DOI 10.1016/j.vetmic.2013.06.007; Nakayama Y, 2017, VET PATHOL, V54, P912, DOI 10.1177/0300985817723692; Oczypok EA, 2015, ULTRASTRUCT PATHOL, V39, P153, DOI 10.3109/01913123.2014.960542; Ordonez NG, 2012, MODERN PATHOL, V25, P1011, DOI 10.1038/modpathol.2012.39; PAYNE LN, 1991, VET REC, V129, P447, DOI 10.1136/vr.129.20.447; PAYNE LN, 1992, LEUKEMIA, V6, P1167; REECE RL, 1992, AVIAN PATHOL, V21, P3, DOI 10.1080/03079459208418815; Reece RL, 2008, DIS POULTRY, P593; Shen YW, 2014, J GEN VIROL, V95, P691, DOI 10.1099/vir.0.059915-0; Shi M, 2011, INT J BIOL, V3, P1; Smith LM, 1998, VIRUS RES, V54, P87, DOI 10.1016/S0168-1702(98)00022-7; Sun F, 2011, J VET DIAGN INVEST, V23, P937, DOI 10.1177/1040638711416631; TSUKAMOTO K, 1991, J VET MED SCI, V53, P399, DOI 10.1292/jvms.53.399; TURK JR, 1980, AVIAN DIS, V24, P507, DOI 10.2307/1589721; Wozniak J, 2004, CYTOM PART B-CLIN CY, V58B, P9, DOI 10.1002/cyto.b.10068; Yui T., 2010, Journal of the Japan Veterinary Medical Association, V63, P935	25	0	0	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						50	55		10.1016/j.jcpa.2018.03.003			6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800007	29729721				2019-10-28	
J	Doring, S; Arzi, B; Winer, JN; Kass, PH; Verstraete, FJM				Doring, S.; Arzi, B.; Winer, J. N.; Kass, P. H.; Verstraete, F. J. M.			Dental and Temporomandibular Joint Pathology of the Grey Wolf (Canis lupus)	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						Canis lupus; dental pathology; grey wolf; temporomandibular joint pathology	ODONTOCLASTIC RESORPTION LESIONS; MARION ISLAND; FERAL CATS; FENESTRATION; DEHISCENCE; SALMON; PREVALENCE; DISORDERS; ANOMALIES; BEHAVIOR	Skulls from 392 grey wolves (Canis lupus) were examined macroscopically according to predefined criteria. Two hundred and seven skulls were included in this study, comprised of 124 young adults (59.9%) and 83 adults (40.1%); of these, 65 (31.4%) specimens were from male wolves and 104 (50.3%) were from females, with 38 (18.4%) of unknown sex. Out of 8,694 possible teeth, 8,339 (95.9%) were present for evaluation. Fifty-five teeth (15.5%) were absent congenitally, 30 (8.5%) were lost during life and 270 (76.1 degrees/0) were lost artefactually post mortem. Skeletal or dental malocclusion was present in 37 specimens (17.9%), with level bite being the most commonly encountered malocclusion. Enamel hypoplasia was present in five skulls (2.4%), affecting eight teeth (0.1%) in total. An abnormal number of roots was found on 23 teeth (0.3%) on 13 skulls (6.3%). Persistent deciduous teeth occurred in two (1.0%) specimens, affecting one (0.01%) tooth each. Fenestration or dehiscence was found associated with 203 teeth (2.4%) in 72 skulls (34.8%). Periodontitis was noted on 115 skulls (55.6%) and 1,000 teeth (11.5%), affecting significantly more adults (n = 63, 75.0%) than young adults = 52, 41.9%; P <0.0001). One hundred and sixty-one skulls (77.8%) showed signs of endodontal disease, including attrition or abrasion on 144 skulls (69.6%) and 2,522 teeth (30.2%) and 424 fractured teeth (5.1%) on 103 skulls (49.8%). Both lesions affected significantly more adults than young adults. Overt periapical disease was associated with six teeth (0.1%) distributed across five skulls (2.4%). A carious lesion was present on one tooth (0.01%) of one specimen (0.5%). Lesions consistent with temporomandibular joint (TMJ) ostcoarthritis were found in 24 specimens (11.6%), affecting 38 joints (9.2%). Trauma to the skull, such as bite marks, bullet holes or blunt trauma, was noted in 44 skulls (21.2%). The grey wolf and the domestic clog (Canis lupus ) share common dental diseases; however, the proportion and severity may vary. Although the clinical significance of dental and TMJ pathology in the grey wolf remains unknown, based on the impact of these disorders on the domestic dog, the occurrence and severity of these lesions arc likely to play an important role in the morbidity and mortality of this wild canid species. (C) 2018 Elsevier Ltd. All rights reserved.	[Doring, S.; Winer, J. N.] William R Pritchard Vet Med Teaching Hosp, Davis, CA USA; [Arzi, B.; Verstraete, F. J. M.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Kass, P. H.] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA	Verstraete, FJM (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	fjverstraete@ucdavis.edu	Verstraete, Frank/I-3120-2019	Verstraete, Frank/0000-0002-7677-3654	University of California, DavisUniversity of California System	The authors thank L. Olsen and A. Gunderson of the Department of Mammalogy, Museum of the North of the University of Alaska, Fairbanks, for making its Canis lupus skull collection available for this study and Dr. C. Toupadakis Skouritakis for assistance with the illustrations. This research was funded by Academic Senate Research Grants and Faculty discretionary funds of F. J. M. Verstraete and B. Arzi, University of California, Davis. The funding sources had no role in the study design or in the collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.	Abbott C, 2005, J COMP PATHOL, V132, P169, DOI 10.1016/j.jcpa.2004.09.007; Adams LG, 2010, ECOL APPL, V20, P251, DOI 10.1890/08-1437.1; Alaska Department of Fish and Game, 2017, SPEC PROF WOLF; Arzi B, 2013, J COMP PATHOL, V149, P486, DOI 10.1016/j.jcpa.2013.03.009; Arzi B, 2013, JAVMA-J AM VET MED A, V242, P69, DOI 10.2460/javma.242.1.69; Buyuk SK, 2016, ANGLE ORTHOD, V86, P431, DOI 10.2319/042715-289.1; Campos PSF, 2005, DENTOMAXILLOFAC RAD, V34, P193, DOI 10.1259/dmfr/59267138; Christiansen P, 2007, ECOLOGY, V88, P347, DOI 10.1890/0012-9658(2007)88[347:BFAEAT]2.0.CO;2; Darimont Chris T., 2008, BMC Ecology, V8, P14, DOI 10.1186/1472-6785-8-14; Darimont CT, 2002, CAN J ZOOL, V80, P1638, DOI 10.1139/Z02-149; Darimont CT, 2003, CAN J ZOOL, V81, P349, DOI 10.1139/Z02-246; DAVIES RM, 1974, J CLIN PERIODONTOL, V1, P107, DOI 10.1111/j.1600-051X.1974.tb01245.x; Ellegren H, 1996, PHILOS T ROY SOC B, V351, P1661, DOI 10.1098/rstb.1996.0148; Enhos S, 2012, ANGLE ORTHOD, V82, P868, DOI 10.2319/111211-702.1; FULLER TK, 1989, WILDLIFE MONOGR, P1; Harvey CE, 1998, VET CLIN N AM-SMALL, V28, P1111, DOI 10.1016/S0195-5616(98)50105-2; Harvey CE, 1990, BSAV MANUAL SMALL AN, p[37, 85]; HELL P, 1990, Z JAGDWISS, V36, P266, DOI 10.1007/BF02242401; Leonard JA, 2007, CURR BIOL, V17, P1146, DOI 10.1016/j.cub.2007.05.072; Linnaeus C, 1758, SYSLEMA ARATUREE REG; Lommer MJ, 2000, J AM VET MED ASSOC, V217, P1866, DOI 10.2460/javma.2000.217.1866; Losey RJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099746; MECH L D, 1974, Mammalian Species, V37, P1; Mech L. D., 2015, WOLVES HUNT BEHAV WO; Mech L. David, 2003, P131; Mech LD, 1998, WOLF IS KEPT FED HIS, P101; Pavlovc Dubravka, 2007, Veterinarski Arhiv, V77, P291; Peterson Rolf O., 2003, P104; Raikkonen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067218; RANDI E, 1995, J ZOOL SYST EVOL RES, V33, P97; Szepanski MM, 1999, OECOLOGIA, V120, P327, DOI 10.1007/s004420050866; Tanaka E, 2008, J DENT RES, V87, P296, DOI 10.1177/154405910808700406; VANVALKENBURGH B, 1993, SYM ZOOL S, P15; VANVALKENBURGH B, 1988, AM NAT, V131, P291, DOI 10.1086/284790; VANVALKENBURGH B, 1991, PALEOBIOLOGY, V17, P340, DOI 10.1017/S0094837300010691; VanValkenburgh B, 1996, J MAMMAL, V77, P240, DOI 10.2307/1382725; Verstracte FJM, 2003, TXB SMALL ANIMAL SUR, V2, P2638; Verstraete FJM, 1996, J COMP PATHOL, V115, P265, DOI 10.1016/S0021-9975(96)80084-3; Verstraete FJM, 1996, J COMP PATHOL, V115, P283, DOI 10.1016/S0021-9975(96)80085-5; Vila C, 1999, MOL ECOL, V8, P2089, DOI 10.1046/j.1365-294x.1999.00825.x; VILA C, 1993, CAN J ZOOL, V71, P968, DOI 10.1139/z93-127; Winer JN, 2017, J COMP PATHOL, V157, P90, DOI 10.1016/j.jcpa.2017.06.006; Winer JN, 2016, J COMP PATHOL, V155, P231, DOI 10.1016/j.jcpa.2016.07.004; Winer JN, 2016, J COMP PATHOL, V155, P242, DOI 10.1016/j.jcpa.2016.07.005; Winer JN, 2013, J COMP PATHOL, V149, P346, DOI 10.1016/j.jcpa.2012.11.243; Wozencralt WC, 2005, MAMMAL SPECIES WORLD; Wright BA, 2011, ALASKAN PREDATORS TH, P28; Yagci A, 2012, ANGLE ORTHOD, V82, P67, DOI 10.2319/040811-250.1	48	3	3	1	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						56	70		10.1016/j.jcpa.2018.03.001			15	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800008	29729722	Green Published			2019-10-28	
J	Silva, JN; Miranda, LHM; Menezes, RC; Gremiao, IDF; Oliveira, RVC; Vieira, SMM; Conceicao-Silva, F; Ferreiro, L; Pereira, SA				Silva, J. N.; Miranda, L. H. M.; Menezes, R. C.; Gremiao, I. D. F.; Oliveira, R. V. C.; Vieira, S. M. M.; Conceicao-Silva, F.; Ferreiro, L.; Pereira, S. A.			Comparison of the Sensitivity of Three Methods for the Early Diagnosis of Sporotrichosis in Cats	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						histopathology; immunohistochemistry; feline sporotrichosis	RIO-DE-JANEIRO; FELINE SPOROTRICHOSIS; SPOROTHRIX-SCHENCKII; EPIDEMIC; LESIONS	Sporotrichosis is caused by species of fungi within the Sporothrix schenckii complex that infect man and animals. In Rio de Janeiro, Brazil, an epidemic has been observed since 1998, with most of the cases being related to transmission from infected cats. Although the definitive diagnosis of feline sporotrichosis is made by fungal culture, cytopathological and histopathological examinations are used routinely, because the long culture period may delay treatment onset. However, alternative methods are desirable in cases of low fungal burden. Immunohistochemistry (IHC) hash been described as a sensitive method for diagnosing human and canine sporotrichosis, but there are no reports of its application to cats. The aim of this study was to analyse the sensitivity of cytopathological examination (Quick Panoptic method), histopathology (Grocott silver stain) and anti-Sporothrix IHC by blinded comparisons, using fungal culture as the reference standard. Samples were collected from 184 cats with sporotrichosis hat exhibited skin ulcers. The sensitivities of Grocott silver stain, cytopathological examination and IHC were 91.3%, 87.0% and 88.6%, respectively. Grocott silver stain showed the best performance. IHC showed high sensitivity, as did cytopathological examination and these may be considered as alternative methodologies. When the three methods were combined, the diagnosis was established in 180 (97.8%) out of 184 cases.Taken together, these findings indicate the need to implement these methods as routine tools for the early diagnosis of sporotrichosis in cats, notably when fungal culture is not available. (C) 2018 Elsevier Ltd. All rights reserved.	[Silva, J. N.; Ferreiro, L.] Univ Fed Rio Grande do Sul, Fac Vet, Lab Micol, Agron, Av Bento Goncalves 9090, Porto Alegre, RS, Brazil; [Silva, J. N.; Miranda, L. H. M.; Menezes, R. C.; Gremiao, I. D. F.; Vieira, S. M. M.; Pereira, S. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Lab Pesquisa Clin Dermatozoonoses Anim Domest, Inst Nacl Infectol Evandro Chagas INI, Av Brasil 4365, Rio De Janeiro, Brazil; [Oliveira, R. V. C.] Fiocruz MS, INI, Lab Epidemiol Clin, Av Brasil 4036,201A, Rio De Janeiro, Brazil; [Conceicao-Silva, F.] Inst Oswaldo Cruz, Lab Imunoparasitol, FIOCRUZ, Av Brasil 4365,Pavilhao 26,406C, Rio De Janeiro, Brazil	Miranda, LHM (reprint author), Fundacao Oswaldo Cruz, FIOCRUZ, Lab Pesquisa Clin Dermatozoonoses Anim Domest, Inst Nacl Infectol Evandro Chagas INI, Av Brasil 4365, Rio De Janeiro, Brazil.	luisa.helena@ini.fiocruz.br	Menezes, Rodrigo/O-8722-2019; Driemeier, David/H-3461-2012	Driemeier, David/0000-0003-3766-0654	'Programa de Apoio 'a Pesquisa Estrategica em Saude' (PAPES VI) Fiocruz/'Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico' (CNPq) [422099/2017-1]; 'Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro' (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) [E-23/203.303/2016]; CNPqNational Council for Scientific and Technological Development (CNPq); Programa Institucional de Bolsas de Iniciacao Cientifica/CNPqNational Council for Scientific and Technological Development (CNPq)	The authors are grateful to the staff of 'Laboratorio de Pesquisa Clinica em Dermatozoonoses em Animais Domesticos' (INI/Fiocruz), to 'Laboratorio de Micologia' and to 'Servico de Anatomia Patologica' for the excellent technical assistance. We especially acknowledge T. M. Pacheco Schubach and R. Mexas for processing the figures. This study was partially supported by grants from the 'Programa de Apoio 'a Pesquisa Estrategica em Saude' (PAPES VI) Fiocruz/'Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico' (CNPq)- Grant number: 422099/2017-1; and 'Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro' (FAPERJ)/Grant number: E-23/203.303/2016 - 'Jovem Cientista do Nosso Estado'. RCM, LF and SAP are recipients of productivity fellowships from CNPq. JNS held a PhD scholarship from CNPq. SMMV held a scholarship from scientific initiation from Programa Institucional de Bolsas de Iniciacao Cientifica/CNPq.	Almeida-Paes R, 2015, BIOMED RES INT, DOI 10.1155/2015/212308; ALVER LL, 1994, GLYCOBIOLOGY, V4, P281, DOI 10.1093/glycob/4.3.281; Boechat JS, 2018, MEM I OSWALDO CRUZ, V113, P185, DOI 10.1590/0074-02760170407; Carson FL, 2009, HISTOLECHNOLOGY SELF, P239; Chakrabarti A, 2015, MED MYCOL, V53, P3, DOI 10.1093/mmy/myu062; Barros MBD, 2011, CLIN MICROBIOL REV, V24, P633, DOI 10.1128/CMR.00007-11; Barros MBD, 2010, REV PANAM SALUD PUBL, V27, P455; de Miranda LHM, 2009, MYCOPATHOLOGIA, V168, P79, DOI 10.1007/s11046-009-9198-4; Gremiao IDF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006077; Gremiao IDF, 2015, MED MYCOL, V53, P15, DOI 10.1093/mmy/myu061; Lopez-Romero E, 2011, FUTURE MICROBIOL, V6, P85, DOI 10.2217/FMB.10.157; MARQUES MEA, 1992, J CLIN PATHOL, V45, P1089, DOI 10.1136/jcp.45.12.1089; Miranda LHM, 2013, COMP IMMUNOL MICROB, V36, P425, DOI 10.1016/j.cimid.2013.03.005; Miranda LHM, 2011, VET J, V190, P408, DOI 10.1016/j.tvjl.2010.12.004; MOORE M, 1946, ARCH DERMATOL SYPH, V53, P253, DOI 10.1001/archderm.1946.01510320043007; Pereira SA, 2015, SPOROTRICHOSIS NEW D, P83; Pereira SA, 2011, J FELINE MED SURG, V13, P220, DOI 10.1016/j.jfms.2010.10.007; Pereira SA, 2014, REV SOC BRAS MED TRO, V47, P392, DOI 10.1590/0037-8682-0092-2013; Quintella LP, 2012, BRIT J DERMATOL, V167, P837, DOI 10.1111/j.1365-2133.2012.11012.x; Quintella LP, 2011, J CUTAN PATHOL, V38, P25, DOI 10.1111/j.1600-0560.2010.01626.x; Rippon J, 1988, MED MYCOLOGY PATHOGE, P325; Rodrigues AM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005638; Rodrigues AM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002281; Schubach TMP, 2004, JAVMA-J AM VET MED A, V224, P1623, DOI 10.2460/javma.2004.224.1623; Schwarz J, 1992, HUM PATHOL, V13, P519; Silva JN, 2015, MED MYCOL, V53, P880, DOI 10.1093/mmy/myv038; Welsh RD, 2003, J AM VET MED ASSOC, V223, P1123, DOI 10.2460/javma.2003.223.1123	27	2	2	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						72	78		10.1016/j.jcpa.2018.03.002			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800009	29729723				2019-10-28	
J	Nakamura, R; Yabuki, A; Ichii, O; Mizukawa, H; Yokoyama, N; Yamato, O				Nakamura, R.; Yabuki, A.; Ichii, O.; Mizukawa, H.; Yokoyama, N.; Yamato, O.			Changes in Renal Peritubular Capillaries in Canine and Feline Chronic Kidney Disease	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						capillary rarefaction; cat; chronic kidney disease; dog	ANGIOTENSIN-CONVERTING ENZYME; ENDOTHELIAL GROWTH-FACTOR; TUBULOINTERSTITIAL INJURY; CHRONIC HYPOXIA; FIBROSIS; ANGIOGENESIS; RAREFACTION; CARBOXYPEPTIDASE; DYSFUNCTION; MECHANISMS	Renal capillary rarefaction is a crucial event that leads to tubulointerstitial damage during the progression of chronic kidney disease (CKD). In the present study, changes in CD34-positive renal capillaries were investigated in dogs and cats with CKD. A significant decrease in CD34-positive capillaries was observed in canine diseased kidneys, even at the early stage of disease. In cats, CD34-positive capillaries were well preserved in the diseased kidneys, with no link to the severity of CKD. Renal capillary rarefaction might be a trigger event that leads to the progression of CKD in dogs, rather than in cats. (C) 2018 Elsevier Ltd. All rights reserved.	[Nakamura, R.; Yabuki, A.; Yamato, O.] Kagoshima Univ, Joint Fac Vet Med, Lab Vet Clin Pathol, Kagoshima, Japan; [Ichii, O.] Hokkaido Univ, Fac Vet Med, Dept Basic Vet Sci, Lab Anat, Sapporo, Hokkaido, Japan; [Mizukawa, H.] Hokkaido Univ, Fac Vet Med, Div Environm Vet Sci, Sapporo, Hokkaido, Japan; [Yokoyama, N.] Hokkaido Univ, Fac Vet Med, Lab Vet Internal Med, Dept Clin Sci, Sapporo, Hokkaido, Japan	Yabuki, A (reprint author), Kagoshima Univ, Joint Fac Vet Med, Lab Vet Clin Pathol, Kagoshima, Japan.	yabu@vet.kagoshima-u.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [16K08056, 15K1613205]	This work was supported by a Grant-in-Aid for Scientific Research (grant numbers 16K08056, 15K1613205) from the Japan Society for the Promotion of Science.	Ballermann BJ, 2014, KIDNEY INT SUPPL, V4, P45, DOI 10.1038/kisup.2014.9; Brown CA, 2016, VET PATHOL, V53, P309, DOI 10.1177/0300985815622975; Chade AR, 2016, J AM SOC NEPHROL, V27, P1741, DOI 10.1681/ASN.2015040346; Chakrabarti S, 2013, VET PATHOL, V50, P147, DOI 10.1177/0300985812453176; Choi YJ, 2000, HUM PATHOL, V31, P1491, DOI 10.1053/hupa.2000.20373; Donoghue M, 2000, CIRC RES, V87, pE1; Eirin A, 2014, CARDIOVASC RES, V103, P461, DOI 10.1093/cvr/cvu157; Fine LG, 2008, KIDNEY INT, V74, P867, DOI 10.1038/ki.2008.350; Geddes RF, 2013, J VET INTERN MED, V27, P234, DOI 10.1111/jvim.12044; Kida Y, 2014, PEDIATR NEPHROL, V29, P333, DOI 10.1007/s00467-013-2430-y; Kida Y, 2011, CLIN EXP PHARMACOL P, V38, P417, DOI 10.1111/j.1440-1681.2011.05531.x; Lawson JS, 2016, VET J, V214, P1, DOI 10.1016/j.tvjl.2016.02.004; Lawson J, 2015, VET J, V203, P18, DOI 10.1016/j.tvjl.2014.10.009; Lin SL, 2011, AM J PATHOL, V178, P911, DOI 10.1016/j.ajpath.2010.10.012; Masum MA, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0694-3; Mayer G, 2011, NEPHROL DIAL TRANSPL, V26, P1132, DOI 10.1093/ndt/gfq832; Mitani S, 2014, J VET MED SCI, V76, P45, DOI 10.1292/jvms.13-0314; Nangaku M, 2004, INTERNAL MED, V43, P9, DOI 10.2169/internalmedicine.43.9; Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757; Palm F, 2011, CLIN EXP PHARMACOL P, V38, P424, DOI 10.1111/j.1440-1681.2011.05532.x; Sanchez-Lara AC, 2015, VET PATHOL, V52, P513, DOI 10.1177/0300985814542811; Silva ACSE, 2012, PEDIATR NEPHROL, V27, P1835, DOI 10.1007/s00467-011-2002-y; Stcegh FM, 2011, J AM SOC NEPHROL, V22, P1024; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Woolf AS, 2009, J AM SOC NEPHROL, V20, P239, DOI 10.1681/ASN.2008020243; Yabuki A, 2010, RES VET SCI, V88, P294, DOI 10.1016/j.rvsc.2009.09.003; Yang S., 2016, MOB INF SYST, V2016, P1, DOI DOI 10.1016/J.FSI.2016.12.001; Zimmerman D, 2012, CLIN SCI, V123, P333, DOI 10.1042/CS20120111	28	0	0	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	APR	2018	160						79	83		10.1016/j.jcpa.2018.03.004			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GG5YC	WOS:000432770800010	29729724				2019-10-28	
J	Elmore, SA				Elmore, Susan A.			The Altmetric Attention Score: What Does It Mean and Why Should I Care?	TOXICOLOGIC PATHOLOGY			English	Editorial Material						altmetrics; attention score; social media			[Elmore, Susan A.] NIEHS, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA	Elmore, SA (reprint author), NIEHS, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27707 USA.	elmore@niehs.nih.gov			National Institutes of Health, National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	[Anonymous], 2016, INN SCHOL COMM DAT G; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Help. altmetric. com, OUTP AND SOURC; Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102; Melero R, 2015, BIOCHEM MEDICA, V25, P152, DOI 10.11613/BM.2015.016; Warren HR, 2017, JAMA-J AM MED ASSOC, V317, P131, DOI 10.1001/jama.2016.18346	6	5	5	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					252	255		10.1177/0192623318758294			4	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800001	29448902	Green Accepted, Bronze			2019-10-28	
J	Schafer, KA; Eighmy, J; Fikes, JD; Halpern, WG; Hukkanen, RR; Long, GG; Meseck, EK; Patrick, DJ; Thibodeau, MS; Wood, CE; Francke, S				Schafer, Kenneth A.; Eighmy, John; Fikes, James D.; Halpern, Wendy G.; Hukkanen, Renee R.; Long, Gerald G.; Meseck, Emily K.; Patrick, Daniel J.; Thibodeau, Michael S.; Wood, Charles E.; Francke, Sabine			Use of Severity Grades to Characterize Histopathologic Changes	TOXICOLOGIC PATHOLOGY			English	Article						histopathology; severity grades; severity scores; adversity; hazard; risk assessment	GROUPS DIFFERENT ENOUGH; RODENT TOXICITY; TOXICOLOGIC PATHOLOGY; NONNEOPLASTIC LESIONS; ASCRIBE; PRINCIPLES; RATS	The severity grade is an important component of a histopathologic diagnosis in a nonclinical toxicity study that helps distinguish treatment-related effects from background findings and aids in determining adverse dose levels during hazard characterization. Severity grades should be assigned based only on the extent (i.e., amount and complexity) of the morphologic change in the examined tissue section(s) and be clearly defined in the pathology report for critical lesions impacting study interpretation. However, the level of detail provided and criteria by which severity grades are assigned can vary, which can lead to inappropriate comparisons and confusion when evaluating pathology results. To help address this issue, a Working Group of the Society of Toxicologic Pathology's Scientific and Regulatory Policy Committee was formed to provide a points to consider article on the assignment and application of pathology severity grades. Overall, the Working Group supports greater transparency and consistency in the reporting of grading scales and provides recommendations to improve selection of diagnoses requiring more detailed severity criteria. This information should enhance the overall understanding by toxicologic pathologists, toxicologists, and regulatory reviewers of pathology findings and thereby improve effective communication in regulatory submissions.	[Schafer, Kenneth A.] Vet Path Serv Inc, 6450 Castle Dr, Mason, OH 45040 USA; [Eighmy, John] Covance Labs Inc, Madison, WI USA; [Fikes, James D.] Biogen, Cambridge, MA USA; [Halpern, Wendy G.] Genentech Inc, San Francisco, CA USA; [Hukkanen, Renee R.] Eisai Inc, Andover, MA USA; [Long, Gerald G.] Expt Pathol Labs Inc, Sterling, VA USA; [Meseck, Emily K.] Novartis Inst Biomed Res, E Hanover, NJ USA; [Patrick, Daniel J.] MPI Res, Mattawan, MI USA; [Thibodeau, Michael S.] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA; [Wood, Charles E.] US EPA, Res Triangle Pk, NC 27711 USA; [Francke, Sabine] US FDA, College Pk, MD USA	Schafer, KA (reprint author), Vet Path Serv Inc, 6450 Castle Dr, Mason, OH 45040 USA.	kschafer@vetpathservicesinc.com					Adams ET, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P149, DOI 10.1016/B978-0-12-415759-0.00006-6; Crissman JW, 2004, TOXICOL PATHOL, V32, P126, DOI 10.1080/01926230490268756; ENGELHARDT JA, 1993, TOXICOL PATHOL, V21, P538, DOI 10.1177/019262339302100603; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Hard GC, 2012, TOXICOL PATHOL, V40, P473, DOI 10.1177/0192623311431948; Holland T, 2011, TOXICOL PATHOL, V39, P1138, DOI 10.1177/0192623311422919; Holland T, 2011, TOXICOL PATHOL, V39, P569, DOI 10.1177/0192623311406289; International Organization for Standardization, 2016, 1099362016 ISO; Kaufmann W, 2009, EXP TOXICOL PATHOL, V61, P591, DOI 10.1016/j.etp.2009.01.001; Kerlin R, 2016, TOXICOL PATHOL, V44, P147, DOI 10.1177/0192623315623265; Levin S, 2011, TOXICOL PATHOL, V39, P1139, DOI 10.1177/0192623311422083; Long GG, 2012, TOXICOL PATHOL, V40, P1079, DOI 10.1177/0192623312443322; Mann PC, 2014, TOXICOL PATHOL, V42, P283, DOI 10.1177/0192623313506880; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Markovits JE, 2013, TOXICOL PATHOL, P77; McConnell EE, 2002, INHAL TOXICOL, V14, P263, DOI 10.1080/08958370252809040; Morton D, 2006, TOXICOL PATHOL, V34, P806, DOI 10.1080/01926230601034624; Morton D, 2010, TOXICOL PATHOL, V38, P1118, DOI 10.1177/0192623310383991; Palazzi X, 2016, TOXICOL PATHOL, V44, P810, DOI 10.1177/0192623316642527; Shackelford C, 2002, TOXICOL PATHOL, V30, P93, DOI 10.1080/01926230252824761; Ward JM, 2011, TOXICOL PATHOL, V39, P745, DOI 10.1177/0192623311408622; Wolf JC, 2017, ENVIRON TOXICOL CHEM, V36, P601, DOI 10.1002/etc.3695; Wolf JC, 2014, AQUAT TOXICOL, V146, P127, DOI 10.1016/j.aquatox.2013.10.033; Wolf JC, 2011, TOXICOL PATHOL, V39, P1017, DOI 10.1177/0192623311418683; Zbinden G., 1976, PROGR TOXICOLOGY SPE, P8	25	18	18	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					256	265		10.1177/0192623318761348			10	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800002	29529947	Bronze			2019-10-28	
J	Woicke, J; Haile, S; Mysore, J; Peden, WM; Lejeune, T; Sanderson, T; Brodie, T				Woicke, Jochen; Haile, Solomon; Mysore, Jagannatha; Peden, W. Michael; Lejeune, Typhaine; Sanderson, Thomas; Brodie, Thomas			Spontaneous Findings in the Eyes of Cynomolgus Monkeys (Macaca fascicularis) of Mauritian Origin	TOXICOLOGIC PATHOLOGY			English	Article						histopathology; nonhuman primate pathology; special senses; eye pathology	PRIMARY IRIS; RETINA; CYSTS; RETINOSCHISIS; MELANOCYTOMA; DEGENERATION; TOXICITY; MACAQUES; GENETICS	Spontaneous findings noted in the eyes of Mauritian cynomolgus monkeys are described and descriptions are supplemented with illustrations. Findings observed after extensive histopathologic examinations (20 to 44 sections per eye) from 20 control, 17 treatment-naive stock monkeys, and 2 findings noted in drug-treated monkeys that were considered to be spontaneous are included. Also included are findings from 361 control monkeys of routine toxicity studies performed at our laboratories, for most of which a standard histopathological examination of 1 section per eye was conducted. Common observations in monkeys examined extensively and in historical controls were limited to lymphocytic or mononuclear cell infiltrations of the uvea and/or conjunctiva/sclera and, less commonly observed, melanocytoma of the ciliary body or iris. Findings noted only in monkeys examined extensively consisted of inflammation of the conjunctiva, ora serrata cysts, glial nodules, focal degeneration of the retina, cystoid degeneration of the central retina, ballooning degeneration of the ciliary epithelium, cyst of the ciliary body, and decreased pigmentation of the retinal pigment epithelium. Changes recorded only in historical controls included retinal atrophy and nuclear displacement in the retina. Lesions are discussed and compared with pertinent literature.	[Woicke, Jochen; Peden, W. Michael; Sanderson, Thomas] Bristol Myers Squibb, Pathol Res & Dev, 3830 Blackford Rd E, Mt Vernon, IN 47620 USA; [Haile, Solomon; Lejeune, Typhaine] Charles River Labs Montreal ULC, Senneville, PQ, Canada; [Mysore, Jagannatha; Brodie, Thomas] Bristol Myers Squibb, Pathol Res & Dev, New Brunswick, NJ USA	Woicke, J (reprint author), Bristol Myers Squibb, Pathol Res & Dev, 3830 Blackford Rd E, Mt Vernon, IN 47620 USA.	woicke@me.com					Ali Mohammad Javed, 2012, Oman J Ophthalmol, V5, P198, DOI 10.4103/0974-620X.106108; Andersson LS, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-21; Baile R, 2011, SAUDI J OPHTHALMOL, V25, P89, DOI 10.1016/j.sjopt.2010.10.002; Bhargava P, 2013, BRAIN, V136, P3212, DOI 10.1093/brain/awt295; Biswas J, 1998, SURV OPHTHALMOL, V42, P378, DOI 10.1016/S0039-6257(97)00087-8; Chamanza R, 2010, TOXICOL PATHOL, V38, P642, DOI 10.1177/0192623310368981; Cibis P A, 1965, Trans Am Ophthalmol Soc, V63, P417; Collins ME, 2010, NEW ENGL J MED, V362, P1720, DOI 10.1056/NEJMicm0907948; Colman K, 2017, TOXICOL PATHOL, V45, P94, DOI 10.1177/0192623316672743; Demirci H, 2005, AM J OPHTHALMOL, V139, P468, DOI 10.1016/j.ajo.2004.10.008; Dubielzig R. R., 2017, TUMORS DOMESTIC ANIM, P903; Dubielzig RR, 2009, INVEST OPHTH VIS SCI, V50, P5344; Fischer AJ, 2001, INVEST OPHTH VIS SCI, V42, P3256; Fortune B, 2005, INVEST OPHTH VIS SCI, V46, P3943, DOI 10.1167/iovs.04-1160; Fujihira S, 1994, ANIM EYE RES, V13, P147; Geiss V., 1999, PATHOLOGY MOUSE REFE, P479; Gills J P Jr, 1966, Trans Am Ophthalmol Soc, V64, P66; Grahn BH, 2004, CAN VET J, V45, P269; ITO T, 1992, EXP ANIM TOKYO, V41, P455, DOI 10.1538/expanim1978.41.4_455; Kanthaswamy S, 2013, J MED PRIMATOL, V42, P120, DOI 10.1111/jmp.12043; Kanthaswamy S, 2008, INT J PRIMATOL, V29, P1295, DOI 10.1007/s10764-008-9295-0; KEITH CG, 1966, BRIT J OPHTHALMOL, V50, P617, DOI 10.1136/bjo.50.11.617; Kodama R, 2010, J TOXICOL PATHOL, V23, P53, DOI 10.1293/tox.23.53; Komaromy AM, 2011, VET OPHTHALMOL, V14, P313, DOI 10.1111/j.1463-5224.2011.00878.x; Kozlosky JC, 2015, REGUL TOXICOL PHARM, V73, P27, DOI 10.1016/j.yrtph.2015.06.008; LAI YL, 1982, EXP EYE RES, V34, P219, DOI 10.1016/0014-4835(82)90056-2; LAI YL, 1980, INVEST OPHTH VIS SCI, V19, P849; MARTYN LJ, 1972, BRIT J OPHTHALMOL, V56, P487, DOI 10.1136/bjo.56.6.487; Mudry MCD, 2013, TOXICOL PATHOL, V41, P813, DOI 10.1177/0192623312469308; Narayanan V, 2003, PEDIATR NEUROL, V29, P404, DOI 10.1016/j.pediatrneurol.2003.09.002; Niwa M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010110; Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004; Pierfelice TJ, 2011, CANCER RES, V71, P1115, DOI 10.1158/0008-5472.CAN-10-0690; Sasaki Y, 2011, J TOXICOL PATHOL, V24, P69, DOI 10.1293/tox.24.69; Sato J, 2012, J TOXICOL PATHOL, V25, P63, DOI 10.1293/tox.25.63; SHIELDS JA, 1984, BRIT J OPHTHALMOL, V68, P152, DOI 10.1136/bjo.68.3.152; Shields JA, 2009, SAUDI J OPHTHALMOL, V23, P197, DOI 10.1016/j.sjopt.2009.10.003; Sinha DP, 2006, TOXICOL PATHOL, V34, P148, DOI 10.1080/01926230500531779; Sorden S. D., 2013, 32 ANN S SOC TOX PAT; Sorden S. D., 2015, CONT ED COURS COMB A; STRAATSMA BR, 1973, AM J OPHTHALMOL, V75, P551, DOI 10.1016/0002-9394(73)90809-X; Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6; VANBUREN JM, 1963, J NEUROL NEUROSUR PS, V26, P402; Wang BH, 2012, J ZHEJIANG UNIV-SC B, V13, P723, DOI 10.1631/jzus.B1200124; Wilcock B. P., 2016, PATHOLOGY DOMESTIC A, V1, P424; Wilcock B. P., 2002, HISTOLOGICAL CLASSIF	46	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					273	282		10.1177/0192623318758619			10	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800004	29478386	Bronze			2019-10-28	
J	Taketa, Y; Horie, K; Goto, T; Ohta, E; Nakano-Ito, K; Hayakawa, K; Seki, Y; Goto, A; Hosokawa, S				Taketa, Yoshikazu; Horie, Kanta; Goto, Tetsuya; Ohta, Etsuko; Nakano-Ito, Kyoko; Hayakawa, Kazuhiro; Seki, Yuki; Goto, Aya; Hosokawa, Satoru			Histopathologic Characterization of Mifepristone-induced Ovarian Toxicity in Cynomolgus Monkeys	TOXICOLOGIC PATHOLOGY			English	Article						cynomolgus monkey; estradiol-17 beta; mifepristone; ovarian toxicity; progesterone	MENSTRUAL-CYCLE; COLLABORATIVE WORK; MACACA-MULATTA; RHESUS-MONKEYS; FEMALE RATS; PROGESTERONE; ULTRASONOGRAPHY; ENDOMETRIUM; ANTAGONISTS; FERTILITY	Mifepristone, which is an orally active synthetic steroid with antiprogesterone activity, is known as an ovarian toxicant. Because the available data regarding the histopathologic characteristics of ovarian toxicity in nonhuman primates are limited, the present study was undertaken in order to investigate detailed histopathologic changes accompanying mifepristone-induced ovarian toxicity and its relationship to changes in menstrual cycle and circulating sex steroid hormone. Twenty mg/kg of mifepristone was orally administered daily to 4 cynomolgus monkeys for 2 months. Mifepristone inhibited the cyclic increases in circulating estradiol-17 and progesterone levels with associated absence of menstruation. Histopathologically, the ovary in the treated animals showed follicular phase without changes in the percentage of atretic antral follicles, and reduced endometrial thickness was noted in the uterus. These changes indicated that a certain degree of antral follicle development had been retained in spite of the menstrual cycle having been arrested in mifepristone-treated animals. Our investigation suggested that it is important to perform detailed histopathologic examination of reproductive organs with precise knowledge of the characteristics of each menstrual stage to detect ovarian toxicity in nonhuman primates. Monitoring menstrual signs and circulating sex steroid hormone levels provides additional evidence for the investigation of the mechanism of ovarian toxicity.	[Taketa, Yoshikazu; Ohta, Etsuko; Nakano-Ito, Kyoko; Hayakawa, Kazuhiro; Seki, Yuki; Goto, Aya; Hosokawa, Satoru] Eisai & Co Ltd, Tsukuba Drug Safety, Global Drug Safety, Biopharmaceut Assessments Core Funct Unit, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan; [Horie, Kanta] Eisai & Co Ltd, Translat Med, Med Creat, Neurol Business Grp, Tsukuba, Ibaraki, Japan; [Goto, Tetsuya] Sunplanet Co Ltd, Preclin Safety Res Unit, Tsukuba R&D Support Div, Tsukuba, Ibaraki, Japan	Taketa, Y (reprint author), Eisai & Co Ltd, Tsukuba Drug Safety, Global Drug Safety, Biopharmaceut Assessments Core Funct Unit, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	y-taketa@hhc.eisai.co.jp					Appt SE, 2006, FERTIL STERIL, V86, P1210, DOI 10.1016/j.fertnstert.2006.05.004; Baerwald AR, 2012, HUM REPROD UPDATE, V18, P73, DOI 10.1093/humupd/dmr039; Bishop CV, 2009, AM J PRIMATOL, V71, P384, DOI 10.1002/ajp.20664; Chwalisz K, 2000, STEROIDS, V65, P741, DOI 10.1016/S0039-128X(00)00190-2; Curry TE, 1996, CLIN OBSTET GYNECOL, V39, P486, DOI 10.1097/00003081-199606000-00022; DANFORTH DR, 1989, CONTRACEPTION, V40, P195, DOI 10.1016/0010-7824(89)90006-1; Deraedt R., 1985, ANTIPROGESTIN STEROI, P123, DOI 10.1007/978-1-4684-1242-0_10; Gaytan F, 2003, BIOL REPROD, V69, P99, DOI 10.1095/biolreprod.102.013755; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Keski-Rahkonen P, 2011, J STEROID BIOCHEM, V127, P396, DOI 10.1016/j.jsbmb.2011.06.006; Koal T, 2012, J STEROID BIOCHEM, V129, P129, DOI 10.1016/j.jsbmb.2011.12.001; KOERING MJ, 1969, AM J ANAT, V126, P73, DOI 10.1002/aja.1001260107; MORGAN PM, 1987, THERIOGENOLOGY, V27, P769, DOI 10.1016/0093-691X(87)90299-8; Nichols SM, 2005, HUM REPROD, V20, P79, DOI 10.1093/humrep/deh576; REMOHI J, 1988, HUM REPROD, V3, P431, DOI 10.1093/oxfordjournals.humrep.a136722; Riffle BW, 2013, J PHARMACOL TOX MET, V68, P314, DOI 10.1016/j.vascn.2013.07.003; Sanbuissho A, 2009, J TOXICOL SCI, V34, pSP1, DOI 10.2131/jts.34.S1; Sato J, 2016, J TOXICOL PATHOL, V29, P155, DOI 10.1293/tox.2016-0021; Sitruk-Ware R, 2003, CONTRACEPTION, V68, P409, DOI 10.1016/S0010-7824(03)00171-9; Sitruk-Ware R, 2006, CONTRACEPTION, V74, P48, DOI 10.1016/j.contraception.2006.03.016; Slayden OD, 2004, ARCH HISTOL CYTOL, V67, P393, DOI 10.1679/aohc.67.393; Tamura T, 2009, J TOXICOL SCI, V34, pSP31, DOI 10.2131/jts.34.S31; WATANABE D, 2006, J TOXICOL PATHOL, V19, P169; Weinbauer GF, 2008, TOXICOL PATHOL, V36, p7S, DOI 10.1177/0192623308327412; Westwood FR, 2008, TOXICOL PATHOL, V36, P375, DOI 10.1177/0192623308315665; Yoshida M, 2009, J TOXICOL SCI, V34, pSP189, DOI 10.2131/jts.34.S189; Yuan Y., 2002, HDB TOXICOLOGIC PATH, V2, P847	27	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					283	289		10.1177/0192623318763586			7	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800005	29558845	Bronze			2019-10-28	
J	Creane, M; McElroy, M; Duffy, A; Dawood, CS; O'Brien, T				Creane, Michael; McElroy, Mary; Duffy, Aoife; Dawood, Chaansha Shaik; O'Brien, Timothy			A 3-month Safety Assessment of Human Bone Marrow Derived Mesenchymal Stromal Cells Administered Once by the Intramuscular Route to Immunodeficient Mice	TOXICOLOGIC PATHOLOGY			English	Article						cell therapy; toxicology; critical limb ischemia; mesenchymal stromal cells; intramuscular; toxicity	CRITICAL LIMB ISCHEMIA; PERIPHERAL ARTERY-DISEASE; LUNG INJURY MODEL; STEM-CELLS; PHASE-I; ENDOTHELIAL-CELLS; BIODISTRIBUTION; TOXICITY; DELIVERY; NEOVASCULARIZATION	Critical limb ischemia (CLI) represents the severest manifestation of peripheral arterial disease and is a major unmet medical need. This disease occurs when the arterial blood supply within the limb fails to meet the metabolic demands of the resting muscle or tissue, resulting in chronic ischemic rest pain and/or tissue necrosis. Human mesenchymal stromal cells, termed hMSCs, represent an exciting therapeutic modality for the treatment of this disease due to their immunomodulatory and tissue reparative functions. The aim of the study was to assess the preclinical toxicity profile of human bone marrow-derived MSCs in support of their use as a treatment for CLI. A 3-month toxicity study was carried out under good laboratory practices in immunodeficient mice who received, intramuscularly, a single dose of 3 x 10(5) (approximately 15 x 10(6) cells/kg) hMSCs manufactured under good manufacturing practices. No significant changes in body weight, food consumption, clinical signs, or histopathological changes were observed in the hMSC-treated mice in comparison to the controls. These results highlight that the administration of hMSCs during the 3-month study period was well tolerated and not associated with any test item-related tumors. This data set supported the initiation of a phase 1b first in human study in "no option" for revascularization patients with CLI.	[Creane, Michael; O'Brien, Timothy] Natl Univ Ireland Galway, Regenerat Med Inst, Galway, Galway, Ireland; [McElroy, Mary] Tranent PCS EDI, Charles River Labs, Preclin Serv, Edinburgh, Midlothian, Scotland; [Duffy, Aoife; Dawood, Chaansha Shaik; O'Brien, Timothy] Natl Univ Ireland Galway, Ctr Cell Mfg Ireland, Galway, Galway, Ireland	Creane, M (reprint author), Natl Univ Ireland Galway, Regenerat Med Inst, Galway, Galway, Ireland.	mikey.creane@gmail.com			Science Foundation Ireland (SFI) Strategic Research ClusterScience Foundation Ireland [SFI: 09/SRC B1794]; European Regional Development FundEuropean Union (EU); SFI-Health Research Board Grant [TRA 201115]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this work was supported by Science Foundation Ireland (SFI) Strategic Research Cluster Grant No. SFI: 09/SRC B1794, European Regional Development Fund and SFI-Health Research Board Grant No. TRA 201115.	Armstrong David G, 2007, Int Wound J, V4, P286; Bortolotti F, 2015, STEM CELL REP, V4, P332, DOI 10.1016/j.stemcr.2015.01.001; Bradbury AW, 2005, LANCET, V366, P1925, DOI 10.1016/S0140-6736(05)67707-5; Braid LR, 2018, CYTOTHERAPY, V20, P232, DOI 10.1016/j.jcyt.2017.09.013; Braun RK, 2016, CYTOTHERAPY, V18, P536, DOI 10.1016/j.jcyt.2016.01.010; Brewster L, 2017, J VASC SURG, V65, P826, DOI 10.1016/j.jvs.2015.02.061; Bura A, 2014, CYTOTHERAPY, V16, P245, DOI 10.1016/j.jcyt.2013.11.011; Burkholder TH, 2010, J AM ASSOC LAB ANIM, V49, P448; Caplan AI, 2008, CELL STEM CELL, V3, P229, DOI 10.1016/j.stem.2008.08.008; Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008; Chen BKK, 2015, TRANSFUSION, V55, P1013, DOI 10.1111/trf.12938; Creane M, 2017, CYTOTHERAPY, V19, P384, DOI 10.1016/j.jcyt.2016.12.003; Das AK, 2013, WORLD J SURG, V37, P915, DOI 10.1007/s00268-012-1892-6; EMA, 2008, GUID HUM CELL BAS ME; EMA, 2011, REFL PAP STEM CELL B; FAWELL J K, 1972, Laboratory Animals (London), V6, P321, DOI 10.1258/002367772781006185; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Gailli D., 2014, BIOMED RES INT, V2014; Gremmels H, 2014, MOL THER, V22, P1960, DOI 10.1038/mt.2014.161; Guess AJ, 2017, STEM CELL TRANSL MED, V6, P1868, DOI 10.1002/sctm.16-0485; Gupta PK, 2017, STEM CELL TRANSL MED, V6, P689, DOI 10.5966/sctm.2016-0237; Gupta PK, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-143; Gupta R, 2011, CIRC-CARDIOVASC INTE, V4, P2, DOI 10.1161/CIRCINTERVENTIONS.110.960716; Hirsch AT, 2013, LANCET, V382, P1312, DOI 10.1016/S0140-6736(13)61576-7; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kitrou P, 2017, EXPERT OPIN BIOL TH, V17, P449, DOI 10.1080/14712598.2017.1289170; Kwon HM, 2014, VASC PHARMACOL, V63, P19, DOI 10.1016/j.vph.2014.06.004; Lasala GP, 2011, CARDIOVASC REVASCULA, V12, P29, DOI 10.1016/j.carrev.2010.01.001; Leroux L, 2010, MOL THER, V18, P1545, DOI 10.1038/mt.2010.108; Lippi G, 2012, BRIT J BIOMED SCI, V69, P67; Lu DB, 2011, DIABETES RES CLIN PR, V92, P26, DOI 10.1016/j.diabres.2010.12.010; MacIsaac ZM, 2012, EXP CELL RES, V318, P416, DOI 10.1016/j.yexcr.2011.12.002; Moon MH, 2006, CELL PHYSIOL BIOCHEM, V17, P279, DOI 10.1159/000094140; O'Brien T, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0145-7; Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22-3-377; Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466; Ramot Y, 2009, TOXICOL PATHOL, V37, P606, DOI 10.1177/0192623309338383; Rengasamy M, 2016, INDIAN J MED RES, V144, P852, DOI 10.4103/ijmr.IJMR_1842_15; Schmuck EG, 2016, STEM CELL TRANSL MED, V5, P1668, DOI 10.5966/sctm.2015-0379; Smadja DM, 2012, BONE MARROW TRANSPL, V47, P997, DOI 10.1038/bmt.2011.196; US FDA, 2013, GUID IND PRECL ASS I; Vilalta M, 2008, STEM CELLS DEV, V17, P993, DOI 10.1089/scd.2007.0201; Wang YW, 2012, STEM CELLS DEV, V21, P1401, DOI 10.1089/scd.2011.0441; Yun JW, 2016, REGUL TOXICOL PHARM, V81, P437, DOI 10.1016/j.yrtph.2016.09.029	45	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					290	301		10.1177/0192623318760516			12	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800006	29504494				2019-10-28	
J	Yasuno, K; Kumagai, K; Iguchi, T; Tsuchiya, Y; Kai, K; Mori, K				Yasuno, Kyohei; Kumagai, Kazuyoshi; Iguchi, Takuma; Tsuchiya, Yoshimi; Kai, Kiyonori; Mori, Kazuhiko			DS-7250, a Diacylglycerol Acyltransferase 1 Inhibitor, Enhances Hepatic Steatosis in Zucker Fatty Rats via Upregulation of Fatty Acid Synthesis	TOXICOLOGIC PATHOLOGY			English	Article						DGAT1; DGAT1 inhibitor; hepatic steatosis; de novo lipogenesis; Zucker fatty rat; high-fat diet	TRIGLYCERIDE SYNTHESIS; NONALCOHOLIC STEATOHEPATITIS; TRIACYLGLYCEROL SYNTHESIS; INSULIN-RESISTANCE; LIVER-DISEASE; DIETARY-FAT; DGAT1; OBESITY; MODELS; ELOVL6	Diacylglycerol acyltransferase 1 (DGAT1) catalyzes the final step in triglyceride synthesis. Since Dgat1(-/-) mice fed a high-fat diet (HFD) are resistant to hepatic steatosis, DGAT1 inhibitors are expected to have antifatty liver effects. To evaluate the hepatic effects of DS-7250, a selective DGAT1 inhibitor, vehicle or 10 mg/kg of DS-7250 was administered orally to male Fisher 344 (F344) and Zucker fatty (ZF) rats fed a standard diet or HFD for 14 or 28 days. ZF rats showed slight hepatic steatosis regardless of feeding conditions. DS-7250 exacerbated hepatic steatosis in ZF rats fed an HFD compared with the vehicle control. Hepatic steatosis did not occur in F344 rats fed an HFD, in which systemic exposures of DS-7250 were comparable to those in ZF rats. There was a higher expression of genes involved in lipid uptake and fatty acid synthesis in ZF rats compared to F344 rats under HFD conditions. DS-7250 upregulated key genes involved in de novo lipogenesis, which causes hepatic steatosis independently of DGAT1, in ZF rats fed an HFD compared with the vehicle control. These data suggest that ZF rats were more susceptible to hepatic steatosis due to their genetic characteristics and DS-7250 exacerbated hepatic steatosis independently of DGAT1.	[Yasuno, Kyohei; Kumagai, Kazuyoshi; Iguchi, Takuma; Kai, Kiyonori; Mori, Kazuhiko] Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kitakasai, Tokyo 1348630, Japan; [Tsuchiya, Yoshimi] Daiichi Sankyo Inc, Quantitat Clin Pharmacol & Translat Sci, Basking Ridge, NJ USA	Kumagai, K (reprint author), Daiichi Sankyo Co Ltd, Med Safety Res Labs, Edogawa Ku, 1-16-13 Kitakasai, Tokyo 1348630, Japan.	kumagai.kazuyoshi.k6@daiichisankyo.co.jp		Kumagai, Kazuyoshi/0000-0003-4974-939X			Ables GP, 2012, J LIPID RES, V53, P2364, DOI 10.1194/jlr.M029041; Angrish MM, 2016, TOXICOL SCI, V150, P261, DOI 10.1093/toxsci/kfw018; Buque X, 2010, J LIPID RES, V51, P500, DOI 10.1194/jlr.M001966; Cao JS, 2011, J BIOL CHEM, V286, P41838, DOI 10.1074/jbc.M111.245456; Carmiel-Haggai M, 2004, FASEB J, V18, P136, DOI 10.1096/fj.04-2291fje; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chen HC, 2005, ARTERIOSCL THROM VAS, V25, P482, DOI 10.1161/01.ATV.0000151874.81059.ad; Chen HC, 2003, AM J PHYSIOL-ENDOC M, V284, pE213, DOI 10.1152/ajpendo.00248.2002; Chen HC, 2000, TRENDS CARDIOVAS MED, V10, P188, DOI 10.1016/S1050-1738(00)00066-9; Choi CS, 2007, J BIOL CHEM, V282, P22678, DOI 10.1074/jbc.M704213200; Fellmann L, 2013, PHARMACOL THERAPEUT, V137, P331, DOI 10.1016/j.pharmthera.2012.11.004; Ferre P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/j.1463-1326.2010.01275.x; Kucera O, 2014, WORLD J GASTROENTERO, V20, P8364, DOI 10.3748/wjg.v20.i26.8364; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Li L, 2016, OBES REV, V17, P510, DOI 10.1111/obr.12407; Li ZZ, 2009, J BIOL CHEM, V284, P5637, DOI 10.1074/jbc.M807616200; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maciejewski BS, 2013, AM J PHYSIOL-GASTR L, V304, pG958, DOI 10.1152/ajpgi.00384.2012; Matsuzaka T, 2007, NAT MED, V13, P1193, DOI 10.1038/nm1662; Matsuzaka T, 2012, HEPATOLOGY, V56, P2199, DOI 10.1002/hep.25932; MELANDER A, 1979, EUR J CLIN PHARMACOL, V15, P269, DOI 10.1007/BF00618516; Shimano H, 2012, PROG LIPID RES, V51, P267, DOI 10.1016/j.plipres.2011.12.004; Takahashi Y, 2012, WORLD J GASTROENTERO, V18, P2300, DOI 10.3748/wjg.v18.i19.2300; TAN KKC, 1995, CLIN PHARMACOL THER, V57, P425, DOI 10.1016/0009-9236(95)90212-0; Tschanz SA, 2011, J MICROSC-OXFORD, V243, P47, DOI 10.1111/j.1365-2818.2010.03481.x; Uematsu T, 1996, J PHARM SCI, V85, P1012, DOI 10.1021/js9600641; Villanueva CJ, 2009, HEPATOLOGY, V50, P434, DOI 10.1002/hep.22980; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; Yamaguchi K, 2007, HEPATOLOGY, V45, P1366, DOI 10.1002/hep.21655; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; Zammit VA, 2013, BIOCHEM J, V451, P1, DOI 10.1042/BJ20121689	31	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					302	311		10.1177/0192623318765909			10	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800007	29587622	Bronze			2019-10-28	
J	Takahashi, N; Yoshida, T; Kojima, S; Yamaguchi, S; Ohtsuka, R; Takeda, M; Kosaka, T; Harada, T				Takahashi, Naofumi; Yoshida, Toshinori; Kojima, Sayuri; Yamaguchi, Satoru; Ohtsuka, Ryoichi; Takeda, Makio; Kosaka, Tadashi; Harada, Takanori			Pathological and Clinical Pathological Changes Induced by Four-week, Repeated-dose, Oral Administration of the Wood Preservative Chromated Copper Arsenate in Wistar Rats	TOXICOLOGIC PATHOLOGY			English	Article						anemia; chromated copper arsenate; hyperplasia; oxidative stress; small intestine	INDUCED OXIDATIVE STRESS; CCA-TREATED WOOD; INDUCED RENAL INJURY; HEXAVALENT CHROMIUM; DRINKING-WATER; DNA-DAMAGE; F344 RATS; (CCA)-TREATED WOOD; N-ACETYLCYSTEINE; SODIUM ARSENITE	Chromated copper arsenate (CCA) is used as a wood preservative worldwide. Exposure to it may adversely affect human health. Some events have increased human exposure to CCA, including the Great East Japan Earthquake, which generated a large amount of lumber debris from CCA-treated woods. We elucidated the toxicity due to daily exposure to CCA over a 4-week period at doses of 0, 8, 40, and 80 mg/kg/day in Wistar Hannover rats. Chromium (Cr) and arsenic (As), but not copper, were detected in the plasma samples of rats treated with various doses of CCA. Males and females showed sedation, and males had poor body weight gain. The clinical pathologies observed in both sexes included hypochromic and microcytic anemia, hepatic and renal dysfunction, and changes in lipid and glucose levels. Histopathologically, males and females showed forestomach hyperkeratosis, mucosal epithelial hyperplasia in the small intestine, rectal goblet cell hypertrophy, and lipofuscin deposition in the proximal renal tubule. Females showed diffuse hepatocellular hypertrophy with increased 8-hydroxydeoxyguanosine levels. These results indicated that oral administration of CCA mainly affected hematopoietic, gastrointestinal, hepatic, and renal systems owing to the toxic effects of As and/or Cr. Major toxic effects were observed in both sexes receiving 40 and 80 mg/kg/day.	[Takahashi, Naofumi; Kojima, Sayuri; Yamaguchi, Satoru; Ohtsuka, Ryoichi; Takeda, Makio; Kosaka, Tadashi; Harada, Takanori] Inst Environm Toxicol, Uchimoriya Machi 4321, Joso, Ibaraki 3030043, Japan; [Yoshida, Toshinori] Tokyo Univ Agr & Technol, Lab Vet Pathol, Fuchu, Tokyo, Japan	Takahashi, N (reprint author), Inst Environm Toxicol, Uchimoriya Machi 4321, Joso, Ibaraki 3030043, Japan.	n.takahashi@iet.or.jp	Yoshida, Toshinori/B-7255-2015		Ministry of Health, Labour and Welfare, JapanMinistry of Health, Labour and Welfare, Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant in aid of research on risk assessment of wood preservatives from the Ministry of Health, Labour and Welfare, Japan.	Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Abu El-Saad AM, 2016, DRUG DES DEV THER, V10, P3425, DOI 10.2147/DDDT.S115339; *AM WOOD PRES ASS, 2005, AM WOOD PRES ASS STA; Arreola-Mendoza L, 2006, TOXICOLOGY, V218, P237, DOI 10.1016/j.tox.2005.11.010; Bashir S, 2006, BASIC CLIN PHARMACOL, V98, P38, DOI 10.1111/j.1742-7843.2006.pto_170.x; Bhadauria S, 2007, CELL BIOL TOXICOL, V23, P91, DOI 10.1007/s10565-006-0135-8; Canonne-Hergaux F, 2001, BLOOD, V98, P3823, DOI 10.1182/blood.V98.13.3823; CARTER DE, 1995, ENVIRON HEALTH PERSP, V103, P17, DOI 10.2307/3432005; Cullen JM, 2016, TOXICOL PATHOL, V44, P279, DOI 10.1177/0192623315611501; Dickey P., 2003, GUIDE SELECTING TREA; Dubey B, 2007, ENVIRON SCI TECHNOL, V41, P1533, DOI 10.1021/es0622812; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Frantzen K., 1998, HAMILTON HARDYS IND, P51; Fukuyama T, 2008, J IMMUNOTOXICOL, V5, P99, DOI 10.1080/15476910802085715; Goodnough LT, 2000, BLOOD, V96, P823, DOI 10.1182/blood.V96.3.823.015k49_823_833; Gupta R, 2006, J APPL TOXICOL, V26, P213, DOI 10.1002/jat.1131; Haney J, 2015, REGUL TOXICOL PHARM, V73, P834, DOI 10.1016/j.yrtph.2015.10.011; Harada T, 2003, TOXICOL PATHOL, V31, P87, DOI 10.1080/01926230390173941; Hingston JA, 2001, ENVIRON POLLUT, V111, P53, DOI 10.1016/S0269-7491(00)00030-0; Hughes MF, 2003, TOXICOL APPL PHARM, V191, P202, DOI 10.1016/S0041-008X(03)00249-7; Hughes MF, 2006, ENVIRON HEALTH PERSP, V114, P1790, DOI 10.1289/ehp.9058; Kenyon EM, 2005, TOXICOL SCI, V85, P468, DOI 10.1093/toxsci/kfi107; Kim H, 2007, SCI TOTAL ENVIRON, V374, P273, DOI 10.1016/j.scitotenv.2006.12.047; Kimura A, 2005, TOXICOL APPL PHARM, V203, P53, DOI 10.1016/j.taap.2004.07.013; Kimura A, 2006, AM J PATHOL, V169, P1118, DOI 10.2353/ajpath.2006.060024; Kojima S, 2009, J TOXICOL SCI, V34, P527, DOI 10.2131/jts.34.527; Kopec AK, 2012, TOXICOL APPL PHARM, V259, P13, DOI 10.1016/j.taap.2011.11.012; Matos RC, 2013, ENVIRON TOXICOL PHAR, V36, P929, DOI 10.1016/j.etap.2013.08.006; McQueen J, 1998, FOREST PROD J, V48, P86; Ministry of the Environment, 2012, PUBL ANN RES 2 SOI B; Nandi D, 2006, FOOD CHEM TOXICOL, V44, P1579, DOI 10.1016/j.fct.2006.04.013; Nandi D, 2005, TOXICOLOGY, V211, P26, DOI 10.1016/j.tox.2005.02.013; Ohgami N, 2015, ENVIRON POLLUT, V206, P456, DOI 10.1016/j.envpol.2015.07.041; Patlolla AK, 2009, ENVIRON TOXICOL, V24, P66, DOI 10.1002/tox.20395; Pedraza-Chaverri Jose, 2005, BMC Nephrol, V6, P4, DOI 10.1186/1471-2369-6-4; PETERS HA, 1984, JAMA-J AM MED ASSOC, V251, P2393, DOI 10.1001/jama.251.18.2393; PETERS HA, 1986, ACTA PHARMACOL TOX, V59, P39; PETERSEN R, 1994, OCCUP ENVIRON MED, V51, P259, DOI 10.1136/oem.51.4.259; Rahman FA, 2004, J ENVIRON QUAL, V33, P173, DOI 10.2134/jeq2004.0173; Rodriguez VM, 2005, TOXICOL SCI, V84, P157, DOI 10.1093/toxsci/kfi057; Ryan PB, 2000, ENVIRON HEALTH PERSP, V108, P731, DOI 10.2307/3434726; Salnikow K, 2008, CHEM RES TOXICOL, V21, P28, DOI 10.1021/tx700198a; Santra A, 2007, TOXICOL APPL PHARM, V220, P146, DOI 10.1016/j.taap.2006.12.029; SAW D, 1988, Journal of the Hong Kong Medical Association, V40, P219; Schafer S. G., 1999, TOXICOLOGY, P755; Scibior A, 2007, J TOXICOL ENV HEAL A, V70, P696, DOI 10.1080/15287390601187906; Shibata T, 2007, SCI TOTAL ENVIRON, V372, P624, DOI 10.1016/j.scitotenv.2006.10.037; Shibata T, 2012, ENVIRON SCI TECHNOL, V46, P3618, DOI 10.1021/es300055m; Stout MD, 2009, ENVIRON HEALTH PERSP, V117, P716, DOI 10.1289/ehp.0800208; Suh M, 2014, FOOD CHEM TOXICOL, V65, P381, DOI 10.1016/j.fct.2014.01.009; Tapio S, 2006, MUTAT RES-REV MUTAT, V612, P215, DOI 10.1016/j.mrrev.2006.02.001; The Japanese Association for Laboratory Animal Science, 1987, EXP ANIM, V36, P285; Thomas C, 2002, CLIN CHEM, V48, P1066; Thompson CM, 2015, MUTAT RES-GEN TOX EN, V789, P61, DOI 10.1016/j.mrgentox.2015.05.004; Ullrich C, 2005, JAMA-J AM MED ASSOC, V294, P924, DOI 10.1001/jama.294.8.924; US Environmental Protection Agency, 2003, FRL73012 US ENV PROT; Vahter M, 2002, TOXICOLOGY, V181, P211, DOI 10.1016/S0300-483X(02)00285-8; Wang XF, 2006, TOXICOLOGY, V228, P16, DOI 10.1016/j.tox.2006.08.005; Wood RJ, 1998, J NUTR, V128, P1841; Yamanaka K, 2004, TOXICOL APPL PHARM, V198, P385, DOI 10.1016/j.taap.2003.10.025	60	0	0	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					312	323		10.1177/0192623318765392			12	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800008	29587599	Bronze			2019-10-28	
J	Kozlowski, C; Brumm, J; Cain, G				Kozlowski, Cleopatra; Brumm, Jochen; Cain, Gary			An Automated Image Analysis Method to Quantify Veterinary Bone Marrow Cellularity on H&E Sections	TOXICOLOGIC PATHOLOGY			English	Article						bone marrow; hematology; image analysis; histopathology	PATHOLOGY	Bone marrow toxicity is a common finding when assessing safety of drug candidate molecules. Standard hematoxylin and eosin (H&E) marrow tissue sections are typically manually evaluated to provide a semiquantitative assessment of overall cellularity. Here, we developed an automated image analysis method that allows quantitative assessment of changes in bone marrow cell population in sternal bone. In order to test whether the method was repeatable and sensitive, we compared the automated method with manual subjective histopathology scoring of total cellularity in rat sternal bone marrow samples across 17 independently run studies. The automated method was consistent with manual scoring methodology for detecting altered bone marrow cellularity and, in multiple cases, identified changes at lower doses. The image analysis method allows rapid and more quantitative assessment of bone marrow toxicity compared to manual examination of H&E slides, making it an excellent tool to aid detection of bone marrow cell depletion in preclinical toxicologic studies.	[Kozlowski, Cleopatra; Cain, Gary] Genentech Inc, Safety Assessment Pathol, 1 DNA Way, San Francisco, CA 94080 USA; [Brumm, Jochen] Genentech Inc, Biostat, San Francisco, CA 94080 USA	Kozlowski, C (reprint author), Genentech Inc, Safety Assessment Pathol, 1 DNA Way, San Francisco, CA 94080 USA.	kozlowski.cleopatra@gene.com			Genentech Inc.Roche HoldingGenentech	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was fully funded and supported by Genentech Inc.	Aeffner F, 2017, ARCH PATHOL LAB MED, V141, P1267, DOI 10.5858/arpa.2016-0386-RA; Aeffner F, 2016, TOXICOL PATHOL, V44, P825, DOI 10.1177/0192623316653492; Arslan S, 2014, CYTOM PART A, V85A, P480, DOI 10.1002/cyto.a.22457; Baatz M, 2009, COMB CHEM HIGH T SCR, V12, P908, DOI 10.2174/138620709789383196; Benz UC, 2004, ISPRS J PHOTOGRAMM, V58, P239, DOI 10.1016/j.isprsjprs.2003.10.002; Haley P, 2005, TOXICOL PATHOL, V33, P404, DOI 10.1080/01926230590934304; Haschek WM, 2010, FUNDAMENTALS OF TOXICOLOGIC PATHOLOGY, 2ND EDITION, P491, DOI 10.1016/B978-0-12-370469-6.00016-7; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Kile BT, 2014, BRIT J HAEMATOL, V165, P217, DOI 10.1111/bjh.12757; Kozlowski C., TOXICOLOGIC PATHOLOG; MoradiAmin M, 2016, MICROSC RES TECHNIQ, V79, P908, DOI 10.1002/jemt.22718; Qualls M, 2010, ACAD EMERG MED, V17, P1113, DOI 10.1111/j.1553-2712.2010.00874.x; Reagan WJ, 2011, VET CLIN PATH, V40, P119, DOI 10.1111/j.1939-165X.2011.00323.x; Reta C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130805; Travlos GS, 2006, TOXICOL PATHOL, V34, P548, DOI 10.1080/01926230600939856; Webster JD, 2014, VET PATHOL, V51, P211, DOI 10.1177/0300985813503570	16	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					324	335		10.1177/0192623318766457			12	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800009	29683091				2019-10-28	
J	Kozlowski, C; Fullerton, A; Cain, G; Katavolos, P; Bravo, J; Tarrant, JM				Kozlowski, Cleopatra; Fullerton, Aaron; Cain, Gary; Katavolos, Paula; Bravo, Joseph; Tarrant, Jacqueline M.			Proof of Concept for an Automated Image Analysis Method to Quantify Rat Bone Marrow Hematopoietic Lineages on H&E Sections	TOXICOLOGIC PATHOLOGY			English	Article						bone marrow; hematopoiesis; image analysis; histopathology; cytology	ANTIBODY; DRUG; MEGAKARYOCYTES; MORPHOLOGY; APOPTOSIS; PATHOLOGY; CELLS	The bone marrow is an important site for assessment of the hematopoietic toxicity of new drug candidates. Here, we extended our previous work, where we developed a computer algorithm to automatically quantitate overall bone marrow cell density by analyzing digitized images of standard hematoxylin and eosin (H&E) slides of rat bone marrow and further evaluated the capability to quantify myeloid: erythroid + lymphoid (M:EL) ratio and megakaryocyte cell density. We tested the algorithm in a toxicity study, where rats were dosed with two molecules known to affect bone marrow composition, monomethyl auristatin E, and a Bcl-xL inhibitor. The image analysis method detected significant changes in M:EL and megakaryocyte number that were either not found or semiquantitatively described by manual microscopic observation of the same slides. The image analysis results were consistent with other more established but time-consuming methods that measure changes in bone marrow cell composition: smear cytology, flow cytometry, and microscopic assessment. Our work demonstrates the feasibility of a rapid and more quantitative assessment of changes in bone marrow cell lineage composition using a computer algorithm compared to microscopic examination of H&E-stained bone marrow sections.	[Kozlowski, Cleopatra; Fullerton, Aaron; Cain, Gary; Katavolos, Paula; Bravo, Joseph] Genentech Inc, Safety Assessment, Dev Sci, San Francisco, CA 94080 USA; [Tarrant, Jacqueline M.] Gilead Sci, Foster City, CA USA	Kozlowski, C (reprint author), Genentech Inc, Safety Assessment Pathol, 1 DNA Way, San Francisco, CA 94080 USA.	kozlowski.cleopatra@gene.com			Genentech Inc.Roche HoldingGenentech	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research was fully funded and supported by Genentech Inc. No support from external sources was received.	Baatz M, 2009, COMB CHEM HIGH T SCR, V12, P908, DOI 10.2174/138620709789383196; Bolliger AP, 2004, VET CLIN PATH, V33, P58, DOI 10.1111/j.1939-165X.2004.tb00351.x; CLINE J M, 1985, Toxicologic Pathology, V13, P349; Donaghy H, 2016, MABS-AUSTIN, V8, P659, DOI 10.1080/19420862.2016.1156829; Everds NE, 2013, TOXICOL PATHOL, V41, P280, DOI 10.1177/0192623312467400; Haley P, 2005, TOXICOL PATHOL, V33, P404, DOI 10.1080/01926230590934304; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Kile BT, 2014, BRIT J HAEMATOL, V165, P217, DOI 10.1111/bjh.12757; Kodama T, 2012, CELL DEATH DIFFER, V19, P1856, DOI 10.1038/cdd.2012.88; Kozlowski C., TOXICOLOGIC PATHOLOG; Reagan WJ, 2011, VET CLIN PATH, V40, P119, DOI 10.1111/j.1939-165X.2011.00323.x; Rehg JE, 2012, TOXICOL PATHOL, V40, P345, DOI 10.1177/0192623311430695; Ru YX, 2015, ULTRASTRUCT PATHOL, V39, P79, DOI 10.3109/01913123.2014.980482; Stagg NJ, 2016, REGUL TOXICOL PHARM, V82, P1, DOI 10.1016/j.yrtph.2016.10.012; Travlos GS, 2006, TOXICOL PATHOL, V34, P548, DOI 10.1080/01926230600939856; Virgo PF, 2012, ANN CLIN BIOCHEM, V49, P17, DOI 10.1258/acb.2011.011128	16	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	APR	2018	46	3					336	347		10.1177/0192623318766458			12	Pathology; Toxicology	Pathology; Toxicology	GF7HJ	WOS:000432138800010	29683092				2019-10-28	
J	Bertero, L; Massa, F; Metovic, J; Zanetti, R; Castellano, I; Ricardi, U; Papotti, M; Cassoni, P				Bertero, Luca; Massa, Federica; Metovic, Jasna; Zanetti, Roberto; Castellano, Isabella; Ricardi, Umberto; Papotti, Mauro; Cassoni, Paola			Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?	VIRCHOWS ARCHIV			English	Review						TNM classification; Cancer classification; UICC; Malignant tumours; Surgical pathology	STAGING PROJECT PROPOSALS; SQUAMOUS-CELL CARCINOMA; IASLC LUNG-CANCER; EPITHELIAL OVARIAN-CANCER; AMERICAN JOINT COMMISSION; RESULTS SEER ANALYSIS; INTRAHEPATIC CHOLANGIOCARCINOMA; PROGNOSTIC-FACTOR; PANCREATIC ADENOCARCINOMA; HEPATOCELLULAR-CARCINOMA	The TNM classification of malignant tumours is a mainstay tool in clinical practice and research for prognostic assessment of patients, treatment allocation and trial enrolment, as well as for epidemiological studies and data collection by cancer registries worldwide. Pathological TNM (pTNM) represents the pathological classification of a tumor, assigned after surgical resection or adequate sampling by biopsy, and periodical updates to the relative classification criteria are necessary to preserve its clinical relevance by integrating newly reported data. A structured approach has been put in place to fulfil this need and, based upon this process, the Eighth Edition of Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours has been published, introducing many significant changes, including novel classification criteria for specific tumour types. In this review, we aim to describe the major changes introduced in the pTNM classification criteria and to summarize the evidence supporting these changes.	[Bertero, Luca; Castellano, Isabella; Cassoni, Paola] Univ Turin, Dept Med Sci, Pathol Unit, Via Santena 7, I-10126 Turin, Italy; [Bertero, Luca; Massa, Federica; Metovic, Jasna; Castellano, Isabella; Papotti, Mauro; Cassoni, Paola] Citta Salute & Sci Hosp, Via Santena 7, I-10126 Turin, Italy; [Massa, Federica; Metovic, Jasna; Papotti, Mauro] Univ Turin, Dept Oncol, Pathol Unit, Via Santena 7, I-10126 Turin, Italy; [Zanetti, Roberto] CPO Ctr Canc Prevent, Piedmont Canc Registry, Via San Massimo 24, I-10123 Turin, Italy; [Ricardi, Umberto] Univ Turin, Dept Oncol, Radiat Oncol Unit, Via Genova 3, I-10126 Turin, Italy; [Ricardi, Umberto] Citta Salute & Sci Hosp, Via Genova 3, I-10126 Turin, Italy; [Ricardi, Umberto; Cassoni, Paola] Italian Natl Comm, TNM, UICC, Rome, Italy	Bertero, L (reprint author), Univ Turin, Dept Med Sci, Pathol Unit, Via Santena 7, I-10126 Turin, Italy.; Bertero, L (reprint author), Citta Salute & Sci Hosp, Via Santena 7, I-10126 Turin, Italy.	luca.bertero@unito.it	; Bertero, Luca/N-5357-2017	Castellano, isabella/0000-0002-9072-1615; Bertero, Luca/0000-0001-9887-7668; Metovic, Jasna/0000-0002-9146-1747	Rete Oncologica Piemonte e Valle d'Aosta	This work was supported by the Rete Oncologica Piemonte e Valle d'Aosta (to P.C.).	Adsay NV, 2012, SEMIN DIAGN PATHOL, V29, P127, DOI 10.1053/j.semdp.2012.08.010; Ali SM, 2015, HPB, V17, P244, DOI 10.1111/hpb.12333; Allen PJ, 2017, ANN SURG, V265, P185, DOI 10.1097/SLA.0000000000001763; Amin MB, 2016, AJCC CANC STAGING MA; [Anonymous], 2009, INT J GYNECOL OBSTET, V105, P3; Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456; Baek Su-Jin, 2008, J Gynecol Oncol, V19, P223, DOI 10.3802/jgo.2008.19.4.223; Balci S, 2015, ANN SURG ONCOL, V22, P4392, DOI 10.1245/s10434-015-4499-y; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; Brierley JD, 2017, TNM CLASSIFICATION M; Chansky K, 2017, J THORAC ONCOL, V12, P1109, DOI 10.1016/j.jtho.2017.04.011; Clayman GL, 2005, J CLIN ONCOL, V23, P759, DOI 10.1200/JCO.2005.02.155; Cliby WA, 2006, GYNECOL ONCOL, V103, P797, DOI 10.1016/j.ygyno.2006.08.047; Dahlstrom KR, 2013, CANCER-AM CANCER SOC, V119, P81, DOI 10.1002/cncr.27727; Davison JM, 2014, MODERN PATHOL, V27, P1521, DOI 10.1038/modpathol.2014.37; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Delahunt B, 2016, HISTOPATHOLOGY, V68, P475, DOI 10.1111/his.12803; Eberhardt WEE, 2015, J THORAC ONCOL, V10, P1515, DOI 10.1097/JTO.0000000000000673; Ebrahimi A, 2014, JAMA OTOLARYNGOL, V140, P1138, DOI 10.1001/jamaoto.2014.1548; El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974; Ferrandina G, 2007, GYNECOL ONCOL, V107, P154, DOI 10.1016/j.ygyno.2007.05.016; Franko J, 2016, LANCET ONCOL, V17, P1709, DOI 10.1016/S1470-2045(16)30500-9; Franko J, 2012, J CLIN ONCOL, V30, P263, DOI 10.1200/JCO.2011.37.1039; Goh BKP, 2016, J SURG ONCOL, V113, P89, DOI 10.1002/jso.24099; Haughey BH, 2016, ORAL ONCOL, V62, P11, DOI 10.1016/j.oraloncology.2016.09.004; Hayakawa Y, 2016, NAT REV CANCER, V16, P305, DOI 10.1038/nrc.2016.24; Huang SH, 2015, J CLIN ONCOL, V33, P836, DOI 10.1200/JCO.2014.58.6412; Igami T, 2011, WORLD J SURG, V35, P2501, DOI 10.1007/s00268-011-1242-0; Jambusaria-Pahlajani A, 2013, JAMA DERMATOL, V149, P402, DOI 10.1001/jamadermatol.2013.2456; Kamarajah SK, 2017, ANN SURG ONCOL, V24, P2023, DOI 10.1245/s10434-017-5810-x; Kanazawa K, 1999, GYNECOL ONCOL, V73, P237, DOI 10.1006/gyno.1999.5349; Kang HJ, 2014, SURGERY, V155, P74, DOI 10.1016/j.surg.2013.08.004; Kim Y, 2017, J SURG ONCOL, V116, P643, DOI 10.1002/jso.24720; Kinoshita A, 2015, WORLD J HEPATOL, V7, P406, DOI 10.4254/wjh.v7.i3.406; Kondo K, 2014, J THORAC ONCOL, V9, pS81, DOI 10.1097/JTO.0000000000000291; Kordan Y, 2009, J UROLOGY, V182, P2291, DOI 10.1016/j.juro.2009.07.020; Matos LL, 2017, ORAL ONCOL, V71, P47, DOI 10.1016/j.oraloncology.2017.05.020; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; Mermod M, 2016, ORAL ONCOL, V62, P60, DOI 10.1016/j.oraloncology.2016.10.003; Misdraji J, 2015, MODERN PATHOL, V28, pS67, DOI 10.1038/modpathol.2014.129; Moch H, 2016, WHO CLASSIFICATION T; Moon A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002064; Moon HJ, 2011, ANN SURG ONCOL, V18, P1916, DOI 10.1245/s10434-011-1556-z; Murakami Y, 2010, J AM COLL SURGEONS, V211, P196, DOI 10.1016/j.jamcollsurg.2010.03.037; Nagtegaal ID, 2017, J CLIN ONCOL, V35, P1119, DOI 10.1200/JCO.2016.68.9091; Ngan HYS, 2002, INT J GYNECOL OBSTET, V77, P285; Nicholson AG, 2014, J THORAC ONCOL, V9, pS73, DOI 10.1097/JTO.0000000000000303; Nowak AK, 2016, J THORAC ONCOL, V11, P2089, DOI 10.1016/j.jtho.2016.08.147; Onda T, 1998, CANCER, V83, P1555, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Park JT, 2015, ANN SURG ONCOL, V22, P248, DOI 10.1245/s10434-014-3870-8; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Prat J, 2009, INT J GYNECOL OBSTET, V104, P177, DOI 10.1016/j.ijgo.2008.12.008; Rami-Porta R, 2015, J THORAC ONCOL, V10, P990, DOI 10.1097/JTO.0000000000000559; Rice D, 2016, J THORAC ONCOL, V11, P2100, DOI 10.1016/j.jtho.2016.09.121; Rice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Rindi G, 2012, JNCI-J NATL CANCER I, V104, P764, DOI 10.1093/jnci/djs208; Saka B, 2016, ANN SURG ONCOL, V23, P2010, DOI 10.1245/s10434-016-5093-7; Schmults CD, 2013, JAMA DERMATOL, V149, P541, DOI 10.1001/jamadermatol.2013.2139; Shin JH, 2013, INT J SURG, V11, P944, DOI 10.1016/j.ijsu.2013.06.015; Shindoh J, 2015, ANN SURG, V261, P733, DOI 10.1097/SLA.0000000000000728; Shindoh J, 2014, SURG ONCOL CLIN N AM, V23, P313, DOI 10.1016/j.soc.2013.11.003; Shindoh J, 2013, ANN SURG ONCOL, V20, P1223, DOI 10.1245/s10434-012-2739-y; Sinha P, 2015, ORAL ONCOL, V51, P514, DOI 10.1016/j.oraloncology.2015.02.098; Sobin LH, 2010, TNM CLASSIFICATION M; Strobel O, 2015, ANN SURG, V261, P961, DOI 10.1097/SLA.0000000000000814; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156; Velazquez EF, 2012, SEMIN DIAGN PATHOL, V29, P96, DOI 10.1053/j.semdp.2011.08.009; Webber C, 2014, INT J CANCER, V135, P371, DOI 10.1002/ijc.28683; Yamashita Y, 2012, ANN SURG ONCOL, V19, P2027, DOI 10.1245/s10434-011-2195-0; Yang L, 2017, ONCOTARGET, V8, P66784, DOI 10.18632/oncotarget.18158; You D, 2014, ARCH PATHOL LAB MED, V138, P1072, DOI 10.5858/arpa.2013-0324-OA	75	14	15	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					519	531		10.1007/s00428-017-2276-y			13	Pathology	Pathology	GE4HL	WOS:000431176200001	29209757				2019-10-28	
J	Soer, E; Brosens, L; van de Vijver, M; Dijk, F; van Velthuysen, ML; Farina-Sarasqueta, A; Morreau, H; Offerhaus, J; Koens, L; Verheij, J				Soer, Eline; Brosens, Lodewijk; van de Vijver, Marc; Dijk, Frederike; van Velthuysen, Marie-Louise; Farina-Sarasqueta, Arantza; Morreau, Hans; Offerhaus, Johan; Koens, Lianne; Verheij, Joanne			Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens	VIRCHOWS ARCHIV			English	Review						Pancreaticoduodenectomy; Pancreatic ductal carcinoma; Surgical pathology; Grossing technique	PANCREATIC DUCTAL ADENOCARCINOMA; LYMPH-NODE MICROMETASTASIS; PAPILLARY MUCINOUS TUMORS; LONG-TERM-SURVIVAL; PERIAMPULLARY ADENOCARCINOMAS; NEOADJUVANT THERAPY; RESECTION MARGINS; HEAD CANCER; PROGNOSTIC RELEVANCE; PRECURSOR LESIONS	A pancreatoduodenectomy specimen is complex, and there is much debate on how it is best approached by the pathologist. In this review, we provide an overview of topics relevant for current clinical practice in terms of gross dissection, and macro- and microscopic assessment of the pancreatoduodenectomy specimen with a suspicion of suspected pancreatic cancer. Tumor origin, tumor size, degree of differentiation, lymph node status, and resection margin status are universally accepted as prognostic for survival. However, different guidelines diverge on important issues, such as the diagnostic criteria for evaluating the completeness of resection. The macroscopic assessment of the site of origin in periampullary tumors and cystic lesions is influenced by the grossing method. Bi-sectioning of the head of the pancreas may offer an advantage in this respect, as this method allows for optimal visualization of the periampullary area. However, a head-to-head comparison of the assessment of clinically relevant parameters, using axial slicing versus bi-sectioning, is not available yet and the gold standard to compare both techniques prospectively might be subject of debate. Further studies are required to validate the various dissection protocols used for pancreatoduodenectomy specimens and their specific value in the assessment of pathological parameters relevant for prognosis.	[Soer, Eline; van de Vijver, Marc; Dijk, Frederike; Koens, Lianne; Verheij, Joanne] Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Brosens, Lodewijk; Offerhaus, Johan] Univ Med Ctr, Dept Pathol, Utrecht, Netherlands; [Brosens, Lodewijk] Radboud Med Ctr, Dept Pathol, Nijmegen, Netherlands; [van de Vijver, Marc] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; [van Velthuysen, Marie-Louise] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Farina-Sarasqueta, Arantza; Morreau, Hans] Leiden Med Ctr, Dept Pathol, Leiden, Netherlands	Soer, E (reprint author), Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	e.c.soer@amc.uva.nl	Dijk, Frederike/C-1627-2008	Dijk, Frederike/0000-0003-3970-6601; Farina Sarasqueta, Aranzazu/0000-0002-6173-592X			Adsay NV, 2014, AM J SURG PATHOL, V38, P480, DOI 10.1097/PAS.0000000000000165; Adsay NV, 2009, MODERN PATHOL, V22, P107, DOI 10.1038/modpathol.2008.167; Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Agalianos C, 2016, HPB, V18, P633, DOI 10.1016/j.hpb.2016.04.007; [Anonymous], 2017, TNM CLASSIFICATION M; Bassi C, 2005, HPB (Oxford), V7, P87, DOI 10.1080/13651820510028855; Basturk O, 2015, ANN SURG ONCOL, V22, pS1187, DOI 10.1245/s10434-015-4861-0; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Bledsoe JR, 2015, ARCH PATHOL LAB MED, V139, P848, DOI 10.5858/arpa.2014-0205-RA; Bosman FT, 2010, WHO CLASSIF TUMOURS, V3, P417; Bouvet M, 2000, AM J SURG, V180, P13, DOI 10.1016/S0002-9610(00)00405-0; Brennan MF, 2004, ANN SURG, V240, P293, DOI 10.1097/01.sla.0000133125.85489.07; Brierley JD, 2017, TNM CLASSIFICATION M; Bronsert P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-428; Campbell F, 2009, HISTOPATHOLOGY, V55, P277, DOI 10.1111/j.1365-2559.2009.03376.x; Carpelan-Holmstrom M, 2005, GUT, V54, P385, DOI 10.1136/gut.2004.047191; Chang DK, 2009, J CLIN ONCOL, V27, P2855, DOI 10.1200/JCO.2008.20.5104; Chatterjee D, 2017, AM J SURG PATHOL, V41, P1097, DOI 10.1097/PAS.0000000000000887; Chatterjee D, 2012, CANCER-AM CANCER SOC, V118, P3182, DOI 10.1002/cncr.26651; Chen JWC, 2010, HPB, V12, P101, DOI 10.1111/j.1477-2574.2009.00140.x; Cleary SP, 2004, J AM COLL SURGEONS, V198, P722, DOI 10.1016/j.jamcollsurg.2004.01.008; College of American Pathologists, 2017, CANC PROT PROT EX SP; de Jong MC, 2011, J SURG ONCOL, V103, P656, DOI 10.1002/jso.21883; Delpero JR, 2014, HPB, V16, P20, DOI 10.1111/hpb.12061; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Furukawa T, 2011, GUT, V60, P509, DOI 10.1136/gut.2010.210567; Garcea G, 2007, EJSO-EUR J SURG ONC, V33, P892, DOI 10.1016/j.ejso.2007.02.024; Hruban RH, 2017, AFIP ATLAS TUMOR PAT, V6; Japan Pancreas Society, CLASS PANCR CARC; Katuchova J, 2012, EUR SURG RES, V48, P10, DOI 10.1159/000334171; Kobari M, 1999, ARCH SURG-CHICAGO, V134, P1131, DOI 10.1001/archsurg.134.10.1131; Konstantinidis IT, 2013, ANN SURG, V257, P731, DOI 10.1097/SLA.0b013e318263da2f; Kurahara H, 2007, WORLD J SURG, V31, P483, DOI 10.1007/s00268-006-0463-0; Lanzoni G, 2016, HEPATOLOGY, V64, P277, DOI 10.1002/hep.28326; Lee SM, 2016, AM J SURG PATHOL, V40, P1653, DOI 10.1097/PAS.0000000000000738; Levy P, 2006, CLIN GASTROENTEROL H, V4, P460, DOI 10.1016/j.cgh.2006.01.018; Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011; Luchini C, 2016, EUR J GASTROEN HEPAT, V28, P205, DOI 10.1097/MEG.0000000000000520; Pai RK, 2011, AM J SURG PATHOL, V35, P228, DOI 10.1097/PAS.0b013e318206c37a; Park H, 2014, HUM PATHOL, V45, P2341, DOI 10.1016/j.humpath.2014.06.030; Pathologists C of A, 2016, PROT EX SPEC PAT CAR; Pawlik TM, 2007, SURGERY, V141, P610, DOI 10.1016/j.surg.2006.12.013; Pomianowska E, 2012, EJSO-EUR J SURG ONC, V38, P1043, DOI 10.1016/j.ejso.2012.07.113; Reddy S, 2009, ANN SURG, V250, P282, DOI 10.1097/SLA.0b013e3181ae9f93; Riediger H, 2009, J GASTROINTEST SURG, V13, P1337, DOI 10.1007/s11605-009-0919-2; Saka B, 2016, ANN SURG ONCOL, V23, P2010, DOI 10.1245/s10434-016-5093-7; Schaberg KB, 2016, AM J SURG PATHOL, V40, P44, DOI 10.1097/PAS.0000000000000528; Schlitter Anna Melissa, 2010, Cancers (Basel), V2, P2001, DOI 10.3390/cancers2042001; Schnelldorfer T, 2008, ANN SURG, V247, P456, DOI 10.1097/SLA.0b013e3181613142; Shepherd NA, 1997, GASTROENTEROLOGY, V112, P1096, DOI 10.1016/S0016-5085(97)70119-7; Shia JR, 2014, AM J SURG PATHOL, V38, P526, DOI 10.1097/PAS.0000000000000123; Sierzega M, 2006, PANCREAS, V33, P240, DOI 10.1097/01.mpa.0000235306.96486.2a; Strobel O, 2017, ANN SURG, V265, P565, DOI 10.1097/SLA.0000000000001731; Strobel O, 2012, SURGERY, V152, pS33, DOI 10.1016/j.surg.2012.05.029; Sugiyama M, 2008, J GASTROENTEROL, V43, P181, DOI 10.1007/s00535-008-2159-8; The Royal College of Pathologists, 2013, STAND DAT REP CANC D; Tol JAMG, 2015, BRIT J SURG, V102, P237, DOI 10.1002/bjs.9709; Tomlinson JS, 2007, ARCH SURG-CHICAGO, V142, P767, DOI 10.1001/archsurg.142.8.767; van Roest MHG, 2008, ANN SURG, V248, P97, DOI 10.1097/SLA.0b013e31817b6609; Verbeke C, 2015, CANCER TREAT REV, V41, P17, DOI 10.1016/j.ctrv.2014.11.002; Verbeke CS, 2008, HISTOPATHOLOGY, V52, P787, DOI 10.1111/j.1365-2559.2007.02935.x; Verbeke CS, 2012, BRIT J SURG, V99, P1036, DOI 10.1002/bjs.8734; Verbeke CS, 2013, SURG CLIN N AM, V93, P647, DOI 10.1016/j.suc.2013.02.008; Verbeke CS, 2009, HPB, V11, P282, DOI 10.1111/j.1477-2574.2009.00055.x; Washington MK, 2010, ARCH PATHOL LAB MED, V134, pE19, DOI 10.1043/1543-2165-134.4.e19; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5; Williams JL, 2017, JAMA SURG, V152, P82, DOI 10.1001/jamasurg.2016.3466; Williams JL, 2015, J SURG ONCOL, V112, P396, DOI 10.1002/jso.24011; Wittekind C, 2002, CANCER, V94, P2511, DOI 10.1002/cncr.10492; Yekebas EF, 2006, WORLD J GASTROENTERO, V12, P6515, DOI 10.3748/wjg.v12.i40.6515	70	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					533	543		10.1007/s00428-018-2321-5			11	Pathology	Pathology	GE4HL	WOS:000431176200002	29589102	Green Published			2019-10-28	
J	Detlefsen, S; Kloppel, G				Detlefsen, Sonke; Kloeppel, Guenter			IgG4-related disease: with emphasis on the biopsy diagnosis of autoimmune pancreatitis and sclerosing cholangitis	VIRCHOWS ARCHIV			English	Review						IgG4-related disease; Histology; Diagnosis; Autoimmune pancreatitis; Sclerosing cholangitis; Hepatopathy	HEPATIC INFLAMMATORY PSEUDOTUMOR; GUIDED TRUCUT BIOPSY; PLASMA-CELLS; CLINICOPATHOLOGICAL FEATURES; HISTOPATHOLOGICAL FEATURES; DIFFERENTIAL-DIAGNOSIS; STEROID-THERAPY; LIVER-BIOPSY; SERUM IGG4; BILE-DUCT	In 2011, chronic fibroinflammatory processes occurring simultaneously or metachronously in various organs and associated with elevated IgG4 serum levels and/or tissue infiltration with IgG4-positive plasma cells have been recognized as manifestations of a systemic disorder called IgG4-related disease (IgG4-RD). The histologic key findings are lymphoplasmacytic infiltration rich in IgG4-positive plasma cells combined with storiform fibrosis and obliterative phlebitis. Among the organs mainly affected by IgG4-RD are the pancreas and the extrahepatic bile ducts. The pancreatic and biliary alterations have been described under the terms autoimmune pancreatitis (AIP) and sclerosing cholangitis, respectively. These diseases are currently more precisely called IgG4-related pancreatitis (or type 1 AIP to distinguish it from type 2 AIP that is unrelated to IgG4-RD) and IgG4-related sclerosing cholangitis (IgG4-related SC). Clinically and grossly, both diseases commonly imitate pancreatic and biliary adenocarcinoma, tumors that are well known for their dismal prognosis. As IgG4-RD responds to steroid treatment, making a resection of a suspected tumor unnecessary, a biopsy is often required to establish the preoperative diagnosis. This review discusses the morphologic spectrum of IgG4-related pancreatitis and IgG4-related SC and focuses on the biopsy relevant histologic features for the diagnosis and differential diagnosis of these diseases.	[Detlefsen, Sonke] Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15, DK-5000 Odense C, Denmark; [Kloeppel, Guenter] Tech Univ Munich, Consultat Ctr Pancreat & Endocrine Tumors, Dept Pathol, Ismaninger Str 22, D-81675 Munich, Germany	Detlefsen, S (reprint author), Odense Univ Hosp, Dept Pathol, JB Winslows Vej 15, DK-5000 Odense C, Denmark.	Sonke.Detlefsen@rsyd.dk			Dutch Cancer Society (DCS) grant	Lianne Koens and Joanne Verheij share senior authorship. E.C. Soer was hired on a Dutch Cancer Society (DCS) grant.	Abraham SC, 2003, AM J SURG PATHOL, V27, P334, DOI 10.1097/00000478-200303000-00006; Asano J, 2015, J RHEUMATOL, V42, P2135, DOI 10.3899/jrheum.150436; BARTHOLOMEW LG, 1963, NEW ENGL J MED, V269, P8, DOI 10.1056/NEJM196307042690102; Bateman AC, 2017, HISTOPATHOLOGY, V70, P798, DOI 10.1111/his.13136; Boonstra K, 2014, HEPATOLOGY, V59, P1954, DOI 10.1002/hep.26977; Cebe KM, 2013, AM J CLIN PATHOL, V139, P323, DOI 10.1309/AJCPT00NHQHXAHDS; Chang SY, 2013, HUM PATHOL, V44, P2432, DOI 10.1016/j.humpath.2013.05.023; Chari ST, 2010, PANCREAS, V39, P549, DOI 10.1097/MPA.0b013e3181e4d9e5; Chari ST, 2009, PANCREAS, V38, P846, DOI 10.1097/MPA.0b013e3181bba281; Chougule A, 2017, MOD RHEUMATOL, V27, P320, DOI 10.1080/14397595.2016.1206241; COMINGS DE, 1967, ANN INTERN MED, V66, P884, DOI 10.7326/0003-4819-66-5-884; Culver EL, 2016, NAT REV GASTRO HEPAT, V13, P601, DOI 10.1038/nrgastro.2016.132; Deshpande V, 2005, ARCH PATHOL LAB MED, V129, P1148; Deshpande V, 2015, ARCH PATHOL LAB MED, V139, P742, DOI 10.5858/arpa.2014-0181-RA; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Deshpande V, 2011, AM J SURG PATHOL, V35, P26, DOI 10.1097/PAS.0b013e3182027717; Deshpande V, 2009, MODERN PATHOL, V22, P1287, DOI 10.1038/modpathol.2009.94; Detlefsen S, 2008, AM J SURG PATHOL, V32, P986, DOI 10.1097/PAS.0b013e31815d2583; Detlefsen S, 2006, MODERN PATHOL, V19, P1019, DOI 10.1038/modpathol.3800613; Detlefsen S, 2009, VIRCHOWS ARCH, V454, P531, DOI 10.1007/s00428-009-0747-5; Detlefsen S, 2017, PATHOL INT, V67, P514, DOI 10.1111/pin.12563; Detlefsen S, 2015, PANCREAS, V44, P845, DOI 10.1097/MPA.0000000000000312; Detlefsen S, 2012, PANCREATOLOGY, V12, P276, DOI 10.1016/j.pan.2012.03.055; Ectors N, 1997, GUT, V41, P263, DOI 10.1136/gut.41.2.263; Esposito I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002539; Ghazale A, 2007, AM J GASTROENTEROL, V102, P1646, DOI 10.1111/j.1572-0241.2007.01264.x; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hart Phil A, 2017, Curr Treat Options Gastroenterol, V15, P538, DOI 10.1007/s11938-017-0147-x; Horiguchi S, 2012, DIGEST ENDOSC, V24, P370, DOI 10.1111/j.1443-1661.2012.01300.x; Inoue D, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000680; Kamisawa T, 2003, AM J GASTROENTEROL, V98, P2811, DOI 10.1111/j.1572-0241.2003.08758.x; Kamisawa T, 2011, PANCREAS, V40, P809, DOI 10.1097/MPA.0b013e3182258a15; Kanno A, 2016, GASTROINTEST ENDOSC, V84, P797, DOI 10.1016/j.gie.2016.03.1511; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; Kawakami H, 2010, J GASTROEN HEPATOL, V25, P1648, DOI 10.1111/j.1440-1746.2010.06346.x; Kerdsirichairat T, 2017, ACG CASE REP J, V4, DOI 10.14309/crj.2017.7; Kimura Y, 2012, HUM PATHOL, V43, P2149, DOI 10.1016/j.humpath.2012.03.001; Kloppel G, 2007, J GASTROENTEROL, V42, P28, DOI 10.1007/s00535-007-2048-6; Kloppel G, 2007, MODERN PATHOL, V20, pS113, DOI 10.1038/modpathol.3800690; Kloppel G, 2010, J GASTROENTEROL, V45, P787, DOI 10.1007/s00535-010-0265-x; KLOPPEL G, 1993, PANCREAS, V8, P659; Kloppel G, 2004, VIRCHOWS ARCH, V445, P1, DOI 10.1007/s00428-004-1021-5; Kojima M, 2007, AM J SURG PATHOL, V31, P521, DOI 10.1097/01.pas.0000213390.55536.47; Larsen MH, 2017, ENDOSC INT IN PRESS; Levy MJ, 2011, PANCREATOLOGY, V11, P76, DOI 10.1159/000324189; Levy MJ, 2005, GASTROINTEST ENDOSC, V61, P467, DOI 10.1016/S0016-5107(04)02802-0; Maire F, 2011, AM J GASTROENTEROL, V106, P151, DOI 10.1038/ajg.2010.314; Mendes F, 2010, NAT REV GASTRO HEPAT, V7, P611, DOI 10.1038/nrgastro.2010.155; Mizuno N, 2009, J GASTROENTEROL, V44, P742, DOI 10.1007/s00535-009-0062-6; Moon SH, 2010, GASTROINTEST ENDOSC, V71, P960, DOI 10.1016/j.gie.2009.12.004; Naitoh I, 2011, J GASTROENTEROL, V46, P269, DOI 10.1007/s00535-010-0319-0; Notohara K, 2003, AM J SURG PATHOL, V27, P1119, DOI 10.1097/00000478-200308000-00009; Ohara H, 2012, J HEPATO-BIL-PAN SCI, V19, P536, DOI 10.1007/s00534-012-0521-y; Okazaki K, 2011, J GASTROENTEROL, V46, P277, DOI 10.1007/s00535-011-0386-x; Sah RP, 2010, GASTROENTEROLOGY, V139, P140, DOI 10.1053/j.gastro.2010.03.054; Saito T, 2002, PANCREATOLOGY, V2, P550, DOI 10.1159/000066092; Samarasena J, 2013, J INTERV GASTROENTER, V3, P147; SARLES H, 1961, AM J DIG DIS, V6, P688, DOI 10.1007/BF02232341; Saxena A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00580; Song MH, 2005, PANCREAS, V30, P83; Stone JH, 2015, MAYO CLIN PROC, V90, P927, DOI 10.1016/j.mayocp.2015.03.020; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Strehl JD, 2011, J CLIN PATHOL, V64, P237, DOI 10.1136/jcp.2010.085613; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Umemura T, 2007, GUT, V56, P1471, DOI 10.1136/gut.2007.122283; Umemura T, 2007, HEPATOLOGY, V46, P463, DOI 10.1002/hep.21700; Umemura T, 2011, J GASTROENTEROL, V46, P48, DOI 10.1007/s00535-010-0323-4; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Yamamoto M, 2012, MOD RHEUMATOL, V22, P414, DOI 10.1007/s10165-011-0520-x; YOSHIDA K, 1995, DIGEST DIS SCI, V40, P1561, DOI 10.1007/BF02285209; Zamboni G, 2004, VIRCHOWS ARCH, V445, P552, DOI 10.1007/s00428-004-1140-z; Zamboni G, 2000, JOP, V1, P77; Zamboni G, 2009, ARCH PATHOL LAB MED, V133, P439, DOI 10.1043/1543-2165-133.3.439; Zen Y, 2004, AM J SURG PATHOL, V28, P1193, DOI 10.1097/01.pas.0000136449.37936.6c; Zen Y, 2007, MODERN PATHOL, V20, P884, DOI 10.1038/modpathol.3800836; Zen Y, 2016, J GASTROENTEROL, V51, P295, DOI 10.1007/s00535-016-1163-7; Zen Y, 2012, AM J SURG PATHOL, V36, P1555, DOI 10.1097/PAS.0b013e31825faae0; Zen Y, 2012, HISTOPATHOLOGY, V60, P261, DOI 10.1111/j.1365-2559.2011.04078.x; Zen Y, 2010, AM J SURG PATHOL, V34, P1812, DOI 10.1097/PAS.0b013e3181f7266b	79	4	6	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					545	556		10.1007/s00428-017-2275-z			12	Pathology	Pathology	GE4HL	WOS:000431176200003	29196804				2019-10-28	
J	Hirsch, B; Endris, V; Lassmann, S; Weichert, W; Pfarr, N; Schirmacher, P; Kovaleva, V; Werner, M; Bonzheim, I; Fend, F; Sperveslage, J; Kaulich, K; Zacher, A; Reifenberger, G; Kohrer, K; Stepanow, S; Lerke, S; Mayr, T; Aust, DE; Baretton, G; Weidner, S; Jung, A; Kirchner, T; Hansmann, ML; Burbat, L; von der Wall, E; Dietel, M; Hummel, M				Hirsch, B.; Endris, V.; Lassmann, S.; Weichert, W.; Pfarr, N.; Schirmacher, P.; Kovaleva, V.; Werner, M.; Bonzheim, I.; Fend, F.; Sperveslage, J.; Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.; Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.; Weidner, S.; Jung, A.; Kirchner, T.; Hansmann, M. L.; Burbat, L.; von der Wall, E.; Dietel, M.; Hummel, M.			Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics	VIRCHOWS ARCHIV			English	Article						German Cancer Research Centers (DKTK-sites); Multicenter trial; FFPE cancer samples; Amplicon-based next-generation sequencing; PGM (TM); MiSeq (TM)	INTEGRATIVE GENOMICS VIEWER; SOMATIC MUTATIONS; IDENTIFICATION; PERFORMANCE	The simultaneous detection of multiple somatic mutations in the context of molecular diagnostics of cancer is frequently performed by means of amplicon-based targeted next-generation sequencing (NGS). However, only few studies are available comparing multicenter testing of different NGS platforms and gene panels. Therefore, seven partner sites of the German Cancer Consortium (DKTK) performed a multicenter interlaboratory trial for targeted NGS using the same formalin-fixed, paraffin-embedded (FFPE) specimen of molecularly pre-characterized tumors (n = 15; each n = 5 cases of Breast, Lung, and Colon carcinoma) and a colorectal cancer cell line DNA dilution series. Detailed information regarding pre-characterized mutations was not disclosed to the partners. Commercially available and custom-designed cancer gene panels were used for library preparation and subsequent sequencing on several devices of two NGS different platforms. For every case, centrally extracted DNA and FFPE tissue sections for local processing were delivered to each partner site to be sequenced with the commercial gene panel and local bioinformatics. For cancer-specific panel-based sequencing, only centrally extracted DNA was analyzed at seven sequencing sites. Subsequently, local data were compiled and bioinformatics was performed centrally. We were able to demonstrate that all pre-characterized mutations were re-identified correctly, irrespective of NGS platform or gene panel used. However, locally processed FFPE tissue sections disclosed that the DNA extraction method can affect the detection of mutations with a trend in favor of magnetic bead-based DNA extraction methods. In conclusion, targeted NGS is a very robust method for simultaneous detection of various mutations in FFPE tissue specimens if certain pre-analytical conditions are carefully considered.	[Hirsch, B.; Burbat, L.; von der Wall, E.; Dietel, M.; Hummel, M.] Charite, Inst Pathol, Campus Mitte,Virchowweg 15, D-10117 Berlin, Germany; [Hirsch, B.; Endris, V.; Lassmann, S.; Weichert, W.; Pfarr, N.; Schirmacher, P.; Kovaleva, V.; Werner, M.; Bonzheim, I.; Fend, F.; Sperveslage, J.; Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.; Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.; Weidner, S.; Jung, A.; Kirchner, T.; Hansmann, M. L.; Burbat, L.; von der Wall, E.; Dietel, M.; Hummel, M.] German Canc Consortium DKTK Partner Site, D-69120 Heidelberg, Germany; [Hirsch, B.; Endris, V.; Lassmann, S.; Weichert, W.; Pfarr, N.; Schirmacher, P.; Kovaleva, V.; Werner, M.; Bonzheim, I.; Fend, F.; Sperveslage, J.; Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.; Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.; Weidner, S.; Jung, A.; Kirchner, T.; Hansmann, M. L.; Burbat, L.; von der Wall, E.; Dietel, M.; Hummel, M.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Endris, V.; Schirmacher, P.] Univ Med Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany; [Lassmann, S.; Kovaleva, V.; Werner, M.] Univ Freiburg, Fac Med, Med Ctr, Inst Surg Pathol, Breisacherstr 115A, D-79106 Freiburg, Germany; [Weichert, W.; Pfarr, N.] Tech Univ Munich, Inst Pathol, Munich, Germany; [Bonzheim, I.; Fend, F.; Sperveslage, J.] Eberhard Karls Univ Tubingen, Univ Hosp Tuebingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.] Heinrich Heine Univ Duesseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.] Heinrich Heine Univ Duesseldorf, Genom & Transcript Lab, Biol & Med Res Ctr BMFZ, D-40225 Dusseldorf, Germany; [Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.] Univ Hosp Carl Gustav Carus, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany; [Weidner, S.; Jung, A.; Kirchner, T.] Ludwig Maximilians Univ Munchen, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany; [Hansmann, M. L.] Goethe Univ, Univ Hosp, Dr Senckenberg Inst Pathol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany	Hirsch, B (reprint author), Charite, Inst Pathol, Campus Mitte,Virchowweg 15, D-10117 Berlin, Germany.; Hirsch, B (reprint author), German Canc Consortium DKTK Partner Site, D-69120 Heidelberg, Germany.; Hirsch, B (reprint author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	burkhard.hirsch@charite.de			German Cancer Consortium (DKTK)	This study was funded by the German Cancer Consortium (DKTK, grant to MH, SL, FF, GB, HML, TK, PS, and WW).	Alioto TS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10001; Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Bonin S, 2010, VIRCHOWS ARCH, V457, P309, DOI 10.1007/s00428-010-0917-5; Chen X, 2017, BIOINFORMATICS, V33, P177, DOI 10.1093/bioinformatics/btw605; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Endris V, 2016, VIRCHOWS ARCH, V468, P697, DOI 10.1007/s00428-016-1919-8; Fawcett GL, 2017, ADV CLIN CHEM, V78, P123, DOI 10.1016/bs.acc.2016.07.006; Fujita S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130219; Ghazani AA, 2017, GENET MED, V19, P787, DOI 10.1038/gim.2016.191; Hirotsu Y, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3166-4; Kovaleva V, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0549-8; Kriegsmann M, 2014, ONCOTARGET, V5, P9952, DOI 10.18632/oncotarget.2481; LaDuca H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170843; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Mendez P, 2016, INT J ONCOL, V49, P235, DOI 10.3892/ijo.2016.3497; Miao D, 2016, CURR OPIN IMMUNOL, V41, P32, DOI 10.1016/j.coi.2016.05.010; Ojamies P, 2017, LEUKEMIA, V31, P1048, DOI 10.1038/leu.2016.286; Paasinen-Sohns A, 2017, NEOPLASIA, V19, P196, DOI 10.1016/j.neo.2017.01.003; Raymond S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42215; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rothberg JM, 2011, NATURE, V475, P348, DOI 10.1038/nature10242; Shokralla S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09687; Sie D, 2014, CELL ONCOL, V37, P353, DOI 10.1007/s13402-014-0196-2; Simbolo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062692; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tops BBJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1015-5; Tsongalis GJ, 2014, CLIN CHEM LAB MED, V52, P707, DOI 10.1515/cclm-2013-0883; Weissbach S, 2015, BRIT J HAEMATOL, V169, P57, DOI 10.1111/bjh.13256	29	3	3	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					557	565		10.1007/s00428-017-2288-7			9	Pathology	Pathology	GE4HL	WOS:000431176200004	29374318	Green Published, Other Gold			2019-10-28	
J	Weissferdt, A				Weissferdt, Annikka			Pulmonary neuroendocrine carcinomas-evidence for a spectrum of differentiation	VIRCHOWS ARCHIV			English	Editorial Material							LUNG; MUTATIONS; TUMORS		[Weissferdt, Annikka] MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA	Weissferdt, A (reprint author), MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aweissferdt@mdanderson.org					Desmeules P, 2017, MODERN PATHOL, V30, p475A; Fabbri A, 2017, VIRCHOWS ARCH, V471, P31, DOI 10.1007/s00428-017-2130-2; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Gridelli C, 2013, CANCER TREAT REV, V39, P466, DOI 10.1016/j.ctrv.2012.06.012; Moran CA, 2000, AM J CLIN PATHOL, V113, P345; Moran CA, 2009, AM J CLIN PATHOL, V131, P206, DOI 10.1309/AJCP9H1OTMUCSKQW; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Quinn AM, 2017, AM J SURG PATHOL, V41, P263, DOI 10.1097/PAS.0000000000000767; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; Travis WD, 2015, PATHOLOGY GENETICS T	10	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					579	580		10.1007/s00428-018-2308-2			2	Pathology	Pathology	GE4HL	WOS:000431176200006	29388011				2019-10-28	
J	Brcic, L; Stanzer, S; Krenbek, D; Gruber-Moesenbacher, U; Absenger, G; Quehenberger, F; Valipour, A; Lindenmann, J; Stoeger, H; Al Effah, M; Fediuk, M; Balic, M; Popper, HH				Brcic, Luka; Stanzer, Stefanie; Krenbek, Dagmar; Gruber-Moesenbacher, Ulrike; Absenger, Gudrun; Quehenberger, Franz; Valipour, Arschang; Lindenmann, Joerg; Stoeger, Herbert; Al Effah, Mohamed; Fediuk, Melanie; Balic, Marija; Popper, Helmut H.			Immune cell landscape in therapy-naive squamous cell and adenocarcinomas of the lung	VIRCHOWS ARCHIV			English	Article						Non-small-cell lung cancer; Immune system; Bronchoalveolar lavage; Immune cells; Dendritic cells; Myeloid-derived suppressor cells	SUPPRESSOR-CELLS; DENDRITIC CELLS; T-CELLS; ANTI-PD-L1 ANTIBODY; ANTITUMOR IMMUNITY; M2 POLARIZATION; TUMOR-GROWTH; HUMAN CANCER; MACROPHAGES; RESPONSES	Squamous cell and adenocarcinomas of the lung develop different mechanisms during carcinogenesis to evade attacks of the immune system. Besides the well-known check-point control programmed death 1 and its ligand, many more mechanisms, acting either tumoricidal or in favor of tumor progression, exist. Analysis of the immune cell profiles in resected tissues and bronchoalveolar lavage samples and correlation between them and with overall survival data was performed. In all tumor samples in this study, cells of the immune system expressed a tumor-cooperating phenotype. High numbers of regulatory T cells, or alternatively expression of Vista on lymphocytes was present. Tumoricidal dendritic cells were absent in tumor tissue, and barely present in bronchoalveolar lavage, whereas tumor-friendly monocytoid and plasmocytoid dendritic cells were seen in both. Alveolar macrophages were predominantly differentiated into tumor-cooperating M2 types, whereas tumoricidal M1 macrophages were absent or rare. The expression of PDL1 on tumor cells did not correlate with any other immune cells. Expression of PD1 on lymphocytes was frequently encountered. None of analyzed immune cells showed correlation with overall survival. Immune cells in bronchoalveolar lavage and tissue did not correlate. For the first time, a tissue-based analysis of different immune cells in squamous cell and adenocarcinomas of the lung is provided, trying to explain their potential role in tumor development and progression. Discordant numbers of cells with bronchoalveolar lavage are most probably due to the fact that bronchoalveolar lavage reflects the situation in the whole lung, where chronic obstructive lung disease and other conditions are present.	[Brcic, Luka; Al Effah, Mohamed; Popper, Helmut H.] Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria; [Stanzer, Stefanie; Absenger, Gudrun; Stoeger, Herbert; Balic, Marija] Med Univ Graz, Div Oncol, Dept Internal Med, Auenbruggerpl 15, A-8036 Graz, Austria; [Krenbek, Dagmar] Otto Wagner Hosp, Inst Pathol & Bacteriol, Baumgartner Hohe 1, A-1140 Vienna, Austria; [Quehenberger, Franz] Med Univ Graz, Inst Med Informat Stat & Documentat, Auenbruggerpl 2, A-8036 Graz, Austria; [Valipour, Arschang] Otto Wagner Hosp, Dept Resp & Crit Care Med, Baumgartner Hohe 1, A-1140 Vienna, Austria; [Lindenmann, Joerg; Fediuk, Melanie] Med Univ Graz, Dept Surg, Div Thorac & Hyperbar Surg, Auenbruggerpl 29, A-8036 Graz, Austria	Brcic, L (reprint author), Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria.	luka.brcic@medunigraz.at	Quehenberger, Franz/N-8825-2019	Quehenberger, Franz/0000-0003-0764-9497; Brcic, Luka/0000-0002-9098-8416	Bristol-Myers SquibbBristol-Myers Squibb; Boehringer IngelheimBoehringer Ingelheim	This work was supported by unrestricted research grants from Bristol-Myers Squibb and Boehringer Ingelheim. There was no interference of these companies with the data presented nor the interpretation of results.	Aguiar PN, 2016, IMMUNOTHERAPY-UK, V8, P479, DOI 10.2217/imt-2015-0002; Antonios JP, 2017, NEURO-ONCOLOGY, V19, P796, DOI 10.1093/neuonc/now287; Barth SD, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv224; Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388; Blidner AG, 2015, J IMMUNOL, V194, P3452, DOI 10.4049/jimmunol.1401144; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bremnes RM, 2011, J THORAC ONCOL, V6, P824, DOI 10.1097/JTO.0b013e3182037b76; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Conlon KC, 2015, J CLIN ONCOL, V33, P74, DOI 10.1200/JCO.2014.57.3329; Dumitriu IE, 2009, J IMMUNOL, V182, P2795, DOI 10.4049/jimmunol.0712671; Enk AH, 2005, IMMUNOL LETT, V99, P8, DOI 10.1016/j.imlet.2005.01.011; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fletcher M, 2015, CANCER RES, V75, P275, DOI 10.1158/0008-5472.CAN-14-1491; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hoeppner LH, 2015, MOL ONCOL, V9, P270, DOI 10.1016/j.molonc.2014.08.008; Karachaliou N, 2015, CANCER BIOL MED, V12, P79, DOI 10.7497/j.issn.2095-3941.2015.0029; Kim PS, 2014, J IMMUNOL, V192, P2622, DOI 10.4049/jimmunol.1301369; Liu QY, 2009, J IMMUNOL, V182, P6207, DOI 10.4049/jimmunol.0803926; Liu Y, 2013, CANCER RES, V73, P550, DOI 10.1158/0008-5472.CAN-12-2290; Ohaegbulam KC, 2015, TRENDS MOL MED, V21, P24, DOI 10.1016/j.molmed.2014.10.009; Peggs KS, 2012, EXPERT REV ANTICANC, V12, P1279, DOI [10.1586/ERA.12.109, 10.1586/era.12.109]; Riedl Karen, 2003, Mol Cancer, V2, P35, DOI 10.1186/1476-4598-2-35; Salvi S, 2012, CANCER IMMUNOL IMMUN, V61, P1463, DOI 10.1007/s00262-012-1211-y; Sawant A, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27401; Sawant A, 2013, CANCER RES, V73, P6609, DOI 10.1158/0008-5472.CAN-13-0987; Scrimini S, 2015, CANCER IMMUNOL IMMUN, V64, P1261, DOI 10.1007/s00262-015-1737-x; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Simpson KD, 2012, J IMMUNOL, V189, P5533, DOI 10.4049/jimmunol.1201161; Suzuki K, 2011, MOL MED, V17, P579, DOI 10.2119/molmed.2010.00157; Sznol M, 2013, CLIN CANCER RES, V19, P1021, DOI 10.1158/1078-0432.CCR-12-2063; Teglasi V, 2017, NEURO-ONCOLOGY, V19, P1058, DOI 10.1093/neuonc/now309; Wang W, 2012, INT J CANCER, V131, pE928, DOI 10.1002/ijc.27613; Wang YP, 2014, CANCER RES, V74, P2217, DOI 10.1158/0008-5472.CAN-13-2928; Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269; Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018; Zong JB, 2016, CANCER IMMUNOL IMMUN, V65, P821, DOI 10.1007/s00262-016-1820-y	36	2	2	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					589	598		10.1007/s00428-018-2326-0			10	Pathology	Pathology	GE4HL	WOS:000431176200008	29520483	Green Published, Other Gold			2019-10-28	
J	Kammerer-Jacquet, SF; Comperat, E; Egevad, L; Hes, O; Oxley, J; Varma, M; Kristiansen, G; Berney, DM				Kammerer-Jacquet, Solene-Florence; Comperat, Eva; Egevad, Lars; Hes, Ondra; Oxley, Jon; Varma, Murali; Kristiansen, Glen; Berney, Daniel M.			Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP)	VIRCHOWS ARCHIV			English	Article						Transperineal template biopsy; Transrectal ultrasound biopsies; Survey; Workload impact	CANCER ERSPC; PATHOLOGISTS; GUIDELINES; CORE	Transperineal template prostate biopsies (TTPB) are performed for assessments after unexpected negative transrectal ultrasound biopsies (TRUSB), correlation with imaging findings and during active surveillance. The impact of TTPBs on pathology has not been analysed. The European Network of Uropathology (ENUP) distributed a survey on TTPB, including how specimens were received, processed and analysed. Two hundred forty-four replies were received from 22 countries with TTPBs seen by 68.4% of the responders (n = 167). Biopsies were received in more than 12 pots in 35.2%. The number of cores embedded per cassette varied between 1 (39.5%) and 3 or more (39.5%). Three levels were cut in 48.3%, between 2 and 3 serial sections in 57.2% and unstained spare sections in 45.1%. No statistical difference was observed with TRUSB management. The number of positive cores was always reported and the majority gave extent per core (82.3%), per region (67.1%) and greatest involvement per core (69.4%). Total involvement in the whole series and continuous/discontinuous infiltrates were reported in 42.2 and 45.4%, respectively. The majority (79.4%) reported Gleason score in each site or core, and 59.6% gave an overall score. A minority (28.5%) provided a map or a diagram. For 19%, TTPB had adversely affected laboratory workload with only 27% managing to negotiate extra costs. Most laboratories process samples thoroughly and report TTPB similarly to TRUSB. Although TTPB have caused considerable extra work, it remains uncosted in most centres. Guidance is needed for workload impact and minimum standards of processing if TTPB work continues to increase.	[Kammerer-Jacquet, Solene-Florence; Berney, Daniel M.] Queen Mary Univ, Barts Canc Univ, Charterhouse Sq, London EC1M 6BQ, England; [Kammerer-Jacquet, Solene-Florence] Univ Bretagne Loire, Univ Rennes 1, Serv Anat & Cytol Pathol, F-35042 Rennes, France; [Comperat, Eva] Univ Sorbonne, Hop Tenon, AP HP, HUEP, Paris, France; [Egevad, Lars] Karolinska Inst, Stockholm, Sweden; [Hes, Ondra] Charles Univ Prague, Plzen, Czech Republic; [Oxley, Jon] North Bristol NHS Trust, Bristol, Avon, England; [Varma, Murali] Univ Hosp Wales, Cardiff, S Glam, Wales; [Kristiansen, Glen] Univ Bonn, Bonn, Germany	Kammerer-Jacquet, SF (reprint author), Queen Mary Univ, Barts Canc Univ, Charterhouse Sq, London EC1M 6BQ, England.; Kammerer-Jacquet, SF (reprint author), Univ Bretagne Loire, Univ Rennes 1, Serv Anat & Cytol Pathol, F-35042 Rennes, France.	jacquet.sf@gmail.com			Orchid; ENUP	We would like to thank all ENUP members for their support and for taking the time to participate in the survey. DB is supported by Orchid.	Babaian RJ, 2000, J UROLOGY, V163, P152, DOI 10.1016/S0022-5347(05)67993-1; Berney DM, 2014, VIRCHOWS ARCH, V464, P583, DOI 10.1007/s00428-014-1554-1; Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284; Biedrzycki O, 2003, J CLIN PATHOL, V56, P341, DOI 10.1136/jcp.56.5.341; Chang DTS, 2013, NAT REV UROL, V10, P690, DOI 10.1038/nrurol.2013.195; Egevad L, 2013, HISTOPATHOLOGY, V62, P247, DOI 10.1111/his.12008; Egevad L, 2009, ANAL QUANT CYTOL, V31, P90; Nafie S, 2017, UROL J, V14, P3008; Nakai Y, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0219-1; Pal RP, 2012, BJU INT, V109, P367, DOI 10.1111/j.1464-410X.2011.10355.x; Pepe P, 2014, UROL INT, V93, P189, DOI 10.1159/000358494; Rhudd A, 2017, CURR OPIN UROL, V27, P488, DOI 10.1097/MOU.0000000000000415; Schroder FH, 2014, LANCET, V384, P2027, DOI 10.1016/S0140-6736(14)60525-0; Sivaraman Arjun, 2015, Urol Oncol, V33, DOI 10.1016/j.urolonc.2015.04.005; Sivaraman A, 2015, INT J UROL, V22, P146, DOI 10.1111/iju.12660; Taira AV, 2013, AM J CLIN ONCOL-CANC, V36, P116, DOI 10.1097/COC.0b013e31823fe639; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valerio M, 2016, BJU INT, V118, P384, DOI 10.1111/bju.13306; Van der Kwast T, 2013, VIRCHOWS ARCH, V463, P367, DOI 10.1007/s00428-013-1466-5; van der Kwast TH, 2003, J CLIN PATHOL, V56, P336, DOI 10.1136/jcp.56.5.336; Varma M, 2013, J CLIN PATHOL, V66, P120, DOI 10.1136/jclinpath-2012-200993; Villers A, 2017, EUR UROL, V72, P333, DOI 10.1016/j.eururo.2016.08.057; Yu JX, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160693	23	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					599	604		10.1007/s00428-017-2265-1			6	Pathology	Pathology	GE4HL	WOS:000431176200009	29327138				2019-10-28	
J	Santi, R; Cai, T; Nobili, S; Galli, IC; Amorosi, A; Comperat, E; Nesi, G				Santi, Raffaella; Cai, Tommaso; Nobili, Stefania; Galli, Ilaria Camilla; Amorosi, Andrea; Comperat, Eva; Nesi, Gabriella			Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study	VIRCHOWS ARCHIV			English	Article						Bladder cancer; Snail; E-cadherin; Slug	TRANSITIONAL-CELL CARCINOMA; TERM-FOLLOW-UP; E-CADHERIN; UROTHELIAL CARCINOMA; MESENCHYMAL TRANSITION; TUMOR PROGRESSION; EXPRESSION; SLUG; SURVIVAL; TWIST	The current WHO/ISUP classification and grading system subdivides urothelial tumours into prognostically distinct categories. Understanding the molecular pathways involved in bladder cancer development can improve patient stratification and management. This study aims to investigate the relationship between Snail, Slug and E-cadherin expressions and clinico-pathological features of non-muscle invasive bladder carcinoma (NMIBC). All patients attending the same urological centre from January to May 2002, who were pathologically diagnosed with NMIBC, were enrolled in this longitudinal cohort study. E-cadherin, Snail and Slug protein expressions were assessed by immunohistochemical analysis and compared with follow-up data. The main outcome measures were recurrence and progression rates. The cohort under investigation included 43 patients (38 men and 5 women, mean age 67.7 +/- 10.6 years). High-grade (HG) carcinomas were 20/43, with 10 invasive cases (pT1). Low-grade (LG) carcinomas were 23/43, with no invasive cases (pTa). Among the eight HGpTa cases with recurrence, strong Snail expression was detected in six (75%). Out of the 17 LGpTa patients who experienced recurrence, 12 (70.6%) showed strong positivity for Snail. Among the 10 HGpT1 cases, recurrence was observed in 4, of which, 3 (75%) stained intensely for Snail. The Kaplan-Meier curves showed significantly different recurrence rates for patients with strong or weak Snail reactivity (p = 0.027). E-cadherin and Slug expression did not correlate with any of the parameters considered. On multivariate analysis, Snail expression was recognised as an independent prognostic factor for tumour recurrence (p = 0.003). In our study population, Snail immunohistochemical overexpression proved to be related to tumour recurrence in patients affected by NMIBC.	[Santi, Raffaella; Galli, Ilaria Camilla; Nesi, Gabriella] Univ Florence, Div Anat Pathol, Florence, Italy; [Cai, Tommaso] Santa Chiara Reg Hosp, Dept Urol, Trento, Italy; [Nobili, Stefania] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, Florence, Italy; [Amorosi, Andrea] Magna Graecia Univ Catanzaro, Inst Pathol, Dept Hlth Sci, Catanzaro, Italy; [Comperat, Eva] UPMC Univ Paris 06, Hop Tenon, AP HP, Acad Dept Pathol, Paris, France; [Nesi, Gabriella] Univ Florence, Dept Surg & Translat Med, Div Anat Pathol, Largo Brambilla 3, I-50134 Florence, Italy	Nesi, G (reprint author), Univ Florence, Div Anat Pathol, Florence, Italy.; Nesi, G (reprint author), Univ Florence, Dept Surg & Translat Med, Div Anat Pathol, Largo Brambilla 3, I-50134 Florence, Italy.	gabriella.nesi@unifi.it	Nobili, Stefania/AAA-5917-2019				Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Blechschmidt K, 2008, BRIT J CANCER, V98, P489, DOI 10.1038/sj.bjc.6604115; Bruyere F, 2010, UROL ONCOL-SEMIN ORI, V28, P591, DOI 10.1016/j.urolonc.2008.11.005; Bryan RT, 2010, J UROLOGY, V184, P423, DOI 10.1016/j.juro.2010.04.016; Byrne RA, 2001, J UROLOGY, V165, P1473, DOI 10.1016/S0022-5347(05)66330-6; Cai T, 2007, ONCOL REP, V17, P925; Castro Alves C, 2007, J Pathol, V211, P507; Eble J. N. S. G., 2004, WHO CLASSIFICATION T; Edge SB, 2010, AM JOINT COMMITTEE C; Fondrevelle ME, 2009, UROL ONCOL-SEMIN ORI, V27, P268, DOI 10.1016/j.urolonc.2007.12.012; Fromont G, 2005, EUR UROL, V48, P764, DOI 10.1016/j.eururo.2005.07.005; Gou YC, 2015, INT UROL NEPHROL, V47, P289, DOI 10.1007/s11255-014-0874-z; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Knuchel-Clarke R, 2010, PATHOLOGE, V31, P234, DOI 10.1007/s00292-010-1324-z; Kosaka T, 2010, CLIN CANCER RES, V16, P5814, DOI 10.1158/1078-0432.CCR-10-0230; Liu B.MiyakeH, 2015, UROL ONCOL, V33, pe11, DOI DOI 10.1016/J.UR0L0NC.2014.08.012; Nomura S, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-73; Patschan O, 2015, EUR UROL, V68, P824, DOI 10.1016/j.eururo.2015.02.021; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pollard C, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001407; Scarpato KR, 2016, CURR OPIN ONCOL, V28, P210, DOI 10.1097/CCO.0000000000000278; Schulte J, 2012, HISTOCHEM CELL BIOL, V138, P847, DOI 10.1007/s00418-012-0998-0; Singh Rinni, 2017, Clin Genitourin Cancer, V15, pe187, DOI 10.1016/j.clgc.2016.07.021; Switula D, 2000, SCI ENG ETHICS, V6, P71, DOI 10.1007/s11948-000-0025-z; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Wu KJ, 2013, UROL ONCOL-SEMIN ORI, V31, P1751, DOI 10.1016/j.urolonc.2012.02.001; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yun SJ, 2013, KOREAN J UROL, V54, P645, DOI 10.4111/kju.2013.54.10.645; Zhang P, 2014, EUR J CLIN INVEST, V44, P1072, DOI 10.1111/eci.12343	32	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					605	613		10.1007/s00428-018-2310-8			9	Pathology	Pathology	GE4HL	WOS:000431176200010	29525824				2019-10-28	
J	Koh, VCY; Thike, AA; Nasir, NDM; Yip, GWC; Bay, BH; Tan, PH				Koh, Valerie Cui Yun; Thike, Aye Aye; Nasir, Nur Diyana Md; Yip, George Wai Cheong; Bay, Boon Huat; Tan, Puay Hoon			Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast	VIRCHOWS ARCHIV			English	Article						Phyllodes tumour; Malignant; Metastasis; Heterologous elements; Tumour size	PRIMARY SURGICAL-TREATMENT; CYSTOSARCOMA-PHYLLODES; LOCAL RECURRENCE; LIPOSARCOMATOUS DIFFERENTIATION; DISTANT METASTASES; SINGLE-CENTER; MED12; MUTATIONS; OVERGROWTH; CRITERIA	Phyllodes tumours (PTs) of the breast are uncommon fibroepithelial neoplasms comprising 0.3-1.0% of all primary breast tumours. The majority of PTs are benign and generally well managed with surgery. However, malignant PTs, and occasionally borderline PTs, can behave in a clinically aggressive manner by metastasizing to distant organs. Although distant metastasis is rare, the prognosis of patients with metastasis is dismal as many are unresponsive to standard chemotherapy and the risk of death is high. In this study, we correlated clinicopathological parameters to survival outcomes in a cohort of patients diagnosed with malignant PTs in our institution. The study cohort comprised 83 cases of malignant PTs diagnosed at the Department of Anatomical Pathology, Singapore General Hospital from 1994 to 2015. Clinicopathological features and follow-up were obtained from hospital records. Metastasis-free survival (MFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared between groups using the log-rank test. Cox regression was carried out to identify factors predictive for metastasis. Mean and median age of patients was 48 years (range 21-71 years). Tumour size measured from 30 to 220 mm (mean 90 mm, median 77 mm). Follow-up data was available for 68 patients. Mean and median follow-up was 90 and 57 months, respectively, with a maximum of 291 months. Distant metastasis occurred in 16 out of 68 patients (23.5%). The most common site of metastasis was the lung. Malignant heterologous elements were observed in 16 (19.3%) cases. Individual clinicopathological parameters had no impact on outcome. On Kaplan-Meier analysis, women with large tumours and presence of malignant heterologous elements showed trends for poorer MFS (p = 0.217 and p = 0.566, respectively). However, the combination of large tumours (ae<yen> 90 mm) containing malignant heterologous elements disclosed significantly worse MFS (p = 0.043) and a trend for poorer OS (p = 0.238). On multivariate analysis, large tumours harbouring malignant heterologous elements independently predicted metastasis (95% CI 1.041-12.517, HR 2.434, p = 0.049). Our study demonstrates that tumour size and presence of malignant heterologous elements predicted metastasis in malignant PTs. Further work needs to be done in determining if protein biomarkers and genomic aberrations are able to additionally refine metastatic risk and define therapeutic targets.	[Koh, Valerie Cui Yun; Thike, Aye Aye; Nasir, Nur Diyana Md; Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Diagnostics Tower Level 7, Singapore 169856, Singapore; [Koh, Valerie Cui Yun; Yip, George Wai Cheong; Bay, Boon Huat; Tan, Puay Hoon] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, MD10,4 Med Dr, Singapore 117594, Singapore; [Thike, Aye Aye; Tan, Puay Hoon] Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore	Tan, PH (reprint author), Singapore Gen Hosp, Div Pathol, 20 Coll Rd,Diagnostics Tower Level 7, Singapore 169856, Singapore.; Tan, PH (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, MD10,4 Med Dr, Singapore 117594, Singapore.; Tan, PH (reprint author), Duke NUS Med Sch, 8 Coll Rd, Singapore 169857, Singapore.	tan.puay.hoon@singhealth.com.sg					Abdalla Hassan M, 2006, J Egypt Natl Canc Inst, V18, P125; Al-Masri M, 2012, ANN SURG ONCOL, V19, P1181, DOI 10.1245/s10434-011-2076-6; Asoglu O, 2004, ANN SURG ONCOL, V11, P1011, DOI 10.1245/ASO.2004.02.001; AUSTIN RM, 1986, HUM PATHOL, V17, P906, DOI 10.1016/S0046-8177(86)80640-2; BARNES L, 1978, AM J SURG PATHOL, V2, P423, DOI 10.1097/00000478-197812000-00009; Chaney AW, 2000, CANCER-AM CANCER SOC, V89, P1502, DOI 10.1002/1097-0142(20001001)89:7<1502::AID-CNCR13>3.0.CO;2-P; Chen WH, 2005, J SURG ONCOL, V91, P185, DOI 10.1002/jso.20334; de Roos WK, 1999, BRIT J SURG, V86, P396, DOI 10.1046/j.1365-2168.1999.01035.x; Guerrero MA, 2003, SURG ONCOL, V12, P27, DOI 10.1016/S0960-7404(03)00005-7; Hallin M, 2017, INT J SURG PATHOL, V25, P435, DOI 10.1177/1066896917696750; HAWKINS RE, 1992, CANCER, V69, P141, DOI 10.1002/1097-0142(19920101)69:1<141::AID-CNCR2820690125>3.0.CO;2-1; Inyang A, 2016, BREAST J, V22, P282, DOI 10.1111/tbj.12567; Kapiris I, 2001, EUR J SURG ONCOL, V27, P723, DOI 10.1053/ejso.2001.1207; Lenhard MS, 2008, EUR J OBSTET GYN R B, V138, P217, DOI 10.1016/j.ejogrb.2007.08.002; Lim WK, 2014, NAT GENET, V46, P877, DOI 10.1038/ng.3037; Liu SY, 2016, MODERN PATHOL, V29, P1012, DOI 10.1038/modpathol.2016.97; Lyle PL, 2016, HISTOPATHOLOGY, V68, P1040, DOI 10.1111/his.12898; Mitus JW, 2016, WORLD J SURG, V40, P323, DOI 10.1007/s00268-015-3262-7; Nagasawa S, 2015, CANCER MED-US, V4, P1117, DOI 10.1002/cam4.462; Ng CCY, 2015, J CLIN PATHOL, V68, P685, DOI 10.1136/jclinpath-2015-202896; Nozad S, 2017, BREAST CANCER RES TR, V162, P597, DOI 10.1007/s10549-017-4156-1; Okaly GVP, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.137996; Piscuoglio S, 2015, HISTOPATHOLOGY, V67, P719, DOI 10.1111/his.12712; Ren DL, 2014, TUMOR BIOL, V35, P9603, DOI 10.1007/s13277-014-2254-9; Sawalhi S, 2013, ANN SAUDI MED, V33, P162, DOI 10.5144/0256-4947.2013.162; Silver SA, 1999, AM J SURG PATHOL, V23, P815, DOI 10.1097/00000478-199907000-00010; Spitaleri G, 2013, CRIT REV ONCOL HEMAT, V88, P427, DOI 10.1016/j.critrevonc.2013.06.005; Tan BY, 2016, HISTOPATHOLOGY, V68, P5, DOI 10.1111/his.12876; Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; Tan PH, 2012, WHO CLASSIFICATION T, P142; Tan PH, 2012, J CLIN PATHOL, V65, P69, DOI 10.1136/jclinpath-2011-200368; Tan WJ, 2014, HISTOPATHOLOGY, V64, P807, DOI 10.1111/his.12329; Tomas D, 2007, APMIS, V115, P367, DOI 10.1111/j.1600-0463.2007.apm_588.x; WARD RM, 1986, CANCER, V58, P2282, DOI 10.1002/1097-0142(19861115)58:10<2282::AID-CNCR2820581021>3.0.CO;2-2; Warrier S, 2015, INT J SURG CASE REP, V11, P91, DOI 10.1016/j.ijscr.2015.02.009; Wei J, 2014, CHIN J CANCER, V33, P492, DOI 10.5732/cjc.014.10048; Yoshida M, 2015, BRIT J CANCER, V112, P1703, DOI 10.1038/bjc.2015.116; Zhang YH, 2016, ARCH PATHOL LAB MED, V140, P665, DOI 10.5858/arpa.2016-0042-RA	39	3	4	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					615	621		10.1007/s00428-017-2257-1			7	Pathology	Pathology	GE4HL	WOS:000431176200011	29127495				2019-10-28	
J	Hotton, J; Agopiantz, M; Leroux, A; Charra-Brunaud, C; Marie, B; Busby-Venner, H; Morel, O; Gueant, JL; Vignaud, JM; Battaglia-Hsu, SF; Gauchotte, G				Hotton, Judicael; Agopiantz, Mikael; Leroux, Agnes; Charra-Brunaud, Claire; Marie, Beatrice; Busby-Venner, Helene; Morel, Olivier; Gueant, Jean-Louis; Vignaud, Jean-Michel; Battaglia-Hsu, Shyue-Fang; Gauchotte, Guillaume			Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma	VIRCHOWS ARCHIV			English	Article						Endometrioid adenocarcinoma; Endometrial carcinoma; Immunohistochemistry; Proliferation; MCM6; Ki-67	GYNECOLOGIC-ONCOLOGY-GROUP; CELL-CYCLE PHASE; DNA-REPLICATION; CLINICOPATHOLOGICAL ANALYSIS; P53 OVEREXPRESSION; COLORECTAL-CANCER; III TRIAL; CARCINOMA; PROTEIN; KI-67	Minichromosome maintenance complex component 6 (MCM6) is involved in initiating DNA replication and is upregulated during licensed G0 phase of the cell cycle. This early expression permits its labeling of more proliferating cells than those by Ki-67. Here using a cohort of 89 endometrioid adenocarcinoma, we report findings made on the prognostic value of MCM6 based on immunohistochemical labeling index (LI) of the protein in comparison with that of Ki67 as no such information is currently available. Additionally, we examined the prognostic values of these markers based on their mRNA expression using a cohort of uterine corpus endometrial carcinoma (UCEC, n = 307) taken from The Cancer Genome Atlas (TCGA) database. Our evidence indicated the presence of a positive correlation between the LI of MCM6 and the histological grade of endometrioid endometrial adenocarcinoma (grade I, 66.7%; grade II, 75.3%; grade III, 81.4%; p < 0.001) and an inverse correlation between the LI of MCM6 and the overall and progression-free survival (p = 0.02 for both). The LI of Ki-67 correlated with grade (p < 0.001), but not survival. The MCM6 and Ki-67 inter-observer intra-class correlation coefficients were excellent: 0.84 (95% confidence interval, 0.83-0.91) and 0.84 (0.77-0.90), respectively. For in silico analyses of the TCGA cohort, both univariate and multivariate Cox analyses (p = 0.003 and p = 0.03, respectively) revealed high MCM6 mRNA Z-scores associated with reduced overall survival. This association was absent for Ki-67. MCM6 is thus a highly reproducible marker of poor prognosis in endometrial cancer. Evaluation of MCM6 should thus be considered in daily practice for risk stratification.	[Hotton, Judicael; Morel, Olivier] CHRU Nancy, Dept Gynecol & Obstet, Nancy, France; [Hotton, Judicael; Agopiantz, Mikael; Busby-Venner, Helene; Gueant, Jean-Louis; Vignaud, Jean-Michel; Battaglia-Hsu, Shyue-Fang; Gauchotte, Guillaume] Univ Lorraine, INSERM, U954, Vandoeuvre Les Nancy, France; [Agopiantz, Mikael] CHRU Nancy, Dept Med Gynecol, Nancy, France; [Leroux, Agnes] Inst Cancerol Lorraine, Dept Pathol, Vandoeuvre Les Nancy, France; [Charra-Brunaud, Claire] Inst Cancerol Lorraine, Dept Radiotherapy, Vandoeuvre Les Nancy, France; [Marie, Beatrice; Busby-Venner, Helene; Vignaud, Jean-Michel; Gauchotte, Guillaume] CHRU Nancy, Dept Pathol, Nancy, France; [Gueant, Jean-Louis] CHRU Nancy, Dept Biochem Mol Biol Nutr & Metab, Dept Mol Med & Personalized Therapeut, Vandoeuvre Les Nancy, France; [Gauchotte, Guillaume] CHRU Nancy, Hop Cent, Serv Anat & Cytol Pathol, 29 Ave Marechal De Lattre de Tassigny, F-54000 Nancy, France	Gauchotte, G (reprint author), Univ Lorraine, INSERM, U954, Vandoeuvre Les Nancy, France.; Gauchotte, G (reprint author), CHRU Nancy, Dept Pathol, Nancy, France.; Gauchotte, G (reprint author), CHRU Nancy, Hop Cent, Serv Anat & Cytol Pathol, 29 Ave Marechal De Lattre de Tassigny, F-54000 Nancy, France.	g.gauchotte@chru-nancy.fr					Agopiantz M, 2017, VIRCHOWS ARCH, V471, P521, DOI 10.1007/s00428-017-2215-y; Alkushi A, 2004, INT J GYNECOL PATHOL, V23, P129, DOI 10.1097/01.pgp.0000116612.98868.fb; Alvarez T, 2012, AM J SURG PATHOL, V36, P753, DOI 10.1097/PAS.0b013e318247b7bb; An HJ, 2007, AM J SURG PATHOL, V31, P846, DOI 10.1097/01.pas.0000213423.30880.ac; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Chakravarty D, 2010, ACTA HISTOCHEM, V112, P355, DOI 10.1016/j.acthis.2009.03.001; Chatrath P, 2006, BRIT J CANCER, V95, P314, DOI 10.1038/sj.bjc.6603262; Colombo N, 2016, INT J GYNECOL CANCER, V26, P2, DOI 10.1097/IGC.0000000000000609; Core Team R., 2015, R LANG ENV STAT COMP; Djordjevic B, 2013, MODERN PATHOL, V26, P1401, DOI 10.1038/modpathol.2013.67; Eward KL, 2004, J CELL SCI, V117, P5875, DOI 10.1242/jcs.01503; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184; Gassel AM, 1998, J CLIN PATHOL, V51, P25, DOI 10.1136/jcp.51.1.25; Gauchotte G, 2012, AM J SURG PATHOL, V36, P283, DOI 10.1097/PAS.0b013e318235ee03; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Kato K, 2003, INT J GYNECOL PATHOL, V22, P334, DOI 10.1097/01.pgp.0000092129.10100.5e; Kingsbury SR, 2005, EXP CELL RES, V309, P56, DOI 10.1016/j.yexcr.2005.05.027; Kohlberger P, 1996, GYNECOL ONCOL, V62, P213, DOI 10.1006/gyno.1996.0218; Kohler MF, 1996, AM J OBSTET GYNECOL, V175, P1246, DOI 10.1016/S0002-9378(96)70036-4; Kudela M, 2012, EUR J GYNAECOL ONCOL, V33, P159; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li SS, 2005, HISTOPATHOLOGY, V46, P307, DOI 10.1111/j.1365-2559.2005.02069.x; Mengel M, 2002, J PATHOL, V198, P292, DOI 10.1002/path.1218; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Narducci F, 2003, Gynecol Obstet Fertil, V31, P581, DOI 10.1016/S1297-9589(03)00173-5; Nelson GS, 2013, GYNECOL ONCOL, V131, P309, DOI 10.1016/j.ygyno.2013.08.003; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Orbo A, 2003, INT J GYNECOL PATHOL, V22, P141, DOI 10.1097/01.PGP.0000055170.26935.F8; Oreskovic S, 2004, GYNECOL ONCOL, V93, P34, DOI 10.1016/j.ygyno.2003.12.038; Ouldamer L, 2017, ANN SURG ONCOL, V24, P1660, DOI 10.1245/s10434-016-5731-0; Ozalp S, 2003, EUR J GYNAECOL ONCOL, V24, P275; Petru E, 2009, EUR J OBSTET GYN R B, V143, P69, DOI 10.1016/j.ejogrb.2008.12.015; Pohlert T, 2014, PARIWAISE MULTIPLE C; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Romanowski P, 1997, TRENDS CELL BIOL, V7, P9, DOI 10.1016/S0962-8924(97)30077-4; Salvesen HB, 1998, CLIN CANCER RES, V4, P2779; Schultheis AM, 2016, INT J GYNECOL PATHOL, V35, P289, DOI 10.1097/PGP.0000000000000243; Scott IS, 2003, J PATHOL, V201, P187, DOI 10.1002/path.1444; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Sorosky JI, 2008, OBSTET GYNECOL, V111, P436, DOI 10.1097/AOG.0b013e318162f690; Soslow RA, 2007, AM J SURG PATHOL, V31, P979, DOI 10.1097/PAS.0b013e31802ee494; Sun HZ, 2017, GYNECOL OBSTET INVES, V82, P30, DOI 10.1159/000445073; Therneau T., 2015, PACKAGE SURVIVAL ANA; Thigpen JT, 2004, J CLIN ONCOL, V22, P3902, DOI 10.1200/JCO.2004.02.088; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; VERHEIJEN R, 1989, J CELL SCI, V92, P531; Vigouroux C, 2015, LUNG CANCER, V89, P189, DOI 10.1016/j.lungcan.2015.05.008; Wolak ME, 2012, METHODS ECOL EVOL, V3, P129, DOI 10.1111/j.2041-210X.2011.00125.x; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85	50	3	3	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					623	633		10.1007/s00428-017-2278-9			11	Pathology	Pathology	GE4HL	WOS:000431176200012	29243125				2019-10-28	
J	Tateishi, A; Ohira, S; Yamamoto, Y; Kanno, H				Tateishi, Ayako; Ohira, Satoshi; Yamamoto, Yoichiro; Kanno, Hiroyuki			Histopathological findings of pregnancy-induced hypertension: histopathology of early-onset type reflects two-stage disorder theory	VIRCHOWS ARCHIV			English	Article						Placenta; Pregnancy-induced hypertension; Preeclampsia; Two-stage disorder theory	UTERINE ARTERY DOPPLER; GROWTH RESTRICTION; PREECLAMPSIA; WOMEN; PREDICTION; ENDOGLIN; SFLT-1; BIRTH; RISK	The placental tissues of pregnancy-induced hypertension (PIH) patients exhibit multiple infarctions, acute atherosis, distal villous hypoplasia, and increased syncytial knots. However, these findings are not observed in all cases of PIH; thus, the significance of these changes in PIH is still unclear. We studied the frequency of histopathological changes of placental tissue in the subgroups of PIH, such as mild and severe PIH and early-onset (< 34 weeks) and late-onset (ae<yen> 34 weeks) PIH. One hundred seven cases of PIH diagnosed at the Shinshu University Hospital, Matsumoto, Japan, between 2008 and 2014 were collected. PIH includes preeclampsia and gestational hypertension. The pathologic changes evaluated in the placenta were multiple infarctions, acute atherosis, distal villous hypoplasia, and increased syncytial knots. Placental tissues of patients with early-onset PIH demonstrated acute atherosis resulting from the incomplete remodeling of the spiral arteries and distal villous hypoplasia and increased syncytial knots reflecting placental hypoxia/ischemia much more frequently than those with late-onset PIH (all p < 0.001). The frequencies of multiple infarctions did not show a statistical difference between early-onset PIH and late-onset PIH. Moreover, there were no significant differences in the frequencies of histopathological features of placental tissue between mild PIH and severe PIH. Early-onset PIH exhibited histopathological changes of placental tissue consistent with the two-stage disorder theory more frequently than late-onset PIH. These findings support the idea that early-onset PIH and late-onset PIH are distinct entities or different extremes of the PIH spectrum.	[Tateishi, Ayako; Yamamoto, Yoichiro; Kanno, Hiroyuki] Shinshu Univ, Sch Med, Dept Pathol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Ohira, Satoshi] Shinshu Univ, Sch Med, Dept Obstet & Gynecol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Yamamoto, Yoichiro] RIKEN Ctr Adv Intelligence Project, Pathol Informat Unit, Chuo Ku, Nihonbashi 1 Chome Mitsui Bldg,15F, Tokyo 1030027, Japan	Tateishi, A (reprint author), Shinshu Univ, Sch Med, Dept Pathol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	atateishi@shinshu-u.ac.jp			medical ethics committee at the Shinshu University School of Medicine [3265]	This study was approved by the medical ethics committee at the Shinshu University School of Medicine (Project #3265 was approved on November 2, 2015).	Allen RE, 2014, EUR J OBSTET GYN R B, V182, P194, DOI 10.1016/j.ejogrb.2014.09.027; Arakaki T, 2015, ULTRASOUND OBST GYN, V45, P539, DOI 10.1002/uog.14633; Benirschke K., 2012, PATHOLOGY HUMAN PLAC, DOI [10.1007/978-3-642-23941-0, DOI 10.1007/978-3-642-23941-0]; Burger O, 2004, PLACENTA, V25, P608, DOI 10.1016/j.placenta.2003.12.009; Correa RRM, 2008, ARCH GYNECOL OBSTET, V277, P201, DOI 10.1007/s00404-007-0452-z; De Vivo A, 2008, ACTA OBSTET GYN SCAN, V87, P837, DOI 10.1080/00016340802253759; Duley L, 2009, SEMIN PERINATOL, V33, P130, DOI 10.1053/j.semperi.2009.02.010; Joshi VV., 2006, HDB PLACENTAL PATHOL; Khalil A, 2009, PRENATAL DIAG, V29, P781, DOI 10.1002/pd.2287; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Kraus FT, 2004, PLACENTAL PATHOLOGY; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Lisonkova S, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.08.019; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Moldenhauer JS, 2003, AM J OBSTET GYNECOL, V189, P1173, DOI 10.1067/S0002-9378(03)00576-3; Papageorghiou AT, 2001, ULTRASOUND OBST GYN, V18, P441, DOI 10.1046/j.0960-7692.2001.00572.x; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; Pinheiro CC, 2014, PRENATAL DIAG, V34, P1084, DOI 10.1002/pd.4432; Prefumo F, 2004, HUM REPROD, V19, P206, DOI 10.1093/humrep/deh037; Redline RW, 2004, PEDIATR DEVEL PATHOL, V7, P237, DOI 10.1007/s10024-003-8083-2; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Roberts JM, 2009, PLACENTA, V30, pS32, DOI 10.1016/j.placenta.2008.11.009; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Saxena AR, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-85; Smith GCS, 2002, J CLIN ENDOCR METAB, V87, P1762, DOI 10.1210/jc.87.4.1762; Speer PD, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.05.052; Stark MW, 2014, PEDIATR DEVEL PATHOL, V17, P181, DOI 10.2350/13-09-1378-OA.1; Steegers EAP, 2010, LANCET, V376, P631, DOI 10.1016/S0140-6736(10)60279-6; VALENSISE H, 1993, ULTRASOUND OBST GYN, V3, P18, DOI 10.1046/j.1469-0705.1993.03010018.x; Valensise H, 2008, HYPERTENSION, V52, P873, DOI 10.1161/HYPERTENSIONAHA.108.117358; Watanabe K, 2013, HYPERTENS RES PREGNA, V1, P3; WHO Guidelines Approved by the Guidelines Review Committee, 2011, WHO REC PREV TREATM; Zhang PL, 2006, AM J OBSTET GYNECOL, V194, P1050, DOI 10.1016/j.ajog.2005.10.196	33	1	3	2	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					635	642		10.1007/s00428-018-2315-3			8	Pathology	Pathology	GE4HL	WOS:000431176200013	29426962				2019-10-28	
J	Abe, H; Saito, R; Ichimura, T; Iwasaki, A; Yamazawa, S; Shinozaki-Ushiku, A; Morikawa, T; Ushiku, T; Yamashita, H; Seto, Y; Fukayama, M				Abe, Hiroyuki; Saito, Ruri; Ichimura, Takashi; Iwasaki, Akiko; Yamazawa, Sho; Shinozaki-Ushiku, Aya; Morikawa, Teppei; Ushiku, Tetsuo; Yamashita, Hiroharu; Seto, Yasuyuki; Fukayama, Masashi			CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8(+)/Foxp3(+) T cells	VIRCHOWS ARCHIV			English	Article						Epstein-Barr virus; Gastric carcinoma; CD47; CD8; Foxp3; Tumor immunity	ADVERSE PROGNOSTIC-FACTOR; PROTEIN-ALPHA; THERAPEUTIC TARGET; HODGKIN-LYMPHOMA; DENDRITIC CELLS; BREAST-CANCER; STEM-CELLS; PD-L1; PHAGOCYTOSIS; MICROENVIRONMENT	Epstein-Barr virus-associated gastric carcinoma (EBVaGC) frequently harbors dense lymphocytic infiltration, suggesting a specific microenvironment allowing coexistence with tumor immunity. CD47, which mediates the "do not eat me" signal in innate immunity, is also important in adaptive anti-tumor immunity. We investigated the significance of CD47 in EBVaGC compared with EBV-negative gastric cancer and the correlation with various immune cells. By immunohistochemistry of CD47, high, low, and negative expression was observed in 24, 63, and 12% of EBVaGC (n = 41), while 11, 49, and 39% of EBV-negative gastric cancer (n = 262), respectively, indicating that high expression of CD47 in cancer cells was significantly frequent and increased in EBVaGC (P = 0.043). In contrast to EBV-negative gastric carcinoma in which no significant correlation was observed between CD47 and survival, high expression of CD47 correlated significantly with worse disease-specific survival (P = 0.011) and overall survival (P = 0.013) in EBVaGC. To further clarify the role of CD47 expression in EBVaGC, digital image analysis of immune cell infiltration revealed that high CD47 expression was correlated with a lower ratio of CD8(+)/Foxp3(+) T cells (P = 0.021), a sensitive indicator of tumor immunity. Thus, CD47 lowers anti-tumor immunity in EBVaGC by finely tuning profile of infiltrating T cells, suggesting that CD47 is an additional target for cancer immunotherapy against this virus-driven gastric cancer.	[Abe, Hiroyuki; Shinozaki-Ushiku, Aya; Morikawa, Teppei; Ushiku, Tetsuo; Fukayama, Masashi] Univ Tokyo Hosp, Dept Pathol, Tokyo, Japan; [Saito, Ruri; Ichimura, Takashi; Iwasaki, Akiko; Yamazawa, Sho; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan; [Saito, Ruri] Teikyo Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Ichimura, Takashi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Chemotherapy, Gastroenterol Ctr,Gastroenterol Internal Med, Tokyo, Japan; [Yamashita, Hiroharu; Seto, Yasuyuki] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Tokyo, Japan	Fukayama, M (reprint author), Univ Tokyo Hosp, Dept Pathol, Tokyo, Japan.; Fukayama, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan.	mfukayama-tky@umin.org	Iwasaki, Akiko/Z-1591-2019	Iwasaki, Akiko/0000-0002-7824-9856	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26253021, 26860232, 16K19074]	This work was supported by a grant in aid for scientific research [KAKENHI] (grant numbers 26253021 (M.F.), 26860232 (H.A.), and 16K19074 (H.A.)) from the Japan Society for the Promotion of Science.	Abe H, 2016, VIRCHOWS ARCH, V468, P539, DOI 10.1007/s00428-016-1915-z; Abe H, 2015, PATHOBIOLOGY, V82, P212, DOI 10.1159/000434683; Asano Y, 2016, BRIT J SURG, V103, P845, DOI 10.1002/bjs.10127; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Betancur PA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14802; Braz-Silva PH, 2011, INT J CANCER, V128, P2501, DOI 10.1002/ijc.25597; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Derks S, 2016, ONCOTARGET, V7, P32925, DOI 10.18632/oncotarget.9076; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Hatogai K, 2016, ONCOTARGET, V7, P47252, DOI 10.18632/oncotarget.10055; Ichimura T, 2016, HUM PATHOL, V56, P74, DOI 10.1016/j.humpath.2016.06.002; Inaguma S, 2016, AM J SURG PATHOL, V40, P1133, DOI 10.1097/PAS.0000000000000653; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Li ZW, 2016, HUM PATHOL, V55, P182, DOI 10.1016/j.humpath.2016.05.012; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Matlung HL, 2017, IMMUNOL REV, V276, P145, DOI 10.1111/imr.12527; Saito R, 2017, MODERN PATHOL, V30, P427, DOI 10.1038/modpathol.2016.202; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Wang HM, 2015, INT J MOL SCI, V16, P3391, DOI 10.3390/ijms16023391; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Yoshida K, 2015, CANCER MED-US, V4, P1322, DOI 10.1002/cam4.478; Yu GT, 2015, ONCOTARGET, V6, P42067, DOI 10.18632/oncotarget.5955; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112; Zhao XW, 2011, P NATL ACAD SCI USA, V108, P18342, DOI 10.1073/pnas.1106550108	32	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					643	651		10.1007/s00428-018-2332-2			9	Pathology	Pathology	GE4HL	WOS:000431176200014	29536167				2019-10-28	
J	Tahkola, K; Mecklin, JP; Wirta, EV; Ahtiainen, M; Helminen, O; Bohm, J; Kellokumpu, I				Tahkola, Kyosti; Mecklin, Jukka-Pekka; Wirta, Erkki-Ville; Ahtiainen, Maarit; Helminen, Olli; Bohm, Jan; Kellokumpu, Ilmo			High immune cell score predicts improved survival in pancreatic cancer	VIRCHOWS ARCHIV			English	Article						Immunoscore; Pancreatic cancer; Microsatellite instability; Microenvironment; Immune cell score	SINGLE-INSTITUTION EXPERIENCE; MICROSATELLITE INSTABILITY; DUCTAL ADENOCARCINOMA; T-CELLS; COLORECTAL-CANCER; IMMUNOSCORE; PANCREATICODUODENECTOMY; MICROENVIRONMENT; CLASSIFICATION; INFILTRATION	Increasing evidence suggests that cancer progression is strongly influenced by host immune response, which is represented by immune cell infiltrates. T-lymphocyte-based immunoscore has proved to be a prognostic factor in colon cancer, but its significance in pancreatic cancer is poorly known. Total of 108 patients operated (R0/R1) for pancreatic ductal adenocarcinoma (PDAC) (TNM stage I-II) were included in the study. Immune cell score (IS) was determined by scoring the samples from grade 0 to 4 according to the number of immune cells (CD3(+) and CD8(+)) in tumor core and invasion margin using tissue microarrays, immunohistochemistry, and digital analysis. Tumors with microsatellite instability were identified by MLH1 immunostaining. High IS and low histological grade were significantly associated with better disease-specific survival (DSS) and overall survival (OS). The 5-year DSS rate for low, moderate, and high IS groups were 5.0, 15.2, and 33.4%, respectively (p = 0.007). The 5-year OS rate for the low, moderate, and high IS groups were 4.2, 13.4, and 31.5%, respectively (p = 0.004). In addition, IS and prognosis varied within a single TNM stage. There was no association between IS and any of the clinicopathological variables. IS was shown to be an independent prognostic factor for better DSS and OS in multivariate analysis, together with the histological grade of the tumor and perineural invasion. Five MLH1-negative tumors (4.6%) were found showing no correlation with IS. IS could be a useful prognostic marker in patients with PDAC treated by primary surgery.	[Tahkola, Kyosti; Wirta, Erkki-Ville; Helminen, Olli; Kellokumpu, Ilmo] Cent Finland Cent Hosp, Dept Surg, Keskussairaalantie 19, Jyvaskyla 40620, Finland; [Mecklin, Jukka-Pekka; Ahtiainen, Maarit] Cent Finland Cent Hosp, Dept Educ & Res, Jyvaskyla, Finland; [Mecklin, Jukka-Pekka; Ahtiainen, Maarit] Univ Eastern Finland, Jyvaskyla, Finland; [Helminen, Olli] Univ Oulu, Med Res Ctr Oulu, Canc & Translat Med Res Unit, Oulu, Finland; [Helminen, Olli] Oulu Univ Hosp, Oulu, Finland; [Bohm, Jan] Cent Finland Cent Hosp, Dept Pathol, Jyvaskyla, Finland	Tahkola, K (reprint author), Cent Finland Cent Hosp, Dept Surg, Keskussairaalantie 19, Jyvaskyla 40620, Finland.	kyosti.tahkola@gmail.com			Finnish Cancer Foundation; Jane and Aatos Erkko Foundation	This study received funding from the Finnish Cancer Foundation, Jane and Aatos Erkko Foundation and the State Research Funding.	Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Cai SW, 2011, SURGERY, V149, P576, DOI 10.1016/j.surg.2010.10.009; Carstens JL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15095; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Diener MK, 2007, ANN SURG, V245, P187, DOI 10.1097/01.sla.0000242711.74502.a9; Edge SB, 2010, AJCC CANC STAGING MA; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Jamieson NB, 2012, ANN SURG ONCOL, V19, P3581, DOI 10.1245/s10434-012-2370-y; Kamarajah SK, 2017, ANN SURG ONCOL, V24, P2023, DOI 10.1245/s10434-017-5810-x; Laghi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046002; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Nakata B, 2002, CLIN CANCER RES, V8, P2536; Nocito A, 2001, INT J CANCER, V94, P1, DOI 10.1002/ijc.1385; Pillarisetty VG, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.950171; Polom K, 2018, BRIT J SURG, V105, P159, DOI 10.1002/bjs.10663; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Poultsides GA, 2010, ANN SURG, V251, P470, DOI 10.1097/SLA.0b013e3181cf8a19; Seppanen H, 2017, SCAND J SURG, V106, P54, DOI 10.1177/1457496916645963; Tang YK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088267; Vayrynen JP, 2012, VIRCHOWS ARCH, V460, P455, DOI 10.1007/s00428-012-1232-0; Verbeke CS, 2006, BRIT J SURG, V93, P1232, DOI 10.1002/bjs.5397; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; WHIPPLE AO, 1945, ANN SURG, V121, P847, DOI 10.1097/00000658-194506000-00008; Wirta EV, 2017, J PATHOL CLIN RES, V3, P203, DOI 10.1002/cjp2.71; Yamamoto H, 2001, CANCER RES, V61, P3139; Yeo CJ, 1997, ANN SURG, V225, P621, DOI 10.1097/00000658-199705000-00018; Yoshikawa K, 2012, CANCER SCI, V103, P2012, DOI 10.1111/j.1349-7006.2012.02411.x	35	4	4	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					653	665		10.1007/s00428-018-2297-1			13	Pathology	Pathology	GE4HL	WOS:000431176200015	29356891				2019-10-28	
J	Shasthry, SM; Rastogi, A; Bihari, C; Vijayaraghavan, R; Arora, V; Sharma, MK; Sarin, SK				Shasthry, Saggere Muralikrishna; Rastogi, Archana; Bihari, Chhagan; Vijayaraghavan, Rajan; Arora, Vinod; Sharma, Manoj Kumar; Sarin, Shiv Kumar			Histological activity score on baseline liver biopsy can predict non-response to steroids in patients with severe alcoholic hepatitis	VIRCHOWS ARCHIV			English	Article						Severe alcoholic hepatitis; Alcoholic liver disease; Mallory-Denk bodies	DISEASE; PROGNOSIS; CIRRHOSIS; SURVIVAL; THERAPY; FAILURE	Baseline clinical and biochemical parameters fail to predict non-response to steroids in severe alcoholic hepatitis patients. Liver biopsy features have not been adequately assessed for predicting response to steroid therapy in severe alcoholic hepatitis. We aimed to identify histological parameters, which can predict steroid response in severe alcoholic hepatitis (SAH). We analyzed histological data of 107 SAH patients (71 in a derivative and 36 in a validation cohort) who presented within 4 weeks after inset of jaundice and were prospectively treated with steroids (40 mg/day). Histopathological parameters were semi-quantitatively scored in the pre-therapy biopsies in the derivative cohort, and a histological scoring system of SAH was developed which differentiated between steroid responders (Lille score < 0.45 at day 7) and non-responders. Seventeen of the 71 (24%) patients in the derivation cohort and 9 of 36 (25%) in the validation cohort were non-responders to steroids. In the derivation cohort, in comparison to responders, non-responders had higher severity of ballooning degeneration (BD) (mean 3.87 +/- 0.91 versus 2.92 +/- 1.33; p = 0.013) and density of Mallory-Denk bodies (MD) (mean 2.27 +/- 0.79 versus. 1.69 +/- 0.97; p = 0.028) on liver histology. A score derived using BD and MD (range 0-8) had high sensitivity (81%), specificity (64%), and negative predictive value (91%) in identifying patients who did not respond to steroids. The AUROC for a combined MD and BD score of > 5 for predicting steroid non-response was 0.731. Baseline histological parameters in SAH, ballooning degeneration, and Mallory-Denk bodies can reliably identify non-response to corticosteroids and help to stratify patients prior to introduction of therapy.	[Shasthry, Saggere Muralikrishna; Vijayaraghavan, Rajan; Arora, Vinod; Sharma, Manoj Kumar; Sarin, Shiv Kumar] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi 110070, India; [Rastogi, Archana; Bihari, Chhagan] Inst Liver & Biliary Sci, Dept Hepatopathol, New Delhi, India	Sarin, SK (reprint author), Inst Liver & Biliary Sci, Dept Hepatol, New Delhi 110070, India.	sksarin@ilbs.in					Adang RP, 1998, SCAND J GASTROENTERO, V33, P70, DOI 10.1080/003655298750027263; Altamirano J, 2014, GASTROENTEROLOGY, V146, P1231, DOI 10.1053/j.gastro.2014.01.018; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Forrest EH, 2005, GUT, V54, P1174, DOI 10.1136/gut.2004.050781; Garg V, 2012, GASTROENTEROLOGY, V142, P505, DOI 10.1053/j.gastro.2011.11.027; Hardy T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-55; Louvet A, 2007, HEPATOLOGY, V45, P1348, DOI 10.1002/hep.21607; Louvet A, 2015, NAT REV GASTRO HEPAT, V12, P231, DOI 10.1038/nrgastro.2015.35; Louvet A, 2009, GASTROENTEROLOGY, V137, P541, DOI 10.1053/j.gastro.2009.04.062; Lucey MR, 2009, NEW ENGL J MED, V360, P2758, DOI 10.1056/NEJMra0805786; MACSWEEN RNM, 1986, SEMIN LIVER DIS, V6, P221, DOI 10.1055/s-2008-1040605; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; Mathurin P, 2011, GUT, V60, P255, DOI 10.1136/gut.2010.224097; McCullough AJ, 1998, AM J GASTROENTEROL, V93, P2022; Mookerjee RP, 2011, J HEPATOL, V55, P1103, DOI 10.1016/j.jhep.2011.02.021; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Rastogi A, 2011, VIRCHOWS ARCH, V459, P121, DOI 10.1007/s00428-011-1115-9; Sarin SK, 2011, HEPATOL INT, V5, P607, DOI 10.1007/s12072-010-9236-9; TELI MR, 1995, LANCET, V346, P987, DOI 10.1016/S0140-6736(95)91685-7; Tome S, 2004, ALIMENT PHARM THER, V19, P707, DOI 10.1111/j.1365-2036.2004.01881.x	20	4	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					667	675		10.1007/s00428-018-2330-4			9	Pathology	Pathology	GE4HL	WOS:000431176200016	29516163				2019-10-28	
J	Patsea, E; Kaklamanis, L; Batistatou, A				Patsea, Eleni; Kaklamanis, Loukas; Batistatou, Anna		Hellenic Soc Pathology	The first report of a 5-year period cancer registry in Greece (2009-2013): a pathology-based cancer registry	VIRCHOWS ARCHIV			English	Article						Pathology; Cancer; Registry; Greece	MORTALITY; EUROPE	Cancer registries are essential in health care, since they allow more accurate planning of necessary health services and evaluation of programs for cancer prevention and control. The Hellenic Society of Pathology (HSP) having recognized the lack of such information in Greece has undertaken the task of a 5-year pathology-based cancer registry in Greece (2009-2013). In this study, > 95% of all pathology laboratories in the national health system hospitals and 100% of pathology laboratories in private hospitals, as well as > 80% of private pathology laboratories have contributed their data. The most common cancer types overall were as follows: breast cancer (18.26%), colorectal cancer (15.49%), prostate cancer (13.49%), and lung cancer (10.24% of all registered cancers). In men, the most common neoplasms were as follows: prostate cancer, colorectal cancer, lung cancer, and gastric cancer. In women, the most common neoplasms were as follows: breast cancer, colorectal cancer, thyroid cancer, and lung cancer. The data on cancer burden in Greece, presented herein, fill the void of cancer information in Greece that affects health care not only nationally but Europe-wise.	[Patsea, Eleni] IASO Hosp Athens, Dept Pathol, Maroussi, Greece; [Kaklamanis, Loukas] ONASSIS Cardiac Surg Ctr, Dept Pathol, Athens, Greece; [Batistatou, Anna] Univ Hosp Ioannina, Dept Pathol, Ioannina, Greece	Batistatou, A (reprint author), Univ Hosp Ioannina, Dept Pathol, Ioannina, Greece.	abatista@cc.uoi.gr			Hellenic Society of Pathology	The work was funded by funds of the Hellenic Society of Pathology (www.pathology.gr).	[Anonymous], 2015, HELL CANC REG HCR 2; Bray F, 2014, IARC TECHNICAL PUBLI, V43; Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015; Saracci R, 2015, INT AGENCY RES CANC; Terracini B, 2003, SOZ PRAVENTIV MED, V48, P3, DOI 10.1007/s000380300001; Tzala L, 2011, HCDCP NEWSLETTER, V11; Whelan SL, 2010, ASIAN PACIFIC J CANC, V11	10	0	0	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					677	682		10.1007/s00428-017-2287-8			6	Pathology	Pathology	GE4HL	WOS:000431176200017	29302754				2019-10-28	
J	Teunissen, BT; Knuiman, GJ; Eijkelenboom, A; Wauters, CAP; Wouda, S; Blokx, WAM				Teunissen, B. T.; Knuiman, G. J.; Eijkelenboom, A.; Wauters, C. A. P.; Wouda, S.; Blokx, W. A. M.			CTNNB1-mutated melanocytic lesions with DPN like features: a distinct subtype of melanocytic tumors? A report of two cases	VIRCHOWS ARCHIV			English	Article							DEEP PENETRATING NEVUS; MELANOMA-CELL-LINES; BETA-CATENIN GENE; EXON-3 MUTATIONS; CTNNB1		[Teunissen, B. T.; Knuiman, G. J.; Eijkelenboom, A.; Blokx, W. A. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [Wauters, C. A. P.] Canisius Wilhelmina Hosp, Dept Pathol, Nijmegen, Netherlands; [Wouda, S.] VieCuri Med Ctr, Dept Pathol, Venlo, Netherlands	Knuiman, GJ (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands.	jimmy.knuiman@radboudumc.nl	Blokx, W.A.M./L-4205-2015; Eijkelenboom, Astrid/P-2795-2015	Blokx, Willeke/0000-0002-4647-8830			Blokx WAM, 2010, HISTOPATHOLOGY, V56, P121, DOI 10.1111/j.1365-2559.2009.03452.x; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Eijkelenboom A, 2016, J MOL DIAGN, V18, P851, DOI 10.1016/j.jmoldx.2016.06.010; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Luzar B, 2011, ARCH PATHOL LAB MED, V135, P321, DOI 10.1043/2009-0493-RA.1; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pollock PM, 2002, MELANOMA RES, V12, P183, DOI 10.1097/00008390-200204000-00013; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Robson A, 2003, HISTOPATHOLOGY, V43, P529, DOI 10.1111/j.1365-2559.2003.01730.x; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Strazzula L, 2014, J AM ACAD DERMATOL, V71, P1234, DOI 10.1016/j.jaad.2014.07.026; van Engen-van Grunsven Adriana C H, 2014, Front Med (Lausanne), V1, P39, DOI 10.3389/fmed.2014.00039; Yeh I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00758-3	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					683	687		10.1007/s00428-017-2250-8			5	Pathology	Pathology	GE4HL	WOS:000431176200018	29086002				2019-10-28	
J	Chen, SB; Kudose, S; Krigman, HR				Chen, Simon B.; Kudose, Satoru; Krigman, Hannah R.			Decidual granulomatous reaction in a placenta from a preeclamptic pregnancy: a case report and review of the literature	VIRCHOWS ARCHIV			English	Review						Decidua; Granuloma; Placenta; Preeclampsia	INFECTION	We report a case of decidual perivascular non-necrotizing granulomas in a placenta from a pregnancy complicated by severe preeclampsia with no evidence of infection. The mother was a 20-year-old primigravida with severe preeclampsia diagnosed in the third trimester with subsequent delivery of a healthy baby boy at 37 weeks 5 days gestation. Pathologic examination of the placenta showed scattered non-necrotizing granulomas in decidua, often adjacent to remodeled decidual arteries without fibrinoid necrosis. These were well-formed, non-necrotizing granulomas with scant lymphoid cuffs. Polarization microscopy did not show foreign material. There were no histopathologic or clinical findings suggestive of maternal-fetal infection or systemic vasculitis at the time of delivery, and the mother had no other reported conditions associated with granulomatous inflammation. Our case demonstrates that granulomatous reaction may be seen in the placenta from a pregnancy complicated by severe preeclampsia, although work-up for infection may be indicated.	[Chen, Simon B.] Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,MC 5324, Stanford, CA 94305 USA; [Kudose, Satoru; Krigman, Hannah R.] Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 South Euclid Ave, St Louis, MO 63110 USA	Chen, SB (reprint author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,MC 5324, Stanford, CA 94305 USA.	sbchen@stanford.edu					Benirschke K, 2012, PATHOLOGY HUMAN PLAC; BITTENCOURT AL, 1976, AM J DIS CHILD, V130, P97, DOI 10.1001/archpedi.1976.02120020099020; BITTENCOURT AL, 1980, AM J TROP MED HYG, V29, P571, DOI 10.4269/ajtmh.1980.29.571; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P466, DOI 10.1038/nrneph.2014.102; DUNCAN ME, 1984, PLACENTA, V5, P189, DOI 10.1016/S0143-4004(84)80028-4; GARCIA AGP, 1963, PEDIATRICS, V32, P895; GARCIA AGP, 1989, PLACENTA, V10, P1; KAPLAN C, 1980, AM J OBSTET GYNECOL, V137, P858, DOI 10.1016/0002-9378(80)90901-1; Kelemen J T, 1969, Zentralbl Allg Pathol, V112, P18; Kraus FT, 2004, ARMED FORCES I PATHO; Laresgoiti-Servitje E, 2010, HUM REPROD UPDATE, V16, P510, DOI 10.1093/humupd/dmq007; LIDE TN, 1947, ARCH PATHOL, V43, P165; Nelson DB, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.09.010; RUSSELL P, 1974, AM J DIS CHILD, V128, P160, DOI 10.1001/archpedi.1974.02110270034007; Yavuz E, 2006, PLACENTA, V27, P780, DOI 10.1016/j.placenta.2005.07.002	15	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	APR	2018	472	4					689	692		10.1007/s00428-018-2333-1			4	Pathology	Pathology	GE4HL	WOS:000431176200019	29541857				2019-10-28	
J	Agrawal, R				Agrawal, Ranjan			From the Editor's Desk	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							EXPRESSION		[Agrawal, Ranjan] Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India	Agrawal, R (reprint author), Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India.	chiefeditor.ijpm@gmail.com					Garg P, 2018, INDIAN J PATHOL MICR, V61, P197, DOI 10.4103/IJPM.IJPM_93_17; Goyal R, 2018, INDIAN J PATHOL MICR, V61, P233, DOI 10.4103/IJPM.IJPM_460_17; Guleria P, 2018, INDIAN J PATHOL MICR, V61, P176, DOI 10.4103/IJPM.IJPM_774_16; Krothapalli M, 2018, INDIAN J PATHOL MICR, V61, P170, DOI 10.4103/IJPM.IJPM_369_16; Rabade N, 2018, INDIAN J PATHOL MICR, V61, P209, DOI 10.4103/IJPM.IJPM_223_17; Sen Turk N, 2018, INDIAN J PATHOL MICR, V61, P192, DOI 10.4103/IJPM.IJPM_161_17; Sterlacci W, 2018, INDIAN J PATHOL MICR, V61, P187, DOI 10.4103/IJPM.IJPM_678_17	7	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					169	169		10.4103/0377-4929.230586			1	Pathology	Pathology	GD9SC	WOS:000430851900001	29676350	DOAJ Gold			2019-10-28	
J	Krothapalli, M; Kini, JR; Kini, H; Sahu, KK; Shenoy, S; Krishna, SG; Tantry, BV				Krothapalli, Mahathi; Kini, Jyoti Ramnath; Kini, Hema; Sahu, Kausalya Kumari; Shenoy, Suresh; Krishna, Sandeep Gopal; Tantry, B. V.			Evaluation of p53 protein expression in Barrett esophagus	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Barrett esophagus; dysplasia; esophageal adenocarcinoma; p53	CLONAL EXPANSION; RISK-FACTORS; ADENOCARCINOMA; PREVALENCE; DYSPLASIA; ACCUMULATION; PROGRESSION; METAPLASIA; BIOMARKERS; EPITHELIUM	Background: Loss of heterozygosity of p53 along with aneuploidy is deemed to be the early molecular steps in Barrett metaplasia-dysplasia-adenocarcinoma sequence. Objective biomarkers need to be used along with microscopy for risk stratification to predict the progression of Barrett esophagus (BE) to carcinoma. Aim: This study aims to study p53 protein expression in dysplasia and correlate the same with morphology in BE. Materials and Methods: A time-bound study was conducted from January 2011 to June 2015. All esophageal biopsies showing histological evidence of columnar epithelium with the presence of goblet cells were included. The cases which showed dysplasia were graded on hematoxylin and eosin stain. Evaluation of p53 immunohistochemistry staining was done on all the cases of BE. Dysplasia was correlated with the expression of p53 using Chi-square value (chi(2)) and Fischer's exact test wherever appropriate. P < 0.05 was considered to be statistically significant. Results: Of 829 esophageal biopsies received, 119 were endoscopically suspected to be BE, of which 85 cases were confirmed on microscopy. In our study, there were 75 cases negative for dysplasia (88.2%), 8 with low-grade dysplasia (LGD) (9.4%), and two with high-grade dysplasia (HGD) (2.4%). Three cases of BE had associated adenocarcinoma. Immunostaining with p53 done on all the 85 cases showed positive staining in all cases with LGD, one with HGD and two with adenocarcinoma. In the present study, immunostaining with p53 showed 90% sensitivity, 89.3% specificity, positive predictive value of 52.9%, and negative predictive value of 98.5%. Conclusion: The technical simplicity, easy availability, and comparatively lower cost enhance the role of p53 as a biomarker in risk stratification for patients with BE.	[Krothapalli, Mahathi; Kini, Jyoti Ramnath; Kini, Hema; Sahu, Kausalya Kumari] Kasturba Med Coll & Hosp, Dept Pathol, Mangalore 575001, Karnataka, India; [Shenoy, Suresh; Krishna, Sandeep Gopal; Tantry, B. V.] Kasturba Med Coll & Hosp, Dept Gastroenterol, Mangalore, Karnataka, India; Manipal Acad Higher Educ, Manipal, Karnataka, India	Kini, JR (reprint author), Kasturba Med Coll & Hosp, Dept Pathol, Mangalore 575001, Karnataka, India.	kinijyoti@gmail.com		KINI, JYOTI/0000-0002-3351-9517			Abrams JA, 2008, CLIN GASTROENTEROL H, V6, P30, DOI 10.1016/j.cgh.2007.10.006; Bansal A, 2015, GASTROENTEROL CLIN N, V44, P373, DOI 10.1016/j.gtc.2015.02.008; Bennett AE, 2009, SURG PATHOLOGY GI TR, P248; Coban S, 2013, DIS ESOPHAGUS, V26, P189, DOI 10.1111/j.1442-2050.2012.01352.x; Coggi G, 1997, CANCER, V79, P425, DOI 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H; Dhawan P S, 2001, Indian J Gastroenterol, V20, P144; Dvorak K, 2006, ANN SURG, V244, P1031, DOI 10.1097/01.sla.0000224913.19922.7e; Feith M, 2004, DIS ESOPHAGUS, V17, P322, DOI 10.1111/j.1442-2050.2004.00434.x; Ford AC, 2005, AM J EPIDEMIOL, V162, P454, DOI 10.1093/aje/kwi218; Gaddam S, 2013, GASTROENTEROLOGY, V145, P548, DOI 10.1053/j.gastro.2013.05.040; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Gimenez A, 1998, CANCER-AM CANCER SOC, V83, P641, DOI 10.1002/(SICI)1097-0142(19980815)83:4<641::AID-CNCR3>3.0.CO;2-N; Hammoud GM, 2014, WORLD J GASTRO ONCOL, V6, P275, DOI 10.4251/wjgo.v6.i8.275; HARDWICK RH, 1994, GUT, V35, P764, DOI 10.1136/gut.35.6.764; Jankowski JA, 1999, AM J PATHOL, V154, P965, DOI 10.1016/S0002-9440(10)65346-1; JONES DR, 1994, ANN THORAC SURG, V57, P598, DOI 10.1016/0003-4975(94)90551-7; Kapoor H, 2015, TRANSL RES, V166, P28, DOI 10.1016/j.trsl.2015.01.009; Kim JH, 2007, J GASTROEN HEPATOL, V22, P908, DOI 10.1111/j.1440-1746.2006.04448.x; Klump B, 1999, Z GASTROENTEROL, V37, P1005; Punia R S, 2006, J Assoc Physicians India, V54, P187; Rajendra S, 2004, DIGEST DIS SCI, V49, P237, DOI 10.1023/B:DDAS.0000017444.30792.94; Rex DK, 2003, GASTROENTEROLOGY, V125, P1670, DOI 10.1053/j.gastro.2003.09.030; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Runge TM, 2015, GASTROENTEROL CLIN N, V44, P203, DOI 10.1016/j.gtc.2015.02.001; Shiao YH, 2000, CANCER EPIDEM BIOMAR, V9, P631; Skacel M, 2002, AM J GASTROENTEROL, V97, P2508; Teh M, 2002, CANCER-AM CANCER SOC, V95, P499, DOI 10.1002/cncr.10697; van Dekken H, 2008, AM J CLIN PATHOL, V130, P745, DOI 10.1309/AJCPO31THGVEUIDH; Wani Irfan R, 2014, Middle East J Dig Dis, V6, P228; Wong DJ, 2001, CANCER RES, V61, P8284; YOUNES M, 1993, GASTROENTEROLOGY, V105, P1637, DOI 10.1016/0016-5085(93)91058-P; Zibadi S, 2015, CANCER CONTROL, V22, P177, DOI 10.1177/107327481502200208	32	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					170	175		10.4103/IJPM.IJPM_369_16			6	Pathology	Pathology	GD9SC	WOS:000430851900002	29676351	DOAJ Gold			2019-10-28	
J	Guleria, P; Srinivas, V; Basannar, D; Dutta, V				Guleria, Prerna; Srinivas, V.; Basannar, D.; Dutta, Vibha			Comparison of lymphangiogenesis, lymphatic invasion, and axillary lymph node metastasis in breast carcinoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						D2-40; Invasive ductal carcinoma breast; lymphangiogenesis	TUMOR LYMPHANGIOGENESIS; VASCULAR INVASION; CANCER METASTASIS; VESSEL INVASION; DENSITY; EXPRESSION; SURVIVAL; MARKER; D2-40; BLOOD	Context: Lymphangiogenesis correlates with poor prognosis in Invasive Ductal Carcinoma (IDC) breast. D2-40 antibody, a specific marker for lymphatic endothelium, differentiates lymphatic from vascular endothelium. Therefore, the aims of this study were to estimate lymphangiogenesis using D2-40 antibody and correlate with lymphatic invasion (LI) and axillary lymph node (LN) status and compare lymphatic mean vessel density (LMVD) with Tumor (T) and Node (N) stages and grade of tumor. Methods and Material: The study was conducted on fifty consecutive cases of IDC breast who underwent modified radical mastectomy (MRM) from Jan 2009 to March 2011. Hematoxylin-eosin sections and Immunohistochemistry (IHC) slides were studied along with their LN status. LMVD was counted after D2-40 immunostaining (100x magnification) in three hot spots in peritumoral areas and averaged. LI as opposed to vascular invasion (BVI), and LN status for all cases were assessed. Statistical Analysis: Statistical analysis was done using SPSS software (version 14.0 for Windows). Pearson's correlations, chi(2) tests and Mann-Whitney U test were used. Results: Lymphangiogenesis varied from 0 to 58 with mean LMVD of 11. Of 50 cases, five showed no lymphatic vessels in peritumoral areas; of these five, three had positive LNs. 21/50 cases had LI. No statistical significant association was seen between lymphangiogenesis and LI. 34/50 cases had positive LNs. Mean LMVD was higher in patients with N2/N3 stage as compared to N0/N1 stage and was statistically significant (P = 0.013). Conclusions: D2-40 is specific marker for lymphatic endothelium. LI and lymphangiogenesis, as opposed to BVI, are better prognostic indicators in IDC breast.	[Guleria, Prerna] Mil Hosp Yol Cantt, Dept Pathol, Kangra 176052, Himachal Prades, India; [Srinivas, V.] Command Hosp Southern Command, Dept Pathol, Pune, Maharashtra, India; [Basannar, D.] AFMC, Dept PSM, Pune, Maharashtra, India; [Dutta, Vibha] Command Hosp Cent Command, Dept Pathol, Lucknow, Uttar Pradesh, India	Guleria, P (reprint author), Mil Hosp Yol Cantt, Dept Pathol, Kangra 176052, Himachal Prades, India.	prernaguleria@yahoo.co.in	vadapalli, srinivas/I-4025-2019	vadapalli, srinivas/0000-0002-6686-8780			Ansari MA, 2014, INT J GEN MED PHARM, V3, P49; Arnaout-Alkarain A, 2007, MODERN PATHOL, V20, P183, DOI 10.1038/modpathol.3800728; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Boenisch T., 2001, DAKO HDB IMMUNOHISTO; Boneberg EM, 2009, BRIT J CANCER, V101, P605, DOI 10.1038/sj.bjc.6605219; Choi WWL, 2005, MODERN PATHOL, V18, P143, DOI 10.1038/modpathol.3800253; Chua B, 2001, ANZ J SURG, V71, P723, DOI 10.1046/j.1445-1433.2001.02266.x; Colleoni M, 2007, ANN ONCOL, V18, P1632, DOI 10.1093/annonc/mdm268; Cunnick GH, 2002, HISTOL HISTOPATHOL, V17, P863, DOI 10.14670/HH-17.863; Cunnick GH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-23; El-Gohary YM, 2008, AM J CLIN PATHOL, V129, P578, DOI 10.1309/2HGNJ1GU57JMBJAQ; Grabau D, 2007, APMIS, V115, P828, DOI 10.1111/j.1600-0463.2007.apm_442.x; He YL, 2004, BBA-REV CANCER, V1654, P3, DOI 10.1016/j.bbcan.2003.07.003; Ito Masahiro, 2007, Breast Cancer, V14, P381, DOI 10.2325/jbcs.14.381; Kahn HJ, 2002, LAB INVEST, V82, P1255, DOI 10.1097/01.LAB.0000028824.03032.AB; Kandemir NO, 2012, PATHOL ONCOL RES, V18, P253, DOI 10.1007/s12253-011-9436-1; Kodera Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2903; Kulkarni D, 2016, J INT ORAL HLTH, V8, P422; Kyzas PA, 2005, J PATHOL, V206, P170, DOI 10.1002/path.1776; Liu HT, 2009, INT J SURG PATHOL, V17, P426, DOI 10.1177/1066896909337505; Mohammed RAA, 2007, AM J SURG PATHOL, V31, P1825, DOI 10.1097/PAS.0b013e31806841f6; Ran Sophia, 2010, Pathophysiology, V17, P229, DOI 10.1016/j.pathophys.2009.11.003; Schoppmann SF, 2010, ANN ONCOL, V21, P955, DOI 10.1093/annonc/mdp532; Schoppmann SF, 2002, ONCOL REP, V9, P455; Sivridis E, 2006, BREAST, V15, P382, DOI 10.1016/j.breast.2005.06.010; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Van den Eynden GG, 2006, BRIT J CANCER, V94, P1643, DOI 10.1038/sj.bjc.6603152; Van der Auwera I, 2005, CLIN CANCER RES, V11, P7637, DOI 10.1158/1078-0432.CCR-05-1142; Williams CSM, 2003, J PATHOL, V200, P195, DOI 10.1002/path.1343; Wilting J, 2002, FASEB J, V16, P1271, DOI 10.1096/fj.01-1010fje; Yeole Balkrishna B, 2003, Asian Pac J Cancer Prev, V4, P51; Zhang XH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-4	32	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					176	180		10.4103/IJPM.IJPM_774_16			5	Pathology	Pathology	GD9SC	WOS:000430851900003	29676352	DOAJ Gold			2019-10-28	
J	Cabuk, FK; Aktepe, F; Kapucuoglu, FN; Coban, I; Sarsenov, D; Ozmen, V				Cabuk, Fatmagul Kusku; Aktepe, Fatma; Kapucuoglu, Fatma Nilgun; Coban, Ipek; Sarsenov, Dauren; Ozmen, Vahit			Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast cancer; breast pathology; tumor immunity; tumor-infiltrating lymphocyte	REGULATORY T-CELLS; PROGNOSTIC-SIGNIFICANCE; NEOADJUVANT CHEMOTHERAPY; PREDICTIVE-VALUE; AGREEMENT; THERAPY; DENSITY	Aim: Tumor-infiltrating lymphocytes (TILs) have a prognostic value in breast cancer (BC); however, because of the lack of standard evaluation methods, we aimed to assess the interobserver agreement of stromal TILs (sTILs) and intratumoral TILs (iTILs) as well as the effect of hot spot areas and molecular subtyping on the overall agreement. Methods: The study consisted of 121 haematoxylin and eosin (H and E)-stained slides of invasive BC samples obtained from the pathology archives. The TIL assessment was based on the International TIL Working Group recommendations for the percentage of sTILs and was conducted by four pathologists. The percentage of iTILs, the number of lymphocytes in hot spot areas (iTILs-HS), and the overall interobserver agreement for the molecular subtypes were evaluated. The interclass correlation coefficient (ICC) was used to assess interobserver agreement among the four pathologists. Results: The ICC score among the observers for the sTIL percentages was 0.74, and the individual ICC values for each molecular subtype were 0.55, 0.88, and 0.79 for luminal, HER2-positive, and triple-negative tumors, respectively. The compliance value for the iTILs was 0.29 (95% confidence interval (CI) = 0.06-0.48], whereas the compliance value for the iTILs-HS was 0.63 (95% CI = 0.49-0.71). The compliance values for the iTILs-HS subtypes were 0.72, 0.43, and 0.55 for luminal, HER2-positive, and triple-negative tumors, respectively. Conclusion: The IWTILG recommendations are reproducible and reliable. The interobserver agreement of the sTIL percentages was considerably higher for the triple-negative and HER2-positive cases than the luminal cases, whereas the interobserver agreement for the assessment of iTILs-HS in tumors was higher for the luminal subtype.	[Cabuk, Fatmagul Kusku; Coban, Ipek] Istanbul Bilim Univ, Dept Pathol, Istanbul, Turkey; [Aktepe, Fatma] Gayrettepe Florence Nightingale Hosp, Dept Pathol, Istanbul, Turkey; [Kapucuoglu, Fatma Nilgun] Acibadem Hosp, Dept Pathol, Istanbul, Turkey; [Sarsenov, Dauren] Istanbul Florence Nightingale Hosp, Dept Gen Surg, Istanbul, Turkey; [Ozmen, Vahit] Istanbul Univ, Dept Gen Surg, Istanbul, Turkey	Cabuk, FK (reprint author), Cumhuriyet Ave,4A-13 Gokturk, Eyup Istanbul, Turkey.	fatmagulkusku@hotmail.com					de Jong RA, 2009, GYNECOL ONCOL, V114, P105, DOI 10.1016/j.ygyno.2009.03.022; Denkert C, 2016, MODERN PATHOL, V29, P1155, DOI 10.1038/modpathol.2016.109; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Flammiger A, 2013, EUR J CANCER, V49, P1273, DOI 10.1016/j.ejca.2012.11.035; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Giatromanolaki A, 2008, GYNECOL ONCOL, V110, P216, DOI 10.1016/j.ygyno.2008.04.021; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hida AI, 2015, ANN ONCOL, V26, P2351, DOI 10.1093/annonc/mdv363; Hodi FS, 2016, J CLIN ONCOL, V34, P1510, DOI 10.1200/JCO.2015.64.0391; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Lee HJ, 2015, AM J CLIN PATHOL, V144, P278, DOI 10.1309/AJCPIXUYDVZ0RZ3G; Lee HJ, 2013, J BREAST CANCER, V16, P32, DOI 10.4048/jbc.2013.16.1.32; Li JF, 2009, BJU INT, V103, P399, DOI 10.1111/j.1464-410X.2008.08151.x; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; Loi S, 2013, CANCER RES, V73; Loi SDD, 2015, SAN ANT BREAST CANC, pS1; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Marrone KA, 2016, CANCER J, V22, P81, DOI 10.1097/PPO.0000000000000178; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sawe RT, 2017, TROP MED HEALTH, V45, DOI 10.1186/s41182-017-0059-4; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Swisher SK, 2016, ANN SURG ONCOL, V23, P2242, DOI 10.1245/s10434-016-5173-8; Tomsova M, 2008, GYNECOL ONCOL, V108, P415, DOI 10.1016/j.ygyno.2007.10.016; Tse BWC, 2014, BIOMED RES INT, DOI 10.1155/2014/981434; Wein L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00156; Yamagami W, 2011, INT J GYNECOL CANCER, V21, P1628, DOI 10.1097/IGC.0b013e31822c271f; Yu X, 2016, CLIN TRANSL ONCOL, V18, P497, DOI 10.1007/s12094-015-1391-y; Yuan YY, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1153	35	2	2	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					181	186		10.4103/IJPM.IJPM_131_17			6	Pathology	Pathology	GD9SC	WOS:000430851900004	29676353	DOAJ Gold			2019-10-28	
J	Sterlacci, W; Fiegl, M; Veits, L; Tzankov, A				Sterlacci, William; Fiegl, Michael; Veits, Lothar; Tzankov, Alexandar			Diagnostic and prognostic impact of mucin 1-6 expression in non-small cell lung cancer	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Immunohistochemistry; mucin expression; non-small cell lung cancer; pancreatic ductal adenocarcinoma; prognosis	PANCREATIC-CANCER; BREAST-CANCER; CARCINOMAS; ADENOCARCINOMA; MARKERS; GENES; LIGAND	Background: The prognostic significance and clinico-pathological characterization of mucin (MUC) expression in non-small cell lung cancer (NSCLC) is controversial and little studied. Aims: This study aims at elucidating this issue on the largest and most detailed cohort so far. Settings and Design: We examined the expression of MUC 1, 2, 4, 5AC and 6 on 371, well documented, surgically resected NSCLC cases. Materials and Methods: Immunohistochemical results were correlated with several of our previously studied, relevant parameters on this cohort including a follow-up period of up to 20 years. An additional point we examined for practical reasons that has not been addressed so far, was the possible assistance of MUC expression for the differentiation between a primary lung adenocarcinoma and metastasis from a known pancreatobiliary primary tumor. Statistical Analysis Used: Cronbach's Alpha reliability correlation, Spearman's correlation, ANOVA means of comparison with additional Kruskall-Wallis H-test, and Kaplan-Meier survival analysis were employed as statistical analyses in this study. Results and Conclusions: MUCs were associated with histologic subtypes, tumor differentiation and members of the epidermal growth factor receptor signaling pathway, although they were not found to be significant for prognosis. Expression of MUC1 correlated with certain other markers and may point to a group of patients relevant for upcoming treatment strategies involving MUC1. According to our findings, we also recommend additional MUC5AC staining for a thyroid transcription factor 1-negative adenocarinoma in the lung for the differentiation of a possible metastasis in the presence of a pancreatic ductal adenocarcinoma.	[Sterlacci, William; Veits, Lothar] Hosp Bayreuth, Dept Pathol, Bayreuth, Germany; [Fiegl, Michael] Med Univ Innsbruck, Div Hematol & Oncol, Dept Internal Med, Innsbruck, Austria; [Fiegl, Michael] Hosp Hochrum, Dept Internal Med Oncol & Geriatr, Rum, Austria; [Tzankov, Alexandar] Univ Hosp Basel, Dept Pathol, Basel, Switzerland	Sterlacci, W (reprint author), Hosp Bayreuth, Inst Pathol, Preuschwitzerstr 101, D-95445 Bayreuth, Germany.	william.sterlacci@klinikum-bayreuth.de	Tzankov, Alexandar/H-5656-2019	Tzankov, Alexandar/0000-0002-1100-3819			Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; BURCHELL J, 1987, CANCER RES, V47, P5476; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; HO SB, 1993, CANCER RES, V53, P641; Hu CL, 2016, CANCER EPIDEM BIOMAR, V25, P207, DOI 10.1158/1055-9965.EPI-15-0455; Jarrard JA, 1998, CANCER RES, V58, P5582; Kaira K, 2012, INT J SURG PATHOL, V20, P223, DOI 10.1177/1066896911429296; Kwon KY, 2007, ARCH PATHOL LAB MED, V131, P593; Laszlo T, 2014, HISTOPATHOLOGY, V65, P283, DOI 10.1111/his.12403; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Nagai S, 2006, J THORAC ONCOL, V1, P46, DOI 10.1097/01243894-200601000-00010; Pomme G, 2015, VIRCHOWS ARCH, V467, P55, DOI 10.1007/s00428-015-1767-y; Raina D, 2011, MOL CANCER THER, V10, P806, DOI 10.1158/1535-7163.MCT-10-1050; Regimbald LH, 1996, CANCER RES, V56, P4244; Samuel J, 1998, INT J CANCER, V75, P295, DOI 10.1002/(SICI)1097-0215(19980119)75:2<295::AID-IJC20>3.0.CO;2-B; Sierzega M, 2016, HISTOPATHOLOGY, V69, P582, DOI 10.1111/his.12994; Sterlacci W, 2014, J THORAC ONCOL, V9, P41, DOI 10.1097/JTO.0000000000000021; Sterlacci W, 2016, PATHOBIOLOGY, V83, P267, DOI 10.1159/000444804; Sterlacci W, 2016, VIRCHOWS ARCH, V468, P463, DOI 10.1007/s00428-015-1900-y; Sterlacci W, 2010, J THORAC ONCOL, V5, P1325, DOI 10.1097/JTO.0b013e3181e77efc; Sterlacci W, 2009, VIRCHOWS ARCH, V455, P125, DOI 10.1007/s00428-009-0812-0; Travis WD, WHO CLASSIFICATION T; Trevor KT, 2001, CANCER IMMUNOL IMMUN, V50, P397, DOI 10.1007/s002620100214; Woenckhaus M, 2008, HUM PATHOL, V39, P126, DOI 10.1016/j.humpath.2007.05.027; Yamada N, 2011, CLIN EPIGENETICS, V2, P85, DOI 10.1007/s13148-011-0037-3; Yonezawa S, 2010, J HEPATO-BIL-PAN SCI, V17, P108, DOI 10.1007/s00534-009-0174-7; Yu CJ, 1996, INT J CANCER, V69, P457, DOI 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3	28	2	2	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					187	191		10.4103/IJPM.IJPM_678_17			5	Pathology	Pathology	GD9SC	WOS:000430851900005	29676354	DOAJ Gold			2019-10-28	
J	Sen Turk, N; Eskicorapci, S; Aybek, Z; Tuncay, L				Sen Turk, Nilay; Eskicorapci, Saadettin; Aybek, Zafer; Tuncay, Levent			The determination of stage in nonmuscle urothelial carcinoma: Staining pattern of caspase-8	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Caspase-8; murine double minute 2; p14(ARF); p53; urothelial carcinoma	CELL-CYCLE ARREST; BLADDER-CANCER; IMMUNOHISTOCHEMICAL ANALYSIS; EXPRESSION; APOPTOSIS; P14(ARF); P53; P21(WAF1/CIP1); PROGRESSION; SURVIVIN	Context: Urothelial carcinoma (UC) is one of the most frequent epithelial tumors worldwide. Aims: We aimed to investigate the protein expressions of caspase-8, p53, murine double minute 2 (mdm2), and p14(ARF) in nonmuscle UCs and to correlate the findings with clinicopathological characteristics. Settings and Design: A total of 50 patients who had pTa and pT1 tumors were analyzed. Subjects and Methods: The protein expressions of caspase-8, p53, mdm2, and p14ARF were analyzed by immunohistochemistry. Statistical Analysis Used: Chi-square test was done using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). Results: Cytoplasmic caspase-8 expression was significantly higher in pT1 UCs while nuclear caspase-8 expression was significantly higher in pTa UCs (P = 0.005 and P = 0.011, respectively). Cytoplasmic caspase-8 expression was also higher in high-grade UCs (P = 0.035). The expression of p53, mdm2, and p14ARF was not also related with pathological stage or grade (P > 0.05 for all). The p14ARF expression was related with nuclear caspase-8 expression in most of the patients. Complete agreement among nonmuscle UCs for immunohistochemical expression of p14 and nuclear caspase-8 was seen in 41 cases, and the pairwise kappa agreement value was substantial (kappa = 0.614). The patients who had recurrence were positive for both p53 and mdm2 or either p53 or mdm2 (P = 0.025). Conclusions: These results suggested that the staining pattern of caspase-8 might be helpful for determining of the stages in nonmuscle UC. It was also showed that the expression status of p53 and mdm2 were related with the recurrence.	[Sen Turk, Nilay] Pamukkale Univ, Dept Pathol, Sch Med, Denizli, Turkey; [Aybek, Zafer; Tuncay, Levent] Pamukkale Univ, Dept Urol, Sch Med, Denizli, Turkey; [Eskicorapci, Saadettin] Acibadem Univ, Dept Urol, Sch Med, Istanbul, Turkey	Sen Turk, N (reprint author), Pamukkale Univ, Sch Med, Dept Pathol, Fahri Goksin Onkoloji Merkezi, Kat 3 Pamukkale, Denizli, Turkey.	sennilay@hotmail.com	Eskicorapci, Saadettin/W-9548-2018				Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200; Cho S, 2010, PATHOL INT, V60, P203, DOI 10.1111/j.1440-1827.2009.02507.x; Cortot AB, 2014, CLIN LUNG CANCER, V15, P124, DOI 10.1016/j.cllc.2013.08.003; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Eble JN, 2004, PATHOLOGY GENETICS T; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Hemmati PG, 2008, ONCOGENE, V27, P6707, DOI 10.1038/onc.2008.193; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2010, J MOL MED, V88, P609, DOI 10.1007/s00109-010-0606-5; Hopkins-Donaldson S, 2000, MED PEDIATR ONCOL, V35, P608; Jahnson S, 2000, CANCER, V89, P619, DOI 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.3.CO;2-W; Kim K, 2015, INT J CLIN EXP PATHO, V8, P743; Koschny R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-532; Lacombe L, 1996, ONCOL RES, V8, P409; Lamm D, 2014, J UROLOGY, V191, P20, DOI 10.1016/j.juro.2013.07.102; Le Frere-Belda MA, 2004, HUM PATHOL, V35, P817, DOI 10.1016/j.humpath.2004.01.019; Lenz P, 2012, CANCER EPIDEM BIOMAR, V21, P1555, DOI 10.1158/1055-9965.EPI-12-0261; Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213; Milojkovic A, 2013, INT J CANCER, V133, P2551, DOI 10.1002/ijc.28279; Mitra AP, 2007, WORLD J UROL, V25, P563, DOI 10.1007/s00345-007-0197-0; Olsson H, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-5; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Salinas-Sanchez AS, 2007, UROL INT, V79, P321, DOI 10.1159/000109717; Samaras V, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-7; Shinohara A, 2009, CANCER SCI, V100, P2376, DOI 10.1111/j.1349-7006.2009.01331.x; Shintani M, 2011, BIOMED RES-TOKYO, V32, P379, DOI 10.2220/biomedres.32.379; Stein JP, 1998, J NATL CANCER I, V90, P1072, DOI 10.1093/jnci/90.14.1072; Xu B, 2008, ONCOLOGY-BASEL, V74, P229, DOI 10.1159/000151392; Yin W, 2006, MODERN PATHOL, V19, P1487, DOI 10.1038/modpathol.3800675; Yurakh AO, 2006, EUR UROL, V50, P506, DOI 10.1016/j.eururo.2006.03.027	30	1	1	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					192	196		10.4103/IJPM.IJPM_161_17			5	Pathology	Pathology	GD9SC	WOS:000430851900006	29676355	DOAJ Gold			2019-10-28	
J	Totadri, S; Munikoty, V; Singh, U; Srinivasan, R; Trehan, A; Jain, R; Kakkar, N; Saxena, AK; Rajwanshi, A; Bansal, D				Totadri, Sidharth; Munikoty, Vinay; Singh, Usha; Srinivasan, Radhika; Trehan, Amita; Jain, Richa; Kakkar, Nandita; Saxena, Akshay Kumar; Rajwanshi, Arvind; Bansal, Deepak			Is a diagnostic lumbar puncture indicated in intraocular retinoblastoma?	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Central nervous system dissemination; cerebrospinal fluid malignant cytology; international retinoblastoma staging system; metastatic retinoblastoma; optic nerve thickening	BONE-MARROW ASPIRATION; DISSEMINATED DISEASE; RECOMMENDATIONS	Background: Lumbar puncture (LP) is frequently performed in patients with advanced intraocular retinoblastoma. However, this may not be necessary in a significant proportion of patients. Materials and Methods: A file review of patients who were diagnosed with retinoblastoma over a 13-year-period was performed. Patients who underwent LP as part of staging were included in the study. Results: The study included 223 patients. One-third had bilateral retinoblastoma. The grouping was C, D, and E in 4 (2.9%), 41 (29.9%), and 92 (67.2%) patients, respectively. The stage was 0, I, II, III, and IV in 14 (6.3), 123 (55.2%), 13 (5.8%), 70 (31.4%), and 3 (1.3%) patients, respectively. Eight (3.6%) patients had a positive cerebrospinal fluid (CSF) cytology. None of the patients with intraocular disease and 7 (10%) patients with extraocular disease had a positive CSF. Conclusions: A diagnostic CSF is not indicated in patients with intraocular retinoblastoma.	[Totadri, Sidharth; Munikoty, Vinay; Trehan, Amita; Jain, Richa; Bansal, Deepak] Postgrad Inst Med Educ & Res, Dept Pediat, Adv Pediat Ctr, Pediat Hematol Oncol Unit, Chandigarh 160012, India; [Singh, Usha] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India; [Srinivasan, Radhika; Rajwanshi, Arvind] Postgrad Inst Med Educ & Res, Dept Cytol, Chandigarh, India; [Kakkar, Nandita] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India; [Saxena, Akshay Kumar] Postgrad Inst Med Educ & Res, Dept Radiodiag, Chandigarh, India	Bansal, D (reprint author), Postgrad Inst Med Educ & Res, Dept Pediat, Adv Pediat Ctr, Pediat Hematol Oncol Unit, Chandigarh 160012, India.	deepakbansaldr@gmail.com					[Anonymous], 2015, GUID MAN CHILDR ADV; [Anonymous], 2002, PDQ CANC INF SUMM; Azar D, 2003, CLIN EXP OPHTHALMOL, V31, P57, DOI 10.1046/j.1442-9071.2003.00601.x; Bakhshi S, 2011, J PEDIAT HEMATOL ONC, V33, pE182, DOI 10.1097/MPH.0b013e3182103f5c; Chantada G, 2006, PEDIATR BLOOD CANCER, V47, P801, DOI 10.1002/pbc.20606; Chantada G, 2013, PEDIATR BLOOD CANCER, V60, P719, DOI 10.1002/pbc.24468; Laurent VE, 2016, JAMA OPHTHALMOL, V134, P1374, DOI 10.1001/jamaophthalmol.2016.4158; Laurent VE, 2013, EUR J CANCER, V49, P2892, DOI 10.1016/j.ejca.2013.04.021; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; MOHNEY BG, 1994, AM J OPHTHALMOL, V118, P707, DOI 10.1016/S0002-9394(14)72548-6; Moscinski LC, 1996, J PEDIAT HEMATOL ONC, V18, P130, DOI 10.1097/00043426-199605000-00006; PRATT CB, 1989, J CLIN ONCOL, V7, P140, DOI 10.1200/JCO.1989.7.1.140; Rodriguez-Galindo C, 2013, PEDIATR BLOOD CANCER, V60, P1016, DOI 10.1002/pbc.24428	13	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					201	203		10.4103/IJPM.IJPM_475_17			3	Pathology	Pathology	GD9SC	WOS:000430851900008	29676357	DOAJ Gold			2019-10-28	
J	Lakshmanan, A; Sikri, D; Patil, S; Kurian, A; Annapurneswari, S; Nair, S				Lakshmanan, Archana; Sikri, Deeksha; Patil, Sushama; Kurian, Ann; Annapurneswari, S.; Nair, Sheila			Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Non-Hodgkin's lymphomas; peripheral T-cell lymphomas; Peripheral T-cell lymphomas Not Otherwise Specified; T-cell lymphoma	NON-HODGKINS-LYMPHOMA; HEALTH-ORGANIZATION CLASSIFICATION; CLINICOPATHOLOGICAL FEATURES; EXPRESSION; PROGNOSIS; NEOPLASMS; PATHOLOGY; VARIANTS; SUBTYPES	Aims: In world literature, Peripheral T-cell lymphomas (PTCLs) constituted about 12% of non-Hodgkin's lymphomas (NHL) of which PTCL not otherwise specified (NOS) was the most common subtype. This study was undertaken to ascertain the frequency and to assess the morphologic and immunophenotypic characteristics of PTCL, NOS over a period of 5 years in a tertiary care referral center in Southern India. Materials and Methods: Slides and blocks of all PTCL, NOS were retrieved, and a detailed morphologic and immunophenotypic study using a wide panel of antibodies was done. Results: During this study, NHL constitutes 77.61% of all lymphomas. PTCL formed about 12.55% (251 cases) of all NHL. PTCL NOS was the most common subtype (30.68%). The most common site of involvement was lymph nodes (75%) followed by extranodal sites such as soft tissue (8.33%), gastrointestinal tract including oral cavity (6.67%), nasal cavity (5%), central nervous system (1.67%), lung (1.67%), and spleen (1.67%). PTCL, NOS showed a broad morphologic spectrum and had varied morphologic patterns with some mimicking reactive hyperplasia and some mimicking known type of T-cell lymphomas, B-cell lymphomas, and Hodgkin's lymphoma. Conclusions: PTCL, NOS constituted about 30.68% of all PTCLs in our institution during a 5-year period and was the second most common type of PTCL. Immunophenotyping using a wide panel of T-cell antibodies is necessary to distinguish PTCL, NOS from other lymphomas which they mimic, as they are known to carry a worse prognosis.	[Lakshmanan, Archana; Sikri, Deeksha; Patil, Sushama; Kurian, Ann; Annapurneswari, S.; Nair, Sheila] Apollo Hosp, Dept Histopathol, Chennai, Tamil Nadu, India	Lakshmanan, A (reprint author), Apollo Hosp, Chennai, Tamil Nadu, India.	mrithulaarchana@gmail.com					Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; Au WY, 2005, ANN ONCOL, V16, P206, DOI 10.1093/annonc/mdi037; Bajor-Dattilo EB, 2013, BEST PRACT RES CL HA, V26, P75, DOI 10.1016/j.beha.2013.04.007; Barry TS, 2003, AM J SURG PATHOL, V27, P1513, DOI 10.1097/00000478-200312000-00003; Bisig B, 2013, HAEMATOLOGICA, V98, P1250, DOI 10.3324/haematol.2012.081935; Burad DK, 2012, INDIAN J PATHOL MICR, V55, P429, DOI 10.4103/0377-4929.107770; de Leval L, 2011, HISTOPATHOLOGY, V58, P49, DOI 10.1111/j.1365-2559.2010.03704.x; Dogan A, 2010, DIAGN HISTOPATHOL, V16, P99; Eberle FC, 2012, AM J SURG PATHOL, V36, P716, DOI 10.1097/PAS.0b013e3182487158; Foss FM, 2011, BLOOD, V117, P6756, DOI 10.1182/blood-2010-05-231548; Gallamini A, 2004, BLOOD, V103, P2474, DOI 10.1182/blood-2003-09-3080; Howard Matthew, 2010, Surg Pathol Clin, V3, P955, DOI 10.1016/j.path.2010.09.001; Huang YL, 2009, AM J SURG PATHOL, V33, P682, DOI 10.1097/PAS.0b013e3181971591; Jaffe Elaine S, 2006, Hematology Am Soc Hematol Educ Program, P317; Jaffe ES, 2013, MODERN PATHOL, V26, pS71, DOI 10.1038/modpathol.2012.181; Miyoshi H, 2012, AM J CLIN PATHOL, V137, P879, DOI 10.1309/AJCPBPNV86VZENGV; Nair RA, 2013, J HEMATOP, V6, P135, DOI 10.1007/s12308-013-0191-y; Naresh KN, 2000, ANN ONCOL, V11, P63, DOI 10.1023/A:1008325827059; Nicolae A, 2013, AM J SURG PATHOL, V37, P816, DOI 10.1097/PAS.0b013e3182785610; Reichard KK, 2006, MODERN PATHOL, V19, P337, DOI 10.1038/modpathol.3800536; Ren YL, 2012, AM J CLIN PATHOL, V138, P435, DOI 10.1309/AJCPWKJ3GPFRT7GA; Rudiger T, 2002, ANN ONCOL, V13, P140, DOI 10.1093/annonc/mdf033; Sahni CS, 2007, LEUKEMIA LYMPHOMA, V48, P122, DOI 10.1080/10428190601043351; Sangle NA, 2011, APPL IMMUNOHISTO M M, V19, P1579, DOI 10.1097/PAI.0b013e318221c672; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; Suzuki Y, 2013, ACTA HAEMATOL-BASEL, V130, P230, DOI 10.1159/000348550; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; ten Berge RL, 2003, HISTOPATHOLOGY, V43, P462, DOI 10.1046/j.1365-2559.2003.01726.x; Uherova P, 2002, MODERN PATHOL, V15, P420, DOI 10.1038/modpathol.3880541; Vose JM, 2008, ANN ONCOL, V19, P74, DOI 10.1093/annonc/mdn203; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Warnke RA, 2007, AM J CLIN PATHOL, V127, P511, DOI 10.1309/QBLAMA321K9AD2XK; Zaja F, 1997, HAEMATOLOGICA, V82, P171	34	1	1	1	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					204	208		10.4103/IJPM.IJPM_405_17			5	Pathology	Pathology	GD9SC	WOS:000430851900009	29676358	DOAJ Gold			2019-10-28	
J	Rabade, N; Subramanian, PG; Kodgule, R; Raval, G; Joshi, S; Chaudhary, S; Mascarenhas, R; Tembhare, P; Gujral, S; Patkar, N				Rabade, Nikhil; Subramanian, P. G.; Kodgule, Rohan; Raval, Goutham; Joshi, Swapnali; Chaudhary, Shruti; Mascarenhas, Russel; Tembhare, Prashant; Gujral, Sumeet; Patkar, Nikhil			Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Calreticulin; Janus kinase 2; molecular genetics of myeloproliferative neoplasms in India; MPL	JAK2 V617F MUTATION; CHRONIC MYELOID-LEUKEMIA; BCR-ABL JUNCTION; ESSENTIAL THROMBOCYTHEMIA; CALRETICULIN MUTATIONS; PRIMARY MYELOFIBROSIS; DISORDERS; PHENOTYPE; SUBTYPES; PATIENT	Introduction: Over the past decade, we have moved on from a predominantly morphological and clinical classification of myeloproliferative neoplasms (MPN) to a more evolved classification that accounts for the molecular heterogeneity that is unique to this subgroup of hematological malignancies. This usually incorporates mutations in Janus kinase 2 (JAK2), MPL, and calreticulin (CALR) genes. In this manuscript, we report the frequency of these mutations in a cohort of Indian patients at a tertiary cancer center. Materials and Methods: One hundred and thirty cases of MPN were included in this study. These cases were diagnosed and classified based on the World Health Organization 2008 criteria. JAK2 and MPL mutations were detected using high sensitivity allele-specific polymerase chain reaction using fluorescent labeled primers followed by capillary electrophoresis. A subset of JAK2 and CALR mutations were assessed using a fragment length assay. Results: Among the MPN, we had 20 cases of polycythemia vera (PV), 34 cases of essential thrombocythemia (ET), and 59 of myelofibrosis (MF). JAK2, MPL, and CALR mutations were mutually exclusive of each other. Seventeen cases were categorized as MPN unclassifiable (MPN-U). JAK2p. V617F and MPL mutations were present in 60% (78 of 130) and 5.3% (7 of 130) of all MPN. All the PV cases harbored the JAK2p. V617F mutation. A total of 23.8% (31 of 130) of patients harbored CALR mutations. CALR exon 9 mutations were detected in 60.8% (14 of 23) and 50% (5 of 10) of JAK2 and MPL negative MF and ET cases, respectively. MPN-U cases included three JAK2p. V617F positive, two MPLp. W515 L, and 12 CALR positive cases. Ten different types of CALR indels (8 deletions and 2 insertions) were detected of which Type I and Type II mutations were the most common, occurring at a frequency of 45.1% (14 of 31) and 22.5% (7 of 31), respectively. Discussion and Conclusion: We report frequencies of JAK2p. V617F, MPL exon 10 and CALR mutations in 130 patients similar to those reported in western literature. These mutations carry not only diagnostic but also prognostic relevance.	[Rabade, Nikhil; Subramanian, P. G.; Kodgule, Rohan; Raval, Goutham; Joshi, Swapnali; Chaudhary, Shruti; Mascarenhas, Russel; Tembhare, Prashant; Gujral, Sumeet; Patkar, Nikhil] Tata Mem Hosp, Hematopathol Lab, Mumbai, Maharashtra, India	Patkar, N (reprint author), Tata Mem Hosp, Hematopathol Lab, ACTREC, CCE Bldg, Mumbai 410210, Maharashtra, India.	nvpatkar@gmail.com	TEMBHARE, PRASHANT R/J-6813-2019	Patkar, Nikhil/0000-0001-9234-2857	wellcome trust-DBT/India AllianceWellcome Trust	Dr Nikhil Patkar is supported by the wellcome trust-DBT/India Alliance through an intermediate Fellowship for Clinicians and Public Health Researchers.	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Campiotti Leonardo, 2009, Leuk Res, V33, pe212, DOI 10.1016/j.leukres.2009.06.011; Cazzola M, 2016, BLOOD, V127, P1219, DOI 10.1182/blood-2016-01-694182; Furtado LV, 2013, J MOL DIAGN, V15, P810, DOI 10.1016/j.jmoldx.2013.07.006; Furtado LV, 2013, J MOL DIAGN, V15, P592, DOI 10.1016/j.jmoldx.2013.04.006; Hussein K, 2008, LEUKEMIA, V22, P1059, DOI 10.1038/sj.leu.2404993; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kramer A, 2007, LANCET ONCOL, V8, P658, DOI 10.1016/S1470-2045(07)70206-1; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pastore F, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-24; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Qiao C, 2014, HAEMATOLOGICA, V99, pE182, DOI 10.3324/haematol.2014.109199; Rotunno G, 2014, BLOOD, V123, P1552, DOI 10.1182/blood-2013-11-538983; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Sazawal S, 2015, HEMATOLOGY, V20, P567, DOI 10.1179/1607845415Y.0000000018; Sazawal S, 2010, INDIAN J MED RES, V132, P423; Tefferi A, 2014, LEUKEMIA, V28, P2300, DOI 10.1038/leu.2014.148; Tefferi A, 2014, LEUKEMIA, V28, P1568, DOI 10.1038/leu.2014.83; Xu WY, 2014, INT J HEMATOL, V99, P87, DOI 10.1007/s12185-013-1480-z	25	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					209	213		10.4103/IJPM.IJPM_223_17			5	Pathology	Pathology	GD9SC	WOS:000430851900010	29676359	DOAJ Gold			2019-10-28	
J	Kumar, S; Garg, IB; Sethi, GR; Kumar, S; Saigal, SR				Kumar, Surinder; Garg, Indu Bala; Sethi, Gulshan Rai; Kumar, Sanchit; Saigal, Sanjeev R.			Detection of immunoglobulin M and immunoglobulin G antibodies to Mycoplasma pneumoniae in children with community-acquired lower respiratory tract infections	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Children; diagnosis; enzyme-linked immunosorbent assays; Mycoplasma pneumoniae; particle agglutination test	COMMERCIAL TESTS; PCR; DIAGNOSIS	Context: Mycoplasma pneumoniae (M. pneumoniae) causes up to 40% of community-acquired pneumonia in children. It is impossible to identify M. pneumoniae infection on the basis of clinical signs, symptoms, and radiological features. Therefore, correct etiological diagnosis strongly depends on laboratory diagnosis. Aims: This study aims to investigate the role of M. pneumoniae in pediatric lower respiratory tract infections (LRTIs) employing enzyme-linked immunosorbent assays (ELISA) and particle agglutination (PA) test. Settings and Design: Two hundred and eighty children, age 6 months to 12 years with community-acquired LRTIs were investigated for M. pneumoniae etiology. Materials and Methods: We investigated 280 children hospitalized for community-acquired LRTIs, using ELISA and PA test for detecting M. pneumoniae immunoglobulin M (IgM) and immunoglobulin G antibodies. Statistical Analysis Used: The difference of proportion between the qualitative variables was tested using the Chi-square test and Fischer exact test. P <= 0.05 was considered as statistically significant. Kappa value was used to assess agreement between ELISA and PA test. Results: M. pneumoniae was positive in 51 (23.2%) <5 years and 33 (54.0%) children in >= 5 years of age group, and this difference was statistically significant (P < 0.001). Clinical and radiological findings in M. pneumoniae positive and negative groups were comparable. ELISA detected M. pneumoniae in 78 (27.8%) and PA test 39 (13.9%) patients; 33 (84.6%) ELISA positive and 6 (15.4%) ELISA negative. ELISA/PA test together detected M. pneumoniae infection in 84 (30%) children. Conclusions: Our data underline that M. pneumoniae plays an important role in children with community-acquired LRTIs and more particularly in children >5 years of age.	[Kumar, Surinder; Garg, Indu Bala; Sethi, Gulshan Rai; Kumar, Sanchit; Saigal, Sanjeev R.] Maulana Azad Med Coll, Dept Microbiol, New Delhi 110002, India	Kumar, S (reprint author), Maulana Azad Med Coll, Dept Microbiol, New Delhi 110002, India.	kumarsurinderdr@yahoo.com					Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171; Beersma MFC, 2005, J CLIN MICROBIOL, V43, P2277, DOI 10.1128/JCM.43.5.2277-2285.2005; CLYDE WA, 1983, YALE J BIOL MED, V56, P523; Hammerschlag MR, 2001, CURR OPIN INFECT DIS, V14, P181, DOI 10.1097/00001432-200104000-00012; Jacobs E, 2012, EUROSURVEILLANCE, V17, P2; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Kashyap B, 2008, INDIAN J MED RES, V128, P134; KLEEMOLA M, 1982, J INFECT DIS, V146, P284, DOI 10.1093/infdis/146.2.284; Kumar S, 2011, TROP DOCT, V41, P160, DOI 10.1258/td.2011.100422; Maheshwari M, 2011, TROP DOCT, V41, P40, DOI 10.1258/td.2010.100149; MARMION BP, 1993, CLIN INFECT DIS, V17, pS90, DOI 10.1093/clinids/17.Supplement_1.S90; Nir-Paz R, 2006, CLIN MICROBIOL INFEC, V12, P685, DOI 10.1111/j.1469-0691.2006.01469.x; Nour M, 2005, PATHOL BIOL, V53, P9, DOI 10.1016/j.patbio.2004.01.002; Pereyre S, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00974; Principi Nicola, 2001, Clinical Infectious Diseases, V32, P1281, DOI 10.1086/319981; Sauteur PMM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00329; Sobieszczanska BM, 2014, ADV CLIN EXP MED, V23, P185, DOI 10.17219/acem/37046; Srifuengfung Somporn, 2004, Journal of the Medical Association of Thailand, V87, P935; Vervloet LA, 2010, J PEDIAT-BRAZIL, V86, P480, DOI 10.2223/JPED.2044; Waites KB, 2004, CLIN MICROBIOL REV, V17, P697, DOI 10.1128/CMR.17.4.697-728.2004	20	1	1	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					214	218		10.4103/IJPM.IJPM_21_17			5	Pathology	Pathology	GD9SC	WOS:000430851900011	29676360	DOAJ Gold			2019-10-28	
J	Mutreja, D; Saxena, R; Tilak, TVSVGK; Tewari, V; Moorchung, N; Nandi, B				Mutreja, Deepti; Saxena, Rajeev; Tilak, T. V. S. V. G. K.; Tewari, Vanmalini; Moorchung, Nikhil; Nandi, Bhaskar			A 37-year-old male with extensive cerebral venous thrombosis: Clinicopathological correlation of a rare case	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Autopsy; Burkitt lymphoma; extensive cerebral vein thrombosis	ACUTE MYELOID-LEUKEMIA; ANTIPHOSPHOLIPID ANTIBODIES; ACTIVATING MUTATION; BURKITTS-LYMPHOMA; ASSOCIATION; MALIGNANCIES; PROGNOSIS; VEIN	We present the autopsy findings and differential diagnosis of a 37-year-old immunocompetent male patient who presented primarily with extensive cerebral vein thrombosis and was found to have a rare association with JAK2V617F mutation positivity.	[Mutreja, Deepti; Tewari, Vanmalini; Moorchung, Nikhil] Command Hosp Air Force, Dept Pathol, Bengaluru 560007, Karnataka, India; [Saxena, Rajeev; Tilak, T. V. S. V. G. K.; Nandi, Bhaskar] Command Hosp Air Force, Dept Med, Bengaluru, Karnataka, India	Mutreja, D (reprint author), Command Hosp Air Force, Dept Pathol, Bengaluru 560007, Karnataka, India.	deeptimutreja@yahoo.com					Chen DT, 2006, OTOLARYNG HEAD NECK, V135, P991, DOI 10.1016/j.otohns.2005.09.012; Chennupati Sri Kiran, 2009, Ear Nose Throat J, V88, pE07; Delgado-Lopez F, 2002, REV NEUROLOGIA, V34, P299, DOI 10.33588/rn.3403.2001431; Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26; Gomez-Puerta JA, 2006, SEMIN ARTHRITIS RHEU, V35, P322, DOI 10.1016/j.semarthrit.2005.07.003; Landolsi A, 2003, ANN MED INTERNE, V154, P67; Levine RL, 2005, BLOOD, V106, P3377, DOI 10.1182/blood-2005-05-1898; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; Palandri F, 2009, LEUKEMIA LYMPHOMA, V50, P481, DOI 10.1080/10428190802713521; Papageorgiou MV, 2011, ANTICANCER RES, V31, P1467; Popoo VM, 2016, ROM J MORPHOL EMBRYO, V57, P313; Pusterla S, 2004, HEMATOL J, V5, P341, DOI 10.1038/sj.thj.6200377; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Swerdlow SH, 2008, WHO CLASSIFICATION T, P262; Tefferi A, 2009, CANCER, V115, P3842, DOI 10.1002/cncr.24440; Tincani A, 2010, AUTOIMMUN REV, V9, P200, DOI 10.1016/j.autrev.2009.04.001; Tirefort Y, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-7; Vaphiades MS, 2005, J NEURO-OPHTHALMOL, V25, P249, DOI 10.1097/01.wno.0000177294.14351.6c; Vicente C, 2007, LEUKEMIA, V21, P2386, DOI 10.1038/sj.leu.2404812	20	0	0	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					219	224		10.4103/IJPM.IJPM_232_17			6	Pathology	Pathology	GD9SC	WOS:000430851900012	29676361	DOAJ Gold			2019-10-28	
J	Mancheno-Valencia, A; Bologna-Molina, RE; Toussaint-Caire, S; Vega-Memije, ME; Cuevas-Gonzalez, JC				Mancheno-Valencia, Alexandra; Eduardo Bologna-Molina, Ronell; Toussaint-Caire, Sonia; Elisa Vega-Memije, Maria; Carlos Cuevas-Gonzalez, Juan			Expression of E-cadherin, syndecan 1, Ki-67, and maintenance minichromosome 3 in tissue lesions of actinic prurigo obtained by incisional biopsy	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Actinic prurigo; histopathological characteristics; Immunohistochemistry panel		Actinic prurigo (AP) is an idiopathic photodermatosis; the initial manifestations usually occur during the first decades of life but can appear at any age. Cases are usually diagnosed late once the lesions have exacerbated; due to the extensive involvement of the vermilion border and the etiology, it has been confused with and related to a potentially malignant process. Syndecan-1 and E-cadherin were positive in the epidermis, with moderate-to-intense staining in 100% of samples. Ki67 and MCM3 were expressed in the lower third of the epidermis and showed greater immunolabeling in samples that contained lymphoid follicles (Ki 67: epidermis [17.7% +/- 6.79%] and dermis [7.73% +/- 6.69%]; MCM3: epidermis [22.92% +/- 10.12%] and dermis [6.13% +/- 6.27%]). In conclusion AP is a disease in which there is no evidence that the lesions are potentially cancerous. AP cheilitis should not be confused with actinic cheilitis because they are separate entities.	[Mancheno-Valencia, Alexandra; Toussaint-Caire, Sonia; Elisa Vega-Memije, Maria] Dr Manuel Gea Gonzalez Gen Hosp, Dept Dermatol, Calzada Tlalpan 4800,Secc 16, Mexico City 14080, DF, Mexico; [Eduardo Bologna-Molina, Ronell] Autonomous Univ Ciudad Juarez, Inst Biomed Sci, Dept Stomatol, Chihuahua, Mexico; [Carlos Cuevas-Gonzalez, Juan] Univ Republica, Fac Dent, Montevideo, Uruguay	Vega-Memije, ME (reprint author), Dr Manuel Gea Gonzalez Gen Hosp, Dept Dermatol, Calzada Tlalpan 4800,Secc 16, Mexico City 14080, DF, Mexico.	elisavega50@gmail.com	Bologna-Molina, Ronell/I-6038-2018	Bologna-Molina, Ronell/0000-0001-9755-4779			Arrese JE, 2001, J AM ACAD DERMATOL, V44, P957, DOI 10.1067/mjd.2001.113477; Carreon-Burciaga R. G, 2014, Int. J. Odontostomat., V8, P439; Chairez-Atienzo P, 2016, REV ADM, V73, P291; Cuevas-Gonzalez JC, 2014, DERMATOL REV MEX, V58, P508; Cuevas-Gonzalez M. V., 2016, DERMATOL REV MEX, V60, P311; Diaz-Lozano M, 2016, PATOLOGIA, V54, P59; Granados-Arriola J, 1993, DERMATOL REV MEX, V37, P314; Ha SA, 2004, CLIN CANCER RES, V10, P8386, DOI 10.1158/1078-0432.CCR-04-1029; Hojyo-Tomoka Maria-Teresa, 2003, Dermatol Ther, V16, P40, DOI 10.1046/j.1529-8019.2003.01606.x; HOJYOTOMOKA T, 1995, INT J DERMATOL, V34, P380, DOI 10.1111/j.1365-4362.1995.tb04435.x; Hua C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-526; Sachdeva S, 2009, INDIAN J DERMATOL VE, V75, P93, DOI 10.4103/0378-6323.45238; Vega ME, 1993, DERMATOL REV MEX, V37, P295; Izaguirre DSV, 2014, INT J DERMATOL, V53, P1080, DOI 10.1111/ijd.12168	14	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					225	227		10.4103/IJPM.IJPM_574_17			3	Pathology	Pathology	GD9SC	WOS:000430851900013	29676362	DOAJ Gold			2019-10-28	
J	Sigamani, E; Chandramohan, J; Nair, S; Chacko, G; Thomas, M; Mathew, LG; Pulimood, S; Manipadam, MT				Sigamani, Elanthenral; Chandramohan, Jagan; Nair, Sheila; Chacko, Geeta; Thomas, Meera; Mathew, Leni Grace; Pulimood, Susanne; Manipadam, Marie Therese			Lymphomatoid granulomatosis: A case series from South India	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Angiodestructive; Epstein-Barr virus; Lymphomatoid granulomatosis	B-LYMPHOCYTES; CLASSIFICATION	Context: Lymphomatoid granulomatosis (LYG) is a rare B-lymphoproliferative disorder characterised by an angiocentric and angiodestructive pattern along with Epstein - Barr virus (EBV) association. It is one of the diagnostic challenges in lymphoma pathology. Deregulation of EBV immune surveillance is one of the narrated hypotheses in the literature. Extrapulmonary manifestations are rare with LYG. Morphological grading is done based on the number of EBV-positive B cells, which is useful to strategize treatment protocol. Aims: We report here a series of nine cases of LYG to discuss the clinical, histological, and immunohistochemistry findings. Settings and Design: This is the first case series from India in published literature. Subjects and Methods: We reviewed cases of LYG diagnosed at our center for the past 11 years (2006-2016). A total of nine cases were included in this study. Histomorphology was studied in conjunction with immunohistochemistry and clinical details. Cases without classical morphology and negative for EBV immunostain were excluded from the study. Results: There were nine patients in our study (7 males and 2 female; M:F ratio 3.5:1). The age of these patients ranged from 4 years to 57 years (mean age: 30 years). The most common site involved was the lung (4, 44%), followed by the skin (2, 22%), central nervous system (2, 22%) and lymph node (1, 11%). One patient had primary immunodeficiency. Another patient had undergone renal transplant 11 years before the development of the lesion. Angiocentricity and angioinvasion were appreciated in all nine cases (9/9) with necrosis in four cases (44%) and ill-defined histiocytic aggregates in three cases (33%). The histological features were as follows: Grade 1(4 cases, 44%), Grade 2(2 cases, 22%), and Grade 3(3 cases, 33%). Conclusion: LYG is a rare EBV driven angiodestructive disease with predominantly lung involvement as well as isolated extrapulmonary sites as seen in our study. It is often progressive and ultimately fatal in the absence of appropriate treatment. Grading of the lesion helps to initiate the appropriate treatment of choice.	[Sigamani, Elanthenral; Chandramohan, Jagan; Nair, Sheila; Chacko, Geeta; Thomas, Meera; Manipadam, Marie Therese] Christian Med Coll & Hosp, Dept Pathol, 4th Floor,Asha Bldg, Vellore 632004, Tamil Nadu, India; [Mathew, Leni Grace] Christian Med Coll & Hosp, Dept Pediat Oncol, Vellore, Tamil Nadu, India; [Pulimood, Susanne] Christian Med Coll & Hosp, Dept Dermatol, Vellore, Tamil Nadu, India	Manipadam, MT (reprint author), Christian Med Coll & Hosp, Dept Pathol, 4th Floor,Asha Bldg, Vellore 632004, Tamil Nadu, India.	mtm2005@cmcvellore.ac.in	SOUNDRARAJAN, JOYSON/I-1779-2019				DONNER LR, 1990, CANCER-AM CANCER SOC, V65, P249, DOI 10.1002/1097-0142(19900115)65:2<249::AID-CNCR2820650212>3.0.CO;2-Y; GUINEE D, 1994, AM J SURG PATHOL, V18, P753, DOI 10.1097/00000478-199408000-00001; Hsi ED, 2017, INT J LAB HEMATOL, V39, P14, DOI 10.1111/ijlh.12650; Jaffe ES, 1997, CANCER SURV, V30, P233; Jancar J, 2000, Adv Clin Path, V4, P59; Joseph R, 2008, TRANSPL INFECT DIS, V10, P52, DOI 10.1111/j.1399-3062.2007.00234.x; KATZENSTEIN ALA, 1979, CANCER, V43, P360, DOI 10.1002/1097-0142(197901)43:1<360::AID-CNCR2820430151>3.0.CO;2-8; Katzenstein ALA, 2010, AM J SURG PATHOL, V34, pE35, DOI 10.1097/PAS.0b013e3181fd8781; LIEBOW AA, 1972, HUM PATHOL, V3, P457, DOI 10.1016/S0046-8177(72)80005-4; NICHOLS PW, 1982, AM J MED, V72, P467, DOI 10.1016/0002-9343(82)90516-2; Sabatini E, 2010, PATHOLOGICA, V102, P83; Sugita Y, 2016, NEUROPATHOLOGY, V36, P313, DOI 10.1111/neup.12276; Tacke ZCA, 2014, J PEDIAT HEMATOL ONC, V36, pE416, DOI 10.1097/MPH.0000000000000090; Tanaka H, 2015, INTERNAL MED, V54, P503, DOI 10.2169/internalmedicine.54.2399; Wilson WH, 1996, BLOOD, V87, P4531, DOI 10.1182/blood.V87.11.4531.bloodjournal87114531	15	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					228	232		10.4103/IJPM.IJPM_471_17			5	Pathology	Pathology	GD9SC	WOS:000430851900014	29676363	DOAJ Gold			2019-10-28	
J	Goyal, R; Kotru, M; Gogia, A; Sharma, S				Goyal, Rachna; Kotru, Mrinalini; Gogia, Aarti; Sharma, Sonal			Qualitative defects with normal sperm counts in a patient attending infertility clinic	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Morphological defects; semen analysis; sperm counts	MORPHOLOGY; SEMEN	Background: Sperm morphology is an important qualitative parameter in semen analysis. Aim: To assess qualitative defects in the semen with normal sperm counts. Setting and Design: This was a prospective and descriptive study done in a tertiary care center. Materials and Methods: Seventy-five semen samples with normal sperm counts were evaluated. Qualitative defects of sperms on Papanicolaou-stained slides were assessed. The defects were noted as follows: head (tapering head, large head, small head, round head, bifid head), middle piece (bent neck, broad middle piece, excess residual cytoplasm), and tail (coiled tail). Results: All cases showed the qualitative defects in spite of the normal counts. The defects found in head - pointed/tapering head (1%-20%), round head (1%-7%), large head (1%-3%) and others (0%-2%); in middle piece - bent neck (1%-8%), excess cytoplasm (1%-3%) or broad middle piece (1%-12%); and in tail - coiled tail (1%-5%). Conclusions: Qualitative defects are often seen even in cases with normal sperm counts.	[Kotru, Mrinalini] Univ Coll Med Sci, Dept Pathol, New Delhi, India; [Kotru, Mrinalini] Guru Teg Bahadur Hosp, New Delhi, India	Kotru, M (reprint author), Univ Coll Med Sci, Dept Pathol, New Delhi, India.; Kotru, M (reprint author), Guru Teg Bahadur Hosp, New Delhi, India.	mrinalinikotru@gmail.com	SHARMA, SONAL/R-9378-2019	SHARMA, SONAL/0000-0003-3532-9749			Agarwal A, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0032-1; Andrade-Rocha FT, 2001, J REPROD MED, V46, P577; Auger J, 2001, HUM REPROD, V16, P2710, DOI 10.1093/humrep/16.12.2710; Auger J, 2010, ASIAN J ANDROL, V12, P36, DOI 10.1038/aja.2009.8; Cao XD, 2017, ONCOTARGET, V8, P55646, DOI 10.18632/oncotarget.17233; Karabulut A, 2013, PAM MED J, V6, P1; Menkveld R, 2010, ASIAN J ANDROL, V12, P47, DOI 10.1038/aja.2009.14; Nikolettos N, 1999, HUM REPROD, V14, P47, DOI 10.1093/humrep/14.suppl_1.47; Singh S, 2011, AM J CLIN PATHOL, V136, P247, DOI 10.1309/AJCPCLCSPP24QPHR; Tasdemir I, 1997, HUM REPROD, V12, P1214, DOI 10.1093/humrep/12.6.1214; Vasan SS, 2011, INDIAN J UROL, V27, P41, DOI 10.4103/0970-1591.78424; 2010, WHO LAB MAN EX PROC, P1	12	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					233	235		10.4103/IJPM.IJPM_460_17			3	Pathology	Pathology	GD9SC	WOS:000430851900015	29676364	DOAJ Gold			2019-10-28	
J	Kumar, S; Mehra, B; Sethi, GR; Saigal, SR				Kumar, Surinder; Mehra, Bhanu; Sethi, Gulshan Rai; Saigal, Sanjeev R.			Rapid detection of respiratory syncytial virus in community-acquired lower respiratory tract infections in children by chromatographic assay	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Chromatographic immunoassay; lower respiratory tract infections; respiratory syncytial virus	DISEASE; INFANTS	Respiratory syncytial virus (RSV) is the single most important viral agent causing pediatric lower respiratory tract infections (LRTIs) worldwide. To evaluate the role of RSV in pediatric LRTIs, we studied 85 children <2 years of age hospitalized for community-acquired LRTIs. Nasopharyngeal aspirates were obtained on admission for the detection of RSV antigen by immunochromatographic assay. Demographic, clinical, and radiological findings for RSV antigen were compared. Data analysis was performed by Chi-square test. A relatively higher number of RSV-infected children 32 (60.4%) were below 6 months of age. Clinical and radiological findings in both RSV-positive and RSV-negative groups were comparable. RSV antigen was positive in 53 (62.4%) with immunochromatography. Our study confirms that RSV plays a significant role in community-acquired LRTIs in children.	[Kumar, Surinder; Mehra, Bhanu; Saigal, Sanjeev R.] Maulana Azad Med Coll, Dept Microbiol, New Delhi 110002, India; [Sethi, Gulshan Rai] Maulana Azad Med Coll, Dept Paediat, New Delhi, India	Kumar, S (reprint author), Maulana Azad Med Coll, Dept Microbiol, New Delhi 110002, India.	kumarsurinderdr@yahoo.com					Bharaj P, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-89; Costa LF, 2006, MEM I OSWALDO CRUZ, V101, P301, DOI 10.1590/S0074-02762006000300014; Fattouh AM, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-14; Gupta S, 2011, INDIAN J PEDIATR, V78, P1495, DOI 10.1007/s12098-011-0491-0; Hemalatha R, 2010, INDIAN J PEDIATR, V77, P755, DOI 10.1007/s12098-010-0108-z; Kassis C, 2010, BIOL BLOOD MARROW TR, V16, P1265, DOI 10.1016/j.bbmt.2010.03.011; Kern S, 2001, EUR RADIOL, V11, P2581, DOI 10.1007/s003300100887; Mathisen M, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-35; Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019; Salih M A, 1994, Clin Diagn Virol, V2, P201, DOI 10.1016/0928-0197(94)90023-X; Sangare L, 2006, J PEDIATR-US, V149, P373, DOI 10.1016/j.jpeds.2006.04.063	11	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					236	238		10.4103/IJPM.IJPM_789_16			3	Pathology	Pathology	GD9SC	WOS:000430851900016	29676365	DOAJ Gold			2019-10-28	
J	Gotmare, SS; Pereira, T; Shetty, S; Kesarkar, KS				Gotmare, Swati Shrikant; Pereira, Treville; Shetty, Subraj; Kesarkar, Kashmira S.			Pindborg tumor: Pathology with special stains	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Amyloid; Congo red stain; modified Gallegos stain; odontogenic tumors; Pindborg tumor	EPITHELIAL ODONTOGENIC-TUMOR	Odontogenic tumors constitute a wide spectrum of lesions ranging from malignant and benign neoplasms to dental hamartomas, all derived from the epithelial and ectomesenchymal remnants of the tooth forming apparatus. Calcifying epithelial odontogenic tumor (CEOT) is an uncommon, benign epithelial odontogenic tumor first described by Pindborg in 1956. It is a universally accepted eponym for this neoplasm. Pindborg tumor or CEOT is a locally aggressive neoplasm that accounts for 1% of the total odontogenic tumors, with recurrence in 14% of cases. The etiology of this tumor remains an enigma to the clinician. Pindborg suggested that the tumor arises from the remnants of reduced enamel epithelium of an unerupted tooth. Recent studies in literature report that the tumor arises from stratum intermedium. We report a case of Pindborg tumor in a 22-year-old male patient in the left mandibular posterior region. Radiographically, a well-defined radiolucency was associated with unerupted mandibular second molar which was displaced to the inferior border of the mandible. Along with routine haematoxylin and eosin stains, this case reports histopathological findings using Congo red stain and modified Gallegos stain.	[Gotmare, Swati Shrikant; Pereira, Treville; Shetty, Subraj; Kesarkar, Kashmira S.] DY Patil Univ, Sch Dent, Dept Oral & Maxillofacial Pathol & Microbiol, Sect 7, Navi Mumbai 400706, Maharashtra, India	Gotmare, SS (reprint author), DY Patil Univ, Sch Dent, Dept Oral & Maxillofacial Pathol & Microbiol, Sect 7, Navi Mumbai 400706, Maharashtra, India.	swatishrikant2003@gmail.com		shetty, subraj/0000-0002-0849-1655			Aviel-Ronen S, 2000, ARCH PATHOL LAB MED, V124, P872; Belmonte-Caro Rodolfio, 2002, Med Oral, V7, P309; Chen Y, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-37; ELLABBAN NG, 1983, J ORAL PATHOL MED, V12, P366, DOI 10.1111/j.1600-0714.1983.tb00349.x; Pereira OHG, 2013, CASE REP PATHOL, DOI 10.1155/2013/725380; Misra SR, 2013, J CLIN IMAG SCI, V3, DOI 10.4103/2156-7514.124056; Singh Neeraj, 2011, Natl J Maxillofac Surg, V2, P225, DOI 10.4103/0975-5950.94489; Tabangay-Lim I. M., 2005, ORAL ONCOLOGY EXTRA, V41, P259; Tamgadge SA, 2014, INT J ORAL MAXILLOF, V5, P2; Vinayakrishna K, 2013, J Oral Biol Craniofac Res, V3, P154, DOI 10.1016/j.jobcr.2013.07.001	10	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					239	241		10.4103/IJPM.IJPM_143_17			3	Pathology	Pathology	GD9SC	WOS:000430851900017	29676366	DOAJ Gold			2019-10-28	
J	Nair, AKAR; George, NA; Kumar, R; Sreekumar, A; Jayasree, K				Nair, Anila Kunjulekshmi Amma Raveendran; George, Nebu A.; Kumar, Rejnish; Sreekumar, A.; Jayasree, K.			Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland: Not so indolent a neoplasm?	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Sclerosing mucoepidermoid carcinoma with eosinophilia; thyroid; indolent	OF-THE-LITERATURE	A 58-year-old female, a known diabetic and hypertensive, presented with left-sided swelling on the anterior aspect of the neck of 1-year duration, which was rapidly increasing in size for the past 6 months. She was on Eltroxin for hypothyroidism for the past 1 year. Computed tomography study of the neck showed a nodule in the left lobe of thyroid which on fine-needle aspiration was suspicious for malignancy. Total thyroidectomy with left posterolateral lymph node dissection was done. Histopathological examination showed sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE) of the thyroid gland with lymph node metastasis. SMECE of the thyroid was initially thought to be a low-grade malignancy with indolent clinical behavior. However, our case showed extra thyroidal spread with lymph node metastasis, necessitating adjuvant therapy for our patient. Such aggressive behavior has been noted in few earlier case reports also.	[Nair, Anila Kunjulekshmi Amma Raveendran; Jayasree, K.] Reg Canc Ctr, Dept Pathol, Thiruvananthapuram 695011, Kerala, India; [George, Nebu A.] Reg Canc Ctr, Dept Surg Oncol, Thiruvananthapuram, Kerala, India; [Kumar, Rejnish] Reg Canc Ctr, Dept Radiotherapy, Thiruvananthapuram, Kerala, India; [Sreekumar, A.] Reg Canc Ctr, Dept Nucl Med, Thiruvananthapuram, Kerala, India	Nair, AKAR (reprint author), Reg Canc Ctr, Dept Pathol, Thiruvananthapuram 695011, Kerala, India.	venuanila@yahoo.com					Baloch ZW, 2000, MODERN PATHOL, V13, P802, DOI 10.1038/modpathol.3880140; CameselleTeijeiro J, 1995, PATHOL RES PRACT, V191, P1214, DOI 10.1016/S0344-0338(11)81129-5; CHAN JKC, 1991, AM J SURG PATHOL, V15, P438, DOI 10.1097/00000478-199105000-00003; Das S, 2008, INDIAN J PATHOL MICR, V51, P34, DOI 10.4103/0377-4929.40389; Geisinger KR, 1998, AM J CLIN PATHOL, V109, P294, DOI 10.1093/ajcp/109.3.294; Lai CY, 2015, INT J CLIN EXP PATHO, V8, P5947; Quiroga-Garza G, 2015, HUM PATHOL, V46, P725, DOI 10.1016/j.humpath.2015.01.012; Shah AA, 2017, MODERN PATHOL, V30, P329, DOI 10.1038/modpathol.2016.180; Shehadeh NJ, 2004, AM J OTOLARYNG, V25, P48, DOI 10.1016/S0196-0709(03)00096-6; Sim SJ, 1997, HUM PATHOL, V28, P1091, DOI 10.1016/S0046-8177(97)90064-2; Solomon AC, 2000, ARCH PATHOL LAB MED, V124, P446	11	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					242	244		10.4103/IJPM.IJPM_169_17			3	Pathology	Pathology	GD9SC	WOS:000430851900018	29676367	DOAJ Gold			2019-10-28	
J	Agrawal, R; Deb, P; Sharan, J; Kumar, P				Agrawal, Ranjan; Deb, Prabal; Sharan, Jagdamba; Kumar, Parbodh			Clear cell sarcoma arising from paraspinal ligament of thoracic spine: Report of an unusual case	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Clear cell sarcoma; melanoma; paraspinal ligament; soft tissue	SOFT PARTS; MALIGNANT-MELANOMA	Clear cell sarcoma (CCS) is an unusual but aggressive soft-tissue tumor with an incidence of <1% of all soft-tissue sarcomas. It was previously termed "malignant melanoma of soft parts" due to its resemblance clinically and morphologically. Normally CCS is seen in patients aged 20-40 years. A rare case of CCS of paraspinal ligament in a 5-year-old boy is being reported. Histopathology and immunohistochemistry markers confirmed the diagnosis. The present case is unique since the entity itself is rare and also due to its occurrence in a child.	[Agrawal, Ranjan; Kumar, Parbodh] Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India; [Sharan, Jagdamba] Rohilkhand Med Coll & Hosp, Dept Surg, Bareilly, Uttar Pradesh, India; [Deb, Prabal] Command Hosp, Dept Pathol, Kolkata, W Bengal, India	Agrawal, R (reprint author), Rohilkhand Med Coll Hosp, Dept Pathol, Pilibhit Bypass Rd, Bareilly, Uttar Pradesh, India.	drranjan68@gmail.com					Bury T, 1997, EUR RESPIR J, V10, P2653, DOI 10.1183/09031936.97.10112653; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; De Beuckeleer LH, 2000, SKELETAL RADIOL, V29, P187, DOI 10.1007/s002560050592; Dim DC, 2007, ARCH PATHOL LAB MED, V131, P152; Fujimura Y, 1996, ONCOGENE, V12, P159; Gollard R, 2008, ACTA ONCOL, V47, P1593, DOI 10.1080/02841860701843068; Hisaoka M, 2008, AM J SURG PATHOL, V32, P452, DOI 10.1097/PAS.0b013e31814b18fb; Kazakos Constantinos J, 2006, World J Surg Oncol, V4, P48, DOI 10.1186/1477-7819-4-48; Malchau SS, 2007, J SURG ONCOL, V95, P519, DOI 10.1002/jso.20730; Mavrogenis AF, 2013, HIPPOKRATIA, V17, P298	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					245	247		10.4103/IJPM.IJPM_516_17			3	Pathology	Pathology	GD9SC	WOS:000430851900019	29676368	DOAJ Gold			2019-10-28	
J	Liao, YS; Chiang, IH; Gao, HW				Liao, Yi-Shu; Chiang, I-Han; Gao, Hong-Wei			A mesenteric primary peripheral Ewing's sarcoma/primitive neuroectodermal tumor with molecular cytogenetic analysis: Report of a rare case and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Ewing's sarcoma/primitive neuroectodermal tumor; Ewing's sarcoma R1 rearrangement; ileum; NKX2.2	SARCOMA; EXPRESSION	Rare cases of Ewing's sarcoma/primitive neuroectodermal tumors (EWS/PNETs) arising from mesenteric tissue have been reported. This report describes an EWS/PNET in a 25-year-old woman who presented with abdominal pain lasting 3 days. Radiologic evaluation revealed a 9 cm x 6 cm homogeneous mass in the lower abdomen with homogeneous enhancement and invasion of the ileum. Surgical resection was completed during exploratory laparotomy. Immunohistochemically, the tumor cells revealed CD99, friend leukemia virus integration-1 and NKX2.2 (NK2 Homeobox 2, a protein coding gene) and subsequently showed EWSR1 rearrangement. The histological feature, immunohistochemical results and genetic fluorescence in situ hybridization analysis of this case were confirming the diagnosis of EWS/PNET. Adjuvant chemotherapy was suggested, but the patient was lost to follow-up.	[Liao, Yi-Shu] Triserv Gen Hosp, Natl Def Med Ctr, Taichung Armed Forces Gen Hosp, Dept Pathol, Taipei, Taiwan; [Chiang, I-Han] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, 3F,325,Sec 2,Chenggong Rd, Taipei 114, Taiwan; [Gao, Hong-Wei] Triserv Gen Hosp, Natl Def Med Ctr, Dept Surg, Div Plast & Reconstruct Surg, Taipei, Taiwan	Gao, HW (reprint author), Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, 3F,325,Sec 2,Chenggong Rd, Taipei 114, Taiwan.	doc31796@gmail.com					AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; Folpe AL, 2000, AM J SURG PATHOL, V24, P1657, DOI 10.1097/00000478-200012000-00010; Gyure K A, 1999, Ann Diagn Pathol, V3, P276, DOI 10.1016/S1092-9134(99)80022-7; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; Li T, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0626-3; Mhawech-Fauceglia P, 2006, HISTOPATHOLOGY, V49, P569, DOI 10.1111/j.1365-2559.2006.02535.x; Mohamed M, 2017, VIRCHOWS ARCH, V471, P631, DOI 10.1007/s00428-017-2207-y; Peng LB, 2015, EXP THER MED, V9, P1299, DOI 10.3892/etm.2015.2242; Stout AP, 1918, P NY PATHOL SOC, V12, P12; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c	10	2	2	0	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					248	251		10.4103/IJPM.IJPM_546_17			4	Pathology	Pathology	GD9SC	WOS:000430851900020	29676369	DOAJ Gold			2019-10-28	
J	Jagtap, SV; Kale, PP; Huddedar, A; Hulwan, AB; Jagtap, SS				Jagtap, Sunil Vitthalrao; Kale, Pradnya Pandurang; Huddedar, Anil; Hulwan, Atul Bhanudas; Jagtap, Swati S.			Primary primitive neuroectodermal tumor of the kidney	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Peripheral primitive neuroectodermal tumor; renal tumor; round cell tumor	EWINGS-SARCOMA	Renal primitive neuroectodermal tumor (PNET) is a rare entity. It should be differentiated from other primary renal malignancies. The differentiation of the malignant small round cell tumors may be challenging; however, it is essential for better management of the patient. We report a 45-year-old male having complaints of pain in the abdomen, hematuria, and mass in the abdomen for 6 months. Abdominal and pelvic sonography finding showed cystic-solid, right renal mass suggestive of malignancy. On histopathology diagnosed as malignant small round blue cell tumor suggestive of primitive neuroectodermal tumor. On immunohistochemistry, CD99 positivity confirmed the diagnosis of primary PNET of the kidney. We are presenting this case for its rarity, clinical presentation, and pathological findings.	[Jagtap, Sunil Vitthalrao; Kale, Pradnya Pandurang; Hulwan, Atul Bhanudas] Krishna Inst Med Sci Deemed Univ, Dept Pathol, Karad, Maharashtra, India; [Jagtap, Swati S.] Krishna Inst Med Sci Deemed Univ, Dept Physiol, Karad, Maharashtra, India; [Huddedar, Anil] Krishna Hosp, Dept Urosurg, Med Res Ctr, Karad, Maharashtra, India	Jagtap, SV (reprint author), Krishna Inst Med Sci Deemed Univ, Dept Pathol, Karad, Maharashtra, India.	drsvjagtap@gmail.com	jagtap, sunil v/I-9965-2019				BRINKHUIS M, 1995, VIRCHOWS ARCH, V425, P611, DOI 10.1007/BF00199351; Casella R, 2001, EUR UROL, V39, P613, DOI 10.1159/000052514; Chakrabarti N, 2015, IRAN J CANCER PREV, V8, P129; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; Friedrichs N, 2002, PATHOL RES PRACT, V198, P563, DOI 10.1078/0344-0338-00303; Gonlusen Gulfiliz, 2001, International Urology and Nephrology, V33, P449, DOI 10.1023/A:1019511205650; Gupta S, 2012, J UROLOGY, V187, P2211, DOI 10.1016/j.juro.2012.03.030; Kumar V, 2008, INDIAN J PATHOL MICR, V51, P386, DOI 10.4103/0377-4929.42518; Mohsin R, 2011, UROL ANNALS, V3, P103, DOI 10.4103/0974-7796.82180	9	5	5	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					252	254		10.4103/IJPM.IJPM_277_16			3	Pathology	Pathology	GD9SC	WOS:000430851900021	30303132	DOAJ Gold			2019-10-28	
J	Ravi, PY; Sigamani, E; Jeelani, Y; Manipadam, MT				Ravi, Priyanka Yogendra; Sigamani, Elanthenral; Jeelani, Yasir; Manipadam, Marie Therese			Methotrexate-associated Epstein-Barr virus mucocutaneous ulcer: A case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Epstein-Barr virus; lymphoproliferative disorder; methotrexate associated; mucocutaneous ulcer	LYMPHOPROLIFERATIVE DISORDERS; DISEASE; SPECTRUM	Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) comprises part of the spectrum of B-cell lymphoproliferative disorders, reported in settings of immunosenescence and iatrogenic immunosuppression, affecting the oropharyngeal mucosa, skin, and gastrointestinal tract. We report a case of a 59-year-old female, known case of rheumatoid arthritis on methotrexate (MTX) for 15 years, who presented with an ulcer in the inner aspect of her cheek region for 2 years. Clinical examination revealed an infiltrative lesion involving the lower gingivobuccal sulcus of size 2 cm x 3 cm extending to the alveolus with level I lymph nodes, suspicious for carcinoma buccal mucosa. Anti-EBV-capsid antigen-immunoglobulin M and qualitative EBV polymerase chain reaction of peripheral blood were negative. Histopathological examination revealed atypical lymphoid cells with enlarged vesicular nuclei, prominent nucleoli, and moderate eosinophilic cytoplasm, few with binucleation (CD20 focally positive, CD79a focally positive, CD30+, EBV LMP-1+, MIB-I 60%) consistent with EBVMCU, MTX-associated. This is the first case report from India.	[Ravi, Priyanka Yogendra; Sigamani, Elanthenral; Jeelani, Yasir; Manipadam, Marie Therese] Christian Med Coll & Hosp, Dept Gen Pathol, 4th Floor,Asha Bldg, Vellore 632004, Tamil Nadu, India	Manipadam, MT (reprint author), Christian Med Coll & Hosp, Dept Gen Pathol, 4th Floor,Asha Bldg, Vellore 632004, Tamil Nadu, India.	mtm2005@cmcvellore.ac.in	SOUNDRARAJAN, JOYSON/I-1779-2019				Dojcinov SD, 2010, AM J SURG PATHOL, V34, P405, DOI 10.1097/PAS.0b013e3181cf8622; Hart M, 2014, AM J SURG PATHOL, V38, P1522, DOI 10.1097/PAS.0000000000000282; Kamel OW, 1996, AM J SURG PATHOL, V20, P1279, DOI 10.1097/00000478-199610000-00015; Kojima M, 2006, PATHOL RES PRACT, V202, P609, DOI 10.1016/j.prp.2006.04.006; Kutok JL, 2006, ANNU REV PATHOL-MECH, V1, P375, DOI 10.1146/annurev.pathol.1.110304.100209; Magalhaes M, 2015, CLIN CASE REP, V3, P531, DOI 10.1002/ccr3.287; Moran NR, 2015, WORLD J GASTROENTERO, V21, P6072, DOI 10.3748/wjg.v21.i19.6072; Rezk SA, 2007, HUM PATHOL, V38, P1293, DOI 10.1016/j.humpath.2007.05.020; Sciallis AP, 2012, MODERN PATHOL, V25, P983, DOI 10.1038/modpathol.2012.38; Vial T, 2002, TOXICOLOGY, V174, P3, DOI 10.1016/S0300-483X(02)00051-3	10	4	4	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					255	257		10.4103/IJPM.IJPM_135_16			3	Pathology	Pathology	GD9SC	WOS:000430851900022	29676371	DOAJ Gold			2019-10-28	
J	Agarwal, P; Pasricha, S; Gupta, G; Sharma, A; Mehta, A				Agarwal, Poojan; Pasricha, Sunil; Gupta, Gurudutt; Sharma, Anila; Mehta, Anurag			Urothelial carcinoma of urinary bladder with exclusive heterologous component of epithelioid rhabdomyosarcoma at metastatic site	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Metastasis; rhabdomyosarcoma; urothelial carcinoma	CARCINOSARCOMA	Urothelial carcinoma of urinary bladder with divergent differentiation into rhabdomyosarcoma (RMS) is an extremely uncommon aggressive phenomenon. We present a case of a 74-year-old male with bladder carcinoma which metastasized to the abdominal wall as epithelioid RMS. To the best knowledge of our literature searches, an oligometastasis of exclusive heterologous component has not been described before. The clinical, radiological, and immunohistochemistry profile of the patient supported the monoclonal nature of the tumor.	[Agarwal, Poojan; Pasricha, Sunil; Gupta, Gurudutt; Sharma, Anila; Mehta, Anurag] Rajiv Gandhi Canc Inst & Res Ctr, Dept Lab Serv, Rohini Sect 5, New Delhi, India	Agarwal, P (reprint author), Rajiv Gandhi Canc Inst & Res Ctr, Dept Lab Serv, Rohini Sect 5, New Delhi, India.	poojanagarwal@gmail.com					Armstrong AB, 2009, MODERN PATHOL, V22, P113, DOI 10.1038/modpathol.2008.176; Bing ZY, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-66; Jo VY, 2011, AM J SURG PATHOL, V35, P1523, DOI 10.1097/PAS.0b013e31822e0907; Cuadra-Urteaga JL, 2016, CANCER BIOL THER, V17, P233, DOI 10.1080/15384047.2016.1139237; Moch H, 2016, WHO CLASSIFICATION T; Parwani AV, 2006, HUM PATHOL, V37, P168, DOI 10.1016/j.humpath.2005.10.002; Pasricha Sunil, 2011, J Cancer Res Ther, V7, P486, DOI 10.4103/0973-1482.92008; SMITH JA, 1983, J UROLOGY, V129, P829, DOI 10.1016/S0022-5347(17)52387-3; Wright JL, 2007, J UROLOGY, V178, P2302, DOI 10.1016/j.juro.2007.08.038; Zin A, 2014, AM J SURG PATHOL, V38, P273, DOI 10.1097/PAS.0000000000000105	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					258	260		10.4103/IJPM.IJPM_785_17			3	Pathology	Pathology	GD9SC	WOS:000430851900023	29676372	DOAJ Gold			2019-10-28	
J	Vasudevan, G; Jaiprakash, P; Guruvare, S; Samanta, N				Vasudevan, Geetha; Jaiprakash, Padmapriya; Guruvare, Shyamala; Samanta, Nivedita			Ovarian borderline mucinous tumor with squamous overgrowth: An unusual finding with review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Borderline; mucinous; overgrowth; squamous	CELL CARCINOMA; MULLERIAN TYPE	Borderline mucinous tumor (BMT) is often associated with other entities such as dermoid cyst, Brenner tumor, and endometriosis. Squamous areas are often associated which may be a part of BMT or its associated conditions. Here, we describe squamous overgrowth in a case of intestinal type of mucinous borderline tumor in a 29-year-old uniparous female and discuss the diagnostic difficulties.	[Vasudevan, Geetha; Jaiprakash, Padmapriya; Samanta, Nivedita] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Basic Sci Block, Udupi 576104, Karnataka, India; [Guruvare, Shyamala] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Obstet & Gynaecol, Udupi, Karnataka, India	Jaiprakash, P (reprint author), Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Basic Sci Block, Udupi 576104, Karnataka, India.	padmapriya.j@gmail.com		Vasudevan, Geetha/0000-0003-4558-5797			D'Angelo E, 2010, INT J GYNECOL PATHOL, V29, P529, DOI 10.1097/PGP.0b013e3181e4b7ae; Hauptmann S, 2017, VIRCHOWS ARCH, V470, P125, DOI 10.1007/s00428-016-2040-8; Kurman RJ, 2016, INT J GYNECOL PATHOL, V35, P78, DOI 10.1097/PGP.0000000000000266; Nagai Y, 2003, AM J SURG PATHOL, V27, P242, DOI 10.1097/00000478-200302000-00014; Pins MR, 1996, AM J SURG PATHOL, V20, P823, DOI 10.1097/00000478-199607000-00005; SWORN MJ, 1995, HUM PATHOL, V26, P344, DOI 10.1016/0046-8177(95)90069-1	6	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					261	263		10.4103/IJPM.IJPM_30_17			3	Pathology	Pathology	GD9SC	WOS:000430851900024	29676373	DOAJ Gold			2019-10-28	
J	Mathur, A; Seth, A; Pant, L				Mathur, Anjali; Seth, Ankit; Pant, Leela			Ovarian fibroma with luteinized thecal cells and minor sex cord element: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Luteinized thecal cells; minor sex cord element; ovarian fibroma	TUMORS	Ovarian fibroma with minor sex cord element (MSCE) is a rare tumor. The increased estrogen production due to the presence of MSCE and/or luteinized thecal cells within fibroma can be a risk factor for endometrial hyperplasia or carcinoma.	[Mathur, Anjali; Seth, Ankit; Pant, Leela] Kasturba Med Coll & Hosp, Dept Pathol, New Delhi, India	Mathur, A (reprint author), Kasturba Med Coll & Hosp, Dept Pathol, MCD North Daryaganj, New Delhi, India.	mathuranjali007@gmail.com					Giriyan SS, 2016, IOSR J DENT MED SCI, V15, P79; Kawatra Vibha, 2008, Cases J, V1, P264, DOI 10.1186/1757-1626-1-264; McCluggage WG, 2005, SEMIN DIAGN PATHOL, V22, P3, DOI 10.1053/j.semdp.2005.11.002; Movahedi-Lankarani S, 2002, AM J SURG PATHOL, V26, P1477, DOI 10.1097/00000478-200211000-00010; Neha B, 2014, J OBSTET GYN INDIA, V64, P368, DOI 10.1007/s13224-012-0260-7; Oliva E, 2005, AM J SURG PATHOL, V29, P143, DOI 10.1097/01.pas.0000149692.21205.9c; Shilpa G, 2016, J OBSTET GYN INDIA, V66, P632, DOI 10.1007/s13224-015-0759-9; Sood N, 2014, PEDIATRIC REP, V6, P37, DOI 10.4081/pr.2014.5447; Yoon YJ, 1993, KOREAN J OBSTET GYNE, V36, P2756; YOUNG RH, 1983, INT J GYNECOL PATHOL, V2, P227, DOI 10.1097/00004347-198303000-00001; Zeloudek CJ, 2013, DIAGNOSTIC HISTOPATH, P679	11	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					264	267		10.4103/IJPM.IJPM_446_17			4	Pathology	Pathology	GD9SC	WOS:000430851900025	29676374	DOAJ Gold			2019-10-28	
J	Sharma, S; Rao, RN; Pani, KC; Paul, P				Sharma, Seema; Rao, Ram Nawal; Pani, Krushna Chandra; Paul, Paramita			Bone marrow oxalosis: An unusual cause of cytopenia in end-stage renal disease; report of two cases	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						End-stage renal disease; nephrolithiasis; oxalosis; pancytopenia	PRIMARY HYPEROXALURIA TYPE-1	Systemic oxalosis can be either primary or secondary hyperoxaluria. Oxalosis is a phenomenon in which calcium oxalate crystals deposit in various visceral organs leading to bone marrow (BM) failure and recurrent renal stones. We describe two rare cases of BM oxalosis. Hyperoxaluria is strongly associated with nephrolithiasis and nephrocalcinosis. Both the patients presented with recurrent renal stones and a variable degree of BM failure. BM oxalosis should be considered as a possible diagnosis in patients in recurrent nephrolithiasis and cytopenia.	[Sharma, Seema; Rao, Ram Nawal; Pani, Krushna Chandra; Paul, Paramita] SGPGIMS, Dept Pathol, Lucknow, Uttar Pradesh, India	Pani, KC (reprint author), SGPGIMS, Dept Pathol, Lucknow, Uttar Pradesh, India.	sushil09.pani@gmail.com					Bergstralh EJ, 2010, AM J TRANSPLANT, V10, P2493, DOI 10.1111/j.1600-6143.2010.03271.x; Cochat P, 2006, PEDIATR NEPHROL, V21, P1075, DOI 10.1007/s00467-006-0124-4; Danpure CJ, 2005, NEPHROL DIAL TRANSPL, V20, P1525, DOI 10.1093/ndt/gfh923; Hoppe B, 2003, PEDIATR NEPHROL, V18, P986, DOI 10.1007/s00467-003-1234-x; Kakkar N, 2011, INDIAN J PATHOL MICR, V54, P659, DOI 10.4103/0377-4929.85145; Kim MJ, 2016, ANN LAB MED, V36, P266, DOI 10.3343/alm.2016.36.3.266; Kopp N, 1995, NEPHROL DIAL TRANSPL, V10, P2224, DOI 10.1093/ndt/10.12.2224; Nematollahi P, 2015, CASE REP HEMATOL, DOI 10.1155/2015/402947; van Woerden CS, 2003, NEPHROL DIAL TRANSPL, V18, P273, DOI 10.1093/ndt/18.2.273; Wong P. N., 2002, Hong Kong Medical Journal, V8, P202	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					268	270		10.4103/IJPM.IJPM_572_17			3	Pathology	Pathology	GD9SC	WOS:000430851900026	29676375	DOAJ Gold			2019-10-28	
J	Verma, A; Epari, S; Gujral, S; Shet, T				Verma, Anuj; Epari, Sridhar; Gujral, Sumeet; Shet, Tanuja			An unusual presentation of large B-cell lymphoma with interferon regulatory factor 4 gene rearrangement	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Diffuse; follicular; interferon regulatory factor 4; lymphoma; multiple myeloma oncogene 1; pediatric	YOUNG-ADULTS; TRANSLOCATIONS; CHILDREN	Rearrangements involving interferon regulatory factor 4 (IRF4) gene has been recently described in a subtype of diffuse large B-cell lymphoma (DLBCL). They occur in a typical clinical setting of a pediatric age group, predominantly with tonsillar mass, usually as a low-stage disease and with good response to chemotherapy. Histomorphologically, they show nodular/follicular architecture with diffuse strong immunopositivity for multiple myeloma oncogene 1. Here, the authors describe one such unusual case of large B-cell lymphoma with IRF4 gene rearrangement in a young child with the unusual location of inguinal region and detailed pathological (histological, immunohistochemical, and molecular) findings.	[Verma, Anuj; Epari, Sridhar; Gujral, Sumeet; Shet, Tanuja] Tata Mem Hosp, Dept Pathol, Mumbai 400012, Maharashtra, India	Epari, S (reprint author), Tata Mem Hosp, Dept Pathol, Mumbai 400012, Maharashtra, India.	sridhep@gmail.com					Chonabayashi K, 2014, ANN HEMATOL, V93, P893, DOI 10.1007/s00277-013-1889-8; de Leval L, 2012, ANN ONCOL, V23, P3143, DOI 10.1093/annonc/mds150; Feldman AL, 2009, LEUKEMIA, V23, P574, DOI 10.1038/leu.2008.320; Harris NL, 2008, WHO CLASSIFICATION T, P220; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Liu QY, 2013, AM J SURG PATHOL, V37, P333, DOI 10.1097/PAS.0b013e31826b9b57; Salaverria I, 2011, BLOOD, V118, P139, DOI 10.1182/blood-2011-01-330795; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Takeuchi Kengo, 2013, Haematologica, V98, pe32, DOI 10.3324/haematol.2012.076851; Tamura A, 2001, CANCER GENET CYTOGEN, V129, P1, DOI 10.1016/S0165-4608(01)00436-8	10	1	1	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					271	274		10.4103/IJPM.IJPM_194_17			4	Pathology	Pathology	GD9SC	WOS:000430851900027	29676376	DOAJ Gold			2019-10-28	
J	Chauhan, R; Tyagi, S; Mirgh, S; Mishra, P; Seth, T; Mahapatra, M; Pati, H; Saxena, R				Chauhan, Richa; Tyagi, Seema; Mirgh, Sumeet; Mishra, Priyanka; Seth, Tulika; Mahapatra, Manoranjan; Pati, Haraprasad; Saxena, Renu			Expect the unexpected - Loss of surface CD3 on flow cytometry in hepatosplenic T-cell lymphoma: An eye opener	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						CD3; hepatosplenic; lymphoma		Hepatosplenic T-cell lymphoma (HSTCL) is a rare extranodal T-cell lymphoma that shows preferential sinusoidal infiltration of spleen and liver. It usually shows bright expression of surface CD3 (sCD3) with restriction for.d-T cell receptors (TCR). We present a case of a 34-year-old male who presented with hepatosplenomegaly and B symptoms. His peripheral blood and bone marrow (BM) was involved by atypical lymphoid cells that were CD2+, CD7+, CD56+, cytoplasmic CD3+, and sCD3-on immunophenotyping by flow cytometry. As sCD3 is a lineage marker for T-cell lymphomas, the loss of sCD3 posed a diagnostic dilemma. However, typical pattern of sinusoidal BM and liver involvement by CD3+ cells and TCR gene rearrangement positivity led to final diagnosis of HSTCL. The differential diagnosis, workup, and clinical course of the case are discussed. To the best of our knowledge, only one case of de novo HSTCL with negative sCD3 has been reported before in the literature.	[Chauhan, Richa; Tyagi, Seema; Mirgh, Sumeet; Mishra, Priyanka; Seth, Tulika; Mahapatra, Manoranjan; Pati, Haraprasad; Saxena, Renu] All India Inst Med Sci, Dept Hematol, Room 202, New Delhi 110029, India	Mirgh, S (reprint author), All India Inst Med Sci, Dept Hematol, Room 202, New Delhi 110029, India.	drsumeetmirgh@gmail.com					FARCET JP, 1990, BLOOD, V75, P2213; Jaffe ES, 1996, BLOOD, V87, P1207, DOI 10.1182/blood.V87.4.1207.bloodjournal8741207; Kapur LH, 2014, ARCH PATHOL LAB MED, V138, P969, DOI 10.5858/arpa.2013-0074-CR; Khan WA, 2001, AM J CLIN PATHOL, V116, P41; Macon WR, 2014, WINTROBES CLIN HEMAT, P1971; Shi Y, 2015, ARCH PATHOL LAB MED, V139, P1173, DOI 10.5858/arpa.2014-0079-RS; Weidmann E, 2000, LEUKEMIA, V14, P991, DOI 10.1038/sj.leu.2401784; Wlodarska I, 2002, GENE CHROMOSOME CANC, V33, P243, DOI 10.1002/gcc.10021	8	0	0	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					275	277		10.4103/IJPM.IJPM_442_17			3	Pathology	Pathology	GD9SC	WOS:000430851900028	29676377	DOAJ Gold			2019-10-28	
J	Pani, KC; Yadav, M; Kumar, S; Agrawal, V				Pani, Krushna Chandra; Yadav, Mahima; Kumar, Shaleen; Agrawal, Vinita			Extranodal histiocytic sarcoma in a child with acute lymphoblastic leukemia: Cytomorphological features of a rare entity with brief review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Acute lymphoblastic leukemia; histiocytic sarcoma; synchronous		Histiocytic sarcoma (HS) is a rare malignant neoplasm showing morphologic and immunophenotypic evidence of histiocytic differentiation. We describe a rare case of synchronous HS in a patient of B-cell acute lymphoblastic leukemia (ALL). A 16-year-old boy diagnosed as ALL also presented with a swelling over the right Achilles tendon. The cytological features of the swelling suggested a histiocytic lesion. Histological and immunohistochemical examination clinched the diagnosis of HS. The available 5-year follow-up showed no recurrence. It was a diagnostic dilemma on fine-needle aspiration. We discuss the cytological features of HS which can help in reaching a diagnosis and emphasize that it should be considered in the differential diagnosis for unexplained swellings in patients of hematological malignancies. Wide local excision of localized HS is associated with a long-term favorable outcome.	[Pani, Krushna Chandra; Yadav, Mahima; Agrawal, Vinita] Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India; [Kumar, Shaleen] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiotherapy, Lucknow, Uttar Pradesh, India	Agrawal, V (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India.	vinita@sgpgi.ac.in					Castro EC, 2009, PEDIAT DEV PATHOL, V30, P1; Grogan TM, 2008, WHO CLASSIFICATION T, P356; Hornick JL, 2004, AM J SURG PATHOL, V28, P1133, DOI 10.1097/01.pas.0000131541.95394.23; Kumar R, 2011, PEDIATR BLOOD CANCER, V56, P307, DOI 10.1002/pbc.22810; Miliauskas JR, 2003, DIAGN CYTOPATHOL, V29, P233, DOI 10.1002/dc.10362; Onciu Mihaela, 2004, Am J Clin Pathol, V122 Suppl, pS128; Soslow RA, 1996, BLOOD, V87, P5207, DOI 10.1182/blood.V87.12.5207.bloodjournal87125207; Takahashi E, 2013, J CLIN EXP HEMATOP, V53, P1; TANI E, 1989, ACTA CYTOL, V33, P363; Wongchanchailert M, 2003, MED PEDIATR ONCOL, V40, P51, DOI 10.1002/mpo.10056	10	0	0	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					278	280		10.4103/IJPM.IJPM_67_16			3	Pathology	Pathology	GD9SC	WOS:000430851900029	29676378	DOAJ Gold			2019-10-28	
J	Kumar, M; Kothari, N; Gupta, BD; Gupta, N				Kumar, Mukesh; Kothari, Nirupama; Gupta, B. D.; Gupta, Neeraj			Hemophagocytic lymphohistiocytosis presenting with acute liver failure and central nervous system involvement in early infancy	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Acute liver failure; familial hemophagocytosis lymphohistiocytosis; infant; neurological manifestations	CHILDREN	Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal and likely underdiagnosed disease characterized by unregulated histiocyte proliferation, hypercytokinemia and hemophagocytosis, causing life-threatening tissue damage and organ failure. We report a case of a 56-day-old infant presenting with fever, acute liver failure, and neurological manifestations as presenting features that succumbed to rapidly progressive HLH. Our objective is to emphasize the importance of early diagnosis by high suspicion in varied initial presentation of HLH so that life-saving therapy may be instituted in time.	[Kumar, Mukesh] Shri Ram Hosp, Dept Pediat, Jodhpur, Rajasthan, India; [Kothari, Nirupama] Super Religare Labs Ltd, Dept Pathol, Jodhpur, Rajasthan, India; [Gupta, B. D.] Dr SN Med Coll, Dept Pediat, Jodhpur, Rajasthan, India; [Gupta, Neeraj] AIIMS, Dept Pediat, Jodhpur, Rajasthan, India	Kumar, M (reprint author), 51-A,Sect D, Jodhpur, Rajasthan, India.	mukeshsms01@gmail.com					Hemophagocytic Lymphohistiocytosis Study Group. Histiocyte Society, 2004, TREATM PROT 2 INT HL; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Kim Myung-Mi, 2012, Korean J Hematol, V47, P273, DOI 10.5045/kjh.2012.47.4.273; KOLLIAS SS, 1994, RADIOLOGY, V192, P743, DOI 10.1148/radiology.192.3.8058942; Ost A, 1998, HISTOPATHOLOGY, V32, P310; Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051; Sundaram SS, 2011, J PEDIATR-US, V159, P813, DOI 10.1016/j.jpeds.2011.04.016	7	2	2	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					281	283		10.4103/IJPM.IJPM_264_17			3	Pathology	Pathology	GD9SC	WOS:000430851900030	29676379	DOAJ Gold			2019-10-28	
J	Mutreja, D; Moorchung, N; Manasa, SJ; Varghese, J				Mutreja, Deepti; Moorchung, Nikhil; Manasa, S. J.; Varghese, Jeenu			Fatal meningococcal septicemia without meningeal signs, contribution of the peripheral smear in diagnosis: Report of a case	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Meningococcemia without meningitis; peripheral smear; postmortem; purpura fulminans	INFECTIOUS PURPURA FULMINANS; MENINGITIS	Acute meningococcemia is characterized by extensive purpurae consisting of both petechiae and ecchymoses. This condition can be rapidly fatal without treatment due to shock and severe consumptive coagulopathy. We report a case of fatal meningococcal septicemia in a military recruit who presented with fever and associated rapidly progressive purpuric rash (purpura fulminans) without any meningeal signs. Evaluation revealed evidence of disseminated intravascular coagulopathy and multiorgan failure. Diplococci were demonstrated in peripheral blood neutrophils and monocytes. On autopsy, extensive hemorrhages were found in both adrenals, lungs, liver, skin, and kidneys with secondary hemophagocytic lymphohistiocytosis in bone marrow. This report highlights useful information obtained from examination of peripheral blood smear in purpura fulminans.	[Mutreja, Deepti; Moorchung, Nikhil; Varghese, Jeenu] Command Hosp Air Force, Dept Pathol, Bengaluru 560007, Karnataka, India; [Manasa, S. J.] Command Hosp Air Force, Dept Dermatol, Bengaluru, Karnataka, India	Mutreja, D (reprint author), Command Hosp Air Force, Dept Pathol, Bengaluru 560007, Karnataka, India.	deeptimutreja@yahoo.com					BISELLI R, 1993, VACCINE, V11, P578, DOI 10.1016/0264-410X(93)90236-Q; Darmstadt GL, 1998, PEDIATR DERMATOL, V15, P169, DOI 10.1046/j.1525-1470.1998.1998015169.x; Gupta Divya, 2016, Indian Dermatol Online J, V7, P132, DOI 10.4103/2229-5178.178093; Harikrishna J, 2015, INDIAN J MED RES, V141, P130; Melican K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003139; Poizeau F, 2016, REV MED INTERNE, V37, P206, DOI 10.1016/j.revmed.2015.07.016; Smith OP, 1999, BRIT J HAEMATOL, V104, P202, DOI 10.1046/j.1365-2141.1999.01186.x	7	0	0	0	1	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					284	286		10.4103/IJPM.IJPM_209_17			3	Pathology	Pathology	GD9SC	WOS:000430851900031	29676380	DOAJ Gold			2019-10-28	
J	Shukla, P; Malaviya, AK				Shukla, Prakriti; Malaviya, Anil K.			Ectopic hidradenoma papilliferum of eyelid: A rare entity with diagnostic challenge	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Ectopic; eyelid nodule; hidradenoma papilliferum		Hidradenoma papilliferum is a rare cutaneous adnexal tumour of middle aged females arising mainly in the apocrine sweat glands of perianal and genital region. Ectopic forms of this entity have been described with majority of them occurring on the head and neck region. We report a case of 16 years young male who presented with two small, well circumscribed, greyish-brown, firm, nodules on his left upper and lower eyelid. A clinical impression of basal cell carcinoma was assumed but on histopathological examination it was diagnosed as hidradenoma papilliferum of eyelid. Immunohistochemistry was performed to support the diagnosis due to its unusual clinical presentation. To the best of our knowledge, only six cases in the upper eyelid and one case in the lower eyelid have been reported in the English literature. This is the first case report of hidradenoma papilliferum involving both upper and lower left eyelid in an adolescent boy.	[Shukla, Prakriti; Malaviya, Anil K.] Eras Lucknow Med Coll & Hosp, Dept Pathol, Lucknow 226003, Uttar Pradesh, India	Shukla, P (reprint author), Eras Lucknow Med Coll & Hosp, Dept Pathol, Lucknow 226003, Uttar Pradesh, India.	prakritishukla24@gmail.com					Daniel F, 2007, GASTROEN CLIN BIOL, V31, P166, DOI 10.1016/S0399-8320(07)89349-3; Fernandez-Acenero M, 2003, AM J DERMATOPATH, V25, P176, DOI 10.1097/00000372-200304000-00024; Lee HJ, 2011, ANN DERMATOL, V23, pS254, DOI 10.5021/ad.2011.23.S2.S254; MacKie RM, 2004, ROOKS TXB DERMATOLOG, P1; Rosmaninho ADN, 2010, DERMAT RES PRACT, DOI 10.1155/2010/709371; NETLAND PA, 1990, OPHTHALMOLOGY, V97, P1593; Vang R, 1999, J AM ACAD DERMATOL, V41, P115, DOI 10.1016/S0190-9622(99)70418-4	7	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					287	289		10.4103/IJPM.IJPM_686_16			3	Pathology	Pathology	GD9SC	WOS:000430851900032	29676381	DOAJ Gold			2019-10-28	
J	Bajpai, M				Bajpai, Manas			Peripheral variant of calcifying epithelial odontogenic tumor with clear cell changes: An enigma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							OF-THE-LITERATURE		[Bajpai, Manas] NIMS Dent Coll, Dept Oral & Maxillofacial Pathol, Jaipur, Rajasthan, India	Bajpai, M (reprint author), NIMS Dent Coll, Dept Oral & Maxillofacial Pathol, Jaipur, Rajasthan, India.	dr.manasbajpai@gmail.com					Afrogheh A, 2014, HEAD NECK PATHOL, V8, P214, DOI 10.1007/s12105-013-0490-8; Bajpai M, 2015, CUKUROVA MED J, V40, P151; Kauzman A, 2011, ORAL SURG ORAL MED O, V112, pE26, DOI 10.1016/j.tripleo.2011.02.041; Pindborg JJ, 1955, ACTA PATHOL MIC SC, V111, P71	4	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					290	291		10.4103/IJPM.IJPM_679_17			2	Pathology	Pathology	GD9SC	WOS:000430851900033	29676382	DOAJ Gold			2019-10-28	
J	Sharma, P; Nampoothiri, RV; Sharma, P; Naseem, S; Malhotra, P; Varma, N				Sharma, Praveen; Nampoothiri, Ram V.; Sharma, Prashant; Naseem, Shano; Malhotra, Pankaj; Varma, Neelam			Leukemic conversion of hepatosplenic T-cell lymphoma with pleomorphic morphology and an aggressive course	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Sharma, Praveen; Sharma, Prashant; Naseem, Shano; Varma, Neelam] Postgrad Inst Med Educ & Res, Dept Hematol, Level 5,Res Block A,Sect 12, Chandigarh 160012, India; [Nampoothiri, Ram V.; Malhotra, Pankaj] Postgrad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India	Sharma, P (reprint author), Postgrad Inst Med Educ & Res, Dept Hematol, Level 5,Res Block A,Sect 12, Chandigarh 160012, India.	sharma.prashant@pgimer.edu.in					Das R, 2011, JPN J CLIN ONCOL, V41, P1303, DOI 10.1093/jjco/hyr132; MASTOVICH S, 1994, HUM PATHOL, V25, P102, DOI 10.1016/0046-8177(94)90179-1; Yabe M, 2016, AM J SURG PATHOL, V40, P676, DOI 10.1097/PAS.0000000000000614	3	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					292	293		10.4103/IJPM.IJPM_495_17			2	Pathology	Pathology	GD9SC	WOS:000430851900034	29676383	DOAJ Gold			2019-10-28	
J	Agarwal, C; Bhardwaj, M; Agarwal, P; Ahuja, A				Agarwal, Charu; Bhardwaj, Minakshi; Agarwal, Palak; Ahuja, Arvind			Intracranial chondrosarcoma: Series of three cases with varied and unusual presentations	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							MESENCHYMAL CHONDROSARCOMA		[Agarwal, Charu] ESIC Med Coll, Dept Pathol, Faridabad, Haryana, India; [Bhardwaj, Minakshi; Agarwal, Palak; Ahuja, Arvind] PGIMER Dr RML Hosp, Dept Pathol, New Delhi, India	Agarwal, C (reprint author), ESIC Med Coll & Hosp, Dept Pathol, Faridabad, Haryana, India.	dr.charu.ag@gmail.com	Ahuja, Arvind/F-3531-2015	Ahuja, Arvind/0000-0001-7003-5952			Altinboga AA, 2011, J NEUROL SCI-TURK, V28, P614; Bloch OG, 2009, J CLIN NEUROSCI, V16, P1547, DOI 10.1016/j.jocn.2009.05.003; Chen JY, 2004, J MED SCI, V20, P187; LEE YY, 1988, AM J NEURORADIOL, V9, P1189; Salvati M, 2005, J EXP CLIN CANC RES, V24, P317; Shakked RJ, 2012, ARCH PATHOL LAB MED, V136, P61, DOI 10.5858/arpa.2010-0362-OA	6	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					294	+		10.4103/IJPM.IJPM_179_17			3	Pathology	Pathology	GD9SC	WOS:000430851900035	29676384	DOAJ Gold			2019-10-28	
J	Singh, M; Wijesinghe, H; Kakkar, N				Singh, Manpreet; Wijesinghe, Hiruni; Kakkar, Nandita			Sunray appearance in lacrimal canaliculitis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							CLINICAL-FEATURES		[Singh, Manpreet; Wijesinghe, Hiruni] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India; [Kakkar, Nandita] Postgrad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India	Singh, M (reprint author), Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India.	drmanu83@gmail.com		Wijesinghe, Hiruni Kaushalya/0000-0001-6234-8537			Freedman JR, 2011, SURV OPHTHALMOL, V56, P336, DOI 10.1016/j.survophthal.2010.12.001; Huang YY, 2016, BRIT J OPHTHALMOL, V100, P1285, DOI 10.1136/bjophthalmol-2015-307500; Kim UR, 2015, SAUDI J OPHTHALMOL, V29, P274, DOI 10.1016/j.sjopt.2015.08.004; Singh M, 2018, J CURR OPHTHALMOL, V30, P87, DOI 10.1016/j.joco.2017.06.010; Zaldivar RA, 2009, OPHTHAL PLAST RECONS, V25, P481, DOI 10.1097/IOP.0b013e3181b8c185	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					296	297		10.4103/IJPM.IJPM_621_17			2	Pathology	Pathology	GD9SC	WOS:000430851900036	29676385	DOAJ Gold			2019-10-28	
J	Goel, D; Pradhan, D; Tiwary, A				Goel, Deepa; Pradhan, Dinesh; Tiwary, Amrita			Fluorodeoxyglucose avid malakoplakia of the laryngohypopharynx masquerading as malignant tumor: A pathological enigma and clinical dilemma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							TRACT		[Goel, Deepa] Artemis Hosp, Dept Pathol, Sect 34, Gurugram, Haryana, India; [Tiwary, Amrita] Artemis Hosp, Dept Nucl Med, Gurugram, Haryana, India; [Pradhan, Dinesh] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA	Goel, D (reprint author), Artemis Hosp, Dept Pathol, Sect 34, Gurugram, Haryana, India.	deepa.goel3@gmail.com	Pradhan, Dinesh/I-7764-2013	Pradhan, Dinesh/0000-0001-8591-1601			Akilesh S, 2011, HEAD NECK PATHOL, V5, P395, DOI 10.1007/s12105-011-0259-x; Gomez GJA, 2008, MED ORAL PATOL ORAL, V13, pE352; Dong H, 2015, UROL CASE REP, V3, P6, DOI 10.1016/j.eucr.2014.10.002; Wong SH, 2016, J CASE REP, V6, P254; Yousef GM, 2007, ARCH PATHOL LAB MED, V131, P297	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					298	299		10.4103/IJPM.IJPM_156_17			2	Pathology	Pathology	GD9SC	WOS:000430851900037	29676386	DOAJ Gold			2019-10-28	
J	Sekhri, R; Kamboj, M; Gupta, G; Pasricha, S				Sekhri, Radhika; Kamboj, Meenakshi; Gupta, Gurudutt; Pasricha, Sunil			Primary squamous cell carcinoma of the ampulla	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							VATER		[Sekhri, Radhika; Kamboj, Meenakshi; Gupta, Gurudutt; Pasricha, Sunil] Rajiv Gandhi Canc Inst & Res Ctr, Dept Histopathol & Cytopathol, Sect 5, New Delhi 110085, India	Kamboj, M (reprint author), Rajiv Gandhi Canc Inst & Res Ctr, Dept Histopathol & Cytopathol, Sect 5, New Delhi 110085, India.	drmeenakshikamboj@gmail.com					Albores-Saavedra J, WHO CLASSIFICATION T; Balci B, 2016, SURG CASE REP, V2, P1, DOI 10.1186/s40792-016-0130-0; Bolanaki H, 2014, J PANCREAS, V15, P42, DOI 10.6092/1590-8577/1649; Kshirsagar AY, 2014, INT J SURG CASE REP, V5, P393, DOI 10.1016/j.ijscr.2014.04.009; Sewkani A, 2005, J PANCREAS, V6, P162	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					300	+		10.4103/IJPM.IJPM_340_17			3	Pathology	Pathology	GD9SC	WOS:000430851900038	29676387	DOAJ Gold			2019-10-28	
J	Vij, M; Bachina, P				Vij, Mukul; Bachina, Prashant			Liver histology in cholesteryl ester storage disease	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							FEATURES		[Vij, Mukul] Gleneagles Global Hlth City, Dept Pathol, Chennai 600100, Tamil Nadu, India; [Bachina, Prashant] Rainbow Hosp, Dept Pediat Hepatol, Hyderabad, Telangana, India	Vij, M (reprint author), Gleneagles Global Hlth City, Dept Pathol, Chennai 600100, Tamil Nadu, India.	mukul.vij.path@gmail.com	vij, mukul/Y-9635-2019	vij, mukul/0000-0003-0149-0294			Bernstein DL, 2013, J HEPATOL, V58, P1230, DOI 10.1016/j.jhep.2013.02.014; Hulkova H, 2012, HISTOPATHOLOGY, V60, P1107, DOI 10.1111/j.1365-2559.2011.04164.x; Jevon GP, 1998, PEDIATR DEVEL PATHOL, V1, P179, DOI 10.1007/s100249900026; Pant M, 2017, ANN DIAGN PATHOL, V31, P66, DOI 10.1016/j.anndiagpath.2017.02.005; RESNICK JM, 1994, HUM PATHOL, V25, P276, DOI 10.1016/0046-8177(94)90200-3	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					302	+		10.4103/IJPM.IJPM_260_17			3	Pathology	Pathology	GD9SC	WOS:000430851900039	29676388	DOAJ Gold			2019-10-28	
J	Tanveer, N				Tanveer, Nadeem			Quality does not reside in files: Its a way of life	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							ACCREDITATION		[Tanveer, Nadeem] Univ Coll Med Sci, Dept Pathol, New Delhi 110095, India	Tanveer, N (reprint author), Univ Coll Med Sci, Dept Pathol, New Delhi 110095, India.	ntobh104@yahoo.co.in					Alkhenizan A, 2012, J FAM COMMUNITY MED, V19, P74, DOI 10.4103/2230-8229.98281; Gough L A, 2000, Clin Perform Qual Health Care, V8, P195, DOI 10.1108/14664100010361746; Handoo A, 2012, CLIN LAB MED, V32, P281, DOI 10.1016/j.cll.2012.04.009; Verstraete A, 1998, Int J Health Care Qual Assur Inc Leadersh Health Serv, V11, P27, DOI 10.1108/09526869810199629; Wadhwa V, 2012, INDIAN J MED MICROBI, V30, P131, DOI 10.4103/0255-0857.96647	5	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					304	305		10.4103/IJPM.IJPM_530_17			2	Pathology	Pathology	GD9SC	WOS:000430851900040	29676389	DOAJ Gold			2019-10-28	
J	Shi, XQ; Jin, HF; Peng, ML; Li, BJ; She, MC; Zhu, T; Wen, S; Qin, DC				Shi, Xiaoqing; Jin, Huifang; Peng, Mengle; Li, Bingjie; She, Mingcong; Zhu, Tao; Wen, Shuang; Qin, Dongchun			Association between NMEI polymorphisms and cancer susceptibility: A meta-analysis based on 1644 cases and 2038 controls	PATHOLOGY RESEARCH AND PRACTICE			English	Review						NME1; Polymorphism; Cancer risk; Susceptibility; Meta-analysis	METASTASIS-SUPPRESSOR GENE; EPITHELIAL OVARIAN-CANCER; 23 TYPE-1 GENE; ECORI POLYMORPHISM; RISK; NM23; EXPRESSION; REPAIR; PROMOTER; SITES	The association between polymorphisms in the nucleoside diphosphate ldnase 1 (NME1) gene and overall risk of cancer remains to be elucidated. Here, we performed a meta-analysis of the association between rs16949649, rs2302254, and rs34214448 polymorphisms in the NME1 gene and cancer risk. PubMed, Web of Science, and CHIC databases (as of June 6, 2017) were searched. Eight studies, encompassing 1644 cases and 2038 controls, were selected. The results revealed no significant relationship between Mel polymorphisms and overall cancer susceptibility. Interestingly, the rs16949649 polymorphism was associated with increased susceptibility to gynecological cancer (heterozygous model: odds ratio [OR] = 1.74, 95% confidence interval [CI] 1.06-2.86, P = 0.029). The rs2302254 polymorphism was linked to decreased susceptibility to gastric cancer in the other groups (recessive model: OR = 0.53, 95% CI = 0.28-0.98, P = 0.045). The rs34214448 polymorphism correlated significantly with increased susceptibility to non-small cell lung cancer according to all genetic models (P < 0.05) and was linked to decreased risk in cervical cancer (recessive model: OR 0.51, 95% CI = 0.27-0.94, P = 0.031). Thus, our meta-analysis found rs16949649 associated with Increased susceptibility to gynecological cancer and rs2302254 was linked to reduced gastric cancer risk; additional, larger studies are required to confirm these findings.	[Shi, Xiaoqing; Li, Bingjie; Zhu, Tao; Qin, Dongchun] Zhengzhou Univ, Key Lab Lab Med Henan Prov, Affiliated Hosp 1, Dept Clin Lab, Zhengzhou, Henan, Peoples R China; [Jin, Huifang] Zhengzhou Univ, Affiliated Hosp 1, Dept Blood Transfus, Zhengzhou, Henan, Peoples R China; [Peng, Mengle] Third Peoples Hosp Henan Prov, Dept Clin Lab, Zhengzhou, Henan, Peoples R China; [She, Mingcong] Zhengzhou Univ, Affiliated Hosp 1, Genet & Prenatal Diag Ctr, Zhengzhou, Henan, Peoples R China; [Wen, Shuang] Zhengzhou Univ, Affiliated Hosp 1, Reprod Med Ctr, Zhengzhou, Henan, Peoples R China	Qin, DC (reprint author), Zhengzhou Univ, Key Lab Lab Med Henan Prov, Affiliated Hosp 1, Dept Clin Lab, Zhengzhou, Henan, Peoples R China.	qindongchunyfy@outlook.com			Scientific and Technological Project of Henan Province [172102310077]; Funds for Creative Research Team of Henan Province	This study was funded by grants from the Scientific and Technological Project of Henan Province (172102310077), Funds for Creative Research Team of Henan Province.	Chagpar A, 2004, CANCER-AM CANCER SOC, V100, P913, DOI 10.1002/cncr.20084; Chen R, 2017, ONCOTARGET, V8, P40204, DOI 10.18632/oncotarget.16319; Collins A, 2011, APPL CLIN GENET, V4, P11, DOI 10.2147/TACG.S13139; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dixon K, 2004, SEMIN CANCER BIOL, V14, P441, DOI 10.1016/j.semcancer.2004.06.007; Feng CY, 2010, REPROD SCI, V17, P886, DOI 10.1177/1933719110373661; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Gao Qing-Lei, 2004, Ai Zheng, V23, P650; Goncharuk Viktor N, 2004, Ann Diagn Pathol, V8, P6, DOI 10.1016/j.anndiagpath.2003.11.002; Guo HB, 2000, J CELL BIOCHEM, V79, P370, DOI 10.1002/1097-4644(20001201)79:3<370::AID-JCB30>3.0.CO;2-Z; Rubio SAG, 2006, BREAST CANCER RES TR, V96, P159, DOI 10.1007/s10549-005-9072-0; Haiman CA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-43; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hsieh YS, 2007, LUNG CANCER, V58, P191, DOI 10.1016/j.lungcan.2007.06.008; Iqbal B, 2016, BREAST J, V22, P673, DOI 10.1111/tbj.12668; Jarrett SG, 2012, CANCER RES, V72, P133, DOI 10.1158/0008-5472.CAN-11-1795; Ju W, 2007, J OBSTET GYNAECOL RE, V33, P155, DOI 10.1111/j.1447-0756.2007.00511.x; Kapitanovic S, 2004, J CLIN PATHOL, V57, P1312, DOI 10.1136/jcp.2004.017954; Krejs GJ, 2010, DIGEST DIS, V28, P600, DOI 10.1159/000320277; Leonard MK, 2017, INT J MOL SCI, V18; LEONE A, 1993, ONCOGENE, V8, P855; Li AL, 2012, TUMOR BIOL, V33, P2159, DOI 10.1007/s13277-012-0476-2; Li QY, 2017, ONCOTARGET, V8, P39818, DOI 10.18632/oncotarget.16242; Li Y, 2012, GYNECOL ONCOL, V126, P455, DOI 10.1016/j.ygyno.2012.06.004; Lin Xian-dong, 2010, Chinese Journal of Pathology, V39, P681, DOI 10.3760/cma.j.issn.0529-5807.2010.10.009; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Miao LM, 2017, ONCOTARGET, V8, P30587, DOI 10.18632/oncotarget.15739; Narod SA, 2010, LANCET, V375, P2123, DOI 10.1016/S0140-6736(10)60876-8; Oda Y, 2000, HUM PATHOL, V31, P709, DOI 10.1053/hupa.2000.8230; Ouatas T, 2002, CLIN EXP METASTAS, V19, P35, DOI 10.1023/A:1013897022827; Qu SM, 2008, CLIN CANCER RES, V14, P4787, DOI 10.1158/1078-0432.CCR-08-0083; Roberts MR, 2017, MOL CARCINOGEN, V56, P1000, DOI 10.1002/mc.22565; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sirotkovic-Skerlev M, 2005, EXP MOL PATHOL, V79, P42, DOI 10.1016/j.yexmp.2005.02.004; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030; Teraoka SN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3057; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang PH, 2010, GYNECOL ONCOL, V119, P70, DOI 10.1016/j.ygyno.2010.06.013; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YAGUE J, 1991, NUCLEIC ACIDS RES, V19, P6663, DOI 10.1093/nar/19.23.6663; Yang MM, 2009, MUTAT RES-FUND MOL M, V660, P74, DOI 10.1016/j.mrfmmm.2008.09.015; Zhang KP, 2017, ONCOTARGET, V8, P45020, DOI 10.18632/oncotarget.16972; Zhao EJ, 2017, ONCOTARGET, V8, P41734, DOI 10.18632/oncotarget.16764; Zintzaras E, 2010, EUR J EPIDEMIOL, V25, P553, DOI 10.1007/s10654-010-9467-z	51	1	2	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					467	474		10.1016/j.prp.2018.02.020			8	Pathology	Pathology	GD8BJ	WOS:000430736900001	29525404	Other Gold			2019-10-28	
J	Son, BK; Kim, DH; Min, KW; Kim, EK; Kwon, MJ				Son, Byoung Kwan; Kim, Dong-Hoon; Min, Kyueng-Whan; Kim, Eun-Kyung; Kwon, Mi Jung			Smad4/Fascin index is highly prognostic in patients with diffuse type EBV-associated gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Smad4 protein; Fascin; Prognosis; Adenocarcinoma; Stomach	EPSTEIN-BARR-VIRUS; BREAST-CANCER; FASCIN EXPRESSION; SMAD4; ADENOCARCINOMA; CARCINOMA; METASTASIS; SURVIVAL; INVASION; CELLS	Gastric cancer is a heterogeneous disorder for which predicting clinical outcomes is challenging, although various biomarkers have been suggested. The Smad4 and Fascin proteins are known prognostic indicators of different types of malignancy. Smad4 primarily functions as a key regulator of tumor suppression, whereas Fascin exhibits oncogenic function by enhancing tumor infiltration. A combined marker based on these opposing roles may improve prognostic accuracy in gastric cancer. Smad4 and Fascin expression was assessed in tissue microarrays obtained from 285 primary gastric adenocarcinoma, 201 normal tissue, and 51 metastatic adenocarcinoma samples. A Smad4/Fascin index based on the relative expression of each protein was divided into low- and high-expression groups using receiver operating characteristic curves. We compared normal tissue, primary adenocarcinoma, and metastatic adenocarcinoma in Smad4 and Fascin expression and the differences in clinicopathological findings between low Smad4/Fascin and high Smad4/Fascin expression in gastric adenocarcinoma. High Smad4/Fascin expression was significantly associated with worse outcomes, such as old age, advanced T and N category, large tumor size, high histological grade, lymphatic and vascular invasion, and presence of Epstein-Barr virus (EBV) (all p < 0.05). Univariate and multivariate analyses revealed a significant relationship between disease-free or overall survival and Smad4/Fascin index in diffuse-type or EBV-associated gastric cancer (all p < 0.05). A dual marker system using Smad4 and Fascin may be a reliable indicator for predicting clinical outcomes in patients with diffuse-type or EBV-associated gastric cancer.	[Son, Byoung Kwan] Eulji Univ, Sch Med, Eulji Hosp, Dept Internal Med, Seoul, South Korea; [Kim, Dong-Hoon] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, Seoul, South Korea; [Min, Kyueng-Whan] Hanyang Univ, Coll Med, Guri Hosp, Dept Pathol, Guri, Gyeonggi Do, South Korea; [Kim, Eun-Kyung] Eulji Univ, Eulji Hosp, Sch Med, Dept Pathol, Seoul, South Korea; [Kwon, Mi Jung] Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Pathol, Anyang, Gyeonggi Do, South Korea	Min, KW (reprint author), Hanyang Univ, Coll Med, Guri Hosp, Dept Pathol, Kyoungchun Ro 153, Guri Ri 11923, Gyeonggi Do, South Korea.	kyueng@hanyang.ac.kr	; Min, Kyueng-Whan/F-3981-2017	Son, Byoung Kwan/0000-0002-9299-5476; Kwon, Mi Jung/0000-0002-2441-0448; Min, Kyueng-Whan/0000-0002-4757-9211	Hanmi Pharm Co., Ltd. Korea [HM-IIT-CAV-005]	This work was supported by Hanmi Pharm Co., Ltd. Korea (HM-IIT-CAV-005) in 2016.	Ali HR, 2012, J PATHOL, V226, P97, DOI 10.1002/path.2976; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Cameron RI, 2002, HISTOPATHOLOGY, V41, P313, DOI 10.1046/j.1365-2559.2002.01465.x; Chen LY, 2015, BREAST CANCER RES TR, V149, P631, DOI 10.1007/s10549-015-3288-4; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Fu H, 2009, ACTA BIOCH BIOPH SIN, V41, P648, DOI 10.1093/abbs/gmp053; Haeger SM, 2016, ONCOGENE, V35, P577, DOI 10.1038/onc.2015.112; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hashimoto Y, 2004, ONCOLOGY-BASEL, V67, P262, DOI 10.1159/000081327; Hernanda PY, 2015, ONCOGENE, V34, P5055, DOI 10.1038/onc.2014.425; Holsken A, 2011, CLIN CANCER RES, V17, P4367, DOI 10.1158/1078-0432.CCR-10-2811; Kato K, 2012, INVEST NEW DRUG, V30, P1621, DOI 10.1007/s10637-011-9709-2; KIDA Y, 1993, VIRCHOWS ARCH A, V423, P383, DOI 10.1007/BF01607151; Kim H.O., 2003, KOREAN J PATHOL; Kim SJ, 2012, PATHOL INT, V62, P777, DOI 10.1111/pin.12012; Kim YH, 2004, ANN ONCOL, V15, P574, DOI 10.1093/annonc/mdh131; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JH, 2009, J GASTROEN HEPATOL, V24, P354, DOI 10.1111/j.1440-1746.2009.05775.x; Li N, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0433-6; Lu XF, 2010, CELL MOL LIFE SCI, V67, P3313, DOI 10.1007/s00018-010-0382-y; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; Mikhail M, 2005, CLIN CANCER RES, V11, P5153, DOI 10.1158/1078-0432.CCR-05-0397; Min KW, 2017, EUR SURG RES, V58, P158, DOI 10.1159/000448945; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Nishikawa J, 2014, CANCERS, V6, P2259, DOI 10.3390/cancers6042259; Park JW, 2014, MOL CANCER RES, V12, P1088, DOI 10.1158/1541-7786.MCR-14-0192-T; Parkin DM, 2004, ONCOGENE, V23, P6329, DOI 10.1038/sj.onc.1207726; Parkin DM, 2001, EUR J CANCER, V37, pS4; Pelosi G, 2003, BRIT J CANCER, V88, P537, DOI 10.1038/sj.bjc.6600731; Pillai K, 2013, AM J CANCER RES, V3, P411; REMMELE W, 1987, PATHOLOGE, V8, P138; Roh MS, 2008, TUBERC RESPIR DIS, V65, P105, DOI 10.4046/trd.2008.65.2.105; Sheehan GM, 2005, HUM PATHOL, V36, P1204, DOI 10.1016/j.humpath.2005.08.015; Sun JW, 2013, J BIOL CHEM, V288, P36971, DOI 10.1074/jbc.M113.506535; Tsai WC, 2007, J HISTOCHEM CYTOCHEM, V55, P955, DOI 10.1369/jhc.7A7235.2007; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vignjevic D, 2007, CANCER RES, V67, P6844, DOI 10.1158/0008-5472.CAN-07-0929; Xing P, 2011, CELL BIOCHEM FUNCT, V29, P303, DOI 10.1002/cbf.1750; Yamaguchi Kensei, 2002, Gastric Cancer, V5, P90, DOI 10.1007/s101200200015; Zhao SJ, 2010, INT J CANCER, V127, P2076, DOI 10.1002/ijc.25412	41	1	1	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					475	481		10.1016/j.prp.2018.03.017			7	Pathology	Pathology	GD8BJ	WOS:000430736900002	29572117				2019-10-28	
J	Liu, YB; Sun, XM; Zhao, XH; An, LP; Wang, ZX; Jiang, J; Shen, WG; Yang, XL; Sun, Y				Liu, Yanbo; Sun, Xuemei; Zhao, Xiaohui; An, Liping; Wang, Zhuxing; Jiang, Jing; Shen, Weigao; Yang, Xueliang; Sun, Ying			Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						IL-17 cytokine family; Colorectal adenocarcinoma; Ulcerative colitis; Inflammatory cell; Structural cell	FAMILY CYTOKINES; CANCER; RISK; PATHOGENESIS	The research aimed to investigate secretion, expression and location of IL-17 relative Uganda, IL-17 relative receptors, infiltrating inflammatory cells and parenchymal structural cells in colorectal cancer (CRC) compared with ulcerative colitis (UC) and benign hyperplastic polyp. 29 human intestinal tissues with CRC, 17 with UC and 7 with polyp were stained using immunohistochemistry to evaluate immunoreactivity for IL-17 family relative ligands including IL-17A, E, F and their respective relative receptors such as IL-17RA, IL-17RB and IL-17RC. At the same time the infiltration of inflammatory cells including lymphocytes, phagocytes, mast cells and neutrophils and parenchymal structural cell changes involving vascular endothelial cells and CD90(+) fibroblast cells were also evaluated using the same methods The immunoreactivity or positive inflammatory cells of all the sections were analyzed using professional image analysis software to determine statistical significance. The immunoreactivity for IL-17A, IL-17RA, IL-17E, IL-17RB and IL-17F showed significant decrease in CRC tissue when compared to UC (p 0.00001. respectively). The reduction of above IL-17 relative ligands and receptors was accompanied by an obvious decrease in the number of infiltrating neutrophils and mast cells in CRC (p = 0.00001 and p 0.007, respectively) but accompanied by a marked increase of CD31(+) blood vessels (p = 0.001). The immunoreactivity of IL-17A, IL-17RA, IL-17E, IL-17RB and IL-17F and the numbers of infiltrating neutrophils and mast cells showed significant decrease in CRC tissues when compared to those in polyp (p < 0.05). In contrast, the immunoreactivity of IL-17RC and the numbers of CD3(+) lymphocytes were elevated in CRC when compared with those in polyp (p = 0.0001, p = 0.007, respectively). In CRC tissues, positive correlations between IL-17A, IL-17RA with CD68(+) macrophages were observed respectively (r = 0.621, p = 0.0001; r 0.75, p = 0.0001). IL-17 cytokine family including ligands and their corresponding receptors were secreted and expressed by infiltrating inflammatory cells. Not only infiltrating lymphocytes but also increased blood endothelial cells were relative significantly to genesis and progression of CRC.	[Liu, Yanbo; Sun, Xuemei; Zhao, Xiaohui; An, Liping; Wang, Zhuxing; Jiang, Jing; Shen, Weigao; Yang, Xueliang; Sun, Ying] Beihua Univ, Clin Immunol Ctr, Jilin 132013, Jilin, Peoples R China; [Sun, Ying] Guys Hosp, Kings Coll London, Div Asthma Allergy & Lung Biol, 5th Floor Tower Wing, London SE1 9RT, England; [Jiang, Jing; Shen, Weigao; Yang, Xueliang] Jinlin Med Coll, Affiliated Hosp, Jilin 132011, Jilin, Peoples R China; [An, Liping] Beihua Univ, Coll Pharm, Jilin 132013, Jilin, Peoples R China; [Liu, Yanbo] Beihua Univ, Res Ctr Clin Immunol, 3999 Binjiang East Rd, Jilin 132013, Jilin, Peoples R China	Sun, Y (reprint author), Guys Hosp, Kings Coll London, Div Asthma Allergy & Lung Biol, 5th Floor Tower Wing, London SE1 9RT, England.	416776466@qq.com; ying.sun@kcl.ac.uk			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81302226]; Science and Technology Project of the Jilin Province [20130101164JC, 20140414059GH]; Science and Technology Project of Jilin Province Education Department [2014200, 20132070]	We thank the financial supports from the Natural Science Foundation of China (81302226), the Science and Technology Project of the Jilin Province (20130101164JC, 20140414059GH), the Science and Technology Project of Jilin Province Education Department (2014200 and 20132070).	Al-Samadi A, 2016, TUMOR BIOL, V37, P1609, DOI 10.1007/s13277-015-3941-x; Benatar T, 2008, CANCER IMMUNOL IMMUN, V57, P1757, DOI 10.1007/s00262-008-0502-9; Boltjes A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00131; Catana CS, 2015, WORLD J GASTROENTERO, V21, P5823, DOI 10.3748/wjg.v21.i19.5823; Chang SH, 2007, CELL RES, V17, P435, DOI 10.1038/cr.2007.35; Cui GL, 2012, SCAND J GASTROENTERO, V47, P1304, DOI 10.3109/00365521.2012.725089; De Angulo A, 2015, PROSTATE, V75, P449, DOI 10.1002/pros.22931; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Erichsen R, 2016, GASTROENTEROLOGY, V150, P895, DOI 10.1053/j.gastro.2015.11.046; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022; Karczewski J, 2014, POSTEP HIG MED DOSW, V68, P42, DOI 10.5604/17322693.1086074; Le Gouvello S, 2008, GUT, V57, P772, DOI 10.1136/gut.2007.123794; Liu YB, 2015, PROSTATE, V75, P1844, DOI 10.1002/pros.23058; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; Ma M, 2015, TUMOR BIOL, V36, P807, DOI 10.1007/s13277-014-2653-y; Matsuda T, 2014, DIGEST ENDOSC, V26, P104, DOI 10.1111/den.12281; Mohamed S. Y., 2017, J GUTROINTEAT CANC; Ning C, 2015, MUCOSAL IMMUNOL, V8, P1275, DOI 10.1038/mi.2015.18; Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x; Roden J. A., 2005, GUT, V48, P26; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Song XY, 2013, CELL SIGNAL, V25, P2335, DOI 10.1016/j.cellsig.2013.07.021; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Xie ZH, 2015, DRUG DES DEV THER, V9, P1679, DOI 10.2147/DDDT.S79431; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033	29	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					482	491		10.1016/j.prp.2018.03.011			10	Pathology	Pathology	GD8BJ	WOS:000430736900003	29548809				2019-10-28	
J	Kinugawa, Y; Uehara, T; Matsuda, K; Kobayashi, Y; Nakajima, T; Hamano, H; Kawa, S; Higuchi, K; Hosaka, N; Shiozawa, S; Ishigame, H; Nakamura, T; Maruyama, Y; Nakazawa, K; Nakaguro, M; Sano, K; Ota, H				Kinugawa, Yasuhiro; Uehara, Takeshi; Matsuda, Kazuyuki; Kobayashi, Yukihiro; Nakajima, Tomoyuki; Hamano, Hideaki; Kawa, Shigeyuki; Higuchi, Kayoko; Hosaka, Noriko; Shiozawa, Satoshi; Ishigame, Hiroki; Nakamura, Toshitsugu; Maruyama, Yasuhiro; Nakazawa, Koh; Nakaguro, Masato; Sano, Kenji; Ota, Hiroyoshi			Promoter hypomethylation of SKI in autoimmune pancreatitis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Autoimmune pancreatitis; Methylation abnormality; SKI	SCLEROSING PANCREATITIS; DNA METHYLATION; C-SKI; EXPRESSION; CANCER; DISEASE; GROWTH; SNON; PROGRESSION; CARCINOMA	The relationship between methylation abnormality and autoimmune pancreatitis (AIP) a representative IgG4related disease has not yet been elucidated. We identified SKI might have a significant methylation abnormality in AIP through methylation array analysis using the Illumine Infinium Human Methylation 450K BeadChip array, and investigated the relationship of SKI with AIP clinicopathological features. The methylation rate of SKI was assessed by quantitative SYBR green methylation-specific PCR, and the degree of SIG expression in tissue specimens was assessed by immtmohistochemistry in 10 AIP cases, 14 cases of obstructive pancreatitis area in pancreatic ductal adenocarcinoma (PDA) without a history of ALP, and 9 normal pancreas (NP) cases. The SKI methylation ratio was significantly lower in AIP than in PDA and NP. Additionally, the inununohistochemical staining-index (SI) score for SKI was significantly higher in AIP than NP, although there was no significant difference between AIP and PDA. There was a strong negative correlation between SI score and SIG methylation ratio, and between the serum concentrations of IgG4 and the SKI methylation ratio. There was a moderate positive correlation between the serum concentrations of IgG4 and SI. SKI is thought to be an oncogene indicating that SKI hypomethylation and carcinogenesis might be linked to MP. Furthermore, the correlation between serum concentrations of IgG4 and SKI methylation levels suggest SKI might be involved in the pathogenesis of AIP. However, the role of SIG has not been clearly elucidated. Further studies are needed to understand further the function of SKI.	[Kinugawa, Yasuhiro; Uehara, Takeshi; Matsuda, Kazuyuki; Kobayashi, Yukihiro; Nakajima, Tomoyuki; Ota, Hiroyoshi] Shinshu Univ, Sch Med, Dept Lab Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Hamano, Hideaki] Shinshu Univ, Sch Med, Dept Gastroenterol, Matsumoto, Nagano, Japan; [Ota, Hiroyoshi] Shinshu Univ, Sch Med, Dept Biomed Lab Med, Matsumoto, Nagano, Japan; [Kawa, Shigeyuki] Matsumoto Dent Univ, Internal Med, Shiojiri, Japan; [Higuchi, Kayoko] Aizawa Hosp, Dept Pathol, Matsumoto, Nagano, Japan; [Hosaka, Noriko] Nagano Municipal Hosp, Dept Pathol, Nagano, Japan; [Shiozawa, Satoshi; Ishigame, Hiroki] Saku Cent Hosp, Dept Pathol, Saku, Japan; [Nakamura, Toshitsugu; Maruyama, Yasuhiro] Suwa Red Cross Hosp, Dept Pathol, Suwa, Japan; [Nakazawa, Koh] Matsumoto Hosp, Matsumoto Med Ctr, Natl Hosp Org, Dept Clin Lab, Matsumoto, Nagano, Japan; [Nakaguro, Masato] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan; [Sano, Kenji] Iida Municipal Hosp, Dept Pathol, Iida, Japan	Uehara, T (reprint author), Shinshu Univ, Sch Med, Dept Lab Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tuehara@shinshu-u.ac.jp		NAKAGURO, MASATO/0000-0001-6987-3043	JSPS KAICENHI [JP17K08738]	We are grateful to Masanobu Momose, Yasuyo Shimojo, Naoko Ogiwara, Mieko Horikawa, Akiko Inamura, Chitoshi Arai, Rie Nakata, Souhei Koiwai, and Marina Nuno at Shinshu University Hospital for their excellent technical assistance. This study was supported by JSPS KAICENHI Grant Number JP17K08738. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Boone B, 2009, J DERMATOL SCI, V53, P26, DOI 10.1016/j.jdermsci.2008.07.010; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; Cai O, 2017, GASTROENT RES PRACT, DOI 10.1155/2017/3246459; Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Detlefsen S, 2010, HISTOPATHOLOGY, V57, P825, DOI 10.1111/j.1365-2559.2010.03717.x; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Field J, 2017, GENES IMMUN, V18, P59, DOI 10.1038/gene.2016.50; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hammaker D, 2016, ARTHRITIS RHEUMATOL, V68, P2637, DOI 10.1002/art.39746; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Hedrich CM, 2014, P NATL ACAD SCI USA, V111, P13457, DOI 10.1073/pnas.1408023111; Heider TR, 2007, ANN SURG, V246, P61, DOI 10.1097/SLA.0b013e318070cafa; Inoue H, 2006, PANCREAS, V33, P208, DOI 10.1097/01.mpa.0000232329.35822.3a; Jeffries MA, 2015, EXPERT REV CLIN IMMU, V11, P45, DOI 10.1586/1744666X.2015.994507; Kamisawa T, 2003, J GASTROENTEROL, V38, P982, DOI 10.1007/s00535-003-1175-y; Kamisawa T, 2009, PANCREAS, V38, P890, DOI 10.1097/MPA.0b013e3181b65a1c; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; Kawaguchi K., 2015, BIOCHEM J, V473, P449; Khalid A, 2011, PANCREATOLOGY, V11, P482, DOI 10.1159/000331505; Kinugawa Y., 2017, METHYLATION TUMOR SU; LI Y, 1986, J VIROL, V57, P1065; Liu TT, 2017, THYROID, V27, P838, DOI 10.1089/thy.2016.0576; Raimondi S, 2010, BEST PRACT RES CL GA, V24, P349, DOI 10.1016/j.bpg.2010.02.007; Reed JA, 2005, CANCER METAST REV, V24, P265, DOI 10.1007/s10555-005-1576-x; Reed JA, 2001, CANCER RES, V61, P8074; Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Theohari I, 2012, APMIS, V120, P92, DOI 10.1111/j.1600-0463.2011.02814.x; Umehara H, 2012, MOD RHEUMATOL, V22, P1, DOI 10.1007/s10165-011-0508-6; Ushiku H, 2016, PANCREAS, V45, P1255, DOI 10.1097/MPA.0000000000000646; Zampieri BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107218	33	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					492	497		10.1016/j.prp.2018.03.005			6	Pathology	Pathology	GD8BJ	WOS:000430736900004	29534839				2019-10-28	
J	Missaoui, N; Mestiri, S; Bdioui, A; Zahmoul, T; Hamchi, H; Mokni, M; Hmissa, S				Missaoui, Nabiha; Mestiri, Sarra; Bdioui, Ahlem; Zahmoul, Thouraya; Hamchi, Hajer; Mokni, Moncef; Hmissa, Sihem			HPV infection and p16(INK4A )and TP53 expression in rare cancers of the uterine cervix	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Rare; Cancer; Uterine cervix; HPV infection; p16(INK4A); TP53	SQUAMOUS-CELL-CARCINOMA; HUMAN-PAPILLOMAVIRUS DNA; NEUROENDOCRINE CARCINOMA; GRANULOCYTIC SARCOMA; TUMORS; P16; P53; ADENOCARCINOMA; OVEREXPRESSION; PROTEINS	Cervix cancer remains among most commonly diagnosed cancer in developing countries. Except squamous cell carcinoma and adenocarcinoma, the etlopathology and oncogenic mechanisms of rare cancers remain largely unknown. The study was performed to investigate the value of HPV infection and the expression of p16(INK4A) and TP53 in rare primitive cancers of the cervix. We conducted a retrospective study of rare primitive cancers of the cervix. Main clinicopathological features were reported. HPV infection was detected by in situ hybridization. Expression of p16(INK4A) and TP53 was analyzed by immunohistochemistry. Overall, seven cases were identified, including basaloid squamous cell carcinoma (BSCC, n = 2), small cell neuroendocrine carcinoma (SCNEC), granulocytic sarcoma without acute myeloid leukemia, leiomyosarcoma, primitive neuroectodermal tumor and botryold-type embryonic rhabdomyosarcoma. The mean age of patients was 53.7 years. Four cancers were diagnosed at advanced stages. The prognosis was unfavorable and associated with patient death in five cases. HPV types 16/18 were detected in BSCCs and SCNEC. Strong and diffuse p16(INK4A) overexpression was described in the nucleus and the cytoplasm of all tumor cells of BSCCs and SCNEC. The remaining cancers exhibited only scattered and focal p16(INK4A) staining. Mutated TP53 protein was detected in BSCC (case 1) and GS. Rare cancers of the cervix are aggressive and associated with poor prognosis. In contrast to mesenchymal tumors, BSCCs and SCNEC are etiologically related to high-risk HPV infection and could be identified by block positive p16(INK4A) overexpression as common cancers of the cervix. TP53 mutations are not a negligible genetic event in rare cervical cancers.	[Missaoui, Nabiha; Bdioui, Ahlem; Zahmoul, Thouraya; Hamchi, Hajer; Hmissa, Sihem] Med Fac, Canc Epidemiol & Cytopathol Tunisian Ctr, Res Unit UR14ES17, Sousse 4002, Tunisia; [Missaoui, Nabiha; Mestiri, Sarra; Bdioui, Ahlem; Zahmoul, Thouraya; Hamchi, Hajer; Mokni, Moncef; Hmissa, Sihem] Farhet Hached Hosp, Pathol Dept, Sousse 4000, Tunisia; [Missaoui, Nabiha] Univ Kairouan, Fac Sci & Technol Sidi Bouzid, Kairouan, Tunisia	Missaoui, N (reprint author), CHU Farhat Hached, Lab Anat & Cytol Pathol, Rue Ibn Eljazzar, Sousse 4000, Tunisia.	missaouinabiha@live.fr		NABIHA, MISSAOUI/0000-0001-6964-075X			Altman AD, 2013, MODERN PATHOL, V26, P1255, DOI 10.1038/modpathol.2013.55; Bansal S, 2010, GYNECOL ONCOL, V118, P134, DOI 10.1016/j.ygyno.2010.04.021; Behtash N, 2003, GYNECOL ONCOL, V91, P452, DOI 10.1016/S0090-8258(03)00539-0; Brooks BE, 2004, GYNECOL ONCOL, V93, P204, DOI 10.1016/j.ygyno.2003.12.029; Castle PE, 2018, GYNECOL ONCOL, V148, P422, DOI 10.1016/j.ygyno.2017.12.001; Cavalcanti MS, 2017, INT J GYNECOL PATHOL, V36, P76, DOI 10.1097/PGP.0000000000000306; Farzaneh Farah, 2011, J Med Case Rep, V5, P489, DOI 10.1186/1752-1947-5-489; Freier CP, 2016, ANTICANCER RES, V36, P3131; Frisch M, 1999, CANCER RES, V59, P753; Gadducci A, 2017, GYNECOL ONCOL, V144, P637, DOI 10.1016/j.ygyno.2016.12.003; Ganesan R, 2016, INT J SURG PATHOL, V24, P490, DOI 10.1177/1066896916643385; Gupta RK, 2014, INDIAN J PATHOL MICR, V57, P345, DOI 10.4103/0377-4929.134747; Hachana M, 2010, BREAST, V19, P541, DOI 10.1016/j.breast.2010.05.007; Herrington CS, 1999, HUM PATHOL, V30, P906, DOI 10.1016/S0046-8177(99)90243-5; Horn LC, 2006, INT J GYNECOL PATHOL, V25, P182, DOI 10.1097/01.pgp.0000185406.85685.df; Kawakami H, 2013, CANCER MED-US, V2, P933, DOI 10.1002/cam4.151; Khosla D, 2012, INT J GYNECOL CANCER, V22, P1026, DOI 10.1097/IGC.0b013e31825a97f6; Kurman RJ, 2014, WHO CLASSIFICATION T; Kurshumliu F, 2009, GYNECOL ONCOL, V115, P127, DOI 10.1016/j.ygyno.2009.06.020; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Lee JW, 2004, INT J GYNECOL CANCER, V14, P553, DOI 10.1111/j.1048-891x.2004.014321.x; Li B, 2013, ONCOTARGETS THER, V6, P707, DOI 10.2147/OTT.S45889; Li SX, 2013, ACTA CYTOL, V57, P54, DOI 10.1159/000342516; Martinez-Giron R, 2015, DIAGN CYTOPATHOL, V43, P993, DOI 10.1002/dc.23364; Masumoto N, 2003, HUM PATHOL, V34, P778, DOI 10.1016/S0046-8177(03)00284-3; McCluggage WG, 2003, INT J GYNECOL PATHOL, V22, P231, DOI 10.1097/01.PGP.0000055172.04957.2F; Missaoui N, 2006, VIRCHOWS ARCH, V448, P597, DOI 10.1007/s00428-005-0141-x; Missaoui N, 2010, INT J CANCER, V127, P2669, DOI 10.1002/ijc.25490; Missaoui N, 2010, PATHOL RES PRACT, V206, P550, DOI 10.1016/j.prp.2010.02.014; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Pathak B, 2005, GYNECOL ONCOL, V98, P493, DOI 10.1016/j.ygyno.2005.04.028; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Semczuk A, 1999, EUR J GYNAECOL ONCOL, V20, P311; Silva DC, 2017, PATHOL RES PRACT, V213, P723, DOI 10.1016/j.prp.2017.03.003; Siriaunkgul S, 2011, INT J GYNECOL OBSTET, V115, P175, DOI 10.1016/j.ijgo.2011.06.010; STOLER MH, 1991, AM J SURG PATHOL, V15, P28, DOI 10.1097/00000478-199101000-00003; Straughn JM, 2001, GYNECOL ONCOL, V83, P216, DOI 10.1006/gyno.2001.6385; Tornesello ML, 2013, GYNECOL ONCOL, V128, P442, DOI 10.1016/j.ygyno.2012.11.017; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valeri RM, 2006, EUR J GYNAECOL ONCOL, V27, P625; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.3.CO;2-E; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang HLL, 2004, AM J SURG PATHOL, V28, P901, DOI 10.1097/00000478-200407000-00009; Wang HLL, 2004, MODERN PATHOL, V17, P732, DOI 10.1038/modpathol.3800112; Wang KL, 2006, J CHEMOTHERAPY, V18, P209, DOI 10.1179/joc.2006.18.2.209; Wang XF, 2017, MOL CLIN ONCOL, V6, P697, DOI 10.3892/mco.2017.1193; Whitcombe DD, 2016, GYNECOL ONCOL REP, V17, P45, DOI 10.1016/j.gore.2016.05.012; Wistuba II, 1999, GYNECOL ONCOL, V72, P3, DOI 10.1006/gyno.1998.5248; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Xiao CJ, 2014, INT J GYNECOL CANCER, V24, P404, DOI 10.1097/IGC.0000000000000082; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	52	1	1	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					498	506		10.1016/j.prp.2018.03.004			9	Pathology	Pathology	GD8BJ	WOS:000430736900005	29572122				2019-10-28	
J	Liu, Y; Ma, J; Yu, KJ; Li, MY; Liu, F; Yan, QG; Wang, Z; Guo, SP				Liu, Yang; Ma, Jing; Yu, Kangjie; Li, Mingyang; Liu, Fang; Yan, Qingguo; Wang, Zhe; Guo, Shuangping			Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Programmed cell death 1; Programmed cell death ligand 1; Expression; Gastrointestinal diffuse large B cell lymphoma	NON-HODGKIN-LYMPHOMA; FOLLICULAR LYMPHOMA; T-CELLS; PD-1; SURVIVAL; CANCER; B7-H1; LYMPHOCYTES; NIVOLUMAB; PATHWAY	Background: Gastrointestinal diffuse large B cell lymphoma (GI DLBCL) is the most common gastrointestinal lymphoma. However, there has not been a comprehensive investigation into the expression patterns of programmed cell death 1 (PD-1) and programmed cell death ligand 1(PD-L1) in GI DLBCL tissues. Methods: PD-1 protein expression in tumor-infiltrating lymphocytes (TILs) was evaluated by immunohistochemical staining, and expression of PD-L1 was evaluated by using PD-L1/PAX5 immunohistochemical double staining in 92 GI DLBCL specimens. Results: The prevalence of positive PD-L1 expression (PD-L1 + ) in GI DLBCL cells and positive PD-L1 expression in non-cancer cells of the GI DLBCL microenvironment (microenvironmental PD-L1, mPD-L1) were 11.96% (11 of 92) and 41.98% (34 of 81), respectively. PD-L1 expression in GI DLBCL was significantly associated with involvement of extranodal sites >= 2 (P = 0.034) and mPD-L1 expression was significantly associated with ECOG performance status (score >= 2) (P = 0.041). PD-Ll expression and mPD-L1 expression had no prognostic significance (P > 0.05) on disease outcome. PD-1 + TILs were significantly lower in patients with extranodal site involvement (P = 0.011) and the quantity of PD-1 + TILs correlated positively with the level of PDL1 expression in non malignant microenvironment cells (P = 0.001). Patients with high levels of PD-1 + TILs had better prognosis (P = 0.0005). Conclusions: The expression patterns of PD-Ll in patients with GI DLBCL are different from patients with common DLBCL. Immunotherapies that target the PD-1/PD-L1 pathway may have therapeutic potential in GI DLBCL.	[Liu, Yang; Ma, Jing; Li, Mingyang; Liu, Fang; Yan, Qingguo; Wang, Zhe; Guo, Shuangping] Fourth Mil Med Univ, Basic Med Sci, Dept Pathol, State Key Lab Tumor Biol, Xian 710032, Shaanxi, Peoples R China; [Liu, Yang; Ma, Jing; Li, Mingyang; Liu, Fang; Yan, Qingguo; Wang, Zhe; Guo, Shuangping] Fourth Mil Med Univ, Xi Jing Hosp, Xian 710032, Shaanxi, Peoples R China; [Yu, Kangjie] Fourth Mil Med Univ, Student Team 1, Class 3, Xian 710032, Shaanxi, Peoples R China	Wang, Z (reprint author), Fourth Mil Med Univ, Dept Pathol, Chang West Rd, Xian 710032, Shaanxi, Peoples R China.	337502823@qq.com; 854700623@qq.com; 3032013061@student.fmmu.edu.cn; limingyang1108@sina.com; leolm0892@163.com; yanqg@fmmu.edu.cn; zhwang@fmmu.edu.cn; guoshp@fmmu.edu.cn			National Natural Science Fundation of ChinaNational Natural Science Foundation of China [81472597]; Foundation of State Key Laboratory of Tumor Biology; Xi Jing Hospital; Fourth Military Medical University	Supported by the National Natural Science Fundation of China, No 81472597. Foundation of State Key Laboratory of Tumor Biology, Xi Jing Hospital, the Fourth Military Medical University.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Carreras J, 2009, J CLIN ONCOL, V27, P1470, DOI 10.1200/JCO.2008.18.0513; Friedberg JW, 2011, HEMATOL-AM SOC HEMAT, P498, DOI 10.1182/asheducation-2011.1.498; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Howell JM, 2012, CAN J GASTROENTEROL, V26, P452, DOI 10.1155/2012/480160; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kim J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060505, 10.1371/journal.pone.0077972]; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Kwon D, 2016, HISTOPATHOLOGY, V68, P1079, DOI 10.1111/his.12882; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; Nayak L, 2017, BLOOD, V129, P3071, DOI 10.1182/blood-2017-01-764209; Rossille D, 2014, LEUKEMIA, V28, P2367, DOI 10.1038/leu.2014.137; Ruskone-Fourmestraux A, 2003, GUT, V52, P912, DOI 10.1136/gut.52.6.912; S H., 2008, DIFFUSE LARGE B CELL, P233; Sanmamed MF, 2014, CANCER J, V20, P256, DOI 10.1097/PPO.0000000000000061; Swerdlow SH, 2008, WHO CLASSIFICATION T, P233; Thompson RH, 2007, CLIN CANCER RES, V13, P1757, DOI 10.1158/1078-0432.CCR-06-2599; Wahlin BE, 2010, CLIN CANCER RES, V16, P637, DOI 10.1158/1078-0432.CCR-09-2487; Yang ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	27	2	2	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					507	512		10.1016/j.prp.2018.03.001			6	Pathology	Pathology	GD8BJ	WOS:000430736900006	29598887				2019-10-28	
J	Mori, A; Nishioka, Y; Yamada, M; Nishibata, Y; Masuda, S; Tomaru, U; Honma, N; Moriyama, T; Ishizu, A				Mori, Ayako; Nishioka, Yusuke; Yamada, Mai; Nishibata, Yuka; Masuda, Sakiko; Tomaru, Utano; Honma, Naoyuki; Moriyama, Takanori; Ishizu, Aldhiro			Brain-derived neurotrophic factor induces angiogenin secretion and nuclear translocation in human umbilical vein endothelial cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						BDNF; VEGF; Angiogenin; Angiogenesis	GASTRIC-CANCER PATIENTS; GROWTH-FACTOR; TUMOR VASCULARIZATION; POOR-PROGNOSIS; LUNG-CANCER; VEGF; EXPRESSION	Brain-derived neurotrophic factor (BDNF) is a well-known humoral protein that induces growth of neurons. Recent studies have suggested that BDNF could act as an angiogenesis inducer similar to vascular endothelial growth factor (VEGF). Angiogenin is a strong mediator of angiogenesis. It has particular characteristics both as a secreted protein and a transcription factor. After being incorporated into the cytoplasm, angiogenin is immediately transferred to the nucleus and then mediates the angiogenic effects of angiogenesis inducers, including VEGF. The aim of this study is to determine the association between BDNF and angiogenin. At first, we determined the secretion of angiogenin from human umbilical vein endothelial cells (HUVEC) induced by BDNF with enzyme-linked Immunosorbent assay. Next, we determined BDNF-induced nuclear translocation of angiogenin by immunofluorescent staining. In addition, we examined the mRNA expression of angiogenin in HUVEC before and after BDNF stimulation by quantitative reverse transcriptase-polymerase chain reaction. As a result, we noted that BDNF induced angiogenin secretion and nuclear translocation without an increase in the mRNA expression in HUVEC. Furthermore, we demonstrated that BDNF-induced HUVEC proliferation was significantly suppressed when neomycin, a specific inhibitor of nuclear translocation of angiogenin, was administered. These findings indicate that nuclear translocation of angiogenin is critically involved in BDNF-induced proliferation of HUVEC. In conclusion, angiogenin contributes to angiogenesis induced by BDNF.	[Mori, Ayako; Nishioka, Yusuke; Yamada, Mai; Ishizu, Aldhiro] Hokkaido Univ, Grad Sch Hlth Sci, Sapporo, Hokkaido, Japan; [Nishibata, Yuka; Masuda, Sakiko; Honma, Naoyuki; Moriyama, Takanori; Ishizu, Aldhiro] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan; [Tomaru, Utano] Hokkaido Univ, Fac Med, Dept Pathol, Sapporo, Hokkaido, Japan; [Tomaru, Utano] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan	Ishizu, A (reprint author), Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan.	aishizu@med..hokudai.ac.jp					Allen SJ, 2006, CLIN SCI, V110, P175, DOI 10.1042/CS20050161; Arakawa M, 2008, J ANTIBIOT, V61, P442, DOI 10.1038/ja.2008.60; Bremnes RM, 2006, LUNG CANCER, V51, P143, DOI 10.1016/j.lungcan.2005.09.005; Chen J, 2014, TUMOR BIOL, V35, P2513, DOI 10.1007/s13277-013-1332-8; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Fontanini G, 1997, CLIN CANCER RES, V3, P861; Fouda AY, 2017, MOL NEUROBIOL, V54, P661, DOI 10.1007/s12035-015-9675-3; Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7; Hirukawa S, 2005, CLIN CANCER RES, V11, P8745, DOI 10.1158/1078-0432.CCR-05-1495; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Huang SM, 2015, ENDOCR-RELAT CANCER, V22, P455, DOI 10.1530/ERC-15-0007; Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Kishimoto K, 2005, ONCOGENE, V24, P445, DOI 10.1038/sj.onc.1208223; Li RS, 1997, BIOCHEM BIOPH RES CO, V238, P305, DOI 10.1006/bbrc.1997.7290; Lin CY, 2014, BIOCHEM PHARMACOL, V91, P522, DOI 10.1016/j.bcp.2014.08.008; Liu XL, 2015, GENET MOL RES, V14, P13496, DOI 10.4238/2015.October.28.10; Matsuda S, 2012, J CELL PHYSIOL, V227, P2123, DOI 10.1002/jcp.22942; Mizokami K, 2006, J SURG ONCOL, V94, P149, DOI 10.1002/jso.20568; MOROIANU J, 1994, BIOCHEM BIOPH RES CO, V203, P1765, DOI 10.1006/bbrc.1994.2391; Sheng JH, 2016, ACTA BIOCH BIOPH SIN, V48, P399, DOI 10.1093/abbs/gmv131; Siveen KS, 2017, CURR VASC PHARMACOL, V15, P339, DOI 10.2174/1570161115666170105124038; Sugihara K, 2015, CELL REP, V13, P1814, DOI 10.1016/j.celrep.2015.10.051; Vidal O, 2008, J GASTROINTEST SURG, V12, P1005, DOI 10.1007/s11605-007-0336-3; Zhang ZG, 2017, INT J MOL MED, V40, P1602, DOI 10.3892/ijmm.2017.3130	25	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					521	526		10.1016/j.prp.2018.02.013			6	Pathology	Pathology	GD8BJ	WOS:000430736900008	29573867				2019-10-28	
J	He, MQ; Wang, YJ; Shen, JB; Duan, CW; Lu, X; Li, JZ				He, Mingqing; Wang, Yueju; Shen, Jiabing; Duan, Chengwei; Lu, Xiang; Li, Jianzhong			Bex1 attenuates neuronal apoptosis in rat intracerebral hemorrhage model	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Bex1; Intracerebral hemorrhage; Neuronal apoptosis; Bcl-2	P75 NEUROTROPHIN RECEPTOR; INDUCED BRAIN-INJURY; EPIGENETIC REGULATION; UP-REGULATION; INHIBITION; REGENERATION; ACTIVATION; MECHANISMS; CASPASE-3; RECOVERY	Brain expressed x-linked gene 1 (Bex1) which is at high levels in several populations of central nervous system (CNS) neurons, belongs to a family of small proteins of unknown function, playing roles as adaptors or modulators of intracellular signaling pathways. But its distribution and function in CNS remains unclear. Neuronal apoptosis is the major pathogenesis in secondary brain injury of intracerebral hemorrhage (ICH). In this study, the roles of Bex1 were explored in the pathophysiology of ICH. Western blot, immunohistochemistry, and immunofluorescence showed that obvious up-regulation of Bexl in neurons adjacent to the hematoma after ICH. Furthermore, the increase of Bexl expression was accompanied by the enhanced expression of Bax and active caspase-3, and decreased expression of B-cell lymphoma 2 (Bcl-2) following ICH. The in vitro study using Beta siRNA transfection in hemin-exposed PC12 cells suggested that Beta exerted anti-apoptotic function. Therefore, Bexl may play the neuronal anti-apoptosis role following ICH, implying a novel molecular target for the therapy of ICH.	[He, Mingqing; Wang, Yueju; Li, Jianzhong] Soochow Univ, Affiliated Hosp 1, Dept Geriatr, Suzhou 215006, Jiangsu, Peoples R China; [He, Mingqing; Lu, Xiang] Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 210011, Jiangsu, Peoples R China; [Shen, Jiabing] Nantong Univ, Affiliated Hosp, Dept Neurol, Nantong 226001, Jiangsu, Peoples R China; [Duan, Chengwei] Second Peoples Hosp Nantong, Nantong 226002, Jiangsu, Peoples R China; [Lu, Xiang] Nanjing Med Univ, Dept Geriatr, Sir Run Run Hosp, Nanjing 211166, Jiangsu, Peoples R China	Li, JZ (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Geriatr, Suzhou 215006, Jiangsu, Peoples R China.; Lu, X (reprint author), Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 210011, Jiangsu, Peoples R China.	luxiang66@njmu.edu.cn; szljz@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81270428]; Suzhou Science and Technology Project [SYS201737]	This work was supported by the National Natural Science Foundation of China (No. 81270428), Suzhou Science and Technology Project (SYS201737).	Accornero F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02005-1; Ahmad I, 2015, NEUROBIOL DIS, V82, P114, DOI 10.1016/j.nbd.2015.05.021; Bernstein SL, 2006, MOL VIS, V12, P147; Brouwers HB, 2013, CEREBROVASC DIS, V35, P195, DOI 10.1159/000346599; Bums J. D., 2017, NEURAL CLIN, V35, P737; Chao MV, 2016, MOL PSYCHIATR, V21, P300, DOI 10.1038/mp.2015.214; Chen JC, 2015, PHYSIOL BEHAV, V151, P421, DOI 10.1016/j.physbeh.2015.07.036; Chen X, 2017, CELL MOL NEUROBIOL, V37, P831, DOI 10.1007/s10571-016-0421-9; Choudhary GS, 2015, METHODS MOL BIOL, V1219, P1, DOI 10.1007/978-1-4939-1661-0_1; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; D'Amelio M, 2012, TRENDS NEUROSCI, V35, P700, DOI 10.1016/j.tins.2012.06.004; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P467, DOI 10.1101/pdb.prot086447; Fang CC, 2003, NEPHROLOGY, V8, P142, DOI 10.1046/j.1440-1797.2003.00149.x; Feng Y, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1017-0; Fernandez EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117206; Fischer C, 2007, LEUKEMIA, V21, P374, DOI 10.1038/sj.leu.2404493; Galluzzi L, 2014, SEMIN CELL DEV BIOL, V35, P24, DOI 10.1016/j.semcdb.2014.02.006; Jiang CH, 2016, DEV BIOL, V409, P16, DOI 10.1016/j.ydbio.2015.11.007; Karakoula K, 2014, CANCER LETT, V346, P34, DOI 10.1016/j.canlet.2013.12.005; Kazi J. U., 1856, BIOCHIM BIOPHYS ACTA, V2015, P226; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Khazaei MR, 2010, J NEUROCHEM, V115, P910, DOI 10.1111/j.1471-4159.2010.06960.x; Koo JH, 2007, BIOCHEM BIOPH RES CO, V363, P405, DOI 10.1016/j.bbrc.2007.08.186; Lee CH, 2013, J PATHOL, V230, P298, DOI 10.1002/path.4173; Li G, 2014, CLIN EXP IMMUNOL, V175, P285, DOI 10.1111/cei.12220; Li L, 2013, CELL MOL NEUROBIOL, V33, P893, DOI 10.1007/s10571-013-9955-2; Li N, 2013, STROKE, V44, P658, DOI 10.1161/STROKEAHA.112.673590; Matusica D, 2016, J CELL SCI, V129, P517, DOI 10.1242/jcs.173864; Meeker RB, 2015, NEURAL REGEN RES, V10, P721, DOI 10.4103/1673-5374.156967; Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394; Nan AR, 2016, ONCOTARGET, V7, P112, DOI 10.18632/oncotarget.6590; Ren JB, 2017, METAB BRAIN DIS, V32, P565, DOI 10.1007/s11011-016-9943-6; Righy C, 2016, CURR NEUROPHARMACOL, V14, P392, DOI 10.2174/1570159X14666151230110058; Schlunk F, 2015, TRANSL STROKE RES, V6, P257, DOI 10.1007/s12975-015-0410-1; Schonfeld LM, 2017, NEUROSCI BIOBEHAV R, V83, P298, DOI 10.1016/j.neubiorev.2017.10.021; Shen HT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.58; Sidhar H, 2017, SCI REP-UK, V7, DOI 10.1038/srep41420; Singh N, 2014, APOPTOSIS, V19, P1017, DOI 10.1007/s10495-014-0975-2; Su X, 2013, NEUROSCIENCE, V245, P99, DOI 10.1016/j.neuroscience.2013.04.032; Su XF, 2015, NEUROCHEM RES, V40, P643, DOI 10.1007/s11064-014-1510-0; Sun HQ, 2013, J MOL HISTOL, V44, P369, DOI 10.1007/s10735-013-9489-4; Vilar M, 2006, EMBO J, V25, P1219, DOI 10.1038/sj.emboj.7601017; Wang YT, 2015, MOL NEUROBIOL, V52, P1821, DOI 10.1007/s12035-014-8972-6; Wang Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00500-5; Wilkinson D. A., 2017, NEUROPHARMACOLOGY; Wilson D, 2014, EXPERT REV NEUROTHER, V14, P661, DOI 10.1586/14737175.2014.918506; Zhang YF, 2015, NEUROCHEM RES, V40, P195, DOI 10.1007/s11064-014-1457-1; Zhao HL, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0940-4	48	2	2	0	2	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					527	535		10.1016/j.prp.2018.02.012			9	Pathology	Pathology	GD8BJ	WOS:000430736900009	29572119				2019-10-28	
J	Lv, ZY; Zhao, ZS; Ye, ZY; Wang, YY; Wang, HJ; Yang, Q				Lv, Zhen-ye; Zhao, Zhong-Sheng; Ye, Zai-Yuan; Wang, Yuan-Yu; Wang, Hui-Ju; Yang, Qiong			Metastasis-associated protein 1 (MTA1) in gastric cancer tissues is positively associated with poorer prognosis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MTA1; Immunopositivity; Gastric cancer; Prognosis; Clinicopathological records	EXPRESSION; CARCINOMA; GENE; SURVIVAL; CELLS; OVEREXPRESSION; CLASSIFICATION; STATISTICS; RECURRENCE	Background: The present study examined the clinical significance of metastasis-associated protein 1 (MTA1) in the progression and patient survival of gastric cancer. Methods: Paraffin-embedded resected tissues of gastric cancer mucosa (n = 436) and adjacent normal mucosa (n = 92) were assessed immunohistochemically for MTA1 protein, and scored according to the percentage of cells positively stained for MTA1 combined with stain intensity. Associations between MTA1 staining scores and clinicopathological factors, including survival time, were evaluated. Results: The staining scores for MTA1 were significantly higher in gastric cancer tissues than in matched normal tissues. MTA1 scores positively correlated with tumor size, depth of invasion, presence of lymph node metastasis, lymphatic involvement, venous invasion, distal metastasis, and advanced clinical staging. Patients with high MTA1 scores in gastric cancer tissues had a significantly lower five-year survival rate compared with patients with low MTA1 scores. The multivariate analysis indicated that MTA1 protein levels in resected gastric cancer tissues, as reflected by immunohistochemical staining, are an independent prognostic index of gastric carcinoma (P < 0.01). Conclusion: MTA1 immunopositivity was significantly associated with progression of gastric cancer, and may be helpful in gastric cancer prognosis.	[Lv, Zhen-ye; Ye, Zai-Yuan; Wang, Yuan-Yu; Yang, Qiong] Peoples Hosp, Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Gen Surg, Hangzhou 310014, Zhejiang, Peoples R China; [Zhao, Zhong-Sheng] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou 310014, Zhejiang, Peoples R China; [Wang, Hui-Ju] Key Lab Gastroenterol Zhejiang Prov, Hangzhou 310014, Zhejiang, Peoples R China	Yang, Q (reprint author), Peoples Hosp, Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Gen Surg, Hangzhou 310014, Zhejiang, Peoples R China.	Tidiq@163.com			Zhejiang Provincial Department of Science and the Technology Research Foundation [2008C33040]	This study was supported by the Zhejiang Provincial Department of Science and the Technology Research Foundation (2008C33040).	Baniak N, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0969-3; Bu Z, 2013, TRANSL GASTROINTEST, V2, P1; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Geisler SA, 2002, CLIN CANCER RES, V8, P3445; Geng Li, 2008, Open Biochem J, V2, P100, DOI 10.2174/1874091X00802010100; Gunal O, 2013, MIKROBIYOL BUL, V47, P265; Hofer MD, 2004, BRIT J CANCER, V90, P455, DOI 10.1038/sj.bjc.6601535; Hofer MD, 2004, CANCER RES, V64, P825, DOI 10.1158/0008-5472.CAN-03-2755; Ignatenko Natalia A., 2009, Cancer Genomics & Proteomics, V6, P161; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Kawakami H, 2013, ONCOTARGET, V4, P9, DOI 10.18632/oncotarget.718; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee HS, 2007, CLIN CANCER RES, V13, P4154, DOI 10.1158/1078-0432.CCR-07-0173; Levi F, 2004, CANCER, V101, P2843, DOI 10.1002/cncr.20666; Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.3.CO;2-C; Oian HL, 2007, BIOL CELL, V99, P573, DOI 10.1042/BC20060130; Ryu SH, 2008, HEPATOLOGY, V47, P929, DOI 10.1002/hep.22124; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; Sasaki H, 2004, LUNG CANCER-J IASLC, V46, P171, DOI 10.1016/j.lungcan.2004.03.021; Sasako M, 2012, SURG ONCOL CLIN N AM, V21, P71, DOI 10.1016/j.soc.2011.09.013; Sasako M, 2010, JPN J CLIN ONCOL, V40, pi28, DOI 10.1093/jjco/hyq124; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Song LB, 2006, CANCER LETT, V242, P258, DOI 10.1016/j.canlet.2005.11.013; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; TNM, 2009, TNM CLASSIFICATION M; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.0.CO;2-4; Toh Y, 2004, INT J CANCER, V110, P362, DOI 10.1002/ijc.20154; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wu HH, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2013.16	32	3	3	2	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					536	541		10.1016/j.prp.2018.02.011			6	Pathology	Pathology	GD8BJ	WOS:000430736900010	29573865				2019-10-28	
J	Goebel, EA; Ettler, H; Walsh, JC				Goebel, Emily A.; Ettler, Helen; Walsh, Joanna C.			Intradepartmental consultations in surgical pathology: Review of a standardized process and factors influencing consultation rates and practices in an academic and community hospital setting	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Intradepartmental consultation; Quality assurance; Surgical pathology		Intradepartmental consultations (ICs) are important for quality assurance (QA) and ensuring diagnostic accuracy in surgical pathology. Few studies have reviewed pathologist factors that influence IC rates. Our study reviews IC data and factors that influence both formal (written) and informal (verbal) consultation practices among pathologists in academic and community hospital settings. Formal IC records from the academic hospital were collected and academic and community pathologists were invited to complete a survey about their IC practices. All centers had a formalized process for documenting ICs; however, 92% of academic and 90% of community pathologists also requested informal IC. The top reasons for selecting a particular colleague for IC was perceived level of expertise; however, interpersonal relationships and office proximity had a greater impact on informal IC practice. Top reasons for requesting a formal IC were mandatory (subspecialty defined) consultation and uncertainty regarding pathological findings. Advice on wording was a common reason for informal IC. Written documentation of IC aids in QA and determination of IC metrics; however, informal, undocumented ICs still occur. Reasons for IC and choice of consulting pathologist are muldfactorial, and identifying these can help target quality improvement initiatives.	[Goebel, Emily A.] London Hlth Sci Ctr, Dept Pathol & Lab Med, 339 Windermere Rd, London, ON N6A 5A5, Canada; Western Univ, London, ON, Canada	Goebel, EA (reprint author), London Hlth Sci Ctr, Dept Pathol & Lab Med, 339 Windermere Rd, London, ON N6A 5A5, Canada.	emily.goebel@londonhospitals.ca					Allen TC, 2014, ARCH PATHOL LAB MED, V138, P589, DOI 10.5858/arpa.2013-0278-ED; East EG, 2017, ARCH PATHOL LAB MED, V141, P578, DOI 10.5858/arpa.2016-0371-OA; Geller BM, 2018, DERMATOL SURG, V44, P177, DOI 10.1097/DSS.0000000000001256; Geller BM, 2014, J CLIN PATHOL, V67, P955, DOI 10.1136/jclinpath-2014-202290; Gordetsky J, 2018, INT J SURG PATHOL, V26, P12, DOI 10.1177/1066896917730903; Kornstein M. J., 2007, ARCH PATHOL LAB MED, V131; Kuijpers CCHJ, 2016, J CLIN PATHOL, V69, P866, DOI 10.1136/jclinpath-2015-203488; Li Fei-ming, 2009, Chinese Journal of Pathology, V38, P47, DOI 10.3760/cma.j.issn.0529-5807.2009.01.011; Qureshi A, 2012, INDIAN J PATHOL MICR, V55, P180, DOI 10.4103/0377-4929.97857; Renshaw AA, 2002, AM J CLIN PATHOL, V117, P751, DOI 10.1309/RD07-39B9-QN1U-L6U0; Renshaw AA, 2006, AM J CLIN PATHOL, V125, P737, DOI 10.1309/6A0RAX9KCR8VWCG4; Srigley J., 2016, PAN CANADIAN QUALITY; Wick MR, 2007, SEMIN DIAGN PATHOL, V24, P89, DOI 10.1053/j.semdp.2007.03.003	13	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					542	546		10.1016/j.prp.2018.02.009			5	Pathology	Pathology	GD8BJ	WOS:000430736900011	29572118				2019-10-28	
J	Cho, J; Ha, SY; Kim, SH; Sung, HH; Kwon, GY				Cho, Junhun; Ha, Sang Yun; Kim, Seok-Hyung; Sung, Hyun Hwan; Kwon, Ghee Young			Prognostic significance of epithelial-mesenchymal transition phenotypes in upper urinary tract urothelial carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Upper urinary tract; Urothelial carcinoma; Epithelial-mesenchymal transition; Immunohistochemistry; E-cadherin; Vimentin	CELL-CARCINOMA; LYMPHOVASCULAR INVASION; E-CADHERIN; EXPRESSION; CANCER; BLADDER; SNAIL	Epithelial-mesenchymal transition (EMT) is a process which epithelial cells gain mesenchymal phenotype such as motility and invasiveness. We investigated the role of EMT in upper urinary tract urothelial carcinoma (UTUC). The patient cohort included 93 cases of UTUC treated with radical nephroureterectomy. Tissue microarrays were constructed from formalin-fixed paraffin-embedded tissue blocks. Immunohistochemical staining was performed for E-cadherin, vimentin, and smooth muscle actin to evaluate the EMT status. Interpretation criteria were defined for the staining results and EMT phenotypes were assigned as wild type, incomplete type (loss of E-cadherin and negative for vimentin), and complete type (loss of E-cadherin and positive for vimentin). The loss of E-cadherin and vimentin-expression was observed in 76 (81.7%) and 10 (10.8%) cases, respectively, yielding EMT phenotypes comprised of 17 cases (18.3%) of wild type, 66 cases (71.0%) of incomplete type, and 10 cases (10.8%) of complete types. In survival analyses, wild type showed statistically significant association with longer extra-bladder recurrence free survival (p < .001) and overall survival (p < .001). In multivariate analyses, complete type was an independent prognostic factor for extra-bladder recurrence free survival and overall survival. EMT phenotype based on the combination of EMT-related markers may provide a useful prognostic marker for UTUC patients.	[Cho, Junhun; Ha, Sang Yun; Kim, Seok-Hyung; Kwon, Ghee Young] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Ilwon Ro, Seoul 06351, South Korea; [Sung, Hyun Hwan] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea	Kwon, GY (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, 81 Ilwon Ro, Seoul 06351, South Korea.	geeo@skku.edu	sung, hh/O-6246-2014		Korean Foundation for Cancer Research [CB-2011-04-01]	This work was supported by a grant from Korean Foundation for Cancer Research (CB-2011-04-01).	Amin MB, 2016, AJCC CANC STAGING MA; Baumgart E, 2007, CLIN CANCER RES, V13, P1685, DOI 10.1158/1078-0432.CCR-06-2330; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Fromont G, 2005, EUR UROL, V48, P764, DOI 10.1016/j.eururo.2005.07.005; Green DA, 2013, J UROLOGY, V189, P1214, DOI 10.1016/j.juro.2012.05.079; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hall MC, 1998, UROLOGY, V52, P594, DOI 10.1016/S0090-4295(98)00295-7; Hurel S, 2013, BJU INT, V111, P1199, DOI 10.1111/bju.12116; Kates M., 2012, BJU INT; Kosaka T, 2010, CLIN CANCER RES, V16, P5814, DOI 10.1158/1078-0432.CCR-10-0230; Lin WC, 2008, J UROLOGY, V180, P879, DOI 10.1016/j.juro.2008.05.022; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Moch H, 2016, WHO CLASSIFICATION T; Muramaki M, 2011, UROLOGY, V78, DOI 10.1016/j.urology.2011.07.1388; Nakanishi K, 1997, INT J CANCER, V74, P446, DOI 10.1002/(SICI)1097-0215(19970822)74:4<446::AID-IJC15>3.0.CO;2-7; Nakanishi K, 2007, VIRCHOWS ARCH, V451, P681, DOI 10.1007/s00428-007-0457-9; Novara G, 2010, EUR UROL, V57, P1064, DOI 10.1016/j.eururo.2009.12.029; Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3; Roupret M, 2015, EUR UROL, V68, P868, DOI 10.1016/j.eururo.2015.06.044; Roupret M, 2008, EUR UROL, V54, P1226, DOI 10.1016/j.eururo.2008.08.008; Saito K, 2007, J UROLOGY, V178, P2291, DOI 10.1016/j.juro.2007.08.019; Sanford T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137141; Sung CO, 2011, MODERN PATHOL, V24, P1060, DOI 10.1038/modpathol.2011.59; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Uematsu K, 2010, BJU INT, V106, P873, DOI 10.1111/j.1464-410X.2009.09144.x; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1	28	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					547	554		10.1016/j.prp.2018.02.007			8	Pathology	Pathology	GD8BJ	WOS:000430736900012	29572121				2019-10-28	
J	Bi, YL; Qu, Y; Liang, ZY; Liu, ZC; Zhang, H; Liang, XL; Luo, YF; Cao, JL; Zhang, HQ; Feng, RE				Bi, Yalan; Qu, Yang; Liang, Zhiyong; Liu, Zichen; Zhang, Hui; Liang, Xiaolong; Luo, Yufeng; Cao, Jinling; Zhang, Haiqing; Feng, Ruie			Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Large cell lung carcinoma (LCC); World Health Organization (WHO) 2015; Classification; Clinicopathological characteristics; Survival; Chemotherapy; EGFR mutation	FACTOR RECEPTOR GENE; CANCER; MUTATIONS; FEATURES; ADENOCARCINOMAS; CLASSIFICATION; GEFITINIB; KRAS; EGFR	Objective: The definition of large cell lung carcinoma (LCC) has undergone an extensive modification in the World Health Organization (WHO) Classification (2015). Present study aimed to investigate the clinicopathological characteristics of patients diagnosed as LCC according to current WHO criteria. Methods: LCCs diagnosed based on the previous WHO classification were reevaluated, and 17 cases of LCC were finally identified at Peking Union Medical College Hospital and Beijing Chest Hospital between 2009 and 2015. The clinicopathologic features were examined and EGFR and KRAS mutations were tested. Survival of the patients was analyzed by Kaplan-Meier method. Results: The median age of the patients was 64 years (range: 40-78). Most patients were male (64.7%) and about half of the patients were at TNM stage III (47.1%). Morphologically, most cases (70.6%) were classic LCC. All patients were treated by lobectomy plus lymph node dissection, 2 with bi-lobectomy and 1 with complex lobectomy, and the other 2 patients were further treated by partial pericardiotomy. Ten patients received postoperative chemotherapy, while only 3 patients were treated with radiotherapy after surgery. Molecular analysis showed two cases of EGFR mutation (L858R) but without non overlapping KRAS mutation. The 3-year overall survival rate was 48.4 +/- 15.1%. Chemotherapy was the only predictive factor that is associated with the prognosis of the patients (P = 0.003). Conclusion: The clinicopathological characteristics of 17 cases of stringently diagnosed LCC were retrospectively analyzed. LCC in our study showed aggressive behavior with high recurrence and metastasis and poor prognosis. Chemotherapy was only predictive factor that is significantly associated with the prognosis of the patients. Future studies based on a larger series and long term follow-up are still needed to characterize it further.	[Bi, Yalan; Liang, Zhiyong; Zhang, Hui; Liang, Xiaolong; Luo, Yufeng; Cao, Jinling; Feng, Ruie] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing 100730, Peoples R China; [Bi, Yalan; Liang, Zhiyong; Zhang, Hui; Liang, Xiaolong; Luo, Yufeng; Cao, Jinling; Feng, Ruie] Peking Union Med Coll, Beijing 100730, Peoples R China; [Qu, Yang; Liu, Zichen; Zhang, Haiqing] Capital Med Univ, Beijing Chest Hosp, Dept Pathol, Beijing 101149, Peoples R China	Feng, RE (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing 100730, Peoples R China.; Feng, RE (reprint author), Peking Union Med Coll, Beijing 100730, Peoples R China.; Zhang, HQ (reprint author), Capital Med Univ, Beijing Chest Hosp, Dept Pathol, Beijing 101149, Peoples R China.	zhqing56@sina.com; fengrule_99@163.com			Central Public-interest Scientific Institution Basal Research Fund [A463800]	This work was supported by the Central Public-interest Scientific Institution Basal Research Fund (no.A463800).	Bethesda M., 2011, BASED NOVEMBER 2010; Buttitta F, 2006, INT J CANCER, V119, P2586, DOI 10.1002/ijc.22143; Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Driver BR, 2016, ARCH PATHOL LAB MED, V140, P312, DOI 10.5858/arpa.2015-0361-OA; Ettinger D, 2015, J NATL COMPR CANC NE, V2, P548; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Huang JJ, 2015, CHIN J CANCER, V34, P94, DOI 10.5732/cjc.014.10151; Kerr K.M., 2014, PATHOLOGY J RCPA, V46, pS39; Lag R., 1975, SEER CANC STAT REV, P1975; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Li X., 2015, BMC GENET, V16; Liang R, 2015, EXP THER MED, V9, P197, DOI 10.3892/etm.2014.2075; Migali C, 2014, LUNG CANCER MANAG, V3, P417, DOI 10.2217/LMT.14.34; Pelosi G, 2015, LUNG CANCER, V87, P226, DOI 10.1016/j.lungcan.2015.01.008; Project TCLCG NGM NGM, 2013, SCI TRANSL MED; Rekhtman N, 2013, MODERN PATHOL, V26, P511, DOI 10.1038/modpathol.2012.195; Rossi G, 2014, VIRCHOWS ARCH, V464, P61, DOI 10.1007/s00428-013-1501-6; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Suzuki M, 2006, CANCER-AM CANCER SOC, V106, P2200, DOI 10.1002/cncr.21853; Travis W.D., 2004, PATHOLOGY GENETICS T, P2004; Travis WD, 2015, WHO CLASSIFICATION T	23	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					555	559		10.1016/j.prp.2018.02.006			5	Pathology	Pathology	GD8BJ	WOS:000430736900013	29525405				2019-10-28	
J	Li, T; Yu, J; Luo, XY; Ren, WG; Zhang, Y; Cao, BW				Li, Teng; Yu, Jing; Luo, Xinyu; Ren, Weiguo; Zhang, Yue; Cao, Bangwei			VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Gastric cancer; VEGFR-2; Meta-analysis	ENDOTHELIAL GROWTH-FACTOR; CONTROLLED PHASE-III; GASTROESOPHAGEAL JUNCTION; PROGNOSTIC-FACTOR; DOUBLE-BLIND; ADENOCARCINOMA; EXPRESSION; CARCINOMA; CHEMOTHERAPY; RAMUCIRUMAB	Background Expression of VEGFRs may affect cancer prognosis. The aim of this work is to evaluate the prognostic significance of VEGFRs of patients with gastric cancer. Methods: The databases PubMed, Embase, Web of Science, and Cochrane Library as well as ASCO and ESMO were searched systematically for articles reporting the prognostic significance of tissue VEGFRs in gastric cancer. The statistical analyses were carried out using Stata version 12.0. Results: A total of 8 articles comprising 950 patients were eligible for meta-analysis. The combined HR of studies evaluating total VEGFRs overexpression was 1.42 (95% CI 1.01-2.00, P = 0.044), suggesting that it had prognosis significance in overall survival of gastric cancer. Subgroup analysis showed that it was VEGFR-2 (HR 1.81, 95% CI 1.31-2.49, P < 0.001) but not VEGFR-3 (HR 0.91, 95% CI 0.45-1.82, P = 0.787) overexpression was associated with an increased risk of median overall survival (mOS) and it can be a potentially predictive biomarker for gastric cancer. Conclusions: VEGFR-2 overexpression is a promising negative prognosis predictor for patients with gastric cancer. The prognosis significance of VEGFR-3 still need further study.	[Li, Teng; Yu, Jing; Luo, Xinyu; Zhang, Yue; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Canc Ctr, Beijing 100050, Peoples R China; [Ren, Weiguo] Beijing Nanyuan Hosp, Dept Endocrinol & Oncol, Beijing 100076, Peoples R China	Cao, BW (reprint author), Capital Med Univ, Beijing Friendship Hosp, Canc Ctr, Beijing 100050, Peoples R China.	oncology@ccmu.edu.cn			Beijing Municipal Natural Science FoundationBeijing Natural Science Foundation [7172061]; Beijing traditional Chinese medicine science and Technology Development Fund Project [JJ2016-16]	The authors have declared no conflicts of financial interest. This work was supported by Beijing Municipal Natural Science Foundation (Grant NO. 7172061), Beijing traditional Chinese medicine science and Technology Development Fund Project (Grant NO. JJ2016-16).	Chang Y, 2016, WORLD J GASTROENTERO, V22, P5422, DOI 10.3748/wjg.v22.i23.5422; Fan MH, 2014, BREAST CANCER RES TR, V143, P141, DOI 10.1007/s10549-013-2793-6; Fuchs CS, 2016, BRIT J CANCER, V115, P974, DOI 10.1038/bjc.2016.293; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Han FH, 2010, EJSO-EUR J SURG ONC, V36, P1172, DOI 10.1016/j.ejso.2010.09.002; Hirashima Y, 2009, CANCER SCI, V100, P310, DOI 10.1111/j.1349-7006.2008.01020.x; Kim JY, 2013, APMIS, V121, P95, DOI 10.1111/j.1600-0463.2012.02942.x; Lello E, 2007, ACTA ONCOL, V46, P308, DOI 10.1080/02841860600996462; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995; Li Q, 2017, ONCOTARGET, V8, P67140, DOI 10.18632/oncotarget.18007; Liu L, 2012, ASIAN PAC J CANCER P, V13, P3089, DOI 10.7314/APJCP.2012.13.7.3089; Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236; Ozdemir F, 2006, J EXP CLIN CANC RES, V25, P83; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87; Sung JY, 2008, ONCOL REP, V19, P939; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Van Cutsem E, 2012, J CLIN ONCOL, V30, P2119, DOI 10.1200/JCO.2011.39.9824; Yu JW, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/210205; Yu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0340-8	21	3	3	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					560	564		10.1016/j.prp.2018.02.005			5	Pathology	Pathology	GD8BJ	WOS:000430736900014	29572120				2019-10-28	
J	Kim, GJ; Kim, DH; Min, KW; Kim, YH; Oh, YH				Kim, Gi Jeong; Kim, Dong-Hoon; Min, Kyueng-Whan; Kim, Young Hwan; Oh, Young Ha			Loss of p27(kip1) expression is associated with poor prognosis in patients with taxane-treated breast cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; p27(kip1); p57(kip2); Taxane; Prognosis; Chemotherapy resistance	CDK INHIBITOR P57(KIP2); GUIDELINE RECOMMENDATIONS; REDUCED EXPRESSION; TUMOR PROGRESSION; CELL-MIGRATION; P27; CHEMOTHERAPY; DEGRADATION; SURVIVAL; CARCINOMAS	Purpose: Decreased expression of p27(kip1) and p57(kip2) is considered as a prognostic indicator in patients with breast cancer receiving adjuvant chemotherapy. Previous in vitro studies have reported that reduced expression of p27(kip1) and p57(kip2) is associated with resistance to taxane, which is one of the most effective chemotherapeutic agents. In this study, we investigated the association of low p27(kip1) and p57(kip2) expression with outcomes in patients with breast cancer. Methods: We investigated 226 cases of breast cancer from Kangbuk SMC between 2000 and 2005. Levels of p27(kip1) and p57(kip2) expression were evaluated using immunohistochemical staining of tumor tissue microarray specimens. The relationships between the expression levels of the markers and patients' outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard model. Results: Low p57(kip2) expression was only associated with negative progesterone receptor status (p = 0.034), whereas p27(kip1) expression was associated with poor prognosis of patients receiving adjuvant chemotherapy (p = 0.005). More detailed analysis revealed that low p27(kip1) expression affects the overall survival rate of patients receiving adjuvant chemotherapy including taxane (p = 0.026), but not that of patients receiving chemotherapy without taxane. Conclusions: Low p27(kip1) expression may be useful to predict overall survival in patients with breast cancer who are treated with taxane. Evaluation of p27(kip1) expression may provide further prognostic information beyond traditional prognostic biomarkers and an understanding of the mechanisms that impart resistance against chemotherapy.	[Kim, Gi Jeong; Kim, Dong-Hoon] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Pathol, 29 Saemunan Ro, Seoul 03181, South Korea; [Min, Kyueng-Whan; Oh, Young Ha] Hanyang Univ, Guri Hosp, Coll Med, Dept Pathol, Guri, Gyeonggi Do, South Korea; [Kim, Young Hwan] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Nucl Med, Seoul, South Korea	Kim, DH (reprint author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Pathol, 29 Saemunan Ro, Seoul 03181, South Korea.; Min, KW (reprint author), Hanyang Univ, Guri Hosp, Coll Med, Dept Pathol, 153 Kyoungchun Ro, Guri Si 11923, Gyeonggi Do, South Korea.	idavid.kim@samsung.com; kyueng@hanyang.ac.kr			Hanyang University (HY)	This work was supported by the research fund of Hanyang University (HY-2017).	Adkins JN, 2002, PROTEINS, V46, P1, DOI 10.1002/prot.10018; Anampa J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0439-8; [Anonymous], 1999, Oncology (Williston Park), V13, P41; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Churchill CDM, 2015, CHEM BIOL DRUG DES, V86, P1253, DOI 10.1111/cbdd.12595; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Dominici LS, 2018, BREAST CANCER RES TR, V167, P555, DOI 10.1007/s10549-017-4528-6; Fan GK, 2006, ACTA OTO-LARYNGOL, V126, P301, DOI 10.1080/00016480500388851; Guan XX, 2010, J CELL MOL MED, V14, P944, DOI 10.1111/j.1582-4934.2009.00730.x; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Hydbring P, 2017, GENES-BASEL, V8, DOI 10.3390/genes8070174; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; Lagendijk M, 2018, INT J CANCER, V142, P165, DOI 10.1002/ijc.31034; Li ZM, 2016, ONCOTARGET, V7, P18927, DOI 10.18632/oncotarget.7816; Liu Z, 2013, DIS MARKERS, P925, DOI 10.1155/2013/251209; Masuda S, 2012, PATHOL INT, V62, P295, DOI 10.1111/j.1440-1827.2012.02790.x; Nozoe Tadahiro, 2007, Breast Cancer, V14, P277, DOI 10.2325/jbcs.14.277; Piccart M J, 1998, Bull Mem Acad R Med Belg, V153, P285; Piccart M.J., 1998, B MEM ACAD R MED BEL, V153, P285; Pillay K, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-31; Podmirseg SR, 2016, ONCOGENE, V35, P4580, DOI 10.1038/onc.2015.524; Porter PL, 2006, J NATL CANCER I, V98, P1723, DOI 10.1093/jnci/djj467; Rakha EA, 2014, HISTOPATHOLOGY, V64, P609, DOI 10.1111/his.12357; REMMELE W, 1987, PATHOLOGE, V8, P138; ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1; Sachdev JC, 2016, CLIN BREAST CANCER, V16, P73, DOI 10.1016/j.clbc.2015.09.007; Sanki A, 2007, PATHOLOGY, V39, P551, DOI 10.1080/00313020701684409; Sarsik B, 2016, PATHOL ONCOL RES, V22, P839, DOI 10.1007/s12253-016-0075-4; Satoh T, 2016, SCI REP-UK, V6, DOI 10.1038/srep27829; Shi ZZ, 2016, ANTICANCER RES, V36, P261; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Slotky M, 2005, BREAST CANCER RES, V7, pR737, DOI 10.1186/bcr1278; Song W, 2015, ONCOTARGETS THER, V8, P1863, DOI 10.2147/OTT.S85866; Spataro VJ, 2003, CANCER, V97, P1591, DOI 10.1002/cncr.11224; Susaki E, 2009, CELL CYCLE, V8, P2497, DOI 10.4161/cc.8.16.9330; Xu XY, 2012, ASIAN PAC J CANCER P, V13, P5033, DOI 10.7314/APJCP.2012.13.10.5033; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang CC, 2015, BREAST CANCER-BASIC, V9, P13, DOI 10.4137/BCBCR.S30101; Yang Q, 2014, BRIT J CANCER, V110, P1958, DOI 10.1038/bjc.2014.136; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhao RY, 2013, CELL CYCLE, V12, P935, DOI 10.4161/cc.23883; Zohny SF, 2017, CANCER BIOMARK, V18, P413, DOI 10.3233/CBM-160308	46	2	2	2	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					565	571		10.1016/j.prp.2018.02.004			7	Pathology	Pathology	GD8BJ	WOS:000430736900015	29482985				2019-10-28	
J	Velizheva, NP; Rechsteiner, MP; Valtcheva, N; Freiberger, SN; Wong, CE; Vrugt, B; Zhong, Q; Wagner, U; Moch, H; Hillinger, S; Schmitt-Opitz, I; Soltermann, A; Wild, PJ; Tischler, V				Velizheva, Nadezda P.; Rechsteiner, Markus P.; Valtcheva, Nadejda; Freiberger, Sandra N.; Wong, Christine E.; Vrugt, Bart; Zhong, Qing; Wagner, Ulrich; Moch, Holger; Hillinger, Sven; Schmitt-Opitz, Isabelle; Soltermann, Alex; Wild, Peter J.; Tischler, Verena			Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Next generation sequencing; Lung adenocarcinoma; Gene fusion; ALK gene	ROS1 REARRANGEMENTS; CANCER; EML4-ALK; ALK; FUSIONS; GENE; RET; IDENTIFICATION; MET	Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver events in lung adenocarcinoma. Accurate and reliable detection of these gene fusions is crucial to select the appropriate targeted therapy for each patient. We compared the targeted next-generation-sequencing Oncomine Focus Assay (OFA; Thermo Fisher Scientific) with conventional ALK FISH and anti-Alk immunohistochemistry in a cohort of 52 lung adenocarcinomas (10 ALK rearranged, 18 non-ALK rearranged, and 24 untested cases). We found a sensitivity and specificity of 100% for detection of ALK rearrangements using the OFA panel. In addition, targeted next generation sequencing allowed us to analyze a set of 23 driver genes in a single assay. Besides EML4-ALK (11/52 cases), we detected EZR-ROS1 (1/52 cases), KIF5B-RET (1/52 cases) and MET-MET (4/52 cases) fusions. All EML4-ALK, EZR-ROS1 and KIF5B-RET fusions were confirmed by multiplexed targeted next generation sequencing assay (Oncomine Solid Tumor Fusion Transcript Kit, Thermo Fisher Scientific). All cases with EML4-ALK rearrangement were confirmed by Alk immunohistochemistry and all but one by ALK FISH. In our experience, targeted next-generation sequencing is a reliable and timesaving tool for multiplexed detection of targetable rearrangements. Therefore, targeted next-generation sequencing represents an efficient alternative to time-consuming single target assays currently used in molecular pathology.	[Velizheva, Nadezda P.; Rechsteiner, Markus P.; Valtcheva, Nadejda; Freiberger, Sandra N.; Wong, Christine E.; Vrugt, Bart; Zhong, Qing; Wagner, Ulrich; Moch, Holger; Soltermann, Alex; Wild, Peter J.; Tischler, Verena] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Zurich, Switzerland; [Hillinger, Sven; Schmitt-Opitz, Isabelle] Univ Hosp Zurich, Dept Thorac Surg, Zurich, Switzerland; [Wild, Peter J.] Univ Hosp Frankfurt, Dr Senckenberg Inst Pathol, Frankfurt, Germany	Tischler, V (reprint author), Univ Hosp Zurich, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	verena.tischler@usz.ch	Tischler, Verena/Q-7263-2017	Tischler, Verena/0000-0002-6673-8329; Zhong, Qing/0000-0002-5340-301X	University Hospital Zurich; ERS/EMBO Long-Term Research fellowship [LTRF 2014-2951]; Swiss Cancer League postdoctoral research fellowship [BIL KFS-3402-02-2014]	We thank Susanne Dettwiler, Fabiola Prutek and Peter Schraml from the Tissue Biobank at USZ and Ursula Rommerscheid-Fuss, Department of Pathology, University Hospital Cologne, Germany, for their excellent technical support. Cell lines were a kind gift of Prof. Dr. Roman Thomas, Cologne, Germany. This project was funded in part by Innovation Pool Grants provided by the University Hospital Zurich to V.T. and P.J.W., respectively. V. T. is the recipient of a joint ERS/EMBO Long-Term Research fellowship re LTRF 2014-2951 and a Swiss Cancer League postdoctoral research fellowship (BIL KFS-3402-02-2014).	Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Blackhall FH, 2014, J CLIN ONCOL, V32, P2780, DOI 10.1200/JCO.2013.54.5921; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Cortot AB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw262; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Gautschi O, 2017, J CLIN ONCOL, V35, P1403, DOI 10.1200/JCO.2016.70.9352; Jang JC, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/9275083; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Paasinen-Sohns A, 2017, NEOPLASIA, V19, P196, DOI 10.1016/j.neo.2017.01.003; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Pekar-Zlotin M, 2015, ONCOLOGIST, V20, P316, DOI 10.1634/theoncologist.2014-0389; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P30, DOI 10.1002/gcc.22297; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rogers TM, 2015, J THORAC ONCOL, V10, P611, DOI 10.1097/JTO.0000000000000465; Salgia R, 2017, MOL CANCER THER, V16, P555, DOI 10.1158/1535-7163.MCT-16-0472; Sasaki T, 2010, EUR J CANCER, V46, P1773, DOI 10.1016/j.ejca.2010.04.002; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Velizheva NP, 2017, CANCER CYTOPATHOL, V125, P30, DOI 10.1002/cncy.21771	21	5	5	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					572	578		10.1016/j.prp.2018.02.001			7	Pathology	Pathology	GD8BJ	WOS:000430736900016	29580750	Green Published, Other Gold, Green Accepted			2019-10-28	
J	Zhang, J; Zhang, TM; Wu, N; Zhao, XH; Wang, QS; Jiang, YY; Gao, M; Gu, L				Zhang, Jun; Zhang, Tiemei; Wu, Nan; Zhao, Xinhua; Wang, Qingsong; Jiang, Yanyang; Gao, Ming; Gu, Lin			Intracystic papillary carcinoma of the breast: Experience of a major Chinese cancer center	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; Intracystic papillary carcinoma; Characteristics; Prognosis	IN-SITU; LESIONS; MANAGEMENT	Background: Intracystic papillary carcinoma (IPC) is a rare breast neoplasm. There are few studies focusing on its clinical features and limited data about its preoperative diagnosis,treatment and outcomes. The purpose of this study is to explore specific characteristics of patients with IPC, investigate Its clinicopathological features, prognosis in China and confirm its surgery management. Methods: We identified 111 patients with IPC from the registry of Tianjin Medical University Cancer Institute and Hospital between 2004 and 2017. Follow-up of cases dating back to January 1, 2004 was obtained from retrospective chart review and patient questionnaires. Differences in clinical features and survival of patients were assessed using the Kaplan-Meier method. Results: The median tumor size was 2.25 cm. Median age was 62 years. In the cases of axillary lymph node dissection(ALND), only 1.1% (1/85) of patients with axillary lymph node metastasis were found. The diagnostic accuracy of preoperative Color Doppler ultrasound and Mammograms for IPC was 62.0% (62/100) and 63.5% (54/85) respectively. The median follow-up period was 52 (range2-149) months. The overall survival rate was 98.9%, 92.2%,and 85.6% at 2,5,and 10 years and the relapse-free rate was 99.1%,97.2%,and 92.0% at 2,5, and 10 years, respectively. The disease-specific survival rate was 100%. Conclusion: Overall, we report some unique features of IPC in the Chinese population. The patients of IPC of the breast in China have more excellent prognosis than in Caucasian and other races. The diagnostic accuracy of imaging was low, and was easily misinterpreted as a cyst or benign disease. Preoperative core needle biopsies are very difficult for accurate pathological diagnosis of IPC. IPC is a localized disease with a low frequency of axillary lymph node involvement, rare distant metastases and excellent survival. The low incidence of axillary lymph node metastasis suggests that quadrectomy + sentinel lymph node biopsy (SLNB) and breast-conserving surgery is recommended for IPC.	[Zhang, Jun; Wu, Nan; Gu, Lin] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Dept Breast Surg,Key L, Tianjin, Peoples R China; [Zhang, Jun; Wu, Nan; Gu, Lin] Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin 300060, Peoples R China; [Zhang, Tiemei] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tanjins Clin Res Cotter Canc,Dept Endoscopy,Key L, Tianjin, Peoples R China; [Zhao, Xinhua] Hebei Prov Qian an Peoples Hosp, Dept Breast Surg, Qian An 064400, Peoples R China; [Wang, Qingsong] Tianjin Med Univ, Sch Basic Med Sci, Tianjin Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China; [Jiang, Yanyang] Florida State Univ, Dept Social Sci, Tallahassee, FL 32306 USA; [Gao, Ming] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjins Clin Res Ctr Canc,Dept Thyroid & Neck Tu, Tianjin 300060, Peoples R China	Gao, M (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjins Clin Res Ctr Canc,Dept Thyroid & Neck Tu, Tianjin 300060, Peoples R China.; Gu, L (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Minist Educ,Key Lab Br, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.	headandneck2008@126.com; doctorgulin@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81702629, 81472052, 81472183]	This work was supported by National Natural Science Foundation of China (Grant No. 81702629; Grant No. 81472052; Grant No. 81472183).	Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Benkaddour Y. Ait, 2012, CASE REPORTS OBSTET, V2012; Collins LC, 2008, HISTOPATHOLOGY, V52, P20, DOI 10.1111/j.1365-2559.2007.02898.x; Collins LC, 2006, AM J SURG PATHOL, V30, P1002, DOI 10.1097/00000478-200608000-00011; Duprez R, 2012, J PATHOL, V226, P427, DOI 10.1002/path.3032; Esposito NN, 2009, AM J CLIN PATHOL, V131, P228, DOI 10.1309/AJCP8A2UVLCYGTPU; Fayanju OM, 2007, AM J SURG, V194, P497, DOI 10.1016/j.amjsurg.2007.06.016; Ferzoco RM, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-015-0487-4; Grabowski J, 2008, CANCER, V113, P916, DOI 10.1002/cncr.23723; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hariprasad S, 2013, J CLIN DIAGN RES, V7, P568, DOI 10.7860/JCDR/2013/4998.2828; Hu ZI, 2016, RARE TUMORS, V8, DOI 10.4081/rt.2016.6050; Ilhan E, 2015, J BREAST HEALTH, V11, P45, DOI 10.5152/tjbh.2014.2006; Kobayashi T, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-5; Kwong A, 2014, ANN SURG ONCOL, V21, P1246, DOI 10.1245/s10434-013-3377-8; Lakhani SREI, 2012, WHO CLASSIFICATION T; LEFKOWITZ M, 1994, HUM PATHOL, V25, P802, DOI 10.1016/0046-8177(94)90250-X; Liu FF, 2011, BREAST CANCER RES TR, V130, P645, DOI 10.1007/s10549-011-1647-3; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; MCKITTRICK J E, 1969, American Surgeon, V35, P195; Mogal H, 2016, BREAST, V27, P87, DOI 10.1016/j.breast.2016.01.003; Mulligan AM, 2007, INT J SURG PATHOL, V15, P143, DOI 10.1177/1066896906299119; Mylonas I, 2005, ANTICANCER RES, V25, P1719; Niewiadomska H, 1998, J EXP CLIN CANC RES, V17, P503; Reefy S, 2010, ANTICANCER RES, V30, P2287; Reefy Sara Al, 2013, Ecancermedicalscience, V7, P286, DOI 10.3332/ecancer.2013.286; Sarode VR, 2011, INT J BREAST CANCER, DOI 10.4061/2011/217060; Solorzano CC, 2002, AM J SURG, V184, P364, DOI 10.1016/S0002-9610(02)00941-8; SOO MS, 1995, AM J ROENTGENOL, V164, P321, DOI 10.2214/ajr.164.2.7839962; Sun YK, 2014, AM SURGEON, V80, pE84; Tan PH, 2013, J CLIN PATHOL, V66, P465, DOI 10.1136/jclinpath-2012-201078; Untch M, 2013, BREAST CARE, V8, P221, DOI 10.1159/000351692; Vagholkar K, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/129353; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wynveen CA, 2011, AM J SURG PATHOL, V35, P1, DOI 10.1097/PAS.0b013e3181fbe20a; Yamamoto D, 2001, ANTICANCER RES, V21, P4113	36	0	0	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					579	585		10.1016/j.prp.2018.01.006			7	Pathology	Pathology	GD8BJ	WOS:000430736900017	29526557				2019-10-28	
J	Sato, M; Yamamoto, H; Hatanaka, Y; Nishijima, T; Jiromaru, R; Yasumatsu, R; Taguchi, K; Masuda, M; Nakagawa, T; Oda, Y				Sato, Masanobu; Yamamoto, Hidetaka; Hatanaka, Yui; Nishijima, Toshimitsu; Jiromaru, Rina; Yasumatsu, Ryuji; Taguchi, Kenichi; Masuda, Muneyuki; Nakagawa, Takashi; Oda, Yoshinao			Wnt/beta-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Basal cell adenoma; Adenoid cystic carcinoma; Salivary gland; beta-catenin; APC; AXIN	CYSTIC CARCINOMA; COLORECTAL-CANCER; BETA-CATENIN; PATHWAY; ADENOCARCINOMA; MUTATIONS; EXPRESSION; FUSION; MYB; REARRANGEMENTS	Differential diagnosis among basal cell adenoma (BCA), basal cell adenocarcinoma (BCAC), adenoid cystic carcinoma (ACC) and pleomorphic adenoma (PA) of the salivary gland can be challenging due to their similar histological appearance. Although frequent nuclear beta-catenin expression and CTNNB1 mutations have been reported in BCA, further details of the Wnt/beta-catenin signal alterations are unclear. The aim of this study was to assess the diagnostic utility of Wnt/beta-catenin signal alteration in BCA and morphological mimics. We performed immunohistochemical staining for beta-catenin and mutation analysis for Wnt/beta-catenin-related genes (CTNNB1, APC, AXIN1 and AXIN2) in BCA (n = 34), BCAC (n = 3), ACC (n = 67) and PA (n = 31). We also analyzed ACC specific MYB and MYBL1 gene rearrangements by fluorescence in situ hybridization (FISH). Nuclear beta-catenin expression (>= 3%) was present in 32/34 cases (94.1%) of BCA, and the nuclear beta-catenin labeling index was significantly higher than in other tumor types (p = < 0.0001). In BCA, we found mutations in CTNNB1, APC and AXIN1 genes (41.1%, 2.9% and 8.8%, respectively). In BCAC, nuclear beta-catenin expression with CTNNB1 mutation was present in 1/3 cases (33.3%). As for ACC, nuclear beta-catenin expression was observed in 3/67 cases (4.4%), but all 3 cases harbored either MYB or MYBL1 gene rearrangement. The results suggest that nuclear beta-catenin immunoreactivity with appropriate criteria may be helpful to distinguish BCA from histologically similar tumors. However, a minor subset of ACCs with nuclear beta-catenin expression require careful diagnosis. In addition, Wnt/beta-catenin signal alteration may play a role in the pathogenesis of BCA and BCAC.	[Sato, Masanobu; Yamamoto, Hidetaka; Hatanaka, Yui; Jiromaru, Rina; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan; [Nishijima, Toshimitsu] Kyushu Hosp, Japan Community Hlth Care Org, Dept Otorhinolaryngol, Yahatanishi Ku, 1-8-1 Kishinoura, Kitakyushu, Fukuoka 8068501, Japan; [Yasumatsu, Ryuji; Nakagawa, Takashi] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan; [Taguchi, Kenichi] Natl Kyushu Canc Ctr, Dept Pathol, Minami Ku, 3-1-1 Notame, Fukuoka, Fukuoka 8111395, Japan; [Masuda, Muneyuki] Natl Kyushu Canc Ctr, Dept Head & Neck Surg, Minami Ku, 3 1-1 Notame, Fukuoka, Fukuoka 8111395, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp					Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bilodeau EA, 2015, HUM PATHOL, V46, P255, DOI 10.1016/j.humpath.2014.10.018; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Chan J.K., 2013, DIAGNOSTIC HISTOPATH, P288; Choi HR, 2002, AM J SURG PATHOL, V26, P778, DOI 10.1097/01.PAS.0000015962.68135.30; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Daa T, 2004, MODERN PATHOL, V17, P1475, DOI 10.1038/modpathol.3800209; do Prado R.F., 2006, MED ORAL PATOL ORAL, V11, P247; Ellis G.L, 2008, TUMOR SALIVARY GLAND, V9, P71; ELLIS GL, 1990, ORAL SURG ORAL MED O, V69, P461, DOI 10.1016/0030-4220(90)90380-B; Furuse C, 2006, INT J SURG PATHOL, V14, P212, DOI 10.1177/1066896906290652; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hidaka Y, 2013, HUM PATHOL, V44, P2438, DOI 10.1016/j.humpath.2013.06.002; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Jo VY, 2016, AM J SURG PATHOL, V40, P1143, DOI 10.1097/PAS.0000000000000669; Jung MJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-171; Kandasamy J, 2007, CANCER GENET CYTOGEN, V177, P1, DOI 10.1016/j.cancergencyto.2007.04.006; Kawahara A, 2011, J ORAL PATHOL MED, V40, P460, DOI 10.1111/j.1600-0714.2011.01010.x; Kikuchi A., 2016, CANCER SCI, V94, P225; Li BB, 2014, ANN DIAGN PATHOL, V18, P5, DOI 10.1016/j.anndiagpath.2013.09.002; Li J, 2017, WHO CLASSIFICATION H, P187; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Muller S, 1996, CANCER, V78, P2471; Nagao T, 1998, CANCER, V82, P439, DOI 10.1002/(SICI)1097-0142(19980201)82:3<439::AID-CNCR3>3.0.CO;2-K; Nakano T, 2013, HISTOPATHOLOGY, V63, P378, DOI 10.1111/his.12183; Nomura R, 2014, HUM PATHOL, V45, P2488, DOI 10.1016/j.humpath.2014.08.016; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Queimado L, 2007, GENE CHROMOSOME CANC, V46, P215, DOI 10.1002/gcc.20402; Ross JS, 2014, AM J SURG PATHOL, V38, P235, DOI 10.1097/PAS.0000000000000102; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tian Z, 2012, HISTOPATHOLOGY, V61, P921, DOI 10.1111/j.1365-2559.2012.04302.x	36	3	3	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					586	592		10.1016/j.prp.2017.12.016			7	Pathology	Pathology	GD8BJ	WOS:000430736900018	29496310				2019-10-28	
J	Khattar, P; Bedi, P; Gonzalez, M; Zhong, MH; Yin, CH; Huang, WH; Islam, HK; Fallon, JT				Khattar, Pallavi; Bedi, Puneet; Gonzalez, Marion; Zhong, Minghao; Yin, Changhong; Huang, Weihua; Islam, Humayun K.; Fallon, John T.			Genomic Analysis Reveals Distinct Subtypes in Two Rare Cases of Primary Ovarian Lymphoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article							B-CELL LYMPHOMA; CLINICOPATHOLOGICAL ANALYSIS; PROTEIN FUNCTION; SERVER; VIEWER; TUMORS; SIFT	Primary (localized) non-Hodgkin lymphoma (NHL) of the ovary is extremely rare; only a few cases have been reported in the literature. We report two cases of primary ovarian lymphoma (POL), one involving bilateral ovaries in a 15-year-old girl and other involving one ovary in a 5-year-old girl. This report describes detailed clinical, histopathological, and imaging findings, along with the review of literature of primary diffuse large B-cell lymphoma (DLBCL) arising from an ovary. In addition, we describe findings of targeted capture panel sequencing on both tumors and identify the major genetic mutations that are recurrently mutated in pan-cancers. Compared to the genomic mutation features of major subtypes of DLBCL, we distinguish that each POL belongs to distinctive subtypes, GCB (germinal center B-cell subtype) DLBCL and ABC (activated B-cell subtype) DLBCL, respectively. The findings from the genomic analysis may help to understand the pathogenesis of POL and to guide potential targeted therapy in the future.	[Khattar, Pallavi; Gonzalez, Marion; Zhong, Minghao; Yin, Changhong; Huang, Weihua; Islam, Humayun K.; Fallon, John T.] Westchester Med Ctr, Dept Pathol, Valhalla, NY 10595 USA; [Khattar, Pallavi; Gonzalez, Marion; Zhong, Minghao; Yin, Changhong; Huang, Weihua; Islam, Humayun K.; Fallon, John T.] New York Med Coll, Valhalla, NY 10595 USA; [Khattar, Pallavi] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, 1275 York Ave, New York, NY 10065 USA; [Bedi, Puneet] Brookdale Univ Hosp Med Ctr, Dept Med, Brooklyn, NY 11212 USA	Khattar, P (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, 1275 York Ave, New York, NY 10065 USA.	khattarp@mskcc.org					Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Bandyopadhyay A, 2012, J CYTOL, V29, P35, DOI 10.4103/0970-9371.93218; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; FERRY JA, 1991, PATHOL ANNU, V26, P227; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; FOX H, 1988, BRIT J OBSTET GYNAEC, V95, P386, DOI 10.1111/j.1471-0528.1988.tb06611.x; Jardin F, 2014, DISCOV MED, V18, P51; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; MONTERROSO V, 1993, AM J SURG PATHOL, V17, P154, DOI 10.1097/00000478-199302000-00007; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morin RD, 2013, SEMIN HEMATOL, V50, P303, DOI 10.1053/j.seminhematol.2013.09.004; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; OSBORNE BM, 1983, CANCER, V52, P1933, DOI 10.1002/1097-0142(19831115)52:10<1933::AID-CNCR2820521026>3.0.CO;2-8; Pasqualucci L, 2015, SEMIN HEMATOL, V52, P67, DOI 10.1053/j.seminhematol.2015.01.005; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; ROSENBERG SA, 1982, CANCER, V49, P2112; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Simons A, 2013, CYTOGENET GENOME RES, V141, P1, DOI 10.1159/000353118; SKODRAS G, 1994, ARCH PATHOL LAB MED, V118, P647; Staudt LM, 2005, ADV IMMUNOL, V87, P163, DOI 10.1016/S0065-2776(05)87005-1; Tai WM, 2011, ANN HEMATOL, V90, P809, DOI 10.1007/s00277-010-1150-7; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Vang R, 2001, MODERN PATHOL, V14, P1093, DOI 10.1038/modpathol.3880442	30	1	2	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					593	598		10.1016/j.prp.2017.12.017			6	Pathology	Pathology	GD8BJ	WOS:000430736900019	29519565				2019-10-28	
J	Yoo, NJ; Kim, MS; Lee, JH; An, CH; Lee, SH				Yoo, Nam Jin; Kim, Min Sung; Lee, Ju Hwa; An, Chang Hyeok; Lee, Sug Hyung			Expressional analysis of APLNR, an essential gene for cancer immunotherapy, in colon and prostate cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Letter									[Yoo, Nam Jin; Kim, Min Sung; Lee, Ju Hwa; Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea; [An, Chang Hyeok] Catholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul, South Korea.	suhulee@catholic.ac.kr					Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Lee JH, 2017, PATHOL RES PRACT, V213, P1019, DOI 10.1016/j.prp.2017.06.011; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Teng MWL, 2016, CANCER DISCOV, V6, P818, DOI 10.1158/2159-8290.CD-16-0694; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	5	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					599	600		10.1016/j.prp.2018.02.008			2	Pathology	Pathology	GD8BJ	WOS:000430736900020	29573866				2019-10-28	
J	Lee, JH; An, CH; Yoo, NJ; Lee, SH				Lee, Ju Hwa; An, Chang Hyeok; Yoo, Nam Jin; Lee, Sug Hyung			Mutational intratumoral heterogeneity of a putative tumor suppressor gene RARRES3 in colorectal cancers	PATHOLOGY RESEARCH AND PRACTICE			English	Letter									[Lee, Ju Hwa; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea; [An, Chang Hyeok] Catholic Univ Korea, Dept Surg, Coll Med, Seoul, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr					DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Lee JH, 2017, PATHOL RES PRACT, V213, P1019, DOI 10.1016/j.prp.2017.06.011; Lee JH, 2016, HUM PATHOL, V50, P146, DOI 10.1016/j.humpath.2015.12.009; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Wang ZT, 2015, AM J CANCER RES, V5, P1988	7	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					601	602		10.1016/j.prp.2017.12.011			2	Pathology	Pathology	GD8BJ	WOS:000430736900021	29496306				2019-10-28	
J	Pierconti, F; Straccia, P; Emilio, S; Bassi, PF; De Pascalis, I; Marques, RC; Volavsek, M; Larocca, LM; Lopez-Beltran, A				Pierconti, Francesco; Straccia, Patrizia; Emilio, Sacco; Bassi, Pier Francesco; De Pascalis, Ivana; Marques, Rita C.; Volavsek, Metka; Larocca, Luigi M.; Lopez-Beltran, Antonio			Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy) (vol 213, pg 1078, 2017)	PATHOLOGY RESEARCH AND PRACTICE			English	Correction									[Pierconti, Francesco; Straccia, Patrizia; De Pascalis, Ivana; Larocca, Luigi M.] Univ Cattolica Sacro Cuore, Dept Pathol & Surg, Fac Med, Largo Francesco Vito 1, I-00168 Rome, Italy; [Emilio, Sacco; Bassi, Pier Francesco] Univ Cattolica Sacro Cuore, Dept Urol, Fac Med, I-00138 Rome, Italy; [Marques, Rita C.; Volavsek, Metka; Lopez-Beltran, Antonio] Univ Ljubljana, Fac Med, Inst Pathol, SI-1000 Ljubljana, Slovenia; [Marques, Rita C.; Volavsek, Metka; Lopez-Beltran, Antonio] Champalimaud Clin Ctr, Anat Pathol Serv, Lisbon, Portugal	Pierconti, F (reprint author), Univ Cattolica Sacro Cuore, Dept Pathol & Surg, Fac Med, Largo Francesco Vito 1, I-00168 Rome, Italy.	francesco.pierconti@unicatt.it; stracciapatrizia@libero.it; bassipf@gmail.com; ivanadepascalis@gmail.com; rita.marques@fundacaochampalimaud.pt; metka.volavsek@mf.uni-lj.si; luigimaria.larocca@unicatt.it; Emllobea@gmail.com	Larocca, Luigi Maria/M-9590-2019	Larocca, Luigi Maria/0000-0003-1739-4758			Pierconti F, 2017, PATHOL RES PRACT, V213, P1078, DOI 10.1016/j.prp.2017.07.026	1	0	0	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	APR	2018	214	4					603	603		10.1016/j.prp.2018.03.012			1	Pathology	Pathology	GD8BJ	WOS:000430736900022	29549984				2019-10-28	
J	McCluggage, WG				McCluggage, W. Glenn			Towards developing a meaningful grading system for cervical squamous cell carcinoma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Editorial Material						cervix; squamous cell carcinoma; grading; tumour budding; cell nest size	GYNECOLOGIC-ONCOLOGY-GROUP; UTERINE CERVIX; STAGE-IB; PROGNOSTIC VALUE; INVASION; CANCER; PROPOSAL; DISEASE; PATTERN; SIZE	Cervical cancer is one of the commonest cancers worldwide, especially in developing countries. In early stage disease, a variety of pathological parameters are of prognostic value but currently this does not include tumour grade which, for a number of reasons, is of limited or no value in cervical squamous cell carcinomas. In a recent article in this journal, Jesinghaus and colleagues investigated a novel histopathological grading system based on tumour budding and cell nest size, which has been shown to outperform conventional grading systems for squamous cell carcinoma at several other sites such as lung, oral cavity, and oesophagus in terms of patient prognostication. They tested the prognostic value of this grading system in two independent cohorts of cervical squamous cell carcinoma. The grading system proved to be a highly effective, stage-independent prognosticator in both cohorts with small cell nest size and high tumour budding indicative of a poor prognosis. It is hoped that the results of this study will be validated in additional independent larger cohorts and will act as an impetus for the development of a meaningful and easy-to-implement grading system for cervical squamous cell carcinoma. As comparable tumour budding/cell nest size-based grading systems have been shown to be of prognostic value for squamous cell carcinomas at other sites, this shows the potential of these parameters to serve as the basis for a common grading system applicable to squamous cell carcinomas of different anatomic sites.	[McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland	McCluggage, WG (reprint author), Royal Grp Hosp Trust, Dept Pathol, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.	glenn.mccluggage@belfasttrust.hscni.net					Berg KB, 2018, MODERN PATHOL, V31, P862, DOI 10.1038/s41379-018-0028-4; BICHEL P, 1985, AM J CLIN ONCOL-CANC, V8, P247, DOI 10.1097/00000421-198506000-00010; Boxberg M, 2017, HISTOPATHOLOGY, V70, P1125, DOI 10.1111/his.13173; Cibula D, INT J GYNEC IN PRESS; DELGADO G, 1990, GYNECOL ONCOL, V38, P352, DOI 10.1016/0090-8258(90)90072-S; Eggen T, 2007, INT J GYNECOL PATHOL, V26, P447, DOI 10.1097/pgp.0b013e3180341111; Graflund M, 2002, INT J GYNECOL CANCER, V12, P32, DOI 10.1046/j.1525-1438.2002.01075.x; Horn LC, 2006, GYNECOL ONCOL, V103, P906, DOI 10.1016/j.ygyno.2006.05.046; Horn LC, 2008, INT J GYNECOL PATHOL, V27, P606, DOI 10.1097/PGP.0b013e31816fc2db; Huang BX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166311; Jesinghaus M, 2018, J PATHOL CLIN RES, V4, P93, DOI 10.1002/cjp2.95; Jesinghaus M, 2017, AM J SURG PATHOL, V41, P1112, DOI 10.1097/PAS.0000000000000865; Koay MHE, 2012, HISTOPATHOLOGY, V61, P1125, DOI 10.1111/j.1365-2559.2012.04326.x; Kristensen GB, 1999, GYNECOL ONCOL, V74, P245, DOI 10.1006/gyno.1999.5420; Kurman RJ, 2014, WHO CLASSIFICATION T; Lindahl B, 2007, ANTICANCER RES, V27, P2829; McAlpine JN, 2017, HISTOPATHOLOGY, V71, P238, DOI 10.1111/his.13205; McCluggage WG, 2018, INT J GYNECOL PATHOL, V37, P205, DOI 10.1097/PGP.0000000000000412; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; STENDAHL U, 1981, ACTA RADIOL ONCOL, V20, P289, DOI 10.3109/02841868109130209; Weichert W, 2016, EUR RESPIR J, V47, P938, DOI 10.1183/13993003.00937-2015; ZAINO RJ, 1992, CANCER, V69, P1750, DOI 10.1002/1097-0142(19920401)69:7<1750::AID-CNCR2820690717>3.0.CO;2-S	22	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					81	85		10.1002/cjp2.98			5	Pathology	Pathology	GD2CH	WOS:000430307200001	29665326	DOAJ Gold, Green Published			2019-10-28	
J	Barria, MA; Lee, A; Green, AJE; Knight, R; Head, MW				Barria, Marcelo A.; Lee, Andrew; Green, Alison J. E.; Knight, Richard; Head, Mark W.			Rapid amplification of prions from variant Creutzfeldt-Jakob disease cerebrospinal fluid	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						prion; Creutzfeldt-Jakob disease; diagnostic test; protein misfolding	MISFOLDING CYCLIC AMPLIFICATION; QUAKING-INDUCED CONVERSION; TRANSMISSION; TIME; BARRIERS; UK	Human prion diseases constitute a group of infectious and invariably fatal neurodegenerative disorders associated with misfolding of the prion protein. Variant Creutzfeldt-Jakob disease (vCJD) is a zoonotic prion disease linked to oral exposure to the infectious agent that causes bovine spongiform encephalopathy (BSE) in cattle. The most recent case of definite vCJD was heterozygous (MV) at polymorphic codon 129 of the prion protein gene PRNP while all of the previous 177 definite or probable vCJD cases who underwent genetic analysis were methionine homozygous (MM). Retrospective prevalence studies conducted on lympho-reticular tissue suggest that the number of asymptomatic vCJD carriers in the United Kingdom might be around 1 in 2000 people. In addition, there have been four known cases of the transmission of vCJD infection via blood transfusion. For these reasons, a sensitive, reliable, and fast diagnostic test is currently needed. We describe a rapid and highly sensitive seeding conversion assay that detects disease-associated prion protein in the brain and cerebrospinal fluid in vCJD after 48-96 h of amplification, with 100% sensitivity and specificity. This method can amplify prions from definite, probable, and possible vCJD cases from patients who are either MM or MV at PRNP-codon 129.	[Barria, Marcelo A.; Lee, Andrew; Green, Alison J. E.; Knight, Richard; Head, Mark W.] Univ Edinburgh, Deanery Clin Med, Ctr Clin Brain Sci, Natl CJD Res & Surveillance Unit, Edinburgh, Midlothian, Scotland	Barria, MA (reprint author), Western Gen Hosp, Bryan Matthews Bldg, Edinburgh EH4 2XU, Midlothian, Scotland.	Marcelo.Barria@ed.ac.uk	Green, Alison/O-7356-2019	Barria Matus, Marcelo/0000-0003-4789-7401	Department of Health Policy Research Programme; Scottish Government	This report is independent research commissioned and funded by the Department of Health Policy Research Programme and the Scottish Government. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health or the Scottish Government.	Barria MA, 2014, EMERG INFECT DIS, V20, P88, DOI 10.3201/eid2001.130858; Belondrade M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146833; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; Bougard D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1257; Concha-Marambio L, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6188; Fairfoul G, 2016, ANN CLIN TRANSL NEUR, V3, P812, DOI 10.1002/acn3.338; Gill ON, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5675; Gonzalez-Montalban N, 2011, BIOCHEMISTRY-US, V50, P7933, DOI 10.1021/bi200950v; Head MW, 2012, NEUROPATH APPL NEURO, V38, P296, DOI 10.1111/j.1365-2990.2012.01265.x; Head MW, 2013, NEUROPATHOLOGY, V33, P221, DOI 10.1111/neup.12016; Imamura M, 2016, J BIOL CHEM, V291, P26478, DOI 10.1074/jbc.M116.745851; Lacroux C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004202; McGuire LI, 2016, ANN NEUROL, V80, P160, DOI 10.1002/ana.24679; McGuire LI, 2012, ANN NEUROL, V72, P278, DOI 10.1002/ana.23589; Moda F, 2014, NEW ENGL J MED, V371, P530, DOI 10.1056/NEJMoa1404401; Mok T, 2017, NEW ENGL J MED, V376, P292, DOI 10.1056/NEJMc1610003; Orru CD, 2014, NEW ENGL J MED, V371, P519, DOI 10.1056/NEJMoa1315200; Ritchie DL, 2017, ACTA NEUROPATHOL, V133, P579, DOI 10.1007/s00401-016-1638-x; Shahnawaz M, 2017, JAMA NEUROL, V74, P163, DOI 10.1001/jamaneurol.2016.4547; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Yokoyama T, 2011, NEUROSCI LETT, V498, P119, DOI 10.1016/j.neulet.2011.04.072	21	2	2	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					86	92		10.1002/cjp2.90			7	Pathology	Pathology	GD2CH	WOS:000430307200002	29665324	DOAJ Gold, Green Published			2019-10-28	
J	Ong, CW; Maxwell, P; Alvi, MA; McQuaid, S; Waugh, D; Mills, I; Salto-Tellez, M				Ong, Chee W.; Maxwell, Pamela; Alvi, Muhammad A.; McQuaid, Stephen; Waugh, David; Mills, Ian; Salto-Tellez, Manuel			A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						prostate cancer; prognostic; gene signature	GENOMIC DELETION; EXPRESSION; ERG; PROGRESSION; RECURRENCE; CARCINOMA; MUTATION; TCTP; AKT	Accurate identification of intermediate risk (Gleason 3+4=7) prostate cancer patients with low risk of disease progression is an unmet challenge in treatment decision making. Here we describe a gene signature that could guide clinicians in the selection of patients with intermediate stage clinically localized prostate cancer for active surveillance. We examined six major drivers of aggressive disease - PTEN, MYC, RB1, TP53, AURKA, AR - by immunohistochemistry in a focused (N=69) cohort predominantly consisting of intermediate risk prostate cancer. Fuzzy clustering and unsupervised hierarchical clustering were utilized to determine the correlation of gene expression and methylation values with immunohistochemical expression. From the immunohistochemistry observation, we found that intermediate risk prostate cancer cases could be classified as 'complex' (differential expression of more than one driver) or 'simple' (differential expression of only one). Focussing on the 'simple' cases, expression and methylation profiling generated signatures which correlated tightly only with differential PTEN expression and not with any of the other drivers assessed by immunohistochemistry. From this, we derived a geneset of 35 genes linked to high PTEN expression. Subsequently we determined its prognostic significance in intermediate-risk cases extracted from three publicly available clinical datasets (Total N=215). Hence, this study shows that, by using immunohistochemistry as an upfront stratifier of intermediate risk prostate cancers, it is possible to identify through differential gene expression profiling a geneset with prognostic power across multiple cohorts. This strategy has not been used previously and the signature has the potential to impact on treatment decisions in patients for whom decision making is currently empirical at best.	[Ong, Chee W.; Maxwell, Pamela; Alvi, Muhammad A.; McQuaid, Stephen; Waugh, David; Mills, Ian; Salto-Tellez, Manuel] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Movember FASTMAN Ctr Excellence, Belfast, Antrim, North Ireland	Ong, CW (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Movember FASTMAN Ctr Excellence, Belfast, Antrim, North Ireland.	cong04@qub.ac.uk			Porter Scholarship; Friends of the Cancer Centre; Medical Research CouncilMedical Research Council UK (MRC) [MR/J007641/1]; Movember/Prostate Cancer UK Centre of Excellence Award [PCUK-CEO-14-02]; HSC Research and Development Division of the Public Health Agency in Northern Ireland; Cancer Research UK through the Belfast CRUK Centre; Northern Ireland Experimental Cancer Medicine Centre; Cancer Research UKCancer Research UK; Sean Crummey Foundation	This work has been carried out with financial support for CWO from the Porter Scholarship and Friends of the Cancer Centre. The study was also supported by funding from the Medical Research Council (MR/J007641/1 to DJJW and MST) and the Movember/Prostate Cancer UK Centre of Excellence Award (PCUK-CEO-14-02). The samples used in this research were received from the Northern Ireland Biobank which is funded by the HSC Research and Development Division of the Public Health Agency in Northern Ireland and Cancer Research UK through the Belfast CRUK Centre and the Northern Ireland Experimental Cancer Medicine Centre. The Northern Ireland Molecular Pathology Laboratory, which is responsible for creating resources for the NIB, has received funding from Cancer Research UK, the Friends of the Cancer Centre and the Sean Crummey Foundation.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Ahearn TU, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv346; Allred DC, 1998, MODERN PATHOL, V11, P155; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bazile F, 2009, CARCINOGENESIS, V30, P555, DOI 10.1093/carcin/bgp022; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; Bingham V, 2016, HUM PATHOL, V47, P95, DOI 10.1016/j.humpath.2015.09.009; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cooperberg MR, 2015, EUR UROL, V67, P326, DOI 10.1016/j.eururo.2014.05.039; Cullen J, 2015, EUR UROL, V68, P123, DOI 10.1016/j.eururo.2014.11.030; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Den RB, 2014, INT J RADIAT ONCOL, V89, P1038, DOI 10.1016/j.ijrobp.2014.04.052; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Garg K, 2012, INT J GYNECOL PATHOL, V31, P48, DOI 10.1097/PGP.0b013e3182230d00; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Gnanasekar M, 2009, INT J ONCOL, V34, P1241, DOI 10.3892/ijo_00000252; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; Gulzar ZG, 2013, ONCOGENE, V32, P70, DOI 10.1038/onc.2012.27; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054; Irshad S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006408; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Lindberg J, 2013, EUR UROL, V63, P702, DOI 10.1016/j.eururo.2012.11.053; Ma Q, 2010, J PROTEOME RES, V9, P40, DOI 10.1021/pr9001367; Maddams J, 2012, BRIT J CANCER, V107, P1195, DOI 10.1038/bjc.2012.366; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mounir Z, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000389; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Roychowdhury S, 2013, J CLIN ONCOL, V31, P1866, DOI 10.1200/JCO.2012.45.3662; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Troyer DA, 2015, PROSTATE, V75, P1206, DOI 10.1002/pros.23003; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	43	3	4	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					103	113		10.1002/cjp2.94			11	Pathology	Pathology	GD2CH	WOS:000430307200004	29665325	DOAJ Gold, Green Published			2019-10-28	
J	Pilskog, M; Bostad, L; Edelmann, RJ; Akslen, LA; Beisland, C; Straume, O				Pilskog, Martin; Bostad, Leif; Edelmann, Reidunn J.; Akslen, Lars A.; Beisland, Christian; Straume, Oddbjorn			Tumour cell expression of interleukin 6 receptor alpha is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						clear cell renal cell carcinoma; sunitinib; interleukin 6; interleukin 6 receptor alpha; response rates; biomarker; anti-angiogenesis; inflammation; immunohistochemistry; treatment efficacy	ENDOTHELIAL GROWTH-FACTOR; PREDICTIVE CLINICAL MARKER; C-REACTIVE PROTEIN; PROGNOSTIC VALUE; CANCER; ANGIOGENESIS; SURVIVAL; INFLAMMATION; CYTOKINES; BIOMARKER	Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and anti-angiogenic treatment is currently first line therapy for metastatic ccRCC (mccRCC). Response rates and duration of response show considerable variation, and adverse events have a major influence on patient quality of life. The need for predictive biomarkers to select responders to receptor tyrosine kinase inhibitors upfront is urgent. We investigated the predictive value of immunohistochemical biomarkers associated with angiogenesis and systemic inflammation in mccRCC. Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib were included. Metastatic and/or primary tumour tissue was stained by immunohistochemistry for selected markers related to angiogenesis [vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFR beta), and heat shock protein 27 (HSP27)] and immune responses [Interleukin 6 receptor alpha (IL6R alpha), interleukin-6 (IL6), and jagged1 (JAG1)]. The predictive potential of the candidate markers was assessed by correlations with response rates (RECIST). In addition, progression free survival (PFS) and overall survival (OS) were analysed. Low tumour cell expression of IL6R alpha was significantly associated with improved response to sunitinib (Fisher's exact test, p=0.03), but not with PFS or OS. Median/high expression of IL6R alpha showed significant association with median/high expression of VEGF-A and HSP27. Furthermore, low expression of IL6 was significantly associated with improved PFS, but not OS or response rates. High expression of IL6 was significantly associated with high expression of JAG1, VEGF-A, VEGFR2, and PDGFR beta. Loss of tumour cell expression of IL6R alpha in mccRCC patients treated with sunitinib predicts improved treatment response, and might represent a candidate predictive marker.	[Pilskog, Martin; Edelmann, Reidunn J.; Akslen, Lars A.; Straume, Oddbjorn] Univ Bergen, Ctr Canc Biomarkers CCBIO, Bergen, Norway; [Pilskog, Martin; Straume, Oddbjorn] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Bostad, Leif; Akslen, Lars A.] Haukeland Hosp, Dept Pathol, Bergen, Norway; [Beisland, Christian] Haukeland Hosp, Dept Urol, Bergen, Norway; [Beisland, Christian] Univ Bergen, Dept Clin Med, Bergen, Norway	Straume, O (reprint author), Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway.	Oddbjorn.straume@helse-bergen.no	Beisland, Christian/R-6046-2019	Beisland, Christian/0000-0002-3216-4937	Norwegian Research CouncilResearch Council of Norway; Norwegian Cancer SocietyNorwegian Cancer Society; Research Council of NorwayResearch Council of Norway [223250]	The study was supported by grants from The Norwegian Research Council and The Norwegian Cancer Society. The authors alone are responsible for the content and writing of the paper. This work was partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 223250.	Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Beuselinck B, 2013, BRIT J CANCER, V108, P887, DOI 10.1038/bjc.2012.548; Beuselinck B, 2016, BJU INT, V118, P890, DOI 10.1111/bju.13585; Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.3.CO;2-N; BLAY JY, 1992, CANCER RES, V52, P3317; Bozkurt O, 2016, J CHEMOTHERAPY, V28, P230, DOI 10.1179/1973947815Y.0000000039; Bromwich EJ, 2003, BRIT J CANCER, V89, P1906, DOI 10.1038/sj.bjc.6601400; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Casamassima A, 2005, J UROLOGY, V173, P52, DOI 10.1097/01.ju.0000146713.50673.e5; Chalaris A, 2011, EUR J CELL BIOL, V90, P484, DOI 10.1016/j.ejcb.2010.10.007; Costes V, 1997, J CLIN PATHOL, V50, P835, DOI 10.1136/jcp.50.10.835; Dalpiaz O, 2017, BRIT J CANCER, V116, P85, DOI 10.1038/bjc.2016.393; del Puerto-Nevado L, 2014, BRIT J CANCER, V110, P2700, DOI 10.1038/bjc.2014.225; Dornbusch J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076386; Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008; Fitzgerald JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030712; Fox P, 2013, BRIT J CANCER, V109, P147, DOI 10.1038/bjc.2013.300; Fu Q, 2015, BRIT J CANCER, V113, P1581, DOI 10.1038/bjc.2015.379; Garcia-Donas J, 2013, ANN ONCOL, V24, P2409, DOI 10.1093/annonc/mdt219; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hrab M, 2013, REP PRACT ONCOL RADI, V18, P304, DOI 10.1016/j.rpor.2013.06.002; Kaminska K, 2015, UROL ONCOL-SEMIN ORI, V33, P476, DOI 10.1016/j.urolonc.2015.07.010; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Kust D, 2014, ANTICANCER RES, V34, P3177; Kwon KA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-203; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Middleton K, 2014, CRIT REV ONCOL HEMAT, V89, P129, DOI 10.1016/j.critrevonc.2013.08.004; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI [10.2217/FON.14.83, 10.2217/fon.14.83]; Pilskog M, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0267-6; Polimeno M, 2013, BJU INT, V112, P686, DOI 10.1111/bju.12068; Rini BI, 2006, BJU INT, V98, P756, DOI 10.1111/j.1464-410X.2006.06376.x; Rini BI, 2011, JNCI-J NATL CANCER I, V103, P763, DOI 10.1093/jnci/djr128; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Scheller J, 2006, SCAND J IMMUNOL, V63, P321, DOI 10.1111/j.1365-3083.2006.01750.x; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schuster C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155242; Straume O, 2001, AM J PATHOL, V159, P223, DOI 10.1016/S0002-9440(10)61688-4; Straume O, 2012, P NATL ACAD SCI USA, V109, P8699, DOI 10.1073/pnas.1017909109; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKENAWA J, 1991, J NATL CANCER I, V83, P1668, DOI 10.1093/jnci/83.22.1668; Terakawa T, 2013, UROL ONCOL-SEMIN ORI, V31, P493, DOI 10.1016/j.urolonc.2011.02.012; Tran HT, 2012, LANCET ONCOL, V13, P827, DOI 10.1016/S1470-2045(12)70241-3; Voron T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00070; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024; Wu KR, 2011, JPN J CLIN ONCOL, V41, P411, DOI 10.1093/jjco/hyq205; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719	53	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					114	123		10.1002/cjp2.96			10	Pathology	Pathology	GD2CH	WOS:000430307200005	29665322	DOAJ Gold, Green Published			2019-10-28	
J	Pepe, G; Di Napoli, A; Cippitelli, C; Scarpino, S; Pilozzi, E; Ruco, L				Pepe, Giuseppina; Di Napoli, Arianna; Cippitelli, Claudia; Scarpino, Stefania; Pilozzi, Emanuela; Ruco, Luigi			Reduced lymphotoxin-beta production by tumour cells is associated with loss of follicular dendritic cell phenotype and diffuse growth in follicular lymphoma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						lymphotoxin-beta lymphotoxin-alpha; TNF-alpha; lymph nodes; lymphoid hyperplasia; follicular lymphoma; follicular dendritic cell; in situ hybridization	NECROSIS-FACTOR; B-CELLS; DEFICIENT MICE; STROMAL CELLS; EXPRESSION; FOLLICLES; TISSUES; TNF; ALPHA-1-BETA-2; RESPONSIVENESS	Cytokine production is essential for follicular dendritic cell (FDC) maintenance and organization of germinal centres. In follicular lymphoma, FDCs are often disarrayed and may lack antigens indicative of terminal differentiation. We investigated the in situ distribution of cells producing lymphotoxin-beta (LTB), lymphotoxin-alpha (LTA), and tumour necrosis factor-alpha (TNFA) transcripts in human reactive lymph nodes and in follicular lymphomas with follicular or diffuse growth pattern. LTB was the cytokine most abundantly produced in germinal centres. LTB was present in nearly 90% of germinal centre cells whereas LTA and TNFA were detected in 30 and 50%, respectively. Moreover, the amount of LTB expressed in reactive germinal centre cells was 80-fold higher than that of LTA and 20-fold higher than that of TNFA. LTB-positive cells were more numerous in the germinal centre dark zone, whereas expression of the FDC proteins CD21, CD23, VCAM, and CXCL13 was more intense in the light zone. Tumour cells of follicular lymphomas produced less LTB than reactive germinal centre cells. The results of the in situ study were confirmed by RT-PCR; LTB was significantly more abundant in reactive lymph nodes than in follicular lymphoma, with the lowest values detected in predominantly diffuse follicular lymphoma. In neoplastic follicles, low production of LTB by tumour B cells was associated with weaker expression of CD21+/CD23+ by FDCs. Our findings detail for the first time the distribution of LTA-, LTB-, and TNFA-producing cells in human reactive germinal centres and in follicular lymphoma. They suggest the possibility that impaired tumour-cell LTB production may represent a determinant of FDC phenotype loss and for defective follicular organization in follicular lymphoma.	[Pepe, Giuseppina; Di Napoli, Arianna; Cippitelli, Claudia; Scarpino, Stefania; Pilozzi, Emanuela; Ruco, Luigi] Sapienza Univ, St Andrea Hosp, Dept Clin & Mol Med, Pathol Unit, Rome, Italy	Di Napoli, A (reprint author), Univ Sapienza Rome, St Andrea Hosp, Dept Clin & Mol Med, Via Grottarossa 1035, I-00189 Rome, Italy.	arianna.dinapoli@uniroma1.it		Di Napoli, Arianna/0000-0002-3159-5380	Sapienza UniversitySapienza University Rome	This work was supported by a grant from Sapienza University.	Aguzzi A, 2014, TRENDS IMMUNOL, V35, P105, DOI 10.1016/j.it.2013.11.001; Aguzzi A, 2010, EUR J IMMUNOL, V40, P2134, DOI 10.1002/eji.201040765; Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; Ame-Thomas P, 2007, BLOOD, V109, P693, DOI 10.1182/blood-2006-05-020800; Ansel KM, 2000, NATURE, V406, P309; BANKS TA, 1995, J IMMUNOL, V155, P1685; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Canzian F, 1996, CANCER RES, V56, P3331; Carbone A, 2014, ADV ANAT PATHOL, V21, P260, DOI 10.1097/PAP.0000000000000030; Chang KC, 2003, J PATHOL, V201, P404, DOI 10.1002/path.1478; El Shikh MEM, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00292; Endres R, 1999, J EXP MED, V189, P159, DOI 10.1084/jem.189.1.159; ENGLISH BK, 1991, J BIOL CHEM, V266, P7108; Gonzalez M, 1998, J EXP MED, V187, P997, DOI 10.1084/jem.187.7.997; Husson H, 2000, CELL IMMUNOL, V203, P134, DOI 10.1006/cimm.2000.1688; Jin MK, 2011, HISTOPATHOLOGY, V58, P586, DOI 10.1111/j.1365-2559.2011.03779.x; Junt T, 2006, EUR J IMMUNOL, V36, P2061, DOI 10.1002/eji.200626255; Katzenberger T, 2009, BLOOD, V113, P1053, DOI 10.1182/blood-2008-07-168682; Koning JJ, 2012, TRENDS IMMUNOL, V33, P264, DOI 10.1016/j.it.2011.10.006; Krautler NJ, 2012, CELL, V150, P194, DOI 10.1016/j.cell.2012.05.032; Kridel R, 2012, J CLIN INVEST, V122, P3424, DOI 10.1172/JCI63186; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Myers RC, 2013, EUR J IMMUNOL, V43, P348, DOI 10.1002/eji.201242471; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RADEMAKERS LHPM, 1992, CELL TISSUE RES, V269, P359, DOI 10.1007/BF00319629; Rodda LB, 2015, J IMMUNOL, V195, P4781, DOI 10.4049/jimmunol.1501191; Siddiqi IN, 2016, MODERN PATHOL, V29, P570, DOI 10.1038/modpathol.2016.51; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tumanov AV, 2002, IMMUNITY, V17, P239, DOI 10.1016/S1074-7613(02)00397-7; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883	35	0	0	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					124	134		10.1002/cjp2.97			11	Pathology	Pathology	GD2CH	WOS:000430307200006	29665320	DOAJ Gold, Green Published			2019-10-28	
J	Xu, J; Xu, L; Lau, YS; Gao, YD; Moore, SA; Han, RZ				Xu, Jing; Xu, Li; Lau, Yeh S.; Gao, Yandi; Moore, Steven A.; Han, Renzhi			A novel ANO5 splicing variant in a LGMD2L patient leads to production of a truncated aggregation-prone Ano5 peptide	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						aggregate; anoctamin; Ano5; LGMD2L; muscular dystrophy; TMEM16	MUSCULAR-DYSTROPHY; MEMBRANE REPAIR; FAMILY; MUTATIONS; PROTEINS; CHANNELS; TMEM16E; GDD1; DYSPLASIA; MEMBERS	Mutations in ANO5 cause several human diseases including gnathodiaphyseal dysplasia 1 (GDD1), limb-girdle muscular dystrophy 2L (LGMD2L), and Miyoshi myopathy 3 (MMD3). Previous work showed that complete genetic disruption of Ano5 in mice did not recapitulate human muscular dystrophy, while residual expression of mutant Ano5 in a gene trapped mouse developed muscular dystrophy with defective membrane repair. This suggests that truncated Ano5 expression may be pathogenic. Here, we screened a panel of commercial anti-Ano5 antibodies using a recombinant adenovirus expressing human Ano5 with FLAG and YFP at the N- and C-terminus, respectively. The monoclonal antibody (mAb) N421A/85 was found to specifically detect human Ano5 by immunoblotting and immunofluorescence staining. The antigen epitope was mapped to a region of 28 residues within the N-terminus. Immunofluorescence staining of muscle cryosections from healthy control subjects showed that Ano5 is localized at the sarcoplasmic reticulum. The muscle biopsy from a LGMD2L patient homozygous for the c.191dupA mutation showed no Ano5 signal, confirming the specificity of the N421A/85 antibody. Surprisingly, strong Ano5 signal was detected in a patient with compound heterozygous mutations (c.191dupA and a novel splice donor site variant c.363+4A>G at the exon 6-intron 6 junction). Interestingly, insertion of the mutant intron 6, but not the wild-type intron 6, into human ANO5 cDNA resulted in a major transcript that carried the first 158-bp of intron 6. Transfection of the construct encoding the first 121 amino acids into C2C12 cells resulted in protein aggregate formation, suggesting that aggregate-forming Ano5 peptide may contribute to the pathogenesis of muscular dystrophy.	[Xu, Jing; Xu, Li; Lau, Yeh S.; Gao, Yandi; Han, Renzhi] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Div Cardiovasc Med,Dept Cardiac Surg, Columbus, OH 43210 USA; [Moore, Steven A.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA	Han, RZ (reprint author), Ohio State Univ, Wexner Med Ctr, Davis Heart & Lung Res Inst, Dept Cardiac Surg, Biomed Res Tower 316, Columbus, OH 43210 USA.	renzhi.han@osumc.edu	Lau, Yeh Siang/D-2136-2016	Lau, Yeh Siang/0000-0002-1770-3058; Han, Renzhi/0000-0002-8202-9186	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL116546, AR064241, NS053672]	R.H. is supported by US National Institutes of Health grants (HL116546 and AR064241). S.A.M. is partially supported by US National Institutes of Health grant U54, NS053672 that funds the Iowa Wellstone Muscular Dystrophy Cooperative Research Center.	BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Brunner JD, 2014, NATURE, V516, P207, DOI 10.1038/nature13984; Duran C, 2012, AM J PHYSIOL-CELL PH, V302, pC482, DOI 10.1152/ajpcell.00140.2011; Duran C, 2011, ACTA PHARMACOL SIN, V32, P685, DOI 10.1038/aps.2011.48; Fallah G, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004697; Galindo BE, 2005, INT J MOL MED, V16, P919; Griffin DA, 2016, HUM MOL GENET, V25, P1900, DOI 10.1093/hmg/ddw063; Gyobu S, 2016, MOL CELL BIOL, V36, P645, DOI 10.1128/MCB.00919-15; Hartzell HC, 2009, J PHYSIOL-LONDON, V587, P2127, DOI 10.1113/jphysiol.2008.163709; Katoh M, 2004, AM J HUM GENET, V75, P927, DOI 10.1086/425341; Katoh M, 2004, INT J ONCOL, V24, P1345; Lek A, 2013, J NEUROSCI, V33, P5085, DOI 10.1523/JNEUROSCI.3560-12.2013; Liewluck T, 2013, EUR J NEUROL, V20, P1383, DOI 10.1111/ene.12191; Malvezzi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3367; Mizuta K, 2007, BIOCHEM BIOPH RES CO, V357, P126, DOI 10.1016/j.bbrc.2007.03.108; Park SH, 2011, ACTA CRYSTALLOGR F, V67, P1250, DOI 10.1107/S1744309111027989; Pedemonte N, 2014, PHYSIOL REV, V94, P419, DOI 10.1152/physrev.00039.2011; Penttila S, 2012, NEUROLOGY, V78, P897, DOI 10.1212/WNL.0b013e31824c4682; Pifferi S, 2012, EXP PHYSIOL, V97, P193, DOI 10.1113/expphysiol.2011.058230; Redpath GMI, 2014, MOL BIOL CELL, V25, P3037, DOI 10.1091/mbc.E14-04-0947; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Rock JR, 2008, DEV DYNAM, V237, P2566, DOI 10.1002/dvdy.21676; Sarkozy A, 2013, HUM MUTAT, V34, P1111, DOI 10.1002/humu.22342; Savarese M, 2015, NEUROMUSCULAR DISORD, V25, P533, DOI 10.1016/j.nmd.2015.03.011; Tran TT, 2014, J CELL PHYSIOL, V229, P181, DOI 10.1002/jcp.24431; Tsutsumi S, 2005, BIOCHEM BIOPH RES CO, V331, P1099, DOI 10.1016/j.bbrc.2005.03.226; van der Kooi AJ, 2013, NEUROMUSCULAR DISORD, V23, P456, DOI 10.1016/j.nmd.2013.03.012; Vaz-Pereira S, 2014, EYE, V28, P102, DOI 10.1038/eye.2013.247; Vihola A, 2018, NEUROPATH APPL NEURO, V44, P441, DOI 10.1111/nan.12410; Xu J, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0069-z; Yamamura Hisao, 2013, Folia Pharmacologica Japonica, V142, P144; Zhao PM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092749	33	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	APR	2018	4	2					135	145		10.1002/cjp2.92			11	Pathology	Pathology	GD2CH	WOS:000430307200007	29665321	DOAJ Gold, Green Published			2019-10-28	
J	Solomon, IH; Borscheid, R; Laga, AC; Askari, R; Granter, SR				Solomon, Isaac H.; Borscheid, Rene; Laga, Alvaro C.; Askari, Reza; Granter, Scott R.			Frozen sections are unreliable for the diagnosis of necrotizing soft tissue infections	MODERN PATHOLOGY			English	Article							LABORATORY RISK INDICATOR; INTRAOPERATIVE GRAM STAIN; EARLY RECOGNITION; UNITED-STATES; FASCIITIS; MANAGEMENT; BIOPSY; SURGERY	Necrotizing soft tissue infections are rare but are associated with high rates of morbidity and mortality. The use of bedside or intraoperative frozen sections has been reported to be associated with faster diagnosis and better outcomes; however, to date no large studies have been published to determine the sensitivity and specificity of frozen sections in this setting. Twenty years of cases suspicious for necrotizing soft tissue infection at a large academic referral center were reviewed, blinded to the final clinical diagnosis (gold standard). Cases were assessed for the number of neutrophils, extent of necrosis, presence of thrombi, bacteria, karyorrhexis, and fibrin, and concordance with permanent sections. A total of 166 cases suspicious for necrotizing soft tissue infection had frozen section slides available for review. Sixty-three cases were clinically determined to be positive and 103 negative. Neutrophils, necrosis, thrombi, bacteria, karyorrhexis, and fibrin were present in both positive and negative cases; however, no histological feature or combination of features was found to be both sensitive and specific for necrotizing soft tissue infection. The combined presence of necrosis and frequent neutrophils was 73% sensitive and 68% specific, with a 58% positive predictive value and 80% negative predictive value. The additional observation of bacteria decreased sensitivity to 32%, whereas raising specificity to 91%, with 69% positive predictive value and 68% negative predictive value. Thirty-two cases (19%) contained findings identified on permanent sections (eg, bacteria) not observed on frozen section slides, highlighting the risk of false negatives owing to technical limitations or sampling errors. Frozen sections in necrotizing soft tissue infections and negative cases may show similar histological findings. Combined with the risk of false negatives, these results suggest that frozen sections are likely to be of limited clinical utility due to lack of sensitivity and specificity, and risk for delayed diagnosis and treatment.	[Solomon, Isaac H.; Laga, Alvaro C.; Granter, Scott R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Borscheid, Rene; Askari, Reza] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Boston, MA USA; [Borscheid, Rene] Houston Methodist Hosp, Dept Surg, Houston, TX USA	Granter, SR (reprint author), Harvard Med Sch, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Granter, SR (reprint author), Harvard Med Sch, Pathol, 75 Francis St, Boston, MA 02115 USA.	sgranter@bwh.harvard.edu					Anaya DA, 2007, CLIN INFECT DIS, V44, P705, DOI 10.1086/511638; Andreasen TJ, 2001, PLAST RECONSTR SURG, V107, P1025, DOI 10.1097/00006534-200104010-00019; Angoules AG, 2007, INJURY, V38, pS19, DOI 10.1016/j.injury.2007.10.030; [Anonymous], 2014, CURR PROB SURG, V51, P344, DOI 10.1067/j.cpsurg.2014.06.001; Arif N, 2016, EPIDEMIOL INFECT, V144, P1338, DOI 10.1017/S0950268815002745; Burner E, 2016, WEST J EMERG MED, V17, P333, DOI 10.5811/westjem.2016.2.29069; Chaudhry AA, 2015, AM J ROENTGENOL, V204, P128, DOI 10.2214/AJR.14.12676; Childers BJ, 2002, AM SURGEON, V68, P109; Elliott D, 2000, AM J SURG, V179, P361, DOI 10.1016/S0002-9610(00)00360-3; Faraklas I, 2016, SURG INFECT, V17, P773, DOI 10.1089/sur.2015.238; Glass GE, 2015, ANN ROY COLL SURG, V97, P46, DOI 10.1308/003588414X14055925058553; Hietbrink F, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0108-z; HOWANITZ PJ, 1990, ARCH PATHOL LAB MED, V114, P355; Keung EZ, 2013, JAMA SURG, V148, P419, DOI 10.1001/jamasurg.2013.173; Majeski J, 1997, SOUTHERN MED J, V90, P1065, DOI 10.1097/00007611-199711000-00001; Malghem J, 2013, JOINT BONE SPINE, V80, P146, DOI 10.1016/j.jbspin.2012.08.009; Misiakos EP, 2014, FRONT SURG, V1, DOI 10.3389/fsurg.2014.00036; Morgan PM, 2009, J BONE JOINT SURG AM, V91A, P2124, DOI 10.2106/JBJS.H.00853; Psoinos CM, 2013, SURGERY, V153, P819, DOI 10.1016/j.surg.2012.11.026; Rudkjobing VB, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1976-2; Sartelli M, 2014, WORLD J EMERG SURG, V9, DOI 10.1186/1749-7922-9-57; Shifflett GD, 2015, SPINE J, V15, P2198, DOI 10.1016/j.spinee.2015.06.001; STAMENKOVIC I, 1984, NEW ENGL J MED, V310, P1689, DOI 10.1056/NEJM198406283102601; Stegeman SA, 2012, J TISSUE VIABILITY, V21, P13, DOI 10.1016/j.jtv.2011.10.002; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Swain RA, 2013, ANN ROY COLL SURG, V95, P57, DOI 10.1308/003588413X13511609956093; Tsitsilonis S, 2013, LANGENBECK ARCH SURG, V398, P153, DOI 10.1007/s00423-012-0983-z; Wang YS, 2007, INT J DERMATOL, V46, P1036, DOI 10.1111/j.1365-4632.2007.03201.x; White VA, 2008, ARCH PATHOL LAB MED, V132, P29, DOI 10.1043/1543-2165(2008)132[29:IFDCRT]2.0.CO;2; Wong CH, 2004, CRIT CARE MED, V32, P1535, DOI 10.1097/01.CCM.0000129486.35458.7D	30	1	1	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					546	552		10.1038/modpathol.2017.173			7	Pathology	Pathology	GD3LE	WOS:000430404600001	29243739	Bronze			2019-10-28	
J	Tian, XJ; Xu, J; Fletcher, C; Hornick, JL; Dorfman, DM				Tian, Xuejun; Xu, Jie; Fletcher, Christopher; Hornick, Jason L.; Dorfman, David M.			Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling	MODERN PATHOLOGY			English	Article							METHYLTRANSFERASE GENE EZH2; REPRESSIVE COMPLEX 2; SOMATIC MUTATIONS; MYELODYSPLASTIC SYNDROMES; HIGH PREVALENCE; BRAF MUTATIONS; CANCER CELLS; HISTONE H3; LYMPHOMA; SARCOMA	EZH2 is an important enzymatic subunit of the epigenetic regulator polycomb repressive complex 2 (PRC2), which controls gene silencing through post-translational modification, and is overexpressed in various carcinomas and hematopoietic neoplasms. We found that the majority of cases of histiocytic and dendritic cell neoplasms, including histiocytic sarcoma, follicular dendritic cell sarcoma, Langerhans cell histiocytosis, and interdigitating dendritic cell sarcoma, show strong EZH2 expression by immunohistochemical staining, in contrast to benign histiocytic lesions and normal cellular counterparts, which did not show EZH2 expression, suggesting that this molecule may function as an oncogenic protein in these neoplasms. We correlated EZH2 expression with that of p-ERK1/2, MYC, and p-STAT3, potential regulators of EZH2, and found that 60-80% of these cases showed strong p-ERK1/2 expression, and only a minority of cases showed positivity for MYC or p-STAT3 in neoplastic cells. In cases of follicular dendritic cell sarcoma, Langerhans cell histiocytosis, histiocytic sarcoma, and interdigitating dendritic cell sarcoma with strong EZH2 expression, 90%, 89%, 70%, and 100% of cases showed co-expression of p-ERK1/2 with EZH2, respectively, while only a small percentage of these cases showed MYC or p-STAT3 co-expression with EZH2 (<= 30%). These findings suggest that the p-ERK1/2 signaling cascade, but not the p-STAT3 and MYC signaling cascades, may regulate EZH2 expression in histiocytic and dendritic cell neoplasms, and that EZH2 and the p-ERK1/2 signaling cascade could serve as therapeutic targets for the treatment of these neoplasms. Interestingly, only a minority of cases of blastic plasmacytoid dendritic cell neoplasm exhibited high EZH2 expression, and only a minority of these cases showed p-ERK1/2 co-expression, suggesting that alternative mechanisms may contribute to tumorigenesis in this aggressive neoplasm.	[Tian, Xuejun; Xu, Jie; Fletcher, Christopher; Hornick, Jason L.; Dorfman, David M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Tian, Xuejun; Xu, Jie; Fletcher, Christopher; Hornick, Jason L.; Dorfman, David M.] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Tian, Xuejun] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA	Dorfman, DM (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Dorfman, DM (reprint author), Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.	ddorfman@bwh.harvard.edu					Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Brown NA, 2014, BLOOD, V124, P1655, DOI 10.1182/blood-2014-05-577361; Bubolz AM, 2014, ONCOTARGET, V5, P4060, DOI 10.18632/oncotarget.2061; Ceribelli M, 2016, CANCER CELL, V30, P764, DOI 10.1016/j.ccell.2016.10.002; Chakraborty R, 2014, BLOOD, V124, P3007, DOI 10.1182/blood-2014-05-577825; Di Liso E, 2015, CANCER BIOL THER, V16, P1128, DOI 10.1080/15384047.2015.1057359; Dorfman DM, 2016, TRANSL CANCER RES, V5, pS1057, DOI 10.21037/tcr.2016.11.18; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Fedoriw Y, 2014, LEUKEMIA LYMPHOMA, V56, P1132; Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Garapaty-Rao S, 2013, CHEM BIOL, V20, P1329, DOI 10.1016/j.chembiol.2013.09.013; Gatalica Z, 2015, ONCOTARGET, V6, P19819, DOI 10.18632/oncotarget.4378; Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; Herviou L, 2016, ONCOTARGET, V7, P2284, DOI 10.18632/oncotarget.6198; Huang WT, 2016, ONCOTARGET, V7, P78355, DOI 10.18632/oncotarget.13058; Idbaih A, 2014, NEUROLOGY, V83, P1478, DOI 10.1212/WNL.0000000000000880; Jiang T, 2016, ONCOTARGET, V7, P4584, DOI 10.18632/oncotarget.6612; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179; Liu QQ, 2016, VIRCHOWS ARCH, V469, P233, DOI 10.1007/s00428-016-1965-2; Majer CR, 2012, FEBS LETT, V586, P3448, DOI 10.1016/j.febslet.2012.07.066; Makishima H, 2010, LEUKEMIA, V24, P1799, DOI 10.1038/leu.2010.167; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; O'Malley DP, 2015, ANN DIAGN PATHOL, V19, P113, DOI 10.1016/j.anndiagpath.2015.02.008; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Rjoop A, 2016, CASE REPORTS CLIN PA, V3, P45; Score J, 2012, BLOOD, V119, P1208, DOI 10.1182/blood-2011-07-367243; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Shi M, 2015, LEUKEMIA LYMPHOMA, V56, P2087, DOI 10.3109/10428194.2014.968780; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tian XJ, 2016, MODERN PATHOL, V29, P1050, DOI 10.1038/modpathol.2016.114; Vaughn John L, 2017, J Med Case Rep, V11, P92, DOI 10.1186/s13256-017-1253-z; Wee S, 2014, ANN NY ACAD SCI, V1309, P30, DOI 10.1111/nyas.12356; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Yan JL, 2016, BLOOD, V128, P948, DOI 10.1182/blood-2016-01-690701; Yan JL, 2013, BLOOD, V121, P4512, DOI 10.1182/blood-2012-08-450494	46	5	5	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					553	561		10.1038/modpathol.2017.174			9	Pathology	Pathology	GD3LE	WOS:000430404600002	29327713	Bronze			2019-10-28	
J	Lin, CY; Mooney, K; Choy, W; Yang, SR; Barry-Holson, K; Horst, K; Wapnir, I; Allison, K				Lin, Chieh-Yu; Mooney, Kelly; Choy, Winward; Yang, Soo-Ryum; Barry-Holson, Keegan; Horst, Kathleen; Wapnir, Irene; Allison, Kimberly			Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions	MODERN PATHOLOGY			English	Article							CARCINOMA IN-SITU; NUYS PROGNOSTIC INDEX; RECURRENCE-SCORE; BREAST-CANCER; PREDICT; VALIDATION; UNIVERSITY; EQUATIONS; FEATURES; IMPACT	Given the increased detection rates of ductal carcinoma in situ (DCIS) and the limited overall survival benefit from adjuvant breast irradiation after breast-conserving surgery, there is interest in identifying subsets of patients who have low rates of ipsilateral breast tumor recurrence such that they might safely forgo radiation. The Oncotype DCIS score is a reverse transcription-PCR (RT-PCR)-based assay that was validated to predict which DCIS cases are most likely to recur. Clinically, these results may be used to assist in selecting which patients with DCIS might safely forgo radiation therapy after breast-conserving surgery; however, little is currently published on how this test is being used in practice. Our study examines traditional histopathologic features used in predicting DCIS risk with Oncotype DCIS results and how these results affect clinical decision-making at our academic institution. Histopathologic features and management decisions for 37 cases with Oncotype DCIS results over the past 4 years were collected. Necrosis, high nuclear grade, biopsy site change, estrogen receptor and progesterone receptor positivity < 90% on immunohistochemistry, and Van Nuys Prognostic Index score of 8 or greater were significant predictors of an intermediate-high recurrence score on multivariate regression analysis (P < 0.02). Low Oncotype DCIS scores and low nuclear grade were associated with lower rate of radiation therapy (P < 0.008). There were seven cases (19%) with Oncotype DCIS results that we considered unexpected in relation to the histopathologic findings (ie, high nuclear grade with comedonecrosis and a low Oncotype score, or hormone receptor discrepancies). Overall, pathologic features correlate with Oncotype DCIS scores but unexpected results do occur, making individual recommendations sometimes challenging.	[Lin, Chieh-Yu; Mooney, Kelly; Yang, Soo-Ryum; Barry-Holson, Keegan; Allison, Kimberly] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Choy, Winward] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Horst, Kathleen] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA; [Wapnir, Irene] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	Allison, K (reprint author), Stanford Univ, Sch Med, Dept Pathol, Breast Pathol, 300 Pasteur Dr, Stanford, CA 94304 USA.	allisonk@stanford.edu					Acs G, 2012, MODERN PATHOL, V25, P556, DOI 10.1038/modpathol.2011.194; Allison KH, 2012, BREAST CANCER RES TR, V131, P413, DOI 10.1007/s10549-011-1416-3; Alvarado M, 2015, J SURG ONCOL, V111, P935, DOI 10.1002/jso.23933; Auerbach J, 2010, ARCH PATHOL LAB MED, V134, P1697, DOI 10.1043/2009-0439-OAR.1; Cadiz F, 2011, LANCET ONCOL, V12, P21; Dabbs DJ, 2011, J CLIN ONCOL, V29, P4279, DOI 10.1200/JCO.2011.34.7963; Eaton AA, 2017, BREAST CANCER RES TR, V161, P435, DOI 10.1007/s10549-016-4069-4; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Flanagan MB, 2008, MODERN PATHOL, V21, P1255, DOI 10.1038/modpathol.2008.54; Harowicz MR, 2017, BREAST CANCER RES TR, V162, P1, DOI 10.1007/s10549-016-4093-4; Klein ME, 2013, MODERN PATHOL, V26, P658, DOI 10.1038/modpathol.2013.36; Knopfelmacher A, 2015, MODERN PATHOL, V28, P1167, DOI 10.1038/modpathol.2015.79; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Rakovitch E, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw256; Rakovitch E, 2015, BREAST CANCER RES TR, V152, P389, DOI 10.1007/s10549-015-3464-6; Raldow AC, 2016, J CLIN ONCOL, V34, P3963, DOI 10.1200/JCO.2016.67.8532; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silverstein Melvin J., 2010, Journal of the National Cancer Institute Monographs, P193, DOI 10.1093/jncimonographs/lgq040; Silverstein MJ, 2003, BREAST, V12, P457, DOI 10.1016/S0960-9776(03)00153-X; Silverstein MJ, 2003, AM J SURG, V186, P337, DOI 10.1016/S0002-9610(03)00265-4; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Turner BM, 2015, MODERN PATHOL, V28, P921, DOI 10.1038/modpathol.2015.50; Wapnir IL, 2011, J NATL CANCER I, V103, P478, DOI 10.1093/jnci/djr027	24	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					562	568		10.1038/modpathol.2017.172			7	Pathology	Pathology	GD3LE	WOS:000430404600003	29243740				2019-10-28	
J	Yeung, CCS; McElhone, S; Chen, XY; Ng, D; Storer, BE; Deeg, HJ; Fang, M				Yeung, Cecilia C. S.; McElhone, Scott; Chen, Xue Yan; Ng, David; Storer, Barry E.; Deeg, H. Joachim; Fang, Min			Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome	MODERN PATHOLOGY			English	Article							WORLD-HEALTH-ORGANIZATION; SNP-ARRAY; UNIPARENTAL DISOMY; HOMOZYGOUS MUTATIONS; CELL TRANSPLANTATION; CHROMOSOMAL LESIONS; PROGNOSTIC IMPACT; LEUKEMIA; CLASSIFICATION; MDS	Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases with varying genetic aberrations. Half of MDS patients have normal karyotype, obscuring the underlying condition indicating a need for new markers for improved diagnostics and prognosis. We performed a retrospective review of sequential MDS patients who underwent chromosomal genetic array testing (CGAT) between November 2008 and March 2014. Total Genomic Aberration (TGA) scores, with and without copy-neutral loss of heterozygosity (cnLOH), were compared to pathology and clinical data. Of 68 MDS participants, 50 patients (73%) had abnormal CGAT results. 32% showedcnLOH, 41% had no cnLOH but displayed copy number aberration (CNAs). Of 26 patients with normal cytogenetics, 46% had clonal abnormalities by CGAT. Abnormal CGAT results were associated with lower overall survival (P = 0.04). Overall survival in patients with TGA above the median (68.6 Mb) was significantly inferior to those below the median (HR = 2.9, 95% CI = 1.3-6.8, P = 0.01). Furthermore, there was an observed association between increased TGA and increased dysplastic lineages (Ptrend=0.003). CGAT studies provide important findings that extend beyond current standard testing. Clinical utility of CGAT includes improved diagnostic yield, correlation of extent of TGA and increased dysplastic features, and survival.	[Yeung, Cecilia C. S.; Storer, Barry E.; Deeg, H. Joachim; Fang, Min] Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,G7-910, Seattle, WA 98109 USA; [Yeung, Cecilia C. S.; Fang, Min] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Yeung, Cecilia C. S.; McElhone, Scott; Fang, Min] Seattle Canc Care Alliance, Seattle, WA USA; [Chen, Xue Yan] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Ng, David] Phenopath, Seattle, WA USA; [Storer, Barry E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Deeg, H. Joachim] Univ Washington, Dept Med, Seattle, WA USA	Yeung, CCS (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,G7-910, Seattle, WA 98109 USA.	cyeung@fredhutch.org			Pilot & Feasibility grant under the Core Center of Excellence in Hematology [P30 DK056465]; Cancer Center Support Grant [P30 CA015704]; Adult Leukemia Research Center Grant - National Cancer Institute, National Institutes of Health, Bethesda, MD [P01 CA018029]; GileadGilead Sciences; Affymetrix	We thank the Seattle Cancer Care Alliance cytogenetics laboratory for the chromosome genomic array testing and karyotype data; UW Hematopathology Flow cytometry laboratory for the flow cytometry data; the UW Genomics and Molecular Pathology laboratory for next-generation sequencing and molecular data; and the Seattle Cancer Care Alliance Pathology Laboratory for the pathology slides and organization of the cases for review. This study was supported in part by a Pilot & Feasibility grant awarded to M. Fang under the Core Center of Excellence in Hematology Grant # P30 DK056465 and with support from the Cancer Center Support Grant # P30 CA015704 and Adult Leukemia Research Center Grant # P01 CA018029 as funded by the National Cancer Institute, National Institutes of Health, Bethesda, MD. CY received research funding from Gilead and MF received research funding from Affymetrix for projects that are unrelated to this manuscript.	Afable MG, 2011, BLOOD, V117, P6876, DOI 10.1182/blood-2010-11-314393; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Arenillas L, 2013, GENE CHROMOSOME CANC, V52, P1167, DOI 10.1002/gcc.22112; Bacher U, 2014, BRIT J HAEMATOL, V164, P822, DOI 10.1111/bjh.12710; Bhatnagar B, 2009, J CLIN ONCOL, V27; Cluzeau T, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.52; Deeg HJ, 2013, J NATL COMPR CANC NE, V11, P1227, DOI 10.6004/jnccn.2013.0145; Deeg HJ, 2012, ARCH IMMUNOL THER EX, V60, P31, DOI 10.1007/s00005-011-0152-z; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; Fang M, 2012, CANCER-AM CANCER SOC, V118, P2411, DOI 10.1002/cncr.26539; Ganster C, 2015, LEUKEMIA RES, V39, P1079, DOI 10.1016/j.leukres.2015.06.011; GHADDAR HM, 1994, LEUKEMIA, V8, P1649; Giagounidis A, 2013, BEST PRACT RES CL HA, V26, P337, DOI 10.1016/j.beha.2013.09.004; Glauser TA, 2013, LEUKEMIA RES, V37, P1656, DOI 10.1016/j.leukres.2013.10.007; Gondek LP, 2008, BLOOD, V111, P1534, DOI 10.1182/blood-2007-05-092304; Gronseth CMS, 2016, CAP TODAY, P82; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Hagenkord JM, 2010, J MOL DIAGN, V12, P184, DOI 10.2353/jmoldx.2010.090118; Heinrichs S, 2009, LEUKEMIA, V23, P1605, DOI 10.1038/leu.2009.82; Huh J, 2013, GENE CHROMOSOME CANC, V52, P44, DOI 10.1002/gcc.22005; Jankowska AM, 2009, BLOOD, V113, P6403, DOI 10.1182/blood-2009-02-205690; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Merkerova MD, 2012, GENE CHROMOSOME CANC, V51, P419, DOI 10.1002/gcc.21927; Mohamedali A, 2007, BLOOD, V110, P3365, DOI 10.1182/blood-2007-03-079673; O'Keefe C, 2010, BLOOD, V115, P2731, DOI 10.1182/blood-2009-10-201848; Palomo L, 2016, AM J HEMATOL, V91, P185, DOI 10.1002/ajh.24227; Paulsson K, 2006, LEUKEMIA, V20, P840, DOI 10.1038/sj.leu.2404145; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Shaffer LG, 2013, ISCN 2013 INT SYSTEM; Shaffer Lisa G, 2013, Methods Mol Biol, V973, P69, DOI 10.1007/978-1-62703-281-0_5; Singh NR, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-59; Slovak ML, 2010, MOL CYTOGENET, V3, DOI 10.1186/1755-8166-3-23; Svobodova K, 2016, LEUKEMIA RES, V42, P7, DOI 10.1016/j.leukres.2016.01.009; Swerdlow SH, 2008, WHO CLASSIFICATION T, P92; Tiu RV, 2011, BLOOD, V117, P4552, DOI 10.1182/blood-2010-07-295857; Vardiman J, 2011, HEMATOL-AM SOC HEMAT, P250, DOI 10.1182/asheducation-2011.1.250; Vardiman JW, 2010, CHEM-BIOL INTERACT, V184, P16, DOI 10.1016/j.cbi.2009.10.009; Volkert S, 2016, LEUKEMIA, V30, P257, DOI 10.1038/leu.2015.257; Wang L, 2014, LEUKEMIA, V28, P938, DOI 10.1038/leu.2014.20; Wood BL, 2005, CURRENT PROTOCOLS CY, P21; Xu XJ, 2013, CANCER GENET-NY, V206, P317, DOI 10.1016/j.cancergen.2013.09.001; Zeidan AM, 2013, J HOSP MED, V8, P351, DOI 10.1002/jhm.2049	43	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					569	580		10.1038/modpathol.2017.157			12	Pathology	Pathology	GD3LE	WOS:000430404600004	29243741	Green Accepted			2019-10-28	
J	Ozkaya, N; Rosenblum, MK; Durham, BH; Pichardo, JD; Abdel-Wahab, O; Hameed, MR; Busam, KJ; Travis, WD; Diamond, EL; Dogan, A				Ozkaya, Neval; Rosenblum, Marc K.; Durham, Benjamin H.; Pichardo, Janine D.; Abdel-Wahab, Omar; Hameed, Meera R.; Busam, Klaus J.; Travis, William D.; Diamond, Eli L.; Dogan, Ahmet			The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort	MODERN PATHOLOGY			English	Review							KINASE ALTERATIONS; MUTATIONS	Erdheim-Chester disease is a rare, non-Langerhans cell histiocytosis histologically characterized by multi-systemic proliferation of mature histiocytes in a background of inflammatory stroma. The disease can involve virtually any organ system; most commonly the bones, skin, retroperitoneum, heart, orbit, lung, and brain are affected. Although a histiocytic proliferation is the histological hallmark of the disease, a wide range of morphological appearances have been described as part of case studies or small series. A comprehensive review of histopathological features in clinically and molecularly defined Erdheim-Chester disease has yet to be characterized. To address this issue and help guide clinical practice, we comprehensively analyzed the pathological spectrum of Erdheim-Chester disease in a clinically and molecularly defined cohort. We reviewed 73 biopsies from 42 patients showing involvement by histiocytosis from a variety of organ systems, including bone (16), retroperitoneum (11), skin (19), orbit (6), brain (5), lung (6), cardiac structures (2), epidural soft tissue (3), oral cavity (2), subcutaneous soft tissue (2), and testis (2). In eight patients, one or more bone marrow biopsies were performed due to clinical indication and an accompanying myeloid neoplasm was detected in six of them. Thirty-eight cases were investigated for genetic abnormalities. Somatic mutations involving BRAF (25/38), MAP2K1 (6/38), ARAF (2/38), MAP2K2 (1/38), KRAS (1/38), and NRAS (1/38) genes were detected. One of the cases with a MAP2K1 mutation also harbored a PIK3CA mutation. We have observed marked heterogeneity in histology and immunophenotype, identified site-specific features, overlap with other histiocytic and myeloid disorders and potential diagnostic pitfalls. We hope that broadening the spectrum of recognized pathologic manifestations of Erdheim-Chester disease will help practicing clinicians and pathologists to diagnose Erdheim-Chester disease early in the disease course and manage these patients effectively.	[Ozkaya, Neval; Rosenblum, Marc K.; Pichardo, Janine D.; Hameed, Meera R.; Busam, Klaus J.; Travis, William D.; Dogan, Ahmet] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Durham, Benjamin H.; Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, Human Oncol Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Diamond, Eli L.] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA	Dogan, A (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	dogana@mskcc.org		Durham, Benjamin/0000-0001-8090-5448	Sloan Kettering Institute for Cancer Research Cancer Center Support Grant [P30CA008748]; American Society of Hematology Senior Research Training Award; New York State Council on Graduate Medical Education Empire Clinical Research Investigator Program Fellowship; Erdheim-Chester Disease Global Alliance; Edward P. Evans Foundation; Dept. of Defense Bone Marrow Failure Research Program [BM150092, W81XWH-12-1-0041]; NIH/NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL128239]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K08CA160647-01]; Josie Robertson Investigator Program; Damon Runyon Clinical Investigator Award; Starr Foundation [I8-A8-075]; Leukemia and Lymphoma SocietyLeukemia and Lymphoma Society; Pershing Square Sohn Cancer Research Alliance; Histiocytosis Association	This study was supported in part by the Sloan Kettering Institute for Cancer Research Cancer Center Support Grant (P30CA008748). BHD is supported by the American Society of Hematology Senior Research Training Award for Fellows and the New York State Council on Graduate Medical Education Empire Clinical Research Investigator Program Fellowship. ELD and OA-W are supported by grants from the Erdheim-Chester Disease Global Alliance and the Histiocytosis Association. OA-W is supported by grants from the Edward P. Evans Foundation, the Dept. of Defense Bone Marrow Failure Research Program (BM150092 and W81XWH-12-1-0041), NIH/NHLBI (R01 HL128239), an NIH K08 Clinical Investigator Award (1K08CA160647-01), the Josie Robertson Investigator Program, a Damon Runyon Clinical Investigator Award, an award from the Starr Foundation (I8-A8-075), the Leukemia and Lymphoma Society, and the Pershing Square Sohn Cancer Research Alliance.	Arnaud L, 2011, BLOOD, V117, P2783, DOI 10.1182/blood-2010-10-313510; Cavalli G, 2013, ANN RHEUM DIS, V72, P1691, DOI 10.1136/annrheumdis-2012-202542; Colomba E, 2013, J MOL DIAGN, V15, P94, DOI 10.1016/j.jmoldx.2012.09.001; Diamond EL, 2016, BLOOD, V128, P1896, DOI 10.1182/blood-2016-06-725143; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Diamond EL, 2014, BLOOD, V124, P483, DOI 10.1182/blood-2014-03-561381; Diamond EL, 2013, BLOOD, V122, P1089, DOI 10.1182/blood-2013-02-482984; Estrada-Veras JI, 2017, BLOOD ADV, V1, P357, DOI 10.1182/bloodadvances.2016001784; Gianfreda D, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003625; Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140; Hyman DM, 2015, CANCER DISCOV, V5, P64, DOI 10.1158/2159-8290.CD-14-0742; Mazor RD, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-137; Ozkaya N, 2017, HEMATOL ONCOL CLIN N, V31, P705, DOI 10.1016/j.hoc.2017.04.008; Papo M, 2017, BLOOD, V130, P1007, DOI 10.1182/blood-2017-01-761718	14	8	8	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					581	597		10.1038/modpathol.2017.160			17	Pathology	Pathology	GD3LE	WOS:000430404600005	29192649	Green Accepted, Bronze			2019-10-28	
J	Rosen, LE; Karrison, T; Ananthanarayanan, V; Gallan, AJ; Adusumilli, PS; Alchami, FS; Attanoos, R; Brcic, L; Butnor, KJ; Galateau-Salle, F; Hiroshima, K; Kadota, K; Klampatsa, A; Le Stang, N; Lindenmann, J; Litzky, LA; Marchevsky, A; Medeiros, F; Montero, MA; Moore, DA; Nabeshima, K; Pavlisko, EN; Roggli, VL; Sauter, JL; Sharma, A; Sheaff, M; Travis, WD; Vigneswaran, WT; Vrugt, B; Walts, AE; Tjota, MY; Krausz, T; Husain, AN				Rosen, Lauren E.; Karrison, Theodore; Ananthanarayanan, Vijayalakshmi; Gallan, Alexander J.; Adusumilli, Prasad S.; Alchami, Fouad S.; Attanoos, Richard; Brcic, Luka; Butnor, Kelly J.; Galateau-Salle, Francoise; Hiroshima, Kenzo; Kadota, Kyuichi; Klampatsa, Astero; Le Stang, Nolween; Lindenmann, Joerg; Litzky, Leslie A.; Marchevsky, Alberto; Medeiros, Filomena; Montero, M. Angeles; Moore, David A.; Nabeshima, Kazuki; Pavlisko, Elizabeth N.; Roggli, Victor L.; Sauter, Jennifer L.; Sharma, Anupama; Sheaff, Michael; Travis, William D.; Vigneswaran, Wickii T.; Vrugt, Bart; Walts, Ann E.; Tjota, Melissa Y.; Krausz, Thomas; Husain, Aliya N.			Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study	MODERN PATHOLOGY			English	Article							SURVIVAL; CANCER	A recently described nuclear grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The current study was undertaken to validate the grading system and to identify additional prognostic factors. We analyzed cases of epithelioid malignant pleural mesothelioma from 17 institutions across the globe from 1998 to 2014. Nuclear grade was computed combining nuclear atypia and mitotic count into a grade of I-III using the published system. Nuclear grade was assessed by one pathologist for three institutions, the remaining were scored independently. The presence or absence of necrosis and predominant growth pattern were also evaluated. Two additional scoring systems were evaluated, one combining nuclear grade and necrosis and the other mitotic count and necrosis. Median overall survival was the primary endpoint. A total of 776 cases were identified including 301 (39%) nuclear grade I tumors, 354 (45%) grade III tumors and 121 (16%) grade III tumors. The overall survival was 16 months, and correlated independently with age (P = 0.006), sex (0.015), necrosis (0.030), mitotic count (0.001), nuclear atypia (0.009), nuclear grade (< 0.0001), and mitosis and necrosis score (< 0.0001). The addition of necrosis to nuclear grade further stratified overall survival, allowing classification of epithelioid malignant pleural mesothelioma into four distinct prognostic groups: nuclear grade I tumors without necrosis (29 months), nuclear grade I tumors with necrosis and grade II tumors without necrosis (16 months), nuclear grade II tumors with necrosis (10 months) and nuclear grade III tumors (8 months). The mitosis-necrosis score stratified patients by survival, but not as well as the combination of necrosis and nuclear grade. This study confirms that nuclear grade predicts survival in epithelioid malignant pleural mesothelioma, identifies necrosis as factor that further stratifies overall survival, and validates the grading system across multiple institutions and among both biopsy and resection specimens. An alternative scoring system, the mitosis-necrosis score is also proposed.	[Rosen, Lauren E.; Gallan, Alexander J.; Tjota, Melissa Y.; Krausz, Thomas; Husain, Aliya N.] Univ Chicago Med, Dept Pathol, Chicago, IL USA; [Karrison, Theodore] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA; [Ananthanarayanan, Vijayalakshmi] Loyola Univ, Med Ctr, Dept Pathol, Chicago, IL 60611 USA; [Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, Dept Thorac Surg, 1275 York Ave, New York, NY 10021 USA; [Alchami, Fouad S.] Univ Hosp Wales, Dept Cell Pathol, Cardiff, S Glam, Wales; [Attanoos, Richard] Univ Hosp Wales, Dept Cellular Pathol, Cardiff, S Glam, Wales; [Attanoos, Richard] Cardiff Univ, Cardiff, S Glam, Wales; [Brcic, Luka] Med Univ Graz, Inst Pathol, Graz, Austria; [Butnor, Kelly J.] Univ Vermont, Dept Pathol, Med Ctr, Burlington, VT 05405 USA; [Galateau-Salle, Francoise] Ctr Leon Berard, BioPathol, Lyon, France; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, Yachiyo, Japan; [Kadota, Kyuichi] Kagawa Univ, Dept Diagnost Pathol, Takamatsu, Kagawa, Japan; [Klampatsa, Astero] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Lindenmann, Joerg] Med Univ Graz, Dept Surg, Div Thorac & Hyperbar Surg, Graz, Austria; [Litzky, Leslie A.] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; [Marchevsky, Alberto; Walts, Ann E.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Medeiros, Filomena] Basildon & Thurrock Univ Hosp, Dept Pathol, Basildon, England; [Montero, M. Angeles] Imperial Coll London, Royal Brompton Hosp, Dept Histopathol, London, England; [Montero, M. Angeles] Imperial Coll London, Harefield Hosp, Dept Histopathol, London, England; [Moore, David A.] Univ Leicester, Dept Canc Studies, Leicester, Leics, England; [Nabeshima, Kazuki] Fukuoka Univ, Dept Pathol, Fukuoka, Japan; [Pavlisko, Elizabeth N.; Roggli, Victor L.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Sauter, Jennifer L.; Travis, William D.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Sharma, Anupama] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA; [Sharma, Anupama] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Sheaff, Michael] Barts Hlth NHS Trust, Dept Pathol, London, England; [Vigneswaran, Wickii T.] Loyola Univ, Med Ctr, Dept Thorac & Cardiovasc Surg, Chicago, IL 60611 USA; [Vrugt, Bart] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Zurich, Switzerland	Husain, AN (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC6101, Chicago, IL 60637 USA.	Aliya.Husain@uchospitals.edu		Klampatsa, Astero/0000-0003-0572-502X; Brcic, Luka/0000-0002-9098-8416	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]		BAAK JPA, 1990, HUM PATHOL, V21, P683, DOI 10.1016/0046-8177(90)90026-2; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Campbell NP, 2011, SEMIN RESP CRIT CARE, V32, P102, DOI 10.1055/s-0031-1272874; COX DR, 1972, J R STAT SOC B, V34, P187; Cross SS, 1998, HISTOPATHOLOGY, V33, P99, DOI 10.1046/j.1365-2559.1998.00495.x; Dalton LW, 2000, MODERN PATHOL, V13, P730, DOI 10.1038/modpathol.3880126; Galateau-Salle F, 2015, WHO CLASSIFICATION T, V7, P156; Habougit C, 2017, VIRCHOWS ARCH, V470, P639, DOI 10.1007/s00428-017-2109-z; Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA; Kadota K, 2012, MODERN PATHOL, V25, P260, DOI 10.1038/modpathol.2011.146; Kadota K, 2011, J THORAC ONCOL, V6, P896, DOI 10.1097/JTO.0b013e318211127a; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kay R., 1977, APPL STATIST, P227; Kotova S, 2015, CANCER MANAG RES, V7, P51, DOI 10.2147/CMAR.S72814; Rusch VW, 2012, J THORAC ONCOL, V7, P1631, DOI 10.1097/JTO.0b013e31826915f1; Sugarbaker DJ, 2013, J THORAC CARDIOV SUR, V145, P955, DOI 10.1016/j.jtcvs.2012.12.037; Taioli W, 2015, PLOS ONE, V10; Thompson LDR, 2002, AM J SURG PATHOL, V26, P551, DOI 10.1097/00000478-200205000-00002; Van Schil PE, 2014, EUR RESPIR J, V44, P754, DOI 10.1183/09031936.00207213; Zellos L, 2014, THORAC SURG CLIN, V14, P469	20	10	10	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					598	606		10.1038/modpathol.2017.170			9	Pathology	Pathology	GD3LE	WOS:000430404600006	29327706	Bronze			2019-10-28	
J	Pfitzner, BM; Lederer, B; Lindner, J; Solbach, C; Engels, K; Rezai, M; Dohnal, K; Tesch, H; Hansmann, ML; Salat, C; Beer, M; Schneeweiss, A; Sinn, P; Bankfalvi, A; Darb-Esfahani, S; von Minckwitz, G; Sinn, BV; Kronenwett, R; Weber, K; Denkert, C; Loibl, S				Pfitzner, Berit M.; Lederer, Bianca; Lindner, Judith; Solbach, Christine; Engels, Knut; Rezai, Mahdi; Dohnal, Karel; Tesch, Hans; Hansmann, Martin L.; Salat, Christoph; Beer, Michaela; Schneeweiss, Andreas; Sinn, Peter; Bankfalvi, Agnes; Darb-Esfahani, Silvia; von Minckwitz, Gunter; Sinn, Bruno V.; Kronenwett, Ralf; Weber, Karsten; Denkert, Carsten; Loibl, Sibylle			Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years	MODERN PATHOLOGY			English	Article							PARAFFIN-EMBEDDED TISSUE; TAXANE-BASED CHEMOTHERAPY; III RANDOMIZED GEPARTRIO; NEOADJUVANT CHEMOTHERAPY; GBG 44; ESTROGEN-RECEPTOR; AMERICAN-SOCIETY; MESSENGER-RNA; PHASE-3 TRIAL; CANCER	Human epidermal growth factor receptor 2 (HER2) is a central predictive biomarker in breast cancer. Inaccurate HER2 results in different laboratories could be as high as 20%. However, this statement is based on data generated more than 13 years ago and may not reflect the standards of modern diagnostic pathology. We compared central and local HER2 testing in a total of 1581 HER2-positive tumors from five clinical trials. We evaluated the clinical relevance for pathological complete response (pCR) and disease-free survival in a subgroup of 677 tumors, which received an anti-HER2 therapy. Over the period of 12 years, the discordance rate for HER2 decreased from 52.4 (GeparTrio) to 8.4% (GeparSepto). Discordance rates were significantly higher in hormone receptor (HR)-positive tumors (26.6%), compared to HR-negative tumors (16.3%, P < 0.0001), which could be explained by a different distribution of HER2 mRNA levels in HR-positive and HR-negative tumors. pCR rates were significantly lower in discordant tumors (13.7%) compared to concordant tumors (32.2%, GeparQuattro and GeparQuinto, P < 0.001). In survival analysis, tumors with discordant HER2 testing had a reduced overall survival (OS) in the HR-negative group (P = 0.019) and a trend for improved OS in the HR-positive group (P = 0.125). The performance of local HER2 testing was considerably improved over time and has reached a 92% concordance, which shows that quality initiatives in diagnostic pathology are working. Tumors with discordant HER2 testing had a reduced therapy response and different survival rates.	[Pfitzner, Berit M.; Lindner, Judith; Darb-Esfahani, Silvia; Sinn, Bruno V.; Denkert, Carsten] Charite Univ Med Berlin, Inst Pathol, Campus Mitte,Charitepl 1, D-10117 Berlin, Germany; [Lederer, Bianca; von Minckwitz, Gunter; Weber, Karsten] German Breast Grp, Neu Isenburg, Germany; [Lindner, Judith; Denkert, Carsten] German Canc Consortium DKTK, Berlin, Germany; [Lindner, Judith] German Canc Res Ctr, Heidelberg, Germany; [Solbach, Christine] Univ Womens Hosp Frankfurt, Frankfurt, Germany; [Engels, Knut] Ctr Pathol Cytol & Mol Pathol Neuss, Neuss, Germany; [Rezai, Mahdi] Luisen Hosp, European Breast Ctr, Dusseldorf, Germany; [Dohnal, Karel] Ctr Pathol & Cytol Dusseldorf, Dusseldorf, Germany; [Tesch, Hans] Oncol Bethanien, Frankfurt, Germany; [Hansmann, Martin L.] Univ Hosp Frankfurt, Inst Pathol, Frankfurt, Germany; [Schneeweiss, Andreas] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Div Gynecol Oncol, Heidelberg, Germany; [Sinn, Peter] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Bankfalvi, Agnes] Univ Hosp Essen, Inst Pathol Essen, Essen, Germany; [Darb-Esfahani, Silvia] Inst Pathol Spandau, Berlin, Germany; [Kronenwett, Ralf] Sividon Diagnost GmbH, Cologne, Germany; [Loibl, Sibylle] Sana Klinikum Offenbach, Gynecol Hosp, Offenbach, Germany	Pfitzner, BM (reprint author), Charite Univ Med Berlin, Inst Pathol, Campus Mitte,Charitepl 1, D-10117 Berlin, Germany.	berit.pfitzner@charite.de	Sinn, Hans-Peter/C-5661-2008	Sinn, Hans-Peter/0000-0003-2836-6699; Lindner, Judith Lea/0000-0003-2223-4468; Lederer, Bianca/0000-0002-4512-2226			Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bohmann K, 2009, CLIN CHEM, V55, P1719, DOI 10.1373/clinchem.2008.122572; Choritz H, 2011, VIRCHOWS ARCH, V459, P283, DOI 10.1007/s00428-011-1132-8; Denkert C, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3384; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Gerber B, 2013, ANN ONCOL, V24, P2978, DOI 10.1093/annonc/mdt361; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hennig G, 2010, CLIN CHEM, V56, P1845, DOI 10.1373/clinchem.2010.151233; Heppner BI, 2016, CLIN CANCER RES, V22, P5747, DOI 10.1158/1078-0432.CCR-15-2338; Huober J, 2013, EUR J CANCER, V49, P2284, DOI 10.1016/j.ejca.2013.02.027; Kaufman PA, 2014, CANCER-AM CANCER SOC, V120, P2657, DOI 10.1002/cncr.28710; Loi S, 2016, JAMA ONCOL, V2, P1040, DOI 10.1001/jamaoncol.2016.0339; McCullough AE, 2014, BREAST CANCER RES TR, V143, P485, DOI 10.1007/s10549-013-2827-0; McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8; Muller BM, 2011, DIAGN MOL PATHOL, V20, P1, DOI 10.1097/PDM.0b013e3181e3630c; Noske A, 2011, BREAST CANCER RES TR, V126, P109, DOI 10.1007/s10549-010-1316-y; Paik S, 2002, J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744; Perez EA, 2014, CANCER TREAT REV, V40, P276, DOI 10.1016/j.ctrv.2013.09.001; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tolaney S, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-013-0359-8; Untch M, 2016, LANCET ONCOL, V17, P345, DOI 10.1016/S1470-2045(15)00542-2; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7; Untch M, 2010, J CLIN ONCOL, V28, P2024, DOI 10.1200/JCO.2009.23.8451; von Minckwitz G, 2005, ANN ONCOL, V16, P56, DOI 10.1093/annonc/mdi001; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P552, DOI 10.1093/jnci/djn089; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; von Minckwitz G, 2010, J CLIN ONCOL, V28, P2015, DOI 10.1200/JCO.2009.23.8303; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	34	1	2	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					607	615		10.1038/modpathol.2017.171			9	Pathology	Pathology	GD3LE	WOS:000430404600007	29271415				2019-10-28	
J	Sharma, SG; Larsen, CP				Sharma, Shree G.; Larsen, Christopher P.			Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study	MODERN PATHOLOGY			English	Article							RECEPTOR; CANCER	Thrombospondin type-1 domain-containing 7A (THSD7A) is the most recently recognized target antigen in patients with membranous nephropathy. We stained membranous nephropathy biopsies processed in our laboratory for phospholipase A(2) receptor and THSD7A over an 18-month period and selected all THSD7A-positive cases for study. Serum samples from most patients were tested by an indirect immunofluorescence assay for the presence of THSD7A antibodies (Euroimmun). A total of 31 patients were diagnosed with THSD7A-associated membranous nephropathy for a prevalence of 2.4% among patients with membranous nephropathy. The patients were most often male (male-to-female ratio of 1.6) with a mean age of 62 years and a mean proteinuria of 9.6 g per day (range 1.1-15.9). Two of the 31 patients had a history of cancer and none were diagnosed with malignancy on follow-up. Serum samples were available at the time of biopsy from 24 patients and all tested positive for antibodies against THSD7A. Conversely, all 20 serum samples from patients with membranous nephropathy who had negative staining for THSD7A were negative for serum reactivity to THSD7A. We conclude that THSD7A tissue staining of kidney biopsies with membranous nephropathy is a sensitive and specific method for the diagnosis of THSD7A-associated membranous nephropathy and it correlates strongly with the serum antibody testing. We also present the clinicopathologic details of the largest cohort to date of THSD7A-associated membranous nephropathy from a single institution.	[Sharma, Shree G.; Larsen, Christopher P.] Arkana Labs, 10810 Execut Ctr Dr,Ste 100, Little Rock, AR 72211 USA	Sharma, SG (reprint author), Arkana Labs, 10810 Execut Ctr Dr,Ste 100, Little Rock, AR 72211 USA.	Shree.Sharma@arkanalabs.com					Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; Cattran DC, 2017, KIDNEY INT, V91, P566, DOI 10.1016/j.kint.2016.09.048; De Vriese AS, 2017, J AM SOC NEPHROL, V28, P421, DOI 10.1681/ASN.2016070776; Debiec H, 2002, NEW ENGL J MED, V346, P2053, DOI 10.1056/NEJMoa012895; HEYMANN W, 1959, P SOC EXP BIOL MED, V100, P660; Hoxha E, 2017, J AM SOC NEPHROL, V28, P520, DOI 10.1681/ASN.2016010050; Hoxha E, 2016, NEW ENGL J MED, V374, P1995, DOI 10.1056/NEJMc1511702; Hoxha E, 2014, J AM SOC NEPHROL, V25, P1357, DOI 10.1681/ASN.2013040430; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group, 2012, KIDNEY INT S, V2, P139, DOI DOI 10.1038/kisup.2012.9; Larsen CP, 2016, MODERN PATHOL, V29, P421, DOI 10.1038/modpathol.2016.32; Larsen CP, 2013, MODERN PATHOL, V26, P709, DOI 10.1038/modpathol.2012.207; Ronco P, 2015, LANCET, V385, P1983, DOI 10.1016/S0140-6736(15)60731-0; Stahl PR, 2017, GENE CHROMOSOME CANC, V56, P314, DOI 10.1002/gcc.22440; Tomas NM, 2014, NEW ENGL J MED, V371, P2277, DOI 10.1056/NEJMoa1409354; Walker PD, 2004, MODERN PATHOL, V17, P1555, DOI 10.1038/modpathol.3800239	15	5	9	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					616	622		10.1038/modpathol.2017.163			7	Pathology	Pathology	GD3LE	WOS:000430404600008	29243738	Other Gold, Green Published			2019-10-28	
J	Cenaj, O; Gibson, J; Odze, RD				Cenaj, Odise; Gibson, Joanna; Odze, Robert D.			Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated &ITversus&IT intestinal dysplasia	MODERN PATHOLOGY			English	Article							COLORECTAL-CARCINOMA; MOLECULAR-FEATURES; ADENOMA; LESIONS; CANCER; PROGRESSION; PREVALENCE; PATHWAY; POLYPS; UPDATE	It is believed that sessile serrated adenomas/polyps lead to the development of microsatellite unstable cancer via a dysplasia-carcinoma sequence. Little is known regarding the morphologic and biologic features, and outcome of sessile serrated adenomas/polyps with dysplasia, or of its specific dysplasia subtypes (intestinal versus serrated). The aims of this study were to analyze and compare the clinical, pathologic, and outcome characteristics of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia. The study included 86 patients with sessile serrated adenomas/polyps with dysplasia (50 serrated dysplasia, 22 intestinal dysplasia, 14 mixed serrated and intestinal dysplasia). The clinical and pathologic features, and the prevalence rate of prior, concurrent, and future neoplastic lesions, were compared between sessile serrated adenomas/ polyps with intestinal versus serrated dysplasia and with matched control patients with >= 1 conventional adenoma. The mean age of the patients, polyp size, and prevalence of adenocarcinoma within the polyps were significantly higher in sessile serrated adenomas/polyps with high versus low-grade dysplasia. Sessile serrated adenomas/polyps with intestinal dysplasia showed a significantly higher rate of adenocarcinoma (23%) compared with those with serrated dysplasia (6%, P = 0.05), and the high-grade lesions occurred at a significantly younger age in the former compared with the latter (65 versus 76 years, P = 0.05). Compared with patients with conventional adenomas, patients with sessile serrated adenomas/polyps with dysplasia showed a significantly higher rate of invasive carcinoma within the polyps (12 versus 0%, P = 0.01) and a significantly lower association with prior or future conventional adenomas. Sessile serrated adenomas/polyps with dysplasia should be considered high-risk neoplastic precursor lesions, particularly those with intestinal dysplasia. Cancer may develop from sessile serrated adenomas/polyps with either type of dysplasia.	[Cenaj, Odise; Odze, Robert D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Cenaj, Odise; Odze, Robert D.] Harvard Med Sch, Boston, MA USA; [Gibson, Joanna] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA	Odze, RD (reprint author), Harvard Med Sch, Dept Pathol, Brigham & Womens Hosp, Gastrointestinal Pathol, 75 Francis St, Boston, MA 02115 USA.	rodze@bwh.harvard.edu					Ban S, 2014, PATHOL INT, V64, P123, DOI 10.1111/pin.12147; Bettington M, 2015, GUT, P1; Bettington ML, 2015, HUM PATHOL, V46, P933, DOI 10.1016/j.humpath.2015.04.002; Fujita K, 2011, AM J SURG PATHOL, V35, P295, DOI 10.1097/PAS.0b013e318205df36; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P132, DOI 10.1309/V8Q9KDD5AJ9LNBAG; Jass JR, 2006, HISTOPATHOLOGY, V49, P121, DOI 10.1111/j.1365-2559.2006.02466.x; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Kim KM, 2011, AM J SURG PATHOL, V35, P1274, DOI 10.1097/PAS.0b013e318224cd2e; Lash RH, 2010, J CLIN PATHOL, V63, P681, DOI 10.1136/jcp.2010.075507; Lazarus R, 2005, AM J CLIN PATHOL, V123, P349, DOI 10.1309/VBAGV3BR96N2EQTR; Lu FI, 2010, AM J SURG PATHOL, V34, P927, DOI 10.1097/PAS.0b013e3181e4f256; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Mitchell G, ENCY BIOSTATISTICS; Oono Y, 2009, DIGEST DIS SCI, V54, P906, DOI 10.1007/s10620-008-0407-7; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Sheridan TB, 2006, AM J CLIN PATHOL, V126, P564, DOI 10.1309/C7JE88VL8420V5VT; Snover DC, 2011, HUM PATHOL, V42, P1, DOI 10.1016/j.humpath.2010.06.002; Snover DC, 2010, WHO CLASSIFICATION T, P160; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yang JF, 2015, ARCH PATHOL LAB MED, V139, P388, DOI 10.5858/arpa.2013-0523-OA	20	6	6	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					633	642		10.1038/modpathol.2017.169			10	Pathology	Pathology	GD3LE	WOS:000430404600010	29271414				2019-10-28	
J	Caliskan, A; Kohlmann, WK; Affolter, KE; Downs-Kelly, E; Kanth, P; Bronner, MP				Caliskan, Aybuke; Kohlmann, Wendy K.; Affolter, Kajsa E.; Downs-Kelly, Erinn; Kanth, Priyanka; Bronner, Mary P.			Intramucosal lipomas of the colon implicate Cowden syndrome	MODERN PATHOLOGY			English	Article							PTEN	Intramucosal lipomas are rare and easily overlooked by pathologists, despite their diagnostic significance for Cowden syndrome (PTEN hamartoma tumor syndrome), an inherited multiorgan cancer syndrome. Only 25-35% of patients harbor identifiable PTEN mutations, thus clinical features, like intramucosal lipomas, remain the mainstay of diagnosis. The significance and diagnostic approach to intramucosal lipomas have not been thoroughly addressed in the literature. Intramucosal lipomas are mimicked by pseudolipomatosis coli, an artifactual mucosal gas infiltration from endoscopic insufflation. This differential was investigated by morphology and S-100 immunohistochemistry. Twenty-five colonic intramucosal lipomas were identified from 176 archival gastrointestinal lipomas from 1998 to 2017. Controls included 40 submucosal lipomas and 30 pseudolipomatoses. S-100 immunohistochemistry on all 95 lesions confirmed delicate fat vacuole membranous and nuclear S-100 staining in lipomas absent from pseudolipomatoses. Differentiating morphology between intramucosal lipoma and pseudolipomatosis, respectively, included consistently large, regular fat vacuoles (92% vs 7%), associated spindle cells (80% vs 0%), and mucosal lymphoid aggregate involvement (12% vs 80%). Of the 25 intramucosal lipomas. five patients (20%) had confirmed Cowden syndrome (four with PTEN mutations). In four of these Cowden patients, the intramucosal lipoma was the index diagnostic lesion. Three (12%) intramucosal lipoma patients had additional clinical features associated with Cowden syndrome, but did not meet the diagnostic criteria. Sporadic-type intramucosal lipomas were identified in 17 patients (68%) without evidence of Cowden syndrome, including three with normal PTEN genetic testing. No distinguishing endoscopic or pathologic polyp features were identified between sporadic and syndromic intramucosal lipomas. These data provide evidence that intramucosal lipomas are important harbingers of Cowden syndrome, making up approximately one-third of this series, the largest in the literature. We also show for the first time that two-thirds of intramucosal lipomas are sporadic. Gastrointestinal pathologists, gastroenterologists, and geneticists should increase their awareness of this subtle but diagnosable lesion strongly associated with Cowden syndrome.	[Caliskan, Aybuke] Acibadem Univ, Sch Med, Istanbul, Turkey; [Kohlmann, Wendy K.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Dept Genet Counselors, Salt Lake City, UT USA; [Affolter, Kajsa E.; Bronner, Mary P.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; [Affolter, Kajsa E.; Bronner, Mary P.] Univ Utah, Hlth Sci Ctr, ARUP Labs, Salt Lake City, UT USA; [Downs-Kelly, Erinn] Cleveland Clin Fdn, Dept Pathol & Lab Med, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Kanth, Priyanka] Univ Utah, Hlth Sci Ctr, Dept Gastroenterol, Salt Lake City, UT USA	Bronner, MP (reprint author), Univ Utah, Huntsman Canc Inst, Dept Pathol, Room N3100,1950 Circle Hope, Salt Lake City, UT 84112 USA.; Bronner, MP (reprint author), Univ Utah, Huntsman Canc Inst, ARUP Labs, Room N3100,1950 Circle Hope, Salt Lake City, UT 84112 USA.	mary.bronner@aruplab.com			Cancer Center Support Grant	This study was conducted with support from the Genetic Counseling and the Biorepository and Molecular Pathology Shared Resources supported by the Cancer Center Support Grant awarded to the Huntsman Cancer Institute by the National Cancer Institute of the National Institutes of Health.	Gammon A, 2009, BEST PRACT RES CL GA, V23, P219, DOI 10.1016/j.bpg.2009.02.007; HENG Y, 1995, AM J GASTROENTEROL, V90, P1747; Lachlan KL, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049981; Nallamothu Geetha, 2011, Gastroenterol Hepatol (N Y), V7, P490; Ngeow J, 2017, ENDOCRIN METAB CLIN, V46, P503, DOI 10.1016/j.ecl.2017.01.013; Ngeow J, 2016, METHODS MOL BIOL, P63, DOI 10.1007/978-1-4939-3299-3_6; Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277; Pilarski R, 2011, J MED GENET, V48, P505, DOI 10.1136/jmg.2011.088807; Shaco-Levy R, 2017, J CLIN GASTROENTEROL, V51, pE60, DOI 10.1097/MCG.0000000000000703; Shaco-Levy R, 2016, HUM PATHOL, V49, P39, DOI 10.1016/j.humpath.2015.10.002; Stanich PP, 2014, WORLD J GASTROENTERO, V20, P1833, DOI 10.3748/wjg.v20.i7.1833; Stanich PP, 2011, MAYO CLIN PROC, V86, P489, DOI 10.4065/mcp.2010.0816; Tan MH, 2011, AM J HUM GENET, V88, P42, DOI 10.1016/j.ajhg.2010.11.013; Wang JH, 2011, INSIGHTS IMAGING, V2, P85, DOI 10.1007/s13244-010-0055-2	14	6	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					643	651		10.1038/modpathol.2017.161			9	Pathology	Pathology	GD3LE	WOS:000430404600011	29192650	Bronze			2019-10-28	
J	Singh, N; Faruqi, A; Kommoss, F; McCluggage, WG; Trevisan, G; Senz, J; Lum, A; Gilks, CB; Anglesio, M				Singh, Naveena; Faruqi, Asma; Kommoss, Friedrich; McCluggage, W. Glenn; Trevisan, Giorgia; Senz, Janine; Lum, Amy; Gilks, C. Blake; Anglesio, Michael			Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on&IT tp53 &ITsequencing results: implications for biology, classification, and staging	MODERN PATHOLOGY			English	Article							TUBAL INTRAEPITHELIAL CARCINOMA; FALLOPIAN-TUBE; PERITONEAL CARCINOMA; OVARIAN; ASSIGNMENT; ORIGIN; AMPLIFICATION; TRAJECTORIES; MUTATIONS; PRECURSOR	A previous multicenter study of 67 cases of Stage I/II tubo-ovarian high-grade serous carcinoma with complete tubal sampling identified 7 cases in which there were only two disease sites, comprising tumor involving opposite adnexa with no extra-adnexal involvement. This study aimed to determine whether such low-stage extrauterine high-grade serous carcinomas with only two sites of involvement, located on opposite adnexa, have identical or different TP53 mutations in order to investigate their clonal relationship. DNA extracted from both sites of involvement was subjected to TP53 sequencing (n = 6) or sequencing of one site and mutation confirmation by droplet digital PCR for the other site (n = 1). Of the 7 cases analyzed, 1 case had unilateral serous tubal intraepithelial carcinoma with contralateral ovarian high-grade serous carcinoma, 3 had tubal high-grade serous carcinomas (+/- serous tubal intraepithelial carcinoma) with contralateral ovarian high-grade serous carcinoma, 2 had bilateral ovarian high-grade serous carcinomas with normal tubes, and 1 had bilateral fallopian tube high-grade serous carcinoma with normal ovaries. All 7 cases showed identical TP53 mutations in tumor from both disease sites. Therefore, these rare cases of high-grade serous carcinoma confined to opposite adnexa all show clonal identity between the two sites of involvement, suggesting unifocal origin and metastasis rather than multifocal origin. Our results suggest that serous tubal intraepithelial carcinoma or adnexal high-grade serous carcinoma can metastasize to the contralateral adnexa without peritoneal involvement. Given the clonal relationship between the two sites, such cases should be considered stage II, with stage I reserved for cases with unilateral and unifocal adnexal involvement. Furthermore, serous tubal intraepithelial carcinoma without invasion should be taken to constitute a disease site for staging purposes.	[Singh, Naveena; Faruqi, Asma; Trevisan, Giorgia] Barts Hlth NHS Trust, Dept Cellular Pathol, 2nd Floor,80 Newark St, London E1 2ES, England; [Kommoss, Friedrich; Gilks, C. Blake] Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Kommoss, Friedrich; Senz, Janine; Lum, Amy; Gilks, C. Blake; Anglesio, Michael] British Columbia Canc Agcy, Mol Oncol, Vancouver, BC, Canada; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland	Singh, N (reprint author), Barts Hlth NHS Trust, Dept Cellular Pathol, 2nd Floor,80 Newark St, London E1 2ES, England.	N.Singh@bartshealth.nhs.uk		Anglesio, Michael/0000-0003-1639-5003			Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bandera CA, 1998, ONCOGENE, V16, P3455, DOI 10.1038/sj.onc.1201901; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bijron JG, 2013, AM J SURG PATHOL, V37, P1123, DOI 10.1097/PAS.0b013e318282da7f; Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814; Chai H, 2009, ANN CLIN LAB SCI, V39, P331; Dakubo GD, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-2; Eckert MA, 2016, CANCER DISCOV, V6, P1342, DOI 10.1158/2159-8290.CD-16-0607; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gilks CB, 2015, AM J SURG PATHOL, V39, P357, DOI 10.1097/PAS.0000000000000353; Gurda GT, 2018, INT J GYNECOL PATHOL, V37, P117, DOI 10.1097/PGP.0000000000000392; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Kuhn E, 2016, MODERN PATHOL, V29, P1254, DOI 10.1038/modpathol.2016.101; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kuhn E, 2010, AM J SURG PATHOL, V34, P829, DOI 10.1097/PAS.0b013e3181dcede7; McCluggage WG, 2017, INT J GYNECOL PATHOL, V36, P230, DOI 10.1097/PGP.0000000000000336; McCluggage WG, 2015, MODERN PATHOL, V28, P1101, DOI 10.1038/modpathol.2015.77; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Morrison JC, 2015, AM J SURG PATHOL, V39, P442, DOI 10.1097/PAS.0000000000000352; MUTO MG, 1995, CANCER RES, V55, P490; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Pothuri B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010358; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Rabban JT, 2015, AM J SURG PATHOL, V39, P35, DOI 10.1097/PAS.0000000000000293; Rabban JT, 2014, AM J SURG PATHOL, V38, P729, DOI 10.1097/PAS.0000000000000199; Schorge JO, 2000, CANCER RES, V60, P1361; Schorge JO, 1998, J NATL CANCER I, V90, P841, DOI 10.1093/jnci/90.11.841; Singh N, 2017, INT J GYNECOL PATHOL, DOI [10.1097/PGP.0000000000000392, DOI 10.1097/PGP.0000000000000392]; Singh N, 2016, GYNECOL ONCOL, V141, P195, DOI 10.1016/j.ygyno.2015.10.022; Singh N, 2016, INT J GYNECOL PATHOL, V35, P230, DOI 10.1097/PGP.0000000000000270; Singh N, 2015, PATHOLOGY, V47, P423, DOI 10.1097/PAT.0000000000000291; Singh N, 2014, HISTOPATHOLOGY, V65, P149, DOI 10.1111/his.12419	40	3	3	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					652	659		10.1038/modpathol.2017.159			8	Pathology	Pathology	GD3LE	WOS:000430404600012	29148539	Bronze			2019-10-28	
J	Lewis, N; Soslow, RA; Delair, DF; Park, KJ; Murali, R; Hollmann, TJ; Davidson, B; Micci, F; Panagopoulos, I; Hoang, LN; Arias-Stella, JA; Oliva, E; Young, RH; Hensley, ML; Leitao, MM; Hameed, M; Benayed, R; Ladanyi, M; Frosina, D; Jungbluth, AA; Antonescu, CR; Chiang, S				Lewis, Natasha; Soslow, Robert A.; Delair, Deborah F.; Park, Kay J.; Murali, Rajmohan; Hollmann, Travis J.; Davidson, Ben; Micci, Francesca; Panagopoulos, Ioannis; Hoang, Lien N.; Arias-Stella, Javier A., III; Oliva, Esther; Young, Robert H.; Hensley, Martee L.; Leitao, Mario M., Jr.; Hameed, Meera; Benayed, Ryma; Ladanyi, Marc; Frosina, Denise; Jungbluth, Achim A.; Antonescu, Cristina R.; Chiang, Sarah			&ITZC3H7B-BCOR&IT high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity	MODERN PATHOLOGY			English	Article							CLEAR-CELL-SARCOMA; INTERNAL TANDEM DUPLICATION; INFLAMMATORY MYOFIBROBLASTIC TUMOR; ACUTE MYELOID-LEUKEMIA; MESENCHYMAL NEOPLASMS; MYXOID-LEIOMYOSARCOMA; SOMATIC MUTATIONS; ROUND-CELL; YWHAE-FAM22 REARRANGEMENT; BCOR	High-grade endometrial stromal sarcoma likely encompasses underrecognized tumors harboring genetic abnormalities besides YWHAE-NUTM2 fusion. Triggered by three initial endometrial stromal sarcomas with ZC3H7B-BCOR fusion characterized by high-grade morphology and aggressive clinical behavior, we herein investigate the clinicopathologic features of this genetic subset by expanding the analysis to 17 such tumors. All of them occurred in adult women with a median age of 54 (range, 28-71) years. They were predominantly based in the endomyometrium and demonstrated tongue-like and/or pushing myometrial invasion. Most were uniformly cellular and displayed haphazard fascicles of spindle cells with mild to moderate nuclear atypia. Myxoid matrix was seen in 14 of 17 (82%) tumors, and collagen plaques were seen in 8 (47%). The mitotic index was >= 10 mitotic figures/10 high-power fields (HPFs) in 14 of 17 (82%) tumors with a median of 14.5 mitotic figures/10 HPFs. No foci of conventional or variant low-grade endometrial stromal sarcoma were seen. All tumors expressed CD10 with only limited or absent desmin, SMA and/or h-caldesmon staining. ER and PR expression in >5% of cells was seen in 4 of 12 (33%) tumors. Diffuse cyclin D1 and BCOR immunoreactivity was present in 7 of 8 (88%) and 7 of 14 (50%) tumors, respectively. Fluorescence in situ hybridization or targeted RNA sequencing confirmed ZC3H7B-BCOR fusion in all tumors, including four and two previously diagnosed as myxoid leiomyosarcoma and undifferentiated uterine sarcoma, respectively. Limited clinical data suggest that patients present at higher stage and have worse prognosis compared with published outcomes in low-grade endometrial stromal sarcoma. Tumors with ZC3H7B-BCOR fusion constitute a distinct group of endometrial stromal sarcomas with high-grade morphology that should be distinguished from other uterine mesenchymal neoplasms that may demonstrate myxoid morphology.	[Lewis, Natasha; Soslow, Robert A.; Delair, Deborah F.; Park, Kay J.; Murali, Rajmohan; Hollmann, Travis J.; Arias-Stella, Javier A., III; Hameed, Meera; Benayed, Ryma; Ladanyi, Marc; Frosina, Denise; Jungbluth, Achim A.; Antonescu, Cristina R.; Chiang, Sarah] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Davidson, Ben] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; [Davidson, Ben] Univ Oslo, Fac Med, Oslo, Norway; [Micci, Francesca; Panagopoulos, Ioannis] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Genet & Informat, Sect Canc Cytogenet, Oslo, Norway; [Hoang, Lien N.] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC, Canada; [Oliva, Esther; Young, Robert H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Oliva, Esther; Young, Robert H.] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Hensley, Martee L.] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Leitao, Mario M., Jr.] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10021 USA	Chiang, S (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	chiangs@mskcc.org					Aisagbonhi O, INT J GYNEC IN PRESS; Antonescu CR, 2014, GENE CHROMOSOME CANC, V53, P183, DOI 10.1002/gcc.22132; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Astolfi A, 2015, ONCOTARGET, V6, P40934, DOI 10.18632/oncotarget.5882; Bennett JA, 2017, MODERN PATHOL, V30, P1489, DOI 10.1038/modpathol.2017.69; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Chiang S, 2017, MODERN PATHOL, V30, P1251, DOI 10.1038/modpathol.2017.42; Chiang S, 2013, HISTOPATHOLOGY, V62, P124, DOI 10.1111/his.12048; Conklin CMJ, 2014, ADV ANAT PATHOL, V21, P383, DOI 10.1097/PAP.0000000000000046; Croce S, 2013, MODERN PATHOL, V26, P1390, DOI 10.1038/modpathol.2013.69; Damm F, 2013, BLOOD, V122, P3169, DOI 10.1182/blood-2012-11-469619; Dobashi A, 2016, GENE CHROMOSOME CANC, V55, P460, DOI 10.1002/gcc.22348; Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913; Fuehrer NE, 2012, ARCH PATHOL LAB MED, V136, P623, DOI 10.5858/arpa.2011-0341-OA; Gadducci A, 2008, CRIT REV ONCOL HEMAT, V65, P129, DOI 10.1016/j.critrevonc.2007.06.011; Goh R, 2016, MODERN PATHOL, V29, p285A; Gremel G, 2015, INT J CANCER, V136, P1608, DOI 10.1002/ijc.29141; Grossmann V, 2011, BLOOD, V118, P6153, DOI 10.1182/blood-2011-07-365320; Hoang LN, 2017, AM J SURG PATHOL, V41, P12, DOI 10.1097/PAS.0000000000000721; Huynh KD, 2000, GENE DEV, V14, P1810; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Karlsson J, 2016, GENE CHROMOSOME CANC, V55, P120, DOI 10.1002/gcc.22316; KING ME, 1982, AM J SURG PATHOL, V6, P589, DOI 10.1097/00000478-198210000-00001; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kruse AJ, 2014, INT J GYNECOL CANCER, V24, P1616, DOI 10.1097/IGC.0000000000000278; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Li WS, 2016, HISTOPATHOLOGY, V69, P792, DOI 10.1111/his.13001; Lindsley RC, 2015, BLOOD, V125, P1367, DOI 10.1182/blood-2014-11-610543; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Oliva E, 2014, WHO CLASSIFICATION T, P135; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P610, DOI 10.1002/gcc.22057; Parra-Herran C, 2016, AM J SURG PATHOL, V40, P285, DOI 10.1097/PAS.0000000000000593; Parra-Herran C, 2015, AM J SURG PATHOL, V39, P157, DOI 10.1097/PAS.0000000000000330; Peters TL, 2015, MODERN PATHOL, V28, P575, DOI 10.1038/modpathol.2014.139; Pinto A, 2016, ARCH PATHOL LAB MED, V140, P286, DOI 10.5858/arpa.2014-0523-RS; Piscuoglio S, 2016, J PATHOL, V238, P381, DOI 10.1002/path.4675; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Sciallis AP, 2014, AM J SURG PATHOL, V38, P1161, DOI 10.1097/PAS.0000000000000256; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Specht K, 2016, AM J SURG PATHOL, V40, P433, DOI 10.1097/PAS.0000000000000591; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	47	13	15	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					674	684		10.1038/modpathol.2017.162			11	Pathology	Pathology	GD3LE	WOS:000430404600014	29192652	Bronze			2019-10-28	
J	Sorscher, S				Sorscher, Steven			Expanding definitions of HER2 positivity	MODERN PATHOLOGY			English	Letter									[Sorscher, Steven] Wake Forest Sch Med, One Med Ctr Blvd, Winston Salem, NC 27101 USA	Sorscher, S (reprint author), Wake Forest Sch Med, One Med Ctr Blvd, Winston Salem, NC 27101 USA.	ssorsche@wakehealth.edu					Stewart RL, 2017, MODERN PATHOL, V30, P1561, DOI 10.1038/modpathol.2017.65; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	2	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					685	685		10.1038/modpathol.2017.141			1	Pathology	Pathology	GD3LE	WOS:000430404600015	29666481	Bronze			2019-10-28	
J	Stewart, RL; Gulbahce, EH; Geiersbach, KB; Downs-Kelly, E				Stewart, Rachel L.; Gulbahce, Evin H.; Geiersbach, Katherine B.; Downs-Kelly, Erinn			Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'	MODERN PATHOLOGY			English	Letter							AMERICAN-SOCIETY; RECOMMENDATIONS; CANCER		[Stewart, Rachel L.; Gulbahce, Evin H.] Univ Utah, Med Ctr, Dept Pathol, ARUP Labs, Salt Lake City, UT 84112 USA; [Geiersbach, Katherine B.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Downs-Kelly, Erinn] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA	Stewart, RL (reprint author), Univ Utah, Med Ctr, Dept Pathol, ARUP Labs, Salt Lake City, UT 84112 USA.	rachel.stewart@aruplab.com		Stewart, Rachel/0000-0001-8031-5720			Stewart RL, 2017, MODERN PATHOL, V30, P1561, DOI 10.1038/modpathol.2017.65; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	3	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	APR	2018	31	4					686	686		10.1038/modpathol.2018.28			1	Pathology	Pathology	GD3LE	WOS:000430404600016	29666479				2019-10-28	
J	Khoury, T				Khoury, Thaer			Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Review						Breast cancer; Delay to formalin fixation; Breast biomarkers; Review	IN-SITU HYBRIDIZATION; PATHOLOGISTS GUIDELINE RECOMMENDATIONS; PARAFFIN-EMBEDDED TISSUE; LARGE MULTICENTER TRIAL; DX RECURRENCE SCORE; CORE NEEDLE-BIOPSY; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; AMERICAN-SOCIETY; INTEROBSERVER REPRODUCIBILITY	Objectives: The gold standard of examining breast biomarkers, including estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)/Ki-67, is to perform these assays on formalin-fixed, paraffin-embedded tissue. However, preanalytical variables may confound these assays. One of these factors is delay to formalin fixation (DFF). The purpose of this review is to evaluate each study that investigated the effect of DFF on breast biomarkers and other molecules. Methods: Thirteen primary research articles were identified by the literature search. The credibility of the studies was judged based on the degree of controlling other confounding factors. Nine studies had a prospective design with a high number of controlled variables. Results: Most of the studies concluded that DFF had an effect on ER/PR/HER2. Some of these studies showed that DFF had negative effect on other markers used either clinically or for research purposes. Conclusions: The vast majority of the studies agree that DFF has negative effect on breast biomarkers.	[Khoury, Thaer] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Khoury, T (reprint author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA.	thaer.khoury@roswellpark.org					Allott EH, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0725-1; Arber DA, 2002, APPL IMMUNOHISTO M M, V10, P183, DOI 10.1097/00022744-200206000-00015; Arnedos M, 2009, ANN ONCOL, V20, P1948, DOI 10.1093/annonc/mdp234; Benini E, 1997, CELL PROLIFERAT, V30, P107, DOI 10.1046/j.1365-2184.1997.00081.x; Besusparis J, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0525-z; Burge CN, 2006, BREAST, V15, P167, DOI 10.1016/j.breast.2005.06.004; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222; Cohen DA, 2012, AM J CLIN PATHOL, V138, P796, DOI 10.1309/AJCP6DKRND5CKVDD; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; De Marzo AM, 2002, HUM PATHOL, V33, P756, DOI 10.1053/hupa.2002.126187; Engel KB, 2011, ARCH PATHOL LAB MED, V135, P537, DOI 10.1043/2010-0702-RAIR.1; Fitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P595, DOI 10.5858/arpa.2013-0566-CP; FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502; Goldstein NS, 2003, AM J CLIN PATHOL, V120, P86, DOI 10.1309/QPHDRB00QXGMUQ9N; Halazun KJ, 2007, TRANSPL P, V39, P1329, DOI 10.1016/j.transproceed.2007.02.061; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Jin X, 2015, ONCOTARGET, V6, P9600, DOI 10.18632/oncotarget.3292; Khoury T, 2017, AM J CLIN PATHOL, V148, P108, DOI [10.1093/AJCP/AQX053, 10.1093/ajcp/aqx053]; Khoury T, 2016, APPL IMMUNOHISTO M M, V24, P703, DOI 10.1097/PAI.0000000000000248; Khoury T, 2014, APPL IMMUNOHISTO M M, V22, P688, DOI 10.1097/PAI.0000000000000018; Khoury T, 2012, APPL IMMUNOHISTO M M, V20, P531, DOI 10.1097/PAI.0b013e318248bf6d; Khoury T, 2011, BREAST J, V17, P180, DOI 10.1111/j.1524-4741.2010.01051.x; Khoury T, 2009, MODERN PATHOL, V22, P1457, DOI 10.1038/modpathol.2009.117; Klein ME, 2013, MODERN PATHOL, V26, P658, DOI 10.1038/modpathol.2013.36; Laurinavicius A, 2013, DIAGN PATHOL S1, V8, pS15; Lee AHS, 2014, J CLIN PATHOL, V67, P573, DOI 10.1136/jclinpath-2013-201978; Lee AHS, 2012, HISTOPATHOLOGY, V60, P880, DOI 10.1111/j.1365-2559.2011.04144.x; Lee AHS, 2011, J CLIN PATHOL, V64, P490, DOI 10.1136/jcp.2011.089177; Li XX, 2013, MODERN PATHOL, V26, P71, DOI 10.1038/modpathol.2012.135; Liu SZ, 2010, BREAST CANCER RES TR, V119, P53, DOI 10.1007/s10549-009-0318-0; Lovrics PJ, 2011, ANN SURG ONCOL, V18, P3407, DOI 10.1245/s10434-011-1699-y; Mann GB, 2005, J CLIN ONCOL, V23, P5148, DOI 10.1200/JCO.2005.02.076; Mengel M, 2002, J PATHOL, V198, P292, DOI 10.1002/path.1218; Moatamed NA, 2011, AM J CLIN PATHOL, V136, P754, DOI 10.1309/AJCP99WZGBPKCXOQ; Murphy JO, 2013, ANN SURG ONCOL, V20, P4121, DOI 10.1245/s10434-013-3166-4; Neumeister VM, 2012, J NATL CANCER I, V104, P1815, DOI 10.1093/jnci/djs438; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Pekmezci M, 2012, PATHOLOG RES INT, V2012, DOI DOI 10.1155/2012/947041.EPUB@; Pinhel IF, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2719; Plancoulaine B, 2015, VIRCHOWS ARCH; POLLARD K, 1987, J HISTOCHEM CYTOCHEM, V35, P1329, DOI 10.1177/35.11.3309048; Portier BP, 2013, MODERN PATHOL, V26, P1, DOI 10.1038/modpathol.2012.123; Potts SJ, 2012, LAB INVEST, V92, P1342, DOI 10.1038/labinvest.2012.91; Qiu JX, 2010, AM J CLIN PATHOL, V134, P813, DOI 10.1309/AJCPVCX83JWMSBNO; Selvarajan S, 2002, J HISTOCHEM CYTOCHEM, V50, P1693, DOI 10.1177/002215540205001215; Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383; Turner BM, 2015, MODERN PATHOL, V28, P921, DOI 10.1038/modpathol.2015.50; von Wasielewski R, 2002, AM J CLIN PATHOL, V118, P675; von Wasielewski R, 1998, BREAST J, V4, P33; Walker RA, 2008, J CLIN PATHOL, V61, P818, DOI 10.1136/jcp.2007.054866; Williams JH, 1997, J CLIN PATHOL, V50, P422, DOI 10.1136/jcp.50.5.422; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yildiz-Aktas IZ, 2012, MODERN PATHOL, V25, P1098, DOI 10.1038/modpathol.2012.59	57	5	5	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					275	292		10.1093/AJCP/AQX164			18	Pathology	Pathology	GC0FU	WOS:000429453100001	29471352	Bronze			2019-10-28	
J	Corean, J; Al-Tigar, R; Pysher, T; Blaylock, R; Metcalf, RA				Corean, Jessica; Al-Tigar, Rami; Pysher, Theodore; Blaylock, Robert; Metcalf, Ryan A.			Quality Improvement After Multiple Fatal Transfusion-Transmitted Bacterial Infections	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Transfusion-transmitted bacterial infection; Quality improvement; Corrective and preventive action; Testing at issue; Pathogen reduction	PLATELET COMPONENTS; CONTAMINATION; CULTURE; RISK; DIVERSION; SYSTEM; VOLUME	Objectives: Transfusion-transmitted bacterial infection (TTBI) from platelet components is likely underrecognized and can be fatal. Twenty-four-hour prospective culture was felt to be insufficiently preventive after multiple TTBIs occurred and strategies to improve safety were sought. Methods: Two fatal and one severe TTBIs occurred from a split-apheresis platelet donation contaminated with Klebsiella pneumoniae. Improvement opportunities were identified and corrective and preventive action (CAPA) followed. Results: To mitigate bacterial contamination and improve detection sensitivity, additional prospective culture 48 hours postcollection was implemented. Since implementation, secondary cultures have caught two true positives (0.01%) missed by 24-hour culture. Bacterial testing at issue and pathogen reduction were later implemented as an added layer of safety. Conclusion: While rare, TTBI is a prominent cause of morbidity and mortality from contaminated platelets. The approach to CAPA presented here may lower the risk of future transfusion-transmitted infections but must be weighed against potential added costs.	[Corean, Jessica; Pysher, Theodore; Blaylock, Robert; Metcalf, Ryan A.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; [Corean, Jessica; Al-Tigar, Rami; Blaylock, Robert; Metcalf, Ryan A.] Univ Utah, Dept Pathol, ARUP Labs, Salt Lake City, UT USA; [Pysher, Theodore] Univ Utah, Sch Med, Dept Pathol, Dept Pediat Pathol, Salt Lake City, UT USA	Metcalf, RA (reprint author), Univ Utah, Dept Pathol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	ryan.metcalf@path.utah.edu		Corean, Jessica/0000-0003-4340-6775			Benjamin RJ, 2008, TRANSFUSION, V48, P2348, DOI 10.1111/j.1537-2995.2008.01853.x; Benjamin RJ, 2014, TRANSFUS MED REV, V28, P61, DOI 10.1016/j.tmrv.2014.01.001; Bloch EM, 2017, TRANSFUSION, V57, P2289, DOI 10.1111/trf.14306; de Korte D, 2002, VOX SANG, V83, P13, DOI 10.1046/j.1423-0410.2002.00189.x; Eder AF, 2017, TRANSFUSION, V57, P2969, DOI 10.1111/trf.14308; Food and Drug Administration, BACT RISK CONTR STRA; Jacobs MR, 2008, CLIN INFECT DIS, V46, P1214, DOI 10.1086/529143; Klausen SS, 2014, TRANSFUS APHER SCI, V51, P97, DOI 10.1016/j.transci.2014.08.007; Li N, 2014, TRANSFUSION, V54, P1666, DOI 10.1111/trf.12520; McDonald CP, 2011, TRANSFUS MED HEMOTH, V38, P255, DOI 10.1159/000330474; Mertens G, 1999, TRANSFUSION, V39, P539, DOI 10.1046/j.1537-2995.1999.39050539.x; Niu MT, 2006, TRANSFUS MED REV, V20, P149, DOI 10.1016/j.tmrv.2005.11.007; Nussbaumer W, 2007, TRANSFUSION, V47, P1125, DOI 10.1111/j.1537-2995.2007.01247.x; Ramirez-Arcos S, 2017, TRANSFUSION, V57, P2174, DOI 10.1111/trf.14202; Schmidt M, 2006, TRANSFUSION, V46, P1367, DOI 10.1111/j.1537-2995.2006.00904.x; Souza S, 2012, TRANSFUSION, V52, P1576, DOI 10.1111/j.1537-2995.2011.03489.x; US Department of Health and Human Services (FDA), FAT REP FDA FOLL BLO; Walther-Wenke G, 2010, ANN HEMATOL, V89, P83, DOI 10.1007/s00277-009-0762-2	18	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					293	299		10.1093/AJCP/AQX167			7	Pathology	Pathology	GC0FU	WOS:000429453100002	29462235				2019-10-28	
J	Lee, WY; Weinberg, OK; Evans, AG; Pinkus, GS				Lee, Winston Y.; Weinberg, Olga K.; Evans, Andrew G.; Pinkus, Geraldine S.			Loss of Full-Length GATA1 Expression in Megakaryocytes Is a Sensitive and Specific Immunohistochemical Marker for the Diagnosis of Myeloid Proliferative Disorder Related to Down Syndrome	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						GATA1; Down syndrome; Megakaryocytes; Immunohistochemistry; Myeloid proliferative disorder; Transient abnormal myelopoiesis; Myeloid leukemia related to Down syndrome	TRANSIENT MYELOPROLIFERATIVE DISORDER; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ABNORMAL MYELOPOIESIS; MUTATIONS; ERYTHROPOIESIS; LEUKEMOGENESIS; DISEASE; MODEL; AMKL	Objectives: Myeloid proliferative disorders associated with Down syndrome (MPD-DS), including transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome (DS), harbor mutations of GATA1, a transcription factor essential for erythroid and megakaryocytic development. These mutations result in a N-terminally truncated GATA1 (GATA1s) and prohibit the production of the full-length GATA1 (GATA1f). Here, we demonstrate the utility of immunohistochemical GATA1f reactivity in diagnosing MPD-DS. Methods: Immunohistochemical studies for GATA1f expression were performed on bone marrow biopsy specimens. Results: In all cases of MPD-DS, megakaryocytes lacked GATA1f expression. In contrast, GATA1f expression was detected in megakaryocytes in all specimen types from patients without DS (normal bone marrows, pediatric myelodysplastic syndrome, juvenile myelomonocytic leukemia, adult acute megakaryocytic leukemia [pediatric and adult; without trisomy 2]), as well as normal bone marrows from patients with DS. Conclusions: The lack of GATA1f expression is a sensitive and specific immunohistochemical marker for MPD-DS.	[Lee, Winston Y.; Weinberg, Olga K.; Pinkus, Geraldine S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA; [Lee, Winston Y.; Weinberg, Olga K.; Pinkus, Geraldine S.] Harvard Med Sch, Boston, MA USA; [Weinberg, Olga K.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Evans, Andrew G.] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY USA	Lee, WY (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA.	wlee0@partners.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL007627]	This work was supported in part by National Institutes of Health-Supported Training Grant Award T32 (HL007627 to W.Y.L.).	Alford KA, 2011, BLOOD, V118, P2222, DOI 10.1182/blood-2011-03-342774; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Banno K, 2016, CELL REP, V15, P1228, DOI 10.1016/j.celrep.2016.04.031; Bhatnagar N, 2016, CURR HEMATOL MALIG R, V11, P333, DOI 10.1007/s11899-016-0338-x; Birger Y, 2013, BLOOD, V122, P988, DOI 10.1182/blood-2012-10-460998; Bombery M, 2014, ARCH PATHOL LAB MED, V138, P1302, DOI 10.5858/arpa.2014-0304-CC; Byrska-Bishop M, 2015, J CLIN INVEST, V125, P993, DOI 10.1172/JCI75714; Cabelof DC, 2009, BLOOD, V114, P2753, DOI 10.1182/blood-2008-11-190330; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Gruber TA, 2015, BLOOD, V126, P943, DOI 10.1182/blood-2015-05-567859; Harigae H, 2004, BLOOD, V103, P3242, DOI 10.1182/blood-2004-01-0016; Hollanda LM, 2006, NAT GENET, V38, P807, DOI 10.1038/ng1825; Karandikar NJ, 2001, AM J CLIN PATHOL, V116, P204; Kazuki Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06136; Langebrake C, 2005, KLIN PADIATR, V217, P126, DOI 10.1055/s-2005-836510; Lee WY, 2017, AM J CLIN PATHOL, V147, P420, DOI 10.1093/ajcp/aqx018; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Nikolaev SI, 2013, BLOOD, V122, P554, DOI 10.1182/blood-2013-03-491936; Pine SR, 2005, LEUKEMIA RES, V29, P1353, DOI 10.1016/j.leukres.2005.04.007; Roberts I, 2014, BRIT J HAEMATOL, V167, P587, DOI 10.1111/bjh.13096; Roberts I, 2013, BLOOD, V122, P3908, DOI 10.1182/blood-2013-07-515148; Roy A, 2009, BRIT J HAEMATOL, V147, P3, DOI 10.1111/j.1365-2141.2009.07789.x; Sankaran VG, 2012, J CLIN INVEST, V122, P2439, DOI 10.1172/JCI63597; Thiollier C, 2012, J EXP MED, V209, P2017, DOI 10.1084/jem.20121343; Toki T, 2013, BLOOD, V121, P3181, DOI 10.1182/blood-2012-01-405746; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759	27	3	3	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					300	309		10.1093/AJCP/AQY001			10	Pathology	Pathology	GC0FU	WOS:000429453100003	29481579	Green Published			2019-10-28	
J	Wilson, ML; Ayers, S; Berney, D; Eslan, A; Guarner, J; Lester, S; Masia, R; Moloo, Z; Mutuku, A; Roberts, D; Stall, J; Sayed, S				Wilson, Michael L.; Ayers, Stephanie; Berney, Daniel; Eslan, Alexia; Guarner, Jeannette; Lester, Susan; Masia, Ricard; Moloo, Zahir; Mutuku, Angela; Roberts, Drucilla; Stall, Jennifer; Sayed, Shahin			Improving Anatomic Pathology in Sub-Saharan Africa to Support Cancer Care	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Global health; Pathology; Cancer care; Education; Training		Objectives: Cancer care requires both accurate pathologic diagnosis as well as pathologic cancer staging. We evaluated three approaches to training pathologists in sub-Saharan Africa to perform pathologic cancer staging of breast, cervix, prostate, and colorectal cancers. Methods: One of three training methods was used at each workshop: didactic, case-based testing (CBT), or a blended approach. The project involved 52 participants from 16 pathology departments in 11 countries in East, Central, and Southern Africa. Evaluation of each method included pre- and postworkshop knowledge assessments, online pre- and postworkshop surveys of practice changes at the individual and institutional levels, and selected site visits. Results: While CBT resulted in the highest overall average postassessment individual scores, both CBT and blended approaches resulted in 19% increases in average scores from pre- to postworkshop assessments. Institutions that participated in the blended workshop had increased changes in practice as indicated by the institutional survey. Conclusions: Both CBT and a blended approach are effective methods for training pathologists in pathologic cancer staging. Both are superior to traditional lectures alone.	[Wilson, Michael L.] Denv Er Hlth, Dept Pathol & Lab Serv, Denver, CO USA; [Wilson, Michael L.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Wilson, Michael L.; Ayers, Stephanie; Berney, Daniel; Eslan, Alexia; Guarner, Jeannette; Moloo, Zahir; Roberts, Drucilla; Sayed, Shahin] African Strategies Adv Pathol, Denver, CO USA; [Berney, Daniel] Queen Mary Univ London, Barts Canc Inst, Dept Cellular Pathol, London, England; [Guarner, Jeannette] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Lester, Susan] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Lester, Susan; Masia, Ricard; Roberts, Drucilla; Stall, Jennifer] Harvard Med Sch, Dept Pathol, Boston, MA USA; [Masia, Ricard; Roberts, Drucilla; Stall, Jennifer] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Moloo, Zahir; Mutuku, Angela; Sayed, Shahin] Coll Pathologists East Cent & South Africa, Nairobi, Kenya; [Moloo, Zahir; Mutuku, Angela; Sayed, Shahin] Aga Khan Univ Hosp Nairobi, Dept Pathol, Nairobi, Kenya	Wilson, ML (reprint author), Dept Pathol & Lab Serv, Mail Code 0224,777 Bannock St, Denver, CO 80204 USA.	michael.wilson@dhha.org	SAYED, SHAHIN/F-8641-2016; Guarner, Jeannette/B-8273-2013		NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA046934]		Abayomi A, 2015, AM J CLIN PATHOL, V143, P325, DOI 10.1309/AJCP6K0DZCNVCSCI; Fleming KA, 2017, AM J CLIN PATHOL, V147, P15, DOI [10.1093/AJCP/AQW143, 10.1093/ajcp/aqw143]; Guarner J, 2015, AM J CLIN PATHOL, V143, P405, DOI 10.1309/AJCPNYT1WPSRCLC6; Mozert MP, 1996, ANN M ASS TEACH ED; Richardson J. T. E, 2005, ASSESS EVAL HIGH EDU, V30, P387, DOI DOI 10.1080/02602930500099193; Sayed S, 2017, AFR J LAB MED, V6, DOI 10.4102/ajlm.v6i1.637; Schwartzstein RM, 2017, NEW ENGL J MED, V377, P605, DOI 10.1056/NEJMp1706474; Sturdy S, 2007, B HIST MED, V81, P760, DOI 10.1353/bhm.2007.0093	8	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					310	315		10.1093/AJCP/AQX158			6	Pathology	Pathology	GC0FU	WOS:000429453100004	29471457	Green Published			2019-10-28	
J	Martins, TR; Longatto, A; Cohen, D; Viscondi, JYK; Fuza, LM; Cury, L; Villa, LL; Levi, JE; Neto, JE				Martins, Toni Ricardo; Longatto-Filho, Adhemar; Cohen, Diane; Kodaira Viscondi, Juliana Yukari; Fuza, Luiz Mario; Cury, Lise; Villa, Luisa Lina; Levi, Jose Eduardo; Eluf-Neto, Jose			Influence of Prior Knowledge of Human Papillomavirus Status on the Performance of Cytology Screening	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cervical cytology; Screening; HPV-DNA; Papanicolaou test; Cervical cancer	LIQUID-BASED CYTOLOGY; CERVICAL-CANCER; PAP TEST; TRIAGE; ATHENA; WOMEN	Objectives: This study aimed to evaluate the influence of prior knowledge of human papillomavirus (HPV) status in cervical cytopathology readings. Methods: Participants comprised 2,376 women who underwent parallel cytology and HPV-DNA testing. Smears were read twice by the same team, first with previous knowledge of HPV-DNA status. Results: Overall, 239 (10.2%) smears had their cytology classification altered by the HPV-informed review. Cytology readings with prior knowledge of the HPV status revealed 10.5% of abnormal smears (atypical squamous cells of undetermined significance or higher), while without prior knowledge, this rate dropped to 7.6%. When HPV status was informed, a significant increase in all categories of altered smears was observed. Cytology with prior knowledge of HPV status detected more cervical intraepithelial neoplasia grade 2 or higher (CIN 2+) compared with blinded: 86.7% vs 60.0%. Conclusions: Our data indicate that cytology interpreted with prior knowledge of the HPV status provides higher sensitivity for CIN 2+ lesions while marginally reducing the overall specificity compared with HPV status blinded cytology.	[Martins, Toni Ricardo; Fuza, Luiz Mario; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil; [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, Lab Med Invest LIM 14, Sao Paulo, Brazil; [Martins, Toni Ricardo] Univ Sao Paulo, Dept Infect Dis, Sch Med, Sao Paulo, Brazil; [Longatto-Filho, Adhemar] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil; [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Liffe & Hlth Sci Res Inst ICVS, Braga, Portugal; [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal; [Longatto-Filho, Adhemar; Villa, Luisa Lina; Levi, Jose Eduardo; Eluf-Neto, Jose] Inst Nacl Ciencia & Tecnol Doencas Papilomavirus, Sao Paulo, Brazil; [Cohen, Diane; Fuza, Luiz Mario; Cury, Lise; Eluf-Neto, Jose] Fundacao Oncoctr Sao Paulo, Oscar Freire St 2396, BR-05409012 Sao Paulo, SP, Brazil; [Kodaira Viscondi, Juliana Yukari; Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil; [Villa, Luisa Lina] Univ Sao Paulo, Fac Med, Dept Radiol & Oncol, Sao Paulo, Brazil; [Villa, Luisa Lina] Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil	Neto, JE (reprint author), Fundacao Oncoctr Sao Paulo, Oscar Freire St 2396, BR-05409012 Sao Paulo, SP, Brazil.	jelufnet@usp.br	longatto-filho, adhemar/D-7039-2013; Eluf-Neto, Jose/B-2522-2009; Longatto-Filho, Adhemar/N-3397-2019	longatto-filho, adhemar/0000-0002-5779-9752; Eluf-Neto, Jose/0000-0001-7504-2115; Longatto-Filho, Adhemar/0000-0002-5779-9752	Instituto Nacional de Ciencia e Tecnologia das Doencas do Papilomavirus Humano INCT-HPV (National Institute of Science and Technology of the Diseases Associated to the Papillomavirus) through CNPq [573799/2008-3]; Instituto Nacional de Ciencia e Tecnologia das Doencas do Papilomavirus Humano INCT-HPV (National Institute of Science and Technology of the Diseases Associated to the Papillomavirus) through FAPESP [2008/57889-1]	We thank Becton-Dickinson (BD) for technical support, equipment, and reagents for the study, as well as cytologists and pathologists of the FOSP Laboratory. We also thank the Instituto Nacional de Ciencia e Tecnologia das Doencas do Papilomavirus Humano INCT-HPV (National Institute of Science and Technology of the Diseases Associated to the Papillomavirus) coordinated by Luisa Lina Villa, Sao Paulo, Brazil, for financial support through CNPq 573799/2008-3 and FAPESP 2008/57889-1 grants.	Benoy IH, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.101; Bergeron C, 2015, J NATL CANC I, V107; Branca M, 2015, ACTA CYTOL, V59, P361, DOI 10.1159/000441515; Castle PE, 2015, HPV TODAY NEWSLETTER; Castle PE, 2013, OBSTET GYN CLIN N AM, V40, P377, DOI 10.1016/j.ogc.2013.03.002; Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754; Ejegod D, 2016, J CLIN MICROBIOL, V54, P2267, DOI 10.1128/JCM.00508-16; El-Zein M, 2016, J CLIN VIROL, V76, pS62, DOI 10.1016/j.jcv.2015.11.020; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Herbert A, 2017, CYTOPATHOLOGY, V28, P9, DOI 10.1111/cyt.12334; INCA. Instituto Nacional do Cancer, 2016, MIN SAUD; Joste N, 2013, OBSTET GYN CLIN N AM, V40, P199, DOI 10.1016/j.ogc.2013.02.001; Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016/S1470-2045(09)70156-1; Lorenzi AT, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0342-0; Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521; Passamonti B, 2007, ACTA CYTOL, V51, P865, DOI 10.1159/000325862; Poljak M, 2016, J CLIN VIROL, V76, pS1, DOI 10.1016/j.jcv.2015.11.010; Richardson LA, 2015, CANCER CYTOPATHOL, V123, P745, DOI 10.1002/cncy.21596; Rijkaart DC, 2012, LANCET ONCOL, V13, P78, DOI 10.1016/S1470-2045(11)70296-0; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Wentzensen N, 2016, J CLIN VIROL, V76, pS49, DOI 10.1016/j.jcv.2015.11.015; Whitlock EP, 2011, ANN INTERN MED, V155, P687, DOI 10.7326/0003-4819-155-10-201111150-00376; Wright TC, 2016, AM J CLIN PATHOL, V146, P391, DOI [10.1093/AJCP/AQW125, 10.1093/ajcp/aqw125]; Wright TC, 2014, INT J CANCER, V134, P1835, DOI 10.1002/ijc.28514; Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ	26	1	1	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					316	323		10.1093/AJCP/AQX163			8	Pathology	Pathology	GC0FU	WOS:000429453100005	29471316	Bronze			2019-10-28	
J	Du, H; Markus, C; Metz, M; Feng, ML; Loh, TP				Du, Hao; Markus, Corey; Metz, Michael; Feng, Mengling; Loh, Tze Ping			Derivation of Outcome-Based Pediatric Critical Values	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Critical values; Pediatric; Children; Outcomes based; Evidence based; Panic value; Alert value	INDIVIDUAL BIOLOGICAL VARIATION; LABORATORY REFERENCE INTERVALS	Objectives: There is currently a lack of an outcomes-based definition of critical values for the pediatric population. This has contributed to a highly heterogeneous critical value reporting practice between laboratories. Methods: Anonymized results were extracted from a laboratory information system for 10 biochemistry tests. The probability of high-dependency/intensive care unit admission (as a proxy for adverse outcomes) for each individual laboratory concentration was calculated and adjusted to fit using a polynomial function to model the probability trend. The laboratory value that intersected the 90% probability trend line was considered the critical value threshold. Results: The critical value thresholds for the serum analytes were sodium (mmol/L: <131, >148), potassium (mmol/L: <2.4, >6.4), bicarbonate (mmol/L: <13, >37), chloride (mmol/L: <91, >115), urea (mmol/L: >12), creatinine (mu mol/L: >129), glucose (mmol/L: >17.2), total calcium (mmol/L: <1.9), magnesium (mmol/L: <0.6, >1.2), and phosphate (mmol/L: <0.4, >2.6). Conclusions: This study described an approach to derive contemporary pediatric critical value thresholds.	[Du, Hao; Feng, Mengling] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Loh, Tze Ping] Natl Univ Singapore, Biomed Inst Global Hlth Res & Technol, Singapore, Singapore; [Markus, Corey; Metz, Michael] Womens & Childrens Hosp, SA Pathol, Div Chem Pathol, Adelaide, SA, Australia; [Metz, Michael] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA, Australia; [Loh, Tze Ping] Natl Univ Singapore Hosp, Dept Lab Med, Singapore, Singapore	Loh, TP (reprint author), 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	tploh@hotmail.com		Markus, Corey/0000-0002-5594-9737; Loh, Tze Ping/0000-0002-4272-0001			Aarsand AK, 2014, CLIN CHIM ACTA, V432, P8, DOI 10.1016/j.cca.2013.12.005; Catrou PG, 1997, AM J CLIN PATHOL, V108, P245; Colantonio DA, 2012, CLIN CHEM, V58, P854, DOI 10.1373/clinchem.2011.177741; Don-Wauchope AC, 2009, CLIN BIOCHEM, V42, P1658, DOI 10.1016/j.clinbiochem.2009.06.029; Gong Y, 2009, CLIN BIOCHEM, V42, P1610, DOI 10.1016/j.clinbiochem.2009.08.004; Koerbin G, 2014, CLIN CHIM ACTA, V432, P99, DOI 10.1016/j.cca.2013.10.021; Loh TP, 2015, AM J CLIN PATHOL, V143, P683, DOI 10.1309/AJCPB7Q3AHYLJTPK; Loh TP, 2014, AM J CLIN PATHOL, V142, P657, DOI 10.1309/AJCPHZLQAEYH94HI; Loh TP, 2014, PATHOLOGY, V46, P336, DOI 10.1097/PAT.0000000000000118; Lundberg GD, 1972, MED LAB OBSERV, V4, P47; Perich C, 2015, CLIN CHEM LAB MED, V53, P299, DOI 10.1515/cclm-2014-0739; Tate J, 2016, JIFCC, V27, P48; Tate Jillian R, 2014, Clin Biochem Rev, V35, P213; Tate Jillian R, 2012, Clin Biochem Rev, V33, P121; Tate Jillian R, 2012, Clin Biochem Rev, V33, P81	15	2	2	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					324	331		10.1093/AJCP/AQX165			8	Pathology	Pathology	GC0FU	WOS:000429453100006	29474506				2019-10-28	
J	Clark, BZ; Farrugia, DJ; Landmann, A; Diego, EJ; Dabbs, DJ; Puhalla, SL; Jankowitz, RC; Brufsky, AM; Ahrendt, GM; McAuliffe, PF; Bhargava, R				Clark, Beth Z.; Farrugia, Daniel J.; Landmann, Alessandra; Diego, Emilia J.; Dabbs, David J.; Puhalla, Shannon L.; Jankowitz, Rachel C.; Brufsky, Adam M.; Ahrendt, Gretchen M.; McAuliffe, Priscilla F.; Bhargava, Rohit			Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Breast carcinoma; Neoadjuvant chemotherapy; Residual disease	PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; TERM-FOLLOW-UP; PREOPERATIVE CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; SYSTEMIC CHEMOTHERAPY; SURVIVAL; RECOMMENDATIONS; CLASSIFICATION	Objectives: We hypothesized that prognostic accuracy of the residual disease in breast and lymph nodes (RDBN) method, which is calculated using residual tumor size, nodal involvement, and tumor grade, may be improved by incorporating residual tumor cellularity. Methods: Cases included 614 patients who underwent neoadjuvant therapy for breast cancer. Tumor size was adjusted for residual cellularity of invasive carcinoma and used to calculate modified RDBN (mRDBN) and compared with unmodified gross tumor size (gRDBN). Results: RDBN could be calculated in 428 cases. Relative risks of recurrence and death were significantly higher for RDBN-3 and RDBN-4 compared with RDBN-1. Kaplan-Meier analysis showed significant differences in disease-free survival and overall survival for estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative and ER-positive/HER2-negative subgroups (P < .0001). Conclusions: Both mRDBN and gRDBN provide prognostic information, particularly in HER2-negative carcinoma; however, mRDBN showed better stratification of RDBN-3 and RDBN-4 patients.	[Clark, Beth Z.; Dabbs, David J.; Bhargava, Rohit] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Pathol, 300 Halket St,Rm 4425, Pittsburgh, PA 15213 USA; [Farrugia, Daniel J.; Landmann, Alessandra; Diego, Emilia J.; Ahrendt, Gretchen M.; McAuliffe, Priscilla F.] Univ Pittsburgh, Dept Surg, Div Surg Oncol, Pittsburgh, PA USA; [Farrugia, Daniel J.] Centegra Hlth Syst, Centegra Comprehens Breast Program, Crystal Lake, IL USA; [Landmann, Alessandra] Univ Oklahoma, Coll Med, Dept Surg, Oklahoma City, OK 73190 USA; [Puhalla, Shannon L.; Jankowitz, Rachel C.; Brufsky, Adam M.] Univ Pittsburgh, Dept Med, Inst Canc, Pittsburgh, PA USA; [Ahrendt, Gretchen M.] Univ Colorado, Dept Surg, Aurora, CO USA	Clark, BZ (reprint author), Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Pathol, 300 Halket St,Rm 4425, Pittsburgh, PA 15213 USA.	clarkbz@upmc.edu					Amat S, 2002, INT J ONCOL, V20, P791; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Bhargava R, 2011, MODERN PATHOL, V24, P367, DOI 10.1038/modpathol.2010.209; Bhargava R, 2010, CANCER-AM CANCER SOC, V116, P1431, DOI 10.1002/cncr.24876; Boughey JC, 2014, ANN SURG, V260, P608, DOI 10.1097/SLA.0000000000000924; Broglio KR, 2016, JAMA ONCOL, V2, P751, DOI 10.1001/jamaoncol.2015.6113; Carey LA, 2005, J NATL CANCER I, V97, P1137, DOI 10.1093/jnci/dji206; Choi M, 2016, BREAST CANCER RES TR, V160, P475, DOI 10.1007/s10549-016-4008-4; Chollet P, 2002, BRIT J CANCER, V86, P1041, DOI 10.1038/sj/bjc/6600210; Chollet P, 2008, CANCER J, V14, P128, DOI 10.1097/PPO.0b013e31816bdea2; Corben AD, 2013, ARCH PATHOL LAB MED, V137, P1074, DOI 10.5858/arpa.2012-0290-OA; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Cure H, 2002, BREAST CANCER RES TR, V76, P37, DOI 10.1023/A:1020274709327; Diaz J, 2013, BREAST CANCER RES TR, V138, P91, DOI 10.1007/s10549-013-2411-7; Diaz-Botero S, 2016, ANN SURG ONCOL, V23, P3831, DOI 10.1245/s10434-016-5339-4; Dieras V, 2004, J CLIN ONCOL, V22, P4958, DOI 10.1200/JCO.2004.02.122; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher ER, 2002, CANCER-AM CANCER SOC, V95, P681, DOI 10.1002/cncr.10741; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Lee HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137885; Li XB, 2016, AM J CLIN PATHOL, V145, P871, DOI 10.1093/ajcp/aqw045; Mazouni C, 2007, J CLIN ONCOL, V25, P2650, DOI 10.1200/JCO.2006.08.2271; Mittendorf EA, 2011, J CLIN ONCOL, V29, P1956, DOI 10.1200/JCO.2010.31.8469; Mombelli S, 2015, ONCOLOGY-BASEL, V88, P261, DOI 10.1159/000368557; Mougalian SS, 2016, JAMA ONCOL, V2, P508, DOI 10.1001/jamaoncol.2015.4935; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Peintinger F, 2015, MODERN PATHOL, V28, P913, DOI 10.1038/modpathol.2015.53; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Yang TJ, 2015, ANN SURG ONCOL, V22, pS495, DOI 10.1245/s10434-015-4697-7; Zhang GC, 2013, CURR ONCOL, V20, pE180, DOI 10.3747/co.20.1294	33	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					332	343		10.1093/AJCP/AQX168			12	Pathology	Pathology	GC0FU	WOS:000429453100007	29481634				2019-10-28	
J	Villa, I; Mathieu, MC; Bosq, J; Auperin, A; Pomerol, JF; Lacroix-Triki, M; Scoazec, JY; Dartigues, P				Villa, Irene; Mathieu, Marie-Christine; Bosq, Jacques; Auperin, Anne; Pomerol, Jean-Francois; Lacroix-Triki, Magali; Scoazec, Jean-Yves; Dartigues, Peggy			Daily Biopsy Diagnosis in Surgical Pathology Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Digital pathology; Whole-slide imaging; Biopsy pathology; Diagnostic concordance	LABORATORY QUALITY CENTER; DIGITAL PATHOLOGY; PEDIATRIC PATHOLOGY; OPTICAL MICROSCOPY; VIRTUAL MICROSCOPY; NEEDLE BIOPSIES; BREAST-CANCER; VALIDATION; DERMATOPATHOLOGY; IMAGES	Objectives: The current challenge for the various digital whole-slide imaging (WSI) systems is to be definitively validated for diagnostic purposes. We designed a concordance study between glass slide and digital slide diagnosis in real-life conditions, coupled with an ergonomic study. Methods: Three senior pathologists evaluated, first in glass slides and then in digital slides, 119 biopsy cases, including 749 slides, with 332 H&E saffron stains and 417 additional techniques, mainly immunohistochemistry. Results: All digital slides, including specially stained slides, were interpretable. Concordance between glass slides and digital slides was observed in 87.4% of cases. Minor discordances were observed in 12 (10.1%) cases and major discordances, with therapeutic impact, in three (2.5%), including one related to WSI. The satisfaction of participants was high and increased with time. Conclusions: Our study confirms the feasibility and accuracy of WSI diagnosis, even for cases having multiple samples and requiring special staining techniques, such as immunohistochemistry and in situ hybridization.	[Villa, Irene; Mathieu, Marie-Christine; Bosq, Jacques; Lacroix-Triki, Magali; Scoazec, Jean-Yves; Dartigues, Peggy] Gustave Roussy Canc Campus, Dept Biol & Pathol Med, Serv Pathol Morphol, Villejuif, France; [Auperin, Anne] Gustave Roussy Canc Campus, Serv Biostat & Epidemiol, Villejuif, France; [Pomerol, Jean-Francois] TRIBVN Healthcare, Chatillon, France; [Scoazec, Jean-Yves] Univ Paris Sud XI, Univ Paris Saclay, Fac Med Bicetre, Le Kremlin Bicetre, France	Scoazec, JY (reprint author), Gustave Roussy, Dept Biol & Pathol Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	jean-yves.scoazec@gustaveroussy.fr					Abels Esther, 2017, J Pathol Inform, V8, P23, DOI 10.4103/jpi.jpi_11_17; Al-Janabi S, 2014, J RENAL INJ PREV, V3, P91, DOI 10.12861/jrip.2014.26; Al-Janabi S, 2013, J CLIN PATHOL, V66, P218, DOI 10.1136/jclinpath-2012-201104; Al-Janabi S, 2012, J CLIN PATHOL, V65, P1107, DOI 10.1136/jclinpath-2012-200878; Al-Janabi S, 2012, HISTOPATHOLOGY, V61, P1, DOI 10.1111/j.1365-2559.2011.03814.x; Al-Janabi S, 2012, HUM PATHOL, V43, P702, DOI 10.1016/j.humpath.2011.06.017; Al-Janabi S, 2012, J CLIN PATHOL, V65, P152, DOI 10.1136/jclinpath-2011-200277; Arnold MA, 2015, PEDIATR DEVEL PATHOL, V18, P109, DOI 10.2350/14-07-1523-OA.1; Bauer Thomas W, 2015, J Pathol Inform, V6, P49, DOI 10.4103/2153-3539.163988; Bauer TW, 2014, ARCH PATHOL LAB MED, V138, P1459, DOI 10.5858/arpa.2013-0541-OA; Bauer TW, 2013, ARCH PATHOL LAB MED, V137, P518, DOI 10.5858/arpa.2011-0678-OA; Boyce BF, 2015, BIOTECH HISTOCHEM, V90, P321, DOI 10.3109/10520295.2015.1033463; Brachtel E, 2012, J BIOPHOTONICS, V5, P327, DOI 10.1002/jbio.201100103; Camparo P, 2012, APMIS, V120, P298, DOI 10.1111/j.1600-0463.2011.02872.x; Campbell WS, 2015, HUM PATHOL, V46, P1945, DOI 10.1016/j.humpath.2015.08.016; Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Campbell WS, 2012, HUM PATHOL, V43, P1739, DOI 10.1016/j.humpath.2011.12.023; Cheng CL, 2016, J CLIN PATHOL, V69, P784, DOI 10.1136/jclinpath-2015-203600; Dunn BE, 1999, TELEMED J, V5, P323, DOI 10.1089/107830299311899; Evans AJ, 2017, ARCH PATHOL LAB MED, V141, P944, DOI 10.5858/arpa.2016-0074-OA; Evans AJ, 2010, SEMIN DIAGN PATHOL, V27, P160, DOI 10.1053/j.semdp.2010.05.002; Gilbertson JR, 2006, BMC CLIN PATHOL, V6, DOI 10.1186/1472-6890-6-4; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Griffin J, 2017, HISTOPATHOLOGY, V70, P134, DOI 10.1111/his.12993; Kondo Y, 2012, PATHOL INT, V62, P592, DOI 10.1111/j.1440-1827.2012.02847.x; Krishnamurthy S, 2013, ARCH PATHOL LAB MED, V137, P1733, DOI 10.5858/arpa.2012-0437-OA; Loughrey MB, 2015, VIRCHOWS ARCH, V467, P137, DOI 10.1007/s00428-015-1780-1; Nunes C, 2014, PATHOL RES PRACT, V210, P713, DOI 10.1016/j.prp.2014.06.031; Onega T, 2016, J DIGIT IMAGING, V29, P243, DOI 10.1007/s10278-015-9836-y; Onega T, 2014, J DIGIT IMAGING, V27, P642, DOI 10.1007/s10278-014-9683-2; Ordi J, 2015, J CLIN PATHOL, V68, P33, DOI 10.1136/jclinpath-2014-202524; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Pekmezci Melike, 2016, J Pathol Inform, V7, P25, DOI 10.4103/2153-3539.181769; Reyes Carolina, 2014, J Pathol Inform, V5, P5, DOI 10.4103/2153-3539.127814; Rodriguez-Urrego PA, 2011, HUM PATHOL, V42, P68, DOI 10.1016/j.humpath.2010.07.001; Shah KK, 2016, J AM ACAD DERMATOL, V75, P1229, DOI 10.1016/j.jaad.2016.08.024; Thrall MJ, 2015, ARCH PATHOL LAB MED, V139, P656, DOI 10.5858/arpa.2014-0073-OA; van der Post RS, 2013, HISTOPATHOLOGY, V63, P114, DOI 10.1111/his.12131	38	0	0	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					344	351		10.1093/AJCP/AQX161			8	Pathology	Pathology	GC0FU	WOS:000429453100008	29452345	Bronze			2019-10-28	
J	Nishikimi, K; Nakagawa, K; Tate, S; Matsuoka, A; Iwamoto, M; Kiyokawa, T; Shozu, M				Nishikimi, Kyoko; Nakagawa, Kiyoshi; Tate, Shinichi; Matsuoka, Ayumu; Iwamoto, Masami; Kiyokawa, Takako; Shozu, Makio			Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Ovarian clear cell carcinoma; TERT promoter mutation; Adenofibroma	MUTANT TERT PROMOTER; DISEASE RECURRENCE; ARID1A EXPRESSION; BLADDER-CANCER; TUMORS; ENDOMETRIOSIS; LENGTH; ADENOFIBROMA; PATHOGENESIS; MELANOMA	Objectives: The present study assessed whether human telomerase reverse transcriptase (TERT) promoter mutations mediate the increased mortality risk observed in patients with ovarian clear cell carcinoma (CCC) and characterized the pathologic features of TERT promoter mutation-associated ovarian CCC. Methods: The TERT promoter region in genomic DNA extracted from paraffin-embedded ovarian CCC specimens (n = 93) was bidirectionally sequenced. Results: A total of 24 TERT promoter mutations were identified among the analyzed CCC cases, of which 11 were known "hotspot" mutations whose frequency was increased in CCC cases with compared to without coexistent adenofibroma (P < .05). In contrast, the 14 (including three novel) identified uncommon site mutations were shown to be associated with a poor progression-free survival rate (P < .01). Conclusions: The identified uncommon TERT promoter mutations exacerbate the poor prognosis characteristic of ovarian CCC cases, and the hotspot mutations appear to be a molecular feature of the adenofibroma-associated form of the disease.	[Nishikimi, Kyoko; Nakagawa, Kiyoshi; Tate, Shinichi; Matsuoka, Ayumu; Shozu, Makio] Chiba Univ, Grad Sch Med, Dept Gynecol, Chiba, Japan; [Iwamoto, Masami; Kiyokawa, Takako] Jikei Univ, Dept Pathol, Sch Med, Tokyo, Japan	Nishikimi, K (reprint author), Chiba Univ, Grad Sch Med, Dept Gynecol, Chuo Ku, Inohana 1-8-1, Chiba, Chiba 2608677, Japan.	kni-shikimi@hospital.chiba-u.jp			Chiba Foundation for Health Promotion and Disease Prevention [4377]	This work was supported in part by a grant (4377) from the Chiba Foundation for Health Promotion and Disease Prevention.	Ayhan A, 2012, INT J GYNECOL CANCER, V22, P1310, DOI 10.1097/IGC.0b013e31826b5dcc; BELL DA, 1985, CANCER, V56, P2922, DOI 10.1002/1097-0142(19851215)56:12<2922::AID-CNCR2820561233>3.0.CO;2-L; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bojesen SE, 2013, NAT GENET, V45, P371, DOI 10.1038/ng.2566; Chen YL, 2014, INT J SURG, V12, P659, DOI 10.1016/j.ijsu.2014.05.066; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Coburn SB, 2017, INT J CANCER, V140, P2451, DOI 10.1002/ijc.30676; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Griewank KG, 2014, JNCI-J NATL CANCER I, P106, DOI DOI 10.1093/JNCI/DJU246; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hurst CD, 2014, EUR UROL, V65, P367, DOI 10.1016/j.eururo.2013.08.057; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Kuhn E, 2011, MODERN PATHOL, V24, P1139, DOI 10.1038/modpathol.2011.67; Kurman RJ, 2014, WHO CLASSIFICATION T; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Labussiere M, 2014, NEUROLOGY, V83, P1200, DOI 10.1212/WNL.0000000000000814; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Liu TT, 2014, ENDOCR-RELAT CANCER, V21, P427, DOI 10.1530/ERC-14-0016; Ma X, 2014, LUNG CANCER, V86, P369, DOI 10.1016/j.lungcan.2014.10.009; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nishikimi K, 2015, HISTOPATHOLOGY, V67, P866, DOI 10.1111/his.12721; Rachakonda PS, 2013, P NATL ACAD SCI USA, V110, P17426, DOI 10.1073/pnas.1310522110; Rahmanto YS, 2016, J BIOL CHEM, V291, P9690, DOI 10.1074/jbc.M115.707612; Ramlee MK, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080050; ROTH LM, 1984, CANCER-AM CANCER SOC, V53, P1156, DOI 10.1002/1097-0142(19840301)53:5<1156::AID-CNCR2820530522>3.0.CO;2-2; Sobin LHMKG, 2011, TNM CLASSIFICATION M; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Veras E, 2009, AM J SURG PATHOL, V33, P844, DOI 10.1097/PAS.0b013e31819c4271; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wu RC, 2014, J PATHOL, V232, P473, DOI 10.1002/path.4315; Xiao WB, 2012, INT J CLIN EXP PATHO, V5, P642; Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200; Yamamoto S, 2008, J PATHOL, V216, P103, DOI 10.1002/path.2386; Yamamoto S, 2012, MODERN PATHOL, V25, P615, DOI 10.1038/modpathol.2011.189; Zhao CQ, 2011, J CANCER, V2, P94, DOI 10.7150/jca.2.107	38	0	0	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					352	361		10.1093/AJCP/AQX166			10	Pathology	Pathology	GC0FU	WOS:000429453100009	29474637				2019-10-28	
J	Libert, D; Procop, GW; Ansari, MQ				Libert, Diane; Procop, Gary W.; Ansari, Mohammad Q.			Histoplasma Urinary Antigen Testing Obviates the Need for Coincident Serum Antigen Testing	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Histoplasma; Histoplasmosis; Diagnosis; Antigen; Test utilization	PULMONARY HISTOPLASMOSIS; PCR ASSAY; DIAGNOSIS; CAPSULATUM; OUTBREAK	Objectives: Serum and urine antigen (SAg, UAg) detection are common tests for Histoplasma capsulatum. UAg detection is more widely used and reportedly has a higher sensitivity. We investigated whether SAg detection contributes meaningfully to the initial evaluation of patients with suspected histoplasmosis. Methods: We reviewed 20,285 UAg and 1,426 SAg tests ordered from 1997 to 2016 and analyzed paired UAg and SAg tests completed on the same patient within 1 week. We determined the positivity rate for each test. Results: Of 601 paired specimens, 542 were concurrent negatives and 48 were concurrent positives (98% agreement). Medical records were available for eight of 11 pairs with discrepant results. UAg was falsely positive in six instances, truly positive once, and falsely negative once. Conclusions: These findings support using a single antigen detection test, rather than both UAg and SAg, as an initial screen for suspected histoplasmosis. This aligns with the current practice of most physicians.	[Libert, Diane] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA; [Procop, Gary W.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Ansari, Mohammad Q.] Cleveland Vet Affairs Med Ctr, Dept Pathol & Lab Med, Cleveland, OH USA	Libert, D (reprint author), Cleveland Clin, Lerner Coll Med, 9980 Carnegie Ave, Cleveland, OH 44195 USA.	dml5335@gmail.com		Ansari, Mohammad/0000-0002-7313-7142			Assi M, 2013, CLIN INFECT DIS, V57, P1542, DOI 10.1093/cid/cit593; Centers for Disease Control and Prevention, 2017, INF HLTH PROF HIST; Davies S F, 1986, Semin Respir Infect, V1, P9; Fandino-Devia E, 2016, MYCOPATHOLOGIA, V181, P197, DOI 10.1007/s11046-015-9965-3; Guedes HLD, 2003, J CLIN MICROBIOL, V41, P535, DOI 10.1128/JCM.41.2.535-539.2003; Guimaraes AJ, 2006, BRAZ J MICROBIOL, V37, P1, DOI 10.1590/S1517-83822006000100001; GUSTAFSON TL, 1981, AM J MED, V71, P759, DOI 10.1016/0002-9343(81)90361-2; Hage CA, 2011, CLIN INFECT DIS, V53, P448, DOI 10.1093/cid/cir435; Kauffman CA, 2016, GOLDMAN CECIL MED, P2070; Kauffman CA, 2007, CLIN MICROBIOL REV, V20, P115, DOI 10.1128/CMR.00027-06; Kaufman L., 1976, MANUAL CLIN IMMUNOLO, P363; Kerwin TC, 2016, CARDIOL RES PRACT, DOI 10.1155/2016/1950191; Koepsell SA, 2012, J CLIN MICROBIOL, V50, P3395, DOI 10.1128/JCM.01705-12; LeMonte A, 2007, CLIN VACCINE IMMUNOL, V14, P802, DOI 10.1128/CVI.00035-07; Nacher M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002319; PICARDI JL, 1976, AM REV RESPIR DIS, V114, P171; Procop GW, 2015, AM J CLIN PATHOL, V143, P623, DOI 10.1309/AJCPJOJ3HKEBD3TU; Procop GW, 2014, AM J CLIN PATHOL, V141, P718, DOI 10.1309/AJCPOWHOIZBZ3FRW; Stewart BA, 2010, J AM MED INFORM ASSN, V17, P341, DOI 10.1136/jamia.2009.001750; Swartzentruber S, 2009, CLIN INFECT DIS, V49, P1878, DOI 10.1086/648421; WARD JI, 1979, AM J MED, V66, P587, DOI 10.1016/0002-9343(79)91168-9; WHEAT J, 1982, ANN INTERN MED, V97, P680, DOI 10.7326/0003-4819-97-5-680; Wheat LJ, 2006, EXPERT OPIN BIOL TH, V6, P1207, DOI 10.1517/14712598.6.11.1207; Wheat LJ, 2016, INFECT DIS CLIN N AM, V30, P207, DOI 10.1016/j.idc.2015.10.009; Wheat LJ, 2004, SEM RESP CRIT CARE M, V25, P129, DOI 10.1055/s-2004-824898; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WHEAT LJ, 1984, MEDICINE, V63, P201, DOI 10.1097/00005792-198407000-00002; WHEAT LJ, 1982, ANN INTERN MED, V96, P159, DOI 10.7326/0003-4819-96-2-159; Wheat LJ, DIAGNOSING HISTOPLAS; WILLIAMS B, 1994, ARCH PATHOL LAB MED, V118, P1205	30	2	2	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	APR	2018	149	4					362	368		10.1093/AJCP/AQX169			7	Pathology	Pathology	GC0FU	WOS:000429453100010	29462251				2019-10-28	
J	Grupp, K; Melling, N; Bogoevska, V; Reeh, M; Uzunoglu, FG; El Gammal, AT; Nentwich, MF; Izbicki, JR; Bogoevski, D				Grupp, Katharina; Melling, Nathaniel; Bogoevska, Valentina; Reeh, Matthias; Uzunoglu, Faik Guntac; El Gammal, Alexander Tarek; Nentwich, Michael Fabian; Izbicki, Jakob Robert; Bogoevski, Dean			Expression of ICAM-1, E-cadherin, periostin and midkine in metastases of pancreatic ductal adenocarcinomas	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						ICAM-1; E-cadherin; Periostin; Midkine; Pancreatic cancer; Liver metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; ADHESION MOLECULE-1 ICAM-1; ALPHA-CATENIN; BETA-CATENIN; INFLAMMATORY CYTOKINES; CARCINOMA-CELLS; CANCER; OVEREXPRESSION; INVASIVENESS; INFILTRATION	Development and progression of malignant tumors is in part characterized by the ability of a tumor cell to overcome cell-cell and cell-matrix adhesion and to disseminate in organs distinct from that in which they originated. This study was undertaken to analyze the clinical significance of the expression of the following cell-cell and cell-matrix adhesion molecules in pancreatic ductal adenocarcinomas (PDACs) and synchronous liver metastases: intercellular adhesion molecule 1 (ICAM-1), E-cadherin, periostin, and midkine (MK). ICAM-1, E-cadherin, periostin and MK expression was analyzed by immunohistochemistry on a tissue microarray containing 34 PDACs and 12 liver metastasis specimens. ICAM-1 expression was predominantly localized in the membranes of the cells and was found in weak to moderate intensities in PDACs and liver metastases. E-cadherin expression was absent in the majority of PDACs and corresponding liver metastases. The secreted proteins periostin and MK were expressed in various intensities in primary cancers and liver metastases. Statistical analysis demonstrated that the expression levels of the analyzed markers were neither significantly associated with metastasis in PDACs nor with clinical outcome of patients. Our study shows that the expression of the cell cell and cell-matrix adhesion molecules ICAM-1, E-cadherin, periostin and MK was not significantly linked to metastatic disease in PDACs. Moreover, our study excludes the analyzed markers as prognostic markers in PDACs.	[Grupp, Katharina; Melling, Nathaniel; Bogoevska, Valentina; Reeh, Matthias; Uzunoglu, Faik Guntac; El Gammal, Alexander Tarek; Nentwich, Michael Fabian; Izbicki, Jakob Robert; Bogoevski, Dean] Univ Med Ctr Hamburg Eppendorf, Gen Visceral & Thorac Surg Dept & Clin, Martinistr 52, D-20246 Hamburg, Germany	Grupp, K (reprint author), Univ Med Ctr Hamburg Eppendorf, Gen Visceral & Thorac Surg Dept & Clin, Martinistr 52, D-20246 Hamburg, Germany.	k.grupp@uke.de; n.melling@uke.de; v.bogoevski@uke.de; f.uzunoglu@uke.de; a.elgammal@uke.de; m.nentwich@uke.de; izbicki@uke.de; d.bogoevski@uke.de					Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Dorado J, 2011, J GASTROENTEROL, V46, P966, DOI 10.1007/s00535-011-0422-x; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hong SM, 2011, MODERN PATHOL, V24, P1237, DOI 10.1038/modpathol.2011.74; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jones DR, 2014, BRIT J PHARMACOL, V171, P2925, DOI 10.1111/bph.12601; Joo YE, 2002, PANCREATOLOGY, V2, P129, DOI 10.1159/000055903; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karayiannakis AJ, 2001, ANTICANCER RES, V21, P4127; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kim CJ, 2011, INT J ONCOL, V38, P1759, DOI 10.3892/ijo.2011.997; Kotteas EA, 2014, ANTICANCER RES, V34, P4665; Ksiazek K, 2010, INT J CANCER, V127, P293, DOI 10.1002/ijc.25036; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li Yu-Jun, 2003, Hepatobiliary Pancreat Dis Int, V2, P471; Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Mirlacher M, 2010, METHODS MOL BIOL, V664, P37, DOI 10.1007/978-1-60761-806-5_4; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428-011-1151-5; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Oida Y, 2006, ONCOL REP, V16, P457; Pryczynicz A, 2010, FOLIA HISTOCHEM CYTO, V48, P128, DOI 10.2478/v10042-008-0089-1; Ratajczak-Wielgomas K, 2015, FOLIA HISTOCHEM CYTO, V53, P120, DOI 10.5603/FHC.a2015.0014; Roland CL, 2010, EXP BIOL MED, V235, P263, DOI 10.1258/ebm.2009.009215; Sakamoto K, 2012, PATHOL INT, V62, P445, DOI 10.1111/j.1440-1827.2012.02815.x; Sandra F, 2004, ORAL ONCOL, V40, P274, DOI 10.1016/j.oraloncology.2003.08.011; Shimamura T, 2003, J CLIN ONCOL, V21, P659, DOI 10.1200/JCO.2003.06.179; Shimoyama S, 1997, PANCREAS, V14, P181, DOI 10.1097/00006676-199703000-00011; Shin SJ, 2005, JPN J CLIN ONCOL, V35, P342, DOI 10.1093/jjco/hyi094; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Tempia-Caliera AA, 2002, J SURG ONCOL, V79, P93, DOI 10.1002/jso.10053; ten Kate M, 2006, J PANCREAS, V7, P454; van Grevenstein WMU, 2006, PANCREAS, V32, P396, DOI 10.1097/01.mpa.0000220865.80034.2a; Winter JM, 2008, CLIN CANCER RES, V14, P412, DOI 10.1158/1078-0432.CCR-07-0487; Yan W, 2006, J BIOL CHEM, V281, P19700, DOI 10.1074/jbc.M601856200; Yonemasu H, 2001, ONCOL REP, V8, P745; Ziprin P, 2003, CELL COMMUN ADHES, V10, P141, DOI 10.1080/15419060390262561	46	1	2	3	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					109	113		10.1016/j.yexmp.2018.01.005			5	Pathology	Pathology	GC8IO	WOS:000430037300001	29355490				2019-10-28	
J	Chistiakov, DA; Melnichenko, AA; Grechko, AV; Myasoedova, VA; Orekhov, AN				Chistiakov, Dimitry A.; Melnichenko, Alexandra A.; Grechko, Andrey V.; Myasoedova, Veronika A.; Orekhov, Alexander N.			Potential of anti-inflammatory agents for treatment of atherosclerosis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review						Atherosclerosis; Inflammation; Cardiovascular disease; Anti-inflammatory therapy; Statins	SECRETORY PHOSPHOLIPASE A(2); ACTIVATED PROTEIN-KINASE; ACUTE CORONARY SYNDROME; SMOOTH-MUSCLE-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; RHEUMATOID-ARTHRITIS PATIENTS; INHIBITOR VIA-2291 ATRELEUTON; NECROSIS-FACTOR INHIBITORS; PLACEBO-CONTROLLED TRIAL; C-REACTIVE PROTEIN	Chronic inflammation is a central pathogenic mechanism of atherosclerosis induction and progression. Vascular inflammation is associated with accelerated onset of late atherosclerosis complications. Atherosclerosis-related inflammation is mediated by a complex cocktail of pro-inflammatory cytokines, chemokines, bioactive lipids, and adhesion molecules, and blocking the key pro-atherogenic inflammatory mechanisms can be beneficial for treatment of atherosclerosis. Therapeutic agents that specifically target some of the atherosclerosis-related inflammatory mechanisms have been evaluated in preclinical and clinical studies. The most promising anti-inflammatory compounds for treatment of atherosclerosis include non-specific anti-inflammatory drugs, phospholipase inhibitors, blockers of major inflammatory cytokines, leukotrienes, adhesion molecules, and pro inflammatory signaling pathways, such as CCL2-CCR2 axis or p38 MAPK pathway. Ongoing studies attempt evaluating therapeutic utility of these anti-inflammatory drugs for treatment of atherosclerosis. The obtained results are important for our understanding of atherosclerosis-related inflammatory mechanisms and for designing randomized controlled studies assessing the effect of specific anti-inflammatory strategies on cardiovascular outcomes.	[Chistiakov, Dimitry A.] Serbsky Fed Med Res Ctr Psychiat & Narcol, Div Basic & Appl Neurobiol, Dept Neurochem, Moscow 119991, Russia; [Melnichenko, Alexandra A.; Myasoedova, Veronika A.; Orekhov, Alexander N.] Russian Acad Sci, Inst Gen Pathol & Pathophysiol, Lab Angiopathol, Moscow 125315, Russia; [Grechko, Andrey V.] Fed Sci Clin Ctr Resuscitat & Rehabil, Moscow 109240, Russia; [Orekhov, Alexander N.] Skolkovo Innovat Ctr, Inst Atherosclerosis Res, Moscow 121609, Russia	Orekhov, AN (reprint author), Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Lab Angiopathol, Moscow 125315, Russia.	a.h.opexob@gmail.com	Melnichenko, Alexandra A/V-5783-2018; Grechko, Andrey/C-8208-2018; Orekhov, Alexander N/J-4838-2013; Myasoedova, Veronika/K-1024-2016	Grechko, Andrey/0000-0003-3318-796X; Orekhov, Alexander N/0000-0002-6495-1628; Myasoedova, Veronika/0000-0001-8414-5300	Russian Science FoundationRussian Science Foundation (RSF) [14-15-00112]	This work was supported by Russian Science Foundation [Grant # 14-15-00112].	Abbate A, 2012, BIODRUGS, V26, P217, DOI 10.2165/11631570-000000000-00000; Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424; Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102; Back M, 2014, BRIT J PHARMACOL, V171, P3551, DOI 10.1111/bph.12665; Back M, 2009, CARDIOVASC DRUG THER, V23, P41, DOI 10.1007/s10557-008-6140-9; Bakin AV, 2002, J CELL SCI, V115, P3193; Bartolucci AA, 2011, AM J CARDIOL, V107, P1796, DOI 10.1016/j.amjcard.2011.02.325; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Belton OA, 2003, CIRCULATION, V108, P3017, DOI 10.1161/01.CIR.0000104565.78013.AD; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boshuizen MCS, 2015, ARTERIOSCL THROM VAS, V35, P1579, DOI 10.1161/ATVBAHA.115.305464; Cerri C, 2016, J NEUROSCI, V36, P3777, DOI 10.1523/JNEUROSCI.0451-15.2016; Chaparro M, 2012, ALIMENT PHARM THER, V35, P971, DOI 10.1111/j.1365-2036.2012.05057.x; Chen DY, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0559-8; Choudhury RP, 2016, J AM COLL CARDIOL, V68, P1769, DOI 10.1016/j.jacc.2016.07.768; Chung EY, 2011, J NUTR BIOCHEM, V22, P902, DOI 10.1016/j.jnutbio.2010.07.012; Chyu Kuang-Yuh, 2017, Ther Adv Vaccines, V5, P39, DOI 10.1177/2051013617693753; Chyu KY, 2005, BIOCHEM BIOPH RES CO, V338, P1982, DOI 10.1016/j.bbrc.2005.10.141; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d; Cronstein BN, 2013, JCR-J CLIN RHEUMATOL, V19, P19, DOI 10.1097/RHU.0b013e31827d8790; Crossman DC, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-8; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Damjanov N, 2009, ARTHRITIS RHEUM-US, V60, P1232, DOI 10.1002/art.24485; Dawson TC, 1999, ATHEROSCLEROSIS, V143, P205; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Deo R, 2004, J AM COLL CARDIOL, V44, P1812, DOI 10.1016/j.jacc.2004.07.047; Dessi Mariarita, 2013, ISRN Inflamm, V2013, P191823, DOI 10.1155/2013/191823; Di Raimondo D, 2012, CURR PHARM DESIGN, V18, P4385, DOI 10.2174/138161212802481282; Ding CH, 2006, CURR OPIN INVESTIG D, V7, P1020; Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209; Dogra S, 2013, INDIAN J DERMATOL VE, V79, pS35, DOI 10.4103/0378-6323.115526; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; DZIEZANOWSKI MA, 1980, J CELL SCI, V42, P379; ELLIS EF, 1976, SCIENCE, V193, P1135, DOI 10.1126/science.959827; Febbraio MA, 2005, EXERC SPORT SCI REV, V33, P114, DOI 10.1097/00003677-200507000-00003; Fiorucci S, 2004, J PHARMACOL EXP THER, V309, P1174, DOI 10.1124/jpet.103.063651; Fraser H, 2009, J CARDIOVASC PHARM, V53, P60, DOI 10.1097/FJC.0b013e318195bfbc; Fredrikson GN, 2005, AUTOIMMUNITY, V38, P171, DOI 10.1080/08916930500050525; Freigang S, 1998, ARTERIOSCL THROM VAS, V18, P1972, DOI 10.1161/01.ATV.18.12.1972; Frostegard J, 1999, ATHEROSCLEROSIS, V145, P33, DOI 10.1016/S0021-9150(99)00011-8; Fujisue K, 2017, CIRC J, V81, P1174, DOI 10.1253/circj.CJ-16-0949; Gabay C, 2016, ANN RHEUM DIS, V75, P1806, DOI 10.1136/annrheumdis-2015-207872; Garnero P, 2010, ARTHRITIS RHEUM-US, V62, P33, DOI 10.1002/art.25053; Gaztanaga J, 2015, ATHEROSCLEROSIS, V240, P53, DOI 10.1016/j.atherosclerosis.2015.02.027; Genovese MC, 2011, J RHEUMATOL, V38, P846, DOI 10.3899/jrheum.100602; Gerards AH, 2003, RHEUMATOLOGY, V42, P1189, DOI 10.1093/rheumatology/keg323; Golias C, 2007, IN VIVO, V21, P757; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Haraoui Boulos, 2007, Ther Clin Risk Manag, V3, P99, DOI 10.2147/tcrm.2007.3.1.99; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hassan Mohamed, 2015, Glob Cardiol Sci Pract, V2015, P6, DOI 10.5339/gcsp.2015.6; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Haverslag Rene, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P252, DOI 10.2174/187152908786786188; He XY, 1998, J IMMUNOL, V160, P1029; Hemkens LG, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011047.pub2; Hemkens LG, 2016, HEART, V102, P590, DOI 10.1136/heartjnl-2015-308542; Herbin O, 2012, ARTERIOSCL THROM VAS, V32, P605, DOI 10.1161/ATVBAHA.111.242800; Hermansson A, 2011, CIRCULATION, V123, P1083, DOI 10.1161/CIRCULATIONAHA.110.973222; Hjeltnes G, 2013, CLIN EXP RHEUMATOL, V31, P415; Hohlfeld T, 2015, THROMB HAEMOSTASIS, V114, P469, DOI 10.1160/TH15-03-0191; Hoyer FF, 2012, MOL CELL BIOCHEM, V359, P25, DOI 10.1007/s11010-011-0995-y; Hurlimann D, 2002, CIRCULATION, V106, P2184, DOI 10.1161/01.CIR.0000037521.71373.44; IKEDA U, 1991, AM J PHYSIOL, V260, pH1713; Ikonomidis I, 2008, CIRCULATION, V117, P2662, DOI 10.1161/CIRCULATIONAHA.107.731877; Jiang Q., 2013, EXPT MOL PATHOLOGY, V104, P114; Jiang Q, 2013, FEBS LETT, V587, P2420, DOI 10.1016/j.febslet.2013.06.011; Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875-010-9440-3; Kavanaugh A, 2013, ANN RHEUM DIS, V72, P674; Kawashiri SY, 2011, RHEUMATOL INT, V31, P451, DOI 10.1007/s00296-009-1303-y; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Ketelhuth DFJ, 2015, PROSTAG OTH LIPID M, V121, P105, DOI 10.1016/j.prostaglandins.2015.05.007; Kim J, 2012, STEM CELL TRANSL MED, V1, P548, DOI 10.5966/sctm.2011-0063; Kim SC, 2017, ARTHRITIS RHEUMATOL, V69, P1154, DOI 10.1002/art.40084; Kirkby NS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098165; Koch M, 2014, IUBMB LIFE, V66, P735, DOI 10.1002/iub.1333; Kokoska LA, 2016, DIABETES RES CLIN PR, V120, P31, DOI 10.1016/j.diabres.2016.07.012; Kunutsor SK, 2017, DIABETIC MED, V34, P316, DOI 10.1111/dme.13133; Le Bel M, 2014, J INNATE IMMUN, V6, P159, DOI 10.1159/000353694; Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914; Libby P, 2014, CIRC RES, V114, P1867, DOI 10.1161/CIRCRESAHA.114.302699; Lim S, 2014, BMB REP, V47, P1, DOI 10.5483/BMBRep.2014.47.1.285; Lopalco G, 2016, CLIN EXP RHEUMATOL, V34, P531; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Major RW, 2016, ATHEROSCLEROSIS, V251, P177, DOI 10.1016/j.atherosclerosis.2016.06.013; Mallat Z, 2010, CIRCULATION, V122, P2183, DOI 10.1161/CIRCULATIONAHA.110.936393; Markworth JF, 2016, EXERC IMMUNOL REV, V22, P110; Martinez GJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002128; Martinez-Gonzalez J, 2004, ATHEROSCLEROSIS, V174, P305, DOI 10.1016/j.atherosclerosis.2004.01.037; Matsumoto S, 2017, CLIN CARDIOL, V40, P210, DOI 10.1002/clc.22646; Matusik P, 2012, THROMB HAEMOSTASIS, V108, P443, DOI 10.1160/TH12-05-0341; Maxwell LJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005468.pub2; MAXWELL MP, 1991, J CARDIOVASC PHARM, V17, P539, DOI 10.1097/00005344-199104000-00003; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje.; Mocco J, 2002, CIRC RES, V91, P907, DOI 10.1161/01.RES.0000042063.15901.20; Mohler ER, 2008, J AM COLL CARDIOL, V51, P1632, DOI 10.1016/j.jacc.2007.11.079; Morton AC, 2015, EUR HEART J, V36, P377, DOI 10.1093/eurheartj/ehu272; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Nava F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010729.pub2; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Nicholls SJ, 2014, JAMA-J AM MED ASSOC, V311, P252, DOI 10.1001/jama.2013.282836; Nicholls SJ, 2012, CARDIOVASC DRUG THER, V26, P71, DOI 10.1007/s10557-011-6358-9; Nidorf M, 2007, AM J CARDIOL, V99, P805, DOI 10.1016/j.amjcard.2006.10.039; Nidorf SM, 2013, J AM COLL CARDIOL, V61, P404, DOI 10.1016/j.jacc.2012.10.027; Niemann-Jonsson A, 2001, ARTERIOSCL THROM VAS, V21, P1909, DOI 10.1161/hq1201.100222; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Ozen S, 2017, SEMIN ARTHRITIS RHEU, V47, P115, DOI 10.1016/j.semarthrit.2017.03.006; Palomo I, 2008, MOL MED REP, V1, P179; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Petri MH, 2017, BRIT J PHARMACOL, V174, P4043, DOI 10.1111/bph.13707; Petri MH, 2015, CARDIOVASC RES, V105, P65, DOI 10.1093/cvr/cvu224; Pirillo A, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/152786; Protogerou AD, 2011, ATHEROSCLEROSIS, V219, P734, DOI 10.1016/j.atherosclerosis.2011.09.015; Qamar A, 2012, CURR OPIN LIPIDOL, V23, P548, DOI 10.1097/MOL.0b013e328359b0a6; Rajagopalan PTR, 2002, P NATL ACAD SCI USA, V99, P13481, DOI 10.1073/pnas.172501499; Raju N, 2016, AM J MED, V129, pE35, DOI 10.1016/j.amjmed.2015.10.046; Raval J, 2015, HEART LUNG CIRC, V24, P660, DOI 10.1016/j.hlc.2015.01.010; Riccioni G, 2010, CURR DRUG TARGETS, V11, P882, DOI 10.2174/138945010791320881; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Ridker PM, 2012, CIRCULATION, V126, P2739, DOI 10.1161/CIRCULATIONAHA.112.122556; Robertson S, 2016, CLIN SCI, V130, P1237, DOI 10.1042/CS20160090; Romano M, 2015, EUR J PHARMACOL, V760, P49, DOI 10.1016/j.ejphar.2015.03.083; Ronda N, 2015, ARTHRITIS RHEUMATOL, V67, P1155, DOI 10.1002/art.39039; Rosenson RS, 2012, EUR HEART J, V33, P2899, DOI 10.1093/eurheartj/ehs148; Rosenson RS, 2011, CARDIOVASC DRUG THER, V25, P539, DOI 10.1007/s10557-011-6344-2; Rosenson RS, 2011, EUR HEART J, V32, P999, DOI 10.1093/eurheartj/ehq374; Rosenson RS, 2010, J AM COLL CARDIOL, V56, P1079, DOI 10.1016/j.jacc.2010.06.015; Rosenson RS, 2009, LANCET, V373, P649, DOI 10.1016/S0140-6736(09)60403-7; Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624; Sanchez A, 2010, ATHEROSCLEROSIS, V213, P392, DOI 10.1016/j.atherosclerosis.2010.09.022; Schneider C, 2006, J AM CHEM SOC, V128, P720, DOI 10.1021/ja056517y; Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013; Schror K, 2015, PROSTAG OTH LIPID M, V121, P17, DOI 10.1016/j.prostaglandins.2015.07.004; Schror K, 1997, SEMIN THROMB HEMOST, V23, P349, DOI 10.1055/s-2007-996108; Shapiro MD, 2016, CIRC RES, V118, P732, DOI 10.1161/CIRCRESAHA.115.306471; Shaposhnik Z, 2009, J LIPID RES, V50, P623, DOI 10.1194/jlr.M800361-JLR200; Shirey KA, 2014, MUCOSAL IMMUNOL, V7, P549, DOI 10.1038/mi.2013.71; Simpson SH, 2011, J GEN INTERN MED, V26, P1336, DOI 10.1007/s11606-011-1757-y; Sordi R, 2013, INT IMMUNOPHARMACOL, V17, P283, DOI 10.1016/j.intimp.2013.06.010; Soubrier M, 2017, RHEUMATOL THER, V4, P133, DOI 10.1007/s40744-016-0049-8; Souza MC, 2015, INT IMMUNOPHARMACOL, V24, P400, DOI 10.1016/j.intimp.2014.12.033; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Strang AC, 2013, ATHEROSCLEROSIS, V229, P174, DOI 10.1016/j.atherosclerosis.2013.04.031; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; SVENSSON J, 1976, ACTA PHYSIOL SCAND, V98, P285, DOI 10.1111/j.1748-1716.1976.tb10313.x; Tabas I, 2017, IMMUNITY, V47, P621, DOI 10.1016/j.immuni.2017.09.008; Tabibiazar R, 2005, PHYSIOL GENOMICS, V22, P213, DOI 10.1152/physiolgenomics.00001.2005; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tardif JC, 2010, CIRC-CARDIOVASC IMAG, V3, P298, DOI 10.1161/CIRCIMAGING.110.937169; Tong SE, 2012, J CLIN PHARMACOL, V52, P717, DOI 10.1177/0091270011405496; Perez-Gomez MV, 2016, EXPERT OPIN INV DRUG, V25, P1045, DOI 10.1080/13543784.2016.1196184; Vanhatupa S, 2008, BIOCHEM J, V409, P179, DOI 10.1042/BJ20070620; Voloshyna I, 2014, TRENDS CARDIOVAS MED, V24, P45, DOI 10.1016/j.tcm.2013.06.003; Walker J, 2011, SHOCK, V36, P410, DOI 10.1097/SHK.0b013e31822798c1; Welt K, 2000, EXP TOXICOL PATHOL, V52, P27, DOI 10.1016/S0940-2993(00)80012-3; Wessels JAM, 2008, RHEUMATOLOGY, V47, P249, DOI 10.1093/rheumatology/kem279; Wilcox J N, 1994, J Atheroscler Thromb, V1 Suppl 1, pS10; Wilensky RL, 2008, NAT MED, V14, P1059, DOI 10.1038/nm.1870; Winston BW, 1997, J IMMUNOL, V159, P4491; Wong PKK, 2003, ARTHRITIS RHEUM-US, V48, P1177, DOI 10.1002/art.10943; Wu B, 2015, PROSTAG LEUKOTR ESS, V94, P55, DOI 10.1016/j.plefa.2014.11.005; Wu L, 2015, J MOL NEUROSCI, V56, P848, DOI 10.1007/s12031-015-0525-6; Xie ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090286; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; Zhang JY, 2007, TRENDS PHARMACOL SCI, V28, P286, DOI 10.1016/j.tips.2007.04.008; Zhang S, 2017, MOLECULES, V22, DOI 10.3390/molecules22050744	166	9	11	5	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					114	124		10.1016/j.yexmp.2018.01.008			11	Pathology	Pathology	GC8IO	WOS:000430037300002	29378168				2019-10-28	
J	Lu, JG; Nguyen, L; Samadzadeh, S; Masouminia, M; Mendoza, A; Sweeney, O; Tillman, B; Afifyan, N; Morgan, T; French, BA; French, SW				Lu, Jiajie George; Nguyen, Luan; Samadzadeh, Sara; Masouminia, Maryam; Mendoza, Alejandro; Sweeney, Owen; Tillman, Brittany; Afifyan, Nikoo; Morgan, Timothy; French, Barbara A.; French, Samuel W.			Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article							DNA METHYLATION; FANCONI-ANEMIA; BCL-XL; CANCER; LIVER; OVEREXPRESSION; RECEPTOR; PATHWAY; TARGET; DNMT1	Both non-alcoholic steatohepatitis (NASH) and alcoholic hepatitis (AH) can lead to cirrhosis and hepatocellular carcinoma. However, the rate of progression to cirrhosis and tumorigenesis in AH is greater than that in NASH. We asked whether there are differences between the two conditions in the expression levels of proteins involved in the pathogenesis of hepatocellular carcinoma. The proteins tested were presented at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting as overexpressed in hepatocellular carcinoma: KLF4, SCL19A1, FANCG, HRH-1, DNMT1, DNMT3B, TNFR2, DUSP4, EGFR, Integrin alpha 6, HDACII, PDE3A, BCL-XL, and MTCO2. The expression of these proteins was measured in liver biopsy sections from NASH and AH patients using immunohistochemical staining with fluorescent antibodies and then quantifying the fluorescence intensity morphometrically. In AH patients, levels of all tested proteins except HRH-1 were elevated compared to normal patients. In NASH patients, KLF4, SCL19A1, FANCG, HDACII, BCL-XL levels were increased compared to normal controls while HRH-1, DNMT1 and PDE3A levels were decreased. The relative expression of all proteins studied except BCL-XL was significantly higher in AH compared to NASH. In conclusion, proteins involved in hepatocellular cancer development are more highly expressed in AH compared to NASH and normal liver, which corresponds with the higher rate of tumorigenesis in AH patients compared to NASH patients.	[Lu, Jiajie George; Nguyen, Luan; Samadzadeh, Sara; Masouminia, Maryam; Mendoza, Alejandro; Sweeney, Owen; Tillman, Brittany; Afifyan, Nikoo; French, Barbara A.; French, Samuel W.] Harbor UCLA Med Ctr, 1000 W Carson St, Torrance, CA 90502 USA; [Morgan, Timothy] Vet Affairs Med Ctr Long Beach, 5901 E 7th St, Long Beach, CA 90822 USA	French, SW (reprint author), Harbor UCLA Med Ctr, 1000 W Carson St, Torrance, CA 90502 USA.	sfrench@labiomed.org			NIH/AAA grant [UO-21898-05]	This study was funded by NIH/AAA grant # UO-21898-05.	Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; BEGUM NA, 1995, HEPATOLOGY, V22, P1447, DOI 10.1002/hep.1840220518; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; Chen Hong Ping, 2015, Critical Reviews in Oncogenesis, V20, P35; Choi BJ, 2006, PATHOL RES PRACT, V202, P585, DOI 10.1016/j.prp.2006.05.001; Cholankeril G, 2017, WORLD J HEPATOL, V9, P533, DOI 10.4254/wjh.v9.i11.533; Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984; Davio C, 1995, Inflamm Res, V44 Suppl 1, pS70, DOI 10.1007/BF01674401; de Waal L, 2016, NAT CHEM BIOL, V12, P102, DOI [10.1038/NCHEMBIO.1984, 10.1038/nchembio.1984]; Ding Bo, 2015, Asian Pac J Cancer Prev, V16, P3629; Fang Y, 2017, ACTA BIOMATER, V64, P323, DOI 10.1016/j.actbio.2017.10.013; Goldman ID, 2010, CURR OPIN INVEST DR, V11, P1409; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang PX, 2014, J CELL MOL MED, V18, P218, DOI 10.1111/jcmm.12153; Kaji K, 2016, HEPATOLOGY, V64, P582, DOI 10.1002/hep.28563; Kodama K, 2013, ALCOHOL CLIN EXP RES, V37, pE247, DOI 10.1111/j.1530-0277.2012.01900.x; Kwon J, 2013, INT J ONCOL, V43, P1523, DOI 10.3892/ijo.2013.2097; Lee E, 2016, NEOPLASIA, V18, P553, DOI 10.1016/j.neo.2016.07.007; Nguyen L, 2018, EXP MOL PATHOL, V104, P45, DOI 10.1016/j.yexmp.2017.12.007; Masri M. A., 2015, J MOL BIOMARK DIAG S, V2; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0; Saigusa S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0620-x; Scaglioni F, 2011, DIGEST DIS, V29, P202, DOI 10.1159/000323886; Schwartz JM, 2012, CLIN LIVER DIS, V16, P659, DOI 10.1016/j.cld.2012.08.001; Shen H, 2015, EXP MOL PATHOL, V99, P326, DOI 10.1016/j.yexmp.2015.08.001; Van der Heijden MS, 2004, AM J PATHOL, V165, P651, DOI 10.1016/S0002-9440(10)63329-9; Vanamee ES, 2017, TRENDS MOL MED, V23, P1037, DOI 10.1016/j.molmed.2017.09.007; Wang JC, 2015, ONCOL LETT, V9, P2499, DOI 10.3892/ol.2015.3077; Wang MH, 2014, INT J MOL MED, V33, P1019, DOI 10.3892/ijmm.2014.1649; Watanabe J, 2004, SURGERY, V135, P604, DOI 10.1016/j.surg.2003.11.015; Watanabe J, 2002, INT J ONCOL, V21, P515; Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477; Zhao R., 2013, MOL ASP MED, V34; Zhao T, 2017, ONCOL LETT, V13, P342, DOI 10.3892/ol.2016.5403	36	3	3	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					125	129		10.1016/j.yexmp.2018.02.001			5	Pathology	Pathology	GC8IO	WOS:000430037300003	29425759	Green Accepted			2019-10-28	
J	Qing, X; Qing, AN; Ji, P; French, SW; Mason, H				Qing, Xin; Qing, Annie; Ji, Ping; French, Samuel W.; Mason, Holli			Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Chronic myelogenous leukemia; Extramedullary blast crisis; Lymphoblastic leukemia/lymphoma	CHRONIC MYELOID-LEUKEMIA	Background: Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome generated by the reciprocal translocation t(9,22)(q34;q11). The natural progression of the disease follows a biphasic or triphasic course. Most cases of CML are diagnosed in the chronic phase. Extramedullary blast crisis rarely occurs during the course of CML, and is extremely rare as the initial presentation of CML. Case presentation: Here, we report the case of a 32-year-old female with enlarged neck lymph nodes and fatigue. She was diagnosed with B-lymphoblastic leukemia/lymphoma with possible mixed phenotype (B/myeloid) by right neck lymph node biopsy at an outside hospital. However, review of her peripheral blood smear and her bone marrow aspirate and biopsy showed features consistent with CML, which was confirmed by PCR and karyotyping. An ultrasound-guided right cervical lymph node core biopsy showed a diffuse infiltrate of blasts, near totally replacing the normal lymph node tissue, admixed with some hematopoietic cells including megakaryocytes, erythroid precursors and maturing myeloid cells. By flow cytometry and immunohistochemistry, the blasts expressed CD2, cytoplasmic CD3, CD5, CD7, CD56, TdT, CD10 (weak, subset), CD19 (subset), CD79a, PAX-5 (subset), CD34, CD38, CD117 (subset), HLA-DR (subset), CDIIb, CD13 (subset), CD33 (subset), and weak cytoplasmic myeloperoxidase, without co-expression of surface CD3, CD4, CD8, CD20, CD22, CD14, CD15, CD16 and CD64, consistent with blasts with mixed phenotype (T/B/myeloid). A diagnosis of extramedullary blast crisis of CML was made. Chromosomal analysis performed on the lymph node biopsy tissue revealed multiple numerical and structural abnormalities including the Ph chromosome (46-49,XX,add(1)(p34),add(3)(p25),add (5) (q13),-6,t(9; 22)(q34;q11.2), + 10,-15,add (17) (p11.2), + 19, + der(22)t(9;22), + mar [cp8]). After completion of one cycle of combined chemotherapy plus dasatinib treatment, she was transferred to City of Hope National Cancer Institute for bone marrow transplantation. Discussion and conclusion: Diagnosis of extramedullary blast crisis should be suspected in patients with leukocytosis and extramedullary blast proliferation. In this case study, we diagnosed extramedullary blast crisis accompanied by chronic phase of CML in the bone marrow. To our knowledge, this is the first reported case of extramedullary blast crisis as the initial presentation of CML with T/B/myeloid mixed phenotype. Other unusual features associated with this case are also discussed.	[Qing, Xin; Qing, Annie; Ji, Ping; French, Samuel W.; Mason, Holli] Harbor UCLA Med Ctr, Dept Pathol, 1000 West Carson St, Torrance, CA 90502 USA	Qing, X (reprint author), Harbor UCLA Med Ctr, Dept Pathol, 1000 West Carson St, Torrance, CA 90502 USA.	xqing@dhs.lacounty.gov					Gao XN, 2016, AM J CASE REP, V17, P793, DOI 10.12659/AJCR.899621; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; Khalidi HS, 1998, MODERN PATHOL, V11, P1211; Reid AG, 2009, LEUKEMIA RES, V33, P418, DOI 10.1016/j.leukres.2008.07.019; Tsukamoto Shokichi, 2013, Leuk Res Rep, V2, P67, DOI 10.1016/j.lrr.2013.07.002; Vardiman J.W., 2017, WHO CLASSIFICATION T, P30	6	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					130	133		10.1016/j.yexmp.2018.02.005			4	Pathology	Pathology	GC8IO	WOS:000430037300004	29501750				2019-10-28	
J	Atkinson, A; Studwell, C; Bejarano, S; Castellon, AMZ; Espinal, JAP; Deharvengt, S; LaRochelle, EPM; Kennedy, LS; Tsongalis, GJ				Atkinson, Aaron; Studwell, Courtney; Bejarano, Suyapa; Castellon, Ana Marcela Zapata; Espinal, Jorge Arturo Plata; Deharvengt, Sophie; LaRochelle, Ethan P. M.; Kennedy, Linda S.; Tsongalis, Gregory J.			Rural distribution of human papilloma virus in low- and middle-income countries	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						High-risk HPV; Low-risk HPV; Cervical cancer; Molecular diagnostics; Low and middle income countries; Human papillomavirus	CERVICAL-CANCER; SCREENING-TESTS; VACCINES; CHINA; DNA	Cervical cancer rates in low- and middle-income countries (LMICs) are higher than in developed countries and account for 80% of an estimated 500,000 new cases annually. Factors that contribute to this are that diagnostic and prevention strategies designed for developed countries suffer from the combination of low vaccination rates and limitations due to lack of consistent access to both healthcare and supplies. Here we: 1) improve upon our LMIC deployable HPV test and 2) determine both the high and low-risk HPV genotype prevalence in an isolated Honduran population. We found an unexpected HPV distribution with an abundance of HPV 52 and HPV 72 infections. In this context, molecular testing using a LMIC deployable approach for the detection of HPV can aid in both the triage of HPV positive cytology-based follow up and provide information regarding HPV genotype distribution in support of vaccination strategies.	[Atkinson, Aaron; Deharvengt, Sophie; Tsongalis, Gregory J.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH 03756 USA; [Studwell, Courtney] Univ Connecticut, Diagnost Genet Sci Program, Storrs, CT USA; [Bejarano, Suyapa; Castellon, Ana Marcela Zapata; Espinal, Jorge Arturo Plata] Liga Canc, San Pedro Sula, Honduras; [LaRochelle, Ethan P. M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Kennedy, Linda S.; Tsongalis, Gregory J.] Norris Cotton Canc Ctr, Lebanon, NH USA; [Kennedy, Linda S.; Tsongalis, Gregory J.] Geisel Sch Med Dartmouth, Hanover, NH USA	Tsongalis, GJ (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lab Clin Genom & Adv Technol CGAT, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Gregory.j.tsongalis@hitchcock.org	Bejarano, Suyapa A/T-6679-2017	Bejarano, Suyapa A/0000-0002-2894-1342; LaRochelle, Ethan Phillip/0000-0002-7883-9987	Geisel School of Medicine at Dartmouth through a Munck-Pfefferkorn Grant [5008]; Norris Cotton Cancer Center	This work was in part supported by a generous grant provided by the Geisel School of Medicine at Dartmouth (MP Award #5008) through a Munck-Pfefferkorn Grant and from the Norris Cotton Cancer Center.	Bruni L, 2017, ICO INFORM CTR HPV C; Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Chen W, 2014, J CLIN VIROL, V61, P553, DOI 10.1016/j.jcv.2014.09.018; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Denny L, 2017, LANCET, V389, P861, DOI 10.1016/S0140-6736(16)31795-0; Hong Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04704; Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1; Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430; Perkins RB, 2011, J WOMENS HEALTH, V20, P85, DOI 10.1089/jwh.2009.1919; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Shi JF, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-123; Tan TQ, 2012, CLIN MICROBIOL REV, V25, P409, DOI 10.1128/CMR.00018-12; Turner SA, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00035; Valdez M, 2016, INT J CANCER, V138, P1453, DOI 10.1002/ijc.29877; Bosch FX, 2013, VACCINE, V31, pH1, DOI 10.1016/j.vaccine.2013.10.003; Zhao FH, 2013, CANCER PREV RES, V6, P938, DOI 10.1158/1940-6207.CAPR-13-0091	16	2	2	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					146	150		10.1016/j.yexmp.2018.03.001			5	Pathology	Pathology	GC8IO	WOS:000430037300007	29551573				2019-10-28	
J	Byers, JT; Qing, X; Lo, C; French, SW; Ji, P				Byers, Joshua T.; Qing, Xin; Lo, Christopher; French, Samuel W.; Ji, Ping			Unilateral localized conjunctival amyloidosis in a patient with a history of contralateral orbit/eyelid lymphoma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Amyloidosis; Primary amyloidosis; Conjunctival amyloidosis; Ocular small cell lymphoma	SYSTEMIC AMYLOIDOSIS; ORBITAL AMYLOIDOSIS; OCULAR ADNEXA	Amyloidosis is a disorder characterized by the deposition of insoluble abnormal proteins in the extracellular space. It may occur as a localized lesion or as a systemic disease involving multiple organs and systems. Localized conjunctival amyloidosis is rare and is less frequently associated with systemic involvement. Although amyloidosis itself is a benign lesion involvement of multiple organs and systems is associated with poor prognosis. Diagnosis of amyloidosis is made on biopsy specimens with Congo red staining for the appearance of apple-green birefringence under polarized light microscopy. Liquid chromatography tandem-mass spectrometry (LC-MS/MS) is much more sensitive in diagnosing amyloidosis and can determine the type of amyloid deposit. Here we reported a case of conjunctival amyloidosis in a 52 year-old male patient who was presented with left lower eyelid swelling to our medical center. He has a complicated past medical history of anti-phospholipid antibody syndrome, Buerger's disease (thromboangitis obliterans), and small cell lymphoma (SLL) of the right orbit/eyelid. The patient received radiation to the right orbit to treat SLL with therapy completed one and a half years prior to presentation. Physical examination revealed a firm, raised yellowish colored lesion in the left lower conjunctiva. The conjunctival lesion was biopsied, and tissue sections were examined with Congo red stains and LC-MS/MS analysis. The biopsy showed amyloid deposits without evidence of malignancy, and the type of proteins in the deposit was immunoglobulin light chain (AL) of kappa type. A complete work up was taken for possible systemic involvement of amyloidosis and results were all negative. To our knowledge, this is the first case of localized conjunctival amyloidosis with a history of contralateral orbit/eyelid SLL.	[Byers, Joshua T.; Qing, Xin; French, Samuel W.; Ji, Ping] Harbor UCLA Med Ctr, Dept Pathol & Lab Med, Torrance, CA 90502 USA; [Lo, Christopher] Ronald Reagan UCLA Med Ctr, Dept Ophthalmol, 757 Westwood Plaza, Los Angeles, CA 90095 USA	Ji, P (reprint author), Harbor UCLA Med Ctr, Dept Pathol & Lab Med, Torrance, CA 90502 USA.	piji@dhs.lacounty.gov	Byers, Joshua/R-7690-2019				Ali Z., 2016, CASE REP OPHTHALMOL, V2016, P2915; Chakraborti Chandana, 2014, Oman J Ophthalmol, V7, P16, DOI 10.4103/0974-620X.127914; Demirci H, 2006, SURV OPHTHALMOL, V51, P419, DOI 10.1016/j.survophthal.2006.04.007; Desport E, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-54; ERIE JC, 1989, ARCH OPHTHALMOL-CHIC, V107, P1428, DOI 10.1001/archopht.1989.01070020502019; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; Ferry JA, 2007, AM J SURG PATHOL, V31, P170, DOI 10.1097/01.pas.0000213350.49767.46; Kay J, 1999, CLEV CLIN J MED, V66, P145; Kourelis T, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.4197.4197; Kourelis TV, 2013, AM J HEMATOL, V88, P375, DOI 10.1002/ajh.23413; Mahmood S, 2015, LANCET HAEMATOL, V2, pE241, DOI 10.1016/S2352-3026(15)00068-X; Mora-Horna ER, 2016, INT OPHTHALMOL, V36, P281, DOI 10.1007/s10792-015-0138-7; Pelton RW, 2001, OPHTHALMIC SURG LAS, V32, P422; Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858; Stefanovic A, 2009, BLOOD, V114, P501, DOI 10.1182/blood-2008-12-195453; Suesskind D, 2015, GRAEF ARCH CLIN EXP, V253, P1377, DOI 10.1007/s00417-015-2932-3; Vrana JA, 2009, BLOOD, V114, P4957, DOI 10.1182/blood-2009-07-230722	17	0	0	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					151	154		10.1016/j.yexmp.2018.03.003			4	Pathology	Pathology	GC8IO	WOS:000430037300008	29551574				2019-10-28	
J	Byers, JT; Kurtz, JL; Mendoza, AS; Oster, CD; Sun, NCJ; Qing, X; Cornford, ME				Byers, Joshua T.; Kurtz, Justin L.; Mendoza, Alejandro S.; Oster, Cyrus D.; Sun, Nora C. J.; Qing, Xin; Cornford, Marcia E.			An unusual presentation of primary pulmonary extranodal marginal zone lymphoma of mucosal associated lymphoid tissue: An autopsy case report	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Autopsy; Extranodal marginal zone lymphoma; MALT lymphoma; Thrombotic thrombocytopenic purpura; ADAMTS13	THROMBOCYTOPENIC PURPURA	A 40 year old female with no documented medical history presented to the Emergency Department with several days of lethargy and altered mental status. She was found to be anemic, thrombocytopenic, and hypotensive. The patient was found to be in severe metabolic acidosis, became bradycardic, and quickly deteriorated. Clinicians suspected thrombotic thrombocytopenic purpura, and the diagnosis was supported by ADAMTS13 testing. The clinicians attempted to place a Quinton catheter for emergent plasmapheresis, but the patient expired before definitive treatment could be initiated. Autopsy was obtained and revealed a right middle lobe consolidation grossly consistent with lymphoid tissue or tumor.	[Byers, Joshua T.; Kurtz, Justin L.; Mendoza, Alejandro S.; Oster, Cyrus D.; Sun, Nora C. J.; Qing, Xin; Cornford, Marcia E.] Harbor UCLA Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA	Byers, JT (reprint author), Harbor UCLA Med Ctr, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA.	jbyers@dhs.lacounty.gov	Byers, Joshua/R-7690-2019				Baecklund E, 2014, SEMIN CANCER BIOL, V24, P61, DOI 10.1016/j.semcancer.2013.12.001; Borie R, 2009, EUR RESPIR J, V34, P1408, DOI 10.1183/09031936.00039309; FINK K, 1976, CANCER, V37, P1999, DOI 10.1002/1097-0142(197604)37:4<1999::AID-CNCR2820370451>3.0.CO;2-U; Gringauz I, 2016, CASE REP HEMATOL, DOI 10.1155/2016/1568586; Kawashima Tetsuo, 2005, Journal of Nippon Medical School, V72, P370, DOI 10.1272/jnms.72.370; Khalil MO, 2014, BRIT J HAEMATOL, V165, P67, DOI 10.1111/bjh.12730; Kosugi N, 2010, INTERNAL MED, V49, P689, DOI 10.2169/internalmedicine.49.2957; Lechner K, 2011, LEUKEMIA LYMPHOMA, V52, P1836, DOI 10.3109/10428194.2011.580474; Olszewski AJ, 2013, CANCER-AM CANCER SOC, V119, P629, DOI 10.1002/cncr.27773; Parissis H, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-23; Pina-Oviedo S, 2015, ADV ANAT PATHOL, V22, P355, DOI 10.1097/PAP.0000000000000090; Streubel B, 2004, LEUKEMIA, V18, P1722, DOI 10.1038/sj.leu.2403501; Thieblemont C, 2014, SEMIN CANCER BIOL, V24, P33, DOI 10.1016/j.semcancer.2013.11.005	13	0	0	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					155	157		10.1016/j.yexmp.2018.02.003			3	Pathology	Pathology	GC8IO	WOS:000430037300009	29452080				2019-10-28	
J	Byers, JT; Gertz, HE; French, SW; Wang, LN				Byers, Joshua T.; Gertz, Henning E.; French, Samuel W.; Wang, Lina			Case report: Retroperitoneal bronchogenic cyst as a diagnostic dilemma after colon cancer diagnosis	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Retroperitoneal cyst; Bronchogenic cyst; Foregut cyst	MASS	A 52 year-old obese male presented with a moderately differentiated adenocarcinoma of the sigmoid colon. On staging CT, the patient was found to have a cystic lesion in the left retroperitoneum.	[Byers, Joshua T.; Gertz, Henning E.; French, Samuel W.; Wang, Lina] Harbor UCLA, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA	Byers, JT (reprint author), Harbor UCLA, Dept Pathol, 1000 W Carson St, Torrance, CA 90509 USA.	jbyers@dhs.lacounty.gov	Byers, Joshua/R-7690-2019				Cao DH, 2014, INT J CLIN EXP PATHO, V7, P3418; Nieto RD, 2010, J GASTROINTEST SURG, V14, P756, DOI 10.1007/s11605-009-0932-5; Dong BA, 2014, ONCOL LETT, V7, P2157, DOI 10.3892/ol.2014.1974; FOERSTER HM, 1991, ARCH PATHOL LAB MED, V115, P1057; Govaerts K, 2012, RARE TUMORS, V4, P37, DOI 10.4081/rt.2012.e13; Haddadin WJ, 2001, J CLIN PATHOL, V54, P801, DOI 10.1136/jcp.54.10.801; O'Neal Patrick B, 2012, Endocr Pract, V18, pe102, DOI 10.4158/EP11186.CR; Ramenofsky M. L., 1982, ADV STUDY BIRTH DEFE, V6; Renzulli Pietro, 2009, Ann R Coll Surg Engl, V91, pW9, DOI 10.1308/147870809X400877; Runge Tina, 2013, Case Rep Gastroenterol, V7, P428, DOI 10.1159/000355879; Sarper A, 2003, TEX HEART I J, V30, P105; Tong HX, 2015, ONCOL LETT, V9, P2701, DOI 10.3892/ol.2015.3076; Trehan M, 2015, J CLIN DIAGN RES, V9, pPD03, DOI 10.7860/JCDR/2015/12949.6761; WANG M, 2017, MEDICINE, V96, DOI DOI 10.1097/MD.0000000000007678; Yoon YR, 2015, NUCL MED MOLEC IMAG, V49, P69, DOI 10.1007/s13139-014-0306-0	15	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	APR	2018	104	2					158	160		10.1016/j.yexmp.2018.02.002			3	Pathology	Pathology	GC8IO	WOS:000430037300010	29452079				2019-10-28	
J	Cramer, SF; Heller, DS				Cramer, Stewart F.; Heller, Debra S.			A Review and Reconsideration of Nonneoplastic Myometrial Pathology	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						hysterectomy; uterus; abnormal uterine bleeding; chronic pelvic pain	VASCULAR SMOOTH-MUSCLE; HUMAN UTERUS; ELASTIN DISTRIBUTION; UTERINE LEIOMYOMAS; DESMIN MYOPATHY; FIBROSIS UTERI; HYPERPLASIA; HYSTERECTOMY; CONTRACTIONS; HYPERTROPHY	From 1861 to 1962, clinicopathologic research tried to explain the association of abnormal uterine bleeding with uterine enlargement. The etiology was theorized as metropathy, suggesting that myometrial dysfunction may predispose to abnormal uterine bleeding. Research reached a nadir in 1962, when a major review dismissed myometrial hypertrophy as a plausible explanation after prior rejections of the theories of chronic myometritis, fibrosis uteri, and subinvolution as causes of bleeding. Subsequent to this arose a crusade against unnecessary hysterectomies in the 1970s. Although myometrial hyperplasia was proposed in 1868, it is only in the past 25 years that tangible evidence has supported that idea. It now appears that clinically enlarged uteri are due to globoid outward bulging of the uterus, caused by increased intramural pressureoften unrelated to either uterine weight or myometrial thickness. Abnormal (dysfunctional) uterine bleeding may often be due to spontaneous rupture of thrombosed dilated endometrial vessels, due to the combined effects of obstructed venous drainage by increased intramural pressure, and Virchow's triad. Despite a century-old known association of parity with naturally occurring outer wall myometrial scars (fibrosis uteri with elastosis), it was not previously suggested that these may reflect healing reactions to muscle tears during labor and delivery. We now suggest that smaller, similar inner wall elastotic scars in the nerve-rich inner myometrium may explain many cases of pelvic pain. This review suggests that diverse pressure-related lesions may be present in clinically abnormal uteri that have been called normal since the crusade against unnecessary hysterectomy.	[Cramer, Stewart F.] Univ Rochester, Rochester Gen Hosp, New York, NY USA; [Heller, Debra S.] Rutgers New Jersey Med Sch, Newark, NJ USA	Heller, DS (reprint author), Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, 185 South Orange Ave,UH E158, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu			Genesee Hospital Foundation; Rochester General Hospital Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by a grant for tissue research from the Genesee Hospital Foundation and the Rochester General Hospital Foundation.	Abraham SC, 1998, HUM PATHOL, V29, P876, DOI 10.1016/S0046-8177(98)90460-9; ACOG Committee on Quality Assessment, 1998, APPR HYST END ABN UT; ARIZA A, 1995, HUM PATHOL, V26, P1032, DOI 10.1016/0046-8177(95)90095-0; BAGGISH MS, 1989, J GYNECOL SURG, V5, P149, DOI 10.1089/gyn.1989.5.149; Baker AB, 1933, AM J PATHOL, V9, P369; Berek JS, 2007, BEREK NOVAKS GYNECOL, V2007, P461; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BIRD CC, 1965, J PATHOL BACTERIOL, V90, P75, DOI 10.1002/path.1700900108; CHALUBINSKI K, 1993, FERTIL STERIL, V59, P225; CRAMER SF, 1990, AM J CLIN PATHOL, V94, P435, DOI 10.1093/ajcp/94.4.435; CRAMER SF, 1995, MODERN PATHOL, V8, P71; Cramer SF, ADV UT LEIOM RES 3 N; Cramer SF, 2005, ADV UT LEIOM RES 2 N; Cramer SF, NEXT CENT ADV UT LEI; Cramer SF, 1991, EXTRACELLULAR MATRIX; Cramer Stewart F, 2003, J Pediatr Adolesc Gynecol, V16, P301, DOI 10.1016/S1083-3188(03)00158-X; Cramer SF, 2007, HUM PATHOL, V38, P652, DOI 10.1016/j.humpath.2007.01.010; Cramer SF, 2017, HUM PATHOL, V67, P211, DOI 10.1016/j.humpath.2017.08.013; Cramer SF, 2015, J PEDIATR ADOL GYNEC, V28, P387, DOI 10.1016/j.jpag.2014.12.002; Cramer SF, 2009, HUM PATHOL, V40, P218, DOI 10.1016/j.humpath.2008.07.004; Dallenbach-Hellweg G, 1984, ATLAS ENDOMETRIAL HI, P76; Daniels JP, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4834; DEVRIES K, 1990, AM J OBSTET GYNECOL, V162, P679, DOI 10.1016/0002-9378(90)90983-E; FARRERBROWN G, 1971, OBSTET GYNECOL, V38, P743; Findley P., 1905, AM J OBST, V52, P71; Finn N., 1868, CENTRALBL MED WISSEN, V6, P564; Gardner W, 1906, BRIT MED J, V1906, P1176; Hartmann W, 1977, SURG PATHOLOGY UTERU, pvii; Hendrickson MR, 1980, SURG PATHOLOGY UTERI, P464; HONORE LH, 1979, ACTA OBSTET GYN SCAN, V58, P283, DOI 10.3109/00016347909154050; Joyner MJ, 2016, JAMA-J AM MED ASSOC, V316, P1355, DOI 10.1001/jama.2016.11076; Kunz G, 1996, HUM REPROD, V11, P627, DOI 10.1093/HUMREP/11.3.627; Kurman RJ, 2002, BLAUSTEINS PATHOLOGY, V575; LANGLOIS PL, 1970, J REPROD MED, V4, P220; LEPPERT PC, 1991, CONNECT TISSUE RES, V27, P15, DOI 10.3109/03008209109006992; LEWIS PL, 1962, AM J OBSTET GYNECOL, V84, P1032, DOI 10.1016/0002-9378(62)90550-1; Lirussi F, 2008, BIOL REPROD, V78, P497, DOI 10.1095/biolreprod.107.064444; LYONS EA, 1991, FERTIL STERIL, V55, P771; Metaxa-Mariatou V, 2002, MOL HUM REPROD, V8, P559, DOI 10.1093/molehr/8.6.559; MOSTELLER F, 1978, J SURG RES, V25, P185, DOI 10.1016/0022-4804(78)90105-1; Munro MG, 2002, AM J OBSTET GYNECOL, V187, P1519; Newcomb PM, 2013, INT J GYNECOL PATHOL, V32, P585, DOI 10.1097/PGP.0b013e31827630d4; Papadimitriou JC, 2000, HUM PATHOL, V31, P1455, DOI 10.1053/hupa.2000.20376; Quinn MJ, 2002, AM J OBSTET GYNECOL, V187, P1515, DOI 10.1067/mob.2002.130007; Rabinowitz M., 1910, AM J OBSTET DIS WOME, V61, P51; Reinicke EA., 1897, ARCH GYNAK, V53, P340; Riemer RK, 1998, PEDIATR RES, V44, P615, DOI 10.1203/00006450-199811000-00001; ROBERTS GT, 1978, J CLIN PATHOL, V31, P633; Roeder HA, 2012, REPROD SCI, V19, P463, DOI 10.1177/1933719111426603; SCHWALM H, 1966, AM J OBSTET GYNECOL, V94, P391, DOI 10.1016/0002-9378(66)90661-2; Schwartz OH., 1940, ANAL SURG, V48, P321; SCOUTT LM, 1991, RADIOLOGY, V179, P403, DOI 10.1148/radiology.179.2.2014282; Shaw FW., 1914, J OBSTET GYN BR EMP, V26, P73; Shaw WF., 1907, J OBSTET GYN BR COMM, V11, P124; SHOEMAKER R, 1947, ARCH PATHOL, V44, P621; Shynlova O, 2006, BIOL REPROD, V74, P839, DOI 10.1095/biolreprod.105.048124; Silverberg SG, 1977, SURG PATHOLOGY UTERU, P58; Silverberg SG, 1977, SURG PATHOLOGY UTERU, P35; Silverberg SG, 1977, SURG PATHOLOGY UTERU, pix; SMITH VV, 1992, HISTOPATHOLOGY, V21, P535, DOI 10.1111/j.1365-2559.1992.tb00441.x; Theilhaber VA, 1902, ARCH J GYNAK, V66, P1; TRUEMNER KM, 1949, AM J CLIN PATHOL, V19, P544; Von Scanzoni FW, 1861, PRACTICAL TREATISE D; West AB, 2006, J CLIN GASTROENTEROL, V40, pS126; Williams JT, 1944, AM J OBSTET GYNECOL, V47, P380, DOI 10.1016/S0002-9378(15)30752-3; Zhang XM, 2010, FERTIL STERIL, V94, P730, DOI 10.1016/j.fertnstert.2009.03.026; Zheng WQ, 2006, ANAL QUANT CYTOL, V28, P115	67	2	2	2	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					104	119		10.1177/1066896917748194			16	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800001	29254394				2019-10-28	
J	Feldman, A; Borak, S; Rais-Bahrami, S; Gordetsky, J				Feldman, Alexander; Borak, Samuel; Rais-Bahrami, Soroush; Gordetsky, Jennifer			Secondary Malignancies of the Bladder: Avoiding the Diagnostic Pitfall	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						bladder cancer; metastatic; secondary malignancy	PATHOLOGY-CONSENSUS-CONFERENCE; UROTHELIAL CARCINOMA; URINARY-BLADDER; GLANDULAR DIFFERENTIATION; PRACTICES RECOMMENDATIONS; HUMAN-PAPILLOMAVIRUS; EXPRESSION; MARKERS; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMA	Although rare, secondary tumors of the bladder can present a diagnostic dilemma to pathologists considering a differential diagnosis of primary bladder cancer. We investigated the clinicopathologic and imaging characteristics of metastatic tumors to the bladder. We retrospectively reviewed the surgical pathology databases from 2 sites from 2013 to 2016, identifying 66 cases of secondary bladder tumors. Clinical, pathologic, and imaging findings were reviewed. Mean age at diagnosis was 63 years (range = 25-87). Females had a significantly higher proportion (44/66, 66.7%) of secondary bladder tumors compared with males (22/66, 33.3%; P = .007). In total, 56/66 (84.8%) patients had a clinical history of an in situ or invasive malignancy in another organ, and 54/66 (81.8%) patients had imaging supporting a metastatic tumor. Only 2/66 (3.0%) patients had a prior history of urothelial carcinoma. In total, 4/66 (6.1%) cases (all females) were originally misdiagnosed as primary bladder malignancies and were corrected after clinicoradiologic correlation. Overall, colorectal origin was most common (15/66, 22.7%), followed by cervical and ovarian primaries (10/66, 15.2% each). Cervical and ovarian origins predominated in the female cohort (10/44, 22.7% each), followed by endometrial (8/44, 18.2%). Colorectal and prostate primaries were the most common among males (10/22, 45.5%, and 7/22, 31.8%, respectively). Secondary bladder tumors can mimic urothelial carcinomas. In our cohort, gynecological, colorectal, and prostatic origins were most common. Clinical history, imaging, and immunohistochemical studies can be useful in avoiding this diagnostic pitfall.	[Feldman, Alexander; Borak, Samuel; Rais-Bahrami, Soroush; Gordetsky, Jennifer] Univ Alabama Birmingham, Birmingham, AL USA; [Borak, Samuel] Community Pathol Practice Program, Montgomery, AL USA	Gordetsky, J (reprint author), Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA.; Gordetsky, J (reprint author), Univ Alabama Birmingham, Dept Urol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA.	jgordetsky@uabmc.edu		Feldman, Alexander/0000-0001-7237-5125			Alexander RE, 2012, MODERN PATHOL, V25, P1526, DOI 10.1038/modpathol.2012.103; Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; Bates AW, 2000, HISTOPATHOLOGY, V36, P32; Epstein JI, 2014, AM J SURG PATHOL, V38, pE6, DOI 10.1097/PAS.0000000000000238; Gordetsky J, 2014, AM J SURG PATHOL, V38, P941, DOI 10.1097/PAS.0000000000000178; Gown AM, 2016, HISTOPATHOLOGY, V68, P86, DOI 10.1111/his.12877; Han JH, 2003, ARCH PATHOL LAB MED, V127, P1330; Howlader N, 2017, SEER CANC STAT REV C; Kao HL, 2016, HISTOPATHOLOGY, V68, P513, DOI 10.1111/his.12769; Kaufmann O, 2001, AM J CLIN PATHOL, V116, P823; Keck B, 2013, ANN SURG ONCOL, V20, P2440, DOI 10.1245/s10434-012-2709-4; Lopez-Beltran A, 2011, HUM PATHOL, V42, P1653, DOI 10.1016/j.humpath.2010.12.024; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Miller JS, 2009, AM J SURG PATHOL, V33, P1241, DOI 10.1097/PAS.0b013e3181a1ff41; Moch H, 2016, WHO CLASSIFICATION T; Nakazawa K, 2009, AM J CLIN PATHOL, V132, P776, DOI 10.1309/AJCP61KNVHJVHAFN; Rao Q, 2013, MODERN PATHOL, V26, P725, DOI 10.1038/modpathol.2012.229; Schwartz LE, 2016, AM J SURG PATHOL, V40, P27, DOI 10.1097/PAS.0000000000000524; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tian W, 2014, AM J SURG PATHOL, V38, P982, DOI 10.1097/PAS.0000000000000214; Williamson SR, 2011, AM J SURG PATHOL, V35, P474, DOI 10.1097/PAS.0b013e31820f709e	21	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					120	125		10.1177/1066896917741550			6	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800002	29166807				2019-10-28	
J	Hariri, N; Qarmali, M; Fadare, O				Hariri, Nosaibah; Qarmali, Morad; Fadare, Oluwole			Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						uterine serous carcinoma; endometrial serous carcinoma; clear-cell carcinoma; clear cells; uterine papillary serous carcinoma	CLINICOPATHOLOGICAL FEATURES; INTEROBSERVER VARIABILITY; VENOUS THROMBOEMBOLISM; DIAGNOSTIC-UTILITY; CANCER; WOMEN; ADENOCARCINOMA; EXPRESSION; RISK; REPRODUCIBILITY	The diagnostic distinction between endometrial serous carcinoma (ESC) and endometrial clear-cell carcinoma (CCC) may occasionally be problematic, and one potentially contributing factor is the finding of clear cells in otherwise classic cases of ESC. This study aimed to define the frequency of this finding and comparatively assessed the immunophenotype of the clear cells. A review of 56 cases of ESC identified 8 (14.28%) with clear cells, representing 1% to 20% (median 7.5) of tumoral volume in these cases. In only 3 cases were clear cells discernible at low (x20) magnification. There was no significant difference in stage distribution or age between ESC patients with and without clear cells. The immunophenotypes of ESC-associated clear cells (group 1) were compared with foci of conventional ESC on another tissue block within the same case (group 2; n = 8) as well as a randomly selected cohort of CCC cases (group 3; n = 8). Groups 1 and 2 showed no significant differences regarding p53, ER, PR, Napsin-A, p504S, and hepatocyte nuclear factor 1 (HNF1) expression, or regarding mitotic indices or Ki67 proliferation rate. In contrast, group 1 cases showed an immunophenotypic profile that was notably different from that of group 3 cases, with the former showing statistically significantly higher/more frequent expression of ER, PR, Ki67, and p53 and lower/less frequent expression of Napsin-A, p504S, and HNF1. We conclude that clear-cell change is seen in 14% of ESCs and is discernible at low magnification in only 5%; these areas show an immunophenotype that is essentially identical to the associated background conventional ESC and are phenotypically dissimilar to CCC.	[Hariri, Nosaibah; Qarmali, Morad; Fadare, Oluwole] Univ Calif San Diego, La Jolla, CA 92093 USA; [Qarmali, Morad] Univ Alabama Birmingham, Birmingham, AL USA	Fadare, O (reprint author), UC San Diego Hlth, Anat Pathol, 9300 Campus Point Dr,Suite 1-200,MC 7723, La Jolla, CA 92037 USA.	oluwole.fadare@gmail.com					Altman AD, 2015, GYNECOL ONCOL, V139, P268, DOI 10.1016/j.ygyno.2015.09.001; Bernardini MQ, 2016, GYNECOL ONCOL, V141, P148, DOI 10.1016/j.ygyno.2016.02.002; CHRISTOPHERSON W M, 1982, Cancer, V49, P1511, DOI 10.1002/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO;2-6; Darvishian T, 2004, AM J SURG PATHOL, V28, P1568, DOI 10.1097/00000478-200412000-00004; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; FACTOR SM, 1974, ARCH PATHOL, V98, P201; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; Fadare O, 2013, AM J CANCER RES, V3, P70; Fadare O, 2012, APPL IMMUNOHISTO M M, V20, P580, DOI 10.1097/PAI.0b013e31824973d1; Fadare O, 2012, AM J SURG PATHOL, V36, P1107, DOI 10.1097/PAS.0b013e31825dd4b3; Fadare O, 2011, INT J GYNECOL PATHOL, V30, P252, DOI 10.1097/PGP.0b013e3181ff9234; Fadare O, 2009, INT J CLIN EXP PATHO, V2, P411; Gatius S, 2016, MODERN PATHOL, V29, pS45, DOI 10.1038/modpathol.2015.141; Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a; Hamilton CA, 2006, BRIT J CANCER, V94, P642, DOI 10.1038/sj.bjc.6603012; Han G, 2008, AM J SURG PATHOL, V32, P955, DOI 10.1097/PAS.0b013e318164edf7; Han GM, 2015, INT J GYNECOL PATHOL, V34, P323, DOI 10.1097/PGP.0000000000000162; Han GM, 2013, MODERN PATHOL, V26, P1594, DOI 10.1038/modpathol.2013.102; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hendrickson M R, 1979, Major Probl Pathol, V12, P1; Hinshaw HD, 2013, INT J GYNECOL CANCER, V23, P1044, DOI 10.1097/IGC.0b013e3182959053; Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed; Kitson S, 2017, MODERN PATHOL, V30, P459, DOI 10.1038/modpathol.2016.203; Kobel M, 2016, AM J SURG PATHOL, V40, P166, DOI 10.1097/PAS.0000000000000536; LAUCHLAN SC, 1981, ARCH PATHOL LAB MED, V105, P615; Lax SF, 1998, HUM PATHOL, V29, P551, DOI 10.1016/S0046-8177(98)80002-6; LEE KR, 1991, AM J SURG PATHOL, V15, P965; Lee L, 2009, J REPROD MED, V54, P133; Lewis GH, US CAN AC PATH 101 A; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Olawaiye AB, 2009, GYNECOL ONCOL, V113, P277, DOI 10.1016/j.ygyno.2009.02.003; Rauh-Hain JA, 2015, OBSTET GYNECOL, V125, P1362, DOI 10.1097/AOG.0000000000000866; SHERMAN ME, 1992, AM J SURG PATHOL, V16, P600, DOI 10.1097/00000478-199206000-00008; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; TAVASSOLI FA, 1987, AM J CLIN PATHOL, V87, P23, DOI 10.1093/ajcp/87.1.23; TOBON H, 1985, INT J GYNECOL PATHOL, V4, P328, DOI 10.1097/00004347-198512000-00005; Zaino R., 2014, WHO CLASSIFICATION T, P125; Zheng WX, 2011, AM J SURG PATHOL, V35, pE1, DOI 10.1097/PAS.0b013e318202772e	38	0	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					126	134		10.1177/1066896917731862			9	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800003	28954565				2019-10-28	
J	Creytens, D; Ferdinande, L; Van Dorpe, J				Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo			A Sclerosing Perineurioma With Collagen Rosette Formation: Benign Mimic of Low-Grade Fibromyxoid Sarcoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						sclerosing perineurioma; collagen rosette; low-grade fibromyxoid sarcoma; MUC4	MARKER	We report the case of a sclerosing perineurioma with conspicious collagen rosette formation in a 20-year-old male presenting with a firm, painless nodule on the palmar side of his right ring finger. The main differential diagnosis is a low-grade fibromyxoid sarcoma. The distinction between these entities is important because low-grade fibromyxoid sarcoma has a metastatic potential, while, as a rule, perineuriomas are benign. The presence of collagen rosettes in this current case makes this distinction even more difficult given that approximately 30% of low-grade fibromyxoid sarcoma cases show the focal presence of collagen rosettes. The demonstration of the characteristic t(7;16), t(11;16) or t(11;22) translocations (resulting in the FUS-CREB3L2, FUS-CREB3L1 or EWSR1-CREB3L1 fusion genes, respectively) or immunoreactivity for MUC4, a recently described sensitive and specific marker for low-grade fibromyxoid sarcoma, remain the gold standard in the diagnosis of low-grade fibromyxoid sarcoma, differentiating it from perineurioma. This case is, to our knowledge, the first report on collagen rosettes in sclerosing perineurioma, extremely well mimicking low-grade fibromyxoid sarcoma, and further expanding the morphological spectrum of this rare subtype of perineurioma.	[Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Canc Res Inst Ghent, Ghent, Belgium	Creytens, D (reprint author), Univ Ghent, Dept Pathol, B-9000 Ghent, Belgium.; Creytens, D (reprint author), Ghent Univ Hosp, B-9000 Ghent, Belgium.	david.creytens@uzgent.be					Creytens D, 2015, HEAD NECK PATHOL, V9, P534, DOI 10.1007/s12105-015-0625-1; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; Fetsch JF, 1997, AM J SURG PATHOL, V21, P1433, DOI 10.1097/00000478-199712000-00005; Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004; Fox MD, 2010, J CUTAN PATHOL, V37, P1053, DOI 10.1111/j.1600-0560.2010.01549.x; Hornick JL, 2013, WHO CLASSIFICATION T, P176; Macarenco RS, 2017, J CUTAN PATHOL, V44, P388, DOI 10.1111/cup.12882; Mohamed M, 2017, ANN DIAGN PATHOL, V28, P60, DOI 10.1016/j.anndiagpath.2017.04.001; Rubin AI, 2009, J CUTAN PATHOL, V36, P60, DOI 10.1111/j.1600-0560.2008.01217.x	9	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					145	147		10.1177/1066896917741551			3	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800005	29172820				2019-10-28	
J	Snow, J; Mosquera, JM; Scognamiglio, T; Robinson, BD; Khani, F				Snow, Justin; Mosquera, Juan Miguel; Scognamiglio, Theresa; Robinson, Brian D.; Khani, Francesca			A Precious Diagnostic "Pearl": The Necklace Pattern in Germ Cell Tumors of the Testis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						germ cell tumor; nonseminomatous; diffuse embryoma; necklace; yolk sac tumor; embryonal carcinoma	DIFFUSE EMBRYOMA	Diffuse embryoma is a rare pattern of nonseminomatous germ cell tumor of the testis originally described in 1983. We report a case with this predominant pattern in an 18-year-old male with a painless palpable testicular mass. Although it is relatively common to see a diffuse embryoma pattern focally in mixed nonseminomatous germ cell tumors of the testis, it is rarely the predominant pattern and can represent a diagnostic pitfall on routine hematoxylin and eosin stain. We emphasize the importance of recognizing the individual components within the diffuse embryoma pattern, review the literature, and briefly discuss the ancillary immunohistochemical stains that may be utilized to help support the diagnosis.	[Snow, Justin; Mosquera, Juan Miguel; Scognamiglio, Theresa; Robinson, Brian D.; Khani, Francesca] Weill Cornell Med, New York, NY USA; [Snow, Justin; Mosquera, Juan Miguel; Scognamiglio, Theresa; Robinson, Brian D.; Khani, Francesca] New York Presbyterian, New York, NY USA	Khani, F (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 525 East 68th St, New York, NY 10065 USA.	frk9007@med.cornell.edu					COULSON WF, 1995, AM J CLIN PATHOL, V103, P533; DEALMEIDA PCC, 1983, AM J SURG PATHOL, V7, P633, DOI 10.1097/00000478-198310000-00004; DEPERALTAVENTURINA MN, 1994, AM J CLIN PATHOL, V102, P402, DOI 10.1093/ajcp/102.4.402; Gopalan A, 2009, MODERN PATHOL, V22, P1066, DOI 10.1038/modpathol.2009.66; Lee WA, 2008, KOREAN J PATHOL, V42, P103; Pectasides D, 2009, CRIT REV ONCOL HEMAT, V70, P114, DOI 10.1016/j.critrevonc.2008.07.018; Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310; Zamecnik M, 2004, HISTOPATHOLOGY, V45, P427, DOI 10.1111/j.1365-2559.2004.01943.x	8	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					148	150		10.1177/1066896917729502			3	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800006	28862048				2019-10-28	
J	Creytens, D				Creytens, David			Melan A Antibody Cross-Reactivity in Molluscum Contagiosum Bodies	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Creytens, David] Univ Ghent, Ghent, Belgium; [Creytens, David] Ghent Univ Hosp, Ghent, Belgium	Creytens, D (reprint author), Ghent Univ Hosp, Dept Pathol, De Pintelaan 185, B-9000 Ghent, Belgium.	david.creytens@uzgent.be					PENNEYS NS, 1986, J CUTAN PATHOL, V13, P97, DOI 10.1111/j.1600-0560.1986.tb01508.x; THOMPSON CH, 1990, PATHOLOGY, V22, P181, DOI 10.3109/00313029009086657	2	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					151	152		10.1177/1066896917725805			2	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800007	28805130				2019-10-28	
J	Cheng, E; Viswanathan, K; Hoda, S				Cheng, Esther; Viswanathan, Kartik; Hoda, Syed			Solitary Neurofibroma of the Breast, and "The Man From Istanbul" Syndrome	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Cheng, Esther; Viswanathan, Kartik; Hoda, Syed] Weill Cornell, 525 E 68th St,Starr 1031c, New York, NY 10065 USA	Hoda, S (reprint author), Weill Cornell, 525 E 68th St,Starr 1031c, New York, NY 10065 USA.	sahoda@med.cornell.edu					Charu V, 2017, SEMIN DIAGN PATHOL, V34, P420, DOI 10.1053/j.semdp.2017.05.011; Friedrich RE, 2010, ANTICANCER RES, V30, P1815; Gokalp G., 2007, BRIT J RADIOL, V80, P234; Gultekin SH, 1996, SOUTHERN MED J, V89, P238, DOI 10.1097/00007611-199602000-00018; Rosai J., 2011, ACKERMAN ROSAIS SURG, P1305; Thompson S, 2015, RADIOL CASE REP, V7, P462	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					153	154		10.1177/1066896917728337			2	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800008	28862066				2019-10-28	
J	Ellington, N; Wang, J; Rakheja, D				Ellington, Natalie; Wang, Jason; Rakheja, Dinesh			A Matter of Mushroom	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							FUNGAL APPENDICITIS		[Ellington, Natalie; Wang, Jason; Rakheja, Dinesh] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Ellington, Natalie; Wang, Jason; Rakheja, Dinesh] Childrens Med Ctr, Dallas, TX 75235 USA	Rakheja, D (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dinesh.rakheja@utsouthwestern.edu					Carlini V, 2016, J PEDIAT HEMATOL ONC, V38, P581, DOI 10.1097/MPH.0000000000000563; Larbcharoensub N, 2013, SE ASIAN J TROP MED, V44, P681	2	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					155	156		10.1177/1066896917728796			2	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800009	28862081				2019-10-28	
J	Reinertsen, E; Neill, SG; Nael, K; Brat, DJ; Hadjipanayis, CG				Reinertsen, Erik; Neill, Stewart G.; Nael, Kambiz; Brat, Daniel J.; Hadjipanayis, Costas G.			Meningioma With Tyrosine-Rich Crystalloids: A Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						meningioma; tyrosine; crystalloid		We report a case of fibrous meningioma with tyrosine-rich crystalloid in the frontal lobe of a middle-aged woman. The patient presented with a history of several years of worsening headaches and blurry vision, which progressed to include syncopal episodes and right-sided weakness. Imaging demonstrated a dural-based extra-axial mass arising from the right orbital roof and extending superiorly along the right frontal convexity causing right-to-left midline shift. The patient underwent a craniotomy and operative resection. Tumor architecture and cytology was similar to that of a Schwannian neoplasm, with spindled cells arranged in a fascicular architecture and displaying focal nuclear palisading. Immunohistochemical stains confirmed a diagnosis of fibrous meningioma. Light microscopy demonstrated extracellular deposits of eosinophilic crystalline material parallel to the spindled tumor cells, reminiscent of tyrosine-rich crystals described in salivary gland neoplasms. This is the third meningioma featuring tyrosine-rich crystalloid reported in the literature; we also summarize the previous 2 reports.	[Reinertsen, Erik; Neill, Stewart G.; Brat, Daniel J.] Emory Univ, Sch Med, 100 Woodruff Circle, Atlanta, GA 30322 USA; [Nael, Kambiz] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Hadjipanayis, Costas G.] Mt Sinai Beth Israel Hosp, New York, NY USA	Reinertsen, E (reprint author), Emory Univ, Sch Med, 100 Woodruff Circle, Atlanta, GA 30322 USA.	ereiner@emory.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008169]		Bellizzi AM, 2008, AM J CLIN PATHOL, V130, P355, DOI 10.1309/J3YVV58V22AKXHWR; Couce ME, 1999, ULTRASTRUCT PATHOL, V23, P341; HALVORSEN S, 1966, ARCH DIS CHILD, V41, P238, DOI 10.1136/adc.41.217.238; KLAVINS JV, 1967, ARCH PATHOL, V84, P238; Schollenberg E, 2013, INT J SURG PATHOL, V21, P411, DOI 10.1177/1066896912470165; THOMAS K, 1981, J CLIN PATHOL, V34, P1003, DOI 10.1136/jcp.34.9.1003	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					157	160		10.1177/1066896917727100			4	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800010	28817996	Green Accepted			2019-10-28	
J	Huber, AR; Gonzalez, RS				Huber, Aaron R.; Gonzalez, Raul S.			Elastotic Lesions of Intestinal Subserosal Fat: Report of Two Cases	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						elastofibroma; elastofibromatous change; colon; small bowel	OF-THE-LITERATURE; GASTROINTESTINAL-TRACT; PSEUDOTUMOR; COLON	We report 2 unusual elastotic lesions of intestinal subserosal fat. The first arose in the small bowel subserosa of a 64-year-old woman with volvulus. It was undetected macroscopically and consisted of a relatively circumscribed focus of elastosis, with essentially no evidence of fibrosis or blood vessel walls within. The second arose in the subserosa of the sigmoid colon in a 46-year-old woman with recurrent diverticulitis. It was also undetected macroscopically and consisted of a well-circumscribed nodule of elastic fibers surrounding prominent veins and arteries. Both patients had unremarkable postoperative courses. These lesions likely represent localized response to injury and are probably underrecognized.	[Huber, Aaron R.; Gonzalez, Raul S.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	Gonzalez, RS (reprint author), Univ Rochester, Dept Pathol, Med Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	raul_gonzalez@urmc.rochester.edu					Chandrasekar C. R., 2008, Sarcoma, P1, DOI 10.1155/2008/756565; Darling MR, 2011, HEAD NECK PATHOL, V5, P254, DOI 10.1007/s12105-011-0274-y; Hobbs CM, 2004, AM J CLIN PATHOL, V122, P232, DOI 10.1309/LBGTCG1QCD96M3NF; Jiang ZG, 2017, AM J GASTROENTEROL, V112, P411, DOI 10.1038/ajg.2016.471; Landau M, 2016, ARCH PATHOL LAB MED, V140, P461, DOI 10.5858/arpa.2015-0105-OA; Lichtmannegger I, 2014, VIRCHOWS ARCH, V465, P257, DOI 10.1007/s00428-014-1605-7; Markl B, 2008, PATHOL RES PRACT, V204, P395, DOI 10.1016/j.prp.2008.01.004; Nowacki NB, 2015, AM J SURG PATHOL, V39, P84, DOI 10.1097/PAS.0000000000000308; Spinzi G, 1996, AM J GASTROENTEROL, V91, P1631; WHITEWAY J, 1985, GUT, V26, P258, DOI 10.1136/gut.26.3.258; Yantiss RK, 2003, AM J SURG PATHOL, V27, P532, DOI 10.1097/00000478-200304000-00015	11	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					161	164		10.1177/1066896917728794			4	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800011	28862055				2019-10-28	
J	Geary, K; Yazici, C; Seibold, A; Guzman, G				Geary, Kyle; Yazici, Cemal; Seibold, Anita; Guzman, Grace			IgG4-Related Cholangiopathy and Its Mimickers: A Case Report and Review Highlighting the Importance of Early Diagnosis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						IgG4-related disease; IgG4-associated cholangiopathy; diagnosis; steroids	IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; AUTOIMMUNE PANCREATITIS; TUBULOINTERSTITIAL NEPHRITIS; DISEASE; AUTOANTIBODIES; RITUXIMAB; BILIARY	Immunoglobulin (Ig) G4 (IgG4)-related disease is a recently described clinical entity that can involve multiple organs. It is an autoimmune disorder characterized by a dense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis. A key distinguishing factor is its dramatic response to steroid therapy. Although best described in cases of autoimmune pancreatitis, IgG4-related disease has also been implicated in patients with cholangitis and is now commonly referred to as IgG4-related cholangiopathy. It is characterized by elevated serum IgG4 levels, an IgG4-positive plasma cell infiltration with storiform fibrosis/obliterative phlebitis of the bile duct wall, and a response to steroids. It is crucial to differentiate IgG4-related cholangiopathy from its mimickers, such as primary biliary cholangitis, secondary biliary cholangitis, primary sclerosing cholangitis, secondary sclerosing cholangitis, and cholangiocarcinoma, because treatment modalities and outcomes of IgG4-related cholangiopathy differ significantly from these disorders. Here, we present an interesting case of IgG4-related cholangiopathy, discuss clinical and pathological features crucial to its early diagnosis, and compare and contrast this condition with its potentially confounding mimickers.	[Geary, Kyle; Yazici, Cemal; Guzman, Grace] Univ Illinois, Chicago, IL USA; [Seibold, Anita] Univ N Carolina, Chapel Hill, NC USA	Guzman, G (reprint author), Univ Illinois, Coll Med, 840 South Wood St,Room 130-MC847, Chicago, IL 60612 USA.	kgeary3@uic.edu					Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Cornell LD, 2007, AM J SURG PATHOL, V31, P1586, DOI 10.1097/PAS.0b013e318059b87c; Detlefsen S, 2010, HISTOPATHOLOGY, V57, P825, DOI 10.1111/j.1365-2559.2010.03717.x; Guarneri F, 2005, J CELL MOL MED, V9, P741, DOI 10.1111/j.1582-4934.2005.tb00506.x; Hart PA, 2015, GASTROENTEROLOGY, V149, P39, DOI 10.1053/j.gastro.2015.03.010; Janeway Jr C. A., 2001, IMMUNOBIOLOGY IMMUNE; Joshi D, 2014, ALIMENT PHARM THER, V40, P1251, DOI 10.1111/apt.12988; Kamisawa T, 2003, J GASTROENTEROL, V38, P982, DOI 10.1007/s00535-003-1175-y; Kamisawa T, 2003, GUT, V52, P683, DOI 10.1136/gut.52.5.683; Kubota T, 2010, ARCH OPHTHALMOL-CHIC, V128, P577, DOI 10.1001/archophthalmol.2010.45; Loffler C, 2016, CLIN RHEUMATOL, V35, P265, DOI 10.1007/s10067-014-2535-0; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Montano-Loza AJ, 2008, CAN J GASTROENTEROL, V22, P840, DOI 10.1155/2008/586173; Nagamachi S, 2011, CASE REP NEPHROL DIA, V1, P7, DOI 10.1159/000330664; Nakazawa T, 2013, WORLD J GASTROENTERO, V19, P7661, DOI 10.3748/wjg.v19.i43.7661; Ngwa T, 2015, PANCREAS, V44, P557, DOI 10.1097/MPA.0000000000000297; Nishi H, 2007, NEPHROL DIAL TRANSPL, V22, P1491, DOI 10.1093/ndt/gfm256; Novotny I, 2012, DIGEST DIS, V30, P216, DOI 10.1159/000336706; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Okazaki K, 2014, J HEPATOL, V61, P690, DOI 10.1016/j.jhep.2014.04.016; Oseini AM, 2011, HEPATOLOGY, V54, P940, DOI 10.1002/hep.24487; Ozdemir C, 2009, CLIN EXP ALLERGY, V39, P626, DOI 10.1111/j.1365-2222.2009.03242.x; Qian Y, 2012, J IMMUNOL, V189, P1535, DOI 10.4049/jimmunol.1200842; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; Sah Raghuwansh P, 2012, Curr Gastroenterol Rep, V14, P95, DOI 10.1007/s11894-012-0246-8; Strohl WR, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818096; Topazian M, 2008, CLIN GASTROENTEROL H, V6, P364, DOI 10.1016/j.cgh.2007.12.020; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697; Zen Y, 2012, INT J HEPATOL, DOI 10.1155/2012/472376	29	2	2	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					165	173		10.1177/1066896917730902			9	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800012	28905689				2019-10-28	
J	Hollowoa, B; Lamps, LW; Mizell, JS; English, GW; Bridge, JA; Ram, R; Gardner, JM				Hollowoa, Blake; Lamps, Laura W.; Mizell, Jason S.; English, George W., III; Bridge, Julia A.; Ram, Roopa; Gardner, Jerad M.			Dedifferentiated Liposarcoma Mimicking a Primary Colon Mass	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						liposarcoma; MDM2; colon cancer; retroperitoneum; sarcoma	RETROPERITONEUM; MESENTERY; SUBGROUP; CRITERIA; MDM2	Dedifferentiated liposarcoma is typically a nonlipogenic high-grade sarcoma that arises from well-differentiated liposarcoma. It most commonly presents as a large mass in the retroperitoneum. Significant involvement of the gastrointestinal tract by dedifferentiated liposarcoma is uncommon. We present a unique case of dedifferentiated liposarcoma radiographically mimicking a primary colon mass with resulting intussusception; stranding of the adjacent adipose tissue was presumed to be a secondary reactive change. On histopathologic analysis of the hemicolectomy specimen, a high-grade sarcoma was seen growing through the colonic wall, and the majority of the surrounding pericolonic adipose tissue was actually composed of well-differentiated liposarcoma with characteristic fibrous bands rather than benign fat with reactive fibrosis. This case raises awareness that well-differentiated liposarcoma and dedifferentiated liposarcoma can rarely present as a primary intestinal mass mimicking colon cancer or other more common entities. When radiographic examination shows a perigastrointestinal or retroperitoneal fatty mass and/or stranding of the fat adjacent to a solid gastrointestinal mass, this unusual scenario should be considered in the radiologic differential diagnosis. Pathologists should keep dedifferentiated liposarcoma in the initial histologic differential diagnosis for any high-grade spindle cell tumor of the retroperitoneum or intra-abdominal visceral organs.	[Hollowoa, Blake; Mizell, Jason S.; Ram, Roopa; Gardner, Jerad M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Lamps, Laura W.] Univ Michigan, Ann Arbor, MI 48109 USA; [English, George W., III] Pathol Serv Texarkana LLP, Texarkana, TX USA; [Bridge, Julia A.] Univ Nebraska Med Ctr, Omaha, NE USA	Gardner, JM (reprint author), Univ Arkansas Med Sci, Dept Pathol, 4301 West Markham,517 Room S4-11, Little Rock, AR 72205 USA.	jmgardnermd@gmail.com					Amato G, 1998, HEPATO-GASTROENTEROL, V45, P2151; Bill KLJ, 2016, CLIN CANCER RES, V22, P1150, DOI 10.1158/1078-0432.CCR-15-1522; Boland JM, 2010, AM J SURG PATHOL, V34, P837, DOI 10.1097/PAS.0b013e3181dbf2f7; Cha EJ, 2011, WORLD J GASTRO ONCOL, V3, P116, DOI 10.4251/wjgo.v3.i7.116; Chen KTK, 2004, INT J SURG PATHOL, V12, P281, DOI 10.1177/106689690401200312; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Clay MR, 2015, AM J SURG PATHOL, V39, P1433, DOI 10.1097/PAS.0000000000000468; Crago AM, 2012, CLIN CANCER RES, V18, P1334, DOI 10.1158/1078-0432.CCR-11-2820; Craig WD, 2009, RADIOGRAPHICS, V29, P261, DOI 10.1148/rg.291085203; DEITOS AP, 2013, WHO CLASSIFICATION T, V4, P33; EVANS HL, 1994, AM J SURG PATHOL, V18, P1150, DOI 10.1097/00000478-199411000-00009; EVANS HL, 1979, AM J SURG PATHOL, V3, P507, DOI 10.1097/00000478-197912000-00004; Goldblum JR, 2001, ENZINGER WEISSS SOFT; Gutsu E, 2006, J GASTROINTEST SURG, V10, P652, DOI 10.1016/j.gassur.2005.09.014; Hasegawa T, 2000, HUM PATHOL, V31, P717, DOI 10.1053/hupa.2000.8222; Horvai AE, 2009, MODERN PATHOL, V22, P1477, DOI 10.1038/modpathol.2009.119; Laroche-Clary A, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0482-3; Marino-Enriquez A, 2010, AM J SURG PATHOL, V34, P1122, DOI 10.1097/PAS.0b013e3181e5dc49; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; Mussi C, 2011, ANN SURG ONCOL, V18, P2136, DOI 10.1245/s10434-011-1742-z; Okabayashi T, 2013, INTERNAL MED, V52, P2753, DOI 10.2169/internalmedicine.52.1230; Song JS, 2009, ANN DIAGN PATHOL, V13, P278, DOI 10.1016/j.anndiagpath.2008.07.002; Thway K, 2016, ADV ANAT PATHOL, V23, P30, DOI 10.1097/PAP.0000000000000101; Winn B, 2007, WORLD J GASTROENTERO, V13, P4147, DOI 10.3748/wjg.v13.i30.4147	24	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					174	179		10.1177/1066896917731517			6	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800013	28950740				2019-10-28	
J	Usui, G; Hashimoto, H; Matsumoto, J; Akahane, M; Tsunoda, H; Sasajima, Y; Horiuchi, H				Usui, Genki; Hashimoto, Hirotsugu; Matsumoto, Jun; Akahane, Masaaki; Tsunoda, Hajime; Sasajima, Yuko; Horiuchi, Hajime			Pulmonary Metastasis of Undifferentiated Uterine Sarcoma Forming Fluid-Containing Cyst	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						cyst; pulmonary metastasis; undifferentiated uterine sarcoma; secondary change	ENDOMETRIAL STROMAL SARCOMA; HIGH-GRADE; UTERUS; FEATURES; LUNG	Undifferentiated uterine sarcoma (UUS) is a high-grade sarcoma with no specific differentiation; however, it exhibits variable positivity for CD10 as an immunohistochemical marker of endometrial stroma, suggesting immunohistochemical differentiation into endometrial stroma. It has been reported that some low-grade endometrial stromal sarcoma pulmonary metastatic foci show cystic changes; however, whether pulmonary metastatic UUS foci are solid or cystic remains undescribed. A 63-year-old woman underwent a hysterectomy. The subsequent pathologic diagnosis was UUS. After the operation, she was treated with chemotherapy; however, pulmonary solitary shadow was radiologically detected. Eight months after the gynecologic operation, her pulmonary lesion was surgically resected. Pathologically, the lesion consisted of a cyst containing serous fluid with thick whitish wall composed of tumor cells, which led to the diagnosis of metastatsis of UUS. The cyst seemed to be formed via secondary degeneration. She remains healthy without recurrence 28 months after her first visit to our hospital.	[Usui, Genki; Hashimoto, Hirotsugu; Matsumoto, Jun; Akahane, Masaaki; Tsunoda, Hajime; Sasajima, Yuko; Horiuchi, Hajime] NTT Med Ctr Tokyo, Tokyo, Japan; [Sasajima, Yuko] Teikyo Univ, Tokyo, Japan	Hashimoto, H (reprint author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Shinagawa Ku, 5-9-2 Higashi Gotanda, Tokyo 1418625, Japan.	hhashimoto-tki@umin.ac.jp					Aubry MC, 2002, AM J SURG PATHOL, V26, P440, DOI 10.1097/00000478-200204000-00005; Fintelmann FJ, 2017, J THORAC IMAG, V32, P176, DOI 10.1097/RTI.0000000000000265; Itoh T, 1997, PATHOL INT, V47, P725, DOI 10.1111/j.1440-1827.1997.tb04449.x; Kurihara S, 2008, AM J SURG PATHOL, V32, P1228, DOI 10.1097/PAS.0b013e31816a3b42; Lee CH, 2012, AM J SURG PATHOL, V36, P1562, DOI 10.1097/PAS.0b013e31825fa931; Lee CH, 2012, AM J SURG PATHOL, V36, P641, DOI 10.1097/PAS.0b013e31824a7b1a; McCluggage WG, 1996, HISTOPATHOLOGY, V29, P369, DOI 10.1111/j.1365-2559.1996.tb01421.x; Oliva E, 1999, INT J GYNECOL PATHOL, V18, P310, DOI 10.1097/00004347-199910000-00004; Oliva E, 2014, WHO CLASSIFICATION T, P135; Oliva E, 2014, AM J SURG PATHOL, V38, P305, DOI 10.1097/PAS.0000000000000145; Park JY, 2013, HISTOPATHOLOGY, V63, P833, DOI 10.1111/his.12232; Pautier P, 2014, INT J GYNECOL CANCER, V24, pS73, DOI 10.1097/IGC.0000000000000281; Philip CA, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-014-0405-1; Tanimoto A, 1996, PATHOL INT, V46, P231, DOI 10.1111/j.1440-1827.1996.tb03604.x; Tanner EJ, 2012, GYNECOL ONCOL, V127, P27, DOI 10.1016/j.ygyno.2012.06.030; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239	16	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					180	184		10.1177/1066896917728795			5	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800014	28862061				2019-10-28	
J	Hirsch, E; Jagirdar, J; Nazarullah, A				Hirsch, Eric; Jagirdar, Jaishree; Nazarullah, Alia			Pulmonary Adenocarcinoma, Intra-alveolar Variant: A Rare Entity Mimicking Desquamative Interstitial Pneumonia	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						adenocarcinoma; intra-alveolar; pulmonary; desquamative	COLORECTAL LUNG METASTASES; SQUAMOUS-CELL CARCINOMA; AIR SPACES; RECURRENCE; SPREAD; PROGNOSIS; RESECTION; DIP	Exclusive discohesive tumor cells within intra-alveolar spaces is a rare pattern of involvement of primary and metastatic lung tumors. In the absence of a tumoral mass, this pattern closely mimics desquamative interstitial pneumonia (DIP) clinically, radiologically, and histologically. However, a secondary DIP pattern may be seen adjacent to a tumor mass not infrequently. Here, we describe a case of a 64-year-old woman status post bilateral lung transplantation, who was radiologically thought to have an interstitial lung disease. The autopsy lung specimen revealed extensive involvement by intra-alveolar adenocarcinoma, with a cytomorphology mimicking alveolar macrophages as seen in DIP in the absence of a tumoral mass. The presence of subtle clustering with signet ring cell features and rare micropapillae were an important clue to the diagnosis. The tumor cells were positive for CK7, napsin-A, and TTF-1, and negative for CD68. This case represents an unusual variant of pulmonary adenocarcinoma with a pure intra-alveolar pattern of involvement, mimicking DIP. To the best of our knowledge, excluding biopsy specimens, only one similar case has been reported in the literature and none in the posttransplant setting.	[Hirsch, Eric; Nazarullah, Alia] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Jagirdar, Jaishree] Cryolife Inc, Kennesaw, GA USA	Nazarullah, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol & Lab Med, 7703 Floyd Curl Dr,MC 7750, San Antonio, TX 78229 USA.	nazarullah@uthscsa.edu					Colby TV, 1995, TUMORS LOWER RESP TR; Kadota K, 2015, J THORAC ONCOL, V10, P806, DOI 10.1097/JTO.0000000000000486; LIEBOW AA, 1965, AM J MED, V39, P369, DOI 10.1016/0002-9343(65)90206-8; Lu SH, 2017, J THORAC ONCOL, V12, P223, DOI 10.1016/j.jtho.2016.09.129; Morimoto J, 2016, J THORAC CARDIOV SUR, V152, P64, DOI 10.1016/j.jtcvs.2016.03.088; Mutton AE, 1998, HISTOPATHOLOGY, V33, P129, DOI 10.1046/j.1365-2559.1998.00463.x; Onozato ML, 2013, AM J SURG PATHOL, V37, P287, DOI 10.1097/PAS.0b013e31826885fb; Raparia K, 2014, AM J SURG PATHOL, V38, P921, DOI 10.1097/PAS.0000000000000227; Shiono S, 2005, ANN THORAC SURG, V80, P1040, DOI 10.1016/j.athoracsur.2004.12.033; Shiono S, 2005, ANN THORAC SURG, V79, P278, DOI 10.1016/j.athoracsur.2004.06.096; Shiono S, 2016, INTERACT CARDIOV TH, V23, P567, DOI 10.1093/icvts/ivw211; Warth A, 2015, AM J SURG PATHOL, V39, P793, DOI 10.1097/PAS.0000000000000409; Yousem SA, 2009, HUM PATHOL, V40, P861, DOI 10.1016/j.humpath.2008.11.008	13	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					185	189		10.1177/1066896917729436			5	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800015	28862049				2019-10-28	
J	Kwon, HJ; Song, PH; Gu, MJ				Kwon, Hee Jung; Song, Phil Hyun; Gu, Mi Jin			Occult Langerhans Cell Histiocytosis in Clear Cell Renal Cell Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						Langerhans cell histiocytosis; clear cell renal cell carcinoma; hyperplasia; neoplasm	BRAF	Langerhans cell histiocytosis is a rare disease that is characterized by a localized or systemic proliferation of Langerhans dendritic cells and a wide spectrum of clinical presentations. We experienced an unusual case of occult Langerhans cell histiocytosis associated with clear cell renal cell carcinoma. A 62-year-old man underwent a partial nephrectomy for left renal mass. Histologic examination showed nests of clear cells with surrounding thin-walled vessel that were suggestive of clear cell renal cell carcinoma. A well-defined nodule composed of atypical mononuclear cells and plentiful eosinophils presented within clear cell renal cell carcinoma. The mononuclear cells were Langerhans cell histiocytes with S-100 and CD1a immunoreactivity. On follow-up comprehensive physical, laboratory, and radiologic examination, there were no other lesions of Langerhans cell histiocytosis.	[Kwon, Hee Jung; Song, Phil Hyun; Gu, Mi Jin] Yeungnam Univ, Daegu, South Korea	Gu, MJ (reprint author), Yeungnam Univ, Dept Pathol, Coll Med, 170 Hyeonchung Ro, Daegu 42415, South Korea.	mjgu@yu.ac.kr					Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Billings SD, 2006, J CUTAN PATHOL, V33, P171, DOI 10.1111/j.0303-6987.2006.00299.x; Bohn OL, 2014, INT J SURG PATHOL, V22, P172, DOI 10.1177/1066896913487985; CRAWFORD ED, 1980, UROLOGY, V15, P520, DOI 10.1016/0090-4295(80)90023-0; EGELER RM, 1993, CANCER, V71, P865, DOI 10.1002/1097-0142(19930201)71:3<865::AID-CNCR2820710334>3.0.CO;2-0; Goyal G, BRIT J HAEMATOL, DOI [10.1111/bjh.14818., DOI 10.1111/BJH.14818.]; Gul OO, 2017, ENDOCRINOL DIAB META, DOI 10.1530/EDM-16-0087; Kaya Akyn, 2002, Can Respir J, V9, P431; O'Kane D, 2009, CLIN EXP DERMATOL, V34, pE829, DOI 10.1111/j.1365-2230.2009.03569.x; Ohtsuki Y, 2008, MED MOL MORPHOL, V41, P175, DOI 10.1007/s00795-008-0402-2; Pimentel A, 2011, J CLIN ONCOL, V29, pE107, DOI 10.1200/JCO.2010.30.9344; Pina-Oviedo S, 2017, MODERN PATHOL, V30, P734, DOI 10.1038/modpathol.2016.235; Pina-Oviedo S, 2017, AM J DERMATOPATH, V39, P388, DOI 10.1097/DAD.0000000000000775; Rizzo FM, 2014, ONCOLOGIST, V19, P151, DOI 10.1634/theoncologist.2013-0341	14	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	APR	2018	26	2					194	196		10.1177/1066896917735171			3	Pathology; Surgery	Pathology; Surgery	GC5SN	WOS:000429848800017	29017411				2019-10-28	
J	Sobel, ME				Sobel, Mark E.			Variations on a Theme by Darwin	AMERICAN JOURNAL OF PATHOLOGY			English	Editorial Material									[Sobel, Mark E.] Amer Soc Invest Pathol, Rockville, MD USA	Sobel, ME (reprint author), 1801 Rockville Pike,Suite 350, Rockville, MD 20852 USA.	mesobel@asip.org	Sobel, Mark E/V-7764-2019				Darwin C., 1859, ORIGIN SPECIES MEANS; Dawkins R., 1976, SELFISH GENE; Fulghum R, 1990, ALL I REALLY NEED KN	3	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					836	837		10.1016/j.ajpath.2018.02.002			2	Pathology	Pathology	GB6NH	WOS:000429185400001	29571324				2019-10-28	
J	Wang, JL; Wang, Y; Wang, JJ; Guo, XS; Chan, EC; Jiang, F				Wang, Jianli; Wang, Yuan; Wang, Jingjing; Guo, Xiaosun; Chan, Elsa C.; Jiang, Fan			Adventitial Activation in the Pathogenesis of Injury-Induced Arterial Remodeling Potential Implications in Transplant Vasculopathy	AMERICAN JOURNAL OF PATHOLOGY			English	Review							PORCINE CORONARY-ARTERIES; SMOOTH-MUSCLE-CELLS; NEOINTIMA FORMATION; VASCULAR INFLAMMATION; PROGENITOR CELLS; MICRORNA EXPRESSION; OXIDATIVE STRESS; LESION FORMATION; VASA VASORUM; MACROPHAGE	Transplant vasculopathy is one of the major causes of chronic rejection after solid organ transplantation. The pathogenic mechanisms of transplant vasculopathy are still poorly understood. Herein, we summarize current evidence suggesting that activation of the tunica adventitia may be involved in the pathogenesis of transplant vasculopathy. Adventitia is an early responder to various vascular injuries and plays an integral role in eliciting vascular inflammation and remodeling. Accumulation of macrophages in the adventitia promotes the development of vascular remodeling by releasing a variety of paracrine factors that have profound impacts on vascular mural cells. Targeting adventitial macrophages has been shown to be effective for repressing transplantation-induced arterial remodeling in animal models. Adventitia also fosters angiogenesis, and neovascularization of the adventitial layer may facilitate the transport of inflammatory cells through the arterial wall. Further investigations are warranted to clarify whether inhibiting adventitial oxidative stress and/or adventitial neovascularization are better strategies for preventing transplant vasculopathy.	[Wang, Jianli; Wang, Jingjing; Guo, Xiaosun; Jiang, Fan] Shandong Univ, Sch Basic Med, Dept Physiol & Pathophysiol, 44 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Wang, Yuan] Shandong Univ, Qilu Hosp, Dept Emergency, Jinan, Shandong, Peoples R China; [Jiang, Fan] Shandong Univ, Qilu Hosp, Chinese Minist Educ, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Shandong, Peoples R China; [Jiang, Fan] Shandong Univ, Qilu Hosp, Chinese Minist Hlth, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Shandong, Peoples R China; [Jiang, Fan] Shandong Univ, Qilu Hosp, State & Shandong Prov Joint Key Lab Translat Card, Jinan, Shandong, Peoples R China; [Chan, Elsa C.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia	Jiang, F (reprint author), Shandong Univ, Sch Basic Med, Dept Physiol & Pathophysiol, 44 Wen Hua Xi Rd, Jinan 250012, Shandong, Peoples R China.	fjiang@sdu.edu.cn	Jiang, Fan/B-7753-2013	Jiang, Fan/0000-0001-9466-2192	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [91539102, 31471087]; National 973 Basic Research ProgramNational Basic Research Program of China [2010CB732605]; Natural Science Foundation of Shandong ProvinceNatural Science Foundation of Shandong Province [ZR2016HM24]; Innovation Fund of Ji'nan City [201401251]	Supported by National Natural Science Foundation of China research grants 91539102 (F.J.) and 31471087 (F.J.), National 973 Basic Research Program 2010CB732605 (F.J.), Natural Science Foundation of Shandong Province ZR2016HM24 (J.W.), and Innovation Fund of Ji'nan City 201401251 (J.W.).	Akhavanpoor M, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00296; Alegre ML, 2007, CURR OPIN IMMUNOL, V19, P563, DOI 10.1016/j.coi.2007.07.019; Allbutt TC, 1915, DIS ARTERIES INCLUDI, VII, P187; Aoki T, 2015, ATHEROSCLEROSIS, V239, P203, DOI 10.1016/j.atherosclerosis.2015.01.016; Ardanaz N, 2006, EXP BIOL MED, V231, P237; BARKER SGE, 1994, ATHEROSCLEROSIS, V105, P131, DOI 10.1016/0021-9150(94)90043-4; Chan EC, 2007, CARDIOVASC RES, V75, P710, DOI 10.1016/j.cardiores.2007.06.005; Datla SR, 2007, ARTERIOSCL THROM VAS, V27, P2319, DOI 10.1161/ATVBAHA.107.149450; Dourron HM, 2005, AM J PHYSIOL-HEART C, V288, pH946, DOI 10.1152/ajpheart.00413.2004; Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403; Enzerink A, 2011, J THROMB HAEMOST, V9, P619, DOI 10.1111/j.1538-7836.2011.04209.x; Grudzinska MK, 2013, ARTERIOSCL THROM VAS, V33, P1271, DOI 10.1161/ATVBAHA.112.300773; Guo XT, 2017, ONCOTARGET, V8, P30100, DOI 10.18632/oncotarget.16279; Haurani MJ, 2007, CARDIOVASC RES, V75, P679, DOI 10.1016/j.cardiores.2007.06.016; Henrichot E, 2005, ARTERIOSCL THROM VAS, V25, P2594, DOI 10.1161/01.ATV.0000188508.40052.35; Herrmann J, 2005, ARTERIOSCL THROM VAS, V25, P447, DOI 10.1161/01.ATV.0000152606.34120.97; Ji J, 2010, TRANSPLANTATION, V89, P945, DOI 10.1097/TP.0b013e3181d05aa7; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Kitchens WH, 2007, AM J TRANSPLANT, V7, P2675, DOI 10.1111/j.1600-6143.2007.01997.x; Kortelainen ML, 2014, CARDIOVASC PATHOL, V23, P193, DOI 10.1016/j.carpath.2014.03.001; Kwon HM, 1998, J AM COLL CARDIOL, V32, P2072, DOI 10.1016/S0735-1097(98)00482-3; Li GH, 2000, CIRCULATION, V101, P1362, DOI 10.1161/01.CIR.101.12.1362; Li XD, 2012, ARTERIOSCL THROM VAS, V32, P2250, DOI 10.1161/ATVBAHA.112.255216; Lindenfeld J, 2004, CIRCULATION, V110, P3858, DOI 10.1161/01.CIR.0000150332.42276.69; Maiellaro K, 2007, CARDIOVASC RES, V75, P640, DOI 10.1016/j.cardiores.2007.06.023; Majesky MW, 2011, ARTERIOSCL THROM VAS, V31, P1530, DOI 10.1161/ATVBAHA.110.221549; McDonald RA, 2013, EUR HEART J, V34, P1636, DOI 10.1093/eurheartj/eht105; Meijles DN, 2016, HYPERTENSION, V67, P14, DOI 10.1161/HYPERTENSIONAHA.115.03622; MENNANDER A, 1991, ARTERIOSCLER THROMB, V11, P671, DOI 10.1161/01.ATV.11.3.671; Michel JB, 2007, ARTERIOSCL THROM VAS, V27, P1259, DOI 10.1161/ATVBAHA.106.137851; Miller LW, 2000, CIRCULATION, V101, P1598, DOI 10.1161/01.CIR.101.13.1598; Mitchell RN, 2007, CIRC RES, V100, P967, DOI 10.1161/01.RES.0000261982.76892.09; Mitchell RN, 2009, ANNU REV PATHOL-MECH, V4, P19, DOI 10.1146/annurev.pathol.3.121806.151449; Okamoto E, 2001, CIRCULATION, V104, P2228, DOI 10.1161/hc4301.097195; Patel S, 2000, CIRCULATION, V101, P524, DOI 10.1161/01.CIR.101.5.524; Pels K, 1999, ARTERIOSCL THROM VAS, V19, P229, DOI 10.1161/01.ATV.19.2.229; Peshavariya H, 2009, N-S ARCH PHARMACOL, V380, P193, DOI 10.1007/s00210-009-0413-0; Peshavariya HM, 2014, J CELL MOL MED, V18, P1172, DOI 10.1111/jcmm.12263; Psaltis PJ, 2014, CIRC RES, V115, P364, DOI 10.1161/CIRCRESAHA.115.303299; SCHWARTZ CJ, 1962, CIRCULATION, V26, P73, DOI 10.1161/01.CIR.26.1.73; Scott NA, 1996, CIRCULATION, V93, P2178, DOI 10.1161/01.CIR.93.12.2178; Shi Y, 1996, CIRCULATION, V93, P340, DOI 10.1161/01.CIR.93.2.340; Shimizu K, 2008, ARTERIOSCL THROM VAS, V28, P1937, DOI 10.1161/ATVBAHA.107.161232; Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802; Sun MY, 2016, EXP MOL PATHOL, V100, P67, DOI 10.1016/j.yexmp.2015.12.001; Sun Y, 2016, ARTERIOSCL THROM VAS, V36, P1230, DOI 10.1161/ATVBAHA.115.306691; Thaunat O, 2008, TRANSPLANTATION, V85, P281, DOI 10.1097/TP.0b013e318160500a; van Hinsbergh VWM, 2015, CURR OPIN LIPIDOL, V26, P405, DOI 10.1097/MOL.0000000000000210; Wang JL, 2013, CHINESE J PHYSIOL, V56, P77, DOI 10.4077/CJP.2013.BAA080; Wedel J, 2015, CURR OPIN ORGAN TRAN, V20, P13, DOI 10.1097/MOT.0000000000000155; Wei YY, 2013, AM J PHYSIOL-HEART C, V304, pH1050, DOI 10.1152/ajpheart.00267.2012; Xu XS, 2009, CARDIOVASC PATHOL, V18, P269, DOI 10.1016/j.carpath.2008.07.004; Yang Z, 2015, BBA-MOL BASIS DIS, V1852, P1477, DOI 10.1016/j.bbadis.2015.04.012	53	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					838	845		10.1016/j.ajpath.2017.12.002			8	Pathology	Pathology	GB6NH	WOS:000429185400002	29341889	Bronze			2019-10-28	
J	Liu, QQ; Cornejo, KM; Cheng, L; Hutchinson, L; Wang, MS; Zhang, SB; Tomaszewicz, K; Cosar, EF; Woda, BA; Jiang, Z				Liu, Qingqing; Cornejo, Kristine M.; Cheng, Liang; Hutchinson, Lloyd; Wang, Mingsheng; Zhang, Shaobo; Tomaszewicz, Keith; Cosar, Ediz F.; Woda, Bruce A.; Jiang, Zhong			Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL-DIAGNOSIS; CYTOGENETIC ANALYSIS; SOMATIC MUTATIONS; KIT CD117; TUMORS; EXPRESSION; CHROMOSOMES; ONCOCYTOMA; CANCER	Overlapping morphologic, immunohistochemical, and ultrastructural features make it difficult to diagnose chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (R0). Because ChRCC is a malignant tumor, whereas R0 is a tumor with benign behavior, it is important to distinguish these two entities. We aimed to identify genetic markers that distinguish ChRCC from R0 by using next-generation sequencing (NGS). NGS for hotspot mutations or gene copy number changes was performed on 12 renal neoplasms, including seven ChRCC and five R0 cases. Matched normal tissues from the same patients were used to exclude germline variants. Rare hotspot mutations were found in cancer-critical genes (TP53 and PIK3CA) in ChRCC but not R0. The NGS gene copy number analysis revealed multiple abnormalities. The two most common deletions were tumor-suppressor genes RB1 and ERBB4 in ChRCC but not R0. Fluorescence in situ hybridization was performed on 65 cases (ChRCC, n = 33; R0, n = 32) to verify hemizygous deletion of RB1 (17/33, 52%) or ERBB4 (11/33, 33%) in ChRCC, but not in R0 (0/32, 0%). In total, ChRCCs (23/33, 70%) carry either a hemizygous deletion of RB1 or ERBB4. The combined use of RB1 and ERBB4 fluorescence in situ hybridization to detect deletion of these genes may offer a highly sensitive and specific assay to distinguish ChRCC from R0.	[Liu, Qingqing] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Cornejo, Kristine M.; Hutchinson, Lloyd; Tomaszewicz, Keith; Cosar, Ediz F.; Woda, Bruce A.; Jiang, Zhong] Univ Massachusetts, Sch Med, Dept Pathol, One Innovat Dr,Biotech 3, Worcester, MA 01605 USA; [Cheng, Liang; Wang, Mingsheng; Zhang, Shaobo] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA	Jiang, Z (reprint author), Univ Massachusetts, Sch Med, Dept Pathol, One Innovat Dr,Biotech 3, Worcester, MA 01605 USA.	jiangz@ummhc.org			Department of Pathology, University of Massachusetts Medical School; Department of Pathology, Indiana University School of Medicine	Supported by the Department of Pathology, University of Massachusetts Medical School, and the Department of Pathology, Indiana University School of Medicine.	Abrahams NA, 2004, HISTOPATHOLOGY, V45, P593, DOI 10.1111/j.1365-2559.2004.02003.x; Al-Saleem T, 2004, CANCER GENET CYTOGEN, V152, P23, DOI 10.1016/j.cancergencyto.2003.10.001; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bismar TA, 2011, BJU INT, V107, P477, DOI 10.1111/j.1464-410X.2010.09470.x; Bugert P, 1996, AM J PATHOL, V149, P2081; Cheng L, 2008, CLIN CANCER RES, V14, P8087, DOI 10.1158/1078-0432.CCR-08-1494; Cheng L, 2009, HUM PATHOL, V40, P10, DOI 10.1016/j.humpath.2008.09.009; CROTTY TB, 1992, CANCER GENET CYTOGEN, V61, P61, DOI 10.1016/0165-4608(92)90372-F; Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014; Decker HJH, 1996, HUM GENET, V97, P770; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Furge KA, 2004, CANCER RES, V64, P4117, DOI 10.1158/0008-5472.CAN-04-0534; Fuzesi L, 1998, CANCER GENET CYTOGEN, V107, P1, DOI 10.1016/S0165-4608(98)00060-0; Gobbo S, 2008, AM J SURG PATHOL, V32, P1780, DOI 10.1097/PAS.0b013e31818649ed; Halat S, 2010, MODERN PATHOL, V23, P931, DOI 10.1038/modpathol.2010.78; Jones TD, 2005, CLIN CANCER RES, V11, P7226, DOI 10.1158/1078-0432.CCR-04-2597; Junker K, 2003, RECENT RES CANCER, V162, P169; Kato N, 2005, PATHOL INT, V55, P479, DOI 10.1111/j.1440-1827.2005.01856.x; Kolnikova G, 2014, Klin Onkol, V27, P138; KOVACS A, 1992, J PATHOL, V167, P273, DOI 10.1002/path.1711670303; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; KOVACS G, 1988, CANCER GENET CYTOGEN, V31, P211, DOI 10.1016/0165-4608(88)90219-1; Kruger S, 2005, ONCOLOGY-BASEL, V68, P269, DOI 10.1159/000086783; Liu QQ, 2016, VIRCHOWS ARCH, V469, P233, DOI 10.1007/s00428-016-1965-2; MacKinnon RN, 2011, GENET RES INT, DOI 10.4061/2011/643628; Memeo L, 2007, AM J CLIN PATHOL, V127, P225, DOI 10.1309/9KWEA4W9Y94D1AEE; Pan CC, 2004, AM J CLIN PATHOL, V121, P878, DOI 10.1309/A7M2XTMJQK0KPQER; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Schwerdtle RF, 1996, CANCER RES, V56, P2927; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; SPEICHER MR, 1994, AM J PATHOL, V145, P356; Srividya MR, 2011, NEUROPATHOLOGY, V31, P376, DOI 10.1111/j.1440-1789.2010.01178.x; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Tan MH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-196; Tickoo SK, 1999, AM J SURG PATHOL, V23, P1094, DOI 10.1097/00000478-199909000-00013; Trpkov K, 2010, HISTOPATHOLOGY, V57, P893, DOI 10.1111/j.1365-2559.2010.03726.x; Weller M, 2007, CLIN CANCER RES, V13, P6933, DOI 10.1158/1078-0432.CCR-07-0573; Wiens AL, 2012, J NEUROPATH EXP NEUR, V71, P618, DOI 10.1097/NEN.0b013e31825b5f7a; Williamson SR, 2013, AM J SURG PATHOL, V37, P1131, DOI 10.1097/PAS.0b013e318282dab8; Young AN, 2003, AM J SURG PATHOL, V27, P199, DOI 10.1097/00000478-200302000-00008	40	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					846	852		10.1016/j.ajpath.2017.12.003			7	Pathology	Pathology	GB6NH	WOS:000429185400003	29353061				2019-10-28	
J	Hochane, M; Raison, D; Coquard, C; Beraud, C; Danilin, S; Bethry, A; Massfelder, T; Barthelmebs, M				Hochane, Mazene; Raison, Denis; Coquard, Catherine; Beraud, Claire; Danilin, Sabrina; Bethry, Audrey; Massfelder, Thierry; Barthelmebs, Mariette			Parathyroid Hormone-Related Protein Contributes to Early Healing of Habu Snake Venom-Induced Glomerulonephritis in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INDUCED GLOMERULAR INJURY; SMOOTH-MUSCLE-CELLS; MESANGIAL CELLS; PROLIFERATIVE GLOMERULONEPHRITIS; DIABETIC-NEPHROPATHY; EXPRESSION; KIDNEY; SURVIVAL; UPDATE; REPAIR	Proliferative glomerulonephritis is characterized by local inflammation and mesangial cell deterioration, followed by mesangial proliferation and glomerular healing. Parathyroid hormone related peptide (PTHrP) is a mesangial cytokine-like growth factor implicated in mesangial proliferation and survival. No data are available about its role in glomerulonephritis. Herein, we analyzed the expression and role of PTHrP in glomerular inflammation and healing in an experimental model of glomerulonephritis induced by i.v. injection of Habu snake venom in mice. The temporal analysis showed marked renal damage in the first days after venom injection and the beginning of recovery within 7 days. Glomerular expression of PTHrP (transcript and protein) was observed in the early phase after venom injection (from day 1 to day 3), along with an inflammatory environment. The inactivation of secreted PTHrP with PTHrP-neutralizing antibody (PTH2E11; 120 mu g i.p. daily) reduced the markers of local inflammation (expression of macrophage chemotactic protein-1; regulated upon activation, normal T cell expressed and secreted; cyclooxygenase 2; IL-6; and macrophage infiltration) and abolished the expression of PTHrP itself. Moreover, the glomerular cell proliferation was hampered, and the healing process was prevented on day 7 after venom injection. These results show that PTHrP has antinomic actions in glomerulonephritis, participating in both the proinflammatory condition and the healing process. Our work reveals the essential role of PTHrP in early glomerular repair in an experimental model of glomerulonephritis.	[Hochane, Mazene; Raison, Denis; Coquard, Catherine; Beraud, Claire; Danilin, Sabrina; Bethry, Audrey; Massfelder, Thierry; Barthelmebs, Mariette] INSERM, UMR S1113, Cell Signalisat & Commun Kidney & Prostate Canc T, Strasbourg, France; [Hochane, Mazene; Raison, Denis; Coquard, Catherine; Massfelder, Thierry; Barthelmebs, Mariette] Strasbourg Univ, UMR S1113, Strasbourg, France; [Coquard, Catherine; Danilin, Sabrina; Massfelder, Thierry; Barthelmebs, Mariette] Strasbourg Federat Translat Med, UMR S1113, Strasbourg, France	Barthelmebs, M (reprint author), Fac Med, INSERM, UMR S1113, Equipe Signalisat & Commun Cellulaires Canc Rein, 11 Rue Humann, F-67085 Strasbourg, France.	barthelm@unistra.fr	Massfelder, Thierry/I-1260-2016		INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); University of Strasbourg; French Ministry of Higher Education fellowship	Supported by INSERM, University of Strasbourg grants 2009 to 2014 (T.M.), and the French Ministry of Higher Education fellowship 2009 to 2012 (M.H.).	ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; Agouni A, 2007, CARCINOGENESIS, V28, P1893, DOI 10.1093/carcin/bgm106; BARNES JL, 1994, LAB INVEST, V70, P460; BARNES JL, 1994, AM J PATHOL, V145, P585; BARNES JL, 1993, AM J PATHOL, V143, P1366; CATTELL V, 1977, AM J PATHOL, V87, P511; Champy MF, 2004, MAMM GENOME, V15, P768, DOI 10.1007/s00335-004-2393-1; Chijiwa T, 2000, BIOCHEM J, V347, P491, DOI 10.1042/0264-6021:3470491; Clemens TL, 2001, BRIT J PHARMACOL, V134, P1113, DOI 10.1038/sj.bjp.0704378; Endlich N, 2001, EXP NEPHROL, V9, P436; Esbrit P, 2000, NEPHROL DIAL TRANSPL, V15, P1109, DOI 10.1093/ndt/15.8.1109; FERGUSON JE, 1995, AM J OBSTET GYNECOL, V173, P448, DOI 10.1016/0002-9378(95)90265-1; Funk JL, 1998, J CLIN INVEST, V101, P1362; Funk JL, 2001, INT IMMUNOPHARMACOL, V1, P1101, DOI 10.1016/S1567-5769(01)00040-6; Haas CS, 2007, VIRCHOWS ARCH, V450, P81, DOI 10.1007/s00428-006-0340-0; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hochane M, 2018, AM J PHYSIOL-CELL PH, V314, pC242, DOI 10.1152/ajpcell.00018.2017; Hochane M, 2013, ENDOCRINOLOGY, V154, P853, DOI 10.1210/en.2012-1802; Huen SC, 2017, ANNU REV PHYSIOL, V79, P449, DOI 10.1146/annurev-physiol-022516-034219; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; Isales CM, 2000, AM J PHYSIOL-ENDOC M, V279, pE654; Izquierdo A, 2006, KIDNEY INT, V69, P2171, DOI 10.1038/sj.ki.5000195; KITAMURA H, 1995, VIRCHOWS ARCH, V427, P195; Kubo A, 2002, NEPHRON, V92, P665, DOI 10.1159/000064115; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Lorenzo O, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015622.33198.BF; Martin-Ventura JL, 2003, STROKE, V34, P1783, DOI 10.1161/01.STR.0000078371.00577.76; MASSFELDER T, 1995, NEPHROL DIAL TRANSPL, V10, P1984; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Masuda S, 1998, EUR J BIOCHEM, V253, P36, DOI 10.1046/j.1432-1327.1998.2530036.x; Morita T, 1998, AM J KIDNEY DIS, V31, P559, DOI 10.1053/ajkd.1998.v31.pm9531171; Nakao N, 1998, AM J PATHOL, V152, P1237; Ortega A, 2005, J AM SOC NEPHROL, V16, P939, DOI 10.1681/ASN.2004040328; Ortega A, 2012, J CELL PHYSIOL, V227, P1980, DOI 10.1002/jcp.22926; Philbrick WM, 1996, PHYSIOL REV, V76, P127; Raison D, 2013, AM J PHYSIOL-RENAL, V305, pF333, DOI 10.1152/ajprenal.00503.2012; Ramila D, 2008, KIDNEY INT, V73, P835, DOI 10.1038/sj.ki.5002775; Rizzoli R, 1992, J Endocrinol Invest, V15, P51; Su H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00405; UIKER S, 1995, VIRCHOWS ARCH, V426, P281; Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012-2142; Zeimer HJ, 1998, AM J PATHOL, V152, P17	42	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					863	875		10.1016/j.ajpath.2017.12.012			13	Pathology	Pathology	GB6NH	WOS:000429185400005	29353060	Bronze			2019-10-28	
J	Habiel, DM; Espindola, MS; Coelho, AL; Hogaboam, CM				Habiel, David M.; Espindola, Milena S.; Coelho, Ana L.; Hogaboam, Cory M.			Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ALLERGIC AIRWAY DISEASE; GROWTH-FACTOR-ALPHA; PERIBRONCHIAL FIBROSIS; IL-13-RESPONSIVE CELLS; ENDOTRACHEAL BLEOMYCIN; EMPHYSEMA SYNDROME; CXCR4 ANTAGONIST; LUNG FIBROBLASTS; FUNGAL ASTHMA; RAT LUNG	Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown etiopathogenesis with limited therapeutic options. IPF is characterized by an abundance of fibroblasts and loss of epithelial progenitors, which cumulates in unrelenting fibrotic lung remodeling and loss of normal oxygenation. IPF has been challenging to model in rodents; nonetheless, mouse models of lung fibrosis provide clues as to the natural progression of lung injury and remodeling, but many have not been useful in predicting efficacy of therapeutics in clinical IPF. We provide a detailed methodologic description of various iterations of humanized mouse models, initiated by the i.v. injection of cells from IPF lung biopsy or explants specimens into severe combined immunodeficiency (SCID)/beige or nonobese diabetic SCID gamma mice. Unlike cells from normal lung samples, IPF cells promote persistent, nonresolving lung remodeling in SCID mice. Finally, we provide examples and discuss potential advantages and pitfalls of human specific targeting approaches in a humanized SCID model of pulmonary fibrosis.	[Habiel, David M.; Espindola, Milena S.; Coelho, Ana L.; Hogaboam, Cory M.] Cedars Sinai Med Ctr, Dept Med, Womens Guild Lung Inst, Los Angeles, CA 90048 USA	Habiel, DM; Hogaboam, CM (reprint author), Cedars Sinai Med Ctr, 127 S San Vicente Blvd,AHSP A9404, Los Angeles, CA 90048 USA.	david.habiel@cshs.org; coxy.hogaboam@cshs.org		Hogaboam, Cory/0000-0003-3366-4850	Cedars Sinai Medical Center; University of MichiganUniversity of Michigan System; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL123899, T32-HL007517-30]; AdAlta; JanssenJohnson & Johnson USAJanssen Biotech Inc; Neo-Phann; Roche/GenentechRoche HoldingGenentech; AstraZeneca/MedImmuneAstraZeneca; NovartisNovartis	Supported by Cedars Sinai Medical Center (D.M.H. and C.M.H.), University of Michigan (C.M.H.), NIH grants R01 HL123899 (C.M.H.) and T32-HL007517-30 (D.M.H.), AdAlta (C.M.H.), Janssen (C.M.H.), Neo-Phann (C.M.H.), Roche/Genentech (C.M.H.), AstraZeneca/MedImmune (C.M.H.), and Novartis (C.M.H.).	Alvarez D, 2017, AM J PHYSIOL-LUNG C, V313, pL1164, DOI 10.1152/ajplung.00220.2017; Baumgartner KB, 2000, AM J EPIDEMIOL, V152, P307, DOI 10.1093/aje/152.4.307; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Camelo A, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00173; Chandriani S, 2014, J IMMUNOL, V193, P111, DOI 10.4049/jimmunol.1301761; Corren J, 2013, CURR ALLERGY ASTHM R, V13, P415, DOI 10.1007/s11882-013-0373-9; Cottin V, 2011, THORAX, V66, P918, DOI 10.1136/thx.2010.151407; Cottin V, 2011, ARTHRITIS RHEUM-US, V63, P295, DOI 10.1002/art.30077; Cottin V, 2009, CHEST, V136, P1, DOI 10.1378/chest.09-0538; Dai SJ, 2010, J MOL CELL CARDIOL, V49, P587, DOI 10.1016/j.yjmcc.2010.07.010; Davis Gerald S., 1998, Journal of Environmental Pathology Toxicology and Oncology, V17, P81; Degryse AL, 2010, AM J PHYSIOL-LUNG C, V299, pL442, DOI 10.1152/ajplung.00026.2010; DePianto DJ, 2015, THORAX, V70, P48, DOI 10.1136/thoraxjnl-2013-204596; do Carmo A, 2010, CANCER BIOL THER, V9, P56, DOI 10.4161/cbt.9.1.10342; du Bois RM, 2010, NAT REV DRUG DISCOV, V9, P129, DOI 10.1038/nrd2958; Epperly MW, 2003, AM J RESP CELL MOL, V29, P213, DOI 10.1165/rcmb.2002-0069OC; Ferreira TPT, 2013, J IMMUNOL, V191, P5220, DOI 10.4049/jimmunol.1203551; Fisher Mark, 2017, J Manag Care Spec Pharm, V23, pS17, DOI 10.18553/jmcp.2017.23.3-b.s17; Hardie WD, 2004, AM J PHYSIOL-LUNG C, V286, pL741, DOI 10.1152/ajplung.00208.2003; Harris JM, 2001, CHEST, V119, P428, DOI 10.1378/chest.119.2.428; Haston CK, 1997, CANCER RES, V57, P5286; Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182; Hecker L, 2011, AM J MED SCI, V341, P431, DOI 10.1097/MAJ.0b013e31821a9d66; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Huang Y, 2017, AM J RESP CRIT CARE, V196, P208, DOI 10.1164/rccm.201607-1525OC; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; Jakubzick C, 2004, IMMUNOL RES, V30, P339, DOI 10.1385/IR:30:3:339; Jakubzick C, 2003, J IMMUNOL, V171, P2684, DOI 10.4049/jimmunol.171.5.2684; Jankowich MD, 2012, CHEST, V141, P222, DOI 10.1378/chest.11-1062; Karo-Atar D, 2016, MUCOSAL IMMUNOL, V9, P240, DOI 10.1038/mi.2015.56; Keane MP, 2007, J IMMUNOL, V178, P511, DOI 10.4049/jimmunol.178.1.511; King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582; King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140-6736(11)60052-4; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; Kolodsick JE, 2004, J IMMUNOL, V172, P4068, DOI 10.4049/jimmunol.172.7.4068; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Kraan TCTMV, 2002, GENES IMMUN, V3, P436; Krook MA, 2014, MOL CANCER RES, V12, P953, DOI 10.1158/1541-7786.MCR-13-0668; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JS, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-64; Lee J, 2009, AM J PHYSIOL-LUNG C, V296, pL57, DOI 10.1152/ajplung.90411.2008; Lehmann M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02367-2016; Li XQ, 2012, CANCER LETT, V322, P169, DOI 10.1016/j.canlet.2012.02.035; Liu TJ, 2013, AM J RESP CELL MOL, V49, P260, DOI 10.1165/rcmb.2012-0514OC; Makino H, 2013, J MED INVESTIG, V60, P127, DOI 10.2152/jmi.60.127; Margaritopoulos GA, 2016, RESPIROLOGY, V21, P57, DOI 10.1111/resp.12576; Mehrad B, 2009, INT J BIOCHEM CELL B, V41, P1708, DOI 10.1016/j.biocel.2009.02.020; Molyneaux PL, 2017, AM J RESP CRIT CARE, V195, P1640, DOI 10.1164/rccm.201607-1408OC; Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007; Moore BB, 2013, AM J RESP CELL MOL, V49, P167, DOI 10.1165/rcmb.2013-0094TR; Murray LA, 2014, AM J RESP CELL MOL, V50, P985, DOI 10.1165/rcmb.2013-0342OC; Naikawadi RP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86704; Naikawadi RP, 2012, CIRC RES, V111, P1517, DOI 10.1161/CIRCRESAHA.112.273078; Noble PW, 2012, J CLIN INVEST, V122, P2756, DOI 10.1172/JCI60323; Oliva I B, 2011, Monaldi Arch Chest Dis, V75, P220; Parker JM, 2018, AM J RESP CRIT CARE, V197, P94, DOI 10.1164/rccm.201704-0784OC; PHAN SH, 1981, AM REV RESPIR DIS, V124, P428; Pierce EM, 2007, AM J PATHOL, V170, P1152, DOI 10.2353/ajpath.2007.060649; Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Sakai N, 2013, BBA-MOL BASIS DIS, V1832, P911, DOI 10.1016/j.bbadis.2013.03.001; Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532; Sime PJ, 1998, AM J PATHOL, V153, P825, DOI 10.1016/S0002-9440(10)65624-6; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Smirnova NF, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0404-x; SNIDER GL, 1978, AM REV RESPIR DIS, V117, P289; SNIDER GL, 1978, AM REV RESPIR DIS, V117, P1099; Song JS, 2010, EXP MOL MED, V42, P465, DOI 10.3858/emm.2010.42.6.048; Taskar Varsha S, 2006, Proc Am Thorac Soc, V3, P293, DOI 10.1513/pats.200512-131TK; Trujillo G, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001510; Wang T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-104; Wang YG, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0472-9; Xia H, 2014, AM J PATHOL, V184, P1369, DOI 10.1016/j.ajpath.2014.01.012; Xu JG, 2007, AM J RESP CELL MOL, V37, P291, DOI 10.1165/rcmb.2006-0187OC; Xu YF, 2016, INT J PHOTOENERGY, DOI 10.1155/2016/4749278; Yuan A, 2015, AM J PHYSIOL-RENAL, V308, pF459, DOI 10.1152/ajprenal.00146.2014; Zendah Ines, 2011, Tanaffos, V10, P59; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu SM, 2013, MOL CANCER RES, V11, P86, DOI 10.1158/1541-7786.MCR-12-0243-T	84	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					891	903		10.1016/j.ajpath.2017.12.020			13	Pathology	Pathology	GB6NH	WOS:000429185400007	29378172	Bronze, Green Published			2019-10-28	
J	Clancy, CS; Van Wettere, AJ; Siddharthan, V; Morrey, JD; Julander, JG				Clancy, Chad S.; Van Wettere, Arnaud J.; Siddharthan, Venkatraman; Morrey, John D.; Julander, Justin G.			Comparative Histopathologic Lesions of the Male Reproductive Tract during Acute Infection of Zika Virus in AG129 and Ifnar(-/-) Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SEXUAL TRANSMISSION; MOUSE MODEL; ANTIVIRAL DEFENSE; INTERFERONS; ORCHITIS; SEMEN	An understanding of the pathogenesis of infection with the Zika virus in the male reproductive tract is vital for the development of vaccines and antivirals that will limit or prevent sexual transmission. Two common immunocompromised mouse strains used in transmission studies-male with genes encoding interferon types I and II receptor gene knockout (IFNAR/IFNGR; AG129) and with interferon type 1 receptor knockout (Ifnar(-/-)) were infected with a Puerto Rican Zika virus isolate (PRVABC59), and pathology was assessed 5 to 11 days after infection. Virus was detected by immunohistochemistry and quantitative RT-PCR in the testicle and epididymis of AG129 and Ifnar(-/-) mice, and by immunohistochemistry in the prostate and seminal vesicle of infected AG129 mice. Severe disease manifestations initiating as epididymitis and progressing to orchitis were observed in both models, with more severe inflammation noted in the AG129 mouse strain. Significant inflammation was not observed in any evaluated accessory sex gland at any point during infection. Time course analysis of infection revealed an increase in the severity of disease within the epididymis of both strains, indicating a potential route of sexual transmission. Male mice with Ifnarl(-/-) may better recapitulate Zika virus in humans and provide insight into the mechanism of sexual transmission, due to milder histopathologic lesions, the presence of histologically normal sperm in epididymal tubules, and an ability to survive the acute phase of disease.	[Clancy, Chad S.; Van Wettere, Arnaud J.] Utah State Univ, Sch Vet Med, Utah Vet Diagnost Lab, Logan, UT 84322 USA; [Clancy, Chad S.; Siddharthan, Venkatraman; Morrey, John D.; Julander, Justin G.] Utah State Univ, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA; [Clancy, Chad S.; Siddharthan, Venkatraman; Morrey, John D.; Julander, Justin G.] Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA	Clancy, CS (reprint author), Utah State Univ, Utah Vet Diagnost Lab, 950 E 1400 N, Logan, UT 84341 USA.	chad.clancy@lusu.edu		Clancy, Chad/0000-0002-5354-9270	NIH/Public Health Service grant [5R33AI101483]; National Institute of Allergy and Infectious Diseases Virology Branch [HHSN272201000039I/HHSN27200004]	Supported by NIH/Public Health Service grant 5R33AI101483 and National Institute of Allergy and Infectious Diseases Virology Branch contract HHSN272201000039I/HHSN27200004 (J.D.M.).	Aliota MT, 2016, PLOS NEGLECT TROP D, V10, P1; Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6; Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107; Chan JFW, 2016, EBIOMEDICINE, V14, P112, DOI 10.1016/j.ebiom.2016.11.017; Chan JFW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.99; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUID CAR US LAB AN; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449; Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P3; Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056; Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939; Froeschl G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2123-9; Gornet ME, 2016, SEMIN REPROD MED, V34, P285, DOI 10.1055/s-0036-1592312; Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556; Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681; Hamer DH, 2017, ANN INTERN MED, V166, P99, DOI 10.7326/M16-1842; Heang V, 2012, EMERG INFECT DIS, V18, P349, DOI 10.3201/eid1802.111224; Julander JG, 2017, ANTIVIR RES, V137, P14, DOI 10.1016/j.antiviral.2016.11.003; Kawiecki AB, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0749-x; Knoblaugh S, 2011, COMPARATIVE ANATOMY AND HISTOLOGY: A MOUSE AND HUMAN ATLAS, P285; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Ma WQ, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.009; Maclachlan NJ, 2010, FENNERS VET VIROLOGY, P467; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X; Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9; Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831; Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363; Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314; OAKBERG EF, 1957, NATURE, V180, P1137, DOI 10.1038/1801137a0; Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108; Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1; Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111; Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929; Smith DR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005296; Suwa T, 2002, TOXICOL PATHOL, V30, P228, DOI 10.1080/019262302753559560; Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010; Trojian TH, 2009, AM FAM PHYSICIAN, V79, P583; VANDENBROEK MF, 1995, J VIROL, V69, P4792; White BA, 2010, BERNE LEVY PHYSL, P758; Wong PSJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002348; Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004	48	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					904	915		10.1016/j.ajpath.2017.12.019			12	Pathology	Pathology	GB6NH	WOS:000429185400008	29378173	Bronze, Green Published			2019-10-28	
J	Oda, S; Takeuchi, M; Akai, S; Shirai, Y; Tsuneyama, K; Yokoi, T				Oda, Shingo; Takeuchi, Masaki; Akai, Sho; Shirai, Yuji; Tsuneyama, Koichi; Yokoi, Tsuyoshi			miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEPATIC VENOOCCLUSIVE DISEASE; BONE-MARROW-TRANSPLANTATION; OBSTRUCTION SYNDROME; HUMAN MICRORNAS; IDENTIFICATION; EXPRESSION; MIR-126; PLASMA; CANCER	Sinusoidal obstruction syndrome is a serious liver injury caused by toxic injury to Liver sinusoidal endothelial cells (LSECs) during clinical chemotherapy. Although circulating miRNAs, such as hepatocyte-specific miR-122-5p and miR-192-5p, have been proposed as potential noninvasive biomarkers of hepatocellular liver injury, these miRNAs may not be specific to damage to other hepatic cell types, including LSECs. We characterized miRNA expression in LSECs and hepatocytes and investigated whether cell type specific miRNAs in plasma can discern pathogenesis of Liver injuries in rats. Comprehensive miRNA expression analyses found that 66 and 12 miRNAs were highly expressed in LSECs and hepatocytes isolated from nontreated rats, respectively. An LSEC-enriched miR-511-3p was relatively liver specific according to public data. For establishing LSEC and hepatocyte injury models, rats were orally treated with monocrotaline and thioacetamide, respectively. In monocrotaline-treated rats, a sinusoidal obstruction syndrome model, LSEC damage was observed 6 hours after dosing, whereas hepatocellular damage was observed after 48 hours. Interestingly, the level of miR-511-3p in plasma was increased as early as 6 hours after monocrotaline dosing, followed by an increase of miR-122-5p after 24 hours. In the thioacetamide-induced hepatocellular injury model, the level of miR-511-3p was not altered in plasma, whereas miR-122-5p levels were increased after 6 hours. In conclusion, we identified miR-511-3p in plasma as a possible biomarker for LSEC damage.	[Oda, Shingo; Takeuchi, Masaki; Akai, Sho; Shirai, Yuji; Yokoi, Tsuyoshi] Nagoya Univ, Grad Sch Med, Div Clin Pharmacol, Dept Drug Safety Sci, Nagoya, Aichi, Japan; [Tsuneyama, Koichi] Tokushima Univ, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, Tokushima, Japan	Oda, S (reprint author), Nagoya Univ, Grad Sch Med, Dept Drug Safety Sci, Div Clin Pharmacol,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	shingo61@med.nagoya-u.ac.jp		Oda, Shingo/0000-0002-8684-601X; Yokoi, Tsuyoshi/0000-0002-3239-2817	Research Foundation for Pharmaceutical Sciences, Japan; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K21057]	Supported by a grant from the Research Foundation for Pharmaceutical Sciences, Japan (S.O.), and Grant-in-Aid for Young Scientists (B) 15K21057 from the Japan Society for the Promotion of Science (S.O.).	Ach RA, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-69; ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1002/hep.1840200231; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Chang HT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S7-S18; Chojkier M, 2003, J HEPATOL, V39, P437, DOI 10.1016/S0168-8278(03)00231-9; Coppell JA, 2010, BIOL BLOOD MARROW TR, V16, P157, DOI 10.1016/j.bbmt.2009.08.024; DeLeve LD, 2007, SEMIN LIVER DIS, V27, P390, DOI 10.1055/s-2007-991515; DeLeve LD, 2015, HEPATOLOGY, V61, P1740, DOI 10.1002/hep.27376; DeLeve LD, 2013, J CLIN INVEST, V123, P1861, DOI 10.1172/JCI66025; DeLeve LD, 1999, HEPATOLOGY, V29, P1779, DOI 10.1002/hep.510290615; DUNN JCY, 1989, FASEB J, V3, P174; Estep M, 2010, ALIMENT PHARM THER, V32, P487, DOI 10.1111/j.1365-2036.2010.04366.x; Fehlmann T, 2016, RNA BIOL, V13, P1084, DOI 10.1080/15476286.2016.1234658; Homby R. J., 2014, EXPERT REV CLIN PHAR, V7, P349; Hu YY, 2015, INT J MOL MED, V35, P358, DOI 10.3892/ijmm.2014.2016; Iwama H, 2013, MOL BIOL EVOL, V30, P613, DOI 10.1093/molbev/mss262; JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011; Krauskopf J, 2015, TOXICOL SCI, V143, P268, DOI 10.1093/toxsci/kfu232; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198; Minami K, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.5; Poisson J, 2017, J HEPATOL, V66, P212, DOI 10.1016/j.jhep.2016.07.009; Rubbia-Brandt L, 2010, HISTOPATHOLOGY, V56, P430, DOI 10.1111/j.1365-2559.2010.03511.x; Smith A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2956-z; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Tokairin T, 2002, J HEPATOL, V36, P725, DOI 10.1016/S0168-8278(02)00048-X; TRENNERY PN, 1983, TOXICOL LETT, V19, P299, DOI 10.1016/0378-4274(83)90134-0; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yakushijin K, 2016, BONE MARROW TRANSPL, V51, P403, DOI 10.1038/bmt.2015.283; Yamaura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030250; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610	38	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					916	928		10.1016/j.ajpath.2017.12.007			13	Pathology	Pathology	GB6NH	WOS:000429185400009	29353062	Bronze			2019-10-28	
J	Liu, N; Gan, WD; Qu, F; Wang, Z; Zhuang, WY; Agizamhan, S; Xu, LF; Yin, JJ; Guo, HQ; Li, DM				Liu, Ning; Gan, Weidong; Qu, Feng; Wang, Zhen; Zhuang, Wenyuan; Agizamhan, Sezim; Xu, Linfeng; Yin, Juanjuan; Guo, Hongqian; Li, Dongmei			Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the Xp11.2 Translocation Renal Cell Carcinoma? A 10-Year Single-Center Study	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PSAMMOMA BODIES; TUMOR; CLASSIFICATION; HETEROGENEITY; PARAMETERS; FEATURES; FUSION; GROWTH; ADULTS; PART	The Fuhrman and World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading systems are widely used to predict survival for patients with conventional renal cell carcinoma. To determine the validity of nuclear grading systems (both the Fuhrman and the WHO/ISUP) and the individual components of the Fuhrman grading system in predicting the prognosis of Xp11.2 trans location renal cell carcinoma (Xp11.2 tRCC), we identified and followed up 47 patients with Xp11.2 tRCC in our center from January 2007 to June 2017. The Fuhrman and WHO/ISUP grading was reassigned by two pathologists. Nuclear size and shape were determined for each case based on the greatest degree of nuclear pleomorphism using image analysis software. Univariate and multivariate analyses were performed to evaluate the capacity of the grading systems and nuclear parameters to predict overall survival and progression-free survival. On univariate Cox regression analysis, the parameters of nuclear size were associated significantly with overall survival and progression-free survival, whereas the grading systems and the parameters of nuclear shape failed to reach a significant correlation. On multivariate analysis, however, none of the parameters was associated independently with survival. Our findings indicate that neither the Fuhrman nor the WHO/ISUP grading system is applicable to Xp11.2 tRCC. The assessment of nuclear size instead may be novel outcome predictors for patients with Xp11.2 tRCC.	[Liu, Ning; Gan, Weidong; Qu, Feng; Wang, Zhen; Zhuang, Wenyuan; Agizamhan, Sezim; Xu, Linfeng; Guo, Hongqian] Nanjing Univ, Sch Med, Affiliated Hosp, Dept Urol,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Yin, Juanjuan] NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA; [Li, Dongmei] Nanjing Univ, Sch Med, Immunol & Reprod Biol Lab, Nanjing, Jiangsu, Peoples R China; [Li, Dongmei] Nanjing Univ, Sch Med, State Key Lab Analyt Chem Life Sci, Nanjing, Jiangsu, Peoples R China; [Li, Dongmei] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China	Gan, WD (reprint author), 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Li, DM (reprint author), 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	gwd@nju.edu.cn; lidm@nju.edu.cn		Qu, Feng/0000-0003-0732-1109; Agizamhan, Sezim/0000-0002-0913-4094; Liu, Ning/0000-0002-7283-7294	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81572512]	Supported by National Natural Science Foundation of China grant 81572512 (W.G.).	Al-Aynati M, 2003, ARCH PATHOL LAB MED, V127, P593; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Camparo P, 2008, AM J SURG PATHOL, V32, P656, DOI 10.1097/PAS.0b013e3181609914; Chen XC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000873; Choueiri TK, 2010, CANCER-AM CANCER SOC, V116, P5219, DOI 10.1002/cncr.25512; Das DK, 2009, DIAGN CYTOPATHOL, V37, P534, DOI 10.1002/dc.21081; DEJONG B, 1988, CANCER GENET CYTOGEN, V30, P53, DOI 10.1016/0165-4608(88)90092-1; Delahunt B, 2007, AM J SURG PATHOL, V31, P957, DOI 10.1097/01.pas.0000249446.28713.53; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Delahunt B, 2011, AM J SURG PATHOL, V35, P1134, DOI 10.1097/PAS.0b013e318220697f; Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208; Fadare O, 2004, ADV ANAT PATHOL, V11, P250, DOI 10.1097/01.pap.0000131823.69694.62; Ficarra V, 2005, CANCER, V103, P68, DOI 10.1002/cncr.20749; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; Hung CC, 2011, J CHIN MED ASSOC, V74, P500, DOI 10.1016/j.jcma.2011.09.005; KUBOTA T, 1985, ACTA NEUROPATHOL, V66, P163, DOI 10.1007/BF00688693; Lim B, 2015, KOREAN J UROL, V56, P212, DOI 10.4111/kju.2015.56.3.212; Liu N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166897; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Macher-Goeppinger S, 2012, MODERN PATHOL, V25, P308, DOI 10.1038/modpathol.2011.169; Medeiros LJ, 1997, CANCER, V80, P990, DOI 10.1002/(SICI)1097-0142(19970901)80:5<990::AID-CNCR25>3.0.CO;2-Q; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Qu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23594; Qu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21677; Rais-Bahrami S, 2007, UROLOGY, V70, DOI 10.1016/j.urology.2007.03.037; Rao Q, 2011, INT J SURG PATHOL, V19, P170, DOI 10.1177/1066896909354337; Sika-Paotonu D, 2006, AM J SURG PATHOL, V30, P1091; Su HH, 2014, KAOHSIUNG J MED SCI, V30, P402, DOI 10.1016/j.kjms.2014.03.003; Sukov WR, 2012, AM J SURG PATHOL, V36, P663, DOI 10.1097/PAS.0b013e31824dd972; Sun M, 2009, EUR UROL, V56, P775, DOI 10.1016/j.eururo.2009.06.008; Zisman A, 2001, J CLIN ONCOL, V19, P1649, DOI 10.1200/JCO.2001.19.6.1649	31	1	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					929	936		10.1016/j.ajpath.2017.12.018			8	Pathology	Pathology	GB6NH	WOS:000429185400010	29571325	Green Published			2019-10-28	
J	Hinrichs, BH; Matthews, JD; Siuda, D; O'Leary, MN; Wolfarth, AA; Saeedi, BJ; Nusrat, A; Neish, AS				Hinrichs, Benjamin H.; Matthews, Jason D.; Siuda, Dorothee; O'Leary, Monique N.; Wolfarth, Alexandra A.; Saeedi, Bejan J.; Nusrat, Asma; Neish, Andrew S.			Serum Amyloid A1 Is an Epithelial Prorestitutive Factor	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FORMYL PEPTIDE RECEPTOR; ACUTE-PHASE RESPONSE; CELL-MIGRATION; RHEUMATOID-ARTHRITIS; CYCLOSPORINE-H; EXPRESSION; PROTEIN; MOUSE; INDUCTION; PHOSPHORYLATION	Several proteins endogenously produced during the process of intestinal wound healing have demonstrated prorestitutive properties. The presence of serum amyloid A1 (SAA1), an acute-phase reactant, within inflamed tissues, where it exerts chemotaxis of phagocytes, is well recognized; however, a putative role in intestinal wound repair has not been described. Herein, we show that SAA1 induces intestinal epithelial cell migration, spreading, and attachment through a formyl peptide receptor 2-dependent mechanism. Induction of the prorestitutive phenotype is concentration and time dependent and is associated with epithelial reactive oxygen species production and alterations in p130 Crk-associated substrate staining. In addition, using a murine model of wound recovery, we provide evidence that SAA1 is dynamically and temporally regulated, and that the elaboration of SAA1 within the wound microenvironment correlates with the influx of SAA1/CD11b coexpressing immune cells and increases in cytokines known to induce SAA expression. Overall, the present work demonstrates an important role for SAA in epithelial wound recovery and provides evidence for a physiological role in the wound environment.	[Hinrichs, Benjamin H.; Matthews, Jason D.; Wolfarth, Alexandra A.; Saeedi, Bejan J.; Neish, Andrew S.] Emory Univ, Div Expt Pathol, 105-L Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA; [Siuda, Dorothee; O'Leary, Monique N.; Nusrat, Asma] Univ Michigan, Dept Pathol, Div Expt Pathol, Ann Arbor, MI 48109 USA	Neish, AS (reprint author), Emory Univ, Div Expt Pathol, 105-L Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.; Nusrat, A (reprint author), Michigan Med, Dept Pathol, 4057 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	anusrat@med.umich.edu; aneish@emory.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK089763, DK055679]; Crohn's and Colitis Foundation Career Development Award [451678]; German Research Foundation (DFG)German Research Foundation (DFG); Emory University Integrated Cellular Imaging Microscopy Core	Supported by NIH grants DK089763 (A.N. and A.S.N.) and DK055679 (A.N.), Crohn's and Colitis Foundation Career Development Award 451678 (J.D.M.), the German Research Foundation (DFG) (D.S.), and the Emory University Integrated Cellular Imaging Microscopy Core.	Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; Alam A, 2014, MUCOSAL IMMUNOL, V7, P645, DOI 10.1038/mi.2013.84; Anthony D, 2014, FASEB J, V28, P3867, DOI 10.1096/fj.14-250332; Atarashi K, 2015, CELL, V163, P367, DOI 10.1016/j.cell.2015.08.058; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; Bae YS, 2004, J IMMUNOL, V173, P607, DOI 10.4049/jimmunol.173.1.607; Belmokhtar K, 2016, ARTERIOSCL THROM VAS, V36, P800, DOI 10.1161/ATVBAHA.115.306349; Chatterjee S, 2012, FREE RADICAL BIO MED, V52, P1666, DOI 10.1016/j.freeradbiomed.2012.02.010; Connolly M, 2011, ANN RHEUM DIS, V70, P1296, DOI 10.1136/ard.2010.142240; Connolly M, 2016, ANN RHEUM DIS, V75, P1392, DOI 10.1136/annrheumdis-2015-207655; Connolly M, 2010, J IMMUNOL, V184, P6427, DOI 10.4049/jimmunol.0902941; Cray C, 2009, COMPARATIVE MED, V59, P517; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Howard BA, 2003, PROTEOMICS, V3, P1720, DOI 10.1002/pmic.200300514; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; Ji YR, 2015, J BIOL CHEM, V290, P12804, DOI 10.1074/jbc.M114.635763; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MS, 2006, J IMMUNOL, V177, P5585, DOI 10.4049/jimmunol.177.8.5585; Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831; Liang TS, 2000, BIOCHEM BIOPH RES CO, V270, P331, DOI 10.1006/bbrc.2000.2416; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Manigrasso MB, 2016, SCI REP-UK, V6, DOI 10.1038/srep22450; Matthews JD, 2016, AM J PHYSIOL-GASTR L, V311, pG458, DOI 10.1152/ajpgi.00189.2016; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MEEK RL, 1989, AM J PATHOL, V135, P411; Mullan RH, 2010, AM J PATHOL, V176, P1999, DOI 10.2353/ajpath.2010.090014; Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843; O'Hara R, 2000, ARTHRITIS RES, V2, P142, DOI 10.1186/ar78; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; Reigstad CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005842; Sano T, 2015, CELL, V163, P381, DOI 10.1016/j.cell.2015.08.061; SMITH JW, 1992, CLIN EXP IMMUNOL, V90, P293; Stenfeldt AL, 2007, INFLAMMATION, V30, P224, DOI 10.1007/s10753-007-9040-4; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Thorn CF, 2004, SCAND J IMMUNOL, V59, P152, DOI 10.1111/j.0300-9475.2004.01369.x; Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591	40	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					937	949		10.1016/j.ajpath.2017.12.013			13	Pathology	Pathology	GB6NH	WOS:000429185400011	29366677	Green Published, Bronze			2019-10-28	
J	Kim, JW; Roh, YS; Jeong, H; Yi, HK; Lee, MH; Lim, CW; Kim, B				Kim, Jong-Won; roh, Yoon-Seok; Jeong, Hyeneui; Yi, Ho-Keun; Lee, Min-Ho; Lim, Chae-Woong; Kim, Bumseok			Spliceosome-Associated Protein 130 Exacerbates Alcohol-Induced Liver Injury by Inducing NLRP3 Inflammasome-Mediated IL-1 beta in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							KILLER T-CELLS; ACTIVATING RECEPTOR; IMMUNE CELLS; DISEASE; MINCLE; FIBROSIS; PATHWAY; ETHANOL; HEPATOCYTES; INHIBITION	Excessive alcohol consumption leads to chronic liver diseases. Macrophage-inducible C-type lectin (MincLe) is a C-type lectin receptor that recognizes spliceosome-associated protein 130 (SAP130) known as an endogenous ligand released from dying cells. The aim was to examine the role of Mincle-SAP130 in the pathogenesis of alcoholic liver disease. Alcohol-induced liver injury was induced in wild-type (WT) and Mincle knockout (KO) mice by using a chronic-binge ethanol-feeding model. Mincle KO mice showed significant lower hepatic steatosis, inflammation with neutrophil infiltration, and fibrosis compared with WT mice after alcohol feeding. In contrast, Mincle activation exacerbated alcohol-induced liver injury. Kupffer cells (KCs) are major sources of Mincle. IL-1 beta expression was significantly down regulated in Mincle KO mice compared with that in WT mice after alcohol consumption. Interestingly, expression and production of IL-1 beta were significantly decreased in SAP130-treated KCs isolated from leucine-rich-containing family pyrin domain containing-3-deficient mice compared with those in WT KCs. Such results were also observed in cells treated with SAP130 plus Syk inhibitor. Furthermore, infiltration of invariant natural killer T cells was decreased in livers of Mincle KO mice. Finally, inhibition of Syk signaling ameliorated alcohol-induced liver injury. Collectively, these results demonstrated that interaction between Mincle and SAP130 may promote the progression of alcoholic Liver disease by IL-1 beta production in KCs and consequently increase inflammatory immune cell infiltration.	[Kim, Jong-Won; Jeong, Hyeneui; Lim, Chae-Woong; Kim, Bumseok] Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, 79 Gobong Ro, Iksan 54596, South Korea; [Kim, Jong-Won; Jeong, Hyeneui; Lim, Chae-Woong; Kim, Bumseok] Chonbuk Natl Univ, Coll Vet Med, Plus Program BK21, Pathol Lab, 79 Gobong Ro, Iksan 54596, South Korea; [roh, Yoon-Seok] Chungbuk Natl Univ, Coll Pharm, Cheongju, Chungbuk, South Korea; [Yi, Ho-Keun; Lee, Min-Ho] Chonbuk Natl Univ, Sch Dent, Inst Oral Biosci, Jeonju, South Korea; [Yi, Ho-Keun; Lee, Min-Ho] Chonbuk Natl Univ, Sch Dent, Plus Project BK21, Jeonju, South Korea	Kim, B (reprint author), Chonbuk Natl Univ, Coll Vet Med, Biosafety Res Inst, 79 Gobong Ro, Iksan 54596, South Korea.; Kim, B (reprint author), Chonbuk Natl Univ, Coll Vet Med, Plus Program BK21, Pathol Lab, 79 Gobong Ro, Iksan 54596, South Korea.	bskms@jbnu.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Republic of Korea [2017R1D1A3B03030521]; Republic of Korea government (MSIP) NRF [2014R1A4A1005309]	Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Republic of Korea grant 2017R1D1A3B03030521 (J.-W.K., Y.-S.R., H.J., C.-W.L., and B.K.), and the Republic of Korea government (MSIP) NRF grant 2014R1A4A1005309 (H.-K.Y., M.-H.L., and B.K.).	Abd-Elgawad H, 2016, CAN J PHYSIOL PHARM, V94, P779, DOI 10.1139/cjpp-2016-0001; Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032; Blom KG, 2009, CLIN EXP IMMUNOL, V155, P320, DOI 10.1111/j.1365-2249.2008.03815.x; Bukong TN, 2016, HEPATOLOGY, V64, P1057, DOI 10.1002/hep.28680; Chen KH, 2016, INT J BIOCHEM CELL B, V74, P135, DOI 10.1016/j.biocel.2016.03.001; Cui KL, 2015, J HEPATOL, V62, P1311, DOI 10.1016/j.jhep.2014.12.027; Desel C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053531; Devi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep15049; Dominguez M, 2009, GASTROENTEROLOGY, V136, P1639, DOI 10.1053/j.gastro.2009.01.056; Gao B, 2011, GASTROENTEROLOGY, V141, P1572, DOI 10.1053/j.gastro.2011.09.002; Gomez-Quiroz L, 2003, HEPATOL RES, V26, P134, DOI 10.1016/S1386-6346(03)00010-X; Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965; He Y, 2015, STROKE, V46, P2277, DOI 10.1161/STROKEAHA.115.010088; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Jaeschke H, 2002, ALCOHOL, V27, P23, DOI 10.1016/S0741-8329(02)00200-8; Kiani A, 2016, WORLD J GASTROENTERO, V22, P4926, DOI 10.3748/wjg.v22.i20.4926; Kubes P, 2012, GASTROENTEROLOGY, V143, P1158, DOI 10.1053/j.gastro.2012.09.008; Lee WB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11322; Lee WB, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002614; Lemmers A, 2009, HEPATOLOGY, V49, P646, DOI 10.1002/hep.22680; Mathews S, 2016, CELL MOL IMMUNOL, V13, P206, DOI 10.1038/cmi.2015.06; Minagawa M, 2004, GASTROENTEROLOGY, V126, P1387, DOI 10.1053/j.gastro.2004.01.022; O'Shea RS, 2010, HEPATOLOGY, V51, P307, DOI 10.1002/hep.23258; Petrasek J, 2015, J LEUKOCYTE BIOL, V98, P249, DOI 10.1189/jlb.3AB1214-590R; Rao R, 2009, HEPATOLOGY, V50, P638, DOI 10.1002/hep.23009; Roh YS, 2015, AM J PHYSIOL-GASTR L, V309, pG30, DOI 10.1152/ajpgi.00031.2015; Schweneker K, 2013, IMMUNOBIOLOGY, V218, P664, DOI 10.1016/j.imbio.2012.07.029; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Syn WK, 2010, HEPATOLOGY, V51, P1998, DOI 10.1002/hep.23599; Tanaka M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5982; Vaccari JCD, 2015, J NEUROTRAUM, V32, P228, DOI 10.1089/neu.2014.3436; Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445; Wheeler MD, 2001, FREE RADICAL BIO MED, V31, P1544, DOI 10.1016/S0891-5849(01)00748-1; Xu MJ, 2015, GASTROENTEROLOGY, V149, P1030, DOI 10.1053/j.gastro.2015.06.009; Yamasaki S, 2009, P NATL ACAD SCI USA, V106, P1897, DOI 10.1073/pnas.0805177106; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Zhou H, 2016, HEPATOLOGY, V64, P1978, DOI 10.1002/hep.28811; Ziol M, 2001, J HEPATOL, V34, P254, DOI 10.1016/S0168-8278(00)00047-7	38	4	5	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					967	980		10.1016/j.ajpath.2017.12.010			14	Pathology	Pathology	GB6NH	WOS:000429185400013	29355515				2019-10-28	
J	Pisarello, ML; Masyuk, TV; Gradilone, SA; Masyuk, AI; Ding, JYF; Lee, PY; LaRusso, NF				Pisarello, Maria Lorenzo; Masyuk, Tatyana V.; Gradilone, Sergio A.; Masyuk, Anatoliy I.; Ding, Jingyi F.; Lee, Pui-Yuen; LaRusso, Nicholas F.			Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HEPATIC CYSTOGENESIS; KIDNEY-DISEASE; CYST GROWTH; CANCER-THERAPY; DEFECTIVE MICE; HDAC6; CHOLANGIOCYTES; OCTREOTIDE; TARGET; PROLIFERATION	Hepatic cystogenesis in polycystic liver disease (PLD) is associated with abnormalities in multiple cellular processes, including elevated cAMP and overexpression of histone deacetylase 6 (HDAC6). Disease progression in polycystic kidney (PCK) rats (an animal model of PLD) is attenuated by inhibition of either cAMP production or HDAC6. Therefore, we hypothesized that concurrent targeting of HDAC6 and cAMP would synergistically reduce cyst growth. Changes in hepatorenal cystogenesis were examined in PCK rats treated with a pan-HDAC inhibitor, panobinostat; three specific HDAC6 inhibitors, ACY-1215, ACY-738, and ACY-241; and a combination of ACY-1215 and the somatostatin receptor analogue, pasireotide. We also assessed effects of ACY-1215 and pasireotide alone and in combination on cell proliferation, cAMP production, and expression of acetylated alpha-tubutin in vitro in cultured cholangiocytes and the length of primary cilia and the frequency of ciliated cholangiocytes in vivo in PCK rats. Panobinostat and all. three HDAC6 inhibitors decreased hepatorenal cystogenesis in PCK rats. ACY-1215 was more effective than other HDAC inhibitors and was chosen for combinational treatment. ACY-1215 + pasireotide combination synergistically reduced cyst growth and increased length of primary cilia in PCK rats. In cultured cystic cholangiocytes, ACY-1215 + pasireotide combination concurrently decreased cell proliferation and inhibited cAMP levels. These data suggest that the combination of drugs that inhibit HDAC6 and cAMP may be an effective therapy for PLD.	[Pisarello, Maria Lorenzo; Masyuk, Tatyana V.; Masyuk, Anatoliy I.; Ding, Jingyi F.; Lee, Pui-Yuen; LaRusso, Nicholas F.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Gradilone, Sergio A.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Gradilone, Sergio A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA	LaRusso, NF (reprint author), Mayo Clin, Coll Med & Sci, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA.	larusso.nicholas@mayo.edu	Lee, Pui Yuen/P-7581-2016	Ding, Jingyi (Francess)/0000-0002-5386-8810	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK24031, CA183764]; Mayo Clinic; Clinical Core and Optical Microscopy Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology [P30DK084567]; Mayo Translational Polycystic Kidney Disease (PKD) Center - National Institute of Diabetes and Digestive and Kidney Diseases grant [P30DK090728]; Mayo Translational PKD Center Pilot and Feasibility award; Eileen Creamer O'Neill award from the PKD Foundation	Supported by NIH grants DK24031 (N.F.L.) and CA183764 (S.A.G.), the Mayo Clinic, the Clinical Core and Optical Microscopy Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology grant P30DK084567 (N.F.L.), the Mayo Translational Polycystic Kidney Disease (PKD) Center supported by National Institute of Diabetes and Digestive and Kidney Diseases grant P30DK090728 (N.F.L.), the Mayo Translational PKD Center Pilot and Feasibility award (T.V.M.), and the Eileen Creamer O'Neill award from the PKD Foundation (T.V.M.).	Asthana J, 2013, J BIOL CHEM, V288, P22516, DOI 10.1074/jbc.M113.489328; Banales JM, 2009, HEPATOLOGY, V49, P160, DOI 10.1002/hep.22636; Banales JM, 2008, AM J PATHOL, V173, P1637, DOI 10.2353/ajpath.2008.080125; Benoy V, 2017, NEUROTHERAPEUTICS, V14, P417, DOI 10.1007/s13311-016-0501-z; Besse W, 2017, J CLIN INVEST, V127, P3558, DOI 10.1172/JCI96729; Cebotaru L, 2016, KIDNEY INT, V90, P90, DOI 10.1016/j.kint.2016.01.026; Ceccacci E, 2016, BRIT J CANCER, V114, P605, DOI 10.1038/bjc.2016.36; Chrispijn M, 2013, J HEPATOL, V59, P153, DOI 10.1016/j.jhep.2013.03.004; Cnossen WR, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-69; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fan LX, 2012, KIDNEY INT, V81, P76, DOI 10.1038/ki.2011.296; Gevers TJG, 2016, LIVER INT, V36, P595, DOI 10.1111/liv.12986; Gevers TJG, 2011, CURR OPIN GASTROEN, V27, P294, DOI 10.1097/MOG.0b013e328343433f; Gradilone SA, 2014, AM J PATHOL, V184, P600, DOI 10.1016/j.ajpath.2013.11.027; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Gradilone SA, 2010, GASTROENTEROLOGY, V139, P304, DOI 10.1053/j.gastro.2010.04.010; Hennika T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169485; Hogan MC, 2010, J AM SOC NEPHROL, V21, P1052, DOI 10.1681/ASN.2009121291; Hopp K, 2015, J AM SOC NEPHROL, V26, P39, DOI 10.1681/ASN.2013121312; Huang PY, 2017, ONCOTARGET, V8, P2694, DOI 10.18632/oncotarget.13738; Lapinska K, 2016, ANTICANCER RES, V36, P5731, DOI 10.21873/anticanres.11156; Larusso NF, 2016, CLIN GASTROENTEROL H, V14, P1031, DOI 10.1016/j.cgh.2016.03.008; Li JY, 2013, CURR MED CHEM, V20, P1858; Masyuk AI, 2018, HEPATOLOGY, V67, P1088, DOI 10.1002/hep.29577; Masyuk TV, 2007, GASTROENTEROLOGY, V132, P1104, DOI 10.1053/j.gastro.2006.12.039; Masyuk TV, 2017, HEPATOLOGY, V66, P1197, DOI 10.1002/hep.29284; Masyuk TV, 2017, CURR DRUG TARGETS, V18, P950, DOI 10.2174/1389450116666150427161743; Masyuk TV, 2014, AM J PATHOL, V184, P110, DOI 10.1016/j.ajpath.2013.09.021; Masyuk TV, 2013, HEPATOLOGY, V58, P409, DOI 10.1002/hep.26140; Masyuk TV, 2012, GASTROENTEROLOGY, V142, P622, DOI 10.1053/j.gastro.2011.11.036; Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898; Munoz-Garrido P, 2015, J HEPATOL, V63, P952, DOI 10.1016/j.jhep.2015.05.023; North BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173507; Peces R, 2011, INT UROL NEPHROL, V43, P565, DOI 10.1007/s11255-010-9748-1; Perugorria MJ, 2014, NAT REV GASTRO HEPAT, V11, P750, DOI 10.1038/nrgastro.2014.155; Porath B, 2016, AM J HUM GENET, V98, P1193, DOI 10.1016/j.ajhg.2016.05.004; Renken C, 2011, NEPHROL DIAL TRANSPL, V26, P92, DOI 10.1093/ndt/gfq384; Riolo MT, 2012, J BIOL CHEM, V287, P10885, DOI 10.1074/jbc.M111.308791; Rivieccio MA, 2009, P NATL ACAD SCI USA, V106, P19599, DOI 10.1073/pnas.0907935106; Spirli C, 2012, HEPATOLOGY, V56, P2363, DOI 10.1002/hep.25872; Spirli C, 2012, HEPATOLOGY, V55, P856, DOI 10.1002/hep.24723; Spirli C, 2010, HEPATOLOGY, V51, P1778, DOI 10.1002/hep.23511; Spirli C, 2010, GASTROENTEROLOGY, V138, P360, DOI 10.1053/j.gastro.2009.09.005; Tsuji G, 2015, J ALLERGY CLIN IMMUN, V135, P1228, DOI 10.1016/j.jaci.2014.10.002; Waanders E, 2008, MODERN PATHOL, V21, P1293, DOI 10.1038/modpathol.2008.115; Wang ZF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19626	46	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					981	994		10.1016/j.ajpath.2017.12.016			14	Pathology	Pathology	GB6NH	WOS:000429185400014	29366679	Green Published			2019-10-28	
J	Zhang, SS; Wang, JX; Wang, HC; Fan, LL; Fan, B; Zeng, B; Tao, JY; Li, XL; Che, L; Cigliano, A; Ribback, S; Dombrowski, F; Chen, B; Cong, WM; Wei, LX; Calvisi, DF; Chen, X				Zhang, Shanshan; Wang, Jingxiao; Wang, Haichuan; Fan, Lingling; Fan, Biao; Zeng, Billy; Tao, Junyan; Li, Xiaolei; Che, Li; Cigliano, Antonio; Ribback, Silvia; Dombrowski, Frank; Chen, Bin; Cong, Wenming; Wei, Lixin; Calvisi, Diego F.; Chen, Xin			Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans	AMERICAN JOURNAL OF PATHOLOGY			English	Article							YES-ASSOCIATED PROTEIN; HEPATOCELLULAR-CARCINOMA DEVELOPMENT; DOWN-REGULATION; POOR-PROGNOSIS; PROMOTER HYPERMETHYLATION; CELL-PROLIFERATION; SIZE-CONTROL; HUMAN CANCER; PATHWAY; YAP	Primary Liver cancer consists mainly of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). A subset of human HCCs expresses a ICC-like gene signature and is classified as ICC-like HCC. The Hippo pathway is a critical regulator of normal and malignant liver development. However, the precise function(s) of the Hippo cascade along liver carcinogenesis remain to be fully delineated. The role of the Hippo pathway in a murine mixed HCC/ICC model induced by activated forms of AKT and Ras oncogenes (AKT/Ras) was investigated. The authors demonstrated the inactivation of Hippo in AKT/Ras liver tumors leading to nuclear localization of Yap and TAZ. Coexpression of AKT/Ras with Lats2, which activates Hippo, or the dominant negative form of TEAD2 (dnTEAD2), which blocks Yap/TAZ activity, resulted in delayed hepatocarcinogenesis and elimination of ICC-like Lesions in the liver. Mechanistically, Notch2 expression was found to be down-regulated by the Hippo pathway in liver tumors. Overexpression of Lats2 or dnTEAD2 in human HCC cell lines inhibited their growth and led to the decreased expression of ICC-like markers, as well as Notch2 expression. Altogether, this study supports the key role of the Hippo cascade in regulating the differentiation status of liver tumors.	[Zhang, Shanshan; Wei, Lixin] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China; [Zhang, Shanshan; Cong, Wenming] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China; [Zhang, Shanshan; Wang, Jingxiao; Wang, Haichuan; Fan, Lingling; Fan, Biao; Tao, Junyan; Li, Xiaolei; Che, Li; Chen, Xin] Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA; [Zhang, Shanshan; Wang, Jingxiao; Wang, Haichuan; Fan, Lingling; Fan, Biao; Tao, Junyan; Li, Xiaolei; Che, Li; Chen, Xin] Univ Calif San Francisco, Therapeut Sci & Liver Ctr, San Francisco, CA 94143 USA; [Zeng, Billy; Chen, Bin] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Zeng, Billy; Chen, Bin] Univ Calif San Francisco, Inst Computat Hlth Sci, San Francisco, CA 94143 USA; [Wang, Jingxiao] Beijing Univ Chinese Med, Clin Med Sch 2, Beijing, Peoples R China; [Wang, Haichuan] Sichuan Univ, West China Hosp, Dept Liver Surg, Liver Transplantat Div, Chengdu, Sichuan, Peoples R China; [Fan, Biao] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Surg, Beijing, Peoples R China; [Cigliano, Antonio] Res Hosp, Natl Inst Gastroenterol S de Bellis, Castellana Grotte, Italy; [Ribback, Silvia; Dombrowski, Frank; Calvisi, Diego F.] Ernst Moritz Arndt Univ Greifswald, Inst Pathol, Greifswald, Germany	Calvisi, DF (reprint author), Univ Med Greifswald, Inst Pathol, Friedrich Loeffler Str 23e, D-17489 Greifswald, Germany.; Chen, X (reprint author), UCSF, 513 Parnassus Ave, San Francisco, CA 94143 USA.	diego.calvisi@uni-greifswald.de; xin.chen@ucsf.edu	Wang, Haichuan/AAA-3997-2019; Cigliano, Antonio/J-4660-2017	Wang, Haichuan/0000-0002-6886-5698; Cigliano, Antonio/0000-0002-6408-3613	China National Key R D program [2017YFA0504503]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA136606, R01CA190606, K01ES028047, P30DK026743]; China Scholarship CouncilChina Scholarship Council [201406580003]	Supported by China National Key R & D program grant 2017YFA0504503 (L.W.); NIH grants R01CA136606 (X.C.), R01CA190606 (X.C.), K01ES028047 (B.C.), and P30DK026743 (UCSF Liver Center); and China Scholarship Council contract 201406580003 (S.Z.)	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Anakk S, 2013, CELL REP, V5, P1060, DOI 10.1016/j.celrep.2013.10.030; Avruch J, 2011, BRIT J CANCER, V104, P24, DOI 10.1038/sj.bjc.6606011; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Bodzin AS, 2015, WORLD J HEPATOL, V7, P1157, DOI 10.4254/wjh.v7.i9.1157; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Che L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.73; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Farshidfar F, 2017, CELL REP, V19, P2878, DOI 10.1016/j.celrep.2017.06.008; Frith C H, 1994, IARC Sci Publ, P223; Furth N, 2017, CELL DEATH DIFFER, V24, P1488, DOI 10.1038/cdd.2017.99; Ghouri Yezaz Ahmed, 2017, J Carcinog, V16, P1, DOI 10.4103/jcar.JCar_9_16; Guo Y, 2015, J CELL BIOCHEM, V116, P2465, DOI 10.1002/jcb.25117; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; Higashi T, 2015, BRIT J CANCER, V113, P252, DOI 10.1038/bjc.2015.170; Ho C, 2012, HEPATOLOGY, V55, P833, DOI 10.1002/hep.24736; Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004; Hu JJ, 2016, SCI TECHNOL NUCL INS, DOI 10.1155/2016/5852328; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kato H, 1997, DEVELOPMENT, V124, P4133; Kim D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009616; Kim W, 2017, J CLIN INVEST, V127, P137, DOI 10.1172/JCI88486; Kowalik MA, 2011, HEPATOLOGY, V53, P2086, DOI 10.1002/hep.24289; Kumar R, 2016, J MED CHEM, V59, P7719, DOI 10.1021/acs.jmedchem.5b01516; LANIGAN DT, 1990, J ORAL MAXIL SURG, V48, P561, DOI 10.1016/S0278-2391(10)80468-9; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Li WQ, 2011, CANCER RES, V71, P2162, DOI 10.1158/0008-5472.CAN-10-3268; Li XL, 2015, ONCOTARGET, V6, P10102, DOI 10.18632/oncotarget.3546; Liu P, 2015, ONCOTARGET, V6, P29048, DOI 10.18632/oncotarget.4804; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mao B, 2014, ONCOGENE, V33, P1468, DOI 10.1038/onc.2013.88; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; Moeini A, 2017, J HEPATOL, V66, P952, DOI 10.1016/j.jhep.2017.01.010; Nishio M, 2016, P NATL ACAD SCI USA, V113, pE71, DOI 10.1073/pnas.1517188113; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Piccolo S, 2013, CLIN CANCER RES, V19, P4925, DOI 10.1158/1078-0432.CCR-12-3172; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Sohn BH, 2016, CLIN CANCER RES, V22, P1256, DOI 10.1158/1078-0432.CCR-15-1447; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009; Wang XD, 2012, EUR J CANCER, V48, P1227, DOI 10.1016/j.ejca.2011.10.001; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yang XY, 2012, PHARMAZIE, V67, P645, DOI 10.1691/ph.2012.1704; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang T, 2012, HEPATOLOGY, V56, P2051, DOI 10.1002/hep.25899; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou X, 2015, J CLIN INVEST, V125, P2123, DOI 10.1172/JCI79573	68	2	2	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					995	1006		10.1016/j.ajpath.2017.12.017			12	Pathology	Pathology	GB6NH	WOS:000429185400015	29378174	Green Published			2019-10-28	
J	Chen, M; Zhao, JW; Ali, IHA; Marry, S; Augustine, J; Bhuckory, M; Lynch, A; Kissenpfennig, A; Xu, HP				Chen, Mei; Zhao, Jiawu; Ali, Imran H. A.; Marry, Stephen; Augustine, Josy; Bhuckory, Mohajeet; Lynch, Aiding; Kissenpfennig, Adrien; Xu, Heping			Cytokine Signaling Protein 3 Deficiency in Myeloid Cells Promotes Retinal Degeneration and Angiogenesis through Arginase-1 Up-Regulation in Experimental Autoimmune Uveoretinitis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MACULAR DEGENERATION; CHRONIC INFLAMMATION; SOCS PROTEINS; ANTI-VEGF; IN-VITRO; MACROPHAGE POLARIZATION; DENDRITIC CELLS; GM-CSF; ACTIVATION; MICE	The suppressor of cytokine signaling protein 3 (SOCS3) critically controls immune cell activation, although its role in macrophage polarization and function remains controversial. Using experimental autoimmune uveoretinitis (EAU) as a model, we show that inflammation-mediated retinal degeneration is exaggerated and retinal angiogenesis is accelerated in mice with SOCS3 deficiency in myeloid cells (LysM(Cre/+)SOCS3(fl/fl)). At the acute stage of EAU, the population of infiltrating neutrophils was increased and the population of macrophages decreased in LysM(Cre/+)SOCS3(fl/fl) mice compared with that in wild-type (WT) mice. Real-time RT-PCR showed that the expression of tumor necrosis factor-alpha, IL-1 beta, interferon-gamma, granulocyte-macrophage colony-stimulating factor, and arginase-1 was significantly higher in the LysM(Cre/+)SOCS3(fl/fl) EAU retina in contrast to the WT EAU retina. The percentage of arginase-1(+) infiltrating cells was significantly higher in the LysM(Cre/+)SOCS3(fl/fl) EAU retina than that in the WT EAU retina. In addition, bone marrow-derived macrophages and neutrophils from the LysM(Cre/+)SOCS3(fl/fl) mice express significantly higher levels of chemokine (C-C motif) Ligand 2 and arginase-1 compared with those from WT mice. Inhibition of arginase using an L-arginine analog amino-2-borono-6-hexanoic suppressed inflammation-induced retinal angiogenesis without affecting the severity of inflammation. Our results suggest that SOCS3 critically controls the phenotype and function of macrophages and neutrophils under inflammatory conditions and loss of SOCS3 promotes the angiogenic phenotype of the cells through up-regulation of arginase-1.	[Chen, Mei; Zhao, Jiawu; Ali, Imran H. A.; Marry, Stephen; Augustine, Josy; Bhuckory, Mohajeet; Lynch, Aiding; Kissenpfennig, Adrien; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland	Xu, HP (reprint author), Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	heping.xu@qub.ac.uk	Xu, Heping/A-4430-2008; , Mei/P-9791-2019	Xu, Heping/0000-0003-4000-931X; , Mei/0000-0001-5661-1386; Kissenpfennig, Adrien/0000-0002-9633-3111; Marry, Stephen/0000-0002-0769-1444	National Eye Research Centre [SCAID061]; Fight for Sight [1361/2]	Supported by National Eye Research Centre grant SCAID061 (H.X.) and Fight for Sight grant 1361/2 (H.X. and M.C.).	Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588; Arnold CE, 2014, IMMUNOLOGY, V141, P96, DOI 10.1111/imm.12173; Avichezer D, 2000, INVEST OPHTH VIS SCI, V41, P127; Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674; Carow B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00058; CASPI RR, 1988, J IMMUNOL, V140, P1490; Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031; Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315; Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020; Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Dhingra N, 2010, INDIAN J OPHTHALMOL, V58, P3, DOI 10.4103/0301-4738.58467; DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834; DICK AD, 1994, IMMUNOLOGY, V82, P625; Dick AD, 1997, OCUL IMMUNOL INFLAMM, V5, P129, DOI 10.3109/09273949709085061; Dimitriou ID, 2008, IMMUNOL REV, V224, P265, DOI 10.1111/j.1600-065X.2008.00659.x; Durante W, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00111; FORRESTER JV, 1992, CURR EYE RES, V11, P33, DOI 10.3109/02713689208999509; Gordon P, 2016, J LEUKOCYTE BIOL, V100, P771, DOI 10.1189/jlb.3A1215-554RR; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Hiwatashi K, 2011, CANCER LETT, V308, P172, DOI 10.1016/j.canlet.2011.04.024; Jost MM, 2003, FASEB J, V17, P2281, DOI 10.1096/fj.03-0071fje; Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006; Liu JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050719; Liu XX, 2012, J IMMUNOL, V189, P1182, DOI 10.4049/jimmunol.1102996; Liu Y, 2008, J IMMUNOL, V180, P6270, DOI 10.4049/jimmunol.180.9.6270; LIVERSIDGE J, 1988, CURR EYE RES, V7, P1231, DOI 10.3109/02713688809033227; Lu W, 2006, EUR J GYNAECOL ONCOL, V27, P363; Luo C, 2012, INFLAMMATION, V35, P1448, DOI 10.1007/s10753-012-9458-1; Majno G, 1998, AM J PATHOL, V153, P1035, DOI 10.1016/S0002-9440(10)65648-9; Marrelli A, 2011, AUTOIMMUN REV, V10, P595, DOI 10.1016/j.autrev.2011.04.020; Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170; McCormick SM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00549; Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088; Narayanan SP, 2013, PROG RETIN EYE RES, V36, P260, DOI 10.1016/j.preteyeres.2013.06.002; O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; Orabona C, 2008, P NATL ACAD SCI USA, V105, P20828, DOI 10.1073/pnas.0810278105; Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200; Patel C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00173; Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168; Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109; Sonoda KH, 2011, ACTA OPHTHALMOL, V89, pE180, DOI 10.1111/j.1755-3768.2010.01953.x; Sun Y, 2015, ARCHAEA, DOI 10.1155/2015/397924; Tortorella C, 2007, AGEING RES REV, V6, P81, DOI 10.1016/j.arr.2006.10.001; Veenbergen S, 2011, ANN RHEUM DIS, V70, P2167, DOI 10.1136/ard.2011.154815; Wilson HM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00357; Wong PKK, 2006, J CLIN INVEST, V116, P1571, DOI 10.1172/JCI25660; Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012; Xu HP, 2008, BLOOD, V112, P1166, DOI 10.1182/blood-2007-06-098327; Yan CG, 2013, FASEB J, V27, P2967, DOI 10.1096/fj.12-225797; Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003; Yoshimura A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00020; Yoshimura A, 2012, IMMUNITY, V36, P157, DOI 10.1016/j.immuni.2012.01.010; Zhao JW, 2014, INVEST OPHTH VIS SCI, V55, P7572, DOI 10.1167/iovs.14-15495	54	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1007	1020		10.1016/j.ajpath.2017.12.021			14	Pathology	Pathology	GB6NH	WOS:000429185400016	29452101	Green Published, Bronze			2019-10-28	
J	Place, DE; Samir, P; Karki, R; Briard, B; Vogel, P; Kanneganti, TD				Place, David E.; Samir, Parimal; Karki, Rajendra; Briard, Benoit; Vogel, Peter; Kanneganti, Thirumala-Devi			ASK Family Kinases Are Required for Optimal NLRP3 Inflammasome Priming	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ACTIVATED PROTEIN-KINASES; CELL-DEATH; DEPENDENT ACTIVATION; CYTOPLASMIC DNA; INNATE IMMUNITY; GASDERMIN D; APOPTOSIS; BETA; MECHANISMS; PYROPTOSIS	Activation of the multimeric inflammasome complex leads to inflammatory responses to biotic and abiotic triggers. The inflammasome sensor, Nod-like receptor family pyrin domain containing 3 (NLRP3), is activated by a range of stimuli and is tightly regulated to restrict excessive inflammation. Because NLRP3 responds broadly to cellular insults and regulates cell death similar to the stress-activated apoptosis signal-regulating kinases 1 and 2 (ASK1/2), we hypothesized that ASK1/2 may regulate NLRP3 activity. Although essential for mediating NLRP3 inflammasome activation, ASK1/2 were not required for NLRC4 or absent in melanoma 2 inflammasome activation. ASK1/2 was required for NLRP3 up-regulation after lipopolysaccharide treatment in primary bone marrow-derived macrophages and lung fibroblasts as well as during infection with Burkholderia thailandensis and influenza virus. Consistent with reduced NLRP3 expression in response to B. thailandensis, caspase-1 cleavage and cell death were reduced in infected bone marrow-derived macrophages, and mice lacking ASK1/2 were resistant to Burkholderia intranasal infection. Single knockouts of either ASK1 or ASK2 showed a partial role for both ASK1 and ASK2 in NLRP3 up-regulation in response to Lipopolysaccharide or B. thailandensis, but ASK2 was required primarily to mediate Lethal pathology during intranasal infection in vivo. Our findings identify the ASK1/2 complex as a regulator of NLRP3 activation and highlight a larger role for ASK2 in lung infection during B. thailandensis infection.	[Place, David E.; Samir, Parimal; Karki, Rajendra; Briard, Benoit; Kanneganti, Thirumala-Devi] St Jude Childrens Res Hosp, Dept Immunol, MS 351,262 Danny Thomas Pl, Memphis, TN 38105 USA; [Vogel, Peter] St Jude Childrens Res Hosp, Vet Pathol Core, 332 N Lauderdale St, Memphis, TN 38105 USA	Kanneganti, TD (reprint author), St Jude Childrens Res Hosp, Dept Immunol, MS 351,262 Danny Thomas Pl, Memphis, TN 38105 USA.	thirumala-devi.kanneganti@stjude.org	Kanneganti, Thirumala-Devi/M-9435-2018; Kanneganti, Thirumala-Devi/Y-2503-2019; Vogel, Peter/N-2490-2018; Samir, Parimal/N-4144-2014	Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Vogel, Peter/0000-0002-7535-0545; Place, David/0000-0002-1904-4164; Samir, Parimal/0000-0001-7655-5713	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI101935, AI124346, AR056296, CA163507]; American Lebanese Syrian Associated CharitiesAmerican Lebanese Syrian Associated Charities (ALSAC); National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA021765-35]; St. Jude Children's Research Hospital	Supported by NIH grants AI101935, AI124346, AR056296, and CA163507 (all to T.-D.K.) and the American Lebanese Syrian Associated Charities (T.-D.K.). The St. Jude Children's Research Hospital Cell and Tissue Imaging Center is supported by St. Jude Children's Research Hospital and National Cancer Institute grant P30 CA021765-35.	Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Ceballos-Olvera I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002452; Choi JR, 2009, FEBS LETT, V583, P3016, DOI 10.1016/j.febslet.2009.08.014; Cockrell LM, 2010, ONCOGENE, V29, P822, DOI 10.1038/onc.2009.382; Federspiel JD, 2016, MOL CELL PROTEOMICS, V15, P1947, DOI 10.1074/mcp.M115.057364; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fujino G, 2007, MOL CELL BIOL, V27, P8152, DOI 10.1128/MCB.00227-07; Gurung P, 2012, J BIOL CHEM, V287, P34474, DOI 10.1074/jbc.M112.401406; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hayakawa Y, 2013, INFECT IMMUN, V81, P4551, DOI 10.1128/IAI.00914-13; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Iriyama T, 2009, EMBO J, V28, P843, DOI 10.1038/emboj.2009.32; Kaji T, 2010, BIOCHEM BIOPH RES CO, V395, P213, DOI 10.1016/j.bbrc.2010.03.164; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kesavardhana S, 2017, INT IMMUNOL, V29, P201, DOI 10.1093/intimm/dxx018; Kim SY, 2012, J BIOL CHEM, V287, P3381, DOI 10.1074/jbc.M111.317875; Kuriakose T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag2045; Lizio M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0560-6; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Man SM, 2015, NAT IMMUNOL, V16, P467, DOI 10.1038/ni.3118; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Maruoka S, 2003, BIOCHEM BIOPH RES CO, V307, P870, DOI 10.1016/S0006-291X(03)01283-X; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459; Nogusa S, 2016, CELL HOST MICROBE, V20, P13, DOI 10.1016/j.chom.2016.05.011; Okazaki T, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1883; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089; Soga Mayumi, 2012, Int J Cell Biol, V2012, P439587, DOI 10.1155/2012/439587; Takeda K, 2007, J BIOL CHEM, V282, P7522, DOI 10.1074/jbc.M607177200; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tzeng TC, 2016, CELL REP, V16, P571, DOI 10.1016/j.celrep.2016.06.011; Vande Walle L, 2014, NATURE, V512, P69, DOI 10.1038/nature13322; Won M, 2010, CELL DEATH DIFFER, V17, P1830, DOI 10.1038/cdd.2010.47; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang R, 2007, J BIOL CHEM, V282, P14788, DOI 10.1074/jbc.M701148200; Zhao Y, 2015, IMMUNOL REV, V265, P85, DOI 10.1111/imr.12293; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	46	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1021	1030		10.1016/j.ajpath.2017.12.006			10	Pathology	Pathology	GB6NH	WOS:000429185400017	29353059	Bronze, Green Published			2019-10-28	
J	Chen, YJ; Wang, SF; Weng, IC; Hong, MH; Lo, TH; Jan, JT; Hsu, LC; Chen, HY; Liu, FT				Chen, Yu-Jung; Wang, Sheng-Fan; Weng, I-Chun; Hong, Ming-Hsiang; Lo, Tzu-Han; Jan, Jia-Tsrong; Hsu, Li-Chung; Chen, Huan-Yuan; Liu, Fu-Tong			Galectin-3 Enhances Avian H5N1 Influenza A Virus-Induced Pulmonary Inflammation by Promoting NLRP3 Inflammasome Activation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							IMMUNE-RESPONSES; ALVEOLAR MACROPHAGES; MURINE MODEL; INFECTION; IMMUNOPATHOLOGY; PATHOGENESIS; NEUTROPHILS; ROLES; MICE; SUSCEPTIBILITY	Highly pathogenic avian influenza A H5N1 virus causes pneumonia and acute respiratory distress syndrome in humans. Virus-induced excessive inflammatory response contributes to severe disease and high mortality rates. Galectin-3, a beta-galactoside-binding protein widely distributed in immune and epithelial cells, regulates various immune functions and modulates microbial infections. Here, we describe galectin-3 up-regulation in mouse lung tissue after challenges with the H5N1 influenza virus. We investigated the effects of endogenous galectin-3 on H5N1 infection and found that survival of galectin-3 knockout (Gal-3K0) mice was comparable with wild-type (WT) mice after infections. Compared with infected WT mice, infected Gal-3K0 mice exhibited less inflammation in the lungs and reduced IL-1 beta levels in bronchoalveolar Lavage fluid. In addition, the bone marrow-derived macrophages (BMMs) from Gal-3K0 mice exhibited reduced oligomerization of apoptosis-associated speck-Like proteins containing caspase-associated recruitment domains and secreted Less IL-1 beta compared with BMMs from WT mice. However, similar levels of the inflammasome component of nucleotide oligomerization domain-like receptor protein 3 (NLRP3) were observed in two genotypes of BMMs. Coimmunoprecipitation data indicated galectin-3 and NLRP3 interaction in BMMs infected with H5N1. An association was also observed between galectin-3 and NLRP3/apoptosis-associated speck-like proteins containing caspase-associated recruitment domain complex. Combined, our results suggest that endogenous galectin-3 enhances the effects of H5N1 infection by promoting host inflammatory responses and regulating IL-1 beta production by macrophages via interaction with NLRP3.	[Chen, Yu-Jung; Wang, Sheng-Fan; Weng, I-Chun; Hong, Ming-Hsiang; Lo, Tzu-Han; Chen, Huan-Yuan; Liu, Fu-Tong] Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan; [Wang, Sheng-Fan] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan; [Jan, Jia-Tsrong] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsu, Li-Chung] Natl Taiwan Univ, Inst Mol Med, Taipei, Taiwan	Chen, HY; Liu, FT (reprint author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan.	hchen9@ibms.sinica.edu.tw; ftliu@ibms.sinica.edu.tw	Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001; Wang, Sheng-Fan/0000-0002-4183-3872	Ministry of Science and Technology, Republic of China [MOST103-100, MOST 106-0210-01-15-02, MOST 106-2321-B-037-001]; Academia SinicaAcademia Sinica - Taiwan	Supported by Academia Sinica and Ministry of Science and Technology, Republic of China grants MOST103-100 (H.-Y.C.), MOST 106-0210-01-15-02 (F.-T.L.), and MOST 106-2321-B-037-001 (S.-F.W.). Anti-caspase-1 (p20) was a gift from Genentech.	Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Beigel H, 2005, NEW ENGL J MED, V353, P1374; Bi YH, 2016, VIROL SIN, V31, P300, DOI 10.1007/s12250-016-3750-4; Campbell GM, 2015, J GEN VIROL, V96, P2951, DOI 10.1099/jgv.0.000240; Chen HY, 2005, ARCH IMMUNOL THER EX, V53, P497; Cheong WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126456; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Damjanovic D, 2012, CLIN IMMUNOL, V144, P57, DOI 10.1016/j.clim.2012.05.005; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Ettensohn DB, 2016, J INFECT DIS, V214, P1658, DOI 10.1093/infdis/jiw413; ETTENSOHN DB, 1984, J INFECT DIS, V149, P942, DOI 10.1093/infdis/149.6.942; Fernandes-Alnemri T, 2008, METHOD ENZYMOL, V442, P251, DOI [10.1016/S0076-6S79(08)01413-4, 10.1016/S0076-6879(08)01413-4]; Ferraz LC, 2008, EUR J IMMUNOL, V38, P2762, DOI 10.1002/eji.200737986; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Korteweg C, 2008, AM J PATHOL, V172, P1155, DOI 10.2353/ajpath.2008.070791; Kreijtz JHCM, 2011, VIRUS RES, V162, P19, DOI 10.1016/j.virusres.2011.09.022; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; Lee SMY, 2012, J LEUKOCYTE BIOL, V92, P1, DOI 10.1189/jlb.0312130; Lin KL, 2008, J IMMUNOL, V180, P2562, DOI 10.4049/jimmunol.180.4.2562; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Liu FT, 2010, ANN NY ACAD SCI, V1183, P158, DOI 10.1111/j.1749-6632.2009.05131.x; Marinova-Petkova A, 2016, EMERG INFECT DIS, V22, P2137, DOI 10.3201/eid2212.160611; McAuley JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003392; Mishra BB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059616; Nicol MQ, 2014, FUTURE VIROL, V9, P847, DOI 10.2217/fvl.14.65; Nieminen J, 2008, J IMMUNOL, V180, P2466, DOI 10.4049/jimmunol.180.4.2466; Norling LV, 2009, J ENDOCRINOL, V201, P169, DOI 10.1677/JOE-08-0512; Pang IK, 2011, TRENDS IMMUNOL, V32, P34, DOI 10.1016/j.it.2010.11.004; Pearce MB, 2017, VIROLOGY, V502, P114, DOI 10.1016/j.virol.2016.12.024; Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004; Pilette C, 2007, EUR RESPIR J, V29, P914, DOI 10.1183/09031936.00073005; Sato S, 2002, J IMMUNOL, V168, P1813, DOI 10.4049/jimmunol.168.4.1813; Schmitz N, 2005, J VIROL, V79, P6441, DOI 10.1128/JVI.79.10.6441-6448.2005; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; SHAW MW, 1992, CLIN MICROBIOL REV, V5, P74; Simovic Markovic B, 2016, J CROHNS COLITIS, V10, P593, DOI DOI 10.1093/ECC0-JCC/JJW013; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Skeik N, 2008, INT J INFECT DIS, V12, P233, DOI 10.1016/j.ijid.2007.07.002; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; Szretter KJ, 2007, J VIROL, V81, P2736, DOI 10.1128/JVI.02336-06; Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006; Tian JJ, 2016, FASEB J, V30, P4202, DOI 10.1096/fj.201600392RR; Tran TT, 2008, INT J BIOCHEM CELL B, V40, P2671, DOI 10.1016/j.biocel.2008.05.019; Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005; Vasta GR, 2009, NAT REV MICROBIOL, V7, P424, DOI 10.1038/nrmicro2146; Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013; Wood JM, 2004, NAT REV MICROBIOL, V2, P842, DOI 10.1038/nrmicro979; Zuberi RI, 2004, AM J PATHOL, V165, P2045, DOI 10.1016/S0002-9440(10)63255-5	56	6	6	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1031	1042		10.1016/j.ajpath.2017.12.014			12	Pathology	Pathology	GB6NH	WOS:000429185400018	29366678	Bronze			2019-10-28	
J	Brunetti, G; Tummolo, A; D'Amato, G; Gaeta, A; Ortolani, F; Piacente, L; Giordano, P; Colucci, S; Grano, M; Papadia, F; Faienza, MF				Brunetti, Giacomina; Tummolo, Albina; D'Amato, Gabriele; Gaeta, Alberto; Ortolani, Federica; Piacente, Laura; Giordano, Paola; Colucci, Silvia; Grano, Maria; Papadia, Francesco; Faienza, Maria F.			Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HOMOGENTISIC ACID; ASCORBIC-ACID; BONE; CHILDREN; RANKL; OSTEOPROTEGERIN; DICKKOPF-1; DIAGNOSIS; WOMEN; DKK1	Alkaptonuria (AKU) is a rare disorder characterized by the deficiency of the enzyme homogentisate 1,2-dioxygenase and consequent homogentisate accumulation, which leads to progressive and severe osteoarthopathy starting from the second decade of life. Thus, in AKU patients, bone involvement represents an important clinical issue, which we investigated. Serum levels of receptor activator of NF-kappa B ligand (RANKL), osteoprotegerin, sclerostin, Dickkopf-1, and bone remodeling markers were measured in nine AKU patients (two children and seven adults) and 22 controls, together with lumbar spine bone mineral density (LS-BMD) and femoral-BMD. In the two AKU children, the average of LS-BMD and femoral-BMD Z-scores were within the normal range, but reduced with respect to the controls. Otherwise, in the adult AKU patients, LS-BMD T-score was inside the normal range, but femoral-BMD T-score reached osteopenic Levels. Consistently, in AKU adults, higher RANKL and C-terminal telopeptide of collagen type 1 and lower osteoprotegerin Levels were observed than in controls. Otherwise, spontaneous osteoclastogenesis was already evident in peripheral blood mononuclear cell cultures from AKU children, together with a high percentage of circulating osteoclast precursors. Osteoclastogenesis was sustained by the high levels of tumor necrosis factor-alpha, RANK, RANKL, and LIGHT. In conclusion, the altered osteoclastogenesis was observed already in AKU children, despite the absence of evident injury. Thus, a preventive approach in young patients, targeting osteoclast activity, may prevent the macroscopic bone disease that appears in adult AKU.	[Brunetti, Giacomina; Colucci, Silvia] Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Sect Human Anat & Histol, Piazza Giulio Cesare 11, I-70124 Bari, Italy; [Piacente, Laura; Giordano, Paola; Faienza, Maria F.] Univ Aldo Moro Bari, Pediat Sect, Dept Biomed Sci & Human Oncol, Piazza G Cesare 11, I-70124 Bari, Italy; [Grano, Maria] Univ Aldo Moro Bari, Sect Human Anat & Histol, Dept Emergency & Organ Transplantat, Bari, Italy; [Tummolo, Albina; Ortolani, Federica; Papadia, Francesco] Giovanni XXIII Childrens Hosp, Dept Metab Dis Clin Genet & Diabetol, Bari, Italy; [Gaeta, Alberto] Giovanni XXIII Childrens Hosp, Radiol Unit, Bari, Italy; [D'Amato, Gabriele] Di Venere Hosp, Neonatal Intens Care Unit, Bari, Italy	Brunetti, G (reprint author), Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Sect Human Anat & Histol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.; Faienza, MF (reprint author), Univ Aldo Moro Bari, Pediat Sect, Dept Biomed Sci & Human Oncol, Piazza G Cesare 11, I-70124 Bari, Italy.	giacomina.brunetti@uniba.it; mariafelicia.faienza@uniba.it	Brunetti, Giacomina/J-7692-2016	Brunetti, Giacomina/0000-0002-0681-1432	Italian Ministry of Education, University and Research Ex	Supported by Italian Ministry of Education, University and Research Ex (M.G. and S.C).	Aliberti G, 2003, J INTERN MED, V254, P296, DOI 10.1046/j.1365-2796.2003.01145.x; Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074; BORY C, 1990, CLIN CHIM ACTA, V189, P7, DOI 10.1016/0009-8981(90)90228-K; Bostanci N, 2007, J CLIN PERIODONTOL, V34, P370, DOI 10.1111/j.1600-051X.2007.01061.x; Braconi D, 2017, BBA-GEN SUBJECTS, V1861, P135, DOI 10.1016/j.bbagen.2016.11.026; Braconi D, 2013, EXPERT REV PROTEOMIC, V10, P521, DOI 10.1586/14789450.2013.858020; Braconi D, 2011, J INHERIT METAB DIS, V34, P1163, DOI 10.1007/s10545-011-9377-6; Braconi D, 2010, J CELL BIOCHEM, V111, P922, DOI 10.1002/jcb.22780; Brunetti G, 2016, OSTEOPOROSIS INT, V27, P2355, DOI 10.1007/s00198-016-3501-2; Brunetti G, 2014, ONCOTARGET, V5, P12950, DOI 10.18632/oncotarget.2633; Chaabo K, 2015, INT IMMUNOPHARMACOL, V27, P180, DOI 10.1016/j.intimp.2015.04.051; Cox TF, 2011, J INHERIT METAB DIS, V34, P1153, DOI 10.1007/s10545-011-9367-8; Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493; Dalbeth N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3123; Davison AS, 2016, J INHERIT METAB DIS, V39, P203, DOI 10.1007/s10545-015-9902-0; Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538; Edwards JR, 2006, ARTHRITIS RHEUM-US, V54, P1451, DOI 10.1002/art.21821; Faienza MF, 2015, BONE, V81, P228, DOI 10.1016/j.bone.2015.07.021; Faienza MF, 2009, J CLIN ENDOCR METAB, V94, P2269, DOI 10.1210/jc.2008-2446; Genovese F, 2015, JIMD REP, V24, P29, DOI 10.1007/8904_2015_430; Giordano P, 2016, BRIT J HAEMATOL, V172, P293, DOI 10.1111/bjh.13481; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Introne WJ, 2011, MOL GENET METAB, V103, P307, DOI 10.1016/j.ymgme.2011.04.016; Jebaraj Isaac, 2013, Indian J Radiol Imaging, V23, P101, DOI 10.4103/0971-3026.113628; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Laschi M, 2016, CHEMMEDCHEM, V11, P674, DOI 10.1002/cmdc.201500578; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Millucci L, 2015, J INHERIT METAB DIS, V38, P797, DOI 10.1007/s10545-015-9842-8; Millucci L, 2015, J CELL PHYSIOL, V230, P1148, DOI 10.1002/jcp.24850; Millucci L, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/258471; Millucci L, 2012, BBA-MOL BASIS DIS, V1822, P1682, DOI 10.1016/j.bbadis.2012.07.011; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Nemethova M, 2016, EUR J HUM GENET, V24, P66, DOI 10.1038/ejhg.2015.60; Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood-2008-01-132134; Ranganath LR, 2016, ANN RHEUM DIS, V75, P362, DOI 10.1136/annrheumdis-2014-206033; Scriver CR, 2000, CECIL TXB MED, P1109; Sealock RR, 1940, P SOC EXP BIOL MED, V44, P580; Taylor AM, 2010, RHEUMATOLOGY, V49, P1412, DOI 10.1093/rheumatology/keq027; Tinti L, 2010, J CELL PHYSIOL, V225, P84, DOI 10.1002/jcp.22199; van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764	41	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1059	1068		10.1016/j.ajpath.2017.12.008			10	Pathology	Pathology	GB6NH	WOS:000429185400020	29353057	Bronze			2019-10-28	
J	Zhao, L; Xiao, Y; Xiu, J; Tan, LC; Guan, ZZ				Zhao, Liang; Xiao, Yan; Xiu, Jin; Tan, Long-Chun; Guan, Zhi-Zhong			Protection against the Neurotoxic Effects of beta-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of alpha 7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CHOLINESTERASE INHIBITOR BLOCKADE; ALZHEIMERS-DISEASE CURRENT; PRECURSOR PROTEIN; STATINS PREVENT; IN-VITRO; CHOLESTEROL; SIMVASTATIN; FORM; MECHANISMS; PATHWAY	The treatment of neurodegenerative diseases with statins has drawn increasing attention, but the related molecular mechanisms remain elusive. To examine the pleiotropic cholesterol-independent effects of statins in connection with the treatment of Alzheimer disease, we probed the influence of Lovastatin on the metabolism of amyloid precursor protein (APP), expression of nicotinic acetylcholine receptors (nAChRs), and activity of mitogen-activated protein kinase (MAPK) in primary cultured neurons and SH-SY5Y cells overexpressing human APP670/671. Lovastatin attenuated the neurotoxic effects of beta-amyloid peptide (A beta) and affected the metabolism of APP, reducing levels of A beta 1 to A beta 42 and beta-site amyloid precursor protein-cleaving enzyme 1; enhancing those of alpha APP, disintegrin metalloproteinase domain-containing protein 10, and beta-site amyloid precursor protein-cleaving enzyme 2; and up-regulating expression of alpha 7 nAChR and stimulating phosphorylation of extracellular signal regulated kinase (ERK)1/2. Interestingly, methyllycaconitine, an antagonist of alpha 7 nAChR, attenuated this effect on aAPP, but not on phospho-ERK1/2; whereas U0126, an inhibitor of MAPK/ERK kinase/ERK, blocked both the elevated expression of alpha 7 nAChR and enhanced secretion of alpha APP. Our findings indicate that Lovastatin up-regulates expression of alpha 7 nAChR by a mechanism involving activation of the MAPK/ERK pathway, which may result in diminished production of A beta.	[Zhao, Liang; Guan, Zhi-Zhong] Guizhou Med Univ, Dept Pathol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China; [Zhao, Liang] Guizhou Med Univ, Affiliated Hosp, Dept Microbiol, Guiyang, Guizhou, Peoples R China; [Zhao, Liang] Guizhou Med Univ, Key Labs Med Microbiol & Parasitol, Guiyang, Guizhou, Peoples R China; [Xiao, Yan; Xiu, Jin; Tan, Long-Chun; Guan, Zhi-Zhong] Guizhou Med Univ, Med Mol Biol, Guiyang, Guizhou, Peoples R China; [Xiao, Yan; Tan, Long-Chun; Guan, Zhi-Zhong] Guizhou Med Univ, Endem & Ethn Dis, Minist Educ, Guiyang, Guizhou, Peoples R China	Guan, ZZ (reprint author), Guizhou Med Univ, Affiliated Hosp, Dept Pathol, Guiyang 550004, Guizhou, Peoples R China.	zzg@gmc.edu.cn			Chinese National Natural Science FoundationNational Natural Science Foundation of China [81760571, 81260173]; Foundation of the Ministry of Education of P.R. China [IRT13058]; Scientific Foundations in Guizhou Province of China [[2014]06, [2014]4010, [2014]6008]	Supported Chinese National Natural Science Foundation grants 81760571 and 81260173; Foundation of the Ministry of Education of P.R. China grant IRT13058; and Scientific Foundations in Guizhou Province of China grants [2014]06, [2014]4010, and [2014]6008.	An Y, 2010, NEUROCHEM INT, V57, P647, DOI 10.1016/j.neuint.2010.08.001; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Bell KA, 2004, J NEUROCHEM, V91, P349, DOI 10.1111/j.1471-4159.2004.02722.x; Berk C, 2014, EXPERT OPIN INV DRUG, V23, P837, DOI 10.1517/13543784.2014.905542; Butterfield DA, 2011, PHARMACOL RES, V64, P180, DOI 10.1016/j.phrs.2011.04.007; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Eckert GP, 2013, PHARMAZIE, V68, P590, DOI 10.1691/ph.2013.6529; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115; Furukawa K, 1996, J NEUROCHEM, V67, P1882; Geldenhuys WJ, 2015, EXPERT REV NEUROTHER, V15, P3, DOI 10.1586/14737175.2015.990884; Giraldo E, 2014, REDOX BIOL, V2, P873, DOI 10.1016/j.redox.2014.03.002; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hosaka A, 2013, NEUROCHEM RES, V38, P589, DOI 10.1007/s11064-012-0956-1; Kandiah N, 2009, J NEUROL SCI, V283, P230, DOI 10.1016/j.jns.2009.02.352; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kojro E, 2010, J ALZHEIMERS DIS, V20, P1215, DOI 10.3233/JAD-2010-091621; Kumar A, 2016, J FORMOS MED ASSOC, V115, P3, DOI 10.1016/j.jfma.2015.04.001; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lin FC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002143; McGuinness B, 2010, J ALZHEIMERS DIS, V20, P925, DOI 10.3233/JAD-2010-091570; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Mendoza-Oliva A, 2015, CNS NEUROSCI THER, V21, P631, DOI 10.1111/cns.12420; Miida Takashi, 2004, J Atheroscler Thromb, V11, P253; Mills J, 1997, J NEUROSCI, V17, P9415; Mozayan M, 2007, AM J PHYSIOL-HEART C, V293, pH1737, DOI 10.1152/ajpheart.00269.2007; Mozayan M, 2006, J CEREBR BLOOD F MET, V26, P1562, DOI 10.1038/sj.jcbfm.9600310; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; Nunez J., 2008, J VIS EXP, V19; Pac-Soo C, 2011, J ALZHEIMERS DIS, V27, P1, DOI 10.3233/JAD-2011-110524; Pacifici M, 2012, JOVE-J VIS EXP, DOI 10.3791/3965; Papadopoulos P, 2014, NEUROBIOL AGING, V35, P203, DOI 10.1016/j.neurobiolaging.2013.07.010; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Peti W, 2013, PROTEIN SCI, V22, P1698, DOI 10.1002/pro.2374; Richardson K, 2013, ANN INTERN MED, V159, P688, DOI 10.7326/0003-4819-159-10-201311190-00007; Roensch J, 2007, NEUROCHEM INT, V50, P800, DOI 10.1016/j.neuint.2007.02.001; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tamboli IY, 2010, J BIOL CHEM, V285, P37405, DOI 10.1074/jbc.M110.149468; Wang CY, 2008, TRENDS MOL MED, V14, P37, DOI 10.1016/j.molmed.2007.11.004; Williams PT, 2015, J ALZHEIMERS DIS, V44, P1121, DOI 10.3233/JAD-141929; Xiu J, 2005, J NEUROSCI RES, V82, P531, DOI 10.1002/jnr.20658; Xiu J, 2006, NEUROCHEM INT, V49, P459, DOI 10.1016/j.neuint.2006.03.007; Zhang LL, 2014, ACTA PHARMACOL SIN, V35, P716, DOI 10.1038/aps.2013.203; Zhi WH, 2014, CNS NEUROSCI THER, V20, P218, DOI 10.1111/cns.12190	51	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1081	1093		10.1016/j.ajpath.2017.11.020			13	Pathology	Pathology	GB6NH	WOS:000429185400022	29341888	Bronze			2019-10-28	
J	Sood, AK; Coffin, JE; Schneider, GB; Fletcher, MS; DeYoung, BR; Gruman, LM; Gershenson, DM; Schaller, MD; Hendrix, MJ				Sood, A. K.; Coffin, J. E.; Schneider, G. B.; Fletcher, M. S.; DeYoung, B. R.; Gruman, L. M.; Gershenson, D. M.; Schaller, M. D.; Hendrix, M. J.			Biological Significance of Focal Adhesion Kinase in Ovarian Cancer: Role in Migration and Invasion (vol 165, pg 1087, 2004)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction																Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	APR	2018	188	4					1104	1104		10.1016/j.ajpath.2018.02.001			1	Pathology	Pathology	GB6NH	WOS:000429185400024		Green Published			2019-10-28	
J	Ohashi, R; Hayama, A; Matsubara, M; Watarai, Y; Sakatani, T; Naito, Z; Shimizu, A				Ohashi, Ryuji; Hayama, Ayako; Matsubara, Miyuki; Watarai, Yasuhiko; Sakatani, Takashi; Naito, Zenya; Shimizu, Akira			Breast carcinoma with osteoclast-like giant cells: A cytological-pathological correlation with a literature review	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Fine needle aspiration; Breast cancer; Osteoclast-like giant cells	FINE-NEEDLE-ASPIRATION; INVASIVE CRIBRIFORM CARCINOMA; MAMMARY-CARCINOMA; LOBULAR CARCINOMA; CANCER	Breast carcinoma with osteoclast-like giant cells (OGCs) is a rare disease characterized by the infiltration of OGCs in the tumor; however, cytological aspects of this tumor type remain elusive. We examined the cytological features in fine needle aspiration (FNA) biopsy smears obtained from 5 patients who were histologically diagnosed with breast carcinoma with OGCs. We compared FNA and clinicopathological findings with results from the published literature. Histological assessment of the resected samples showed that all tumors exhibited a histological grade 1 phenotype with a predominant cribriform architecture. Four patients were estrogen receptor positive, and 1 patient showed a triple negative phenotype. All patients survived without tumor recurrence. In the FNA smears, tumor cells were arranged in loosely cohesive clusters, characterized by varying degrees of OGCs infiltration and rare formation of solid tumor nests. Occasionally, 2- or 3-dimensional clusters of tumor cells were found, accompanied by OGCs at the peripheral regions. In all patients, tumor cells were small without severe nuclear atypia. None of the patients showed significant background necrosis. In summary, cytological features of breast carcinoma with OGCs are characterized by loose aggregates of low grade tumor cells, the presence of OGCs, and the absence of necrosis, all of which were consistent with features reported previously. This peculiar form of breast tumors should be included in the differential diagnosis, when physicians encounter	[Ohashi, Ryuji; Hayama, Ayako; Matsubara, Miyuki; Watarai, Yasuhiko; Sakatani, Takashi; Naito, Zenya; Shimizu, Akira] Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan; [Sakatani, Takashi; Naito, Zenya] Nippon Med Sch, Dept Integrated Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan	Ohashi, R (reprint author), Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	r-ohashi@nms.ac.jp					BONDESON L, 1984, ACTA CYTOL, V28, P313; Cai GP, 2004, DIAGN CYTOPATHOL, V30, P396, DOI 10.1002/dc.20069; Cyrta J, 2013, CYTOPATHOLOGY, V24, P377, DOI 10.1111/cyt.12016; DEY P, 1993, CYTOPATHOLOGY, V4, P382, DOI 10.1111/j.1365-2303.1993.tb00119.x; FACTOR SM, 1977, VIRCHOWS ARCH A, V374, P1, DOI 10.1007/BF00430566; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; GUPTA RK, 1988, ACTA CYTOL, V32, P79; HOLLAND R, 1984, CANCER, V53, P1963, DOI 10.1002/1097-0142(19840501)53:9<1963::AID-CNCR2820530927>3.0.CO;2-N; KOBAYASHI S, 1984, ACTA PATHOL JAPON, V34, P1475; Ng WK, 2002, ACTA CYTOL, V46, P535, DOI 10.1159/000326873; Ng WK, 2001, ACTA CYTOL, V45, P593, DOI 10.1159/000327870; PETTINATO G, 1989, PATHOL RES PRACT, V185, P388, DOI 10.1016/S0344-0338(89)80019-6; PETTINATO G, 1984, Applied Pathology, V2, P168; PHILLIPSON J, 1994, ACTA CYTOL, V38, P479; Rakha E, 2012, WHO CLASSIFICATION T, P43; ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1; ROSEN PP, 1979, CANCER, V44, P1305, DOI 10.1002/1097-0142(197910)44:4<1305::AID-CNCR2820440421>3.0.CO;2-8; Saimura M, 1999, BREAST CANC, V6, P121; Shabb NS, 1997, ACTA CYTOL, V41, P1284; Shishido-Hara Y, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-55; STEWART CJR, 1991, CYTOPATHOLOGY, V2, P215, DOI 10.1111/j.1365-2303.1991.tb00407.x; SUGANO I, 1983, CANCER, V52, P74, DOI 10.1002/1097-0142(19830701)52:1<74::AID-CNCR2820520115>3.0.CO;2-D; Tajima S, 2015, PATHOL INT; Takahashi T, 1998, ACTA CYTOL, V42, P734, DOI 10.1159/000331836; Tse GMK, 2001, PATHOLOGY, V33, P153; Vicandi B, 2004, CYTOPATHOLOGY, V15, P321, DOI 10.1111/j.1365-2303.2004.00166.x; VOLPE R, 1983, ACTA CYTOL, V27, P184; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Yamada S, 2013, DIAGN PATHOL; Zhou SL, 2014, VIRCHOWS ARCH, V464, P681, DOI 10.1007/s00428-014-1573-y	30	2	2	2	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						1	5		10.1016/j.anndiagpath.2017.11.003			5	Pathology	Pathology	GB7ZR	WOS:000429294200001	29566940				2019-10-28	
J	Kakkar, A; Rajeshwari, M; Sakthivel, P; Sharma, MC; Sharm, SC				Kakkar, Aanchal; Rajeshwari, Madhu; Sakthivel, Pirabu; Sharma, Mehar C.; Sharm, Suresh C.			Biphenotypic sinonasal sarcoma: A series of six cases with evaluation of role of beta-catenin immunohistochemistry iii differential diagnosis	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Nasal cavity; Paranasal sinus; Spindle cell tumor; Biphasic; beta-catenin; Immunohistochemistry	MYOGENIC FEATURES; EXPRESSION; FUSION; TRACT; CHALLENGE; TUMORS	Introduction: Biphenotypic sinonasal sarcoma (BSNS) is a recently described mesenchymal tumor exclusive to the sinonasal region. It is a low grade sarcoma, displaying evidence of myogenic and neural differentiation. Role of beta-catenin immunohistochemistry in distinguishing it from its morphological mimics is not well-established. We conducted this study to identify cases of BSNS from our archives, and to examine immunopositivity for beta-catenin in them as well as in its close differential diagnosis. Methods: All cases of nasal cavity and paranasal sinus mesenchymal neoplasms were identified. Histopathological features were reviewed. Cases showing smooth muscle actin (SMA) and S-100 immunopositivity, and typical morphology were reclassified as BSNS. beta-catenin immunoexpression was assessed. Results: Twenty-one mesenchymal tumors, including 12 sinonasal hemangiopericytoma (SNHPC), five solitary fibrous tumors (SFT), three BSNS, and one synovial sarcoma were identified. Three SNHPC cases were reclassified as BSNS. BSNS patients included one male and five females, with mean age of 51 years. Five BSNS cases (83.3%) showed nuclear beta-catenin immunopositivity. SNHPC cases also were beta-catenin positive (60%). Conclusion: BSNS is a rare sinonasal neoplasm, frequently misdiagnosed as SNHPC and SFT. beta-catenin immunopositivity is seen in majority of cases, indicating a role in pathogenesis. However, due to positivity in other tumors like SNHPC, it has limited role in differential diagnosis.	[Kakkar, Aanchal; Rajeshwari, Madhu; Sharma, Mehar C.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Sakthivel, Pirabu; Sharm, Suresh C.] All India Inst Med Sci, Dept Otolaryngol & Head & Neck Surg, New Delhi 110029, India	Sharma, MC (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	sharmamehar@yahoo.co.in					Bishop JA, 2016, SEMIN DIAGN PATHOL, V33, P62, DOI 10.1053/j.semdp.2015.12.001; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Fritchie KJ, 2016, HISTOPATHOLOGY, V69, P930, DOI 10.1111/his.13045; Huang SC, AM J SURG PATHOL, V40, P9; Jo VY, 2017, HEAD NECK PATHOL, V11, P119, DOI 10.1007/s12105-016-0737-2; Johncilla M, 2016, SEMIN DIAGN PATHOL, V33, P81, DOI 10.1053/j.semdp.2015.09.009; Kakkar A, 2016, APPL IMMUNOHISTO M M, V24, P729, DOI 10.1097/PAI.0000000000000247; Kane SV, 2017, AURIS NASUS LARYNX; Kondo S, 2001, HISTOPATHOLOGY, V38, P482, DOI 10.1046/j.1365-2559.2001.1163d.x; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Powers KA, 2015, OR SURG OR MED OR PA, V119, pE265, DOI 10.1016/j.oooo.2014.10.007; Rooper LM, 2016, HUM PATHOL, V55, P44, DOI 10.1016/j.humpath.2016.04.009; Triki M, 2017, ARCH PATHOL LAB MED, V141, P718, DOI 10.5858/arpa.2016-0133-RS; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295	15	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						6	10		10.1016/j.anndiagpath.2017.11.005			5	Pathology	Pathology	GB7ZR	WOS:000429294200002	29566950				2019-10-28	
J	Yun, SH; Roh, MS; Jeong, JS; Park, JI				Yun, Seong-Hoon; Roh, Mee-Sook; Jeong, Jin-Sook; Park, Joo-In			Peroxisome proliferator-activated receptor gamma coactivator-1 alpha is a predictor of lymph node metastasis and poor prognosis in human colorectal cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						PGC-1 alpha; Colorectal cancer; Lymph node metastasis; Prognosis	ALPHA ERR-ALPHA; PPAR-GAMMA; COLON-CANCER; CELL-GROWTH; EXPRESSION; DIFFERENTIATION; PROGRESSION; INHIBITION; PGC-1	Peroxisome proliferator-activated receptor gamma (PPAR gamma) and PPAR gamma coactivator-1 alpha (PGC-1 alpha) expression levels are correlated with clinical outcome in breast cancer. However, the potential biological and clinical significance of PPAR gamma and PGC-1 alpha in colorectal cancer remains unknown. Here we investigated PPAR gamma and PGC-1 alpha expression in colorectal cancer, and the associations of these expression levels with clinicopathological features. We also evaluated the roles of PPAR gamma and PGC-1 alpha as prognostic factors in colorectal cancer. We performed immunohistochemical analysis to investigate PPAR gamma and PGC-1 alpha expression in human colorectal cancer tissues and adjacent normal tissues from 108 primary colorectal cancer patients. We then examined how these expression levels correlated with clinicopathological features. Using the Kaplan-Meier method, we evaluated 3-year diseasefree survival (DFS) and overall survival (OS) in patients with tumors expressing different levels of PPAR gamma and PGC-1 alpha. Our results revealed that PPAR gamma expression was not significantly correlated with age at surgery, gender, differentiation, depth of infiltration, relapse, or TNM stage. Additionally, PGC-1 alpha expression was not significantly correlated with age at surgery, differentiation, depth of infiltration, relapse, or TNM stage. However, PGC-1 alpha expression was significantly correlated with nodal metastasis (p = 0.020). Survival analysis demonstrated reduced OS in the PGC-1 alpha-positive group compared to the PGC-1 alpha-negative group (p = 0.03). Our present findings suggest that PGC-1 alpha may be useful for predicting nodal metastasis, and may represent a biomarker for poor prognosis in colorectal cancer.	[Yun, Seong-Hoon; Park, Joo-In] Dong A Univ, Coll Med, Dept Biochem, 32 Daesingongwon Ro, Busan 49201, South Korea; [Roh, Mee-Sook; Jeong, Jin-Sook] Dong A Univ, Coll Med, Dept Pathol, 32 Daesingongwon Ro, Busan 49201, South Korea	Park, JI (reprint author), Dong A Univ, Coll Med, Dept Biochem, 32 Daesingongwon Ro, Busan 49201, South Korea.	jipark@dau.ac.kr			National Research Foundation of Korea (NRF) - Korean Government (MSIP) [2016R1A5A2007009]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2017R1A2B4011428]	This research was supported by National Research Foundation of Korea (NRF), funded by the Korean Government (MSIP) (No. 2016R1A5A2007009), and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2017R1A2B4011428).	Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Cavallini A, 2005, EUR J CANCER, V41, P1487, DOI 10.1016/j.ejca.2005.04.008; Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024; Goel A, 2001, GASTROENTEROLOGY, V121, P1497, DOI 10.1053/gast.2001.29978; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; Lan YT, 2012, INT J COLORECTAL DIS, V27, P657, DOI 10.1007/s00384-011-1366-6; Lee CJ, 2006, APOPTOSIS, V11, P401, DOI 10.1007/s10495-006-4003-z; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Motomura W, 2000, CANCER RES, V60, P5558; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/eoid.12.12.1925.21991; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Shin SW, 2015, INT J ONCOL, V46, P1328, DOI 10.3892/ijo.2015.2834; Shin SW, 2009, ONCOL REP, V21, P101, DOI 10.3892/or_00000195; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Zhou W, 2002, LANCET, V359, P219, DOI 10.1016/S0140-6736(02)07448-2	27	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						11	16		10.1016/j.anndiagpath.2017.11.007			6	Pathology	Pathology	GB7ZR	WOS:000429294200003	29566941				2019-10-28	
J	Svajdler, M; Mezencev, R; Ondic, O; Saskova, B; Mukensnabl, P; Michal, M				Svajdler, Marian; Mezencev, Roman; Ondic, Ondrej; Saskova, Bohuslava; Mukensnabl, Petr; Michal, Michal			P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Small cell lung carcinoma; Non-small cell lung carcinoma; Poorly differentiated; Neuroendocrine carcinoma; p16; Immunohistochemistry	NEUROENDOCRINE LUNG-TUMORS; TRANSCRIPTION FACTOR-I; EXTENSIVE CRUSH ARTIFACT; DIFFERENTIAL-DIAGNOSIS; EXPRESSION; SPECTRUM; CANCER; TTF-1; P63; REPRODUCIBILITY	Pulmonary small cell carcinoma (SCLC) is usually diagnosed in small biopsy or cytological specimens based on cytomorphology; however in ambiguous cases diagnosis requires additional support by immunohistochemistry. While TP53 and RB1 alterations with secondary overexpression of p16 are mainstay events in SCLC pathogenesis, diagnostic value of p16-positivity in the diagnosis of SCLC has not yet been fully investigated. We examined the expression of p16, CD56, synaptophysin (SYP), chromogranin A and thyroid transcription factor-1 (TTF1) in a series of pulmonary and extrapulmonary small cell carcinomas, pulmonary carcinoids and non-small cell lung carcinomas, and compared diagnostic performance of these markers in the diagnosis of SCLC. P16 was positive in 95 of 101 SCLCs, and displayed highest diagnostic sensitivity of similar to 94%. Composite biomarkers CD56 + p16 + TTF1 and CD56 + p16 + SYP were both able to detect correctly all SCLC cases. Importantly, three (similar to 3%) SCLC cases completely negative for all conventional markers displayed diffuse positivity for p16. CD56 and p16 demonstrated highest concordance between paired small biopsy and cytology specimens. 50% of squamous cell carcinomas, similar to 41% of adenocarcinoma/NSCLC-favour adenocarcinoma cases, and similar to 93% of extrapulmonary small cell carcinomas also showed p16-positivity. Combination of CD56, p16 and TTF1 produced diagnostic classifier that outperformed best single marker CD56 in differential diagnosis between SCLC and NSCLC. In conclusion, in the appropriate morphological context p16 represents a useful supplementary marker for diagnosis of SCLC, even in cases where only cytological material is available.	[Svajdler, Marian; Ondic, Ondrej; Saskova, Bohuslava; Mukensnabl, Petr; Michal, Michal] Charles Univ Prague, Fac Med, Sikls Dept Pathol, Prague, Czech Republic; [Svajdler, Marian; Ondic, Ondrej; Saskova, Bohuslava; Mukensnabl, Petr; Michal, Michal] Charles Univ Prague, Fac Hosp Pilsen, Prague, Czech Republic; [Svajdler, Marian; Ondic, Ondrej; Saskova, Bohuslava; Michal, Michal] Biopt Lab Sro, Mikulasske 4, Plzen 32600, Czech Republic; [Mezencev, Roman] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA	Svajdler, M (reprint author), Biopt Lab Sro, Mikulasske 4, Plzen 32600, Czech Republic.	svajdler@biopticka.cz	Mezencev, Roman/O-8489-2019; Svajdler, Marian/N-5600-2019	Mezencev, Roman/0000-0003-4361-7628; Svajdler, Marian/0000-0001-8052-4741; Ondic, Ondrej/0000-0002-4038-5641			Aslan DL, 2005, AM J CLIN PATHOL, V123, P874, DOI 10.1309/QYV05GEGKUL2RTT; Beasley MB, 2003, HUM PATHOL, V34, P136, DOI 10.1053/hupa.2003.8; Brown AF, 2013, ARCH PATHOL LAB MED, V137, P1274, DOI 10.5858/arpa.2012-0635-OA; Chhieng DC, 2001, DIAGN CYTOPATHOL, V25, P356, DOI 10.1002/dc.10011; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Duan K, 2016, CANCER CYTOPATHOL, V124, P871, DOI 10.1002/cncy.21765; Fink G, 2001, CHEST, V119, P1647, DOI 10.1378/chest.119.6.1647; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; GUINEE DG, 1994, AM J CLIN PATHOL, V102, P406, DOI 10.1093/ajcp/102.4.406; Hiroshima K, 2006, MODERN PATHOL, V19, P1358, DOI 10.1038/modpathol.3800659; Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97; Kalhor N, 2006, MODERN PATHOL, V19, P1117, DOI 10.1038/modpathol.3800629; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P415; Kontogianni K, 2005, J CLIN PATHOL, V58, P978, DOI 10.1136/jcp.2004.023044; La Rosa S, 2010, VIRCHOWS ARCH, V457, P497, DOI 10.1007/s00428-010-0954-0; Lantuejoul S, 2000, HUM PATHOL, V31, P415, DOI 10.1053/hp.2000.6552; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; Leversha MA, 2003, J PATHOL, V200, P610, DOI 10.1002/path.1374; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Meder L, 2016, INT J CANCER, V138, P927, DOI 10.1002/ijc.29835; Nicholson SA, 2002, AM J SURG PATHOL, V26, P1184, DOI 10.1097/01.PAS.0000022995.91977.CD; Ordonez NG, 2000, AM J SURG PATHOL, V24, P1217, DOI 10.1097/00000478-200009000-00004; Pelosi G, 2005, AM J SURG PATHOL, V29, P179, DOI 10.1097/01.pas.0000149690.75462.29; Pelosi G, 2014, J THORAC ONCOL, V9, P273, DOI 10.1097/JTO.0000000000000092; Sturm N, 2003, HISTOPATHOLOGY, V42, P156, DOI 10.1046/j.1365-2559.2003.01541.x; Sturm N, 2002, HUM PATHOL, V33, P175, DOI 10.1053/hupa.2002.31299; Swarts DRA, 2012, BBA-REV CANCER, V1826, P255, DOI 10.1016/j.bbcan.2012.05.001; Thunnissen E, 2017, J THORAC ONCOL, V12, P334, DOI 10.1016/j.jtho.2016.12.004; Travis WD, 2012, MODERN PATHOL, V25, pS18, DOI 10.1038/modpathol.2011.150; Wick MR, 2000, SEMIN DIAGN PATHOL, V17, P194; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wong YNS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-209; Wu MX, 2005, DIAGN CYTOPATHOL, V33, P223, DOI 10.1002/dc.20337; Wu MX, 2003, AM J CLIN PATHOL, V119, P696, DOI 10.1309/XCP6EWPB3BMRKA; Yeh YC, 2014, J SURG ONCOL, V109, P280, DOI 10.1002/jso.23497; Yuan JP, 1999, J PATHOL, V189, P358; Zhang H, 2005, MODERN PATHOL, V18, P111, DOI 10.1038/modpathol.3800251	38	2	3	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						23	29		10.1016/j.anndiagpath.2017.11.008			7	Pathology	Pathology	GB7ZR	WOS:000429294200005	29566943				2019-10-28	
J	AbdullGaffar, B; Seliem, RM				AbdullGaffar, Badr; Seliem, Rania M.			Hodgkin lymphoma with an interfollicular growth pattern: A clinicopathologic study of 8 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Early; Focal; Hodgkin lymphoma; Interfollicular	CASTLEMANS-DISEASE; ASSOCIATION; INVOLVEMENT; VARIANT; BENIGN; NODES	Classic Hodgkin lymphoma (CHL) has four subtypes. Different morphologic variations can be seen in lymph nodes involved by CHL. Primary interfollicular (IF) involvement is not considered a separate subtype but an unusual diagnostically challenging morphologic variant. Our aim was to study the prevalence of IF growth pattern and coexistence of other morphologic variants in lymph nodes involved by CHL, to investigate the diagnostic challenges and clinical importance of this growth pattern, and to find helpful histologic clues in cases with subtle morphologic features to help avoid misinterpretation and missed diagnosis. We performed a retrospective review study over 10 years. We searched for diagnosed cases of nodal CHL. We retrieved and reviewed cases of CHL with IF involvement. The clinical and pathologic features of each case were collected and compared. We found 103 cases of CHLs. Eight cases (7.8%) demonstrated IF growth patterns. The age range was between 3 and 48 years with an average age of 26 years. The male to female ratio was 7:1. Six cases were mixed cellularity HLs. Three cases had associated epithelioid granulomas, one had follicular involvement and one had an associated. HHV-8 negative plasma cell rich Castleman disease. One case was initially missed as benign follicular hyperplasia, one case was referred as CD and three cases were initially suspected as HL. IF growth pattern in nodal CHLs can be missed because it can be mild and focal with subtle morphologic features. The presence of epithelioid histiocytes, eosinophils and other coexistent morphologic variants are helpful histologic clues. In doubtful cases, immunohistochemistry study is essential. The majority were early stage cervical node MCHLs in young adults and children. Pathologists should be aware of this possibility when examining reactive lymph nodes. The clinical significance is limited and needs further validation by larger studies.	[AbdullGaffar, Badr; Seliem, Rania M.] Rashid Hosp, Pathol Sect, Oud Metha Rd, Dubai 4545, U Arab Emirates	AbdullGaffar, B (reprint author), Rashid Hosp, Pathol Sect, Oud Metha Rd, Dubai 4545, U Arab Emirates.	baabdulhamid@dha.gov.ae		AbdullGaffar, Badr/0000-0001-6350-1214			Allal AS, 1996, PATHOL INT, V46, P787, DOI 10.1111/j.1440-1827.1996.tb03550.x; Andriko JAW, 1997, MODERN PATHOL, V10, P366; Basu Debdatta, 2006, Indian J Pathol Microbiol, V49, P221; Cajaiba MM, 2012, LEUKEMIA LYMPHOMA, V53, P1814, DOI 10.3109/10428194.2012.658389; COLBY TV, 1982, CANCER, V49, P1848, DOI 10.1002/1097-0142(19820501)49:9<1848::AID-CNCR2820490918>3.0.CO;2-Y; DELSOL G, 1982, HISTOPATHOLOGY, V6, P451, DOI 10.1111/j.1365-2559.1982.tb02742.x; DOGGETT RS, 1983, AM J SURG PATHOL, V7, P145, DOI 10.1097/00000478-198303000-00004; FELLBAUM C, 1988, HISTOPATHOLOGY, V12, P253, DOI 10.1111/j.1365-2559.1988.tb01940.x; Grosso LE, 2001, LEUKEMIA LYMPHOMA, V41, P675, DOI 10.3109/10428190109060359; Haque S, 2009, INDIAN J MED PAEDIAT, V30, P76, DOI 10.4103/0971-5851.60052; LENNERT K, 1958, Frankf Z Pathol, V69, P103; LUKES RJ, 1971, CANCER RES, V31, P1755; Macak J, 1992, Cesk Patol, V28, P93; MOLINIE V, 1994, ANN PATHOL, V14, P384; Pileri SA, 2002, J CLIN PATHOL, V55, P162, DOI 10.1136/jcp.55.3.162; Rao TV, 2007, PATHOL RES PRACT, V203, P479, DOI 10.1016/j.prp.2006.12.006; STRUM SB, 1970, CANCER-AM CANCER SOC, V25, P1314, DOI 10.1002/1097-0142(197006)25:6<1314::AID-CNCR2820250609>3.0.CO;2-V; Swerdlow SH, 2008, WHO CLASSIFICATION T; Weiss LM, 2013, MODERN PATHOL, V26, pS88, DOI 10.1038/modpathol.2012.176; Zanetto U, 2006, HISTOPATHOLOGY, V48, P317, DOI 10.1111/j.1365-2559.2005.02234.x; ZARATEOSORNO A, 1994, ARCH PATHOL LAB MED, V118, P270	21	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						30	34		10.1016/j.anndiagpath.2017.11.009			5	Pathology	Pathology	GB7ZR	WOS:000429294200006	29566944				2019-10-28	
J	Obek, C; Saglican, Y; Ince, U; Argu, OB; Tuna, MB; Doganca, T; Tufek, I; Keskin, S; Kural, AR				Obek, Can; Saglican, Yesim; Ince, Umit; Argu, Omer Burak; Tuna, Mustafa Bilal; Doganca, Tunkut; Tufek, Ilter; Keskin, Selcuk; Kural, Ali Riza			Infra-surgical total and re-constructible pathological prostate examination for safer margins and nerve preservation (Istanbul preserve)	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							INTRAOPERATIVE FROZEN-SECTION; RADICAL PROSTATECTOMY; NEUROSAFE; BIOPSIES; CANCER	Purpose: To demonstrate a novel frozen section analysis technique during robot assisted radical prostatectomy with 2 distinct advantages: evaluation of the entire circumference and easier reconstruction for whole mount evaluation. Material and methods: Istanbul Preserve was performed on patients who underwent robotic prostatectomy with nerve sparing between 10/2014 and 7/2016. Gland was sectioned at 3-4 mm intervals from apex to bladder neck. Entire tissue representing margins (except for the most anterior portion) was circumferentially excised and microscopically analyzed. In margin positivity, approach was individualized based on extent of positive margin and Gleason pattern. A matched cohort was established for comparison. Retrospective analysis of a prospectively maintained database was performed. Impact of FSA on PSM rate was primarily assessed. Results: Data on 170 patients was analyzed. Positive surgical margin was reported in 56(33%) on frozen section. Neurovascular bundle was partially or totally resected in 79% and 18%. Conversion of positive margin to negative was achieved in 85%. Overall positive margin rate decreased from 22.5% to 7.5%. Nerve sparing increased from 87% to 93%. Location of positive margin at frozen was at the neurovascular bundle area in 39%; thus Istanbul Preserve detected 61% additional margin positivity compared to other techniques. Reconstruction for whole mount was easy. Conclusion: Istanbul Preserve is a novel technique for intraoperative FSA during RARP allowing for microscopic examination of the entire prostate for margin status and easy re-construction for whole mount examination. It guarantees safer margins together with increased rate of nerve sparing.	[Obek, Can; Doganca, Tunkut] Acibadem Taksim Hosp, Dept Urol, Nizamiye Cad 1, TR-34373 Istanbul, Turkey; [Saglican, Yesim; Ince, Umit] Acibadem Univ, Dept Pathol, Istanbul, Turkey; [Argu, Omer Burak; Tufek, Ilter; Keskin, Selcuk; Kural, Ali Riza] Acibadem Univ, Dept Urol, Istanbul, Turkey; [Tuna, Mustafa Bilal] Acibadem Maslak Hosp, Dept Urol, Istanbul, Turkey	Doganca, T (reprint author), Acibadem Taksim Hosp, Dept Urol, Nizamiye Cad 1, TR-34373 Istanbul, Turkey.	tunkut.doganca@acibadem.com	ince, umit/T-8783-2017; Argun, Omer/D-5236-2016	ince, umit/0000-0002-6113-661X; Keskin, Mehmet Selcuk/0000-0003-2542-6289			Beyer B, 2014, EUR UROL, V66, P138, DOI 10.1016/j.eururo.2013.12.014; Eichelberg C, 2006, EUR UROL, V49, P1011, DOI 10.1016/j.eururo.2006.02.035; Lepor H, 2004, UROLOGY, V63, P499, DOI 10.1016/j.urology.2003.10.017; Meeks JJ, 2013, UROL ONCOL-SEMIN ORI, V31, P974, DOI 10.1016/j.urolonc.2011.12.011; Menon M, 2007, EUR UROL, V51, P648, DOI 10.1016/j.eururo.2006.10.055; Palisaar RR, 2005, EUR UROL, V47, P176, DOI 10.1016/j.eururo.2004.09.002; Rabbani F, 2009, BJU INT, V104, P605, DOI 10.1111/j.1464-410X.2009.08757.x; Schlomm T, 2012, EUR UROL, V62, P333, DOI 10.1016/j.eururo.2012.04.057; Soloway MS, 2006, EUR UROL, V49, P950, DOI 10.1016/j.eururo.2006.03.062; Sooriakumaran P, 2016, J SURG ONCOL, V113, P310, DOI 10.1002/jso.24109; Vasdev Nikhil, 2016, Curr Urol, V9, P93, DOI 10.1159/000442860; von Bodman C, 2013, J UROLOGY, V190, P515, DOI 10.1016/j.juro.2013.02.011; Wright JL, 2010, J UROLOGY, V183, P2213, DOI 10.1016/j.juro.2010.02.017; Ye HH, 2011, UROLOGY, V78, P399, DOI 10.1016/j.urology.2011.03.022; Yossepowitch O, 2007, J UROLOGY, V178, P493, DOI 10.1016/j.juro.2007.03.105; Yossepowitch O, 2014, EUR UROL, V65, P303, DOI 10.1016/j.eururo.2013.07.039	16	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						35	39		10.1016/j.anndiagpath.2017.11.010			5	Pathology	Pathology	GB7ZR	WOS:000429294200007	29566945				2019-10-28	
J	Compton, ML; Sweeting, RS; Reisenbichler, ES				Compton, Margaret L.; Sweeting, Raeshell S.; Reisenbichler, Emily S.			Intraoperative sentinel lymph node evaluation: Optimizing surgical pathology practices in an era of changing clinical management	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Breast; Axilla; Sentinel lymph node; Intraoperative evaluation; Surgical pathology	TOUCH IMPRINT CYTOLOGY; IMMEDIATE BREAST RECONSTRUCTION; AXILLARY DISSECTION; FROZEN-SECTION; CANCER; TRIAL; MASTECTOMY; SURGERY; BIOPSY; RADIOTHERAPY	Axillary lymph node status is an independent prognostic indicator in breast cancer. Intraoperative identification of metastatic carcinoma in sentinel lymph nodes may allow for concurrent axillary lymph node dissection at the time of primary tumor excision. A retrospective review of patients undergoing primary breast cancer excision with sentinel lymph node sampling was performed. Sensitivity and specificity of imprint cytology (touch prep) with and without the incorporation of gross evaluation was determined using permanent section results as the gold standard. Five hundred sixteen lymph nodes were analyzed by imprint cytology in 213 patients, and 203 lymph nodes were analyzed in 74 patients incorporating gross examination. Sensitivity and specificity for the detection of macrometastases by touch prep alone were 60% and 99% respectively with 4 patients undergoing same-day axillary dissection for only micrometastatic disease. False negative causes included lack of transfer of malignant cells in 8 cases and misinterpretation of tumor cells in 6 cases. Incorporating gross examination in the modified protocol resulted in reduced sensitivity of 38%, but achieved the desired 100% specificity and positive predictive value. Imprint cytology alone did not reliably distinguish between micro- and macrometastatic disease. Gross assessment combined with imprint cytology allows for improved assessment of volume of axillary disease, but is an insensitive technique.	[Compton, Margaret L.; Reisenbichler, Emily S.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 1161 21st Ave South CC-3322 Med Ctr North, Nashville, TN 37232 USA; [Sweeting, Raeshell S.] Vanderbilt Univ, Med Ctr, Dept Surg, 1161 21st Ave South CC-3322 Med Ctr North, Nashville, TN 37232 USA; [Reisenbichler, Emily S.] Yale Univ, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA	Compton, ML (reprint author), Vanderbilt Univ, Med Ctr, 1161 21st Ave South,MCN CC3322, Nashville, TN 37232 USA.	Margaret.L.Compton@Vanderbilt.edu		Reisenbichler, Emily/0000-0002-1570-6538			Arlicot C, 2013, ANTICANCER RES, V33, P1045; Chen JJ, 2013, EJSO-EUR J SURG ONC, V39, P442, DOI 10.1016/j.ejso.2013.02.005; Donker M, 2014, LANCET ONCOL, V15, P1303, DOI 10.1016/S1470-2045(14)70460-7; Elliott RM, 2014, ARCH PATHOL LAB MED, V138, P814, DOI 10.5858/arpa.2013-0281-OA; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Kronowitz SJ, 2006, CANCER-AM CANCER SOC, V107, P893, DOI 10.1002/cncr.22079; Lumachi F, 2012, ANTICANCER RES, V32, P3523; Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177; Mannell A, 2014, S AFR J SURG, V52, P75, DOI [10.7196/sajs.1954, 10.7196/SAJS.1954]; Mannu GS, 2012, INT J SURG, V10, P259, DOI 10.1016/j.ijsu.2012.04.010; Mannu GS, 2015, ANZ J SURG, V85, P438, DOI 10.1111/ans.12603; Mullenix PS, 2003, AM J SURG, V185, P420, DOI 10.1016/S0002-9610(03)00041-2; Richards ADM, 2013, ANZ J SURG, V83, P539, DOI 10.1111/j.1445-2197.2012.06293.x; St John ER, 2017, ANN SURG, V265, P300, DOI 10.1097/SLA.0000000000001897; Wang F, 2016, PLAST RECONSTR SURG, V137, P1, DOI 10.1097/PRS.0000000000001866; Wang YS, 2012, CANCER SCI, V103, P1989, DOI 10.1111/cas.12001	18	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						45	50		10.1016/j.anndiagpath.2017.12.003			6	Pathology	Pathology	GB7ZR	WOS:000429294200009	29566947				2019-10-28	
J	Padayachee, RS; Perner, Y; MacKinnon, D; Rowe, B; Pather, S				Padayachee, Rushen Siva; Perner, Yvonne; MacKinnon, Diane; Rowe, Biance; Pather, Sugeshnee			A retrospective analysis of paediatric lymphomas at Chris Hani Baragwanath Academic Hospital in Soweto, South Africa	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Editorial Material							NON-HODGKIN-LYMPHOMA; PLASMABLASTIC LYMPHOMA; CHILDREN; HIV; INFECTION; CHILDHOOD; BIOLOGY; FUTURE; CANCER		[Padayachee, Rushen Siva; Pather, Sugeshnee] Univ Witwatersrand, Fac Hlth Sci, Chris Hani Baragwanath Acad Hosp, Dept Anat Pathol,Natl Hlth Lab Serv, Johannesburg, South Africa; [MacKinnon, Diane; Rowe, Biance] Univ Witwatersrand, Fac Hlth Sci, Chris Hani Baragwanath Acad Hosp, Dept Paediat Haematol & Oncol, Johannesburg, South Africa; [Perner, Yvonne] Univ Witwatersrand, Fac Hlth Sci, Charlotte Maxeke Johannesburg Acad Hosp, Dept Anat Pathol,Natl Hlth Lab Serv, Johannesburg, South Africa	Padayachee, RS (reprint author), POB 769 Morningside, ZA-2057 Johannesburg, South Africa.	rushen.padayachee@nhls.ac.za			SATBAT/FCI [3U2RTW007370-05S1]	We sincerely acknowledge our patients and staff at CHBAH. Mr E. Liebenberg provided assistance with photography. Sugeshnee Pather was supported by SATBAT/FCI (grant number 3U2RTW007370-05S1).	Bazzeh F, 2010, LEUKEMIA LYMPHOMA, V51, P2198, DOI 10.3109/10428194.2010.525724; Bollard CM, 2013, PEDIATR BLOOD CANCER, V60, P979, DOI 10.1002/pbc.24416; Cairo MS, 2005, PEDIATR BLOOD CANCER, V45, P753, DOI 10.1002/pbc.20342; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Davidson A, 2010, CME, V28, P337; Davidson A, 2014, J PEDIAT HEMATOL ONC, V36, P111, DOI 10.1097/MPH.0b013e31829cdd49; Engel M, 2000, J CLIN PATHOL, V53, P182, DOI 10.1136/jcp.53.3.182; Goedhals J, 2014, S AFR J CHILD HEALTH, V8, P39, DOI 10.7196/SAJCH.613; Gross Thomas G, 2007, Curr Oncol Rep, V9, P459, DOI 10.1007/s11912-007-0064-6; Mittal P, 2006, INDIAN PEDIATR, V43, P1088; Patel M, 2011, ADV HEMATOL, V6; Pather S, 2013, ANN DIAGN PATHOL, V17, P80, DOI 10.1016/j.anndiagpath.2012.08.005; Raphael M., 2008, WHO CLASSIFICATION T, P340; Shankar A, 2012, BRIT J HAEMATOL, V159, P288, DOI 10.1111/bjh.12055; Shukla Neerav N, 2006, Curr Oncol Rep, V8, P387, DOI 10.1007/s11912-006-0062-0; Stefan DC, 2011, PEDIATR BLOOD CANCER, V56, P77, DOI 10.1002/pbc.22672; Stefan DC, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-19; Stefan DC, 2013, TRANSFUS APHER SCI, V49, P144, DOI 10.1016/j.transci.2013.07.016; Stefan DC, 2013, J PEDIAT HEMATOL ONC, V35, P590, DOI 10.1097/MPH.0b013e3182913e6a; Stein H, 2008, WHO CLASSIFICATION T, P326; Trehan A, 2013, J PEDIAT HEMATOL ONC, V35, P174, DOI 10.1097/MPH.0b013e318271f587; Vaubell JI, 2014, INT J SURG PATHOL, V22, P607, DOI 10.1177/1066896914531815; Weitzman S, 2002, CURR ONCOL REP, V4, P108	23	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						51	57		10.1016/j.anndiagpath.2017.11.006			7	Pathology	Pathology	GB7ZR	WOS:000429294200010	29566948				2019-10-28	
J	Kravtsov, O; Hunt, B; Peterson, J; Carrillo, L; Bonneau, P; Giorgadze, T				Kravtsov, Oleksandr; Hunt, Bryan; Peterson, Jess; Carrillo, Luis; Bonneau, Peter; Giorgadze, Tamara			Secretory carcinoma of the parotid with adenoid cystic carcinoma cytological pattern: A cytological-pathological correlation with literature review	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							SALIVARY-GLAND; DIAGNOSIS	Secretory carcinoma (SC) is a rare low-grade malignant tumor, defined by ETV6-NTRK3 fusion, identifiable by FISH. We describe a case in a 58-year-old male with a painless slowly growing 16 mm palpable mass within left superficial parotid. FNA of the mass showed highly cellular specimen with moderate to large pleomorphic cells with round to ovoid nuclei with vesicular chromatin and distinct nucleoli. Cells had moderate to large amounts of vacuolated cytoplasm. Abundant globular metachromatic material, resembling that of adenoid cystic carcinoma, was noted. This material was seen extracellularly and intracytoplasmic, and stained magenta on Diff-Quik and blue-green on Papanicolaou-stained slides. The tumor cells on a cell block preparation were positive for Mammaglobin and S-100. PAS stain highlighted extracellular and intracytoplasmic secretions. FNA diagnosis was "Positive for Malignancy. Morphologic features most compatible with Mammary Analogue Secretory Carcinoma". ETV6 FISH studies as well as histologic examination of excised tumor confirmed the diagnosis. Finding the globular metachromatic material in SC, that is generally seen in adenoid cystic carcinoma, broadens a cytological differential diagnosis of both entities. Cytological differential diagnosis, clinical, histological, immunohistochemical, and molecular features of secretory carcinomas are discussed in this study.	[Kravtsov, Oleksandr; Hunt, Bryan; Carrillo, Luis; Giorgadze, Tamara] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Peterson, Jess] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA; [Bonneau, Peter] San Antonio Mil Med Ctr, Pathol Serv, 3551 Roger Brooke Dr JBSA, Ft Sam Houston, TX 78234 USA; [Bonneau, Peter] San Antonio Mil Med Ctr, Area Lab Serv, 3551 Roger Brooke Dr JBSA, Ft Sam Houston, TX 78234 USA	Kravtsov, O (reprint author), Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	okravtsov@mcw.edu; bhunt@mcw.edu; Peterson.Jess@mayo.edu; lucarrillo@mcw.edu; peter.n.bonneau.mil@mail.mil; tgiorgadze@mcw.edu					Bajaj J, 2014, ACTA CYTOL, V58, P501, DOI 10.1159/000368070; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Griffith CC, 2013, CANCER CYTOPATHOL, V121, P234, DOI 10.1002/cncy.21249; Kai K, 2017, ACTA CYTOL, V61, P469, DOI 10.1159/000477390; Kawahara A, 2015, CANCER CYTOPATHOL, V123, P603, DOI 10.1002/cncy.21594; Keisling M, 2014, INT J PEDIAT OTOR EX, V9, P163, DOI 10.1016/j.pedex.2014.09.003; Klijanienko J, 1997, DIAGN CYTOPATHOL, V17, P36, DOI 10.1002/(SICI)1097-0339(199707)17:1<36::AID-DC7>3.0.CO;2-N; Kralik JM, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-19; MCDIVITT RW, 1966, J AMER MED ASSOC, V195, P388, DOI 10.1001/jama.195.5.388; Samulski TD, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.139726; Schwartz LE, 2013, HEAD NECK PATHOL, V7, P311, DOI 10.1007/s12105-013-0442-3; Sethi R, 2014, LARYNGOSCOPE, V124, P188, DOI 10.1002/lary.24254; Skalova A, 2017, WHO CLASSIFICATION H, P177; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc	18	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	APR	2018	33						58	61		10.1016/j.anndiagpath.2017.12.006			4	Pathology	Pathology	GB7ZR	WOS:000429294200011	29566949				2019-10-28	
J	Gu, HY; Sui, SF; Cui, XJ; Han, B; Zhang, CY; Qi, M; Li, CC; Liu, ZY				Gu, Haiyan; Sui, Shaofeng; Cui, Xiujie; Han, Bo; Zhang, Chunyan; Qi, Mei; Li, Congcong; Liu, Zhiyan			Thyroid carcinoma producing -human chorionic gonadotropin shows different clinical behavior	PATHOLOGY INTERNATIONAL			English	Article						clinicopathological feature; columnar cell variant; papillary thyroid carcinoma; paraneoplastic hyperthyroidism; beta-hCG	COLUMNAR CELL VARIANT; PAPILLARY CARCINOMA; HYPERTROPHIC OSTEOARTHROPATHY; CDX2 EXPRESSION; CANCER; SERUM; HCG	Columnar cell variant of papillary thyroid carcinoma (CCV-PTC) is an unusual neoplasm, the clinical behavior of which mainly depends on the encapsulation or infiltration. Patients with extensive extrathyroidal extension usually have an aggressive biological behavior. This study confirmed that beta-human chorionic gonadotropin (-hCG) secreting invasive CCV-PTC has good prognosis comparing with a cohort of follicular cell differentiated thyroid carcinoma. On the contrary, positive immunoreaction with -hCG was proved in three anaplastic thyroid carcinoma patients showing aggressive clinical courses. The clinicopathologic characteristics of CCV-PTC and the paraneoplastic syndromes in follicular cell differentiated thyroid carcinoma were further summarized using literature review.	[Gu, Haiyan; Cui, Xiujie; Han, Bo; Zhang, Chunyan; Li, Congcong; Liu, Zhiyan] Shandong Univ, Dept Pathol, Sch Basic Med Sci, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Gu, Haiyan] Qingdao Univ, Dept Pathol, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China; [Sui, Shaofeng] Shandong Ctr Dis Control & Prevent, Inst Occupat & Environm Hlth, 16992 Jingshi Rd, Jinan 250014, Shandong, Peoples R China; [Cui, Xiujie] Shandong Univ, Dept Pathogeny Biol, Sch Basic Med Sci, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Han, Bo; Qi, Mei; Liu, Zhiyan] Shandong Univ, Dept Pathol, Qilu Hosp, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Chunyan] Jining Med Coll, Dept Pathol, Affiliated Hosp, 89 Guhuai Rd, Jining 272029, Shandong, Peoples R China; [Li, Congcong] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Obstet & Gynecol, Shanghai 200120, Peoples R China	Liu, ZY (reprint author), Shandong Univ, Dept Pathol, Sch Basic Med Sci, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	zhiyanliu@sdu.edu.cn	Liu, Zhiyan/C-5298-2016	Liu, Zhiyan/0000-0001-9668-7756	Ministry of Education [2013693]	This research was supported by Research start fund of the returnees of the Ministry of Education [grant number 2013693].	Alikhan M, 2015, CLIN CHIM ACTA, V438, P181, DOI 10.1016/j.cca.2014.08.026; Attarian H, 2007, EUR NEUROL, V58, P182, DOI 10.1159/000104721; Baloch ZW, 2011, ENDOCR PATHOL, V22, P200, DOI 10.1007/s12022-011-9174-7; Becker N, 2014, THYROID, V24, P319, DOI 10.1089/thy.2013.0117; Beier Fabian, 2010, J Med Case Rep, V4, P110, DOI 10.1186/1752-1947-4-110; Bongiovanni M, 2013, THYROID, V23, P1498, DOI 10.1089/thy.2013.0146; Chen JH, 2011, MODERN PATHOL, V24, P739, DOI 10.1038/modpathol.2011.2; Cole LA, 2012, AM J CANCER RES, V2, P22; Dao BD, 2015, J INVEST MED HIGH IM, V3, DOI 10.1177/2324709615603723; Demirtas E, 2007, OBSTET GYNECOL SURV, V62, P675, DOI 10.1097/01.ogx.0000281557.04956.61; Enriquez ML, 2012, AM J CLIN PATHOL, V137, P722, DOI 10.1309/AJCPXE3PUBWVZCGZ; EVANS HL, 1986, AM J CLIN PATHOL, V85, P77, DOI 10.1093/ajcp/85.1.77; Fujita M, 2008, RHEUMATOL INT, V29, P203, DOI 10.1007/s00296-008-0642-4; Gehring C, 2016, BREAST, V26, P135, DOI 10.1016/j.breast.2016.01.010; Gratwicke JP, 2014, J NEUROL SCI, V341, P183, DOI 10.1016/j.jns.2014.03.042; Hershman JM, 2004, BEST PRACT RES CL EN, V18, P249, DOI 10.1016/j.beem.2004.03.010; Hughes Emily, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-216998; Iguchi H, 1998, J CLIN ENDOCR METAB, V83, P2653, DOI 10.1210/jc.83.8.2653; Ikeda T, 2012, RHEUMATOL INT, V32, P959, DOI 10.1007/s00296-010-1763-0; Kalliabakos Dimitrios, 2008, Cases J, V1, P289, DOI 10.1186/1757-1626-1-289; Kopec-Medrek Magdalena, 2010, Wiad Lek, V63, P24; KURODA Y, 1993, J NEUROL SCI, V120, P29, DOI 10.1016/0022-510X(93)90020-Y; Lee JH, 2005, CLIN RHEUMATOL, V24, P437, DOI 10.1007/s10067-004-0979-3; Lloyd RV, 2017, PATHOLOGY GENETICS T; Lombardo GA, 2016, ACTA DERM-VENEREOL, V96, P414, DOI 10.2340/00015555-2219; Nagashima T, 2009, RHEUMATOL INT, V29, P1261, DOI 10.1007/s00296-009-0858-y; Nakayama R, 2012, THYROID, V22, P200, DOI 10.1089/thy.2011.0258; Oosting SF, 2010, ANN ONCOL, V21, P104, DOI 10.1093/annonc/mdp265; Pierru A, 2013, J FR OPHTALMOL, V36, pE207, DOI 10.1016/j.jfo.2012.12.009; Portela Rafael Antonio, 2015, Ear Nose Throat J, V94, pE43; Rosai J, 2014, TUMORS THYROID PARAT; RVOR Lloyd, 2017, WHO CLASSIFICATION T; Sen A, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.143303; Shah M, 2013, ENDOCR PRACT, V19, pE154, DOI 10.4158/EP13145.CR; Shi XG, 2016, J CLIN ENDOCR METAB, V101, P263, DOI 10.1210/jc.2015-2917; Sola D, 2013, BRIT J HOSP MED, V74, P530, DOI 10.12968/hmed.2013.74.9.530; Sujoy V, 2013, THYROID, V23, P714, DOI 10.1089/thy.2012.0455; TABATA M, 1994, INTERNAL MED, V33, P41, DOI 10.2169/internalmedicine.33.41; Taconet S, 2016, INT J SURG PATHOL, V24, P336, DOI 10.1177/1066896915626281; Tahmasebi FC, 2013, VIRCHOWS ARCH, V462, P473, DOI 10.1007/s00428-013-1394-4; Talsania Narmita, 2010, Dermatol Online J, V16, P8; Tavarelli M, 2015, EUR THYROID J, V4, P266, DOI 10.1159/000437052; Tranchida P, 2012, DIAGN CYTOPATHOL, V40, pE4, DOI 10.1002/dc.21616; Vassilatou Evangeline, 2006, Hormones (Athens), V5, P303; VASSILOPOULOUSELLIN R, 1992, AM J CLIN ONCOL-CANC, V15, P273; VICO P, 1992, J RHEUMATOL, V19, P1153; Wenig BN, 1998, CANCER, V82, P740, DOI 10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.3.CO;2-T; Yazdi S, 2010, CLIN EXP DERMATOL, V35, P152, DOI 10.1111/j.1365-2230.2009.03211.x	48	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					207	213		10.1111/pin.12639			7	Pathology	Pathology	GB4CC	WOS:000429006900001	29446856				2019-10-28	
J	Fujii-Nishimura, Y; Yamazaki, K; Masugi, Y; Douguchi, J; Kurebayashi, Y; Kubota, N; Ojima, H; Kitago, M; Shinoda, M; Hashiguchi, A; Sakamoto, M				Fujii-Nishimura, Yoko; Yamazaki, Ken; Masugi, Yohei; Douguchi, Junya; Kurebayashi, Yutaka; Kubota, Naoto; Ojima, Hidenori; Kitago, Minoru; Shinoda, Masahiro; Hashiguchi, Akinori; Sakamoto, Michiie			Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells	PATHOLOGY INTERNATIONAL			English	Article						focal differentiation; mesenchymal-epithelial transition; perineural invasion; pancreatic ductal adenocarcinoma; Schwann cells	E-CADHERIN EXPRESSION; INDEPENDENT PROGNOSTIC-FACTOR; TUMOR-BUDDING PHENOTYPE; DUCTAL ADENOCARCINOMA; MORPHOLOGICAL HETEROGENEITY; DISTANT METASTASIS; POOR-PROGNOSIS; MOUSE MODELS; EMT; CARCINOMAS	Epithelial-mesenchymal transition (EMT) promotes invasion and metastasis of pancreatic ductal adenocarcinoma (PDAC). However, the importance of its reverse process, mesenchymal-epithelial transition (MET), for PDAC remains unclear. We aimed to characterize the histological finding focal differentiation in PDAC at perineural invasion sites in the context of MET and to investigate the role of Schwann cells in inducing tumor MET. Tumor differentiation and immunohistochemical expressions of E-cadherin, SMAD3, and vimentin at perineural invasion sites were examined in 168 PDAC tissues. Four PDAC cell lines were co-cultured with Schwann cells to investigate cell morphology, motility, or EMT-related markers using immunocytochemistry and quantitative PCR. Of 168 tumors, 124 (74%) showed focal differentiation with enhanced E-cadherin membrane expression (P<0.001) and decreased nuclear accumulation of SMAD3 (P<0.001). Among 115 PDACs harboring grade 1/2 tumor, tumors with focal differentiation showed worse survival compared to those without focal differentiation (P=0.019). PDAC cells co-cultured with Schwann cells demonstrated a sheet-like appearance, increased E-cadherin expression, decreased expressions of SMAD3 and vimentin, and reduced cell motility. In conclusion, MET-like change is induced by Schwann cells, suggesting that Schwann cells contribute to PDAC colonization in pancreatic nerves through activating the MET machinery inside tumor cells in the pancreatic tumor microenvironment.	[Fujii-Nishimura, Yoko; Yamazaki, Ken; Masugi, Yohei; Douguchi, Junya; Kurebayashi, Yutaka; Kubota, Naoto; Ojima, Hidenori; Hashiguchi, Akinori; Sakamoto, Michiie] Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Kitago, Minoru; Shinoda, Masahiro] Keio Univ, Dept Surg, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan	Sakamoto, M (reprint author), Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	msakamot@z5.keio.jp		Yamazaki, Ken/0000-0002-7220-7479			Adsay NV, 2005, AM J SURG PATHOL, V29, P724, DOI 10.1097/01.pas.0000163360.40357.f1; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bosman F.T., 2010, WHO CLASSIFICATION T, P281; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Galvan JA, 2015, BRIT J CANCER, V112, P1944, DOI 10.1038/bjc.2015.177; Hamada S, 2016, DIGEST DIS SCI, V61, P1561, DOI 10.1007/s10620-015-4001-5; Hanoun M, 2015, NEURON, V86, P360, DOI 10.1016/j.neuron.2015.01.026; Hibi T, 2009, CLIN CANCER RES, V15, P2864, DOI 10.1158/1078-0432.CCR-08-2946; Hruban R., 2007, AFIP ATLAS TUMOR PAT, P111; Imai T, 2004, HUM PATHOL, V35, P1469, DOI 10.1016/j.humpath.2004.09.014; Jang TJ, 2016, PATHOL RES PRACT, V212, P113, DOI 10.1016/j.prp.2015.12.003; Karamitopoulou E, 2013, EUR J CANCER, V49, P1032, DOI 10.1016/j.ejca.2012.10.022; Karamitopoulou E, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-311; Koide N, 2006, CLIN CANCER RES, V12, P2419, DOI 10.1158/1078-0432.CCR-05-1852; Koulouris AI, 2017, DIGEST DIS SCI, V62, P861, DOI 10.1007/s10620-017-4488-z; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Liao JD, 2007, HISTOL HISTOPATHOL, V22, P661, DOI 10.14670/HH-22.661; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Masugi Y, 2015, LAB INVEST, V95, P308, DOI 10.1038/labinvest.2014.166; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; Matsuzaki K, 2011, CARCINOGENESIS, V32, P1578, DOI 10.1093/carcin/bgr172; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; O'Connor K, 2015, AM J SURG PATHOL, V39, P472, DOI 10.1097/PAS.0000000000000333; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902; Schorn S, 2017, SURG ONCOL, V26, P105, DOI 10.1016/j.suronc.2017.01.007; Shan T, 2017, INT J ONCOL, V50, P121, DOI 10.3892/ijo.2016.3779; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shimada K, 2011, PANCREAS, V40, P464, DOI 10.1097/MPA.0b013e31820b5d37; Shimamura T, 2003, J CLIN ONCOL, V21, P659, DOI 10.1200/JCO.2003.06.179; Sobin LH, 2016, TNM CLASSIFICATION M; Society JP., 2011, CLASS PANCR CARC, P1; Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483; Takano S, 2016, GENE DEV, V30, P233, DOI [10.1101/gad.263327.115, 10.1101/gad.263327]; Verbeke C, 2016, PANCREATOLOGY, V16, P295, DOI 10.1016/j.pan.2016.02.004; Wartenberg M, 2015, ONCOTARGET, V6, P4190, DOI 10.18632/oncotarget.2775; Yamazaki K, 2014, LAB INVEST, V94, P683, DOI 10.1038/labinvest.2014.53; Yates CC, 2007, BRIT J CANCER, V96, P1246, DOI 10.1038/sj.bjc.6603700	39	4	4	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					214	223		10.1111/pin.12641			10	Pathology	Pathology	GB4CC	WOS:000429006900002	29457853				2019-10-28	
J	Dai, T; Dai, YC; Murata, Y; Husni, RE; Nakano, N; Sakashita, S; Noguchi, M				Dai, Tomoko; Dai, Yuichi; Murata, Yoshihiko; Husni, Ryan Edbert; Nakano, Noriyuki; Sakashita, Shingo; Noguchi, Masayuki			The prognostic significance of N-myc downregulated gene 1 in lung adenocarcinoma	PATHOLOGY INTERNATIONAL			English	Article						c-Myc; immunohistochemistry; lung adenocarcinoma; NDRG1	C-MYC; PROSTATE-CANCER; HISTOLOGIC TYPE; BREAST-CANCER; NDRG1 GENE; OPEN-LABEL; ANGIOGENESIS; CAP43/NDRG1/DRG-1; OVEREXPRESSION; TRANSCRIPTION	It has been reported that N-myc downstream regulated gene 1 (NDRG1) is related to the prognosis of non-small cell lung cancer (NSCLC), and associated with c-Myc degradation in NSCLC cell lines. However, the relationship of NDRG1 to prognosis or c-Myc expression in lung adenocarcinoma has not been well clarified. The present study was designed to investigate the prognostic significance of NDRG1 and/or c-Myc expression in lung adenocarcinoma using immunohistochemistry with a tissue microarray. We examined 184 lung adenocarcinomas and observed low expression of NDRG1 in adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA), whereas high expression of NDRG1 was seen in invasive adenocarcinoma. Each of the clinicopathological features except age was significantly correlated with NDRG1 expression. Kaplan-Meier curves indicated that high expression of NDRG1 was significantly correlated with poor prognosis in comparison with low expression (log-rank, P<0.001). Univariate and multivariate analyses indicated that vascular invasion (P=0.012), lymphatic permeation (P=0.038), and NDRG1 expression (P=0.026) were independent prognostic factors. Expression of NDRG1 and positivity for c-Myc were significantly correlated (P=0.005). These findings indicate that NDRG1 expression is associated with both prognosis and c-Myc expression in lung adenocarcinoma.	[Dai, Tomoko; Husni, Ryan Edbert] Univ Tsukuba, Doctoral Program Biomed Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Dai, Yuichi] Tsukuba Mem Hosp, Diagnost Pathol, Tsukuba, Ibaraki, Japan; [Murata, Yoshihiko; Nakano, Noriyuki; Sakashita, Shingo; Noguchi, Masayuki] Univ Tsukuba, Dept Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan	Noguchi, M (reprint author), Univ Tsukuba, Dept Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nmasayuk@md.tsukuba.ac.jp					Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P591, DOI 10.1007/s10549-010-1028-3; Azuma K, 2012, J THORAC ONCOL, V7, P779, DOI 10.1097/JTO.0b013e31824c92b4; Bae DH, 2013, J CLIN PATHOL, V66, P911, DOI 10.1136/jclinpath-2013-201692; Bandyopadhyay S, 2004, ONCOGENE, V23, P5675, DOI 10.1038/sj.onc.1207734; Brierley J. D., 2016, TNM CLASSIFICATION M; Cangul H, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-27; Chua MS, 2007, MODERN PATHOL, V20, P76, DOI 10.1038/modpathol.3800711; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Hida T, 2017, LANCET, V390, P29, DOI 10.1016/S0140-6736(17)30565-2; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Li J, 2003, MOL CELL BIOCHEM, V250, P91, DOI 10.1023/A:1024918328162; Maruyama Y, 2006, CANCER RES, V66, P6233, DOI 10.1158/0008-5472.CAN-06-0183; Menezes SV, 2017, J BIOL CHEM, V292, P12772, DOI 10.1074/jbc.R117.776393; Minami Y, 2005, LUNG CANCER, V48, P339, DOI 10.1016/j.lungcan.2004.11.016; Nishio S, 2008, CANCER LETT, V264, P36, DOI 10.1016/j.canlet.2008.01.020; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Rubin MA, 2002, AM J SURG PATHOL, V26, P312, DOI 10.1097/00000478-200203000-00004; Salnikow K, 2008, CARCINOGENESIS, V29, P1493, DOI 10.1093/carcin/bgn088; Seo AN, 2014, BRIT J CANCER, V110, P2688, DOI 10.1038/bjc.2014.218; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shi JX, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002162; Soria JC, 2017, LANCET, V389, P917, DOI 10.1016/S0140-6736(17)30123-X; Torhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1; Travis WD, 2015, WHO CLASSIFICATION T; Vinayanuwattikun C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31628; Volm M, 1998, BRIT J CANCER, V77, P663, DOI 10.1038/bjc.1998.106; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang YF, 2017, CANCER LETT, V401, P53, DOI 10.1016/j.canlet.2017.04.031; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zhang J, 2008, GENE, V417, P5, DOI 10.1016/j.gene.2008.03.002	36	1	1	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					224	231		10.1111/pin.12644			8	Pathology	Pathology	GB4CC	WOS:000429006900003	29431240				2019-10-28	
J	Matsumoto, T; Nagashio, R; Ryuge, S; Igawa, S; Kobayashi, M; Fukuda, E; Goshima, N; Ichinoe, M; Jiang, SX; Satoh, Y; Masuda, N; Murakumo, Y; Saegusa, M; Sato, Y				Matsumoto, Toshihide; Nagashio, Ryo; Ryuge, Shinichiro; Igawa, Satoshi; Kobayashi, Makoto; Fukuda, Eriko; Goshima, Naoki; Ichinoe, Masaaki; Jiang, Shi-Xu; Satoh, Yukitoshi; Masuda, Noriyuki; Murakumo, Yoshiki; Saegusa, Makoto; Sato, Yuichi			Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma	PATHOLOGY INTERNATIONAL			English	Article						adenocarcinoma; basigin; immunohistochemistry; prognostic marker; random immunization method	SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; LUNG-CANCER; EMMPRIN; CD147; BIOMARKER; LOCALIZATION; GLYCOPROTEIN; MATRIPTASE; INVASION	We established the KU-Lu-8 monoclonal antibody (MoAb) using a lung cancer cell line as an antigen and a random immunization method. The KU-Lu-8 MoAb recognizes basigin (BSG), which is a transmembrane-type glycoprotein that is strongly expressed on the cell membranes of lung cancer cells. This study aimed to clarify the relationships between BSG expression and clinicopathological parameters and determine the prognostic significance of BSG expression in pulmonary adenocarcinoma (AC) patients. To evaluate the significance of BSG expression in lung cancer, we immunohistochemically analyzed 113 surgically resected pulmonary adenocarcinomas, and the associations between BSG expression and various clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to investigate the effects of BSG expression on survival. Clinicopathologically, BSG expression was significantly associated with tumor differentiation, vascular invasion, lymphatic invasion, and a poor prognosis. In particular, BSG expression was significantly correlated with poorer survival in patients with stage I AC. The high BSG expression group (compared with the low BSG expression group) exhibited adjusted hazard ratios for mortality of 4.694. BSG expression is indicative of a poor prognosis in AC patients, particularly in those with stage I disease.	[Matsumoto, Toshihide; Ichinoe, Masaaki; Jiang, Shi-Xu; Murakumo, Yoshiki; Saegusa, Makoto] Kitasato Univ, Sch Med, Dept Pathol, Sagamihara, Kanagawa, Japan; [Nagashio, Ryo; Kobayashi, Makoto; Sato, Yuichi] Kitasato Univ, Dept Appl Tumor Pathol, Grad Sch Med Sci, Sagamihara, Kanagawa, Japan; [Ryuge, Shinichiro; Igawa, Satoshi; Masuda, Noriyuki] Kitasato Univ, Dept Resp Med, Sch Med, Sagamihara, Kanagawa, Japan; [Fukuda, Eriko; Goshima, Naoki] Natl Inst Adv Ind Sci & Technol, Div Quantitat Prote Team, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan; [Satoh, Yukitoshi] Kitasato Univ, Dept Thorac & Cardiovasc Surg, Sch Med, Sagamihara, Kanagawa, Japan	Sato, Y (reprint author), Kitasato Univ, Dept Appl Tumor Pathol, Grad Sch Med Sci, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520373, Japan.	yuichi@med.kitasato-u.ac.jp	直樹, 五島/M-8363-2018; Fukuda, Eriko/M-2854-2018	Fukuda, Eriko/0000-0003-3086-3707; Kobayashi, Makoto/0000-0001-7176-7207	School of Allied Health Sciences, Kitasato University [2014-1002, 2017-1027]; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26460441, 23590414]	This study was funded in part by Grants-in-Aid for Scientific Research C (23590414 and 26460441) from the Japan Society for the Promotion of Science (to Y. Sato) and Research Projects (No. 2017-1027 and No. 2014-1002) from the School of Allied Health Sciences, Kitasato University (to Y. Sato).	Akishima-Fukasawa Y, 2010, AM J CLIN PATHOL, V134, P71, DOI 10.1309/AJCPRJP39MIDSGBH; BISWAS C, 1995, CANCER RES, V55, P434; Bovenzi CD, 2015, BIOMED RES INT, DOI 10.1155/2015/242437; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Chen X, 2006, CANCER RES, V66, P11323, DOI 10.1158/0008-5472.CAN-06-1536; Cheng MF, 2006, DIS ESOPHAGUS, V19, P482, DOI 10.1111/j.1442-2050.2006.00613.x; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Hakuma N, 2007, ONCOLOGY-BASEL, V72, P197, DOI 10.1159/000112826; HIROHASHI S, 1984, GANN, V75, P485; Jiang SX, 2004, MODERN PATHOL, V17, P222, DOI 10.1038/modpathol.3800038; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kobayashi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033952; Kong XY, 2017, MOL NEUROBIOL, V54, P1568, DOI 10.1007/s12035-016-9894-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Marionnet C, 2003, ONCOGENE, V22, P3500, DOI 10.1038/sj.onc.1206571; Matsumoto T, 2012, INT J ONCOL, V74, P405; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Nitori N, 2005, CLIN CANCER RES, V11, P2531, DOI 10.1158/1078-0432.CCR-04-0866; Riethdorf S, 2006, INT J CANCER, V119, P1800, DOI 10.1002/ijc.22062; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sienel W, 2008, MODERN PATHOL, V21, P1130, DOI 10.1038/modpathol.2008.102; Sun JX, 2001, CANCER RES, V61, P2276; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang Y, 2006, MOL CANCER RES, V4, P371, DOI 10.1158/1541-7786; Travis WD, 2015, WHO CLASSIFICATION T; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Tsai WC, 2006, HISTOPATHOLOGY, V49, P388, DOI 10.1111/j.1365-2559.2006.02516.x; van Rens MTM, 2000, CHEST, V117, P374, DOI 10.1378/chest.117.2.374; Xu XY, 2013, PATHOL RES PRACT, V209, P345, DOI 10.1016/j.prp.2013.02.015; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Zheng HC, 2006, BRIT J CANCER, V95, P1371, DOI 10.1038/sj.bjc.6603425; Zhong XW, 2013, ANN SURG ONCOL, V20, P1044, DOI 10.1245/s10434-012-2377-4	34	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					232	240		10.1111/pin.12646			9	Pathology	Pathology	GB4CC	WOS:000429006900004	29431238				2019-10-28	
J	Ushida, K; Asai, N; Uchiyama, K; Enomoto, A; Takahashi, M				Ushida, Kaori; Asai, Naoya; Uchiyama, Kozo; Enomoto, Atsushi; Takahashi, Masahide			Development of a method to preliminarily embed tissue samples using low melting temperature fish gelatin before sectioning: A technical note	PATHOLOGY INTERNATIONAL			English	Article						low melting temperature gelatin; paraffin embedding; preliminary embedding; tissue sample preparation		Embedding of tissue samples that maintains a desired orientation is critical for preparing sections suitable for diagnosis and study objectives. Methods to prepare tissue sections include: (i) paraffin embedding or snap-freezing followed by microtome or cryostat sectioning; and (ii) agarose embedding followed by cutting on a vibrating microslicer. Although these methods are useful for routine laboratory work, preparation of small and fragile tissues such as mouse organs, small human biopsy samples, and cultured floating spheres is difficult and requires special skills. In particular, tissue specimen orientation can be lost during embedding in molds and subsequent sectioning. Here, we developed a method using low melting temperature (LM) gelatin either alone or mixed with agarose to preliminarily embed collected tissues that are either prefixed or unfixed, followed by conventional fixation, paraffin embedding, freezing, and sectioning. The advantage of the method is that the LM gelatin and its mixture with agarose can be handled at room temperature but quickly hardens at 4 degrees C, which allows embedding, trimming, and arranging of small and fragile tissues in a desired orientation and are compatible with traditional stainings. Thus, this method can have various laboratory applications and can be modified according to the needs of each laboratory.	[Ushida, Kaori; Asai, Naoya; Uchiyama, Kozo; Enomoto, Atsushi; Takahashi, Masahide] Nagoya Univ, Dept Pathol, Grad Sch Med, Nagoya, Aichi, Japan; [Ushida, Kaori; Uchiyama, Kozo] Nagoya Univ, Ctr Tech, Nagoya, Aichi, Japan	Ushida, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	utchan@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Enomoto, Atsushi/I-7272-2014	Enomoto, Atsushi/0000-0002-9206-6116	 [25930006]	We gratefully thank Reika Hatano, Shoma Tsubota, and Kenji Kadomatsu (Nagoya University) for providing cultured neurospheres. We also thank Masato Asai (Institute for Developmental Research, Aichi Human Service Center) and Daisuke Kuga (Anjo Kosei Hospital) for providing the images of mouse intestinal tissues. This work was supported by a Grant-in-Aid for Encouragement of Scientists (25930006 to K.U.) commissioned by the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Aoki S, 2015, J NEUROSCI, V35, P9424, DOI 10.1523/JNEUROSCI.0490-15.2015; BLEWITT ES, 1982, J CLIN PATHOL, V35, P365, DOI 10.1136/jcp.35.3.365-b; Brown DA, 2005, J BIOMED MATER RES B, V72B, P79, DOI 10.1002/jbm.b.30116; ELLIOTT MD, 1975, MED LAB TECHNOL, V32, P105; GHASSEMIFAR R, 1992, BIOTECH HISTOCHEM, V67, P363, DOI 10.3109/10520299209110051; Haug IJ, 2004, FOOD HYDROCOLLOID, V18, P203, DOI 10.1016/S0268-005X(03)00065-1; Jones MV, 2007, BIOTECHNIQUES, V42, P569, DOI 10.2144/000112456; Karim AA, 2009, FOOD HYDROCOLLOID, V23, P563, DOI 10.1016/j.foodhyd.2008.07.002; Kuga D, 2017, J HISTOCHEM CYTOCHEM, V65, P347, DOI 10.1369/0022155417702586; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Zwemer RL, 1933, ANAT REC, V57, P41, DOI 10.1002/ar.1090570106	11	0	0	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					241	245		10.1111/pin.12652			5	Pathology	Pathology	GB4CC	WOS:000429006900005	29465759				2019-10-28	
J	Yasuoka, H; Nakamura, Y; Yoshida, K; Shimo, T; Tori, M; Matsui, Y; Sakamaki, Y; Tsujimoto, M				Yasuoka, Hironao; Nakamura, Yasushi; Yoshida, Ken-ichi; Shimo, Toshiro; Tori, Masayuki; Matsui, Yuuki; Sakamaki, Yasushi; Tsujimoto, Masahiko			A rare case of ectopic papillary thyroid carcinoma transformed into squamous cell carcinoma	PATHOLOGY INTERNATIONAL			English	Article						BRAF; ectopic; papillary thyroid carcinoma; PAX-8; squamous cell carcinoma	BRAF MUTATIONS; LUNG-CANCER; PAX8; TUMORS; FEATURES	A rare case of a metastatic ectopic papillary thyroid carcinoma (PTC) of the lung that transformed into a squamous cell carcinoma (SCC) that resembles pulmonary SCC is reported. A subcutaneous ectopic PTC in the left anterior neck area, together with a normal thyroid gland, were excised. The ectopic PTC showed thyroglobulin, TTF-1 and PAX-8 immunoreactivity and a BRAF V600E mutation. During the post-operative follow-up period, a rapidly growing 2cm nodular lesion in the lower left lobe of the lung was detected. The lung tumor consisted of solid sheets and nests of squamous cells but without the nuclear features of PTC. Neither papillary nor follicular structures of cancer cells were identified. Carcinoma cells were positive for TTF-1, PAX-8, p40, CK14, and p63, while showing a high Ki-67 labeling index and a BRAF V600E mutation. These results support our interpretation of a PTC that originated from ectopic thyroid tissue in the left anterior neck and that developed a lung metastasis showing squamous cell differentiation.	[Yasuoka, Hironao; Tsujimoto, Masahiko] Osaka Police Hosp, Dept Diagnost Pathol, Osaka, Japan; [Nakamura, Yasushi] Osaka Cytopathol Lab, Dept Pathol, Osaka, Japan; [Yoshida, Ken-ichi] Natl Canc Ctr, Dept Pathol, Tokyo, Japan; [Yoshida, Ken-ichi] Natl Canc Ctr, Clin Labs, Tokyo, Japan; [Shimo, Toshiro; Tori, Masayuki] Osaka Police Hosp, Dept Endocrine Surg, Osaka, Japan; [Matsui, Yuuki; Sakamaki, Yasushi] Osaka Police Hosp, Dept Thorac Surg, Osaka, Japan	Yasuoka, H (reprint author), Osaka Police Hosp, Dept Pathol, Tennouji Ku, 10-31 Kitayama Cho, Osaka, Osaka, Japan.	hyasuoka@oph.gr.jp		Yoshida, Ken-ichi/0000-0002-1549-1514			Acosta AM, 2016, VIRCHOWS ARCH, V468, P239, DOI 10.1007/s00428-015-1875-8; Alhanafy AM, 2016, J CLIN DIAGN RES, V10, pED11, DOI 10.7860/JCDR/2016/16664.7263; Besic N, 2013, THYROID, V23, P709, DOI 10.1089/thy.2012.0252; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; Evans WD, 2012, BMJ CASE REP; Ito Y, 2012, J THROID RES, DOI 10.1155/2012/230283; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Kleer CG, 2000, MODERN PATHOL, V13, P742, DOI 10.1038/modpathol.3880129; Kobayashi M, 2011, ANTICANCER RES, V31, P4619; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Lianos G, 2013, G CHIR, V34, P114; LIVOLSI VA, 1978, AM J SURG PATHOL, V2, P133, DOI 10.1097/00000478-197806000-00002; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Noussios G, 2011, EUR J ENDOCRINOL, V165, P375, DOI 10.1530/EJE-11-0461; Patel Kepal N, 2006, Cancer Control, V13, P119; Ryan N, 2015, HEAD NECK-J SCI SPEC, V37, pE125, DOI 10.1002/hed.23936; Sevinc Ali Ibrahim, 2010, Am J Surg, V200, pe17, DOI 10.1016/j.amjsurg.2009.06.032; Suzuki A, 2015, ENDOCR J, V62, P991, DOI 10.1507/endocrj.EJ15-0226; Yasuoka H, 2017, BMC CLIN PATHOL, V17, DOI 10.1186/s12907-017-0048-x	20	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					246	250		10.1111/pin.12649			5	Pathology	Pathology	GB4CC	WOS:000429006900006	29451347				2019-10-28	
J	Sakakibara, A; Kohno, K; Kuroda, N; Yorita, K; Megahed, NA; Eladl, AE; Daroontum, T; Ishikawa, E; Suzuki, Y; Shimada, S; Nakaguro, M; Shimoyama, Y; Satou, A; Kato, S; Yatabe, Y; Asano, N; Nakamura, S				Sakakibara, Ayako; Kohno, Kei; Kuroda, Naoto; Yorita, Kenji; Megahed, Nirmeen A.; Eladl, Ahmed E.; Daroontum, Teerada; Ishikawa, Eri; Suzuki, Yuka; Shimada, Satoko; Nakaguro, Masato; Shimoyama, Yoshie; Satou, Akira; Kato, Seiichi; Yatabe, Yasushi; Asano, Naoko; Nakamura, Shigeo			Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: Two cases highlighting a broad diversity in the diagnostics	PATHOLOGY INTERNATIONAL			English	Article						anaplastic variant; classic Hodgkin lymphoma; diffuse large B-cell lymphoma; gray zone lymphoma; hallmark cell	CLASSICAL HODGKIN LYMPHOMA; GRAY ZONE LYMPHOMA; KIEL CLASSIFICATION; EXPRESSION; FEATURES; OUTCOMES	The anaplastic variant of diffuse large B-cell lymphoma (A-DLBCL) is morphologically defined but remains an enigmatic disease in its clinicopathologic distinctiveness. Here, we report two cases involving Japanese women aged 59 years, both with A-DLBCL with the hallmark cell appearance and both indistinguishable from common and giant cell-rich patterns, respectively, of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Case 1 was immunohistochemically positive for CD20, CD79a and OCT-2 but not for the other pan-B-cell markers, CD30 and ALK. Case 2 showed CD20 and CD30 positivity for 50% and 20% of tumor cells in addition to strong expression of p53 and MYC. Both were positive for fascin without Epstein-Barr virus association. Our cases provide additional support for the earlier reports that A-DLBCL exhibits clinicopathologic features distinct from ordinal diffuse large B-cell lymphoma (DLBCL), and documented its broader morphologic diversity than previously recognized. They also shed light on the unique feature of absent expression of pan-B-cell markers except for CD20 and CD79a, suggesting that A-DLBCL may biologically mimic a gray zone or intermediate lymphoma between DLBCL and classic Hodgkin lymphoma.	[Sakakibara, Ayako; Kohno, Kei; Megahed, Nirmeen A.; Eladl, Ahmed E.; Daroontum, Teerada; Ishikawa, Eri; Suzuki, Yuka; Shimada, Satoko; Nakaguro, Masato; Shimoyama, Yoshie; Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan; [Sakakibara, Ayako] Okazaki City Hosp, Dept Pathol, Okazaki, Aichi, Japan; [Kuroda, Naoto; Yorita, Kenji] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Japan; [Megahed, Nirmeen A.; Eladl, Ahmed E.] Mansoura Univ, Dept Pathol, Fac Med, Mansoura, Egypt; [Daroontum, Teerada] Chiang Mai Univ, Dept Pathol, Fac Med, Chiang Mai, Thailand; [Satou, Akira] Aichi Med Univ Hosp, Dept Surg Pathol, Nagakute, Aichi, Japan; [Kato, Seiichi; Yatabe, Yasushi] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagano, Japan; [Asano, Naoko] Nagano Prefectural Suzaka Hosp, Dept Clin Lab, Nagano, Japan	Kohno, K (reprint author), Nagoya Univ Hosp, Dept Pathol & Lab Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	skay77jp@yahoo.co.jp	YATABE, Yasushi/N-3588-2019; Yatabe, Yasushi/J-6461-2014; KATO, Seiichi/I-7298-2014; Nakamura, Shigeo/I-1571-2012	YATABE, Yasushi/0000-0003-1788-559X; Yatabe, Yasushi/0000-0003-1788-559X; Suzuki, Yuka/0000-0002-2288-7162; NAKAGURO, MASATO/0000-0001-6987-3043			Bakshi NA, 2007, ARCH PATHOL LAB MED, V131, P742; Carey CD, 2017, BLOOD, V130, P2420, DOI 10.1182/blood-2017-03-770719; Diebold J, 2002, LEUKEMIA LYMPHOMA, V43, P97, DOI 10.1080/10428190210173; Engelhard M, 1997, BLOOD, V89, P2291; Evens AM, 2015, AM J HEMATOL, V90, P778, DOI 10.1002/ajh.24082; Haralambieva E, 2000, BRIT J HAEMATOL, V109, P584, DOI 10.1046/j.1365-2141.2000.02045.x; Lai R, 2000, MODERN PATHOL, V13, P223, DOI 10.1038/modpathol.3880041; Li MY, 2017, AM J SURG PATHOL, V41, P1322, DOI 10.1097/PAS.0000000000000836; Miyoshi H, 2016, BLOOD, V128, P1374, DOI 10.1182/blood-2016-02-698936; Nakamura S, 1997, AM J SURG PATHOL, V21, P1420, DOI 10.1097/00000478-199712000-00004; NOORDUYN LA, 1994, J CLIN PATHOL, V47, P33, DOI 10.1136/jcp.47.1.33; Sarkozy C, 2017, HAEMATOLOGICA, V102, P150, DOI 10.3324/haematol.2016.152256; Shimada K, 2016, LEUKEMIA, V30, P1568, DOI 10.1038/leu.2016.67; Shimada K, 2009, LANCET ONCOL, V10, P895, DOI 10.1016/S1470-2045(09)70140-8; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tilly H, 1997, BLOOD, V90, P3727, DOI 10.1182/blood.V90.9.3727	17	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					251	255		10.1111/pin.12653			5	Pathology	Pathology	GB4CC	WOS:000429006900007	29479776				2019-10-28	
J	Miyasaka, C; Ishida, M; Ohe, C; Uemura, Y; Ando, Y; Fukui, T; Tsuta, K				Miyasaka, Chika; Ishida, Mitsuaki; Ohe, Chisato; Uemura, Yoshiko; Ando, Yugo; Fukui, Toshiro; Tsuta, Koji			Tubular adenomas with clear cell change in the colorectum: A case with four lesions and a review of the literature	PATHOLOGY INTERNATIONAL			English	Letter							ADENOCARCINOMA		[Miyasaka, Chika; Ishida, Mitsuaki; Ohe, Chisato; Uemura, Yoshiko; Tsuta, Koji] Kansai Med Univ, Dept Pathol & Lab Med, Hirakata, Osaka, Japan; [Ando, Yugo; Fukui, Toshiro] Kansai Med Univ, Dept Internal Med 3, Hirakata, Osaka, Japan	Miyasaka, C (reprint author), Kansai Med Univ, Dept Pathol & Lab Med, Hirakata, Osaka, Japan.			Ando, Yukio/0000-0001-7115-9105			Domoto H, 1999, HISTOPATHOLOGY, V34, P250; Eloy C, 2009, INT J SURG PATHOL, V17, P438, DOI 10.1177/1066896908319211; Gushima R, 2016, VIRCHOWS ARCH, V468, P169, DOI 10.1007/s00428-015-1870-0; Shi CJ, 2010, AM J SURG PATHOL, V34, P1344, DOI 10.1097/PAS.0b013e3181ec0810; Yao T., 2016, PATHOL CLIN MED, V34, P1072	5	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					256	258		10.1111/pin.12628			3	Pathology	Pathology	GB4CC	WOS:000429006900008	29330907				2019-10-28	
J	Murase, Y; Maeda, N; Katano, H; Tsuzuki, T				Murase, Yota; Maeda, Nagako; Katano, Harutaka; Tsuzuki, Toyonori			Fulminant adenovirus hepatitis with adenovirus-associated esophagitis complicating malignant lymphoma	PATHOLOGY INTERNATIONAL			English	Letter									[Murase, Yota; Tsuzuki, Toyonori] Aichi Med Univ Hosp, Dept Surg Pathol, 1-1 Yazakokarimata, Nagakute, Aichi, Japan; [Murase, Yota; Maeda, Nagako] Japanese Red Cross Nagoya Daini Hosp, Dept Pathol, 2-9 Myoken Cho, Nagoya, Aichi 4668650, Japan; [Katano, Harutaka] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan	Murase, Y (reprint author), Aichi Med Univ Hosp, Dept Surg Pathol, 1-1 Yazakokarimata, Nagakute, Aichi, Japan.; Murase, Y (reprint author), Japanese Red Cross Nagoya Daini Hosp, Dept Pathol, 2-9 Myoken Cho, Nagoya, Aichi 4668650, Japan.						Boumans D, 2012, INFECT DIS CLIN PRAC, V20, P354; Katano H, 2011, J MED VIROL, V83, P322, DOI 10.1002/jmv.21962; Ronan BA, 2014, INFECTION, V42, P105, DOI 10.1007/s15010-013-0527-7; Schaberg KB, 2017, AM J SURG PATHOL, V41, P810, DOI 10.1097/PAS.0000000000000834; SHIROKI K, 1984, J VIROL, V50, P854	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					259	261		10.1111/pin.12632			3	Pathology	Pathology	GB4CC	WOS:000429006900009	29350488				2019-10-28	
J	Kai, KT; Udo, K; Yamaguchi, K; Tobu, S; Noguchi, M; Aishima, S				Kai, Keita; Udo, Kazuma; Yamaguchi, Ken; Tobu, Shohei; Noguchi, Mitsuru; Aishima, Shinichi			A dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features	PATHOLOGY INTERNATIONAL			English	Letter									[Kai, Keita; Aishima, Shinichi] Saga Univ Hosp, Dept Pathol, Saga, Japan; [Udo, Kazuma; Tobu, Shohei; Noguchi, Mitsuru] Saga Univ, Dept Urol, Fac Med, Saga, Japan; [Yamaguchi, Ken] Saga Univ, Dept Radiol, Fac Med, Saga, Japan; [Aishima, Shinichi] Saga Univ, Dept Pathol, Fac Med, Saga, Japan; [Aishima, Shinichi] Saga Univ, Dept Microbiol, Fac Med, Saga, Japan	Kai, KT (reprint author), Saga Univ Hosp, Dept Pathol, Saga, Japan.						Dei Tos AP, 2013, WHO CLASSIFICATION T, P33; Dei Tos AP, 2013, WHO CLASSIFICATION T, P37; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Hisaoka M, 1997, PATHOL INT, V47, P642, DOI 10.1111/j.1440-1827.1997.tb04556.x; Lucas DR, 2010, AM J SURG PATHOL, V34, P844, DOI 10.1097/PAS.0b013e3181db34d8	5	0	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	APR	2018	68	4					262	264		10.1111/pin.12645			3	Pathology	Pathology	GB4CC	WOS:000429006900010	29446522				2019-10-28	
J	Verine, J; Colin, D; Nheb, M; Prapotnich, D; Ploussard, G; Cathelineau, X; Desgrandchamps, F; Mongiat-Artus, P; Feugeas, JP				Verine, Jerome; Colin, Delphine; Nheb, Mary; Prapotnich, Dominique; Ploussard, Guillaume; Cathelineau, Xavier; Desgrandchamps, Francois; Mongiat-Artus, Pierre; Feugeas, Jean-Paul			Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment Comparisons With WHO/ISUP Grade and Integrated Staging Systems	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						clear cell renal cell carcinoma; pathology; grade; tumor architecture; prognosis	INTERNATIONAL-SOCIETY; DIFFERENTIAL-DIAGNOSIS; TUMOR NECROSIS; PATHOLOGY; FEATURES; CLASSIFICATION; VALIDATION; PREDICTION; NEOPLASMS; SCORE	We developed and validated an architecture-based grading for clear cell renal cell carcinoma (ccRCC) in an observational retrospective cohort study including 506 tumors (principal cohort, n=254; validation cohort, n=252). Study endpoints were disease-free survival (DFS) and cancer-specific survival (CSS). Relationships with outcome were analyzed using Harrell concordance index, time-dependent receiver operating characteristic curve, area under curve, and Cox regression model. An architecture-based grading was devised on positive likelihood ratio (LR+) for DFS at 50 months as follows: grade 1 (LR+<0.8), cystic, compact, acinar, clear cell papillary RCC-like, and/or regressive patterns; grade 2 (1.2 <= LR+< 5), large nest, alveolar, papillary, chromophobe/oncocytic cell-like, eosinophilic hyaline globule, and/or intratumoral inflammatory reaction patterns; grade 3 (5 <= LR+<10), rhabdoid, tumor giant cell, enlarged vascular space, and/or hereditary leiomyomatosis renal cell carcinoma (HLRCC)-like patterns; grade 4 (LR+>= 10), sarcomatoid, infiltrative growth patterns, and lymphatic invasion. In the principal cohort, 3-tier (grades 1-2, 3, and 4) and 4-tier architectural scores outperformed World Health Organization/International Society of Urological Pathology, and World Health Organization/International Society of Urological Pathology+necrosis gradings for DFS and CSS, and constituted an independent predictor for DFS (hazard ratio [HR]=5.91; P<6.7E-10) and CSS (HR=4.49; P=2.2E-03), retained in the localized (pT1-3N0M0) ccRCC subgroup (HR=6.10; P=1.3E-07 for DFS, and HR=20.09; P=9.4E-05 for CSS). On comparing with integrated staging systems, architectural grade with 1 morphologic datum remained an independent predictor of CSS, as did University of California Los Angeles Integrated Staging System and SSIGN, and was associated with the highest HR (HR=2.60; P=9.1E-04 in all patients; HR=4.38; P=2.0E-05 in the localized ccRCC subgroup). Architecture-based score for ccRCC outperforms all other morphologic grading systems and constitutes an independent predictor for DFS and CSS. As the predictive values of 3-tier and 4-tier architecture-based scores were similar throughout the study, we proposed to keep the simplified version as the final score, and to define 3 risk groups as follows: low risk (grades 1 to 2), intermediate risk (grade 3), and high risk (grade 4).	[Verine, Jerome; Nheb, Mary] St Louis Hosp, AP HP, Dept Pathol, Paris, France; [Verine, Jerome; Desgrandchamps, Francois] CEA, Inst Emerging Dis & Innovat Therapies iMETI, Res Div Hematol & Immunol SRHI, Paris, France; [Verine, Jerome; Desgrandchamps, Francois] Univ Paris Diderot, St Louis Hosp, Sorbone Paris Cite, UMR E 5, Paris, France; [Verine, Jerome; Mongiat-Artus, Pierre] Univ Paris Diderot, INSERM, UMR S1165, Paris, France; [Colin, Delphine] Inst Mutualiste Montsouris, Dept Pathol, Paris, France; [Prapotnich, Dominique; Cathelineau, Xavier] Inst Mutualiste Montsouris, Dept Urol, Paris, France; [Ploussard, Guillaume; Desgrandchamps, Francois; Mongiat-Artus, Pierre] St Louis Hosp, AP HP, Dept Urol, Paris, France; [Feugeas, Jean-Paul] Univ Paris Diderot, INSERM, IAME, UMR 1137, Paris, France; [Feugeas, Jean-Paul] Univ Franche Comte, INSERM, U1098, Besancon, France	Verine, J (reprint author), Hop St Louis, Lab Pathol, 1 Ave Claude Vellefaux, F-75010 Paris, France.	jerome.verine@aphp.fr					Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Delahunt B, 2014, EUR UROL, V66, P795, DOI 10.1016/j.eururo.2014.05.027; Delahunt B, 2013, AM J SURG PATHOL, V37, P311, DOI 10.1097/PAS.0b013e318270f71c; Delahunt B, 2009, MODERN PATHOL, V22, pS24, DOI 10.1038/modpathol.2008.183; Dhakal HP, 2016, AM J SURG PATHOL, V40, P141, DOI 10.1097/PAS.0000000000000583; Eusebi P, 2013, CEREBROVASC DIS, V36, P267, DOI 10.1159/000353863; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; Fukatsu A, 2013, AM J CLIN PATHOL, V140, P500, DOI 10.1309/AJCPIMPE6ZFT8AME; Gulati S, 2014, EUR UROL, V66, P936, DOI 10.1016/j.eururo.2014.06.053; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Kara O, 2016, INT UROL NEPHROL, V48, P1253, DOI 10.1007/s11255-016-1314-z; Khor LY, 2016, AM J SURG PATHOL, V40, P1224, DOI 10.1097/PAS.0000000000000690; Krishnan B, 2002, HUM PATHOL, V33, P68, DOI 10.1053/hupa.2002.30210; Leibovich BC, 2003, CANCER-AM CANCER SOC, V97, P1663, DOI 10.1002/cncr.11234; Lohse CM, 2015, SEMIN DIAGN PATHOL, V32, P172, DOI 10.1053/j.semdp.2015.02.008; McGee S, 2002, J GEN INTERN MED, V17, P646; Miquel C, 2011, AM J SURG PATHOL, V35, P623, DOI 10.1097/PAS.0b013e31820f6d11; Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029; Montironi R, 2014, EUR UROL, V66, P806, DOI 10.1016/j.eururo.2014.04.022; Parker WP, 2017, EUR UROL, V71, P665, DOI 10.1016/j.eururo.2016.05.034; Patard JJ, 2004, J UROLOGY, V172, P858, DOI 10.1097/01.ju.0000135837.64840.55; Pichler M, 2011, J UROLOGY, V186, P1773, DOI 10.1016/j.juro.2011.07.034; Sica G, 2010, AM J SURG PATHOL, V34, P1155, DOI 10.1097/PAS.0b013e3181e4ee32; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Trpkov K, 2013, AM J SURG PATHOL, V37, P1505, DOI 10.1097/PAS.0b013e31829a85d0; Verine J, 2009, VIRCHOWS ARCH, V454, P479, DOI 10.1007/s00428-009-0741-y; Verine J, 2014, EUR UROL, V65, pE69, DOI 10.1016/j.eururo.2013.12.001; Verine J, 2013, VIRCHOWS ARCH, V462, P365, DOI 10.1007/s00428-013-1379-3; Verine J, 2010, EUR UROL, V58, P701, DOI 10.1016/j.eururo.2010.08.031; Williamson SR, 2015, AM J SURG PATHOL, V39, P1502, DOI 10.1097/PAS.0000000000000514; Williamson SR, 2014, HUM PATHOL, V45, P735, DOI 10.1016/j.humpath.2013.10.033; Williamson SR, 2013, HISTOPATHOLOGY, V63, P767, DOI 10.1111/his.12239; Zhang BY, 2015, EUR UROL, V68, P5, DOI 10.1016/j.eururo.2015.01.002; Zisman A, 2001, J CLIN ONCOL, V19, P3792, DOI 10.1200/JCO.2001.19.17.3792	34	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					423	441		10.1097/PAS.0000000000001025			19	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200001	29356723				2019-10-28	
J	Weinreb, I; Bishop, JA; Chiosea, SI; Seethala, RR; Perez-Ordonez, B; Zhang, L; Sung, YS; Chen, CL; Assaad, A; Oliai, BR; Antonescu, CR				Weinreb, Ilan; Bishop, Justin A.; Chiosea, Simion I.; Seethala, Raja R.; Perez-Ordonez, Bayardo; Zhang, Lei; Sung, Yun-Shao; Chen, Chun-Liang; Assaad, Adel; Oliai, Bahram R.; Antonescu, Cristina R.			Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						intraductal carcinoma; low-grade cribriform cystadenocarcinoma; low-grade salivary duct carcinoma; RET; NCOA4-RET	DUCT CARCINOMA; LUNG-CANCER; HMGA2 REARRANGEMENTS; IN-SITU; FUSION; MUTATIONS; VARIANT; LESIONS; SYSTEM; PLAG1	Intraductal carcinoma (IC) is the World Health Organization designation for lesions previously called low-grade cribriform cystadenocarcinoma. The relationship of IC to salivary duct carcinoma (SDC) is controversial, but currently these are considered distinct entities. It is hypothesized that IC and SDC should have different genomic signatures that may be identifiable by next-generation sequencing. A total of 23 ICs were identified: 14 pure IC and 9 invasive carcinomas with an intraductal component. Five invasive carcinomas were subjected to next-generation paired-end RNA sequencing. Data analysis was performed using FusionSeq and Mutation detection algorithms (MuTect and VarScan) for variant callers. Gene fusion candidates were validated by fluorescence in situ hybridization and reverse transcription polymerase chain reaction, and mutations by Sanger sequencing. Among the 9 invasive carcinomas, all except 1 were apocrine SDCs with an intraductal component. The remaining case showed typical intercalated duct type IC with invasive adenocarcinoma. The 14 pure ICs had typical intercalated duct features (2 showed hybrid intercalated/apocrine features). RNA sequencing predicted a NCOA4-RET fusion, confirmed by reverse transcription polymerase chain reaction, in the intercalated duct type IC invasive component. Six additional cases of pure IC showed RET rearrangement by fluorescence in situ hybridization (7/15=47%). No apocrine carcinomas showed RET rearrangement. RNA sequencing and Sanger sequencing identified PIK3CA (p.E545K/p.H1047R) and/or HRAS (p.Q61R) hotspot mutations in 6 of 8 (75%) apocrine carcinomas. In conclusion, 2 distinctive types of intraductal lesions are emerging based on molecular analysis. Classic intercalated type ICs commonly harbor fusions involving RET and rarely show widespread invasion. Apocrine intraductal lesions are typically associated with widespread invasion with no pure examples and show similar PIK3CA and HRAS mutations to SDC.	[Weinreb, Ilan; Perez-Ordonez, Bayardo] Univ Hlth Network, Dept Pathol, 200 Elizabeth St, Toronto, ON M5N 1N7, Canada; [Weinreb, Ilan; Perez-Ordonez, Bayardo] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Bishop, Justin A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Chiosea, Simion I.; Seethala, Raja R.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; [Zhang, Lei; Sung, Yun-Shao; Chen, Chun-Liang; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Assaad, Adel] Virginia Mason Hosp, Dept Pathol, Seattle, WA USA; [Assaad, Adel] SeattleMed Ctr, Seattle, WA USA; [Oliai, Bahram R.] ProPath Lab, Dallas, TX USA	Weinreb, I (reprint author), Univ Hlth Network, Dept Pathol, 200 Elizabeth St, Toronto, ON M5N 1N7, Canada.	ilan.weinreb@uhn.ca		Chiosea, Simion/0000-0002-5766-8779	 [P01CA47179];  [P50 CA 140146-01]	Supported in part by P01CA47179 (C.R.A.) and P50 CA 140146-01 (C.R.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Bahrami A, 2013, HISTOPATHOLOGY, V63, P250, DOI 10.1111/his.12152; Brandwein-Gensler M, 2004, AM J SURG PATHOL, V28, P1040, DOI 10.1097/01.pas.0000128662.66321.be; Brandwein-Gensler MS, 2005, PATHOLOGY GENETICS H, P233; CHEN KTK, 1983, J LARYNGOL OTOL, V97, P189, DOI 10.1017/S002221510009397X; Cheuk W, 2004, AM J SURG PATHOL, V28, P266, DOI 10.1097/00000478-200402000-00017; Chiosea SI, 2016, CANCER-AM CANCER SOC, V122, P3136, DOI 10.1002/cncr.30179; Chiosea SI, 2015, AM J SURG PATHOL, V39, P744, DOI 10.1097/PAS.0000000000000410; Delgado R, 1996, CANCER-AM CANCER SOC, V78, P958, DOI 10.1002/(SICI)1097-0142(19960901)78:5<958::AID-CNCR4>3.0.CO;2-8; Habegger L, 2011, BIOINFORMATICS, V27, P281, DOI 10.1093/bioinformatics/btq643; Huang SC, 2016, AM J SURG PATHOL, V40, P876, DOI 10.1097/PAS.0000000000000612; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Loening T, 2017, WHO CLASSIFICATION H, P170; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P1075, DOI 10.1002/gcc.22102; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Quail MA, 2008, NAT METHODS, V5, P1005, DOI 10.1038/nmeth.1270; Sboner A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r104; Simpson RHW, 2008, HISTOPATHOLOGY, V53, P416, DOI 10.1111/j.1365-2559.2008.03135.x; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wang K, 2016, CLIN CANCER RES, V22, P6061, DOI 10.1158/1078-0432.CCR-15-2568; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477; Weinreb I, 2006, AM J SURG PATHOL, V30, P1014, DOI 10.1097/00000478-200608000-00013; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096; Weinreb I, 2014, GENE CHROMOSOME CANC, V53, P845, DOI 10.1002/gcc.22195; Williams L, 2015, AM J SURG PATHOL, V39, P705, DOI 10.1097/PAS.0000000000000413	29	13	13	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					442	452		10.1097/PAS.0000000000000952			11	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200002	29443014	Green Accepted			2019-10-28	
J	Hissong, E; Ramrattan, G; Zhang, P; Zhou, XK; Young, G; Klimstra, DS; Shia, J; Fernandes, H; Yantiss, RK				Hissong, Erika; Ramrattan, Girish; Zhang, Pan; Zhou, Xi Kathy; Young, Gloria; Klimstra, David S.; Shia, Jinru; Fernandes, Helen; Yantiss, Rhonda K.			Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						next-generation sequencing; medullary gastric cancer; immune response; microsatellite instability; Epstein-Barr virus	EPSTEIN-BARR-VIRUS; MICROSATELLITE INSTABILITY; CLINICOPATHOLOGICAL FEATURES; GASTROINTESTINAL-TRACT; GENOMIC ALTERATIONS; CANCER; MUTATIONS; ADENOCARCINOMA; EXPRESSION; SUBTYPES	Gastric carcinoma with lymphoid stroma is an uncommon variant enriched for mutually exclusive Epstein-Barr virus (EBV) positivity and mismatch repair (MMR) deficiency. We performed this study to evaluate molecular alterations in this morphologically homogeneous subtype and compare them with 295 conventional gastric cancers analyzed in The Cancer Genome Atlas study. We identified 31 study cases and subjected them to in situ hybridization for EBV-encoded RNAs and assessment for MMR status. Immunostains for PD-L1, -catenin, and HER2 were performed; extracted DNA was sequenced with a Comprehensive Cancer Panel. Most study patients were older adult men with stage I or II disease (76%). Tumors were classified as EBV+/MMR-proficient (MMR-P) (n=7), EBV-/MMR deficient (n=12), and EBV-/MMR-P (n=12). EBV-/MMR-P tumors were usually located in the proximal stomach (83%) and showed heterogenous growth patterns with glandular differentiation (83%). Tumors in all groups showed numerous tumor infiltrating lymphocytes and PD-L1 expression, infrequent nuclear -catenin accumulation (10%), and lacked both membranous HER2 staining and HER2 amplification. EBV-/MMR-deficient tumors showed significantly higher tumor mutation burden (P=0.001) and KRAS alterations (56%) compared with EBV-/MMR-P tumors (9%, P=0.05). TP53 variants were more common among EBV-/MMR-P tumors (82%) compared with EBV+/MMR proficient (0%, P=0.01) and EBV-/MMR-deficient (11%, P<0.01) tumors. Alterations in KRAS, ARID1A, PIK3CA, and TP53 followed similar patterns of distribution compared with The Cancer Genome Atlas dataset. We conclude that gastric carcinomas with lymphoid stroma show a spectrum of molecular changes and frequent PD-L1 expression, raising the possibility that this subgroup of tumors may be susceptible to checkpoint inhibitors and/or agents that target receptor tyrosine kinase-mediated signaling.	[Hissong, Erika; Ramrattan, Girish; Zhang, Pan; Yantiss, Rhonda K.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Zhou, Xi Kathy] Weill Cornell Med, Dept Biostat & Epidemiol, New York, NY USA; [Klimstra, David S.; Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Young, Gloria] NYU Langone Hlth, Dept Pathol, New York, NY USA; [Fernandes, Helen] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY USA	Hissong, E (reprint author), New York Presbyterian Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA.	emh9016@nyp.org			Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine	Supported by Translational Research Program, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ali SM, 2015, ONCOLOGIST, V20, P499, DOI 10.1634/theoncologist.2014-0378; Amin MB, 2010, AJCC CANC STAGING MA; Bang YJ, 2010, LANCET, V376, P1302; Bang Y-J, 2015, 2015 ASCO ANN M CHIC; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Bosman F. T., 2010, WHO classification of tumours of the digestive system; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng N, 2015, GASTRIC CANCER, V18, P246, DOI 10.1007/s10120-014-0376-9; Chetty R, 2012, J CLIN PATHOL, V65, P1062, DOI 10.1136/jclinpath-2012-201067; Choi YY, 2014, J SURG ONCOL, V110, P129, DOI 10.1002/jso.23618; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Cui J, 2015, INT J CANCER, V137, P86, DOI 10.1002/ijc.29352; Jacome AAD, 2016, REV SOC BRAS MED TRO, V49, P150, DOI 10.1590/0037-8682-0270-2015; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso C, 2015, J MOL DIAGN, V17, P53, DOI 10.1016/j.jmoldx.2014.09.008; Grogg KL, 2003, MODERN PATHOL, V16, P641, DOI 10.1097/01.MP.0000076980.73826.C0; Herath CHP, 2008, ARCH PATHOL LAB MED, V132, P706, DOI 10.1043/1543-2165(2008)132[706:EVLGC]2.0.CO;2; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Lim B, 2016, WORLD J GASTROENTERO, V22, P1190, DOI 10.3748/wjg.v22.i3.1190; Lim H, 2015, CLIN GASTROENTEROL H, V13, P1738, DOI 10.1016/j.cgh.2015.04.015; Lin Y, 2015, TUMOR BIOL, V36, P7385, DOI 10.1007/s13277-015-4002-1; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lu BJ, 2004, HISTOPATHOLOGY, V45, P485, DOI 10.1111/j.1365-2559.2004.01998.x; Ma CQ, 2016, AM J SURG PATHOL, V40, P1496, DOI 10.1097/PAS.0000000000000698; Mori Y, 2002, CANCER RES, V62, P3641; Odze RD, 2009, SURG PATHOLOGY GI TR; Oliveira C, 1998, AM J PATHOL, V153, P1211, DOI 10.1016/S0002-9440(10)65665-9; Pai RK, 2016, AM J SURG PATHOL, V40, pE17, DOI 10.1097/PAS.0000000000000620; Papadopoulou E, 2016, WORLD J GASTRO ONCOL, V8, P772, DOI 10.4251/wjgo.v8.i11.772; Song HJ, 2010, GASTROENTEROLOGY, V139, P84, DOI 10.1053/j.gastro.2010.04.002; Sugimoto R, 2016, INT J CANCER, V138, P1689, DOI 10.1002/ijc.29916; Sunakawa Y, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0331-y; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Tobo T, 2013, MOL CLIN ONCOL, V1, P220, DOI 10.3892/mco.2012.56; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; WATANABE H, 1976, CANCER, V38, P232, DOI 10.1002/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.3.CO;2-R; Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397; Yamamoto H, 2014, WORLD J GASTROENTERO, V20, P3927, DOI 10.3748/wjg.v20.i14.3927; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	48	5	6	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					453	462		10.1097/PAS.0000000000001018			10	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200003	29438172				2019-10-28	
J	Leeman, A; Pirog, EC; Doorbar, J; van de Sandt, MM; van Kemenade, FJ; Jenkins, D; Quint, WGV				Leeman, Annemiek; Pirog, Edyta C.; Doorbar, John; van de Sandt, Miekel M.; van Kemenade, Folkert J.; Jenkins, David; Quint, Wim G. V.			Presence or Absence of Significant HPVE4 Expression in High-grade Anal Intraepithelial Neoplasia With p16/Ki-67 Positivity Indicates Distinct Patterns of Neoplasia A Study Combining Immunohistochemistry and Laser Capture Microdissection PCR	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						AIN; HGAIN; HPV; immunohistochemistry; E4; p16; Ki-67	METHYLATION ANALYSIS; CERVICAL SCRAPES; RISK HPV; LESIONS; CANCER; MEN; SEX; P16(INK4A); ABLATION; P16	Progression of anal intraepithelial neoplasia (AIN) involves transition from productive to transforming human papillomavirus (HPV) infection. Grading aims to distinguish productive low-grade AIN from high-grade anal intraepithelial neoplasia (HGAIN) with risk of cancer. We describe immunohistochemical patterns in AIN adding a novel marker for initiation of the productive phase of the HPV life cycle (panHPVE4) to those for cell cycle activity (Ki-67) and transforming activity of HPVE7 gene (p16). We studied 67 anal biopsies for suspected anal neoplasia (17 normal, 15 AIN1, 20 AIN2, 15 AIN3) from 54 men who have sex with men at New York Presbyterian Hospital, USA. Two pathologists generated consensus AIN and immunogrades. Whole tissue and laser capture microdissection samples from multiple HPV-infected biopsies were tested for HPV with SPF10-PCR-DEIA-LiPA25, version 1. (Para)basal Ki-67 expression distinguished normal from AIN (lower-third Ki-67) with sensitivity 0.92 and specificity 1.0. Ki-67 did not distinguish grades of AIN. Null/patchy p16 versus diffuse lower-third patterns discriminated HGAIN (sensitivity, 1.0; specificity, 0.84). There was marked heterogeneity in E4 expression within HGAIN. Most AIN2 (14/20) was E4(+) versus 0/15 AIN3 (sensitivity, 0.70; specificity 1.0). HPV was detected in 63 (94%) biopsies, with 49 (77.8%) high-risk HPV+. HPV16 was the most frequent (13%). Multiple HPV genotypes were found in 15 (24%) biopsies and laser capture microdissection -polymerase chain reaction confirmed specific HPV types in E4 +/- AIN. Although Ki-67 discriminated AIN and p16 HGAIN, E4(+)/p16(+) staining shows that most AIN2 is different from transformed AIN3 in showing both entry into productive HPV infection and transforming activity.	[Leeman, Annemiek; van de Sandt, Miekel M.; Jenkins, David; Quint, Wim G. V.] DDL Diagnost Lab, Visseringlaan, Rijswijk, Netherlands; [van Kemenade, Folkert J.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Pirog, Edyta C.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA; [Doorbar, John] Univ Cambridge, Dept Pathol, Cambridge, England	Quint, WGV (reprint author), DDL Diagnost Lab, Visseringlaan 25, NL-2288 ER Rijswijk, Netherlands.	wim.quint@ddl.nl			Medical Research CouncilMedical Research Council UK (MRC) [MC_PC_13050]		Bean SM, 2007, AM J SURG PATHOL, V31, P555, DOI 10.1097/PAS.0b013e31802ca3f4; Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Chiao EY, 2006, CLIN INFECT DIS, V43, P223, DOI 10.1086/505219; Cornall AM, 2013, INT J CANCER, V133, P2253, DOI 10.1002/ijc.28228; Dalla Pria A, 2014, AIDS, V28, P861, DOI 10.1097/QAD.0000000000000160; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; De Strooper LMA, 2014, CANCER PREV RES, V7, P1251, DOI 10.1158/1940-6207.CAPR-14-0237; De Strooper LMA, 2014, J CLIN PATHOL, V67, P1067, DOI 10.1136/jclinpath-2014-202616; Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634; Doorbar J, 2013, VIROLOGY, V445, P80, DOI 10.1016/j.virol.2013.07.008; Egawa N, 2017, VIRUS RES, V231, P119, DOI 10.1016/j.virusres.2016.12.017; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Goldstone RN, 2011, DIS COLON RECTUM, V54, P1284, DOI 10.1097/DCR.0b013e318227833e; Goldstone SE, 2014, DIS COLON RECTUM, V57, P316, DOI 10.1097/DCR.0000000000000058; Griffin H, 2015, MODERN PATHOL, V28, P977, DOI 10.1038/modpathol.2015.52; Hoots BE, 2009, INT J CANCER, V124, P2375, DOI 10.1002/ijc.24215; Johnson LG, 2004, CANCER-AM CANCER SOC, V101, P281, DOI 10.1002/cncr.20364; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Kleter B, 1999, J CLIN MICROBIOL, V37, P2508; Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3; Marks DK, 2012, JAIDS-J ACQ IMM DEF, V59, P259, DOI 10.1097/QAI.0b013e3182437469; Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011; Pirog EC, 2010, AM J SURG PATHOL, V34, P1449, DOI 10.1097/PAS.0b013e3181f0f52a; Quint W, 2012, J PATHOL, V227, P62, DOI 10.1002/path.3970; Richel O, 2014, J INFECT DIS, V210, P111, DOI 10.1093/infdis/jiu052; Saraiya M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv086; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012; van Baars R, 2015, AM J SURG PATHOL, V39, P1518, DOI 10.1097/PAS.0000000000000498; van der Marel J, 2014, AM J SURG PATHOL, V38, P470, DOI 10.1097/PAS.0000000000000174; van Heukelom MLS, 2016, BRIT J DERMATOL, V175, P735, DOI 10.1111/bjd.14567; Walts AE, 2006, AM J SURG PATHOL, V30, P795, DOI 10.1097/01.pas.0000208283.14044.a9; Zbar AP, 2002, INT J COLORECTAL DIS, V17, P203, DOI 10.1007/s00384-001-0369-0	34	3	3	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					463	471		10.1097/PAS.0000000000000984			9	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200004	29438174				2019-10-28	
J	Tse, JY; Chan, MP; Ferry, JA; Deshpande, V; Sohani, AR; Nardi, V; Schaffer, A; Nazarian, RM; Zukerberg, LR				Tse, Julie Y.; Chan, May P.; Ferry, Judith A.; Deshpande, Vikram; Sohani, Aliyah R.; Nardi, Valentina; Schaffer, Andras; Nazarian, Rosalynn M.; Zukerberg, Lawrence R.			Syphilis of the Aerodigestive Tract	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						syphilis; Treponema pallidum; aerodigestive tract; gastrointestinal; mucocutaneous	INFLAMMATORY-BOWEL-DISEASE; SECONDARY SYPHILIS; ORAL SYPHILIS; DIAGNOSIS; RECTUM; MANIFESTATION; PROCTITIS; FEATURES; CHANCRE; CAVITY	Syphilis, a sexually transmitted infection caused by the Gram-negative bacterium Treponema pallidum, is increasing in prevalence in the United States. It has been our experience that primary and secondary syphilis of the aerodigestive tract can afflict a large age spectrum with varied clinical and histopathologic findings, which can lead to diagnostic problems and frequent misdiagnosis. In this study, we describe the histopathologic patterns of syphilis of the aerodigestive tract to expand awareness of its varied appearance. We identify 3 patterns of inflammatory response to syphilis: plasma cell-rich, lymphohistiocytic, and lymphoma-like. We also report the presence of immunoglobulin G4-predominant plasma cells in the inflammatory response as a potential mimicker of immunoglobulin G4-related disease. Lastly, we found that use of T. pallidum immunohistochemical stain is more reliable than Steiner silver stain at the identification of spirochetes. Our study highlights that despite convention, plasma cells are not always abundant in syphilis. Awareness of the histopathologic range of syphilis in the aerodigestive tract by the surgical pathologist can lead to the correct diagnosis and guide appropriate treatment.	[Tse, Julie Y.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA USA; [Ferry, Judith A.; Deshpande, Vikram; Sohani, Aliyah R.; Nardi, Valentina; Nazarian, Rosalynn M.; Zukerberg, Lawrence R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Chan, May P.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Schaffer, Andras] Washington Univ, Dept Pathol, St Louis Med Ctr, St Louis, MO 63130 USA	Tse, JY (reprint author), 800 Washington St,Box 802, Boston, MA 02111 USA.	jtse@tuftsmedicalcenter.org		Chan, May/0000-0002-0650-1266			Adachi E, 2011, J CLIN MICROBIOL, V49, P4394, DOI 10.1128/JCM.01240-11; Arnold CA, 2015, AM J CLIN PATHOL, V144, P771, DOI 10.1309/AJCPOID4JIJ6PISC; Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; BASSI O, 1991, DIS COLON RECTUM, V34, P1024, DOI 10.1007/BF02049969; Chen CY, 2006, J CLIN MICROBIOL, V44, P3452, DOI 10.1128/JCM.00721-06; de Voux A, 2017, MMWR-MORBID MORTAL W, V66, P349, DOI 10.15585/mmwr.mm6613a1; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Febbraro I, 2008, DIGEST LIVER DIS, V40, P579, DOI 10.1016/j.dld.2007.09.004; Fregnani ER, 2017, J FORMOS MED ASSOC, V116, P326, DOI 10.1016/j.jfma.2016.07.004; Bensusan IG, 2014, ENDOSCOPY, V46, pE533, DOI 10.1055/s-0034-1377638; Hertel M, 2014, J ORAL MAXIL SURG, V72, P338, DOI 10.1016/j.joms.2013.07.015; Hoentjen F, 2012, DIGEST DIS SCI, V57, P269, DOI 10.1007/s10620-011-1935-0; Martin-Ezquerra G, 2009, HUM PATHOL, V40, P624, DOI 10.1016/j.humpath.2008.10.017; Ruiz SJ, 2016, ARCH PATHOL LAB MED, V140, P1021, DOI 10.5858/arpa.2016-0004-LE; Schon MP, 2016, NEW ENGL J MED, V374, P372, DOI 10.1056/NEJMicm1502476; Seibt CE, 2016, BRAZ J INFECT DIS, V20, P393, DOI 10.1016/j.bjid.2016.03.008; Song SH, 2005, J KOREAN MED SCI, V20, P886, DOI 10.3346/jkms.2005.20.5.886; Soni S, 2010, ALIMENT PHARM THER, V32, P59, DOI 10.1111/j.1365-2036.2010.04313.x; Strieder LR, 2015, ANN DIAGN PATHOL, V19, P76, DOI 10.1016/j.anndiagpath.2015.01.003; Vera-Kellet C, 2014, BRAZ J INFECT DIS, V18, P570, DOI 10.1016/j.bjid.2014.03.006; Yang Juliana F, 2016, Proc (Bayl Univ Med Cent), V29, P327; Yilmaz M, 2011, J INFECT CHEMOTHER, V17, P713, DOI 10.1007/s10156-011-0234-1; Zeidman JA, 2016, NEW ENGL J MED, V375, P676, DOI 10.1056/NEJMcpc1602815; Zhao Wen-Tao, 2010, World J Gastrointest Pathophysiol, V1, P112, DOI 10.4291/wjgp.v1.i3.112	24	1	1	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					472	478		10.1097/PAS.0000000000000987			7	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200005	29135519				2019-10-28	
J	Umphress, B; Sanchez, B; Paintal, A; Nayar, R; Maniar, KP				Umphress, Brandon; Sanchez, Beatriz; Paintal, Ajit; Nayar, Ritu; Maniar, Kruti P.			Utility of CK7 Versus p16 as a Prognostic Biomarker in CIN 2	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						p16ink4; cervical intraepithelial neoplasia; CIN 2; squamocolumnar junction; CK7	CERVICAL INTRAEPITHELIAL NEOPLASIA; IMPROVES INTEROBSERVER AGREEMENT; HUMAN-PAPILLOMAVIRUS INFECTION; HPV-VACCINE-TRIALS; SQUAMOCOLUMNAR JUNCTION; P16(INK4A) EXPRESSION; CYTOKERATIN 7; HIGH-RISK; POTENTIAL MARKERS; PREDICTIVE-VALUE	Cervical intraepithelial neoplasia (CIN) 2 is an equivocal diagnosis, with p16 immunohistochemical positivity currently recommended for diagnostic confirmation. Biomarkers characteristic of squamocolumnar junction cells were recently found to be positive in almost all CIN 2 and CIN 3. CIN 1 lesions which express squamocolumnar junction markers (in particular cytokeratin 7 [CK7]) are associated with a higher rate of subsequent high-grade squamous intraepithelial lesion, suggesting that CK7 may be a useful prognostic biomarker for CIN 1. We sought to determine the utility of CK7 as a prognostic biomarker in the setting of morphologic CIN 2, and to compare this to the utility of p16 in this setting. We performed CK7 immunohistochemical on 116 cases originally diagnosed as CIN 2. Of these, 68.1% were p16(+) and 90.5% were CK7(+). A total of 19.5% of patients had a subsequent diagnosis of CIN 3 on biopsy or excision; the index CIN 2 lesion was CK7(+) in all of these cases (sensitivity 100%) and p16(+) in all but 1 (21/22; sensitivity 95.5%). The specificity of p16 (37.4%) and CK7 (8.0%) for predicting subsequent CIN 3 were significantly different (P<0.001). While p16 expression was significantly associated with subsequent CIN 3 (P=0.002), CK7 expression was not (P=0.202). We conclude that CK7, unlike p16, is not useful as a prognostic biomarker in CIN 2. While it is still promising as a prognostic marker in CIN 1, additional studies are needed to determine optimal staining/interpretation criteria.	[Umphress, Brandon; Paintal, Ajit; Nayar, Ritu; Maniar, Kruti P.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Sanchez, Beatriz] Indiana Univ, Dept Pathol, Hlth Bloomington Hosp, Bloomington, IN USA	Maniar, KP (reprint author), Northwestern Univ, Dept Pathol, Feinberg Pavil 7-332,251 E Huron St, Chicago, IL 60641 USA.	Kruti.Maniar@northwestern.edu					Agoff SN, 2003, MODERN PATHOL, V16, P665, DOI 10.1097/01.MP.0000077518.78046.0C; Benevolo M, 2006, MODERN PATHOL, V19, P384, DOI 10.1038/modpathol.3800551; Benevolo M, 2010, HISTOPATHOLOGY, V57, P580, DOI 10.1111/j.1365-2559.2010.03674.x; Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Cao LQ, 2017, HUM PATHOL, V65, P194, DOI 10.1016/j.humpath.2017.05.017; Castle PE, 2007, AM J CLIN PATHOL, V127, P805, DOI 10.1309/PT3PNC1QL2F4D2VL; Conesa-Zamora P, 2009, AM J CLIN PATHOL, V132, P378, DOI 10.1309/AJCPO0WY1VIFCYDC; Cortecchia S, 2013, INT J GYNECOL CANCER, V23, P1663, DOI 10.1097/IGC.0b013e3182a80b14; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; del Pino M, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.046; Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634; Doorbar J, 2005, J CLIN VIROL, V32, pS7, DOI 10.1016/j.jcv.2004.12.006; da Costa LBE, 2017, J LOW GENIT TRACT DI, V21, P171, DOI 10.1097/LGT.0000000000000310; Genoves J, 2014, HUM PATHOL, V45, P826, DOI 10.1016/j.humpath.2013.10.035; Guedes AC, 2007, INT J GYNECOL CANCER, V17, P1099, DOI 10.1111/j.1525-1438.2007.00899.x; Hariri J, 2007, INT J GYNECOL PATHOL, V26, P223, DOI 10.1097/01.pgp.0000236942.51840.56; Heatley MK, 2002, HISTOPATHOLOGY, V40, P377, DOI 10.1046/j.1365-2559.2002.01365.x; Herfs M, 2015, INT J CANCER, V136, P1043, DOI 10.1002/ijc.28978; Herfs M, 2013, AM J SURG PATHOL, V37, P1311, DOI 10.1097/PAS.0b013e3182989ee2; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Horn LC, 2008, AM J SURG PATHOL, V32, P502, DOI 10.1097/PAS.0b013e31815ac420; Huang EC, 2016, MODERN PATHOL, V29, P1501, DOI 10.1038/modpathol.2016.141; ISMAIL SM, 1990, HISTOPATHOLOGY, V16, P371, DOI 10.1111/j.1365-2559.1990.tb01141.x; Kalof AN, 2005, AM J SURG PATHOL, V29, P674, DOI 10.1097/01.pas.0000155164.78785.c2; Keating JT, 2001, AM J SURG PATHOL, V25, P884, DOI 10.1097/00000478-200107000-00006; Klaes R, 2002, AM J SURG PATHOL, V26, P1389, DOI 10.1097/00000478-200211000-00001; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Kurman RJ, 2014, WHO CLASSIFICATION T, P169; Lee H, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0609-4; Liao GD, 2015, J LOW GENIT TRACT DI, V19, P207, DOI 10.1097/LGT.0000000000000080; Liao GD, 2014, INT J CANCER, V134, P1715, DOI 10.1002/ijc.28485; Liu C, 2017, INT J GYNECOL PATHOL, V36, P281, DOI 10.1097/PGP.0000000000000326; Maniar KP, 2015, AM J SURG PATHOL, V39, P1708, DOI 10.1097/PAS.0000000000000494; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Mills AM, 2017, AM J SURG PATHOL, V41, P143, DOI 10.1097/PAS.0000000000000747; Mills AM, 2015, AM J SURG PATHOL, V39, P611, DOI 10.1097/PAS.0000000000000374; Miralpeix E, 2017, MODERN PATHOL, V30, P304, DOI 10.1038/modpathol.2016.168; Murphy N, 2005, J CLIN PATHOL, V58, P525, DOI 10.1136/jcp.2004.018895; Negri G, 2004, VIRCHOWS ARCH, V445, P616, DOI 10.1007/s00428-004-1127-9; Omori M, 2007, AM J CLIN PATHOL, V128, P208, DOI 10.1309/0UP5PJK9RYF7BPHM; Ozaki S, 2011, HUM PATHOL, V42, P1007, DOI 10.1016/j.humpath.2010.10.021; Paquette C, 2016, AM J SURG PATHOL, V40, P236, DOI 10.1097/PAS.0000000000000548; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; ROBERTSON AJ, 1989, J CLIN PATHOL, V42, P231, DOI 10.1136/jcp.42.3.231; Sagasta A, 2016, MODERN PATHOL, V29, P51, DOI 10.1038/modpathol.2015.126; Sano T, 1998, PATHOL INT, V48, P580, DOI 10.1111/j.1440-1827.1998.tb03954.x; Sayed Kadria, 2007, J Low Genit Tract Dis, V11, P141, DOI 10.1097/01.lgt.0000265777.36797.e7; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; SMEDTS F, 1993, OBSTET GYNECOL, V82, P465; van der Marel J, 2014, AM J SURG PATHOL, V38, P470, DOI 10.1097/PAS.0000000000000174; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; Wang SS, 2004, CANCER EPIDEM BIOMAR, V13, P1355; Wilbur CD, 2015, BETHESDA SYSTEM REPO	54	2	3	3	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					479	484		10.1097/PAS.0000000000001032			6	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200006	29438168				2019-10-28	
J	Cates, JMM				Cates, Justin M. M.			Modeling Continuous Prognostic Factors in Survival Analysis Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						osteosarcoma; continuous variables; nonlinear regression; restricted cubic splines; fractional polynomials; National Cancer Database	HIGH-GRADE OSTEOSARCOMA; PREOPERATIVE CHEMOTHERAPY; FRACTIONAL POLYNOMIALS; OSTEOGENIC-SARCOMA; REGRESSION-MODELS; OLDER	Extent of response to neoadjuvant chemotherapy, tumor size, and patient age are important prognostic variables for patients with osteosarcoma, but applying information from these continuous variables in survival models is difficult. Dichotomization is usually inappropriate and alternative statistical techniques should be considered instead. Nonlinear multivariable regression methods (restricted cubic splines and fractional polynomials) were applied to data from the National Cancer Database to model continuous prognostic factors for overall survival from localized, high-grade osteosarcoma of the appendicular and nonspinal skeleton following neoadjuvant chemotherapy and surgical resection (N=2493). The assumption that log hazard ratios were linear in relation to these continuous prognostic factors was tested using likelihood ratio tests of model deviance and Wald tests of spline coefficients. Log hazard ratios for increasing patient age were linear over the range of 4 to 80 years, but showed evidence for variation in the coefficient over elapsed follow-up time. Tumor size also showed a linear relationship with log hazard over the range of 1 to 30cm. Hazard ratios for chemotherapy effect profoundly deviated from log-linear (P<0.004), with significantly decreased hazard for death from baseline for patients with >= 90% tumor necrosis (hazard ratio, 0.32; 95% confidence interval, 0.20-0.52; P<0.0001). Important implications of these results include: (1) >= 90% tumor necrosis defines good chemotherapy response in a clinically useful manner; (2) staging osteosarcoma by dichotomizing tumor size is inappropriate; and (3) patient age can be modeled as a linear effect on the log hazard ratio in prognostic models with the caveat that risk may change over duration of the analysis.	[Cates, Justin M. M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Med Ctr North C-3322,1161 21st Ave South, Nashville, TN 37232 USA	Cates, JMM (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Med Ctr North C-3322,1161 21st Ave South, Nashville, TN 37232 USA.	justin.m.cates@vanderbilt.edu	Cates, Justin/D-5927-2014	Cates, Justin/0000-0002-7336-5196			American College of Surgeons Commission on Cancer, 2016, CANC PROGR STRAND EN; Bacci G, 2005, J PEDIAT HEMATOL ONC, V27, P129, DOI 10.1097/01.mph.0000155860.38641.83; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Bielack S, 2009, CANCER TREAT RES, V152, P289, DOI 10.1007/978-1-4419-0284-9_15; Bilimoria KY, 2008, ANN SURG ONCOL, V15, P683, DOI 10.1245/s10434-007-9747-3; Boffa DJ, 2017, JAMA ONCOL, V3, P1722, DOI 10.1001/jamaoncol.2016.6905; Bramer JAM, 2009, EJSO-EUR J SURG ONC, V35, P1030, DOI 10.1016/j.ejso.2009.01.011; Cates JMM, 2017, AM J SURG PATHOL, V41, P405, DOI 10.1097/PAS.0000000000000774; Cates JMM, 2017, MODERN PATHOL, V30, P52, DOI 10.1038/modpathol.2016.163; Collins GS, 2016, STAT MED, V35, P4124, DOI 10.1002/sim.6986; Collins M, 2013, J CLIN ONCOL, V31, P2303, DOI 10.1200/JCO.2012.43.8598; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; In H, 2014, ANN SURG ONCOL, V21, P1520, DOI 10.1245/s10434-014-3516-x; Inwards CY, 2013, WHO CLASSIFICATION T, P281; Janeway KA, 2012, CANCER-AM CANCER SOC, V118, P4597, DOI 10.1002/cncr.27414; Jeon DG, 2006, J KOREAN MED SCI, V21, P715, DOI 10.3346/jkms.2006.21.4.715; Laurini JA, PROTOCOL EXAMINATION; Lazar A, 2013, WHO CLASSIFICATION T, P292; Lee JA, 2008, J PEDIAT HEMATOL ONC, V30, P419, DOI 10.1097/MPH.0b013e318168e7dc; Lee JA, 2008, PEDIATR BLOOD CANCER, V50, P195, DOI 10.1002/pbc.21446; Nagarajan R, 2003, MED PEDIATR ONCOL, V41, P480, DOI 10.1002/mpo.10403; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E; Royston P, 2005, METHOD INFORM MED, V44, P561; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; SALZERKUNTSCHIK M, 1983, J CANCER RES CLIN, V106, P21, DOI 10.1007/BF00625047; Song WS, 2010, EJSO-EUR J SURG ONC, V36, P483, DOI 10.1016/j.ejso.2010.03.006	30	4	4	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					485	491		10.1097/PAS.0000000000000995			7	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200007	29200101				2019-10-28	
J	Agbay, RLMC; Loghavi, S; Zuo, Z; Fayad, L; Dabaja, B; Medeiros, LJ; Khoury, JD				Agbay, Rose Lou Marie C.; Loghavi, Sanam; Zuo, Zhuang; Fayad, Luis; Dabaja, Bouthaina; Medeiros, L. Jeffrey; Khoury, Joseph D.			Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						nodular lymphocyte predominant Hodgkin lymphoma; bone marrow; staging; large B-cell lymphoma; lymphoid aggregates; immunohistochemistry	B-CELL LYMPHOMA; DISEASE; PATTERN; TRANSFORMATION; CANCER	The spectrum of bone marrow lesions in patients with nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has not been evaluated systematically. In this study, we analyzed a cohort of 262 NLPHL patients who underwent staging bone marrow evaluation or targeted bone biopsy as a part of their initial diagnostic workup, among which lymphoma was detected in 24 (9.2%) patients. Eleven patients had bone marrow findings of NLPHL (few large B cells in a background of small B cell and T cell), and 13 patients had either T-cell/histiocyte-rich large B-cell lymphoma (large B cells in a background of T cells and histiocytes) or typical diffuse large B-cell lymphoma (sheets of large B cells). Bone marrow involvement was more common in patients with variant NLPHL histologic patterns in the lymph node as compared with those who had classic patterns (12/18 vs. 4/16; P=0.02). An additional 27 NLPHL patients had bone marrow specimens involved by lymphoid aggregates composed of small T cells and B cells without large B cells; this subgroup had a longer event-free survival than patients with lymphoma in the bone marrow (145 vs. 35mo). Disease recurrence or progression was more frequent in patients with bone marrow involvement by either NLPHL or LBCL, compared with patients who had lymphoid aggregates (13/21 vs. 8/26; P=0.04). In conclusion, staging bone marrow sampling detects lymphoma in a sizeable subset of NLPHL patients, particularly those with variant histologic patterns. Lymphoid aggregates lacking large B cells in staging bone marrow specimens from NLPHL patients can be regarded as clinically benign without impact on stage, outcome, or risk stratification.	[Agbay, Rose Lou Marie C.; Loghavi, Sanam; Zuo, Zhuang; Medeiros, L. Jeffrey; Khoury, Joseph D.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,MS-072, Houston, TX 77030 USA; [Fayad, Luis] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; [Dabaja, Bouthaina] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	Khoury, JD (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd,MS-072, Houston, TX 77030 USA.	jkhoury@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Al-Mansour M, 2010, J CLIN ONCOL, V28, P793, DOI 10.1200/JCO.2009.24.9516; Anagnostopoulos I, 2000, BLOOD, V96, P1889; Biasoli I, 2010, CANCER-AM CANCER SOC, V116, P631, DOI 10.1002/cncr.24819; Chen RC, 2010, J CLIN ONCOL, V28, P136, DOI 10.1200/JCO.2009.24.0945; Fan Z, 2003, AM J SURG PATHOL, V27, P1346, DOI 10.1097/00000478-200310000-00007; Farrell K, 2011, LEUKEMIA LYMPHOMA, V52, P1920, DOI 10.3109/10428194.2011.584993; Hartmann S, 2013, BLOOD, V122, P4246, DOI 10.1182/blood-2013-07-515825; Khoury JD, 2004, AM J SURG PATHOL, V28, P489, DOI 10.1097/00000478-200404000-00008; Khoury JD, 2018, CLIN CANCER RES, V24, P521, DOI 10.1158/1078-0432.CCR-17-1597; LUKES RJ, 1966, CANCER RES, V26, P1063; Nogova L, 2008, J CLIN ONCOL, V26, P434, DOI 10.1200/JCO.2007.11.8869; Panjwani P, 2015, LEUKEMIA LYMPHOMA, V56, P236, DOI 10.3109/10428194.2014.916802; Pillai G, 2003, HISTOPATHOLOGY, V43, P203, DOI 10.1046/j.1365-2559.2003.01634.x; POPPEMA S, 1985, ADV EXP MED BIOL, V186, P963; Shankar AG, 2017, BRIT J HAEMATOL, V177, P106, DOI 10.1111/bjh.14518; Strobbe L, 2016, ANN HEMATOL, V95, P417, DOI 10.1007/s00277-015-2578-6; Swerdlow SH, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Wilder RB, 2002, CANCER, V94, P1731, DOI 10.1002/cncr.10404	19	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					492	499		10.1097/PAS.0000000000001005			8	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200008	29309302				2019-10-28	
J	Larque, AB; Kradin, RL; Chebib, I; Nielsen, GP; Selig, MK; Thiele, EA; Stemmer-Rachamimov, A; Bredella, MA; Kurzawa, P; Deshpande, V				Larque, Ana B.; Kradin, Richard L.; Chebib, Ivan; Nielsen, G. Petur; Selig, Martin K.; Thiele, Elizabeth A.; Stemmer-Rachamimov, Anat; Bredella, Miriam A.; Kurzawa, Pawel; Deshpande, Vikram			Fibroma-like PEComa A Tuberous Sclerosis Complex-related Lesion	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						PEComa; perivascular epithelioid cell; fibroma; tuberous sclerosis; HMB-45	PERIVASCULAR EPITHELIOID CELLS; SUGAR TUMOR; FAMILY; ANGIOMYOLIPOMA; PREDILECTION; MEMBER; TERES; GENE; LUNG	Perivascular epithelioid cell tumor (PEComa), mesenchymal tumors morphologically characterized by epithelioid cells, coexpress melanocytic and muscle markers. Herein, we describe a heretofore-undescribed tuberous sclerosis complex (TSC)-related neoplasm, morphologically resembling a soft tissue fibroma-like lesion, but showing an immunophenotype resembling PEComa. We identified 3 soft tissue fibroma-like lesions in individuals with TSC. We also evaluated 6 TSC-related periungual fibroma as well as a range of non-TSC fibroma-like lesions (n=19). Immunohistochemistry for HMB-45, desmin, smooth muscle actin, TFE3, and S100 was performed on the TSC-related fibromas. Periungual fibromas and non-TSC fibroma-like lesions were also stained for HMB-45. All 3 TSC patients were female, ranging in age from 4 to 51 years (mean, 26.7y). Two tumors were located in extremities and 1 on the chest wall. The tumors showed elongated to stellate spindle-shape cells, prominent collagenous background, and lacked mitotic activity and cytologic atypia. Immunohistochemically, all 3 tumors were positive for HMB-45; smooth muscle actin or desmin was positive in both tumors tested. TFE3 was negative. All patients were alive with no evidence of disease with median follow-up of 55 months (range, 6 to 131mo). Non-TSC fibroma-like lesions and oral and periungual fibromas were negative for HMB-45. Fibroma-like PEComa, a newly recognized soft tissue tumor with a strong association with TSC, mimics soft tissue fibroma but shows reactivity with melanocytic markers.	[Larque, Ana B.; Kradin, Richard L.; Chebib, Ivan; Nielsen, G. Petur; Selig, Martin K.; Stemmer-Rachamimov, Anat; Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA; [Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Thiele, Elizabeth A.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Boston, MA 02114 USA; [Larque, Ana B.] Harvard Med Sch, 55 Fruit St,Warren 2, Boston, MA 02114 USA; [Kurzawa, Pawel] Poznan Univ Med Sci, Dept Clin Pathol, Poznan, Poland	Larque, AB (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA.; Larque, AB (reprint author), Harvard Med Sch, 55 Fruit St,Warren 2, Boston, MA 02114 USA.	ablarque@clinic.ub.es		Larque Daza, Ana Belen/0000-0002-1492-2116	Alfonso Martin Escudero Foundation	A.B.L. acknowledges the support from the Alfonso Martin Escudero Foundation.	BONETTI F, 1991, HUM PATHOL, V22, P727, DOI 10.1016/0046-8177(91)90298-4; BONETTI F, 1994, PATHOLOGY, V26, P230, DOI 10.1080/00313029400169561; Cao J, 2017, J CLIN INVEST, V127, P349, DOI 10.1172/JCI84262; Coffin CM, 2007, AM J SURG PATHOL, V31, P410, DOI 10.1097/01.pas.0000213348.65014.0a; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Folpe AL, 2000, AM J SURG PATHOL, V24, P1239, DOI 10.1097/00000478-200009000-00007; Gao X, 2015, P NATL ACAD SCI USA, V112, P14676, DOI 10.1073/pnas.1512570112; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Hornick JL, 2008, AM J SURG PATHOL, V32, P493, DOI 10.1097/PAS.0b013e318161dc34; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; Malinowska I, 2012, AM J SURG PATHOL, V36, P783, DOI 10.1097/PAS.0b013e31824a8a37; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Pan CC, 2008, J PATHOL, V214, P387, DOI 10.1002/path.2289; Tanaka Y, 2000, AM J SURG PATHOL, V24, P1295, DOI 10.1097/00000478-200009000-00015; Zamboni G, 1996, AM J SURG PATHOL, V20, P722, DOI 10.1097/00000478-199606000-00010	15	1	1	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					500	505		10.1097/PAS.0000000000001024			6	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200009	29324470				2019-10-28	
J	Kim, SJ; Akita, M; Sung, YN; Fujikura, K; Lee, JH; Hwang, S; Yu, E; Otani, K; Hong, SM; Zen, Y				Kim, Sung Joo; Akita, Masayuki; Sung, You-Na; Fujikura, Kohei; Lee, Jae Hoon; Hwang, Shin; Yu, Eunsil; Otani, Kyoko; Hong, Seung-Mo; Zen, Yoh			MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						MDM2; liver; bile duct; drug target; KRAS	IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; CANCER STATISTICS; ONCOPROTEIN MDM2; BREAST-CANCER; P53; TUMORIGENESIS; ACTIVATION; INHIBITOR; FEATURES	The present study aimed to characterize intrahepatic cholangiocarcinomas (iCCAs) with MDM2 amplification. A total of 213 cases of iCCA were examined using dual-color in situ hybridization for MDM2, immunohistochemistry for p53 and SMAD4, and gene sequencing for KRAS and IDH1/2. In situ hybridization on tissue microarrays identified MDM2 amplification in 13/213 (6%) cases. Using the recently proposed classification scheme of iCCAs (small-duct and large-duct types), all MDM2-amplified cases were of the large-duct type (13/110 cases, 12%). In whole section hybridization, MDM2 amplification appeared to be diffusely present in invasive areas. The loss of SMAD4 expression was more common in MDM2-amplified iCCAs than in those without MDM2 amplification. The relationship between MDM2 amplification and molecular alterations in p53 or KRAS was weak, with p53 overexpression and KRAS mutations only being found in 23% and 0% of cases, respectively. Overall survival was shorter in patients with MDM2-amplified iCCAs than in those with MDM2-nonamplified cancer (P = 0.017); however, the lack of a prognostic impact of MDM2 amplification was confirmed in a subgroup analysis using only large-duct iCCAs. Additional studies on extrahepatic malignancies also identified MDM2 amplification in 8/68 (12%) hilar cholangiocarcinomas and 30/216 (14%) gallbladder cancers, but in 0/65 distal cholangiocarcinomas. In conclusion, MDM2 amplification in large-duct iCCAs is more common than presently considered, and it may represent a unique biliary carcinogenetic process in which KRAS and TP53 mutations are less frequent. MDM2 may become a promising drug target for not only large-duct iCCAs but also hilar and gallbladder cancers.	[Kim, Sung Joo; Sung, You-Na; Yu, Eunsil; Hong, Seung-Mo] Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, Seoul 05505, South Korea; [Lee, Jae Hoon; Hwang, Shin] Univ Ulsan, Coll Med, Dept Surg, Asan Med Ctr, Seoul, South Korea; [Akita, Masayuki; Fujikura, Kohei; Otani, Kyoko; Zen, Yoh] Kobe Univ, Dept Diagnost Pathol, Grad Sch Med, Kobe, Hyogo 6500017, Japan	Hong, SM (reprint author), Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, Seoul 05505, South Korea.; Zen, Y (reprint author), Kobe Univ, Dept Diagnost Pathol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.	yohzen@med.kobe-u.ac.jp; yohzen@med.kobe-u.ac.jp		Fujikura, Kohei/0000-0002-0520-733X; Hong, Seung-Mo/0000-0002-8888-6007			Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Akita M, 2017, MODERN PATHOL, V30, P986, DOI 10.1038/modpathol.2017.22; Arai Y, 2014, HEPATOLOGY, V59, P1427, DOI 10.1002/hep.26890; Bae YK, 2012, J BREAST CANCER, V15, P381, DOI 10.4048/jbc.2012.15.4.381; Bill KLJ, 2016, CLIN CANCER RES, V22, P1150, DOI 10.1158/1078-0432.CCR-15-1522; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Carr MI, 2016, TRANSL CANCER RES, V5, P707, DOI 10.21037/tcr.2016.11.75; Chen JX, 2017, ONCOTARGET, V8, P25200, DOI 10.18632/oncotarget.15633; Choschzick M, 2010, CANCER BIOMARK, V8, P53, DOI 10.3233/DMA-2011-0806; Fujikura K, 2016, HISTOPATHOLOGY, V69, P950, DOI 10.1111/his.13037; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Hayashi A, 2016, AM J SURG PATHOL, V40, P1021, DOI 10.1097/PAS.0000000000000670; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Karni-Schmidt O, 2016, ANNU REV PATHOL-MECH, V11, P617, DOI 10.1146/annurev-pathol-012414-040349; Liau JY, 2014, MODERN PATHOL, V27, P1163, DOI 10.1038/modpathol.2013.241; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; Obrador-Hevia A, 2015, CANCER INVEST, V33, P440, DOI 10.3109/07357907.2015.1064534; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pikor LA, 2013, CANCER RES, V73, P7301, DOI 10.1158/0008-5472.CAN-13-1897; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Shaikh MF, 2016, ANN CLIN LAB SCI, V46, P627; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang SM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026245; West J, 2006, BRIT J CANCER, V94, P1751, DOI 10.1038/sj.bjc.6603127; Yu Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-71; Yuan Y, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-16; Zen Y, 2006, J HEPATOL, V44, P350, DOI 10.1016/j.jhep.2005.09.025; Zen Y, 2011, HISTOPATHOLOGY, V59, P1100, DOI 10.1111/j.1365-2559.2011.04048.x; Zhang G, 2016, ARCH PATHOL LAB MED, V140, P1111, DOI 10.5858/arpa.2015-0249-OA; Zhang WJ, 2011, APPL IMMUNOHISTO M M, V19, P54, DOI 10.1097/PAI.0b013e3181ee8e14	36	7	7	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					512	521		10.1097/PAS.0000000000001006			10	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200011	29309301				2019-10-28	
J	Kao, YC; Flucke, U; Eijkelenboom, A; Zhang, L; Sung, YS; Suurmeijer, AJH; Antonescu, CR				Kao, Yu-Chien; Flucke, Uta; Eijkelenboom, Astrid; Zhang, Lei; Sung, Yun-Shao; Suurmeijer, Albert J. H.; Antonescu, Cristina R.			Novel EWSR1-SMAD3 Gene Fusions in a Group of Acral Fibroblastic Spindle Cell Neoplasms	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						EWSR1; SMAD3; ERG; spindle cell tumor; fibroblastic tumor; acral	PHOSPHATURIC MESENCHYMAL TUMORS; TRANSCRIPTION FACTOR; ERG; EXPRESSION; RECURRENT; MUTATIONS; FIBROSIS; SMADS	Benign/low-grade fibroblastic tumors encompass a broad spectrum of tumors with different morphologies and molecular genetic abnormalities. However, despite significant progress in recent genomic characterization, there are still tumors in this histologic spectrum that are difficult to classify, lacking known molecular characteristics. Triggered by a challenging congenital spindle cell neoplasm arising in the heel of a 1-year-old boy, we applied RNA sequencing for genetic discovery and identified a novel EWSR1-S-MAD3 gene fusion. On the basis of the index case superficial acral location and fibroblastic appearance with a nonspecific immunophenotype, we searched our files for similar cases and screened them by fluorescence in situ hybridization for these abnormalities. Thus an identical EWSR1-SMAD3 fusion was identified in 2 additional spindle cell tumors with similar clinicopathologic features. Both cases occurred in the feet of adult women (58 and 61 y old) and were characterized by distinctive nodular growth with zonation pattern of peripheral hypercellular areas arranged in short fascicles, transitioning to hypocellular central areas of hyalinization and infarction. Focal stippled calcification in the collagenous area was present in 1 case. All 3 tumors had similar immunoprofiles, being negative for SMA, CD34, CD31, and S100, but showing consistent ERG positivity of uncertain significance. Follow-up information was available in 2 patients who developed local recurrences after incomplete initial excisions, at 5 and 14 months, respectively. None developed metastatic disease. In summary, we report a group of locally recurrent superficial acral tumors, characterized by bland spindle cell fascicular growth, occasional zonation pattern, ERG positivity, and recurrent EWSR1-SMAD3 gene fusions.	[Kao, Yu-Chien] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan; [Zhang, Lei; Sung, Yun-Shao; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Flucke, Uta; Eijkelenboom, Astrid] Radboud Univ Nijmegen, Dept Pathol, Med Ctr Nijmegen, Nijmegen, Netherlands; [Suurmeijer, Albert J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands	Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	antonesc@mskcc.org		Suurmeijer, Albert/0000-0003-1361-9454	Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30-CA008748]	Supported in part by P50 CA140146-01 (CRA); P30-CA008748 (CRA); Kristen Ann Carr Foundation (CRA); Cycle for Survival (CRA).	Agaimy A, 2017, AM J SURG PATHOL, V41, P1371, DOI 10.1097/PAS.0000000000000890; Agaimy A, 2017, AM J SURG PATHOL, V41, P195, DOI 10.1097/PAS.0000000000000752; Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-507; Fang J, 2014, J PHARM PHARM SCI, V17, P187, DOI 10.18433/J3KC7P; Fisher GJ, 2016, AGING CELL, V15, P67, DOI 10.1111/acel.12410; Hill CS, 1999, INT J BIOCHEM CELL B, V31, P1249, DOI 10.1016/S1357-2725(99)00093-X; Hung YP, 2017, AM J SURG PATHOL, V41, P1034, DOI 10.1097/PAS.0000000000000862; Lan HY, 2012, SEMIN NEPHROL, V32, P236, DOI 10.1016/j.semnephrol.2012.04.002; Lee JC, 2016, MODERN PATHOL, V29, P1335, DOI 10.1038/modpathol.2016.137; Lee JW, 2010, OTOLARYNG HEAD NECK, V143, P525, DOI 10.1016/j.otohns.2010.06.912; Miettinen M, 2011, AM J SURG PATHOL, V35, P432, DOI 10.1097/PAS.0b013e318206b67b; Park JY, 2016, AM J SURG PATHOL, V40, P1713, DOI 10.1097/PAS.0000000000000729; Prokova V, 2005, NUCLEIC ACIDS RES, V33, P3708, DOI 10.1093/nar/gki679; Puls F, 2016, J PATHOL, V238, P502, DOI 10.1002/path.4683; Shon W, 2015, J CLIN PATHOL, V68, P125, DOI 10.1136/jclinpath-2014-202601; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Tajima S, 2016, MED MOL MORPHOL, V49, P203, DOI 10.1007/s00795-015-0115-2; Varga J, 2002, ARTHRITIS RHEUM, V46, P1703, DOI 10.1002/art.10413; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang WL, 2012, MODERN PATHOL, V25, P1378, DOI 10.1038/modpathol.2012.97; Yamada Y, 2018, HISTOPATHOLOGY, V72, P460, DOI 10.1111/his.13377	22	6	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					522	528		10.1097/PAS.0000000000001002			7	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200012	29309308	Green Accepted			2019-10-28	
J	Assem, H; Rambau, PF; Lee, S; Ogilvie, T; Sienko, A; Kelemen, LE; Kobel, M				Assem, Hisham; Rambau, Peter F.; Lee, Sandra; Ogilvie, Travis; Sienko, Anna; Kelemen, Linda E.; Kobel, Martin			High-grade Endometrioid Carcinoma of the Ovary A Clinicopathologic Study of 30 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ovarian cancer; endometrioid carcinoma; high grade; grade 3	TUBAL-INTRAEPITHELIAL-CARCINOMA; SEROUS CARCINOMA; PAX2 EXPRESSION; CELL-TYPE; CANCER; MUTATION; TUMOR; P53; ALGORITHM; PATTERNS	Although infrequently encountered, the diagnosis of ovarian high-grade endometrioid carcinoma remains a diagnostic challenge with potential consequences for targeted therapies and genetic counselling. We studied the clinical, morphologic, and immunohistochemical features of ovarian high-grade endometrioid carcinomas and their diagnostic reproducibility compared with tuboovarian high-grade serous carcinomas. Thirty cases confirmed as International Federation of Gynecology and Obstetrics grade 3 endometrioid carcinomas were identified from 182 ovarian endometrioid carcinomas diagnosed in Alberta, Canada, between 1978 and 2010, from the population-based Alberta Ovarian Tumor Types cohort. Cases of lower grade endometrioid and high-grade serous carcinoma served for comparison. Ten immunohistochemical markers were assessed on tissue microarrays. Clinical data were abstracted and survival analyses performed using Cox regression. Interobserver reproducibility for histologic type was assessed using 1 representative hematoxylin and eosin-stained slide from 25 randomly selected grade 3 endometrioid carcinomas and 25 high-grade serous carcinomas. Histotype was independently assigned by 5 pathologists initially blinded to immunohistochemical WT1/p53 status, with subsequent reassessment unblinded to WT1/p53 status. Patients diagnosed with grade 3 endometrioid carcinoma had a significantly longer survival compared with high-grade serous carcinoma in univariate analysis (hazard ratio [HR] = 0.34, 95% confidence interval [CI] = 0.16-0.67, P = 0.0012) but not after adjusting for age, stage, treatment center, and residual tumor (HR = 1.01, 95% CI = 0.43-2.16, P = 0.98). Grade 3 endometrioid carcinoma cases (N = 30) were identical to grade 2 endometrioid carcinoma cases (N = 23) with respect to survival in univariate analysis (HR = 1.07, 95% CI = 0.39-3.21, P = 0.89) and immunohistochemical profile. Using histomorphology alone, interobserver agreement for the diagnosis of grade 3 endometrioid or high-grade serous carcinoma was 69%, which significantly increased (P < 0.0001) to 96% agreement with the knowledge of WT1/p53 status. Our data support the diagnostic value of WT1/p53 status in differentiating between grade 3 endometrioid carcinoma and high-grade serous carcinoma. However, grade 3 and grade 2 endometrioid carcinomas showed no differences in immunophenotype or clinical parameters, suggesting that they could be combined into a single group.	[Assem, Hisham; Rambau, Peter F.; Lee, Sandra; Ogilvie, Travis; Sienko, Anna; Kobel, Martin] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Rambau, Peter F.] Catholic Univ Hlth & Allied Sci, Dept Pathol, Mwanza, Tanzania; [Kelemen, Linda E.] Med Univ South Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC USA; [Kelemen, Linda E.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA	Kobel, M (reprint author), Univ Calgary, Dept Pathol & Lab Med, Foothill Med Ctr, 7564-1403 29th St NW, Calgary, AB T2N 2T9, Canada.	martin.koebel@cls.ab.ca		Kobel, Martin/0000-0002-6615-2037	Cancer Research Society [19319]; CLS [RS11-508]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-86727]; Thomas E. Feasby PhD student fund	Supported by the Cancer Research Society (19319) and CLS internal research support RS11-508. The AOVT study was supported by the Canadian Institutes of Health Research (MOP-86727). P.F.R. was supported by a Thomas E. Feasby PhD student fund. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Ali RH, 2012, INT J GYNECOL PATHOL, V31, P499, DOI 10.1097/PGP.0b013e31824d7445; Anglesio MS, 2015, J PATHOL, V236, P201, DOI 10.1002/path.4516; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bromley AB, 2012, INT J GYNECOL PATHOL, V31, P397, DOI 10.1097/PGP.0b013e31824c2372; Chen WQ, 2017, INT J GYNECOL PATHOL, V36, P128, DOI 10.1097/PGP.0000000000000291; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; Coatham M, 2016, MODERN PATHOL, V29, P1586, DOI 10.1038/modpathol.2016.156; Conlon N, 2014, AM J SURG PATHOL, V38, P1583, DOI 10.1097/PAS.0000000000000327; Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004; Gilks CB, 2008, HUM PATHOL, V39, P1239, DOI 10.1016/j.humpath.2008.01.003; Gilks CB, 2015, AM J SURG PATHOL, V39, P357, DOI 10.1097/PAS.0000000000000353; Gilks CB, 2011, MODERN PATHOL, V24, P1281, DOI 10.1038/modpathol.2011.94; Hoang LN, 2015, INT J GYNECOL CANCER, V25, P1187, DOI 10.1097/IGC.0000000000000492; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Kelemen LE, 2016, GYNECOL ONCOL, V140, P124, DOI 10.1016/j.ygyno.2015.11.008; KLINE RC, 1990, GYNECOL ONCOL, V39, P337, DOI 10.1016/0090-8258(90)90263-K; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kobel M, 2018, AM J SURG PATHOL, V42, P76, DOI 10.1097/PAS.0000000000000941; Kobel M, 2010, AM J SURG PATHOL, V34, P984, DOI 10.1097/PAS.0b013e3181e1a3bb; Kobel M, 2010, INT J GYNECOL PATHOL, V29, P203, DOI 10.1097/PGP.0b013e3181c042b6; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kurman RJ, 2014, WHO CLASSIFICATION T, P29; Ledermann JA, 2016, LANCET ONCOL, V17, P1579, DOI 10.1016/S1470-2045(16)30376-X; Lee S, 2016, INT J GYNECOL PATHOL, V35, P209, DOI 10.1097/PGP.0000000000000251; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Lim D, 2016, AM J SURG PATHOL, V40, P302, DOI 10.1097/PAS.0000000000000550; Mackenzie R, 2015, AM J SURG PATHOL, V39, P1548, DOI 10.1097/PAS.0000000000000476; Madore J, 2010, J PATHOL, V220, P392, DOI 10.1002/path.2659; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; McAlpine JN, 2012, MODERN PATHOL, V25, P740, DOI 10.1038/modpathol.2011.211; McConechy MK, 2014, MODERN PATHOL, V27, P128, DOI 10.1038/modpathol.2013.107; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Morrison JC, 2015, AM J SURG PATHOL, V39, P442, DOI 10.1097/PAS.0000000000000352; Parra-Herran C, 2017, MODERN PATHOL, V30, P1748, DOI 10.1038/modpathol.2017.81; Rambau PF, 2016, HISTOPATHOLOGY, V69, P288, DOI 10.1111/his.12934; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Schwartz DR, 2002, CANCER RES, V62, P4722; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183	40	3	3	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					534	544		10.1097/PAS.0000000000001016			11	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200014	29309296				2019-10-28	
J	Kung, VL; Liu, TC; Ma, CQ				Kung, Vanderlene Liu; Liu, Ta-Chiang; Ma, Changqing			Collagenous Enteritis is Unlikely a Form of Aggressive Celiac Disease Despite Sharing HLA-DQ2/DQ8 Genotypes	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						refractory sprue; olmesartan; NSAID; aspirin; PPI; statin; HLA	PROTON PUMP INHIBITORS; MICROSCOPIC COLITIS; INCREASED RISK; SPRUE; ENTEROPATHY; OLMESARTAN; HISTOPATHOLOGY; MALABSORPTION; RESOLUTION; GENETICS	Collagenous enteritis is an uncommon small intestinal injury pattern with unclear pathogenesis. While it has been speculated that collagenous enteritis represents a form of refractory celiac disease, recent clinical studies suggest a potential link to exposure to the antihypertensive medication olmesartan. Here we hypothesized that the pathogenesis of collagenous enteritis involves both genetic and environmental factors. All subjects with biopsy-proven collagenous enteritis diagnosed between 2002 and 2015 were identified from 2 tertiary care medical centers. Human leukocyte antigen (HLA)-DQ genotyping was performed by polymerase chain reaction on archived tissue. Celiac disease serology, past medical history, medications, smoking history, demographics, histology, clinical management, and follow-up were recorded. A total of 32 subjects were included. In contrast to celiac disease, subjects with collagenous enteritis were mostly elderly (median age at diagnosis, 69 y; range, 33 to 84 y). Seventy percent of collagenous enteritis subjects harbored celiac disease susceptibility alleles HLA-DQ2/DQ8; however, only 1 subject had elevated serum levels of celiac disease-associated autoantibodies while on a gluten-containing diet. Furthermore, 56% of subjects were taking nonsteroidal anti-inflammatory drugs, 36% proton-pump inhibitors, 28% statins, and 32% olmesartan at the time of diagnosis. Discontinuation of olmesartan and treatments with steroids and/or gluten-free diet resulted in symptomatic and histologic improvement. Neither lymphoma nor collagenous enteritis-related death was seen in this cohort. Therefore, while collagenous enteritis shares similar HLA genotypes with celiac disease, the difference in demographics, the lack of celiac disease-associated autoantibodies, and potential link to medications as environmental triggers suggest the 2 entities are likely distinct in pathogenesis.	[Kung, Vanderlene Liu; Liu, Ta-Chiang] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Ma, Changqing] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA	Liu, TC; Ma, CQ (reprint author), Univ Pittsburgh, Dept Pathol, Sch Med, 200 Lothrop St,A-610, Pittsburgh, PA 15213 USA.	ta-chiang.liu@wustl.edu; mac2@upmc.edu		Liu, Ta-Chiang/0000-0002-2800-9360	Department of Pathology, University of Pittsburgh, School of Medicine	Supported by the Department of Pathology, University of Pittsburgh, School of Medicine. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	ALDENERCANNAVA A, 1994, EUR J IMMUNOGENET, V21, P447, DOI 10.1111/j.1744-313X.1994.tb00217.x; Bonderup OK, 2014, INFLAMM BOWEL DIS, V20, P1702, DOI 10.1097/MIB.0000000000000143; BOSSART R, 1975, GUT, V16, P18, DOI 10.1136/gut.16.1.18; Burbure N, 2016, HUM PATHOL, V50, P127, DOI 10.1016/j.humpath.2015.12.001; Cellier C, 2000, LANCET, V356, P203, DOI 10.1016/S0140-6736(00)02481-8; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; Daniels JA, 2007, AM J SURG PATHOL, V31, P1800, DOI 10.1097/PAS.0b013e3180cab60c; Daum S, 2006, CLIN GASTROENTEROL H, V4, P1232, DOI 10.1016/j.cgh.2006.07.003; DeGaetani M, 2013, AM J GASTROENTEROL, V108, P647, DOI 10.1038/ajg.2013.45; Fernandez-Banares F, 2013, INFLAMM BOWEL DIS, V19, P411, DOI 10.1002/ibd.23009; Freeman HJ, 2006, CAN J GASTROENTEROL, V20, P357, DOI 10.1155/2006/893928; Liu E, 2017, GASTROENTEROLOGY, V152, P1329, DOI 10.1053/j.gastro.2017.02.002; Liu TC, 2016, ANNU REV PATHOL-MECH, V11, P127, DOI 10.1146/annurev-pathol-012615-044152; Ludvigsson JF, 2013, AM J GASTROENTEROL, V108, P818, DOI 10.1038/ajg.2013.60; Maguire AA, 2009, AM J SURG PATHOL, V33, P1440, DOI 10.1097/PAS.0b013e3181ae2545; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Marthey L, 2014, ALIMENT PHARM THER, V40, P1103, DOI 10.1111/apt.12937; Masclee GMC, 2015, AM J GASTROENTEROL, V110, P749, DOI 10.1038/ajg.2015.119; Nielsen OH, 2014, ANN MED, V46, P311, DOI 10.3109/07853890.2014.899102; O'Brien BH, 2011, AM J SURG PATHOL, V35, P1151, DOI 10.1097/PAS.0b013e3182206ef5; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Papadopoulos GK, 2001, J CLIN INVEST, V108, P1261; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Robert ME, 2000, AM J SURG PATHOL, V24, P676, DOI 10.1097/00000478-200005000-00006; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Rubio-Tapia A, 2012, MAYO CLIN PROC, V87, P732, DOI 10.1016/j.mayocp.2012.06.003; Rubio-Tapia A, 2010, CLIN GASTROENTEROL H, V8, P344, DOI 10.1016/j.cgh.2009.12.023; Scialom S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125024; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Vader W, 2003, P NATL ACAD SCI USA, V100, P12390, DOI 10.1073/pnas.2135229100; Vakiani E, 2010, MODERN PATHOL, V23, P12, DOI 10.1038/modpathol.2009.151; Verhaegh BPM, 2016, ALIMENT PHARM THER, V43, P1004, DOI 10.1111/apt.13583; WEINSTEI.WM, 1970, NEW ENGL J MED, V283, P1297, DOI 10.1056/NEJM197012102832401; Westerlind H, 2017, GUT, V66, P421, DOI 10.1136/gutjnl-2015-309934; Zhao XR, 2011, ARCH PATHOL LAB MED, V135, P803, DOI 10.1043/2010-0028-RS.1	35	1	1	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	APR	2018	42	4					545	552		10.1097/PAS.0000000000001022			8	Pathology; Surgery	Pathology; Surgery	GB1HZ	WOS:000428803200015	29324472				2019-10-28	
J	Moore, DA; Young, CA; Morris, HT; Oien, KA; Lee, JL; Jones, JL; Salto-Tellez, M				Moore, David A.; Young, Caroline A.; Morris, Hayley T.; Oien, Karin A.; Lee, Jessica L.; Jones, J. Louise; Salto-Tellez, Manuel			Time for change: a new training programme for morpho-molecular pathologists?	JOURNAL OF CLINICAL PATHOLOGY			English	Review						histopathology; molecular pathology; morphology; cancer; diagnostics	CANCER BIOMARKER; ARCHITECTURE; EVOLUTION; REVEALS	The evolution of cellular pathology as a specialty has always been driven by technological developments and the clinical relevance of incorporating novel investigations into diagnostic practice. In recent years, the molecular characterisation of cancer has become of crucial relevance in patient treatment both for predictive testing and subclassification of certain tumours. Much of this has become possible due to the availability of next-generation sequencing technologies and the whole-genome sequencing of tumours is now being rolled out into clinical practice in England via the 100000 Genome Project. The effective integration of cellular pathology reporting and genomic characterisation is crucial to ensure the morphological and genomic data are interpreted in the relevant context, though despite this, in many UK centres molecular testing is entirely detached from cellular pathology departments. The CM-Path initiative recognises there is a genomics knowledge and skills gap within cellular pathology that needs to be bridged through an upskilling of the current workforce and a redesign of pathology training. Bridging this gap will allow the development of an integrated morphomolecular pathology' specialty, which can maintain the relevance of cellular pathology at the centre of cancer patient management and allow the pathology community to continue to be a major influence in cancer discovery as well as playing a driving role in the delivery of precision medicine approaches. Here, several alternative models of pathology training, designed to address this challenge, are presented and appraised.	[Moore, David A.] Univ Leicester, Dept Canc Studies, Leicester, Leics, England; [Young, Caroline A.] St James Univ Hosp, Sch Med, Leeds, W Yorkshire, England; [Morris, Hayley T.; Oien, Karin A.] Univ Glasgow, Inst Canc Sci Pathol, Glasgow, Lanark, Scotland; [Lee, Jessica L.] Natl Inst Canc Res, Strategy & Initiat, London, England; [Jones, J. Louise] Barts & London Queen Marys Sch Med & Dent, Ctr Tumour Biol, London, England; [Salto-Tellez, Manuel] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Northern Ireland Mol Pathol Lab, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland	Salto-Tellez, M (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Northern Ireland Mol Pathol Lab, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.salto-tellez@qub.ac.uk		Morris, Hayley Theresa/0000-0002-9408-6671	Bloodwise; Breast Cancer Now; Cancer Research UKCancer Research UK; Chief Scientist Office (Scotland); Department of Health (England); Health and Care Research Wales (Wales); Health and Social Care (Northern Ireland); Medical Research CouncilMedical Research Council UK (MRC); Prostate Cancer UK; Tenovus Cancer Care	CM-Path is funded by ten National Cancer Research Institute partner organisations (Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief Scientist Office (Scotland), the Department of Health (England), Health and Care Research Wales (Wales), Health and Social Care (Northern Ireland), the Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care).	Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915; Chan JY, 2012, ADV ANAT PATHOL, V19, P425, DOI 10.1097/PAP.0b013e318271a593; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; Flynn C, 2014, J CLIN PATHOL, V67, P632, DOI 10.1136/jclinpath-2014-202176; Gal AA, 2001, ADV ANAT PATHOL, V8, P1, DOI 10.1097/00125480-200101000-00001; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Hamilton PW, 2014, METHODS, V70, P59, DOI 10.1016/j.ymeth.2014.06.015; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Kern SE, 2012, CANCER RES, V72, P6097, DOI 10.1158/0008-5472.CAN-12-3232; Lauwers GY, 2010, AM J SURG PATHOL, V34, P115, DOI 10.1097/PAS.0b013e3181bbbcaa; Lewis C, 2016, EUR J CANCER, V67, P191, DOI 10.1016/j.ejca.2016.08.009; Liu G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165457; Maxwell P, 2016, CANCER CYTOPATHOL, V124, P540, DOI 10.1002/cncy.21692; Mcart DG, 2015, MOL ONCOL, V9, P1234, DOI 10.1016/j.molonc.2015.02.002; McCourt CM, 2013, J CLIN PATHOL, V66, P58, DOI 10.1136/jclinpath-2012-201140; National Cancer Institute, DIR CHALL MOL CLASS; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Salto-Tellez M, 2013, PRINCIPLES MOL DIAGN; Salto-Tellez M, 2007, CLIN CHEM, V53, P1188, DOI 10.1373/clinchem.2007.088088; Salto-Tellez M, 2014, MOL ONCOL, V8, P1163, DOI 10.1016/j.molonc.2014.07.021; Salto-Tellez M, 2014, J PATHOL, V234, P5, DOI 10.1002/path.4365; Siok-Bian Ng, 2008, Expert Opin Med Diagn, V2, P1401, DOI 10.1517/17530050802506310; van den Tweel JG, 2010, VIRCHOWS ARCH, V457, P3, DOI 10.1007/s00428-010-0934-4	25	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					285	290		10.1136/jclinpath-2017-204821			6	Pathology	Pathology	GB2VG	WOS:000428913200001	29113995	Green Published, Green Accepted			2019-10-28	
J	Babwah, F; Buch, HN				Babwah, Feaz; Buch, Harit N.			Normocalcaemic primary hyperparathyroidism: a pragmatic approach	JOURNAL OF CLINICAL PATHOLOGY			English	Article						parathyroid; calcium metabolism; bone; vitamin D	ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; 4TH INTERNATIONAL WORKSHOP; MILD PRIMARY HYPERPARATHYROIDISM; BONE-MINERAL DENSITY; PARATHYROID-HORMONE; SERUM-CALCIUM; SECONDARY HYPERPARATHYROIDISM; SURGICAL-MANAGEMENT; MENOPAUSAL WOMEN; IONIZED CALCIUM	It is well recognised that over the past three to four decades the incidence of asymptomatic primary hyperparathyroidism has increased significantly. However, more recently this pattern has further evolved into a presentation with normocalcaemia and raised parathyroid hormone (PTH) level without the presence of a recognised stimulus for its rise, in the form of vitamin D deficiency or renal impairment. A diagnostic label of normocalcaemic hyperparathyroidism (NPHPT) has been given to this phenotype and in most such individuals, the initial PTH measurement is driven by the presence of metabolic bone disease. The reported prevalence, degree of end-organ involvement and the rate of progression vary considerably and are related to patients studied and the biochemical cut-offs used in its definition. A majority of patients are diagnosed during assessment of metabolic bone disease of varying degrees. Once the diagnosis is confirmed by excluding confounding factors, the patient should undergo full assessment of end-organ involvement, which is the main determinant of further therapeutic decisions. Surgery, with prior localisation, is considered in patients with significant end-organ involvement in keeping with the guidance for hypercalcaemic patients. If a patient does not meet these criteria, annual clinical and biochemical surveillance is recommended to identify progression to hypercalcaemia or worsening end-organ involvement. It is less clear if patients identified during routine' requests for evaluation of unrelated symptoms require similar close monitoring. In conclusion, in this review on NPHPT we focus on its definition, planning of further investigations, selection of patients for intervention and devising an appropriate follow-up strategy.	[Babwah, Feaz; Buch, Harit N.] New Cross Hosp, Wolverhampton Endocrine & Diabet Unit, Wolverhampton, W Midlands, England	Buch, HN (reprint author), New Cross Hosp, Wolverhampton Endocrine & Diabet Unit, Wolverhampton, W Midlands, England.	harit.buch@nhs.net					Amaral LM, 2012, J OSTEOPOROS, DOI 10.1155/2012/128352; Berger C, 2011, 33 ANN M AM SOC BON; Bilezikian JP, 2014, J CLIN ENDOCR METAB, V99, P3561, DOI 10.1210/jc.2014-1413; Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008-1763; Bilezikian JP, 2002, J CLIN ENDOCR METAB, V87, P5353, DOI 10.1210/jc.2002-021370; Brardi S, 2015, ARCH ITAL UROL ANDRO, V87, P66, DOI 10.4081/aiua.2015.1.66; Cakir I, 2012, ENDOCRINE, V42, P419, DOI 10.1007/s12020-012-9627-x; Calvi LM, 2008, J AM SOC NEPHROL, V19, P1257, DOI 10.1681/ASN.2007121327; Charopoulos I, 2006, J CLIN ENDOCR METAB, V91, P1748, DOI 10.1210/jc.2005-2102; Chen G, 2015, J CLIN ENDOCR METAB, V100, P2420, DOI 10.1210/jc.2014-4432; COE FL, 1973, J CLIN INVEST, V52, P134, DOI 10.1172/JCI107156; Couchman L, 2014, CLIN CHEM LAB MED, V52, P1251, DOI 10.1515/cclm-2014-0150; Crowley RK, 2016, CLIN ENDOCRINOL, V84, P809, DOI 10.1111/cen.13056; Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2734, DOI 10.1210/jc.2013-1300; Cusano NE, 2013, J CLIN DENSITOM, V16, P33, DOI 10.1016/j.jocd.2012.12.001; Diaz-Soto G, 2012, HORM-INT J ENDOCRINO, V11, P390, DOI 10.14310/horm.2002.1370; Eastell R, 2014, J CLIN ENDOCR METAB, V99, P3570, DOI 10.1210/jc.2014-1414; Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140-6736(09)60507-9; Garcia-Martin A, 2012, ENDOCRINE, V42, P764, DOI 10.1007/s12020-012-9694-z; GRIMELIUS L, 1976, AM J PATHOL, V83, P475; Harvey A, 2012, ENDOCR PRACT, V18, P124, DOI 10.4158/EP10389.OR; Julian M-T, 2012, NORMOCALCEMIC PRIMAR; Kanis JA, 2016, FRAX FRACTURE RISK A; Kontogeorgos G, 2015, CLIN ENDOCRINOL, V83, P277, DOI 10.1111/cen.12819; Koumakis E, 2013, J CLIN ENDOCR METAB, V98, P3213, DOI 10.1210/jc.2013-1518; Lowe H, 2007, J CLIN ENDOCR METAB, V92, P3001, DOI 10.1210/jc.2006-2802; Lundgren E, 1997, SURGERY, V121, P287, DOI 10.1016/S0039-6060(97)90357-3; Lundgren E, 2002, WORLD J SURG, V26, P931, DOI 10.1007/s00268-002-6621-0; Macfarlane DP, 2013, LANCET DIABETES ENDO, V1, P329, DOI 10.1016/S2213-8587(13)70083-4; Marques TF, 2011, ARQ BRAS ENDOCRINOL, V55, P314, DOI 10.1590/S0004-27302011000500003; Diaz-Guerra GM, 2013, ENDOCRINOL NUTR, V60; Maruani G, 2003, J CLIN ENDOCR METAB, V88, P4641, DOI 10.1210/jc.2002-021404; Mirzazadeh M, 2016, EMERG MED J, V33, P181, DOI 10.1136/emermed-2015-204669; National Institute for Biological Standards and Control NIBSC, 2010, 95646 NIBSC; Nordenstrom E, 2011, CLIN BIOCHEM, V44, P849, DOI 10.1016/j.clinbiochem.2011.04.002; Ozturk FY, 2016, ENDOCR J, V63, P111, DOI 10.1507/endocrj.EJ15-0392; Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009-1472; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; Rejnmark L, 2013, J CLIN ENDOCR METAB, V98, P87, DOI 10.1210/jc.2012-2499; Rejnmark L, 2011, CALCIFIED TISSUE INT, V88, P238, DOI 10.1007/s00223-010-9454-0; Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007-1215; Saleh F, 2006, J BONE MINER METAB, V24, P58, DOI 10.1007/s00774-005-0647-y; Sankaran S, 2010, J CLIN ENDOCR METAB, V95, P1653, DOI 10.1210/jc.2009-2384; Silverberg SJ, 2003, J CLIN ENDOCR METAB, V88, P5348, DOI 10.1210/jc.2003-031014; Siprova H, 2016, ENDOCR PRACT, V22, P294, DOI 10.4158/EP15704.OR; Souberbielle JC, 2015, ANN ENDOCRINOL-PARIS, V76, P134, DOI 10.1016/j.ando.2015.03.005; Sturgeon CM, 2013, BIOCH CLIN S, V37, pS431; Tordjman KN, 2004, AM J MED, V117, P861, DOI 10.1016/j.amjmed.2004.06.037; Udelsman R, 2014, J CLIN ENDOCR METAB, V99, P3595, DOI 10.1210/jc.2014-2000; Wade TJ, 2012, WORLD J SURG, V36, P761, DOI 10.1007/s00268-012-1438-y; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2; Wermers RA, 2006, J BONE MINER RES, V21, P171, DOI 10.1359/JBMR.050910; WILLS MR, 1969, AM J MED, V47, P384, DOI 10.1016/0002-9343(69)90222-8; Yeh MW, 2013, J CLIN ENDOCR METAB, V98, P1122, DOI 10.1210/jc.2012-4022; Yu N, 2011, CLIN ENDOCRINOL, V75, P169, DOI 10.1111/j.1365-2265.2010.03958.x	55	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					291	297		10.1136/jclinpath-2017-204455			7	Pathology	Pathology	GB2VG	WOS:000428913200002	29437827	Bronze, Green Published			2019-10-28	
J	Vinciguerra, M; Cassara, F; Cannata, M; Renda, D; Calvaruso, G; Leto, F; Passarello, C; Maggio, A; Giambona, A				Vinciguerra, Margherita; Cassara, Filippo; Cannata, Monica; Renda, Disma; Calvaruso, Giuseppina; Leto, Filippo; Passarello, Cristina; Maggio, Aurelio; Giambona, Antonino			Phenotypic evaluations of HBB:c.93-23T > C, a nucleotide substitution in the IVS I nt 108 of -globin gene	JOURNAL OF CLINICAL PATHOLOGY			English	Article						haemoglobinopathies; thalassaemia; single nucleotide variation; prenatal diagnosis; prenatal genetic counseling	BETA-THALASSEMIA; HEMOGLOBIN DISORDERS; PRENATAL-DIAGNOSIS; IDENTIFICATION; HETEROGENEITY; EPIDEMIOLOGY; MUTATIONS; GREECE	Background Thalassaemia and variant haemoglobin are the most common severe monogenic disorders worldwide. Aims To develop prenatal diagnosis programmes for the prevention of the most important haemoglobin disorders and identify healthy carriers of thalassaemia. Methods Sequencing analysis was used to obtain complete data on gene structure and to correlate specific phenotypic expression with mutations, especially for new or very rare mutations in globin genes. Results A rare single nucleotide variation, HBB:c.93-23T>C, located in nucleotide 108 of the first intervening sequence of the HBB gene, was identified. This variation was previously reported but its clinical significance was not known. Six heterozygous patients had this nucleotide variation and eight further cases co-inherited it together with other defects in the globin genes. Heterozygous subjects for this substitution showed normal haematological and electrophoretic features, whereas subjects who were compound heterozygotes for this mutation and another defect in globin genes showed the classic phenotype of a healthy carrier. Conclusion This nucleotide can be considered a single nucleotide polymorphism and not a thalassaemic mutation that reduces the production of haemoglobin. This is another example of a very rare nucleotide variation. Knowledge of this is important so that appropriate genetic counselling can be carried out of a couple potentially at risk, where one of the partners is a carrier of -thalassaemia and the other is carrier of a nucleotide variation.	[Vinciguerra, Margherita; Cassara, Filippo; Cannata, Monica; Renda, Disma; Calvaruso, Giuseppina; Leto, Filippo; Passarello, Cristina; Maggio, Aurelio; Giambona, Antonino] Villa Sofia Cervello Hosp, Dept Hematol Rare Dis Blood & Blood Forming Organ, Lab Mol Diag Rare Dis, Palermo, Italy	Giambona, A (reprint author), Villa Sofia Cervello Hosp, Dept Hematol Rare Dis Blood & Blood Forming Organ, Lab Mol Diag Rare Dis, Palermo, Italy.	a.giambona@villasofia.it		GIAMBONA, ANTONINO/0000-0002-5147-9547	Piera and Franco Cutino Foundation O.N.L.U.S.	The authors are grateful to the Piera and Franco Cutino Foundation O.N.L.U.S.	Angastiniotis M, 1998, ANN NY ACAD SCI, V850, P251, DOI 10.1111/j.1749-6632.1998.tb10482.x; Boussiou M, 2008, BLOOD CELL MOL DIS, V40, P317, DOI 10.1016/j.bcmd.2007.11.003; Foglietta E, 1996, HAEMATOLOGICA, V81, P387; GIAMBONA A, 1995, HUM GENET, V95, P526, DOI 10.1007/BF00223864; Giambona A, 2015, INT J CLIN PRACT, V69, P1129, DOI 10.1111/ijcp.12628; Giambona A, 2006, HAEMATOL-HEMATOL J, V91, P1681; Giambona A, 2011, BLOOD CELL MOL DIS, V46, P282, DOI 10.1016/j.bcmd.2011.01.006; Giardine B, 2014, NUCLEIC ACIDS RES, V42, pD1063, DOI 10.1093/nar/gkt911; Guler E, 2010, PEDIATR HEMAT ONCOL, V27, P608, DOI 10.3109/08880018.2010.503772; Khelil AH, 2010, HEMOGLOBIN, V34, P1, DOI 10.3109/03630260903571286; Ladis V, 2013, EUR J HAEMATOL, V90, P313, DOI 10.1111/ejh.12076; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Modell B, 2008, B WORLD HEALTH ORGAN, V86, P480, DOI 10.2471/BLT.06.036673; Muniz A, 2000, AM J HEMATOL, V64, P7, DOI 10.1002/(SICI)1096-8652(200005)64:1<7::AID-AJH2>3.3.CO;2-M; Traeger-Synodinos J, 2015, EUR J HUM GENET, V23, P426, DOI 10.1038/ejhg.2014.131; Weatherall DJ, 2001, THALASSAEMIA SYNDROM	16	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					298	302		10.1136/jclinpath-2017-204651			5	Pathology	Pathology	GB2VG	WOS:000428913200003					2019-10-28	
J	Daar, S; Al Zadjali, S; Alkindi, S; Wali, Y; Al-Rawas, A; Al-Haddabi, H; Al-Riyami, AZ				Daar, Shahina; Al Zadjali, Shoaib; Alkindi, Salam; Wali, Yasser; Al-Rawas, Abdulhakeem; Al-Haddabi, Humood; Al-Riyami, Arwa Z.			Haemoglobin Fontainebleau (HBA2: c. 64G > C) in Oman: molecular and haematological characteristics and interaction with various haemoglobinopathies	JOURNAL OF CLINICAL PATHOLOGY			English	Article						Haemoglobinopathy; Diagnosis; Diagnostic Screening	GLOBIN GENE; POPULATION; VARIANTS; SPECTRUM	Objectives To describe the laboratory features of haemoglobin Fontainebleau (Hb FB) and its interactions with various and globin gene mutations in the Omani population. Methods Over a period of 10 years, a total of 94 blood samples were suspected to have an variant on HPLC at the Sultan Qaboos University Hospital, Muscat, Oman. Molecular testing was performed using PCR based techniques to define the variant and to analyse other interacting mutations in either or globin genes. Results Of 94 subjects, molecular analysis confirmed the Hb FB variant in 55 samples (38 non-cord and 17 cord blood). A total of 36/38 non-cord samples were heterozygous for the variant, while all 17 cord blood samples were heterozygotes. A total of 43/55 individuals had a concomitant and/or globin gene mutation. Conclusions Hb FB is the the most common variant in the Omani population. We report the different HPLC profiles of this variant that we observed, with and without other haemoglobinopathies in non-cord and cord blood samples. This is the first report describing the HPLC profiles of this globin chain variant on 1year follow-up testing of cord blood samples. With careful analysis by HPLC, it is possible not only to identify Hb FB but also to predict any concomitant and/or globin gene mutations.	[Daar, Shahina; Alkindi, Salam; Wali, Yasser; Al-Haddabi, Humood] Sultan Qaboos Univ, Dept Haematol, Muscat, Oman; [Al Zadjali, Shoaib; Al-Rawas, Abdulhakeem; Al-Riyami, Arwa Z.] Sultan Qaboos Univ Hosp, Dept Haematol, Muscat, Oman	Al Zadjali, S (reprint author), Sultan Qaboos Univ Hosp, POB 38, Muscat 123, Oman.	shoaibzad@gmail.com	kindi, Salam Al/Q-5172-2019				Al Zadjali S, 2013, INT J HEMATOL, V98, P240, DOI 10.1007/s12185-013-1388-7; Al Zadjali S, 2011, HEMOGLOBIN, V35, P111, DOI 10.3109/03630269.2011.558226; Alkindi S, 2010, HEMOGLOBIN, V34, P135, DOI 10.3109/03630261003677213; Alkindi SS, 2013, EUR J HAEMATOL, V91, P164, DOI 10.1111/ejh.12136; Canatan D, 2016, TURK J HEMATOL, V33, P71, DOI 10.4274/tjh.2015.0299; Daar S, 2011, HEMOGLOBIN, V35, P117, DOI 10.3109/03630269.2011.553557; Hardison RC, 2002, HUM MUTAT, V19, P225, DOI 10.1002/humu.10044; Hassan SM, 2014, HEMOGLOBIN, V38, P422, DOI 10.3109/03630269.2014.976414; Joutovsky A, 2004, CLIN CHEM, V50, P1736, DOI 10.1373/clinchem.2004.034991; Liu YT, 2000, BRIT J HAEMATOL, V108, P295; Morgado A, 2007, EUR J HAEMATOL, V79, P422, DOI 10.1111/j.1600-0609.2007.00949.x; Purohit A, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.051; Rodriguez-Capote K, 2015, CLIN BIOCHEM, V48, P904, DOI 10.1016/j.clinbiochem.2015.05.020; Sutcharitchan P, 2005, CLIN CHEM, V51, P641, DOI 10.1373/clinchem.2004.044396; Turner A, 2014, HEMOGLOBIN, V38, P216, DOI 10.3109/03630269.2014.912221; Upadhye DS, 2012, J CLIN PATHOL, V65, P654, DOI 10.1136/jclinpath-2011-200642; WAJCMAN H, 1989, HEMOGLOBIN, V13, P421, DOI 10.3109/03630268908998081	17	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					303	308		10.1136/jclinpath-2017-204617			6	Pathology	Pathology	GB2VG	WOS:000428913200004	28784617				2019-10-28	
J	Sun, Y; Tang, GL; Hu, ZH; Thakral, B; Miranda, RN; Medeiros, LJ; Wang, SA				Sun, Yi; Tang, Guilin; Hu, Zhihong; Thakral, Beenu; Miranda, Roberto N.; Medeiros, L. Jeffrey; Wang, Sa A.			Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia	JOURNAL OF CLINICAL PATHOLOGY			English	Article						Haematology; Leukaemia; Fish; Immunohistochemistry	PROTOONCOGENE TCL1; EXPRESSION; LYMPHOMAS	Aims T cell prolymphocytic leukaemia (T-PLL) is defined as an aggressive T cell leukaemia composed of small to medium-sized lymphocytes with a mature T cell immunophenotype. Most of these cases are known to be associated with inv(14q11q32)/t(14;14)(q11;q32) or rarely t(X;14)(q28;q11). However, T-PLL can show variations in clinical presentation, morphology or immunophenotype that can make a diagnosis of T-PLL challenging. We aim to explore the value of ancillary testing in the diagnosis of T-PLL. Methods With this large cohort of 69 patients with T-PLL, we compared the diagnostic utility of conventional cytogenetics, TCL1 rearrangement by fluorescence in situ hybridisation (FISH) and TCL1 expression by immunohistochemistry (IHC). Results Conventional karyotyping was performed in all 69 patients and was abnormal in 44 (65%), showing 14q32 abnormalities in 31 (43%) and t(X;14) (MTCP) in 2 (3%). TCL1 rearrangement was assessed by FISH in 26 cases and was positive in 23 (85%). All cases with 14q32 abnormalities shown by karyotype were positive for TCL1 rearrangement by FISH, whereas 12/15 (80%) cases without 14q32 abnormalities were also positive. TCL1 overexpression by IHC was detected in 51/64 (81%), including 40/42 (95%) cases with TCL1/14q32 rearrangement, and 3 cases without, showing a concordance of 89%. TCL1 IHC was negative in both cases with t(X;14)(q28;q11). Conclusions Our study shows that TCL1 by IHC is a convenient test, positive in >80% T-PLL. Conventional cytogenetics is insensitive in the detection of 14q32/TCL1 rearrangements but provides more complete information of the chromosomal landscape of T-PLL. FISH for TCL1 rearrangement is very valuable in diagnostic challenging cases.	[Sun, Yi; Tang, Guilin; Hu, Zhihong; Thakral, Beenu; Miranda, Roberto N.; Medeiros, L. Jeffrey; Wang, Sa A.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Sun, Yi] Cent S Univ, Dept Pathol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China	Wang, SA (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	swang5@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Aggarwal N, 2015, AM J SURG PATHOL, V39, P1679, DOI 10.1097/PAS.0000000000000496; Catovsky D M HH Ralfkiaer, 2008, WHO CLASSIFICATION T; Cavazzini F, 2003, AM J HEMATOL, V74, P145, DOI 10.1002/ajh.10398; Chen XY, 2013, AM J CLIN PATHOL, V140, P727, DOI 10.1309/AJCPG71KYOXTKLQW; Despouy G, 2007, BLOOD, V110, P4406, DOI 10.1182/blood-2006-11-059501; Feldman AL, 2008, AM J CLIN PATHOL, V130, P178, DOI 10.1309/PNXUKA1CFJMVGCN1; Foucar K, 2007, AM J CLIN PATHOL, V127, P496, DOI 10.1309/KWJYBCCGTB90B6AE; Garand R, 1998, BRIT J HAEMATOL, V103, P488, DOI 10.1046/j.1365-2141.1998.00977.x; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Herling M, 2004, BLOOD, V104, P328, DOI 10.1182/blood-2004-01-0002; Herling M, 2008, BLOOD, V111, P328, DOI 10.1182/blood-2007-07-101519; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Hu Z, 2017, HUM PATHOL; Krishnan B, 2006, SEMIN ONCOL, V33, P257, DOI 10.1053/j.seminoncol.2006.01.015; Kussick SJ, 2002, LEUKEMIA, V16, P2457, DOI 10.1038/sj.leu.2402715; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Loghavi S, 2016, LEUKEMIA LYMPHOMA, V57, P2804, DOI 10.3109/10428194.2016.1170827; Maljaei SH, 1998, CANCER GENET CYTOGEN, V103, P110, DOI 10.1016/S0165-4608(97)00410-X; MATUTES E, 1991, BLOOD, V78, P3269; MATUTES E, 1986, BRIT J HAEMATOL, V64, P111, DOI 10.1111/j.1365-2141.1986.tb07579.x; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; Rashidi A, 2015, EUR J HAEMATOL, V95, P199, DOI 10.1111/ejh.12560; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Shaffer L. G., 2013, RECOMMENDATIONS INT; Stengel A, 2016, GENE CHROMOSOME CANC, V55, P82, DOI 10.1002/gcc.22313; Valbuena JR, 2005, AM J CLIN PATHOL, V123, P456, DOI 10.1309/93P42RNG5XBG3KBE; Yokohama A, 2012, INT J HEMATOL, V95, P77, DOI 10.1007/s12185-011-0986-5; Yokohama Akihiko, 2000, Journal of Medicine (Westbury), V31, P183; Yuille MR, 2001, GENE CHROMOSOME CANC, V30, P336, DOI 10.1002/gcc.1099	30	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					309	315		10.1136/jclinpath-2017-204616			7	Pathology	Pathology	GB2VG	WOS:000428913200005	28821581				2019-10-28	
J	Conroy, S; Hale, MF; Cross, SS; Swallow, K; Sidhu, RH; Sargur, R; Lobo, AJ				Conroy, Samantha; Hale, Melissa F.; Cross, Simon S.; Swallow, Kirsty; Sidhu, Reena H.; Sargur, Ravishankar; Lobo, Alan J.			Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care	JOURNAL OF CLINICAL PATHOLOGY			English	Article						faecal calprotectin; inflammatory bowel disease; colonoscopy; primary healthcare	MANAGEMENT; GUIDELINES	Background Faecal calprotectin (FC) measurement distinguishes patients with inflammatory bowel disease (IBD) from those with irritable bowel syndrome but evidence of its performance in primary care is limited. Aims To assess the yield of IBD from FC testing in primary care. Methods Retrospective review of hospital records to assess the outcome following FC testing in primary care. Investigations for all patients undergoing FC testing in a single laboratory for 6months from 1 October 2013 to 28 February 2014 were reviewed. Results 410 patients (162 male; median age 42; range 16-91) were included. FC>50 mu g/g was considered positive (FC+). 148/410 (36.1%; median age 44 (17-91)) were FC+ (median FC 116.5 mu g/g (51-1770)). 122/148 FC-positive patients (82.4%) underwent further investigation. 97 (65.5%) underwent lower gastrointestinal endoscopy (LGIE), of which 7 (7.2%) had IBD. 49/262 (18.7%) FC-negative (FC-) patients (FC 50 mu g/g) (median age 47 (19-76)) also underwent LGIE, of whom 3 (6.1%) had IBD. IBD was diagnosed in 11/410 (2.7%; 4 ulcerative colitis, 3 Crohn's disease, 4 microscopic colitis). 8/11 were FC+ (range 67-1170) and 3 FC-. At a 50 mu g/g threshold, sensitivity for detecting IBD was 72.7%, specificity 64.9%, positive predictive value (PPV) 5.41% and negative predictive value 98.9%. Increasing the threshold to 100 mu g/g reduced the sensitivity of the test for detecting IBD to 54.6%. Conclusions FC testing in primary care has low sensitivity and specificity with poor PPV for diagnosing IBD. Its use needs to be directed to those with a higher pretest probability of disease. Local services and laboratories should advise general practitioners accordingly.	[Conroy, Samantha; Hale, Melissa F.; Sidhu, Reena H.; Lobo, Alan J.] Royal Hallamshire Hosp, Dept Gastroenterol, Sheffield, S Yorkshire, England; [Cross, Simon S.] Univ Sheffield, Acad Unit Pathol, Sheffield, S Yorkshire, England; [Swallow, Kirsty; Sargur, Ravishankar] Sheffield Teaching Hosp NHS Fdn Trust, Dept Immunol, Sheffield, S Yorkshire, England	Lobo, AJ (reprint author), Royal Hallamshire Hosp, Gastroenterol Unit, P Floor, Sheffield S10 2JF, S Yorkshire, England.	alan.lobo@sth.nhs.uk	Sargur, Ravishankar/C-2270-2009	Sargur, Ravishankar/0000-0002-8535-630X	Vifor Pharma; Takeda UKTakeda Pharmaceutical Company Ltd; AbbvieAbbott Laboratories; Shield Therapeutics; JanssenJohnson & Johnson USAJanssen Biotech Inc; Dr Falk	AJL has received fees for lectures or as a member of advisory boards for Vifor Pharma, Takeda UK, Abbvie, Shield Therapeutics, Janssen and Dr Falk. Other authors have no competing interest to declare.	Bourreille A, 2009, ENDOSCOPY, V41, P618, DOI 10.1055/s-0029-1214790; Brookes M, BSG GUIDANCE DOCUMEN; Feakins RM, 2013, J CLIN PATHOL, V66, P1005, DOI 10.1136/jclinpath-2013-201885; Mow WS, 2004, CLIN GASTROENTEROL H, V2, P31, DOI 10.1053/S1542-3565(04)00289-1; Mowat C, 2011, GUT, V60, P571, DOI 10.1136/gut.2010.224154; National Institute for Health and Care Excellence (NICE), 2015, NG12 NICE; NICE DG11, 2013, DG11 NICE; Pavlidis P, 2013, SCAND J GASTROENTERO, V48, P1048, DOI 10.3109/00365521.2013.816771; Poullis A, 2003, EUR J GASTROEN HEPAT, V15, P573, DOI 10.1097/01.meg.0000059108.41030.23; Roseth AG, 1999, SCAND J GASTROENTERO, V34, P50; Seenan JP, 2015, FRONTLINE GASTROENTE, V6, P156, DOI 10.1136/flgastro-2014-100467; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Tibble JA, 1999, GUT, V45, P362, DOI 10.1136/gut.45.3.362; Turvill J, 2016, PRIM HEALTH CARE RES, V17, P428, DOI 10.1017/S1463423616000049	15	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					316	322		10.1136/jclinpath-2017-204506			7	Pathology	Pathology	GB2VG	WOS:000428913200006	28844038	Green Accepted			2019-10-28	
J	Rajeswarie, RT; Rao, S; Nandeesh, BN; Yasha, TC; Santosh, V				Rajeswarie, R. T.; Rao, Shilpa; Nandeesh, Bevinahalli N.; Yasha, T. Chickabasaviah; Santosh, Vani			A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up	JOURNAL OF CLINICAL PATHOLOGY			English	Article						diffuse glioma; integrated diagnosis; resource constraint; algorithmic approach	TERT PROMOTER MUTATIONS; PROGNOSTIC-FACTORS; LOW-GRADE; TUMORS; OLIGODENDROGLIOMA; ASTROCYTOMA; ATRX; IDH	Aims The WHO 2016 classification of diffuse gliomas combines histological and molecular parameters for diagnosis. However, in view of cost constraints for molecular testing, an economical working formula is essential to reach a meaningful diagnosis in a resource-limited setting. The aim of this study was to establish a practical algorithmic approach using histology and immunohistochemistry (IHC) in the classification of diffuse gliomas in such a set-up. Methods Diffuse gliomas of WHO grade II and III diagnosed in our institute in the year 2016 were analysed for histological and IHC features, using the markers isocitrate dehydrogenase 1 (IDH1R132H) and thalassemia/mentalretardation syndrome X-linked gene (ATRX). Fluorescence in situ hybridisation (FISH) for 1p/19q co-deletion was performed when requested. Results 449 diffuse gliomas (grades II/III) were included in the study. Integrating histology and IHC features, as per the WHO 2016 guidelines, we derived the following groups: Astrocytoma, IDH-mutant (A,IDH-mt, 37.2%); astrocytoma, not otherwise specified (A,NOS, 12.7%); oligoastrocytoma, NOS (OA,NOS, 4.5%); and oligodendroglioma, NOS (ODG,NOS, 45.6%). FISH was performed in a subset of ODG,NOS, OA,NOS and A,NOS gliomas. This revealed 1p/19q co-deletion in all cases of ODG,NOS, 15.8% of OA,NOS and 37.5% of A,NOS. Sequencing for rare IDH 1/2 mutations was not carried out in this study. Conclusion In a resource-limited set-up, histology with IHC (IDH1(R132H) and ATRX) form the baseline to reasonably derive four histomolecular subgroups of diffuse glioma. Of these, we recommend, OA,NOS and IDH1(R132H)-non-mt ODG,NOS to be our priority for performing 1p/19q co-deletion studies in comparison to IDH-mt ODG,NOS, and it would not be mandatory for astrocytoma. Sequencing for rare IDH mutations is advised for A,NOS and OA,NOS groups, but not for the IDH1(R132H)-non-mutant diffuse gliomas with 1p/19q co-deletion.	[Rajeswarie, R. T.; Rao, Shilpa; Nandeesh, Bevinahalli N.; Yasha, T. Chickabasaviah; Santosh, Vani] NIMHANS, Dept Neuropathol, Bangalore 560029, Karnataka, India	Santosh, V (reprint author), NIMHANS, Dept Neuropathol, Bangalore 560029, Karnataka, India.	vani.santosh@gmail.com					Capper D, 2009, ACTA NEUROPATHOL, V118, P599, DOI 10.1007/s00401-009-0595-z; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Jiao YC, 2012, ONCOTARGET, V3, P709, DOI 10.18632/oncotarget.588; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Louis DN, 2017, ACTA NEUROPATHOL, V133, P1, DOI 10.1007/s00401-016-1646-x; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Louis DN, 2014, BRAIN PATHOL, V24, P429, DOI 10.1111/bpa.12171; Louis DN, 2016, WHO CLASSIFICATION T; Malzkorn B, 2016, CURR OPIN ONCOL, V28, P494, DOI 10.1097/CCO.0000000000000327; Paulus W, 2017, ACTA NEUROCHIR, V159, P419, DOI 10.1007/s00701-016-3067-y; Pignatti F, 2002, J CLIN ONCOL, V20, P2076, DOI 10.1200/JCO.2002.08.121; Rajmohan KS, 2016, J CLIN PATHOL, V69, P686, DOI 10.1136/jclinpath-2015-203456; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Sahm F, 2014, ACTA NEUROPATHOL, V128, P551, DOI 10.1007/s00401-014-1326-7; Sanson Marc, 2003, Curr Neurol Neurosci Rep, V3, P223, DOI 10.1007/s11910-003-0082-1; Scerrati M, 1996, J NEUROL NEUROSUR PS, V61, P291, DOI 10.1136/jnnp.61.3.291	17	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					323	329		10.1136/jclinpath-2017-204638			7	Pathology	Pathology	GB2VG	WOS:000428913200007	28801347				2019-10-28	
J	Buoro, S; Manenti, B; Seghezzi, M; Dominoni, P; Barbui, T; Ghirardi, A; Carobbio, A; Marchesi, G; Riva, I; Nasi, A; Ottomano, C; Lippi, G				Buoro, Sabrina; Manenti, Barbara; Seghezzi, Michela; Dominoni, Paola; Barbui, Tiziano; Ghirardi, Arianna; Carobbio, Alessandra; Marchesi, Gianmariano; Riva, Ivano; Nasi, Alessandra; Ottomano, Cosimo; Lippi, Giuseppe			Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit	JOURNAL OF CLINICAL PATHOLOGY			English	Article						Automated hematology analyzer; Sysmex; liver impairment; sepsis; Immature Platelet Fraction; reticolocytes	IMMATURE PLATELET FRACTION; INTERNATIONAL CONSENSUS DEFINITIONS; SEPTIC SHOCK SEPSIS-3; MORTALITY; SEVERITY; ANALYZER; CRITERIA; DISEASE; IMMUNE	Aims This study was aimed to investigate the role of erythrocyte, platelet and reticulocyte (RET) parameters, measured by new haematological analyser Sysmex XN and C reactive protein (CRP), for early diagnosis of sepsis during intensive care unit (ICU) stay. Methods The study population consisted of 62 ICU patients, 21 of whom developed sepsis during ICU stay and 41 who did not. The performance for early diagnosing of sepsis was calculated as area under the curve (AUC) of receiver operating characteristics curves analysis. Results Compared with CRP (AUC 0.81), immature platelet fraction (IPF) (AUC 0.82) showed comparable efficiency for identifying the onset of sepsis. The association with the risk of developing sepsis during ICU stay was also assessed. One day before the onset of sepsis, a decreased of RET% was significantly associated with the risk of developing sepsis (OR=0.35, 95%CI 0.14 to 0.87), whereas an increased of IPF absolute value (IPF#) was significantly associated with the risk of developing sepsis (OR=1.13, 95%CI 1.03 to 1.24) 2days before the onset of sepsis. The value of CRP was not predictive of sepsis at either time points. Conclusions IPF# and RET% may provide valuable clinical information for predicting the risk of developing sepsis, thus allowing early management of patients before the onset of clinically evident systemic infections.	[Buoro, Sabrina; Manenti, Barbara; Seghezzi, Michela; Dominoni, Paola] Papa Giovanni XXIII Hosp, Clin Chem Lab, Piazza OMS 1, I-24127 Bergamo, Italy; [Barbui, Tiziano; Ghirardi, Arianna; Carobbio, Alessandra] Papa Giovanni XXIII Hosp, FROM Res Fdn, Bergamo, Italy; [Marchesi, Gianmariano; Riva, Ivano; Nasi, Alessandra] Hosp Papa Giovanni XXIII, Intens Care Unit, Bergamo, Italy; [Ottomano, Cosimo] Synlab, Clin Chem Lab, Castenedolo, Italy; [Lippi, Giuseppe] Univ Verona, Dept Clin Biochem, Verona, Italy	Manenti, B (reprint author), Papa Giovanni XXIII Hosp, Clin Chem Lab, Piazza OMS 1, I-24127 Bergamo, Italy.	barbara.manenti@unimi.it	Carobbio, Alessandra/S-2849-2019; Lippi, Giuseppe/X-7198-2018	Carobbio, Alessandra/0000-0001-9664-7084; Lippi, Giuseppe/0000-0001-9523-9054; Buoro, Sabrina/0000-0001-7637-0727			Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623; [Anonymous], 2014, EP05A3E CLSI; Arneth BM, 2014, J CLIN LAB ANAL, V28, P130, DOI 10.1002/jcla.21656; Bernstein LH, 2011, CLIN CHEM LAB MED, V49, P2089, DOI 10.1515/CCLM.2011.688; Buoro S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.73; Buoro S, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.09.41; De Blasi RA, 2013, INTENS CARE MED, V39, P636, DOI 10.1007/s00134-012-2725-7; Di Mario A, 2009, J INFECTION, V59, P201, DOI 10.1016/j.jinf.2009.07.007; Hubert RME, 2015, SCI REP-UK, V5, DOI 10.1038/srep08019; Ha SO, 2015, SCAND J CLIN LAB INV, V75, P36, DOI 10.3109/00365513.2014.965736; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kaukonen KM, 2015, NEW ENGL J MED, V372, P1629, DOI 10.1056/NEJMoa1415236; Ko YJ, 2015, CLIN CHEM LAB MED, V53, P1091, DOI 10.1515/cclm-2014-0839; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160; MORABIA A, 1995, OCCUP ENVIRON MED, V52, P489, DOI 10.1136/oem.52.7.489; Morrell CN, 2014, BLOOD, V123, P2759, DOI 10.1182/blood-2013-11-462432; Muronoi T, 2016, THROMB RES, V144, P169, DOI 10.1016/j.thromres.2016.06.002; Park SH, 2015, INT J LAB HEMATOL, V37, P190, DOI 10.1111/ijlh.12261; Park SH, 2016, ANN LAB MED, V36, P1, DOI 10.3343/alm.2016.36.1.1; Pizzolato E, 2014, CLIN CHEM LAB MED, V52, P1395, DOI 10.1515/cclm-2014-0199; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Weimann A, 2016, CLIN LAB, V62, P667, DOI 10.7754/Clin.Lab.2015.150830; Wiersinga WJ, 2014, VIRULENCE, V5, P36, DOI 10.4161/viru.25436	26	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					330	335		10.1136/jclinpath-2017-204643			6	Pathology	Pathology	GB2VG	WOS:000428913200008	28824010				2019-10-28	
J	Johnston, L; Power, M; Sloan, P; Long, A; Silmon, A; Chaffey, B; Lisgo, AJ; Little, L; Vercauteren, E; Steiniche, T; Meyer, T; Simpson, J				Johnston, Louise; Power, Michael; Sloan, Philip; Long, Anna; Silmon, Angela; Chaffey, Ben; Lisgo, Andrea Jane; Little, Liam; Vercauteren, Ellen; Steiniche, Torben; Meyer, Tine; Simpson, John			Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue	JOURNAL OF CLINICAL PATHOLOGY			English	Article						colorectal cancer; molecular oncology; molecular pathology	REAL-TIME PCR; MULTICENTER EVALUATION; PLUS IRINOTECAN; RAS ONCOGENES; CETUXIMAB; THERAPY; SYSTEM; KRAS; CHEMOTHERAPY; PANITUMUMAB	Aims Understanding the molecular mechanisms of underlying disease has led to a movement away from the one-drug-fits-all paradigm towards treatment tailored to the genetic profile of the patient. The Biocartis Idylla platform is a novel fully automated, real-time PCR-based in vitro diagnostic system. The Idylla NRAS-BRAF mutation test has been developed for the qualitative detection of mutations in NRAS and BRAF oncogenes, facilitating genetic profiling of patients with cancer. The aim of this study was to carry out a formal clinical performance evaluation. Methods Two-hundred and forty-two formalin-fixed paraffin-embedded (FFPE) human malignant colorectal cancer (CRC) tissue samples were identified in departmental archives and tested with both the Idylla NRAS-BRAF mutation test and the Agena Bioscience MassARRAY test. Results The overall concordance between the Idylla NRAS-BRAF mutation test and the MassARRAY comparator reference test result was 241/242 (99.59%, lower bound of one-sided 95%CI=98.1%) for NRAS and 242/242 (lower bound of 95% one-sided 95%CI=98.89%) for BRAF. The Idylla NRAS-BRAF test detected one NRAS mutation that had not been reported by the MassARRAY comparator reference test. Reanalysis of this sample by droplet digital PCR confirmed that the mutation was present, but at an allelic frequency below the stated sensitivity level of the MassARRAY system. Conclusion These results confirm that the Idylla NRAS-BRAF mutation test has high concordance with a widely used NRAS-BRAF test, and is therefore suitable for use as an in vitro diagnostic device for this application.	[Johnston, Louise; Power, Michael; Simpson, John] Newcastle Univ, Natl Inst Hlth Res NIHR Diagnost Evidence Coopera, Newcastle Upon Tyne, Tyne & Wear, England; [Sloan, Philip; Long, Anna] Newcastle Upon Tyne Hosp NHS Trust, Dept Cellular Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Sloan, Philip] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Silmon, Angela; Chaffey, Ben; Lisgo, Andrea Jane; Little, Liam] NewGene Ltd, Int Ctr Life, Biosci Bldg, Newcastle Upon Tyne, Tyne & Wear, England; [Vercauteren, Ellen] Biocartis NV, Gen Wittelaan, Mechelen, Belgium; [Steiniche, Torben; Meyer, Tine] Aarhus Univ Hosp, Inst Pathol, Aarhus, Denmark	Power, M (reprint author), Newcastle Univ, Natl Inst Hlth Res NIHR Diagnost Evidence Coopera, Newcastle Upon Tyne, Tyne & Wear, England.	Michael.Power@ncl.ac.uk		Steiniche, Torben/0000-0001-5689-3555	Biocartis	The Idylla system and cartridges were provided by Biocartis who funded the study.	Allegra CJ, 2016, J CLIN ONCOL, V34, P179, DOI 10.1200/JCO.2015.63.9674; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Colling R, 2017, J CLIN PATHOL, V70, P610, DOI 10.1136/jclinpath-2017-204356; Colling R, 2016, J CLIN PATHOL, V69, P398, DOI 10.1136/jclinpath-2015-203345; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; de Biase D, 2016, J CLIN PATHOL, V69, P986, DOI 10.1136/jclinpath-2016-203696; De Luca C, 2017, J CLIN PATHOL, V70, P295, DOI 10.1136/jclinpath-2016-203989; Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141; Er TK, 2014, BIOMED RES INT, DOI 10.1155/2014/591867; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076; Janku F, 2015, ONCOTARGET, V6, P26886, DOI 10.18632/oncotarget.4723; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melchior L, 2015, EXP MOL PATHOL, V99, P485, DOI 10.1016/j.yexmp.2015.09.004; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Nicholson RI, 2001, EUR J CANCER, V37, pS9; Oikonomou E, 2014, ONCOTARGET, V5, P11752, DOI 10.18632/oncotarget.2555; Prenen H, 2010, CLIN CANCER RES, V16, P2921, DOI 10.1158/1078-0432.CCR-09-2029; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Schiefer AI, 2016, J MOL DIAGN, V18, P370, DOI 10.1016/j.jmoldx.2015.12.005; SHEPHERD FA, 2009, J CLIN ONCOL S, V27; Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280; Soeda H, 2014, ONCOLOGY-BASEL, V87, P7, DOI 10.1159/000360989; Solassol J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163444; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Weyn C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3112-0; Yeo MK, 2017, J CLIN PATHOL, V70, P260, DOI 10.1136/jclinpath-2016-204025; Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97	32	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					336	343		10.1136/jclinpath-2017-204629			8	Pathology	Pathology	GB2VG	WOS:000428913200009	28899979	Green Published			2019-10-28	
J	D'Angelo, E; Zanon, C; Sensi, F; Digito, M; Rugge, M; Fassan, M; Scarpa, M; Pucciarelli, S; Nitti, D; Agostini, M				D'Angelo, Edoardo; Zanon, Carlo; Sensi, Francesca; Digito, Maura; Rugge, Massimo; Fassan, Matteo; Scarpa, Marco; Pucciarelli, Salvatore; Nitti, Donato; Agostini, Marco			miR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article						rectal cancer; tumour markers; oncology	COLORECTAL-CANCER; RESISTANCE; CARCINOMA; PATHWAY; CELLS; IDENTIFICATION; PROLIFERATION; STATISTICS; MICRORNAS; MECHANISM	Aims Curative surgery remains the primary form of treatment for locally advanced rectal cancer (LARC). Recent data support the use of preoperative chemoradiotherapy (pCRT) to improve the prognosis of LARC with a significant reduction of local relapse and an increase of overall survival. Unfortunately, only 20% of the patients with LARC present complete pathological response after pCRT, whereas in 20%-40%,the response is poor or absent. Methods We investigated the expression level of miR-194 in n=38 patients with LARC using our public microRNA (miRNA) expression dataset. miR-194 expression was further validated by real-time quantitative PCR (qRT-PCR) and in situ hybridisation (ISH). Protein-protein interaction network and pathway enrichment analysis were performed on miR-194 targets. Results and discussion Using biopsy samples collected at diagnosis, mir-194 was significantly upregulated in patients responding to treatment (p value=0.016). The data was confirmed with qRT-PCR (p value=0.0587) and ISH (p value=0.026). Protein-protein interaction network and pathway enrichment analysis reveal a possible mechanism of susceptibility to pCRT involving Wnt pathway via its downstream mediator TRAF6. Finally, we interrogated the Comparative Toxicogenomics Database database in order to identify those chemical compounds able to mimic the biological effects of miR-194 as new possible therapeutic option in LARC treatment. The present study combining miRNA expression profiling with integrative computational biology identified miR-194 as predictive biomarker of response to pCRT. Using known and predicted drug mechanism of action, we then identified possible chemical compounds for further in vitro validation.	[D'Angelo, Edoardo; Pucciarelli, Salvatore; Nitti, Donato; Agostini, Marco] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy; [D'Angelo, Edoardo; Sensi, Francesca; Digito, Maura; Agostini, Marco] Fdn Citta Speranza, Pediat Res Inst, Nanoinspired Biomed Lab, Padua, Italy; [Zanon, Carlo] Fdn Citta Speranza, Neuroblastoma Lab, Pediat Res Inst, Padua, Italy; [Rugge, Massimo; Fassan, Matteo] Univ Padua, Dept Med DIMED, Padua, Italy; [Scarpa, Marco] IOV IRCCS, Surg Oncol Unit, Ist Oncol Veneto, Padua, Italy	Agostini, M (reprint author), Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy.	m.agostini@unipd.it	D'Angelo, Edoardo/Q-3554-2019; agostini, marco ma/K-2449-2018; D'Angelo, Edoardo/P-1668-2014; Pucciarelli, Salvatore/J-5050-2018; agostini, marco/AAC-3408-2019	D'Angelo, Edoardo/0000-0002-4554-2140; agostini, marco ma/0000-0001-7578-1233; D'Angelo, Edoardo/0000-0002-4554-2140; Pucciarelli, Salvatore/0000-0001-5289-9925; agostini, marco/0000-0001-7578-1233	Ministry of HealthMinistry of Health - Turkey [RF-2011-02349645]; AIRC FellowshipAssociazione Italiana per la Ricerca sul Cancro (AIRC) [19486, 19104]; Fondazione CARIPARO-Fondazione Citta della Speranza, Pediatric Research Grant	This work was supported by grants from the Ministry of Health RF-2011-02349645; AIRC Fellowship (No. 19486) and Investigator Grant (IG 2016 Id. 19104); Fondazione CARIPARO-Fondazione Citta della Speranza, Pediatric Research Grant.	Agostini M, 2015, ONCOTARGET, V6, P32561, DOI 10.18632/oncotarget.4935; Agostini M, 2015, CANCER BIOL THER, V16, P1160, DOI 10.1080/15384047.2015.1046652; Agostini Marco, 2014, Front Biosci (Schol Ed), V6, P110; Agostini M, 2010, CLIN CHIM ACTA, V411, P1181, DOI 10.1016/j.cca.2010.05.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chiang YP, 2012, EXP THER MED, V3, P560, DOI 10.3892/etm.2011.436; D'Angelo E, 2016, ONCOTARGET, V7, P28647, DOI 10.18632/oncotarget.8725; Drebber U, 2011, INT J ONCOL, V39, P409, DOI 10.3892/ijo.2011.1036; Hayashi H, 2010, INT J CANCER, V126, P2563, DOI 10.1002/ijc.24987; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Kotlyar M, 2016, NUCLEIC ACIDS RES, V44, pD536, DOI 10.1093/nar/gkv1115; Li ZJ, 2014, DIGEST DIS SCI, V59, P2145, DOI 10.1007/s10620-014-3159-6; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Millino C, 2017, J CELL PHYSIOL, V232, P426, DOI 10.1002/jcp.25441; Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Perilli L, 2014, ONCOTARGET, V5, P6611, DOI 10.18632/oncotarget.2245; Pichiorri F, 2013, J EXP MED, V210, P951, DOI 10.1084/jem.20120950; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Rahmati S, 2017, NUCLEIC ACIDS RES, V45, pD419, DOI 10.1093/nar/gkw1082; Shirdel EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017429; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Sundaram P, 2011, CANCER RES, V71, P7490, DOI 10.1158/0008-5472.CAN-11-1124; Trakarnsanga A, 2012, WORLD J GASTROENTERO, V18, P5521, DOI 10.3748/wjg.v18.i39.5521; Wang B, 2015, CELL CYCLE, V14, P1046, DOI 10.1080/15384101.2015.1007767; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang HN, 2015, P NATL ACAD SCI USA, V112, P15084, DOI 10.1073/pnas.1521316112; Zhao HJ, 2014, THERANOSTICS, V4, P1193, DOI 10.7150/thno.8712; Zhao YL, 2015, INT J CLIN EXP PATHO, V8, P12446; Zhu X, 2016, ONCOTARGET, V7, P13139, DOI 10.18632/oncotarget.7545	33	6	6	2	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					344	350		10.1136/jclinpath-2017-204690			7	Pathology	Pathology	GB2VG	WOS:000428913200010	28870889				2019-10-28	
J	Ooft, ML; van Ipenburg, J; van Loo, R; de Jong, R; Moelans, C; Braunius, W; de Bree, R; van Diest, P; Koljenovic, S; de Jong, RB; Hardillo, J; Willems, SM				Ooft, Marc L.; van Ipenburg, Jolique; van Loo, Rob; de Jong, Rick; Moelans, Cathy; Braunius, Weibel; de Bree, Remco; van Diest, Paul; Koljenovic, Senada; de Jong, Rob Baatenburg; Hardillo, Jose; Willems, Stefan M.			Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification	JOURNAL OF CLINICAL PATHOLOGY			English	Article						tumour biology; tumour Virology; molecular oncology; molecular pathology; oncology	EPSTEIN-BARR-VIRUS; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; ORAL-CANCER; IN-SITU; METHYLATION; DNA; EXPRESSION; THERAPY; RASSF1A	Aims To assess differences in methylation profiles, and thus pathogenesis, between Epstein-Barr virus (EBV)-positive and negative nasopharyngeal carcinomas (NPCs). Also, promoter hypermethylation is a common phenomenon in early carcinogenesis to inactivate tumour suppressor genes. Since epigenetic changes are reversible, the therapeutic application of methylation inhibitors could provide treatment options. Methods We evaluated promoter hypermethylation profiles of 22 common tumour suppressor genes in 108 NPCs using methylation-specific multiplex ligation-dependent probe amplification. Correlation between methylation, clinicopathological features (including EBV) and survival was examined. Cluster analysis was also performed. Results Hypermethylation of RASSF1A and ESR1 was significantly more frequent in EBV-positive NPC, while hypermethylation of DAPK1 was more frequent in EBV-negative NPC. In logistic regression, age, with EBV-positive NPC occurring at earlier age, and RASSF1, with RASSF1 hypermethylation being more frequent in EBV-positive NPC, remained significant. In EBV-positive NPC, hypermethylation of RASSF1A predicted worse overall survival (OS) (HR 3.058,95% CI 1.027 to 9.107). In EBV-negative NPC, hypermethylated adenomatous polyposis coli (APC) was a predictor of poor disease-free survival (DFS) (HR 6.868, 95%CI 2.142 to 22.022). Conclusion There are important epigenetic differences between EBV-negative and EBV-positive NPCs, with EBV-negative NPC having a more similar hypermethylation profile to other head and neck squamous cell carcinomas than EBV-positive NPC. Hypermethylation of RASSF1A might contribute to worse OS in EBV-positive NPC, and may be an important event in the pathogenesis of EBV-infected NPC. Hypermethylation of APC might contribute to worse DFS in EBV-negative NPC.	[Ooft, Marc L.; van Loo, Rob; de Jong, Rick; Moelans, Cathy; van Diest, Paul; Willems, Stefan M.] Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3583 CX Utrecht, Netherlands; [van Ipenburg, Jolique; Koljenovic, Senada] Erasmus MC, Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands; [Braunius, Weibel] Univ Med Ctr Utrecht, Dept Otorhinolaryngol, Utrecht, Netherlands; [Braunius, Weibel; de Bree, Remco] Univ Med Ctr Utrecht, Dept Head & Neck Surg Oncol, UMC Utrecht Canc Ctr, Utrecht, Netherlands; [de Jong, Rob Baatenburg; Hardillo, Jose] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Otorhinolaryngol & Head & Neck Surg, Rotterdam, Netherlands	Ooft, ML (reprint author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3583 CX Utrecht, Netherlands.	m.l.ooft@umcutrecht.nl					Challouf S, 2012, CLIN CHIM ACTA, V413, P795, DOI 10.1016/j.cca.2012.01.018; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chen C, 2013, CANCER CHEMOTH PHARM, V71, P371, DOI 10.1007/s00280-012-2020-x; Dai W, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.03.06; Demokan S, 2011, CLIN EPIGENETICS, V2, P123, DOI 10.1007/s13148-011-0045-3; Don K R, 2014, Indian J Dent Res, V25, P797, DOI 10.4103/0970-9290.152208; Elston C W, 2002, Histopathology, V41, P154; Er TK, 2015, ORAL DIS, V21, P872, DOI 10.1111/odi.12357; Gylling A, 2007, GUT, V56, P926, DOI 10.1136/gut.2006.114876; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; Homig-Holzel C, 2012, DIAGN MOL PATHOL, V21, P189, DOI 10.1097/PDM.0b013e3182595516; Hutajulu SH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-48; Ji XM, 2011, INT J CANCER, V129, P724, DOI 10.1002/ijc.25696; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220; Licht JD, 2015, CELL, V162, P938, DOI 10.1016/j.cell.2015.08.005; Mani S, 2010, ADV GENET, V70, P327, DOI [10.1016/B978-0-12-380866-0.60012-5, 10.1016/S0065-2660(10)70012-2]; Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930; Niller HH, 2016, ADV EXP MED BIOL, V879, P39, DOI 10.1007/978-3-319-24738-0_3; Noorlag R, 2015, HEAD NECK-J SCI SPEC, V37, P1130, DOI 10.1002/hed.23716; Noorlag R, 2014, EPIGENETICS-US, V9, P1220, DOI 10.4161/epi.29785; Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127; Pavicic W, 2011, MOL MED, V17, P726, DOI 10.2119/molmed.2010.00239; Robinson M, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-30; Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014; Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409; Tsai ST, 1996, CANCER, V77, P231, DOI 10.1002/(SICI)1097-0142(19960115)77:2<231::AID-CNCR2>3.0.CO;2-P; Tsao SW, 2014, ORAL ONCOL, V50, P330, DOI 10.1016/j.oraloncology.2014.02.006; van Diest PJ, 2002, BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648; van Kempen PMW, 2015, CANCER MED-US, V4, P1525, DOI 10.1002/cam4.499; van Kempen PMW, 2014, CANCER MED-US, V3, P1185, DOI 10.1002/cam4.313; Vasef MA, 1997, ANN OTO RHINOL LARYN, V106, P348, DOI 10.1177/000348949710600416; Whang YM, 2009, CANCER-AM CANCER SOC, V115, P1253, DOI 10.1002/cncr.24113; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	35	3	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					351	359		10.1136/jclinpath-2017-204661			9	Pathology	Pathology	GB2VG	WOS:000428913200011	28893862				2019-10-28	
J	Swedan, SF				Swedan, Samer Fuad			Increased incidence of BK virus viraemia among patients undergoing chronic haemodialysis: a case-control study	JOURNAL OF CLINICAL PATHOLOGY			English	Article						virus; uropathology; pcr; kidney; epidemiology	KIDNEY-TRANSPLANT PATIENTS; HEPATITIS-C; POLYOMAVIRUS BK; INFECTION; PREVALENCE; RECIPIENTS	Aims Incidence of BK virus (BKV) viraemia, a major risk factor for nephropathy, among patients undergoing chronic haemodialysis remains poorly investigated. This case-control study evaluated the risk of infection by BKV, in addition to hepatitis C virus (HCV) among haemodialysis subjects (n=100), compared with age-matched controls (n=100). Methods Subjects' blood plasma samples were subjected to nucleic acid extraction, followed by real-time PCR to evaluate viraemia by BKV and HCV, while sera samples were subjected to ELISA, to identify IgG seropositivity for HCV. Results Mean ageSD was 47.8 +/- 20.4and 48.9 +/- 17.6 years for the haemodialysis and control groups, respectively. BKV and HCV viraemia was observed among 19% versus 8% (OR 2.38, 95%CI 1.09 to 5.18; p=0.023) and 3% versus 0% (p=0.081) of the haemodialysis and control groups, respectively. Mean BK viral load +/- SD did not vary significantly among the two groups; 914.8 +/- 2868 versus 44.30 +/- 74.04copies/mL for the haemodialysis and control groups, respectively (p=0.4041). HCV seropositivity rates were 6% versus 2% (p=0.149), among the haemodialysis and control groups, respectively. Conclusions Subjects on haemodialysis may be at increased risk of nephropathy due to increased incidence of BK virus reactivations and may require optimisation of immunosuppressive therapy.	[Swedan, Samer Fuad] Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid 22110, Jordan	Swedan, SF (reprint author), Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid 22110, Jordan.	sfswedan4@just.edu.jo	swedan, samer/H-4228-2014	swedan, samer/0000-0002-2847-9397	Deanship of Research of Jordan University of Science and Technology [20140083]	This work was supported by the Deanship of Research of Jordan University of Science and Technology (grant number 20140083).	Baid-Agrawal S, 2008, REV MED VIROL, V18, P97, DOI 10.1002/rmv.565; Bdour S, 2002, J MED MICROBIOL, V51, P700, DOI 10.1099/0022-1317-51-8-700; Bechert CJ, 2010, AM J CLIN PATHOL, V133, P242, DOI 10.1309/AJCP63VDFCKCRUUL; Boukoum H, 2016, MICROB PATHOGENESIS, V97, P204, DOI 10.1016/j.micpath.2016.06.015; Costa Cristina, 2012, World J Transplant, V2, P84, DOI 10.5500/wjt.v2.i6.84; Hamoudi W, 2013, J EPIDEMIOL GLOB HEA, V3, P67, DOI 10.1016/j.jegh.2013.02.003; Hirsch HH, 2013, AM J TRANSPLANT, V13, P179, DOI 10.1111/ajt.12110; Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9; Hussein MM, 2010, SAUDI J KIDNEY DIS T, V21, P909; Mbaeyi C, 2013, SEMIN DIALYSIS, V26, P439, DOI 10.1111/sdi.12097; Mitterhofer AP, 2014, CLIN TRANSPLANT, V28, P299, DOI 10.1111/ctr.12312; Pakfetrat M, 2015, INT J TRANSPLANT MED, V6, P77; Qadi AA, 2004, AM J INFECT CONTROL, V32, P493, DOI 10.1016/j.ajic.2003.12.009; Rerambiah LK, 2014, BLOOD TRANSFUS-ITALY, V12, P330, DOI 10.2450/2013.0144-13; Said R A, 1995, Saudi J Kidney Dis Transpl, V6, P140; Sharif A, 2015, INFECT DIS-NOR, V47, P345, DOI 10.3109/00365548.2014.1002107; Yassin Mohamed H., 2013, Infectious Disorders - Drug Targets, V13, P162	17	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					360	363		10.1136/jclinpath-2017-204707			4	Pathology	Pathology	GB2VG	WOS:000428913200012	28942429				2019-10-28	
J	England, JT; Dalal, B; Leitch, HA				England, James T.; Dalal, Bakul; Leitch, Heather A.			Frequency of and reasons for paroxysmal nocturnal haemoglobinuria screening in patients with unexplained anaemia	JOURNAL OF CLINICAL PATHOLOGY			English	Article						haemolytic anaemia; diagnostic screening; complement		Referral to hematology for anemia is common. In paroxysmal nocturnal hemoglobinuria (PNH), cells deficient in the glycosylphosphatidyl inositol (GPI) anchor are lysed by complement. Eculizumab improves overall survival and quality of life while reducing hemolysis, transfusion requirements, and thrombosis. We evaluated the frequency of screening for PNH in patients with unexplained anemia. Key clinical features, laboratory data, and investigations were recorded for patients referred for anemia since 2010, without a specific cause found. PNH testing was done by flow cytometry. 540 patients had: anemia not yet diagnosed (NYD, n=318 (including unexplained iron deficiency, n=92; DAT-negative hemolysis, n=9)); anemia of chronic disease, n=173; and pancytopenia NYD, n=49. 82.4% had LDH testing done; 85.0% total bilirubin; 78.7% reticulocyte counts; and 40.6% haptoglobin level; 131 (24.2%) had possible hemolysis. PNH testing was done in 56 (10.4%). Those screened for PNH were more likely to have: younger age (P=0.04); a history of thrombosis (P<0.001); undergone a BMBx (P<0.001); received RBC transfusions (P=0.0018); or evidence of DAT-negative hemolysis (P<0.001). In summary, PNH was tested for in a minority of patients with unexplained anemia (10.4%) despite potential indicators of hemolysis in 24.2%. Increased screening could identify patients who would benefit from treatment and should be considered.	[England, James T.] Univ British Columbia, Internal Med, Vancouver, BC, Canada; [Dalal, Bakul] Vancouver Gen Hosp, Div Lab Hematol, Vancouver, BC, Canada; [Leitch, Heather A.] Univ British Columbia, St Pauls Hosp, Dept Hematol, Vancouver, BC, Canada	England, JT (reprint author), St Pauls Hosp, Vancouver, BC V6Z 2A5, Canada.	james.england@alumni.ubc.ca					Ageno W, 2014, THROMB RES, V133, P1052, DOI 10.1016/j.thromres.2014.03.044; Borowitz MJ, 2010, CYTOM PART B-CLIN CY, V78B, P211, DOI 10.1002/cyto.b.20525; Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128; Brodsky RA, 2009, BLOOD, V113, P6522, DOI 10.1182/blood-2009-03-195966; Gulbis B, 2010, EPIDEMIOLOGY RARE AN, P375; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688; Kelly RJ, 2011, BLOOD, V117, P6786, DOI 10.1182/blood-2011-02-333997; Lazo-Langner A, 2015, THROMB RES, V135, P1107, DOI 10.1016/j.thromres.2015.04.006; Luzzatto Lucio, 2016, F1000Res, V5, DOI 10.12688/f1000research.7288.1; Raza Azra, 2013, Cytometry B Clin Cytom, DOI 10.1002/cytob.21139; World Health Organization, 2011, HAEM CONC DIAGN AN A	12	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					364	367		10.1136/jclinpath-2017-204724			4	Pathology	Pathology	GB2VG	WOS:000428913200013	29138283				2019-10-28	
J	German, AL; Fleming, K; Kaye, P; Davies, S; Goldin, R; Hubscher, SG; Tiniakos, D; McGregor, A; Wyatt, JI				German, Alyn L.; Fleming, Kenneth; Kaye, Philip; Davies, Susan; Goldin, Robert; Hubscher, Stefan G.; Tiniakos, Dina; McGregor, Angus; Wyatt, Judith I.			Can reference images improve interobserver agreement in reporting liver fibrosis?	JOURNAL OF CLINICAL PATHOLOGY			English	Article						liver disease; fibrosis; histopathology; liver	CHRONIC VIRAL-HEPATITIS; DISEASE; STEATOSIS; SYSTEMS	Staging of fibrosis in medical liver biopsies has inherent interobserver variability. There are a number of disease-specific scoring systems available. While recognising the importance of these scoring systems, there is scope to consider how concordance amongst histopathologists could be improved using a generic fibrosis staging system. Using virtual slides, we approached both specialist liver histopathologists and general histopathologists from the UK to assess the degree of fibrosis against a proposed four-tiered reporting system. Example reference images were then produced and distributed to the same responders who were asked to rate a second set of slides to assess if the use of reference images improved concordance between pathologists. The use of reference images eliminated spread across three categories (from 15% to 0%). Overall, agreement was already good; our study showed an improved agreement amongst all participants for percentage agreement (67.79% to 70.08%) and interobserver agreement improved (Fleiss' Kappa 0.55 to 0.59).	[German, Alyn L.; Wyatt, Judith I.] Leeds Teaching Hosp NHS Trust, Dept Histopathol, Leeds, W Yorkshire, England; [Fleming, Kenneth] Univ Oxford, Green Templeton Coll, Oxford, England; [Kaye, Philip] Nottingham Univ Hosp NHS Trust, Dept Histopathol, Nottingham, England; [Davies, Susan] Cambridge Univ Hosp NHS Trust, Dept Pathol, Cambridge, England; [Goldin, Robert] Imperial Coll, Ctr Pathol, London, England; [Hubscher, Stefan G.] Univ Hosp Birmingham NHS Fdn Trust, Dept Histopathol, Birmingham, W Midlands, England; [Tiniakos, Dina] Newcastle Univ, Inst Cellular Med, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Tiniakos, Dina] Univ Athens, Aretaieio Hosp, Dept Histopathol, Athens, Greece; [McGregor, Angus] Univ Hosp Leicester NHS Trust, Dept Histopathol, Leicester, Leics, England	German, AL (reprint author), Leeds Teaching Hosp NHS Trust, St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England.	alyn.german@nhs.net		Cratchley, Alyn/0000-0003-1620-7826			Agrawal S, 2017, SCAND J GASTROENTERO, V52, P107, DOI 10.1080/00365521.2016.1233578; Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043; Bedossa P, 2014, HEPATOLOGY, V60, P565, DOI 10.1002/hep.27173; Bedossa P, 2009, J HEPATOL, V50, P1, DOI 10.1016/j.jhep.2008.10.014; Colloredo G, 2003, J HEPATOL, V39, P239, DOI 10.1016/S0168-8278(03)00191-0; Deolekar M, 2003, HISTOPATHOLOGY, V42, P227, DOI 10.1046/j.1365-2559.2003.01566.x; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Goodman ZD, 2007, J HEPATOL, V47, P598, DOI 10.1016/j.jhep.2007.07.006; Kakuda Y, 2013, HUM PATHOL, V44, P1107, DOI 10.1016/j.humpath.2012.09.017; Kleiner DE, 2015, GASTROENTEROLOGY, V149, P1305, DOI 10.1053/j.gastro.2015.09.015; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lefkowitch JH, 2016, SCHEUERS LIVER BIOPS, P163; Parham DM, 2006, J CLIN PATHOL, V59, P130, DOI 10.1136/jcp.2004.025619; Rousselet MC, 2005, HEPATOLOGY, V41, P257, DOI 10.1002/hep.20535; Sanyal Arun J, 2011, Hepatology, V54, P344, DOI 10.1002/hep.24376; Theise ND, 2007, MODERN PATHOL, V20, pS3, DOI 10.1038/modpathol.3800693; Wong GLH, 2013, GASTROENTEROL REP, V1, P19, DOI 10.1093/gastro/got007; Wyatt J, 2014, TISSUE PATHWAYS LIVE	18	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					368	371		10.1136/jclinpath-2017-204760			4	Pathology	Pathology	GB2VG	WOS:000428913200014	29127142				2019-10-28	
J	Shen, W; Paxton, CN; Szankasi, P; Longhurst, M; Schumacher, JA; Frizzell, KA; Sorrells, SM; Clayton, AL; Jattani, RP; Patel, JL; Toydemir, R; Kelley, TW; Xu, XJ				Shen, Wei; Paxton, Christian N.; Szankasi, Philippe; Longhurst, Maria; Schumacher, Jonathan A.; Frizzell, Kimberly A.; Sorrells, Shelly M.; Clayton, Adam L.; Jattani, Rakhi P.; Patel, Jay L.; Toydemir, Reha; Kelley, Todd W.; Xu, Xinjie			Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing	JOURNAL OF CLINICAL PATHOLOGY			English	Article						leukaemia; chromosomes; molecular oncology	NORMAL KARYOTYPE; LEUKEMIA; MUTATIONS; ARRAY; DISCOVERY; LESIONS	Aims Genetic abnormalities, including copy number variants (CNV), copy number neutral loss of heterozygosity (CN-LOH) and gene mutations, underlie the pathogenesis of myeloid malignancies and serve as important diagnostic, prognostic and/or therapeutic markers. Currently, multiple testing strategies are required for comprehensive genetic testing in myeloid malignancies. The aim of this proof-of-principle study was to investigate the feasibility of combining detection of genome-wide large CNVs, CN-LOH and targeted gene mutations into a single assay using next-generation sequencing (NGS). Methods For genome-wide CNV detection, we designed a single nucleotide polymorphism (SNP) sequencing backbone with 22 762 SNP regions evenly distributed across the entire genome. For targeted mutation detection, 62 frequently mutated genes in myeloid malignancies were targeted. We combined this SNP sequencing backbone with a targeted mutation panel, and sequenced 9 healthy individuals and 16 patients with myeloid malignancies using NGS. Results We detected 52 somatic CNVs, 11 instances of CN-LOH and 39 oncogenic mutations in the 16 patients with myeloid malignancies, and none in the 9 healthy individuals. All CNVs and CN-LOH were confirmed by SNP microarray analysis. Conclusions We describe a genome-wide SNP sequencing backbone which allows for sensitive detection of genome-wide CNVs and CN-LOH using NGS. This proof-of-principle study has demonstrated that this strategy can provide more comprehensive genetic profiling for patients with myeloid malignancies using a single assay.	[Shen, Wei; Paxton, Christian N.; Szankasi, Philippe; Longhurst, Maria; Schumacher, Jonathan A.; Frizzell, Kimberly A.; Sorrells, Shelly M.; Clayton, Adam L.; Jattani, Rakhi P.; Patel, Jay L.; Toydemir, Reha; Kelley, Todd W.; Xu, Xinjie] ARUP Labs, Salt Lake City, UT USA; [Shen, Wei; Patel, Jay L.; Toydemir, Reha; Kelley, Todd W.; Xu, Xinjie] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84108 USA	Xu, XJ (reprint author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84108 USA.	xinjie.xu@aruplab.com	Toydemir, Reha/U-9739-2019				Conte N, 2013, LEUKEMIA, V27, P1820, DOI 10.1038/leu.2013.117; Courtier F, 2017, HAEMATOLOGICA, V102, pE11, DOI 10.3324/haematol.2016.152363; Duncavage EJ, 2012, MODERN PATHOL, V25, P795, DOI 10.1038/modpathol.2012.29; Fromer M, 2012, AM J HUM GENET, V91, P597, DOI 10.1016/j.ajhg.2012.08.005; Garrison EBG, 2012, ARXV12073907, P1207; Gondek LP, 2008, BLOOD, V111, P1534, DOI 10.1182/blood-2007-05-092304; Jasek M, 2010, LEUKEMIA, V24, P216, DOI 10.1038/leu.2009.189; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Krumm N, 2012, GENOME RES, V22, P1525, DOI 10.1101/gr.138115.112; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Nibourel O, 2017, LEUKEMIA, V31, P555, DOI 10.1038/leu.2016.265; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Plagnol V, 2012, BIOINFORMATICS, V28, P2747, DOI 10.1093/bioinformatics/bts526; Sathirapongsasuti JF, 2011, BIOINFORMATICS, V27, P2648, DOI 10.1093/bioinformatics/btr462; Shen W, 2016, BRIT J HAEMATOL, V173, P49, DOI 10.1111/bjh.13921; Tiu RV, 2009, J CLIN ONCOL, V27, P5219, DOI 10.1200/JCO.2009.21.9840; Xu XJ, 2013, CANCER GENET-NY, V206, P317, DOI 10.1016/j.cancergen.2013.09.001; Yi JH, 2011, J CLIN ONCOL, V29, P4702, DOI 10.1200/JCO.2011.35.5719; Zhao M, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S11-S1	20	2	2	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					372	378		10.1136/jclinpath-2017-204823			7	Pathology	Pathology	GB2VG	WOS:000428913200015	29197855				2019-10-28	
J	Aries, P; Hoffmann, C; Schaal, JV; Leclerc, T; Donat, N; Cirodde, A; Masson, Y; Renner, J; Soler, C				Aries, Philippe; Hoffmann, Clement; Schaal, Jean-Vivien; Leclerc, Thomas; Donat, Nicolas; Cirodde, Audrey; Masson, Yannick; Renner, Julie; Soler, Charles			Aspergillus tamarii: an uncommon burn wound infection	JOURNAL OF CLINICAL PATHOLOGY			English	Letter						fungi; infections; microbiology; skin; trauma	FUNGAL-INFECTIONS		[Aries, Philippe; Hoffmann, Clement; Schaal, Jean-Vivien; Leclerc, Thomas; Donat, Nicolas; Cirodde, Audrey; Masson, Yannick; Renner, Julie] Percy Mil Teaching Hosp, Burn Ctr, F-92140 Clamart, France; [Aries, Philippe] French Mil Hlth Serv Acad, French Mil Hlth Serv, Paris, France; [Soler, Charles] Percy Mil Teaching Hosp, Clin Biol Lab, Clamart, France	Hoffmann, C (reprint author), Percy Mil Teaching Hosp, Burn Ctr, F-92140 Clamart, France.	clement.hoffmann@yahoo.fr					[Anonymous], 2015, INT J CURR MICRO BIO, V4, P588; Ballard J, 2008, J BURN CARE RES, V29, P213, DOI 10.1097/BCR.0b013e31815f6ecb; Katz T, 2014, BURNS, V40, P881, DOI 10.1016/j.burns.2013.11.025; Kredics L, 2007, J CLIN MICROBIOL, V45, P3464, DOI 10.1128/JCM.00920-07; Kristensen L, 2005, ACTA DERM-VENEREOL, V85, P261, DOI 10.1080/00015550510025605; Schaal JV, 2015, BURNS, V41, P853, DOI 10.1016/j.burns.2014.10.024; Schofield CM, 2007, BURNS, V33, P341, DOI 10.1016/j.burns.2006.08.040; Sharma S, 2013, BMJ CASE REP; Tam EWT, 2014, J CLIN MICROBIOL, V52, P1153, DOI 10.1128/JCM.03258-13	9	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	APR	2018	71	4					379	380		10.1136/jclinpath-2017-204858			2	Pathology	Pathology	GB2VG	WOS:000428913200016	29358477				2019-10-28	
J	Kidd, SE; Halliday, CL; Morris, AJ; Chen, SCA				Kidd, Sarah E.; Halliday, Catriona L.; Morris, Arthur J.; Chen, Sharon C-A.			Antifungal susceptibility testing in Australasian clinical laboratories: we must improve our performance	PATHOLOGY			English	Editorial Material							CANDIDA; MICRODILUTION; CASPOFUNGIN		[Kidd, Sarah E.] SA Pathol, Natl Mycol Reference Ctr, Adelaide, SA, Australia; [Halliday, Catriona L.; Chen, Sharon C-A.] Univ Sydney, ICPMR NSW Hlth Pathol, Ctr Infect Dis & Microbiol Lab Serv, Clin Mycol Reference Lab, Westmead, NSW, Australia; [Halliday, Catriona L.; Chen, Sharon C-A.] Univ Sydney, Westmead Hosp, Westmead, NSW, Australia; [Morris, Arthur J.] Royal Coll Pathologists, Australasia Qual Assurance Programs, St Leonards, NSW, Australia	Kidd, SE (reprint author), SA Pathol, Natl Mycol Reference Ctr, Microbiol & Infect Dis, Frome Rd, Adelaide, SA 5000, Australia.	sarah.kidd@sa.gov.au	Kidd, Sarah E/N-1362-2013	Kidd, Sarah E/0000-0002-5957-4178			Albataineh MT, 2016, INFECT DIS CLIN N AM, V30, P13, DOI 10.1016/j.idc.2015.10.014; Arendrup MC, 2015, 731 EUCAST; Arendrup MC, 2015, 931 EUCAST; Astvad KM, 2013, ANTIMICROB AGENTS CH, V57, P177, DOI 10.1128/AAC.01382-12; Clinical and Laboratory Standards Institute [CLSI], 2018, EP CUT VAL ANT SUSC; Clinical and Laboratory Standards Institute (CLSI), 2017, REF METH BROTH DIL A, pM38; CLSI-Clinical and Laboratory Standards Institute, 2017, PERF STAND ANT SUSC; Cuenca-Estrella M, 2010, J CLIN MICROBIOL, V48, P1782, DOI 10.1128/JCM.02316-09; EUCAST, 2017, ANT AG BREAKP TABL I; Kahlmeter G, 2006, CLIN MICROBIOL INFEC, V12, P501, DOI 10.1111/j.1469-0691.2006.01454.x; Peterson JF, 2011, J CLIN MICROBIOL, V49, P1765, DOI 10.1128/JCM.02517-10; Pfaller MA, 2013, DIAGN MICR INFEC DIS, V77, P37, DOI 10.1016/j.diagmicrobio.2013.05.019; REX JH, 1993, CLIN MICROBIOL REV, V6, P367	13	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					257	260		10.1016/j.pathol.2018.01.001			4	Pathology	Pathology	GA7OF	WOS:000428525100001	29499872				2019-10-28	
J	Flodrova, P; Flodr, P; Pika, T; Vymetal, J; Holub, D; Dzubak, P; Hajduch, M; Scudla, V				Flodrova, Pavla; Flodr, Patrik; Pika, Tomas; Vymetal, Jiri; Holub, Dusan; Dzubak, Petr; Hajduch, Marian; Scudla, Vlastimil			Cardiac amyloidosis: from clinical suspicion to morphological diagnosis	PATHOLOGY			English	Review						Amyloidosis; immunoglobulin light chains; transthyretin; AL amyloid; AA amyloid; echocardiography	BRAIN NATRIURETIC PEPTIDE; PRIMARY SYSTEMIC AMYLOIDOSIS; LIGHT-CHAIN AMYLOIDOSIS; MAGNETIC-RESONANCE; AL AMYLOIDOSIS; ENDOMYOCARDIAL BIOPSY; MASS-SPECTROMETRY; PROGNOSTIC VALUE; STAGING SYSTEM; CLASSIFICATION	Amyloidosis is a heterogeneous group of diseases characterised by extracellular accumulation of amyloid in various tissues and organs of the body, leading to alteration and destruction of tissues. Heart involvement is the most important prognostic factor in patients with systemic amyloidosis and the diagnosis and typing of amyloid must be made properly. The clinical picture shows congestive heart failure with predominant right-sided heart failure symptoms in fully developed disease, various types of arrhythmias and characteristic electrocardiography and echocardiography findings. Blood and urine monoclonal protein studies and cardiac biomarkers belong to the spectrum of standard laboratory examinations. Cardiac cardiomyopathy is connected with amyloid based on immunoglobulin light chains, serum amyloid A, transthyretin, atrial natriuretic factor or apolipoprotein A1. In the routine diagnostic algorithm, biopsy specimens are examined using special histological staining, immunohistochemistry and immunofluorescence; proteomic analysis is only performed in specialised centres.	[Flodrova, Pavla; Flodr, Patrik] Palacky Univ Olomouc, Fac Med & Dent, Dept Clin & Mol Pathol, Hnevotinska 3, Olomouc 77900, Czech Republic; [Pika, Tomas; Scudla, Vlastimil] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic; [Vymetal, Jiri] Univ Hosp Olomouc, Dept Internal Med Nephrol Rheumatol & Endocrinol, Olomouc, Czech Republic; [Holub, Dusan; Dzubak, Petr; Hajduch, Marian] Palacky Univ Olomouc, Fac Med & Dent, Inst Mol & Translat Med, Olomouc, Czech Republic	Flodrova, P (reprint author), Palacky Univ Olomouc, Fac Med & Dent, Dept Clin & Mol Pathol, Hnevotinska 3, Olomouc 77900, Czech Republic.	pavla.flodrova@upol.cz	Hajduch, Marian/J-4015-2014	Hajduch, Marian/0000-0002-4834-908X	Ministry of Health of the Czech RepublicMinistry of Health, Czech Republic [16-31156A]; Czech Ministry of Education, Youth and SportsMinistry of Education, Youth & Sports - Czech Republic [LO1304, UP 61989592]; EATRIS-CZ [LM2015064]; Faculty of Medicine and Dentistry Palacky University Olomouc [IGA_LF_2017_021, IGA_LF_2017_026]; University Hospital Olomouc [RVO-FNOL16_2016]	Supported by grants from the Ministry of Health of the Czech Republic (16-31156A), the Czech Ministry of Education, Youth and Sports (LO1304 and UP 61989592), EATRIS-CZ (LM2015064), the Faculty of Medicine and Dentistry Palacky University Olomouc (IGA_LF_2017_021, IGA_LF_2017_026) and the University Hospital Olomouc (RVO-FNOL16_2016). The authors state that there are no conflicts of interest to disclose.	Adams D, 2016, CURR OPIN NEUROL, V29, pS14, DOI 10.1097/WCO.0000000000000289; Ando Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-31; Apridonidze T, 2012, AM J CARDIOL, V110, P1180, DOI 10.1016/j.amjcard.2012.05.061; Arbustini E, 2002, AMYLOID, V9, P108, DOI 10.3109/13506120208995243; Ariyarajah V, 2009, CARDIOLOGY, V113, P132, DOI 10.1159/000177950; Asl LH, 1999, AM J PATHOL, V154, P221, DOI 10.1016/S0002-9440(10)65268-6; Basso C, 2013, HEART FAIL REV, V18, P673, DOI 10.1007/s10741-012-9355-6; Benson MD, 2015, BLOOD, V125, P3281, DOI 10.1182/blood-2014-12-618108; Bever KM, 2016, HAEMATOLOGICA, V101, P86, DOI 10.3324/haematol.2015.133900; Brambilla F, 2013, PROTEOM CLIN APPL, V7, P136, DOI 10.1002/prca.201200097; Brambilla F, 2012, BLOOD, V119, P1844, DOI 10.1182/blood-2011-07-365510; Brunjes DL, 2016, J CARD FAIL, V22, P996, DOI 10.1016/j.cardfail.2016.10.008; Chee CE, 2010, CL LYMPH MYELOM LEUK, V10, P177, DOI 10.3816/CLML.2010.n.027; Collins AB, 2009, CARDIOVASC PATHOL, V18, P205, DOI 10.1016/j.carpath.2008.05.004; COOPER JH, 1969, J CLIN PATHOL, V22, P410, DOI 10.1136/jcp.22.4.410; D'Souza A, 2013, AM J HEMATOL, V88, P577, DOI 10.1002/ajh.23456; de Larrea CF, 2015, BLOOD, V125, P2239, DOI 10.1182/blood-2014-11-609883; Desport E, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-54; Dinner S, 2013, BRIT J HAEMATOL, V161, P367, DOI 10.1111/bjh.12269; Dispenzieri A, 2004, BLOOD, V104, P1881, DOI 10.1182/blood-2004-01-0390; Dispenzieri A, 2004, J CLIN ONCOL, V22, P3751, DOI 10.1200/JCO.2004.03.029; Dispenzieri A, 2003, LANCET, V361, P1787, DOI 10.1016/S0140-6736(03)13396-X; Dispenzieri A, 2012, BLOOD REV, V26, P137, DOI 10.1016/j.blre.2012.03.001; Dubrey S, 2015, POSTGRAD MED J, V91, P439, DOI 10.1136/postgradmedj-2014-133224; Dubrey SW, 1998, QJM-MON J ASSOC PHYS, V91, P141, DOI 10.1093/qjmed/91.2.141; Esplin BL, 2013, CURR PROB CARDIOLOGY, V38, P53, DOI 10.1016/j.cpcardiol.2012.11.002; Falk RH, 2005, CIRCULATION, V112, P2047, DOI 10.1161/CIRCULATIONAHA.104.489187; FENOGLIO JJ, 1987, HUM PATHOL, V18, P609, DOI 10.1016/S0046-8177(87)80361-1; Fradley MG, 2012, TEX HEART I J, V39, P71; Genschel J, 1998, FEBS LETT, V430, P145, DOI 10.1016/S0014-5793(98)00668-1; Gilbertson JA, 2015, J CLIN PATHOL, V68, P314, DOI 10.1136/jclinpath-2014-202722; Gillmore JD, 2016, CIRCULATION, V133, P2404, DOI 10.1161/CIRCULATIONAHA.116.021612; Haase CL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003063; Hutt DF, 2016, AMYLOID, V23, P134, DOI 10.3109/13506129.2016.1158160; Hutt DF, 2014, EUR HEART J-CARD IMG, V15, P1289, DOI 10.1093/ehjci/jeu107; Kapoor P, 2011, AM J MED, V124, P1006, DOI 10.1016/j.amjmed.2011.04.013; Kebbel A, 2006, AM J SURG PATHOL, V30, P673, DOI 10.1097/00000478-200606000-00002; KLEIN AL, 1990, J AM COLL CARDIOL, V16, P1135, DOI 10.1016/0735-1097(90)90545-Z; KOSMA VM, 1985, ANAL QUANT CYTOL, V7, P267; Koyama J, 2010, JACC-CARDIOVASC IMAG, V3, P333, DOI 10.1016/j.jcmg.2009.11.013; Kristen AV, 2010, BLOOD, V116, P2455, DOI 10.1182/blood-2010-02-267708; Kumar S, 2012, J CLIN ONCOL, V30, P989, DOI 10.1200/JCO.2011.38.5724; Kumar S, 2010, BLOOD, V116, P5126, DOI 10.1182/blood-2010-06-290668; Lachmann HJ, 2006, CURR OPIN PHARMACOL, V6, P214, DOI 10.1016/j.coph.2005.10.005; Lehrke S, 2009, AMYLOID, V16, P187, DOI 10.3109/13506120903421538; Leone O, 2012, CARDIOVASC PATHOL, V21, P245, DOI 10.1016/j.carpath.2011.10.001; Leung N, 2012, BLOOD, V120, P3206, DOI 10.1182/blood-2012-03-413682; Maleszewski JJ, 2013, CARDIOVASC PATHOL, V22, P189, DOI 10.1016/j.carpath.2012.09.001; Maurer MS, 2016, J AM COLL CARDIOL, V68, P161, DOI 10.1016/j.jacc.2016.03.596; Menter T, 2016, PATHOBIOLOGY, V84, P49, DOI 10.1159/000447304; Merlini G, 2011, J CLIN ONCOL, V29, P1924, DOI 10.1200/JCO.2010.32.2271; Mohty D, 2013, ARCH CARDIOVASC DIS, V106, P528, DOI 10.1016/j.acvd.2013.06.051; Palecek T, 2015, CURR PHARM DESIGN, V21, P491; Palladini G, 2003, CIRCULATION, V107, P2440, DOI 10.1161/01.CIR.0000068314.02595.B2; Palladini G, 2016, BLOOD, V128, P159, DOI 10.1182/blood-2016-01-629790; Patel KS, 2015, J INTERN MED, V278, P126, DOI 10.1111/joim.12383; Pepys MB, 2006, ANNU REV MED, V57, P223, DOI 10.1146/annurev.med.57.121304.131243; Pepys-Vered ME, 2014, ISR MED ASSOC J, V16, P277; Pilebro B, 2016, UPSALA J MED SCI, V121, P17, DOI 10.3109/03009734.2015.1122687; Pinney JH, 2013, BRIT J HAEMATOL, V161, P525, DOI 10.1111/bjh.12286; Podduturi Varsha, 2013, Proc (Bayl Univ Med Cent), V26, P387; de Asua DR, 2014, CLIN EPIDEMIOL, V6, P369, DOI 10.2147/CLEP.S39981; Ruberg FL, 2012, CIRCULATION, V126, P1286, DOI 10.1161/CIRCULATIONAHA.111.078915; Sanchorawala V, 2006, AM J HEMATOL, V81, P692, DOI 10.1002/ajh.20635; Satoskar AA, 2011, AM J SURG PATHOL, V35, P1685, DOI 10.1097/PAS.0b013e3182263d74; Sattianayagam PT, 2012, EUR HEART J, V33, P1120, DOI 10.1093/eurheartj/ehr383; Schonland SO, 2012, BLOOD, V119, P488, DOI 10.1182/blood-2011-06-358507; Sekijima Y, 2014, J CLIN PHARM THER, V39, P225, DOI 10.1111/jcpt.12145; Selvanayagam JB, 2007, J AM COLL CARDIOL, V50, P2101, DOI 10.1016/j.jacc.2007.08.028; Siddiqi OK, 2018, TRENDS CARDIOVAS MED, V28, P10, DOI 10.1016/j.tcm.2017.07.004; Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858; Srkalovic Gordan, 2005, Int Semin Surg Oncol, V2, P17, DOI 10.1186/1477-7800-2-17; Syed IS, 2010, JACC-CARDIOVASC IMAG, V3, P155, DOI 10.1016/j.jcmg.2009.09.023; Telio D, 2010, AM J HEMATOL, V85, P805, DOI 10.1002/ajh.21814; Vogelsberg H, 2008, J AM COLL CARDIOL, V51, P1022, DOI 10.1016/j.jacc.2007.10.049; Vrana JA, 2014, HAEMATOLOGICA, V99, P1239, DOI 10.3324/haematol.2013.102764; Vrana JA, 2009, BLOOD, V114, P4957, DOI 10.1182/blood-2009-07-230722; Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X; Zhang Q, 2016, PATHOL RES PRACT, V212, P185, DOI 10.1016/j.prp.2015.08.007	79	6	6	3	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					261	268		10.1016/j.pathol.2017.10.012			8	Pathology	Pathology	GA7OF	WOS:000428525100002	29448998				2019-10-28	
J	Csanadi, A; Oser, A; Aumann, K; Gumpp, V; Rawluk, J; Nestle, U; Kayser, C; Wiesemann, S; Werner, M; Kayser, G				Csanadi, Agnes; Oser, Annika; Aumann, Konrad; Gumpp, Vera; Rawluk, Justyna; Nestle, Ursula; Kayser, Claudia; Wiesemann, Sebastian; Werner, Martin; Kayser, Gian			Overexpression of SLC1a5 in lymph node metastases outperforms assessment in the primary as a negative prognosticator in non-small cell lung cancer	PATHOLOGY			English	Article						Lung cancer; glutamine metabolism; SLC1a5; survival; immunohistochemistry	ACID TRANSPORTER ASCT2; GLUTAMINE TRANSPORT; GROWTH; EXPRESSION; SURVIVAL	Despite recent advances in therapeutic options, lung cancer is the leading cause of death among malignant diseases worldwide. Glutamine-dependence is an established attribute in cancer tissue with emerging importance as a diagnostic and therapeutic target. We analysed the expression of SLC1a5, a major glutamine transporter, in the primary tumour and corresponding nodal metastasis of non-small cell lung cancer (NSCLC) to investigate its biological impact. Expression of SLC1a5 was analysed by immunohistochemistry in 259 NSCLC and in 142 nodal metastases and correlated with clinicopathological parameters including overall survival. SLC1a5 expression in the primary tumour and in the corresponding lymph node metastasis revealed a positive correlation (p = 0.005). Moreover, overexpression of SLC1a5 was found to be an independent prognostic factor (p = 0.027) if assessed in lymph node metastases only. SLC1A5 expression was studied for the first time in both primary NSCLC and its corresponding nodal metastasis. Our results indicate that overexpression of SLC1a5 is associated with shorter overall survival. This proved to be an independent prognosticator if assessed in the lymph node metastases. Thus, diagnostics in lymph node metastasis provide superior prognostic information for SLC1a5 overexpression and may open target prediction for future therapeutic options.	[Csanadi, Agnes; Oser, Annika; Aumann, Konrad; Kayser, Claudia; Werner, Martin; Kayser, Gian] Univ Freiburg, Med Ctr, Inst Surg Pathol, Freiburg, Germany; [Csanadi, Agnes; Oser, Annika; Aumann, Konrad; Rawluk, Justyna; Nestle, Ursula; Kayser, Claudia; Wiesemann, Sebastian; Werner, Martin; Kayser, Gian] Univ Freiburg, Fac Med, Freiburg, Germany; [Gumpp, Vera] Univ Freiburg, Med Ctr, Comprehens Canc Ctr Freiburg, Clin Canc Registry, Freiburg, Germany; [Rawluk, Justyna] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Freiburg, Germany; [Nestle, Ursula] Univ Freiburg, Med Ctr, Dept Radiat Oncol, Freiburg, Germany; [Wiesemann, Sebastian] Univ Freiburg, Med Ctr, Dept Thorac Surg, Freiburg, Germany	Kayser, G (reprint author), Univ Hosp Freiburg, Inst Surg Pathol, Dept Pathol, Breisacher Str 115a, D-79106 Freiburg, Germany.	gian.kayser@uniklinik-freiburg.de					BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Binder D, 2013, CLIN MED INSIGHTS-ON, V7, P221, DOI 10.4137/CMO.S10269; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Csanadi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126357; Esslinger CS, 2005, BIOORGAN MED CHEM, V13, P1111, DOI 10.1016/j.bmc.2004.11.028; Fuchs BC, 2007, AM J PHYSIOL-CELL PH, V293, pC55, DOI 10.1152/ajpcell.00330.2006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hassanein M, 2016, MOL IMAGING BIOL, V18, P18, DOI 10.1007/s11307-015-0862-4; Hassanein M, 2015, INT J CANCER, V137, P1587, DOI 10.1002/ijc.29535; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Kayser G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056333; Li RL, 2003, ANTICANCER RES, V23, P3413; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Schabath MB, 2014, CANCER CONTROL, V21, P51, DOI 10.1177/107327481402100107; Shimizu K, 2014, BRIT J CANCER, V110, P2030, DOI 10.1038/bjc.2014.88; Sobin LH, 2009, TNM CLASSIFICATION M; Travis WD, 2015, WHO CLASSIFICATION T; van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381; Wang Q, 2015, J PATHOL, V236, P278, DOI 10.1002/path.4518; Wang Q, 2014, INT J CANCER, V135, P1060, DOI 10.1002/ijc.28749; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Witte D, 2002, ANTICANCER RES, V22, P2555; Zhu YH, 2015, AMINO ACIDS, V47, P2185, DOI 10.1007/s00726-014-1785-0	24	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					269	275		10.1016/j.pathol.2017.10.016			7	Pathology	Pathology	GA7OF	WOS:000428525100003	29455869				2019-10-28	
J	Fadare, O; Roma, AA; Mhawech-Fauceglia, P; Parkash, V; Rabban, JT				Fadare, Oluwole; Roma, Andres A.; Mhawech-Fauceglia, Paulette; Parkash, Vinita; Rabban, Joseph T.			The diagnosis of mucinous lesions in endometrial samplings by gynaecological pathologists: an analysis of diagnostic reproducibility	PATHOLOGY			English	Article						Mucinous metaplasia; atypical mucinous glandular proliferation; endometrial biopsy; endometrial curettage; mucinous carcinoma	RISK-FACTOR; EPITHELIAL LESIONS; ADENOCARCINOMA; PROLIFERATIONS; CARCINOMA; CANCER; METAPLASIA; BIOPSIES; CRITERIA	The purpose of this study is to assess the reproducibility among gynaecological pathologists in their diagnosis of mucinous alterations in endometrial sampling specimens. Twenty-six cases were independently reviewed by four experienced gynaecological pathologists from four academic medical centres. Pathologists were asked to classify each case into one of four groups, including three World Health Organization (WHO)-recognised categories: (1) mucinous metaplasia; (2) atypical mucinous glandular proliferation; (3) carcinoma; and (4) 'other' (absence of a true mucinous alteration and/or an alteration of non-endometrial origin). The overall reproducibility was 'fair' (k = 0.39). In an analytical scenario that established three clinically significant groups ('benign/non-neoplastic', 'atypical', and 'carcinoma') by redis-tributing all group 4 responses, the resultant kappa improved to 0.51 (moderate reproducibility). In another analysis with only two categories-'benign/nonneoplastic' versus 'atypical/carcinoma'-reproducibility was similarly moderate (k = 0.46). However, with one exception, all cases that were ultimately diagnosed as carcinoma in a follow-up hysterectomy specimen, were classified as atypical or carcinoma in the preceding sampling. For 11 cases that were classified as either 'carcinoma' or 'atypical' by all observers, there was moderate reproducibility (k = 0.53) in making that distinction, and none of a wide array of morphological features were found to significantly distinguish between these two categories. For five cases that all observers classified as either mucinous metaplasia or benign endocervix, reproducibility was substantial (k = 0.67). In summary, gynaecological pathologists show moderate reproducibility in categorising mucinous alterations in endometrial sampling specimens as benign, atypical, or carcinomatous. They accurately classify as at least 'atypical' those cases that are ultimately diagnosed as carcinoma in the subsequent resection. Our findings suggest that there are indeed some mucinous alterations which have features that do not allow for reproducible assignment by pathologists into the WHO-recognised categories. In this subset of cases, there may be a need for better-defined diagnostic criteria and/or extra-morphological diagnostic tools.	[Fadare, Oluwole; Roma, Andres A.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Roma, Andres A.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA; [Mhawech-Fauceglia, Paulette] Univ Southern Calif, Keck Sch Med, Dept Lab Med & Pathol, Los Angeles, CA USA; [Parkash, Vinita] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Rabban, Joseph T.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA	Fadare, O (reprint author), Univ Calif San Diego Hlth, Div Anat Pathol, Dept Pathol, 9300 Campus Point Dr,Suite 1-200,MC 7723, La Jolla, CA 92037 USA.	oluwole.fadare@gmail.com					Abdulfatah E, 2017, MODERN PATHOL, V30, p271A; Alomari A, 2014, MODERN PATHOL, V27, P675, DOI 10.1038/modpathol.2013.186; Bartosch C, 2016, AM J SURG PATHOL, V40, P1177, DOI 10.1097/PAS.0000000000000684; Berman JJ, 2006, CANCER DETECT PREV, V30, P387, DOI 10.1016/j.cdp.2006.09.002; Carlson JW, 2008, HISTOPATHOLOGY, V53, P325, DOI 10.1111/j.1365-2559.2008.03104.x; Chekmareva M, 2008, INT J GYNECOL PATHOL, V27, P547, DOI 10.1097/PGP.0b013e318177eadc; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Creasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105, DOI 10.1016/S0020-7292(06)60031-3; Fleiss JL, 2003, STAT METHODS RATES P, P614; Fujiwara M, 2011, AM J SURG PATHOL, V35, P537, DOI 10.1097/PAS.0b013e31820f1cc2; Galic V, 2013, CANCER INVEST, V31, P500, DOI 10.3109/07357907.2013.820321; Gungorduk K, 2015, INT J CLIN ONCOL, V20, P782, DOI 10.1007/s10147-014-0767-2; He M, 2015, AM J CLIN PATHOL, V143, P778, DOI 10.1309/AJCP69RBNUHHOJRI; HENDRICKSON MR, 1980, AM J SURG PATHOL, V4, P525, DOI 10.1097/00000478-198012000-00004; Ip PPC, 2013, AM J SURG PATHOL, V37, P167, DOI 10.1097/PAS.0b013e318272d428; Jalloul RJ, 2012, INT J GYNECOL CANCER, V22, P812, DOI 10.1097/IGC.0b013e31824aa877; Kihara A, 2017, AM J SURG PATHOL, V41, P896, DOI 10.1097/PAS.0000000000000856; Lehman MB, 2001, AM J SURG PATHOL, V25, P1347, DOI 10.1097/00000478-200111000-00001; LONGACRE TA, 1995, AM J SURG PATHOL, V19, P371, DOI 10.1097/00000478-199504000-00001; Marotti JD, 2011, ARCH PATHOL LAB MED, V135, P464, DOI 10.1043/2010-0139-OA.1; MELHEM MF, 1987, INT J GYNECOL PATHOL, V6, P347, DOI 10.1097/00004347-198712000-00007; Musa F, 2012, GYNECOL ONCOL, V125, P541, DOI 10.1016/j.ygyno.2012.03.004; Nucci MR, 1999, MODERN PATHOL, V12, P1137; Owusu-Darko S, 2014, J REPROD MED, V59, P527; Park CK, 2016, ONCOTARGET, V7, P39197, DOI 10.18632/oncotarget.10049; Pavlakis K, 2012, APPL IMMUNOHISTO M M, V20, P607, DOI 10.1097/PAI.0b013e31825251a4; Qiu WS, 2003, INT J GYNECOL PATHOL, V22, P261, DOI 10.1097/01.PGP.0000071043.12278.8D; Rauh-Hain JA, 2016, AM J CLIN ONCOL-CANC, V39, P43, DOI 10.1097/COC.0000000000000015; Rawish KR, 2017, HUM PATHOL, V63, P53, DOI 10.1016/j.humpath.2017.02.002; Roma AA, 2015, HUM PATHOL, V46, P1529, DOI 10.1016/j.humpath.2015.06.015; ROSS JC, 1983, AM J SURG PATHOL, V7, P715, DOI 10.1097/00000478-198307080-00001; Sloan EA, 2017, INT J GYNECOL PATHOL, V36, P205, DOI 10.1097/PGP.0000000000000315; Vang R, 2003, INT J SURG PATHOL, V11, P261, DOI 10.1177/106689690301100403; Yoo SH, 2012, MODERN PATHOL, V25, P1496, DOI 10.1038/modpathol.2012.113; Zaino R., 2014, WHO CLASSIFICATION T, P125	35	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					276	285		10.1016/j.pathol.2017.09.014			10	Pathology	Pathology	GA7OF	WOS:000428525100004	29428179				2019-10-28	
J	Stewart, CJR; Bigby, S; Giardina, T; Grieu-Iacopetta, F; Amanuel, B				Stewart, Colin J. R.; Bigby, Susan; Giardina, Tino; Grieu-Iacopetta, Fabienne; Amanuel, Benhur			An immunohistochemical and molecular analysis of papillary proliferation of the endometrium	PATHOLOGY			English	Article						Endometrium; papillary proliferation; immunohistochemistry; next generation sequencing; molecular; histopathology	P16 EXPRESSION; HYPERPLASIA; CARCINOMA; PAX2; ADENOCARCINOMAS; DISTINCTION; METAPLASIA; MUTATION; ARID1A; TUMORIGENESIS	Papillary proliferations of the endometrium (PPEs) are uncommon lesions that are often associated with endometrial polyps. PPEs occasionally precede or co-exist with atypical endometrial hyperplasia or adenocarcinoma, but their pathogenesis and relationship to endometrial neoplasia is uncertain. In the present study 11 PPEs, including eight benign papillary proliferations (BPPs) and three complex papillary hyperplasias (CPHs) were examined immunohistochemically for expression of PAX2, BAF250a, p16, beta-catenin and DNA mismatch repair (MMR) proteins. Molecular analysis was also performed on the CPHs using targeted next generation sequencing (NGS). All PPEs demonstrated at least one immunohistochemical abnormality with altered expression of p16 and PAX2 in nine and seven cases, respectively, and beta-catenin in one case. However, none of the cases showed loss of BAF250a or MMR protein staining. All CPHs showed KRAS mutations with additional mutations in AKT1 and FBXW7 in one case each, and both PIK3CA and CTNNB1 in the remaining case. Therefore, PPEs demonstrate immunophenotypical and molecular overlap with endometrial endometrioid neoplasia, although loss of BAF250a and MMR protein function do not appear to contribute significantly to these lesions. KRAS mutations may be important drivers in CPHs but this finding needs to be confirmed in larger studies.	[Stewart, Colin J. R.] Univ Western Australia, King Edward Mem Hosp, Dept Histopathol, Perth, WA, Australia; [Stewart, Colin J. R.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia; [Bigby, Susan] Middlemore Hosp, Dept Histopathol, Auckland, New Zealand; [Giardina, Tino; Grieu-Iacopetta, Fabienne; Amanuel, Benhur] Queen Elizabeth II Med Ctr, PathWest Lab Med, Div Anat Pathol, Perth, WA, Australia	Stewart, CJR (reprint author), King Edward Mem Hosp, Dept Histopathol, Bagot Rd, Perth, WA 6008, Australia.	colin.stewart@health.wa.gov.au					Allison KH, 2012, INT J GYNECOL PATHOL, V31, P159, DOI 10.1097/PGP.0b013e318226b376; Ansari-Lari MA, 2004, AM J SURG PATHOL, V28, P160, DOI 10.1097/00000478-200402000-00002; Ardakani NM, 2017, AM J SURG PATHOL, V41, P1261, DOI 10.1097/PAS.0000000000000875; Brachtel EF, 2005, AM J SURG PATHOL, V29, P1322, DOI 10.1097/01.pas.0000171001.87599.e2; Chekmareva M, 2008, INT J GYNECOL PATHOL, V27, P547, DOI 10.1097/PGP.0b013e318177eadc; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Ip PPC, 2013, AM J SURG PATHOL, V37, P167, DOI 10.1097/PAS.0b013e318272d428; Lehman MB, 2001, AM J SURG PATHOL, V25, P1347, DOI 10.1097/00000478-200111000-00001; Matias-Guiu X, 2013, HISTOPATHOLOGY, V62, P111, DOI 10.1111/his.12053; McCluggage G, 2012, INT J GYNECOL PATHOL, V31, P206, DOI 10.1097/PGP.0b013e31823bb1a1; Monte NM, 2010, CANCER RES, V70, P6225, DOI 10.1158/0008-5472.CAN-10-0149; Moritani S, 2012, VIRCHOWS ARCH, V461, P141, DOI 10.1007/s00428-012-1276-1; Mutter GL, 2014, PATHOLOGY FEMALE REP, P370; Nicolae A, 2011, J CLIN PATHOL, V64, P97, DOI 10.1136/jcp.2010.085555; Owings RA, 2014, ARCH PATHOL LAB MED, V138, P484, DOI 10.5858/arpa.2012-0709-RA; Park CK, 2016, ONCOTARGET, V7, P39197, DOI 10.18632/oncotarget.10049; Rekhi B, 2015, DIAGN CYTOPATHOL, V43, P163, DOI 10.1002/dc.23170; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Stewart CJR, 2015, PATHOLOGY, V47, P112, DOI 10.1097/PAT.0000000000000211; Stewart CJR, 2015, INT J GYNECOL PATHOL, V34, P90, DOI 10.1097/PGP.0000000000000107; Stewart CJR, 2013, PATHOLOGY, V45, P559, DOI 10.1097/PAT.0b013e3283650ad7; Stewart CJR, 2009, MODERN PATHOL, V22, P725, DOI 10.1038/modpathol.2009.33; Takeda T, 2016, ONCOL REP, V35, P607, DOI [10.3892/or.20154421, 10.3892/or.2015.4421]; Tong GX, 2007, MODERN PATHOL, V20, P856, DOI 10.1038/modpathol.3800827; van der Putten LJM, 2017, CARCINOGENESIS, V38, P329, DOI 10.1093/carcin/bgx008; Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280; Werner HMJ, 2013, MODERN PATHOL, V26, P428, DOI 10.1038/modpathol.2012.174; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5; Yoo SH, 2012, MODERN PATHOL, V25, P1496, DOI 10.1038/modpathol.2012.113	31	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					286	292		10.1016/j.pathol.2017.10.013			7	Pathology	Pathology	GA7OF	WOS:000428525100005	29449000				2019-10-28	
J	Lubig, S; Thiesler, T; Muller, S; Vorreuther, R; Leipner, N; Kristiansen, G				Lubig, Sabine; Thiesler, Thore; Muller, Stefan; Vorreuther, Roland; Leipner, Norbert; Kristiansen, Glen			Quantitative perineural invasion is a prognostic marker in prostate cancer	PATHOLOGY			English	Article						Prostate cancer; perineural invasion; perineural carcinosis; prognostic factor	RADICAL PROSTATECTOMY; NEEDLE-BIOPSY; BIOCHEMICAL RECURRENCE; INDEPENDENT PREDICTOR; RADIATION-THERAPY; MEN; CARCINOMA; FAILURE; GRADE; ADENOCARCINOMA	This study aimed to investigate the prognostic value of a quantitative, detailed, yet practical analysis of perineural invasion in radical prostatectomy specimens in a high-risk prostate cancer cohort. A total of 114 patients with prostate cancer who underwent radical prostatectomy between 2000 and 2013 were analysed. Using S100 protein immunohistochemistry assisted in the detection of nerves. In the area of closest proximity of the tumour to the dorso-lateral margins, nerves were counted and the infiltration of nerves was categorised (0-3). Category 0 was nerves without immediate tumour-cell-contact. All nerves being fully surrounded by tumour (classical perineural carcinosis) were categorised group 3. Two further categories discriminated between nerves that were touched either by carcinoma cells below 50% of the circumference (category 1) or above (category 2). Perineural carcinosis (Pn1) was seen in 61.4% of cases and correlated positively with ISUP grades, pT categories and presence of intraductal carcinoma but failed significance on Kaplan-Meier analysis. A more quantitative analysis of percentual perineural involvement did demonstrate significant survival differences: cases with less than one Pn1-positive nerve in 5 high power fields had longer survival times. Incomplete perineural involvement (category 1-2) did not have a prognostic value, endorsing the current definition of perineural carcinosis as full circumferential encasement of a nerve by tumour cells. A quantitative analysis of the percentage of nerves positive for perineural invasion has a higher prognostic value than the classical dichotomous statement on the mere presence of perineural invasion.	[Lubig, Sabine; Thiesler, Thore; Kristiansen, Glen] Univ Hosp Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany; [Muller, Stefan] Univ Hosp Bonn, Dept Urol, Bonn, Germany; [Vorreuther, Roland] Evangel Kliniken Bonn, Dept Urol, Bonn, Germany; [Leipner, Norbert] Practice Radiotherapy Bonn Rhein Sieg, Bonn, Germany	Kristiansen, G (reprint author), Univ Hosp Bonn, Inst Pathol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	Glen.Kristiansen@ukbonn.de					Ali TZ, 2005, AM J SURG PATHOL, V29, P1159, DOI 10.1097/01.pas.0000160980.62586.05; Andersen S, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-49; Anderson PR, 1998, INT J RADIAT ONCOL, V41, P1087, DOI 10.1016/S0360-3016(98)00167-9; [Anonymous], 2004, CANCER RES, V64, P6082; Ayala GE, 2001, PROSTATE, V49, P213, DOI 10.1002/pros.1137; BASTACKY SI, 1993, AM J SURG PATHOL, V17, P336, DOI 10.1097/00000478-199304000-00003; BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426; Beard CJ, 2004, INT J RADIAT ONCOL, V58, P19, DOI 10.1016/S0360-3016(03)01433-0; Boswick DG, 1999, ARCH PATHOL LAB MED, V124, P995; Brundl J, 2014, EUR UROL, V65, P802, DOI 10.1016/j.eururo.2013.04.043; D'Amico AV, 2001, J UROLOGY, V165, P126, DOI 10.1097/00005392-200101000-00031; de la Taille A, 1999, UROLOGY, V54, P1039, DOI 10.1016/S0090-4295(99)00350-7; Duraker N, 2003, SURG TODAY, V33, P95, DOI 10.1007/s005950300020; Egan AJM, 1997, AM J SURG PATHOL, V21, P1496, DOI 10.1097/00000478-199712000-00013; Endrizzi J, 2000, BJU INT, V85, P696, DOI 10.1046/j.1464-410x.2000.00518.x; Feng FY, 2011, INT J RADIAT ONCOL, V81, pE361, DOI 10.1016/j.ijrobp.2011.04.048; Gorin MA, 2014, UROLOGY, V83, P1117, DOI 10.1016/j.urology.2013.12.042; Harnden P, 2007, CANCER, V109, P13, DOI 10.1002/cncr.22388; Hirai I, 2002, PANCREAS, V24, P15, DOI 10.1097/00006676-200201000-00003; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Jeon HG, 2009, INT J UROL, V16, P682, DOI 10.1111/j.1442-2042.2009.02331.x; Jung JH, 2011, ANN SURG ONCOL, V18, P3828, DOI 10.1245/s10434-011-1790-4; Kumano M, 2009, INT UROL NEPHROL, V41, P581, DOI 10.1007/s11255-008-9467-z; Kurtz KA, 2005, ARCH PATHOL LAB MED, V129, P354; Law WL, 2004, ANN SURG, V240, P260, DOI 10.1097/01.sla.0000133185.23514.32; Lee IH, 2007, INT J RADIAT ONCOL, V68, P1059, DOI 10.1016/j.ijrobp.2007.01.039; Lee JT, 2010, KOREAN J UROL, V51, P745, DOI 10.4111/kju.2010.51.11.745; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Masieri L, 2010, UROL INT, V85, P396, DOI 10.1159/000315491; Meng Y, 2015, INT J CLIN EXP MED, V8, P13267; Merrick GS, 2001, CANCER J, V7, P404; Merrilees AD, 2008, MODERN PATHOL, V21, P1095, DOI 10.1038/modpathol.2008.81; Miyake Hideaki, 2005, Hinyokika Kiyo, V51, P241; Moreira DM, 2015, J UROLOGY, V194, P1258, DOI 10.1016/j.juro.2015.04.113; Ng JC, 2004, J UROLOGY, V172, P2249, DOI 10.1097/01.ju.0000143973.22897.f8; Olar A, 2014, HUM PATHOL, V45, P1365, DOI 10.1016/j.humpath.2014.02.011; Quinn DI, 2003, CANCER-AM CANCER SOC, V97, P1884, DOI 10.1002/cncr.11263; Reeves F, 2015, CUAJ-CAN UROL ASSOC, V9, pE252, DOI 10.5489/cuaj.2619; Saeter T, 2016, PROSTATE, V76, P207, DOI 10.1002/pros.23112; Somford DM, 2012, WORLD J UROL, V30, P105, DOI 10.1007/s00345-010-0641-4; VILLERS A, 1989, J UROLOGY, V142, P763, DOI 10.1016/S0022-5347(17)38881-X	42	3	3	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					298	304		10.1016/j.pathol.2017.09.013			7	Pathology	Pathology	GA7OF	WOS:000428525100007	29448999				2019-10-28	
J	Korbl, JD; Wood, BA; Harvey, NT				Korbl, Jasmin Dvorah; Wood, Benjamin Andrew; Harvey, Nathan Tobias			'Why don't they ever call?' Expectations of clinicians and pathologists regarding the communication of critical diagnoses in dermatopathology	PATHOLOGY			English	Article						Dermatopathology; critical diagnoses	OF-AMERICAN-PATHOLOGISTS; CRITICAL-VALUES; ANATOMIC PATHOLOGY; SURGICAL PATHOLOGY; Q-PROBES; LABORATORIES; NOTIFICATION; RADIOLOGISTS; PARAMETER; CYTOLOGY	Certain diagnoses in dermatopathology have significant implications for patient management and on occasion appropriate clinical care may be facilitated by a phone call from the reporting dermatopathologist to the referring doctor. Whether this is appropriate depends on a number of factors. The concept of 'critical diagnoses' is now well established in surgical pathology, having evolved from critical value policies in clinical pathology and haematology. However, only limited attempts have been made to assess perceptions among different clinical groups. We designed a survey to assess the attitudes of pathologists, dermatologists, surgeons and general practitioners as to what circumstances warrant telephone contact in addition to a standard written report, as well as their approaches to routine histology follow-up. The survey was distributed Australia-wide via a combination of specialist colleges, medical forums and collegiate contacts. A total of 262 responses were received, encompassing representations from all of the targeted specialties. Approximately 20% of respondents were aware of adverse outcomes or 'near misses' which they felt had been due in some part to inadequate communication of histopathology results. While most practitioners have formal systems in place to review histopathology reports, this practice is not universal. There were a number clinical situations where there was a discrepancy between the expectations of clinicians and those of pathologists, in particular with regard to a diagnosis of cutaneous melanoma as well as cutaneous lesions which might be associated with inherited cancer syndromes. It is our hope that the results of this study will facilitate discussion between pathologists and referring clinicians at a local level to minimise the potential for miscommunication.	[Korbl, Jasmin Dvorah] Sir Charles Gairdner Hosp, Perth, WA, Australia; [Wood, Benjamin Andrew; Harvey, Nathan Tobias] PathWest, Dept Anat Pathol, Dermatopathol Grp, Perth, WA, Australia; [Wood, Benjamin Andrew; Harvey, Nathan Tobias] Univ Western Australia, Sch Med, Div Pathol & Lab Med, Perth, WA, Australia	Harvey, NT (reprint author), QEII Med Ctr, PathWest, Dept Anat Pathol, Hosp Ave, Nedlands, WA 6009, Australia.	nathan.harvey@health.wa.gov.au		Harvey, Nathan/0000-0001-5253-976X			Berlin L, 2002, AM J ROENTGENOL, V178, P27, DOI 10.2214/ajr.178.1.1780027; Bosmans JML, 2011, INSIGHTS IMAGING, V2, P577, DOI 10.1007/s13244-011-0118-z; Dighe AS, 2006, AM J CLIN PATHOL, V125, P758, DOI 10.1309/R53XVC2U5CH6TNG8; Emancipator K, 1997, AM J CLIN PATHOL, V108, P247; ESR, 2011, INSIGHTS IMAGING, V2, P93, DOI 10.1007/s13244-011-0066-7; Howanitz PJ, 2002, ARCH PATHOL LAB MED, V126, P663; Huang EC, 2009, AM J SURG PATHOL, V33, P1098, DOI 10.1097/PAS.0b013e3181a05ea9; Kim RH, 2016, J AM ACAD DERMATOL, V75, P1078, DOI 10.1016/j.jaad.2016.07.053; KOST GJ, 1990, JAMA-J AM MED ASSOC, V263, P704, DOI 10.1001/jama.263.5.704; LiVolsi VA, 2004, AM J CLIN PATHOL, V122, P171, DOI 10.1309/G1C51DYVMPDJ3DD7; LiVolsi VA, 2006, ARCH PATHOL LAB MED, V130, P641; LUNDBERG GD, 1990, JAMA-J AM MED ASSOC, V263, P709, DOI 10.1001/jama.263.5.709; Nakhleh RE, 2012, ARCH PATHOL LAB MED, V136, P148, DOI 10.5858/arpa.2011-0400-SA; Nakhleh RE, 2009, ARCH PATHOL LAB MED, V133, P1375, DOI 10.1043/1543-2165-133.9.1375; Orta L, 2009, AM J SURG PATHOL, V33, P934, DOI 10.1097/PAS.0b013e318199edca; Pereira TC, 2006, DIAGN CYTOPATHOL, V34, P447, DOI 10.1002/dc.20443; Pereira TC, 2004, AM J CLIN PATHOL, V122, P201, DOI 10.1309/7NRW7G684VEPWPMR; Pereira TC, 2008, AM J CLIN PATHOL, V130, P731, DOI 10.1309/AJCPEHGNFGBEJZ7H; Renshaw SA, 2011, ARCH PATHOL LAB MED, V135, P1391, DOI 10.5858/arpa.2011-0317-OA; Silverman JF, 2006, ARCH PATHOL LAB MED, V130, P638; Silverman JF, 2006, HUM PATHOL, V37, P982, DOI 10.1016/j.humpath.2006.03.001; Tillman J, 2003, ANN CLIN BIOCHEM, V40, P181, DOI 10.1258/000456303763046148; Visscher DW, 2008, AM J CLIN PATHOL, V130, P681, DOI 10.1309/AJCPT10TAXUYAILG; Zarbo RJ, 2003, ARCH PATHOL LAB MED, V127, P23	24	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					305	312		10.1016/j.pathol.2017.10.015			8	Pathology	Pathology	GA7OF	WOS:000428525100008	29496200				2019-10-28	
J	Bundell, C; Brunt, SJ; Cysique, LA; Brusch, A; Brew, BJ; Price, P				Bundell, Christine; Brunt, Samantha J.; Cysique, Lucette A.; Brusch, Anna; Brew, Bruce J.; Price, Patricia			The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy	PATHOLOGY			English	Article						Autoantibodies; B-cell expansion; HIV; antiretroviral therapy	AUTOIMMUNITY; ETHNICITY	Autoantibodies have been described in samples from HIV positive patients, but the effects of antiretroviral therapy (ART) remain unclear. In a retrospective longitudinal study, we applied clinical assays for autoantibodies to sera collected from 13 HIV positive patients as they began ART with <210 CD4 T-cells/mu L and over 2 years on treatment. Twelve of the 13 patients had at least one autoantibody. The frequency peaked before ART (21 from 156 assays) and declined to 8/143 positive reactions after 2 years. As anti-smooth muscle (ASM) antibodies remained common, these assays were applied to HIV patients (n = 67) who had <50 copies HIV RNA/mL plasma after 13 (2-17) years on ART, and healthy controls (n = 55). The frequency of ASM was high in these patients and correlated with levels of total IgG. Hence the high frequency of autoantibodies before ART declined, but did not disappear, with successful therapy. Autoantibody levels may reflect B-cell hyperactivity in patients stable on ART.	[Bundell, Christine; Brusch, Anna] QEII Med Ctr, PathWest Lab Med, Clin Immunol, Nedlands, WA, Australia; [Brunt, Samantha J.] Univ Western Australia, Pathol & Lab Med, Nedlands, WA, Australia; [Cysique, Lucette A.; Brew, Bruce J.] St Vincents Appl Med Res Ctr, Peter Duncan Neurosci Unit, Sydney, NSW, Australia; [Cysique, Lucette A.; Brew, Bruce J.] Neurosci Res Australia, Sydney, NSW, Australia; [Cysique, Lucette A.; Brew, Bruce J.] St Vincents Hosp, Dept Neurol, Sydney, NSW, Australia; [Price, Patricia] Curtin Univ, Sch Biomed Sci, Perth, WA, Australia	Price, P (reprint author), Curtin Univ, Sch Biomed Sci, Kent St, Bentley, WA 6102, Australia.	patricia.price@curtin.edu.au	Price, Patricia/K-1336-2019	brew, bruce/0000-0003-0622-1392	Medical Research Foundation (WA); Sir Charles Gairdner Hospital Research Project [0801]	This work was supported by the Medical Research Foundation (WA) and the Sir Charles Gairdner Hospital Research Project 0801. The authors state that there are no conflicts of interest to disclose.	Amendola A, 2002, J IMMUNOL METHODS, V265, P145, DOI 10.1016/S0022-1759(02)00077-7; Baroncelli S, 2013, ANTIVIR THER, V18, P321, DOI 10.3851/IMP2433; Brunt SJ, 2016, AIDS RES HUM RETROV, V32, P567, DOI [10.1089/aid.2015.0328, 10.1089/AID.2015.0328]; Brunt SJ, 2014, DIS MARKERS, DOI 10.1155/2014/947432; Connelly K, 2013, INTERN MED J, V43, P618, DOI 10.1111/imj.12070; Cysique LA, 2014, J NEUROVIROL, V20, P258, DOI 10.1007/s13365-014-0242-x; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Deshpande P, 2016, PATHOLOGY, V48, P483, DOI 10.1016/j.pathol.2016.03.014; Giannakopoulos B, 2009, BLOOD, V113, P985, DOI 10.1182/blood-2007-12-129627; Iordache L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006230; Katchamart W, 2010, ARTHRIT CARE RES, V62, P1128, DOI 10.1002/acr.20188; Krzyszczak ME, 2011, CLIN RHEUMATOL, V30, P1333, DOI 10.1007/s10067-011-1751-0; Lleo A, 2008, AUTOIMMUN REV, V7, P626, DOI 10.1016/j.autrev.2008.06.009; Lleo A, 2010, AUTOIMMUN REV, V9, pA259, DOI 10.1016/j.autrev.2009.12.002; Loizou S, 2003, ANN RHEUM DIS, V62, P1106, DOI 10.1136/ard.62.11.1106; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Meng ZF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003285; Moir S, 2004, J EXP MED, V200, P587, DOI 10.1084/jem.20032236; Navarta L. M., 2014, American Journal of Immunology, V10, P144, DOI 10.3844/ajisp.2014.144.155; Ng VL, 1996, CLIN REV ALLERG IMMU, V14, P367; Regidor DL, 2011, AIDS, V25, P303, DOI 10.1097/QAD.0b013e32834273ad; Yang S, 2014, CRIT REV ONCOL HEMAT, V91, P113, DOI 10.1016/j.critrevonc.2014.02.004	22	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					313	316		10.1016/j.pathol.2017.10.017			4	Pathology	Pathology	GA7OF	WOS:000428525100009	29463387				2019-10-28	
J	Badman, SG; Causer, LM; Guy, R; Wand, H; Donovan, B; Tabrizi, SN; Speers, D; Shephard, MD; Vallely, A; Whiley, D				Badman, S. G.; Causer, L. M.; Guy, R.; Wand, H.; Donovan, B.; Tabrizi, S. N.; Speers, D.; Shephard, M. D.; Vallely, A.; Whiley, D.		TTANGO Investigators	A reliable and easy to transport quality control method for chlamydia and gonorrhoea molecular point of care testing	PATHOLOGY			English	Article						GeneXpert; chlamydia; gonorrhoea; DNA; quality; control; assurance; point-of-care	REMOTE ABORIGINAL COMMUNITIES; XPERT CT/NG ASSAY; NEISSERIA-GONORRHOEAE; FIELD-EVALUATION; TRACHOMATIS; POSITIVITY; INFECTION; PCR	Quality control (QC) is an essential component of point-of-care testing programs. In the context of a randomised-controlled trial (TTANGO) using GeneXpert (Xpert) Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) point-of-care testing in remote areas of Australia, we aimed to develop and utilise a stable positive control material. Bacterial cultures of CT and NG were resuspended together to provide cycle threshold (C-t) values of approximately 25 cycles for both CT and NG when tested on the Xpert CT/NG assay. These positive control suspensions were dried in aliquots, heat inactivated, and then provided to 12 participating health services as research-only QC samples in kit form. At each service, a QC sample was resuspended and tested each month on the Xpert. QC results, including Xpert C-t values, were analysed from each site over 30 months and we calculated costs per QC sample. Overall, at 12 health services there were 89 QC samples tested (average of 8 tests per site per year). Mean C-t values for the 89 controls samples were 25.25 cycles (SD = 1.15) for CT, 24.04 cycles (SD = 1.400) for one NG target and 23.35 cycles (SD = 1.55) for the other NG target. No significant differences in C-t value for CT or NG controls were observed over a trial period of 30 months. Positive QC samples for research use in a trial of a molecular point-of-care assay were inexpensive to produce and stable when stored at 2-8 degrees C. For routine use, additional requirements such as meeting National Association of Testing Authority (NATA) regulations and Therapeutic Goods Administration (TGA) approval will need to be achieved.	[Badman, S. G.; Causer, L. M.; Guy, R.; Wand, H.; Donovan, B.; Vallely, A.] UNSW Sydney, Kirby Inst, Level 6,Wallace Wurth Bldg, Sydney, NSW 2052, Australia; [Donovan, B.] Sydney Sexual Hlth Ctr, Sydney, NSW, Australia; [Tabrizi, S. N.] Royal Womens Hosp, Dept Microbiol & Infect Dis, Melbourne, Vic, Australia; [Tabrizi, S. N.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Tabrizi, S. N.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Speers, D.] Pathwest Lab Med, Nedlands, WA, Australia; [Speers, D.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Shephard, M. D.] Flinders Univ S Australia, Int Ctr Point Of Care Testing, Adelaide, SA, Australia; [Whiley, D.] Univ Queensland, UQ Ctr Clin Res, Brisbane, Qld, Australia; [Whiley, D.] Pathol Queensland Cent Lab, Brisbane, Qld, Australia	Badman, SG (reprint author), UNSW Sydney, Kirby Inst, Level 6,Wallace Wurth Bldg, Sydney, NSW 2052, Australia.	sbadman@kirby.unsw.edu.au	Donovan, Basil J/K-1246-2012; Whiley, David/E-8955-2011	Donovan, Basil J/0000-0001-8851-4126; Whiley, David/0000-0001-5969-3161; Tangey, Annie/0000-0003-0798-0542; Vallely, Andrew/0000-0003-1558-4822; Anderson, David/0000-0002-9969-3905; Guy, Rebecca/0000-0002-2929-4634; Badman, Steven G/0000-0003-4222-3176; Ward, James/0000-0002-2892-4542	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [109902]; NHMRCNational Health and Medical Research Council of Australia [GNT1092503]	The TTANGO Trial was funded by a National Health and Medical Research Council (NHMRC) project grant #109902 and an NHMRC partnership project grant # GNT1092503. The authors state that there are no conflicts of interest to disclose.	Badman SG, 2016, SEX TRANSM INFECT, V92, P350, DOI 10.1136/sextrans-2015-052384; Bristow CC, 2014, J MICROBIOLOGY EXPT, V1, P26; Causer LM, 2015, SEX HEALTH, V12, P27, DOI 10.1071/SH14158; Cepheid Innovation, 2014, XPERT CT NG ASS ENGL; Chan M, 2016, J MICROBIOL METH, V125, P87, DOI 10.1016/j.mimet.2016.04.010; Garton L, 2016, SEX HEALTH, V13, P568, DOI 10.1071/SH16025; Gaydos CA, 2014, EXPERT REV MOL DIAGN, V14, P135, DOI 10.1586/14737159.2014.871495; Gaydos CA, 2013, J CLIN MICROBIOL, V51, P1666, DOI 10.1128/JCM.03461-12; Grebely J, 2017, LANCET GASTROENTEROL, V2, P514, DOI 10.1016/S2468-1253(17)30075-4; Guy R, 2015, SEX TRANSM INFECT, V91, P201, DOI 10.1136/sextrans-2014-051535; Guy R, 2012, SEX HEALTH, V9, P205, DOI 10.1071/SH11074; Guy RJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-485; Li SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180725; MCLEAN RA, 1991, AM STAT, V45, P54, DOI 10.2307/2685241; National Pathology Accreditation Advisory Council (NPAAC), 2015, GUID POINT CAR TEST; Natoli L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145993; Shephard M, 2016, PRACTICAL GUIDE TO GLOBAL POINT-OF-CARE TESTING, P54; Shephard M, 2016, PRACTICAL GUIDE TO GLOBAL POINT-OF-CARE TESTING, P343; Tabrizi SN, 2013, J CLIN MICROBIOL, V51, P1945, DOI 10.1128/JCM.00806-13; The Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2015, COMMON SENSE PAT APR, P1; Toliman P, 2016, J CLIN MICROBIOL, V54, P1734, DOI 10.1128/JCM.00529-16; University of Guelph Food Science, THERM DESTR MICR; ZeptoMetrix Corporation, NATTROL CHLAM TRACH; ZeptoMetrix Corporation, NATTROL NEISS GON PO	24	3	3	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					317	321		10.1016/j.pathol.2017.09.012			5	Pathology	Pathology	GA7OF	WOS:000428525100010	29336823				2019-10-28	
J	Fong, W; Timms, V; Holmes, N; Sintchenko, V				Fong, Winkie; Timms, Verlaine; Holmes, Nadine; Sintchenko, Vitali			Detection and incidence of Bordetella holmesii in respiratory specimens from patients with pertussis-like symptoms in New South Wales, Australia	PATHOLOGY			English	Article						Pertussis; Bordetella holmesii; PCR; Bordetella pertussis	INFECTION; OUTBREAK; DIAGNOSIS; CHILDREN	Bordetella pertussis, the aetiological agent of whooping cough is routinely diagnosed by polymerase chain reaction (PCR) directed at IS481, an insertion sequence target also found in Bordetella holmesii. Recent reports have suggested that B. holmesii infections can be misdiagnosed as pertussis, which can have a significant impact on public health surveillance. This study investigated the presence of B. holmesii in B. pertussis positive clinical samples, in order to determine the incidence of B. holmesii. Clinical cases of pertussis diagnosed by IS481-specific PCR between October 2008 and March 2016 in New South Wales were included. Bordetella holmesii was detected through the simultaneous amplification of IS481 and B. holmesii specific insertions sequence, hIS1001. A total of 46 of 802 patients were identified to be positive for B. holmesii rather than B. pertussis, suggesting an incidence rate of 6.5% in 2009, 16.8% in 2010, 7.6% during 2013 and 8.1% during 2015. Bordetella holmesii infections were diagnosed during and between pertussis epidemics, however cases of B. holmesii and B. pertussis co-infections were not found. The predominant age group of B. holmesii infection was 11-18 years old, which was significantly different to the mean age of B. pertussis infections (0-6 years, p = 0.023). These findings revealed that B. holmesii was co-circulating alongside the B. pertussis epidemic for seven years, hidden from view, as B. holmesii infections have been diagnosed as B. pertussis. Confirmatory testing of B. pertussis positive samples for the presence of B. holmesii, especially during pertussis epidemics, should improve the quality of laboratory diagnosis and laboratory surveillance for pertussis. The presence of B. holmesii in Australia highlights the importance of testing for this pathogen and ongoing molecular surveillance that can guide the control of whooping cough.	[Fong, Winkie; Timms, Verlaine; Holmes, Nadine; Sintchenko, Vitali] Westmead Hosp, Inst Clin Pathol & Med Res NSW Hlth Pathol, Ctr Infect Dis & Microbiol Publ Hlth, Westmead, NSW, Australia; [Fong, Winkie; Holmes, Nadine; Sintchenko, Vitali] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia	Fong, W (reprint author), Westmead Hosp C24, ICPMR, Ctr Infect Dis & Microbiol, Level 3,Hawkesbury Rd & Darcy Rd, Westmead, NSW 2145, Australia.	wfon4473@uni.sydney.edu.au	; Timms, Verlaine/E-8326-2011	Sintchenko, Vitali/0000-0002-9261-3650; Timms, Verlaine/0000-0002-3883-4428	Centre for Infectious Diseases and Microbiology - Public Health	WF was supported by a postgraduate research scholarship from the Centre for Infectious Diseases and Microbiology - Public Health. The authors state that there are no conflicts of interest to disclose.	Acosta AM, 2015, PEDIATRICS, V135, P981, DOI [10.1542/peds.2014-4118, 10.1542/peds.2014-3358]; Antila M, 2006, J MED MICROBIOL, V55, P1043, DOI 10.1099/jmm.0.46331-0; BASS JW, 1986, PEDIATR INFECT DIS J, V5, P154, DOI 10.1097/00006454-198601000-00051; Breakwell L, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3973; Cherry JD, 1996, J INFECT DIS, V174, pS259, DOI 10.1093/infdis/174.Supplement_3.S259; Cherry JD, 1998, FEIGIN CHERRYS TXB P; Crowcroft NS, 2003, LANCET INFECT DIS, V3, P413, DOI 10.1016/S1473-3099(03)00669-8; Kamiya H, 2012, EMERG INFECT DIS, V18, P1166, DOI 10.3201/eid1807.120130; Lam C, 2014, EMERG INFECT DIS, V20, P626, DOI 10.3201/eid2004.131478; Mazengia E, 2000, J CLIN MICROBIOL, V38, P2330; Miranda C, 2013, REV CHIL INFECTOL, V30, P237, DOI 10.4067/S0716-10182013000300001; Miranda C, 2012, J CLIN MICROBIOL, V50, P1505, DOI 10.1128/JCM.06747-11; Misegades LK, 2010, JAMA-J AM MED ASSOC, V2012, P2126; Muller FMC, 1997, J CLIN MICROBIOL, V35, P2435; Muloiwa R, 2016, PEDIATR INFECT DIS J, V35, P611, DOI 10.1097/INF.0000000000001132; Njamkepo E, 2011, J CLIN MICROBIOL, V49, P4347, DOI 10.1128/JCM.01272-11; Pittet LF, 2015, EXPERT REV ANTI-INFE, V13, P965, DOI 10.1586/14787210.2015.1056161; Pittet LF, 2014, LANCET INFECT DIS, V14, P510, DOI 10.1016/S1473-3099(14)70021-0; Rodgers L, 2013, CLIN INFECT DIS, V56, P322, DOI 10.1093/cid/cis888; Stojanov S, 2000, INFECTION, V28, P106, DOI 10.1007/s150100050056; Tizolova A, 2013, EUR J CLIN MICROBIOL, V32, P89, DOI 10.1007/s10096-012-1718-3; Yih WK, 1999, EMERG INFECT DIS, V5, P441, DOI 10.3201/eid0503.990317	22	1	1	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					322	326		10.1016/j.pathol.2017.10.014			5	Pathology	Pathology	GA7OF	WOS:000428525100011	29455870				2019-10-28	
J	Bosic, M; Kirchner, M; Brasanac, D; Leichsenring, J; Lier, A; Volckmar, AL; Oliveira, C; Buchhalter, I; Stogbauer, F; Zivkovic-Perisic, S; Goeppert, B; Schirmacher, P; Penzel, R; Endris, V; Stenzinger, A				Bosic, Martina; Kirchner, Martina; Brasanac, Dimitrije; Leichsenring, Jonas; Lier, Amelie; Volckmar, Anna-Lena; Oliveira, Cristiano; Buchhalter, Ivo; Stoegbauer, Fabian; Zivkovic-Perisic, Snezana; Goeppert, Benjamin; Schirmacher, Peter; Penzel, Roland; Endris, Volker; Stenzinger, Albrecht			Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas	PATHOLOGY			English	Article						Poroma; porocarcinoma; UV signature; HRAS; TP53; PIK3CA	ECCRINE POROMA; CANCER GENES; LUNG-CANCER; P53 PROTEIN; MUTATIONS; PHOSPHORYLATION; HETEROZYGOSITY; INHIBITORS; RECURRENT; PATHWAY	The genetic landscape of rare benign tumours and their malignant counterparts is still largely unexplored. While recent work showed that mutant HRAS is present in subsets of poromas and porocarcinomas, a more comprehensive genetic view on these rare adnexal neoplasms is lacking. Using high-coverage next generation sequencing, we investigated the mutational profile of 50 cancer-related genes in 12 cases (six poromas and six porocarcinomas). Non-synonymous mutations were found in two-thirds of both poromas and porocarcinomas. Hotspot HRAS mutations were identified in two poromas (p.G13R and p.Q61R) and one porocarcinoma (p.G13C). While in poromas only few cases showed single mutated genes, porocarcinomas showed greater genetic heterogeneity with up to six mutated genes per case. Recurrent TP53 mutations were found in all porocarcinomas that harboured mutated genes. Non-recurrent mutations in porocarcinomas were found in several additional tumour suppressors (RB1, APC, CDKN2A, and PTEN), and genes implicated in PI3K-AKT and MAPK signalling pathways (ABL1, PDGFRA, PIK3CA, HRAS, and RET). UV-associated mutations were found in TP53, APC, CDKN2A, PTEN, and RET. In conclusion, our study confirms and extends the spectrum of genetic lesions in poromas and porocarcinomas. While poromas exhibited only few mutations, which did not involve TP53, the majority of porocarcinomas harboured UV-mediated mutations in TP53 with some of these cases showing considerable genetic heterogeneity that may be clinically exploitable.	[Bosic, Martina; Brasanac, Dimitrije] Univ Belgrade, Inst Pathol, Fac Med, Belgrade, Serbia; [Kirchner, Martina; Leichsenring, Jonas; Lier, Amelie; Volckmar, Anna-Lena; Oliveira, Cristiano; Buchhalter, Ivo; Stoegbauer, Fabian; Goeppert, Benjamin; Schirmacher, Peter; Penzel, Roland; Endris, Volker; Stenzinger, Albrecht] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Zivkovic-Perisic, Snezana] Inst Publ Hlth Dr Milan Jovanov Batut, Belgrade, Serbia; [Schirmacher, Peter; Stenzinger, Albrecht] German Canc Consortium DKTK, Heidelberg, Germany	Stenzinger, A (reprint author), Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	albrecht.stenzinger@med.uni-heidelberg.de		Buchhalter, Ivo/0000-0003-0764-5832; Goeppert, Benjamin/0000-0002-4135-9250	German Cancer Consortium (DKTK); Giordano Fellowship of the European Society of Pathology (ESP); Serbian Ministry of Education, Science and Technological Development grant [175026]	This work was supported by the German Cancer Consortium (DKTK, to PS and AS), a Giordano Fellowship of the European Society of Pathology (ESP) and Serbian Ministry of Education, Science and Technological Development grant (project No. 175026, to MB). The authors state that there are no conflicts of interest to disclose.	Akalin T, 2001, AM J DERMATOPATH, V23, P402, DOI 10.1097/00000372-200110000-00003; Cecchini MJ, 2011, BIOCHEM J, V434, P297, DOI 10.1042/BJ20101210; Dai J, 2013, CLIN CANCER RES, V19, P6935, DOI 10.1158/1078-0432.CCR-13-1266; Gonzalez-Vela MDC, 2017, J INVEST DERMATOL, V137, P197, DOI 10.1016/j.jid.2016.08.015; Dias-Santagata D, 2011, MODERN PATHOL, V24, P974, DOI 10.1038/modpathol.2011.48; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gorges LL, 2008, AM J PHYSIOL-CELL PH, V295, pC1151, DOI 10.1152/ajpcell.00300.2008; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Harms PW, 2016, HUM PATHOL, V51, P25, DOI 10.1016/j.humpath.2015.12.015; Harvey NT, 2016, PATHOLOGY, V48, P454, DOI 10.1016/j.pathol.2016.05.004; Ichihashi N, 2000, J DERMATOL SCI, V22, P102, DOI 10.1016/S0923-1811(99)00052-3; Kazakov DV, 2012, CUTANEOUS ADNEXAL TU; Kusters-Vandevelde HVN, 2010, INT J CANCER, V126, P2123, DOI 10.1002/ijc.24871; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Le LP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047290; LeBoit PE, 2006, WHO CLASSIFICATION T; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; Pfarr N, 2017, HUM PATHOL, V62, P246, DOI 10.1016/j.humpath.2016.09.034; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P113, DOI 10.1002/gcc.22315; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Robson A, 2001, AM J SURG PATHOL, V25, P710, DOI 10.1097/00000478-200106000-00002; Salih AM, 2017, INT J SURG CASE REP, V30, P13, DOI [10.1016/j.ijscr.2016.10.051, 10.1016/j.ijscr.2016.11.051]; Stenzinger A, 2014, ONCOTARGET, V5, P6404, DOI 10.18632/oncotarget.2223; Stratikopoulos EE, 2016, CLIN CANCER RES, V22, P2605, DOI 10.1158/1078-0432.CCR-15-2389; Takata M, 1996, J INVEST DERMATOL, V106, P1141, DOI 10.1111/1523-1747.ep12340190; TATEYAMA H, 1995, AM J DERMATOPATH, V17, P457, DOI 10.1097/00000372-199510000-00005; Wang XM, 1997, PHOTOCHEM PHOTOBIOL, V66, P294, DOI 10.1111/j.1751-1097.1997.tb08658.x; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6	33	3	3	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					327	332		10.1016/j.pathol.2017.10.011			6	Pathology	Pathology	GA7OF	WOS:000428525100012	29269125				2019-10-28	
J	Reagh, J; Clarkson, A; Bullock, M; Shepherd, P; Gill, AJ				Reagh, Jessica; Clarkson, Adele; Bullock, Martyn; Shepherd, Phillip; Gill, Anthony J.			Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma	PATHOLOGY			English	Letter							BRAF V600E MUTATION; LYNCH SYNDROME; CANCER		[Reagh, Jessica; Clarkson, Adele; Gill, Anthony J.] Royal North Shore Hosp, Dept Anat Pathol, Pathol NSW, St Leonards, NSW, Australia; [Reagh, Jessica; Clarkson, Adele; Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Res Grp, St Leonards, NSW, Australia; [Bullock, Martyn] Royal North Shore Hosp, Kolling Inst Med Res, Canc Genet Lab, Hormones & Canc Grp, St Leonards, NSW, Australia; [Shepherd, Phillip] Liggins Inst, Auckland UniServ Sequenom Facil, Auckland, New Zealand; [Gill, Anthony J.] Univ Sydney, Sydney Univ Med Sch, Sydney, NSW, Australia	Gill, AJ (reprint author), Royal North Shore Hosp, Dept Anat Pathol, Pathol NSW, St Leonards, NSW, Australia.; Gill, AJ (reprint author), Univ Sydney, Sydney Univ Med Sch, Sydney, NSW, Australia.	affgill@med.usyd.edu.au	Gill, Anthony J./M-5015-2019				Adackapara CA, 2013, HISTOPATHOLOGY, V63, P187, DOI 10.1111/his.12154; Capper D, 2013, INT J CANCER, V133, P1624, DOI 10.1002/ijc.28183; Day F, 2015, TARGET ONCOL, V10, P99, DOI 10.1007/s11523-014-0319-8; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Estrella JS, 2015, MOL CANCER THER, V14, P2887, DOI 10.1158/1535-7163.MCT-15-0615; Jin M, 2013, AM J CLIN PATHOL, V140, P177, DOI 10.1309/AJCPB9FOVH1HGKFR; Lasota J, 2014, AM J SURG PATHOL, V38, P1235, DOI 10.1097/PAS.0000000000000229; Loes IM, 2015, TUMOR BIOL, V36, P1003, DOI 10.1007/s13277-014-2711-5; Nakaji Y, 2017, J CANCER RES CLIN, V143, P151, DOI 10.1007/s00432-016-2275-4; Parsons MT, 2012, J MED GENET, V49, P151, DOI 10.1136/jmedgenet-2011-100714; Toon CW, 2014, MODERN PATHOL, V27, P644, DOI 10.1038/modpathol.2013.200; Toon CW, 2013, AM J SURG PATHOL, V37, P1592, DOI 10.1097/PAS.0b013e31828f233d	12	2	2	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					342	344		10.1016/j.pathol.2017.09.025			3	Pathology	Pathology	GA7OF	WOS:000428525100014	29477276				2019-10-28	
J	Chou, A; Kim, Y; Samra, JS; Pajic, M; Gill, AJ				Chou, Angela; Kim, Yoomee; Samra, Jaswinder S.; Pajic, Marina; Gill, Anthony J.			BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma	PATHOLOGY			English	Letter							ADENOCARCINOMA; FUSIONS; TUMORS		[Chou, Angela; Kim, Yoomee] St Vincents Hosp, SydPath, Dept Anat Pathol, Darlinghurst, NSW, Australia; [Chou, Angela; Gill, Anthony J.] Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia; [Chou, Angela; Samra, Jaswinder S.; Gill, Anthony J.] Univ Sydney, Sydney, NSW, Australia; [Chou, Angela; Pajic, Marina] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Chou, Angela; Pajic, Marina] Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Samra, Jaswinder S.] Univ Sydney, Royal North Shore Hosp, Dept Gastrointestinal Surg, Sydney, NSW, Australia; [Samra, Jaswinder S.] Univ Sydney, North Shore Private Hosp, Sydney, NSW, Australia; [Pajic, Marina] Univ NSW, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Gill, Anthony J.] Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW, Australia	Gill, AJ (reprint author), Royal North Shore Hosp, Kolling Inst Med Res, Canc Diag & Pathol Grp, St Leonards, NSW, Australia.; Gill, AJ (reprint author), Univ Sydney, Sydney, NSW, Australia.; Gill, AJ (reprint author), Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW, Australia.	affgill@med.usyd.edu.au	Gill, Anthony J./M-5015-2019	Pajic, Marina/0000-0002-3871-3829	Cancer Institute NSW (CINSW) Early Career Fellowship [AC00430]; Sydney Vital, Translational Cancer Research Centre, through a Cancer Institute NSW competitive grant	Dr Chou is supported by the Cancer Institute NSW (CINSW) Early Career Fellowship AC00430. This project was also supported by the Sydney Vital, Translational Cancer Research Centre, through a Cancer Institute NSW competitive grant. The views expressed herein are those of the authors and are not necessarily those of the Cancer Institute NSW (CINSW).	Bosman FT, 2010, WHO CLASSIFICATION T; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Holen KD, 2002, J CLIN ONCOL, V20, P4673, DOI 10.1200/JCO.2002.02.005; Jang JS, 2015, SCI REP-UK, V5, DOI 10.1038/srep09755; Klimstra DS, 2016, SEMIN DIAGN PATHOL, V33, P307, DOI 10.1053/j.semdp.2016.05.009; Lowery MA, 2011, ONCOLOGIST, V16, P1714, DOI 10.1634/theoncologist.2011-0231; Miller VA, 2014, J CLIN ONCOL S, V32; Omiyale AO, 2015, GLAND SURG, V4, P322, DOI 10.3978/j.issn.2227-684X.2015.04.05; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Schmidt CM, 2008, J GASTROINTEST SURG, V12, P2078, DOI 10.1007/s11605-008-0705-6; Wang Y, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0919-0	11	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					345	348		10.1016/j.pathol.2017.09.027			4	Pathology	Pathology	GA7OF	WOS:000428525100015	29506751				2019-10-28	
J	Tay, TKY; Kuick, CH; Lim, TH; Chang, KTE; Kesavan, S				Tay, Timothy Kwang Yong; Kuick, Chik Hong; Lim, Tse Hui; Chang, Kenneth Tou En; Kesavan, Sittampalam			A case of low grade fibromyxoid sarcoma with dedifferentiation	PATHOLOGY			English	Letter									[Tay, Timothy Kwang Yong] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore; [Kuick, Chik Hong; Chang, Kenneth Tou En] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore; [Lim, Tse Hui] Singapore Gen Hosp, Dept Mol Pathol, Singapore, Singapore	Tay, TKY (reprint author), Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore.						Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; EVANS HL, 1993, AM J SURG PATHOL, V17, P595, DOI 10.1097/00000478-199306000-00007; Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004; Perigny M, 2006, ANN PATHOL, V26, P419, DOI 10.1016/S0242-6498(06)70750-7	4	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					348	+		10.1016/j.pathol.2017.09.022			5	Pathology	Pathology	GA7OF	WOS:000428525100016	29486962				2019-10-28	
J	Quesada, AE; Young, KH; Medeiros, LJ; Thakral, B				Quesada, Andres E.; Young, Ken H.; Medeiros, L. Jeffrey; Thakral, Beenu			Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease	PATHOLOGY			English	Letter							LYMPHOMA		[Quesada, Andres E.; Young, Ken H.; Medeiros, L. Jeffrey; Thakral, Beenu] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Thakral, B (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	BThakral@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019				Eun S, 2010, J KOREAN MED SCI, V25, P309, DOI 10.3346/jkms.2010.25.2.309; Hartert M, 2010, AM J SURG PATHOL, V34, P742, DOI 10.1097/PAS.0b013e3181d7a2ee; Hsu C, 2011, J CLIN ONCOL, V29, pE369, DOI 10.1200/JCO.2010.32.7932; Kansal R, 2015, HUM PATHOL, V46, P1057, DOI 10.1016/j.humpath.2015.03.007; Kim WY, 2010, HUM PATHOL, V41, P129, DOI 10.1016/j.humpath.2009.05.014; McClory S, 2012, J CLIN INVEST, V122, P1403, DOI 10.1172/JCI46125; Nathwani BN, 2015, HUM PATHOL, V46, P1786, DOI 10.1016/j.humpath.2015.07.025; O'Malley DP, 2006, HAEMATOL-HEMATOL J, V91, P1139; Ohgami RS, 2014, AM J SURG PATHOL, V38, P1298, DOI 10.1097/PAS.0000000000000197; Ohgami RS, 2013, ADV ANAT PATHOL, V20, P137, DOI 10.1097/PAP.0b013e31828d17ec; Ohgami RS, 2012, AM J SURG PATHOL, V36, P1619, DOI 10.1097/PAS.0b013e318264e223; Velankar MM, 1999, AM J SURG PATHOL, V23, P977, DOI 10.1097/00000478-199908000-00017	12	3	3	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					351	352		10.1016/j.pathol.2017.09.017			3	Pathology	Pathology	GA7OF	WOS:000428525100017	29486963				2019-10-28	
J	Nell, RJ; Wong, DD; van Vliet, C; Parry, J; Fermoyle, S				Nell, Roxanne J.; Wong, Daniel D.; van Vliet, Chris; Parry, Jeremy; Fermoyle, Soraya			Inflammatory angiomyolipoma of the liver: a diagnostic pitfall	PATHOLOGY			English	Letter							HEPATIC ANGIOMYOLIPOMA; PSEUDOTUMOR; VARIANT		[Nell, Roxanne J.; Wong, Daniel D.; van Vliet, Chris] QEII Med Ctr, PathWest Lab Med, Dept Anat Pathol, Nedlands, WA, Australia; [Wong, Daniel D.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia; [Parry, Jeremy; Fermoyle, Soraya] Fiona Stanley Hosp, PathWest Lab Med, Dept Anat Pathol, Murdoch, WA, Australia	Wong, DD (reprint author), QEII Med Ctr, PathWest Lab Med, Dept Anat Pathol, Nedlands, WA, Australia.; Wong, DD (reprint author), Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia.	Daniel.wong@health.wa.gov.au					Agaimy A, 2013, INT J CLIN EXP PATHO, V6, P771; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Ishak KG, 1976, HEPATOCELLULAR CARCI; Jyothi CR, 2013, CASE REP HEPATOL, V2013, P3; Kai K, 2015, WORLD J GASTROENTERO, V21, P9675, DOI 10.3748/wjg.v21.i32.9675; Kojima M, 2004, PATHOL RES PRACT, V200, P713, DOI 10.1016/j.prp.2004.08.001; Liu Y, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-122; Nguyen TT, 2008, AM J SURG PATHOL, V32, P793, DOI 10.1097/PAS.0b013e3181607349; Shi HY, 2010, ANN DIAGN PATHOL, V14, P240, DOI 10.1016/j.anndiagpath.2010.03.002; Singh S, 2015, TRANSL GASTROIN CANC, V4, P320, DOI 10.3978/j.issn.2224-4778.2015.07.06; Sun HX, 2016, ANN CLIN LAB SCI, V46, P78; Sun K, 2014, INT J CLIN EXP PATHO, V7, P8170	12	1	1	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					352	355		10.1016/j.pathol.2017.09.021			5	Pathology	Pathology	GA7OF	WOS:000428525100018	29496202				2019-10-28	
J	Martinez-Ciarpaglini, C; Agusti, J; Alvarez, E; Hueso, L; Terradez, L; Monteagudo, C				Martinez-Ciarpaglini, Carolina; Agusti, Jaime; Alvarez, Esther; Hueso, Luis; Terradez, Liria; Monteagudo, Carlos			h-caldesmon immunoreactivity in atypical fibroxanthoma: implications for the differential diagnosis	PATHOLOGY			English	Letter							SMOOTH-MUSCLE DIFFERENTIATION; SOFT-TISSUE; LEIOMYOSARCOMA; EXPRESSION; CALPONIN; SKIN; TUMORS		[Martinez-Ciarpaglini, Carolina; Monteagudo, Carlos] Biomed Res Inst INCLIVA, Valencia, Spain; [Agusti, Jaime] Consorcio Hosp Prov Castellon, Dept Pathol, Castellon de La Plana, Spain; [Alvarez, Esther; Terradez, Liria; Monteagudo, Carlos] Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain; [Hueso, Luis] Hosp Manises, Dept Dermatol, Valencia, Spain; [Terradez, Liria; Monteagudo, Carlos] Univ Valencia, Valencia, Spain	Monteagudo, C (reprint author), Biomed Res Inst INCLIVA, Valencia, Spain.; Monteagudo, C (reprint author), Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain.; Monteagudo, C (reprint author), Univ Valencia, Valencia, Spain.	carlos.monteagudo@uv.es	, Monteagudo/H-6555-2016		Generalitat Valenciana, SpainGeneralitat Valenciana [PROMETEO II/2015/009]	Supported by grant PROMETEO II/2015/009 from Generalitat Valenciana, Spain. The authors state that there are no conflicts of interest to disclose.	Beer TW, 2010, AM J DERMATOPATH, V32, P533, DOI 10.1097/DAD.0b013e3181c80b97; Harding-Jackson N, 2015, AM J DERMATOPATH, V37, P509, DOI 10.1097/DAD.0000000000000313; Jarkovska K, 2014, BIOL CELL, V106, DOI 10.1111/boc.201400014; LONGACRE TA, 1993, AM J SURG PATHOL, V17, P1199, DOI 10.1097/00000478-199312000-00001; Miettinen M, 2014, HISTOPATHOLOGY, V64, P101, DOI 10.1111/his.12298; Miettinen MM, 1999, MODERN PATHOL, V12, P756; Nonaka D, 2014, AM J SURG PATHOL, V38, P956, DOI 10.1097/PAS.0000000000000210; Perez-Montiel MD, 2006, AM J DERMATOPATH, V28, P105, DOI 10.1097/01.dad.0000200009.02939.cc; Perot G, 2014, MODERN PATHOL, V27, P840, DOI 10.1038/modpathol.2013.205; Sakamoto A, 2002, VIRCHOWS ARCH, V440, P404, DOI 10.1007/s004280100521; Watanabe K, 1999, HUM PATHOL, V30, P392, DOI 10.1016/S0046-8177(99)90113-2; Winchester DS, 2014, J AM ACAD DERMATOL, V71, P919, DOI 10.1016/j.jaad.2014.07.020	12	2	2	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					358	+		10.1016/j.pathol.2017.09.020			5	Pathology	Pathology	GA7OF	WOS:000428525100020	29490873				2019-10-28	
J	Korbl, JD; Chan, J; Wood, BA; Harvey, NT				Korbl, Jasmin Dvorah; Chan, Jonathan; Wood, Benjamin Andrew; Harvey, Nathan Tobias			Localised lymphoedema forming a papillated lesion on the scalp	PATHOLOGY			English	Letter							OF-THE-LITERATURE; MORBIDLY OBESE		[Korbl, Jasmin Dvorah; Chan, Jonathan] Sir Charles Gairdner Hosp, Dept Dermatol, Perth, WA, Australia; [Wood, Benjamin Andrew; Harvey, Nathan Tobias] PathWest, Dept Anat Pathol, Dermatopathol Grp, Perth, WA, Australia; [Wood, Benjamin Andrew; Harvey, Nathan Tobias] Univ Western Australia, Sch Med, Div Pathol & Lab Med, Perth, WA, Australia	Harvey, NT (reprint author), PathWest, Dept Anat Pathol, Dermatopathol Grp, Perth, WA, Australia.; Harvey, NT (reprint author), Univ Western Australia, Sch Med, Div Pathol & Lab Med, Perth, WA, Australia.	nathan.harvey@health.wa.gov.au		Harvey, Nathan/0000-0001-5253-976X			ALLEN PW, 1988, AM J SURG PATHOL, V12, P519, DOI 10.1097/00000478-198807000-00003; Carlson JA, 2014, CLIN DERMATOL, V32, P599, DOI [10.1016/j.clindermato1.2014.04.007, 10.1016/j.clindermatol.2014.04.007]; Fadare O, 2011, INT J GYNECOL PATHOL, V30, P306, DOI 10.1097/PGP.0b013e3181fde244; Farshid G, 1998, AM J SURG PATHOL, V22, P1277, DOI 10.1097/00000478-199810000-00013; Kacerovska D, 2012, J AM ACAD DERMATOL, V67, P1319, DOI 10.1016/j.jaad.2012.03.021; Kurt H, 2016, MODERN PATHOL, V29, P75, DOI 10.1038/modpathol.2015.135; Lu S, 2009, J CUTAN PATHOL, V36, P1, DOI 10.1111/j.1600-0560.2008.00990.x; Lu S, 2012, J CUTAN PATHOL, V39, P391, DOI 10.1111/j.1600-0560.2011.01691.x; Plaza JA, 2014, J AM ACAD DERMATOL, V71, P320, DOI 10.1016/j.jaad.2014.01.907; Requena L, 2015, CUTANEOUS SOFT TISSU; Shon W, 2011, J CUTAN PATHOL, V38, P560, DOI 10.1111/j.1600-0560.2011.01703.x; Warren AG, 2007, ANN PLAS SURG, V59, P464, DOI 10.1097/01.sap.0000257149.42922.7e	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					361	364		10.1016/j.pathol.2017.09.016			5	Pathology	Pathology	GA7OF	WOS:000428525100021	29496201				2019-10-28	
J	Solinas, A; Mahar, A; Cooper, WA; Thompson, JF; Spillane, AJ; Scolyer, RA				Solinas, Annalisa; Mahar, Annabelle; Cooper, Wendy A.; Thompson, John F.; Spillane, Andrew J.; Scolyer, Richard A.			Pigmented Paget's disease of the nipple mistaken for melanoma in situ: a diagnostic pitfall for the unwary	PATHOLOGY			English	Letter							MIMICKING MELANOMA		[Solinas, Annalisa; Mahar, Annabelle; Cooper, Wendy A.; Thompson, John F.; Scolyer, Richard A.] Royal Prince Alfred Hosp, Camperdown, NSW, Australia; [Cooper, Wendy A.; Thompson, John F.; Spillane, Andrew J.; Scolyer, Richard A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Cooper, Wendy A.] Western Sydney Univ, Sch Med, Sydney, NSW, Australia; [Thompson, John F.; Spillane, Andrew J.; Scolyer, Richard A.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia	Scolyer, RA (reprint author), Royal Prince Alfred Hosp, Camperdown, NSW, Australia.; Scolyer, RA (reprint author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.; Scolyer, RA (reprint author), Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia.	richard.scolyer@sswahs.nsw.gov.au		Scolyer, Richard/0000-0002-8991-0013			Hilliard NJ, 2009, J CUTAN PATHOL, V36, P995, DOI 10.1111/j.1600-0560.2009.01174.x; Lakhani SREI, 2012, WHO CLASSIFICATION T; Park JS, 2011, J AM ACAD DERMATOL, V65, P247, DOI 10.1016/j.jaad.2009.12.059; Petersson F, 2009, AM J DERMATOPATH, V31, P223, DOI 10.1097/DAD.0b013e3181930dc6; Pizzichetta MA, 2004, MELANOMA RES, V14, pS13, DOI 10.1097/01.cmr.0000124656.32909.74; Requena L, 2002, AM J DERMATOPATH, V24, P189, DOI 10.1097/01.DAD.0000014605.93587.33; Tang XY, 2014, BREAST CANCER-TOKYO, V21, P370, DOI 10.1007/s12282-010-0249-y	7	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					364	367		10.1016/j.pathol.2017.09.018			5	Pathology	Pathology	GA7OF	WOS:000428525100022	29490872				2019-10-28	
J	Muronda, M; Russell, P				Muronda, Mudiwa; Russell, Peter			Combined ovarian serous cystadenoma and thecoma	PATHOLOGY			English	Letter							GRANULOSA-CELL TUMOR; COLLISION TUMOR; PROLIFERATION; NEOPLASMS		[Muronda, Mudiwa; Russell, Peter] Douglass Hanly Moir Pathol, Gynaepath, Macquarie Pk, Macquarie Pk, NSW, Australia	Russell, P (reprint author), Douglass Hanly Moir Pathol, Gynaepath, Macquarie Pk, Macquarie Pk, NSW, Australia.	russell2@bigpond.net.au					Bige O, 2009, ARCH GYNECOL OBSTET, V279, P767, DOI 10.1007/s00404-008-0781-6; Chandanwale SS, 2015, J PATHOL TRANSL MED, V49, P163, DOI 10.4132/jptm.2013.11.25; CHANDRAN R, 1993, AUST NZ J OBSTET GYN, V33, P437, DOI 10.1111/j.1479-828X.1993.tb02134.x; Kurman RJ, 2014, WHO CLASSIFICATION T; Kushida Y, 2005, PATHOL INT, V55, P797, DOI 10.1111/j.1440-1827.2005.01909.x; Mishra A, 2017, INT J REPROD CONTRAC, V6, P1643; Moid Farah Y, 2004, Ann Diagn Pathol, V8, P96, DOI 10.1053/j.anndiagpath.2004.01.007; Muronda M, 2017, PATHOLOGY, V49, P438, DOI 10.1016/j.pathol.2017.01.012; PRICE A, 1990, INT J GYNECOL PATHOL, V9, P372, DOI 10.1097/00004347-199010000-00009; Russell P, 2009, ROBBOYS PATHOLOGY FE, P693; Singh N, 2014, HISTOPATHOLOGY, V64, P626, DOI 10.1111/his.12314; Staats PN, 2010, INT J GYNECOL PATHOL, V29, P228, DOI 10.1097/PGP.0b013e3181c04007; Vang R, 2013, HISTOPATHOLOGY, V62, P44, DOI 10.1111/his.12046	13	0	0	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					367	369		10.1016/j.pathol.2017.09.026			4	Pathology	Pathology	GA7OF	WOS:000428525100023	29499871				2019-10-28	
J	Ondic, O; Alaghehbandan, R				Ondic, Ondrej; Alaghehbandan, Reza			Response to: High-grade squamous intraepithelial lesion (HSIL) of the cervix with bizarre cytological appearances ('pleomorphic HSIL')	PATHOLOGY			English	Letter							CELL DYSPLASIA		[Ondic, Ondrej] Charles Univ Prague, Plzen, Czech Republic; [Ondic, Ondrej] Charles Univ Hosp Pilsen, Dept Pathol, Fac Med, Plzen, Czech Republic; [Ondic, Ondrej] Biopt Lab Sro, Plzen, Czech Republic; [Alaghehbandan, Reza] Univ British Columbia, Dept Pathol, Royal Columbian Hosp, Vancouver, BC, Canada	Ondic, O (reprint author), Charles Univ Prague, Plzen, Czech Republic.; Ondic, O (reprint author), Charles Univ Hosp Pilsen, Dept Pathol, Fac Med, Plzen, Czech Republic.; Ondic, O (reprint author), Biopt Lab Sro, Plzen, Czech Republic.	ondic@medima.cz		Ondic, Ondrej/0000-0002-4038-5641			Kaspirkova J, 2015, MODERN PATHOL, V28, p293A; Masand R, 2017, MODERN PATHOL, V30, p299A; Masand R, 2017, MODERN PATHOL, V30, p107A; Ondic O, 2018, CYTOPATHOLOGY, V29, P58, DOI 10.1111/cyt.12494; Ondic O, 2017, J OBSTET GYNAECOL RE, V43, P345, DOI 10.1111/jog.13196; Stewart CJR, 2017, PATHOLOGY, V49, P465, DOI 10.1016/j.pathol.2017.05.002	6	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					369	370		10.1016/j.pathol.2017.09.023			3	Pathology	Pathology	GA7OF	WOS:000428525100024	29490871				2019-10-28	
J	Carr, NJ				Carr, Norman J.			Incidental single-organ vasculitis of the appendix	PATHOLOGY			English	Letter									[Carr, Norman J.] Univ Hosp Southampton, Cellular Pathol, Southampton, Hants, England	Carr, NJ (reprint author), Univ Hosp Southampton, Cellular Pathol, Southampton, Hants, England.	n.j.carr@soton.ac.uk					Daniels J, 2017, PATHOLOGY, V49, P661, DOI 10.1016/j.pathol.2017.05.013; MOYANA TN, 1988, ARCH PATHOL LAB MED, V112, P738	2	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					370	371		10.1016/j.pathol.2017.10.018			4	Pathology	Pathology	GA7OF	WOS:000428525100026	29478693				2019-10-28	
J	Stewart, CJR				Stewart, Colin J. R.			Response to: High-grade squamous intraepithelial lesion (HSIL) of the cervix with bizarre cytological appearances ('pleomorphic HSIL'): author reply	PATHOLOGY			English	Letter									[Stewart, Colin J. R.] Univ Western Australia, Dept Histopathol, King Edward Mem Hosp, Sch Womens & Infants Hlth, Perth, WA, Australia	Stewart, CJR (reprint author), Univ Western Australia, Dept Histopathol, King Edward Mem Hosp, Sch Womens & Infants Hlth, Perth, WA, Australia.	colin.stewart@health.wa.gov.au					ALNAFUSSI AI, 1994, J CLIN PATHOL, V47, P799, DOI 10.1136/jcp.47.9.799; Ondic O, 2017, J OBSTET GYNAECOL RE, V43, P345, DOI 10.1111/jog.13196; Stewart CJR, 2017, PATHOLOGY, V49, P465, DOI 10.1016/j.pathol.2017.05.002	3	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	APR	2018	50	3					370	370		10.1016/j.pathol.2017.09.024			1	Pathology	Pathology	GA7OF	WOS:000428525100025	29506750				2019-10-28	
J	Garg, P; Pathak, P; Goyal, R; Arora, VK; Singh, N				Garg, Paritosh; Pathak, Priya; Goyal, Rachna; Arora, Vinod K.; Singh, Navjeevan			Current practice in handling and reporting needle biopsies: A hospital-based survey	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast; core needle biopsy; lymph node; prostate; soft tissue; survey	FINE-NEEDLE; BREAST-LESIONS; SOFT-TISSUE; PROSTATE BIOPSY; CORE; ASPIRATION; ACCURACY; DIAGNOSIS; AUDIT; SIZE	Context: Core-needle biopsy (CNB) is a minimally invasive screening and diagnostic tool which provides intact tissue fragments for histopathological examination. Aims: This study was conducted to review the current practices of handling and reporting CNBs performed for core-needle biopsies from four organ systems which are frequently encountered in our institution. These include breast, prostate, soft tissues, and lymph nodes. Settings and Design: This was a retrospective study conducted at a tertiary care hospital. Materials and Methods: CNB reports of breast, prostate, soft tissue, and lymph nodes were accessed and categorized based on the site of biopsy, number, and average length of the cores. The CNB reports were categorized into diagnostic or nondiagnostic. In case of diagnosis of malignancy, reports were recorded as structured or nonstructured reports. Statistical Analysis Used: Fisher's exact test and Chi-square tests were applied to check the significance of the results obtained on comparing the number of cores and size of cores with the outcome of report. Results: Out of 16,300 surgical pathology specimens received, 400 were CNBs comprising breast (n = 211), prostate (n = 108), soft tissue (n = 50), and lymph node (n = 31). Majority of the CNBs had 2-5 cores and the size of the core was >= 0.5 cm, which accounted for most of the reports which were diagnostic. There was a lack of clinical and radiological detail in many of the cases. Out of the malignant cases diagnosed, structured reports were given in 30% of breast, 79.3% of prostate, 41.7% soft tissue, and 60% of lymph node needle biopsies. Conclusions: The audit helped to identify areas of improvement in CNB services.	Univ Coll Med Sci, Dept Pathol, New Delhi, India; Guru Teg Bahadur Hosp, New Delhi, India	Pathak, P (reprint author), 33-A Una Enclave,Mayur Vihar Phase 1, New Delhi 110091, India.	priyaa.pathak@gmail.com					Allin D, 2016, ANN R COLL SURG ENGL, V5, P1; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bilous M, 2010, MODERN PATHOL, V23, pS36, DOI 10.1038/modpathol.2010.34; Bjurlin MA, 2013, J UROLOGY, V189, P2039, DOI 10.1016/j.juro.2013.02.072; Brancato B, 2012, BREAST, V21, P449, DOI 10.1016/j.breast.2011.10.008; Dojcinov S, 2015, STANDARDS SPECIALIST; Ellis IO, 2016, ROYAL COLL PATHOLOGI; Fisher C., 2017, STANDARDS DATASETS R; Focke CM, 2016, HISTOPATHOLOGY, V69, P1047, DOI 10.1111/his.13036; Fraggetta F, 2013, ANAL QUANT CYTOL, V35, P130; Frederiksen JK, 2015, ARCH PATHOL LAB MED, V139, P245, DOI 10.5858/arpa.2013-0674-RA; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Lachar WA, 2007, ARCH PATHOL LAB MED, V131, P1033; Layfield LJ, 2014, DIAGN CYTOPATHOL, V42, P476, DOI 10.1002/dc.23005; Muezzinoglu B, 2015, PATHOL RES PRACT, V211, P374, DOI 10.1016/j.prp.2015.01.001; Nakhleh RE, 2011, ARCH PATHOL LAB MED, V135, P1394, DOI 10.5858/arpa.2011-0192-RA; Obek C, 2012, J UROLOGY, V187, P2051, DOI 10.1016/j.juro.2012.01.075; Oh KH, 2016, EUR ANN OTORHINOLARY, V133, P401, DOI 10.1016/j.anorl.2016.01.013; Oxley J, 2016, ROYAL COLL PATHOLOGI; Peer S, 2011, MED ULTRASON, V13, P187; Radhakrishna S, 2013, INDIAN J MED PAEDIAT, V34, P252, DOI 10.4103/0971-5851.125237; Ryu YJ, 2015, HEAD NECK-J SCI SPEC, V37, P229, DOI 10.1002/hed.23580; Seng CS, 2013, J ORTHOP SURG-HONG K, V21, P92, DOI 10.1177/230949901302100123; Shah RB, 2016, PATHOL INT, V66, P260, DOI 10.1111/pin.12398; Sluijter CE, 2016, VIRCHOWS ARCH, V468, P639, DOI 10.1007/s00428-016-1935-8; Srigley JR, 2012, PROTOCOL EXAMINATION; Strauss DC, 2010, J SURG ONCOL, V102, P523, DOI 10.1002/jso.21600; Tuttle R, 2015, J SURG ONCOL, V111, P504, DOI 10.1002/jso.23870; van der Kwast TH, 2003, J CLIN PATHOL, V56, P336, DOI 10.1136/jcp.56.5.336; VanderLaan PA, 2016, CANCER CYTOPATHOL, V124, P862, DOI 10.1002/cncy.21742; Willems SM, 2012, J CLIN PATHOL, V65, P287, DOI 10.1136/jclinpath-2011-200410	31	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	APR-JUN	2018	61	2					197	200		10.4103/IJPM.IJPM_93_17			4	Pathology	Pathology	GD9SC	WOS:000430851900007	29676356	DOAJ Gold			2019-10-28	
J	Petriceks, AH; Salmi, D				Petriceks, Aldis H.; Salmi, Darren			Trends in Pathology Graduate Medical Education Programs and Positions, 2001 to 2017	ACADEMIC PATHOLOGY			English	Article						fellowship; graduate medical education; pathology; physician trends; residency	SUBSPECIALTY; RESIDENTS	The US medical workforce is facing an impending physician shortage. This shortage holds special concern for pathologists, as many senior practitioners are set to retire in the coming years. Indeed, studies indicate a "pathologist gap" may grow through 2030. As such, it is important to understand current and future trends in US pathology. One key factor is graduate medical education. In this study, we analyzed data from the Accreditation Council of Graduate Medical Education, to determine the change in pathology graduate medical education programs and positions, from 2001 to 2017. We found that pathology programs and positions have increased since the 2001 to 2002 academic year, even after adjusting for population growth. However, this increase is much lower than that of total graduate medical education. Furthermore, many pathology subspecialties have declined in population-adjusted levels. Other subspecialties, such as selective pathology, have grown disproportionately. Our findings may be valuable for understanding the state of US pathology, now and in the future. They imply that more resources-or technological innovations-may be needed for specific pathology programs, in hopes of closing the pathologist gap for both this specialty and its subspecialties.	[Petriceks, Aldis H.; Salmi, Darren] Stanford Univ, Sch Med, Div Clin Anat, Stanford, CA 94305 USA; [Salmi, Darren] Stanford Univ, Sch Med, Dept Pathol, 269 Campus Dr,CCSR 0135A, Stanford, CA 94305 USA	Salmi, D (reprint author), Stanford Univ, Sch Med, Dept Pathol, 269 Campus Dr,CCSR 0135A, Stanford, CA 94305 USA.	dsalmi@stanford.edu		Petriceks, Aldis/0000-0001-5136-1023			[Anonymous], 2017, 2017 NRMP MAIN RESID; [Anonymous], 2018, PATH PROGR; [Anonymous], 2018, TRAIN DIR; [Anonymous], 2017, ACGME DATA RESOURCE; [Anonymous], 2015, CLIN INF; Association of American Medical Colleges (AAMC), 2015, PHYS SUPPL DEM 2025; Crawford JM, 2011, HUM PATHOL, V42, P774, DOI 10.1016/j.humpath.2010.08.002; Gilbertson John R, 2012, J Pathol Inform, V3, P11, DOI 10.4103/2153-3539.93893; Haidari M, 2017, ARCH PATHOL LAB MED, V141, P203, DOI 10.5858/arpa.2015-0547-OA; Iglehart JK, 2013, NEW ENGL J MED, V369, P297, DOI 10.1056/NEJMp1306445; Lagwinski N, 2009, ARCH PATHOL LAB MED, V133, P1431, DOI 10.1043/1543-2165-133.9.1431; Longhurst CA, 2016, J AM MED INFORM ASSN, V23, P829, DOI 10.1093/jamia/ocv209; Mullan F, 2015, NEW ENGL J MED, V373, P2397, DOI 10.1056/NEJMp1511707; National Institutes of Health, 2016, NIH AW LOC ORG; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA; Robertson S, 2018, TRANSL RES, V194, P19, DOI 10.1016/j.trsl.2017.10.010; Yoshida H, 2017, ONCOTARGET, V8, P90719, DOI 10.18632/oncotarget.21819	17	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	MAR 28	2018	5								UNSP 2374289518765457	10.1177/2374289518765457			6	Pathology	Pathology	GC4GX	WOS:000429744100001	29623293	DOAJ Gold, Green Published			2019-10-28	
J	Velasco, IA; Zhang, R; Li, TJ; Wang, DC				Velasco, Ignacio A.; Zhang, Ran; Li, Tiejun; Wang, Diancan			Ossifying Fibromyxoid tumor of soft parts in head and neck: case report and literature review	DIAGNOSTIC PATHOLOGY			English	Review						Ossifying Fibromyxoid tumor; Head and neck Neoplasms	MALIGNANT VARIANTS; CLINICOPATHOLOGICAL ANALYSIS; DIAGNOSIS; REGION; CAVITY; SINUS	Background: Ossifying fibromyxoid tumor of soft parts (OFMT), is a rare but morphologically distinctive neoplasm of uncertain histogenesis that most frequently affects middle-aged male adults. Clinically, it usually presents as a slowly enlarging, small, circumscribed mass, which in most cases is painless. OFMT is most frequently found within the subcutaneous tissues of extremities or trunk, and rarely in the oral/head and neck region. We present an unusual case of this tumor in the submandibular region, and, based on the current medical literatures this is probably the first case described in this anatomical location. Case presentation: A 32-year-old male presented to our outpatient clinic with a right submandibular mass with 1-year of evolution. Excisional biopsy showed that it was characterized by ossification along the periphery of the lesion. The neoplastic cells were spindle-like with scant eosinophilic cytoplasm. These cells were arranged with uniform cell-to-cell space in a fibromyxoid stroma. Small and large clusters of calcifications were present within the tumor. Immunohistochemically, the case showed positive staining of S-100 protein, vimentin, nestin, calponin, SMA, GFAF, desmin, INI-1, caldesmon, and CD34. It also showed negative staining of CK, CK7, CK8/18, NF, and EMA. About 2% of neoplastic cells showed positive staining of Ki67. Based on these features, the final pathological diagnosis was OFMT. Conclusions: It is hoped that a greater understanding of OFMT in the head and neck region will avoid potential misdiagnosis, and contribute to determining the correct management, which appears to be complete surgical excision with close follow-up for recurrence surveillance.	[Velasco, Ignacio A.; Wang, Diancan] Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 22 South Zhongguancun Ave, Beijing 100081, Peoples R China; [Zhang, Ran; Li, Tiejun] Peking Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Beijing, Peoples R China	Wang, DC (reprint author), Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 22 South Zhongguancun Ave, Beijing 100081, Peoples R China.	bjwdc@sina.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81702689]	This study was supported by the National Nature Science Foundation of China (81702689).	Aigner T, 2004, MODERN PATHOL, V17, P214, DOI 10.1038/modpathol.3800036; Al-Mazrou KA, 2004, INT J PEDIATR OTORHI, V68, P225, DOI 10.1016/j.ijporl.2003.09.016; Bakiratharajan D, 2016, ARCH PATHOL LAB MED, V140, P371, DOI 10.5858/arpa.2014-0590-RS; Blum A, 2006, AURIS NASUS LARYNX, V33, P325, DOI 10.1016/j.anl.2006.01.008; Dantey K, 2017, HUM PATHOL, V60, P174, DOI 10.1016/j.humpath.2016.10.012; DONNER LR, 1992, HUM PATHOL, V23, P200, DOI 10.1016/0046-8177(92)90246-Y; Ekfors TO, 1998, APMIS, V106, P1124, DOI 10.1111/j.1699-0463.1998.tb00268.x; ENZINGER FM, 1989, AM J SURG PATHOL, V13, P817, DOI 10.1097/00000478-198910000-00001; Fletcher CDM, 2002, PATHOLOGY GENETICS T, P196; Folpe AL, 2003, AM J SURG PATHOL, V27, P421, DOI 10.1097/00000478-200304000-00001; Gao M, INT J ORAL MAXILLOFA; Graham RP, 2013, AM J SURG PATHOL, V37, P1751, DOI 10.1097/PAS.0b013e31829644b4; Hart J, 2016, AM J SURG PATHOL, V40, P704, DOI 10.1097/PAS.0000000000000589; Hirose T, 2007, ULTRASTRUCT PATHOL, V31, P233, DOI 10.1080/01913120701351157; KILPATRICK SE, 1995, AM J SURG PATHOL, V19, P1039, DOI 10.1097/00000478-199509000-00007; Kondylidou-Sidira A, 2011, J ORAL MAXIL SURG, V69, P1355, DOI 10.1016/j.joms.2010.05.011; LAX SF, 1995, PATHOL RES PRACT, V191, P57, DOI 10.1016/S0344-0338(11)80924-6; Matsumoto K, 1999, PATHOL INT, V49, P742, DOI 10.1046/j.1440-1827.1999.00924.x; Miettinen M, 2008, AM J SURG PATHOL, V32, P996, DOI 10.1097/PAS.0b013e318160736a; Miliaras D, 2007, INT J SURG PATHOL, V15, P437, DOI 10.1177/1066896907304987; Mollaoglu Nur, 2006, J Clin Pediatr Dent, V31, P136; NG WK, 1995, ARCH OTOLARYNGOL, V121, P1321; Nonaka CFW, 2009, J PERIODONTOL, V80, P687, DOI 10.1902/jop.2009.080535; Ohta K, 2013, HEAD FACE MED, V9, DOI 10.1186/1746-160X-9-16; Park DJJ, 2006, OPHTHAL PLAST RECONS, V22, P87, DOI 10.1097/01.iop.0000199236.03985.40; Paschen C, 2001, LARYNGO RHINO OTOL, V80, P522, DOI 10.1055/s-2001-17086; Rubin BP, 2002, PATHOLOGY GENETICS T, V5; Schneider N, 2016, ANN DIAGN PATHOL, V20, P52, DOI 10.1016/j.anndiagpath.2015.11.002; SCHOFIELD JB, 1993, HISTOPATHOLOGY, V22, P101, DOI 10.1111/j.1365-2559.1993.tb00088.x; Seykora JT, 2006, J CUTAN PATHOL, V33, P569, DOI 10.1111/j.1600-0560.2006.00444.x; Sharif MA, 2008, JCPSP-J COLL PHYSICI, V18, P181, DOI 03.2008/JCPSP.181182; Suehiro K, 2006, ANN THORAC SURG, V81, P2289, DOI 10.1016/j.athoracsur.2005.07.098; THOMPSON J, 1995, AM J NEURORADIOL, V16, P1132; Vassiliou LV, 2017, ORAL ONCOL, V65, P16, DOI 10.1016/j.oraloncology.2016.12.005; WILLIAMS RW, 1994, BRIT J ORAL MAX SURG, V32, P174, DOI 10.1016/0266-4356(94)90104-X; WILLIAMS SB, 1993, J LARYNGOL OTOL, V107, P75, DOI 10.1017/S0022215100122200; Zamecnik M, 1997, Ann Diagn Pathol, V1, P73, DOI 10.1016/S1092-9134(97)80011-1; Zhao D, 2017, BIOCHEM BIOPH RES CO, V483, P237, DOI 10.1016/j.bbrc.2016.12.160	38	0	0	1	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAR 27	2018	13								21	10.1186/s13000-018-0699-7			9	Pathology	Pathology	GA8CF	WOS:000428565000001	29587781	DOAJ Gold, Green Published			2019-10-28	
J	Eriksen, AC; Andersen, JB; Lindebjerg, J; Christensen, RD; Hansen, TF; Kjaer-Frifeldt, S; Sorensen, FB				Eriksen, Ann C.; Andersen, Johnnie B.; Lindebjerg, Jan; Christensen, Rene dePont; Hansen, Torben F.; Kjaer-Frifeldt, Sanne; Sorensen, Flemming B.			Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer?	DIAGNOSTIC PATHOLOGY			English	Article						Colon cancer; Heterogeneity; Tumour budding; Tumour stroma ratio	COLORECTAL-CANCER; STAGE-II; HIGH-RISK; SURVIVAL; INDEX; MICROENVIRONMENT; REPRODUCIBILITY; VALIDATION; PROPORTION; PREDICT	Background: Tumour budding (TB) and Tumour Stroma Ratio (TSR) may be rewarding in the treatment stratification of patients with stage II colon cancer. However, lack of standardization may exclude these parameters from being used in a clinical setting. The purpose of this methodologic study was to compare stereology with semi-quantitative estimations of TSR, to investigate the intra-tumoural heterogeneity of TB and TSR, and to assess the intra-and inter-observer agreement. Methods: Three paraffin embedded tumour blocks, one of them representing the deepest invasive front, were selected from each of 43 patients treated for stage II colon cancer. TSR was estimated in H&E sections semi-quantitatively using conventional microscopy, and stereologically on scanned slides, using the newCAST stereology platform. TB was scored across 10 high power fields at the invasive front in cytokeratin AE1/AE3 stained sections. Results: Subjective, semi-quantitative estimates of TSR significantly correlated to the stereological estimates, with the best correlation found for sections with the deepest invasive tumour penetration (sigma = 0.621, p < 0.001). Inter-observer agreement was moderate to substantial for both TB (Kappa = 0.46-0.73) and TSR (Kappa = 0.70-0.75). The Intraclass correlation coefficient (ICC) for TSR varied from 0.322 based on stereological hotspot estimation to 0.648 for the semi-quantitative evaluation. For TB, ICC varied from 0.646 based on continuous data to 0.698 based on categorical data (cut-off: 10 buds). Thus, the intra-tumoural heterogeneity for both TB and the semi-quantitative estimation of TSR was low. Conclusion: We recommend using only one tissue section representing the deepest invasive tumour area for estimation of TSR. For TB we recommend using one tissue section; however due to low representation of high-budding tumours, results must be considered with caution.	[Eriksen, Ann C.; Lindebjerg, Jan; Hansen, Torben F.; Sorensen, Flemming B.] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark; [Eriksen, Ann C.; Lindebjerg, Jan; Hansen, Torben F.; Kjaer-Frifeldt, Sanne; Sorensen, Flemming B.] Vejle Hosp, Dept Pathol, Danish Colorectal Canc Ctr South, Beriderbakken 4, DK-7100 Vejle, Denmark; [Andersen, Johnnie B.; Sorensen, Flemming B.] Aarhus Univ, Dept Clin Med, Stereol Res Lab, Norrebrogade 44,10G, DK-8000 Aarhus C, Denmark; [Andersen, Johnnie B.; Sorensen, Flemming B.] Aarhus Univ, Univ Inst Pathol, Norrebrogade 44,10G, DK-8000 Aarhus C, Denmark; [Andersen, Johnnie B.] Visiopharm AS, Horsholm, Denmark; [Christensen, Rene dePont] Univ Southern Denmark, Res Unit Gen Practice, JB Winslows Vej 9A,1st, DK-5000 Odense C, Denmark; [Sorensen, Flemming B.] Aarhus Univ Hosp, Univ Inst Pathol, PalleJuul Jensen Blvd 99,Entrance F,Plan 1,C 1-11, DK-8200 Aarhus C, Denmark	Eriksen, AC (reprint author), Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark.; Eriksen, AC (reprint author), Vejle Hosp, Dept Pathol, Danish Colorectal Canc Ctr South, Beriderbakken 4, DK-7100 Vejle, Denmark.	ann.christina.eriksen@rsyd.dk	Hansen, Torben Frostrup/K-5583-2019	Hansen, Torben Frostrup/0000-0001-7476-671X; Sorensen, Flemming Brandt/0000-0002-5446-1035; Eriksen, Ann Christina/0000-0002-3905-4132	Research Council of Lillebaelt Hospital; Beckett Foundation; Danish Cancer Research Foundation	The study was conducted under Danish Colorectal Center South at Vejle Hospital and was financially supported by The Research Council of Lillebaelt Hospital, The Beckett Foundation, and the Danish Cancer Research Foundation. The funding organizations did not play any role in the study design, data collection, analysis or interpretation of the data, decision to publish, or preparation of the manuscript.	Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; De Smedt L, 2016, VIRCHOWS ARCH, V468, P397, DOI 10.1007/s00428-015-1886-5; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Horcic M, 2013, HUM PATHOL, V44, P697, DOI 10.1016/j.humpath.2012.07.026; Huijbers A, 2013, ANN ONCOL, V24, P179, DOI 10.1093/annonc/mds246; Hutchins GGA, 2017, HISTOPATHOLOGY; Hynes SO, 2017, HISTOPATHOLOGY, V71, P12, DOI 10.1111/his.13181; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Karamitopoulou E, 2013, MODERN PATHOL, V26, P295, DOI 10.1038/modpathol.2012.155; Koelzer VH, 2017, J PATHOL CLIN RES, V3, P171, DOI 10.1002/cjp2.73; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; Lai YH, 2014, COLORECTAL DIS, V16, P259, DOI 10.1111/codi.12454; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Mesker WE, 2007, CELL ONCOL, V29, P387; Mesker WE, 2009, CELL ONCOL, V31, P169, DOI 10.3233/CLO-2009-0478; Morris M, 2006, BRIT J SURG, V93, P866, DOI 10.1002/bjs.5345; Nakamura T, 2008, DIS COLON RECTUM, V51, P568, DOI 10.1007/s10350-008-9192-9; Park JH, 2014, ANN ONCOL, V25, P644, DOI 10.1093/annonc/mdt593; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Rehemtulla A, 2012, NEOPLASIA, V14, P1278, DOI 10.1593/neo.122096; Staal EFWC, 2011, EUR J CANCER, V47, P375, DOI 10.1016/j.ejca.2010.09.043; SVANHOLM H, 1989, APMIS, V97, P689, DOI 10.1111/j.1699-0463.1989.tb00464.x; Tanaka M, 2003, DIS COLON RECTUM, V46, P1054, DOI 10.1097/01.DCR.0000074867.87213.D1; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; West NP, 2010, BRIT J CANCER, V102, P1519, DOI 10.1038/sj.bjc.6605674	28	2	2	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAR 20	2018	13								20	10.1186/s13000-018-0697-9			9	Pathology	Pathology	FZ8XP	WOS:000427894300001	29558947	DOAJ Gold, Green Published			2019-10-28	
J	Gibson, B; Bracamonte, E; Krupinski, EA; Briehl, MM; Barker, GP; Weinstein, JB; Weinstein, RS				Gibson, Blake; Bracamonte, Erika; Krupinski, Elizabeth A.; Briehl, Margaret M.; Barker, Gail P.; Weinstein, John B.; Weinstein, Ronald S.			A "Pathology Explanation Clinic (PEC)" for Patient-Centered Laboratory Medicine Test Results	ACADEMIC PATHOLOGY			English	Article						communication; laboratory medicine; patient-centered care; Second Flexner Century; surgical pathology	BREAST-CANCER; CARE	This concept paper addresses communication issues arising between physicians and their patients. To facilitate the communication of essential diagnostic pathology information to patients, and address their questions and concerns, we propose that Pathology Explanation Clinics be created. The Pathology Explanation Clinics would provide a channel for direct communications between pathologists and patients. Pathologists would receive special training as Certified Pathologist Navigators in preparation for this role. The goal of Pathology Explanation Clinics would be to help fill gaps in communication of information contained in laboratory reports to patients, further explain its relevance, and improve patient understanding of the meaning of such information and its impact on their health and health-care choices. Effort would be made to ensure that Certified Pathologist Navigators work within the overall coordination of care by the health-care team.	[Gibson, Blake; Bracamonte, Erika; Briehl, Margaret M.; Weinstein, Ronald S.] Univ Arizona, Dept Pathol, Coll Med Tucson, Tucson, AZ USA; [Krupinski, Elizabeth A.; Barker, Gail P.; Weinstein, Ronald S.] Univ Arizona, Arizona Telemed Program, Tucson, AZ USA; [Krupinski, Elizabeth A.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA; [Barker, Gail P.; Weinstein, Ronald S.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA; [Weinstein, John B.] Bard Coll, Bard Early Coll, Annandale on Hudson, NY 12504 USA	Weinstein, RS (reprint author), Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA.	rweinstein@telemedicine.arizona.edu			Milestone Medical Inc., a laboratory equipment company headquartered in Bergamo, Italy	The Sirmione Group Meeting, May 2 to 4, 2008, was sponsored by Milestone Medical Inc., a laboratory equipment company headquartered in Bergamo, Italy. The company president, Franco Visinoni, participated in the initial session and the closing session of this 5-day meeting.	Allen TC, 2017, CASE PATIENT CTR PAT; [Anonymous], 2017, RES FOC TEL; [Anonymous], 2017, FAQ IN UND YOUR SURG; Bracamonte E, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516659079; Briehl MM, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516680217; Butow PN, 1996, CANCER-AM CANCER SOC, V77, P2630, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2630::AID-CNCR29>3.0.CO;2-S; Christensen Clayton M., 2004, SEEING WHATS NEXT US; Epstein JI, 2017, MODERN PATHOL, V34, P1058; Epstein RM, 2011, ANN FAM MED, V9, P100, DOI 10.1370/afm.1239; Fiscella J., 2014, CAP TODAY, V28, P54; Gutmann EJ, 2003, MODERN PATHOL, V16, P515, DOI 10.1097/01.MP.0000068260.01286.AC; Hammond EH, 1997, ARCH PATHOL LAB MED, V121, P1171; Lehr HA, 2016, VIRCHOWS ARCH, V468, P61, DOI 10.1007/s00428-015-1848-y; Lopez AM, 2009, HUM PATHOL, V40, P1082, DOI 10.1016/j.humpath.2009.04.005; Manek S, 2012, CYTOPATHOLOGY, V23, P146, DOI 10.1111/j.1365-2303.2012.00985.x; Mossanen M, 2016, J UROLOGY, V196, P1383, DOI 10.1016/j.juro.2016.05.083; Mossanen M, 2014, UROL ONCOL-SEMIN ORI, V32, P1091, DOI 10.1016/j.urolonc.2014.04.011; Our Story, 2014, OUR STOR; Ries E., 2011, THE LEAN STARTUP; Smith L, 2016, US CAN AC PATH USCAP; Stevenson MM, 2013, J ONCOL PRACT, V9, pE77, DOI 10.1200/JOP.2013.000882; Sun V, 2018, CONTEMP CLIN TRIALS, V64, P167, DOI 10.1016/j.cct.2017.10.008; Thompson JF, 2004, PATHOLOGY, V36, P496, DOI 10.1080/00313020412331283897; Uthman EO, 2014, ARCH PATHOL LAB MED, V138, P12, DOI 10.5858/arpa.2013-0194-ED; Wallner LP, 2016, J CLIN ONCOL, V34, P3969, DOI 10.1200/JCO.2016.67.8896; Weinstein RS, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517718872; Weinstein RS, 2016, ACAD PATHOL, V3, DOI 10.1177/2374289516636132; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006	28	2	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	MAR 19	2018	5								UNSP 2374289518756306	10.1177/2374289518756306			7	Pathology	Pathology	GA0UX	WOS:000428031000001	29582001	DOAJ Gold, Green Published			2019-10-28	
J	Powell, SZE; Kragel, PJ; Domen, RE				Powell, Suzanne Zein-Eldin; Kragel, Peter J.; Domen, Ronald E.			The Continuing Fellowship Conundrum	ACADEMIC PATHOLOGY			English	Editorial Material						ethics; fellowship; honor code; medical education; professionalism	PATHOLOGY; RESIDENTS		[Powell, Suzanne Zein-Eldin] Houston Methodist Hosp, Dept Pathol, Houston, TX USA; [Kragel, Peter J.] East Carolina Univ, Dept Pathol & Lab Med, Brody Sch Med, Greenville, NC USA; [Domen, Ronald E.] Penn State Hershey Med Ctr, Dept Pathol & Lab Med, Hershey, PA USA; [Domen, Ronald E.] Coll Med, H160,500 Univ Dr, Hershey, PA 17033 USA	Domen, RE (reprint author), Coll Med, H160,500 Univ Dr, Hershey, PA 17033 USA.; Domen, RE (reprint author), Penn State Hershey Med Ctr, Dept Pathol, H160,500 Univ Dr, Hershey, PA 17033 USA.	rdomen@pennstatehealth.psu.edu					Bernacki KD, 2012, AM J CLIN PATHOL, V137, P543, DOI 10.1309/AJCP2YNIJ0ZPMJNE; Black-Schaffer WS, 2012, AM J CLIN PATHOL, V137, P513, DOI 10.1309/AJCPF0WTY3XEMILP; Crawford JM, 2011, AM J CLIN PATHOL, V135, P338, DOI 10.1309/AJCP16DQXAMQKVNK; Domen RE, 2008, HUM PATHOL, V39, P484, DOI 10.1016/j.humpath.2007.10.028; Kragel P., 2017, APC PRODS ANN M JUL; Myers JL, 2011, AM J CLIN PATHOL, V135, P335, DOI 10.1309/AJCPZA19TUVBXDJV	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	MAR 19	2018	5								UNSP 2374289518763810	10.1177/2374289518763810			3	Pathology	Pathology	GA0VB	WOS:000428031400001	29582002	DOAJ Gold, Green Published			2019-10-28	
J	Scheel, AH; Penault-Llorca, F; Hanna, W; Baretton, G; Middel, P; Burchhardt, J; Hofmann, M; Jasani, B; Ruschoff, J				Scheel, Andreas H.; Penault-Llorca, Frederique; Hanna, Wedad; Baretton, Gustavo; Middel, Peter; Burchhardt, Judith; Hofmann, Manfred; Jasani, Bharat; Rueschoff, Josef			Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer	DIAGNOSTIC PATHOLOGY			English	Article						HER2/neu; Immunohistochemistry; Breast cancer; Gastric cancer; Magnification rule; Predictive biomarker	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DIGITAL IMAGE-ANALYSIS; AMERICAN-PATHOLOGISTS; PROTEIN EXPRESSION; ADENOCARCINOMAS; REPRODUCIBILITY; RECOMMENDATIONS; PEMBROLIZUMAB; VALIDATION	Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the 'magnification rule': Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods: HER2-IHC was performed on 120 breast cancer biopsy specimens (n = 40 per category). Width and color-intensity of membranous DAB chromogen precipitates were measured by whole-slide scanning and digital morphometry. Image-analysis data were related to semi-quantitative manual scoring according to the magnification rule and to the optical properties of the employed microscope objectives. Results: The semi-quantitative manual HER2-IHC scores are correlated to color-intensity measured by image-analysis and to the width of DAB-precipitates. The mean widths +/- standard deviations of precipitates were: IHC-score 1+, 0.64 +/- 0.1 mu m; score 2+, 1.0 +/- 0.23 mu m; score 3+, 2.14 +/- 0.4 mu m. The width of precipitates per category matched the optical resolution of the employed microscope objective lenses: Approximately 0.4 mu m (40x), 1.0 mu m (10x) and 2.0 mu m (5x). Conclusions: Perceived intensity, width of the DAB chromogen precipitate, and absolute color-intensity determined by image-analysis are linked. These interrelations form the physical basis of the 'magnification rule': 2+ precipitates are too narrow to be observed with 5x microscope objectives, 1+ precipitates are too narrow for 10x objectives. Thus, the rule uses the optical resolution windows of standard diagnostic microscope objectives to derive the width of the DAB-precipitates. The width is in turn correlated with color-intensity. Hereby, the more or less subjective estimation of IHC scores based only on the staining-intensity is replaced by a quasi-morphometric measurement. The principle seems universally applicable to immunohistochemical stainings of membrane-bound biomarkers that require an intensity-dependent scoring.	[Scheel, Andreas H.] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Penault-Llorca, Frederique] Ctr Jean Perrin, Dept Pathol, 58 Rue Montalembert,392, F-63011 Clermont Ferrand 1, France; [Hanna, Wedad] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Baretton, Gustavo] Univ Hosp Dresden, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany; [Middel, Peter; Burchhardt, Judith; Hofmann, Manfred; Rueschoff, Josef] Inst Pathol Nordhessen, Germaniastr 7, D-34119 Kassel, Germany; [Middel, Peter] Univ Hosp Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Jasani, Bharat; Rueschoff, Josef] Targos Mol Pathol GmbH, Germaniastr 7, D-34119 Kassel, Germany	Scheel, AH (reprint author), Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany.	andreas.scheel@uk-koeln.de					ADELSON EH, 1993, SCIENCE, V262, P2042, DOI 10.1126/science.8266102; Ali HR, 2013, BRIT J CANCER, V108, P602, DOI 10.1038/bjc.2012.558; Bang YJ, 2010, LANCET, V376, P1302; Baretton G, 2016, PATHOLOGE, V37, P361, DOI 10.1007/s00292-016-0179-3; Bartley AN, 2017, J ONCOL PRACT, V13, P53, DOI 10.1200/JOP.2016.018929; Behrens HM, 2015, CANCER MED-US, V4, P235, DOI 10.1002/cam4.365; Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2; Choritz H, 2011, VIRCHOWS ARCH, V459, P283, DOI 10.1007/s00428-011-1132-8; Cunningham D, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.16; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1243, DOI 10.5858/arpa.2015-0542-OA; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Goldstein EB, 2001, BLACKWELL HDB PERCEP, P53; Helin HO, 2016, VIRCHOWS ARCH, V468, P191, DOI 10.1007/s00428-015-1868-7; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Jeung J, 2012, ARCH PATHOL LAB MED, V136, P610, DOI 10.5858/arpa.2011-0371-OA; Laurinaviciene A, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-87; Lotto RB, 1999, P NATL ACAD SCI USA, V96, P5245, DOI 10.1073/pnas.96.9.5245; MONGES G, 2013, JCO SUPPLEMENT S, V31; Nielsen SL, 2017, APPL IMMUNOHISTO M M, V25, P320, DOI 10.1097/PAI.0000000000000463; Orlando L, 2016, BREAST, V30, P151, DOI 10.1016/j.breast.2016.09.015; Piccart-Gebhart MJ, 2009, ST GALL INT BREAST C; Rakha EA, 2014, HISTOPATHOLOGY, V64, P609, DOI 10.1111/his.12357; Ross DS, 2017, J MOL DIAGN, V19, P244, DOI 10.1016/j.jmoldx.2016.09.010; Ruschoff J, 2017, MODERN PATHOL, V30, P217, DOI 10.1038/modpathol.2016.164; Ruschoff J, 2013, ARCH PATHOL LAB MED, V137, P1255, DOI 10.5858/arpa.2012-0605-OA; Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198; Ruschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Vyberg M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1018-6; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	32	2	3	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAR 12	2018	13								19	10.1186/s13000-018-0696-x			7	Pathology	Pathology	FY9JX	WOS:000427182800001	29530054	DOAJ Gold, Green Published			2019-10-28	
J	Paksoy, N; Ozbek, B				Paksoy, Nadir; Ozbek, Busra			Cytopathologist-performed and ultrasound-guided fine needle aspiration cytology enhances diagnostic accuracy and avoids pitfalls: An overview of 20 years of personal experience with a selection of didactic cases	CYTOJOURNAL			English	Review						Cytopathologist-performed ultrasound-guided fine-needle aspiration cytology; fine-needle aspiration diagnostic accuracy; fine-needle aspiration pitfalls; one-stop fine-needle aspiration clinic; ultrasound guidance	METASTATIC NASOPHARYNGEAL CARCINOMA; PAPILLARY THYROID-CARCINOMA; CERVICAL LYMPH-NODES; DIFFERENTIAL-DIAGNOSIS; INADEQUATE RATES; BIOPSY; FEATURES; LESIONS; BREAST; FNA	Over the last few decades, fine needle aspiration cytology (FNA) has emerged as a SAFE (Simple, Accurate, Fast, Economical) diagnostic tool based on the morphologic evaluation of cells. The first and most important step in obtaining accurate results from FNA is to procure sufficient and representative material from the lesion and to appropriately transfer this material to the laboratory. Unfortunately, the most important aspect of this task occurs beyond the control of the cytopathologist, a key reason for obtaining unsatisfactory results with FNA. There is growing interest in the field of cytology in "cytopathologist-performed ultrasound (US)-guided FNA,"which has been reported to yield accurate results. The first author has been applying FNA in his own private cytopathology practice with a radiologist and under the guidance of US for more than 20 years. This study retrospectively reviews the utility of this practice. We present a selection of didactic examples under different headings that highlight the application of FNA by a cytopathologist, accompanied by US, under the guidance of a radiologist, in the form of an "outpatient FNA clinic." The use of this technique enhances diagnostic accuracy and prevents pitfalls. The highlights of each case are also outlined as "take-home messages."	[Paksoy, Nadir] Kocaeli Univ, Fac Med, Private Cytopathol Practice, Izmit, Kocaeli, Turkey; [Paksoy, Nadir; Ozbek, Busra] Kocaeli Univ, Fac Med, Dept Pathol, Izmit, Kocaeli, Turkey	Paksoy, N (reprint author), Kocaeli Univ, Fac Med, Private Cytopathol Practice, Izmit, Kocaeli, Turkey.; Paksoy, N (reprint author), Kocaeli Univ, Fac Med, Dept Pathol, Izmit, Kocaeli, Turkey.	nadirpaksoy@gmail.com; drbusrasahin@hotmail.com					Abele JS, 2013, AJSP-REV REP, V18, P53, DOI 10.1097/PCR.0b013e318281ca61; Abele JS, 2008, CANCER CYTOPATHOL, V114, P463, DOI 10.1002/cncr.23950; Bellevicine C, 2016, CYTOPATHOLOGY, V27, P115, DOI 10.1111/cyt.12243; Bhanote M, 2008, DIAGN CYTOPATHOL, V36, P876, DOI 10.1002/dc.20920; BURGESS KL, 1993, ACTA CYTOL, V37, P494; DiMaggio Paul J, 2015, J Am Soc Cytopathol, V4, P313, DOI 10.1016/j.jasc.2015.06.003; Dray M, 2000, CYTOPATHOLOGY, V11, P32, DOI 10.1046/j.1365-2303.2000.00216.x; Dueber Julie, 2015, J Am Soc Cytopathol, V4, P195, DOI 10.1016/j.jasc.2014.12.002; Kamal MM, 2014, J CYTOL, V31, P91, DOI 10.4103/0970-9371.138674; Khurana KK, 1998, CANCER CYTOPATHOL, V84, P84, DOI 10.1002/(SICI)1097-0142(19980425)84:2<84::AID-CNCR3>3.0.CO;2-D; Kocjan G, 2003, CYTOPATHOLOGY, V14, P307, DOI 10.1046/j.0956-5507.2003.00103.x; Kollur SM, 2003, DIAGN CYTOPATHOL, V28, P18, DOI 10.1002/dc.10218; Koo JS, 2010, ACTA CYTOL, V54, P249, DOI 10.1159/000325030; Landry CS, 2011, ENDOCR PRACT, V17, P240, DOI 10.4158/EP10134.OR; Lieu D, 2008, DIAGN CYTOPATHOL, V36, P317, DOI 10.1002/dc.20800; Lieu D, 2009, DIAGN CYTOPATHOL, V37, P262, DOI 10.1002/dc.20984; Ljung BM, 2001, CANCER CYTOPATHOL, V93, P263, DOI 10.1002/cncr.9040; Ljung BM, 2013, AJSP-REV REP, V18, P48, DOI 10.1097/PCR.0b013e31828lca50; Masood S, 2013, DIAGN CYTOPATHOL, V41, P1017, DOI 10.1002/dc.23057; Mohanty SK, 2002, DIAGN CYTOPATHOL, V27, P340, DOI 10.1002/dc.10197; Paksoy N, 2007, ACTA CYTOL, V51, P222, DOI 10.1159/000325722; Paksoy N, 2011, CYTOJOURNAL, V8, DOI 10.4103/1742-6413.86970; Paksoy N, 2010, ACTA CYTOL, V54, P733, DOI 10.1159/000325244; Poflee S, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.126222; Rafael OC, 2017, CANCER CYTOPATHOL, V125, P161, DOI 10.1002/cncy.21840; Rollins SD, 2015, AJSP-REV REP, V20, P230, DOI 10.1097/PCR.0000000000000110; Sharma S, 2017, CANCER CYTOPATHOL, V125, P104, DOI 10.1002/cncy.21799; Singh N, 2003, CYTOPATHOLOGY, V14, P327, DOI 10.1046/j.0956-5507.2003.00084.x; Sira J, 2011, ANN OTO RHINOL LARYN, V120, P409, DOI 10.1177/000348941112000611; Song SJ, 2017, DIAGN CYTOPATHOL, V45, P359, DOI 10.1002/dc.23670; Tseng FY, 2002, ACTA CYTOL, V46, P1043, DOI 10.1159/000327105; Wu MX, 2016, DIAGN CYTOPATHOL, V44, P787, DOI 10.1002/dc.23544; Wu MX, 2011, DIAGN CYTOPATHOL, V39, P743, DOI 10.1002/dc.21460	33	0	0	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	MAR 8	2018	15								8	10.4103/cytojournal.cytojournal_20_17			10	Pathology	Pathology	FZ0VI	WOS:000427291300001	29599813	DOAJ Gold, Green Published			2019-10-28	
J	Takahashi, H; Ogata, S; Domoto, H; Oda, T; Kawaguchi, S; Kato, K; Teramura, Y; Nakanishi, K				Takahashi, Hiromi; Ogata, Sho; Domoto, Hideharu; Oda, Tomohiro; Kawaguchi, Saki; Kato, Kei; Teramura, Yasuyo; Nakanishi, Kuniaki			A mass protruding from the pancreas featuring extensive myxoid change	CYTOJOURNAL			English	Editorial Material							SOLITARY FIBROUS TUMOR; DIAGNOSIS; CYTOLOGY		[Takahashi, Hiromi; Ogata, Sho; Domoto, Hideharu; Oda, Tomohiro; Kawaguchi, Saki; Kato, Kei; Nakanishi, Kuniaki] Natl Def Med Coll Hosp, Dept Lab Med, Tokorozawa, Saitama, Japan; [Teramura, Yasuyo] Natl Def Med Coll, Dept Radiol, Tokorozawa, Saitama, Japan; [Nakanishi, Kuniaki] Natl Def Med Coll, Dept Pathol & Lab Med, Tokorozawa, Saitama, Japan	Ogata, S (reprint author), Natl Def Med Coll Hosp, Dept Lab Med, Tokorozawa, Saitama, Japan.	hirohaya@ndmc.ac.jp; sogata@ndmc.ac.jp; hdomoto31@keio.jp; oda0621@ndmc.ac.jp; kawakami@ndmc.ac.jp; lab040@ndmc.ac.jp; gongon3038@msn.com; nknsknak@ndmc.ac.jp					Akerman M, 1987, Diagn Cytopathol, V3, P295, DOI 10.1002/dc.2840030407; Ali SZ, 1997, CANCER CYTOPATHOL, V81, P116, DOI 10.1002/(SICI)1097-0142(19970425)81:2<116::AID-CNCR5>3.0.CO;2-Q; Axelson J, 1998, SURG DIS PANCREAS, P633; Bellizzi AM, 2009, ARCH PATHOL LAB MED, V133, P388, DOI 10.1043/1543-2165-133.3.388; Chetty R, 2009, ANN DIAGN PATHOL, V13, P339, DOI 10.1016/j.anndiagpath.2009.02.006; GUILLOU L, 2002, WHO CLASSIFICATION T, P86; Gupta N, 2012, CYTOPATHOLOGY, V23, P250, DOI 10.1111/j.1365-2303.2011.00880.x; Iyer VK, 2008, J CYTOL, V25, P81, DOI 10.4103/0970-9371.44034; Lau SK, 2009, VIRCHOWS ARCH, V454, P189, DOI 10.1007/s00428-008-0721-7; Luttges J, 1999, VIRCHOWS ARCH, V435, P37, DOI 10.1007/s004280050392; Santos LAM, 2012, AN SIST SANIT NAVAR, V35, P133, DOI 10.4321/s1137-66272012000100013; Shidham VB, 1998, ACTA CYTOL, V42, P1159, DOI 10.1159/000332106; Somerhausen NDA, 1999, MODERN PATHOL, V12, P463; Vij M, 2013, J CYTOL, V30, P8, DOI 10.4103/0970-9371.107505; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	15	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	MAR 8	2018	15								9	10.4103/cytojournal.cytojournal_24_17			4	Pathology	Pathology	FZ0VI	WOS:000427291300002	29599814	DOAJ Gold, Green Published			2019-10-28	
J	[Anonymous]				[Anonymous]			Barshop Symposium on Aging 2017 Abstracts Abstracts	PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES			English	Article																	0	0	0	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2001-0001			PATHOBIOL AGING AGE	Pathobiol. Aging Age-relat. Dis.	MAR 7	2018	8								1444939	10.1080/20010001.2018.1444939			20	Pathology	Pathology	FZ9DA	WOS:000427908600001		DOAJ Gold, Green Published			2019-10-28	
J	Sachak, T; Heerema, NA; Mayerson, J; Payne, JE; Parwani, A; Iwenofu, OH				Sachak, Taha; Heerema, Nyla A.; Mayerson, Joel; Payne, Jason E.; Parwani, Anil; Iwenofu, O. Hans			Novel t(1;2)(p36.1;q23) and t(7;19)(q32;q13.3) chromosomal translocations in ischemic fasciitis: expanding the spectrum of pseudosarcomatous lesions with clonal pathogenetic link	DIAGNOSTIC PATHOLOGY			English	Article						Ischemic fasciitis; Pseudosarcoma; Clonal chromosomal translocations	PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA; DECUBITAL FIBROPLASIA; ONCOGENES; USP6	Background: Ischemic fasciitis is a distinctive pseudosarcomatous entity with a marked predilection for elderly and physically debilitated or immobilized patients. The etiology of these lesions is unknown but felt to be related to ischemic vascular events. Case presentation: Herein, we report for the first time, two cytogenetic translocations, t(1;2)(p36.1;q23) and t(7;19) (q32;q13.3) in a 75 year-old ambulating female with a history of left total hip arthroplasty 20 years ago. Conclusion: These translocations suggest a possible clonal pathogenetic link though their significance remains to be established.	[Sachak, Taha; Heerema, Nyla A.; Parwani, Anil; Iwenofu, O. Hans] Ohio State Univ, Wexner Med Ctr, Dept Pathol & Lab Med, 410 West 10th Ave, Columbus, OH 43210 USA; [Mayerson, Joel] Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA; [Payne, Jason E.] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Columbus, OH 43210 USA	Iwenofu, OH (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Pathol & Lab Med, 410 West 10th Ave, Columbus, OH 43210 USA.	Hans.Iwenofu@osumc.edu	Mayerson, Joel/O-8938-2019				Baranzelli MC, 1996, B CANCER, V83, P81; DEMBINSKI A, 1992, CANCER GENET CYTOGEN, V60, P27, DOI 10.1016/0165-4608(92)90228-Z; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Kendall BS, 1997, ACTA CYTOL, V41, P598, DOI 10.1159/000332565; Liegl B, 2008, AM J SURG PATHOL, V32, P1546, DOI 10.1097/PAS.0b013e31816be8db; Liegl-Atzwanger B., 2013, WHO CLASSIFICATION T, P52; McComb EN, 1997, CANCER GENET CYTOGEN, V98, P142, DOI 10.1016/S0165-4608(96)00428-1; MONTGOMERY EA, 1992, AM J SURG PATHOL, V16, P708, DOI 10.1097/00000478-199207000-00009; Oguejiofor LN, 2011, J AM MED DIR ASSOC, V12, P240, DOI 10.1016/j.jamda.2010.06.006; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Simons A, 2013, CYTOGENET GENOME RES, V141, P1, DOI 10.1159/000353118; Trombetta D, 2011, CANCER GENET-NY, V204, P211, DOI 10.1016/j.cancergen.2011.01.002; Wader J, 2013, J CLIN DIAGN RES, V7, P2952, DOI [10.7860/JCDR/2013.5942.3687, 10.7860/JCDR/2013/5942.3687]; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322	15	0	0	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	MAR 2	2018	13								18	10.1186/s13000-018-0695-y			4	Pathology	Pathology	FY2YU	WOS:000426684200001	29499721	DOAJ Gold, Green Published			2019-10-28	
J	Hoang, LN; Gilks, BC				Hoang, Lien N.; Gilks, Blake C.			Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						hereditary breast and ovarian cancer; breast; ovary; BRCA; BRCA1; BRCA2; homologous recombination repair; synthetic lethality; molecular; high-grade serous carcinoma	GRADE SEROUS CARCINOMA; DNA-REPAIR MECHANISMS; BASE EXCISION-REPAIR; GERMLINE MUTATIONS; FALLOPIAN-TUBE; HIGH-RISK; SUSCEPTIBILITY GENE; POLY(ADP-RIBOSE) POLYMERASE; GENOMIC REARRANGEMENTS; SALPINGO-OOPHORECTOMY	The recent implementation of next generation sequencing and multigene platforms has expanded the spectrum of hereditary breast and ovarian cancer syndrome, beyond the traditional genes BRCA1 and BRCA2. A large number of other moderate penetrance genes have now been uncovered, which also play critical roles in repairing double stranded DNA breaks through the homologous recombination pathway. This review discusses the landmark discoveries of BRCA1 and BRCA2, the homologous repair pathway and new genes discovered in hereditary breast and ovarian cancer syndrome, as well as their clinicopathologic significance and implications for genetic testing. It also highlights the new role of PARP inhibitors in the context of synthetic lethality and prophylactic surgical options.	[Gilks, Blake C.] Vancouver Gen Hosp, Dept Pathol & Lab Med, Room 1503,1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada; [Gilks, Blake C.] Univ British Columbia, Room 1503,1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada	Gilks, BC (reprint author), Vancouver Gen Hosp, Dept Pathol & Lab Med, Room 1503,1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada.; Gilks, BC (reprint author), Univ British Columbia, Room 1503,1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada.	Blake.Gilks@vch.ca					Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Andrews L, 2017, BEST PRACT RES CL OB, V41, P31, DOI 10.1016/j.bpobgyn.2016.10.017; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004; Baretta Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004975; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Candido-dos-Reis FJ, 2015, CLIN CANCER RES, V21, P652, DOI 10.1158/1078-0432.CCR-14-2497; Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034; Cobain EF, 2016, SEMIN ONCOL, V43, P528, DOI 10.1053/j.seminoncol.2016.10.001; Conner JR, 2014, GYNECOL ONCOL, V132, P280, DOI 10.1016/j.ygyno.2013.12.009; Couch FJ, 2015, J CLIN ONCOL, V33, P304, DOI 10.1200/JCO.2014.57.1414; Coyne GO, 2017, DRUGS, V77, P113, DOI 10.1007/s40265-016-0688-7; Crum CP, 2007, CURR OPIN OBSTET GYN, V19, P3, DOI 10.1097/GCO.0b013e328011a21f; Cunningham JM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04026; Desmond A, 2015, JAMA ONCOL, V1, P943, DOI 10.1001/jamaoncol.2015.2690; Dexheimer TS, 2013, DNA REPAIR CANC STEM, P19, DOI DOI 10.1007/978-94-007-4590-2_2; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; Falconer H, 2015, JNCI-J NATL CANCER I, V107, P2; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finch A, 2006, JAMA-J AM MED ASSOC, V296, P185, DOI 10.1001/jama.296.2.185; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Friedenson Bernard, 2005, MedGenMed, V7, P60; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Fujiwara M, 2012, AM J SURG PATHOL, V36, P1170, DOI 10.1097/PAS.0b013e31825d9b8d; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; George SHL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00108; Graffeo R, 2016, BREAST CANCER RES TR, V160, P393, DOI 10.1007/s10549-016-4003-9; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hassler M, 2012, CURR OPIN STRUC BIOL, V22, P721, DOI 10.1016/j.sbi.2012.08.005; Hogervorst FBL, 2003, CANCER RES, V63, P1449; Hoogerbrugge N, 2016, EUR J HUM GENET, V24, pS19, DOI 10.1038/ejhg.2016.95; Horton JK, 2014, MOL CANCER RES, V12, P1128, DOI 10.1158/1541-7786.MCR-13-0502; Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891; Hussein YR, 2016, AM J SURG PATHOL, V40, P404, DOI 10.1097/PAS.0000000000000556; KALACHAND RD, 2015, J CLIN ONCOL S, V33; Karanam K, 2012, MOL CELL, V47, P320, DOI 10.1016/j.molcel.2012.05.052; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konecny GE, 2016, BRIT J CANCER, V115, P1157, DOI 10.1038/bjc.2016.311; Kotsopoulos J, 2016, GYNECOL ONCOL, V140, P42, DOI 10.1016/j.ygyno.2015.11.009; Krammer J, 2017, BREAST CANCER RES TR, V163, P565, DOI 10.1007/s10549-017-4198-4; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 2004, CLIN CANCER RES, V10, P2473, DOI 10.1158/1078-0432.CCR-1029-3; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Lee E, 2011, J CLIN ONCOL, V29, P4373, DOI 10.1200/JCO.2010.33.6446; Li M, 2013, CANCER CELL, V23, P693, DOI 10.1016/j.ccr.2013.03.025; Lin PH, 2016, ONCOTARGET, V7, P8310, DOI 10.18632/oncotarget.7027; Liu C, 2017, J CELL BIOCH, V9999; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; McAlpine JN, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2014.01.003; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Michailidou K, 2015, NAT GENET, V47, P373, DOI 10.1038/ng.3242; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moller P, 2007, EUR J CANCER, V43, P1713, DOI 10.1016/j.ejca.2007.04.023; Moschetta M, 2016, ANN ONCOL, V27, P1449, DOI 10.1093/annonc/mdw142; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Murata S, 2016, BIOMED RES INT, DOI 10.1155/2016/2346585; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Norquist BM, 2016, JAMA ONCOL, V2, P482, DOI 10.1001/jamaoncol.2015.5495; Perez MRO, 2015, SURG ONCOL, V24, P335, DOI 10.1016/j.suronc.2015.09.008; Palma MD, 2008, CANCER RES, V68, P7006, DOI 10.1158/0008-5472.CAN-08-0599; Park B, 2017, BREAST CANCER RES TR, V163, P139, DOI 10.1007/s10549-017-4142-7; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Pennington KP, 2014, CLIN CANCER RES, V20, P764, DOI 10.1158/1078-0432.CCR-13-2287; Perets R, 2016, CANCER RES, V76, P10, DOI 10.1158/0008-5472.CAN-15-1382; Petrucelli N, 1993, GENEREVIEWS; Pinto C, 2016, FUTURE ONCOL, V12, P2071, DOI 10.2217/fon-2016-0189; Rafnar T, 2011, NAT GENET, V43, P1104, DOI 10.1038/ng.955; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Reyes MC, 2014, MODERN PATHOL, V27, P1405, DOI 10.1038/modpathol.2013.237; Richter S, 2013, ANN ONCOL, V24, P69, DOI 10.1093/annonc/mdt312; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Risch HA, 2006, J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Ritterhouse LL, 2016, MODERN PATHOL, V29, P893, DOI 10.1038/modpathol.2016.82; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schrader KA, 2012, OBSTET GYNECOL, V120, P235, DOI 10.1097/AOG.0b013e31825f3576; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schwartz MD, 2012, CANCER-AM CANCER SOC, V118, P510, DOI 10.1002/cncr.26294; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shaw PA, 2002, INT J GYNECOL PATHOL, V21, P407, DOI 10.1097/PGP.0000035810.01856.c8; Skol AD, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0759-4; Song HL, 2015, J CLIN ONCOL, V33, P2901, DOI 10.1200/JCO.2015.61.2408; Soslow RA, 2012, MODERN PATHOL, V25, P625, DOI 10.1038/modpathol.2011.183; Stoppa-Lyonnet D, 2016, EUR J HUM GENET, V24, pS3, DOI 10.1038/ejhg.2016.93; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Symington LS, 2011, ANNU REV GENET, V45, P247, DOI 10.1146/annurev-genet-110410-132435; Thompson ER, 2016, J CLIN ONCOL, V34, P1455, DOI 10.1200/JCO.2015.63.7454; Tung N, 2016, J CLIN ONCOL, V34, P1460, DOI 10.1200/JCO.2015.65.0747; Tung N, 2015, CANCER-AM CANCER SOC, V121, P25, DOI 10.1002/cncr.29010; van den Broek AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120189; Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang YK, 2017, NAT GENET, V49, P856, DOI 10.1038/ng.3849; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhong Q, 2015, CLIN CANCER RES, V21, P211, DOI 10.1158/1078-0432.CCR-14-1816; Zhu YN, 2016, ONCOTARGET, V7, P70113, DOI 10.18632/oncotarget.12158	109	2	2	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	MAR	2018	25	2					85	95		10.1097/PAP.0000000000000177			11	Pathology	Pathology	FY7GZ	WOS:000427031100002	28914618				2019-10-28	
J	He, J; Huo, L; Ma, JS; Zhao, J; Bassett, RL; Sun, XP; Ueno, NT; Lim, B; Gong, Y				He, Jing; Huo, Lei; Ma, Junsheng; Zhao, Jun; Bassett, Roland L.; Sun, Xiaoping; Ueno, Naoto T.; Lim, Bora; Gong, Yun			Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						PD-L1; Inflammatory breast cancer; Survival; Prognosis; Breast; Immunohistochemistry	TUMOR-INFILTRATING LYMPHOCYTES; CELL-CARCINOMA; POOR-PROGNOSIS; ANTI-PD-L1 ANTIBODY; B7-H1 EXPRESSION; PDL1 EXPRESSION; IMMUNE-SYSTEM; BLOCKADE; ASSOCIATION; SURVIVAL	Objectives: Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods: In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results: Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions: These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.	[He, Jing; Huo, Lei; Zhao, Jun; Gong, Yun] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Ma, Junsheng; Bassett, Roland L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Sun, Xiaoping] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA; [Ueno, Naoto T.; Lim, Bora] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Huo, Lei; Ueno, Naoto T.; Lim, Bora; Gong, Yun] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA	Gong, Y (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030 USA.	yungong@mdanderson.org	, 0000-0002-4182-6058/F-9978-2014	, 0000-0002-4182-6058/0000-0002-4182-6058	faculty research fund of The University of Texas MD Anderson Cancer Center	The study was supported by the faculty research fund of The University of Texas MD Anderson Cancer Center (to Y.G.).	Adams S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-OT1-03-20; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Bae SB, 2016, J BREAST CANCER, V19, P242, DOI 10.4048/jbc.2016.19.3.242; Baptista MZ, 2016, HUM PATHOL, V47, P78, DOI 10.1016/j.humpath.2015.09.006; Beckers RK, 2016, HISTOPATHOLOGY, V69, P25, DOI 10.1111/his.12904; Bertucci F, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1085148; Bertucci F, 2015, ONCOTARGET, V6, P13506, DOI 10.18632/oncotarget.3642; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Botti G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071046; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Cristofanilli M, 2007, CANCER-AM CANCER SOC, V110, P1436, DOI 10.1002/cncr.22927; Dill EA, 2017, AM J SURG PATHOL, V41, P334, DOI 10.1097/PAS.0000000000000780; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Emens LA, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-2859; Eto S, 2016, GASTRIC CANCER, V19, P466, DOI 10.1007/s10120-015-0519-7; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Garcia-Teijido P, 2016, CLIN MED INSIGHTS-ON, V10, P31, DOI 10.4137/CMO.S34540; Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654; Ghebeh H, 2006, NEOPLASIA, V8, P190, DOI 10.1593/neo.05733; Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179; Guo L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2513-x; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hamm CA, 2016, MOL CANCER THER, V15, P1746, DOI 10.1158/1535-7163.MCT-15-0353; Hance KW, 2005, JNCI-J NATL CANCER I, V97, P966, DOI 10.1093/dji172; Hartkopf AD, 2016, BREAST CARE, V11, P385, DOI 10.1159/000453569; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Li XX, 2016, AM J CLIN PATHOL, V146, P496, DOI [10.1093/ajcp/aqw134, 10.1093/AJCP/AQW134]; Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549; Lipson EJ, 2015, SEMIN ONCOL, V42, P587, DOI 10.1053/j.seminoncol.2015.05.013; Lipson EJ, 2013, CANCER IMMUNOL RES, V1, P54, DOI 10.1158/2326-6066.CIR-13-0034; Massi D, 2014, ANN ONCOL, V25, P2433, DOI 10.1093/annonc/mdu452; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Mori H, 2017, ONCOTARGET, V8, P15584, DOI 10.18632/oncotarget.14698; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Qin T, 2015, ONCOTARGET, V6, P33972, DOI 10.18632/oncotarget.5583; Reiss KA, 2014, IMMUNOTHERAPY-UK, V6, P459, DOI 10.2217/imt.14.9; Rimm D, 2014, BREAST CANCER RES TR, V147, P457, DOI 10.1007/s10549-014-3061-0; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Scognamiglio G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050790; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shin SJ, 2016, ANN SURG ONCOL, V23, P694, DOI 10.1245/s10434-015-4903-7; Sholl LM, 2016, ARCH PATHOL LAB MED, V140, P341, DOI 10.5858/arpa.2015-0506-SA; Soliman H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088557; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Sun WY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0925-6; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Thompson RH, 2007, CLIN CANCER RES, V13, p709S, DOI 10.1158/1078-0432.CCR-06-1868; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403	64	5	5	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	MAR	2018	149	3					253	261		10.1093/AJCP/AQX162			9	Pathology	Pathology	FW8WW	WOS:000425618700007	29425258	Green Published			2019-10-28	
J	Sellers, SL; Milad, N; Chan, R; Mielnik, M; Jermilova, U; Huang, PL; de Crom, R; Hirota, JA; Hogg, JC; Sandor, GG; Van Breemen, C; Esfandiarei, M; Seidman, MA; Bernatchez, P				Sellers, Stephanie L.; Milad, Nadia; Chan, Rayleigh; Mielnik, Michael; Jermilova, Una; Huang, Paul L.; de Crom, Rini; Hirota, Jeremy A.; Hogg, James C.; Sandor, George G.; Van Breemen, Casey; Esfandiarei, Mitra; Seidman, Michael A.; Bernatchez, Pascal			Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; COMMERCIAL ANTIBODIES LEADS; TYPE-1 RECEPTOR PROTEIN; ENDOTHELIAL-CELLS; MOUSE MODEL; ANEURYSM; MICE; BLOCKADE; ATENOLOL	Marfan syndrome (MFS) is a genetic disorder that frequently leads to aortic root dissection and aneurysm. Despite promising preclinical and pilot clinical data, a recent large-scale study using anti-hypertensive angiotensin II (AngII) receptor type 1 (ATR1) blocker losartan has failed to meet expectations at preventing MFS-associated aortic root dilation, casting doubts about optimal therapy. To study the deleterious role of normal ATR1 signaling in aortic root widening, we generated MFS mice lacking ATR1a expression in an attempt to preserve protective ATR2 signaling. Despite being hypotensive and resistant to AngII vasopressor effects, MFS/ATR1a-null mice showed unabated aortic root enlargement and remained fully responsive to losartan, confirming that blood pressure lowering is of minor therapeutic value in MFS and that losartan's antiremodeling properties may be ATR1 independent. Having shown that MFS causes endothelial dysfunction and that losartan can activate endothelial function in mice and patients, we found that nitric oxide synthase (NOS) inhibition renders losartan therapeutically inactive, whereas multiple transgenic and pharmacologic models of endothelial NOS activation block aortic root dilation by correcting extracellular signal-regulated kinase signaling. In vitro, losartan can increase endothelial NO release in the absence of AngII and correct MFS NO levels in vivo. Our data suggest that increased protective endothelial function, rather than ATR1 inhibition or blood pressure lowering, might be of therapeutic significance in preventing aortic root disease in MFS.	[Sellers, Stephanie L.; Milad, Nadia; Chan, Rayleigh; Mielnik, Michael; Jermilova, Una; Bernatchez, Pascal] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC, Canada; [Sellers, Stephanie L.; Milad, Nadia; Chan, Rayleigh; Mielnik, Michael; Jermilova, Una; Hirota, Jeremy A.; Hogg, James C.; Seidman, Michael A.; Bernatchez, Pascal] Univ British Columbia, UBC Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Sellers, Stephanie L.; Milad, Nadia; Chan, Rayleigh; Mielnik, Michael; Hirota, Jeremy A.; Hogg, James C.; Seidman, Michael A.; Bernatchez, Pascal] Univ British Columbia, St Pauls Hosp, Vancouver, BC, Canada; [Hirota, Jeremy A.] Univ British Columbia, Chan Yeung Ctr Occupat & Environm Resp Dis, Dept Med, Div Resp Med, Vancouver, BC, Canada; [Hogg, James C.; Seidman, Michael A.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Sandor, George G.] Univ British Columbia, Providence Hlth Care & Child & Family Res Inst, Vancouver, BC, Canada; [Huang, Paul L.] Harvard Univ, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA; [de Crom, Rini] Erasmus Univ, Med Ctr, Dept Cell Biol & Genet, Rotterdam, Netherlands; [Esfandiarei, Mitra] Midwestern Univ, Dept Biomed Sci, Glendale, AZ USA	Bernatchez, P (reprint author), Univ British Columbia, St Pauls Hosp, Ctr Heart & Lung Innovat, Dept Anesthesiol Pharmacol & Therapeut, 1081 Burrard St,Room 166, Vancouver, BC V6Z 1Y6, Canada.	pascal.bernatchez@ubc.ca	Esfandiarei, Mitra/V-1258-2019; Esfandiarei, Mitra/R-9903-2019	Esfandiarei, Mitra/0000-0003-3218-7781; Huang, Paul/0000-0002-5436-8658	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of British Columbia Yukon; Yukon and Canadian Foundation for Innovation; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; CIHR New Investigator AwardsCanadian Institutes of Health Research (CIHR); CIHR studentship funding; CIHR Michael Smith Foreign Study Fund; University of British Columbia studentship funding; Frank & Marilyn Anfield Distinguished Heart Center Scholar Award; Early Career Research Initiative; Designated Ward-Research Award from the St. Paul's Foundation	Supported by a Canadian Institutes of Health Research (CIHR) grant (C.V.B., M.E., and P.B.), the Heart and Stroke Foundation of British Columbia & Yukon (P.B.), the Yukon and Canadian Foundation for Innovation (P.B.), the Michael Smith Foundation for Health Research (P.B.), CIHR New Investigator Awards (P.B. and J.A.H.), CIHR studentship funding (S.L.S.), the CIHR Michael Smith Foreign Study Fund (S.L.S.), University of British Columbia studentship funding (S.L.S.), a Frank & Marilyn Anfield Distinguished Heart Center Scholar Award (M.A.S.), the Early Career Research Initiative (M.A.S.), and a Designated Ward-Research Award from the St. Paul's Foundation (M.A.S.).	Abe K, 2010, CIRCULATION, V121, P2747, DOI 10.1161/CIRCULATIONAHA.109.927681; Baek Sung Uk, 2014, J Med Case Rep, V8, P48, DOI 10.1186/1752-1947-8-48; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bernatchez P, 2011, J CLIN INVEST, V121, P3747, DOI [10.1172/JC144778, 10.1172/JCI44778]; Bernatchez PN, 2005, P NATL ACAD SCI USA, V102, P761, DOI 10.1073/pnas.0407224102; Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585; Cheung C, 2012, NAT BIOTECHNOL, V30, P165, DOI 10.1038/nbt.2107; Chiu HH, 2013, MAYO CLIN PROC, V88, P271, DOI 10.1016/j.mayocp.2012.11.005; Chung AWY, 2007, BRIT J PHARMACOL, V150, P1075, DOI 10.1038/sj.bjp.0707181; Chung AWY, 2008, CIRC RES, V102, pE73, DOI 10.1161/CIRCRESAHA.108.174367; Cook JR, 2014, J CLIN INVEST, V124, P1329, DOI 10.1172/JCI71059; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.3.CO;2-S; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gembardt F, 2008, FASEB J, V22, P3068, DOI 10.1096/fj.08-108316; Gibson C, 2017, J APPL PHYSIOL, V123, P147, DOI 10.1152/japplphysiol.00132.2017; Habashi JP, 2011, SCIENCE, V332, P361, DOI 10.1126/science.1192152; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; HALPERN BL, 1971, JOHNS HOPKINS MED J, V129, P123; Herrera M, 2013, HYPERTENSION, V61, pE32, DOI 10.1161/HYPERTENSIONAHA.111.00982; Herrera M, 2013, HYPERTENSION, V61, P253, DOI 10.1161/HYPERTENSIONAHA.112.203679; Hirota JA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-120; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Jackson CL, 2015, NITRIC OXIDE-BIOL CH, V44, P3, DOI 10.1016/j.niox.2014.11.003; Jones JA, 2009, J VASC RES, V46, P119, DOI 10.1159/000151766; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kashiwagi S, 2013, BIOCHEM BIOPH RES CO, V431, P284, DOI 10.1016/j.bbrc.2012.12.110; Lacro RV, 2014, NEW ENGL J MED, V371, P2061, DOI 10.1056/NEJMoa1404731; Lee L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164778; Looft-Wilson R, 2007, J CLIN INVEST, V117, P1961, DOI 10.1172/JCI29877; Mallat Z, 2017, CIRC RES, V120, P1718, DOI 10.1161/CIRCRESAHA.116.310371; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; Napione LAM, 2017, PHYSL PATHOLOGIC ANG; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Nollen GJ, 2002, CARDIOL YOUNG, V12, P320, DOI 10.1017/S1047951100012907; Oller J, 2017, NAT MED, V23, P200, DOI 10.1038/nm.4266; Phomakay V, 2014, J PEDIATR-US, V165, P951, DOI 10.1016/j.jpeds.2014.07.008; Podowski M, 2012, J CLIN INVEST, V122, P229, DOI 10.1172/JCI46215; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Rossi GP, 2009, HYPERTENSION, V54, P710, DOI 10.1161/HYPERTENSIONAHA.109.138883; Sandor GGS, 2015, INT J CARDIOL, V179, P470, DOI 10.1016/j.ijcard.2014.11.082; Saura M, 2005, CIRC RES, V97, P1115, DOI 10.1161/01.RES.0000191538.76771.66; Sharma A, 2015, DIABETES, V64, P3937, DOI 10.2337/db15-0472; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Singh MN, 2016, CAN J CARDIOL, V32, P66, DOI 10.1016/j.cjca.2015.11.003; Siragusa M, 2013, ARTERIOSCL THROM VAS, V33, P1852, DOI 10.1161/ATVBAHA.112.300985; Syyong HT, 2009, BRIT J PHARMACOL, V158, P1597, DOI 10.1111/j.1476-5381.2009.00439.x; van Haperen R, 2003, AM J PATHOL, V163, P1677, DOI 10.1016/S0002-9440(10)63524-9; Wagenaar LJ, 2002, CAN J CARDIOL, V18, P1331; Watanabe T, 2005, CIRCULATION, V112, P1798, DOI 10.1161/CIRCULATIONAHA.104.509760; Wilson DG, 1999, CIRCULATION, V99, P909, DOI 10.1161/01.CIR.99.7.909; Yang HHC, 2010, J THORAC CARDIOV SUR, V140, P305, DOI 10.1016/j.jtcvs.2009.10.039; Yang HHC, 2010, VASC PHARMACOL, V52, P37, DOI 10.1016/j.vph.2009.10.005	53	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					574	585		10.1016/j.ajpath.2017.11.006			12	Pathology	Pathology	FY4OT	WOS:000426805100004	29433732	Bronze			2019-10-28	
J	Carpino, G; Cardinale, V; Folseraas, T; Overi, D; Floreani, A; Franchitto, A; Onori, P; Cazzagon, N; Berloco, PB; Karlsen, TH; Alvaro, D; Gaudio, E				Carpino, Guido; Cardinale, Vincenzo; Folseraas, Trine; Overi, Diletta; Floreani, Annarosa; Franchitto, Antonio; Onori, Paolo; Cazzagon, Nora; Berloco, Pasquale B.; Karlsen, Tom H.; Alvaro, Domenico; Gaudio, Eugenio			Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							HISTOLOGIC SCORING SYSTEMS; PROGENITOR CELLS; DUCTULAR REACTION; LIVER-DISEASE; STEM-CELLS; ALCOHOLIC HEPATITIS; PROGNOSTIC VALUE; CIRRHOSIS; REGENERATION; PROGRESSION	Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are human primary cholangiopathies characterized by the damage of mature cholangiocytes and by the appearance of ductular reaction (DR) as the results of hepatic progenitor cell activation. This study evaluated the differences in progenitor cell niche activation between these two cholangiopathies. Liver tissue was obtained from healthy liver donors (n = 5) and from patients with PSC (n = 20) or PBC (n = 20). DR, progenitor cell phenotype, and signaling pathways were investigated by IHC analysis and immunofluorescence. Our results indicated that DR was more extended, appeared earlier, and had a higher proliferation index in PBC compared with PSC. In PBC, DR was strongly correlated with clinical prognostic scores. A higher percentage of sex determining region Y-box (SOX)9(+) and cytokeratin 19(+) cells but fewer features of hepatocyte fate characterized progenitor cell activation in PBC versus PSC. Lower levels of laminin and neurogenic locus notch homolog protein 1 but higher expression of wingless-related integration site (WNT) family pathway components characterize progenitor cell niche in PSC compared with PBC. In conclusion, progenitor cell activation differs between PSC and PBC and is characterized by a divergent fate commitment and different signaling pathway predominance. In PBC, DR represents a relevant histologic prognostic marker.	[Carpino, Guido] Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Div Hlth Sci, Piazza Lauro De Bosis 6, I-00135 Rome, Italy; [Cardinale, Vincenzo; Alvaro, Domenico] Sapienza Univ Rome, Dept Medicosurg Sci & Biotechnol, Latina, Italy; [Folseraas, Trine; Karlsen, Tom H.] Oslo Univ Hosp, Rigshosp, Norwegian PSC Res Ctr, Dept Transplantat Med,Div Canc Surg & Transplanta, Oslo, Norway; [Overi, Diletta; Franchitto, Antonio; Onori, Paolo; Gaudio, Eugenio] Sapienza Univ Rome, Dept Anat Histol Forens Med & Orthoped Sci, Rome, Italy; [Berloco, Pasquale B.] Sapienza Univ Rome, Dept Gen Surg & Organ Transplantat, Rome, Italy; [Floreani, Annarosa; Cazzagon, Nora] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Karlsen, Tom H.] Univ Oslo, Oslo Univ Hosp, Internal Med Res Inst, Div Surg Inflammatory Dis & Transplantat,Rikshosp, Oslo, Norway; [Karlsen, Tom H.] Univ Oslo, Inst Clin Med, Oslo, Norway	Carpino, G (reprint author), Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, Div Hlth Sci, Piazza Lauro De Bosis 6, I-00135 Rome, Italy.	guido.carpino@uniroma1.it	Cardinale, Vincenzo/AAB-9296-2019; Franchitto, Antonio/C-8095-2009; Onori, Paolo/J-9394-2013; Carpino, Guido/AAB-9692-2019; ALVARO, Domenico/J-8600-2018	Cardinale, Vincenzo/0000-0003-0234-3341; Onori, Paolo/0000-0002-7195-3760; ALVARO, Domenico/0000-0003-3771-9644	Sapienza University of RomeSapienza University Rome; Fondo per gli Investimenti della Ricerca di Base (FIRB)Ministero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [RBAP10Z7FS_001]; Progetti di ricerca di Rilevante Interesse Nazionale (PRIN)Ministero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [2009X84L84_001]; FIRB grant [RBAP10Z7FS_004]; PRIN grant [2009X84L84_002]; Consorzio Interuniversitario Trapianti d'Organo (Rome, Italy); Vesta Therapeutics (Bethesda, MD); Norwegian Primary Sclerosing Cholangitis Research Center (Oslo, Norway)	Supported by a research project grant from the Sapienza University of Rome, Fondo per gli Investimenti della Ricerca di Base (FIRB) grant RBAP10Z7FS_001, and Progetti di ricerca di Rilevante Interesse Nazionale (PRIN) grant 2009X84L84_001 (E.G.); FIRB grant RBAP10Z7FS_004, PRIN grant 2009X84L84_002, and a grant from Consorzio Interuniversitario Trapianti d'Organo (Rome, Italy; D.A.); a sponsored research agreement from Vesta Therapeutics (Bethesda, MD; E.G.); and a grant from the Norwegian Primary Sclerosing Cholangitis Research Center (Oslo, Norway; T.H.K.).	Alvaro D, 2004, J HEPATOL, V41, P905, DOI 10.1016/j.jhep.2004.08.022; Alvaro D, 2007, GASTROENTEROLOGY, V132, P415, DOI 10.1053/j.gastro.2006.07.023; Angulo P, 1999, AM J GASTROENTEROL, V94, P3310, DOI 10.1111/j.1572-0241.1999.01543.x; Beuers U, 2009, J HEPATOL, V51, P237, DOI 10.1016/j.jhep.2009.04.009; Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452; Boulter L, 2013, J CLIN INVEST, V123, P1867, DOI 10.1172/JCI66026; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Burak KW, 2003, AM J GASTROENTEROL, V98, P1155, DOI 10.1111/j.1572-0241.2003.07401.x; Carbone M, 2016, HEPATOLOGY, V63, P930, DOI 10.1002/hep.28017; Cardinale V, 2012, NAT REV GASTRO HEPAT, V9, P231, DOI 10.1038/nrgastro.2012.23; Carpino G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157246; Carpino G, 2016, J ANAT, V228, P474, DOI 10.1111/joa.12418; Carpino G, 2015, J HEPATOL, V63, P1220, DOI 10.1016/j.jhep.2015.06.018; Carpino G, 2014, J HEPATOL, V60, P1194, DOI 10.1016/j.jhep.2014.01.026; Carpino G, 2012, J ANAT, V220, P186, DOI 10.1111/j.1469-7580.2011.01462.x; Cavazza A, 2009, HEPATOLOGY, V50, P1162, DOI 10.1002/hep.23095; de Vries EMG, 2017, HEPATOLOGY, V65, P907, DOI 10.1002/hep.28963; de Vries EMG, 2015, J HEPATOL, V63, P1212, DOI 10.1016/j.jhep.2015.06.008; Della Corte C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168216; Dubuquoy L, 2015, GUT, V64, P1949, DOI 10.1136/gutjnl-2014-308410; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; Fickert P, 2014, J HEPATOL, V60, P1290, DOI 10.1016/j.jhep.2014.02.006; Forbes SJ, 2016, NAT REV GASTRO HEPAT, V13, P473, DOI 10.1038/nrgastro.2016.97; Gadd VL, 2014, HEPATOLOGY, V59, P1393, DOI 10.1002/hep.26937; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Guest RV, 2016, P NATL ACAD SCI USA, V113, P12250, DOI 10.1073/pnas.1600067113; Guldiken N, 2016, J HEPATOL, V65, P552, DOI 10.1016/j.jhep.2016.04.024; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Hrad V, 2016, GASTROENT RES PRACT, DOI 10.1155/2016/3432640; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Invernizzi P, 2014, SEMIN LIVER DIS, V34, P253, DOI 10.1055/s-0034-1383724; Katoonizadeh A, 2006, LIVER INT, V26, P1225, DOI 10.1111/j.1478-3231.2006.01377.x; Lammers WJ, 2015, GASTROENTEROLOGY, V149, P1804, DOI 10.1053/j.gastro.2015.07.061; Lanthier N, 2015, J HEPATOL, V63, P609, DOI 10.1016/j.jhep.2015.04.003; Lanzoni G, 2016, HEPATOLOGY, V64, P277, DOI 10.1002/hep.28326; Lazaridis KN, 2016, NEW ENGL J MED, V375, P1161, DOI 10.1056/NEJMra1506330; Libbrecht L, 2002, SEMIN CELL DEV BIOL, V13, P389, DOI 10.1016/S1084-9521(02)00125-8; Lorenzini S, 2010, GUT, V59, P645, DOI 10.1136/gut.2009.182345; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010; Nobili V, 2012, HEPATOLOGY, V56, P2142, DOI 10.1002/hep.25742; Onori P, 2007, J HISTOCHEM CYTOCHEM, V55, P327, DOI 10.1369/jhc.6R7125.2006; Ponsioen CY, 2016, HEPATOLOGY, V63, P1357, DOI 10.1002/hep.28256; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Spee B, 2010, GUT, V59, P247, DOI 10.1136/gut.2009.188367; Stueck AE, 2015, HEPATOLOGY, V61, P1696, DOI 10.1002/hep.27706; Tabibian JH, 2014, HEPATOLOGY, V59, P2263, DOI 10.1002/hep.26993; Trivedi PJ, 2016, GUT, V65, P321, DOI 10.1136/gutjnl-2014-308351; Tummala KS, 2017, CELL REP, V19, P584, DOI 10.1016/j.celrep.2017.03.059; Turner R, 2011, HEPATOLOGY, V53, P1035, DOI 10.1002/hep.24157; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Yoon SM, 2011, HEPATOLOGY, V53, P964, DOI 10.1002/hep.24122	52	12	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					627	639		10.1016/j.ajpath.2017.11.010			13	Pathology	Pathology	FY4OT	WOS:000426805100008	29248458	Bronze			2019-10-28	
J	Tanjaya, J; Lord, EL; Wang, CC; Zhang, YL; Kim, JK; Nguyen, A; Baik, L; Pan, HC; Chen, E; Kwak, JH; Zhang, XL; Wu, B; Soo, C; Ting, K				Tanjaya, Justine; Lord, Elizabeth L.; Wang, Chenchao; Zhang, Yulong; Kim, Jong K.; Nguyen, Alan; Baik, Llyod; Pan, Hsin C.; Chen, Eric; Kwak, Jin H.; Zhang, Xinli; Wu, Benjamin; Soo, Chia; Ting, Kang			The Effects of Systemic Therapy of PEGylated NEL-Like Protein 1 (NELL-1) on Fracture Healing in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BONE MORPHOGENETIC PROTEIN-2; RAT SPINAL-FUSION; BISPHOSPHONATE DRUG HOLIDAY; STEM-CELLS; CALVARIAL DEFECTS; IN-VIVO; MODEL; REGENERATION; OSTEOPOROSIS; ALENDRONATE	Fractures are common, with an incidence of 13.7 per 1000 adults annually. Systemic agents have been widely used for enhancing bone regeneration; however, the efficacy of these therapeutics for the management and prevention of fracture remains unclear. NEL-like protein 1 (NELL-1) is a potent pro-osteogenic cytokine that has been modified with polyethylene glycol (PEG)ylation [PEGylated NELL-1 (NELL-PEG)] to enhance its pharmacokinetics for systemic therapy. Our aim was to investigate the effects of systemic administration of NELL-PEG on fracture healing in mice and on overall bone properties in uninjured bones. Ten-week old CD-1 mice were subjected to an open osteotomy of bilateral radii and treated with weekly injections of NELL-PEG or PEG phosphate-buffered saline as control. Systemic injection of NELL-PEG resulted in improved bone mineral density of the fracture site and accelerated callus union. After 4 weeks of treatment, mice treated with NELL-PEG exhibited substantially enhanced callus volume, callus mineralization, and biomechanical properties. NELL-PEG injection significantly augmented bone regeneration, as confirmed by high expression of bone turnover rate, bone formation rate, and mineral apposition rate. Consistently, the immunohistochemistry results also confirmed a high bone remodeling activity in the NELL-PEG treated group. Our findings suggest that weekly injection of NELL-PEG may have the clinical potential to accelerate fracture union and enhance overall bone properties, which may help prevent subsequent fractures.	[Tanjaya, Justine; Kim, Jong K.; Nguyen, Alan; Baik, Llyod; Pan, Hsin C.; Chen, Eric; Kwak, Jin H.; Zhang, Xinli; Ting, Kang] Univ Calif Los Angeles, Div Growth & Dev, Los Angeles, CA USA; [Tanjaya, Justine; Kim, Jong K.; Nguyen, Alan; Baik, Llyod; Pan, Hsin C.; Chen, Eric; Kwak, Jin H.; Zhang, Xinli; Ting, Kang] Univ Calif Los Angeles, Sect Orthodont, Los Angeles, CA USA; [Lord, Elizabeth L.; Soo, Chia] Univ Calif Los Angeles, Sch Dent, Dept Orthopaed Surg, Los Angeles, CA 90024 USA; [Lord, Elizabeth L.; Soo, Chia] Univ Calif Los Angeles, Orthopaed Hosp Res Ctr, Los Angeles, CA USA; [Wang, Chenchao; Soo, Chia] Univ Calif Los Angeles, Div Plast & Reconstruct Surg, Los Angeles, CA USA; [Zhang, Yulong; Wu, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [Zhang, Yulong; Wu, Benjamin] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA; [Zhang, Yulong; Wu, Benjamin] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA; [Wang, Chenchao] China Med Univ, Hosp 1, Dept Plast Surg, Shenyang, Liaoning, Peoples R China	Ting, K (reprint author), Univ Calif Los Angeles, Sch Dent, CHS 30-117,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kting@dentistry.ucla.edu	Pan, Hsin Chuan/D-1485-2019	Pan, Hsin Chuan/0000-0001-9859-0309	National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute (CTSI) [UL1TR000124]; NIH/National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [AR068835-01A1, R01 AR066782-01, AR061399-01A1]; American Association of Orthodontists Foun- dation Orthodontic Faculty Development Fellowship award	Supported by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases grants R01 AR066782-01 (K.T.), AR068835-01A1 (C.S.), and AR061399-01A1 (C.S.), an American Association of Orthodontists Foundation Orthodontic Faculty Development Fellowship award (J.H.K.), and National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute (CTSI) grant UL1TR000124 (K.T.).	Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708; Aghaloo T, 2007, MOL THER, V15, P1872, DOI 10.1038/sj.mt.6300270; Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210; Babu S, 2015, WORLD J ORTHOP, V6, P457, DOI 10.5312/wjo.v6.i6.457; Bao QW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02705-0; Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926-010-0097-y; Black DM, 2006, JAMA-J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927; Brandi ML, 2013, EXPERT OPIN PHARMACO, V14, P1441, DOI 10.1517/14656566.2013.801959; Brandi ML, 2012, EXPERT OPIN INV DRUG, V21, P1169, DOI 10.1517/13543784.2012.696610; Bucicwalter JA, 1996, LANCET S2, V348, ps1118; Burge R, 2007, J BONE MINER RES, V22, P465, DOI 10.1359/JBMR.061113; Chung CG, 2014, STEM CELL TRANSL MED, V3, P1231, DOI 10.5966/sctm.2014-0027; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Diab DL, 2013, THER ADV MUSCULOSKEL, V5, P107, DOI 10.1177/1759720X13477714; Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-66; Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164; Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698; Emara KM, 2015, WORLD J ORTHOP, V6, P623, DOI 10.5312/wjo.v6.i8.623; Fayaz HC, 2011, INT ORTHOP, V35, P1587, DOI 10.1007/s00264-011-1338-z; Fong K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-103; Grauer AL, 1996, AM J PHYS ANTHROPOL, V100, P531, DOI 10.1002/(SICI)1096-8644(199608)100:4<531::AID-AJPA7>3.0.CO;2-T; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hoang-Kim A, 2009, CLIN CASES MINER BON, V6, P136; Horner EA, 2010, TISSUE ENG PART B-RE, V16, P263, DOI 10.1089/ten.TEB.2009.0224; James AW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92573; James AW, 2016, TISSUE ENG PART B-RE, V22, P284, DOI [10.1089/ten.teb.2015.0357, 10.1089/ten.TEB.2015.0357]; James AW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8362; Jing D, 2016, SCI REP-UK, V6, DOI 10.1038/srep28537; Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4; Kang Ho, 2017, J Bone Metab, V24, P97, DOI 10.11005/jbm.2017.24.2.97; Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020-1383(16)30015-8; Kawakami Y, 2013, LAB INVEST, V93, P1036, DOI 10.1038/labinvest.2013.93; Kim Sang-Min, 2017, J Bone Metab, V24, P65, DOI 10.11005/jbm.2017.24.1.65; Kooistra BW, 2010, J ORTHOP TRAUMA, V24, pS81, DOI 10.1097/BOT.0b013e3181ca3fd1; Kwak JH, 2015, BIOMATERIALS, V57, P73, DOI 10.1016/j.biomaterials.2015.03.063; Kyllonen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006; Li WM, 2011, PLAST RECONSTR SURG, V127, P580, DOI 10.1097/PRS.0b013e3181fed5ae; Li WM, 2010, TISSUE ENG PT A, V16, P2861, DOI 10.1089/ten.tea.2009.0550; Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020; Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031; MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150; Meganck JA, 2013, BONE, V56, P204, DOI 10.1016/j.bone.2013.06.003; Nauth A, 2012, INDIAN J ORTHOP, V46, P19, DOI 10.4103/0019-5413.91630; Ning B, 2017, MOL MED REP, V15, P1017, DOI 10.3892/mmr.2017.6155; Oetgen ME, 2008, INJURY, V39, P1119, DOI 10.1016/j.injury.2008.04.008; Owen JL, 2007, CAN J SURG, V50, P115; Pang S, 2015, STEM CELLS, V33, P904, DOI 10.1002/stem.1884; Ro C, 2013, CURR OSTEOPOROS REP, V11, P45, DOI 10.1007/s11914-012-0129-9; Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11; Shefelbine SJ, 2005, BONE, V36, P480, DOI 10.1016/j.bone.2004.11.007; Shen J, 2016, AM J PATHOL, V186, P419, DOI 10.1016/j.ajpath.2015.10.011; Shen J, 2012, J CELL BIOCHEM, V113, P3620, DOI 10.1002/jcb.24253; Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691; Solomon DH, 2009, OSTEOPOROSIS INT, V20, P895, DOI 10.1007/s00198-008-0759-z; Solomon DH, 2014, J BONE MINER RES, V29, P1929, DOI 10.1002/jbmr.2202; Tanjaya J, 2016, BIORESEARCH OPEN ACC, V5, P159, DOI 10.1089/biores.2016.0018; Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80; Xue DT, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-45; Yin HG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082852; Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.tea.2010.0555, 10.1089/ten.TEA.2010.0555]; Zhang XL, 2011, TISSUE ENG PT A, V17, P2497, DOI [10.1089/ten.TEA.2010.0705, 10.1089/ten.tea.2010.0705]; Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; Zhang YL, 2014, BIOMATERIALS, V35, P6614, DOI 10.1016/j.biomaterials.2014.04.061	65	2	2	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					715	727		10.1016/j.ajpath.2017.11.018			13	Pathology	Pathology	FY4OT	WOS:000426805100014	29294300	Green Published, Bronze			2019-10-28	
J	Sulas, P; Di Tommaso, L; Novello, C; Rizzo, F; Rinaldi, A; Weisz, A; Columbano, A; Roncalli, M				Sulas, Pia; Di Tommaso, Luca; Novello, Chiara; Rizzo, Francesca; Rinaldi, Antonio; Weisz, Alessandro; Columbano, Amedeo; Roncalli, Massimo			A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development	AMERICAN JOURNAL OF PATHOLOGY			English	Article							YES-ASSOCIATED PROTEIN; LIVER-CANCER; COMPREHENSIVE ANALYSIS; SIGNALING PATHWAY; EXPRESSION; IDENTIFICATION; HEPATOCARCINOGENESIS; PROGRESSION; ACTIVATION; PROGNOSIS	Hepatocellular carcinoma (HCC) typically results from a stepwise process characterized by the development of premalignant lesions, such as low- or high-grade dysplastic nodules (LGDNs and HGDNs, respectively), in a cirrhotic setting. MicroRNAs (miRNAs) are small noncoding RNAs involved in post transcriptional regulation of gene expression that can act as oncogenes or tumor suppressors. Whether and which miRNAs are involved in the early stages of HCC development remains elusive. Here, small-RNA sequencing was applied to profile miRNA expression in 55 samples (cirrhotic nodules; CNs), LGDNs, HGDNs, early HCCs, and small progressed HCCs, obtained from 17 patients bearing HCCs of different etiologies. An miRNA expression signature of 62 miRNAs distinguishing small progressed HCCs from matched CNs was identified. Interestingly, 52 of these miRNAs discriminated CNs from LGDNs/HGDNs, regardless of etiology, and remained modified along the tumorigenic process. Functional analysis of the predicted mRNA targets of deregulated miRNAs identified common modifications between the early and late stages of HCC development likely involved in the stepwise process of HCC development. Our results demonstrate that miRNA deregulation happens very early in HCC in humans, implying their crucial role in the tumorigenic process. The identification of miRNAs discriminating CNs from neoplastic nodules may have relevant translational implications in early diagnosis.	[Sulas, Pia; Columbano, Amedeo] Univ Cagliari, Dept Biomed Sci, Unit Oncol & Mol Pathol, Via Porcell 4, I-09124 Cagliari, Italy; [Di Tommaso, Luca; Novello, Chiara; Roncalli, Massimo] Humanitas Univ, Humanitas Clin & Res Ctr, Pathol Unit, Milan, Italy; [Sulas, Pia; Di Tommaso, Luca; Novello, Chiara; Roncalli, Massimo] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Rizzo, Francesca; Rinaldi, Antonio; Weisz, Alessandro] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Lab Mol Med & Genom, Baronissi, Italy	Columbano, A (reprint author), Univ Cagliari, Dept Biomed Sci, Unit Oncol & Mol Pathol, Via Porcell 4, I-09124 Cagliari, Italy.; Weisz, A (reprint author), Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Via S Allende 1, I-84081 Baronissi, SA, Italy.	aweisz@unisa.it; columbano@unica.it	Weisz, Alessandro/A-1317-2014; Rizzo, Francesca/K-3057-2016; Novello, Chiara/K-2569-2016	Weisz, Alessandro/0000-0003-0455-2083; Rizzo, Francesca/0000-0003-1783-5015; Columbano, Amedeo/0000-0002-6956-9030; di tommaso, luca/0000-0002-9013-4728; Novello, Chiara/0000-0001-5405-0300	National Research Council Flagship Project InterOmics; Associazione Italiana Ricerca sul CancroAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG-15437, IG-15279, IG-17426]; Fondazione di SardegnaFondazione Banco di Sardegna	Supported by Associazione Italiana Ricerca sul Cancro grants IG-15279 (A.C.), IG-17426 (A.W.), and IG-15437 (M.R.), National Research Council Flagship Project InterOmics, and a grant from the Fondazione di Sardegna (A.C.).	Augello C, 2012, LIVER INT, V32, P772, DOI 10.1111/j.1478-3231.2012.02795.x; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Gao HJ, 2014, BIOMED PHARMACOTHER, V68, P943, DOI 10.1016/j.biopha.2014.09.005; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Giordano S, 2013, HEPATOLOGY, V57, P840, DOI 10.1002/hep.26095; Humphries B, 2015, ONCOTARGET, V6, P6472, DOI 10.18632/oncotarget.3052; Imbeaud S, 2010, SEMIN LIVER DIS, V30, P75, DOI 10.1055/s-0030-1247134; Jin B, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2904-y; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Kowalik MA, 2011, HEPATOLOGY, V53, P2086, DOI 10.1002/hep.24289; Kwon GY, 2005, J KOREAN MED SCI, V20, P242, DOI 10.3346/jkms.2005.20.2.242; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Marquardt JU, 2014, J HEPATOL, V60, P346, DOI 10.1016/j.jhep.2013.10.014; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Nault JC, 2014, HEPATOLOGY, V60, P1983, DOI 10.1002/hep.27372; Ng R, 2012, J CLIN INVEST, V122, P1097, DOI 10.1172/JCI46039; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Panero R, 2017, BIOINFORMATICS, V33, P938, DOI 10.1093/bioinformatics/btw734; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Peskoe SB, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3008-4; Petrelli A, 2014, HEPATOLOGY, V59, P228, DOI 10.1002/hep.26616; Rizzo F, 2016, ONCOTARGET, V7, P54650, DOI 10.18632/oncotarget.10567; Sciarra A, 2016, J HEPATOL, V64, P87, DOI 10.1016/j.jhep.2015.08.031; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang JL, 2017, ONCOL RES, V25, P1, DOI 10.3727/096504016X14685034103798; Wong CM, 2015, ONCOTARGET, V6, P13658, DOI 10.18632/oncotarget.3700; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Xue HY, 2016, ONCOTARGET, V7, P86675, DOI 10.18632/oncotarget.13431; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou N, 2016, TUMOR BIOL, V37, P2145, DOI 10.1007/s13277-015-3841-0; Zhu JH, 2016, ONCOL LETT, V12, P4829, DOI 10.3892/ol.2016.5295; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	38	3	3	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					785	794		10.1016/j.ajpath.2017.10.024			10	Pathology	Pathology	FY4OT	WOS:000426805100019	29248455	Bronze			2019-10-28	
J	Tsai, SH; Xie, WK; Zhao, M; Rosa, RH; Hein, TW; Kuo, L				Tsai, Shu-Huai; Xie, Wankun; Zhao, Min; Rosa, Robert H., Jr.; Hein, Travis W.; Kuo, Lih			Alterations of Ocular Hemodynamics Impair Ophthalmic Vascular and Neuroretinal Function	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RETINAL ARTERIOLAR DILATION; SYSTEMIC BLOOD-PRESSURE; NITRIC-OXIDE; HYPERTENSIVE RETINOPATHY; INTRAOCULAR-PRESSURE; OXIDATIVE STRESS; OSCILLATORY POTENTIALS; HYDROGEN-PEROXIDE; FLOW; AUTOREGULATION	Hypertension is associated with numerous diseases, but its direct impact on the ocular circulation and neuroretinal function remains unclear. Herein, mouse eyes were challenged with different levels of hemodynamic insult via transverse aortic coarctation, which increased blood pressure and flow velocity by 50% and 40%, respectively, in the right common carotid artery, and reduced those parameters by 30% and 40%, respectively, in the left common carotid artery. Blood velocity in the right central retinal artery gradually increased up to 40% at 4 weeks of transverse aortic coarctation, and the velocity in the left central retinal artery gradually decreased by 20%. The fundus and retinal architecture were unaltered by hemodynamic changes. Endothelium-dependent vasodilations to acetylcholine and adenosine were reduced only in right (hypertensive) ophthalmic arteries. Increased cellularity in the nerve fiber/ganglion cell layers, enhanced glial fibrillary acidic protein expression, and elevated superoxide level were found only in hypertensive retinas. The electroretinogram showed decreased scotopic b-waves in the hypertensive eyes and decreased scotopic oscillatory potentials in both hypertensive and hypotensive eyes. In conclusion, hypertension sustained for 4 weeks causes ophthalmic vascular dysfunction, retinal glial cell activation, oxidative stress, and neuroretinal impairment. Although ophthalmic vasoregulation is insensitive to hypotensive insult, the ocular hypoperfusion causes neuroretinal dysfunction.	Texas A&M Univ, Coll Med, Hlth Sci Ctr, Dept Med Physiol, Temple, TX 76508 USA; Baylor Scott & White Hlth, Scott & White Eye Inst, Dept Ophthalmol, Ophthalm Vasc Res Program, Temple, TX USA	Kuo, L (reprint author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, 702 SW HK Dodgen Loop, Temple, TX 76504 USA.	lkuo@tamhsc.edu	; Xie, Wankun/K-8623-2017	Tsai, Shu-Huai/0000-0002-5459-8672; Zhao, Min/0000-0003-0521-9186; Xie, Wankun/0000-0003-0178-3361	Kruse Chair Endowment; Baylor Scott & White Central Texas Foundation; Retina Research Foundation; Liles Macular Degeneration Research Fund; Ophthalmic Vascular Research Program of Baylor Scott White Health; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY024624, R01EY018420]	Supported by the Liles Macular Degeneration Research Fund (R.H.R.), Kruse Chair Endowment (L.K.), Baylor Scott & White Central Texas Foundation (L.K.), Ophthalmic Vascular Research Program of Baylor Scott & White Health (L.K.), Retina Research Foundation (L.K.), and NIH grants R01EY018420 and R01EY024624 (T.W.H.).	Aissopou EK, 2015, J HYPERTENS, V33, P2303, DOI 10.1097/HJH.0000000000000702; BELLINI G, 1995, HYPERTENSION, V25, P839, DOI 10.1161/01.HYP.25.4.839; BRAUNAGEL SC, 1988, J OCUL PHARMACOL, V4, P61, DOI 10.1089/jop.1988.4.61; BRESNICK GH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1307, DOI 10.1001/archopht.1984.01040031057023; de Hoz R, 2016, BIOMED RES INT, DOI 10.1155/2016/2954721; Delles C, 2004, STROKE, V35, P1289, DOI 10.1161/01.STR.0000126597.11534.3b; Dorner GT, 2003, AM J PHYSIOL-HEART C, V285, pH631, DOI 10.1152/ajpheart.00111.2003; Dumskyj MJ, 1996, MICROVASC RES, V51, P378, DOI 10.1006/mvre.1996.0034; Erden S, 2012, CLIN EXP HYPERTENS, V34, P397, DOI 10.3109/10641963.2012.663028; Feng YQ, 2013, CURR EYE RES, V38, P396, DOI 10.3109/02713683.2012.748919; Fletcher EL, 2010, PROG RETIN EYE RES, V29, P284, DOI 10.1016/j.preteyeres.2010.03.003; Garhofer G, 2004, VISION RES, V44, P833, DOI 10.1016/j.visres.2003.11.013; GIDDAY JM, 1993, INVEST OPHTH VIS SCI, V34, P2713; HAEFLIGER IO, 1992, INVEST OPHTH VIS SCI, V33, P2340; Hartley CJ, 2008, ULTRASOUND MED BIOL, V34, P892, DOI 10.1016/j.ultrasmedbio.2007.11.019; Hein TW, 2015, INVEST OPHTH VIS SCI, V56, P5381, DOI 10.1167/iovs15-16950; Hein TW, 2012, INVEST OPHTH VIS SCI, V53, P30, DOI 10.1167/iovs.11-8753; Hein TW, 2010, INVEST OPHTH VIS SCI, V51, P1583, DOI 10.1167/iovs.09-4391; Hein TW, 2006, INVEST OPHTH VIS SCI, V47, P693, DOI 10.1167/iovs.05-1224; Hein TW, 2005, INVEST OPHTH VIS SCI, V46, P2113, DOI 10.1167/iovs.04-1438; Henderson AD, 2012, WEST J EMERG MED, V13, P529, DOI 10.5811/westjem.2011.10.6755; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Jehle T, 2008, INVEST OPHTH VIS SCI, V49, P1056, DOI 10.1167/iovs.07-1050; Kabedi NN, 2014, CARDIOVASC J AFR, V25, P228, DOI 10.5830/CVJA-2014-045; Katsi V, 2012, CURR HYPERTENS REP, V14, P581, DOI 10.1007/s11906-012-0283-6; KEITH NM, 1974, AM J MED SCI, V268, P336, DOI 10.1097/00000441-197412000-00004; Klein BEK, 2005, BRIT J OPHTHALMOL, V89, P284, DOI 10.1136/bjo.2004.048710; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026; Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329; Klein R., 1997, T AM OPHTHAL SOC, V95, p[; KUO L, 1990, AM J PHYSIOL, V259, pH1063, DOI 10.1152/ajpheart.1990.259.4.H1063; Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004; Laspas P, 2014, EXP EYE RES, V127, P1, DOI 10.1016/j.exer.2014.06.018; Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815; Luna G, 2010, MOL VIS, V16, P2511; Luu CD, 2012, INVEST OPHTH VIS SCI, V53, P2218, DOI 10.1167/iovs.11-8490; Machalinska A, 2017, J OPHTHALMOL, DOI 10.1155/2017/4089262; McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7; Michelson G, 2006, RETINA-J RET VIT DIS, V26, P437, DOI 10.1097/00006982-200604000-00010; Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088; Movaffaghy A, 1998, EXP EYE RES, V67, P561, DOI 10.1006/exer.1998.0556; Nagaoka T, 2006, ARCH OPHTHALMOL-CHIC, V124, P665, DOI 10.1001/archopht.124.5.665; Nagaoka T, 2002, INVEST OPHTH VIS SCI, V43, P1941; Nakano T, 2005, OPHTHALMOLOGY, V112, P609, DOI 10.1016/j.ophtha.2004.10.046; National Research Council, 2011, GUIDE CARE USE LAB A; Nebbioso M, 2012, DIABETES TECHNOL THE, V14, P257, DOI 10.1089/dia.2011.0172; Petit-Jacquea J, 2005, J NEUROPHYSIOL, V94, P1770, DOI 10.1152/jn.00279.2005; Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P4592, DOI 10.1167/iovs.04-0842; Pinto CC, 2007, FREE RADICAL RES, V41, P1151, DOI 10.1080/10715760701632816; Poulet R, 2006, J CEREBR BLOOD F MET, V26, P253, DOI 10.1038/sj.jcbfm.9600188; Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002; RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834; Ravalico G, 1997, DOC OPHTHALMOL, V94, P321, DOI 10.1007/BF02580857; Reichhart N, 2016, CLIN SCI, V130, P1075, DOI 10.1042/CS20160092; Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Roman BB, 2001, AM J PHYSIOL-HEART C, V280, pH2264; Sicard P, 2007, BRIT J PHARMACOL, V151, P979, DOI 10.1038/sj.bjp.0707322; Tani T, 2014, INVEST OPHTH VIS SCI, V55, P360, DOI 10.1167/iovs.13-12591; Thengchaisri N, 2003, AM J PHYSIOL-HEART C, V285, pH2255, DOI 10.1152/ajpheart.00487.2003; Tormene A P, 1989, Metab Pediatr Syst Ophthalmol (1985), V12, P76; Tsai SH, 2017, CARDIOVASC RES, V113, P1329, DOI 10.1093/cvr/cvx103; Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003; Wilkinson-Berka JL, 2006, INT J BIOCHEM CELL B, V38, P752, DOI 10.1016/j.biocel.2005.08.002; WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667; Winkler BS, 2004, NEUROCHEM INT, V45, P311, DOI 10.1016/j.neuint.2003.08.017; Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865; Yada T, 2008, AM J PHYSIOL-HEART C, V294, pH441, DOI 10.1152/ajpheart.01021.2007; Yada T, 2007, J AM COLL CARDIOL, V50, P1272, DOI 10.1016/j.jacc.2007.05.039; Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83; Yuan ZX, 2008, INVEST OPHTH VIS SCI, V49, P720, DOI 10.1167/iovs.07-1208	71	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2018	188	3					818	827		10.1016/j.ajpath.2017.11.015			10	Pathology	Pathology	FY4OT	WOS:000426805100022	29309745	Green Published, Bronze			2019-10-28	
J	Sanfrancesco, JM; Trevino, KE; Xu, HP; Ulbright, TM; Idrees, MT				Sanfrancesco, Joseph M.; Trevino, Karen E.; Xu, Huiping; Ulbright, Thomas M.; Idrees, Muhammad T.			The Significance of Spermatic Cord Involvement by Testicular Germ Cell Tumors Should We Be Staging Discontinuous Invasion From Involved Lymphovascular Spaces Differently From Direct Extension?	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						germ cell tumor; AJCC staging; spermatic cord; lymphovascular space invasion; testis	PROGNOSTIC-FACTORS; CLINICAL STAGE; SEMINOMA; CANCER; RELAPSE; SURVEILLANCE; DIAGNOSIS; CONSENSUS; PREDICT; RISK	The recent 8th edition of the American Joint Committee on Cancer (AJCC) staging manual had multiple changes concerning how pathologists should stage germ cell tumors (GCTs) of the testis. A significant one concerns the impact of different types of spermatic cord involvement, specifically direct tumor extension versus discontinuous involvement by invasion through lymphovascular spaces. We compared clinicopathologic findings and outcome data between 2 cohorts with these findings to evaluate the validity of the change in the AJCC 8th edition manual. GCTs (seminomatous and nonseminomatous) of the testis were identified that had previously been staged as pT3 due to involvement of the spermatic cord. Pathologic, radiographic, and clinical findings were reviewed. Tumors were restaged based on AJCC 8th edition criteria and the cohorts were split into direct extension by tumor into the spermatic cord (pT3), spermatic cord soft tissue invasion via spread from discontinuously involved lymphovascular spaces (pT2pM1), or a combination of both (pT3pM1). One hundred cases of primary GCTs of the testis, previously classified as pT3 by the AJCC 6th or 7th cancer staging manuals from 2007 to 2015, were selected. Mixed malignant GCTs were the predominant tumor type, comprising 66% of all cases. Pure tumor morphologies included embryonal carcinoma (n = 17), seminoma (n = 14), teratoma (n = 2), and yolk sac tumor (n = 1). The tumors either directly invaded into the spermatic cord (n = 78), involved the cord discontinuously via spread from lymphovascular spaces (n = 18), or had both findings (n = 4). Overall, 93% of patients presented at advanced clinical stage (CS). Using the AJCC 8th parameters, 12% of all tumors were upstaged. Changes included CSI (n = 1) and CSII (n = 11) tumors being reclassified as prognostic stage group III. Clinical and/or pathologic recurrence was identified in 19% of all patients, including 12 pT3 and 7 pM1 patients (P = 0.11). Overall mean time to recurrence was 24.6 months, with a mean of 28.0 months for pT3 tumors and 18.9 months for pM1 tumors. Five patients were dead at the time of this study, including 3 (4%) with pT3 tumors and 2 (9%) in the pM1 cohort. Our findings support that seminomatous and nonseminomatous GCTs with spermatic cord invasion have a high frequency of advanced CS at presentation, regardless of involvement by direct extension or discontinuous spread via invasion from lymphovascular spaces. By designating the latter as M1, a spurious upstaging to prognostic stage group III is required by the AJCC 8th edition. We were unable to identify statistically significant difference between the 2 groups as it pertained to CS at presentation and likelihood of recurrence. Conversely, statistical trends favor that pM1 patients have more likely recurrence and worse prognosis than pT3 patients.	[Sanfrancesco, Joseph M.; Trevino, Karen E.; Ulbright, Thomas M.; Idrees, Muhammad T.] Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St,IUHPL Room 4082, Indianapolis, IN 46202 USA; [Xu, Huiping] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA	Idrees, MT (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St,IUHPL Room 4082, Indianapolis, IN 46202 USA.	midrees@iupui.edu					Berney DM, 2015, HISTOPATHOLOGY, V67, P313, DOI 10.1111/his.12657; Chung P, 2015, CANCER MED-US, V4, P155, DOI 10.1002/cam4.324; Edge SB, 2010, AJCC CANC STAGING MA; Edge SB, 2017, AJCC CANC STAGING MA; FOX EP, 1993, J CLIN ONCOL, V11, P1294, DOI 10.1200/JCO.1993.11.7.1294; FUNG CY, 1988, J CLIN ONCOL, V6, P1467, DOI 10.1200/JCO.1988.6.9.1467; Krege S, 2008, EUR UROL, V53, P497, DOI 10.1016/j.eururo.2007.12.025; Osunkoya AO, 2012, SEMIN DIAGN PATHOL, V29, P154, DOI 10.1053/j.semdp.2011.10.001; Perrotti M, 2004, UROL ONCOL-SEMIN ORI, V22, P174, DOI 10.1016/j.urolonc.2004.04.004; Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703; RODRIGUEZ PN, 1986, J UROLOGY, V136, P604, DOI 10.1016/S0022-5347(17)44988-3; Soper MS, 2014, AM J CLIN ONCOL-CANC, V37, P356, DOI 10.1097/COC.0b013e318277d839; Valdevenito JP, 2007, UROLOGY, V70, P777, DOI 10.1016/j.urology.2007.05.020; Vogt AP, 2010, HUM PATHOL, V41, P1339, DOI 10.1016/j.humpath.2010.03.005; Warde P, 2002, J CLIN ONCOL, V20, P4448, DOI 10.1200/JCO.2002.01.038; Yilmaz A, 2013, MODERN PATHOL, V26, P579, DOI 10.1038/modpathol.2012.189	16	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	MAR	2018	42	3					306	311		10.1097/PAS.0000000000001008			6	Pathology; Surgery	Pathology; Surgery	GA9MO	WOS:000428665600004	29309304				2019-10-28	
J	Sanchez-Romero, C; Carlos, R; Molina, JPD; Thompson, LDR; de Almeida, OP; Pina, AR				Sanchez-Romero, Celeste; Carlos, Roman; Diaz Molina, Juan Pablo; Thompson, Lester D. R.; de Almeida, Oslei Paes; Pina, Alicia Rumayor			Nasopharyngeal Angiofibroma: A Clinical, Histopathological and Immunohistochemical Study of 42 Cases with Emphasis on Stromal Features	HEAD & NECK PATHOLOGY			English	Article						Nasopharyngeal angiofibroma; Sinonasal tumor; Vascular tumor; Immunohistochemistry; Imagenology; Adolescent; Males	VASCULAR MALFORMATION; HORMONAL MARKERS; FACTOR-XIIIA; RECEPTORS; CAVITY; TUMORS; CELLS	Nasopharyngeal angiofibroma is a benign but aggressive tumor of unknown etiology, typically occurring in adolescent males. It is described as a rare neoplasm; however, the prevalence seems to have geographic differences. All cases referred to our head and neck clinical and pathology service were reviewed. Most of the patients presented at an advanced stage. The clinical and radiographic features are presented and discussed. Histologically, the tumor shows a highly vascular fibrous proliferation with characteristic plump, angulated and stellate cells, categorized as fibroblasts. Immunohistochemistry was performed on 42 cases to further elucidate the nature of these cells. The stromal cells expressed vimentin and factor XIIIa, the latter expressed most commonly in the giant stellate cells. Inflammation was almost exclusively present in peripheral subepithelial areas. Mast cells were abundant, even in the absence of other inflammatory cells. Lymphatics were observed principally in peripheral regions. Proliferating cells (Ki-67 reactive) were restricted to endothelial cells.	[Sanchez-Romero, Celeste; de Almeida, Oslei Paes; Pina, Alicia Rumayor] Univ Estadual Campinas, Piracicaba Dent Sch, Oral Pathol Sect, Dept Oral Diag, Piracicaba, Brazil; [Carlos, Roman; Diaz Molina, Juan Pablo] Hosp Herrera Llerandi, Ctr Clin Cabeza & Cuello, Guatemala City, Guatemala; [Diaz Molina, Juan Pablo] Ctr Clin Cabeza & Cuello, UNOP, Guatemala City, Guatemala; [Thompson, Lester D. R.] Southern Calif Permanente Med Grp, Dept Pathol, Woodland Hills Med Ctr, Woodland Hills, CA USA	Sanchez-Romero, C (reprint author), Univ Estadual Campinas, Piracicaba Dent Sch, Oral Pathol Sect, Dept Oral Diag, Piracicaba, Brazil.	csr_90@hotmail.com	Pina, Alicia Rumayor/A-5327-2013; Thompson, Lester D. R./J-8404-2016; Pina, Alicia Rumayor/K-3548-2019	Pina, Alicia Rumayor/0000-0002-0391-9739; Thompson, Lester D. R./0000-0003-3714-1432; Pina, Alicia Rumayor/0000-0002-0391-9739; Sanchez-Romero, Celeste/0000-0001-5365-2692			APOSTOL JV, 1965, CANCER, V18, P869, DOI 10.1002/1097-0142(196507)18:7<869::AID-CNCR2820180715>3.0.CO;2-A; Bakshi SS, 2016, J PEDIAT HEMATOL ONC, V38, P491, DOI 10.1097/MPH.0000000000000568; Beham A, 1997, EUR ARCH OTO-RHINO-L, V254, P196, DOI 10.1007/BF00879273; BEHAM A, 1993, VIRCHOWS ARCH A, V423, P281, DOI 10.1007/BF01606891; Beham A, 2000, ADV ANAT PATHOL, V7, P36, DOI 10.1097/00125480-200007010-00006; Martins MBB, 2013, INT ARCH OTORHINOLAR, V17, P14, DOI 10.7162/S1809-97772013000100003; Carlos R, 2008, HEAD NECK PATHOL, V2, P145, DOI 10.1007/s12105-008-0069-y; CERIO R, 1989, BRIT J DERMATOL, V121, P421, DOI 10.1111/j.1365-2133.1989.tb15509.x; DONALD PJ, 1979, OTOLARYNG HEAD NECK, V87, P42, DOI 10.1177/019459987908700112; FARAG MM, 1987, LARYNGOSCOPE, V97, P208; FINERMAN WB, 1951, AMA ARCH OTOLARYNGOL, V54, P620; FU YS, 1974, CANCER, V33, P1275, DOI 10.1002/1097-0142(197405)33:5<1275::AID-CNCR2820330513>3.0.CO;2-4; GISSELSSON LENNART, 1958, ACTA PATHOL ET MICROBIOL SCAND, V42, P305; Hwang HC, 1998, MODERN PATHOL, V11, P1122; Kania RE, 2005, AM J NEURORADIOL, V26, P82; Labra A, 2004, OTOLARYNG HEAD NECK, V130, P466, DOI 10.1016/j.otohns.2004.01.007; Mishra S, 2013, J CLIN IMAG SCI, V3, DOI 10.4103/2156-7514.109469; NEMETH AJ, 1989, J CUTAN PATHOL, V16, P266, DOI 10.1111/j.1600-0560.1989.tb00050.x; OSBORN DA, 1965, ARCHIV OTOLARYNGOL, V82, P629; Pardhe N, 2015, J CLIN DIAGN RES, V9, pZD31, DOI 10.7860/JCDR/2015/12935.6118; Patrocinio JA, 2005, AM J OTOLARYNG, V26, P198, DOI 10.1016/j.amjoto.2004.08.012; Pauli J, 2008, PATHOLOGY, V40, P396, DOI 10.1080/00313020802035857; Ponti G, 2008, APPL IMMUNOHISTO M M, V16, P173, DOI 10.1097/PAI.0b013e31806bee12; Prasad ML, 2017, WHO CLASSIFICATION H, P74; Renkonen S, 2011, VIRCHOWS ARCH, V458, P189, DOI 10.1007/s00428-010-1010-9; Rogers DJ, 2012, ADV OTO-RHINO-LARYNG, V73, P132, DOI 10.1159/000334470; Salimov A, 2015, INT ARCH OTORHINOLAR, V19, P187, DOI 10.1055/s-0034-1398471; Saylam G, 2006, INT J PEDIATR OTORHI, V70, P227, DOI 10.1016/j.ijporl.2005.06.007; Silveira SM, 2012, HEAD NECK-J SCI SPEC, V34, P485, DOI 10.1002/hed.21767; SPAGNOLO DV, 1984, HISTOPATHOLOGY, V8, P339, DOI 10.1111/j.1365-2559.1984.tb02346.x; Thakar A, 2011, HEAD NECK-J SCI SPEC, V33, P1747, DOI 10.1002/hed.21667; Zhang MJ, 2011, ACTA HISTOCHEM, V113, P626, DOI 10.1016/j.acthis.2010.07.003	32	4	4	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					52	61		10.1007/s12105-017-0824-z			10	Pathology	Pathology	GA6TM	WOS:000428467200007	28508272	Green Published			2019-10-28	
J	Smith, MH; Islam, NM; Bhattacharyya, I; Cohen, DM; Fitzpatrick, SG				Smith, Molly Housley; Islam, Nadim M.; Bhattacharyya, Indraneel; Cohen, Donald M.; Fitzpatrick, Sarah G.			STAT6 Reliably Distinguishes Solitary Fibrous Tumors from Myofibromas	HEAD & NECK PATHOLOGY			English	Article						STAT6; Myofibroma; Solitary fibrous tumor; Hemangiopericytoma; Immunohistochemistry	INFANTILE MYOFIBROMATOSIS; NAB2-STAT6 FUSION; ORAL-CAVITY; SOFT-TISSUE; HEMANGIOPERICYTOMA; EXPRESSION; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; FEATURES; GENE	Solitary fibrous tumors (SFT) and myofibromas (MF) historically have belonged to the same morphologic spectrum and have been lumped together under the nonspecific umbrella term, "hemangiopericytoma" along with other pericytic/myoid tumors. While current evidence shows clear distinction between the two entities, they frequently remain in the same histopathologic differential diagnosis. This diagnostic dilemma especially is common for smaller incisional biopsies from the oral cavity. STAT6 immunohistochemistry (IHC) recently was established as a reliable method to detect solitary fibrous tumor; however, the literature is sparse regarding STAT6 reactivity in MFs. The authors report ten new cases of oral solitary fibrous tumor, discuss histopathologic similarities and differences between the two tumors, and list respective STAT6 IHC expressivity. After IRB approval, 10 cases diagnosed as SFT and 24 cases of MF were collected from the University of Florida Oral and Maxillofacial Pathology Biopsy Service between the years 1994 and 2016. The original hematoxylin and eosin slides and related IHC were reviewed. IHC with STAT6 antibody was performed on all 34 samples, and the findings were analyzed. All cases were from the oral cavity or perioral regions. 10/10 SFTs expressed STAT6 nuclear reactivity, while no cases of MF showed nuclear expression of STAT6. STAT6 is a dependable marker to differentiate SFTs from MFs.	[Smith, Molly Housley; Islam, Nadim M.; Bhattacharyya, Indraneel; Cohen, Donald M.; Fitzpatrick, Sarah G.] Univ Florida, Coll Dent, Div Oral & Maxillofacial Pathol, 1395 Ctr Dr, Gainesville, FL 32610 USA	Smith, MH (reprint author), Univ Florida, Coll Dent, Div Oral & Maxillofacial Pathol, 1395 Ctr Dr, Gainesville, FL 32610 USA.	molly.housley.smith@gmail.com		Smith, Molly/0000-0002-8502-4305			Agaimy A, 2017, AM J SURG PATHOL, V41, P195, DOI 10.1097/PAS.0000000000000752; Ahluwalia N, 2015, Ann R Coll Surg Engl, V97, pe105, DOI 10.1308/rcsann.2015.0023; Arts FA, 2016, ONCOGENE, V35, P3239, DOI 10.1038/onc.2015.383; Carlos R, 2016, OR SURG OR MED OR PA, V121, P390, DOI 10.1016/j.oooo.2015.11.001; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Fletcher C, 2013, WHO CLASSIFICATION T; Fukunaga M, 1997, MODERN PATHOL, V10, P443; Gengler C, 2006, HISTOPATHOLOGY, V48, P63, DOI 10.1111/j.1365-2559.2005.02290.x; GUILLOU L, 2002, WHO CLASSIFICATION T; Han YA, 2015, INT J CLIN EXP PATHO, V8, P13166; Hasegawa T, 1999, HUM PATHOL, V30, P1464, DOI 10.1016/S0046-8177(99)90169-7; Hornick JL, 2014, MODERN PATHOL, V27, pS47, DOI 10.1038/modpathol.2013.177; Hung YP, 2017, AM J SURG PATHOL, V41, P1034, DOI 10.1097/PAS.0000000000000862; Kiyohara T, 2016, J DERMATOL, V43, P1088, DOI 10.1111/1346-8138.13400; Klemperer P, 1931, ARCH PATHOL, V11, P60; Koelsche C, 2014, HISTOPATHOLOGY, V65, P613, DOI 10.1111/his.12431; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; Nielsen GP, 1997, MODERN PATHOL, V10, P1028; O'Regan EM, 2009, HEAD NECK PATHOL, V3, P106, DOI 10.1007/s12105-009-0111-8; Rechsteiner M, 2015, ANN ONCOL, V26, P246, DOI 10.1093/annonc/mdu471; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Shine Neville, 2006, Ear Nose Throat J, V85, P437; Smith MH, 2017, OR SURG OR MED OR PA, V124, P62, DOI 10.1016/j.oooo.2017.03.051; Stout AP, 1942, ANN SURG, V116, P26, DOI 10.1097/00000658-194207000-00004; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Vogels RJC, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0224-6; WISWELL TE, 1988, J PEDIATR SURG, V23, P314, DOI 10.1016/S0022-3468(88)80196-9; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	30	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1936-055X	1936-0568		HEAD NECK PATHOL	Head Neck Pathol.	MAR	2018	12	1					110	117		10.1007/s12105-017-0836-8			8	Pathology	Pathology	GA6TM	WOS:000428467200015	28689369	Green Published			2019-10-28	
J	Yamamoto, H; Iwasaki, T; Yamada, Y; Matsumoto, Y; Otsuka, H; Yoshimoto, M; Kohashi, K; Taguchi, K; Yokoyama, R; Nakashima, Y; Oda, Y				Yamamoto, Hidetaka; Iwasaki, Takeshi; Yamada, Yuichi; Matsumoto, Yoshihiro; Otsuka, Hiroshi; Yoshimoto, Masato; Kohashi, Kenichi; Taguchi, Kenichi; Yokoyama, Ryohei; Nakashima, Yasuharu; Oda, Yoshinao			Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone	HUMAN PATHOLOGY			English	Article						Giant cell tumor of bone; H3F3A; Mutation; Immunohistochemistry; Denosumab	DRIVER MUTATIONS; DENOSUMAB; H3F3A; CHONDROBLASTOMA; MARKER	Giant cell tumors of bone (GCTBs) are characterized by mononuclear stromal cells and osteoclast-like giant cells; up to 95% have H3F3A gene mutation. The RANKL inhibitor denosumab, when used for the treatment of GCTB, leads to histological changes such as new bone formation and giant cell depletion. Here we assessed the diagnostic utility of immunohistochemical staining with the antibodies against histone H3.3 G34W, G34R and G34V mutant proteins for GCTB and other histologically similar bone and joint lesions. H3.3 G34W, G34R and G34V expressions were detected in mononuclear stromal cells in 47/51 (92%), 1/51 (2%) and 3/51 (6%) cases of primary GCTBs, respectively, in a mutually exclusive manner. All recurrent/metastatic GCTBs (n = 14), post-denosumab GCTBs (n = 8) and secondary malignant GCTBs (n = 2) were positive for H3.3 G34W. The immunohistochemical results were essentially correlated with the H3F3A genotype determined by mutation analysis. In post-denosumab GCTBs, H3.3 G34W expression was seen in immature bone-forming cells. H3.3 G34W, G34R and G34V were negative in 121/122 cases of non-GCTB, including chondroblastoma, osteosarcoma, primary aneurysmal bone cyst and other giant cell rich lesions. The exception was a single case of undifferentiated high-grade pleomorphic sarcoma that was positive for H3.3 G34W, suggesting the possibility of sarcomatous overgrowth of primary malignant GCTB. Therefore, H3.3 G34W/R/V mutant-specific antibodies are useful surrogate markers for the H3F3A genotype and helpful for the diagnosis of GCTB and its variants. The expression of H3.3 G34W mutant protein in post-denosumab GCTB suggests that neoplastic stromal cells may play a role in new bone formation. (C) 2017 Elsevier Inc. All rights reserved.	[Yamamoto, Hidetaka; Iwasaki, Takeshi; Yamada, Yuichi; Otsuka, Hiroshi; Yoshimoto, Masato; Kohashi, Kenichi; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan; [Matsumoto, Yoshihiro; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan; [Taguchi, Kenichi] Natl Hosp Org Kyushu Canc Ctr, Dept Pathol, Fukuoka 8111395, Japan; [Yokoyama, Ryohei] Natl Hosp Org Kyushu Canc Ctr, Dept Orthoped Surg, Fukuoka 8111395, Japan	Yamamoto, H (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan.	hidetaka@surgpath.med.kyushu-u.ac.jp		Iwasaki, Takeshi/0000-0001-5277-2932			Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859; Amary MF, 2016, HISTOPATHOLOGY, V69, P121, DOI 10.1111/his.12945; Athanasou NA, 2013, WHO CLASSIFICATION T, P321; Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814; Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359; Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078-0432.CCR-12-0578; Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470-2045(13)70277-8; Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512; Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002; Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath-2015-203248; Gong LH, 2012, VIRCHOWS ARCH, V460, P327, DOI 10.1007/s00428-012-1198-y; Gupta R, 2008, ANN DIAGN PATHOL, V12, P239, DOI 10.1016/j.anndiagpath.2007.09.002; Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013; James IE, 1996, J BONE MINER RES, V11, P1453; Kallappagoudar S, 2015, CHROMOSOMA, V124, P177, DOI 10.1007/s00412-015-0510-4; Kervarrec T, 2017, MODERN PATHOL, V30, P393, DOI 10.1038/modpathol.2016.212; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Luke J, 2017, HISTOPATHOLOGY, V71, P125, DOI 10.1111/his.13190; Moller E, 2008, GENE CHROMOSOME CANC, V47, P21, DOI 10.1002/gcc.20501; Murata A, 2005, J ORTHOP SCI, V10, P581, DOI 10.1007/s00776-005-0946-0; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13; Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833; Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006; Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307; Venneti S, 2014, ACTA NEUROPATHOL, V128, P743, DOI 10.1007/s00401-014-1338-3; Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506	27	6	7	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						41	50		10.1016/j.humpath.2017.11.020			10	Pathology	Pathology	GB3PJ	WOS:000428969600006	29241742				2019-10-28	
J	Shi, M; He, R; Feldman, AL; Viswanatha, DS; Jevremovic, D; Chen, D; Morice, WG				Shi, Min; He, Rong; Feldman, Andrew L.; Viswanatha, David S.; Jevremovic, Dragan; Chen, Dong; Morice, William G.			STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia	HUMAN PATHOLOGY			English	Article						STAT3; T-LGLL; Clinical correlation; Histopathologic correlation; Response to therapy	CHRONIC LYMPHOPROLIFERATIVE DISORDERS; NK-CELLS; JAK/STAT PATHWAY; LGL LEUKEMIA; APLASIA; REARRANGEMENTS; PATHOGENESIS; ASSOCIATION; ACTIVATION; RESPONSES	Although T-cell large granular lymphocytic leukemia (T-LGLL) is a clinically indolent disorder, patients with moderate to severe cytopenia require therapeutic intervention. The recent discovery of STAT3 mutations has shed light on the genetic basis of T-LGLL pathogenesis. However, the association of STAT3 mutational status with patients' clinical, histopathologic, and other laboratory features has not been thoroughly evaluated in T-LGLL. In this study, STAT3 mutations were identified in 18 of 36 patients with T-LGLL (50%), including Y640F (12/18, 66.7%), N647I (3/18, 16.7%), E638Q (1/18, 5.6%), 1659L (1/18, 5.6%), and K657R (1/18, 5.6%). Interestingly, pure red cell aplasia was seen exclusively in T-LGLL patients without STAT3 mutations (6/15 in the wild-type STAT3 group versus 0/13 in the mutant STAT3 group; P=.02); these patients also were the only responders to T-LGLL therapy (mainly cyclophosphamide) in wild type STAT3 group. Patients harboring STAT3 mutations were more prone to rheumatoid arthritis (4/13 versus 0/15 in the wild-type STAT3 group; P = .04), frequently requiring therapy for neutropenia/neutropenia-associated infections, and demonstrated good therapeutic responses to methotrexate. No significant differences were seen in complete blood count, flow cytometric immunophenotypic features, T-cell receptor gamma V-J rearrangement repertoire, and bone marrow biopsy morphology among the STAT3-mutation and wild-type groups other than significantly larger tumor burden in patients with STAT3 mutations. The distinct disease association and therapeutic responses observed in patients with mutant and wild-type STAT3 warrant further investigation to elucidate the underlying mechanisms. They also highlight the importance of identifying STAT3 mutational status in patients with T-LGLL, which may aid in clinical therapeutic choice. (C) 2017 Elsevier Inc. All rights reserved.	[Shi, Min; He, Rong; Feldman, Andrew L.; Viswanatha, David S.; Jevremovic, Dragan; Chen, Dong; Morice, William G.] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA	Shi, M (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	Shi.Min@mayo.edu	Chen, Dong/V-8825-2019	Jevremovic, Dragan/0000-0002-1792-5822			Andersson EI, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.65; Bareau B, 2010, HAEMATOL-HEMATOL J, V95, P1534, DOI 10.3324/haematol.2009.018481; Cady FM, 2007, CLIN LAB MED, V27, P513, DOI 10.1016/j.cll.2007.05.004; Chen J, 2012, BLOOD, V119, P137, DOI 10.1182/blood-2011-04-346759; Clemente MJ, 2013, BLOOD, V122, P4077, DOI 10.1182/blood-2013-05-506386; Coppe A, 2017, LEUKEMIA, V31, P1243, DOI 10.1038/leu.2017.49; Go RS, 2001, BLOOD, V98, P483, DOI 10.1182/blood.V98.2.483; Ishida F, 2014, CANCER SCI, V105, P342, DOI 10.1111/cas.12341; Isomaki P, 2015, RHEUMATOLOGY, V54, P1103, DOI 10.1093/rheumatology/keu430; Jerez A, 2012, BLOOD, V120, P3048, DOI 10.1182/blood-2012-06-435297; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Lacy MQ, 1996, BLOOD, V87, P3000, DOI 10.1182/blood.V87.7.3000.bloodjournal8773000; Lamy T, 1998, BLOOD, V92, P4771, DOI 10.1182/blood.V92.12.4771.424k32_4771_4777; Lamy T, 2017, BLOOD, V129, P1082, DOI 10.1182/blood-2016-08-692590; Liu JH, 2002, BLOOD, V100, P1449, DOI 10.1182/blood.V100.4.1449.h81602001449_1449_1453; Moreau EJ, 1999, LEUKEMIA, V13, P1620, DOI 10.1038/sj.leu.2401540; Morice WG, 2007, AM J CLIN PATHOL, V127, P881, DOI 10.1309/Q49CRJ030L22MHLF; Morice WG, 2007, BRIT J HAEMATOL, V137, P237, DOI 10.1111/j.1365-2141.2007.06564.x; Rajala HLM, 2015, HAEMATOLOGICA, V100, P91, DOI 10.3324/haematol.2014.113142; Sandberg Y, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2013.70; Schumacher JA, 2014, AM J CLIN PATHOL, V141, P348, DOI 10.1309/AJCP5TYGBVW4ZITR; Shi M, 2016, LEUKEMIA LYMPHOMA, V57, P1230, DOI 10.3109/10428194.2015.1081191; Sokol L, 2005, LEUKEMIA RES, V29, P381, DOI 10.1016/j.leukres.2004.08.010; Teramo A, 2013, BLOOD, V121, P3843, DOI 10.1182/blood-2012-07-441378; THEODOROU I, 1994, J PATHOL, V174, P233; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wlodarski MW, 2005, BLOOD, V106, P2769, DOI 10.1182/blood-2004-10-4045; Yang J, 2008, BLOOD, V111, P1610, DOI 10.1182/blood-2007-06-093823; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29; Zhang RR, 2008, P NATL ACAD SCI USA, V105, P16308, DOI 10.1073/pnas.0806447105	30	7	7	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						74	81		10.1016/j.humpath.2017.12.014			8	Pathology	Pathology	GB3PJ	WOS:000428969600010	29288042				2019-10-28	
J	Oltulu, P; Mannan, AASR; Gardner, JM				Oltulu, Pembe; Mannan, Abul Ala Syed Rifat; Gardner, Jerad M.			Effective use of Twitter and Facebook in pathology practice	HUMAN PATHOLOGY			English	Article						Twitter; Facebook; Social media; Pathology; Live tweeting; #insitupathologists	SOCIAL MEDIA; MICROSCOPIC PHOTOGRAPHY; IMPACT; YOURE	Social networking has become a part of daily life for most people. In the era of globalization, it has become indispensable for effective communication between friends and peers across the world. Today, social media use is not restricted only to our personal lives; it is becoming increasingly incorporated into our professional lives, as well. Social media platforms are rapidly becoming a necessary tool for medical professionals. Apt use of social media platforms can revolutionize scientific communication and collaboration. Pathologists are increasingly counted among Facebook's 2 billion users and Twitter's 328 million members. Social media can be a powerful tool not only for individual career progression but also for raising the public profile of the specialty of pathology. It is now possible for us to reach out to millions of people, simultaneously and instantaneously, just by touching a screen. Real-time interactions between physicians, across geographic borders and subspecialty borders, will undeniably open unexplored avenues for effective communication, consultation, research collaboration, and education. Knowledge sharing through social media will immensely enrich and grow our careers as pathologists; it will also enlighten the public and physicians of other specialties as to the crucial role of pathologists in patient care. We discuss the uses of Facebook and Twitter in modem day pathology, its implication in routine daily practice, pros and cons, and tips for effective social media use by pathologists. (C) 2018 Elsevier Inc. All rights reserved.	[Oltulu, Pembe] Necmettin Erbakan Univ, Meram Fac Med, Dept Pathol, TR-42000 Konya, Turkey; [Mannan, Abul Ala Syed Rifat] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Gardner, Jerad M.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	Oltulu, P (reprint author), Necmettin Erbakan Univ, Meram Fac Med, Dept Pathol, TR-42000 Konya, Turkey.	drpembe@yahoo.com					[Anonymous], 2016, SOCIAL MEDIA EVALUAT; Bellina L, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-19; Bert F, 2016, SCAND J PUBLIC HEALT, V44, P130, DOI 10.1177/1403494815612932; Carlquist E, 2018, ARCH PATHOL LAB MED, V142, P184, DOI 10.5858/arpa.2017-0064-OA; Chretien KC, 2013, CIRCULATION, V127, P1413, DOI 10.1161/CIRCULATIONAHA.112.128017; Cohen D, 2017, MODERN PATHOL, V30, P160, DOI 10.1038/modpathol.2016.223; Constine J., FACEBOOK NOW HAS 2 B; Cosco TD, 2015, CAN MED ASSOC J, V187, P1353, DOI 10.1503/cmaj.150976; Crane Genevieve M, 2016, AMA J Ethics, V18, P817, DOI 10.1001/journalofethics.2016.18.8.stas1-1608; Diaz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145406; Dizon DS, 2012, J ONCOL PRACT, V8, pE114, DOI 10.1200/JOP.2012.000610; Fiegerman S., 2017, TWITTER STOCK SURGES; Freitag CE, 2017, ARCH PATHOL LAB MED, V141, P1567, DOI 10.5858/arpa.2016-0612-SA; Gardner JM, 2017, ARCH PATHOL LAB MED, V141, P188, DOI 10.5858/arpa.2016-0447-ED; Gardner JM, 2016, INTRO PATHOLOGY HASH; Gardner JM, PATHOLOGIST COLLABOR; Gardner JM, WHY PATHOLOGISTS SHO; Gardner JM, 2014, SOCIAL MEDIA GUIDE P; Gardner JM, PATHOLOGIST INVOLVEM; Gayo-Avello D, 2011, COMMUN ACM, V54, P121, DOI 10.1145/2001269.2001297; Glassy EF, 2010, ARCH PATHOL LAB MED, V134, P1421, DOI 10.1043/2010-0255-ED.1; Gonzalez RS, 2017, ARCH PATHOL LAB MED, V141, P690, DOI 10.5858/arpa.2016-0369-OA; Haller J., IMPACT PATHOLOGISTS; Haller J, 2016, MODERN PATHOL, V29, p141A; Ingber S., 2017, IS IT GOOD IDEA SHAR; Isom J, 2017, ADV ANAT PATHOL, V24, P294, DOI 10.1097/PAP.0000000000000159; @JMGardnerMD, TOUR IST W MY FRIEND; Lefebvre C, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5612; Lepe M, 2017, DIAGN CYTOPATHOL, V45, P705, DOI 10.1002/dc.23713; Madke B, 2017, AM J DERMATOPATHOL; McGuigan R, 2016, PATHOLOGIST, V5, P46; Misialek MJ, 2016, ARCH PATHOL LAB MED, V140, P393, DOI 10.5858/arpa.2015-0493-ED; Morrison AO, 2015, ARCH PATHOL LAB MED, V139, P1558, DOI 10.5858/arpa.2014-0315-RA; Morrison AS, 2014, ARCH PATHOL LAB MED, V138, P1002, DOI 10.5858/arpa.2013-0425-ED; Roy Somak, 2014, J Pathol Inform, V5, P24, DOI 10.4103/2153-3539.137728; Singaravel S, 2016, ARCH PATHOL LAB MED, V140, P741, DOI 10.5858/arpa.2016-0081-LE; Smith B, BEGINNERS GUIDE TWIT; Thompson MA, 2015, CURR HEMATOL MALIG R, V10, P405, DOI 10.1007/s11899-015-0286-x; Tumasjan A, 2010, ICWSM, V10, P178, DOI DOI 10.1074/JBC.M501708200	39	7	7	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						128	143		10.1016/j.humpath.2017.12.017			16	Pathology	Pathology	GB3PJ	WOS:000428969600017	29307629				2019-10-28	
J	Neil, DAH; Bellamy, CO; Smith, M; Haga, H; Zen, Y; Sebagh, M; Ruppert, K; Lunz, J; Hubscher, SG; Demetris, AJ				Neil, Desley A. H.; Bellamy, Christopher O.; Smith, Maxwell; Haga, Hinori; Zen, Yoh; Sebagh, Mylene; Ruppert, Kristine; Lunz, John; Hubscher, Stefan G.; Demetris, Anthony J.			Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue	HUMAN PATHOLOGY			English	Article						Complement fragment 4d; Liver allograft; Antibody-mediated rejection; Method; Tissue microarray	DONOR-SPECIFIC ANTIBODIES; ACUTE HUMORAL REJECTION; LYMPHOCYTE CROSS-MATCH; KIDNEY TRANSPLANTATION; COMPLEMENT ACTIVATION; HLA ANTIBODIES; RECIPIENTS; PATHOLOGY; FAILURE; RISK	Discussion of liver antibody-mediated rejection during the 2011, 2013, and 2015 Banff liver sessions raised concerns over reliability of complement fragment 4d (C4d) staining, precipitating a global survey followed by a tissue microarray staining quality assessment study among centers on formalin-fixed, paraffin-embedded tissue. Tissue microarray sections containing tissue plugs of resected native and allograft (with acute antibody-mediated rejection) liver, heart, and kidney (n = 33 total cores) were sent to 31 centers for C4d staining using local method(s) and pathologist scoring. Digital whole-slide images (n = 40) were then semiquantitatively scored by 7 experts for background, distribution, and intensity of portal vein and capillary, hepatic artery, sinusoidal, and central vein endothelia and portal and central stromal staining. Results showed that strong and diffuse portal vein and capillary C4d staining, as determined by both local and central pathologists, clearly distinguished allografts showing acute antibody-mediated rejection from native livers and from those with evidence of weaker donor-specific antibody. Downstream vascular endothelial cell C4d staining and assessment were more variable and difficult to identify. C4d staining in the majority of laboratories reliably detects acute liver allograft antibody-mediated rejection in formalin-fixed, paraffin embedded tissues. Assessment should focus on portal veins and capillaries, sinusoids, and central veins present in peripheral core needle biopsies. C4d staining in one organ does not always translate to staining in another. (C) 2018 Elsevier Inc. All rights reserved.	[Neil, Desley A. H.] Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Mindelsohn Way, Birmingham B15 2GW, W Midlands, England; [Bellamy, Christopher O.] Royal Infirm Edinburgh NHS Trust, Dept Histopathol, Edinburgh EH16 4SA, Midlothian, Scotland; [Smith, Maxwell] Mayo Clin, Dept Lab Med & Pathol, Phoenix, AZ 85054 USA; [Haga, Hinori] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 6068507, Japan; [Zen, Yoh] Kobe Univ Hosp, Dept Diagnost Pathol, Kobe, Hyogo 6500017, Japan; [Sebagh, Mylene] Hop Paul Brousse, AP HP, Dept Pathol, Villejuif, France; [Sebagh, Mylene] Paris Sud Univ, INSERM, U785, Villejuif, France; [Ruppert, Kristine] Univ Pittsburgh, Epidemiol Data Ctr, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Lunz, John] Univ Pittsburgh, Med Ctr, UPMC Montefiore Univ Hosp, Tissue Typing Lab, Pittsburgh, PA 15213 USA; [Hubscher, Stefan G.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England; [Demetris, Anthony J.] Univ Pittsburgh, Med Ctr, UPMC Montefiore Univ Hosp, Dept Pathol, Pittsburgh, PA 15213 USA; [Lunz, John] Gift Hope Organ & Tissue Donor Network, Histocompatibil & Immunogenet Lab, 425 Spring Lake Dr, Itasca, IL 60143 USA	Neil, DAH (reprint author), Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Mindelsohn Way, Birmingham B15 2GW, W Midlands, England.	Desley.neil@uhb.nhs.uk; C.bellamy@ed.ac.uk; Smith.maxwell@mayo.edu; haga@kuhp.kyoto-u.ac.jp; Yohzen@med.kobe-u.ac.jp; Mylene.sebagh@aphp.fr; ruppertk@pitt.edu; lunzjg@gmail.com; S.g.hubscher@bham.ac.uk; demetrisaj@upmc.edu	SEBAGH, Mylene/T-7464-2018				AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; Astarcioglu I, 1999, J SURG RES, V87, P258, DOI 10.1006/jsre.1999.5734; BATTS KP, 1988, TRANSPLANTATION, V45, P376, DOI 10.1097/00007890-198802000-00026; Bellamy COC, 2007, HISTOPATHOLOGY, V50, P739, DOI 10.1111/j.1365-2559.2007.02677.x; Cohen D, 2012, KIDNEY INT, V81, P628, DOI 10.1038/ki.2011.497; Demetris AJ, 2016, AM J TRANSPLANT, V16, P2816, DOI 10.1111/ajt.13909; Demetris AJ, 2016, AM J TRANSPLANT, V16, P1653, DOI 10.1111/ajt.13749; DEMETRIS AJ, 1987, TRANSPLANT P, V19, P121; EID A, 1990, TRANSPLANTATION, V50, P331; Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046; GORDON RD, 1986, SURGERY, V100, P705; Hadaya K, 2009, TRANSPL INT, V22, P242, DOI 10.1111/j.1432-2277.2008.00775.x; Haga H, 2006, LIVER TRANSPLANT, V12, P457, DOI 10.1002/lt.20652; Hathaway M, 1997, TRANSPLANTATION, V64, P54, DOI 10.1097/00007890-199707150-00011; Hubscher SG, 2012, CURR OPIN ORGAN TRAN, V17, P280, DOI 10.1097/MOT.0b013e328353584c; Jenkins CP, 2010, ARCH PATHOL LAB MED, V134, P256, DOI 10.1043/1543-2165-134.2.256; Kaneku H, 2013, AM J TRANSPLANT, V13, P1541, DOI 10.1111/ajt.12212; Kozlowski T, 2012, LIVER TRANSPLANT, V18, P641, DOI 10.1002/lt.23403; Kozlowski T, 2011, LIVER TRANSPLANT, V17, P357, DOI 10.1002/lt.22233; Mihlan M, 2011, FASEB J, V25, P4198, DOI 10.1096/fj.11-186460; Musat AI, 2011, AM J TRANSPLANT, V11, P500, DOI 10.1111/j.1600-6143.2010.03414.x; Neil DAH, 2010, TRANSPL INT, V23, P971, DOI 10.1111/j.1432-2277.2010.01143.x; O'Leary JG, 2016, AM J TRANSPLANT, V16, P603, DOI 10.1111/ajt.13476; O'Leary JG, 2013, CURR OPIN ORGAN TRAN, V18, P279, DOI 10.1097/MOT.0b013e3283614a10; OGURA K, 1994, CLIN TRANSPLANT, V8, P111; Paterno F, 2012, AM J TRANSPLANT, V12, P2526, DOI 10.1111/j.1600-6143.2012.04126.x; RATNER LE, 1993, TRANSPLANTATION, V55, P814, DOI 10.1097/00007890-199304000-00025; Rostron A, 2005, TRANSPLANT INT, V18, P1298, DOI 10.1111/j.1432-2277.2005.00200.x; Saidman S L, 1994, Transpl Immunol, V2, P61, DOI 10.1016/0966-3274(94)90080-9; Sakashita H, 2007, MODERN PATHOL, V20, P676, DOI 10.1038/modpathol.3800784; Silva MA, 2008, TRANSPLANTATION, V85, P718, DOI 10.1097/TP.0b013e3181663366; Takaya S, 1999, TRANSPLANT P, V31, P2028, DOI 10.1016/S0041-1345(99)00256-0; Watson R, 2006, AM J TRANSPLANT, V6, P3022, DOI 10.1111/j.1600-6143.2006.01554.x; Wilson CH, 2006, TRANSPLANTATION, V82, P988, DOI 10.1097/01.tp.0000229939.85412.27	34	3	3	2	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						144	155		10.1016/j.humpath.2017.12.007			12	Pathology	Pathology	GB3PJ	WOS:000428969600018	29288041				2019-10-28	
J	Bonometti, A; Bagnoli, F; Fanoni, D; Venegoni, L; Corti, L; Bianchi, P; Elli, EM; Isimbaldi, G; L'Imperio, V; Nazzaro, G; Passoni, E; Berti, E				Bonometti, Arturo; Bagnoli, Filippo; Fanoni, Daniele; Venegoni, Luigia; Corti, Laura; Bianchi, Paola; Elli, Elena Maria; Isimbaldi, Giuseppe; L'Imperio, Vincenzo; Nazzaro, Gianluca; Passoni, Emanuela; Berti, Emilio			JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib	HUMAN PATHOLOGY			English	Article						Langerhans cell histiocytosis; Primary myelofibrosis; JAK2; Ruxolitinib; Multilineage myeloid neoplasms; Laser microdissection	CLASSIFICATION; NEOPLASMS	The pathogenesis and cellular origin of Langerhans cell histiocytosis (LCH) are debated. Recently, mutations on MAPK and PI3K pathways have been linked to disrupted cell proliferation in LCH. Janus Kinase 2 (JAK2) mutations play the same role in Philadelphia-negative chronic myeloproliferative neoplasms. We describe the case of a patient affected by JAK2-positive primary myelofibrosis (PMF) who developed a clonally related LCH while in treatment with ruxolitinib. JAK inhibitors are well known to affect function and differentiation of different hematological lineages, including mononuclear phagocytes precursors. Nevertheless, the literature describes cases of LCH clonally associated with non-LCH hematological neoplasm, suggesting how multilinear myeloid neoplasms may arise from bone marrow. Hence, we briefly discuss the possible pathogenic roles of genetic mutations and JAK inhibition therapy in the pathogenesis of LCH and associated neoplasms. (C) 2017 Elsevier Inc. All rights reserved.	[Bonometti, Arturo; Bagnoli, Filippo; Venegoni, Luigia; Berti, Emilio] Univ Milan, Dept Pathophysiol & Organ Transplantat, Via Pace 9, I-20122 Milan, Italy; [Fanoni, Daniele; Corti, Laura; Nazzaro, Gianluca; Passoni, Emanuela; Berti, Emilio] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Dermatol, I-20122 Milan, Italy; [Bianchi, Paola] Osped Maggiore Milano, Fdn IRCCS Ca Granda, Anemia Pathophysiol Sect, Dept Oncohematol, I-20122 Milan, Italy; [Elli, Elena Maria] S Gerardo Hosp, Unit Bone Marrow Transplantat, Div Hematol, I-20052 Monza, MB, Italy; [Isimbaldi, Giuseppe; L'Imperio, Vincenzo] Univ Milano Bicocca, Pathol Sect, Dept Surg & Interdisciplinary Med, I-20052 Monza, MB, Italy	Bonometti, A (reprint author), Univ Milan, Dept Pathophysiol & Organ Transplantat, Via Pace 9, I-20122 Milan, Italy.	arturo.bonomettill@gmail.com	Nazzaro, Gianluca/C-5966-2017; L'Imperio, Vincenzo/R-4242-2018; Bianchi, Paola/L-2531-2016; Venegoni, Luigia/K-6085-2018	Nazzaro, Gianluca/0000-0001-8534-6497; L'Imperio, Vincenzo/0000-0002-9284-2998; Bianchi, Paola/0000-0001-5976-5233; Venegoni, Luigia/0000-0002-1846-1206; Berti, Emilio/0000-0001-6753-4910; Bonometti, Arturo/0000-0003-3258-0727			Abedalthagafi M, 2009, LEUKEMIA RES, V33, P173; Allen CE, 2015, HEMATOL-AM SOC HEMAT, P559, DOI 10.1182/asheducation-2015.1.559; Allen CE, 2010, J IMMUNOL, V184, P4557, DOI 10.4049/jimmunol.0902336; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Berres ML, 2013, ADV IMMUNOL, V120, P127, DOI 10.1016/B978-0-12-417028-5.00005-3; Delprat C, 2014, BLOOD, V124, P867, DOI 10.1182/blood-2014-02-556407; DURHAM BH, 2016, BLOOD, V128; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Fukunaga M, 2004, ARCH PATHOL LAB MED, V128, P1167; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Haroche J, 2017, LANCET ONCOL, V18, pE113, DOI 10.1016/S1470-2045(17)30031-1; Koschmieder S, 2016, LEUKEMIA, V30, P1018, DOI 10.1038/leu.2016.12; McLornan DP, 2015, CURR HEMATOL MALIG R, V10, P370, DOI 10.1007/s11899-015-0284-z; Tefferi A, 2013, BLOOD, V122, P1096, DOI 10.1182/blood-2013-07-509612; Yohe SL, 2014, MODERN PATHOL, V27, P651, DOI 10.1038/modpathol.2013.181	15	0	0	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	MAR	2018	73						171	175		10.1016/j.humpath.2017.10.017			5	Pathology	Pathology	GB3PJ	WOS:000428969600021	29107666				2019-10-28	
J	Kythreotou, A; Siddique, A; Mauri, FA; Bower, M; Pinato, DJ				Kythreotou, Anthousa; Siddique, Abdul; Mauri, Francesco A.; Bower, Mark; Pinato, David J.			PD-L1	JOURNAL OF CLINICAL PATHOLOGY			English	Article							PHOSPHOLIPASE C-GAMMA; T-CELL PROLIFERATION; LIGAND 1 EXPRESSION; B7-H1 EXPRESSION; OVARIAN-CANCER; CARCINOMA; MELANOMA; PEMBROLIZUMAB; LYMPHOCYTES; ACTIVATION	Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive immune cell activity that can lead to tissue destruction and autoimmunity. PD-L1 expression is an immune evasion mechanism exploited by various malignancies and is generally associated with poorer prognosis. PD-L1 expression is also suggested as a predictive biomarker of response to anti-PD-1/PD-L1 therapies; however, contradictory evidence exists as to its role across histotypes. Over the years, anti-PD-1/PDL-1 agents have gained momentum as novel anticancer therapeutics, by inducing durable tumour regression in numerous malignancies including metastatic lung cancer, melanoma and many others. In this review, we discuss the immunobiology of PD-L1, with a particular focus on its clinical significance in malignancy.	[Kythreotou, Anthousa; Siddique, Abdul; Mauri, Francesco A.; Pinato, David J.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England; [Bower, Mark] Chelsea & Westminster Hosp, Natl Ctr HIV Malignancy, London, England	Pinato, DJ (reprint author), Imperial Coll London, Med Oncol, Hammersmith Hosp Campus, London W12 0HS, England.	david.pinato09@imperial.ac.uk					Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Abiko K, 2013, CLIN CANCER RES, V19, P1363, DOI 10.1158/1078-0432.CCR-12-2199; [Anonymous], 2017, CD274 MOL HOM HUM GE; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Baracco EE, 2016, ONCOIMMUNOLOGY, P5; Bellmunt J, 2015, ANN ONCOL, V26, P812, DOI 10.1093/annonc/mdv009; Berthon C, 2010, CANCER IMMUNOL IMMUN, V59, P1839, DOI 10.1007/s00262-010-0909-y; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Boussiotis VA, 2014, CANCER J, V20, P265, DOI 10.1097/PPO.0000000000000059; Calderaro J, 2016, HEPATOLOGY, V64, P2038, DOI 10.1002/hep.28710; Cao YJ, 2011, CANCER RES, V71, P1235, DOI 10.1158/0008-5472.CAN-10-2217; Chamoto K, 2017, CURR TOP MICROBIOL I; Charlton JJ, 2013, J IMMUNOL, V190, P6104, DOI 10.4049/jimmunol.1201617; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dong HD, 1999, NAT MED, V5, P1365; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006; Finkelmeier F, 2016, EUR J CANCER, V59, P152, DOI 10.1016/j.ejca.2016.03.002; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Haendeler J, 2003, J BIOL CHEM, V278, P49936, DOI 10.1074/jbc.M307317200; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hou JY, 2014, EXP MOL PATHOL, V96, P284, DOI 10.1016/j.yexmp.2014.03.005; Hwang WT, 2012, GYNECOL ONCOL, V124, P192, DOI 10.1016/j.ygyno.2011.09.039; Inman BA, 2007, CANCER, V109, P1499, DOI 10.1002/cncr.22588; Jiang XF, 2013, CLIN CANCER RES, V19, P598, DOI 10.1158/1078-0432.CCR-12-2731; Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515; Kaunitz GJ, 2017, LAB INVEST, V97, P1063, DOI 10.1038/labinvest.2017.64; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Konishi J, 2004, CLIN CANCER RES, V10, P5094, DOI 10.1158/1078-0432.CCR-04-0428; Kumar R, 2017, CURR PROB CANCER, V41, P111, DOI 10.1016/j.currproblcancer.2016.12.002; Kumar V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00049; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665; Lu C, 2017, ONCOIMMUNOLOGY, P6; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Muller T, 2017, ONCOTARGET, V8, P52889, DOI 10.18632/oncotarget.17547; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Okita R, 2017, CANCER IMMUNOL IMMUN, V66, P865, DOI 10.1007/s00262-017-1986-y; Olmeda D, 2008, ONCOGENE, V27, P4690, DOI 10.1038/onc.2008.118; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Patsoukis N, 2013, MOL CELL BIOL, V33, P3091, DOI 10.1128/MCB.00319-13; Patsoukis N, 2012, CELL CYCLE, V11, P4305, DOI 10.4161/cc.22135; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pinato DJ, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1213934; Pinato DJ, 2017, ONCOIMMUNOLOGY; Pitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001; Probst HC, 2005, NAT IMMUNOL, V6, P280, DOI 10.1038/ni1165; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ritprajak P, 2015, ORAL ONCOL, V51, P221, DOI 10.1016/j.oraloncology.2014.11.014; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Sabbatino F, 2016, CLIN CANCER RES, V22, P470, DOI 10.1158/1078-0432.CCR-15-0715; Scherbatyuk Alexander, 2016, OCEANS 2016 - Shanghai, DOI 10.1109/OCEANSAP.2016.7485436; Sheppard KA, 2004, FEBS LETT, V574, P37, DOI 10.1016/j.febslet.2004.07.083; Suzuki A, 2003, CANCER RES, V63, P674; Thompson ED, 2017, MOD PATHOL; Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009; Tsao MS, 2017, ANN ONCOL, V28, P882, DOI 10.1093/annonc/mdx003; Walter D, 2017, HISTOPATHOLOGY, V71, P383, DOI 10.1111/his.13238; Wang L, 2017, CLIN RES HEPATOL GAS, V2017, P1, DOI DOI 10.1371/J0URNAL.P0NE.01; Wang LC, 2010, WORLD J SURG, V34, P1059, DOI 10.1007/s00268-010-0448-x; Wankowicz SAM, 2017, J UROLOGY, V198, P817, DOI 10.1016/j.juro.2017.04.102; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wu CP, 2006, ACTA HISTOCHEM, V108, P19, DOI 10.1016/j.acthis.2006.01.003; Xing Y, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006957; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741	90	24	25	7	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					189	194		10.1136/jclinpath-2017-204853			6	Pathology	Pathology	GB5HD	WOS:000429094200001	29097600				2019-10-28	
J	Mulder, BGS; Mieog, JSD; Sarasqueta, AF; Handgraaf, HJM; Vasen, HFA; Swijnenburg, RJ; Luelmo, SAC; Feshtali, S; Inderson, A; Vahrmeijer, AL; Bonsing, BA; van Wezel, T; Morreau, H				Mulder, Babs G. Sibinga; Mieog, J. Sven D.; Sarasqueta, Arantza Farina; Handgraaf, Henricus J. M.; Vasen, Hans F. A.; Swijnenburg, Rutger-Jan; Luelmo, Saskia A. C.; Feshtali, Shirin; Inderson, Akin; Vahrmeijer, Alexander L.; Bonsing, Bert A.; van Wezel, Tom; Morreau, Hans			Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article							FINE-NEEDLE-ASPIRATION; PARAFFIN-EMBEDDED TISSUE; ENDOSCOPIC ULTRASOUND; AUTOIMMUNE PANCREATITIS; DUCTAL ADENOCARCINOMA; LESIONS; CLASSIFICATION; RESECTIONS; EXPERIENCE; CYSTS	Aims Radiological imaging and morphological assessment of cytology material have limitations for preoperative classification of pancreatic or periampullary lesions, often resulting in surgical resection without definitive diagnosis. Our prospective study aims to define the diagnostic value of targeted next-generation sequencing (NGS) of DNA from cytology material. Methods Patients with a suspect pancreatic or periampullary lesion underwent standard diagnostic evaluation including preoperative morphological cytology assessment. Treatment options for suspect lesions were surgical exploration with possible resection, follow-up or palliation. The cytology samples were analysed with NGS, in which 50 genes were sequenced for the presence of pathogenic variants. The NGS results were integrated with the clinical information during multidisciplinary team meetings, and changes in the treatment plan were scored. Diagnostic accuracy of NGS analysis (malignancy vs benign disease) was calculated. Results NGS results of the cytology samples were confirmed in the resection specimens of the first 10 included patients. The integration of the NGS results led to a change in treatment plan in 7 out of 70 patients (from exploration to follow-up, n=4; from follow-up to exploration and resection, n=2; from palliation to resection, n=1). In four patients, the NGS results were contradictory, but did not affect the treatment plan. In the remaining 59 patients, NGS analysis supported the initial treatment plan. The diagnostic accuracy of NGS analysis was 94% (sensitivity=93%; specificity=100%). Conclusions NGS can change the treatment plan in a significant portion of patients with suspect pancreatic or periampullary lesions. Application of NGS can optimise treatment selection and diminish unnecessary surgeries.	[Mulder, Babs G. Sibinga; Mieog, J. Sven D.; Handgraaf, Henricus J. M.; Swijnenburg, Rutger-Jan; Vahrmeijer, Alexander L.; Bonsing, Bert A.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; [Sarasqueta, Arantza Farina; van Wezel, Tom; Morreau, Hans] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; [Vasen, Hans F. A.; Inderson, Akin] Leiden Univ, Med Ctr, Dept Gastroenterol, Leiden, Netherlands; [Luelmo, Saskia A. C.] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands; [Feshtali, Shirin] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands	Morreau, H (reprint author), Leiden Univ, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.	j.morreau@lumc.nl	van Wezel, Tom/Z-3092-2019; Handgraaf, Henricus/P-3059-2014	van Wezel, Tom/0000-0001-5773-7730; Vasen, Hans/0000-0003-2682-2603; Farina Sarasqueta, Aranzazu/0000-0002-6173-592X; Handgraaf, Henricus/0000-0002-5114-3584	Bas Mulder Award from the Dutch Cancer Society [UL2015-7665]; LUMC	This work was supported by the Bas Mulder Award (grant UL2015-7665) from the Dutch Cancer Society. The NGS analysis was financially supported by an institutional grant in the LUMC in order to install up-to-date molecular testing in the Department of Pathology with the purpose to refine primary diagnoses and for companion diagnostic stratification.	Abraham SC, 2003, AM J SURG PATHOL, V27, P110, DOI 10.1097/00000478-200301000-00012; Afify AM, 2003, ACTA CYTOL, V47, P341; Amato E, 2014, J PATHOL, V233, P217, DOI 10.1002/path.4344; Bolognesi C, 2016, SCI REP-UK, V6, DOI 10.1038/srep20944; Bosman FT, 2010, WHO CLASSIFICATION T; Brand B, 2000, SCAND J GASTROENTERO, V35, P1221; Chu PG, 2005, AM J SURG PATHOL, V29, P359, DOI 10.1097/01.pas.0000149708.12335.6a; Eijkelenboom A, 2016, J MOL DIAGN, V18, P851, DOI 10.1016/j.jmoldx.2016.06.010; Fritscher-Ravens A, 2002, AM J GASTROENTEROL, V97, P2768; Gleeson FC, 2016, ONCOTARGET, V7, P54526, DOI 10.18632/oncotarget.9440; Hur BY, 2012, J MAGN RESON IMAGING, V36, P188, DOI 10.1002/jmri.23609; Iqbal S, 2012, PATHOL RES INT, V2012, P1; Jones M, 2016, GASTROINTEST ENDOSC, V83, P140, DOI 10.1016/j.gie.2015.06.047; Kennedy T, 2006, AM J SURG, V191, P437, DOI 10.1016/j.amjsurg.2005.10.051; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Lee-Felker SA, 2015, AM J ROENTGENOL, V205, P2, DOI 10.2214/AJR.14.14059; Mulder BGS, 2017, J CLIN PATHOL, V70, P174, DOI 10.1136/jclinpath-2016-203928; Plon SE, 2008, HUM MUTAT, V29, P1282, DOI 10.1002/humu.20880; Saftoiu A, 2009, J CLIN ULTRASOUND, V37, P1, DOI 10.1002/jcu.20534; Scarpa A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080478; Shrikhande SV, 2012, HPB, V14, P658, DOI 10.1111/j.1477-2574.2012.00508.x; Springer S, 2015, GASTROENTEROLOGY, V149, P1501, DOI 10.1053/j.gastro.2015.07.041; Valero V, 2016, ANN SURG, V263, P153, DOI 10.1097/SLA.0000000000001156; van Eijk R, 2013, EXP MOL PATHOL, V94, P121, DOI 10.1016/j.yexmp.2012.06.004; Varadarajulu S, 2005, GASTROINTEST ENDOSC, V6251, P72853; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Woolf KMW, 2013, CANCER CYTOPATHOL, V121, P449, DOI 10.1002/cncy.21299; Wright GP, 2016, AM J SURG, V211, P506, DOI 10.1016/j.amjsurg.2015.11.002; Zhang TT, 2017, ONCOTARGET, V8, P1744, DOI 10.18632/oncotarget.12120	29	2	2	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					246	252		10.1136/jclinpath-2017-204607			7	Pathology	Pathology	GB5HD	WOS:000429094200009	28775172				2019-10-28	
J	Barton, C; Kausar, S; Kerr, D; Bitetti, S; Wynn, R				Barton, Chris; Kausar, Sabiha; Kerr, Deborah; Bitetti, Stefania; Wynn, Rob			SIFD as a novel cause of severe fetal hydrops and neonatal anaemia with iron loading and marked extramedullary haemopoiesis	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CONGENITAL SIDEROBLASTIC ANEMIA; DEVELOPMENTAL DELAY SIFD; NONIMMUNE HYDROPS; IMMUNODEFICIENCY; MUTATIONS; FEVERS	SIFD describes a heritable, syndromic condition characterised principally by sideroblastic anaemia (SA) with immunodeficiency, fevers and developmental delay, arising in mutations within the TRNT1 gene. Other clinical manifestations of SIFD include cardiomyopathy, seizures, sensorineural hearing loss, renal dysfunction, metabolic abnormalities, hepatosplenomegaly and retinitis pigmentosa. Presentation of SIFD is variable but typically in early childhood with SA or with fever. In this report, we extend the described SIFD phenotype. We describe a kindred in which the index case presented with fetal hydrops, and early neonatal death, and the second child had severe anaemia at delivery. Both cases had prominent extramedullary erythropoiesis and numerous circulating nucleated red blood cells.	[Barton, Chris] Univ Liverpool, Inst Child Hlth, Dept Haematol & Oncol, Liverpool, Merseyside, England; [Barton, Chris; Kausar, Sabiha; Wynn, Rob] Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, Dept Hematol & Cellular Therapy, Manchester, Lancs, England; [Kerr, Deborah] Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, Dept Clin Genet, Manchester, Lancs, England; [Bitetti, Stefania] Cent Manchester Hosp NHS Fdn Trust, St Marys Hosp, Dept Pathol & Histopathol, Manchester, Lancs, England	Wynn, R (reprint author), Royal Manchester Childrens NHS Fdn Trust, Dept Bone Marrow Transplantat & Haematol, Oxford Rd, Manchester M13 9WL, Lancs, England.	Robert.Wynn@cmft.nhs.uk					Bellini C, 2012, AM J MED GENET A, V158A, P597, DOI 10.1002/ajmg.a.34438; Bergmann AK, 2010, PEDIATR BLOOD CANCER, V54, P273, DOI 10.1002/pbc.22244; Chakraborty PK, 2014, BLOOD, V124, P2867, DOI 10.1182/blood-2014-08-591370; Desilets V, 2013, J OBSTET GYNAECOL CA, V35, P923, DOI 10.1016/S1701-2163(15)30816-1; Ismail K M, 2001, J Matern Fetal Med, V10, P175; WARSOF SL, 1986, CLIN OBSTET GYNECOL, V29, P533, DOI 10.1097/00003081-198609000-00009; Wiseman DH, 2013, BLOOD, V122, P112, DOI 10.1182/blood-2012-08-439083	7	8	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					275	278		10.1136/jclinpath-2017-204698			4	Pathology	Pathology	GB5HD	WOS:000429094200013	29055896	Other Gold, Green Published			2019-10-28	
J	de Sousa, SF; Diniz, MG; Franca, JA; Pereira, TDF; Moreira, RG; dos Santos, JN; Gomez, RS; Gomes, CC				de Sousa, Silvia Ferreira; Diniz, Marina Goncalves; Franca, Josiane Alves; Fontes Pereira, Thais dos Santos; Moreira, Rennan Garcias; dos Santos, Jean Nunes; Gomez, Ricardo Santiago; Gomes, Carolina Cavalieri			Cancer genes mutation profiling in calcifying epithelial odontogenic tumour	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SUPPRESSOR; EXPRESSION; PATHWAY	Aims To identify calcifying epithelial odontogenic tumour (CEOT) mutations in oncogenes and tumour suppressor genes. Methods A panel of 50 genes commonly mutated in cancer was sequenced in CEOT by next-generation sequencing. Sanger sequencing was used to cover the region of the frameshift deletion identified in one sample. Results Missense single nucleotide variants (SNVs) with minor allele frequency (MAF) < 1% were detected in PTEN, MET and JAK3. A frameshift deletion in CDKN2A occurred in association with a missense mutation in the same gene region, suggesting a second hit in the inactivation of this gene. APC, KDR, KIT, PIK3CA and TP53 missense SNVs were identified; however, these are common SNVs, showing MAF > 1%. Conclusion CEOT harbours mutations in the tumour suppressor PTEN and CDKN2A and in the oncogenes JAK3 and MET. As these mutations occurred in only one case each, they are probably not driver mutations for these tumours.	[de Sousa, Silvia Ferreira] UFS, Biol Sci & Hlth Inst, Dept Dent, Rua Claudio Batista, BR-49060108 Aracaju, Brazil; [Diniz, Marina Goncalves; Fontes Pereira, Thais dos Santos; Gomez, Ricardo Santiago] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG, Brazil; [Franca, Josiane Alves; Gomes, Carolina Cavalieri] Univ Fed Minas Gerais, Biol Sci Inst, Dept Pathol, Belo Horizonte, MG, Brazil; [Moreira, Rennan Garcias] Univ Fed Minas Gerais, Biol Sci Inst, Genom Lab, Belo Horizonte, MG, Brazil; [dos Santos, Jean Nunes] Univ Fed Bahia, Dept Oral Surg & Pathol, Salvador, BA, Brazil	de Sousa, SF (reprint author), UFS, Biol Sci & Hlth Inst, Dept Dent, Rua Claudio Batista, BR-49060108 Aracaju, Brazil.	silviafsousa@ufs.br	DE SOUSA, SILVIA/M-5721-2015; Gomez, Ricardo Santiago/G-1976-2012; Gomes, Carolilna/D-1807-2018; Franca, Josiane/V-5039-2019	DE SOUSA, SILVIA/0000-0001-7820-4749; Gomez, Ricardo Santiago/0000-0001-8770-8009; Franca, Josiane/0000-0002-6005-783X; santos, jean/0000-0001-7225-5879	National Council for Scientific and Technological Development (CNPq)/BrazilNational Council for Scientific and Technological Development (CNPq); Coordination for the Improvement of Higher Education Personnel (CAPES)/BrazilCAPES; CNPqNational Council for Scientific and Technological Development (CNPq); CAPES (Brazil)CAPES [88881.118879/2016A01, 88881.119257/2016A01]	This work was supported by grants from the National Council for Scientific and Technological Development (CNPq)/Brazil and the Coordination for the Improvement of Higher Education Personnel (CAPES)/Brazil. SFS, JNS, JAF, CCG, RSG and MGD are supported by CNPq. CCG (Proc. 88881.118879/2016A01), RSG (Proc. 88881.119257/2016A01) and MGD are research fellows at CAPES (Brazil).	Beck TF, 2016, CLIN CHEM, V62, P647, DOI 10.1373/clinchem.2015.249623; Chen X, 2011, J ORAL PATHOL MED, V40, P235, DOI 10.1111/j.1600-0714.2010.00940.x; Chrcanovic BR, 2017, J CRANIO MAXILL SURG, V45, P1117, DOI 10.1016/j.jcms.2017.05.007; de Sousa SF, 2016, ORAL ONCOL, V57, pE1, DOI 10.1016/j.oraloncology.2016.04.010; Diniz MG, 2017, ORAL ONCOL, V72, P165, DOI 10.1016/j.oraloncology.2017.07.021; Gomes CC, 2016, ORAL ONCOL, V56, pE3, DOI 10.1016/j.oraloncology.2016.03.001; Iengar P, 2012, NUCLEIC ACIDS RES, V40, P6401, DOI 10.1093/nar/gks290; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Kumamoto H, 2007, ORAL DIS, V13, P461, DOI 10.1111/j.1601-0825.2006.01321.x; Molinari F, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00326; Peacock ZS, 2010, ORAL ONCOL, V46, P387, DOI 10.1016/j.oraloncology.2010.02.023; Perdigao PF, 2009, ANTICANCER RES, V29, P3065; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SAKU T, 1992, J ORAL PATHOL MED, V21, P113, DOI 10.1111/j.1600-0714.1992.tb00993.x; Santos JN, 2017, J ORAL PATHOL MED, V46, P1036, DOI 10.1111/jop.12598; Scheper MA, 2008, ORAL DIS, V14, P561, DOI 10.1111/j.1601-0825.2007.01421.x; Sikkema-Raddatz B, 2013, HUM MUTAT, V34, P1035, DOI 10.1002/humu.22332; Siqueira EC, 2017, ORAL SURG ORAL MED O, pS2212; Strom SP, 2016, CANCER BIOL MED, V13, P3, DOI 10.28092/j.issn.2095-3941.2016.0004	20	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	MAR	2018	71	3					279	+		10.1136/jclinpath-2017-204813			5	Pathology	Pathology	GB5HD	WOS:000429094200014	29127140				2019-10-28	
J	Lindeman, NI; Cagle, PT; Aisner, DL; Arcila, ME; Beasley, MB; Bernicker, EH; Colasacco, C; Dacic, S; Hirsch, FR; Kerr, K; Kwiatkowski, DJ; Ladanyi, M; Nowak, JA; Sholl, L; Temple-Smolkin, R; Solomon, B; Souter, LH; Thunnissen, E; Tsao, MS; Ventura, CB; Wynes, MW; Yatabe, Y				Lindeman, Neat I.; Cagle, Philip T.; Aisner, Dara L.; Arcila, Maria E.; Beasley, Mary Beth; Bernicker, Eric H.; Colasacco, Carol; Dacic, Sanja; Hirsch, Fred R.; Kerr, Keith; Kwiatkowski, David J.; Ladanyi, Marc; Nowak, Jan A.; Sholl, Lynette; Temple-Smolkin, Robyn; Solomon, Benjamin; Souter, Lesley H.; Thunnissen, Erik; Tsao, Ming S.; Ventura, Christina B.; Wynes, Murry W.; Yatabe, Yasushi			Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							GROWTH-FACTOR-RECEPTOR; GENE COPY NUMBER; ANAPLASTIC LYMPHOMA KINASE; IN-SITU-HYBRIDIZATION; PHASE-II TRIAL; PROGRESSION-FREE SURVIVAL; SELUMETINIB PLUS DOCETAXEL; DETECTING EGFR MUTATIONS; SEOM CLINICAL GUIDELINES; MET PROTEIN EXPRESSION	Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. Objective: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. Design: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. Results: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. Conclusions: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of immunohistochemistry for EGFR testing. Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.	[Lindeman, Neat I.; Sholl, Lynette] Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Shapiro 5,Room 020, Boston, MA 02115 USA; [Kwiatkowski, David J.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Cagle, Philip T.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA; [Aisner, Dara L.] Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; [Arcila, Maria E.] Mem Sloan Kettering Canc Ctr, Diagnost & Mol Pathol Lab, 1275 York Ave, New York, NY 10021 USA; [Arcila, Maria E.; Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Mol Diagnost Serv, 1275 York Ave, New York, NY 10021 USA; [Beasley, Mary Beth] Dept Pathol & Med Pulm Crit Care & Sleep Med, New York, NY USA; [Bernicker, Eric H.] Houston Methodist Res Inst, Canc Res Program, Houston, TX USA; [Colasacco, Carol; Ventura, Christina B.] Coll Amer Pathologists, Pathol & Lab Qual Ctr, Northfield, IL USA; [Dacic, Sanja] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Hirsch, Fred R.] Univ Colorado, Dept Med & Pathol, Denver, CO 80202 USA; [Kerr, Keith] Univ Aberdeen, Dept Pathol, Aberdeen, Scotland; [Nowak, Jan A.] Roswell Pk Canc Inst, Dept Mol Pathol, Buffalo, NY 14263 USA; [Temple-Smolkin, Robyn] Assoc Mol Pathol, Clin & Sci Affairs Div, Bethesda, MD USA; [Solomon, Benjamin] Peter Maccallum Canc Ctr, Mol Therapeut & Biomarkers Lab, Melbourne, Vic, Australia; [Thunnissen, Erik] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Tsao, Ming S.] Princess Margaret Canc Ctr, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Wynes, Murry W.] Int Assoc Study Lung Canc, Aurora, CO USA; [Yatabe, Yasushi] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan	Lindeman, NI (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Shapiro 5,Room 020, Boston, MA 02115 USA.	nlindeman@partners.org	Yatabe, Yasushi/J-6461-2014; YATABE, Yasushi/N-3588-2019	Yatabe, Yasushi/0000-0003-1788-559X; YATABE, Yasushi/0000-0003-1788-559X; Tsao, Ming/0000-0002-9160-5405			Aleric Ivan, 2012, Med Pregl, V65, P210; Ali G, 2014, ARCH PATHOL LAB MED, V138, P1449, DOI 10.5858/arpa.2013-0388-OA; Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013; [Anonymous], 2015, OPDIVO PACK INS; [Anonymous], 2014, KEYTRUDA PACK INS; [Anonymous], 2015, COB EGFR MUT TEST V2; [Anonymous], 2016, TECENTRIQ PACK INS; Arcila ME, 2012, CLIN CANCER RES, V18, P4910, DOI 10.1158/1078-0432.CCR-12-0912; Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Bae NC, 2007, CANCER GENET CYTOGEN, V173, P107, DOI 10.1016/j.cancergencyto.2006.10.007; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Blackhall FH, 2014, J CLIN ONCOL, V32, P2780, DOI 10.1200/JCO.2013.54.5921; Boland JM, 2009, HUM PATHOL, V40, P1152, DOI 10.1016/j.humpath.2009.01.012; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boyle TA, 2015, CLIN LUNG CANCER, V16, P106, DOI 10.1016/j.cllc.2014.10.003; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Broet P, 2011, CLIN CANCER RES, V17, P3542, DOI 10.1158/1078-0432.CCR-10-2185; Brustugun OT, 2014, LUNG CANCER, V84, P36, DOI 10.1016/j.lungcan.2014.01.023; Cabillic F, 2014, J THORAC ONCOL, V9, P295, DOI 10.1097/JTO.0000000000000072; Cai W, 2013, ANN ONCOL, V24, P1822, DOI 10.1093/annonc/mdt071; Calikusu Z, 2009, ASIAN PAC J CANCER P, V10, P479; Camps C, 2013, CLIN TRANSL ONCOL, V15, P977, DOI 10.1007/s12094-013-1085-2; Caparica R, 2017, J THORAC ONCOL, V12, P141, DOI 10.1016/j.jtho.2016.09.116; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657; Carter CA, 2016, ANN ONCOL, V27, P693, DOI 10.1093/annonc/mdw008; Cha YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103333; Chen YF, 2014, J THORAC ONCOL, V9, P1171, DOI 10.1097/JTO.0000000000000232; Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Chuang JC, 2017, J THORAC ONCOL, V12, P833, DOI 10.1016/j.jtho.2017.01.023; Cohen V, 2010, CANCER-AM CANCER SOC, V116, P4309, DOI 10.1002/cncr.25214; Conde E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107200; Cooper W, 2014, ASIA-PAC J CLIN ONCO, V10, P11, DOI 10.1111/ajco.12190; Cote ML, 2011, J THORAC ONCOL, V6, P627, DOI 10.1097/JTO.0b013e31820a0ec0; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Cutz JC, 2014, J THORAC ONCOL, V9, P1255, DOI 10.1097/JTO.0000000000000239; Dacic S, 2016, ONCOTARGET, V7, P82943, DOI 10.18632/oncotarget.12705; Dacic S, 2010, MODERN PATHOL, V23, P159, DOI 10.1038/modpathol.2009.154; Dietel M, 2016, THORAX, V71, P177, DOI 10.1136/thoraxjnl-2014-206677; Ding D, 2014, ONCOTARGETS THER, V7, P387, DOI 10.2147/OTT.S58870; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Douillard JY, 2014, J THORAC ONCOL, V9, P1345, DOI 10.1097/JTO.0000000000000263; Douillard JY, 2010, J CLIN ONCOL, V28, P744, DOI 10.1200/JCO.2009.24.3030; Drilon A, 2016, LANCET ONCOL, V17, P1653, DOI 10.1016/S1470-2045(16)30562-9; Drilon A, 2015, CLIN CANCER RES, V21, P3631, DOI 10.1158/1078-0432.CCR-14-2683; Drilon A, 2013, CANCER DISCOV, V3, P630, DOI 10.1158/2159-8290.CD-13-0035; Duffy MJ, 2015, CLIN CHEM, V61, P809, DOI 10.1373/clinchem.2015.239863; Dziadziuszko R, 2012, J THORAC ONCOL, V7, P340, DOI 10.1097/JTO.0b013e318240ca0d; Ellison G, 2013, J CLIN PATHOL, V66, P79, DOI 10.1136/jclinpath-2012-201194; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Ettinger DS, 2017, NCCN CLIN PRACTICE G; Felip E, 2015, CLIN TRANSL ONCOL, V17, P103, DOI 10.1007/s12094-014-1248-9; Feng Y, 2012, J THORAC ONCOL, V7, P459, DOI 10.1097/JTO.0b013e3182417e44; Fiala O, 2013, CANCER GENET-NY, V206, P26, DOI 10.1016/j.cancergen.2012.12.003; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; Gainor JF, 2016, J THORAC ONCOL, V11, pE83, DOI 10.1016/j.jtho.2016.02.021; Gao X, 2015, J THORAC ONCOL, V10, P1648, DOI 10.1097/JTO.0000000000000665; Garcia-Campelo R, 2015, CLIN TRANSL ONCOL, V17, P1020, DOI 10.1007/s12094-015-1455-z; Gatzemeier U, 2004, ANN ONCOL, V15, P19, DOI 10.1093/annonc/mdh031; Gautschi O, 2017, J CLIN ONCOL, V35, P1403, DOI 10.1200/JCO.2016.70.9352; Gautschi O, 2013, J THORAC ONCOL, V8, pE43, DOI 10.1097/JTO.0b013e31828a4d07; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Girard N, 2012, EUR RESPIR J, V39, P366, DOI 10.1183/09031936.00010111; Go H, 2013, J THORAC ONCOL, V8, P1445, DOI 10.1097/JTO.0b013e3182a4dd6e; Gridelli C, 2015, CLIN LUNG CANCER, V16, P325, DOI 10.1016/j.cllc.2015.02.006; Gruber K, 2015, J THORAC ONCOL, V10, P713, DOI 10.1097/JTO.0000000000000427; Guerin A, 2015, CANCER EPIDEMIOL, V39, P307, DOI [10.1016/j.canep.2015.04.005, 10.]; Guibert N, 2017, J THORAC ONCOL, V12, P963, DOI 10.1016/j.jtho.2017.02.001; Guo BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099399; Han JY, 2014, LUNG CANCER, V85, P161, DOI 10.1016/j.lungcan.2014.04.009; Haneda H, 2006, JPN J CLIN ONCOL, V36, P69, DOI 10.1093/jjco/hyi228; Harada T, 2011, ONCOGENE, V30, P1744, DOI 10.1038/onc.2010.545; Hata A, 2013, CANCER-AM CANCER SOC, V119, P4325, DOI 10.1002/cncr.28364; Head SR, 2014, BIOTECHNIQUES, V56, P61, DOI 10.2144/000114133; Heist RS, 2016, ONCOLOGIST, V21, P481, DOI 10.1634/theoncologist.2015-0510; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003; Hotta K, 2007, J THORAC ONCOL, V2, P632, DOI 10.1097/JTO.0b013e318074bc0d; Hsu KH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120852; Huang DH, 2013, GENOMICS, V102, P157, DOI 10.1016/j.ygeno.2013.02.006; Hutarew G, 2014, HISTOPATHOLOGY, V65, P398, DOI 10.1111/his.12399; Ilie M, 2013, ANN ONCOL, V24, P742, DOI 10.1093/annonc/mds534; Ilie MI, 2015, ANN ONCOL, V26, P238, DOI 10.1093/annonc/mdu484; Inamura K, 2009, MODERN PATHOL, V22, P508, DOI 10.1038/modpathol.2009.2; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Janjigian YY, 2014, CANCER DISCOV, V4, P1036, DOI 10.1158/2159-8290.CD-14-0326; Janne PA, 2017, JAMA-J AM MED ASSOC, V317, P1844, DOI 10.1001/jama.2017.3438; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Jin Y, 2014, ANN SURG ONCOL, V21, P621, DOI 10.1245/s10434-013-3355-1; Joseph L, 2016, J MOL DIAGN, V18, P605, DOI 10.1016/j.jmoldx.2016.05.007; Jurmeister P, 2015, LUNG CANCER, V87, P122, DOI 10.1016/j.lungcan.2014.11.018; Kawada I, 2008, J THORAC ONCOL, V3, P1096, DOI 10.1097/JTO.0b013e318186fadd; Kemner A, PHASE 2 SAFETY EFFIC; Kerr KM, 2014, ANN ONCOL, V25, P1681, DOI 10.1093/annonc/mdu145; Kim HR, 2013, ANN ONCOL, V24, P2364, DOI 10.1093/annonc/mdt220; Kim Hyojin, 2014, Korean J Pathol, V48, P1, DOI 10.4132/KoreanJPathol.2014.48.1.1; Kim H, 2011, J THORAC ONCOL, V6, P1359, DOI 10.1097/JTO.0b013e31821cfc73; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Kitamura A, 2010, CLIN CANCER RES, V16, P3349, DOI 10.1158/1078-0432.CCR-10-0129; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kondo M, 2005, LUNG CANCER, V50, P385, DOI 10.1016/j.lungcan.2005.06.008; Kowalczuk O, 2014, TRANSL ONCOL, V7, P605, DOI 10.1016/j.tranon.2014.08.002; Kris MG, 2015, ANN ONCOL, V26, P1421, DOI 10.1093/annonc/mdv186; Krug LM, 2005, CANCER, V104, P2149, DOI 10.1002/cncr.21428; Kukita Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081468; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lantuejoul S, 2015, EUR RESPIR J, V46, P207, DOI 10.1183/09031936.00119914; Layfield LJ, 2016, DIAGN CYTOPATHOL, V44, P1000, DOI 10.1002/dc.23549; Lee SE, 2015, MODERN PATHOL, V28, P468, DOI 10.1038/modpathol.2014.107; Lee YJ, 2009, J CANCER RES CLIN, V135, P1647, DOI 10.1007/s00432-009-0611-7; Leidner RS, 2009, J CLIN ONCOL, V27, P5620, DOI 10.1200/JCO.2009.23.1431; Leighl NB, 2014, J CLIN ONCOL, V32, P3673, DOI 10.1200/JCO.2014.57.3055; Li BT, 2016, J THORAC ONCOL, V11, P414, DOI 10.1016/j.jtho.2015.10.025; Li CG, 2012, J THORAC ONCOL, V7, P85, DOI 10.1097/JTO.0b013e318234f0a2; Li F, 2012, CELL RES, V22, P928, DOI 10.1038/cr.2012.27; Li H, 2013, LUNG CANCER, V79, P8, DOI 10.1016/j.lungcan.2012.09.018; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Li S, 2014, BRIT J CANCER, V110, P2812, DOI 10.1038/bjc.2014.210; Li YL, 2016, J THORAC ONCOL, V11, P924, DOI 10.1016/j.jtho.2016.03.004; Li ZJ, 2014, TARGET ONCOL, V9, P381, DOI 10.1007/s11523-014-0312-2; Lindeman NI, 2013, J THORAC ONCOL, V8, P823, DOI 10.1097/JTO.0b013e318290868f; Lindeman NI, 2013, ARCH PATHOL LAB MED, V137, P828, DOI 10.5858/arpa.2012-0720-OA; Lindeman NI, 2013, J MOL DIAGN, V15, P415, DOI 10.1016/j.jmoldx.2013.03.001; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Liu LX, 2010, J THORAC ONCOL, V5, P1922, DOI 10.1097/JTO.0b013e3181f26266; Liu Stephen V, 2014, Eur J Cancer, V50, P2747, DOI 10.1016/j.ejca.2014.07.027; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Ludovini V, 2011, J THORAC ONCOL, V6, P707, DOI 10.1097/JTO.0b013e31820a3a6b; Luo J, 2014, SCI REP-UK, V4, DOI 10.1038/srep06269; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Ma PC, 2015, CANCER DISCOV, V5, P802, DOI 10.1158/2159-8290.CD-15-0769; Mao C, 2010, LUNG CANCER, V69, P272, DOI 10.1016/j.lungcan.2009.11.020; Marchetti A, 2016, J THORAC ONCOL, V11, P487, DOI 10.1016/j.jtho.2015.12.111; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Marks JL, 2008, J THORAC ONCOL, V3, P111, DOI 10.1097/JTO.0b013e318160c607; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Mazieres J, 2015, J CLIN ONCOL, V33, P992, DOI 10.1200/JCO.2014.58.3302; McLeer-Florin A, 2012, J THORAC ONCOL, V7, P348, DOI 10.1097/JTO.0b013e3182381535; Melosky B, 2016, CURR ONCOL, V23, P196, DOI 10.3747/co.23.3120; Meng DQ, 2013, LUNG CANCER, V81, P1, DOI 10.1016/j.lungcan.2013.03.019; Mescam-Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019; Minca EC, 2013, J MOL DIAGN, V15, P341, DOI 10.1016/j.jmoldx.2013.01.004; Mino-Kenudson M, 2010, CLIN CANCER RES, V16, P1561, DOI 10.1158/1078-0432.CCR-09-2845; Moiseyenko VM, 2010, ONKOLOGIE, V33, P231, DOI 10.1159/000302729; Mok T, 2015, CLIN CANCER RES, V21, P3196, DOI 10.1158/1078-0432.CCR-14-2594; Molina-Vila MA, 2008, J THORAC ONCOL, V3, P1224, DOI 10.1097/JTO.0b013e318189f579; Monso E, 2015, ARCH BRONCONEUMOL, V51, P462, DOI 10.1016/j.arbres.2014.11.010; Mouliere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023418; Noonan SA, 2016, J THORAC ONCOL, V11, P1293, DOI 10.1016/j.jtho.2016.04.033; Noro R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1019-1; Otani H, 2008, J THORAC ONCOL, V3, P472, DOI 10.1097/JTO.0b013e31816de2cd; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Oxnard GR, 2014, CLIN CANCER RES, V20, P1698, DOI 10.1158/1078-0432.CCR-13-2482; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Park HS, 2012, LUNG CANCER, V77, P288, DOI 10.1016/j.lungcan.2012.03.004; Pekar-Zlotin M, 2015, ONCOLOGIST, V20, P316, DOI 10.1634/theoncologist.2014-0389; Piotrowska Z, 2015, CANCER J, V21, P371, DOI 10.1097/PPO.0000000000000147; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Politi K, 2015, CANCER CELL, V27, P751, DOI 10.1016/j.ccell.2015.05.012; Popper HH, 2016, MEMO-MAG EUR MED ONC, V9, P191, DOI 10.1007/s12254-016-0297-x; Porta R, 2011, EUR RESPIR J, V37, P624, DOI 10.1183/09031936.00195609; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reinersman JM, 2011, J THORAC ONCOL, V6, P28, DOI 10.1097/JTO.0b013e3181fb4fe2; Rekhtman N, 2012, CLIN CANCER RES, V18, P1167, DOI 10.1158/1078-0432.CCR-11-2109; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rodig SJ, 2009, CLIN CANCER RES, V15, P5216, DOI 10.1158/1078-0432.CCR-09-0802; Sahoo R, 2011, LUNG CANCER, V73, P316, DOI 10.1016/j.lungcan.2011.01.004; Sakai K, 2013, CANCER SCI, V104, P1198, DOI 10.1111/cas.12211; Sasaki H, 2008, J CANCER RES CLIN, V134, P569, DOI 10.1007/s00432-007-0320-z; Sasaki H, 2013, LUNG CANCER, V82, P51, DOI 10.1016/j.lungcan.2013.06.014; Sasaki H, 2012, CANCER MED-US, V1, P68, DOI 10.1002/cam4.13; Satouchi M, 2007, BRIT J CANCER, V96, P1191, DOI 10.1038/sj.bjc.6603710; Savic S, 2015, LUNG CANCER, V89, P104, DOI 10.1016/j.lungcan.2015.05.012; Scarpa A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080478; Scheffler M, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9018; Scheffler M, 2015, ONCOTARGET, V6, P10577, DOI 10.18632/oncotarget.3387; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Scottish Intercollegiate Guidelines Network (SIGN), 2014, SIGN PUBL, V137; Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807; Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120422; Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130447; Shan L, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-3; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sholl LM, 2016, ARCH PATHOL LAB MED, V140, P341, DOI 10.5858/arpa.2015-0506-SA; Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7; Sholl LM, 2013, J THORAC ONCOL, V8, P322, DOI 10.1097/JTO.0b013e31827db604; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; Smit E, 2014, J THORAC ONCOL, V9, P1594, DOI 10.1097/JTO.0000000000000382; Soda M, 2012, CLIN CANCER RES, V18, P5682, DOI 10.1158/1078-0432.CCR-11-2947; Soh J, 2007, INT J CANCER, V121, P1162, DOI 10.1002/ijc.22818; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Su J, 2014, CHIN J CANCER, V33, P346, DOI 10.5732/cjc.013.10195; Suehara Y, 2012, CLIN CANCER RES, V18, P6599, DOI 10.1158/1078-0432.CCR-12-0838; Sugio K, 2009, LUNG CANCER, V64, P314, DOI 10.1016/j.lungcan.2008.09.010; Sun JM, 2013, LUNG CANCER, V82, P294, DOI 10.1016/j.lungcan.2013.08.023; Sunaga N, 2007, LUNG CANCER, V56, P383, DOI 10.1016/j.lungcan.2007.01.025; Suzuki M, 2015, LUNG CANCER, V87, P14, DOI 10.1016/j.lungcan.2014.10.014; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tang XM, 2008, CANCER PREV RES, V1, P192, DOI 10.1158/1940-6207.CAPR-08-0032; Tantraworasin A, 2014, ASIAN PAC J CANCER P, V15, P3057, DOI 10.7314/APJCP.2014.15.7.3057; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004; Thu KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033003; Thunnissen E, 2014, VIRCHOWS ARCH, V464, P347, DOI 10.1007/s00428-014-1535-4; To KF, 2013, J THORAC ONCOL, V8, P883, DOI 10.1097/JTO.0b013e3182904e22; Tomizawa K, 2011, LUNG CANCER, V74, P139, DOI 10.1016/j.lungcan.2011.01.014; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tsai TH, 2015, LUNG CANCER, V88, P208, DOI 10.1016/j.lungcan.2015.02.018; Tsuta K, 2012, J THORAC ONCOL, V7, P331, DOI 10.1097/JTO.0b013e318241655f; Tuononen K, 2013, GENE CHROMOSOME CANC, V52, P503, DOI 10.1002/gcc.22047; Uramoto H, 2006, LUNG CANCER-J IASLC, V51, P71, DOI 10.1016/j.lungcan.2005.08.006; US Food and Drug Administration, AT TECENTRIQ; US Food and Drug Administration, XALKORI PRESCR INF; van der Heijden EHFM, 2014, RESPIRATION, V88, P500, DOI 10.1159/000368857; Alvarez FV, 2016, ARCH BRONCONEUMOL, V52, P378, DOI 10.1016/j.arbres.2016.02.016; von Laffert M, 2017, LUNG CANCER, V103, P1, DOI 10.1016/j.lungcan.2016.11.008; Wang BG, 2003, CANCER RES, V63, P3966; Wang JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096899; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477; Wang SH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0290-1; Wang Z, 2008, ONKOLOGIE, V31, P174, DOI 10.1159/000116736; Wang Z, 2014, PR GR LAK SYMP VLSI, P9, DOI 10.1145/2591513.2591519; Warth A, 2014, HISTOPATHOLOGY, V65, P187, DOI 10.1111/his.12379; Wei ZJ, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2141-5; Weingertner N, 2015, PATHOLOGY, V47, P320, DOI 10.1097/PAT.0000000000000269; Wiesweg M, 2017, J THORAC ONCOL, V12, P54, DOI 10.1016/j.jtho.2016.08.137; Wu CC, 2008, CANCER, V113, P3199, DOI 10.1002/cncr.23925; Wu JY, 2011, MEDICINE, V90, P159, DOI 10.1097/MD.0b013e31821a16f4; Wu Y, 2014, J CLIN ONCOL, V32; Xu JM, 2009, J CANCER RES CLIN, V135, P771, DOI 10.1007/s00432-008-0512-1; Yale University School of Medicine, GUIDELINES DECISION; Yang P, 2012, J THORAC ONCOL, V7, P90, DOI 10.1097/JTO.0b013e31823c5c32; Yeung SF, 2015, J THORAC ONCOL, V10, P1292, DOI 10.1097/JTO.0000000000000620; Ying J, 2013, ANN ONCOL, V24, P2589, DOI 10.1093/annonc/mdt295; Yoh K, 2017, LANCET RESP MED, V5, P42, DOI 10.1016/S2213-2600(16)30322-8; Yoshida A, 2014, MODERN PATHOL, V27, P711, DOI 10.1038/modpathol.2013.192; Yoshizawa A, 2014, LUNG CANCER, V85, P373, DOI 10.1016/j.lungcan.2014.06.007; Yu HA, 2015, JAMA ONCOL, V1, P981, DOI 10.1001/jamaoncol.2015.1066; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729; Zwaenepoel K, 2014, HISTOPATHOLOGY, V65, P539, DOI 10.1111/his.12414	261	44	45	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					129	159		10.1016/j.jmoldx.2017.11.004			31	Pathology	Pathology	GA8SA	WOS:000428608800002	29398453	Bronze			2019-10-28	
J	Hung, SS; Meissner, B; Chavez, EA; Ben-Neriah, S; Ennishi, D; Jones, MR; Shulha, HP; Chan, FC; Boyle, M; Kridel, R; Gascoyne, RD; Mungall, AJ; Marra, MA; Scott, DW; Connors, JM; Steidl, C				Hung, Stacy S.; Meissner, Barbara; Chavez, Elizabeth A.; Ben-Neriah, Susana; Ennishi, Daisuke; Jones, Martin R.; Shulha, Hennady P.; Chan, Fong Chun; Boyle, Merrill; Kridel, Robert; Gascoyne, Randy D.; Mungall, Andrew J.; Marra, Marco A.; Scott, David W.; Connors, Joseph M.; Steidl, Christian			Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MARGINAL ZONE LYMPHOMA; FOLLICULAR LYMPHOMA; SOMATIC MUTATIONS; CODING GENOME; RECURRENT MUTATIONS; HODGKIN-LYMPHOMA; CLINICAL IMPACT; GENE-MUTATIONS	Targeted next-generation sequencing panels are increasingly used to assess the value of gene mutations for clinical diagnostic purposes. For assay development, amplicon-based methods have been preferentially used on the basis of short preparation time and small DNA input amounts. However, capture sequencing has emerged as an alternative approach because of high testing accuracy. We compared capture hybridization and amplicon sequencing approaches using fresh-frozen and formalin-fixed, paraffin-embedded tumor samples from eight lymphoma patients. Next, we developed a targeted sequencing pipeline using a 32-gene panel for accurate detection of actionable mutations in formalin-fixed, paraffin-embedded tumor samples of the most common lymphocytic malignancies: chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. We show that hybrid capture is superior to amplicon sequencing by providing deep more uniform coverage and yielding higher sensitivity for variant calling. Sanger sequencing of 588 variants identified specificity limits of thresholds for mutation calling, and orthogonal validation on 66 cases indicated 93% concordance with whole-genome sequencing. The developed pipeline and assay identified at least one actionable mutation in 91% of tumors from 219 lymphoma patients and revealed subtype-specific mutation patterns and frequencies consistent with the literature. This pipeline is an accurate and sensitive method for identifying actionable gene mutations in routinely acquired biopsy materials, suggesting further assessment of capture-based assays in the context of personalized lymphoma management.	[Hung, Stacy S.; Meissner, Barbara; Chavez, Elizabeth A.; Ben-Neriah, Susana; Ennishi, Daisuke; Shulha, Hennady P.; Chan, Fong Chun; Boyle, Merrill; Kridel, Robert; Gascoyne, Randy D.; Scott, David W.; Connors, Joseph M.; Steidl, Christian] BC Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada; [Jones, Martin R.; Mungall, Andrew J.; Marra, Marco A.] BC Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Gascoyne, Randy D.; Steidl, Christian] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada	Steidl, C (reprint author), BC Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	csteidl@bccancer.bc.ca	Kridel, Robert/V-8739-2019; Marra, Marco A/B-5987-2008; Mungall, Andrew J./U-7067-2018	Kridel, Robert/0000-0003-0287-7124; Marra, Marco A/0000-0001-7146-7175; Mungall, Andrew J./0000-0002-0905-2742; Chavez, Elizabeth/0000-0002-8859-0425	Genome CanadaGenome Canada [4108]; Genome British Columbia [141LYM]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [148393]; Terry Fox Research Institute [1061]; Michael Smith FoundationMichael Smith Foundation for Health Research; Canadian Institutes of Health Research New Investigator awardCanadian Institutes of Health Research (CIHR)	Supported by Genome Canada grant 4108 (J.M.C.), Genome British Columbia grant 141LYM (J.M.C.), the Canadian Institutes of Health Research grant 148393 (J.M.C.), and the Terry Fox Research Institute grant 1061 (C.S.). C.S. is the recipient of a Michael Smith Foundation for Health Research Career Investigator award and a Canadian Institutes of Health Research New Investigator award.	Altmuller J, 2014, BIOL CHEM, V395, P231, DOI 10.1515/hsz-2013-0199; Amin NA, 2016, CLIN CANCER RES, V22, P4525, DOI 10.1158/1078-0432.CCR-15-3103; Bosdet IE, 2013, J MOL DIAGN, V15, P796, DOI 10.1016/j.jmoldx.2013.07.004; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; Cheung KJJ, 2010, CANCER RES, V70, P9166, DOI 10.1158/0008-5472.CAN-10-2460; Chiaretti S, 2014, LEUKEMIA LYMPHOMA, V55, P2785, DOI 10.3109/10428194.2014.898760; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Diamandis M, 2010, MOL CANCER RES, V8, P1175, DOI 10.1158/1541-7786.MCR-10-0264; Ding JR, 2012, BIOINFORMATICS, V28, P167, DOI 10.1093/bioinformatics/btr629; Dubois S, 2016, CLIN CANCER RES, V22, P2919, DOI 10.1158/1078-0432.CCR-15-2305; Ennishi D, 2017, BLOOD, V129, P2760, DOI 10.1182/blood-2016-11-747022; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Flicek P, 2014, NUCLEIC ACIDS RES, V42, pD749, DOI 10.1093/nar/gkt1196; Gebauer N, 2013, ANTICANCER RES, V33, P4771; Guieze R, 2015, BLOOD, V126, P2110, DOI 10.1182/blood-2015-05-647578; Gunawardana J, 2014, NAT GENET, V46, P329, DOI 10.1038/ng.2900; Jiang YW, 2017, CANCER DISCOV, V7, P38, DOI 10.1158/2159-8290.CD-16-0975; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kridel R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002197; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Li H., 2013, 13033997V2 ARXIV, P1; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lim MS, 2016, CLIN CANCER RES, V22, P2829, DOI 10.1158/1078-0432.CCR-16-0232; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419; Mamedov TG, 2008, COMPUT BIOL CHEM, V32, P452, DOI 10.1016/j.compbiolchem.2008.07.021; Meynert AM, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-195; Morin RD, 2016, CLIN CANCER RES, V22, P2290, DOI 10.1158/1078-0432.CCR-15-2123; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Mwenifumbo JC, 2013, NAT REV GENET, V14, P321, DOI 10.1038/nrg3445; Nadeu F, 2016, BLOOD, V127, P2122, DOI 10.1182/blood-2015-07-659144; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; O'Shea D, 2008, BLOOD, V112, P3126, DOI 10.1182/blood-2008-05-154013; Okosun J, 2016, CURR OPIN HEMATOL, V23, P385, DOI 10.1097/MOH.0000000000000255; Pasqualucci L, 2015, SEMIN HEMATOL, V52, P67, DOI 10.1053/j.seminhematol.2015.01.005; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Pastore A, 2015, LANCET ONCOL, V16, P1111, DOI 10.1016/S1470-2045(15)00169-2; Peters TL, 2016, ONCOTARGET, V7, P63362, DOI 10.18632/oncotarget.11457; Pon JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8953; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rodriguez D, 2015, BLOOD, V126, P195, DOI 10.1182/blood-2014-10-604959; Rohr J, 2016, LEUKEMIA, V30, P1062, DOI 10.1038/leu.2015.357; Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904; Samorodnitsky E, 2015, HUM MUTAT, V36, P903, DOI 10.1002/humu.22825; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schrijver I, 2012, J MOL DIAGN, V14, P525, DOI 10.1016/j.jmoldx.2012.04.006; SCOTT DW, 2014, BLOOD, V124; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shukla VM, 2014, BLOOD, V124, P891; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865; Tyryshkin K, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.3037.3037; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Wang J, 2016, GENET MED, V18, P513, DOI 10.1038/gim.2015.121; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Wilson WH, 2015, NAT MED, V21, P922, DOI 10.1038/nm.3884; Wong SQ, 2013, SCI REP-UK, V3, DOI 10.1038/srep03494; Yildiz M, 2015, BLOOD, V125, P668, DOI 10.1182/blood-2014-06-582650; Ying CY, 2013, NAT IMMUNOL, V14, P1084, DOI 10.1038/ni.2688; Yost SE, 2013, BIOINFORMATICS, V29, P1908, DOI 10.1093/bioinformatics/btt305; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhang XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088075	72	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					203	214		10.1016/j.jmoldx.2017.11.010			12	Pathology	Pathology	GA8SA	WOS:000428608800009	29429887	Bronze			2019-10-28	
J	Zhu, LZ; Huang, YQ; Fang, XF; Liu, CL; Deng, WL; Zhong, CH; Xu, JH; Xu, D; Yuan, Y				Zhu, Lizhen; Huang, Yanqin; Fang, Xuefeng; Liu, Chenglin; Deng, Wanglong; Zhong, Chenhan; Xu, Jinghong; Xu, Dong; Yuan, Ying			A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MISMATCH-REPAIR DEFICIENCY; LYNCH-SYNDROME; MUTATIONS; PANELS	Two types of molecular tests have been established to assess the deficiency of the DNA mismatch repair (MMR) system: microsatellite instability (MSI) and immunohistochemical (IHC) analysis. We have developed a reliable method to analyze the MSI status by next-generation sequencing (NGS) based on read-count distribution. A total of 91 patients with primary colorectal cancer were recruited. These patients included 54 cases with loss of expression of any MMR protein in IHC, suggesting deficient MMR (dMMR), and 37 cases of colorectal cancer with staining of all four MMR proteins in IHC, suggesting proficient MMR in the sample after surgery. DNA was extracted from paired tumor normal tissue for MSI detection by both the ColonCore NGS panel and PCR. The sequencing data from the NGS panel was processed using various MSI detection pipelines for a comparison with the ColonCore panel. Using the MSI-PCR test as the gold standard, MSI-ColonCore achieved 97.9% sensitivity (47 of 48) and 100% specificity (37 of 37) for the detection of MSI status. MSI-ColonCore also showed more efficient and robust performance compared with other NGS-based MSI detection algorithms. The concordance rate was 92.3% between MSI-ColonCore and IHC testing, and 93.4% between MSI-PCR and IHC testing. These results suggest that MSI-ColonCore is a reliable and robust method for MSI status detection by NGS based on read count distribution.	[Zhu, Lizhen; Fang, Xuefeng; Zhong, Chenhan; Yuan, Ying] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, 88 Jie Fang Rd, Hangzhou 310009, Zhejiang, Peoples R China; [Xu, Jinghong] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Xu, Dong] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China; [Zhu, Lizhen; Huang, Yanqin; Fang, Xuefeng; Zhong, Chenhan; Yuan, Ying] Zhejiang Univ, Affiliated Hosp 2, Chinese Natl Minist Educ,Key Lab Mol Biol Med Sci, Key Lab Canc Prevent & Intervent,Sch Med,Canc Ins, Hangzhou, Zhejiang, Peoples R China; [Liu, Chenglin] Burning Rock Biotech, Dept Bioinformat, Guangzhou, Guangdong, Peoples R China; [Deng, Wanglong] Burning Rock Biotech, Dept Res & Dev, Guangzhou, Guangdong, Peoples R China	Yuan, Y (reprint author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, 88 Jie Fang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	yuanying1999@zju.edu.cn			National Science & Technology Pillar Program during the Twelfth Five-year Plan Period grant [2014BA109B07]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY16H160027]; National Key R&D Program of China [2017YFC0908200]	Supported by Key Projects in the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period grant 2014BA109B07 (Y.Y.), the Natural Science Foundation of Zhejiang Province grant LY16H160027 (X.F.), and the National Key R&D Program of China grant 2017YFC0908200 (Y.Y.).	Boland CR, 1998, CANCER RES, V58, P5248; Duval A, 2002, CANCER RES, V62, P2447; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950; Huang MN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13321; Kurian AW, 2014, J CLIN ONCOL, V32, P2001, DOI 10.1200/JCO.2013.53.6607; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Moreira L, 2012, JAMA-J AM MED ASSOC, V308, P1555, DOI 10.1001/jama.2012.13088; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Nowak JA, 2017, J MOL DIAGN, V19, P84, DOI 10.1016/j.jmoldx.2016.07.010; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Shen T, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00215; Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Yan WY, 2016, ONCOTARGETS THER, V9, P7415, DOI 10.2147/OTT.S117089; Yuan L, 2015, INT J CLIN EXP MED, V8, P20988	18	6	7	2	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	MAR	2018	20	2					225	231		10.1016/j.jmoldx.2017.11.007			7	Pathology	Pathology	GA8SA	WOS:000428608800011	29277635	Bronze			2019-10-28	
J	Lee, Y; Park, H; Lee, H; Cho, JY; Yoon, YS; Choi, YR; Han, HS; Jang, ES; Kim, JW; Jeong, SH; Ahn, S; Kim, H				Lee, Yangkyu; Park, Hyunjin; Lee, Hyejung; Cho, Jai Young; Yoon, Yoo-Seok; Choi, Young-Rok; Han, Ho-Seong; Jang, Eun Sun; Kim, Jin-Wook; Jeong, Sook-Hyang; Ahn, Soomin; Kim, Haeryoung			The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; hepatocellular; Gross classification; Prognosis	EARLY RECURRENCE; 19 EXPRESSION; RESECTION	Background: We aimed to determine the clinicopathological significance of the gross classification of hepatocellular carcinoma (HCC) according to the Korean Liver Cancer Association (KLCA) guidelines. Methods: A retrospective analysis was performed on 242 cases of consecutively resected solitary primary HCC between 2003 and 2012 at Seoul National University Bundang Hospital. The gross classification (vaguely nodular [VN], expanding nodular [EN], multinodular confluent [MC], nodular with perinodular extension [NP], and infiltrative [INF]) was reviewed for all cases, and were correlated with various clinicopathological features and the expression status of "stemness"-related (cytokeratin 19 [CK19], epithelial cell adhesion molecule [EpCAM]), and epithelial-mesenchymal transition (EMT)-related (urokinase plasminogen activator receptor [uPAR] and Ezrin) markers. Results: Significant differences were seen in overall survival (p = .015) and disease-free survival (p = .034) according to the gross classification; INF type showed the worst prognosis while VN and EN types were more favorable. When the gross types were simplified into two groups, type 2 HCCs (MC/NP/INF) were more frequently larger and poorly differentiated, and showed more frequent microvascular and portal venous invasion, intratumoral fibrous stroma and higher pT stages compared to type 1 HCCs (EN/VN) (p < .05, all). CK19, EpCAM, uPAR, and ezrin expression was more frequently seen in type 2 HCCs (p < .05, all). Gross classification was an independent predictor of both overall and disease-free survival by multivariate analysis (overall survival: p = .030; hazard ratio, 4.118; 95% confidence interval, 1.142 to 14.844; disease-free survival: p = .016; hazard ratio, 1.617; 95% confidence interval, 1.092 to 2.394). Conclusions: The gross classification of HCC had significant prognostic value and type 2 HCCs were associated with clinicopathological features of aggressive behavior, increased expression of "stemness"-and EMT-related markers, and decreased survival.	[Lee, Yangkyu; Ahn, Soomin] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Pathol, Seongnam, South Korea; [Park, Hyunjin; Lee, Hyejung; Kim, Haeryoung] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea; [Cho, Jai Young; Yoon, Yoo-Seok; Choi, Young-Rok; Han, Ho-Seong] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Surg, Seongnam, South Korea; [Jang, Eun Sun; Kim, Jin-Wook; Jeong, Sook-Hyang] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seongnam, South Korea	Kim, H (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	haeryoung.kim@snu.ac.kr	Choi, YoungRok/D-5532-2012	Choi, YoungRok/0000-0003-2408-7086; Kim, Jin-Wook/0000-0003-0934-3344	SNUBH Research Fund [14-2014-012]; Basic Science Research Program through NRF - the Ministry of Education [NRF-2016R1D1A1A09919042]	This work was supported by grant number 14-2014-012 from the SNUBH Research Fund, and the Basic Science Research Program through NRF funded by the Ministry of Education (NRF-2016R1D1A1A09919042).	Choi GH, 2009, AM J SURG, V198, P693, DOI 10.1016/j.amjsurg.2008.09.019; Fu X, 2016, HEPATOL RES, V46, P298, DOI 10.1111/hepr.12540; Gong SC, 2016, J GASTROEN HEPATOL, V31, P206, DOI 10.1111/jgh.13063; Hui AM, 2000, J HEPATOL, V33, P975, DOI 10.1016/S0168-8278(00)80131-2; Inayoshi J, 2003, J GASTROEN HEPATOL, V18, P673, DOI 10.1046/j.1440-1746.2003.03021.x; KANAI T, 1987, CANCER, V60, P810, DOI 10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO;2-1; Kim H, 2014, DIGEST DIS, V32, P778, DOI 10.1159/000368021; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; 장재영, 2017, [Journal of Liver Cancer, 대한간암학회지], V17, P19; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Kurogi M, 2006, J GASTROEN HEPATOL, V21, P1470, DOI 10.1111/j.1440-1746.2006.04372.x; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liver Cancer Study Group of Japan, 2003, GEN RUL CLIN PATH ST; Manghisi G, 1998, HEPATOLOGY, V28, P751; Murakata A, 2011, ANN SURG, V253, P94, DOI 10.1097/SLA.0b013e3181f9bc00; Okamura D, 2008, MODERN PATHOL, V21, P847, DOI 10.1038/modpathol.2008.59; Shimada M, 2001, AM J SURG, V182, P177, DOI 10.1016/S0002-9610(01)00682-1; TREVISANI F, 1993, CANCER, V72, P1557, DOI 10.1002/1097-0142(19930901)72:5<1557::AID-CNCR2820720512>3.0.CO;2-5; Tsujita E, 2013, HEPATO-GASTROENTEROL, V60, P1726, DOI 10.5754/hge13365; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	20	3	3	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					85	92		10.4132/jptm.2017.11.13			8	Pathology	Pathology	GA3BJ	WOS:000428202100003	29172395	DOAJ Gold, Green Published			2019-10-28	
J	Jung, J; Chae, YS; Kim, CH; Lee, Y; Lee, JH; Kim, DS; Yu, YD; Kim, JY				Jung, Jiyoon; Chae, Yang-Seok; Kim, Chul Hwan; Lee, Youngseok; Lee, Jeong Hyeon; Kim, Dong-Sik; Yu, Young-Dong; Kim, Joo Young			Combined Adenosquamous and Large Cell Neuroendocrine Carcinoma of the Gallbladder	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; adenosquamous; Large cell neuroendocrine carcinoma; Gallbladder; Prognosis		Large cell neuroendocrine carcinoma (LCNEC) of the gallbladder is extremely rare and usually combined with other type of malignancy, mostly adenocarcinoma. We report an unusual case of combined adenosquamous carcinoma and LCNEC of the gallbladder in a 54-year-old woman. A radical cholecystectomy specimen revealed a 4.3 x 4.0 cm polypoid mass in the fundus with infiltration of adjacent liver parenchyma. Microscopically, the tumor consisted of two distinct components. Adenosquamous carcinoma was predominant and abrupt transition from adenocarcinoma to squamous cell carcinoma was observed. LCNEC showed round cells with large, vesicular nuclei, abundant mitotic figures, and occasional pseudorosette formation. The patient received adjuvant chemotherapy. However, multiple liver metastases were identified at 3-month follow-up. Metastatic nodules were composed of LCNEC and squamous cell carcinoma components. Detecting LCNEC component is important in gallbladder cancer, because the tumor may require a different chemotherapy regimen and show early metastasis and poor prognosis.	[Jung, Jiyoon; Chae, Yang-Seok; Kim, Chul Hwan; Lee, Youngseok; Lee, Jeong Hyeon; Kim, Joo Young] Korea Univ, Coll Med, Anam Hosp, Dept Pathol, 73 Inchon Ro, Seoul 02841, South Korea; [Kim, Dong-Sik; Yu, Young-Dong] Korea Univ, Coll Med, Anam Hosp, Dept Surg, Seoul, South Korea	Kim, JY (reprint author), Korea Univ, Coll Med, Anam Hosp, Dept Pathol, 73 Inchon Ro, Seoul 02841, South Korea.	lepetit80@hanmail.net		Jung, Jiyoon/0000-0001-9553-5283			Acosta AM, 2016, ARCH PATHOL LAB MED, V140, P1157, DOI 10.5858/arpa.2015-0102-RS; ALBORESSAAVEDRA J, 1988, PATHOL RES PRACT, V183, P169, DOI 10.1016/S0344-0338(88)80044-X; Alpuerto AC, 2017, CASE REP SURG, DOI 10.1155/2017/2534029; Bosman FT, 2010, WHO CLASSIFICATION T, P274; Buscemi S, 2016, INT J SURG, V28, pS128, DOI 10.1016/j.ijsu.2015.12.045; Chen C, 2015, INT J CLIN EXP PATHO, V8, P8218; CHRISTIE AC, 1954, J CLIN PATHOL, V7, P318, DOI 10.1136/jcp.7.4.318; Eltawil KM, 2010, J CLIN GASTROENTEROL, V44, P687, DOI 10.1097/MCG.0b013e3181d7a6d4; HART IR, 1981, BIOCHIM BIOPHYS ACTA, V651, P37, DOI 10.1016/0304-419X(81)90004-4; HENSON DE, 1992, CANCER, V70, P1493, DOI 10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U; Hoshimoto S, 2017, SCAND J GASTROENTERO, V52, P425, DOI 10.1080/00365521.2016.1273383; Kanthan R, 2015, J ONCOL, DOI 10.1155/2015/967472; Liu W, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0533-6; National Cancer Institute, 2008, SEER DAT 1973 2005; Noske A, 2006, VIRCHOWS ARCH, V449, P135, DOI 10.1007/s00428-006-0171-z; Verlicchi L, 2015, J CELL SCI R, V6, P212	16	2	2	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					121	125		10.4132/jptm.2017.08.20			5	Pathology	Pathology	GA3BJ	WOS:000428202100008	28994275	DOAJ Gold, Green Published			2019-10-28	
J	Kim, B; Yang, HK; Kim, WH				Kim, Bohyun; Yang, Han-Kwang; Kim, Woo Ho			Multiple Neuroendocrine Tumors in Stomach and Duodenum in a Multiple Endocrine Neoplasia Type 1 Patient	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Multiple endocrine neoplasia type 1; Stomach neoplasms; Neuroendocrine tumors; Histologic mapping	MANAGEMENT	A 67-year-old woman with a history of subtotal parathyroidectomy, distal pancreatectomy, and total splenectomy 23 years prior underwent surgical gastric resection for neuroendocrine tumors of the stomach and duodenum. Meticulous examination of the entire stomach and duodenum revealed multiple scattered, minute neuroendocrine tumors. To the best of our knowledge, this is the first case report of a patient diagnosed with gastroduodenal neuroendocrine tumors associated with multiple endocrine neoplasia type 1 (MEN 1) in whom complete histologic mapping of the whole gastrectomy specimen was performed. The presence of MEN 1-associated neuroendocrine tumors in the stomach is very rare, but should be considered in patients diagnosed with MEN 1 who present with a new tumor in the stomach.	[Kim, Bohyun; Kim, Woo Ho] Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea; [Yang, Han-Kwang] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea	Kim, WH (reprint author), Seoul Natl Univ, Coll Med, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	woohokim@snu.ac.kr					Christopoulos C, 2005, ANN GASTROENTEROL, V18, P127; de Laat JM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0708-1; Falchetti A, 2010, F1000 MED REP, V2, P14, DOI 10.3410/M2-14; Feliberti E, 2000, ENDOTEXT; Grin A, 2015, ARCH PATHOL LAB MED, V139, P750, DOI 10.5858/arpa.2014-0130-RA; Kouvaraki MA, 2002, ARCH SURG-CHICAGO, V137, P641, DOI 10.1001/archsurg.137.6.641; Li TT, 2014, WORLD J GASTROENTERO, V20, P118, DOI 10.3748/wjg.v20.i1.118; Sato Y, 2016, WORLD J GASTROENTERO, V22, P6817, DOI 10.3748/wjg.v22.i30.6817; Thakker RV, 2014, MOL CELL ENDOCRINOL, V386, P2, DOI 10.1016/j.mce.2013.08.002; Tsikitis VL, 2012, J CANCER, V3, P292, DOI 10.7150/jca.4502; Turner JJO, 2010, HUM MUTAT, V31, pE1089, DOI 10.1002/humu.21170; Wang GG, 2005, MODERN PATHOL, V18, P1079, DOI 10.1038/modpathol.3800389	12	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					126	129		10.4132/jptm.2017.09.16			4	Pathology	Pathology	GA3BJ	WOS:000428202100009	29268593	DOAJ Gold, Green Published			2019-10-28	
J	Ahn, H; Kwon, HJ; Park, E; Kim, H; Chung, JH				Ahn, Hyein; Kwon, Hyun Jung; Park, Eunhyang; Kim, Hyojin; Chung, Jin-Haeng			Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article									[Ahn, Hyein; Kwon, Hyun Jung; Kim, Hyojin; Chung, Jin-Haeng] Seoul Natl Univ, Bundang Hosp, Dept Pathol, 82 Gumi Ro 173Beon Gil, Seongnam 13620, South Korea; [Park, Eunhyang] Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea	Chung, JH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Pathol, 82 Gumi Ro 173Beon Gil, Seongnam 13620, South Korea.	chungjh@snu.ac.kr					Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Mink SR, 2010, MOL CANCER RES, V8, P809, DOI 10.1158/1541-7786.MCR-09-0460; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rubio R, 2014, STEM CELLS, V32, P1136, DOI 10.1002/stem.1647; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003	5	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	MAR	2018	52	2					130	132		10.4132/jptm.2016.11.17			3	Pathology	Pathology	GA3BJ	WOS:000428202100010	28372343	DOAJ Gold, Green Published			2019-10-28	
J	Busser, B; Moncayo, S; Trichard, F; Bonneterre, V; Pinel, N; Pelascini, F; Dugourd, P; Coll, JL; D'Incan, M; Charles, J; Motto-Ros, V; Sancey, L				Busser, Benoit; Moncayo, Samuel; Trichard, Florian; Bonneterre, Vincent; Pinel, Nicole; Pelascini, Frederic; Dugourd, Philippe; Coll, Jean-Luc; D'Incan, Michel; Charles, Julie; Motto-Ros, Vincent; Sancey, Lucie			Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy	MODERN PATHOLOGY			English	Article							TRACE-ELEMENTS; LYMPH-NODES; ALUMINUM; TITANIUM; GRANULOMA; INJECTION; BODY; MICROANALYSIS; RESOLUTION; PARTICLES	Pathologists typically encounter many disparate exogenous materials in clinical specimens during their routine histopathological examinations, especially within the skin, lymph nodes, and lungs. These foreign substances may be free extracellular deposits or induce several clinical abnormalities or histopathological patterns. However, pathologists almost never investigate or report the chemical nature of exogenous metals in clinical specimens due to a lack of convenient and available technologies. In this paper, a novel strategy based on laser-induced breakdown spectroscopy (LIBS) technology is evaluated for in situ multi-elemental tissue imaging. The improved procedures allow visualization of the presence of chemical elements contained within paraffin-embedded specimens of medical interest with elemental images that are stackable with conventional histology images. We selected relevant medical situations for which the associated pathology reports were limited to the presence of lymphohistiocytic and inflammatory cells containing granules (a granuloma and a pseudolymphoma) or to lymph nodes or skin tissues containing pigments or foreign substances. Exogenous elements such as aluminum, titanium, copper, and tungsten were identified and localized within the tissues. The all-optical LIBS elemental imaging instrument that we developed is fully compatible with conventional optical microscopy used for pathology analysis. When combined with routine histopathological analysis, LIBS is a versatile technology that might help pathologists establish or confirm diagnoses for a wide range of medical applications, particularly when the nature of external agents present in tissues needs to be investigated.	[Busser, Benoit; Coll, Jean-Luc; Charles, Julie; Sancey, Lucie] UGA Inserm U1209 CNRS UMR 5309 Joint Res Ctr, Inst Adv Biosci, Site Sante Allee Alpes, F-38700 Grenoble, France; [Busser, Benoit; Bonneterre, Vincent; Pinel, Nicole; Charles, Julie] Grenoble Alpes Univ Hosp, Grenoble, France; [Busser, Benoit; Moncayo, Samuel; Trichard, Florian; Dugourd, Philippe; Motto-Ros, Vincent] Univ Claude Bernard Lyon 1, CNRS, UMR 5306, Inst Lumiere Mat, Villeurbanne, France; [Pelascini, Frederic] CRITT Mat Alsace, Schiltigheim, France; [D'Incan, Michel] Univ Hosp Clermont Ferrand, Clermont Ferrand, France	Busser, B (reprint author), UGA Inserm U1209 CNRS UMR 5309 Joint Res Ctr, Inst Adv Biosci, Site Sante Allee Alpes, F-38700 Grenoble, France.	bbusser@chu-grenoble.fr	Coll, Jean-Luc/G-2520-2013; Lucie, Sancey/H-5914-2016; charles, julie/E-8929-2013; Dugourd, Philippe/H-6574-2018; Busser, Benoit/N-1841-2013	Lucie, Sancey/0000-0002-0084-3775; charles, julie/0000-0003-4667-6009; Dugourd, Philippe/0000-0003-4395-1140; Busser, Benoit/0000-0002-9425-1577; Coll, Jean-Luc/0000-0002-2453-3552; Moncayo, Samuel/0000-0001-9774-1259	ITMO Cancer et ITMO Technologies pour la sante de l'alliance nationale pour les sciences de la vie et de la sante (AVIESAN); Institut National du Cancer (INCa)Institut National du Cancer (INCA) France; INSERM within the project LAST [PC201513]	We are thankful for research funding from the ITMO Cancer et ITMO Technologies pour la sante de l'alliance nationale pour les sciences de la vie et de la sante (AVIESAN), the Institut National du Cancer (INCa), and INSERM within the project LAST (#PC201513).	ALBORESSAAVEDRA J, 1994, AM J SURG PATHOL, V18, P83, DOI 10.1097/00000478-199401000-00008; Bergfors E, 2005, EUR J PEDIATR, V164, P691, DOI 10.1007/s00431-005-1704-1; Bergfors Elisabet, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2012-007779; Berlin JM, 2003, J AM ACAD DERMATOL, V49, P939, DOI 10.1067/S0190-9622(03)1555-X; Bich C, 2015, BIOINTERPHASES, V10, DOI 10.1116/1.4901511; Chao WL, 2005, NATURE, V435, P1210, DOI 10.1038/nature03719; Chikkamuniyappa Shylashree, 2005, Dermatol Online J, V11, P14; Chong H, 2006, HISTOPATHOLOGY, V48, P182, DOI 10.1111/j.1365-2559.2005.02312.x; Culora GA, 1996, J CLIN PATHOL, V49, P844, DOI 10.1136/jcp.49.10.844; DALEY TD, 1990, ORAL SURG ORAL MED O, V69, P339, DOI 10.1016/0030-4220(90)90296-5; Fage SW, 2016, CONTACT DERMATITIS, V74, P323, DOI 10.1111/cod.12565; FernandezMartin JL, 1996, NEPHROL DIAL TRANSPL, V11, P80; Flatebo RS, 2011, J ORAL PATHOL MED, V40, P412, DOI 10.1111/j.1600-0714.2010.00958.x; Friedman T, 2003, PLAST RECONSTR SURG, V111, P2120, DOI 10.1097/01.PRS.0000057101.95872.A1; Gimenez Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29936; Goldyn SR, 2008, SEMIN RESP CRIT CARE, V29, P591, DOI 10.1055/s-0028-1101269; HARTMAN LC, 1986, J ORAL MAXIL SURG, V44, P628, DOI 10.1016/S0278-2391(86)80074-X; HENRY L, 1993, HISTOPATHOLOGY, V22, P457, DOI 10.1111/j.1365-2559.1993.tb00159.x; Jack C M, 2005, Int Semin Surg Oncol, V2, P28; Koppang HS, 2007, J ORAL PATHOL MED, V36, P161, DOI 10.1111/j.1600-0714.2007.00512.x; Lobinski R, 2006, BIOCHIMIE, V88, P1591, DOI 10.1016/j.biochi.2006.10.003; Lohmann CH, 2013, J BONE JOINT SURG AM, V95A, P1561, DOI 10.2106/JBJS.L.01273; Maubec E, 2005, J AM ACAD DERMATOL, V52, P623, DOI 10.1016/j.jaad.2004.12.021; McRae R, 2009, CHEM REV, V109, P4780, DOI 10.1021/cr900223a; Molina-Ruiz AM, 2015, DERMATOL CLIN, V33, P497, DOI 10.1016/j.det.2015.03.014; Moncayo S, 2017, SPECTROCHIM ACTA B, V133, P40, DOI 10.1016/j.sab.2017.04.013; MOWRY RG, 1991, ARCH DERMATOL, V127, P692, DOI 10.1001/archderm.127.5.692; Nihon-Yanagi Y, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0291-3; Peoch M, 1996, NEW ENGL J MED, V335, P133, DOI 10.1056/NEJM199607113350214; Peterson Steven L, 2008, Hand (N Y), V3, P282, DOI 10.1007/s11552-008-9107-1; Qiao SJ, 2015, APPL SPECTROSC REV, V50, P1, DOI 10.1080/05704928.2014.911746; Requena L, 2012, DERMATOL CLIN, V30, P731, DOI 10.1016/j.det.2012.06.006; Sancey L, 2014, SCI REP-UK, V4, DOI 10.1038/srep06065; Sancey L, 2015, ACS NANO, V9, P2477, DOI 10.1021/acsnano.5b00552; Scimeca M, 2014, EUR J HISTOCHEM, V58, P233, DOI 10.4081/ejh.2014.2403; SHELLEY WB, 1960, J INVEST DERMATOL, V34, P107, DOI 10.1038/jid.1960.17; Susnea I, 2016, MASS SPECTROM REV, V35, P666, DOI 10.1002/mas.21454; TORGERSEN S, 1995, ACTA ODONTOL SCAND, V53, P65, DOI 10.3109/00016359509005948; Urgast DS, 2014, CURR OPIN CLIN NUTR, V17, P431, DOI 10.1097/MCO.0000000000000087; Viraben R, 1995, CONTACT DERMATITIS, V33, P437, DOI 10.1111/j.1600-0536.1995.tb02089.x; Willardson HB, 2017, PHOTOMED LASER SURG, V35, P176, DOI 10.1089/pho.2016.4162	41	5	5	4	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					378	384		10.1038/modpathol.2017.152			7	Pathology	Pathology	FY7KC	WOS:000427040000001	29148536	Bronze			2019-10-28	
J	Gibier, JB; Gnemmi, V; Glowacki, F; Boyle, EM; Lopez, B; MacNamara, E; Hoffmann, M; Azar, R; Guincestre, T; Bourdon, F; Copin, MC; Buob, D				Gibier, Jean-Baptiste; Gnemmi, Viviane; Glowacki, Francois; Boyle, Eileen M.; Lopez, Benjamin; MacNamara, Evelyne; Hoffmann, Maxime; Azar, Raymond; Guincestre, Thomas; Bourdon, Franck; Copin, Marie-Christine; Buob, David			Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis	MODERN PATHOLOGY			English	Article							MULTIPLE-MYELOMA; AL AMYLOIDOSIS; WALDENSTROM MACROGLOBULINEMIA; RENAL IMPAIRMENT; IN-VITRO; DISEASE; SURVIVAL; TUBULOPATHY; DEPOSITION; DIAGNOSIS	Light chain cast nephropathy is the most common form of kidney disease in patients with multiple myeloma. Light chain casts may occasionally show amyloid staining properties, that is, green birefringence after Congo red staining. The frequency and clinical significance of this intratubular amyloid are poorly understood. Here, we retrospectively assessed the clinicopathological features of 60 patients with histologically proven light chain cast nephropathy with a specific emphasis on intratubular amyloid, especially, its association with extrarenal systemic light chain amyloidosis. We found intratubular amyloid in 17 cases (17/60, 28%) and it was more frequent in patients with. light chain gammopathy (13/17 in the 'intratubular amyloid' group vs 19/43 in the 'no intratubular amyloid' group, P=0.02). Pathological examination of extrarenal specimens showed that intratubular amyloid was significantly associated with the occurrence of systemic light chain amyloidosis (5/13 in the 'intratubular amyloid' group vs 0/30 in the 'no intratubular amyloid' group, P=0.001). Our results indicate that first, intratubular amyloid is not a rare finding in kidney biopsies of patients with light chain cast nephropathy, and, second, it reflects an amyloidogenic capacity of light chains that can manifest as systemic light chain amyloidosis. Thus, intratubular amyloid should be systematically screened for in kidney biopsies from patients with light chain cast nephropathy and, if detected, should prompt a work-up for associated systemic light chain amyloidosis.	[Gibier, Jean-Baptiste; Gnemmi, Viviane; Copin, Marie-Christine] Univ Lille, Dept Pathol, Ctr Biol Pathol, CHU Lille, F-59000 Lille, France; [Glowacki, Francois] Univ Lille, Dept Nephrol, Hop Claude Huriez, CHU Lille, Lille, France; [Boyle, Eileen M.] Univ Lille, Dept Hematol, Hop Claude Huriez, CHU Lille, Lille, France; [Lopez, Benjamin] Univ Lille, Dept Immunol, Ctr Biol Pathol, CHU Lille, Lille, France; [MacNamara, Evelyne] Ctr Hosp Bethune Beuvry, Dept Nephrol, Bethune, France; [Hoffmann, Maxime] Hop Prive La Louviere, Dept Nephrol, Lille, France; [Azar, Raymond] Ctr Hosp Dunkerque, Dept Nephrol, Dunkerque, France; [Guincestre, Thomas] Ctr Hosp Roubaix, Dept Nephrol, Roubaix, France; [Bourdon, Franck] Clin Bois, Dept Nephrol, Lille, France; [Buob, David] Hop Tenon, AP HP, Dept Pathol, Paris, France	Gibier, JB (reprint author), Univ Lille, Dept Pathol, Ctr Biol Pathol, CHU Lille, F-59000 Lille, France.	jeanbaptiste.gibier@chru-lille.fr	Lopez, Benjamin/M-5035-2018; Boyle, Eileen M./Y-5179-2019	Lopez, Benjamin/0000-0002-0457-1981; Boyle, Eileen M./0000-0001-8791-1744; Glowacki, Francois/0000-0001-5443-9172; Gnemmi, Viviane/0000-0001-7403-4607; Gibier, Jean-Baptiste/0000-0002-1194-5590			AZZOPARDI JG, 1966, J CLIN PATHOL, V19, P539, DOI 10.1136/jcp.19.6.539; Azzopardi JG, 1962, BRIT MED J, V1, P169; Bahlis NJ, 2006, BONE MARROW TRANSPL, V38, P7, DOI 10.1038/sj.bmt.1705395; D'Agati VD, 2005, NONNEOPLASTIC KIDNEY, P603; Decourt A, 2016, CLIN J AM SOC NEPHRO, V11, P431, DOI 10.2215/CJN.06290615; DEFRONZO RA, 1975, MEDICINE, V54, P209, DOI 10.1097/00005792-197505000-00003; Dimopoulos MA, 2014, ANN ONCOL, V25, P195, DOI 10.1093/annonc/mdt483; Dimopoulos MA, 2013, LEUKEMIA, V27, P423, DOI 10.1038/leu.2012.182; Drayson M, 2006, BLOOD, V108, P2013, DOI 10.1182/blood-2006-03-008953; Ecotiere L, 2016, NEPHROL DIAL TRANSPL, V31, P64, DOI 10.1093/ndt/gfv283; El-Zoghby Z, 2007, KIDNEY INT, V72, P1282, DOI 10.1038/sj.ki.5002411; FRIMAN C, 1970, Annals of Clinical Research, V2, P161; Gnemmi V, 2012, AM J KIDNEY DIS, V60, P487, DOI 10.1053/j.ajkd.2012.01.030; Hemminger J, 2012, AM J SURG PATHOL, V36, P1253, DOI 10.1097/PAS.0b013e31825b845e; HILL GS, 1983, AM J KIDNEY DIS, V2, P423, DOI 10.1016/S0272-6386(83)80075-4; Hutchison CA, 2007, J AM SOC NEPHROL, V18, P886, DOI 10.1681/ASN.2006080821; Iliuta IA, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.74; Kato H, 2015, INTERNAL MED, V54, P3023, DOI 10.2169/internalmedicine.54.5174; Keeling J, 2004, LAB INVEST, V84, P1322, DOI 10.1038/labinvest.3700161; Larsen CP, 2012, CLIN KIDNEY J, V5, P130, DOI 10.1093/ckj/sfs004; Leung N, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfv294; LIMAS C, 1973, AM J MED, V54, P166, DOI 10.1016/0002-9343(73)90220-9; Linke RP, 2000, VIRCHOWS ARCH, V436, P439, DOI 10.1007/s004280050471; Madan S, 2010, MAYO CLIN PROC, V85, P232, DOI 10.4065/mcp.2009.0547; MELATO M, 1980, VIRCHOWS ARCH A, V387, P133, DOI 10.1007/BF00430695; Nasr SH, 2012, AM J KIDNEY DIS, V59, P786, DOI 10.1053/j.ajkd.2011.12.028; Nasr S, 2008, KIDNEY INT, V73, P517, DOI 10.1038/sj.ki.5002416; PIRANI CL, 1987, AM J KIDNEY DIS, V10, P208, DOI 10.1016/S0272-6386(87)80176-2; Rajkumar SV, 1998, CANCER-AM CANCER SOC, V82, P1501, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.3.CO;2-M; Reule S, 2016, J AM SOC NEPHROL, V27, P1487, DOI 10.1681/ASN.2014090876; ROTA S, 1987, MEDICINE, V66, P126, DOI 10.1097/00005792-198703000-00004; Sethi S, 2009, AM J KIDNEY DIS, V54, P970, DOI 10.1053/j.ajkd.2009.01.273; SHIRAHAMA T, 1975, AM J PATHOL, V81, P101; Solomon A, 1995, AMYLOID, V2, P269, DOI 10.3109/13506129508999010; Tagouri YM, 1996, LAB INVEST, V74, P290; VASSAR PS, 1962, ARCH PATHOL, V73, P59; Vela-Ojeda J, 2009, ANN HEMATOL, V88, P59, DOI 10.1007/s00277-008-0554-0; Vos JM, 2016, BRIT J HAEMATOL, V175, P623, DOI 10.1111/bjh.14279	38	2	2	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					452	462		10.1038/modpathol.2017.124			11	Pathology	Pathology	FY7KC	WOS:000427040000008	29052601	Bronze			2019-10-28	
J	Calio, A; Brunelli, M; Segala, D; Pedron, S; Tardanico, R; Remo, A; Gobbo, S; Meneghelli, E; Doglioni, C; Hes, O; Zampini, C; Argani, P; Martignoni, G				Calio, Anna; Brunelli, Matteo; Segala, Diego; Pedron, Serena; Tardanico, Regina; Remo, Andrea; Gobbo, Stefano; Meneghelli, Emanuela; Doglioni, Claudio; Hes, Ondrej; Zampini, Claudia; Argani, Pedram; Martignoni, Guido			t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma	MODERN PATHOLOGY			English	Article							DISTINCTIVE TRANSLOCATION CARCINOMA; ALPHA-TFEB FUSION; CHROMOSOME-TRANSLOCATION; FEATURES; KIDNEY; T(6/11)(P21,Q12); TUMOR; EXPRESSION; PATIENT; IMMUNOREACTIVITY	Renal cell carcinomas with t(6;11) chromosome translocation involving the TFEB gene are indolent neoplasms which often occur in young patients. In this study, we report seven cases of renal cell carcinoma with TFEB rearrangement, two of whom had histologically proven metastasis. Patients (4F, 3M) ranged in age from 19 to 55 years (mean 37). One patient developed paratracheal and pleural metastases 24 months after surgery and died of disease after 46 months; another one recurred with neoplastic nodules in the perinephric fat and pelvic soft tissue. Histologically, either cytological or architectural appearance was peculiar in each case whereas one tumor displayed the typical biphasic morphology. By immunohistochemistry, all tumors labelled for cathepsin K, Melan-A and CD68 (KP1 clone). HMB45 and PAX8 staining were detected in six of seven tumors. All tumors were negative for CD68 (PG-M1 clone), CKAE1-AE3, CK7, CAIX, and AMACR. Seven pure epithelioid PEComa/epithelioid angiomyolipomas, used as control, were positive for cathepsin K, melanocytic markers, and CD68 (PG-M1 and KP1) and negative for PAX8. Fluorescence in situ hybridization results showed the presence of TFEB gene translocation in all t(6;11) renal cell carcinomas with a high frequency of split TFEB fluorescent signals (mean 74%). In the primary and metastatic samples of the two aggressive tumors, increased gene copy number was observed (3-5 fluorescent signals per neoplastic nuclei) with a concomitant increased number of CEP6. Review of the literature revealed older age and larger tumor size as correlating with aggressive behavior in these neoplasms. In conclusion, we present the clinical, morphological and molecular features of seven t(6;11) renal cell carcinomas, two with histologically demonstrated metastasis. We report the high frequency of split signals by FISH in tumors with t(6;11) chromosomal rearrangement and the occurrence of TFEB gene copy number gains in the aggressive cases, analyzing either the primary or metastatic tumor. Finally, we demonstrate the usefulness of CD68 (PG-M1) immunohistochemical staining in distinguishing t(6;11) renal cell carcinoma from pure epithelioid PEComa/epithelioid angiomyolipoma.	[Calio, Anna; Brunelli, Matteo; Pedron, Serena; Zampini, Claudia; Martignoni, Guido] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy; [Segala, Diego; Gobbo, Stefano; Martignoni, Guido] Pederzoli Hosp, Dept Pathol, Peschiera Del Garda, Italy; [Tardanico, Regina] Spedali Civil Brescia, Dept Pathol, Brescia, Italy; [Remo, Andrea] Hosp Mater Salutis, Dept Pathol, Legnago, Italy; [Meneghelli, Emanuela] Univ Verona, Dept Life & Reprod Sci, Clin Biochem Lab, Verona, Italy; [Doglioni, Claudio] Hosp San Raffaele, Dept Pathol, Milan, Italy; [Hes, Ondrej] Charles Univ Hosp Plzen, Dept Pathol, Plzen, Czech Republic; [Argani, Pedram] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	Martignoni, G (reprint author), Univ Verona, Dept Diagnost & Publ Hlth, Largo L Scuro 10, I-37134 Verona, Italy.	guido.martignoni@univr.it	Calio, Anna/Y-1465-2018; Brunelli, Matteo/AAA-7679-2019	Calio, Anna/0000-0001-7352-6327; Gobbo, Stefano/0000-0001-5247-5233			Argani P, 2005, CLIN LAB MED, V25, P363, DOI 10.1016/j.cll.2005.01.008; Argani P, 2006, J CLIN ONCOL, V24, P1529, DOI 10.1200/JCO.2005.04.4693; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Argani P, 2016, WHO CLASSIFICATION T, P40; Argani P, 2016, AM J SURG PATHOL, V40, P1484, DOI 10.1097/PAS.0000000000000720; Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003; Argani P, 2012, AM J SURG PATHOL, V36, P1516, DOI 10.1097/PAS.0b013e3182613d8f; Arneja SK, 2015, INT J SURG CASE REP, V7, P16, DOI 10.1016/j.ijscr.2014.12.026; Brimo F, 2010, AM J SURG PATHOL, V34, P715, DOI 10.1097/PAS.0b013e3181d90370; Camparo P, 2008, AM J SURG PATHOL, V32, P656, DOI 10.1097/PAS.0b013e3181609914; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Geller JI, 2008, CANCER-AM CANCER SOC, V112, P1607, DOI 10.1002/cncr.23331; Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24; Hora M, 2009, INT UROL NEPHROL, V41, P553, DOI 10.1007/s11255-008-9495-8; Inamura K, 2012, AM J SURG PATHOL, V36, P35, DOI 10.1097/PAS.0b013e3182293ec3; Ishihara A, 2011, PATHOL INT, V61, P539, DOI 10.1111/j.1440-1827.2011.02711.x; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Lilleby Wolfgang, 2015, J Med Case Rep, V9, P281, DOI 10.1186/s13256-015-0749-7; Malouf GG, 2011, J UROLOGY, V185, P24, DOI 10.1016/j.juro.2010.08.092; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Martignoni G, 2015, SEMIN DIAGN PATHOL, V32, P140, DOI 10.1053/j.semdp.2015.02.006; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; Matsuura K, 2014, HISTOPATHOLOGY, V64, P306, DOI 10.1111/his.12238; Pecciarini L, 2007, GENE CHROMOSOME CANC, V46, P419, DOI 10.1002/gcc.20422; Peckova K, 2014, ANN DIAGN PATHOL, V18, P351, DOI 10.1016/j.anndiagpath.2014.10.002; Petersson F, 2012, HUM PATHOL, V43, P726, DOI 10.1016/j.humpath.2011.07.001; Rao Q, 2013, INT J CLIN EXP PATHO, V6, P1452; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Smith NE, 2014, AM J SURG PATHOL, V38, P604, DOI 10.1097/PAS.0000000000000203; Suarez-Vilela D, 2011, INT J SURG PATHOL, V19, P506, DOI 10.1177/1066896909340531; Williamson SR, 2017, HUM PATHOL, V62, P175, DOI 10.1016/j.humpath.2016.10.024; Williamson SR, 2017, AM J SURG PATHOL, V41, P287, DOI 10.1097/PAS.0000000000000776; Wolff N, 2010, J CLIN ONCOL, V28, pE65, DOI 10.1200/JCO.2009.26.3061; Zhan HQ, 2010, J CLIN ONCOL, V28, pE709, DOI 10.1200/JCO.2010.30.3172; Zhong MH, 2012, AM J SURG PATHOL, V36, P654, DOI 10.1097/PAS.0b013e31824f24a6	36	8	8	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					474	487		10.1038/modpathol.2017.144			14	Pathology	Pathology	FY7KC	WOS:000427040000010	29052596	Bronze			2019-10-28	
J	Borowsky, J; Dumenil, T; Bettington, M; Pearson, SA; Bond, C; Fennell, L; Liu, C; McKeone, D; Rosty, C; Brown, I; Walker, N; Leggett, B; Whitehall, V				Borowsky, Jennifer; Dumenil, Troy; Bettington, Mark; Pearson, Sally-Ann; Bond, Catherine; Fennell, Lochlan; Liu, Cheng; McKeone, Diane; Rosty, Christophe; Brown, Ian; Walker, Neal; Leggett, Barbara; Whitehall, Vicki			The role of APC in WNT pathway activation in serrated neoplasia	MODERN PATHOLOGY			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; MUTATION CLUSTER REGION; BETA-CATENIN EXPRESSION; COLORECTAL-CANCER; COLON-CANCER; BRAF MUTATION; MOLECULAR CHARACTERIZATION; HYPERPLASTIC POLYPS; GENETIC ALTERATIONS; SOMATIC MUTATIONS	Conventional adenomas are initiated by APC gene mutation that activates the WNT signal. Serrated neoplasia is commonly initiated by BRAF or KRAS mutation. WNT pathway activation may also occur, however, to what extent this is owing to APC mutation is unknown. We examined aberrant nuclear beta-catenin immunolocalization as a surrogate for WNT pathway activation and analyzed the entire APC gene coding sequence in serrated and conventional pathway polyps and cancers. WNT pathway activation was a common event in conventional pathway lesions with aberrant nuclear immunolocalization of beta-catenin and truncating APC mutations in 90% and 89% of conventional adenomas and 82% and 70% of BRAF wild-type cancers, respectively. WNT pathway activation was seen to a lesser extent in serrated pathway lesions. It occurred at the transition to dysplasia in serrated polyps with a significant increase in nuclear beta-catenin labeling from sessile serrated adenomas (10%) to sessile serrated adenomas with dysplasia (55%) and traditional serrated adenomas (9%) to traditional serrated adenomas with dysplasia (39%) (P = 0.0001). However, unlike the conventional pathway, truncating APC mutations were rare in the serrated pathway lesions especially sessile serrated adenomas even when dysplastic (15%) and in the BRAF mutant cancers with microsatellite instability that arise from them (8%). In contrast, APC missense mutations that were rare in conventional pathway adenomas and cancers (3% in BRAF wild-type cancers) were more frequent in BRAF mutant cancers with microsatellite instability (32%). We conclude that increased WNT signaling is important in the transition to malignancy in the serrated pathway but that APC mutation is less common and the spectrum of mutations is different than in conventional colorectal carcinogenesis. Moderate impact APC mutations and non-APC-related causes of increased WNT signaling may have a more important role in serrated neoplasia than the truncating APC mutations common in conventional adenomas.	[Borowsky, Jennifer; Dumenil, Troy; Pearson, Sally-Ann; Bond, Catherine; Fennell, Lochlan; Liu, Cheng; McKeone, Diane; Leggett, Barbara; Whitehall, Vicki] Queensland Inst Med Res Berghofer, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; [Borowsky, Jennifer; Liu, Cheng; Leggett, Barbara; Whitehall, Vicki] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Borowsky, Jennifer; Bettington, Mark; Rosty, Christophe; Brown, Ian; Walker, Neal] Envoi Specialist Pathologists, Brisbane, Qld, Australia; [Brown, Ian; Whitehall, Vicki] Queensland Hlth, Pathol Queensland, Brisbane, Qld, Australia; [Leggett, Barbara] Royal Brisbane & Womens Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia	Whitehall, V (reprint author), Univ Queensland, QIMR Berghofer Med Res Inst, Canc & Cell Biol, 300 Herston Rd, Herston, Qld 4029, Australia.	Vicki.Whitehall@qimrberghofer.edu.au	Whitehall, Vicki/E-5414-2019; Walker, Neal I/E-7039-2011; Fennell, Lochlan/J-3376-2019; Brown, Ian/R-7763-2016	Fennell, Lochlan/0000-0003-3214-3527; Brown, Ian/0000-0001-6329-2547; Borowsky, Jennifer/0000-0003-3957-1364; Rosty, Christophe/0000-0001-7671-2651	National Health and Medical Research Council grant (NHMRC)National Health and Medical Research Council of Australia [1050455]; Pathology Queensland; Gastroenterological Society of Australia Senior Research Fellowship	This study was funded by a National Health and Medical Research Council grant (NHMRC: 1050455) and by Pathology Queensland. Vicki Whitehall is supported by a Gastroenterological Society of Australia Senior Research Fellowship.	[Anonymous], AL VIS VERS 2 6; Aust DE, 2010, VIRCHOWS ARCH, V457, P291, DOI 10.1007/s00428-010-0945-1; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248; Bettington M, 2017, GUT, V66, P97, DOI 10.1136/gutjnl-2015-310456; Bettington M, 2016, HISTOPATHOLOGY, V68, P578, DOI 10.1111/his.12788; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Bettington ML, 2015, MODERN PATHOL, V28, P414, DOI 10.1038/modpathol.2014.122; Bond CE, 2016, ONCOTARGET, V7, P70589, DOI 10.18632/oncotarget.12130; Boparai KS, 2011, AM J PATHOL, V178, P2700, DOI 10.1016/j.ajpath.2011.02.023; Boparai KS, 2008, GASTROENTEROLOGY, V135, P2014, DOI 10.1053/j.gastro.2008.09.020; Bosman FT, 2010, WHO CLASSIFICATION T; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cheadle JP, 2002, CANCER RES, V62, P363; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dhir M, 2011, INT J CANCER, V129, P1889, DOI 10.1002/ijc.25847; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fu XS, 2012, J CLIN PATHOL, V65, P675, DOI 10.1136/jclinpath-2011-200602; Fu XS, 2009, HISTOPATHOLOGY, V55, P554, DOI 10.1111/j.1365-2559.2009.03411.x; Fujita K, 2011, AM J SURG PATHOL, V35, P295, DOI 10.1097/PAS.0b013e318205df36; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hiyama T, 1998, J PATHOL, V186, P131; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; JEN J, 1994, CANCER RES, V54, P5523; Johnson V, 2005, GUT, V54, P264, DOI 10.1136/gut.2004.048132; Joo M, 2009, HUM PATHOL, V40, P872, DOI 10.1016/j.humpath.2008.12.003; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; O'Brien MJ, 2015, HISTOPATHOLOGY, V66, P49, DOI 10.1111/his.12564; O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Qiu Y, 2014, J CLIN PATHOL, V67, P491, DOI 10.1136/jclinpath-2013-202092; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Rosenberg DW, 2007, CANCER RES, V67, P3551, DOI 10.1158/0008-5472.CAN-07-0343; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Samowitz WS, 2007, MOL CANCER RES, V5, P165, DOI 10.1158/1541-7786.MCR-06-0398; Scholtka B, 2009, CANCER EPIDEMIOL, V33, P123, DOI 10.1016/j.canep.2009.05.001; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Sheridan TB, 2006, AM J CLIN PATHOL, V126, P564, DOI 10.1309/C7JE88VL8420V5VT; Shi Y, 2013, INT J SURG PATHOL, V21, P442, DOI 10.1177/1066896913499628; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Snover DC, 2011, HUM PATHOL, V42, P1, DOI 10.1016/j.humpath.2010.06.002; Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038; Suehiro Y, 2008, CLIN CANCER RES, V14, P2560, DOI 10.1158/1078-0432.CCR-07-1802; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2008, ANTICANCER RES, V28, P1821; Torlakovic EE, 2008, AM J SURG PATHOL, V32, P21, DOI 10.1097/PAS.0b013e318157f002; Tranah GJ, 2005, CANCER EPIDEM BIOMAR, V14, P863, DOI 10.1158/1055-9965.EPI-04-0687; Uchida H, 1998, JPN J CANCER RES, V89, P299, DOI 10.1111/j.1349-7006.1998.tb00562.x; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19; Yan HHN, 2017, GUT, V66, P1645, DOI 10.1136/gutjnl-2016-311849; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Young J, 2005, CLIN GASTROENTEROL H, V3, P254, DOI 10.1016/S1542-3565(04)00673-1	75	10	10	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	MAR	2018	31	3					495	504		10.1038/modpathol.2017.150			10	Pathology	Pathology	FY7KC	WOS:000427040000012	29148535	Bronze			2019-10-28	
J	Masago, K; Fujita, S; Hata, A; Okuda, C; Yoshizumi, Y; Kaji, R; Katakami, N; Hirata, Y; Yatabe, Y				Masago, Katsuhiro; Fujita, Shiro; Hata, Akito; Okuda, Chiyuki; Yoshizumi, Yuko; Kaji, Reiko; Katakami, Nobuyuki; Hirata, Yukio; Yatabe, Yasushi			Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer	PATHOLOGY INTERNATIONAL			English	Article						digital PCR; epidermal growth factor receptor; next generation sequence; re-biopsy; T790M	GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; GENE-MUTATIONS; T790M; ADENOCARCINOMA; CHEMOTHERAPY; AZD9291; BIOPSY; ERA	The aim of this study was to compare the accuracy of the QuantStudio 3D Digital polymerase chain reaction (dPCR) system and a PCR-based next generation sequencing (NGS) system for detecting a secondary mutation in the epidermal growth factor receptor (EGFR) gene T790M in non-small cell lung cancer (NSCLC) patients previously diagnosed with EGFR-activating mutations. Twenty-five patients with NSCLC previously treated with EGFR-TKIs were examined. The patients were treated daily with either erlotinib or gefitinib. New biopsies, followed by DNA sequencing on an Ion Torrent systems using the Ion Torrent AmpliSeq Cancer Hotspot Panel and dPCR were performed. A comparison of NGS, sensitive PCR, and dPCR revealed that the sensitivities of NGS and dPCR were similar in this study. As well, T790M was detected in as low as about 5% of mutant allelic frequencies, which represented 5% of the total reads on site mapped reads in NGS and greater than 5% of the dPCR reads, which represented mutant and wild type copies. The strategy in which NGS sequencing is followed by revealed acquired mutation with dPCR may be a reasonable one. We demonstrated the utility of combining NGS and dPCR as a tool for monitoring T790M. NGS and dPCR with formalin-fixed paraffin-embedded (FFPE) specimens might become a standard genomic test for exploring acquired resistance to targeted molecular medicines.	[Masago, Katsuhiro; Fujita, Shiro; Yatabe, Yasushi] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan; [Masago, Katsuhiro; Fujita, Shiro; Hata, Akito; Okuda, Chiyuki; Yoshizumi, Yuko; Kaji, Reiko; Katakami, Nobuyuki; Hirata, Yukio] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo, Japan	Masago, K (reprint author), Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	masago@aichi-cc.jp	YATABE, Yasushi/N-3588-2019; Yatabe, Yasushi/J-6461-2014	YATABE, Yasushi/0000-0003-1788-559X; Yatabe, Yasushi/0000-0003-1788-559X; Fujita, Shiro/0000-0002-2629-0152			Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Barnes S, 2006, J NUTR, V136, p2709S; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Gridelli C, 2014, CLIN LUNG CANCER, V15, P173, DOI 10.1016/j.cllc.2013.12.002; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Kawamura T, 2016, CANCER SCI, V107, P1001, DOI 10.1111/cas.12963; Kosaka T, 2009, J THORAC ONCOL, V4, P22, DOI 10.1097/JTO.0b013e3181914111; Kuiper JL, 2014, LUNG CANCER, V85, P19, DOI 10.1016/j.lungcan.2014.03.016; Masago K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1925-2; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Nosaki K, 2016, LUNG CANCER, V101, P1, DOI 10.1016/j.lungcan.2016.07.007; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Rosell R, 2016, J CLIN ONCOL, V34, P3361, DOI 10.1200/JCO.2016.68.3458; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sheikine Y, 2016, CLIN LUNG CANCER, V17, P483, DOI 10.1016/j.cllc.2016.05.016; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Stinchcombe TE, 2014, THER ADV MED ONCOL, V6, P240, DOI 10.1177/1758834014532510; Sundaresan TK, 2016, CLIN CANCER RES, V22, P1103, DOI 10.1158/1078-0432.CCR-15-1031; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004; Ulivi P, 2013, MOL CLIN ONCOL, V1, P575, DOI 10.3892/mco.2013.100; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yatabe Y, 2014, J CLIN ONCOL, V32, P4029, DOI 10.1200/JCO.2014.58.4375; Yoon HJ, 2012, RADIOLOGY, V265, P939, DOI 10.1148/radiol.12112613; Yu HA, 2014, CLIN CANCER RES, V20, P5898, DOI 10.1158/1078-0432.CCR-13-2437	27	0	0	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2018	68	3					167	173		10.1111/pin.12630			7	Pathology	Pathology	FY0SL	WOS:000426521900003	29341374				2019-10-28	
J	Hong, SA; Jang, SH; Oh, MH; Kim, SJ; Kang, JH; Hong, SH				Hong, Soon Auck; Jang, Si-Hyong; Oh, Mee-Hye; Kim, Sung Joon; Kang, Jin-Hyung; Hong, Sook-Hee			Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lung adenocarcinoma; YAP1; EGFR tyrosine kinase inhibitor; Prognosis	YES-ASSOCIATED PROTEIN; SOLID TUMORS; CANCER; CHEMOTHERAPY; SENSITIVITY; ERLOTINIB; RECEPTOR; GROWTH	EGFR tyrosine kinase inhibitor (EGFR TKI) is approved as first-line treatment for advanced-stage EGFR mutant lung adenocarcinoma (LADC). Yes-associated protein 1 (YAP1), a main effector of the Hippo pathway, is associated with adverse prognosis and disruption of EGFR TKI modulation of non-small cell lung cancer. In this study, we demonstrated a prognostic role of YAP1 in EGFR mutant LADC and efficacy of EGFR TKI therapy. A total of 63 patients, including 41 with paired lung cancer specimens before and after EGFR TKI therapy and 22 with non-paired lung cancer specimens prior to EGFR TKI, were enrolled for examination. Expression of YAP1 protein was evaluated using immunohistochemistry. Fifteen paired cases (36.6%) with high nuclear YAP1 expression were detected in the pre-EGFR TKI LADC group and 21 paired cases (52.5%) after treatment with EGFR TKI. Nuclear YAP1 expression was significantly upregulated after EGFR TKI therapy (P=.002). Fifteen paired cases with high nuclear YAP1 expression before EGFR TKI LADCs showed poorer overall survival (OS) (P=.023) and progression-free survival (PFS) (P=.041). Among the 63 patients under study, those with high nuclear YAP1 expression before EGFR TKI showed shorter OS (P=.038) and PFS (P<.001). High nuclear YAP1 expression in cases with acquired EGFR exon 20 T790 M mutant LADCs showed poorer OS (P<.001). We demonstrated that YAP1 burden before clinical application of EGFR TKI plays a crucial role in prognosis of EGFR mutant LADC treated using EGFR TKI.	[Hong, Soon Auck; Jang, Si-Hyong; Oh, Mee-Hye] Soonchunhyang Univ, Cheonan Hosp, Dept Pathol, Cheonan, South Korea; [Kim, Sung Joon] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Resp & Crit Care Med, Seoul, South Korea; [Kang, Jin-Hyung; Hong, Sook-Hee] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Med Oncol, 222 Banpodaero, Seoul 06591, South Korea; [Hong, Sook-Hee] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul, South Korea	Hong, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Med Oncol, 222 Banpodaero, Seoul 06591, South Korea.	ssuki76@catholic.ac.kr			National Research Foundation of Korea (NRF) - Ministry of Education [2016R1D1A1A02937400]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the 2016 Ministry of Education (2016R1D1A1A02937400).	Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Chaib I, 2017, JNCI-J NATL CANCER I, P109; Cheng HY, 2016, ONCOTARGET, V7, P28976, DOI 10.18632/oncotarget.6721; Cui ZL, 2012, INT J IMMUNOPATH PH, V25, P989, DOI 10.1177/039463201202500416; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Han HS, 2012, J THORAC ONCOL, V7, P355, DOI 10.1097/JTO.0b013e31823c4c1b; Horie M, 2016, CANCER SCI, V107, P1755, DOI 10.1111/cas.13078; Hsu PC, 2016, ONCOTARGET, V7, P51922, DOI 10.18632/oncotarget.10458; Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231; Ito T, 2016, CANCER SCI, V107, P1527, DOI 10.1111/cas.13013; Kim MH, 2015, INT J CLIN EXP PATHO, V8, P15933; Lee JE, 2016, BIOCHEM BIOPH RES CO, V474, P154, DOI 10.1016/j.bbrc.2016.04.089; Lee JK, 2017, J CLIN ONCOL, V35, P3065, DOI 10.1200/JCO.2016.71.9096; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mitsudomi Tetsuya, 2006, Int J Clin Oncol, V11, P190, DOI 10.1007/s10147-006-0583-4; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Song SM, 2015, CLIN CANCER RES, V21, P2580, DOI 10.1158/1078-0432.CCR-14-2191; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wu C, 2010, CANCER RES, V70, P9721, DOI 10.1158/0008-5472.CAN-10-1493; Yamamoto H, 2009, LUNG CANCER, V63, P315, DOI 10.1016/j.lungcan.2008.06.021; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112	25	2	3	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					335	342		10.1016/j.prp.2018.01.010			8	Pathology	Pathology	GB5EK	WOS:000429085700002	29487002				2019-10-28	
J	Kim, BS; Kim, JK; Kang, CH; Kim, YT; Jung, KC; Won, JK				Kim, Bo-Sung; Kim, Jin Kuk; Kang, Chang Hyun; Kim, Young Tae; Jung, Kyeong Cheon; Won, Jae-Kyung			An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Thymoma; Thymic carcinoma; EZH2; C-KIT; CD205; Immunohistochemistry	POLYCOMB GROUP GENE; CD5 IMMUNOREACTIVITY; EPITHELIAL NEOPLASMS; INCREASED EXPRESSION; DIAGNOSTIC UTILITY; CANCER; DIFFERENTIATION; CLASSIFICATION; MARKERS; TISSUE	Type B3 thymoma and thymic squamous cell carcinoma (SqCC) often cause a diagnostic problem due to their histological similarities. The aim of this study is to identify EZH2 as a novel and powerful biomarker that can effectively distinguish thymic SqCC from type B3 thymoma, and find optimal combinations among 11 markers. A total of 53 patients, comprising 26 with type B3 thymoma and 27 with thymic SqCC, were allocated to the discovery or validation cohorts, and immunohistochemical staining was performed and analyzed. The expression level of each marker was scored, and receiver-operator characteristic curve analysis was performed to evaluate their diagnostic accuracies. This analysis identified EZH2, C-KIT, and CD205 as useful markers for distinguishing thymic SqCC, and a combined panel approach using them further improved diagnostic accuracy in both the discovery and validation cohorts. In the combined cohorts analysis, EZH2 was the single best marker with 88.9% sensitivity and 100% specificity [area under the curve (AUC) = 0.967]. The sensitivity and specificity were 85.2% and 100% (AUC = 0.962) for C-KIT, and 100% and 73.1% (AUC = 0.844) for CD205. The combined panel had the highest sensitivity and specificity at 96.3% and 100%, which was significantly or marginally higher than those of EZH2, C-KIT, and CD205 alone (P=0.071, 0.034, and 0.005, respectively). The present findings indicate that EZH2 is useful as a novel diagnostic marker for distinguishing thymic SqCC and that the panel approach can be used as an effective differential diagnostic tool in daily practice.	[Kim, Bo-Sung] Natl Med Ctr, Dept Pathol, Seoul 100799, South Korea; [Kim, Jin Kuk] Dongguk Univ, Coll Med, Dept Family Med, Goyang Si 410773, South Korea; [Kang, Chang Hyun; Kim, Young Tae] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Thorac & Cardiovasc Surg, Seoul 110744, South Korea; [Jung, Kyeong Cheon; Won, Jae-Kyung] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea	Won, JK (reprint author), Seoul Natl Univ Hosp, Dept Pathol, 103 Daehak Ro, Seoul 110744, South Korea.	jkwon@snuh.org		Won, Jae-Kyung/0000-0003-1459-8093	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI); Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HI14C1277]	This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1277).	Barisella M, 2002, AM J CLIN PATHOL, V118, P470; Berezowski K, 1996, AM J CLIN PATHOL, V106, P483; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300; Dorfman DM, 1997, AM J SURG PATHOL, V21, P936, DOI 10.1097/00000478-199708000-00008; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467; Harris NL, 1999, AM J CLIN PATHOL, V112, P299; HISHIMA T, 1994, AM J PATHOL, V145, P268; Khoury T, 2011, INT J EXP PATHOL, V92, P87, DOI 10.1111/j.1365-2613.2010.00745.x; KOGA K, 1994, PATHOL INT, V44, P359; Kojika M, 2009, MODERN PATHOL, V22, P1341, DOI 10.1038/modpathol.2009.105; Kornstein MJ, 1998, AM J CLIN PATHOL, V109, P722; Marx A, 2014, J THORAC ONCOL, V9, P596, DOI 10.1097/JTO.0000000000000154; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001; Nakagawa K, 2005, CHEST, V128, P140, DOI 10.1378/chest.128.1.140; Nonaka D, 2007, AM J SURG PATHOL, V31, P1038, DOI 10.1097/PAS.0b013e31802b4917; Pan CC, 2004, J PATHOL, V202, P375, DOI 10.1002/path.1514; Pepe M. S., 2003, STAT EVALUATION MED, P267; Pomplun S, 2002, HISTOPATHOLOGY, V40, P152, DOI 10.1046/j.1365-2559.2002.01328.x; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Strobel P., 2015, WHO CLASSIFICATION T, P184; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	31	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					343	349		10.1016/j.prp.2018.01.009			7	Pathology	Pathology	GB5EK	WOS:000429085700003	29487009				2019-10-28	
J	Powrozek, T; Mlak, R; Dziedzic, M; Malecka-Massalska, T; Sagan, D				Powrozek, Tomasz; Mlak, Radoslaw; Dziedzic, Marcin; Malecka-Massalska, Teresa; Sagan, Dariusz			Investigation of relationship between precursor of miRNA-944 and its mature form in lung squamous-cell carcinoma - the diagnostic value	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Squamous-cell carcinoma; Lung cancer; Primary miRNA; miRNA	CANCER; BIOMARKERS; MICRORNAS; REVEALS; MIR-944	Introduction: MicroRNA (miRNA) are attractive markers of lung cancer, due to their regulatory role in cell cycle. However, we know more about function of miRNA in cancer development, there is still little known about role of their precursors (primary miRNA; pri-miRNA) in tumorgenesis. In present study we investigated potential role of miRNA-944 and its precursor pri-miRNA-944 in development of squamous-cell lung cancer (SCC) and explored interdependence between miRNA precursor and its mature form. This is a first available literature report analyzing pri-miRNA as a cancer diagnostic marker. Material and methods: Expression of miRNA-944 and its precursor was analyzed in 58 fresh-frozen tissues of non small cell lung cancer and corresponding adjacent non-cancerous tissues using qRT-PCR. Expression of pri-miRNA-944 was correlated with TP63 and miRNA-944. Using ROC analysis diagnostic accuracy of studied markers was evaluated. Results: miRNA-944 and its precursor were significantly overexspressed in SCC compared to adenocarcinoma (AC) and non-cancerous tissue. pri-miRNA-944 strongly and positively correlated with TP63 (r = 0.739, p < 0.001) and with mature miRNA-944 expression (r = 0.691, p < 0.001). Also, TP63 expression significantly correlated with mature miRNA (r = 0.785, p < 0.001). Combined analysis of pri-miRNA-944 and mature miRNA-944 allowed to distinguish SCC tissue form AC with sensitivity of 93.3% and specificity of 100% (AUC = 0.978), and SCC from non-cancerous tissue with 92.9% sensitivity and 100% specificity (AUC = 0.992). Conclusion: We assumed that pri-miRNA-944 and miRNA-944 may be involved in early squamous-type differentiation of lung tumors. Moreover, analysis of both markers provided high diagnostic accuracy for SCC detection.	[Powrozek, Tomasz; Mlak, Radoslaw; Malecka-Massalska, Teresa] Med Univ Lublin, Dept Human Physiol, Radziwillowska 11, PL-20080 Lublin, Poland; [Dziedzic, Marcin] Med Univ Lublin, Dept Lab Diagnost, Lublin, Poland; [Sagan, Dariusz] Med Univ Lublin, Dept Thorac Surg, Lublin, Poland	Powrozek, T (reprint author), Med Univ Lublin, Dept Human Physiol, Radziwillowska 11, PL-20080 Lublin, Poland.	tomaszpowrozek@gmail.com; radoslawmlak@umlub.pl; marcindziedzic@umlub.pl; teresa.malecka-massalska@umlub.pl; dariuszsagan@umlub.pl	Miak, Radoslaw/I-9994-2019	Miak, Radoslaw/0000-0001-7399-8340; Sagan, Dariusz/0000-0001-5077-3624; Powrozek, Tomasz/0000-0001-9174-8548; Malecka-Massalska, Teresa/0000-0003-3384-0324			Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Au NHC, 2004, APPL IMMUNOHISTO M M, V12, P240, DOI 10.1097/00129039-200409000-00010; Bach PB, 2012, JAMA-J AM MED ASSOC, V307, P2418, DOI 10.1001/jama.2012.5521; Chang TC, 2015, GENOME RES, V25, P1401, DOI 10.1101/gr.193607.115; Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hulf T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-54; Kim KH, 2015, NUCLEIC ACIDS RES, V43, P7462, DOI 10.1093/nar/gkv735; Kramer BS, 2011, J MED SCREEN, V18, P109, DOI 10.1258/jms.2011.011055; Levenson VV, 2012, PHARMACEUTICALS, V5, P94, DOI 10.3390/ph5010094; Liu MX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101493; Ma J, 2014, MOL ONCOL, V8, P1208, DOI 10.1016/j.molonc.2014.03.019; Patnaik S, 2015, J THORAC ONCOL, V10, P446, DOI 10.1097/JTO.0000000000000423; Pawlicki JM, 2008, J CELL BIOL, V182, P61, DOI 10.1083/jcb.200803111; Powrozek T, 2016, TUMOR BIOL, V37, P2049, DOI 10.1007/s13277-015-3971-4; Powrozek T, 2015, TRANSL RES, V166, P315, DOI 10.1016/j.trsl.2015.05.009; Quarles KA, 2013, BIOCHEMISTRY-US, V52, P795, DOI 10.1021/bi301452a; Romero-Cordoba SL, 2014, CANCER BIOL THER, V15, P1444, DOI 10.4161/15384047.2014.955442; Rommer A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-364; Ru Zhao Ying, 2011, Cancer Imaging, V11 Spec No A, pS79, DOI 10.1102/1470-7330.2011.9020; Saghir Z, 2011, AM J RESP CRIT CARE, V183; Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357; Tang DF, 2013, EUR J CANCER PREV, V22, P540, DOI 10.1097/CEJ.0b013e32835f3be9; Wozniak M. B., 2016, PLOS ONE, V2015; Xiang D, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-4; Xiang L., 2010, MODERN PATHOL, V23, P1157; Xie H, 2015, INT J CANCER, V136, pE230, DOI 10.1002/ijc.29160	30	2	2	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					368	373		10.1016/j.prp.2018.01.002			6	Pathology	Pathology	GB5EK	WOS:000429085700007	29496309				2019-10-28	
J	Zhu, Y; Han, Y; Tian, T; Su, PH; Jin, G; Chen, J; Cao, YG				Zhu, Yue; Han, Ying; Tian, Tian; Su, Peihong; Jin, Guan; Chen, Juan; Cao, Yungui			MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for cervical cancer progression	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miRNA-21-5p; miR-34a; hTERC; Cervical cancer progression; Biomarker	SQUAMOUS-CELL CARCINOMA; GENE TERC; GENOMIC AMPLIFICATION; HUMAN-PAPILLOMAVIRUS; ONCOGENIC HPV; PAP-SMEARS; EXPRESSION; MICRORNAS; DIAGNOSIS; GAIN	Objective: This study aimed to demonstrate the predictive value of miR-21-5p, miR-34a, and human telomerase RNA component (hTERC) in cervical cancer (CC) development and evaluated their potential possibility for future clinical applications. Methods: Specimens were collected from the normal cervix, cervical intraepithelial neoplasia (CIN) I, CIN II/III, cervical squamous cell carcinoma. Cytological evaluations and histopathologic examinations were conducted in all subjects, along with the assessment of human papillomavirus (HPV) DNA. The expression levels of the miR-21-5p and miR-34a were detected by RT-PCR. hTERC amplification was detected by dual-color interphase fluorescence in situ hybridization (FISH). Then miRNA, hTERC expressions were compared with the cytological and histologic examination. Results: Compared to that in the benign samples, the expression of miR-21-5p and miR-34a in abnormal samples was significantly upregulated and downregulated, gradually corresponding to the severity of cervical lesions (P < 0.05). There was a trend toward an increasing amplification of hTERC with the increasing severity of cervical lesions. miR-21-5p and miR-34a expression, and hTERC amplification were more specific than HPV positivity in differentiating low-grade cervical disorders from high-grade ones (P < 0.05). Conclusions: MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC.	[Zhu, Yue] Yiwu Cent Hosp, Dept Obstet & Gynaecol, Yiwu 322000, Zhejiang, Peoples R China; [Han, Ying; Tian, Tian; Su, Peihong; Jin, Guan; Chen, Juan] Gongli Hosp Pudong New Dist Shanghai City, Dept Gynecol, Shanghai 200135, Peoples R China; [Cao, Yungui] Jiading Dist Maternal & Child Hlth Hosp, Dept Gynecol, Shanghai 201800, Peoples R China	Chen, J (reprint author), Gongli Hosp Pudong New Dist Shanghai City, Dept Gynecol, Shanghai 200135, Peoples R China.; Cao, YG (reprint author), Jiading Dist Maternal & Child Hlth Hosp, Dept Gynecol, Shanghai 201800, Peoples R China.	huchuanyi2001@163.com; cygui@126.com			Technology Commission from the Shanghai Municipal Health Bureau Project, China [201440595]	This study was supported by the Technology Commission, a grant (No. 201440595 to YH) from the Shanghai Municipal Health Bureau Project, China.	Andersson S, 2006, BRIT J CANCER, V95, P331, DOI 10.1038/sj.bjc.6603253; Andersson S, 2009, AM J PATHOL, V175, P1831, DOI 10.2353/ajpath.2009.090122; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Caraway NP, 2008, GYNECOL ONCOL, V110, P37, DOI 10.1016/j.ygyno.2008.01.040; de Wilde J, 2008, INT J CANCER, V122, P877, DOI 10.1002/ijc.23210; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Di Saia P, 2012, CLIN GYNECOLOGIC ONC; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Ferlay J, 2016, IARC CANC BASE; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Han Y, 2015, INT J CLIN EXP PATHO, V8, P7131; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.3.CO;2-K; Heselmeyer-Haddad K, 2005, AM J PATHOL, V166, P1229, DOI 10.1016/S0002-9440(10)62341-3; Heselmeyer-Haddad K, 2003, AM J PATHOL, V163, P1405, DOI 10.1016/S0002-9440(10)63498-0; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Hopman AHN, 2006, J PATHOL, V210, P412, DOI 10.1002/path.2070; Insinga RP, 2008, CANCER EPIDEM BIOMAR, V17, P1611, DOI 10.1158/1055-9965.EPI-07-2922; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jin Y, 2011, ASIAN PAC J CANCER P, V12, P1167; Li BH, 2010, INT J GYNECOL CANCER, V20, P597, DOI 10.1111/IGC.0b013e3181d63170; Li DD, 2013, AM J PATHOL, V182, P64, DOI 10.1016/j.ajpath.2012.08.042; Li Y, 2011, GYNECOL ONCOL, V120, P73, DOI 10.1016/j.ygyno.2010.10.007; Li Y, 2010, INT J GYNECOL CANCER, V20, P631, DOI 10.1111/IGC.0b013e3181c50c7e; Liu SK, 2015, BIOCHEM BIOPH RES CO, V459, P679, DOI 10.1016/j.bbrc.2015.03.004; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Shishodia G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-996; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Tian QF, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju241; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tu Z, 2009, CANCER GENET CYTOGEN, V191, P10, DOI 10.1016/j.cancergencyto.2009.01.004; Vaccarella S, 2016, LANCET ONCOL, V17, P1445, DOI 10.1016/S1470-2045(16)30275-3; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; Wang WT, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-6; WANG XH, 2008, PLOS ONE, V3, DOI DOI 10.1371/JOURNAL.PONE.0002557; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wright Jr T. C., 2017, J LOW GENIT TRACT DI, V11, P201; Xiang LB, 2012, DIAGN CYTOPATHOL, V40, P849, DOI 10.1002/dc.21635; Yao Q, 2009, BIOCHEM BIOPH RES CO, V388, P539, DOI 10.1016/j.bbrc.2009.08.044; Yao TT, 2012, BBA-MOL BASIS DIS, V1822, P248, DOI 10.1016/j.bbadis.2011.09.018	45	12	12	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					374	379		10.1016/j.prp.2018.01.001			6	Pathology	Pathology	GB5EK	WOS:000429085700008	29487007				2019-10-28	
J	Choi, SH; Park, HC; Kim, MS; Chung, YJ; Lee, SH				Choi, Su Hye; Park, Hyeon-Chun; Kim, Min Sung; Chung, Yeun-Jun; Lee, Sug Hyung			Whole-exome sequencing of chondroid hamartoma of lung identified no driver mutations	PATHOLOGY RESEARCH AND PRACTICE			English	Letter							HIGH-FREQUENCY; GENES		[Choi, Su Hye; Park, Hyeon-Chun] Catholic Univ Korea, Dept Integrated Res, Ctr Genome Polymorphism, Seoul, South Korea; [Choi, Su Hye; Park, Hyeon-Chun; Chung, Yeun-Jun; Lee, Sug Hyung] Catholic Univ Korea, Dept Precis Med Res Ctr, Seoul, South Korea; [Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Seoul, South Korea; [Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Dept Canc Evolut Res Ctr, Seoul, South Korea; [Chung, Yeun-Jun] Catholic Univ Korea, Dept Microbiol, Seoul, South Korea; [Chung, Yeun-Jun] Catholic Univ Korea, Dept Integrated Res Ctr Genome Polymorphism, Seoul, South Korea	Chung, YJ (reprint author), Catholic Univ Korea, Coll Med, Integrated Res Ctr Genome Polymorphism, 505 Banpo Dong, Seoul 137701, South Korea.; Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	yejun@catholic.ac.kr; suhulee@catholic.ac.kr					BATESON EM, 1973, CANCER, V31, P1458, DOI 10.1002/1097-0142(197306)31:6<1458::AID-CNCR2820310622>3.0.CO;2-Y; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cosio BG, 2002, CHEST, V122, P202, DOI 10.1378/chest.122.1.202; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Jung SH, 2016, P NATL ACAD SCI USA, V113, P10672, DOI 10.1073/pnas.1606946113; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054	8	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	MAR	2018	214	3					459	462		10.1016/j.prp.2017.12.013			4	Pathology	Pathology	GB5EK	WOS:000429085700020	29482990				2019-10-28	
